<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>nanaokunote</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:font/woff;base64,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) format('woff'),url(data:font/ttf;base64,AAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw//8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS/YAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv+5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o+U1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg//8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl/CYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4////AAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD+AB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl+IA4gniEOIY4iHiI+Iw4kDiUOJg+P/////j/9r/Zv9i4Ajf5N+132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH/4f+B/3H/Ef6x/lH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl/AAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm+gAAJvoAAAAbAAAnCQAAJwkAAAAcAAAnDwAAJw8AAAAdAADgAQAA4AMAAAAeAADgBQAA4AkAAAAhAADgEAAA4BkAAAAmAADgIAAA4CkAAAAwAADgMAAA4DkAAAA6AADgQAAA4EkAAABEAADgUAAA4FkAAABOAADgYAAA4GAAAABYAADgYgAA4GkAAABZAADgcAAA4HkAAABhAADggAAA4IkAAABrAADgkAAA4JcAAAB1AADhAQAA4QkAAAB9AADhEAAA4RkAAACGAADhIAAA4SkAAACQAADhMAAA4TkAAACaAADhQAAA4UYAAACkAADhSAAA4UkAAACrAADhUAAA4VkAAACtAADhYAAA4WkAAAC3AADhcAAA4XkAAADBAADhgAAA4YkAAADLAADhkAAA4ZUAAADVAADhlwAA4ZkAAADbAADiAAAA4gYAAADeAADiCQAA4gkAAADlAADiEAAA4hYAAADmAADiGAAA4hkAAADtAADiIQAA4iEAAADvAADiIwAA4icAAADwAADiMAAA4jkAAAD1AADiQAAA4kkAAAD/AADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4/wAA+P8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf//AAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA/ujw8AMg/OAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc+AR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg+eBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg+eBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX+oh0VyBUd/qIVHR0VAV4dBEwdFf6iHRXIFR3+ohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE+ATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5+goFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP/u0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK+hkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI+AzUzBgcGIyInLgEnIzczNjcjNzM+ATc2AujycDwGtSM0QDkXEys4MjAPAXtk/tQGAZZk/tQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ+H3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE+ATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP/vUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j+1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2+gMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc+AT0BA+gdFTJjUVFjMhUd/OAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB//IBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY+ARYfATc2AyEnAwL2IAkKiAHTHhQe+1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7/RYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI/cwIBQMBCAgI/vgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI/vgIBQoCJgoF/vABCAgFCv3aCgUIAQgIFID+lAgKCggBbAgIpAgIpAgAAAAD//D/8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA+AmDpkNDWPWXyL9mdYCZv4f/rNuBLoNmQ4mDlzWYP50/ZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V+v4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm/2iKmAVGilucRoYEQJ/JioAAAACAAn/+AS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI+ATQmAZDItoNOAQFOARMXARY7GikT/u13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15/u4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE+Ah4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4+p4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ/gHk5QHZTLQVIAAAAAf/TAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH+qoIHDxH+qf6qEQ8Hgv6lEQYUAyABYRMT/p8RDPn+bxQLDPb3DAsUAZD7DBEAAv/TAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH+qoIHDxH+qf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP+nxEM+f5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU+AT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR+Cg8PCvuCCg8PVWQCo/3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh/doKDw8KAiYKDw/872QDIGT8GGQDIGQETA8K++YKDw8KBBoKD2RkZA8K/qIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX+cBUdHQJtAZAVHR0V/nAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX+cBUdHQRMHRX+cBUdHRUBkBUdHRX+cBUdHRUBkBUd/agdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA/AE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd/nAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3+cB0VyBUdHRXIFR0dFcgVHR0VyBUd/nAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH/oAICLEHFAirBxYB3QI7CAixBxQI/PAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI/vUBCwgIsggVB/70/vQHFQiyCAgBC/71CAiyCBUHAQwBDAcVBDuzCBUH/vT+9AcVCLIICAEL/vUICLIIFQcBDAEMBxUIsggI/vUBDAcAAwAX/+sExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj+1HeOYrSBTU2BAW+zmFhYmLOZWFj+vJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15/tUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF//rBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI+ATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K/qIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V/nAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P/t6WCg8PCpYKDw/+3pYKDw8KlgoPD/7elgoPDwqWCg8PBLAPCvuCCg8PCgR+Cg/+cA8K/RIKDw8KAu4KD/7UDwr+PgoPDwoBwgoPyA8K+goPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ/AjY/ASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ+frJ+BJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF+frEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD/u0DwoBEzspASwBLDsp/UQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT+1PzgKTs7KQMgZP1EArz9RAK8/UQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg/+1A8K+goPrwoFAmoCYAcH/aAICv3BCg8PCgF3/okKDw8KAj8KAAIAZAAAA+gEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V/OAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd/nAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI+ATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb/oxXJyxejFcnL+fDIKD68KDw8K+goPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr+7Q8KMgoPDwoBXgoPAAAAAAL/nAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp/eYBr9EVohTQ/p4b4BsBkP5wBLD+1AEs/nD+1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN/rkNCxS/HQJUMgoPDwr75goPDwoyCg8DhA8EsB0V/j4XEP5wEBABkBAXAcIVHfzgDwr+ogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4+rWm1tbm9bq1ptbW5sBv+jFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K/u0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4+rWm1tbm9bq1ptbW5sBv+jFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf+7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY/AT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX/dQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K/XQYGf5XDB4CBggEDRkBqRkYAowKDsgOC/4+Cw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG/6MVycsXoxXJy/ov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2+DCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ+AjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL/pYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ+AjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L/pcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv+lwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB/AI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA/K4KDw8KA1IKDw/9CDIKDw8KMgoPD9IBwgoPDwr+PgoPD74yCg8PCjIKDw/SAcIKDw8K/j4KDw++MgoPDwoyCg8P0gHCCg8PCv4+Cg8PvjIKDw8KMgoPD9IBwgoPDwr+PgoPDwSwDwr7ggoPDwoEfgoPyA8K/K4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT/tRSdmQpOzspA4QpOzsp/ageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE+ATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH+WwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT++uSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF//tQKDw8KASx03qP9wAwI/jQIDAwIAcwIDAwI/jQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ/AScmND8BNjIXAUEBAgkMDAn+/hUZ+goPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg+EeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY/ATYBQQECCQwMCf7+FRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7+FRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK/RIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd+hGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk/nBkAfQCvMjI/tTIZAJY+7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs/UQBLGRkZAOEZGT+DGRkAfT+1AEsA4RkZGQCWP4MZMgBLAEsyGT+1AEs/tQBLMhkZGT+DP4MAfRk/tRkZGRkyGTI/tQBLMhkZGT+1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI/OD+1AEsyGRkyGRkASzIyMgD6PwYA+j8GAPo/BgD6PwYA+j7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj+MAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI/jAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj+MAgUCP1WAQ8KAwYCqggI/jAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg/9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj//wRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4+/j4dBLAdFfuCAbz+QwR/FR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY/ATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2/kQLEAFOBw45BhcKAcIKFwY+DgdTARABVpYKFgROBBYK/doKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw/+sf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg/+cA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP/agOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE+BAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT+z76Hh76H/u9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K/7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE/AQEDIQMCqQGBFCgSJQkK/l81LBFS/nk6IgsJKjIe/pM4HAwaBwcBj6wBVKIEr/waMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu/VoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU+ATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD+DCk7AQYLFyEaAdc5dWM+Hy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb/K5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK/gy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL/tQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI+AzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn+cAQOIhoWyBkYJhMZCwgyA+j7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI/OCnpwMgpwACACH/tQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ/nAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V/agVHR0VA+gVHR0V/BgVHR0VAyAVHR0V/OAVHR0VBEwVHR0V+7QVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V/UQVHR2zBEwVHR0V+7QVHR3dArwVHR0V/UQVHR2zBEwVHR0V+7QVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR3+1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V/agVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V/OAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3+6WQVHR0VZBUdHf7pZBUdHRVkFR0d/ulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA/AAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd/tQdFWQVHR0VZBUd/tQdFWQVHR0VZBUd/tQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA/AE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR3+6WQVHR0VZBUdHQFBAyAVHR0V/OAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd/tQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3+1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG/5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V/gwVHR3++qfIyAHCASwVHR0V/tQVHR0VAlgVHR0V/agVHR0ETB0VZBUdHRVkFR3+1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd/tQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V/gwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd+7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3+1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH/0SHywsBIT+1AEsA+gsH/12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs/NJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7+4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4+rWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab/G8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ+BQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ/f4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA+hsAgYUFR0OFgoFBmz9BQGQMje7/pApOzspAfQpO8i7o/5wpbm5Azj+lqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp/gwpOzsptsj+tKW5uaUBkKW5/tf+ljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml/nClubkCfwFTCAj+rAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn+DCk7OymZZ6W5uaUBkKW5G/7TBxUH/s4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX+cKW5uQHKAYsHFQdlBwf97QcVB/gHB2UHFQdvCBQETBexOyn+DCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH+AcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE+AQgIFAgBBAcFCqrICggBCAgI/vgICsiqCgUH/vwIFAj++AgFCq/ICgj++AgIAQgICsivCgUDlgEICAj++AgKyK0KBAf+/AcVB/73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ/+MB0VZBUdHQRMHRX+SgHFDggV/BgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ/+MBUP/jAdFWQVHR0ETB0V/koBxQ4IFf5KAcUOCBX8GBUIDgHF/koVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ/+MBUP/hQPDwHsDxUB0A8VBBr8GBUIDgHF/koVCA4B4A4qDgHgDggV/koBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS/NISGRkEMv4OCx4L/g4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2+sgVHR0VyBUdHQGlyBUdHRXIFR0dA+gdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw/+FA8V/jAPFRUPAmQBthUIDv4gDioO/iAOCBUBtv47DggVA+gVCA4AAAH//gACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL+MQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX+OQ4JFAPoFQkP/j4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA+gVCA7+OwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW++4WCQ8B9Q8q/fcD6BUdHRX8GBUdHQQ5/eQPFhYPAhwP/UgdFWQVHR0VZBUdAAEAiP/8A3UESgAFAAAJAgcJAQN1/qABYMX92AIoA4T+n/6fxgIoAiYAAAAAAQE7//wEKARKAAUAAAkBJwkBNwQo/dnGAWH+n8YCI/3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4+rWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX+DBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm/5+HRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI/ARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ+AQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB/IHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm/4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ+AQUiDgMVFDsBFjc+ATMyFhUUBgciDgUHBhY7ATI+AzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ/eMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD/7UDwoyCg/IDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw+5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP/s2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA/AAAAMh4CFA4CIi4CND4BBCIOARQeATI+ATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb/oxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG/6MVycsXoxXJyg2oHB/7ACBQIyggIagcVB0/FBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf+vwcHywcVB2oICE/FBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ+AQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV/t0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA/kAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ/AgoQEP32EBf92hUdHRUCJhcD8f5VDSYN/lUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3+3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN/lUNJg3+VQ0KFQEjHQSwHRX92hcQ/fYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ/AgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN/lUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I/iH+1BUdFQ5e+QgUCGoHB/leDggEsB0V/tQVCA5e+QcHaggUCPleDhX7UB0VASwVCA5e+QcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ/AScmNgP2agcH+V4OCBX+1BUdFQ5e+QgU/QwBLBUdFQ5e+QgUCGoHB/leDggEYGoIFAj5Xg4VHRUBLBUIDl75B/3xHRX+1BUIDl75BwdqCBQI+V4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3+DA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc+BAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP/nDI/nAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe/okKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf+iQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc+ATc+AScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy/t3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U/M0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc+ATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY+BDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA//cAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl+DiINfWjIWCwQMWv3/Iw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP/cAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ+BTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2/VFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP/ngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U/BQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR/plkGhPNzRMaZP6ZERgWDwFrBLBYPv6t/rsOMRQpFA0M+f75XRRAFRAJgIAJEBVAFF0BB/kMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA/AEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk/HxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd/nD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb/kPD/kOFZ/9qP7dFR0dFdECWPEV/amNetEVHR0VASMDGvkPD/kOFfG1jXqfFQSN5g4qDuYOCBWW/agdFWQVHQJYlhUI/piNeh0VZBUd/k3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7/tQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3+1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6+hUdHRX6+hUd/nD+1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB//8A1ARMA8IABQAAAQcJAScBBEzG/p/+n8UCJwGbxwFh/p/HAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH/p8BYQAAAAAC/1EAZAVfA+gAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW/oP+HOYOCBWWAYHX/RIVHZYVCA7mDioD6B0V/dkVDvkPD/kOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3+1B0qHR8SHQYFyTYUHh4EsBYQoiUY/iUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw+1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz+1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY/ATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO+Q8P+Q4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ/5Dg75DxUCWBUDYOUPKQ/lDwkUl5cUCQ/lDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt/BgpOzspA+gpOzv+q2RkZAGQAtwXLSgV/R1kOylkKTs7KWQpO8hkZGRkAAAAA/+cAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k/V0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj+7BAIHBUBUQ76AgQQDw36/tT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM+ATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU+LwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N/rmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI+ARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW+v4+Mv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3+qBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv/tQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo/rgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl+IZJZkMjIBwvoETCEY/qgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX+DBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP/qoHphwOOmQBJYMGGw/LFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7+rRUoog0CDRElCkj+CVkBUxUoMjIBAgIDBQIZFrdT5B0V/gwVHR0VAfQVHQAAAAP/nABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf+qg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH+Jd0PHAaCASZq/qoCUGQVHR0VZBUdHQRP5gEFEBEXC/3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE+AR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN/fMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V/gwVHR0FDm5UaoMGGw/+qgemHA4OAWsfFm4NAQxUAS5U1ssVExIW/jgCCgIJAwcDBQMBDBGSVv6tZAElgwYb/QsdFWQVHR0VZBUdAAP//QAGA+gFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM+BDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX+DBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf+qg8bBgHP/q1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob+7RAX/u0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm/453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX+7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm+jfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm/5AARMQEP7tEBf+7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg+JFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD+7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ+ASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY+ATc+AzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU/OR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg/KhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh+WYcrIgsW/awQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA+gpOzsp/BgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH+1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E/tTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv+DMj+DDspASw7KcgB9Dsp/BgpOwSwOylkOyn+cGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj+L2oHB8deDggV/tQVHRUOXscIFALLXg4VHRX+1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX+1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX+1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5/d8t2gXl6gAcbgv29vv+C/b2/+LS0gIC0gAUwtICAWDg83ETNIMykfegEJ/octICAtIAIdLSAgLSAEqF+f3fLdoF5eoN3y3Z9Xb7/gv29vv+C/BiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf/YAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr+qw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB/0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH/6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6+RAH/SBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg+PqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB/slVVsn+AeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn/8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ/ARYfAQcXAQKru0KNQjgiHR8uEl/3/nvUaRONQkIBGxJpCgmNQkL+5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl/4/nvUahKNQrpCARv+RmkICY1CukL+5UJCjUK7Qjc3LxFf+AGFAAAAAAMAyAAAA+gEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7/Vj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8/RY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT+6dT+zP7oywEz0gEsAQsjDx0qBKH+5g8qHQ8j/vX+1NL+zcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH/s0NBxMtPGQ+i6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ/soCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc+ATM2FjMyNxcOAyMiLgEHDgEPASc+BTc+AScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig/IhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn//wSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF+YOCBWWyJYVCA7mDioBLBYO+g8P+g4WA4QQ+Q4V/HwDhBUO+Q8AAAQAGf//A+gEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI/tTIyAEsArxkZAH0/HwWDvoPD/oOFgOEZMjI/RL6ZJb6ZAAAAAAEABn//wPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO+g8P+g4WA4SW+mSW+mT7UGRkAfRkyMgAAAAEABn//wRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD/oOFgOE/gwBkGT7UGQBkGTIyAAAAAAEABn//wRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD/oOFgOE/gxkAZBkyMj7tAGQZAAAAAAFABn//wSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk/nABkGT+DAH0ASwWDvoPD/oOFgOEyMj+DMj+DMj+DMgABQAZ//8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD+DAH0ZP5wAZBk/tQBLGTIyAEsFg76Dw/6DhYDhMjI/gzI/gzI/gzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P+cKW5uQJn/gwpOzspAfQpOzsETLuj/nClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml/nCju7wCZP4MKTs7KQH0KTs7/m/9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn+DCk7OykB9Ck7gr4MJAy+DAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX+cKW5uQJn/gwpOzspAfQpOzv+FQGQFQsMvgwkDL4MCwRMvKL+cKW5uaUBkKO7yDsp/gwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf+DCk7OykB9Ck7O/77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn+DCk7OykB9Ck7z/0QGBgQ/REAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX+cBUdHRUBwik7Oyn+PhUdHb8BRBAQ/rwQFvoVHR0V+hYETLml/nCluR0VZBUdOykB9Ck7HRVkFR3p/uQOJg7+5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B/vf+8wQMDgkJCQUCUCcn/tIXCAoQSwENuwUJEASeCQoRC/5TBwEjEv7K/sUFDwgLFQnlbm4TFRRWAS/TBhAAAAACAAAAAAT+BEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4+KTs7KQHCFR0dFf5wpbm5AvEBRBAQ/rwQFvoVHR0V+hYETB0VZBUdOyn+DCk7HRVkFR25pQGQpbnp/uQOJg7+5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj+75wpOzspAfQpO8i7o/5wpbm5pQEsBLAdFf5wFQgObf7IDw+NDykPAThtDhX+1Dsp/gwpOzsplMj+1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx/nugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO/oEOJw3+hQ0JFfod/oUD6BUd+7QdA2dkBLAdFf6iFg/+Vg8PAaoPFgFeFR38fB0V+voVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE+AQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n/fkD6BUd+7QdA2dkBJ7+TQ8g+hQeHRX6IQ8BrxAC/H8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB/7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH/fMICAEjCBQIiwcH/dIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY/ASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A+gVHfu0HQNnZAP/jg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V+voVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ/AQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A+gVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3+WB0V+voVHWQyMgACAAT/7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d/sb+cQSs/TMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V+gH0ZMhkZAPo/K4VHQGQ/nAdFQPoFB7+1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC/tVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf+XAgUCMoICGoHFQdPASkHFQPolf7VXwkJk/5wHRUD6BQe/tQBLMjI/c5qBxUH/lsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72/reWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw+Dgw8PRg8pD4ODDykD6P7zZ4YPAw7+9v5wHRUD6BQe/tQBLMjI/YxGDykPg4MPKQ9GDw+Dgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM/qIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA+j+1B0Vlv5wHRUD6BQe/tQBLMjI/agdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75/m6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P/vf+cB0VA+gUHv7UASzIyP2F5Q8V+hQeHhT6FQ/lDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd+1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U/doVHR0VAib+1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX+cAGQFf0vMhUdHRUyyGRk/oL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI/oUdFWQVHcjI/cvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ+AzMyFh8BETMRPAE+AjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX+4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH/uuFR0dFQGNAQgbHzUeAWcfRJEZDA3+Phw/MSkLC/5BFR0dFQG/BA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn+DBlL/nAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr+diUNODgBBQoUDgN4FhkBAjg4DSX+dgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn+2cj+cGQBd/4lASwpOzsp/tQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn+DCk7OykB9Ck7ZMjI/veFo4XGyMhm+BUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE+BRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB/LimdWQ/LAkJHRTKFB2N/sKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V+7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy/tEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI/OAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7/Rv+1DspZCk7BEw7KfwYA+gpO/7UOyn9RAK8KTv84AGQKTs7KQAAAAAF/5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8/UR8sLAYA4T+DMjI/tTIyAEsAZBkyMhkZARMsHz+DHywsHwB9HywyP1EArzIZP7UZGQBLGT+1GQB9GT+1AEsAAAABf+cAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE/gxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI/UQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP+cAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj+1AEsAZDIyP7UASwETLB8/gx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP+cAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE/gz+1AEsAZD+1ARMsHz+DHywsHwB9HywyP1EArz+DJaWlpYBLAAAAAX/nAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8/gx8sLB8AfR8sMj9RAK8/agB9GRWQUFUASz+1FRBQVYAAAAF/5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8/UR8sLAYA4T+DMjI/tTIyAEsAZBkZMjIZGQETLB8/gx8sLB8AfR8sMj9RAK8yGT+1GRkASz+DAGQZP4MZAAG/5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8/UR8sLAYA4T9RMj+1GQCWGRkyP2oZAEsZGQETLB8/gx8sLB8AfR8sMj9RAK8yP5wAfT+DAGQZMjIyP7UZAAF/5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8/UR8sLAYA4T+DMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI/UQCvP5wyDLIlmT+DAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz+1AEs/tRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ+AQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv/y/50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V/tQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi/bMPCv7tFxD0EBD0EBcBEwoPAAAAAAL/8v+cBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr+hg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ+teGOkHAFoEBD+k3NPRWsOExNkqWP9kuQQF/7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD+8qr+8qr+1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3+s/7U/tRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd/tQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd+x5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc+ATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ/j0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb/7V/tVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s/oQPCgI/ASzIZKLU1KJktP51Cg8DhA8KwwMg/oTIyALzCg/+1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz+ov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9+AFe/doERwoP/tTI/HzIyNT+ZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT+ogHCJCsRBP5w/nAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX+1BUdHRUyHQFzKTs7Kf2oARP2/ro7KVg+ASw+WP201MjIBEwdFTIdFWQVHR0VZBUdMhUd+pY7KfzgKTsE9gFGAUQpO5Y+WFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG/2oKTs7KVg+ASw+WAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd+pY7Kf4M/tQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP/ogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs+wQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf+TB0U/tIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K+goPDwr6Cg8PCvoKDw8BmvoKDw8K+goPD/zq+goPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K+goPD/zq+goPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K+goPDwRMDwqWCg8PCpYKD/7UDwqWCg8PCpYKDw8KlgoPDwqWCg/+1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD/7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko/PwoKUIcMT4BXmRkyP4+ArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3+1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq/9WrIiCikBSAOvArwVHR0VlgET/EoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb+lR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf+vCcrI/7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW/us5Okxra0w6Of5yHSodZGQdKh3+1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ/68Jysj/s0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2+jGv4KOTpMa2tMOjn+ch0qHWRkHSod/tQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ+AjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz+1CU/P00T/e48PUJtj0r+ogK8FR0dFQ2K/EqJDBUdHbMETBUd+1AdBLChizlmUT9IGVO9VFShdksE/H4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA+gFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U/5wU3V1BRQ7KU4aXDYyMjZcGk4p/kc2LmRkZGRkU3V1UwGQU3UAAAMAZP//BEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr+5eANGiUNWP30Vw0mGg3g/t8KDw8BqmQBRGQETB0V/gwVHR0VAfQVHf1EDwoyCg/gDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn+1AEsKTv+DDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg/4f/fsgIAEnH1n+rAFWAS/+q6IDIBUd/HwdBI39VR9ZH4MCBh9ZHwEoH/5u/qoBMAFV/BsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV/nAVJwi9CBMVAnEdKh19FROo/a0dFTIdFTDILxUdMhUdAocB+hMcHBP+BhMclhUdHRWWHP2MMhUdMhUdASz+1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr+if7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD/7UyP4M/cEKDw8KA7YKD/7UyAAC/5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc+ARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF+goPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb/nP/mBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL/CtqQ0geZgM3FR0cE/0fFyIJKjr+1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g+yD5YrBwVODMQEAtEERzJLUAtLUD+24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz++QFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg/+1MgVHR0LCgQOIhoW/nDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb+YDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj/sIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn+PilUrAFINhWWFTYFFKxn/gwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn+PilUrAFINhWWFTYFFJaz/kIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO/YL+hk5klpZkAQEBBQQvkwKCAVz+ov6iAV4BXgL//uWqPOCWx5SVyJb6BA0GCgYDKEEBG/1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz+yFh8WFh8/shYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP/nAPCpYKDw8KlgoP/nAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o/4Mpbm5Asv9qCk7OykCWCk7O/2xAfQVHR0V/gwVHR1HAZAEsLuj/gylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX+1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA+gVHR0VMjIVHR0VMjIVHR0VMjIVHR0V/BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA+gEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8/V1c/P/75fLB8sAK8sHyw/cB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy/sCwfLB8fLB8sP7UsHywfHywfLD+05AVHR0VjgQAAAH/tQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc/KZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS/tkLHw8OEw0dNkY4MhwBIBgXBAQYF/7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn+cAQOIhoWyBkYJhMZCwgyA+j9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH+VwsNATIyGQGpAQUKEw+WAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE/t9F/tQSFQkfCwsBETE7EkUBJT0NISf+7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr/Q4jFQkTBQUyMisusKYiQTIBhwFW/qr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F/tUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B/uAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM/gUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX+cBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k/tQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX+cBUdHQJtAZAVHR0V/nAVHR1HASzI+1AEsASwHRX8fBUdHRUDhBUd/gwdFf5wFR0dFQGQFR1k/tQBLP2oZAAAAAACAAAAZASwA+gAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX+cBUdZB0V/nAVHR0CnwEsA+gdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3+1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs/qIDhBUdHRX8fBUdHQSwZB0V/nAVHR0VAZAVHWT+1AEs/gwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX+cBUdZB0V/nAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs/K4DhBUdHRX8fBUdHQSwZB0V/nAVHR0VAZAVHWT+1AEs/gwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H+EhcSDhAQDhIXAe4OAjX+EhcbGQPoGRsX/hIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3+Eg4CewHuHREp/BgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA+gpER3+Eg4qDv4SHREDhCod/hIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8/UwBnf5jBKj84AMgAuW2/r3dwcHd+9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI/tTIyAEs+1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy/OADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ/nAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr+KQcHAdcKBEoWDP4w/jAMFgkB1wgUCAHXCQAAAQE+AGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf+KQoNoBAKDAHQ/jAMCgRKCf4pCBQI/ikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI/ikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA+gAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz+MP4wDBYJAdcIFAPh/ikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ//kEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc+Ah4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A+iwfLD+VmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR+TDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V/nAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9/UQCWP1EZB8BDWQEsFEs/Ft1A7Z9/BgEARc0/V1kFGQAAQAAAAECTW/DBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f/Uf+cBdwFFAAAAAgAAgAAAAAAAAABAAAFFP+FAAAFFP9R/tQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD/8gSwAAAEsAAABLD/8ASwAAAEsAAOBLAACQSwAGQEsP/TBLD/0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP+cBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw/7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP+cBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP/+BLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw/9wEsP/cBLD/nwSwAGQEsAAABLAAAASwAAAEsABkBLD//wSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD/nASwAEoEsAAUBLAAAASwAAAEsAAABLD/nASwAGEEsP/9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD/2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP+c/5z/nP+c/5z/nP+c/5wACQAJ//L/8gBkAHkAJwBkAGQAAAAAAGT/ogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP+c/5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs/7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi+CTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA+mD+YQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh/SIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ+JuYnUCe8J/goNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi/4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8+D0yPew+Oj6MPtQ/KD9uP6o/+kBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA/gADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB+gADAAEECQALACQCEAADAAEECQAMACQCNAADAAEECQATACQCWAADAAEECQDIABYCfAADAAEECQDJADACkgADAAEECdkDABoCwnd3dy5nbHlwaGljb25zLmNvbQBDAG8AcAB5AHIAaQBnAGgAdAAgAKkAIAAyADAAMQA0ACAAYgB5ACAASgBhAG4AIABLAG8AdgBhAHIAaQBrAC4AIABBAGwAbAAgAHIAaQBnAGgAdABzACAAcgBlAHMAZQByAHYAZQBkAC4ARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAFIAZQBnAHUAbABhAHIAMQAuADAAMAA5ADsAVQBLAFcATgA7AEcATABZAFAASABJAEMATwBOAFMASABhAGwAZgBsAGkAbgBnAHMALQBSAGUAZwB1AGwAYQByAEcATABZAFAASABJAEMATwBOAFMAIABIAGEAbABmAGwAaQBuAGcAcwAgAFIAZQBnAHUAbABhAHIAVgBlAHIAcwBpAG8AbgAgADEALgAwADAAOQA7AFAAUwAgADAAMAAxAC4AMAAwADkAOwBoAG8AdABjAG8AbgB2ACAAMQAuADAALgA3ADAAOwBtAGEAawBlAG8AdABmAC4AbABpAGIAMgAuADUALgA1ADgAMwAyADkARwBMAFkAUABIAEkAQwBPAE4AUwBIAGEAbABmAGwAaQBuAGcAcwAtAFIAZQBnAHUAbABhAHIASgBhAG4AIABLAG8AdgBhAHIAaQBrAEoAYQBuACAASwBvAHYAYQByAGkAawB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQBXAGUAYgBmAG8AbgB0ACAAMQAuADAAVwBlAGQAIABPAGMAdAAgADIAOQAgADAANgA6ADMANgA6ADAANwAgADIAMAAxADQARgBvAG4AdAAgAFMAcQB1AGkAcgByAGUAbAAAAAIAAAAAAAD/tQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE+AT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG/AcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB+gH7AfwB/QH+Af8CAAIBAgICAwIEAgUCBgIHAggCCQIKAgsCDAINAg4CDwIQAhECEgZnbHlwaDEGZ2x5cGgyB3VuaTAwQTAHdW5pMjAwMAd1bmkyMDAxB3VuaTIwMDIHdW5pMjAwMwd1bmkyMDA0B3VuaTIwMDUHdW5pMjAwNgd1bmkyMDA3B3VuaTIwMDgHdW5pMjAwOQd1bmkyMDBBB3VuaTIwMkYHdW5pMjA1RgRFdXJvB3VuaTIwQkQHdW5pMjMxQgd1bmkyNUZDB3VuaTI2MDEHdW5pMjZGQQd1bmkyNzA5B3VuaTI3MEYHdW5pRTAwMQd1bmlFMDAyB3VuaUUwMDMHdW5pRTAwNQd1bmlFMDA2B3VuaUUwMDcHdW5pRTAwOAd1bmlFMDA5B3VuaUUwMTAHdW5pRTAxMQd1bmlFMDEyB3VuaUUwMTMHdW5pRTAxNAd1bmlFMDE1B3VuaUUwMTYHdW5pRTAxNwd1bmlFMDE4B3VuaUUwMTkHdW5pRTAyMAd1bmlFMDIxB3VuaUUwMjIHdW5pRTAyMwd1bmlFMDI0B3VuaUUwMjUHdW5pRTAyNgd1bmlFMDI3B3VuaUUwMjgHdW5pRTAyOQd1bmlFMDMwB3VuaUUwMzEHdW5pRTAzMgd1bmlFMDMzB3VuaUUwMzQHdW5pRTAzNQd1bmlFMDM2B3VuaUUwMzcHdW5pRTAzOAd1bmlFMDM5B3VuaUUwNDAHdW5pRTA0MQd1bmlFMDQyB3VuaUUwNDMHdW5pRTA0NAd1bmlFMDQ1B3VuaUUwNDYHdW5pRTA0Nwd1bmlFMDQ4B3VuaUUwNDkHdW5pRTA1MAd1bmlFMDUxB3VuaUUwNTIHdW5pRTA1Mwd1bmlFMDU0B3VuaUUwNTUHdW5pRTA1Ngd1bmlFMDU3B3VuaUUwNTgHdW5pRTA1OQd1bmlFMDYwB3VuaUUwNjIHdW5pRTA2Mwd1bmlFMDY0B3VuaUUwNjUHdW5pRTA2Ngd1bmlFMDY3B3VuaUUwNjgHdW5pRTA2OQd1bmlFMDcwB3VuaUUwNzEHdW5pRTA3Mgd1bmlFMDczB3VuaUUwNzQHdW5pRTA3NQd1bmlFMDc2B3VuaUUwNzcHdW5pRTA3OAd1bmlFMDc5B3VuaUUwODAHdW5pRTA4MQd1bmlFMDgyB3VuaUUwODMHdW5pRTA4NAd1bmlFMDg1B3VuaUUwODYHdW5pRTA4Nwd1bmlFMDg4B3VuaUUwODkHdW5pRTA5MAd1bmlFMDkxB3VuaUUwOTIHdW5pRTA5Mwd1bmlFMDk0B3VuaUUwOTUHdW5pRTA5Ngd1bmlFMDk3B3VuaUUxMDEHdW5pRTEwMgd1bmlFMTAzB3VuaUUxMDQHdW5pRTEwNQd1bmlFMTA2B3VuaUUxMDcHdW5pRTEwOAd1bmlFMTA5B3VuaUUxMTAHdW5pRTExMQd1bmlFMTEyB3VuaUUxMTMHdW5pRTExNAd1bmlFMTE1B3VuaUUxMTYHdW5pRTExNwd1bmlFMTE4B3VuaUUxMTkHdW5pRTEyMAd1bmlFMTIxB3VuaUUxMjIHdW5pRTEyMwd1bmlFMTI0B3VuaUUxMjUHdW5pRTEyNgd1bmlFMTI3B3VuaUUxMjgHdW5pRTEyOQd1bmlFMTMwB3VuaUUxMzEHdW5pRTEzMgd1bmlFMTMzB3VuaUUxMzQHdW5pRTEzNQd1bmlFMTM2B3VuaUUxMzcHdW5pRTEzOAd1bmlFMTM5B3VuaUUxNDAHdW5pRTE0MQd1bmlFMTQyB3VuaUUxNDMHdW5pRTE0NAd1bmlFMTQ1B3VuaUUxNDYHdW5pRTE0OAd1bmlFMTQ5B3VuaUUxNTAHdW5pRTE1MQd1bmlFMTUyB3VuaUUxNTMHdW5pRTE1NAd1bmlFMTU1B3VuaUUxNTYHdW5pRTE1Nwd1bmlFMTU4B3VuaUUxNTkHdW5pRTE2MAd1bmlFMTYxB3VuaUUxNjIHdW5pRTE2Mwd1bmlFMTY0B3VuaUUxNjUHdW5pRTE2Ngd1bmlFMTY3B3VuaUUxNjgHdW5pRTE2OQd1bmlFMTcwB3VuaUUxNzEHdW5pRTE3Mgd1bmlFMTczB3VuaUUxNzQHdW5pRTE3NQd1bmlFMTc2B3VuaUUxNzcHdW5pRTE3OAd1bmlFMTc5B3VuaUUxODAHdW5pRTE4MQd1bmlFMTgyB3VuaUUxODMHdW5pRTE4NAd1bmlFMTg1B3VuaUUxODYHdW5pRTE4Nwd1bmlFMTg4B3VuaUUxODkHdW5pRTE5MAd1bmlFMTkxB3VuaUUxOTIHdW5pRTE5Mwd1bmlFMTk0B3VuaUUxOTUHdW5pRTE5Nwd1bmlFMTk4B3VuaUUxOTkHdW5pRTIwMAd1bmlFMjAxB3VuaUUyMDIHdW5pRTIwMwd1bmlFMjA0B3VuaUUyMDUHdW5pRTIwNgd1bmlFMjA5B3VuaUUyMTAHdW5pRTIxMQd1bmlFMjEyB3VuaUUyMTMHdW5pRTIxNAd1bmlFMjE1B3VuaUUyMTYHdW5pRTIxOAd1bmlFMjE5B3VuaUUyMjEHdW5pRTIyMwd1bmlFMjI0B3VuaUUyMjUHdW5pRTIyNgd1bmlFMjI3B3VuaUUyMzAHdW5pRTIzMQd1bmlFMjMyB3VuaUUyMzMHdW5pRTIzNAd1bmlFMjM1B3VuaUUyMzYHdW5pRTIzNwd1bmlFMjM4B3VuaUUyMzkHdW5pRTI0MAd1bmlFMjQxB3VuaUUyNDIHdW5pRTI0Mwd1bmlFMjQ0B3VuaUUyNDUHdW5pRTI0Ngd1bmlFMjQ3B3VuaUUyNDgHdW5pRTI0OQd1bmlFMjUwB3VuaUUyNTEHdW5pRTI1Mgd1bmlFMjUzB3VuaUUyNTQHdW5pRTI1NQd1bmlFMjU2B3VuaUUyNTcHdW5pRTI1OAd1bmlFMjU5B3VuaUUyNjAHdW5pRjhGRgZ1MUY1MTEGdTFGNkFBAAAAAAFUUMMXAAA=) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style>h1 {font-size: 34px;}
h1.title {font-size: 38px;}
h2 {font-size: 30px;}
h3 {font-size: 24px;}
h4 {font-size: 18px;}
h5 {font-size: 16px;}
h6 {font-size: 12px;}
code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
pre:not([class]) { background-color: white }</style>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<style type="text/css">.hljs-literal {
color: #990073;
}
.hljs-number {
color: #099;
}
.hljs-comment {
color: #998;
font-style: italic;
}
.hljs-keyword {
color: #900;
font-weight: bold;
}
.hljs-string {
color: #d14;
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>






<link rel="stylesheet" href="../css/JhengHei.css" type="text/css" />



<style type="text/css">
.main-container {
max-width: 940px;
margin-left: auto;
margin-right: auto;
}
img {
max-width:100%;
}
.tabbed-pane {
padding-top: 12px;
}
.html-widget {
margin-bottom: 20px;
}
button.code-folding-btn:focus {
outline: none;
}
summary {
display: list-item;
}
details > summary > p:only-child {
display: inline;
}
pre code {
padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
display: inline-table;
max-height: 500px;
min-height: 44px;
overflow-y: auto;
border: 1px solid #ddd;
border-radius: 4px;
}
.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
content: "\e259";
font-family: 'Glyphicons Halflings';
display: inline-block;
padding: 10px;
border-right: 1px solid #ddd;
}
.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
content: "\e258";
font-family: 'Glyphicons Halflings';
border: none;
}
.tabset-dropdown > .nav-tabs > li.active {
display: block;
}
.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
border: none;
display: inline-block;
border-radius: 4px;
background-color: transparent;
}
.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
display: block;
float: none;
}
.tabset-dropdown > .nav-tabs > li {
display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div id="header">



<h1 class="title toc-ignore">nanaokunote</h1>

</div>


<div id="section" class="section level1">
<h1>701012983</h1>
<div id="section-1" class="section level2">
<h2>221229</h2>
<ul>
<li>diagnosis
<ul>
<li>Malignant neoplasm of duodenum</li>
</ul></li>
<li>past history]
<ul>
<li>Past medical history:
<ul>
<li>Cardiovascular disease - CAD, DM</li>
<li>Hepatitis B or C carrier - denied</li>
<li>Current medications – DAPT</li>
</ul></li>
<li>Past surgical history:
<ul>
<li>no gastrectomy/colectomy/splenectomy   </li>
</ul></li>
</ul></li>
<li>family history]
<ul>
<li>There is no family history of cancer, hypertension, mental diseases
or asthma.</li>
<li>No members of the family with diabetes.     </li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-08 CT - abdomen
<ul>
<li>Clinical history: 56 y/o male patient with duodenal adenocarcinoam
pT3bN2 cM0; stage IIIB, s/p Op in May 2022.</li>
<li>With and without contrast enhancement CT of abdomen whole:
<ul>
<li>S/P whipple operation.</li>
<li>Right renal cyst, 1.2cm.</li>
<li>Unremarkable change of the liver, spleen and left kidney.</li>
<li>There are multiple enlarged lymph nodes in the paraaortic,
aortocaval and peripancreatic regions.</li>
<li>Presence of ascites.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P whipple operation.</li>
<li>Multiple metastatic lymph nodes and ascites, progression.</li>
<li>R/O right renal cyst.</li>
</ul></li>
</ul></li>
<li>2022-11-08 CXR
<ul>
<li>Spondylosis of the T-spine</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-11-01 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Dilated CBD</li>
<li>Dilated left intrahepatic duct</li>
<li>Splenomegaly, mild</li>
<li>Ascites</li>
<li>Pancreas masked</li>
</ul></li>
<li>Suggestion
<ul>
<li>No more fever</li>
<li>elevated CEA/CA 19-9</li>
<li>highly suspected tumor reucrrent</li>
<li>Suggest medical ONC follow up and treat, but patient refuse (due to
no money). suggest him seeking help from social worker but also
refuse.</li>
</ul></li>
</ul></li>
<li>2022-06-13 CXR
<ul>
<li>Ground glass opacity in bilateral lower lungs.</li>
</ul></li>
<li>2022-06-08 CXR
<ul>
<li>Ground glass opacity in RLL.</li>
</ul></li>
<li>2022-05-31 Patho - pancreas total/subtotal resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Duodenum, 2nd and 3rd portion, whpple operation — Periampullary
adenocarcinoma, poorly differentiated</li>
<li>Pancreas, head, whpple operation — Involved by adenocarcinoma</li>
<li>Lymph node, peripancreatic, dissection — Metastatic adenocarcinoma
(2/2)</li>
<li>Lymph node, group 7,8,9, dissection — Metastatic adenocarcinoma
(2/3)</li>
<li>Gallbladder, whpple operation — Negative for malignancy</li>
<li>Omentum, whpple operation — Negative for malignancy</li>
<li>AJCC 8th edition Pathology stage: pT3bN2(if cM0); AJCC stage
IIIB</li>
</ul></li>
</ul></li>
<li>2022-05-24 CT - chest
<ul>
<li>History: Duodenal cancer</li>
<li>Impression
<ul>
<li>no abnormality in both lungs. 2nd portion duodenal tumor with
pancreatic head involvement and complete obstruction.</li>
<li>suspect old subendocardial infarct in LAD territory.</li>
</ul></li>
</ul></li>
<li>2022-05-19 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (109 - 33) / 109 = 69.72%
<ul>
<li>M-mode (Teichholz) = 68</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Dilated aortic root</li>
<li>Septal hypertrophy; LV diastolic dysfunction, Gr 1</li>
<li>Trivial MR and trivial TR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2022-05-18 Pulmonary Flow Volume Loop
<ul>
<li>Mild restrictive lung defect</li>
</ul></li>
<li>2022-05-17 MRI - pancreas
<ul>
<li>History and indication: Duodenal stricture</li>
<li>Findings
<ul>
<li>Marked motion artifact.</li>
<li>Wall thickening of duodenum, 2nd portion, with pancreas invasion.
Some LNs at retroperitoneum.</li>
<li>Distention of stomach.</li>
<li>Tiny renal cysts.</li>
<li>Normal appearance of liver, spleen, adrenals.</li>
<li>Normal appearance of gallbladder.</li>
<li>Patency of portal vein.</li>
<li>No ascites.</li>
<li>No abnormal intensity in bilateral basal lungs.</li>
</ul></li>
<li>IMP:
<ul>
<li>In favor of duodenal tumor with pancreas invasion and
obstruction.</li>
</ul></li>
</ul></li>
<li>2022-05-17 Patho - stomach
<ul>
<li>Labeled as “Some white and plaque-like lesions were noted at lower
esophagus”, biopsy (B) — ulcer. PAS stain shows no fungal species.</li>
</ul></li>
<li>2022-05-17 Patho - stomach
<ul>
<li>Duodenum, SDA, s/p biopsy (A) — adenocarcinoma.</li>
<li>IHC stain: Her2/neu: negative (score =0)</li>
<li>Section shows duodenal mucosal tissue with irregular aborted glands
and isolated signet ring-like neoplastic cells.</li>
</ul></li>
<li>2022-05-16 Upper GI and Small Intestine
<ul>
<li>UGI and small bowel series revealed:
<ul>
<li>The contrast medium passage from oral cavity through esophagus to
stomach smoothly without obstruction.</li>
<li>Normal contour and mucosal pattern of the esophagus.</li>
<li>Distention of stomach.</li>
<li>Normal appearance of duodenal bulb.</li>
<li>Partial obstruction of duodenum (2nd portion).</li>
<li>No abnormal bowel loop displacement.</li>
<li>The passage time is about 120 minutes.</li>
</ul></li>
</ul></li>
<li>2022-05-16 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade D</li>
<li>Suspected esophageal candidiasis, lower esophagus, s/p biopsy
(B)</li>
<li>Superficial gastritis</li>
<li>Duodenal obstruction, SDA, r/o peptic stricture according to the
recent endoscopic diagnosis of duodenal ulcers in other hospital, s/p
biopsy (A)</li>
<li>Incomplete study due to residual food retention</li>
</ul></li>
<li>Suggestion
<ul>
<li>Consult GS for surgical evaluation</li>
<li>Arrange upper GI series</li>
</ul></li>
</ul></li>
<li>2022-05-13 CT - abdomen
<ul>
<li>History: vomit with coffee ground for days accompanied with tarry
stool for once since this morning. Abdominal distended</li>
<li>Indication: GI bleeding.</li>
<li>MD CT (Aquilion Prime SP) of the abdomen and pelvis was performed
with 0.625 mm collimation &amp; 5 mm slice thickness reconstruction.
Oral and rectal contrast was not given for bowel opacification. CT
images were obtained during non-enhanced and portal venous phase scan
following IV contrast injection through autoinjector. Coronal reformated
isotropic images were obtained in portal venous phase scan.</li>
<li>Findings:
<ul>
<li>There is asymmetrical wall thickening at the duodenal 2nd portion,
causing marked distension of the stomach S/P nasogastric tube insertion.
<ul>
<li>Please correlate with gastroscopy to R/O ulcer with deformity or
cancer?</li>
</ul></li>
<li>There is a poor enhancing lesion in the pancreatic uncinate process,
measuring 1.5 cm in size.
<ul>
<li>Please correlate with CA199 and MRI.</li>
</ul></li>
<li>A renal cyst measuring 1.5 cm in right upper pole is noted.</li>
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, spleen &amp; left kidney.</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>There is asymmetrical wall thickening at the duodenal 2nd portion,
causing obstruction.
<ul>
<li>Please correlate with gastroscopy to R/O ulcer with deformity or
cancer?</li>
</ul></li>
<li>There is a poor enhancing lesion in the pancreatic uncinate process,
measuring 1.5 cm in size.
<ul>
<li>Please correlate with CA199 and MRI.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-13 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Suboptimal study due to much residual food retention</li>
<li>Reflux esophagitis LA Classification grade C</li>
<li>Superficial gastritis</li>
<li>Suspicious of duodenal ileus</li>
</ul></li>
<li>Suggestion
<ul>
<li>Suggest NG tube decompression use</li>
<li>Arrange KUB</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient has been diagnosed with duodenal cancer for several
months. There may be a reason why he does not actively participate in
treatment because he is financially underprivileged (according to social
service team’s note 2022-12-28). The availability of treatment options
may be limited as a result.</li>
<li>With adequate hydration and flomoxef treatment, the decreased blood
pressure has returned to normal (95/55 to 127/70) on 2022-12-29.</li>
</ul>
</div>
</div>
<div id="section-2" class="section level1">
<h1>700022077</h1>
<div id="section-3" class="section level2">
<h2>221228</h2>
<ul>
<li>exam findings
<ul>
<li>2022-12-03 CT - abdomen
<ul>
<li>Findings:
<ul>
<li>Wall thickening of cecum and proximal A-colon with adjacent
mesentery and peritoneal invasions.</li>
<li>Multiple enlarged regional lymph nodes, more than 10.</li>
<li>Multiple mass lesions with peripheral enhancement in liver.</li>
<li>No ascites or extraluminal free air.</li>
<li>Enlarged lymph nodes in para-aortic region.</li>
<li>No bony destructive lesion on these images.</li>
<li>Multiple nodular lesions in both lung fields.</li>
</ul></li>
<li>Impression
<ul>
<li>suspected Acending colon CA with peritoneal invaion, lymph node
metastasis, and liver &amp; lung metastasis</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-4" class="section level3">
<h3>==========</h3>
</div>
<div id="section-5" class="section level3">
<h3>2022-12-28</h3>
<ul>
<li>A nasogastric tube can be used to administer all of the oral
medications listed in the active prescription.</li>
<li>There may be an enhanced CNS depressant effect when tramadol,
chlorzoxazone, and oxazolam are administered together.</li>
<li>Amlodipine and tramadol’s serum concentrations may be increased by
fluconazole, a moderate CYP3A4 inhibitor.</li>
<li>The ingredients in Acetal, Sketa, and Tramacet all include
acetaminophen. The maximum daily dose of acetaminophen is not
recommended to exceed 3000mg.</li>
<li>Please continue to monitor any potential adverse reactions caused by
drug interactions.</li>
</ul>
</div>
<div id="section-6" class="section level3">
<h3>2022-12-05</h3>
<ul>
<li>The CT image taken on 2022-12-03 indicated that cancer of the colon
or cecum may be present. A work-up is currently being conducted on the
patient. As far as the active prescription is concerned, there is no
problem.</li>
</ul>
</div>
</div>
</div>
<div id="section-7" class="section level1">
<h1>701173809</h1>
<div id="section-8" class="section level2">
<h2>221228</h2>
<ul>
<li>diagnosis
<ul>
<li>Sigmoid cancer with obstruction and invasion to cecum s/p Colostomy
then Sigmoid colectomy with lymph nodes dissection and Right
hemicolectomy on 2019/03/23, pT4bN2bM0, stage IIIC s/p adjuvant
chemotehrapy with FOLFOX for 6 cycles with tumor seeding with posterior
lateral aspect</li>
<li>Left Kidney clear cell renal carcinoma , pT1aN0M0 s/p partial
nephrectomy on 2019/12/31</li>
<li>Chronic viral hepatitis B without delta-agent</li>
</ul></li>
<li>past history
<ul>
<li>GERD history 20+ years ago;</li>
<li>Lumbar spondylolisthesis, L2-L3 post medical treatment in
hospitalized 20+ years ago;</li>
<li>Sigmoid colon cancer with obstruction, pT4bN2bM0, stage IIIC s/p
T-loop colostomy on 2019/03/23; s/p sigmoid colectomy and right
hemicolectomy on 2019/03/27; s/p post Port A catheterimplatation on
2019/04/03. mFOLFOX-6 adjuvant chemotherapy x 6 times then shifted to
high dose 5-FU x 6 times on 2019/07/08 to 2019/09/18.</li>
<li>Left Kidney clear cell renal carcinoma , pT1aN0M0 s/p partial
nephrectomy on 2019/12/31</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-30 CT - abdomen
<ul>
<li>History:
<ul>
<li>20190323 CT: sigmoid colon cancer with total obstruction.</li>
<li>20190327 surgery: Sigmoid cancer with obstruction and invasion to
the cecum s/p Sigmoid colectomy + Right hemicolectomy. Patho: pT4bN2bM0,
pstage IIIC</li>
<li>20191231 S/P partial Lt nephrectomy:RCC, clear cell, pT1aN0M0</li>
<li>20220413 CT: a lesion in Lt 11th rib intercostal space, Suspected
meta.</li>
<li>20220502 CT-guided biopsy patho favor metastasis c/w colon origin. a
lesion in Lt kidney middle pole, suspected recurrent RCC? clinician
favor old hematoma.</li>
</ul></li>
<li>Findings:
<ul>
<li>S/P partial nephrectomy at left kidney upper pole.
<ul>
<li>Prior CT identified a poor enhancing lesion 1.6 x 1.3 cm in left
kidney middle pole is noted again, mild decreasing in size to 1.2 x 0.7
cm. Follow up is indicated.</li>
<li>Prior CT identified a metastasis measuring 2.7 x 1.4 cm in the
posterior lateral aspect of left 11th-12th rib intercostal space is not
noted again in the current CT that is c/w metastasis S/P surgical
resection.</li>
</ul></li>
<li>Prior CT identified a cyst 7 mm in S4 and a hemangioma 1.3 cm in S7
of the liver are noted again, stationary.</li>
<li>S/P right hemicolectomy and S/P LAR with autosuture retention over
the sigmoid colon.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P partial nephrectomy at left kidney upper pole.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-05-27 Patho - peritoneum biopsy
<ul>
<li>Diaphragm, left, excision — Metastatic adenocarcinoma, consistent
with colorectal origin</li>
<li>Sections show fibroadipose and skeletal muscular tissue with
invasive neoplastic glandular cells.</li>
<li>The immunohistochemical stain of CDX2 is positive. Lymphovascular
invasion is found. The result and morphology are consistent with
metastatic adenocarcinoma from colorectal origin. The peripheral
resection margins are free of tumor. The tumor is very close (&lt;0.1cm)
to the serosal surface.</li>
</ul></li>
<li>2022-05-26 CXR
<ul>
<li>Thoracic aortic arch calcified atheriosclerotic plaque</li>
</ul></li>
<li>2022-05-19 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a focal area in the posterior lateral
aspect of left 11th-12th intercostal space, in a focal area in the
posterior aspect of left kidney, in a focal area in the middle lower
pelvis just in the left anterolateral aspect of rectum and in a focal
area in the right anterior lower pelvis. Multiple metastatic lesions
should be considered. Please correlate with other clinical findings for
further evaluation and to rule out other possibilities.</li>
<li>A glucose hypermetabolic lesion in the middle pole of left kidney.
Recurrent malignancy should be watched out. Please also correlate with
other clinical findings for further evaluation.</li>
</ul></li>
<li>2022-05-03 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>Labeled as “left 11 rib”, (clinically: sigmoid colon cancer and
renal cell cancer), CT guided biopsy — metastatic adenocarcinoma.</li>
<li>IHC stains:
<ul>
<li>CD10 (-) and RCC (-): dis-favor RCC,</li>
<li>CK20 (+): compatible with colon origin;</li>
<li>TTF-1 (-): dis-favor pulmonary origin;</li>
<li>PSA (-): dis-favor prostatic origin.</li>
</ul></li>
<li>Section shows soft tissue with many small nests of criform pattern
adenocarcinoma.</li>
</ul></li>
<li>2022-04-13 CT - abdomen
<ul>
<li>History:
<ul>
<li>20190323 CT:sigmoid colon cancer with total obstruction.</li>
<li>20190327 surgery: Sigmoid cancer with obstruction and invasion to
the cecum s/p Sigmoid colectomy + Right hemicolectomy
<ul>
<li>Patho: pT4bN2bM0, pstage IIIC</li>
</ul></li>
<li>20191231 S/P partial Lt nephrectomy: RCC, clear cell, pT1aN0M0</li>
</ul></li>
<li>Findings
<ul>
<li>S/P partial nephrectomy at left kidney upper pole.
<ul>
<li>Prior CT identified a poor enhancing lesion 0.9 cm in left kidney
middle pole is noted again, mild increasing in size to 1.6 x 1.3
cm.</li>
<li>A newly-developed renal cell carcinoma is suspected. Please
correlate with contrast enhanced dynamic CT or MRI.</li>
<li>In addition, another newly-developed heterogeneous poor enhancing
mass measuring 2.7 x 1.4 cm in the posterior lateral aspect of left
11th-12th rib rintercostal space is noted that may be tumor
seeding.</li>
</ul></li>
<li>Prior CT identified a cyst 7 mm in S4 and a hemangioma 1.3 cm in S7
of the liver are noted again, stationary.</li>
<li>S/P right hemicolectomy and S/P LAR with autosuture retention over
the sigmoid colon.</li>
</ul></li>
<li>Impression
<ul>
<li>RCC 1.6 x 1.3 cm in Lt kidney middle pole is suspected.</li>
<li>Tumor seeding 2.7 x 1.4 cm in the posterior lateral aspect of left
11th-12th rib rintercostal space is highly suspected. please correlate
with clinical condition and biopsy.</li>
</ul></li>
</ul></li>
<li>2021-12-30 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Negative finding</li>
<li>Pancreas not shown</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver, especially liver dome and S1 was diffcult to
approach and easy missed</li>
</ul></li>
</ul></li>
<li>2021-07-01 CT - abdomen
<ul>
<li>S/P colon operation.</li>
<li>Small liver cyst and hemangioma.</li>
<li>Left renal tumors (0.9cm, 2.7cm) without interval change.</li>
</ul></li>
<li>2021-04-01 CT - abdomen
<ul>
<li>S/P colon operation.</li>
<li>Small liver cyst and hemangioma.</li>
<li>Left renal tumors (0.9cm, 2.7cm).</li>
</ul></li>
<li>2020-03-20 CT - abdomen
<ul>
<li>dilated small bowel. suspected small bowel ileus.</li>
<li>recent renal infarction in the left kidney.</li>
</ul></li>
<li>2020-01-02 Surgical pathology Level V
<ul>
<li>PATHOLOGIC DIAGNOSIS:
<ul>
<li>Kidney, left, partial nephrectomy — Clear cell renal cell carcinoma
with sarcomatoid feature<br />
</li>
<li>Pathology stage: pT1aNx, stage I at least</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histological type: Clear cell renal cell carcinoma<br />
</li>
<li>Sarcomatoid features: Present (80%)<br />
</li>
<li>Rhabdoid features: Not identified<br />
</li>
<li>Histologic grade: Grade 4<br />
</li>
<li>Tumor necrosis: Present (20%)<br />
</li>
<li>Tumor Extension: Tumor limited to kidney<br />
</li>
<li>Margins: Uninvolved by invasive carcinoma<br />
</li>
<li>Lymphovascular invasion: Not identified<br />
</li>
<li>Regional lymph nodes (pN): No lymph node found<br />
</li>
<li>Distant metastasis (pM): Not applicable<br />
</li>
<li>Nonneoplastic kidney: Chronic pyelonephritis<br />
</li>
</ul></li>
</ul></li>
<li>2019-12-02 MRI - liver, spleen
<ul>
<li>A hemangioma (1.3cm) in S7 of liver. A cyst (0.5cm) in S4 of
liver.</li>
<li>A poor enhancing tumor (2.7cm) in left kidney suspected hypovascular
RCC.</li>
</ul></li>
<li>2019-09-26 CT - abdomen
<ul>
<li>Colon cancer s/p operation with colostomy. No evidence of tumor
recurrence.</li>
<li>A poor enhancing tumor (2.7cm) in left kidney (mild increased
size).</li>
<li>A poor enhancing tumor (1.1cm) in S7 of liver without interval
change.</li>
</ul></li>
<li>2019-06-25 CT - abdomen
<ul>
<li>No evidence of recurrent tumor in the study.</li>
</ul></li>
<li>2019-03-27 Surgical pathology Level VI
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Sigmoid colon, colectomy — Adenocarcinoma, moderately
differentiated</li>
<li>Ascending colon, R’t hemicoloectomy — Adenocarcinoma, compatible
with direct tumor invasion from sigmoid cancer</li>
<li>Proximal &amp; distal surgical margins — Free of tumor invasion</li>
<li>Lymph nodes, mesocolic, dissection — Positive for tumor metastasis
(8/43) with extracapsular extension (2/8)</li>
<li>Appendix, terminal ileum — Free of tumor invasion</li>
<li>AJCC pathologic stage — pT4bN2bMx, stage IIIC at least</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology: sigmoid adenocarcinoma directly invades to ascending
colon</li>
<li>Histology Grade: G2: moderately differentiated<br />
</li>
<li>Depth of invasion: direct invades adjacent colon</li>
<li>Angiolymphatic invasion: Present</li>
<li>Perineural invasion: NOT identified</li>
<li>Discontinuous extramural tumor extension: Not identified.</li>
<li>Circumferential (radial) margin of rectosigmoid: Involved</li>
<li>Lymph node metastasis, mesocolic: Positive for tumor metastasis
(8/43)</li>
<li>Lymph node metastasis, IMA / SMA: N/A</li>
<li>Extranodal involvement: Present (2/8)</li>
<li>Pathological TNM Stage: pT4bN2bMx, stage IIIC at least</li>
<li>Type of polyp in which invasive carcinoma arose: N/A</li>
<li>Additional pathologic findings: N/A</li>
<li>TNM descriptors: N/A<br />
</li>
<li>Tumor regression grading S/P CCRT: N/A</li>
<li>Proximal &amp; distal margins: free from tumor invasion</li>
</ul></li>
</ul></li>
<li>2019-03-26 Surgical pathology Level IV
<ul>
<li>Colon, sigmoid, 20 cm from anal verge, biopsy — Adenocarcinoma,
moderately differentiated</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>The immunohistochemical stains reveal EGFR(+), PMS2(+), MLH1(+),
MSH2(+), and MSH6(+).</li>
</ul></li>
<li>2019-03-23 CT - abdomen
<ul>
<li>Indication: Abdominal dull pain for 2-3 days, mostly over the right,
abdominal fullness with no stool passage for 2 days, N∕V(+), no chest
pain, no SOB, no flank pain, denied OP history</li>
<li>Imaging Report Form for Colorectal Carcinoma</li>
<li>Impression:
<ul>
<li>Dilated colon and small intestines with transitional point at
sigmoid colon, suspected foreign body related or sigmoid colon
cancer.<br />
</li>
<li>T3N1Mx, IIIB</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-27 Excision of chest wall and repair of diaphragmatic
defect.
<ul>
<li>One solid nodular lesion was noted over left CP angle, near diaphram
and 11th intercostal muscle, size about 3cm in max. diameter.</li>
<li>One J-P drain was inserted beneth the wound.</li>
</ul></li>
<li>2020-03-23 Enterolysis with bowel decompression
<ul>
<li>Adhesion band and causing small bowel dilatation</li>
</ul></li>
<li>2019-12-31 Partial nephrectomy</li>
<li>2019-10-30 Closure of enterostomy or Colostomy (loop or
double-barrel)</li>
<li>2019-03-27 Left hemicolectomy or sigmoid colectomy with anastomosis
with lymph node</li>
<li>2019-03-23 Enterostomy for suspected S-colon cancer with
obstruction</li>
</ul></li>
<li>drug allergy
<ul>
<li>Eloxatin (oxaliplatin 50 mg/vial) - whole body rash, fever all
over</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-27 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-12-07 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-11-03 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-10-17 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-09-13 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-09-13 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-08-30 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 760mg 2hr + fluorouracil 400mg/m2
760mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg ST &amp; 4mg BID D1-3 + diphenhydramine
30mg + atropine 0.5mg SC + palonosetron 250ug + aprepitant 125mg ST
&amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-08-02 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
280mg 90min + leucovorin 400mg/m2 760mg 2hr + fluorouracil 400mg/m2
760mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + atropine 0.5mg
SC + palonosetron 250ug + aprepitant 125mg ST &amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-06-29 - bevacizumab 5mg/kg 400mg 90min + irinotecan 120mg/m2
230mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 400mg/m2
750mg 10min + fluorouracil 2400mg/m2 4500mg 46hr (Avastin + FOLFIRI,
Q2WK)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + atropine 0.5mg
SC + palonosetron 250ug + aprepitant 125mg ST &amp; 125mg QD D2-3</li>
</ul></li>
<li>2022-06-14 - irinotecan 120mg/m2 225mg 90min + leucovorin 400mg/m2
760mg 2hr + fluorouracil 200mg/m2 380mg 10min + fluorouracil 2400mg/m2
4570mg 46hr (FOLFIRI, Q2WK)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + atropine 1mg IVD
+ granisetron 2mg</li>
</ul></li>
<li>2019-07-08 ~ 2019-09-18 - Adjuvant chemotherapy with mFOLFOX6 for 6
times.</li>
</ul></li>
</ul>
<div id="section-9" class="section level3">
<h3>==========</h3>
</div>
<div id="section-10" class="section level3">
<h3>2022-12-28</h3>
<ul>
<li>The CEA and CA199 markers did not show any obvious trend over the
past six months.</li>
<li>Lab data for 2022-12-27 showed a WBC level of 3.82K/uL and a
neutrophil percentage of 37%. The possibility of potential infectious
events and neutropenia might be kept in mind.</li>
<li>The most recent CT was dated on 2022-09-30. Possibly, the lesion in
the middle pole of the left kidney should be followed up. It may be
updated if it is considered to be beneficial to clinical
decision-making.</li>
<li>The active prescription does not pose a problem.</li>
</ul>
</div>
<div id="section-11" class="section level3">
<h3>2022-10-18</h3>
<p>The patient’s vital signs, laboratory data (2022-10-11), and the
disease are in a generally stable state.</p>
</div>
<div id="section-12" class="section level3">
<h3>2022-09-28</h3>
<p>There is no issue with the active prescription. It is recommended
that the last abdomen CT image be updated as it is dated 2022-04-13. A
metastatic adenocarcinoma around the left 11th and 12th ribs (2022-05-03
pathology) might be surgically removed if it is symptomatic and
feasible.</p>
</div>
<div id="section-13" class="section level3">
<h3>2022-09-14</h3>
<p>There was a generally normal lab result on 2022-09-12 and a
relatively stable TPR and BP reading during this hospital stay. With the
current regimen, the patient has tolerated it. In this case, the patient
has only a muscle power of 4 or less, so some assistive devices might be
beneficial.</p>
</div>
</div>
</div>
<div id="section-14" class="section level1">
<h1>700132375</h1>
<div id="section-15" class="section level2">
<h2>221226</h2>
<p>{drug identification}</p>
<p>The drug imprinted “CTP A23” on the red-white capsule has not been
found in available databases and remains unidentified.</p>
</div>
</div>
<div id="section-16" class="section level1">
<h1>700555339</h1>
<div id="section-17" class="section level2">
<h2>221226</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-25 KUB
<ul>
<li>Disc space narrowing with marginal osteophyte formation and vacuum
phenomenon of L5-S1.</li>
<li>There are few calcified nodular shadows projecting over the both
side buttock area, which may be due to old injection granuloma or bone
island of the ilium. please correlate with clinical history.</li>
</ul></li>
<li>2022-11-25 Chest supine view
<ul>
<li>Widening of the right upper mediastinum is noted, which may be due
to torturous innomiate vessel or tumor. Please correlate with standing
p-a view or CT.</li>
<li>Borderline cardiomegaly</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion?</li>
</ul></li>
<li>2022-11-25 Chest plain film
<ul>
<li>Unremarkable change in the visible trachea</li>
<li>cardiomegaly; mediastinal widening.</li>
<li>Lung markings: unremarkable.</li>
<li>Normal bilateral hemidiaphrams</li>
<li>Clear bilateral costophrenic angles</li>
<li>Unremarkable change in bilateral clavicles</li>
</ul></li>
<li>2022-06-05 CT - abdomen (at Shin Kong Hospital)
<ul>
<li>Tumor location: U-M/3 rectum</li>
<li>Tumor size: Measurable: around 3.5-cm (largest diameter)</li>
<li>Tumor invasion: T4b, transmural, right adnexal to right uteirne
border.</li>
<li>Regional nodal metastasis: N2, five nodes along IMA.</li>
<li>Distant metastasis (In this study): No Other findings: small nodes
around IMA orifice level of aorta/IVC.</li>
<li>Impression :
<ul>
<li>Locally invasive U-M/3 rectal cancer, T4bN2M0 stage with segmental
obstructive colitis.</li>
<li>Questionable small nodes around IMA orifice level of aorta/IVC.</li>
<li>CBD dilatation with sludge.</li>
<li>A-colon diverticulae.</li>
<li>Uneven fatty liver with S5 cyst.</li>
<li>L3-5 spinal stenosis with left L4-5</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-18" class="section level3">
<h3>==========</h3>
</div>
<div id="section-19" class="section level3">
<h3>2022-12-26</h3>
<p>[ABX use evaluation]</p>
<p>For most adults, the initial recommended antifungal treatment is an
echinocandin (caspofungin, micafungin, or anidulafungin) given through
the vein. Fluconazole, amphotericin B, and other antifungal medications
may also be appropriate in certain situations.</p>
</div>
<div id="section-20" class="section level3">
<h3>2022-11-28</h3>
<ul>
<li>Based on the recent diagnosis and prescription in the PharmaCloud,
the patient should have underlying conditions such as CKD stage 3
(N18.3), lumbar region spondylosis with radiculopathy (M4726),
cardiovascular promblem (nicorandil, bisoprolol, spironolactone), and
diabetes (vildagliptin, gliclazide).</li>
<li>Nicorandil and bisoprolol have been added to the active prescription
as patient-carried items and regular insulin 2 units BID is being used,
both the blood pressure and blood sugar levels are within acceptable
ranges.</li>
<li>As of 2022-11-28, the eGFR is 72.1, so there is no need to adjust
the dosage.</li>
<li>The elevated CRP level is decreasing (4.63mg/dL 2022-11-28 &lt;-
13.09ng/dL 2022-11-25), which might suggest a mitigation in the
condition.</li>
<li>The active prescription does not pose an issue.</li>
</ul>
</div>
</div>
</div>
<div id="section-21" class="section level1">
<h1>700864309</h1>
<div id="section-22" class="section level2">
<h2>221222</h2>
<ul>
<li>exam findings
<ul>
<li>2022-12-09 SONO - urology
<ul>
<li>Right renal stone</li>
<li>Right renal cyst</li>
</ul></li>
<li>2022-12-09 Bladder Sonography
<ul>
<li>PVR: 22.8ml (PVR = postvoided residual)</li>
</ul></li>
<li>2022-12-09 TRUS-P, Transrectal Ultrasound of Prostate
<ul>
<li>Benign prostatic hyperplasia</li>
</ul></li>
<li>2022-11-23 Patho - stomach biopsy
<ul>
<li>Labeled as “30cm below the incisors”, Biopsy (B) — benign
hyperplastic squamous mucosa.</li>
<li>Stomach, antrum. Biopsy (A) — Chronic gastritis, H pylori
present</li>
</ul></li>
<li>2022-11-23 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesions in the left soft palate, compatible
with the primary malignant neoplasm of soft palate.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral cervical lymph nodes,
highly suspected cancer with regional lymph nodes metastases.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral pulmonary hilar regions,
probably reactive nodes.<br />
</li>
<li>Malignant neoplasm of soft palate, no evidence of distant
metastasis, by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2022-11-22 MRI - nasopharynx
<ul>
<li>Indication: soft palate cancer</li>
<li>MRI of the head and neck in multiplanar projections, multisequence
imaging acquisition without and with IV Gd-DTPA administration shows:
<ul>
<li>A left soft palate tumor, extending to right, up to 3 cm.</li>
<li>Enlarged bil. neck LNs.</li>
<li>After IV contrast administration shows well or heterogenous
enhancement of the mass or tumor and LNs.</li>
</ul></li>
<li>IMP:
<ul>
<li>Left soft palate tumor, T2N2M0 stage II (P16+), IVA (P16-).</li>
</ul></li>
<li>Imaging Report Form for Oropharynx Carcinoma
<ul>
<li>Impression (Imaging stage): T:T2(T_value) N:N2(N_value)
M:M0(M_value) STAGE:II (P16+), IVA(P16-)(Stage_value)<br />
</li>
</ul></li>
</ul></li>
<li>2022-11-22 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Hiatal hernia.</li>
<li>Esophageal ulcer, M/3, s/p biopsy (B)</li>
<li>Superficial gastritis, s/p CLO test</li>
<li>Gastric shallow ulcers, antrum, s/p biopsy (A)</li>
<li>CLO test: Positive</li>
</ul></li>
<li>2022-11-22 Pulmonary flow volume loop
<ul>
<li>Mild to moderate obstructive ventilatory impairment</li>
</ul></li>
<li>2022-11-22 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (99 - 24) / 99 = 75.76%
<ul>
<li>M-mode (Teichholz) = 76</li>
</ul></li>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Dilated both atria and RV, grade 1 LV diastolic dysfunction</li>
<li>Mild AR, MR, and PR, moderate to severe TR</li>
<li>Pulmonary hypertension</li>
</ul></li>
<li>2022-11-21 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Voltage criteria for left ventricular hypertrophy</li>
<li>ST &amp; T wave abnormality, consider anterolateral ischemia</li>
</ul></li>
<li>2022-11-21 CXR
<ul>
<li>No cardiomegaly</li>
<li>Tortuosity of the aorta with atherosclerotic change.</li>
<li>Increased lung markings over both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-11-16 Patho - nasopharyngeal/oropharyngeal biopsy
<ul>
<li>Tumor, soft palate, biopsy — Compatible with squamous cell carcinoma
and candidiasis</li>
<li>The specimen submitted consisted of three small pieces of tumor
tissue measuring up to 0.5 x 0.3 x 0.2 cm in size, fixed in formalin.
Grossly, they were gray in color and soft in consistence. All embedded
for sections in one cassette.</li>
<li>Microscopically, the sections show a picture of ulcer with fungal
hyphae and spores, morphology consistent with candidiasis and high grade
(severe) dysplasia with pleomorphic and hyperchromatic nuclei and
dyskeratosis. However, no convincing stromal tissue included in the
limited specimen. According to histopathologic finding and clinical
information (Show Chwan Memorail Hospital: pathlology revealed
malignancy. Uvula, biopsy — Squamous cell carcinoma, moderately
differentiated), it is compatible with squamous cell carcinoma,
moderately differentiated. Closely follow up</li>
<li>Immunohistochemistry of P16(-)</li>
</ul></li>
<li>2022-11-15 Nasopharyngoscopy
<ul>
<li>soft palate cancer</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-24 Radiation Oncology
<ul>
<li>Q
<ul>
<li>After admitted, MRI showed : left soft palate tumor, T2N2M0. Abd
echo showed some parts of pancreas blocked by bowel gas, especially head
and tail. PES showed reflux esophagitis LA Classification grade A.
Superficial gastritis, and gastric shallow ulcers. Under the impression
of soft palate cancer, cT2N2M0, HPV pending, we suggest him to recevied
surgery or CCRT. His daughter need opinion for radiotherpy. We need your
help for further evaluation. Thank you very much!!</li>
</ul></li>
<li>A
<ul>
<li>He has no genuine teeth now. CT-simulation will be arranged on
20221130. Plan to deliver 50 Gy/ 25 fx to the bil. neck lymphatic
drainage area and orophayrnx. Then boost the soft palate tumor and LAPs
to 70 Gy/ 35 fx. RT will start around 20221202 or 20221205. Thank you
very much.</li>
</ul></li>
</ul></li>
<li>2022-11-24 Cardiology
<ul>
<li>Q
<ul>
<li>This is a 91-year-old man with underlying hypertension and coronary
artery disease under medication control for many years. No operation
history. He had odynophagia for 3 months. Soft palate cancer was told at
Show Chwan Hospital. He admitted to our ENT OPD for cancer work up.
After work up, soft palate cancer stage IV was diagnosed.</li>
<li>We also arrange 2D echo which revealed Dilated both atria and RV,
grade 1 LV diastolic dysfunction, mild AR, MR, and PR, moderate to
severe TR, pulmonary hypertension. PFT showed: Mild to moderate
obstructive ventilatory impairment.</li>
<li>We request your consultation for further evaluation.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This patient suffered from soft palate cancer and was admitted to
our hospital for evaluation about the treatment, including surgical,
chemotherapy or radiotherapy. After admission, noted to have mild to
modeate pulmonary hypertension while pre-OP heart function survey and CV
had been consulted. However, they changed mind about surgical tratment
and preferred CCRT at the meantime.</li>
</ul></li>
<li>O
<ul>
<li>Lung function test: Mild to moderate obstructive ventilatory
impairment</li>
<li>EChocardiography: M-mode(Teichholz) = 76; TR: moderate to severe;
Max pressure gradient = 38 mmHg
<ul>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Dilated both atria and RV, grade 1 LV diastolic dysfunction</li>
<li>Mild AR, MR, and PR, moderate to severe TR</li>
<li>Pulmonary hypertension</li>
</ul></li>
</ul></li>
<li>Diagnosis:
<ul>
<li>mild to moderate pulmonary hypertension</li>
</ul></li>
<li>Suggestion:
<ul>
<li>This patient currently had no signs of dyspnea, acute heart failure
sign or chest pain. Since preserved LV systolic dysfunction noted, there
was no acute contra-indication for surgical intervention.
<ul>
<li>If surgical treatment was arranged, may try pre-operative statin to
prevent CAD attack, e.g. Short-term Atorvastatin 1/2# ~1# QD (20mg)</li>
</ul></li>
<li>Since the pulmonary hypertension was only mild to moderate, and
patient had no active symptom, conservative management and search for
underlying cause are recommended.
<ul>
<li>The most obvious cause of pulmonary hypertension might be lung
disease, since patient’s tricuspid valve showed no thickening at the
meantime</li>
<li>Suspected Group 3: Pulmonary Hypertension Due to Lung Disease
<ul>
<li>may arrange chest CT to evaluate the lung parenchymal (group 3) and
with contrast for pulmonary artery (artery intimal narrow, group 1 or
thrombus group 4)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-14 - Erbitux (cetuximab) 250mg/m2 400mg 2hr (CCRT) dose 400
&lt;- 600
<ul>
<li>premed - betamethasone 4mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-12-14 - Erbitux (cetuximab) 400mg/m2 600mg 2hr (CCRT)
<ul>
<li>premed - betamethasone 4mg + diphenhydramine 30mg</li>
</ul></li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Cetuximab-Containing Combinations in Locally Advanced and Recurrent
or Metastatic Head and Neck Squamous Cell Carcinoma (Front. Oncol., 20
May 2019 <a href="https://doi.org/10.3389/fonc.2019.00383" class="uri">https://doi.org/10.3389/fonc.2019.00383</a>)
<ul>
<li>Cetuximab remains to date the only targeted therapy approved for the
treatment of head and neck squamous cell carcinoma (HNSCC). The EGFR
pathway plays a key role in the tumorigenesis and progression of this
disease as well as in the resistance to radiotherapy (RT). While several
anti-EGFR agents have been tested in HNSCC, cetuximab, an IgG1 subclass
monoclonal antibody against EGFR, is the only drug with proven efficacy
for the treatment of both locoregionally-advanced (LA) and
recurrent/metastatic (R/M) disease. The addition of cetuximab to
radiotherapy is a validated treatment option in LA-HNSCC. However, its
use has been limited to patients who are considered unfit for standard
of care chemoradiotherapy (CRT) with single agent cisplatin given the
lack of direct comparison of these two regimens in randomized phase III
trials and the inferiority suggested by metanalysis and phase II
studies. The current use of cetuximab in HNSCC is about to change given
the recent results from randomized prospective clinical trials in both
the LA and R/M setting. Two phase III studies evaluating RT-cetuximab
vs. CRT in Human Papillomavirus (HPV)-positive LA oropharyngeal squamous
cell carcinoma (De-ESCALaTE and RTOG 1016) showed inferior overall
survival and progression-free survival for RT-cetuximab combination, and
therefore CRT with cisplatin remains the standard of care in this
disease. In the R/M HNSCC, the EXTREME regimen has been the standard of
care as first-line treatment for the past 10 years. However, the results
from the KEYNOTE-048 study will likely position the anti-PD-1 agent
pembrolizumab as the new first line treatment either alone or in
combination with chemotherapy in this setting based on PD-L1 status.
Interestingly, cetuximab-mediated immunogenicity through antibody
dependent cell cytotoxicity (ADCC) has encouraged the evaluation of
combined approaches with immune-checkpoint inhibitors in both LA and
R/M-HNSCC settings. This article reviews the accumulated evidence on the
role of cetuximab in HNSCC in the past decade, offering an overview of
its current impact in the treatment of LA and R/M-HNSCC disease and its
potential use in the era of immunotherapy.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>During the past month, the patient’s liver and kidney functions
have declined.</p>
<ul>
<li>Creatinine
<ul>
<li>2022-12-21 Creatinine 2.06 mg/dL<br />
</li>
<li>2022-12-14 Creatinine 1.58 mg/dL<br />
</li>
<li>2022-11-21 Creatinine 1.29 mg/dL<br />
</li>
</ul></li>
<li>BUN
<ul>
<li>2022-12-21 BUN 67 mg/dL<br />
</li>
<li>2022-12-14 BUN 51 mg/dL<br />
</li>
<li>2022-11-21 BUN 34 mg/dL<br />
</li>
</ul></li>
<li>S-GPT/ALT
<ul>
<li>2022-12-21 S-GPT/ALT 89 U/L<br />
</li>
<li>2022-12-14 S-GPT/ALT 54 U/L<br />
</li>
<li>2022-11-21 S-GPT/ALT 10 U/L<br />
</li>
</ul></li>
<li>S-GOT/AST
<ul>
<li>2022-12-21 S-GOT/AST 51 U/L<br />
</li>
<li>2022-12-14 S-GOT/AST 36 U/L<br />
</li>
<li>2022-11-21 S-GOT/AST 19 U/L</li>
</ul></li>
</ul></li>
<li><p>As the patient’s CrCl level is 17 mL/min according to the
Cockcroft-Gault formula, it is recommended that the dosage of
clarithromycin and amoxicillin be halved.</p></li>
<li><p>For patients with severely impaired kidney function, neither
cisplatin nor carboplatin is recommended. Cetuximab is being
administered as part of the patient’s treatment with CCRT.</p></li>
<li><p>In this patient, transthoracic echocardiography (2022-11-22)
revealed dilated atria and RV, grade 1 LV diastolic dysfunction, mild
AR, MR, and PR, moderate to severe TR, and pulmonary hypertension.
Cardiopulmonary arrest or sudden death occurred in patients with
squamous cell carcinoma of the head and neck receiving cetuximab with
radiation therapy or a cetuximab product with platinum-based therapy and
fluorouracil. It is recommended to closely monitor serum electrolytes,
including magnesium, potassium, and calcium, during and after cetuximab
administration.</p></li>
</ul>
</div>
</div>
<div id="section-23" class="section level1">
<h1>701448280</h1>
<div id="section-24" class="section level2">
<h2>221222</h2>
<p>{not completed}</p>
<ul>
<li>exam findings
<ul>
<li>2022-11-23 PD-L1 IHC
<ul>
<li>Tumor cell (TC) staining assessment: TC &gt;= 10% and &lt; 50%</li>
<li>Percentage of 28-8 expressing tumor cells (%TC): 30%</li>
</ul></li>
<li>2022-11-23 PD-L1 22C3
<ul>
<li>Tumor Proportion Score(TPS) assessment: &lt;1%
<ul>
<li>Tumor Proportion Score(TPS): &lt;1%</li>
</ul></li>
<li>Combined Positive Score(CPS) assessment: &lt;1
<ul>
<li>Combined Positive Score(CPS): &lt;1</li>
</ul></li>
</ul></li>
<li>2022-11-23 PD-L1 SP142
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana)
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percentage of PD-L1 expressing tumor cells (%TC): &lt; 1 %</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC &lt;
1%</li>
<li>Proportion of tumor area occupied by PD-L1 expressing
tumor-infiltrating immune cells (% IC): &lt; 1 %</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
<li>2022-11-15 CT - abdomen
<ul>
<li>Regression of prior seen liver dome marginal enhanced tumor as
compare with CT study on 2022-09-03.</li>
<li>Liver cirrhosis.</li>
<li>Paraaortic and mesentery lymph nodes.</li>
<li>Left lower lung nodule, suspected lung metastasis.</li>
</ul></li>
<li>2022-11-14 Nasopharyngoscopy
<ul>
<li>no obvious tumor mass noticed over hupopharynx</li>
</ul></li>
<li>2022-10-04 Patho - stomach biopsy
<ul>
<li>Stomach, upper body, biopsy — Chronic gastritis, H pylori NOT
present</li>
</ul></li>
<li>2022-10-03 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Hypopharyngeal cancer, post CCRT, with esophageal inlet
involvement</li>
<li>Esophageal varices, F1CbLi, RCS(-)</li>
<li>Superficial gastritis, s/p CLO test and biopsy at LC of upper
body</li>
<li>Suspected Portal hypertensive gastropathy</li>
<li>Shallow duodenal ulcer, bulb</li>
<li>R/O Papillitis or periampullary lesion</li>
<li>Failure of endoscopy-guided NG insertion</li>
</ul></li>
<li>Suggestion
<ul>
<li>Suggest surgical gastrostomy</li>
<li>Correlate with other clinical data for the endoscopic finding of
enlargement of papilla</li>
</ul></li>
</ul></li>
<li>2022-09-08 CT - abdomen
<ul>
<li>In favor of liver, lung and LNs metastases.</li>
</ul></li>
<li>2022-09-02 Whole body PET scan
<ul>
<li>Glucose hypermetabolism involving the right and posterior aspects of
the hypopharynx with invasion to the the right thyroid cartilage and
proximal portion of the esophagus, compatible with advanced
hypopharyngeal malignancy. Please correlate with other clinical findings
for further evaluation.</li>
<li>Glucose hypermetabolism in multiple bilateral neck lymph nodes,
compatible with metastatic lymph nodes.</li>
<li>Glucose hypermetabolism in a a focal area in the dome of liver.
Either liver metastasis or primary liver malignancy may show this
picture.</li>
<li>Mild glucose hypermetabolism in the soft palate. The nature is to be
determined. Please correlate with other clinical findings for further
evaluation.<br />
</li>
<li>Mild to moderate glucose hypermetabolism in the distal portion of
the esophagus and mild glucose hypermetabolism in a focal area in the
anterior aspect of right lower lung field. The nature is also to be
determined (inflammatory process? other nature?). Please also correlate
with other clinical findings for further evaluation.</li>
</ul></li>
<li>2022-09-01 MRI - larynx
<ul>
<li>Imaging Report Form for Hypopharynx Carcinoma
<ul>
<li>Impression (Imaging stage) : T:T4(T_value) N:N3(N_value)
M:M0(M_value) STAGE:____(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-09-01 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Propable Cirrhosis</li>
<li>Suspected regenerative nodules,bil</li>
<li>Right pleural effusion ,mild</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Please correlate with other image</li>
<li>Follow liver function test and AFP,HBV,HCV</li>
<li>Some area of liver,especially liver dome and S1 was diffcult to
approach and easy missed</li>
<li>Because of cirrhosis ,infiltrative lesion or small lesion may not be
excluded completely. Please correlate with other image or follow sono
abd every 3-6 months</li>
</ul></li>
</ul></li>
<li>2022-09-01 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Hypopharygeal lesion extended to upper esophagus</li>
<li>Esophageal varices, F2CbLm</li>
<li>Duodenal ulcer scar, bulb</li>
<li>Portal hypertensive gastropathy</li>
</ul></li>
<li>Suggestion
<ul>
<li>Suspected liver cirrhosis</li>
</ul></li>
</ul></li>
<li>2022-08-22 Patho - nasopharyngeal/oropharyngeal biopsy
<ul>
<li>DIAGNOSIS
<ul>
<li>Soft palate, right, biopsy— squamous cell carcinoma, moderately
differentiated (p16: -)</li>
<li>Posterior pharyngeal wall tumor, right, biopsy— high-grade dysplasia
(p16: -)</li>
</ul></li>
<li>Microscopically, section A shows moderately differentiated squamous
cell carcinoma consisting of proliferation of atypical squamous cells
with focal stromal invasion and areas of dyskeratosis. The tumor cells
have abundant eosinophilic cytoplasm, round to oval nuclei, prominent
nucleoli, pleomorphism, hyperchromasia, higher necleus to cytoplasm
ratio and some mitiotic activity. Section B show a small piece of
high-grade dysplastic squamous cells.</li>
<li>Immunohistochemical stain reverals p16(-).</li>
</ul></li>
<li>2022-08-22 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>smooth nasopharynx, bulging of right lateral pharyngeal wall with
obliteration of right pyriform sinus; posterior wall mass with partial
necrotic tissue; suspect R vocal cord palsy; poor visualization of
glottis.</li>
</ul></li>
<li>Diagnosis/Conclusion
<ul>
<li>suspect R hypopharyngeal cancer</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-05 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>We request your consultation for further management.</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>advanced hypopharyngeal malignancy with invasion to the the right
thyroid cartilage and proximal portion of the esophagus, cT:T4N3M0,
stage IVB, soft palate biopsy SCC</li>
<li>Propable Cirrhosis, Suspected regenerative nodules, bil, Right
pleural effusion, mild</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Since a case of iver cirrhosis, the primary tumor of liver is needed
to be considered. Triple phase liver CT and AFP would be helpful.</li>
<li>CCRT is indicated. Then, consult RT for further evaluation.</li>
<li>May arrange my OPD if discharge.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-02 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>This 50 y/o man is a case of hypopharyngeal cancer. The patient
suffered from lumping throat on and off and hoarseness for 2 weeks. Body
weight loss was noted too. He had smoking habit 1 pack/day, beer about 3
bottle/day, and betel nuts about 2pack/day.</li>
<li>He was admission due to right vocal palsy and soft palate tumor
biopsy revealed: soft palate squamous cell carcinoma, moderately
differentiated (p16: -); posterior pharyngeal wall high-grade dysplasia
(p16: -).</li>
<li>After admission, cancer work up was arranged. The neck MRI on 9/1
which revealed the tumor invasion to hypopharynx, thyroid cartilage,
cricoid cartilage and extended to esophagus, cT4bN3M0, stage IVB. The
abdominal sono revealed suspect liver cirrhosis, and right pleural
effusion.</li>
<li>We request your consultation for pre-chemotherapy dental
evaluaion.</li>
</ul></li>
<li>A
<ul>
<li>For pre-chemotherapy dental evaluaion.</li>
<li>O:
<ul>
<li>Hopeless tooth of 11, 21, 28, 43, 44, 45 were noted.</li>
<li>Panoramic film revealed severe periodontitis of full mouth.</li>
<li>Severe poor oral hygiene.</li>
</ul></li>
<li>P:
<ul>
<li>Take panoramic X-ray film to check up.</li>
<li>Explain findings and treatment plan to the patient and his
brother.</li>
<li>Suggest extraction of tooth 11, 21, 28, 43, 44, 45 before
chemotherapy and radiotherapy.</li>
</ul></li>
<li>The risk of osteomyelitis after tooth extraction or implantation
after radiotherapy has been informed, the patient said that he did not
want to have the tooth extracted, and he had to think again</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-25" class="section level1">
<h1>700365018</h1>
<div id="section-26" class="section level2">
<h2>221221</h2>
<p>{not completed}</p>
<ul>
<li>lab data
<ul>
<li>2022-10-19 HBsAg (NMed) Negative<br />
</li>
<li>2022-10-19 HBsAg Value (NMed) 0.396<br />
</li>
<li>2022-10-19 Anti-HBc (NMed) Positive<br />
</li>
<li>2022-10-19 Anti-HBc Value (NMed) 0.00702<br />
</li>
<li>2022-10-19 Anti-HCV (NMed) Negative<br />
</li>
<li>2022-10-19 Anti-HCV Value (NMed) 0.0379</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-10-26 All-RAS + BRAF mutations assay
<ul>
<li>All-RAS: Detected (KRAS codon 12 GGT&gt;GTT, p.G12V</li>
<li>BRAF: There was no variant detected in the BRAF gene.</li>
</ul></li>
<li>2022-10-25 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the middle T-spines and some L-spines.
Degenerative change may show this picture. However, please correlate
with other imaging modalities for further evaluation and to rule out
other possibilities.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions and hips, compatible with benign joint
lesions.</li>
</ul></li>
<li>2022-10-24 Whole body PET scan
<ul>
<li>Increased FDG uptake in the rectal region and peripheral lymph
nodes, compatible with rectal cancer with regional lymph nodes
metastases.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral retromolar and
submandibular lymph nodes, the nature is to be determined (reactive
nodes, distant lymph nodes metastases, lymphoma, or others ?),
suggesting biopsy for investigation.<br />
</li>
<li>Increased FDG uptake in bilateral palatine tonsils, probably a
chronic inflammation/infection process.<br />
</li>
<li>Increased FDG uptake in bilateral pulmonary hilar and mediastinal
lymph nodes, probably reactive nodes.</li>
<li>Malignant neoplasm of rectum with regional lymph nodes metastases,
cTxN2M0, by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2022-10-18 CT - abdomen
<ul>
<li>Clinical history: 59 y/o male patient with rectal cancer.</li>
<li>With and without contrast enhancement CT of whole abdomen:
<ul>
<li>Thickening wall at the rectum, suspected rectal malignancy.</li>
<li>Presence of perirectal lymph nodes.</li>
<li>Unremarkable change of the liver, spleen, pancreas and both
kidneys.</li>
<li>No enlarged lymph node in the paraaortic region.</li>
<li>No ascites.</li>
<li>Fibrotic infiltrates in bilateral lung apex.</li>
<li>Suspicious right upper lung nodule, suggest follow up.</li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3(T_value) N:N2(N_value)
M:M0(M_value) STAGE: IIIC__(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-09-20 Patho - colon biopsy
<ul>
<li>Large intestine, rectum, 5cm to 10cm from anal verge, biopsy —
Adenocarcinoma, moderately differentiated</li>
<li>Specimen submitted in formalin consists of several pieces of tan,
irregular tissue measuring up to 0.3 x 0.2 x 0.1 cm.</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>The immunohistochemical stains reveal EGFR(+), PMS2(+), MLH1(+),
MSH2(+), and MSH6(+).</li>
</ul></li>
<li>2020-09-20 Colonoscopy
<ul>
<li>Findings
<ul>
<li>The scope reach the cecum under fair colon preparation. Many liquid
fece with seeds were noted, which blocked almost half of the colon.</li>
<li>One semi-annular rectal tumor was noted from 5cm AAV to 10cm AAV.
Biopsy was done.</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Highly suspected rectal cancer, s/p biopsy</li>
<li>Suboptimal study</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
<li>CRS OPD follow up</li>
<li>Small lesions may be missed due to suboptimal bowel
preparation.</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-20 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>After fully explained of the condition, pre-op CCRT first followed
by surgical treatment was suggested. We needs your expert experience for
evaluation of pre-op CCRT. Thanks a lot !!</li>
</ul></li>
<li>A
<ul>
<li>I would like to take over this case for neoadjuvant CCRT for his
rectal cancer with perirectal lymph nodes, cstage T3N2bM0.</li>
</ul></li>
</ul></li>
<li>2022-10-19 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This 59 y/o male patient sufferre from loose stool and blood in
stool for 1 year. Tumor maker with CEA showed 7.18 ng/mL. Colonscopy was
performed on 2022/09/20 and revealed highly suspected rectal cancer,
5~10 cm from anal verge, s/p biopsy. Biopsy pathology showed
adenocarcinoma, moderately differentiated. Lab data showed anemia (6.6
g/dL) and blood transfusion was done. Abdominal CT revealed rectal
cancer with perirectal lymph nodes, cstage T3N2bM0, stage IIIC.</li>
</ul></li>
<li>A
<ul>
<li>Pre-op CCRT is indicated. CT-simulation will be arranged on
20221024. Plan to deliver 45 Gy/ 25 fx to the pelvis. Then boost the
rectal tumor and LAPs to 50.4 Gy/ 28 fx. RT will start around 20221026
or 27.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-12-20 - oxaliplatin 85mg/m2 130mg 2hr + leucovorin 400mg/m2
620mg 2hr + fluorouracil 400mg/m2 620mg 2hr + fluorouracil 2400mg/m2
3700mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
3mg</li>
</ul></li>
<li>2022-12-06</li>
<li>2022-11-21</li>
<li>2022-11-07</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>According to the available lab data, the levels of MCV, MCH, and
MCHC have been frequently low since July 2022.</li>
<li>Low MCV, MCH, and MCHC can be caused by anemia which could include
iron-deficiency anemia and anemia due to chronic disease.</li>
<li>Thalassemia can also affect the production of hemoglobin, leading to
low MCV, MCH, and MCHC.</li>
<li>Foliromin (ferrous sodium citrate) has been prescribed since mid-Nov
2022, but the readings of the MCV, MCH, and MCHC have only shown a
minimal improvement.</li>
<li>As far as FOLFOX treatment is concerned, there are no issues.</li>
</ul>
</div>
</div>
<div id="section-27" class="section level1">
<h1>701446872</h1>
<div id="section-28" class="section level2">
<h2>221221</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-29, -11-03, -11-01 Body fluid cytology - ascites
<ul>
<li>negative</li>
</ul></li>
<li>2022-10-21 CT - abdomen
<ul>
<li>History: Gastric adenocarcinoma of proximal middle body great
curvature, metastasis to adjacent omentum pT4aN1M1 stage IV post total
gastrectomy with lymphadenectomy of station 1 to 12A and 14V, Retrocolic
Roux-en-Y anastomosis reconstruction with Endo GIA on 2022-09-07.</li>
<li>Findings:
<ul>
<li>S/P total gastrectomy.</li>
<li>S/P Jackson-Pratt drainage tube insertion from right and left
abdominal wall.</li>
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, pancreas, spleen &amp; both kidney.</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P total gastrectomy.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-09-08 Patho - stomach subtotal/total (tumor)
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Tumor, stomach, total gastrectomy — Poorly cohesive carcinoma</li>
<li>Margins, bilateral cutting ends, ditto — Free of tumor invasion</li>
<li>Lymph nodes, LN 1, ditto — Free of tumor metastasis (0/7)</li>
<li>Lymph nodes, LN 2, ditto — Free of tumor metastasis (0/7)</li>
<li>Lymph nodes, LN 3, ditto — Tumor metastasis (1/19) with isolated
tumor cells and tumor deposits</li>
<li>Lymph nodes, LN 4, ditto — Free of tumor metastasis (0/20)</li>
<li>Lymph nodes, LN 5, ditto — Free of tumor metastasis (0/1)</li>
<li>Lymph nodes, LN 6, ditto — Free of tumor metastasis (0/4)</li>
<li>Lymph nodes, LN 7,8,9,11,12, ditto — Free of tumor metastasis
(0/8)</li>
<li>Lymph nodes, LN 10, ditto — Free of tumor metastasis (0/5)</li>
<li>Lymph nodes, LN 14v, ditto — Fat only<br />
</li>
<li>Omentum, omentectomy — Free of tumor invasion</li>
<li>AJCC Pathologic staging — pT4aN1M1, stage IV</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Specimen type: Stomach, lymph node and omentum</li>
<li>Specimen size: 19.3 x 10.2 x 1.3 cm in size, 189 gm in weight</li>
<li>Number of lesions: Solitary</li>
<li>Tumor site: middle body, greater curvature</li>
<li>Tumor size: 1.2 x 0.8 cm</li>
<li>Tumor configuration: ulcerative tumor</li>
<li>Omentum: 38 x 16 x 1.2 cm, no significant change</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histologic type: Poorly cohesive carcinoma</li>
<li>Histologic grade: Grade 3, poorly differentiated</li>
<li>Depth of tumor invasion: serosa layer</li>
<li>Lymph nodes: tumor metastasis (1/71) in total number without
extracapsular extension</li>
<li>Omentum: free of tumor invasion</li>
<li>AJCC Pathologic Staging: pT4aN1M1</li>
<li>Bilateral resection margins: Free of tumor invasion</li>
<li>Additional pathologic findings: ulcer with mild intestinal
metaplasia</li>
<li>Perineural invasion: Present</li>
<li>Lymphovascular space invasion: Present</li>
<li>Immunohistochemical stains:
<ul>
<li>CAM5.2(+) for serosal invasion</li>
<li>CK(+) for isolate tumor cells within lymph node and tumor deposits
in LN3</li>
<li>HER2(-, Dako score 0 ) for tumor</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-22 CT - abdomen
<ul>
<li>Imaging Report Form for Gastric Carcinoma</li>
<li>Impression (Imaging stage): T:T1a(T_value) N:N0(N_value)
M:M0(M_value) STAGE:I(Stage_value)</li>
</ul></li>
<li>2022-08-16 Patho - stomach biopsy
<ul>
<li>Stomach, antrum to lower body, biopsy— chronic gastritis with
intestinal metaplasia. No H.pylori present
<ul>
<li>Microscopically, it shows chronic gastritis with lymphoplasmacytic
infiltrate and intestinal metaplasia. No Helicobacter-like bacillus is
seen.</li>
</ul></li>
<li>Stomach, middle body, biopsy— poorly differentiated adenocarcinoma
<ul>
<li>Microscopically, it shows poorly differentiated adenocarcinoma
composed of proliferation of atypical tumor cells arranged in solid
architecture. The tumor shows pabundant cytoplasm and pushing nuclei
with signet ring cell-like picture. No H.pylori is seen.</li>
<li>Immunohistochemical stain reveals CK(+) at tumor cells.</li>
</ul></li>
</ul></li>
<li>2022-08-15 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Esophageal phleboectasia, lower and middle esophagus</li>
<li>Chronic superficial gastritis, s/p CLO</li>
<li>Gastric ulcer, A2-H1, middle body, suspected dysplastic or malignant
lesion, s/p biopsy (A)</li>
<li>Probable intestinal metaplasia, antrum to lower body, s/p biopsy
(B)</li>
<li>Gastric xanthoma</li>
<li>Bile reflux in stomach</li>
</ul></li>
<li>Suggestion
<ul>
<li>PPI therapy</li>
<li>Pursue CLO test and pathology result</li>
<li>EGD follow-up is indicated</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-12 - oxaliplatin 50mg/m2 75mg 2hr + leucovorin 400mg/m2
600mg 2hr + fluorouracil 2500mg/m2 3700mg 46hr + [docetaxel 40mg/m2 60mg
+ cisplatin 30mg/m2 40mg + gentamicin 40mg + NaHCO3 2800mg] IP 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-11-29 - oxaliplatin 50mg/m2 75mg 2hr + leucovorin 400mg/m2
600mg 2hr + fluorouracil 2500mg/m2 3760mg 46hr + [docetaxel 40mg/m2 60mg
+ cisplatin 30mg/m2 40mg + gentamicin 40mg + NaHCO3 2800mg] IP 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-10-31 - oxaliplatin 50mg/m2 70mg 2hr + leucovorin 400mg/m2
625mg 2hr + fluorouracil 2500mg/m2 3800mg 46hr + [docetaxel 40mg/m2 60mg
+ cisplatin 30mg/m2 40mg + gentamicin 40mg + NaHCO3 2800mg] IP 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-10-21 - oxaliplatin 70mg/m2 100mg 2hr + leucovorin 400mg/m2
625mg 2hr + fluorouracil 2500mg/m2 4000mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
1mg</li>
</ul></li>
<li>2022-09-14 - mitomycin-c 16mg/m2 25mg 2hr D2 + [fluorouracil
500mg/m2 780mg + gentamicin 40mg + NaHCO3 2800mg] IP 1hr D1-5
<ul>
<li>premed - betamethasone 4mg</li>
</ul></li>
</ul></li>
</ul>
<div id="section-29" class="section level3">
<h3>==========</h3>
</div>
<div id="section-30" class="section level3">
<h3>2022-12-21</h3>
<ul>
<li>The bowl movement in this patient reached 3 times on 2022-12-20. It
is recommended to hold the Through (sennoside) temperately and monitor
the changes in the bowl movement these days.</li>
</ul>
</div>
</div>
</div>
<div id="section-31" class="section level1">
<h1>701464956</h1>
<div id="section-32" class="section level2">
<h2>221221</h2>
<p>{drug identification}</p>
<p>A request has been made for us to identify drugs for 10 items.</p>
<p>In total, 9 items have been identified as follows, with 1 item
remaining unidentified.</p>
<ul>
<li>Meptin-mini (procaterol 25mcg)</li>
<li>Nexium (esomeprazole 40mg)</li>
<li>Tareg (valsartan 80mg)</li>
<li>Norvasc (amlodipine 5mg)</li>
<li>Solaxin (chlorzoxazone 200mg)</li>
<li>Rovo (repaglinide 1mg)</li>
<li>Aricept (donepezil 10mg)</li>
<li>Gaslan (dimethicone 40mg)</li>
<li>Medicon-A (dextromethorphan 20mg)</li>
</ul>
<p>These drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-33" class="section level1">
<h1>701428029</h1>
<div id="section-34" class="section level2">
<h2>221220</h2>
<ul>
<li>diagnosis - 20221130 discharge note
<ul>
<li>Malignant neoplasm of sigmoid colon</li>
<li>S-colon adenocarcinoma with reginal and distant lymph nodes and
hepatic metastasis, T4N2M1a, stage IV s/p T-colostomy.</li>
<li>hepatitis B anti-Hbc :positive</li>
</ul></li>
<li>past history
<ul>
<li>DM with diet control</li>
<li>Denied hypertension, CAD, CHF, Cancer</li>
<li>OP: Nil   </li>
</ul></li>
<li>family history
<ul>
<li>Denied hypertension, DM, CAD, CHF, Cancer history with famliy</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-09-22 CT - abdomen
<ul>
<li>History and indication: Malignant neoplasm of sigmoid colon</li>
<li>Findings
<ul>
<li>Mild regression of S-colon cancer with liver metastases. S/P
colostomy.</li>
<li>Renal cysts (up to 2.1cm).</li>
<li>Normal appearance of spleen, pancreas, adrenals.</li>
<li>Normal appearance of gallbladder.</li>
<li>Patency of portal vein.</li>
<li>Intact bony structures.</li>
<li>No ascites.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
<li>No abnormal density at bilateral basal lungs.</li>
</ul></li>
<li>IMP: -Mild regression of S-colon cancer with liver metastases.</li>
</ul></li>
<li>2022-06-29 CT - chest
<ul>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T4(T_value) N:N2(N_value)
M:M1b(M_value) STAGE:____(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-06-29 Patho - colon biopsy
<ul>
<li>Sigmoid colon, 20 cm AAV, biopsy — Adenocarcinoma</li>
<li>The sections show a picture of adenocarcinoma, composed of
moderately differentiated columnar to cuboidal neoplastic cells,
arranged in glandular and cribriform patterns with subtle desmoplastic
stromal reaction.</li>
</ul></li>
<li>2022-06-28 Sigmoidoscopy
<ul>
<li>Findings
<ul>
<li>The scope reach the 20cm AAV</li>
<li>One tumor with luminal narrowing was noted at S-colon (20cm AAV),
s/p biopsy</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Highly suspect colon cancer with luminal narrowing, S-colon (20cm
AAV), s/p biopsy</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-07 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 55y/o man with PMH of DM under diet control. This time he
was admitted due to S colon tumor with reginonal lymphadnopathy and
several hepatic metastasis. Due to poor intake and prominent obstructive
symptoms, after discussing with the patient, he underwent T-loop
colostomy and port A insertion. Now that the patient is relatively
stable with much improved of the previous symptoms, OP wound and
colostomy site with no infection signs, we would like to consult you for
further treatment.</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>Sigmoid colon cancer with regional and distant LNs and hepatic
metastases T4N2M1a s/p T-loop colostomy and port A insertion</li>
<li>COVID-19 infection</li>
<li>DM</li>
</ul></li>
<li>Suggestion:
<ul>
<li>We will discuss with patient about further chemotherapy. We may take
over this case</li>
<li>Pending AntiHbc, HbsAg, Anti-HCV, CEA data</li>
<li>Pening colon patholgy for MMR IHC stain (MLH1、MSH2、MSH6、PMS2) and
All RAS mutation survey</li>
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-30 T-loop colostomy</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-12-19 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
360mg 90min + leucovorin 400mg/m2 800mg 2hr + fluorouracil 2800mg/m2
5650mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-11-28 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
360mg 90min + leucovorin 400mg/m2 800mg 2hr + fluorouracil 2800mg/m2
5650mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-11-14 bevacizumab 5mg/kg 300mg 90min + irinotecan 180mg/m2
360mg 90min + leucovorin 400mg/m2 800mg 2hr + fluorouracil 2800mg/m2
5650mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-10-31 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
360mg 90min + leucovorin 400mg/m2 800mg 2hr + fluorouracil 2800mg/m2
5600mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-10-17 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
370mg 90min + leucovorin 400mg/m2 820mg 2hr + fluorouracil 2800mg/m2
5700mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-09-26 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
350mg 90min + leucovorin 400mg/m2 780mg 2hr + fluorouracil 2800mg/m2
5500mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-09-12 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
350mg 90min + leucovorin 400mg/m2 780mg 2hr + fluorouracil 2800mg/m2
5500mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-08-29 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
340mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 2800mg/m2
5320mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-08-16 bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
340mg 90min + leucovorin 400mg/m2 750mg 2hr + fluorouracil 2800mg/m2
5320mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 2mg
+ atropine 1mg</li>
</ul></li>
<li>2022-08-03 irinotecan 180mg/m2 330mg 90min + leucovorin 400mg/m2
750mg 2hr + fluorouracil 2800mg/m2 5275mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 3mg
+ atropine 1mg + aprepitant 125mg PO</li>
</ul></li>
<li>2022-07-20 irinotecan 180mg/m2 330mg 90min + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5200mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 3mg
+ atropine 1mg + aprepitant 125mg PO</li>
</ul></li>
<li>2022-07-05 irinotecan 160mg/m2 290mg 90min + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5200mg 46hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 3mg
+ atropine 1mg + aprepitant 125mg PO</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-35" class="section level1">
<h1>701006949</h1>
<div id="section-36" class="section level2">
<h2>221219</h2>
<p>{not completed}</p>
<ul>
<li>exam findings
<ul>
<li>2022-12-12 Chest PA + Lat LT
<ul>
<li>Diffuse osteoblastic change of the T-and L-spine are suspected.
Please correlate with bone scan.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-10-24 - Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>The Tc-99m MDP bone scan with SPECT at 3 hrs after injection of 20
mCi radiotracer revealed inhomogenously increased activity in the skull,
multiple C-, T- and L-spines, sternum, bilateral multiple ribs,
clavicles, sacrum, bilateral multiple pelvic bones, bilateral S-I
joints, humeri and femurs.</li>
<li>IMPRESSION: Some of the previous bone lesions including the left rib
cage, some T- and L-spine, right S-I joint, and left femoral trochanters
come to slightly more evident compared with the previus study on
2022-03-31, suggesting metastatic bone disease in progression.</li>
</ul></li>
<li>2022-10-13 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>Increased pulmonary vasculature is found.</li>
</ul></li>
<li>2022-10-12 CT - abdomen
<ul>
<li>Findings:
<ul>
<li>There is a newly-developed hypodense lesion 1 cm in S4/8 dome of the
liver at non-enhanced CT and that may be metastasis? Please correlate
with MRI.</li>
<li>Presence of gallbladder stone.</li>
<li>There are few hyperdense lesions in the distal CBD that are c/w
distal CBD stones.</li>
<li>Bilateral renal cysts (up to 1.1 cm).</li>
<li>Diffuse osteoblastic bony metastases with L2 compression
fracture.</li>
<li>S/P colostomy at the sigmoid colon.</li>
<li>s/p Abdominal-perineal resection.</li>
</ul></li>
<li>Impression:
<ul>
<li>Metastasis 1 cm in S4/8 of the liver is highly suspected. Please
correlate with MRI.</li>
<li>Few gallstones and distal CBD stones.</li>
</ul></li>
</ul></li>
<li>2022-03-31 Tc-99m MDP whole body bone scan
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi
radiotracer revealed inhomogenously increased activity in the skull,
multiple C-, T- and L-spines, sternum, bilateral multiple ribs,
clavicles, sacrum, bilateral multiple pelvic bones, bilateral S-I
joints, humeri and femurs.</li>
<li>IMPRESSION: The scintigraphic findings are compatible with diffuse
bone metastases.</li>
</ul></li>
<li>2022-03-01 KUB
<ul>
<li>Presence of ileus.</li>
<li>Heterogeneous density of bony structures.</li>
<li>Compression fracture of L2.</li>
<li>A calcified spot at RUQ.</li>
</ul></li>
<li>2022-02-24 Patho - colon segmental resection for tumors
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Lower rectum, laparoscopic abdominal perineal resection —-
Metastatic adenocarcinoma, compatible with prostatic acinar
adenocarcinoma, Gleason score 4 + 5 = 9, with rectum invasion<br />
</li>
<li>Bilateral resection margins — Free</li>
<li>Lymph node, mesocolic, dissection —- Tumor present (2/7) without
extracapsular extension (0/2)</li>
<li>AJCC 8th edition Pathology stage (prostatic cancer) — pT4N1(cM1b: by
CT finding), stage IVB</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Operation procedure: laparoscopic abdominal perineal resection</li>
<li>Specimen site: lower rectum, 1.5 cm above dentate line<br />
</li>
<li>Specimen size: 16.5 cm in length including a portion of skin
measuring 1.2 cm in length</li>
<li>Tumor size: annularly ulcerated, 4.5 x 2.5 cm</li>
<li>Tumor location: 8.5 cm and 4.0 cm away from the two resection
margins, respectively<br />
</li>
<li>Depth of invasion grossly: perirectal fat tissue<br />
</li>
<li>Mucosa elsewhere: congestion, ulcer</li>
<li>Another segment of unremarkable colon measuring 6.5 cm in length is
reveived</li>
<li>Representative sections are taken and labeled as: A1-2: bilateral
resection margin; A3: colon, non-tumor; A4-9: tumor; A10-13 and X1-30:
lymph node, mesocolic.</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology: prostatic acinar adenocarcinoma, Gleason score 4 + 5 =
9</li>
<li>Depth of invasion: rectal wall to mucosa</li>
<li>Angiolymphatic invasion: Present</li>
<li>Perineural invasion: Present.<br />
</li>
<li>Lymph node metastasis, mesocolic: tumor present (2/7)</li>
<li>Extranodal involvement: Not identified<br />
</li>
<li>Pathologic Stage Classification (prostatic cancer): pT4N1 (cM1b: by
CT finding), stage IVB</li>
<li>Type of polyp in which invasive carcinoma arose: N/A<br />
</li>
<li>Immunohistochemistry: EGFR(+), CK7(-), CK20(-), PSA(+, focal),
CDX-2(+), CD56(-)</li>
</ul></li>
</ul></li>
<li>2022-01-25 CT - abdomen
<ul>
<li>S/P colostomy. Suggest follow up.</li>
<li>Lymph nodes in the mediastinum and right hilar region, suspected
lymph node metastasis. Stationary.</li>
<li>Gallbladder stone.</li>
<li>Intralumal hyperdense lesions in the CBD, suspected CBD stones.</li>
<li>Bilateral renal cysts.</li>
<li>Ascending colon diverticula.</li>
<li>Bone metastasis. L2 compression fracture.</li>
</ul></li>
<li>2022-01-25 CXR
<ul>
<li>Ground glass opacity in LLL.</li>
<li>Interstitial pattern at right lung.</li>
<li>Presence of ileus.</li>
<li>Heterogeneous density of bony structures.</li>
</ul></li>
<li>2022-01-07 Bronchodilator Test
<ul>
<li>Mild obstructive ventilatory impairment with significant
bronchodilator response</li>
</ul></li>
<li>2022-01-07 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (105 - 29) / 105 = 72.38%
<ul>
<li>M-mode (Teichholz) = 73</li>
</ul></li>
<li>Normal LV filling pressure; mild RV hypertrophy with impaired RV
relaxation.</li>
<li>Normal LV and RV systolic function.</li>
<li>Aortic valve sclerosis with trivial AR; mild TR.</li>
<li>Dilated aortic root and proximal ascending aorta (38mm) with mild
calcification.</li>
</ul></li>
<li>2021-11-22, -11-03 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
</ul></li>
<li>2021-10-12 Patho - colon biopsy
<ul>
<li>Colon tumor, 1 cm above dentate line, biopsy — Adenocarcinoma,
pooylr differentiated<br />
</li>
<li>Microscopically, the sections show a picture of
poorly-differentiated adenocarcinoma characterized by nest or individual
tumor cells infiltration.</li>
<li>Immunohistochemistry shows CK(+); MLH1(+), MSH2(+), MSH6(+) and
PMS2(+) for tumor cells.<br />
</li>
</ul></li>
<li>2021-10-12 Colonoscopy
<ul>
<li>Rectal tumor, 1cm above dentate line, with luminal narrowing, s/p
biopsy</li>
<li>Mixed hemorrhoid</li>
</ul></li>
<li>2021-10-07 CT - abdomen
<ul>
<li>History and indication: suspected colon cancer survey</li>
<li>Findings
<ul>
<li>Enlargement of prostate.</li>
<li>Wall thickening of rectum with adjacent fat stranding.</li>
<li>Multiple bony metastases.</li>
<li>Some LNs at pelvic cavity and paraaortic region.</li>
<li>A calcified spot (1.2cm) at gallbladder fossa.</li>
<li>Small renal cysts.</li>
<li>Left minimal pleural effusion. Some ground glass opacities at bil.
lungs. A nodule at LLL.</li>
<li>Gallbladder stone (0.8cm).</li>
<li>Atherosclerosis of aorta, iliac, coronary arteries.</li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3(T_value) N:N2a(N_value)
M:M1b(M_value) STAGE:IVB(Stage_value)</li>
</ul></li>
</ul></li>
<li>2021-09-29 MRI - L-spine
<ul>
<li>Bony metastasis in T12-S4 vertebral bodies and bilateral iliac
wings.</li>
<li>Multiple para-aortic metastatic LAPs.</li>
<li>Lumbar spondylosis.</li>
</ul></li>
<li>2021-09-28 CT - chest
<ul>
<li>no evidence lung infection. moderate centrilobular emphysema in both
upper lobes of lungs. no lung tumor.</li>
<li>extensive bony lesion, metastasis or hematogical disorder.</li>
<li>extensive LAD CAD.</li>
</ul></li>
<li>2021-09-23 CXR
<ul>
<li>Tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch and D-aorta. dilated ascending aorta?</li>
<li>mild enlarged cardiac silhoutte</li>
<li>Platelike lung atelectasis over Rt midlung zone hazy areas of
increased opacity (ground-glass opacitie) over Lt lower lung zone</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-14 - Abraxane (nab-paclitaxel) 75mg/m2 100mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron 1mg
(palliative, for prostate cancer)</li>
</ul></li>
<li>2021-12-06 - fluorouracil 200mg/m2 340mg 24hr D1-D2 (CCRT for
colorectal cancer)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2021-11-29 - fluorouracil 200mg/m2 340mg 24hr (CCRT for colorectal
cancer)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2021-11-22 - fluorouracil 200mg/m2 340mg 24hr D1-D2 (CCRT for
colorectal cancer)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2021-11-08 - fluorouracil 200mg/m2 340mg 24hr D1-D2 (CCRT for
colorectal cancer)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2021-11-01 - fluorouracil 200mg/m2 340mg 24hr D1-D2 (CCRT for
colorectal cancer)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-37" class="section level1">
<h1>701070156</h1>
<div id="section-38" class="section level2">
<h2>221219</h2>
<ul>
<li>diagnosis - 2022-11-09 discharge note
<ul>
<li>Malignant neoplasm of cervix uteri, unspecified</li>
<li>Carcinoma of the uterine cervix, stage T1N1M0, stage IIIB s/p CCRT
with recurrence and paraaortic lymph node metastasis with bone
invasion</li>
<li>hepatitis B of anti-Hbc : positive</li>
<li>Hyperkalemia</li>
<li>Hyponatremia</li>
</ul></li>
<li>family history
<ul>
<li>Mother died of cervical cancer when 53 y/o.</li>
<li>There is no family history of, hypertension, mental diseases or
asthma.</li>
<li>First older sister diagnosed of diabetes.</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-08, -10-31, -10-28, -09-22 KUB
<ul>
<li>Wedge deformity and total collapse at right lateral aspect of L4
vertebral body and suggestive osteolytic lesion at right lateral aspect
of L3 vertebral body are noted that are c/w bony metastase after
correlate with CT.</li>
<li>scoliosis of L-spine with convex to left side</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-11-07, -10-21, -09-26, -08-30 CXR
<ul>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-10-11 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower L-spines. Bone metastases should be
watched out.</li>
<li>Increased activity in the sacrum and right S-I joint. Either
degenerative change or bone metastases may show this picture. Please
correlate with other imaging modalities for further evaluation.</li>
<li>A faint hot spot in the anterior aspect of right 6th rib. The nature
is to be determined (post-traumatic change? other nature?). Please
follow up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, hips and knees,
compatible with benign joint lesions.</li>
</ul></li>
<li>2022-09-21 CT - abdomen
<ul>
<li>Findings
<ul>
<li>osteolytic lesions in right lateral aspect of L3 and L4 vertebral
bodies with right lateral extension and invasion to right psoas muscle,
about 122.8mm.</li>
<li>Tumor encasement of the right internal and external iliac arteries
was noted. Right hydornephrosis and right hydroureter were also
noted.</li>
</ul></li>
<li>IMP:
<ul>
<li>tumors in the right paraspinal region.</li>
<li>rihgt hydronephrosis and right hydroureter</li>
</ul></li>
</ul></li>
<li>2022-09-21 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Right bundle branch block</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-26 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Incomplete right bundle branch block</li>
<li>Cannot rule out Inferior infarct, age undetermined</li>
<li>ST &amp; T wave abnormality, consider anterior ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-19 CT - abdomen
<ul>
<li>History:
<ul>
<li>2022/08/18 right hip pain radiated to foot for a peroid of time</li>
<li>2021/11 visited our gyn OPD:
<ul>
<li>Carcinoma of the uterine cervix, stage T1N1M0, stage IIIB</li>
<li>Completion of radiotherapy on 2015-04-21. Suspicious paraaortic
lymph node metastasis.</li>
</ul></li>
<li>2021/11 MRI here showed suspect recurrence</li>
<li>She said she has received C/T at Tailand this year, result?</li>
</ul></li>
<li>Indication: Suspected recurrent tumor in right paraspinal region and
L3-4 invasion</li>
<li>MD CT of the abdomen and pelvis was performed with 0.625 mm
collimation &amp; 5 mm slice thickness reconstruction. Oral and rectal
contrast was not given for bowel opacification. CT images were obtained
during non-enhanced and portal venous phase scan following IV contrast
injection through autoinjector. Coronal reformated isotropic images were
obtained in portal venous phase scan.</li>
<li>Findings:
<ul>
<li>There is osteolytic lesion in right lateral aspect of L3 and L4
vertebral body with right lateral extension and invaded into right psoas
muscle, causing a heterogeneous poor enhancing soft tissue mass lesion
(the cranial-caudal diemsnion:12.5 cm) that is c/w bony metastasis.
<ul>
<li>In addition, right external iliac artery shows small size that is
c/w encasement by the metastatic mass in right psoas muscle.</li>
</ul></li>
<li>There is right side hydroureteronephrosis and the etiology is due to
passive comprssion of right M/3 ureter by the upper described metastatic
mass in right psoas muscle .</li>
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, pancreas, spleen &amp; both kidney.
<ul>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Bony metastases in L3 and L4 vertebral body with metastatic mass in
right psoas muscle.</li>
</ul></li>
</ul></li>
<li>2022-08-15 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae free</li>
<li>EM 2.5mm</li>
</ul></li>
<li>2021-11-29 MRI - pelvis
<ul>
<li>Clinical history: 56 y/o female patient with carcinoma of the
uterine cervix, stage T1N1M0, stage IIIB.</li>
<li>Cervical cancer s/p RT.</li>
<li>Infiltrative soft tissue tumor, 4.6x9.8cm in right paraspinal region
with L3-4 invasion, suspected metastasis.</li>
</ul></li>
<li>2021-11-25 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae free</li>
<li>EM 1.6mm</li>
</ul></li>
<li>2017-12-25 CT - pelvis
<ul>
<li>Clinical history: 52 y/o female patient with carcinoma of the
uterine cervix, stage T1N1M0, stage IIIB, hx of appendectomy/LC for
ectopic pregnancy.</li>
<li>Findings
<ul>
<li>Lymph node in left paraaortic region, up to 1.25cm, r/o metastatic
lymph node. Progression.</li>
</ul></li>
<li>Impression:
<ul>
<li>Cervical cancer s/p RT, progression of paraaortic lymph node
(1.25cm).</li>
</ul></li>
</ul></li>
<li>2017-07-20 CT - pelvis
<ul>
<li>Clinical history: 52 y/o female patient with carcinoma of the
uterine cervix, stage T1N1M0, stage IIIB, hx of appendectomy∕LC for
ectopic pregnancy.</li>
<li>Findings
<ul>
<li>Lymph node in left paraaortic region, up to 1.03cm, r/o metastatic
lymph node.</li>
</ul></li>
<li>Impression:
<ul>
<li>Cervical cancer s/p RT, regression of pelvic lymph nodes. But
presence of paraaortic lymph node, 1.03cm, suggest follow up study.</li>
</ul></li>
</ul></li>
<li>2017-06-26 Mammography
<ul>
<li>Impression: No mammographic evidence of malignancy, suggest clinical
correlation and regular follow up.</li>
<li>BI-RADS: Category 1: negative. - annual screening.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-29 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Patient could not understand our language very well. She said she
has received C/T and has MST from Tailand on 2022 ?? This time ,she wa
admitted for further management.</li>
</ul></li>
<li>A
<ul>
<li>S: For radiotherapy due to L3, L4, and right psoas muscle metastases
with pain.
<ul>
<li>The patient only received ICRT x 4 fractions at TSGH due to severe
left abdomen pain during the 5th ICRT procedure.</li>
<li>Chemotherapy: 2015-2-2; 2015-3-2; 2015-4-9</li>
<li>PI: This is a case of squamous cell carcinoma of the uterine cervix,
initial stage T1N1M0, stage IIIB, s/p CCRT, with L3, L4, and right psoas
muscle metastases. The patient suffered from pain of right flank area.
She said ever received radiotherapy at Bangkok in 2022.</li>
<li>Hx of appendectomy/LC for ectopic pregnancy.</li>
<li>Family Hx: mother (died of cervical cancer)</li>
</ul></li>
<li>O:
<ul>
<li>ECOG: 2</li>
<li>PE: neck and bil SCF: neg; bil low limbs: no edema; pain of right
flank area.</li>
</ul></li>
<li>A:
<ul>
<li>Squamous cell carcinoma of the uterine cervix, stage T1N1M0, stage
IIIB, s/p CCRT, with L3, L4, and right psoas muscle metastases.</li>
</ul></li>
<li>P:
<ul>
<li>The patient said she ever received radiotherapy of the right flank
area at Bangkok in 2022. We need to understand the details of
radiotherapy at Bangkok. She is applying these information. RTC:
2022-08-31.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-21 - bevacizumab 15mg/kg 500mg 1.5hr + paclitaxel 175mg/m2
200mg 3hr + cisplatin 50mg/m2 58mg 2hr</li>
<li>2022-10-25 - bevacizumab 15mg/kg 500mg 1.5hr + paclitaxel 175mg/m2
200mg 3hr + cisplatin 50mg/m2 58mg 2hr</li>
<li>2022-09-29 - bevacizumab 15mg/kg 500mg 1.5hr + paclitaxel 175mg/m2
200mg 3hr + cisplatin 50mg/m2 58mg 2hr</li>
<li>2022-09-07 - bevacizumab 15mg/kg 500mg 1.5hr + paclitaxel 175mg/m2
200mg 3hr + cisplatin 50mg/m2 58mg 2hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>In the lab data collected on 2022-12-18, there were no extreme
abnormalities that warranted postponing the chemotherapy schedule.</li>
<li>It was noted that the blood pressure dropped to 90/50 at dusk on
2022-12-18. Prior to the administration of the chemotherapy, the vital
signs should be within a fairly stable range.</li>
</ul>
</div>
</div>
<div id="section-39" class="section level1">
<h1>701236803</h1>
<div id="section-40" class="section level2">
<h2>221219</h2>
<ul>
<li>diagnosis - 20221216 admission note
<ul>
<li>Small cell B-cell lymphoma, lymph nodes of head, face, and neck</li>
<li>Pleural effusion, not elsewhere classified</li>
<li>Pneumonia, unspecified organism</li>
<li>Localized enlarged lymph nodes</li>
<li>Essential (primary) hypertension</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-12-18 CXR
<ul>
<li>approriately positioned endotracheal tube in place</li>
<li>Lt internal jugular central venous catheter in place with tip
projecting over Rt paratracheal space</li>
<li>regression of Lt pleural effusion s/p chest tubes placement</li>
<li>Port-A catheter inserted into SVC junction via left subclavian
vein.</li>
<li>extensive hazy increased opacity in the right mid to lower lung zone
with obscuration of silhouttes of the right left heart border</li>
</ul></li>
<li>2022-12-16 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-12-06 Cell Block Cytology
<ul>
<li>50 cc brown turbid pleural effusion - Atypia</li>
<li>The smears and cell block show small lymphocytes and reactive
mesothelial cells.</li>
<li>Immunocytochemistry shows CD20(+) &gt; CD3(+) lymphocytes,
Bcl-6(+/-, equivocal) and CD10(+, focal) for lymphocytes, follicular
lymphoma can not be excluded entirely. Follow up</li>
</ul></li>
<li>2022-12-06 SONO - chest
<ul>
<li>Right thorax: minimal amount pleural effusion.</li>
<li>Left thorax: moderate amount, serosanguinous pleural effusion s/p
insertion of 14 Fr. pig-tail catheter and fixed at 15cm.</li>
</ul></li>
<li>2022-12-05 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Hypoinflation of both lung is noted.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Left pleura effusion is noted.</li>
<li>Prominence of left hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
</ul></li>
<li>2022-11-22 Patho - peritoneum biopsy
<ul>
<li>Abdomen, CT-guide biopsy— Follicular lymphoma<br />
</li>
<li>Histology type: B-cell neoplasms - Follicular lymphoma</li>
<li>Immunohistochemical stain profiles: CD20(+), CD3(-), CD10(+),
Bcl-2(+), Bcl-6(+), CD5(+), CD23(-), cyclin D1(-).</li>
</ul></li>
<li>2022-11-21 CXR
<ul>
<li>Hypoinflation of both lung is noted.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-10-26 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesions in the left NP region and left
axillary lymph nodes come to less evident, and glucose hypermetabolic
lesions in bilateral cervical lymph nodes, left iliac bone, right pubic
bone and right femur disappear compared with the previous study on
2020-09-17, indicating response to current therapy.</li>
<li>However, glucose hypermetabolic lesions in bilateral supraclavicular
and left infraclavicular lymph nodes, bilateral mediastinal lymph nodes,
abdominal and pelvic lymph nodes, and spleen become markedly more
prominent, suggesting lymphoma in progression.<br />
</li>
<li>B-cell lymphoma s/p treatment with residual/recurrent tumor
involving lymph node regions on both sides of the diaphragm and spleen,
c-stage IIIS (AJCC 8th ed.), by this F-18 FDG PET scan.</li>
</ul></li>
<li>2022-10-25 Neurosonology
<ul>
<li>Mild atherosclerosis in Rt ECA.</li>
<li>Normal pulsatility index (PI) in detected intracranial artery
system.</li>
<li>Inadequate total blood flow volume of bilateral Vertebral artery (85
ml/min), indicating Vertebrobasilar insufficiency (VBI).</li>
</ul></li>
<li>2022-10-25 Brainstem Auditory Evoked Potentials, BAEP
<ul>
<li>This abnormal BAEP study suggests a peripheral sensori-neural
hearing disorder on both sides.</li>
</ul></li>
<li>2022-10-01 CT - chest
<ul>
<li>Indication:
<ul>
<li>Small cell B-cell lymphoma, lymph nodes of head, face, and neck</li>
<li>Localized enlarged lymph nodes</li>
<li>Essential (primary) hypertension</li>
</ul></li>
<li>Chest CT with and without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Lymphadenopathy at bilateral thoracic inlet and superior
mediastinum. In comparison with CT dated on 2022-03-19, the lesion
enlarged.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Lymphadenopathy at paraaortic and pelvic floor is found.</li>
<li>The urinary bladder is well distended without soft tissue
lesion.</li>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>IMp:
<ul>
<li>Lymphadenopathy at bilateral thoracic inlet and mediastinum and
abdominal paraaortic and pelvic floor, in enlargement.</li>
</ul></li>
</ul></li>
<li>2022-09-15 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>bi nasal cavity clear; smooth nasopharynx, tongue base and
hypopharynx mucosa; normal vocal function; no tumor found at bi pharynx;
mucus coating on left nasopharynx, local treatment done</li>
</ul></li>
<li>Conclusion
<ul>
<li>Head neck lymphoma (nasopharynx and neck) s/p chemotherapy, No
evidence of tumor recurrence</li>
</ul></li>
</ul></li>
<li>2022-06-23, -03-03, -01-06, 2021-10-14, -08-12, -06-10, -05-18
Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>bi nasal cavity clear; smooth nasopharynx, tongue base and
hypopharynx mucosa; normal vocal function; no tumor found at bi
pharynx</li>
</ul></li>
<li>Conclusion
<ul>
<li>Head neck lymphoma (nasopharynx and neck) s/p chemotherapy, No
evidence of tumor recurrence</li>
</ul></li>
</ul></li>
<li>2022-03-19 CT - chest
<ul>
<li>S/p port-A placement with its tip at Superior vena cava</li>
<li>No evidence of recurrent/residual lymphadenopathy in the study.</li>
</ul></li>
<li>2021-09-09 CT - chest
<ul>
<li>NO evidence of lymphadenopathy in the current study.</li>
<li>Minimal right lower lobe and left lower lobe lung collpase.</li>
</ul></li>
<li>2021-04-12 CT - neck
<ul>
<li>a small nodular lesion in the right parotid gland</li>
<li>suspicious a nodular lesion in the right thyroid gland.</li>
</ul></li>
<li>2020-11-30 CT - neck
<ul>
<li>a nodular lesion in the right parotid gland.</li>
<li>regression of the left nasopharyngeal tumor</li>
</ul></li>
<li>2020-09-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (100 - 17) / 100 = 83%
<ul>
<li>M-mode (Teichholz) = 83</li>
</ul></li>
<li>Normal LV filling pressure; mild RV hypertrophy with impaired RV
relaxation.</li>
<li>Normal LV and RV systolic function.</li>
<li>Mild aortic valve sclerosis.</li>
<li>Mildly dilated proximal ascending aorta (35mm).</li>
</ul></li>
<li>2020-09-17 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving the left
aspect of the nasopharynx, multiple lymph nodes on both sides of the
diaphragm and multiple bones as mentioned above. Please correlate with
other clinical findings for further evaluation.</li>
</ul></li>
<li>2020-09-16 CXR
<ul>
<li>Hypoinflation of both lung is noted.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2020-09-16 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — lymphoid aggregation<br />
</li>
<li>Microscopically, it shows 40% of cellularity with 2:2 or M:E ratio,
trilineage cellular component, mature megakaryocyts and presence of
lymphoid aggregations.<br />
</li>
<li>Immunohistochemical stain reveals CD20(+), Bcl-2(+ at aggregation),
CD10(focal+), CD138(1~2%), CD117(-), Bcl-6(-), CD34(-), CYCLIN D1(-),
MPO (+), CD71(+).<br />
</li>
<li>NOTE: Clinical correlation is essential.<br />
</li>
</ul></li>
<li>2020-09-04 Patho - nasopharyngeal/oropharyngeal biopsy
<ul>
<li>Nasopharynx, left, biopsy— B cell type lymphoma, low grade<br />
</li>
<li>Microscopically, it shows B cell type lymphoma characterized by
proliferation of low-grade B cell type lymphoid cells. The follicular
architecture is not significant. Mitoses are not common.<br />
</li>
<li>Immunohistochemical stain reveals CD20(+), CK(-), CD10(+), Bcl-2(+),
cyclin D1(-), CD3 (+ at background T cell), MUM1(-), C-myc(-), CD23(-),
CD5(+), Ki67 index: &lt; or = 10%.<br />
</li>
<li>NOTE: The result of IHC stain is in favor of follicular
lymphoma.</li>
</ul></li>
<li>2020-09-03 Nasopharyngoscopy
<ul>
<li>Findings: left nasopharynx mild swelling, biopsy done</li>
<li>Diagnosis: left nasopharyngeal lesion</li>
</ul></li>
<li>2020-08-28 CT - neck
<ul>
<li>Findings
<ul>
<li>a heterogeneous enhancing lesion, about 22mm in the longest axis, in
the left nasopharynx.</li>
<li>enlarged lymph nodes in the bilateral posterior cervical spaces, and
left supraclavicular fossa.</li>
</ul></li>
<li>IMP: suspected left NPC with bilateral neck enlarged lymph
nodes</li>
</ul></li>
<li>2020-05-12 Patho - lymph node region resection
<ul>
<li>Lymph node, level IV, V, excision — reactive follicular
hyperplasia</li>
<li>Microscopically, sections of regional lymph nodes show reactive
follicular hyperplasia characterized by prominent uniformly spaced but
enlarged germinal centers.They vary considerably in size and shape,and
display dumbbell, hourglass,round or bizarre configurations. The mantle
zone and germinal centers are sharply demarcated in a reactive follicle.
The germinal centers are prominent and hyperplastic and comprise a
mixture of small and large lymphoid cells,centrocytes, and
centroblasts.Mitotic activity and tingible body macrophages are noted
within the germinal centers. The nodal capsule is intact and extranodal
extension is not present.<br />
</li>
<li>Immunohistochemical study revelas Bcl-2: focal negative in
germinalcenter, cycline-D1: negative, CD10: neagtive in
perigerminal</li>
</ul></li>
<li>2020-05-11 Nasopharyngoscopy
<ul>
<li>left neck mass</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-12-17 Thoracic Surgery
<ul>
<li>Q
<ul>
<li>For insertion chest tube.</li>
<li>Under sono- and CT-guiding, drainage of left pleural effusion was
performed smoothly (8 Fr. pig-tail catheter) and some yellowish fluid
was obtained on 20221216.</li>
<li>Now obstruction, so we need help insertion chest tube.</li>
</ul></li>
<li>A
<ul>
<li>I have visited the patient and reviewed the images. Complicated
effusion pending empyema was impressed. VATS (Video-assisted
Thoracoscopic Surgery) decortication will be indicated. I have explained
the current condition with her family. I will arrange operation as soon
as possible. Thanks for your consultation!! (Decortication is a type of
surgical procedure performed to remove a fibrous tissue that has
abnormally formed on the surface of the lung, chest wall or
diaphragm.)</li>
</ul></li>
</ul></li>
<li>2020-09-23 Dermatology
<ul>
<li>Q
<ul>
<li>However vesicles on left waist for one week and pain sensation was
noted. we need your expertise for further management, thanks</li>
</ul></li>
<li>A
<ul>
<li>Skin finding: some erythematous papules and macules and patches with
excoriations on face, trunk and 4 limbs</li>
<li>Imp: eczema, r/o chichenpox (low probability)</li>
<li>Plan:
<ul>
<li>xyzal 1# HS</li>
<li>mycomb cream BID topical used for face, trunk and 4 limbs</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-05-08 ENT
<ul>
<li>Q
<ul>
<li>This 61 year old female is a case of H/T for 6 years regular
medication control.</li>
<li>She complained left lower neck mass for one month and went to
TaoYuan Land Seed Hospital for help. CT showed left neck mass, suspected
lymphoma (3.5<em>3.5cm fixed to spine r/o neuroma and one lymph node
above it around 1</em>1cm). Sono guide biopsy done on 2020/04/28 which
revealed atypical lymphoid hyperplasia. Owing to personal reason, she
came to our hospital for second opinion and was admitted for further
management on 2020/05/07.</li>
<li>Deaf and mutism<br />
</li>
<li>we need your expertise for biopsy of left lower neck, thanks</li>
</ul></li>
<li>A
<ul>
<li>We will arrange tumor excision next week</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-41" class="section level1">
<h1>700541887</h1>
<div id="section-42" class="section level2">
<h2>221216</h2>
<ul>
<li>diagnosis - 20221215 admission note
<ul>
<li>Malignant neoplasm of transverse colon</li>
<li>T-colon CA, pT3N1a cM0, stage IIIB, s/p Op</li>
</ul></li>
<li>past history
<ul>
<li>The patient had no systemic diseases, including CNS,、CV, and
infection</li>
<li>history of operation:
<ul>
<li>Uterine myoma s/p myomectomy (2014)</li>
<li>Left adrenal tumor s/p op (2017),</li>
<li>Thyroid benign nodule s/p bil. thyroidectomy (2020), taking thyroid
and hypertension drugs</li>
<li>Internal hemorrhoid s/p Ligation (2021/12/21, 2022/01/18)</li>
</ul></li>
</ul></li>
<li>family history
<ul>
<li>Her elder sister was diagnosed of endometrial cancer</li>
<li>No members of the family with diabetes.</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-30 CT - chest
<ul>
<li>Indication: colon cancer S/P op A nodule (4.6mm) at RLL. A ground
glass opacity (1.6cm) at RLL.</li>
<li>Chest CT with and without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>One ground glass nodule at right lower lobe up to 1.69cm in largest
dimension is found. A daughter nodule up to 0.63cm is also found. The
lesions are more solid as compared with previous CT on 2022-09-08,
infectious process is considered.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Small lymph nodes are found at left axillary region.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Low density lesion at S2 about 1.71cm in largest dimension is found.
Simple cyst is considered.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>The liver, pancreas, both kidneys and adrenals are intact.</li>
</ul></li>
</ul></li>
<li>Imp: One ground glass nodule at right lower lobe up to 1.69cm in
largest dimension is found. A daughter nodule up to 0.63cm is also
found. the lesions are more solid as compared with previous CT on
2022-09-08, infectious process is considered.</li>
</ul></li>
<li>2022-09-08 CT - abdomen
<ul>
<li>History and indication:
<ul>
<li>Adenocarcinoma of esophagogastric junction status post laparotomy
partial gastrectomy, thoracostomy partial esophacectomy with gastric
tube reconstruction and feeding jejunostomy on 2022/07/18, pT3N2M0 stage
IIIB</li>
</ul></li>
<li>With and without-contrast CT of abdomen-pelvis revealed:
<ul>
<li>S/P left adrenectomy.</li>
<li>Wall thickening of colon at splenic flexure of colon.</li>
<li>Wall thickening of EG junction.</li>
<li>A nodule (4.6mm) at RLL. A ground glass opacity (1.6cm) at RLL.</li>
<li>Liver and renal cysts (up to 1.6cm).</li>
<li>A calcified spot (5.7mm) at pancreatic body.</li>
<li>Normal appearance of spleen, pancreas.</li>
<li>Normal appearance of gallbladder. Bile sludge in CBD.</li>
<li>Intact bony structures.</li>
<li>No ascites, nor enlarged lymph node.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
<li>Atherosclerosis of the aorta, coronary and iliac arteries.</li>
</ul></li>
<li>IMP:
<ul>
<li>S/P left adrenectomy.</li>
<li>Wall thickening of colon at splenic flexure of colon.</li>
<li>Wall thickening of EG junction.</li>
<li>A nodule (4.6mm) at RLL. A ground glass opacity (1.6cm) at RLL.</li>
</ul></li>
</ul></li>
<li>2022-07-19 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-07-01 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Liver cyst, S3</li>
<li>Renal cyst, right</li>
<li>suspicious, angiomyolipoma of right kidney</li>
</ul></li>
<li>Suggestion
<ul>
<li>semi-annual ultrasound follow up.</li>
</ul></li>
</ul></li>
<li>2022-04-15 Patho - colon segmental resection for tumor
<ul>
<li>Diagnosis
<ul>
<li>Large intestine, transverse, laparoscopic left segmental colectomy —
Adenocarcinoma, moderately differentiated</li>
<li>Omentum, partial omentectomy — Negative for malignancy</li>
<li>Resection margins: free</li>
<li>Lymph node, mesocolic, dissection —- Adenocarcinoma, metastatic
(1/14)</li>
<li>Lymph node, IMA / SMA, dissection —- Not received</li>
<li>AJCC 8th edition Pathology stage: pStage IIIB, pT3N1a(if cM0)</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Histologic Type: Adenocarcinoma</li>
<li>Histologic Grade: G2: Moderately differentiated</li>
<li>Tumor Extension: Tumor invades through the muscularis propria into
pericolorectal tissue<br />
</li>
<li>Margins
<ul>
<li>Proximal margin: Uninvolved</li>
<li>Distal margin: Uninvolved</li>
<li>Radial or Mesenteric Margin: very close, impending perforation,
Distance of tumor from margin: &lt; 0.1 mm<br />
</li>
</ul></li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Perineural Invasion: Present</li>
<li>Tumor Budding: Low score (0-4)</li>
<li>Type of Polyp in Which Invasive Carcinoma Arose: Not identified</li>
<li>Tumor Deposits: Not identified</li>
<li>Regional Lymph Nodes:
<ul>
<li>Number of Lymph Nodes Involved/Examined: 1/14; Extranodal
involvement: Not identified</li>
</ul></li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply): absent</li>
<li>Primary Tumor (pT): pT3: Tumor invades through the muscularis
propria into pericolorectal tissues</li>
<li>Regional Lymph Nodes (pN): pN1: One to three regional lymph nodes
are positive (tumor in lymph nodes measuring &gt;=0.2 mm), or any number
of tumor deposits are present and all identifiable lymph nodes are
negative</li>
<li>Distant Metastasis (pM): if cM0</li>
</ul></li>
<li>Additional Pathologic Findings (select all that apply): None
identified</li>
</ul></li>
</ul></li>
<li>2022-03-25 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>There is asymmetrical wall thickening of the distal transverse colon
that is c/w adenocarcinoma.
<ul>
<li>In addition, there are five enlarged nodes in the adjacent mesocolon
that may be metastatic nodes.</li>
</ul></li>
<li>There are two poor enhancing lesion 4 mm in S6 and 6 mm in S4 of the
liver that may be cyst. Please correlate with sonography. A hepatic cyst
measuring 1.5 cm in S3 is noted.</li>
<li>There is no focal lesion in both lung and mediastinum.</li>
<li>There are several renal cysts on both kidney and the largest one
measuring 1.9 cm in size at right middle pole.</li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3 (T_value) N:N2a (N_value) M:M0
(M_value) STAGE:IIIB (Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-03-21 Patho - colon biopsy
<ul>
<li>Colon, 40 cm from anal verge, biopsy (B) — Adenocarcinoma.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul></li>
<li>2022-03-21 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Suspect colon cancer, probable distal transverse colon, s/p biopsy,
tatto and clipping for localization</li>
<li>Colon polyps s/p biopsy removal</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-12-27 Gynecologic ultrasonography
<ul>
<li>suspected uterine myoma</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-14 Laparoscopic left segmental colectomy
<ul>
<li>A 1.5cm depressed tumor lesion is located at distal T-colon</li>
<li>After mobilization of splenic and hepatic frexure of colon,
segmental resection of T-colon was carried out smoothly. Blood loss was
about 30ml.</li>
</ul></li>
<li>2022-01-18 Occlusion of Hemorrhoidal Plexus, Open Approach</li>
<li>2021-12-21 Occlusion of Hemorrhoidal Plexus, Open Approach</li>
<li>2020-09-15 Bil. thyroidectomy + neck lymph node resection
<ul>
<li>Hard, ill-defined tumor mass over L’T thyroid gland without
extrathyroid extension noted ( frozen section: follicular neoplasm)</li>
<li>Several enlarged pre-trachea LNs also noted</li>
</ul></li>
<li>2017-11-24 Adrenalectomy</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-15 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 2800mg/m2 5140mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-11-18 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5160mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-11-04 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5180mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-10-19 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 2800mg/m2 5150mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-10-19 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 2800mg/m2 5140mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-09-07 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5110mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-08-24 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5090mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + granisetron
2mg</li>
</ul></li>
<li>2022-08-09 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5090mg 46hr</li>
<li>2022-07-19 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5060mg 46hr</li>
<li>2022-07-04 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
<li>2022-06-20 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
<li>2022-06-01 - oxaliplatin 70mg/m2 120mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-43" class="section level1">
<h1>700946496</h1>
<div id="section-44" class="section level2">
<h2>221214</h2>
<p>{Left breast cancer, pT2N1aM0, ER(+), PR(+), Her2(-), stage IIA s/p
MRM on 2022-05-13}</p>
<ul>
<li>diagnosis - 2022-11-22 discharge note
<ul>
<li>Malignant neoplasm of unspecified site of left female breast</li>
<li>Left breast cancer, pT2N1aM0, ER(+), PR(+), Her2 (-), stage IIA s/p
MRM on 2022/05/13 s/p chemotherapy with AC by-T(Adriamycin 60mg/m2,
Cyclophosphamide 600mg/m2) on 2022/06/16~2022/08/17 for 4 cycles,
(Taxotere 60mg/m2) on 2022/09/07~</li>
<li>Essential (primary) hypertension</li>
<li>Hyperlipidemia, unspecified</li>
<li>Gout, unspecified</li>
</ul></li>
<li>past history
<ul>
<li>Hypertension for &gt;10 years, under medical control in Cathay
General Hospital</li>
<li>Dyslipidemia for about 3 years under medical control    </li>
</ul></li>
<li>exam finding
<ul>
<li>2022-12-06 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (116 - 22) / 116 = 81.03%
<ul>
<li>LVEF (%) = 81</li>
<li>M-mode (Teichholz) 65</li>
</ul></li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>LV posterior wall thickening, dilated LA; LV diastolic dysfunction
Gr 2</li>
<li>Normal RV systolic function.</li>
<li>Mild to moderate MR; mild TR; aortic valve sclerosis with no AS and
AR.</li>
</ul></li>
<li>2022-12-05 24Hr Holter ECG
<ul>
<li>Baseline was sinus rhythm</li>
<li>Rare isolated VPCs</li>
<li>Rare isolated APCs</li>
<li>1 episode of short-run AT, 4 beats</li>
<li>No long pause</li>
</ul></li>
<li>2022-11-14 Patho - gallbladder (benign lesion)
<ul>
<li>Gallbladder,laparoscopic cholecystectomy — acute cholecystitis</li>
<li>The specimen submitted is a gallbladder, in fixed state. The
gallbladder measures 6x 3.4x 1.1 cm in size. The serosa is congested and
smooth. On opening, the mucosa is eroded. No ulceration is seen. The
wall is elastic measuring up to 0.4 cm in thickness. The cystic duct
measures 0.3 cm in length and is not remarkable. No gallstone is
submitted. Representative sections are taken.</li>
<li>Microscopically, it shows chronic cholecystitis with congestion,
submucosal fibrosis,and mixed inflammatory infiltrate with
Rokitansky-Aschoff sinus formation.</li>
</ul></li>
<li>2022-10-28 Patho - stomach biopsy
<ul>
<li>Stomach, PW site of antrum, biopsy — erosion with Helicobacter
infection</li>
<li>The specimen submitted consists of 3 tissue fragments measuring up
to 0.1x 0.1x 0.1 cm in size, fixed in formalin. Grossly, they are
brownish and elastic. All for section.</li>
<li>Microscopically, it shows erosion with loss of superficial mucosal
epithelium. Mild Helicobacter-like bacilli are seen.</li>
</ul></li>
<li>2022-10-27 Panendoscopy
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis, s/p CLO test</li>
<li>Gastric shallow ulcers and erosions, antrum</li>
<li>Gastric ulcer scar, PW site of antrum, s/p biopsy</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue CLO test and biopsy result; EGD F/U if clinincally
needed</li>
<li>oral PPI use</li>
</ul></li>
</ul></li>
<li>2022-10-24 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.<br />
</li>
</ul></li>
<li>2022-10-21 CT - abdomen
<ul>
<li>History: Left breast cancer, pT2N1aM0, ER(+), PR(+), Her2 (-), stage
IIA s/p MRM on 2022/05/13 s/p chemotherapy with AC by-T (Adriamycin
60mg/m2, Cyclophosphamide 600mg/m2) on 2022/06/16~2022/08/17 for 4
cycles
<ul>
<li>MD CT (Revolution) of the chest, abdomen and pelvis was performed
with 0.625 mm collimation &amp; 5 mm slice thickness reconstruction.
Oral and rectal contrast was not given for bowel opacification.
Tri-phasic dynamic CT images were obtained during non-enhanced, arterial
phase, portal venous phase, and delayed phase scan following IV contrast
injection through autoinjector. Coronal reformated isotropic images were
obtained in portal venous phase scan.</li>
</ul></li>
<li>Findings:
<ul>
<li>S/P Mastectomy, left.
<ul>
<li>There is a cystic-like lesion in the subcutaneous fat layer of left
lower chest wall. please correlate with clinical condition.</li>
</ul></li>
<li>There is no focal lesion in both lung.
<ul>
<li>There are few enlarged nodes in paratracheal space.</li>
<li>Follow up is indicated.</li>
</ul></li>
<li>Left lobe thyroid shows enlarged in size and a lobulated poor
enhancing lesion that may be nodular goiter.
<ul>
<li>Please correlate with sonography.</li>
</ul></li>
<li>The gallbladder shows mild wall thickening but no evidence of
calcified stone or distension.
<ul>
<li>A renal cyst measuring 2.5 cm in right middle pole is noted.</li>
</ul></li>
<li>There are several ovoid-shaped enlarged lymph nodes in the
hepatoduodenal ligament that may be benign reactive nodes.
<ul>
<li>Follow up is indicated.</li>
</ul></li>
<li>There is no focal abnormality in the liver, biliary system,
pancreas, spleen &amp; left kidney.<br />
</li>
<li>There is no ascites.<br />
</li>
<li>There is no bowel wall thickening, and no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P Mastectomy, left.</li>
<li>There is a cystic-like lesion in the subcutaneous fat layer of left
lower chest wall. please correlate with clinical condition.</li>
</ul></li>
</ul></li>
<li>2022-10-21 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver,mild</li>
<li>Suspected fatty infiltration of pancreas</li>
<li>Propable GB stone with cholecystopathy</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Please correlate with other image</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver,especially liver dome and S1 was diffcult to
approach and easy missed</li>
</ul></li>
</ul></li>
<li>2022-08-15 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>Skin and soft tissue, left chest wall wound, debridement — acute
inflammation.</li>
</ul></li>
<li>2022-07-28 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.<br />
</li>
</ul></li>
<li>2022-07-07 Foot Bilat
<ul>
<li>fracture at the base of the right 5th metatarsal bone</li>
</ul></li>
<li>2022-07-06 CXR</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>2022-06-16 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with normal resting wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated LA, septal hypertrophy; LV diastolic dysfunction, Gr 1</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Trivial MR and trivial TR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved RV systolic function</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Minimal pericardiac effusion</li>
</ol></li>
</ul></li>
<li>2022-05-16 Patho - breast mastectomy with regional lymph nodes
<ul>
<li>Diagnosis
<ul>
<li>Breast, left, modified radical mastectomy (S2022-8352A) —- Invasive
carcinoma. Micro-papillary type.</li>
<li>Resection margin: free</li>
<li>Lymph node, left, sentinel lymph node biopsy with frozen section
(F2022-228FS) — metastatic carcinoma (2/2)</li>
<li>Lymph node, left, axilla lymph node dissection (S2022-8352B) — Free
(0/22)</li>
<li>pT2 pN1a (if cM0); anatomic stage: IIB, at least; pathology
prognostic stage: IIA, at least.</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>For Invasive Carcinoma
<ul>
<li>Histologic type: Invasive carcinoma, micropapillary type</li>
<li>Size of invasive carcinoma (mm): 31 x 26 x 25 mm</li>
<li>Histologic grade (Nottingham histologic score): grade III (score
8,9)</li>
<li>Extent of tumor (required only if the structures are present and
involved)
<ul>
<li>Skin involvement: Absent</li>
<li>Chest wall invasion deeper than pectoralis muscle: no tissue
submitted</li>
</ul></li>
</ul></li>
<li>For Ductal Carcinoma In Situ: not present</li>
<li>Margins:
<ul>
<li>Negative, Closest margin (26 mm from deep margin)</li>
</ul></li>
<li>Nodal status: Positive = 2/2 SLN and 0/22 left axilary LN
<ul>
<li>No. examined: 24</li>
<li>No. macrometastases (&gt;2 mm): 2</li>
<li>No. micrometastases (&gt;0.2 ~ 2 mm and/or &gt;200 cells): 0</li>
<li>No. isolated tumor cells (&lt;=0.2 mm and &lt;=200 cells): 0</li>
</ul></li>
<li>Treatment Effect: Response to presurgical (neoadjuvant) therapy - no
neoadjuvant therapy</li>
<li>Immunohistochemical Study: result of biopsy specimen: S2022-07648
<ul>
<li>ER(+, strong intensity, &gt;95%), PR(+, strong intensity, 70%),
Her2/Neu: (-, score= 0/1+), Ki-67 index: 5%.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-13 Frozen resection
<ul>
<li>Preliminary diagnosis: SLN left - metstatic carcinoma (2/2)</li>
</ul></li>
<li>2022-05-13 Lymphoscintigraphy
<ul>
<li>The sentinel lymph node mapping was performed immediately after
injection of 0.5 mCi of Tc-99m phytate (s.c) above the left breast. The
sequential static images over the chest revealed a focal area of
increased accumulation of radioactivity at the left axilla.</li>
<li>Impression: Probably a sentinel lymph node at the left axillary
region.</li>
</ul></li>
<li>2022-05-12 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine and lower L-spines.
Degenerative change may show this picture. However, please correlate
with other imaging modalities for further evaluation.</li>
<li>Increased activity in the mandible. Dental problem may show this
picture.</li>
<li>A hot spot in the left parietal area of the skull and some faint hot
spots in the anterior aspect of bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?). Please follow up bone
scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions and knees, compatible with benign joint
lesions.</li>
</ul></li>
<li>2022-05-11 2D transthoracic echocardiography
<ul>
<li>Dilated LA</li>
</ul></li>
<li>2022-05-11 Lung Flow-Volume Curve
<ul>
<li>mild restrictive impairment</li>
</ul></li>
<li>2022-05-11 SONO - abdomen
<ul>
<li>renal cyst, left</li>
</ul></li>
<li>2022-05-02 Patho - breast biopsy
<ul>
<li>Diagnosis
<ul>
<li>Breast, left, sono-guide biopsy — invasive carcinoma</li>
</ul></li>
<li>Microscopically, the breast shows invasive carcinoma characterized
by proliferation of tumor cells arranged in single-file or cord-like
architecture and infiltrative growth pattern, and stromal fibrosis. The
tumor cell shows round to oval nuclei, nuclear hyperchromasia,
plemorphism,and dot-like nucleoli.</li>
<li>IHC stain — ER(+, strong intensity, &gt;95%), PR(+, strong
intensity, 70%), Her2/Neu: (-, 0/1+), Ki-67 index: 5%,
E-cadherin(+).</li>
</ul></li>
<li>2022-05-02 SONO - breast
<ul>
<li>core needle biopsy</li>
<li>Left breast tumors, 2’ region and subareolar region, suspected
malignancy, suggest biopsy.<br />
</li>
<li>BI-RADS: Category 4c: highly suspicious abnormality-biopsy should be
considered.</li>
</ul></li>
<li>2022-03-21 Nerve Conduction Electromyography
<ul>
<li>Findings
<ul>
<li>normal motor DLs, CMAP amplitudes and NCVs of bil. median and ulnar
n. Conduction slowing of bil. ulnar n. at elbow.</li>
<li>normal sensory DLs, lower SNAP amplitudes and normal NCVs of bil.
ulnar n.</li>
<li>the F-wave latencies of bil. median and ulnar n. were normal.</li>
</ul></li>
<li>Conclusion: bil. ulnar n. lesion at elbow</li>
</ul></li>
<li>2021-12-06 Neurosonology
<ul>
<li><ol style="list-style-type: decimal">
<li>Minimal atherosclerosis in right CCA bifurcation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Adequate total VA flow volume (88 ml/min).</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased RI in right CCA, bilateral ICA and bilateral VA,
indicating distal stenosis.</li>
</ol></li>
</ul></li>
<li>2021-02-14 CXR
<ul>
<li>Normal heart size.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>There is no evidence of destructive bone lesion.</li>
<li>Scoliotic alignment of the thoracolumbar spine is noted.</li>
<li>The lung fields are clear.</li>
<li>Clear bilateral costophrenic angle is noticed.</li>
<li>Patent airway is found.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>2021-02-14 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
<li>2018-12-10 Flow-volume curve
<ul>
<li>FVC 78%, VC redueced.</li>
</ul></li>
<li>2017-09-28 Neck soft tissue
<ul>
<li>mild anterior and posterior spur formation in the lower C-spine</li>
<li>moderate decreased disc spaces in the C5/6 and C6/7 discs</li>
</ul></li>
<li>2017-01-25 CT - abdomen
<ul>
<li>Findings
<ul>
<li>Diverticulosis of cecum and ascending colon. Perifocal fat stranding
of proximal A-colon</li>
<li>Bilateral renal cysts.</li>
</ul></li>
<li>Impression:
<ul>
<li>Acute diverticulitis of A-colon</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-28 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>This 76-year-old woman patient is a case of Left breast cancer,
pT2N1aM0, ER(+), PR(+), Her2 (-), stage IIA s/p MRM on 2022/05/13 s/p
chemotherapy with AC by-T(Adriamycin 60mg/m2, Cyclophosphamide 600mg/m2)
on 2022/06/16~2022/08/17 for 4 cycles. This time, for right chest pain
radiation back pain developed. Abdominal echo on 2022/10/21 showed fatty
liver, mild, suspected fatty infiltration of pancreas and propable GB
stone with cholecystopathy. Lab deta with TBI showed increased
(6.61–&gt;2.71–&gt;1.28–&gt;1.27mg/dL). Now, for evaluate OP of GB
stone. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>S: Due to suspected GB stones with acute cholecystitis, surgical
evaluation is consulted.</li>
<li>O:
<ul>
<li>vital signs: stable, no fever</li>
<li>abdomen: soft, ovoid, decrease bowel sound, mild RUQ &amp; R’t back
tenderness, no Murphy’s sign<br />
</li>
<li>lab data: see chart<br />
</li>
<li>CT: GB wall thickness</li>
</ul></li>
<li>A: Acute acalculous cholecystitis</li>
<li>P: NPO, adequate hydration, antibiotics treatment, and closely
observation is suggested.</li>
</ul></li>
</ul></li>
<li>2022-05-11 Rehabilitation
<ul>
<li>This 76 year-old women, she has left breast cancer withleft simple
mastectomy + SLNB on 2022/05/13. We were consulted for rehabilitation
for preventing complications and post-operation lymphedema.</li>
<li>Premorbid functional status
<ul>
<li>Walk ID, ADLs ID.</li>
</ul></li>
<li>Physical examination
<ul>
<li>Consciousness: clear</li>
<li>Cognition: intact</li>
<li>MP: RUE/RLE: 5/5, LUE/LLE: 5/5</li>
<li>Functional status: ID</li>
<li>ADLs: ID</li>
<li>Bilateral shoulders PROM:
<ul>
<li>right shoulder pain . Right forward flexion PROM 0-160 with pain. ER
0-60 pain+</li>
<li>left shoulder no limitation.</li>
</ul></li>
<li>Hand and arm circumference (R/L,cm):
<ul>
<li>Elbow joint above 5cm 35/34</li>
<li>Elbow joint below 5cm 27/27 rt handed</li>
</ul></li>
</ul></li>
<li>Imp
<ul>
<li>left breast cancer</li>
<li>partial mastectomy + SLNB 5/13</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation and home program
education</li>
<li>Goal: Functional ability ID, maintain ROM, prevent post-OP
complications</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-08-12 Excision of skin or subcutaneous tumor within 2cm</li>
<li>2022-05-13 Simple mastectomy sentinel lymph node biopsy
<ul>
<li>Surgery
<ul>
<li>Left breast MRM (Modified Radical Mastectomy)</li>
</ul></li>
<li>Finding
<ul>
<li>left breast tumors x2</li>
<li>size: 1cm</li>
<li>location: retroalreolar</li>
<li>size: 2cm</li>
<li>location: 2’/2.5cm</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-05-19 OPD
<ul>
<li>Plan:
<ul>
<li>Adjuvant chemotherapy followed by radiotherapy is indicated for this
patient with the following indicators: stage pT2N1a (cM0)</li>
<li>Goal: curative</li>
<li>Treatment target and volume: left chest wall to SCF</li>
<li>Technique: IMRT</li>
<li>Preliminary planning dose: 5000cGy/25 fractions of the left chest
wall to SCF</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-13 - docetaxel 60mg/m2 100mg 1hr - D(Q3W)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-11-21 - docetaxel 60mg/m2 100mg 1hr - D(Q3W)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-09-26 - docetaxel 60mg/m2 100mg 1hr - D(Q3W)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-09-06 - docetaxel 60mg/m2 100mg 1hr - D(Q3W)
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-08-17 - doxorubicin 60mg/m2 100mg 10min + cyclophosphamide
600mg/m2 1000mg 1hr - AC(Q3W)
<ul>
<li>premed - dexamethasone 4mg + aprepitant 125mg D1-D3</li>
</ul></li>
<li>2022-07-28 - doxorubicin 60mg/m2 100mg 10min + cyclophosphamide
600mg/m2 1000mg 1hr - AC(Q3W)
<ul>
<li>premed - dexamethasone 4mg + aprepitant 125mg D1-D3</li>
</ul></li>
<li>2022-07-06 - doxorubicin 60mg/m2 100mg 10min + cyclophosphamide
600mg/m2 1000mg 1hr - AC(Q3W)
<ul>
<li>premed - dexamethasone 4mg + aprepitant 125mg D1-D3</li>
</ul></li>
<li>2022-06-16 - doxorubicin 60mg/m2 100mg 10min + cyclophosphamide
600mg/m2 1000mg 1hr - AC(Q3W)
<ul>
<li>premed - dexamethasone 4mg + aprepitant 125mg D1-D3</li>
</ul></li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Breast Cancer NCCN Evidence Blocks, version 2.2022, 2021-12-20
<ul>
<li>BCS (breast-conserving surgery) not possible (p20)
<ul>
<li>Mastectomy and surgical axillary staging + reconstruction (optional)
<ul>
<li>Adjuvant systemic therapy + post-mastectomy adjuvant RT
<ul>
<li>cN+ and ypN0: Strongly consider RT to the chest wall and
comprehensive RNI (regional nodal irradiation) with inclusion of any
portion of the undissected axilla at risk.</li>
<li>Any ypN+: RT is indicated to the chest wall + comprehensive RNI with
inclusion of any portion of the undissected axilla at risk.</li>
</ul></li>
<li>Adjuvant systemic therapy without adjuvant RT for any cN0,ypN0 if
axilla was assessed by SLNB or axillary node dissection</li>
</ul></li>
</ul></li>
<li>Preoperative/Adjuvant therapy regimens (p55)
<ul>
<li>HER2-Negative
<ul>
<li>Preferred Regimens:
<ul>
<li>Dose-dense AC (doxorubicin/cyclophosphamide) followed by paclitaxel
every 2 weeks</li>
<li>Dose-dense AC (doxorubicin/cyclophosphamide) followed by weekly
paclitaxel</li>
<li>TC (docetaxel and cyclophosphamide)</li>
<li>Olaparib, if germline BRCA1/2 mutations</li>
<li>High-risk triple-negative breast cancer (TNBC): Preoperative
pembrolizumab + carboplatin + paclitaxel, followed by preoperative
pembrolizumab + cyclophosphamide + doxorubicin or epirubicin, followed
by adjuvant pembrolizumab</li>
<li>TNBC and residual disease after preoperative therapy with taxane-,
alkylator-, and anthracycline-based chemotherapy: Capecitabine</li>
</ul></li>
<li>Useful in Certain Circumstances:
<ul>
<li>Dose-dense AC (doxorubicin/cyclophosphamide)</li>
<li>AC (doxorubicin/cyclophosphamide) every 3 weeks (category 2B)</li>
<li>CMF (cyclophosphamide/methotrexate/fluorouracil)</li>
<li>AC followed by weekly paclitaxel</li>
<li>Capecitabine (maintenance therapy for TNBC after adjuvant
chemotherapy)</li>
</ul></li>
<li>Other Recommended Regimens:
<ul>
<li>AC followed by docetaxel every 3 weeks</li>
<li>EC (epirubicin/cyclophosphamide)</li>
<li>TAC (docetaxel/doxorubicin/cyclophosphamide)</li>
<li>Select patients with TNBC: -Paclitaxel + carboplatin (various
schedules) -Docetaxel + carboplatin (preoperative setting only)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-45" class="section level3">
<h3>==========</h3>
</div>
<div id="section-46" class="section level3">
<h3>2022-12-14</h3>
<ul>
<li>The underlying conditions in this patient include: essential
(primary) hypertension, hyperlipidemia, gout.</li>
<li>2D transthoracic echocardiography (2022-12-06) revealed: LV
posterior wall thickening, dilated LA; LV diastolic dysfunction Gr 2;
Mild to moderate MR; mild TR; aortic valve sclerosis.</li>
<li>Available records of blood uric acid levels showed no exceeding the
upper limit of normal.
<ul>
<li>2022-10-22 Uric Acid 3.9 mg/dL<br />
</li>
<li>2022-07-19 Uric Acid 5.1 mg/dL<br />
</li>
</ul></li>
<li>Gout patients with established cardiovascular (CV) disease treated
with febuxostat had a higher rate of CV death compared to those treated
with allopurinol in a CV outcomes study. Consider the risks and benefits
of febuxostat when deciding to prescribe or continue patients on
febuxostat. Febuxostat is recommended only used in patients who have an
inadequate response to a maximally titrated dose of allopurinol, who are
intolerant to allopurinol, or for whom treatment with allopurinol is not
advisable.</li>
<li>As an alternative to xanthine oxidase inhibitors, the uric aicd
resorption suppressor benzbromarone might be another candidate for
treating gout.</li>
</ul>
</div>
<div id="section-47" class="section level3">
<h3>2022-09-07</h3>
<ul>
<li>A decline in renal function has been observed. Time series lab log:
<ul>
<li>Date // Creatinine // eGFR</li>
<li>2022-09-06 1.22 45.55 (CrCl ~ 40 mL/min)</li>
<li>2022-08-30 1.19 46.87</li>
<li>2022-08-17 0.91 63.88</li>
<li>2022-08-09 0.77 77.46</li>
</ul></li>
<li>The kidneys excrete little docetaxel (~6%), therefore, the need for
docetaxel dosage adjustments for renal dysfunction is unlikely.</li>
<li>Allegra (fexofenadine 60mg/tab) for GFR 10 to 50 mL/min: Recommended
dose every 12 to 24 hours. A possible change is from BID to QD.</li>
<li>Promeran (metoclopramide 3.84mg/tab) for CrCl &gt;10 to 60 mL/min:
Administer ~50% of usual total daily dose. A change from TIDAC to BIDAC
might be considered.</li>
<li>During this hospitalization, the blood pressure was well controlled.
The laboratory data related to hyperlipidemia have not been updated
since October 2021. A number of tests might be ordered, e.g., TC, LDL-C,
Non-HDL-C, ApoB, TG, HDL-C, and ApoA-1.</li>
</ul>
</div>
<div id="section-48" class="section level3">
<h3>2022-08-18</h3>
<ul>
<li>There was no evidence of intolerance.</li>
<li>The TPR and blood pressure were stable during this hospitalization
and the lab results for 2022-08-17 were generally normal.</li>
<li>Underlying cardiovascular conditions are managed with Sevikar
(amlodipine + olmesartan), Concor (bisoprolol) and Crestor
(rosuvastatin) without issues.</li>
</ul>
</div>
<div id="section-49" class="section level3">
<h3>2022-07-07</h3>
<ul>
<li>Since mid-June 2022, the patient has been receiving doxorubicin and
cyclophosphamide.</li>
<li>An optional addition might be tamoxifen or an aromatase inhibitor.
(A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with
Early Breast Cancer. <a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa052258" class="uri">https://www.nejm.org/doi/pdf/10.1056/NEJMoa052258</a> )</li>
</ul>
</div>
</div>
</div>
<div id="section-50" class="section level1">
<h1>701362191</h1>
<div id="section-51" class="section level2">
<h2>221214</h2>
<ul>
<li>diagnosis
<ul>
<li>2022-07-18 discharge note
<ul>
<li>Malignant neoplasm of pyloric antrum</li>
<li>Gastric cancer s/p lap radical Subtotal gastrectomy with D2
dissection on 2022/03/07, pT4aN1M0, stage IIIA s/p chemotherapy with
FOLFOX (from 2022/04/12~2022/06/21 for 6 cycles)</li>
<li>Type 2 diabetes mellitus without complications</li>
</ul></li>
</ul></li>
<li>exam findings
<ul>
<li>2022-10-09 Wrist RT
<ul>
<li>Normal bone alignment</li>
<li>mild decreased right wrist joint space</li>
</ul></li>
<li>2022-08-10 SONO - abdomen
<ul>
<li>Normal sonographic study of the hepatobiliary system.</li>
</ul></li>
<li>2022-07-01 CT - abdomen
<ul>
<li>History: epigastric pain
<ul>
<li>UGI scope revealed gastric ca at lower body.</li>
<li>20220223 CT:gastric cancer, cT3N0M0, cSTAGE:IIB</li>
<li>20220308 subtotal gastrectomy PATHO: pT4aN1(if cM0); pstage
IIIA</li>
</ul></li>
<li>Findings:
<ul>
<li>S/P subtotal gastrectomy</li>
<li>S/P IUD retention within the endometrial cavity.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P subtotal gastrectomy.</li>
<li>There is no evidence of tumor recurrence.<br />
</li>
</ul></li>
</ul></li>
<li>2022-03-08 Patho - stomach subtotal/total (tumor)
<ul>
<li>Diagnosis:
<ul>
<li>Stomach, middle body, lesser curvature, laparoscpic subtotal
gastrectomy — Poorly cohesive carcinoma with signet-ring cell
differentiation</li>
<li>Cut-ends, proximal and distal, laparoscpic subtotal gastrectomy —
Free</li>
<li>Lymph node, LN 1, dissection — Negative for malignancy (0/1)</li>
<li>Lymph node, LN 3, dissection — Metastatic carcinoma (2/8)</li>
<li>Lymph node, LN 4, dissection — Negative for malignancy (0/9)</li>
<li>Lymph node, LN 5, dissection — Negative for malignancy (0/3)</li>
<li>Lymph node, LN 6, dissection — Negative for malignancy (0/4)</li>
<li>Lymph node, LN 7,8,9,11p, 12a, dissection — Negative for malignancy
(0/18)</li>
<li>Lymph node, LN14V, dissection — Negative for malignancy (0/1)</li>
<li>AJCC 8th edition Pathology stage: pT4aN1(if cM0); AJCC stage
IIIA</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type — Poorly cohesive carcinoma with signet-ring cell
differentiation</li>
<li>Histologic Grade — Poorly differentiated</li>
<li>Tumor Extension — Tumor invades the serosa (visceral
peritoneum)</li>
<li>Margins
<ul>
<li>Proximal margin: uninvolved by invasive carcinoma</li>
<li>Distal margin: uninvolved by invasive carcinoma</li>
<li>Radial margin: uninvolved by invasive carcinoma</li>
</ul></li>
<li>Lymphovascular Invasion: present<br />
</li>
<li>Perineural Invasion: present<br />
</li>
<li>Regional Lymph Nodes — Number of lymph nodes examined: positive
(2/44)<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply)
<ul>
<li>m (multiple primary tumors) r (recurrent) y (posttreatment)</li>
<li>Primary Tumor (pT) — pT4a: Tumor invades the serosa (visceral
peritoneum)</li>
<li>Regional Lymph Nodes (pN) — pN1: Metastasis in one or two regional
lymph nodes</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case) — N/A</li>
</ul></li>
<li>IHC stain— CK(+), CK20(focal+), CK7(+), CDX-2(+)</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-04 Patho - stomach biopsy
<ul>
<li>Tumor, gastric angle, biopsy — Poorly cohesive carcinoma with
signet-ring cell differentiation</li>
<li>Microscopically, the sections show a picture of poorly cohesive
carcinoma with signet-ring cell differentiation characterized by linear
or individual tumor cells infiltrating in stroma.</li>
<li>Immunohistochemistry of CK(+) and Her2 (-, Dako score 0) for tumor
cell.</li>
<li>Besides, colony of Helicobacter Pylori is not present in the
submitted specimen.</li>
</ul></li>
<li>2022-02-23 CT - abdomen, gastric filling with water
<ul>
<li>Imaging Report Form for Gastric Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3 (T_value) N:N0 (N_value) M:M0
(M_value) STAGE:IIB(Stage_value)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-07 laparoscpe subtotal gastrectomy with LN D2 dissection
<ul>
<li>Finding
<ul>
<li>3cm ulcerative mass at middle body lesser curvature with serosa
involve</li>
<li>regional LN enlarge at station 3</li>
<li>peritoneal seeding (-)</li>
<li>ascite (-)</li>
<li>cT4aN1M0</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-13 - oxaliplatin 85mg/m2 165mg 24hr + leucovorin 300mg/m2
580mg 2hr + fluorouracil 300mg/m2 580mg 10min + fluorouracil 2400mg/m2
4500mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + palonosetron
250ug + famodidine 20mg + aprepitant 125mg PO D1-D3</li>
</ul></li>
<li>2022-11-24 - oxaliplatin 85mg/m2 165mg 24hr + leucovorin 300mg/m2
580mg 2hr + fluorouracil 300mg/m2 580mg 10min + fluorouracil 2400mg/m2
4500mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + palonosetron
250ug + famodidine 20mg + aprepitant 125mg PO D1-D3</li>
</ul></li>
<li>2022-11-09 - oxaliplatin 75mg/m2 145mg 24hr + leucovorin 300mg/m2
580mg 2hr + fluorouracil 300mg/m2 580mg 10min + fluorouracil 2400mg/m2
4500mg 46hr
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + palonosetron
250ug + famodidine 20mg + aprepitant 125mg PO D1-D3</li>
</ul></li>
<li>2022-10-17 - oxaliplatin 65mg/m2 120mg 24hr + leucovorin 300mg/m2
580mg 2hr + fluorouracil 300mg/m2 580mg 10min + fluorouracil 2400mg/m2
4500mg 46hr # Allergy with whole body skin redness rash with itch after
chemotherapy with Oxalip
<ul>
<li>premed - dexamethasone 4mg + diphenhydramine 30mg + palonosetron
250ug + famodidine 20mg + aprepitant 125mg PO D1-D3</li>
</ul></li>
<li>2022-09-13 - oxaliplatin 75mg/m2 150mg 24hr + leucovorin 300mg/m2
580mg 2hr + fluorouracil 300mg/m2 580mg 10min + fluorouracil 2400mg/m2
4500mg 46hr
<ul>
<li>premed - dexamethasone 4mg + palonosetron 250ug + aprepitant 125mg
PO D1-D3</li>
</ul></li>
<li>2022-08-24 - oxaliplatin 75mg/m2 150mg 24hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 300mg/m2 600mg 10min + fluorouracil 2400mg/m2
5000mg 46hr
<ul>
<li>premed - dexamethasone 4mg + palonosetron 250ug + aprepitant 125mg
PO D1-D3</li>
</ul></li>
<li>2022-07-18 - leucovorin 20mg/m2 40mg 10min D1 + fluorouracil
400mg/m2 600mg 10min D1 (CCRT)
<ul>
<li>premed - dexamethasone 4mg + metoclopramide 10mg D1</li>
</ul></li>
<li>2022-07-12 - leucovorin 20mg/m2 40mg 10min D1-4 + fluorouracil
400mg/m2 600mg 10min D1-D4 (CCRT)
<ul>
<li>premed - dexamethasone 4mg + metoclopramide 10mg D1-D4</li>
</ul></li>
<li>2022-06-21 - oxaliplatin 75mg/m2 150mg 24hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 300mg/m2 600mg 10min + fluorouracil 2400mg/m2
5000mg 46hr
<ul>
<li>premed - dexamethasone 4mg + palonosetron 250ug + aprepitant 125mg
PO D1-D3</li>
</ul></li>
<li>2022-06-07 - oxaliplatin 75mg/m2 150mg 24hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 300mg/m2 600mg 10min + fluorouracil 2400mg/m2
5000mg 46hr</li>
<li>2022-05-24 - oxaliplatin 75mg/m2 150mg 24hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 300mg/m2 600mg 10min + fluorouracil 2400mg/m2
5000mg 46hr</li>
<li>2022-05-10 - oxaliplatin 85mg/m2 170mg 24hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
5000mg 46hr</li>
<li>2022-04-26 - oxaliplatin 85mg/m2 170mg 24hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
5000mg 46hr</li>
<li>2022-04-12 - oxaliplatin 85mg/m2 170mg 24hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
5000mg 46hr</li>
</ul></li>
</ul>
<div id="section-52" class="section level3">
<h3>==========</h3>
</div>
<div id="section-53" class="section level3">
<h3>2022-12-14</h3>
<ul>
<li>It has not been observed that there is an allergy resulting in a
skin rash or itching after the addition of diphenhydramine and
famodidine as the premedication since Oct 2022.</li>
<li>During this hospital stay, the FS blood sugar levels were around 200
mg/dL. The available blood sugar records indicate that the patient’s
blood sugar levels almost always exceed the upper limit of normal for
the past months. If no imaging is scheduled that requires iodinated
contrast, metformin 500mg BID is recommended since her kidneys do not
exhibit any insufficiency.</li>
</ul>
</div>
<div id="section-54" class="section level3">
<h3>2022-11-25</h3>
<ul>
<li>Perhaps due to a lack of authorization from the patient, the recent
3-month prescription list is not available from PharmaCloud at
present.</li>
<li>According to the admission note, the patient regularly takes both
Amepiride (glimepiride) and meformin to control her type 2 DM.</li>
<li>For the renal hyperfiltration (2022-11-23 eGFR 133) was still noted
and her preprandial blood sugar level is still high (173mg/dL 2022-11-25
07:02) under current single antidiabetic agent Amepiride (glimepiride),
it is recommended that metformin be added to her active prescription as
a patient-carried item if no imaging scheduled.</li>
</ul>
</div>
<div id="section-55" class="section level3">
<h3>2022-11-10</h3>
<ul>
<li>A preprandial blood sugar level of 198mg/dL was recorded on
2022-11-10 morning.</li>
<li>The renal hyperfiltration (2022-11-03 eGFR 125) driven by increased
glomerular filtration pressure and by glucose diuresis can affect renal
O2 consumption that unleashes detrimental sympathetic activation. The
sodium-glucose co-transporters inhibitors (SGLTi) can rebalance the
reabsorption of Na+ coupled with glucose and can restore renal O2
demand, diminishing neuroendocrine activation. (ref: The Benefit of
Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of
the Kidney. Int J Mol Sci. 2022;23(19):11987. Published 2022 Oct 9. <a href="doi:10.3390/ijms231911987" class="uri">doi:10.3390/ijms231911987</a>)</li>
<li>There is only one antidiabetic agent Amepiride (glimepiride) in the
active prescription. The SGLT2i drugs empagliflozin, dapagliflozin, and
canagliflozin are available in stock and could be considered if UTI is
unlikely.</li>
</ul>
</div>
<div id="section-56" class="section level3">
<h3>2022-10-18</h3>
<ul>
<li>This patient has been prescribed Amepiride (glimepiride) for months,
which may cause body weight gain, however, her body weight has decreased
by more than 15kg during the past seven months (85kg 2022-10-17 &lt;-
101kg 2022-03-06). Is it an intentional diet cuased weight loss or an
unintentional weight loss? Did insulin resistance result in body
breakdown or poor dietary intake?</li>
<li>Pre-breakfast blood sugar level reached 215 mg/dL on 2022-10-18
under metformin and glimepiride. If fasting levels persist over 200
mg/dL for two consecutive days, acarbose, vidagliptin, or dapagliflozin
might be added to the current medication list.</li>
</ul>
</div>
</div>
</div>
<div id="section-57" class="section level1">
<h1>700105612</h1>
<div id="section-58" class="section level2">
<h2>221212</h2>
<ul>
<li>exam findings
<ul>
<li>2022-12-09 CT - brain
<ul>
<li>Indication: confusion</li>
<li>Findings
<ul>
<li>brain atrophy with prominent sulci, fissures and dilated
ventricles.</li>
<li>confluent hypodensity at bilateral periventricular white matter,
indicating leukoaraiosis.</li>
<li>no acute intracranial hemorrhage.</li>
<li>no definite skull lesion.</li>
<li>chronic left maxillary sinusitis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Brain atrophy and leukoaraiosis.</li>
<li>Chronic left maxillary sinusitis.</li>
</ul></li>
</ul></li>
<li>2022-12-09 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Osteopenia of the bony structure is noted.</li>
<li>Senile fibrotic change is noted at lung fields.</li>
</ul></li>
<li>2022-11-04 Water’s view
<ul>
<li>Opacification of left maxillary sinus.</li>
</ul></li>
<li>2022-11-04 Nasopharyngoscopy
<ul>
<li>sticky post nasal drip</li>
</ul></li>
<li>2022-10-26 CXR
<ul>
<li>S/P coronary artery stent implantation.</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-02-11 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (82.2 - 29.0) / 82.2 = 64.72%
<ul>
<li>M-mode (Teichholz) = 64.7</li>
</ul></li>
<li>Adequate LV systolic function with no regional wall motion
abnormality at resting state</li>
<li>Trivial mitral and tricuspid regurgitation</li>
<li>Impaired LV relaxation</li>
<li>Mildly thick IVS and LVPW</li>
</ul></li>
<li>2022-02-09 CXR
<ul>
<li>Patchy opacity projecting in the right lower mediastinum shows
stationary.</li>
<li>S/P coronary artery stent implantation.</li>
</ul></li>
<li>2022-02-09 ECG
<ul>
<li>Sinus rhythm with Premature supraventricular complexes and with
occasional Premature ventricular complexes</li>
</ul></li>
<li>2022-09-23 CXR
<ul>
<li>Patchy opacity projecting in the right lower mediastinum is
suspected. Follow up is indicated.</li>
<li>S/P coronary artery stent implantation.</li>
</ul></li>
<li>2021-09-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (87.7 - 36.2) / 87.7 = 58.72%
<ul>
<li>M-mode (Teichholz) = 58.7</li>
</ul></li>
<li>Normal chamber size</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>AV sclerosis with trivial AR, mild MR, TR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2021-08-26 Patho - gingival/oral mucosa biopsy
<ul>
<li>Bone, left maxilla, excisional biopsy — Dead bone with acute and
chronic inflammation<br />
</li>
<li>Section shows squamous mucosa and dead bone with granulation tissue,
fibrosis, and acute and chronic inflammation.</li>
<li>The immunohistochemical stain of CD138 shows no aggregation of
plasma cells in bone.<br />
</li>
</ul></li>
<li>2020-12-07 CXR
<ul>
<li>Patchy opacity projecting in the right lower mediastinum is
suspected. Follow up is indicated. Otherwise, Please correlate with
CT.</li>
<li>S/P coronary artery stent implantation.</li>
</ul></li>
<li>2020-12-07 ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
<li>Increased R/S ratio in V1, consider early transition or posterior
infarct</li>
</ul></li>
<li>2020-11-03 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — Myeloma.</li>
<li>IHC stains: CD138 : 10-15%, lambda light chain &gt; kappa light
chain. IgA: 10-15%, IgG: &lt;5%.</li>
<li>Section shows piece(s) of bone marrow with 40-50% cellularity and
M:E ratio of approximately 3:1. Three cell lineages are present with
normal maturation of leukocytes. Megakaryocytes are adequate in number.
There are a few plasmacytoid cells present.</li>
</ul></li>
<li>2020-08-14 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Negative for malignacy (CD138+ plasma cell:
&lt; 5%)<br />
</li>
<li>Microscopically, it shows 3 % of cellularity, 1:1 of M:E ratio,
presece of trilinegae cellular component and ocassional
megakaryocytes.<br />
</li>
<li>Immunohistochemical stain reveals CD138(&lt; 5%), CD71(+), CD20(-),
CD117(-), Kappa(-), MPO(focal+), CD117(-).<br />
</li>
<li>NOTE: Clincal correlation is essential.<br />
</li>
</ul></li>
<li>2020-06-24 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (116 - 30) / 116 = 74.14%
<ul>
<li>M-mode (Teichholz) = 74</li>
</ul></li>
<li>Septal hypertrophy with Gr I LV diastolic dysfunction and impaired
RV relaxation.</li>
<li>Normal LV and RV systolic function.</li>
<li>Aortic valve sclerosis; degenerative changes of mitral valve with
trivial MR.</li>
<li>Dilated proximal ascending aorta (35mm); mild aortic root
calcification.</li>
</ul></li>
<li>2020-04-10 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, history of myeloma (S2018-2795), biopsy —
Compaible with replased of myeloma.</li>
<li>IHC stains: CD138: 10-15% of the nucleated cells, lambda &gt; kappa,
approximately 3:1.<br />
</li>
<li>Section shows one piece of bone marrow with 30 % cellularity and M:E
ratio of approximately 3:1. There is aprroxomately 10-15% of the
plasmcytoid cells demonstrated by IHC stain of CD138. lambda &gt; kappa,
approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number.</li>
</ul></li>
<li>2020-03-20 Patho - breast biopsy
<ul>
<li>Breast, right, sono-guided biopsy — Gynecomastia<br />
</li>
</ul></li>
<li>2020-03-20 SONO - breast
<ul>
<li>Subareolar duct development, both side, gynecomastia should be
considered. Suggest clinical correlation.</li>
</ul></li>
<li>2019-03-01 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (105 - 36) / 105 = 65.71%
<ul>
<li>M-mode (Teichholz) = 65</li>
</ul></li>
<li>Septal and RV hypertrophy with Gr I LV diastolic dysfunction and
impaired RV relaxation.</li>
<li>Normal LV and RV systolic function.</li>
<li>Mild AV sclerosis; mild MR; mild PR.</li>
</ul></li>
<li>2018-10-25 transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (102 - 30.3) / 102 = 70.29%
<ul>
<li>M-mode (Teichholz) = 70.3</li>
</ul></li>
<li>Normal chamber size</li>
<li>Adequate LV and RV performance</li>
<li>Possibly impaired LV relaxation</li>
<li>AV sclerosis with trivial AR ; mild MR, TR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2018-09-07 Surgical pathology Level IV
<ul>
<li>Bone marrow, iliac, biopsy — see description.</li>
<li>Section shows one piece of bone marrow with 50 % cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number.</li>
<li>IHC stain shows approximately 10 % of CD138 (+) plasmacytoid cells
with slightly more kappa than lambda light chain stain, suggestive of
few residual neoplastic cells. Additional CD34 (+) &lt;1%, CK (-).</li>
</ul></li>
<li>2018-04-03 MRI - T-spine
<ul>
<li>Indication: A case of myeloma, T, L spine survey, for chest
pain</li>
<li>Findings:
<ul>
<li>Moderate degree of old compression fracture of T3 vertebral
body.</li>
<li>Abnormal enhanced lesions in T3, T4, T5, T7, T8 T12, and L1
vertebrae (as hypointense on T1WI).</li>
<li>Mild degree of compression fracture of T9 vertebral body
(hypointense on T1WI, hyperintense on STIR images), with abnormal
enhancement.</li>
<li>Marginal spurs of multiple vertebral bodies.</li>
<li>Mild thickening of ligamentum flavum at T10-T11 level..</li>
<li>The visualizedl spinal cord shows normal size and signal intensity.
There is no extrinsic compression of the cord.</li>
</ul></li>
<li>Impression:
<ul>
<li>multiple myeloma with T4 and T9 compression fracture and small
enhancing</li>
<li>lesions in multiple vertebrae.</li>
</ul></li>
</ul></li>
<li>2018-03-19 transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (111 - 28) / 111 = 74.77%
<ul>
<li>M-mode (Teichholz) = 74</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Dilated LA, LV diastolic dysfunction, Gr 1</li>
<li>Mild MR, mild TR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2018-03-19 ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
</ul></li>
<li>2018-02-20 Surgical pathology Level IV
<ul>
<li>Bone marrow, biopsy — Plasma cell myeloma</li>
<li>The sections show slightly hypercellular marrow (50%). Sheets of
mature plasma cells with numerous Russell bodies in interstitium,
account for 50% nucleated cells in CD138 immunostain. These plasma cells
also reveal kappa light chain restriction and negative for lambda light
chain.</li>
</ul></li>
<li>2017-04-17 CT - heart CTA
<ul>
<li>History:
<ul>
<li>20110128
<ul>
<li>Admitted due to exertional dyspnea and palpitation, cardiac
catheterlization was perforemd smoothly and reveaeld CAD, LAD. middle,
right hand cath wound clear, still irregular heart rate and DOE, keep
medication therapy.<br />
</li>
<li>History of abnormal LFT told in Cathay General Hospital even with
lipitor for 10 mg ∕QD</li>
</ul></li>
<li>200812
<ul>
<li>Referred from chief Lin, hx of Palpitation, and short run of Af;
palpitation when emotional upset. Palpitation and chest pain for 17
years.</li>
<li>Holter ECG in Cathay General Hospital showed occasional APC and VPCs
with 4minutes of short run Af with no symptoms even with lipitor for 10
mg ∕QD</li>
</ul></li>
</ul></li>
<li>Nonenhanced ECG-gated CT for calcium scoring and enhanced spiral CT
of heart and coronary arteries were obtained using 256-slice
multidetector row CT scanner (iCT philips) showed:
<ul>
<li>Calcification of the coronary arteries (total calcium score=643,
LMA=7.33, LAD=514.48, LCX=77.31, RCA=43.87)</li>
<li>Left main coronary artery: Patent</li>
<li>Left anterior descending coronary artery: calcified plaques in S6,
S7, and S8, with severe stenosis in S7 and S8.</li>
<li>Visible diagonal branches: Patent</li>
<li>Left circumflex coronary artery: Patent</li>
<li>Visible obtuse marginal branches: Patent</li>
<li>Right coronary artery: Patent</li>
<li>Posterolateral and posterior descending branches: Patent</li>
<li>Pericardium : Unremarkable</li>
<li>Cardiac structure and morphology: Normal cardiac chamber size</li>
<li>Lungs: Unremarkable</li>
<li>Mediastinum and hilars: No mass lesion</li>
<li>Visible abdominal contents: Unremarkable</li>
</ul></li>
<li>Impression
<ul>
<li>Total calcium score = 643, indicating extensive atherosclerotic
plaque burden.</li>
<li>Atherosclerosis major coronary arteries with significant stenosis in
LAD, S7 and S8.</li>
<li>No lung nodule.</li>
</ul></li>
</ul></li>
<li>2017-04-12 24hrs Holtor’s scan
<ul>
<li>Sinus rhythm</li>
<li>Occasional isolated apcs</li>
<li>Rare apc couplets</li>
<li>A few isolated vpcs</li>
<li>No long pause</li>
<li>No significant tachyarrhythmia</li>
</ul></li>
<li>2017-03-06 MRI - L-spine
<ul>
<li>Mild cervical spondylosis.</li>
<li>Disc bulge with mild stenotic lateral recesses, L3-L4,L4-L5.</li>
<li>Multilevel degenerative disc disease.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-12-12 Family Medicine
<ul>
<li>Q
<ul>
<li>The 76 y/o man has IgA Multiple myeloma, 20180223 proved with bone
marrow study. VTD from 20180301, S/P autoPBSCT on 20190306, complicated
with HSV-1 genital ulcer infection (20190401). S/P Lenalidomide + dexa.
Daraturumab + Velcade + dexa. Kyrolip + dexa. IgA level in progress.
Last time, he received chemotherapy as Kyrolip on 2022/11/11. He has
poor intake for 3 weeks, just 1 meal a day and lay down all day. He
denied take medicine as oral steroid and oral chemotherapy. This time,
he has multiple bone pain for 2 weeks and in progress, and yellow snivel
around 1 month (his wife not sure), so he was brought to our ED for
help. At ED, the lab data showed anemia, mild elevated CRP level and
hypokalemia. Due to confusion consciousness, brain CT was arranged at ER
and showed 1. Brain atrophy and leukoaraiosis, 2. Chronic left maxillary
sinusitis. Under the impression of IgA MM without control and severe
bone pain, and malnutrition, so he was admitted on 2022/12/09.</li>
<li>Due to disease progression, the patient’s family ask for palliative
care. We need your help for further evaluation. Thank you very
much.</li>
</ul></li>
</ul></li>
<li>2022-12-12 Neurology
<ul>
<li>Q
<ul>
<li>Due to confusion consciousness, brain CT was arranged at ER and
showed: 1. Brain atrophy and leukoaraiosis, 2. Chronic left maxillary
sinusitis. We need your help for further evaluation and treatment
suggestion. Thank you very much.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>20190306 autoPBSCT</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-11 - Kyprolis (carfilzomib) 70mg/m2 100mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-09-21 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-09-07 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-08-17 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-08-03 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-07-20 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-07-06 - Kyprolis (carfilzomib) 70mg/m2 110mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-06-15 - Kyprolis (carfilzomib) 70mg/m2 115mg 1hr</li>
<li>2022-05-25 - Kyprolis (carfilzomib) 70mg/m2 115mg 1hr</li>
<li>2022-05-04 - Kyprolis (carfilzomib) 70mg/m2 116mg 1hr</li>
<li>2022-04-20 - Kyprolis (carfilzomib) 70mg/m2 116mg 1hr</li>
<li>2022-04-06 - Kyprolis (carfilzomib) 70mg/m2 116mg 1hr</li>
<li>2022-03-23 - Kyprolis (carfilzomib) 70mg/m2 118mg 1hr</li>
<li>2022-03-09 - Kyprolis (carfilzomib) 70mg/m2 118mg 1hr</li>
<li>2022-03-02 - Kyprolis (carfilzomib) 50mg/m2 85mg 1hr
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2022-03-02 - Kyprolis (carfilzomib) 20mg/m2 34mg 1hr
<ul>
<li>premed - diphenhydramine 50mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2021-12-29 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr
<ul>
<li>premed - diphenhydramine 50mg + dexamethasone 20mg + acetaminophen
1000mg</li>
</ul></li>
<li>2021-12-01 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-11-03 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-10-06 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-09-01 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-08-04 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-07-07 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-06-15 - Darzalex (daratumumab) 1000mg 3.5hr</li>
<li>2021-05-18 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-04-27 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-04-06 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-03-16 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-02-23 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 1000mg 3.5hr</li>
<li>2021-02-02 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2021-01-29 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min</li>
<li>2021-01-26 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2021-01-22 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min</li>
<li>2021-01-19 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2021-01-11 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2021-01-04 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2020-12-31 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min</li>
<li>2020-12-28 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2020-12-21 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 3.5hr</li>
<li>2020-12-14 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 7hr</li>
<li>2020-12-11 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min</li>
<li>2020-12-07 - Velcade (bortezomib) 1.3mg/m2 2.2mg SC 1min + Darzalex
(daratumumab) 900mg 7hr</li>
<li>2018-03-19 ~ 2018-11-28 - Velcade (bortezomib) 2.25mg SC (weekly,
biweekly, triweekly)</li>
<li>2020-11-13 ~ 2021-07-21 - Xgeva (denosumab) 120mg Q1M SC</li>
<li>2018-04-06 ~ 2019-01-03 - Zobonic (zoledronic acid) 4mg IV (roughly
monthly)</li>
<li>2021-08-04 ~ 2022-11-25 - Endoxan (cyclophosphamide) 50mg BID
PO</li>
<li>2020-05-15 ~ 2020-10-29 - Revlimid (lenalidomide) 25mg QD PO</li>
<li>2018-03-19 ~ 2020-01-31 - Thado (thalidomide) 50mg HS PO</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>FS blood sugar levels from 2022-12-10 to 2022-12-11 were
approximately 300 to 400 mg/dL. If the reading on 2022-12-12 still
exceeds 200 mg/dL (regular insulin 8 unit has been prescribed since
2022-12-11), then addition of basal insulin might be considered.</li>
</ul>
</div>
</div>
<div id="section-59" class="section level1">
<h1>700071716</h1>
<div id="section-60" class="section level2">
<h2>221209</h2>
<p>{NSCLC, not completed}</p>
<ul>
<li>diagnosis - 2022-12-09 discharge note
<ul>
<li>Right upper lobe lung cancer, adenocarcinoma, T2bN1M1b with bone
metastasis, ECOG 1</li>
<li>Encounter for antineoplastic chemotherapy</li>
<li>Encounter for antineoplastic immunotherapy</li>
<li>Chronic viral hepatitis B without delta-agent</li>
<li>Hypertension</li>
<li>paronychia with granulation over toenail</li>
<li>Suspect folliculitis with secondary irriation eczema</li>
<li>mebomian gland dyusfunction</li>
<li>Dry eye</li>
<li>Reflux esophagitis LA Classification grade A</li>
</ul></li>
<li>lab data
<ul>
<li>2021-10-13 ROS1 FISH not detected<br />
</li>
<li>2021-10-08 ROS1 IHC Negative<br />
</li>
<li>2021-10-06 EGFR G719X not detected<br />
</li>
<li>2021-10-06 EGFR Exon19 del not detected<br />
</li>
<li>2021-10-06 EGFR S768I not detected<br />
</li>
<li>2021-10-06 EGFR T790M not detected<br />
</li>
<li>2021-10-06 EGFR Exon20 ins not detected<br />
</li>
<li>2021-10-06 EGFR L858R detected<br />
</li>
<li>2021-10-06 EGFR L861Q not detected<br />
</li>
<li>2021-10-05 ALK IHC Negative<br />
</li>
<li>2021-10-05 PD-L1 (22C3) TPS&gt;=1% and &lt;50%<br />
</li>
<li>2021-09-22 Anti-HCV Nonreactive<br />
</li>
<li>2021-09-22 Anti-HCV Value 0.05 S/CO<br />
</li>
<li>2021-09-22 HBsAg Nonreactive<br />
</li>
<li>2021-09-22 HBsAg (Value) 0.35 S/CO<br />
</li>
<li>2021-09-22 Anti-HBs 7.64 mIU/mL</li>
</ul></li>
<li>exam findings
<ul>
<li>2021-09-22 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy—adenocarcinoma, moderately
differentiated<br />
</li>
<li>Sections show neoplastic glandular cells infiltrating in a fibrotic
stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(+), Napsin A(+), p40(-),
and CD56(-). The results are supportive for the diagnosis.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-12-06 Dermatology
<ul>
<li>A
<ul>
<li>The patient had sufferred from pronychia with granulation formaiton.
several itchy papules over expose area with mild vesicles was
noted.<br />
</li>
<li>Under the impression of paronychia with granulation over toenail.
suspected folliculitis with secondary irriation eczema.<br />
</li>
<li>The following sugeetion:
<ul>
<li>Do cryotherapy at Derma OPD and further wound care with tetracycline
onit 1 tube topical bid use.</li>
<li>consider Doxycycline 1# bid and allgrea 1# bid po use for 7
days.</li>
<li>Ulex cream 1 tube topical bid over itchy papules of the trunk.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-12-06 Ophthalmology
<ul>
<li>A
<ul>
<li>S: bilateral eye strain and pain for 2 days</li>
<li>O
<ul>
<li>bcva od 0.15(1.0/-2.5) os 0.1(1.0x-2.25)</li>
<li>pt 18/18 mmHg</li>
<li>pupil: 3mm+/+, 3mm+/+, no rapd</li>
<li>MGD</li>
<li>conj: np ou</li>
<li>K: cl ou</li>
<li>ac deep and clear ou</li>
<li>lens ns+</li>
<li>c/d: 0.5-6 neurorim ok</li>
</ul></li>
<li>A
<ul>
<li>mebomian gland dyusfunction ou</li>
<li>dry eye ou</li>
</ul></li>
<li>P
<ul>
<li>tear nature 1gtt qid ou</li>
<li>if s/s worsen, come back earlier</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-06 - Opdivo (nivolumab) 100mg 1hr</li>
<li>2022-12-05 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-11-14 - Opdivo (nivolumab) 100mg 1hr</li>
<li>2022-11-10 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-10-09 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-09-27 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-09-06 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-08-16 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-07-26 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-07-05 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-06-14 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-05-24 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-05-03 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-04-12 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-03-22 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-03-01 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-02-08 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-01-11 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-12-21 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2022-11-30 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2021-11-09 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2021-10-19 - Avastin (bevacizumab) 7.5mg/m2 500mg 1hr
<ul>
<li>premed - diphenhydramine 30mg</li>
</ul></li>
<li>2021-10-07 ~ undergoing - Giotrif (afatinib 30mg) 1# QDAC</li>
<li>2022-09-05 - Xgeva (denosumab) 120mg SC</li>
<li>2022-08-13 - Xgeva (denosumab) 120mg SC</li>
<li>2022-07-15 - Xgeva (denosumab) 120mg SC</li>
<li>2022-06-13 - Xgeva (denosumab) 120mg SC</li>
<li>2022-05-02 - Xgeva (denosumab) 120mg SC</li>
<li>2022-04-08 - Xgeva (denosumab) 120mg SC</li>
<li>2022-03-11 - Xgeva (denosumab) 120mg SC</li>
<li>2022-02-07 - Xgeva (denosumab) 120mg SC</li>
<li>2022-01-07 - Xgeva (denosumab) 120mg SC</li>
<li>2021-12-10 - Xgeva (denosumab) 120mg SC</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-61" class="section level1">
<h1>700191291</h1>
<div id="section-62" class="section level2">
<h2>221209</h2>
<ul>
<li>lab data
<ul>
<li>2022-04-21 ROS1 IHC
<ul>
<li>The immunostaining of the section slide labeled S2022-03626, using
ROS1(SP384) antibody along with a Ventana autostainer system, revealed
1+ cytoplasmic staining, in over 50%, of tumor cells.</li>
</ul></li>
<li>2022-03-28 PD-L1 (22C3)
<ul>
<li>Tumor Proportion Score (TPS) assessment: TPS &gt;= 50%</li>
<li>Tumor Proportion Score (TPS): 50%</li>
</ul></li>
<li>2022-03-21 ROS1 FISH
<ul>
<li>Rearrangement of ROS1 gene is NOT detected.</li>
<li>Patients with NO ROS1 gene arrangement may not benefit from therapy
with ROS1-targeted inhibitors.</li>
</ul></li>
<li>2022-03-18 EGFR gene mutation
<ul>
<li>The EGFR mutation testing was for detection of exons 18 (G719X), 19
(Deletions), 20 (T790M, S7681, Insertions), 21 (L858R, L861Q) mutations
of EGFR gene.</li>
<li>A point mutation was detected at exon 21 (L858R) of EGFR gene in
this specimen.</li>
</ul></li>
<li>2022-03-17 ALK IHC
<ul>
<li>The immunostaining of the section slide labeled S2022-03626, using
ALK antibody D5F3 along with a Ventana autostainer system, revealed no
staining of tumor cells.</li>
</ul></li>
<li>2022-03-03 Anti-HCV Nonreactive<br />
</li>
<li>2022-03-03 Anti-HCV Value 0.04 S/CO<br />
</li>
<li>2022-03-03 HBsAg Nonreactive<br />
</li>
<li>2022-03-03 HBsAg (Value) 0.39 S/CO<br />
</li>
<li>2022-03-02 Mycoplasma IgM Negative Index<br />
</li>
<li>2022-03-02 Mycoplasma IgM Value 0.1 Index</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-12-07 Tc-99m MDP whole body bone scan
<ul>
<li>Findings:
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi of
radiotracer revealed increased activity in the sternum, multiple T- and
L-spine, sacrum, bilateral rib cages, scapulae, bilateral multiple
pelvic bones, S-I joints, and femurs in whole body bone survey.</li>
</ul></li>
<li>Impression:
<ul>
<li>All of above-mentioned bone lesions are old and most of them show
stationary or less evident compared with the previous study on
2022-07-13, indicating partial response to current therapy.<br />
</li>
<li>There is still lung cancer with multiple bone metastases in the
sternum, multiple T- and L-spine, sacrum, bilateral rib cages, scapulae,
bilateral multiple pelvic bones, S-I joints, and femurs.</li>
</ul></li>
</ul></li>
<li>2022-12-06 MRI - brain
<ul>
<li>As compared with prior MRI (2022/07/12), markedly regression of the
multiple nodules over bil. cerebellar and cerebral, no obvious edema was
found.</li>
<li>Mild periventricular small vessel disease. NO acute ischemic
infarct.</li>
<li>Paranasal sinusitis.</li>
</ul></li>
<li>2022-12-06 CT - chest
<ul>
<li>Indication: lung cancer restaging</li>
<li>Findings: Comparison was made with previous CT dated on 2022/07/12
<ul>
<li>Lungs:
<ul>
<li>normal appearance of RML, RLL, and left lung.</li>
<li>residual spiculated RUL tumor with corona radiata (26mm in longest
dimension), in comparison with the previous study, the lesion is
slightly decreasing in size.</li>
<li>Mediastinum and hila: no enlarged LN.</li>
</ul></li>
<li>Vessels:
<ul>
<li>Aorta: normal caliber of thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
<li>Heart: normal in size of cardiac chambers.</li>
</ul></li>
<li>Pleura: minimal residual bilateral effusions.</li>
<li>Visible abdominal contents:
<ul>
<li>no abnormal density and size of visible portion of the liver,
spleen, both adrenal glands, and pancreas</li>
<li>no enlarged lymph node.</li>
</ul></li>
<li>Visualized bones: destructive lytic or blastic change in visualized
bones with pathological compression fracture of many vertebral bodies,
stationary.</li>
</ul></li>
<li>Impression:
<ul>
<li>RUL cancer with slightly decrease in size of primary tumor and
stationary of bony metastasis as compared with CT on 2022/07/12</li>
</ul></li>
</ul></li>
<li>2022-12-05, -09-04, -08-08 CXR
<ul>
<li>osteolytic/blastic metastases in multiple bones of thoracic
cage</li>
<li>a nodular opacity (ill-defined) over RUL, consistent a primary lung
cancer, stationary</li>
<li>marginal spurs of multiple vertebral bodies due to spondylosis</li>
<li>Lt subpulmonary effusion?</li>
</ul></li>
<li>2022-07-13 Tc-99m MDP whole body bone scan
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi of
radiotracer revealed increased activity in the sternum, multiple T- and
L-spine, sacrum, bilateral rib cages, scapulae, bilateral multiple
pelvic bones, S-I joints, and femurs in whole body bone survey.</li>
<li>IMPRESSION:
<ul>
<li>Most of above-mentioned bone lesions are old and show stationary or
less evident compared with the previous study on 2022-03-09, indicating
partial response to current therapy.<br />
</li>
<li>Highly suspected cancer with multiple bone metastases in the
sternum, multiple T- and L-spine, sacrum, bilateral rib cages, scapulae,
bilateral multiple pelvic bones, S-I joints, and femurs.</li>
</ul></li>
</ul></li>
<li>2022-07-12 MRI - brain
<ul>
<li>Findings: comparison 2022/03/08 MRI
<ul>
<li>Markedly regression of the multiple bil. cerebellar and cerebral
nodules, no obvious edema was found<br />
</li>
<li>After IV contrast administration shows no obvious focal
nodule.<br />
</li>
<li>Normal cisterns and sulcal systems.</li>
<li>Normal bilateral ventricular size and shapes.</li>
<li>Normal appearance of bilateral cochlear and vestibular nerves
complexes.</li>
<li>MRA shows patency of the major vessels of the Willis circle,
bilateral ICAs and vertebrobasilar trunk.</li>
</ul></li>
<li>Imp:
<ul>
<li>Markedly regression of the multiple bil. cerebellar and cerebral
nodules</li>
</ul></li>
</ul></li>
<li>2022-07-12 CT - chest
<ul>
<li>Findings: Comparison was made with previous CT dated on 20220303
<ul>
<li>Lungs:
<ul>
<li>normal appearance of RML, RLL, and left lung.</li>
<li>residual spiculated RUL tumor (26mm in longest dimension), in
comparison with the previous study, the lesion is significantly
dencreasing in size.</li>
<li>Mediastinum and hila: complete resolution of extensive
lymphadenopathy in the visceral space and anterior prevascular space and
Rtt hilum as compared with previous CT</li>
</ul></li>
<li>Vessels:
<ul>
<li>Aorta: normal caliber of thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
<li>Heart: normal in size of cardiac chambers.</li>
</ul></li>
<li>Pleura: minimal residual bilateral effusions.</li>
<li>Visible abdominal contents:
<ul>
<li>Rt Lt bilateral renal cysts stone up to cm (longest axial
diameter)</li>
<li>a hepatic cyst multiple hepatic cysts up to cm (longest axial
diameter).</li>
<li>normal appearance of gallbladder. gall bladder stones up to cm.</li>
<li>no abnormal density and size of visible portion of the unremarkable
of the liver, spleen, both adrenal glands, pancreas, and both kidneys.
bile ducts: No dilatation.</li>
<li>no enlarged lymph node.</li>
</ul></li>
<li>Visualized bones: destructive lytic or blastic in visualized bones
with pathological compression fracture of many vertebral bodies, in
regression.</li>
</ul></li>
<li>Impression:
<ul>
<li>RUL cancer with significant decreased size of primary tumor and
resolution of mediastinal-hilar LAPs, and regression bony metastasis
compared with CT on 20220303</li>
</ul></li>
</ul></li>
<li>2022-07-11, -06-04, -04-07, -03-28 CXR
<ul>
<li>osteolytic/blastic metastases in multiple bones of thoracic
cage</li>
<li>a mass opacity (ill-defined) over RUL-anterior segment along the
minor fissure,consistent with a primary lung cancer,stationary</li>
<li>marginal spurs of multiple vertebral bodies due to spondylosis</li>
<li>Rt and Lt subpulmonary effusion?</li>
</ul></li>
<li>2022-05-04 Mammography
<ul>
<li>BI-RADS category 1, Negative.</li>
</ul></li>
<li>2022-03-30 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the right upper lung and right
mediastinal lymph nodes, compatible with the primary lung cancer with
regional lymph nodes involvement.<br />
</li>
<li>Glucose hypermetabolism in the skeleton including sternum, multiple
C-, T- and L-spine, sacrum, bilateral rib cages, scapulae, bilateral
multiple pelvic bones, S-I joints, and femurs, highly suspected lung
cancer with multiple bone metastases.<br />
</li>
<li>Right upper lung cancer with regional lymph nodes and multiple bone
metastases, cTxN2M1c, stage IVB (AJCC 8th ed.), by this F-18 FDG PET
scan.</li>
</ul></li>
<li>2022-03-09 Tc-99m MDP whole body bone scan
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi of
radiotracer revealed increased activity in the sternum, multiple T- and
L-spine, sacrum, bilateral rib cages, scapulae, bilateral multiple
pelvic bones, S-I joints, and femurs in whole body bone survey.</li>
<li>IMPRESSION: Highly suspected cancer with multiple bone metastases in
the sternum, multiple T- and L-spine, sacrum, bilateral rib cages,
scapulae, bilateral multiple pelvic bones, S-I joints, and femurs.</li>
</ul></li>
<li>2022-03-08 MRI - brain
<ul>
<li>Findings
<ul>
<li>Multiple bil. cerebellar and cerebral nodules, up to 14 mm in left
parietal lobes.</li>
<li>After IV contrast administration shows well or heterogenous
enhancement of the nodules.<br />
</li>
<li>Normal cisterns and sulcal systems.</li>
<li>Normal bilateral ventricular size and shapes.</li>
<li>Normal appearance of bilateral cochlear and vestibular nerves
complexes.</li>
<li>MRA shows patency of the major vessels of the Willis circle,
bilateral ICAs and vertebrobasilar trunk.</li>
</ul></li>
<li>Imp: Multiple bil. cerebellar and cerebral metastases.</li>
</ul></li>
<li>2022-03-04 Patho - lung transbronchial biopsy
<ul>
<li>Lung, RUL, CT-duide biopsy—adenocarcinoma, poorly
differentiated</li>
<li>Specimen submitted in formalin consists of 3 strips of tan,
irregular tissue measuring up to 0.6 x 0.1 x 0.1 cm. All for section in
one cassette.</li>
<li>Sections show solid nests, acinar and cribriform glandular cells
infiltrating in a fibrotic stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(+), Napsin A(+),
GATA3(-), p40(focal +), and CD56(-). The results are supportive for the
diagnosis.</li>
</ul></li>
<li>2022-03-04 CXR
<ul>
<li>no pneumothorax or pleural effusion s/p transthoracic needle biopsy
of RUL mass</li>
<li>osteolytic metastases in multiple bones of thoracic cage</li>
<li>bilateral pleural effusions</li>
<li>marginal spurs of multiple vertebral bodies due to spondylosis.</li>
</ul></li>
<li>2022-03-03 CT - chest
<ul>
<li>Indication: RUL mass</li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Spiculated mass at right upper lobe up to 4.35cm in largest
dimension is found. Lung cancer is considered.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>Lymphadenopathy at bilateral mediastinum and bilateral axillary
region.</li>
<li>Minimal atelectatic change at right middle lobe is found.</li>
<li>Bilateral pleural effusion is found.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
<li>Visible brain
<ul>
<li>Several enhanced nodules at brain parenchyma is found. Brain meta is
considered.</li>
<li>There is no evidence of destructive bone lesion.</li>
<li>No evidence of ICH, SAH or SDH.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Right upper lobe lung cancer with mediastinal lymphadenopathy, bone
meta and brain meta.</li>
</ul></li>
</ul></li>
<li>2022-03-01 CXR
<ul>
<li>a mass opacity (ill-defined) over RUL-anterior segmnmt along the
minor fissur, stationary</li>
<li>small Rt pleural effusion</li>
<li>lytic change at Rt 3rd rib, left inferior scapular body and axillary
border and may be left 5th rib too due to metastases</li>
<li>old fracture of Rt 4th and Lt 4th ribs</li>
<li>hazy area of increased opacity Lt lower lung zone</li>
<li>Normal heart size</li>
</ul></li>
<li>2022-03-01 SONO - chest
<ul>
<li>Right side minimal pleural effusion; thoracocentesis was not
performed due to high risk of complications.</li>
<li>Left thorax: no pleural effusion.</li>
</ul></li>
<li>2022-03-01 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (120 - 46) / 120 = 61.67%
<ul>
<li>M-mode (Teichholz) = 61</li>
</ul></li>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Dilated LA, grade 1 LV diastolic dysfunction</li>
<li>Mild AR, MR</li>
</ul></li>
<li>2022-02-26 CXR
<ul>
<li>a mass opacity (ill-defined) over RUL-anterior segmnmt along the
minor fissur, high possibly of a malignant lesion suggest do CT
study</li>
<li>small Rt pleural effusion</li>
<li>lytic change at Rt 3rd rib, left inferior scapular body and axillary
border and may be left 5th rib too due to metastases</li>
<li>old fracture of Rt 4th and Lt 4th ribs</li>
<li>hazy area of increased opacity Lt lower lung zone</li>
<li>disc space narrowing and marginal spurs of vertebral bodies at
multiple levels due to spondylosis, T-spine.</li>
<li>Normal heart size</li>
</ul></li>
<li>2022-02-18 CXR
<ul>
<li>An opacity in right middle lung zone; DDx: loculated pleural
effusion, mass</li>
<li>Bilateral pleural effusion</li>
<li>Normal heart size and configuration</li>
<li>Left ribs old fracture</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-05 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-10-03 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-09-05 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-08-08 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-07-11 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-04-19 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-03-29 - ramucirumab 10mg/kg 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-05-04 ~ undergoing - Giotrif (afatinib 30mg/tab) 1# QDAC</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li><p>this patient EGFR L858R mutation detected, ROS1 (IHC 1+, FISH
undetected)</p></li>
<li><p>NCCN v5.2022</p>
<ul>
<li>EGFR L858R
<ul>
<li>Preferred
<ul>
<li>Osimertinib (category 1)</li>
</ul></li>
<li>Other Recommended
<ul>
<li>Erlotinib (category 1)</li>
<li>or Afatinib (category 1)</li>
<li>or Gefitinib (category 1)</li>
<li>or Dacomitinib (category 1)</li>
<li>or Erlotinib + ramucirumab</li>
<li>or Erlotinib + bevacizumab,</li>
</ul></li>
</ul></li>
<li>ROS1
<ul>
<li>Preferred
<ul>
<li>Entrectinib</li>
<li>or Crizotinib</li>
</ul></li>
<li>or Other Recommended
<ul>
<li>Ceritinib</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-63" class="section level1">
<h1>701350013</h1>
<div id="section-64" class="section level2">
<h2>221209</h2>
<ul>
<li><p>lab data</p>
<ul>
<li>2021-12-23 ALK IHC specimen S2021-17986<br />
</li>
<li>2021-12-23 ALK IHC Negative<br />
</li>
<li>2021-12-22 EGFR specimen S2021-17986<br />
</li>
<li>2021-12-22 EGFR G719X not detected<br />
</li>
<li>2021-12-22 EGFR Exon19 del not detected<br />
</li>
<li>2021-12-22 EGFR S768I not detected<br />
</li>
<li>2021-12-22 EGFR T790M not detected<br />
</li>
<li>2021-12-22 EGFR Exon20 ins not detected<br />
</li>
<li>2021-12-22 EGFR L858R detected<br />
</li>
<li>2021-12-22 EGFR L861Q not detected<br />
</li>
<li>2021-12-21 PD-L1(22C3) specimen S2021-17986<br />
</li>
<li>2021-12-21 PD-L1(22C3) TPS &lt; 1%<br />
</li>
<li>2021-12-15 Anti-HCV Nonreactive<br />
</li>
<li>2021-12-15 Anti-HCV Value 0.08 S/CO<br />
</li>
<li>2021-12-15 HBsAg Nonreactive<br />
</li>
<li>2021-12-15 HBsAg (Value) 0.33 S/CO<br />
</li>
<li>2021-12-15 Anti-HBs 23.01 mIU/mL</li>
</ul></li>
<li><p>exam findings</p>
<ul>
<li>2022-12-05, -11-09, -10-17, -09-21, -08-29, -08-03, -07-04,… CXR
<ul>
<li>an ill-defined nodular opacity with reticular opacities over Lt
lower lung zone stationary</li>
<li>reticular opacities over Rt lower lung zone</li>
<li>mixed osteolytic and osteoblastic metastasis in spine</li>
</ul></li>
<li>2022-09-29 CT - chest
<ul>
<li>Indication: Left lower lung cancer, adenocarcinoma, T3N0M1c with
multiple bone metastasis, ECOG 1</li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Irregular mass like lesion attaching interlobar fissure at left
lower lobe is found about 2.39cm in largest dimension. In comparison
with CT dated on 2022-06-16, the lesion is stationary.</li>
<li>Calcified coronary arteries is found.</li>
<li>There is no evidence of mediastinal LAP</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>IMp: left lower lobe lung cancer with interlobar fissure attachment
and bone meta. The primary tumor is stationary in size.</li>
</ul></li>
<li>2022-09-28 Tc-99m MDP bone scan
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi
radiotracer revealed increased activity in multiple T- and L-spines,
some bilateral ribs, left S-I joint and left iliac bone.</li>
<li>IMPRESSION: In comparison with the previous study on 2022/06/17, all
of above-mentioned bone lesions are stationary, indicating multiple bone
metastases in stable condition.</li>
</ul></li>
<li>2022-09-27 MRI - brain
<ul>
<li>Findings
<ul>
<li>Mild but generalized sulci widening and ventricle dilatation is seen
in bilateral cerebral and cerebellar hemispheres.</li>
<li>The interhemispheric fissure is centered on the midline.</li>
<li>Sella and pituitary are normal. The parasellar structures are
unremarkable.</li>
<li>There are no abnormalities in the cerebellopontine angle areas on
both sides.</li>
<li>There are no abnormalities in the calvarium.<br />
</li>
<li>No abnormal enhancement after contrast administration.</li>
</ul></li>
<li>Imp: No brain nodule or metastasis. Mild cortical brain
atrophy.</li>
</ul></li>
<li>2022-06-17 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 2022/02/11, all the
previous bone lesions are less evident, suggesting multiple bone
metastases with some resolution.</li>
</ul></li>
<li>2022-06-16 CT - chest
<ul>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Fibrotic mass at left lower lobe up to 2.47cm is found. In
comparison with CT dated on 2022-02-10, the lesion regressed.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Calcified coronary arteries is found.</li>
<li>Fibrotic change at left lingula lobe, left lower lobe and right
middle lobe and right lower lobe is found.</li>
<li>Calcified coronary arteries is found.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>The GB is well distended without soft tissue lesion</li>
</ul></li>
</ul></li>
<li>IMp: Left lower lobe lung cancer with bone meta. The left lower lobe
primary tumor regressed.</li>
</ul></li>
<li>2022-02-11 Tc-99m MDP bone scan
<ul>
<li>The Tc-99m MDP bone scan at 3 hrs after injection of 20 mCi
radiotracer revealed increased activity in multiple T- and L-spines,
some bilateral ribs, left S-I joint and left iliac bone.</li>
<li>IMPRESSION: The scintigraphic findings suggest multiple bone
metastases.</li>
</ul></li>
<li>2022-02-10 CT - chest
<ul>
<li>Lung cancer, adenocarcinoma, T3N0M1c with multiple bone
metastasis</li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Spiculated mass at left lower lobe up to 2.95cm in largest dimension
is found. In comparison with previous CT performed at other hospital on
2021-11-24, the lesion regressed.</li>
<li>Minimal left pleural effusion is found.</li>
<li>Calcified coronary arteries is found.</li>
<li>Linear atelectatic change at bilateral basal lungs is found.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
<li>Visible brain
<ul>
<li>No evidence of space occupying lesion in the brain parenchyma is
found.</li>
<li>No evidence of ICH, SAH or SDH.</li>
</ul></li>
</ul></li>
<li>IMp:
<ul>
<li>left lower lobe lung cancer with primary tumor regression.</li>
<li>Bone meta. Suggest correlate with bone scan for comparison.</li>
</ul></li>
</ul></li>
<li>2021-12-08 Whole body PET scan
<ul>
<li>Glucose hypermetablic lesion in the left lower lung, compatible with
the primary lung cancer.<br />
</li>
<li>Glucose hypermetablic lesions in the left lower ribs, some T-spine,
L1-3 spines with adjacent left-sided soft tissue, left S-I joint, and
left iliac bone, highly suspected lung cancer with distant metastases.
Please correlate with other clinical findings for further
evaluation.</li>
<li>Left lower lung cancer with multiple bone metastases, cTxNxM1c,
stage IVB (AJCC 8th ed.), by this F-18 FDG PET scan.</li>
</ul></li>
<li>2021-12-07 Patho - lung transbronchial biopsy
<ul>
<li>Lung, LLL, CT-guide biopsy — adenocarcinoma, poorly
differentiated<br />
</li>
<li>Sections show large pleomorphic tumor cells infiltrating in a
fibrotic stroma.</li>
<li>The immunohistochemical stains reveal CK(+), TTF-1(+), Napsin A(+),
p40(-), and CD56(-). The results are supportive for the diagnosis.</li>
</ul></li>
<li>2021-12-06 MRI - brain
<ul>
<li>No evidence of intracranial lesion.</li>
</ul></li>
</ul></li>
<li><p>consultation</p>
<ul>
<li>2022-06-09 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>This is a 52-year-old man with past history of Left lower lobe Lung
cancer, adenocarcinoma, T3N0M1c with multiple bone metastasis, ECOG 1,
diagnosed on 2021-12; T3: LLL mass with parietal pleura invades, N0: no
definite mediastinal LAPs, M1c: multiple bone metasatsis,
<ul>
<li>EGFR mutation: L858R (+), exon 19 (-), ALK(-), PD-L1: &lt;1%; with
chemotherapy and radiotherapy.</li>
<li>The lung cancer treatment regimen as below:
<ul>
<li>1st chemotherapy with TKI Giotrif since 2021-12-29.</li>
<li>Angiogenesis inhibitor with Cyramza C1 since 2021-12-16.</li>
<li>Immunetherapy with nivo C1 on 2022-01-11 and Ipi C1 on
2022-03-28.</li>
<li>Radiotherapy 2400cGy/8 fractions to T7-8, T12-L3 and paraspinal
mass, 2021-12-09 ~ 2021-12-22.</li>
</ul></li>
</ul></li>
<li>This time, he was admitted for TKI induced severe diarrhea, due to
severe diarrhea, we hold chemotherapy and TKI with Giotrif.</li>
<li>Laboratory data showed TSH: 7.841 uIU/mL. So we sicerely need your
help for evaluation. Thanks a lot!!!</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This 52-year-old male, with past history of left lower lobe Lung
cancer, adenocarcinoma, T3N0M1c with multiple bone metastasis, ECOG 1,
diagnosed on 2021-12, was admitted for chemotherapy and immunotherapy.
We were consulted for abnormal TFT.</li>
</ul></li>
<li>O
<ul>
<li>BW: 57-58 kg</li>
<li>HR: 100-114</li>
<li>Possible related medication: Nivolumab</li>
<li>AST/ALT: 19/16</li>
<li>BUN/Cr: 20/0.67</li>
<li>Na: 128, K: 2.9</li>
<li>TSH/FT4: 7.841/1.01</li>
<li>ATPO, ATG, TSH receptor Ab: unavailable</li>
<li>ACTH/Cortisol: 16.9/21.26</li>
<li>Thyroid echo: nil</li>
</ul></li>
<li>A:
<ul>
<li>Suspected immunotherapy related subclinical hypothyroidism</li>
</ul></li>
<li>Suggestions:
<ul>
<li>Check anti-TPO Ab, Anti-thyroglobulin Ab</li>
<li>Recheck TSH/FT4 2 weeks later</li>
<li>No need of thyroxine supplement at this moment.</li>
<li>Arrange thyroid sonography</li>
<li>Endocrine OPD F/U. Contact us if needed. I’d like to follow up this
patient.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-19 Dermatology
<ul>
<li>Q
<ul>
<li>This is a 52-year-old man who denied any systemic disease history.
He was admitted for scheduled chemotherapy and PortA insertion for LLL
cancer with spine metastasis. According to his history, he was in his
usual status of health until 2021/10, when he started to note left
tronchanteric area tenderness, accompanied with left lateral thigh and
bilateral sole numbness. Therefore, he went to local clinic for
analgesic injection. However, on 2021/11/22 when he was working, another
painful episode occurred and usual analgesic injection would not relieve
the pain. Also, marked dyspnea on exertion was noted on the same day,
when he had difficulty climbing stairs. The patient also mentioned body
weight loss for 16kg (72 -&gt; 56kg) in one month. Therefore, he first
went to the NS OPD in Cardinal Tien Hospital for help.</li>
<li>After spine MRI and chest CT image were obtained, he went to our OPD
for help. At OPD, interpretation of the image revealed LLL spiculated
tumor with pleural effusion and spine tumors (T9, T12, L1, and L2),
suspected LLL cancer with pleura and bone metastases. Under the
impression of LLL cancer with spine metastasis, he was admitted for
CT-guided lung biopsy and further cancer staging work-up. He had started
EGFR TKIs with afatinib since 2021.12.29. And is admitted scheduled
chemotherapy and port A insertion.</li>
<li>For skin rash of abdominal. We sinecrely need your professional
evaluation, thank you!!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from generalized erythematous papules on whole
trunk and scalp and 4 limbs for days.</li>
<li>Imp: Subacute dermatitis</li>
<li>Suggestion:
<ul>
<li>Zaditen (ketotifen) 1/ Bid</li>
<li>Xyzal (levocetirizine) 1 / Hs</li>
<li>Zalain Gel (sertaconazole) * 1 BT/Qd</li>
<li>Mycomb (nystatin, neomycin, gramicidin, triamcinolone) * 6
tubes/bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-25 Radiation Oncology
<ul>
<li>Q
<ul>
<li>consult for radiotherapy</li>
<li>This is a 52-year-old man who denied any systemic disease history.
He was admitted for scheduled chemotherapy for LLL cancer with spine
metastasis. According to his history, he was in his usual status of
health until 2021/10, when he started to note left tronchanteric area
tenderness, accompanied with left lateral thigh and bilateral sole
numbness. Therefore, he went to local clinic for analgesic injection.
However, on 2021/11/22 when he was working, another painful episode
occurred and usual analgesic injection would not relieve the pain. Also,
marked dyspnea on exertion was noted on the same day, when he had
difficulty climbing stairs. The patient also mentioned body weight loss
for 16kg (72-＞56kg) in one month. Therefore, he first went to the NS
OPD in Cardinal Tien Hospital for help. After spine MRI and chest CT
image were obtained, he went to our OPD for help.</li>
<li>At OPD, interpretation of the image revealed LLL spiculated tumor
with pleural effusion and spine tumors (T9, T12, L1, and L2), suspected
LLL cancer with pleura and bone metastases. Under the impression of LLL
cancer with spine metastasis.<br />
</li>
<li>He had started EGFR TKIs with afatinib since 2021.12.29. And this
time is admitted for C5 Ramu 600mg, C4 Nivo 200mg free (20X10), Ipi 50mg
charge, NGS liquid biopsy.</li>
<li>Bone scan reveals increased activity in multiple T- and L-spines,
some bilateral ribs, left S-I joint and left iliac bone. Some bone pain
over SI and iliac joint.</li>
<li>We need your ptofessional expertise for help, thank you very
much.</li>
</ul></li>
<li>A
<ul>
<li>Subjective:
<ul>
<li>This is a 52-year-old man who denied any systemic disease history.
He was in his usual status of health until 2021/10, when he started to
note tenderness over left tronchanteric area, accompanied with left
lateral thigh and bilateral sole numbness. Therefore, he went to local
clinic for analgesic injection. However, on 2021/11/22 when he was
working, another painful episode occurred and usual analgesic injection
would not relieve the pain. Also, marked dyspnea on exertion was noted
on the same day, when he had difficulty climbing stairs. The patient
also mentioned body weight loss for 16kg (72-&gt;56kg) in one
month.</li>
<li>Therefore, he first went to the NS OPD in Cardinal Tien Hospital for
help. After spine MRI and chest CT image were obtained, he went to our
OPD for help. At OPD, interpretation of the image revealed LLL
spiculated tumor with pleural effusion and spine tumors (T9, T12, L1,
and L2), suspected LLL cancer with pleura and bone metastases. Under the
impression of LLL cancer with spine metastasis.<br />
</li>
<li>He had started EGFR TKIs with afatinib since 2021/12/29. And this
time is admitted for C5 Ramu 600mg, C4 Nivo 200mg free (20X10), Ipi 50mg
charge, NGS liquid biopsy.</li>
<li>Some bone pain over SI and iliac joint has been noted for weeks.
<ul>
<li>Previous RT: s/p RT to T7-8, T12, L1-3 spines, 3000cGy/10 fx,
2021/12/09-22.</li>
<li>Other disease: denied.</li>
<li>Family history: denied.</li>
</ul></li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2022/3/25: No SCF LAPs.</li>
<li>Pathology, CT-guided biopsy, 2021/12/07 10am: adenocarcinoma, poorly
differentiated.</li>
<li>Images:
<ul>
<li>Chest CT, 2022/2/10: Spiculated mass at left lower lobe up to 2.95cm
in largest dimension is found. (Se202 IM64). In comparison with previous
CT performed at other hospital on 2021-11-24, the lesion regressed.
Minimal left pleural effusion is found. Linear atelectatic change at
bilateral basal lungs is found. Sclerotic and lytic changes of the bony
structure is found. Bony metastasis is considered.</li>
<li>Bone scan, 2022/2/11: increased activity in multiple T- and
L-spines, some bilateral ribs, left S-I joint and left iliac bone. IMP:
The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
</ul></li>
<li>Diagnosis:
<ul>
<li>Lung cancer, LLL, PD adenocarcinoma, cT1cN0M1c, with minimal left
pleural effusion, bone metastasis over T8, T12, L1, L2, with extensive
paraspinal mass over left L2 which compresses the spinal cord s/p RT on
2021/12/22, under EGFR TKIs with afatinib since 2021/12/29. And this
time is admitted for C5 Ramu 600mg, C4 Nivo 200mg free (20X10), Ipi 50mg
charge; ECOG: 1.</li>
</ul></li>
<li>Suggest: Radiotherapy.
<ul>
<li>Goal: Palliative.</li>
<li>RT Plan:
<ul>
<li>Target &amp; Volume: left S-I joint and left iliac bone.</li>
<li>Technique: IMRT by linear accelerator.</li>
<li>Dose &amp; Fractionation: 3000cGy/10 fractions.</li>
</ul></li>
</ul></li>
<li>Plan:
<ul>
<li>RT to bone metastasis is suggested for pain control. CT simulation
is arranged on March 28, 10:30am. Possible treatment toxicity (radiation
dermatitis) is told. To prevent heavy weight bearing and falling
accidence was told.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-17 Dermatology
<ul>
<li>Q
<ul>
<li>He had started EGFR TKIs with afatinib since 2021.12.29. And is
admitted for C2 Ramu 600mg, Nivo 200mg injection treatment.</li>
<li>This time, skin rash over head and chest, we need your help, thank
you a lot!</li>
</ul></li>
<li>A
<ul>
<li>Skin finding: multiple erythematous papules with pustules on face,
scalp and chest</li>
<li>Imp: acniform eruption due to EGFR TKI</li>
<li>Plan:
<ul>
<li>doxycycline 1# BID</li>
<li>clindamycin gel BID for scalp, face and chest</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-11 Dermatology
<ul>
<li>Q
<ul>
<li>He had started EGFR TKIs with afatinib since 2021.12.29. And is
admitted for C2 Ramu 600mg, Nivo 200mg injection treatment.</li>
<li>However, TKI related side effect was noted. paronychia and some eash
over face was noted. We need your help to evalaute his problems and give
further suggestion. Thanks for your kindly help.</li>
</ul></li>
<li>A
<ul>
<li>Skin finding: erythematous macules and patches on T area of
face</li>
<li>Imp: seborrheic dermatitis</li>
<li>Plan:
<ul>
<li>rinderon-V cream (betamethasone) BID topical used</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-10 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This is a 52-year-old male patient without underlying disease. This
time he has experienced low back pain with radiation to left leg since
one month ago. Cancer staging work-up revealed poorly differentiated
adenocarcinoma, LLL of lung, with metastases to left lower ribs, some
T-spines, L1 to L3 spines with adjacent left-sided soft tissue, left S-I
joint, and left iliac bone, cT2aN0M1c, sage IVB.</li>
<li>We sincerely need your expertise for lung cancer treatment. Thank
you very much!</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>LLL lung cancer with lung to lung, bone metastasis, T4N0M1ic, stage
IVB</li>
</ul></li>
<li>Suggesion:
<ul>
<li>Check EGFR, ALK, PDL1 mutation</li>
<li>Bone radiotherapy</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-09 Painology
<ul>
<li>Q
<ul>
<li>This is a 52-year-old male patient without underlying disease. This
time he has experienced low back pain with radiation to left leg since
one month ago. Image studies were done at Cardinal Tien Hospital, and
LLL lung cancer with T and L spine metastases is strongly suspected. He
was admitted for cancer survey. After admission, we consulted Radiation
Oncology for spine tumor radiotherapy. This time, we sincerely need your
expertise for bone pain control. Thank you very much!</li>
<li>Regular medications:
<ul>
<li>Muaction 100 mg/SR tab (Tramadol)  1 tab     PO      TID     </li>
<li>Acetal 500 mg/tab (Acetaminophen)  1 tab     PO      TID     </li>
<li>Aelocon 50mg &amp; 5mg/tab (Thiamine Disulfide &amp; Riboflavin; B1
&amp; B2)  1 tab     PO      BID     </li>
<li>Votan-SR 100mg/tab  1 TAB     PO      TID  </li>
</ul></li>
<li>Morphine 5mg IV prnq6h use</li>
</ul></li>
<li>A
<ul>
<li>S:
<ul>
<li>left lateral pelvis pain with radiation to inguinal area for
weeks</li>
</ul></li>
<li>O:
<ul>
<li>NRS (Numerical Rating Scale for pain measurement): 3-8 (after taking
tramadol can remain 4-5 hours down to 3, it can be up to 8 if not
well-timing; morphine IV 5mg can remain up to over night &gt; 6
hours)</li>
<li>Touch pain, tenderness, allodynia. No rash, local heat or
nodule</li>
<li>Tenderness at lateral and post waist and paraspinal area (Left L1-3
level) and left iliac</li>
</ul></li>
<li>A:
<ul>
<li>Left lower lung cancer with multiple bone metastases, cTxNxM1c,
stage IV</li>
<li>Susp L1-3 spine, susp left psoas or QL muscle? metastasis with
intercostal nerve, ilioinguinal, genitofemoral nerve entrapement.</li>
<li>Diagnostic USG intervention: Left lumbar plexus block (T12-L1):
reactive</li>
<li>US: a hypoechoic lesion over QL/Psoas muscle: soft tissue
metastasis?</li>
</ul></li>
<li>P:
<ul>
<li>According to latest NCCN guideline, you may shift tramadol to low
dose oral morphine/oxycontin (for pain NRS &gt; 4, low dose high potent
opioids +- adjuvant medication and interventional treatment). Morphine
15mg PO Q6H-Q8H (or Oxycontin 10mg Q12H) was suggested first.</li>
<li>Due to multiple metastasis at bone/ soft tissue and his fear to
intervention, I suggested that medication adjustment and RT would be
better for him now.</li>
</ul></li>
<li>Please record the pain scale and the PRN dose</li>
</ul></li>
</ul></li>
<li>2021-12-06 Radiation Oncology
<ul>
<li>A
<ul>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1. On wheel chair use due to bone pain.</li>
<li>PE, 2021/12/06: No SCF LAPs.</li>
<li>Pathology, CT-guided biopsy, 2021/12/07 10am: pending.</li>
<li>Images:
<ul>
<li>L spine MRI, 2021/11/23: bone metastasis over T8, T12, L1, L2, with
extensive paraspinal mass over left L2 which compresses the spinal
cord.</li>
<li>Chest CT, 2021/11/24: 23-mm tumor over LLL, small mediastinal LNs,
minimal left pleural effusion, bone metastasis over T8, T12, L1, L2,
with extensive paraspinal mass over left L2 which compresses the spinal
cord. Imp: cT1cN0M1c.</li>
<li>Brain MRI, 2021/12/06: No brain metastasis.</li>
</ul></li>
</ul></li>
<li>Diagnosis: Lung cancer, LLL, R/O adenocarcinoma, cT1cN0M1c, with
minimal left pleural effusion, bone metastasis over T8, T12, L1, L2,
with extensive paraspinal mass over left L2 which compresses the spinal
cord; ECOG: 1.</li>
<li>Suggest: Radiotherapy.</li>
<li>Goal: Palliative.</li>
<li>RT Plan:
<ul>
<li>Target &amp; Volume: bone metastasis over T8, T12, L1, L2.</li>
<li>Technique: IMRT by linear accelerator.</li>
<li>Dose &amp; Fractionation: 3000cGy/10 fractions.</li>
</ul></li>
<li>Plan:
<ul>
<li>RT to bone metastasis is suggested for pain control. CT simulation
is arranged on Dec 07 11am. Possible treatment toxicity (radiation
dermatitis and esophagitis) is told. To prevent heavy weight bearing and
falling accidence was told. Diet education is given.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li><p>radiotherapy</p></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2022-12-07 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-12-06 - Opdivo (nivolumab) 100mg 1 hr</li>
<li>2022-12-05 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-11-12 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-11-11 - Opdivo (nivolumab) 100mg 1hr</li>
<li>2022-11-10 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-10-20 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-10-19 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-10-18 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-09-23 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-09-22 - Opdivo (nivolumab) 100mg 1hr</li>
<li>2022-09-21 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-09-01 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-08-31 - Opdivo (nivolumab) 100mg 1hr</li>
<li>2022-08-30 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-08-05 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-08-05 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-08-04 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-07-06 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-07-05 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-07-04 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-06-13 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-05-18 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-05-17 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-05-16 - Cyramza (ramucirumab) 500mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-04-20 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-04-19 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-04-18 - Cyramza (ramucirumab) 600mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-03-28 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-03-25 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-03-24 - Cyramza (ramucirumab) 600mg 1.5hr
<ul>
<li>premed - dexamethasone 8mg + diphenhydramine 30mg</li>
</ul></li>
<li>2022-03-02 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-03-01 - Cyramza (ramucirumab) 600mg 2hr</li>
<li>2022-02-08 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-02-07 - Cyramza (ramucirumab) 600mg 2hr</li>
<li>2022-01-11 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-01-10 - Cyramza (ramucirumab) 600mg 2hr</li>
<li>2021-12-16 - Cyramza (ramucirumab) 600mg 2hr</li>
<li>2022-08-03, 2022-08-14 ~ 2022-11-01 undergoing - Vizimpro
(dacomitinib) 15mg/tab 1# QD</li>
<li>2021-12-29 ~ 2022-07-27 - Giotrif (afatinib) 30mg/tab 1# QDAC</li>
<li>2021-12-05, 2022-02-28, 2022-04-17, 2022-05-15 - Xgeva (denosumab)
120mg SC</li>
</ul></li>
</ul>
<div id="section-65" class="section level3">
<h3>==========</h3>
</div>
<div id="section-66" class="section level3">
<h3>2022-10-19</h3>
<ul>
<li><p>The disease is characterized by L858R(+), exon19del(-), ALK(-),
and PD-L1&lt;1%. This patient has been treated with oral
afatinib(2021-12 ~ 2022-07)/dacomitinib(2022-08 ~ undergoing) and IV
ramu(2021-12 ~)/nivo(2022-01 ~)/ipi(2022-03 ~). It appears that the
current regimen is still effective to keep the disease stable (2022-02
and 2022-06 CT: regression; 2022-09 CT: stationary).</p></li>
<li><p>The serum potassium level in 2022-10-17 was 2.9 mmol/L, and it
might be beneficial to add potassium supplements.</p></li>
<li><p>The main concern for the patient and his caregiver might be pain
management. For patients who require four or more doses of short-acting
opioids consistently each day, addition of a long-acting opioid should
be considered based on the total daily dose. A controlled-release
oxycondone regimen has been prescribed to the patient since
2022-10-18.</p></li>
<li><p>In the event that the patient’s goals are not met (uncontrolled
pain persists), then administer an opioid dose equivalent to 10%~20% of
the total opioid taken in the previous 24 hours and reassess
effectiveness and adverse effects (at 15 minutes if administered IV or
at 60 minutes if administered PO).</p>
<ul>
<li>pain unchanged or increased =&gt; increase dose by 50%~100%</li>
<li>pain decreased but inadequately controlled =&gt; repeat same
dose</li>
<li>pain improved and adequately controlled =&gt; continue at current
effective dose as needed over initial 24h</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-67" class="section level1">
<h1>700806859</h1>
<div id="section-68" class="section level2">
<h2>221208</h2>
<p>{gastric cancer, T1a pN3a (6/32) cM0, pStage: IIB, s/p Op on
20220414}</p>
<ul>
<li>diagnosis - 2022-12-07 admission note
<ul>
<li>gastric CA. T1a pN3a (6/32) cM0,  pStage: IIB, s/p Op</li>
<li>chronic peptic ulcer, site unspecified, without hemorrhage or
perforation</li>
<li>myasthenia gravis without (acute) exacerbation</li>
</ul></li>
<li>past history - 2022-12-07 admission note
<ul>
<li>Myasthenia Gravis s/p thymic OP with regular using steroid control
for 20 years</li>
<li>Right breast cancer s/p</li>
<li>hypothyroidism with medication control</li>
</ul></li>
<li>current medications - 2022-12-07 admission note
<ul>
<li>Thyroxin 0.1mg/tab 1 TAB QW123456PO</li>
<li>Thyroxin 0.1mg/tab 2 TAB QW7</li>
<li>prednisolone 15mg QD</li>
<li>pyridostigmine 1 tab BID</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-23 CT - abdomen
<ul>
<li>History: gastric CA. T1a pN3a (6/32) cM0, pStage: IIB, s/p Op on
20220414</li>
<li>Findings:
<ul>
<li>S/P subtotal gastrectomy.</li>
<li>Moderate fatty liver, grade 4-5.</li>
<li>There is fat sparing area in S1 and S2/3.</li>
<li>S/P hysterectomy</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P subtotal gastrectomy.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-10-03 SONO - abdomen
<ul>
<li>suboptimal examination of liver</li>
<li>fatty liver, severe</li>
<li>fatty infiltration of pancreas</li>
</ul></li>
<li>2022-09-20 CXR
<ul>
<li>right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
</ul></li>
<li>2022-09-20, -06-24 KUB
<ul>
<li>Disc space narrowing with marginal osteophyte formation of
L2-3.</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-04-14 Patho - stomach subtotal/total (tumor)
<ul>
<li>Diagnosis
<ul>
<li>Stomach, lesser curvature midbody, laparoscope subtotal gastrectomy
with LN D2 dissection — adenocarcinoma, moderately differentiated.
invading muscularis mucosa, confirmed with IHC stain of
cytokeratin.</li>
<li>Lymph node, LN 1,3-9, 11p ,12a, 14v, LN D2 dissection — metastatic
carcinoma</li>
<li>pT1a pN3a (if cM0); pStage: IIB, at least.</li>
</ul></li>
<li>Gross Description:
<ul>
<li>Procedure: laparoscope subtotal gastrectomy with LN D2
dissection</li>
<li>Tumor Site: lesser curvature midbody</li>
<li>Tumor Size: 1.8 x 1.5 cm</li>
<li>Gross configuration: Type IIc: Flat, slightly depressed</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Adenocarcinoma
<ul>
<li>Lauren classification of adenocarcinoma: Intestinal type</li>
</ul></li>
<li>Histologic Grade: G2: Moderately differentiated</li>
<li>Tumor Extension: Tumor invades the muscularis mucosae</li>
<li>Margins
<ul>
<li>Proximal margin: uninvolved by invasive carcinoma. &gt; 4 cm
away</li>
<li>Distal margin: uninvolved by invasive carcinoma. &gt; 4 cm
away.</li>
<li>Radial margin: uninvolved by invasive carcinoma.</li>
</ul></li>
<li>Lymphovascular Invasion: not identified.</li>
<li>Perineural Invasion: not identified.</li>
<li>Regional Lymph Nodes
<ul>
<li>Number of lymph nodes involved/examined: 8/32.</li>
</ul></li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition): IIB, at
least.
<ul>
<li>TNM Descriptors (required only if applicable): N/A.
<ul>
<li>Primary Tumor (pT): pT1a: Tumor invades the lamina propria or
muscularis mucosa</li>
<li>Regional Lymph Nodes (pN): pN3a: Metastasis in seven to 15 regional
lymph nodes</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case) (if cM0);</li>
</ul></li>
</ul></li>
<li>Additional Pathologic Findings- None identified</li>
<li>Ancillary Studies – IHC stains: (result of biopsy specimen
S2022-06142): Her2/neu: negative (score=0)</li>
</ul></li>
</ul></li>
<li>2022-04-12 Patho - stomach biopsy
<ul>
<li>Stomach, LC side of low body, biopsy — Adenocarcinoma.</li>
<li>IHC stains: CK highlights neoplastic cells. Her2/neu: negative
(score=0).</li>
</ul></li>
<li>2022-04-12 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (96 - 28) / 96 = 70.83%
<ul>
<li>LVEF (%) = 71</li>
<li>M-mode (Teichholz) = 71</li>
</ul></li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>Normal LV diastolic function.</li>
<li>Normal RV systolic function.</li>
<li>Trivial MR; trivial TR; trivial PR.</li>
</ul></li>
<li>2022-03-29 CT - abdomen
<ul>
<li>Imaging Report Form for Gastric Carcinoma</li>
<li>Impression (Imaging stage): T:Tx(T_value) N:N0(N_value)
M:M0(M_value) STAGE:____(Stage_value)</li>
<li>Impression: Clinical gastric cancer, cstage T1N0M0. Suggest clinical
correlation.</li>
</ul></li>
<li>2022-03-16 Patho - stomach biopsy
<ul>
<li>Stomach, low body, biopsy — Adenocarcinoma</li>
<li>Microscopically, the sections show a picture of adenocarcinoma of
the gastric tissue characterized by tumor cells arranged in tubular,
fused glandular or cribriform pattern with enlarged and hyperchromatic
nuclei infiltrating in ulcerative stroma.</li>
<li>Immunohistochemistry of CK(+) and Her2/neu (-, Dako score 1+) for
tumor cells.</li>
<li>Besides, mild intestinal metaplasia and colony of Helicobacter
pylori are also present.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-19 Ophthalmology
<ul>
<li>Q
<ul>
<li>for left eye reddish &amp; dry</li>
<li>This 55-year-old female, a pt of gastric CA. T1a pN3a (6/32) cM0,
pStage: IIB, s/p Op on 20220414 S/P C/T with FOLFOX. She was admitted
for C/T.</li>
<li>She complained of left eye reddish &amp; dry for days. We need
expertise to evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>Itchy and soreness ou for 3 days, redness os for days, no worsen
BV</li>
<li>Gastric cancer T1a pN3a cM0, pStage: IIB, s/p op, under chemotherapy
(Oxaliplatin, high-dose 5-fluorouracil)
<ul>
<li>HBV infection under entacavir</li>
<li>OPHx: op(-), nka</li>
<li>BCVA: OD 0.05(0.5X-2.50/-1.25X55) OS 0.05(0.5X-2.00/-1.50X95)</li>
<li>PT: 11/11mmHg</li>
<li>Pupil: 3mm, light reflex + ou, no RAPD</li>
<li>Conj: np od, temporal SCH os</li>
<li>K: clear ou</li>
<li>a/c: deep/clear ou</li>
<li>lens: co+ od, co++, psc + os</li>
<li>c/d 0.3 ou</li>
<li>fundus macula ok, retinal vessels ok ou</li>
</ul></li>
<li>A:
<ul>
<li>Subconjunctival hemorrhage os</li>
<li>Cataract ou</li>
</ul></li>
<li>P:
<ul>
<li>Kary 1gtt BID ou + Eyehelp 1gtt QID ou</li>
<li>oph opd f/u</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-15 Rheumatology
<ul>
<li>Q
<ul>
<li>This 55yo female has underlying diseases of:
<ul>
<li>breast cancer</li>
<li>myasthenia gravis, prednisolone 15mg QD (0413 hold) and
pyridostigmine</li>
<li>hypothyroidism</li>
</ul></li>
<li>This time, she was admitted for gastrectomy on 20220414.</li>
<li>We would like to consult your expertise for post-operative
medication (IV form) adjustment due to NPO for many days.</li>
</ul></li>
<li>A
<ul>
<li>History review was perdormed. Patient was admitted for gastrectomy.
She has medical Hx of MG &amp; took prednisolone 15mg QD. For
post-operation NPO, I was consulted for adjusting IV form steroid
dosage.</li>
<li>Suggestion:
<ul>
<li>Treatment as current your expert’s maangement.</li>
<li>Please add Decan 4mg IV QD for 3-7 days. Then shift to regular oral
prednisolone dosage.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-14 laparoscope subtotal gastrectomy with LN D2 dissection
<ul>
<li>subtotal gastrectomy with LN 1,3-9, 11p ,12a, 14v dissection</li>
<li>anticolic isoperistalsis B-II anastomosis</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-05-18 ~ 2022-06-24 - 4500cGy/25 fractions (6 MV photon) to
stomach and regional lymphatics</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-07 - oxaliplatin 80mg/m2 135mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4780mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-11-04 - oxaliplatin 80mg/m2 135mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4750mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-10-19 - oxaliplatin 80mg/m2 135mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4800mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-09-21 - oxaliplatin 80mg/m2 135mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4780mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-08-25 - oxaliplatin 80mg/m2 130mg 2hr + leucovorin 400mg/m2
670mg 2hr + fluorouracil 2800mg/m2 4720mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-08-12 - oxaliplatin 70mg/m2 118mg 2hr + leucovorin 400mg/m2
670mg 2hr + fluorouracil 2800mg/m2 4720mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-07-20 - oxaliplatin 60mg/m2 100mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4790mg 46hr (adjuvant)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + granisetron
2mg</li>
</ul></li>
<li>2022-06-20 - fluorouracil 225mg/m2 380mg 24hr D1-5 (adjuvant CCRT)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-06-13 - fluorouracil 225mg/m2 380mg 24hr D1-5 (adjuvant CCRT)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
<li>2022-06-10 - fluorouracil 225mg/m2 380mg 24hr D1 (adjuvant CCRT)
<ul>
<li>premed - diphenhydramine 30mg + dexamethasone 4mg + metoclopramide
10mg</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>The serum ALT level trended upward.</p>
<ul>
<li>2022-12-07 S-GPT/ALT 61 U/L</li>
<li>2022-11-22 S-GPT/ALT 66 U/L</li>
<li>2022-11-14 S-GPT/ALT 66 U/L</li>
<li>2022-10-19 S-GPT/ALT 52 U/L</li>
<li>2022-09-20 S-GPT/ALT 58 U/L</li>
<li>2022-08-25 S-GPT/ALT 25 U/L</li>
<li>2022-08-16 S-GPT/ALT 36 U/L</li>
<li>2022-08-11 S-GPT/ALT 22 U/L</li>
<li>2022-07-26 S-GPT/ALT 14 U/L</li>
<li>2022-07-19 S-GPT/ALT 26 U/L</li>
<li>2022-06-20 S-GPT/ALT 14 U/L</li>
<li>2022-06-13 S-GPT/ALT 18 U/L</li>
<li>2022-06-10 S-GPT/ALT 26 U/L</li>
<li>2022-06-01 S-GPT/ALT 25 U/L</li>
</ul></li>
<li><p>The use of oxaliplatin has been associated with an increase in
ALT levels (incidence of 36% with monotherapy)</p></li>
<li><p>There is no need to adjust the dosage of the components in the
current regimen of FOLFOX.</p></li>
<li><p>The addition of pyridostigmine as a self-carried item is
recommended for the patient with myasthenia gravis since this medication
has no known heavy interactions with the active prescription.</p></li>
</ul>
</div>
</div>
<div id="section-69" class="section level1">
<h1>700261909</h1>
<div id="section-70" class="section level2">
<h2>221206</h2>
<ul>
<li>exam findings
<ul>
<li>2022-12-05 CXR
<ul>
<li>Distention of stomach.</li>
<li>Ground glass opacity in bilateral lower lungs.</li>
</ul></li>
<li>2022-11-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac crest, biopsy — See description</li>
<li>The sections show normocellular marrow (20%). The CD71+ erythroid
precursors are markedly decreased (10%). The myeloid cells show left
shift in MPO stain. The CD61+ megakaryocytes are slightly increased, and
few micromegakaryocytes are present. No increased CD34+ blasts.
Scattered CD117+ immature cells (&lt;3%) are present. Myelodysplastic
syndrome can be considered in differential diagnosis. Suggest further
bone marrow smear evaluation and clinic correlation.</li>
</ul></li>
<li>2022-09-01 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, right pelvic, biopsy — Suggested myelodysplastic
syndrome<br />
</li>
<li>Sections show 10-70 % cellularity. The M/E ratio is about 4/1–5/1.
Dysgranulopoiesis is seen. Anisocytosis and poikilocytosis are present.
Atypical micromegakaryocytes are found about 4-7/HPF. No increase of
blasts is noted. There are no granulomas, nor foreign malignant
cells.</li>
<li>IHC stains: CD117: 2%; CD34: &lt;1%; CD71: 10-30%; Hemoglobin A:
10-20%; CD138: 5%. The morphology is suggesting myelodysplastic
syndrome. Please correlate with the bone marrow smear, peripheral blood
smear and lab data for final diagnosis.</li>
</ul></li>
<li>2022-08-16 Panendoscopy
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis, antrum</li>
</ul></li>
<li>2022-07-28 SONO - abdomen
<ul>
<li>Liver cirrhosis with splenomegaly.</li>
<li>Left liver cyst (0.87x0.59cm).</li>
<li>S/P cholecystectomy.</li>
</ul></li>
<li>2022-07-12 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
<li>Elevation of left hemidiaphragm is found.</li>
</ul></li>
<li>2022-07-06 ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Left atrial enlargement</li>
</ul></li>
<li>2021-03-16, 2020-09-18 SONO - nephrology
<ul>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2019-11-22 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
<li>Elevation of left hemidiaphragm is found.</li>
<li>Blunted left CP angle is found.</li>
</ul></li>
<li>2019-10-24 Flow-Volume Curve and Bronchodilator Test
<ul>
<li>Severe lung restriction</li>
</ul></li>
<li>2019-10-24, -10-22 CXR
<ul>
<li>Elevation of Lt hemidiaphragm may be due to LLL volume loss and
fibrosis or bronchiectasis</li>
<li>bronchiectasis at Rt lung base</li>
</ul></li>
<li>2019-10-18 CXR
<ul>
<li>Elevated left hemidiaphragm.</li>
<li>Increased infiltration at RLL</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-05 - Vidaza (azacitidine) 75mg/m2 100mg SC D1-D2</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>In the past, serum iron, total iron-binding capacity, ferritin,
vitamin B12, and folate have been measured. Since the patient’s renal
function appears to be in good condition, it is unlikely that the anemia
is caused by low EPO levels.</li>
<li>No increase in blasts has been observed. WBC sometimes falls below
normal range, RBC and HGB often fall below normal ranges. The results of
the pathology indicated that MDS may be present. (with single lineage or
multilineage dysplasia?) No cytogenetic del (11q, 5q, 12p, 20q,…) data
available currently.</li>
<li>The patient is receiving azacitadine for the first time. Please
monitor for any signs of intolerance.</li>
<li>The recommended dosing of azacitadine for patients with MDS: Initial
cycle: 75 mg/m2/day for 7 days of a 28-day treatment cycle. Subsequent
cycles: 75 mg/m2/day for 7 days every 4 weeks; dose may be increased to
100 mg/m2/day if no benefit is observed after 2 cycles and no toxicity
other than nausea and vomiting have occurred. Patients should be treated
for a minimum of 4 to 6 cycles; treatment may be continued as long as
patient continues to benefit.</li>
</ul>
</div>
</div>
<div id="section-71" class="section level1">
<h1>700307071</h1>
<div id="section-72" class="section level2">
<h2>221206</h2>
<p>{Left ovarian cancer (clear cell carcinoma) post Debulking surgery on
2022/06/08, pT2aN0M0, FIGO stage IIA}</p>
<ul>
<li>family history
<ul>
<li>Father: esophageal cancer</li>
<li>Mother: lung adenocarcinoma</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-11-15 CT - abdomen
<ul>
<li>S/P hysterectomy and oophorectomy.</li>
<li>Ground glass opacity, 0.6cm in RUL. Nature?</li>
</ul></li>
<li>2022-10-06 SONO - joint soft tissue
<ul>
<li>right shoulder supraspinatus tendinitis</li>
<li>limitation of passive movement in the glenohumeral joint, compatible
with right shoulder adhesive capsulitis.</li>
</ul></li>
<li>2022-10-05 T-L spine AP + Lat
<ul>
<li>mild anterior spur formation at the middle and lower L-spine.</li>
</ul></li>
<li>2022-09-28 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Scoliosis of the T-spine with convex to right side.</li>
</ul></li>
<li>2022-07-29 CXR
<ul>
<li>Scoliotic alignment of the thoracolumbar spine is noted.</li>
</ul></li>
<li>2022-06-09 Patho - ovary (tumor)
<ul>
<li>pathologic diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Ovary, left, BSO — Mixed clear cell carcinoma and endometroid
carcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Lymph nodes, pelvic and para-aortic, bilateral, BPLND — Negative for
malignancy (0/28)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Soft tissue, labeled “tumor seeding on colon”, excision —
Inflammation and fibrosis, no malignancy</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>AJCC 8 th edition, Pathology stage: pT2aN0; stageIIA; FIGO stage IIA
if cM0</li>
</ol></li>
</ul></li>
<li>macroscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Procedure: ATH + BSO + omentectomy + BPLND + para-aortic LN
dissection + tumor seeding on colon excision</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Specimen Size: 16.5 x 11.8 x 7.0 cm (Lt ovary), 2.5 x 1.0 x 0.6 cm
(Rt ovary), 8.2 x 0.5 cm (Lt tube), 4.2 x 0.5 cm (Rt tube), 6.0 x 3.8 x
2.2 cm (uterus), 0.6 x 0.4 x 0.3 cm (colon tumor), 24 x 8.5 x 0.5 cm
(omentum)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Specimen Integrity</li>
</ol>
<ul>
<li>3.1. Right ovary: Capsule intact</li>
<li>3.2. Left ovary: Capsule ruptured</li>
<li>3.3. Right fallopian tube: Serosa intact</li>
<li>3.4. Left fallopian tube: Serosa intact</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Tumor Site: Left ovary</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Ovarian Surface Involvement: Present</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Fallopian tube Surface Involvement: Absent</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Tumor Size: Tri-cystic and aolid tumor, 16 x 11.8 x 7.0 cm</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymph Nodes: Six groups including left iliac, left obturator, right
iliac, right obturator, left para-aortic and right para-aortic</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Representative parts are taken for section and labeled as:
F2022-00264FSA1, FSA2, FSA3= left ovary tumor, A1= left tube, A2-A10=
left ovary tumor. S2022-09335 A= left iliac LNs, B= left obturator LNs,
C= right iliac LNs, D= right obturator LNs, E= left para-aortic, F=
right para-aortic LNs, G1= cervix, G2-G3= uterine corpus, G4= right
ovary and fallopian tube, G5= left parametrium, G6= right parametrium,
H= omentum, I= tumor seeding on colon.</li>
</ol></li>
</ul></li>
<li>microscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic Type: Mixed clear cell carcinoma and endometroid
carcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic grade: High grade</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Implants: Not identified</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Other Tissue/Organ Involvement: Tumor invades uterine wall</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Peritoneal Fluid: Not submitted</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Regional Lymph Nodes: All lymph nodes are negative for tumor cells
(0/28)</li>
</ol>
<ul>
<li>number of lymph node examined: 3 (left iliac), 7 (left obturator), 4
(right iliac), 6 (right obturator), 3 (left para-aortic) and 5 (right
para-aortic)</li>
<li>number with metastases &gt;10 mm: 0</li>
<li>number with metastases 10mm or less: 0</li>
<li>number with isolated tumor cells (&lt;=0.2mm): 0</li>
</ul></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Pathologic Stage</li>
</ol>
<ul>
<li>7.1. Primary Tumor: pT2a (tumor extension on the uterus)</li>
<li>7.2. Regional Lymph Nodes: pN0 (no regional lymph node
metastasis)</li>
<li>7.3. Distant Metastasis: Not applicable</li>
</ul></li>
<li><ol start="8" style="list-style-type: decimal">
<li>FIGO Stage: Stage IIA if cM0</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymphovascular invasion: Absent</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Perineural invasion: Absent</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Additional Pathologic Findings:</li>
</ol>
<ul>
<li>11.1. Cervix: Chronic cervicitis with Nabothian cysts</li>
<li>11.2. Endometrium: Atrophy</li>
<li>11.3. Myometrium: Leiomyoma</li>
<li>11.4. Ovary, right: Cortical inclusion cysts</li>
<li>11.5. Fallopian tube, right: Para-tubal cyst</li>
<li>11.6. Fallopian tube, left: Unremarkable</li>
<li>11.7. Omentum: No remarkable change</li>
<li>11.8. Specimen labeled “tumor seeding on colon”: Chronic and acute
inflammatory cells infiltrate, fibrin exudate, and fibrosis</li>
</ul></li>
<li><ol start="12" style="list-style-type: decimal">
<li>IHC: Napsin A (rare + for clear cell carcinoma component), PR(+ in
endometroid carcinoma), WT1(-), p53(wide type)</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-08 Frozen section
<ul>
<li>Ovary, frozen section — Malignant, favor clear cell carcinoma</li>
</ul></li>
<li>2022-06-08 Patho - colon biopsy
<ul>
<li>Colon, ileocecal valve, s/p cold snare polypectomy — Hyperplastic
polyp with chronic inflammation.</li>
</ul></li>
<li>2022-06-06 Patho - stomach biopsy
<ul>
<li>Labeled as “30cm below the incisor, s/p biopsy(B)”, biopsy — benign
squamous mucosa with abundant granular cytoplas, in favor of
glycogenosis.</li>
<li>Stomach, LC site of antrum, s/p biopsy (A) — Chronic gastritis, H
pylori NOT present</li>
</ul></li>
<li>2022-06-06 CT - abdomen, pelvis
<ul>
<li>Huge soft tissue mass at pelvis with solid and cystic component is
found up to 16.5cm in largest dimension. Ovarian cancer is
considered.</li>
<li>Imaging Report Form for Ovarian Carcinoma
<ul>
<li>Impression (Imaging stage): T:T1(T_value) N:Nx(N_value)
M:M0(M_value) STAGE:____(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-05-30 Gynecologic ultrasonography
<ul>
<li>huge ovarian mass 183mm x 105mm</li>
</ul></li>
<li>2022-05-30 SONO - abdomen
<ul>
<li>suspected liver parenchymal disease, mild</li>
<li>lower abdomen tumor: cause to be determined</li>
</ul></li>
<li>2020-04-29 Patho - stomach biopsy
<ul>
<li>Stomach, low body, biopsy — fundic gland polyp. No H.pylori
present</li>
</ul></li>
<li>2017-07-26 Mammography
<ul>
<li>Impression: Dense breast.
<ul>
<li><ol style="list-style-type: decimal">
<li>Asymmetry in axillary tail region of left breast, stationary.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Benign calcifications in bilateral breasts.</li>
</ol></li>
</ul></li>
<li>BI-RADS: Category 2: benign findings. - annual screening.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-08 Debulking surgery (ATH + BSO + BPLND + paraaortic LN
disection + infracolic omentectomy), Bilateral ureteral
catheterization</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-12-05 - paclitaxel 175mg/m2 260mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-11-14 - paclitaxel 175mg/m2 270mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-10-24 - paclitaxel 175mg/m2 250mg 3hr + carboplatin AUC 5 500mg
2hr (Owing to Leukopenia (ANC: 368) was noted on 20221011 and next will
given Lenograstim x 3 post C/T, 2022-10-26 ~ 2022-10-28)</li>
<li>2022-09-27 - paclitaxel 175mg/m2 250mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-09-06 - paclitaxel 175mg/m2 246mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-08-15 - paclitaxel 175mg/m2 246mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-07-15 - paclitaxel 175mg/m2 246mg 3hr + carboplatin AUC 5 530mg
2hr</li>
</ul></li>
</ul>
<div id="section-73" class="section level3">
<h3>==========</h3>
</div>
<div id="section-74" class="section level3">
<h3>2022-09-28</h3>
<ul>
<li>If there is a suspicion of megaloblastic anemia (RBC 2.75 *10^6/uL,
HGB 9.4 g/dL, MCV 104 fL, 2022-09-27), a vitamin B12 (cobalamin) and/or
a vitamin B9 (folate) supplement might be beneficial to the
patient.</li>
</ul>
</div>
</div>
</div>
<div id="section-75" class="section level1">
<h1>701024299</h1>
<div id="section-76" class="section level2">
<h2>221205</h2>
<ul>
<li><p>2022-12-03 CXR</p>
<ul>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Bilateral pleural effusion.</li>
</ul></li>
<li><p>2022-11-21, -11-17 CXR</p>
<ul>
<li>Borderline cardiomegaly<br />
</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
</ul></li>
<li><p>2022-11-18 SONO - chest</p>
<ul>
<li>right side minimal amount of pleural effusion</li>
<li>left side small amount of pleural effusion, 290cc serosangious fluid
was aspirated for analysis.</li>
</ul></li>
<li><p>2022-11-13 ECG</p>
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li><p>2022-10-20 CT - abdomen</p>
<ul>
<li>History and indication: ovary cancer with peritonal seeding right
breast cancer with bone mets</li>
<li>Findings
<ul>
<li>Right breast cancers. Bil. pleural effusions. Enlarged LNs at left
neck, mediastinum, bil. axillary regions, mesentery and
retroperitoneum.</li>
<li>S/P hysterectomy. Some tumors in peritoneal cavity.</li>
<li>Tiny liver cysts. A metastases at left hepatic lobe. Progression of
metastases at spleen and LUQ.</li>
<li>Swelling of right chest wall and abdominal wall.</li>
</ul></li>
<li>IMP:
<ul>
<li>Right breast cancers. Bil. pleural effusions. Enlarged LNs at left
neck, mediastinum, bil. axillary regions, mesentery and
retroperitoneum.</li>
<li>S/P hysterectomy. Some tumors in peritoneal cavity.</li>
<li>A metastases at left hepatic lobe. Progression of metastases at
spleen and LUQ.</li>
</ul></li>
</ul></li>
<li><p>2022-10-14 CXR</p>
<ul>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Borderline cardiomegaly<br />
</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
</ul></li>
<li><p>2022-07-29 Whole body PET scan</p>
<ul>
<li>In comparison with the previous study on 2021/12/09, the lesions in
the right breast, two right supraclvicular lymph nodes, multiple right
axillary lymph nodes and multiple bilateral parasternal lymph nodes are
new. Primary breast malignancy with multiple lymph node metastases may
show this picture. However, please correlate with the pathologic
findings for further evaluation.</li>
<li>A new glucose hypermetabolic lesion in the the region about the skin
of right upper back, compatible with a metastatic lesion.</li>
<li>The glucose hypermetabolic lesions in the left supraclavicular
fossa, mediastinum, spleen, abdominal and pelvic cavities seem either
new, more evident or larger in size, suggesting multiple metastases in
progression. However, other lesions such as the lesions in the left
pulmonary hilar region, pleura of right lung and left lobe of the liver
are either a little less evident or disappeared.</li>
</ul></li>
<li><p>2022-07-28 CT - chest</p>
<ul>
<li>History
<ul>
<li>45 y/o female, a pt of ovarian CA wt peritoneal seeding, rpT3bN0 (If
cM0); pStage: IIIB , FIGO stage: IIIB, s/p pre-Op NIPS wt Taxotere /
Carbopaltin IV and Taxotere / Cisplatin IP Q3W x 4 finihsed in Oct 2020
s/p debulking Op on 11/30 20 by Dr Wu, s/p post-Op salvage C/T wt
Taxotere/PF + IP C/T wt Taxotere / Cisplatin x 4 finished in Feb 2021
&amp; s/p post-Op salvage Avastin 7.5mg/kg IV Q3W x 1yr since 3/9
21.</li>
</ul></li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Soft tissue mass/noduless at lateral breast up to 2.57cm and inner
breast about 3.5cm in largest dimension. breast cancer is
considered.</li>
<li>Lymphadenopathy at right axillary region, mediasitnum and paraaortic
region. Lymphadenopathy from breast cancer or residual ovarian cancer is
favored.</li>
<li>Very tiny nodule at right upper lobe is found.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Tiny low density nodules at S6 of liver about 0.34cm and 0.2cm in
largest dimension. In comparison with CT dated on 2022-06-01, the
lesions are stationary.</li>
<li>Low density change at splenic hilum is found. In progression.</li>
<li>The pancreas, both kidneys, adrenals are intact.</li>
<li>Suggest clinical correlation</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Right breast cancer with lymphadenopathy at right axillary,
mediastinal and abdominal hepatic hilar and paraaortic region.</li>
<li>SPlenic hilar tumor, in progression.</li>
<li>Liver meta. Stable.</li>
</ul></li>
</ul></li>
<li><p>2022-06-06 Patho - lymphnode biopsy</p>
<ul>
<li>Labeled as “left supraclavicular fossa/ lymph node”, past history of
ovarian and breast cancers, excision biopsy — metastatic carcinoma.</li>
<li>Section shows pieces of soft tissue with metastatic carcinoma</li>
<li>IHC stains: PAX-8 (+) and GATA-3 (-): pattern is in favor of ovarian
origin rather than breast origin.</li>
<li>Residual lymph node-like tissue is present.</li>
</ul></li>
<li><p>2022-06-06 CT - abdomen</p>
<ul>
<li>History and Indication:
<ul>
<li>2020/08/05: Echo: susp pelvic mass with ascites.</li>
<li>OP: ATH + RSO 3 yr ago</li>
<li>2020/08/05 CT: Cystic adenocarcinoma of ovary &amp;
carcinomatosis</li>
<li>2020/11/30 PATHO: serous carcinoma, high grade, involved bilateral
ovary, Fallopian tube and Peritoneum,rpT3bN0(If cM0); pStage:IIIB , FIGO
stage: IIIB,</li>
<li>20220309 CT: Metastases in the liver, spleen, and multiple LNs.</li>
</ul></li>
<li>Findings:
<ul>
<li>S/P hysterectomy</li>
<li>Prior CT identified a metastasis 1.7 x 1.1 cm in S3 of the liver is
not noted in the current CT that is c/w liver metastasis S/P C/T with
complete response .
<ul>
<li>Prior CT identified two lobulated metastases 3 cm and 2.5 cm in
between the gastrosplenic ligament, spleen, and pancreatic tail are
noted again, decreasing in size to 2 cm and 1 cm that are c/w metastases
S/P C/T with partial response .</li>
<li>Prior CT identiifed multiple metastatic nodes in the celiac trunk,
hepatoduodenal ligament, para-aortic space and para-cava space are noted
again, stable in size that is c/w metastatic nodes S/P C/T with stable
disease .</li>
<li>Prior CT identified A enlarged node with central low density
measuring 2 x 1.2 cm in left side neck is noted again, stationary.</li>
</ul></li>
<li>Prior CT identified a cyst 4 mm in S5/8 of the liver is noted again,
stationary.<br />
</li>
<li>Mild ascites in the cul-de-sac is noted.</li>
<li>Others
<ul>
<li>There is no focal abnormality in the gallbladder, biliary system,
&amp; both kidney.<br />
</li>
<li>There is no bowel wall thickening and no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion in the omentum.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Metastasis in the liver shows complete response.</li>
<li>Metastases in the spleen shows partial response.</li>
<li>Metastatic nodes show stable disease</li>
</ul></li>
</ul></li>
<li><p>2022-05-31 2D transthoracic echocardiography</p>
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (62 - 18) / 62 = 70.97%
<ul>
<li>M-mode (Teichholz) = 71</li>
</ul></li>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Normal chamber size</li>
<li>Trivial MR</li>
</ul></li>
<li><p>2022-05-23 Patho - lymphnode biopsy</p>
<ul>
<li>Lymph node, right axillary, score biopsy — positive for invasive
carcinoma</li>
<li>Microscopically, it shows presence of invasive carcinoma nestes with
necrosis and stromal fibrosis in a lymphoid background.</li>
<li>IHC stain — CK(+)</li>
</ul></li>
<li><p>2022-05-23 Patho - breast biopsy (no need margin)</p>
<ul>
<li>Breast, right, core biopsy — invasive carcinoma of no special
type</li>
<li>Microscopically, the breast shows invasive carcinoma characterized
by proliferation of tumor cells with infiltrative growth pattern, ductal
differentiation and stromal fibrosis with necrosis. The tumor cell shows
hyperchromatic nuclei, plemorphism and high N/C ratio.</li>
</ul></li>
<li><p>2022-05-17 SONO - breast</p>
<ul>
<li>Bil. fibroadenomas and cysts</li>
<li>BI-RADS: 2. benign finding</li>
</ul></li>
<li><p>2022-03-09 CT - abdomen</p>
<ul>
<li>Findings:
<ul>
<li>S/P hysterectomy</li>
<li>There is a newly-developed poor enhancing mass 1.7 x 1.1 cm in S3 of
the liver that is c/w liver metastasis.
<ul>
<li>There are two lobulated poor enhancing mass 3 cm and 2.5 cm in
between the gastrosplenic ligament, spleen, and pancreatic tail that are
c/w metastases.</li>
<li>In addition, There are newly-developed multiple enlarged nodes in
the celiac trunk, hepatoduodenal ligament, para-aortic space and
para-cava space that are c/w metastatic nodes.</li>
<li>A enlarged node with central low density measuring 2 x 1.2 cm in
left side neck that is c/w metastatic node.</li>
</ul></li>
<li>Prior CT identified a cyst 4 mm in S5/8 of the liver is noted again,
stationary.<br />
</li>
</ul></li>
<li>Impression:
<ul>
<li>Metastases in the liver, spleen, and multiple lymph nodes.</li>
</ul></li>
</ul></li>
<li><p>2021-12-09 Whole body PET scan</p>
<ul>
<li>Multiple glucose hypermetabolic lesions in the left supracalvicular
fossa, mediastinum, left pulmonary hilar region, pleura of right lung,
spleen, left lobe of the liver, abdominal and pelvic cavities,
compatible with multiple metastatic lesions. Please correlate with other
clinical findings for further evaluation.</li>
<li>Glucose hypermetabolism in the fat tissues in bilateral necks,
bilateral supraclavicular fossae and bilateral paraspinal regions.
Physiological FDG uptake is more likely.</li>
</ul></li>
<li><p>2021-11-26 CT - abdomen</p>
<ul>
<li>Findings
<ul>
<li>S/P hysterectomy</li>
<li>The long segmental terminal ileum shows mild dilatation with
feces-like material (Srs:302 Img:63-69) that may be partial obstruction?
<ul>
<li>The differential diagnosis include normal variation. please
correlate with clinical condition.</li>
<li>In addition, there is a suspicious soft tissue nodule in the
cul-de-sac that may be tumor seeding. The differential diagnosis include
normal variation? Follow up is indicated.</li>
</ul></li>
<li>There is a small poor enhancing lesion 4 mm in S5/8 of the liver
that may be cyst.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P hysterectomy</li>
<li>Partial obstruction of the terminal ileum and a tumor seeding in the
cul-de-sac is suspected.
<ul>
<li>The differential diagnosis include normal variation.</li>
<li>please correlate with clinical condition.</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>2021-11-18 SONO - abdomen</p>
<ul>
<li>Hepatic lesion, right lobe, suspected cyst.</li>
</ul></li>
<li><p>2021-08-27 CT - abdomen</p>
<ul>
<li>Findings
<ul>
<li>S/P hysterectomy -There is a small poor enhancing lesion 4 mm in
S5/8 of the liver that may be cyst.<br />
</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li><p>2021-07-08 Gynecologic ultrasonography</p>
<ul>
<li>ATH + BSO</li>
<li>minimal fluid</li>
</ul></li>
<li><p>2021-06-10 CT - abdomen</p>
<ul>
<li>Findings
<ul>
<li>S/P hysterectomy. Minimal ascites in pelvic cavity.</li>
<li>Tiny liver cysts.</li>
<li>Some low attenuations in both kidneys.</li>
</ul></li>
<li>IMP:
<ul>
<li>S/P hysterectomy. Minimal ascites in pelvic cavity. No evidence of
tumor recurrence.</li>
</ul></li>
</ul></li>
<li><p>2021-05-27 SONO - abdomen</p>
<ul>
<li>pancreatic cystic lesion, body</li>
</ul></li>
<li><p>2021-03-10 CT - abdomen</p>
<ul>
<li>Findings:
<ul>
<li>S/P hysterectomy</li>
<li>There is mild ascites in the pelvis.</li>
<li>There is a small poor enhancing lesion 4 mm in S5/8 of the liver
that may be cyst.<br />
</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li><p>2020-12-01 Patho - soft tissue tumor, extensive resection</p>
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Ovary and fallopian tube? right, labeled “right pelvic peritonum”,
peritonectomy — Involved by serous carcinoma<br />
</li>
<li>Round ligament of liver, peritonectomy — Involved by serous
carcinoma<br />
</li>
<li>Appendix, appendectomy — Involved by serous carcinoma<br />
</li>
<li>Ovary and fallopian tube? left, labeled “left pelvic peritonum”,
peritonectomy — Involved by serous carcinoma<br />
</li>
<li>Right diaphragm peritoneum, peritonectomy — Involved by serous
carcinoma<br />
</li>
<li>PD tube with its tract, peritonectomy — Free of carcinoma<br />
</li>
<li>Ometum, omentectomy — Involved by serous carcinoma<br />
</li>
<li>AJCC 8 th edition, Pathology stage: ypT3bNx; stage IIIB; FIGO stage
IIIB if cM0<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Procedure: Debulking surgery + peritonectomy + appendectomy<br />
</li>
<li>Specimen Size
<ul>
<li>Right pelvic peritonum (including right adnexa): three pieces, up to
3.2 x 2.8 x 2.5 cm<br />
</li>
<li>Round ligament of liver: 5.0 x 2.5 x 2.2 cm<br />
</li>
<li>Appendix: 4.0 x 1.0 x 1.0 cm<br />
</li>
<li>Left pelvic peritoneum (including left adnexa): three pieces, up to
3.4 x 2.9 x 2.8 cm<br />
</li>
<li>Right diaphragm peritoneum: multiple pieces up to 12.5 x 8.0 x 4.5
cm<br />
</li>
<li>PD tube with its tract: 8.0 x 0.9 cm with tract 5.0 x 1.2 cm<br />
</li>
<li>Omenum: 22.0 x 11.0 x 1.5 cm</li>
</ul></li>
<li>Specimen Integrity: Fragmented<br />
</li>
<li>Tumor Site: Both adnexa<br />
</li>
<li>Ovarian Surface Involvement: Present<br />
</li>
<li>Fallopian tube Surface Involvement: Present<br />
</li>
<li>Representative parts are taken for section and labeled as: A1-A3=
right pelvic peritonum (including right ovary and fallopian tube),
B1-B3= round ligament of liver, C1-C2= appendix, D1-D3= left pelvic
peritoneum (including left ovary and fallopian tube), E1-E3= right
diaphragm peritoneum, F= PD tube with its tract, G1-G3= omentum<br />
</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histologic Type: Serous carcinoma<br />
</li>
<li>Histologic grade: High grade<br />
</li>
<li>Ovary and fallopian tube? right, labeled “right pelvic peritonum”:
Involved by serous carcinoma<br />
</li>
<li>Round ligament of liver: Involved by serous carcinoma<br />
</li>
<li>Appendix: Involved by serous carcinoma<br />
</li>
<li>Ovary and fallopian tube?left, labeled “left pelvic peritonum”:
Involved by serous carcinoma<br />
</li>
<li>Right diaphragm peritoneum: Involved by serous carcinoma<br />
</li>
<li>PD tube with its tract: Chronic inflammation, fibrosis and free of
carcinoma<br />
</li>
<li>Ometum: Involved by serous carcinoma<br />
</li>
<li>Pathologic Stage
<ul>
<li>Primary Tumor: ypT3b (macroscopic peritoneal metastasis beyond the
pelvis 2 cm or less in greatest dimension)<br />
</li>
<li>Regional Lymph Nodes: Not submitted<br />
</li>
<li>Distant Metastasis: Not applicable<br />
</li>
</ul></li>
<li>FIGO Stage: Stage IIIB if CM0<br />
</li>
<li>Additional Pathologic Findings: Psammoma bodies</li>
</ul></li>
</ul></li>
<li><p>2020-11-30 Patho - ovary (tumor)</p>
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Ovary, right, debulking surgery (s/p neoadjuvant treatment) — serous
carcinoma, high-grade<br />
</li>
<li>Ovary, left, debulking operation — serous carcinoma,
high-grade<br />
</li>
<li>Fallopian tube, right, debulking operation — involved by serous
carcinoma<br />
</li>
<li>Fallopian tube, left, debulking operation — involved by serous
carcinoma<br />
</li>
<li>Lymph node, right iliac, dissection — negative for malignancy ( 0 /
3 )<br />
</li>
<li>Lymph node right obturator, dissection — negative for malignancy ( 0
/ 1 )<br />
</li>
<li>Lymph node, left iliac, dissection — negative for malignancy ( 0 / 4
)<br />
</li>
<li>Lymph node, left obturator, dissection — negative for malignancy ( 0
/ 1 )<br />
</li>
<li>Pelvic mass, debulking surgery — involved by serous carcinoma<br />
</li>
<li>Omentum, debulking surgery — involved by serous carcinoma<br />
</li>
<li>pTNM: rpT3bN0 (If cM0); FIGO stage: IIIB; pStage:IIIB<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Operation Procedure: debulking surgery<br />
</li>
<li>Specimen type: bilateral ovaries, fallopian tubes, regional LNs,
omentum<br />
</li>
<li>Specimen size:
<ul>
<li>right ovary: 4.2x 3.5x 2.2 cm;<br />
</li>
<li>left ovary: 5x 4x 2.5 cm;<br />
</li>
<li>right tube: 4.5 cm in length;<br />
</li>
<li>left tube: 4.5 cm in length;<br />
</li>
<li>uterus: not received<br />
</li>
</ul></li>
<li>Tumor site: right and left ovaries<br />
</li>
<li>Tumor size: up to 1.3 cm in size<br />
</li>
<li>Tumor appearance: solid and papillary<br />
</li>
<li>Specimen integrity: Ovarian capsule ruptured (right)<br />
</li>
<li>Lymph node: (tissue size) up to 1 cm<br />
</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histologic type: serous carcinoma<br />
</li>
<li>Histologic grade: high grade<br />
</li>
<li>Contralateral ovary involvement: present<br />
</li>
<li>Tumor side ovarian surface involvement: present<br />
</li>
<li>Contralateral ovary surface involvement: present<br />
</li>
<li>Right tube involvement: present<br />
</li>
<li>Left tube involvement: present<br />
</li>
<li>In situ adenocarcinoma in right and/or left fallopian tube:
absent<br />
</li>
<li>Right adnexa soft tissue involvement: absent<br />
</li>
<li>Left adnexa soft tissue involvement: absent<br />
</li>
<li>Pelvic soft tissue involvement: present (labeled pelvic mass)<br />
</li>
<li>Uterine serosa involvement: non-applicable<br />
</li>
<li>Omentum involvement: present<br />
</li>
<li>Uterine Cervix involvement: N/A<br />
</li>
<li>Endometrium involvement: N/A<br />
</li>
<li>Myometrium involvement: N/A<br />
</li>
<li>Appendix involvement: N/A<br />
</li>
<li>Lymph nodes metastasis:
<ul>
<li>Group as specified No. Positive / No. Total<br />
</li>
<li>Right iliac ( 0 / 3)<br />
</li>
<li>Right obturator ( 0 / 1 )<br />
</li>
<li>Left iliac ( 0 / 4 )<br />
</li>
<li>Left obturator ( 0 / 1 )<br />
</li>
</ul></li>
<li>Other organs or specimens involvement: none<br />
</li>
<li>Immunohistochemical stain shows WT-1(+), CK7(+), CK20(-)</li>
</ul></li>
</ul></li>
<li><p>2020-11-18 Whole body PET scan</p>
<ul>
<li>Glucose hypermetabolism in the left pelvis, compatible with the CT
findings of much regression of ovary cancer and peritoneal
carcinomatosis with residual tumor at the left ovary.<br />
</li>
<li>Glucose hypermetabolism in bilateral palatine tonsils, probably
chronic inflammation/infection process.<br />
</li>
<li>Glucose hypermetabolism in bilateral pulmonary hilar regions,
probably physiological uptake of FDG or reactive nodes.<br />
</li>
<li>Increased FDG accumulation in the colon and urinary bladder,
physiological FDG accumulation may show this picture. However, please
also correlate with other clinical findings for further evaluation and
to rule out other possibilities.</li>
</ul></li>
<li><p>2020-11-18 Gynecologic ultrasonography</p>
<ul>
<li>ATH</li>
<li>Suspected Lt ovarian mass: 48x42mm</li>
</ul></li>
<li><p>2020-11-16 CT - abdomen</p>
<ul>
<li>History and indication: ovary cancer with peritonal seeding</li>
<li>Findings
<ul>
<li>Much regression of ovary cancer and peritoneal carcinomatosis
(residual tumor at left ovary).</li>
<li>Thyroid nodules (3-5mm).</li>
<li>Tiny liver cysts.</li>
<li>Some low attenuations in both kidneys.</li>
<li>S/P Port-A infusion catheter insertion.</li>
</ul></li>
<li>IMP:
<ul>
<li>Much regression of ovary cancer and peritoneal carcinomatosis
(residual tumor at left ovary).</li>
</ul></li>
</ul></li>
<li><p>2020-10-28, -09-16, -09-15, -08-26, -08-25, -08-13 Body fluid
cytology - ascites</p>
<ul>
<li>Malignancy</li>
</ul></li>
<li><p>2020-08-13 Patho - peritoneum biopsy</p>
<ul>
<li>Labeled as “ovary cancer with diffuse peritoneal seeding”, biopsy —
adenocarcinoma<br />
</li>
<li>Section shows adenocarcinoma.</li>
</ul></li>
<li><p>2020-08-07 Patho - ovary biopsy/wedge resection</p>
<ul>
<li>Labeled as “s/p 3 yr rt partial ovrain tumor excision, intraabd
peritoenal tumor with ascite”, biopsy — adenocarcinoma, serous type,
high grade.</li>
<li>Section shows piece of tissue with short papillae of neoplastic
cells containing hyperchromatic nuclei and abundant eosinophilic
cytoplasm.</li>
<li>IHC stains: PAX-8 (+), WT-1 (+), CK20 (-), a pattern of ovarian
origin.</li>
<li>IHC stains: ER (+, 1-5%, moderate intensity); PR (+, 1-5%, moderate
intensity).</li>
</ul></li>
<li><p>2020-08-06 Gynecologic ultrasonography</p>
<ul>
<li>ATH + RSO</li>
<li>Imp:
<ul>
<li>Ascites</li>
<li>Suspected Lt ovarian mass (RI: 0.13) 144x106mm, malignancy cannot be
ruled out.</li>
</ul></li>
</ul></li>
<li><p>2020-08-05 CT - abdomen</p>
<ul>
<li>Findings:
<ul>
<li>There is a large multilocular mixed cystic and solid masses in the
pelvis that may be cystic adenocarcinoma of the ovary. please correlate
with clinical history.</li>
<li>There is massive ascites and soft tissue nodules in the omentum and
right perihepatic space (Srs:3, Img:25) that is compatible with
carcinomatoais.</li>
<li>There is a small poor enhancing lesion 4 mm in S5/8 of the liver
that may be cyst. The differential diagnosis include metastasis. Please
correlate with sonography.</li>
</ul></li>
<li>Impression:
<ul>
<li>Cystic adenocarcinoma of the ovary with carcinomatosis is highly
suspected. please correlate with clinical condition.</li>
<li>A hepatic cyst 4 mm in S5/8 is suspected. The differential diagnosis
include metastasis. Please correlate with sonography.</li>
</ul></li>
</ul></li>
<li><p>2020-08-05 SONO - abdomen</p>
<ul>
<li>Diagnosis
<ul>
<li>Suspected pelvic mass lesion</li>
<li>Ascites with peritoneal nodule; D/D: peritonitis,
carcinomatosis</li>
</ul></li>
<li>Suggestion
<ul>
<li>CT scan</li>
<li>GYN survey</li>
</ul></li>
</ul></li>
<li><p>2020-05-16 Mammography</p>
<ul>
<li>Impression: Dense breast. Probably benign calcifications in
bilateral breasts.</li>
<li>BI-RADS: Category 2: benign findings.-annual screening.</li>
</ul></li>
<li><p>consultation</p></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2022-06-07 doxorubicin 50mg/m2 70mg 10min + cyclophosmamide 500mg/m2
700mg 1hr</li>
<li>2021-11-16 bevacizumab 17.5mg/kg 375mg 1.5hr</li>
<li>2021-10-26</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-77" class="section level1">
<h1>700356362</h1>
<div id="section-78" class="section level2">
<h2>221202</h2>
<p>{Pseudomyxoma peritonei (mucinous carcinoma peritonei), grade 1}</p>
<ul>
<li>diagnosis
<ul>
<li>malignant neoplasm of appendix</li>
<li>secondary malignant neoplasm of retroperitoneum and peritoneum</li>
<li>hypertensive chronic kidney disease with stage 5 chronic kidney
disease or end stage renal disease</li>
<li>anemia, unspecified</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-11-17, -09-29 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
<li>Nodular and linear opacities projecting in right middle lung, right
lower lung, and left lower lung are noted. Please correlate with
CT.</li>
</ul></li>
<li>2022-09-09 ECG
<ul>
<li>Sinus bradycardia with Premature atrial complexes</li>
</ul></li>
<li>2022-09-08 24hr portable ECG
<ul>
<li>Sinus rhythm</li>
<li>Occasional isolated apcs</li>
<li>Rare apc couplets</li>
<li>Rare episodes short run atrial tachycardia (longest: 11 beats)</li>
<li>Rare isolated vpcs</li>
<li>No long pause</li>
<li>No significant tachyarrhythmia</li>
<li>Frequent sinus bradycardia even at day-time, please correlate with
clinical and drug history to r/o chronotropic incompetence</li>
</ul></li>
<li>2022-09-08 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (146 - 31) / 146 = 78.77%
<ul>
<li>M-mode (Teichholz) = 78</li>
</ul></li>
<li>Mild septal hypertrophy with indeterminated LV filling pressure;
moderately dilated LA.</li>
<li>Dilated LV with normal LV and RV systolic function.</li>
<li>Prominent aortic valve sclerosis with mild AR; mild MR; mild TR;
mild PR.</li>
<li>Dilated aortic root with mild calcification.</li>
<li>Sinus bradycardia.</li>
</ul></li>
<li>2022-09-06 ECG
<ul>
<li>atrial fibrillation with slow ventricular response</li>
</ul></li>
<li>2022-07-08 Flow volume loop and volume time curve
<ul>
<li>mild restrictive ventilatory impairment</li>
</ul></li>
<li>2022-07-08 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (147 - 56) / 147 = 61.90%</li>
<li>Dilated LA, LV, Ao</li>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Thick IVS, Impaired LV relaxation</li>
<li>Mild MR,TR,AR</li>
</ul></li>
<li>2022-06-30 Electroencephalogram, EEG
<ul>
<li>normal awake EEG with alpha rhythm 9-10Hz.</li>
</ul></li>
<li>2022-06-07 CT - chest
<ul>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>lobular areas of consolidation and centrilobular nodular and
branching opacities as well as septal thickening at LLL, RML and RLL, in
progression.</li>
<li>centrilobular nodular and branching opacities at posterior RUL.</li>
<li>subsegmental consolidation with centrilobular nodular and branching
opacities at LLL.</li>
</ul></li>
<li>Mediastinum and hila: a 5 mm nodule in thymic bed.</li>
<li>Several mildly enlarged LNs in visceral space.</li>
<li>Aorta: normal caliber, mild atherosclerotic change of descending
thoracic aorta.</li>
<li>pulmonary arteries: normal caliber and well opacification.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: small bilateral effusions.</li>
<li>Visible abdominal-pelvic contents: s/p peritoneal drains in place.
<ul>
<li>extensive and large soft-tissue mass at anterior peritoneal cavity,
displacing and compressing liver surface, with Rt perihepatic loculated
ascites, and moderate free ascites.</li>
<li>several small Rt renal cysts.</li>
<li>unremarkable of the spleen, adrenal glands, the pancreas.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>lung infection in progression. hyperplastic reactive mediastinal
LNs.</li>
<li>peritoneal carcinomatosis.</li>
</ul></li>
</ul></li>
<li>2022-06-06 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
<li>Nodular and linear opacities projecting in right middle lung, right
lower lung, and left lower lung are noted. Please correlate with
CT.</li>
</ul></li>
<li>2022-05-09 Chest XR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
<li>Nodular opacities projecting in right middle lung, right lower lung,
and left lower lung are noted. Please correlate with CT.</li>
</ul></li>
<li>2022-04-12 CT - CTA, chest
<ul>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>lobular areas of consolidation and centrilobular nodular and
branching opacities at RML and RLL. centrilobular nodular and branching
opacities at posterior RUL.</li>
<li>subsegmental consolidation with centrilobular nodular and branching
opacities at LLL.</li>
<li>ground glass nodule solid nodule at RUL RML RLL LUL LLL (up to 2.
Mediastinum and hila: a 5 mm nodule in thymic bed.</li>
</ul></li>
<li>Aorta: normal caliber, mild atherosclerotic change of descending
thoracic aorta.</li>
<li>pulmonary arteries: normal caliber and well opacification.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: small Lt-sided effusion.</li>
<li>Visible abdominal-pelvic contents:
<ul>
<li>extensive and large soft-tissue mass at anterior peritoneal cavity,
displacing and compressing liver surface, with Rt perihepatic loculated
ascites.</li>
<li>several small Rt renal cysts.</li>
<li>unremarkable of the spleen, adrenal glands, the pancreas.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>no pulmonary embolism.</li>
<li>lung infection or aspiration pneumonia.</li>
<li>peritoneal carcinomatosis.</li>
</ul></li>
</ul></li>
<li>2022-04-02 Chest PA/AP view
<ul>
<li>Supine chest image shows:
<ul>
<li>elongated and tortuosity of thoracic aorta and calcified
atherosclerotic change at aortic arch</li>
<li>reticular opacities over Lt lower lung zone</li>
<li>marginal spurs of multiple vertebral bodies</li>
</ul></li>
</ul></li>
<li>2022-03-28 Body fluid cytology - ascites
<ul>
<li>Atypia</li>
<li>Smears show mucinous material, neutrophils and reactive mesothelial
cells.</li>
</ul></li>
<li>2022-01-17 Tc-99m MDP whole body bone scan
<ul>
<li>Faint hot spots in the left 11th costovertebral junction and both
rib cages, the nature is to be determined (DJD, post-traumatic change or
other nature ?), suggesting follow-up with bone scan in 3-6 months for
further evaluation.</li>
<li>Suspected benign lesions in the maxilla, some T- and L-spine,
bilateral shoulders, hips, and ankles.</li>
</ul></li>
<li>2022-01-17 MRA - brain
<ul>
<li>Mild general brain atrophy. Left mastoiditis. Bilateral chronic
paranasal sinusitis.</li>
</ul></li>
<li>2022-01-13 CT - CTA, chest
<ul>
<li>Post op. change of the abodominal cavity.</li>
<li>Locualted effusion at RLQ of the abdomen. Nature?</li>
<li>No evidence of pulmonary embolism nor aortic dissection is
found.</li>
<li>Some small patches at both lungs. suspected infection.</li>
</ul></li>
<li>2022-01-13 CT - brain
<ul>
<li>Mild ventriculomegaly. Intracraniaal artherosclerosis.</li>
</ul></li>
<li>2022-01-13 KUB
<ul>
<li>The psoas shadow is clear.</li>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>Increased intestinal gas is found.</li>
<li>Osteopenia of the bony structure is noted.</li>
</ul></li>
<li>2021-12-31 Patho - soft tissue tumor, extensive resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Peritoneum, RUQ and right flank, peritonectomy - Pseudomyxoma
peritonei (mucinous carcinoma peritonei), grade 1</li>
<li>Round ligament of liver, excision - Pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1</li>
<li>Greater omentum, omentectomy - Pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show a picture of pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1, composed of abundant mucin with scant
cohesive strips of low-grade mucinous epithelium.</li>
</ul></li>
</ul></li>
<li>2021-12-27 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, left, CT-guide biopsy - interstitial fibrosis and chronic
inflammation - atypical pneumocyte present<br />
</li>
<li>Sections show alveolar lung tissue with interstitial fibrosis,
chronic inflammatory cell infiltration and atypical pneumocyte
proliferating along the alveolar wall.</li>
<li>No granuloma or malignancy is found.</li>
<li>IHC: CK7(+), CK20(-), TTF-1(+), Napsin A(+), and CDX2(-).</li>
</ul></li>
<li>2021-12-14 CT - lung/mediastinum/pleura
<ul>
<li>lung infection or aspiration pneumonia.</li>
<li>peritoneal carcinomatosis. RUQ free air due to infection or prior
abdominal intervention.</li>
</ul></li>
<li>2021-12-06 Patho - peritoneum biopsy
<ul>
<li>diagnosis
<ul>
<li>Omentum, biopsy - metastatic mucinous adenocarcinoma, origin?</li>
<li>Peritoneum, biopsy - metastatic mucinous adenocarcinoma,
origin?</li>
</ul></li>
<li>IHC: CK7(-), CK20(+), CDX2(+), and PAX8(-). The results are in favor
of GI tract (including appendix) tumor.</li>
</ul></li>
<li>2021-12-03 Colonoscopy
<ul>
<li>mixed hemorrhoid</li>
<li>no tumor was found in colonic lumen</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-08 Cardiology
<ul>
<li>Q
<ul>
<li>For bradycardia was noted last night, associated symptoms with
syncope, chest tightness, we need your further evaluation and
management.</li>
<li>The patient is an 72-year-old man with a history of Benign prostatic
hyperplasia with Hamalidge OCAS control, Appendix cancer with peritoneal
metastatic mucinous adenocarcinoma, cT4aN1aM1, stage IVA status post
laparoscopic examination and biopsy on 2021/12/06, immunohistochemical
stains reveal CK7(-), CK20(+), CDX2(+), with IP chemotherapy (Docetaxel
+ cisplatin 60ml each with N/S 500ml and Gentamycin + Jusomin equally
split to port-a at abdomen and oral chemotherapy with TS1 25mg/cap 3cap
QD for one weeks and add IV chemotherapy.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This is a 72 years old man who was admitted for chemotherapy for
appendiceal cancer.</li>
<li>We were consulted for near syncope survey. She is currently in
abdominal pain for intraperitoneal assess route catheter infection.</li>
</ul></li>
<li>O
<ul>
<li>Vital sign : stable</li>
<li>2022/07/08 echography showing
<ul>
<li>EF: 66%</li>
<li>Dilated LA, LV, Ao</li>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Thick IVS, Impaired LV relaxation</li>
<li>Mild MR, TR, AR</li>
</ul></li>
<li>EKG: sinus bradycardia with poor isoelectric line.</li>
</ul></li>
<li>Impression
<ul>
<li>Near syncope rule out vaso-vagal. syncope or sick sinus
syndrome</li>
<li>PD assess site infection under tapimycin</li>
<li>Sinus bradycardia.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Adequate pain control and fluid support</li>
<li>to check BP and HR at supine, sitting and standing position with 5
mins of interval to exclude postural hypotension</li>
<li>to check thyroid function and to arrange 24 H holter monitor due to
marked sinus bradycardia episode.</li>
<li>Consider to consult neurology for neurogenic cause.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-14 Neurology
<ul>
<li>Q
<ul>
<li>For seizure evaluation</li>
<li>This 72 y/o male has history of BPH. He just discharge on 20220108
due to mucinous adenocarcinoma of appendix with peritoneal metastatic,
cT4aN1aM1, stage IVA, status post omentectomy and peritonectomy and PD
tube inserted and intraperitoneal port implantation + HIPEC on
20211230.</li>
<li>According to his statement, he suffered from chest tightness,
dyspnea since yesterday. He went to our ER for help on 20220113. His EKG
data showed NSR, cardiac enzyme within normal range, D-dimer: 3730ng/ml.
Unfortunately, he had seizure(hanging eyes) for 5 seconds at ER, Ativan
and Keppra stat were given. Brain CT without constrast was done and
showed mild ventriculomegaly, intracranial atherosclerosis. Chest CTA
was done it revealed (1) no evidence of pulmonary embolism nor aortic
dissection, (2) left pleural effusion and minimal right pleural
effusion, (3) locualted effusion at RLQ of the abdomen. Nature?, (4)
Some small patches at both lungs. suspected infection. Now, his con’s
clear, stable of vital sign, pupil size 3.0 (OU) light reflux, four
limbs muscle power 5point. We need your expertise for seizure evaluation
and management. Thanks for your times.</li>
</ul></li>
<li>A
<ul>
<li>Due to seizure at ER, we are consulted. Patient told he had no
history of seizure and he didn’t remember during seizure attack. He also
denied tongue biting, urinary/bowel incontinence, todd’s paralysis,
diplopia, swallowing problem, slurred speech, limbs numbness or limbs
weakness.</li>
<li>NE
<ul>
<li>Consciouness: E4V5M6</li>
<li>Visual field: no hemianopia</li>
<li>EOM: free</li>
<li>Pupil: 3.0/3.0 mm, Light reflex: +/+</li>
<li>Face: no central facial palsy</li>
<li>No dysarthria</li>
<li>no tongue deviation</li>
<li>Muscle power: 5/5</li>
<li>Babinski: down/down</li>
<li>Sensory: no hypoesthesia</li>
<li>FNF &amp; HKS: no dysmetria</li>
<li>D dimer : 3700, Na 124, CRP 4.9</li>
</ul></li>
<li>Assessment
<ul>
<li>Generalized tonic clonic seizure, 1st episode, suspected metastasis
related or electrolyte imbalance</li>
<li>mucinous adenocarcinoma of appendix, stage IV A</li>
</ul></li>
<li>Suggestion
<ul>
<li>Arrange EEG and MRA brain with/without contrast to r/o
metastasis</li>
<li>Vit B6 1# bid po and Keppra 500mg bid po for seizure</li>
<li>We have given seizure educations to caution on driving
scooter/car</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-06 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For further bidirectional chemotherapy evaluation</li>
<li>This 71 years old male has history of benign prostatic hyperplasia
under medication treatment. According to his statement, he suffered from
abdomen fullness for half year and body weight loss 4 kgs within 6
months, ever has tarry stool at 3 months ago. Then the symptom of RLQ
pain worse since 2021-09, so he went to the Shin Kong Hospital for
help.</li>
<li>On 2021-11-25 abdomen CT showed (1) Ruptured appendix mucinous
cancer with peritoneal carcinomatosis, omental caking and hepatic
surface implantation, (2) Focal peribronchial inflammation. And he was
admitted to our Oncology ward for survey on 2021-11-29. During last
admitted, he underwent laparoscopic examination with peritoneal tumor
biopsy was done on 2021-12-06.</li>
<li>The pathology revealed metastatic mucinous adenocarcinoma. On
2021-12-14 following chest and abdomen CT was performed which showed (1)
lung infection or aspiration pneumonia, (2) peritoneal carcinomatosis.
Abdomen echo was done and showed no GB stone. Heart echo revealed LVEF:
80%, aortic valve sclerosis with mild AR; mild to moderate MR; mild TR;
moderate PR. We check tumor marker showed CEA: 10.93ng/ml, CA-199:
283.12U/ml.</li>
<li>Under stable condition condition and fair oral intake, he was
discharge on 20211215. After discharge, he was followed at GS OPD. He
denied of poor appetite, no nausea or vomit, no tarry stool, no bloody
stool, no abdomen fullness, no abdomen pain. Physical examination showed
andomen ovoid and soft, no tenderness, no palpable mass. After fully
explain, right hemicolectomy and cytoreductive surgery and HIPEC was
suggested. This time, he was admitted to our ward for lung lesion biopsy
and surgical intervention. However, during operation his PCI: 29/39 was
noted, thus underwent omentectomy, peritonectomy, CAPD and IP port
implantation and HIPEC with oxaliplatin 300mg/m2 was done on 20211230.
Now, he try to semi-liquid diet was smoothly, normal bowel function and
stable condtion. We need your expertise for further bidirectional
chemotherapy evaluation. Thanks for your times.</li>
</ul></li>
<li>A
<ul>
<li>This 71 years old man is a case of Appendix cancer with peritoneal
metastatic mucinous adenocarcinoma, cT4aN1aM1, stage IVA status post
laparoscopic examination and biopsy on 2021/12/06, immunohistochemical
stains reveal CK7(-), CK20(+), CDX2(+), and PAX8(-), ECOG:0 s/p
omentectomy, peritonectomy, CAPD and IP port implantation and HIPEC with
oxaliplatin 300mg/m2 was done on 20211230. For bidirectional
chemotherapy, we are consulted.</li>
<li>The impact of adjuvant chemotherapy following CRS/HIPEC in
appendiceal mucinous neoplasms has not been well established due to
rareness of this disease and lack of randomized trials. In the
advanced-disease setting, available retrospective data suggest
beneficial effect from systemic chemotherapy in moderate- to high‐grade
appendiceal mucinous tumors.</li>
<li>Systemic therapy with FOLFOX/bevacizumab +/- IP chemotherpay as
ajuvant chemotherapy may consider in this case</li>
<li>We will disucss with patient, thanks for your consultation</li>
</ul></li>
</ul></li>
<li>2021-12-09 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>for metastatic mucinous adenocarcinoma surgery, prepare the IP
chemotherapy and on port-a evaluation</li>
<li>This time, he is admitted for colonfibroscopy examination and biopsy
and staging, follow-up colonoscopy: no tumor was found in colonic lumen
on 20211203, and he received the laparoscopy for tumor biopsy showed
metastatic mucinous adenocarcinoma, origin? The immunohistochemical
stains reveal CK7(-), CK20(+), CDX2(+), and PAX8(-). The results are in
favor of GI tract (including appendix) tumor. So we need your help for
metastatic mucinous adenocarcinoma (for peritoneum biopsy) surgery,
prepare the IP chemotherapy and on port-a evaluation, thanks a
lot!!</li>
</ul></li>
<li>A
<ul>
<li>impression
<ul>
<li>psudomyxoma with peritoni, favor appendical mucinous adenocarcinoma
related</li>
</ul></li>
<li>suggest
<ul>
<li>radical right hemicolectomy with cytoreductive surgery and HIPEC is
indicated</li>
<li>please arrange 2D echo and PFT first</li>
<li>please transfer to our survice next Monday</li>
<li>PPN support</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-30
<ul>
<li>omentectomy</li>
<li>RUQ and right flank peritonectomy</li>
<li>CAPD (continuous ambulatory peritoneal dialysis)</li>
<li>IP port implantation</li>
</ul></li>
<li>2021-12-06 Laparoscopic exploration and biopsy
<ul>
<li>Post-Op Dx: suspect pseudomyxoma peritoni        </li>
<li>Finding
<ul>
<li>Multiple white nodular lesions within omentum and peritoneal surface
were noted. pieces were excised of them for biopsy.</li>
<li>Gelly like ascites about 100 ml and ascites cytology was done.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-12-01 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-11-18 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-11-04 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-10-17 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-09-30 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-08-15 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D7 + oxaliplatin 85mg/m2 100mg IVD 2hr + [docetaxel
40mg/m2 60mg + cisplatin 40mg/m2 60mg + gentamicin 40mg + NaHCO3 70mg/mL
40mL] in N/S 500mL IP 1.5hr (The patient complaints poor intake due to
the oral chemotherapy, so shift to TS1 25mg/cap 3cap QD for one
week)</li>
<li>2022-06-06 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 40mg + NaHCO3 70mg/mL 40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-05-10 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 40mg + NaHCO3 70mg/mL 40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-04-15 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 40mg + NaHCO3 70mg/mL 40mL] in N/S 500mL IP 1.5hr</li>
<li>2022-03-25 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 80mg + NaHCO3 70mg/mL 80mL] in N/S 500mL IP 1.5hr x2 =
3hr ?</li>
<li>2022-03-04 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 80mg + NaHCO3 70mg/mL 80mL] in N/S 500mL IP 1.5hr x2 =
3hr ?</li>
<li>2022-02-09 - TS-1 (tegafur + gimeracil + oteracil) 25mg/cap 50mg/m2
3# 75mg QD PO D1-D14 + + [docetaxel 40mg/m2 60mg + cisplatin 40mg/m2
60mg + gentamicin 80mg + NaHCO3 70mg/mL 80mL] in N/S 500mL IP 1.5hr x2 =
3hr ?
<ul>
<li>Neoadjuvant Intraperitoneal Chemotherapy in Patients with
Pseudomyxoma Peritonei - A Novel Treatment Approach
<ul>
<li>Cancers 2020, 12(8), 2212; <a href="https://doi.org/10.3390/cancers12082212" class="uri">https://doi.org/10.3390/cancers12082212</a></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-79" class="section level3">
<h3>==========</h3>
</div>
<div id="section-80" class="section level3">
<h3>2022-12-02</h3>
<ul>
<li>The vital signs are stable, and laboratory results indicate a
grossly normal condition, except for hypomagnesemia (2022-12-01 1.6
mg/dL) which is being treated with magnesium sulfate injection.</li>
</ul>
</div>
<div id="section-81" class="section level3">
<h3>2022-09-06</h3>
<ul>
<li>If neoadjuvant or adjuvant systemic chemotherapy is needed, a
combination of fluoropyrimidine and an alkylating agent is recommended.
5-FU (TS-1) and oxaliplatin were included in the regimen used in the
last hospitalization (2022-08-15). (ref: Lin, YL. et al. Consensuses and
controversies on pseudomyxoma peritonei: a review of the published
consensus statements and guidelines. Orphanet J Rare Dis 16, 85 (2021).
<a href="https://doi.org/10.1186/s13023-021-01723-6" class="uri">https://doi.org/10.1186/s13023-021-01723-6</a> ).</li>
<li>Due to the patient’s poor intake caused by TS-1, the regimen has
been changed to 7 consecutive days of administration. If this is also
followed by a week of rest, thereby making the cycle 14 days, then the
dose of oxaliplatin might need to be adjusted to accommodate this
modification in cycle length.</li>
</ul>
</div>
<div id="section-82" class="section level3">
<h3>2022-06-07</h3>
<ul>
<li>This case represents a patient with pseudomyxoma peritonei (PMP),
who underwent omentectomy, RUQ, and right flank peritonectomy in
2021-12-30 along with hyperthermic intraperitoneal chemotherapy
(HIPEC).</li>
<li>The patient has been receiving intraperitoneal treatment with
[docetaxel + cisplatin + gentamicin] since 2022-02-09 in conjunction
with oral TS-1, a regimen that has been outlined at <a href="doi:10.3390/cancers12082212" class="uri">doi:10.3390/cancers12082212</a>.</li>
<li>Since records began in Nov 2021, certain items of lab results have
been consistently outside normal ranges. These include low HGB
(2022-06-07 8.7g/dL), low RBC (2022-06-07 2.61 <em>10</em>6/uL), and
high D-dimer (2022-06-06 6969.93 ng/mL FEU).</li>
<li>Anemia is rarely mentioned in PMP case reports, so it is possible
that anemia could be caused by another condition which might be worth
further investigation.</li>
<li>TPR and BP are generally normal and stable since this hospital stay
from 2022-06-06.</li>
</ul>
</div>
<div id="section-83" class="section level3">
<h3>2022-06-06</h3>
<p>[drug identification]</p>
<p>Total 1 drug for identification.</p>
<p>The identified item is Vemlidy film-coated tablet containing
tenofovir alafenamide 25mg which is indicated for the treatment of
chronic hepatitis B virus (HBV) infection in adults with compensated
liver disease.</p>
<p>The drug will be sent back to ward by the in-hospital porter.</p>
</div>
<div id="section-84" class="section level3">
<h3>2022-04-06</h3>
<ul>
<li>This is a patient with pseudomyxoma peritonei (PMP), s/p
omentectomy, RUQ and right flank peritonectomy (2021-12-30) and
hyperthermic intraperitoneal chemotherapy (HIPEC).</li>
<li>From 2022-02-09, he has been receiving intraperitoneal [docetaxel
plus cisplatin + gentamicin] in combination with oral TS-1, a regimen
which was published at <a href="doi:10.3390/cancers12082212" class="uri">doi:10.3390/cancers12082212</a>.</li>
<li>Hypoosmolarity and hypoelectrolytemia are treated with appropriate
electrolyte solutions.</li>
<li>A low WBC reading of 910/uL was recorded on 2022-04-05. G-CSF might
be an option.</li>
</ul>
</div>
</div>
</div>
<div id="section-85" class="section level1">
<h1>700561561</h1>
<div id="section-86" class="section level2">
<h2>221202</h2>
<p>{pancreatic cancer, endometrial cancer}</p>
<ul>
<li>diagnosis
<ul>
<li>Pancreatic cancer with peritoneum metastasis s/p Laparoscopic
exploration on 2022/02/25</li>
<li>Endometrial cancer, pT1bN0M0, Stage IB status post laparoscopic
vaginal total hysterectomy on 2018/04/17</li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-07-26 CEA 5.21 ng/mL<br />
</li>
<li>2022-05-02 CEA 3.10 ng/mL<br />
</li>
<li>2022-01-24 CEA 1.96 ng/mL<br />
</li>
<li>2021-10-25 CEA 1.84 ng/mL<br />
</li>
</ul></li>
<li>CA125
<ul>
<li>2022-07-26 CA125 788.2 U/mL<br />
</li>
<li>2022-05-02 CA125 460.8 U/mL<br />
</li>
<li>2022-01-24 CA125 15.1 U/mL<br />
</li>
<li>2021-10-25 CA125 5.8 U/mL<br />
</li>
<li>2021-07-26 CA125 5.5 U/mL<br />
</li>
<li>2021-04-26 CA125 3.5 U/mL<br />
</li>
</ul></li>
<li>CA199
<ul>
<li>2022-07-26 CA199 12024.11 U/mL<br />
</li>
<li>2022-05-23 CA199 &gt;19680.00 U/mL<br />
</li>
<li>2020-04-13 CA199 23.72 U/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-11-28 CT - abdomen
<ul>
<li>Indication: Pancreatic cancer with peritoneal carcinomatosis</li>
<li>Findings
<ul>
<li>Abdomen and pelvis
<ul>
<li>Low density change at pancreatic tail about 4.74cm in largest
dimension is found. pancreatic cancer is considered. In comparison with
CT dated on 2022-09-05, the lesion is stationary.</li>
<li>Massive ascites is found. Cancerous peritontitis is considered
first</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>Low density lesion at S4 of liver about 2.5cm in largest dimension
is found. Liver meta is considered. In progression.</li>
<li>No evidence of abnormal soft tissue mass at pelvic cavity.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
</ul></li>
<li>Visible chest
<ul>
<li>Cardiomegaly is noted.</li>
<li>No pleural effusion is found.</li>
<li>Clear bilateral basal lungs.</li>
</ul></li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>Imp:
<ul>
<li>Pancreatic tail cancer with cancerous peritonitis and massive
ascites. Stable.</li>
<li>Liver meta. In progression.</li>
<li>Bone meta. Please correlate with bone scan study.</li>
</ul></li>
</ul></li>
<li>2022-11-16 CXR
<ul>
<li>Fracture of left clavicle, M/3.</li>
<li>Pleura effusion of right and left costal-phrenic angle</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-09-05 CT - abdomen
<ul>
<li>Indication: Pancreatic cancer with peritoneal seedings</li>
<li>Findings
<ul>
<li>Abdomen and pelvis
<ul>
<li>s/p ATH and BSO.</li>
<li>Low density lesion at pancreatic tail about 4.6cm is found. In
comparison with CT dated on 2022-05-09, the lesion is stationary.</li>
<li>Massive ascites is found. Cancerous peritonitis is considered.</li>
<li>The GB is well distended without soft tissue lesion</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>Low density lesion at S4 of liver about 0.7cm in largest dimension
is found. suspected liver meta or others. Stationary.</li>
<li>There is no evidence of paraarotic LAPs.</li>
</ul></li>
<li>Visible chest
<ul>
<li>Normal heart size.</li>
<li>The lung fields are clear.</li>
<li>No pleural effusion is found.</li>
</ul></li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>Imp:
<ul>
<li>Massive ascites, suspected cancerous peritonitis</li>
<li>Pancreatic tail tumor, 4.6cm, stable. Pancreatic cancer is
favored.</li>
<li>Bone meta. New.</li>
<li>Liver low density lesion. S4, meta?</li>
</ul></li>
</ul></li>
<li>2022-06-14 SONO - abdomen
<ul>
<li>Gallbladder sludge</li>
<li>Asictes</li>
</ul></li>
<li>2022-06-10 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Fracture of left clavicle, M/3.</li>
<li>Pleura effusion of right and left costal-phrenic angle</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-06-09 Pure Tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 18 dB HL; LE 24 dB HL</li>
<li>bil normal to moderate SNHL (sensorineural hearing loss)</li>
</ul></li>
<li>2022-05-25 Patho - peritoneum biopsy
<ul>
<li>Peritoneum, biopsy — Metastatic adenocarcinoma, origin? (please see
microdescription)</li>
<li>Section shows fibroadipose tissue with metastatic
adenocarcinoma.</li>
<li>The immunohistochemical stians reveal CK7(+), CD20(-), CDX2(focal
weak +), GATA3(+), PAX8(-), and Calretinin(-).</li>
<li>The results are more favor pancreatic tumor than endometrial
tumor.</li>
</ul></li>
<li>2022-05-25 Patho - omentum biopsy
<ul>
<li>Greater omentum, biopsy — Negative for malignancy</li>
</ul></li>
<li>2022-05-24 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Low voltage QRS</li>
</ul></li>
<li>2022-05-24 SONO - abdomen
<ul>
<li>massive ascites</li>
<li>diffuse wall-thickening of small bowel, suspected
carcinomatosis</li>
</ul></li>
<li>2022-05-13 Clavicle LT
<ul>
<li>Left M/3 clavicle fracture</li>
</ul></li>
<li>2022-05-09 CT - abdomen, pelvis
<ul>
<li>s/p ATH and BSO.</li>
<li>Massive ascites and bilateral pleural effusion is found.</li>
<li>Pancreatic body lesion about 5.53cm in largest dimension is found.
Either meta or primary tumor should be D.D.</li>
</ul></li>
<li>2022-05-09 Gynecologic ultrasonography
<ul>
<li>p/s ATH + BSO</li>
<li>Ascites (+)</li>
</ul></li>
<li>2022-05-04 Gynecologic ultrasonography
<ul>
<li>Bil adnexa: s/p BSO</li>
<li>EM cancer post staging, ascites (+)</li>
<li>suspected tumor recurrence</li>
</ul></li>
<li>2022-05-04 KUB
<ul>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-05-04 CXR
<ul>
<li>Fracture of left clavicle.</li>
<li>Left pleural effusion.</li>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-04-01 Clavicle LT
<ul>
<li>Left M/3 clavicle fracture with displacement</li>
</ul></li>
<li>2022-01-26 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
<li>A lesion in S4 liver shows stationary.</li>
<li>The gallbladder shows few small stones and posterior displacement by
the S4 liver lesion.</li>
</ul></li>
<li>2021-11-01 Gynecologic ultrasonography
<ul>
<li>p/s ATH + BSO</li>
<li>no obvious uterine or ovarian lesion</li>
</ul></li>
<li>2021-07-26 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>No evidence of tumor recurrence.</li>
</ul></li>
<li>2021-05-03 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Hepatic high echoic lesions, nature? fibrosis lesions?</li>
<li>GB stones</li>
<li>Fatty pancreas</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with clinical information and other image studies,
and follow sonography in 3-6 mon.</li>
<li>Please check tumor, hepatitis markers and LFTs q3-6 mon</li>
</ul></li>
</ul></li>
<li>2021-05-03 Gynecologic ultrasonography
<ul>
<li>p/s ATH + BSO</li>
<li>no obvious uterine or ovarian lesion</li>
</ul></li>
<li>2020-10-07 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Hepatic low echoic lesions, nature?</li>
<li>GB stones</li>
<li>Fatty pancreas</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with clinical information and other image studies,
and follow sonography in 3-6 mon.</li>
<li>Please check tumor, hepatitis markers and LFTs q3-6 mon</li>
</ul></li>
</ul></li>
<li>2020-07-27 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>No evidence of tumor recurrence.</li>
</ul></li>
<li>2020-04-13 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>GB stones?</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please follow sonography in 3-6 mon.</li>
</ul></li>
</ul></li>
<li>2020-04-13 Gynecologic ultrasonography
<ul>
<li>p/s ATH + BSO</li>
<li>no obvious uterine or ovarian lesion</li>
</ul></li>
<li>2020-01-03 CT - abdomen
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
<li>A lesion in S4 liver is suspected. Follow up MRI 3 months later may
be indicated.</li>
<li>The gallbladder shows few small stones and posterior displacement by
the S4 liver lesion.</li>
</ul></li>
<li>2019-09-26 Transvaginal Ultrasonography
<ul>
<li>No obvious uterine or ovarian lesion</li>
</ul></li>
<li>2019-06-03 CT - abdomen
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
<li>A lesion in S4 liver is suspected.</li>
<li>The gallbladder shows few small stones and posterior displacement by
the S4 liver lesion.</li>
</ul></li>
<li>2019-02-25 Transvaginal Ultrasonography
<ul>
<li>No obvious uterine or ovarian lesion</li>
</ul></li>
<li>2018-11-27 CT - abdomen
<ul>
<li>s/p ATH and BSO.</li>
<li>No focal lesion in the pelvis</li>
</ul></li>
<li>2018-05-11 CT - abdomen
<ul>
<li>S/P hysterectomy.</li>
<li>Relative dirty mesentery fat plane, post-op change?</li>
<li>Loculated fluid density in right obturator region, suspected
lymphocele or seroma, suggest follow up study.</li>
</ul></li>
<li>2018-05-11 Transvaginal Ultrasonography
<ul>
<li>No obvious uterine or ovarian lesion</li>
</ul></li>
<li>2018-04-18 Patho - laparoscopic vaginal total hysterectomy (LAVH),
Level VI
<ul>
<li>Uterus, endometrium, laparoscopic vaginal total hysterectomy (LAVH)
— Endometrioid adenocarcinoma, grade 1</li>
<li>Uterus, myometrium, laparoscopic vaginal total hysterectomy (LAVH) —
Endometrioid adenocarcinoma, invading &gt;1/2 of the thickness of the
myometrium.</li>
<li>Uterus, cervix, laparoscopic vaginal total hysterectomy (LAVH) —
Free.</li>
<li>Ovaries and fallopian tubes, bilateral, laparosocpic
salpingo-oophorectomy (BSO) — Free</li>
<li>Lymph node, bilateral pelvic, dissection (BPLND) — Free (0/25)</li>
<li>Omentum, omentectomy — Free (with one lymph node free of malignancy
0/1)</li>
<li>AJCC 8th edition Pathology stage: pT1bN0 (if cM0); pStage: IB.</li>
<li>S2018-05404: ER (+, 90%), PR (+, 90%)</li>
</ul></li>
<li>2018-04-14 MRI - pelvis
<ul>
<li>Imaging Report Form for Endometrial Carcinoma</li>
<li>Impression:
<ul>
<li>Endometrial malignancy, cstage T1bN0Mx.</li>
<li>Right obturator lymph node, suggest follow up.</li>
</ul></li>
</ul></li>
<li>2018-04-03 Surgical pathology Level IV
<ul>
<li>Uterus, endometrium, D&amp;C — Adenocarcinoa with squamous
metaplasia.</li>
<li>IHC: ER (+, 90%), PR (+, 90%), p40 (-), p16 (+, 70%), vimentin (+,
80%).</li>
</ul></li>
<li>2018-04-02 Gynecologic ultrasonography
<ul>
<li>Suspected endometrial hyperplasia</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-04 Obstetrics and Gynecology
<ul>
<li>Q
<ul>
<li>poor appetite after traffic accident in Feburary</li>
<li>diarrhea, nausea for 2 weeks</li>
<li>periumbilical fullness for 2 weeks</li>
<li>EGD at LMD last week: GERD</li>
<li>abdominal sono at LMD on 5/2: ascites</li>
<li>PH: Malignant neoplasm of endometrium S/P hysterectomy, R/T</li>
<li>Allergy: NKA</li>
</ul></li>
<li>A
<ul>
<li>findings
<ul>
<li>a case of endometrial cancer post staging surgery (ATH + BSO + BPLND
+ omentectomy) + radiotherapy in 2018.</li>
<li>post op course was smooth without recurrence, checked by CT scan,
sonar and tumor marker until 2022/2</li>
<li>c/o abdominal distension, poor appetite for 2 weeks (c/o: complaint
of)</li>
<li>no fever nor pain</li>
<li>CA125: 15 -&gt; 460 elevated</li>
<li>GYN sonar: ascites &gt; 1000 c.c</li>
<li>PV – vaginal stump no mass palpated, seemed free</li>
<li>no bleeding</li>
</ul></li>
<li>Imp
<ul>
<li>ascites,</li>
<li>suspected cancer recurrence</li>
</ul></li>
<li>Suggestion:
<ul>
<li>consider to arrange abdominal tapping (+ send ascites cytology) if
indicated</li>
<li>symptom treatment with gascon, etc</li>
<li>please arrange abdominal CT scan</li>
<li>scheduled 20220509 W1 GYN OPD for further Tx</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-25
<ul>
<li>Operation
<ul>
<li>Laparoscopic exploration</li>
</ul></li>
<li>Finding
<ul>
<li>Massive turbid ascites, &gt; 4000cc</li>
<li>Multiple peritoneal seedings, compatible with carcinomatosis</li>
<li>Culture: ascites*1</li>
</ul></li>
</ul></li>
<li>2018-04-17
<ul>
<li>Diagnosis
<ul>
<li>endometrial cancer (adenocarcinoma)</li>
</ul></li>
<li>PCS
<ul>
<li>80424B</li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: enlarged, 12x10x7cm</li>
<li>endometrium – thickened, soft necrotic tissues at fundus; EM cancer
cells likely</li>
<li>myometrium – seemed invaded by cancer</li>
<li>cervix eroded</li>
<li>bil adnexa: normal-looking, seemed free of cancer invasion</li>
<li>omentum, appendix, bowels: seemed free of cancer invasion</li>
<li>CDS: no fluid (send ascites washing cytology) but severe pelvic
bowel adhesion (due to previous vertival laparotomy?) was noted between
ant peritoneum, left pelvis and bowels; between uterus and ant bladder
s/p LSC adhesiolysis</li>
<li>A 7mm JP drain was placed in CDS</li>
</ul></li>
</ul></li>
<li>2018-04-02
<ul>
<li>Diagnosis
<ul>
<li>Suspected endometrial hyperplasia or cancer – EM 2.43cm</li>
</ul></li>
<li>PCS
<ul>
<li>80423B</li>
</ul></li>
<li>Finding
<ul>
<li>Under IVGA, Hysteroscopic endometrial curettage were done.</li>
<li>Thickened endometrium noted with a lot of soft necrotic tissues,
suspected endometrial hyperplasia or cancer</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-09 - gemcitabine 800mg/m2 1300mg 30min + nab-paclitaxel
100mg/m2 160mg 90min</li>
<li>2022-10-26 - gemcitabine 800mg/m2 1300mg 30min + nab-paclitaxel
100mg/m2 160mg 90min</li>
<li>2022-10-19 - gemcitabine 800mg/m2 1300mg 30min + nab-paclitaxel
100mg/m2 160mg 90min</li>
<li>2022-10-05 - gemcitabine 800mg/m2 1300mg 30min + nab-paclitaxel
100mg/m2 160mg 90min</li>
<li>2022-09-28 - gemcitabine 800mg/m2 1300mg 30min + nab-paclitaxel
100mg/m2 160mg 90min</li>
<li>2022-09-14 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 90min</li>
<li>2022-09-07 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 90min</li>
<li>2022-08-24 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-08-17 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-08-04 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-07-28 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-07-14 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-07-08 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-06-21 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 120mg 90min</li>
<li>2022-06-14 - gemcitabine 800mg/m2 1250mg 30min + cisplatin 20mg/m2
30mg 24hr</li>
</ul></li>
</ul>
<div id="section-87" class="section level3">
<h3>==========</h3>
</div>
<div id="section-88" class="section level3">
<h3>2022-12-02</h3>
<ul>
<li><p>It should be noted that both serum creatinine and BUN increased
50% in the last two weeks (Cre 1.76 mg/dL 2022-11-30 &lt;- 1.18 mg/dL
2022-11-16; BUN 33 mg/dL 2022-11-30 &lt;- 20 mg/dL 2022-11-16), as well
as bilirubin total exceeded 6 x ULN (6.95 mg/dL 2022-11-30).</p></li>
<li><p>2022-11-30 eGFR 31.2</p>
<ul>
<li>gemcitabine for patients with altered kidney function:
<ul>
<li>CrCl &gt;= 30 mL/minute: IV: No dosage adjustment necessary (Cetina
2004; Delaloge 2004; Li 2007; Lichtman 2007; Venook 2000).</li>
<li>CrCl &lt;30 mL/minute: IV: No dosage adjustment necessary. However,
risk of hematologic toxicity may be increased in these patients, which
may require gemcitabine dose modification (Cetina 2004; Li 2007;
Lichtman 2007; Mir 2005; Tanji 2013; Venook 2000).</li>
</ul></li>
<li>nab-paclitaxel for patients with altered kidney function:
<ul>
<li>CrCl &lt;30 mL/minute: There are no dosage adjustments provided in
the manufacturer’s labeling (insufficient data).</li>
</ul></li>
</ul></li>
<li><p>2022-11-30 bilirubin total 6.95 mg/dL, ALT 442 U/L, AST 342
U/L</p>
<ul>
<li>gemcitabine for patients with hepatic Impairment - there are no
dosage adjustments provided in the manufacturer’s labeling. The
following adjustments have been reported:
<ul>
<li>Transaminases elevated (with normal bilirubin): No dosage adjustment
necessary (Venook 2000).</li>
<li>Serum bilirubin &gt; 1.6 mg/dL: Use initial dose of 800 mg/m2; may
escalate if tolerated (Ecklund 2005; Floyd 2006; Venook 2000).</li>
<li>Dosage adjustment for hepatotoxicity during treatment: Discontinue
if severe hepatotoxicity occurs during gemcitabine treatment.</li>
</ul></li>
<li>nab-paclitaxel for patients with hepatic Impairment
<ul>
<li>Not recommended in case of AST &gt; 10x ULN or bilirubin &gt; 5x
ULN</li>
</ul></li>
</ul></li>
<li><p>It is suggested to ensure that the patient’s kidney and liver
function are in good condition prior to the chemotherapy.</p></li>
</ul>
</div>
<div id="section-89" class="section level3">
<h3>2022-07-29</h3>
<ul>
<li>Tumor markers
<ul>
<li>CEA
<ul>
<li>2022-07-26 5.21 ng/mL<br />
</li>
<li>2022-05-02 3.10 ng/mL<br />
</li>
<li>2022-01-24 1.96 ng/mL<br />
</li>
<li>2021-10-25 1.84 ng/mL<br />
</li>
</ul></li>
<li>CA125
<ul>
<li>2022-07-26 788.2 U/mL<br />
</li>
<li>2022-05-02 460.8 U/mL<br />
</li>
<li>2022-01-24 15.1 U/mL<br />
</li>
<li>2021-10-25 5.8 U/mL<br />
</li>
<li>2021-07-26 5.5 U/mL<br />
</li>
<li>2021-04-26 3.5 U/mL<br />
</li>
</ul></li>
<li>CA199
<ul>
<li>2022-07-26 12024.11 U/mL<br />
</li>
<li>2022-05-23 &gt;19680.00 U/mL<br />
</li>
<li>2020-04-13 23.72 U/mL<br />
</li>
</ul></li>
</ul></li>
<li>In recent months, tumor markers have trended upward. The current
regimen has been used to treat patients since mid-June 2022 (still less
than 2 months).</li>
<li>FOLFIRINOX vs Gemtabine plus Nab-Paclitaxel, there is disagreement
among studies regarding the choice between the two. references:
<ul>
<li>Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D.
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as
First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
JAMA Netw Open. 2022;5(6):e2216199. <a href="doi:10.1001/jamanetworkopen.2022.16199" class="uri">doi:10.1001/jamanetworkopen.2022.16199</a></li>
<li>Riedl JM, Posch F, Horvath L, et al. Gemcitabine/nab-Paclitaxel
versus FOLFIRINOX for palliative first-line treatment of advanced
pancreatic cancer: A propensity score analysis. Eur J Cancer.
2021;151:3-13. <a href="doi:10.1016/j.ejca.2021.03.040" class="uri">doi:10.1016/j.ejca.2021.03.040</a></li>
<li>Chun JW, Lee SH, Kim JS, et al. Comparison between FOLFIRINOX and
gemcitabine plus nab-paclitaxel including sequential treatment for
metastatic pancreatic cancer: a propensity score matching approach. BMC
Cancer. 2021;21(1):537. Published 2021 May 11. <a href="doi:10.1186/s12885-021-08277-7" class="uri">doi:10.1186/s12885-021-08277-7</a></li>
<li>Tahara J, Shimizu K, Otsuka N, Akao J, Takayama Y, Tokushige K.
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with
advanced pancreatic cancer. Cancer Chemother Pharmacol.
2018;82(2):245-250. <a href="doi:10.1007/s00280-018-3611-y" class="uri">doi:10.1007/s00280-018-3611-y</a></li>
</ul></li>
</ul>
</div>
<div id="section-90" class="section level3">
<h3>2022-07-06</h3>
<ul>
<li>No mutation test results were found for BRCA1/2 or PALB2. A change
in the regimen from gemcitabine + cisplatin to gemcitabine +
nab-paclitael has been made in late June 2022. Whereas FOLFINOX or
modified FOLFINOX (not used in this case) should be limited to patients
with an ECOG of 0 or 1.</li>
<li>There has been a low potassium level of 1.9 mmol/L on 2022-07-05. A
KCl injection, oral potassium gluconate, and a spironolactone dose have
been prescribed.</li>
</ul>
</div>
</div>
</div>
<div id="section-91" class="section level1">
<h1>701450418</h1>
<div id="section-92" class="section level2">
<h2>221201</h2>
<ul>
<li>exam findings
<ul>
<li>2022-10-04 Pelvis and Bilat. Hip. Lat.
<ul>
<li>Narrowed joint or discal space with bony sclerosis but without acute
fracture, bone destruction or dislocation.</li>
</ul></li>
<li>2022-10-03 CXR
<ul>
<li>Left pleural effusion. A LLL tumor mass.</li>
<li>No cardiomegaly by cardiac/thoracic ratio.</li>
<li>Post operative appearance in or at the area of TL spine.</li>
<li>Presence of numerous small miliary-like lesions in bilateral lung
fields, metastases should be rule out.</li>
</ul></li>
<li>2022-09-28 T-L spine AP + Lat.
<ul>
<li>Presence of spondylolisthesis at L4/5, grade I.</li>
<li>Presence of anterior wedge deformity or body collapse of the
thoracic or lumbar spine due to compression fracture(s) L2.</li>
<li>S/P posterior longitudinal transpedicular spine screws and rods
fixation.</li>
</ul></li>
<li>2022-09-27 EGFR mutation
<ul>
<li>A deleteion was detected at exon 19 of EGFR gene in this
specimen.</li>
<li>The EGFR mutation testing was based on real-time PCR technique for
detection of exons 18 (G719X), 19 (Deletions), 20 (T790M, S7681I,
Insertions), 21 (L858R, L861Q) mutations of EGFR gene. The limit of
detection (LoD) of this test was 10% mutant gene of whole EGFR
gene.</li>
</ul></li>
<li>2022-09-29 PD-L1 (22C3)
<ul>
<li>Tumor Proportion Score (TPS) assessment: TPS &lt; 1%</li>
</ul></li>
<li>2022-09-29 PD-L1 28-8 IHC
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percent of PD-L1 expression in tumor cells (TC): &lt; 1%</li>
</ul></li>
<li>2022-08-11 PD-L1 (SP142)
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana) - S2022-16383
<ul>
<li>Tumor type: adenocarcinoma</li>
<li>Tumor location: lung</li>
<li>Testing assay: SP142 Assay (Ventana)</li>
<li>Testing platform: BenchMark XT</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit</li>
<li>Control slide result: Pass,</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells): Yes,</li>
</ul></li>
<li>Result:
<ul>
<li>Tumor cell (TC) staining assessment: TC category: TC &lt; 1%</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC &lt; 1%</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
<li>2022-09-26 Patho - lung transbronchial biopsy
<ul>
<li>Lung, left, CT-guide biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show neoplastic acinar glandular cells infiltrating in a
fibrotic stroma.</li>
</ul></li>
<li>2022-09-21 Whole body PET scan
<ul>
<li>Glucose-hypermetabolic lesions in the left upper and lower lungs
with pleura involvement, highly suspected lung cancer with lung to lung
mets and malignant pleural effusion.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral mediastinal and right
pulmonary hilar lymph nodes, highly suspected lung cancer with regional
lymph nodes metastases.<br />
</li>
<li>Increased uptake of FDG in the right adrenal gland, L2 spine, and
left frontal skull, highly suspected lung cancer with multiple distant
metastases.<br />
</li>
<li>Left lung cancer with lung to lung, bilateral mediastinal and right
pulmonary hilar lymph nodes, right adrenal gland, L2 spine, and left
frontal skull metastases, cT4N3M1c, stage IVB (AJCC 8th ed.), by this
F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2022-09-20 MRI - brain
<ul>
<li>No obvious brain or intracranial nodule or metastasis 2. r/o Focal
left frontal skull metastasis.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-30 Rehabilitation
<ul>
<li>A
<ul>
<li>Assessment
<ul>
<li>Left lower lobe lung cancer with bilateral lung to lung meta,
mediastinal lymphadenopathy, lumbar spine pathological fracture, right
adrenal meta and probably liver meta</li>
<li>Multiple bone metastases with L2 pathological fracture</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT, OT rehabilitation programs;
apply ant. AFO for left drop foot</li>
<li>Goal: improve ADL, muscle power and endurance</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-11-09 Rehabilitation
<ul>
<li>Assessment
<ul>
<li>Malignant neoplasm of lower lobe, left bronchus or lung</li>
<li>Secondary malignant neoplasm of bone</li>
<li>Left lung adenocarcinoma with pathology fracture of L2 status post
L2-L3 laminectomy, fixation and postero-lateral spinal fusion on
2022/09/12 s/p TKI with Afatinib from 2022/10/25</li>
<li>Chronic viral hepatitis B without delta-agent</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT and OT rehabilitation
programs</li>
<li>Goal: improved ADL and muscle power, ambulate with device under
supervision</li>
</ul></li>
</ul></li>
<li>2022-11-10 Dermatology
<ul>
<li>Q
<ul>
<li>This 48-year-old woman patient is a csae of Left lung adenocarcinoma
with pathology fracture of L2 status post L2-L3 laminectomy, fixation
and postero-lateral spinal fusion on 2022/09/12 s/p TKI with Afatinib
from 2022/10/25. This time, for whole body skin red rash after TKI. Now,
for evaluate whole body red rash therapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>The patient had sufferred from exfoliative reddish plaques with
scales over face and mutiple pustular lesions over chest/back.<br />
</li>
<li>Under the impression of seborrheic dermatitis (immunocompressed
state?) and follculitis on the trunk.</li>
<li>The following sugeetion:
<ul>
<li>Oral doxycycline and broen-C 1# bid po for 5 days.</li>
<li>For face, Free gel 1 tube topical bid use over large area first and
consider Rinderon-V cream 2 tube topical bid over reddish itchy
area.</li>
<li>For trunk, Clindamycin gel 1 tube topical bid use on the pustular
lesions.<br />
</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-23 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>This 48 years old female patient was diagnosed of lung cancer with
bone metastatic. She had underwent L2, L3 laminectomy and fixation and
posterior-lateral fusion cause by L2 pathological fracture with spinal
stenosis. We had keep lung cancer treatment, and prepare use denosumab.
We need your professional evaluation and recommendation for dental
evaluation. Thank you very much for your time!</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>Full mouth chronic periodontitis</li>
<li>Fair oral hygiene.</li>
<li>No visible caries was notd.</li>
</ul></li>
<li>P:
<ul>
<li>Explain the finding to the patient.</li>
<li>Home care instrcution.</li>
<li>OPD follow up<br />
</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-21 Hemato-Oncology
<ul>
<li>A
<ul>
<li>Impression:
<ul>
<li>LEFT LOWER LOBE lung cancer with bilateral lung to lung meta.
Mediastinal lymphadenopathy, lumbar spine pathological fracture, right
adrenal meta and probably liver meta, cT4N3M1c, StageIVB</li>
</ul></li>
<li>Suggestion:
<ul>
<li>family meeting has been arranged on 20220922 18:00</li>
<li>Arrange Chest CT guide biopsy for EGFR gene mutation test,
PD-L1</li>
<li>May check Anti Hbc, HbsAg, Anti-HCV</li>
<li>Consult oral surgery for denal evaluation (prepare use denosumab
which has been associated with osteonecrosis of the jaws)</li>
<li>We woukd like to follow up this case, thanks for your consultation.
If there is any problem, please feel free to let us know.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-14 Rehabilitation
<ul>
<li>A
<ul>
<li>Assessment
<ul>
<li>suspected left L1-L3 radiculopathy due to multiple bone metastases
with L2 pathological fracture</li>
</ul></li>
<li>Plan
<ul>
<li>Keep pain control medication</li>
<li>suggest waist support when sitting up</li>
<li>futher L-spine image could be follow up if pain exaggerates</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-25 ~ 2022-11-08 Giotrif (afatinib 30mg) 1# QDAC</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Giotrif (afatinib 30mg) nasogastric tube feeding - Alternative
Methods of Administration (package insert 20210526)
<ul>
<li>If dosing of whole tablets is not possible, GIOTRIF tablets can be
dispersed in approximately 100 mL of noncarbonated drinking water. No
other liquids should be used. The tablet should be dropped into the
water without crushing it, and stirred occasionally until the tablet is
broken up into very small particles (approximately 15 minutes). The
dispersion should be consumed immediately. The glass should be rinsed
with approximately 100 mL of water which should also be consumed. The
dispersion can also be administered through a gastric tube.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>In accordance with NCCN recommendations for NSCLC (guideline version
5.2022), osimertinib is preferred for patients with EGFR exon 19
deletion, along with erlotinib, afatinib, and dacomitinib.</li>
<li>Giotrif (afatinib) was prescribed to the patient during 2022-10-25
and 2022-11-08.</li>
<li>As of 2022-11-30, there were no extrem results in the lab test, and
the patient’s vital signs remained stable.</li>
<li>There is no issue with the active prescription.</li>
</ul>
</div>
</div>
<div id="section-93" class="section level1">
<h1>700341408</h1>
<div id="section-94" class="section level2">
<h2>221130</h2>
<p>{This 80-year-old man patient is a case of Diffuse large B-cell
lymphoma, Non-GCB type, at the right maxillary gingiva and tuberosity,
Ki-67 index &gt;95%, Lugano stage II, IPI score: 1, Low risk group,
PS:0}</p>
<ul>
<li>past history
<ul>
<li>Hyperlipidemia</li>
<li>Arrythmia</li>
<li>Coronary artery disease, with middle left anterior descending artery
myocardial bridge</li>
</ul></li>
<li>operation history:
<ul>
<li>s/p appendectomy</li>
<li>pituitary macroadenoma s/p transsphenoisia reemoval of pituitary
adenoma on 20131105.</li>
<li>tumor excision over mesenchymal origin tumor over left buttock on
20210304 showed benign fibrotic cystic wall tissue  </li>
</ul></li>
<li>family history
<ul>
<li>There is no family history of cancer, hypertension, mental diseases
or asthma.</li>
<li>No members of the family with diabetes.</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-29 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
<li>2022-11-24, -11-14, -10-27, -08-17 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-11-16 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (58 - 16) / 58 = 72.41%
<ul>
<li>M-mode (Teichholz) = 72</li>
</ul></li>
<li>Mild septal hypertrophy with Gr I LV diastolic dysfunction.</li>
<li>Normal LV and RV systolic function.</li>
<li>Aortic valve sclerosis with mild AR; prominent posterior mitral
annulus calcification with mild MR; moderate TR; mild PR.</li>
</ul></li>
<li>2022-11-03 SONO - abdomen
<ul>
<li>Hepatic calcification, right lobe</li>
<li>Renal cysts, both</li>
<li>Renal lesion, LK, favor angiomyolipoma</li>
</ul></li>
<li>2022-11-02 MRI - nasopharynx
<ul>
<li>Indication: He was just proved lymphoma in his mouth. He was
referred by a local dentist because of an oral tumor. According to his
statement, he notes this mass aroud one month ago. He has history of
pitutary problem, hypertension for years.</li>
<li>Findings
<ul>
<li>metallic artifacts in the oral cavity</li>
<li>mild mucosal thickening in the bilateral maxilalry sinuses.</li>
<li>mucasal thickening in the upper esophagus. Please correlate with
other image modality.</li>
<li>a multi-lobulated heterogeneous enhancing tumor, about 33mm, in the
head of the right medial pterygoid muscle, inferior aspect of the
maxillary sinus and right upper buccogingival mucosa.<br />
</li>
<li>no neck LAP.</li>
</ul></li>
<li>IMP:
<ul>
<li>a multi-lobulated heterogeneous enhancing tumor, about 33mm, in the
head of the right medial pterygoid muscle, inferior aspect of the
maxillary sinus and right upper buccogingival mucosa.</li>
<li>mucosal thickening in the upper esophagus.</li>
</ul></li>
</ul></li>
<li>2022-09-29 Sonography - thyroid gland
<ul>
<li>Normal size of the thyroid gland.</li>
<li>A heterogenic nodule (0.47x0.78cm) in left thyroid gland.</li>
</ul></li>
<li>2022-09-20 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably mild myocardial ischemia at the lateral wall.</li>
</ul></li>
<li>2022-09-19 ECG
<ul>
<li>Sinus bradycardia</li>
<li>T wave abnormality, consider anterolateral ischemia</li>
</ul></li>
<li>2022-09-05 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (49.8 - 11.9) / 49.8 = 76.10%
<ul>
<li>M-mode (Teichholz) = 76.1</li>
</ul></li>
<li>Adequate LV systolic function with no regional wall motion
abnormality at resting state</li>
<li>Mild to moderate MR and TR, mild AR and PR</li>
<li>Mildly thick IVS and LVPW</li>
</ul></li>
<li>2022-09-03 ECG
<ul>
<li>Atrial flutter with variable A-V block</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-09-03 ECG
<ul>
<li>Possible atrial flutter with 2:1 AV conduction</li>
<li>ST &amp; T wave abnormality, consider anterolateral ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-18 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (67.5 - 15.3) / 67.5 = 77.33%
<ul>
<li>M-mode (Teichholz) = 77.3</li>
</ul></li>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild MR, TR</li>
</ul></li>
<li>2022-08-16 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a focal area involving the right
maxillary sinus, right nasal cavity, soft palate and right oropharynx,
in the left maxillary sinus and in two left submandibular lymph nodes,
compatible with lymphoma.</li>
<li>Glucose hypermetabolism in a focal area in the pituitary fossa,
compatible with a macroadenoma. However, please correlate with other
clinical finidngs for further evaluation and to rule out other
possibilities.</li>
<li>Increased FDG accumulation in both kidneys and bilateral ureters.
Physiological FDG accumulation may show this picture.</li>
</ul></li>
<li>2022-08-02 Patho - gingival/oral mucosa biopsy
<ul>
<li>Pathologic diagnosis
<ul>
<li>Oral cavity, right maxillary gingiva, incisional biopsy — Diffuse
large B-cell lymphoma, Non-GCB<br />
</li>
</ul></li>
<li>Macroscopic description
<ul>
<li>Operation procedure: incisional biopsy</li>
<li>Topology: Oral cavity, right maxillary gingiva</li>
<li>Specimen size and number: 2 pieces, up to 1.2x 0.8x 0.4 cm</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology type: B-cell neoplasms - Diffuse large B-cell lymphoma
(any subtype)</li>
<li>Immunohistochemical stain profiles: C-myc(+, &gt;40%), CD3(-),
CD20(+), CD10(-), CD56(-), Cyclin D1(-), Bcl-6(+),Bcl-2(+),MUM-1(+),
CK(-), Ki-67 index: &gt; 95%.</li>
</ul></li>
</ul></li>
<li>2022-05-26 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Hepatic cysts, bilateral lobes</li>
<li>Fatty infiltration of pancreas</li>
<li>Pancreatic cystic lesion, neck-body</li>
</ul></li>
<li>Suggestion
<ul>
<li>Hepatic lesion may be masked by fatty liver background</li>
</ul></li>
</ul></li>
<li>2022-05-18 MRI - sella
<ul>
<li>Indication: for follow up brain tumor. patient had diplopia
pituitary macroadenoma, s/p resection 7 yrs ago. residual tumor
enlarging in size recently. S: for SRS arrangement. check prolactin
level, consider surgical intervention. PATIENT REQUEST FOR STEREOTACTIC
RADIOSURGERY. for follow up image study.</li>
<li>Findings
<ul>
<li>The high SI on T1WI in the posterior lobe of the pituitary gland was
preserved.</li>
<li>a pituitary gland tumor, about 15mm x 16mm x 17mm, in the pituitary
fossa and suprasellar cistern. The pituitary stalk was elevated. The
lesion revealed low SI on T1WI and heterogeneous high SI on T2WI. Tumor
invasion to the left cavernous sinus was noted. Tumor encasement of the
left caverous ICA was noted.</li>
<li>unremarkable change in the bony middle cranial fossa</li>
<li>some white matter gliosis in the bilateral frontal and parietal
lobes.</li>
</ul></li>
<li>IMP: pituitary gland macroadenoma with invasion to the left
cavernous sinus and tumor encasement of the left cavernous ICA.</li>
</ul></li>
<li>2022-04-14 Sonography - thyroid gland
<ul>
<li>Normal size of the thyroid gland.</li>
<li>Some hypoechoic nodules (0.26x0.36cm, 0.41x0.69cm) in left thyroid
gland.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-03 Cardiology
<ul>
<li>A
<ul>
<li>O
<ul>
<li>ECG: suspected atrial flutter or atrial tachycardia (less than 24
hours)</li>
<li>CxR: RLL infiltration; L’t pleural effusion</li>
<li>SBP 140 mmHG;</li>
<li>PH of thyroxine supplement;</li>
</ul></li>
<li>Suggestion
<ul>
<li>Amiodarone infusion for possibly atrial flutter; concor 0.5# st and
qd if SBP &gt; 110 mmHg.</li>
<li>F/U Tn-I level; if further elevation, may admit to ICU for close
monitoring.</li>
<li>Check thyroid function.</li>
<li>Infection survey and empiric antibiotic for suspected
pneumonia.</li>
<li>Arrange 2D echo after admission.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-01-14 Cardiology
<ul>
<li>Q
<ul>
<li>Hx of myocadial bridge</li>
</ul></li>
<li>A
<ul>
<li>I was consulted for elevated troponin I of a 79-year-old man who
visited to ED acute onset of chest pain relieved by SL NTG this
morning.</li>
<li>S
<ul>
<li>No cold sweating and radiation pain.</li>
<li>Episodes of chest pain for 4 times in recent months.</li>
<li>Hx of myocardial bridge in 2017.</li>
</ul></li>
<li>O
<ul>
<li>2021/01/14 07:12 hs-Troponin I = 16.5 pg/mL;</li>
<li>2021/01/14 09:45 hs-Troponin I = 71.8 pg/mL;</li>
<li>No chest pain on visit</li>
<li>No signicant murmur, no pitting edema</li>
<li>EKG: TWI from V1-6 on admission to ED, then resolution of TWI at
V1-2, persistent TWI at V4-6</li>
<li>Beside cardiace echo: normal wall motion.</li>
</ul></li>
<li>Impression:
<ul>
<li>Elevated troponin I due to myocardial bridge is more likely</li>
<li>Angina pectoris due to myocardial bridge</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Regular medication for myocardial bridge with angina pectoris is
suggested. Please prescribe Diltiazem (30) 0.5# BID and Coxine 0.5# BID
PO (may hold Diltiazem if SBP &lt;90mmHg or dizziness)</li>
<li>Option for cardiac catheterization was explained to the patient and
his wife; if they want to recieve cardiac cathetertization, please call
me (before noon).</li>
<li>The patient was informed to observe the symptoms and also informed
about the warning sign.</li>
<li>CV OPD follow up if they choose to discharge</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy (R-mCHOP)
<ul>
<li>2022-11-17 - rituximab 375mg/m2 600mg 8hr + cyclophosphamide
750mg/m2 1000mg 1hr + liposome doxorubicin 30mg/m2 50mg 1hr +
vincristine 1.4mg/m2 2mg 10min + prednisolone 60mg/m2 40mg TID
D1-D5</li>
<li>2022-10-17 - rituximab 375mg/m2 600mg 8hr + cyclophosphamide
750mg/m2 1000mg 1hr + liposome doxorubicin 30mg/m2 50mg 1hr +
vincristine 1.4mg/m2 2mg 10min + prednisolone 60mg/m2 40mg TID
D1-D5</li>
<li>2022-09-21 - rituximab 375mg/m2 600mg 8hr + cyclophosphamide
750mg/m2 1000mg 1hr + liposome doxorubicin 30mg/m2 50mg 1hr +
vincristine 1.4mg/m2 2mg 10min + prednisolone 60mg/m2 40mg TID
D1-D5</li>
<li>2022-08-26 - rituximab 375mg/m2 600mg 8hr + cyclophosphamide
750mg/m2 1000mg 1hr + liposome doxorubicin 30mg/m2 50mg 1hr +
vincristine 1.4mg/m2 2mg 10min + prednisolone 60mg/m2 40mg TID
D1-D5</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>WBC 410/uL 2022-11-30 &lt;- 580/uL 2022-11-29. For (febrile)
neutropenia, filgrastim and cefepime have been used. The results of the
blood culture are pending.</li>
<li>The heart rate is volatile (63 ~ 122 beat/minute), 2022-11-29 ECG
showed sinus tachycardia and nonspecific ST abnormality. Please continue
to monitor the hemodynamic parameters.</li>
</ul>
</div>
</div>
<div id="section-95" class="section level1">
<h1>701125676</h1>
<div id="section-96" class="section level2">
<h2>221130</h2>
<p>{Esophageal cancer, cT2N2Mo stage III, Port-A insertion at left
cephalic vein on 20220922, jejunostomy tube insertion at abdomen on
20220922}</p>
<ul>
<li>lab data
<ul>
<li>2022-09-16 HBsAg High Reactive<br />
</li>
<li>2022-09-16 HBsAg Value 551.57 IU/mL<br />
</li>
<li>2022-09-16 Anti-HBc Reactive<br />
</li>
<li>2022-09-16 Anti-HBc-Value 8.41 S/CO<br />
</li>
<li>2022-09-16 Anti-HCV Nonreactive<br />
</li>
<li>2022-09-16 Anti-HCV Value 0.07 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-11-02 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Increased activity in the left iliac crest and bilateral acetabula,
the nature is to be determined (post-traumatic change or other nature
?), suggesting follow-up with bone scan in 3 months for further
evaluation.</li>
<li>Suspected benign lesions in both rib cages, maxilla, some T- and
L-spine, sacrum, bilateral shoulders, and S-I joints.</li>
</ul></li>
<li>2022-11-01, -10-03, -09-27, -09-21 Abdomen - standing (diaphragm)
<ul>
<li>S/P compression plate and screws fixation at right ilium and right
acetabulum.</li>
</ul></li>
<li>2022-09-16 CT - chest
<ul>
<li>Indication: Malignant neoplasm of esophagus, unspecified.
<ul>
<li>He was referred on account of due to difficult of swallowing and
chest dyscomfort for about one week. PES and biopsy showed esophageal
cancer (at New Taipei City Hospital)</li>
</ul></li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Dilated upper and middle third esophagus with narrowing at lower
third extending to EG junction is found.</li>
<li>Enlarged lymph nodes are found at gastric cardiac region.
(n＝5)</li>
<li>Paraseptal Emphysematous change over both apical lungs is
found.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Lower third esophageal cancer with regional lymphadenopathy</li>
</ul></li>
<li>Imaging Report Form for Esophageal Carcinoma
<ul>
<li>Impression (Imaging stage): cT2N2M0, Stage III</li>
</ul></li>
</ul></li>
<li>2022-09-15 CXR (New Taipei City Hospital SanChong Branch)
<ul>
<li>No cardiomegaly.</li>
<li>Prominent bronchovasculature over bilateral lung fields.</li>
<li>No blunting of bilateral costo-phrenic angles.</li>
</ul></li>
<li>2022-09-13 Pathology (New Taipei City Hospital SanChong Branch)
<ul>
<li>Diagnosis
<ul>
<li>S22-4658 Esophago-cardia junction, endoscopic biopsies,
Adenocarcinoma, moderate to poorly differentiation.</li>
</ul></li>
<li>MACROSCOPIC:
<ul>
<li>Quantity: one tissue fragments, 0.5 x 0.2 x 0.2 cm in size. All for
section.</li>
</ul></li>
<li>MICROSCOPIC:
<ul>
<li>Histological diagnosis: Adenocarcinoma.</li>
<li>High grade dysplasia (including severe dysplasia and carcinoma in
situ): present.</li>
<li>Invasive carcinoma: present.</li>
<li>Lymphovascular invasion: absent.</li>
<li>Histologic grade: G2, moderately to poorly differentiated with focal
individually cells infiltration throughout muscularis mucosa.</li>
<li>Comment: No Helicobactor bacillus found on Giemsa stain.</li>
<li>Immunohistochemical stains: the tumor cells showed cytoplasmic
stains for CK7 and nuclear stain for STAB2.</li>
</ul></li>
</ul></li>
<li>2022-09-17 UGI panendoscopy (New Taipei City Hospital SanChong
Branch)
<ul>
<li>swelling and irregular mucosa which was easily contact bleeding was
found at EC junction post biopsy was taken.</li>
</ul></li>
<li>2018-05-05 SONO - abdomen (Nephrology)
<ul>
<li>Left parapelvic renal cyst.</li>
<li>Suspected left small renal stone.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-01 Dermatology
<ul>
<li>Q
<ul>
<li>for skin rash at the face.</li>
<li>This time, he is admitted for C2 CCRT with PF on 2022/11/01, and the
skin rash at the face noted, so we need your help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>The patient had sufferred from bilateral facial reddish
flush/papules with fine scales on the nasalfold and cheek area.<br />
</li>
<li>Under the impression of seborrheic dermatitis.</li>
<li>The following sugeetion:
<ul>
<li>Free gel 1 tube topical bid use for facial erythema region</li>
<li>If severe itchy sensation, consider futisone cream 1 tube topical
bid PRN use on these itchy area.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-22 Radiatoin Oncology
<ul>
<li>A
<ul>
<li>S:
<ul>
<li>For preoperative CCRT due to low third esophageal carcinoma.</li>
<li>PI: The patient suffered from dysphagia and chest discomfort since
2022-8. He went to New Taipei City Hospital SanChong Branch for help.
The Panendoscopy and biopsy showed esophageal cancer. Under the personal
reason, he was referred to our Hematology Oncology. Followed-up chest CT
(Sep 16,22) showed Lower third esophageal cancer with regional
lymphadenopathy cT2N2M0, stage III.</li>
<li>Family history: (-)</li>
<li>Cancer site specific factors: Alcohol (quit); Smoking (+); Betel nut
(quit).</li>
<li>Personal Hx: DM(-); HTN(-)</li>
<li>Allergy(-)</li>
<li>Previous RT Hx: (-)</li>
</ul></li>
<li>O:
<ul>
<li>ECOG: 0</li>
<li>PE: neck and bil SCF: neg.</li>
<li>UGI panendoscopy (2022-09-07, New Taipei City Hospital SanChong
Branch): swelling and irregular mucosa which was easily contact bleeding
was found at EC junction post biopsy was taken.</li>
<li>Pathology (2022-09-13, New Taipei City Hospital SanChong Branch):
S22-4658 Esophago-cardia junction, endoscopic biopsies, Adenocarcinoma,
moderate to poorly differentiation. MACROSCOPIC: Quantity: one tissue
fragments, 0.5 x 0.2 x 0.2 cm in size. All for section. MICROSCOPIC:
Histological diagnosis: Adenocarcinoma. High grade dysplasia (including
severe dysplasia and carcinoma in situ): present. Invasive carcinoma:
present. Lymphovascular invasion: absent. Histologic grade: G2,
moderately to poorly differentiated with focal individually cells
infiltration throughout muscularis mucosa. Comment: No Helicobactor
bacillus found on Giemsa stain. Immunohistochemical stains: the tumor
cells showed cytoplasmic stains for CK7 and nuclear stain for
STAB2.</li>
<li>CXR (2022-09-15, New Taipei City Hospital SanChong Branch): No
cardiomegaly. Prominent bronchovasculature over bilateral lung fields.
No blunting of bilateral costo-phrenic angles.</li>
<li>CT scan of lung (2022-09-16): Lower third esophageal cancer with
regional lymphadenopathy, AJCC stage cT2N2M0 (stage III).</li>
</ul></li>
<li>A:
<ul>
<li>Adenocarcinoma, moderate to poorly differentiation of the low third
esophagus to EG junction, AJCC stage cT2N2M0 (stage III).</li>
</ul></li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: AJCC stage cT2N2M0 (stage III)
<ul>
<li>Goal: curative</li>
<li>Treatment target and volume: esophageal tumor, periphjeral involved,
to regional involved nodal area.</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 4500cGy/25 fractions of the esophageal
tumor, periphjeral involved, to regional involved nodal area, and
5040cGy/28 fractions of the esophageal tumor and involved nodal
lesions.</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and his son. They understand and agree to
receive radiotherapy, The treatment planning of radiotherapy will be
started at 1530, 2022-9-26.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-10-03 ~ 2022-11-17 - 4500cGy/25 fractions (15MV photon) of the
esophageal tumor, periphjeral involved, to regional involved nodal, and
5040cGy/28 fractions of the reduced area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-29 - cisplatin 75mg/m2 120mg 4hr D1 + fluorouracil 1000mg/m2
1600mg 24hr D1-D4 (PF, CCRT)</li>
<li>2022-11-03 - cisplatin 75mg/m2 120mg 4hr D1 + fluorouracil 1000mg/m2
1650mg 24hr D1-D4 (PF, CCRT)</li>
<li>2022-10-03 - cisplatin 75mg/m2 120mg 4hr D1 + fluorouracil 1000mg/m2
1700mg 24hr D1-D4 (PF, CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>In one month, there has been a substantial loss of weight, almost
ten kilograms (52.3kg 2022-11-29 &lt;- 61.1kg 2022-10.27).</li>
<li>A low serum creatinine level (0.68mg/dL 2022-11-29) was noted.
Creatinine generation could be reduced in the setting of low skeletal
muscle mass.</li>
<li>It is recommended that intake be increased.</li>
<li>In terms of the active prescription, there is no problem.</li>
</ul>
</div>
</div>
<div id="section-97" class="section level1">
<h1>700021863</h1>
<div id="section-98" class="section level2">
<h2>221128</h2>
<p>{Protocol: Capsule suspension preparation and NG tube dispensing
procedures for Xtandi (enzalutamide, 160mg dose)}</p>
<p>The following in-situ oral dosing syringe suspension preparation and
NG tube dispensing procedures were identified as being facile and which
essentially eliminate human exposure to capsule components:</p>
<p>Utensils: Tweezers, medical grade scissors, 2-3mL oral dosing
syringe, 20mL oral dosing syringe, NG tube, and one 2-3 oz (60-90 mL)
glass or plastic dosing container (e.g., beaker or med cup).</p>
<p>Materials: Ethanol, 95%, Deionized water, 4x40mg enzalutamide
capsules</p>
<ul>
<li>Prepare 40-50mL of 90% v/v ethanol:water. Transfer 30mL to a
container. Cover if not used immediately. Use as reservoir for
subsequent steps.</li>
<li>Swipe-clean the dosing container, tweezers and scissors with alcohol
wipes.</li>
<li>Using tweezers and scissors carefully cut a small vent, ~2mm long,
through a soft gel capsule wall-just enough to vent internal pressure.
Note: cut vent over dosing cup since some material may flow out of the
vent hole. Place vented capsule in dosing cup. Repeat for remaining 3
capsules.</li>
<li>Using tweezers and scissors, slowly cut each capsule in half
laterally. Allow capsule contents (enzalutamide in Labrasol) to empty
into dosing cup (fill material flows out easily). Repeat for all
capsules. Note: all 8 capsule shell pieces and fill contents will be in
in the dosing cup.</li>
<li>Hold each capsule shell piece with tweezers and rinse the inside and
outside into the dosing cup using 90% ethanol. Use 1-2mL per capsule
half (2-3mL syringe). Discard rinsed capsule shells.</li>
<li>Withdraw 10mL of ethanol solution and rinse the tweezers and
scissors into the dosing cup.</li>
<li>Withdraw and dispense solution back into dosing cup at least 5 times
to ensure a homogeneous mixture.</li>
<li>Withdraw the solution into the dosing syringe.</li>
<li>Slowly dispense through the NG tube.</li>
<li>Withdraw the remaining ~10mL of 90% ethanol, rinse dosing cup,
withdraw into dosing syringe, cap and shake, and dose through the NG
tube. Flush tube with 6mL of water.</li>
</ul>
<p>Please prepare two vials of 99.5% alcohol (drug code ‘CALCO01’), add
one ml of purified water, take eight ml of the solution to dissolve one
split capsule of 40 mg Xtandi, and tube feed this solution containing
enzalutamide with prandial.</p>
</div>
</div>
<div id="section-99" class="section level1">
<h1>701321501</h1>
<div id="section-100" class="section level2">
<h2>221125</h2>
<p>{Mesenchymal chondrosarcoma, high grade}</p>
<ul>
<li>exam finding
<ul>
<li>2022-11-17, -10-20, -09-22, -08-22, -07-21 Sinoscopy
<ul>
<li>Right maxillary sinus sarcoma s/p op on 2022-03-30, no evidence of
tumor</li>
</ul></li>
<li>2022-11-01 MRI - nasopharynx
<ul>
<li>Clinical information: Right maxillary sinus sarcoma s/p Right total
Maxillectomy on 2022-03-30, patho: high grade mesenchymal
chondrosarcoma, pT4aN0M0, Grade 3</li>
<li>Findings:
<ul>
<li>The current study was compared to the prior one obtained on
2022/08/09.</li>
<li>Known a case of right maxillary sinus sarcoma S/P operation and flap
reconstruction. Progression of abnormal enhancing lesion over right
face, near the reconstructive area. Suggest tissue proof to rule out
recurrence.</li>
<li>Paranasal sinusitis.</li>
<li>The right parotid gland enhance as before. It is consistent with
post-radiation inflammation.</li>
<li>S/P resection of right submandibular gland.</li>
</ul></li>
</ul></li>
<li>2022-08-09 MRI - nasopharynx
<ul>
<li>Post total right maxillectomy, no obvious residual tumor or mass. No
neck LAP.</li>
</ul></li>
<li>2022-07-07 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (87 - 25) / 87 = 71.26%
<ul>
<li>M-mode (Teichholz) = 70</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Trivial MR, and trivial TR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2022-06-09, 2022-05-26, 2022-05-12, 2022-04-28 Sinoscopy
<ul>
<li>Right maxillary sinus sarcoma s/p op on 2022-03-30</li>
</ul></li>
<li>2022-05-26 Hearing Test
<ul>
<li>Tymp:
<ul>
<li>R’t type B; L’t type As.</li>
</ul></li>
<li>ART:
<ul>
<li>R’t and L’t contra absent.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 60 dB HL; LE 23 dB HL.</li>
<li>R’t moderate to profound MHL.</li>
<li>L’t normal to moderate HL.</li>
<li>(masking dilemma)</li>
</ul></li>
</ul></li>
<li>2022-04-21 Nasopharyngoscopy
<ul>
<li>Right maxillary sinus sarcoma s/p op on 2022-03-30</li>
</ul></li>
<li>2022-03-31 Patho - oral cancer (wide excision + lymph node)
<ul>
<li>Pathologic diagnosis
<ul>
<li>Maxillary sinus, right, total maxillectomy — Mesenchymal
chondrosarcoma, high grade</li>
<li>Lymph nodes, right neck, selective neck dissection — Negative for
malignancy (0/31)</li>
<li>Submandibular gland, right, neck dissection — No remakable
change</li>
<li>Pathology stage: pT1N0; Stage IIA if cM0</li>
</ul></li>
<li>Macroscopic examination
<ul>
<li>Surgical Procedure(s): Total maxillectomy + right selective neck
dissection</li>
<li>Specimen Type:
<ul>
<li>Main location: Maxillary sinus</li>
<li>Lymph node dissection: Yes, including right neck level I, level II,
and level III</li>
</ul></li>
<li>Specimen Integrity: intact</li>
<li>Specimen Size: 6.2 x 5.5 x 5.4 cm</li>
<li>Tumor Site: Maxillary sinus; Laterality: Right</li>
<li>Tumor Focality: Single focus</li>
<li>Tumor Size: 6.0 x 4.5 x 4.0 cm, 0.5 cm from posterior margin</li>
<li>Mucosal Surface : Ulcerated</li>
<li>Gross Tumor Extension: Tumor invades submucosa</li>
<li>Representative parts are taken for section and labeled: A1-A2 =
level I LN + submandibular gland, B = level II LNs, C = level III LNs, D
= pterygoid plate, E = zygoma with soft tissue, F1 = tumor + posterior
margin, A2 = tumor + lateral margin, F3 = tumor + upper margin, F4-F10 =
tumor, G = posterior nasal margin, H = temporalis margin.</li>
<li>F2022-00138FSA1 = post. nasal margin, post. orbital floor and post.
oral floor margin; FSA2 = lat. margin, masseter margin, and tempolais
margin; FSA3 = orbital lat. margin and lat pterygoid margin; FSA4 = med.
pterygoid margin and tissue near zygoma; FSE = posterior nasal margin
(re-excision).</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Mesenchymal chondrosarcoma</li>
<li>Histologic Grade: G3 (poorly differentiated, high grade)</li>
<li>Mitotic Rate: 6/10 high power fields</li>
<li>Necrosis: Present (10%)</li>
<li>Microscopic Tumor Extension: To submucosa</li>
<li>Margins: Margins free, Distance from closest margin: 0.5 cm
(posterior margin)</li>
<li>Lymph-Vascular Invasion: Not identified</li>
<li>Perineural Invasion: Not identified</li>
<li>Neck Lymph Nodes, Right: Negative (0/31)
<ul>
<li>Number of LN examined: 11 (level I), 9 (level II), and 11 (level
III)</li>
<li>Number of LN metastasis: 0</li>
</ul></li>
<li>Submandibular gland, right: Unremarkable and free of tumor</li>
<li>Pterygoid plate, right: Involved by tumor</li>
<li>Zygoma with soft tissue, right: Free of tumor</li>
<li>Post nasal margin, right: Free of tumor</li>
<li>Temporalis margin, right: Free of tumor</li>
<li>Post nasal margin and temporalis margin, received frozen section:
Involved by tumor</li>
<li>Surgical margins received for frozen section, including post.
orbital floor, post oral floor margin, lat margin, masseter margin,
tempolais margin, orbital lat margin, lat pterygoid margin, med
pterygoid margin, tissue near zygoma, and posterior nasal margin
(re-excision): Free of tumor</li>
</ul></li>
</ul></li>
<li>2022-03-30 Frozen section
<ul>
<li>Post. nasal margin #1, right, frozen section — Involved by
tumor</li>
<li>Temporalis margin, right, frozen section — Favor inflammation but
tumor involvement can not be excluded</li>
<li>Tissue near zygoma, right, frozen section — Favor inflammation</li>
<li>Post. orbital floor, post. oral floor margin, lat. margin, masseter
margin, orbital lat. margin, lat. pterygoid margin, med. pterygoid
margin; right, frozen section — Free of tumor</li>
<li>Posterior nasal margin #2, right, frozen section — Free of
tumor</li>
</ul></li>
<li>2022-03-25 Nasopharyngoscopy
<ul>
<li>Right maxillary sinus sarcoma</li>
</ul></li>
<li>2022-03-22 SONO - abdomen
<ul>
<li>GB polyp</li>
<li>Pleural effusion, right</li>
</ul></li>
<li>2022-03-21 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the right maxillary sinus and adjacent
facial soft tissue, compatible with the primary maxillary sarcoma.
.<br />
</li>
<li>Glucose hypermetabolism in the left nasal cavity with left maxilla
bone involvement, the nature is to be determined (another nasal cavity
tumor or other nature ?), suggesting biopsy for further
investigation.<br />
</li>
<li>Right maxillary sinus sarcoma, cTxN0M0; suspected left nasal cavity
tumor, by this F-18 FDG PET scan.</li>
</ul></li>
<li>2022-03-18 CT - lung/mediastinum/pleura
<ul>
<li>Bilateral pleural effusion and lung partial collapse</li>
<li>suspected acute pancreatitis.</li>
</ul></li>
<li>2022-03-17 MRI - nasopharynx
<ul>
<li>Huge lobulated mass lesion (6.4cmx4.6cm) over right maxillary sinus
with destruction of sinus walls, heterogeneous enhancement and cetral
necrosis of this tumor. Highly suspect malignancy such as SCC or
sarcomatous tumor.</li>
<li>Marked swollen change of right face and masticator space with
subcutaneous fatty strandings.</li>
</ul></li>
<li>2022-03-15 Patho - gingival/oral mucosa biopsy
<ul>
<li>Oral cavity, right upper gingiva, biopsy — sarcoma</li>
<li>IHC: CK(-), Vimentin(+), SMA(focal +), CD34(-), CD56(-), and
S-100(-). The Ki-67 is about 15%. The results are in favor of sarcoma.
Please correlate with the clinical presentation and image study.</li>
</ul></li>
<li>2022-03-15 2D transthoracic echocardiography
<ul>
<li>Normal AV/MV with trivial MR</li>
<li>Normal LV chamber size and wall thickness</li>
<li>Preserved LV and RV systolic function</li>
<li>Mild PR, trivial TR, normal IVC size</li>
</ul></li>
<li>2022-03-14 CT - brain
<ul>
<li>IMP: Right maxillary sinus lesion as described.</li>
<li>DDX: malignancy, osteomyelitis, sinusitis.</li>
</ul></li>
<li>2022-03-14 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right superior axis deviation</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-12 Radiation Oncology
<ul>
<li>A: Mesenchymal chondrosarcoma, high grade, of the right maxillary
sinus, stage pT1N0(cM0); Stage IIA, s/p operation (Rt. total
Maxillectomy; Rt. selective neck dissection, level I~III; Tracheostomy;
Tooth extraction of #46; free right anterolateral thigh flap resurfacing
to the defect of right cheek, palate, and nasal cavity; reconstruction
of right orbital bony frame with titanic microplates and screws).</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: margin involve and close (depend on HN tumor board
conclusion).
<ul>
<li>Goal: curative</li>
<li>Treatment target and volume: right maxillary tumor bed area</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 6000 ~ 6600cGy/30 ~33 fractions</li>
</ul></li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and his mother. They understand and agree
to receive radiotherapy, The treatment planning of radiotherapy will be
started at 0830, 2022-04-25.</li>
<li>HN tumor board (2022-04-15). RTC: at 2pm, 2022-04-15.</li>
</ul></li>
<li>2022-03-23 Oral and Maxillofacial Surgery
<ul>
<li>This is a 43 year-old male patient suffering from osteosarcoma of
right maxilla and is scheduled for surgical intervention including right
hemi-maxillectomy next week.</li>
<li>This time, we were consulted for pre-OP and pre-RT dental
evaluation</li>
<li>O:
<ul>
<li>Radiographic findings:
<ul>
<li>Progressive destruction of right maxilla with root resorption of
tooth 14 was noted.</li>
<li>Residual roots of tooth 46 was noted.</li>
</ul></li>
<li>Full mouth poor oral hygiene with periodontitis</li>
</ul></li>
<li>P:
<ul>
<li>Took panoramic film to evaluate full mouth condition</li>
<li>Explained the findings and treatment plan to the patient and his
family</li>
<li>Suggest extraction of residual roots 46 during surgery.</li>
<li>Oral hygiene instruction.</li>
</ul></li>
</ul></li>
<li>2022-03-16 Gastroenterology
<ul>
<li>S
<ul>
<li>According to the patient, no HBV history</li>
</ul></li>
<li>O
<ul>
<li>AST: x, ALT: 18, Bil T: 0.78, ALP: x, r-GT: x, Cr: 0.79</li>
<li>HBsAg(-), Anti-HBc(+), Anti-HCV(-)</li>
<li>Abdominal echo: nil</li>
</ul></li>
<li>Impression
<ul>
<li>Occult or resolved HBV infection</li>
</ul></li>
<li>Suggestion
<ul>
<li>No NHI indication for HBV medication now; if patient needed
chemotherapy or immunotherapy, please tell us</li>
<li>GI OPD follow up</li>
</ul></li>
</ul></li>
<li>2022-03-15 Hemato-Oncology
<ul>
<li>A
<ul>
<li>Impression:
<ul>
<li>Right maxillary sinus lesion. DDX: malignancy, osteomyelitis,
sinusitis.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Please check EB V EA/NA IgA, SCC, LDH</li>
<li>Pending pathology and culture result</li>
<li>Treat sepsis as your expertise</li>
<li>We wound like to follow up this case, thanks for your consultation.
If there is any problem, please feel free to let us known.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-15 ENT
<ul>
<li>Granular tumor with pus discharge at right upper gingiva and hard
palate was noted.</li>
<li>Malignant tumor of right maxillary sinus with oral cavity
involvement was highly suspected.</li>
<li>Biopsy was done smoothly.</li>
<li>Please pursue the pathologic result.</li>
</ul></li>
<li>2022-03-14 Oral and Maxillofacial Surgery
<ul>
<li>S: My right face swelling and my upper right gingiva ozzing</li>
<li>O:
<ul>
<li>Right face swelling was noted</li>
<li>15 16 17 missing with a mass over upper right gingiva, about 5x7 cm,
ulcerative surface was noted</li>
</ul></li>
<li>A:
<ul>
<li>Impression: SCC or osteosarcoma</li>
</ul></li>
<li>P:
<ul>
<li>Physical exam and explain the finding to the patient</li>
<li>Please prescribe curam for infection control</li>
<li>Admission in MICU for infection control and arrange OPD follow
up</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-20
<ul>
<li>Right grommet insertion</li>
</ul></li>
<li>2022-03-30
<ul>
<li>free right anterolateral thigh flap resurfacing to the defect of
right cheek, palate, and nasal cavity</li>
<li>reconstruction of right orbital bony frame with titanic microplates
and screws</li>
</ul></li>
<li>2022-03-30
<ul>
<li>Rt. total Maxillectomy</li>
<li>Rt. selective neck dissection, level I~III</li>
<li>Tracheostomy</li>
<li>Tooth extraction of #46</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-04-29 ~ 2022-06-16
<ul>
<li>4000cGy/20 fractions of the right maxillary tumor bed area,</li>
<li>5000cGy/25 fractions of the reduced right maxillary tumor bed area,
and</li>
<li>6600cGy/33 fractions of the right maxillary tumor bed.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-24 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-10-28 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-10-03 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-09-01 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-08-05 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-07-07 - mesna 800mg D1-5 + ifosfamide 1800mg/m2 3000mg 2hr D1-5
+ doxorubicin 37.5mg/m2 65mg 20hr D1-2 (with mesna 800mg PRNQ4H)</li>
<li>2022-05-03 ~ 2022-06-14 - cisplatin 40mg/m2 65mg 2hr (weekly x7,
CCRT)</li>
</ul></li>
</ul>
<div id="section-101" class="section level3">
<h3>==========</h3>
</div>
<div id="section-102" class="section level3">
<h3>2022-11-25</h3>
<ul>
<li>Despite the absence of tumor evidence by sinoscopy (2022-11-17), the
nasopharynx MRI (2011-11-01) suggested a tissue proof to rule out
recurrence for the abnormally enhancing lesions near the reconstruction
area.</li>
<li>In addition to slight tachycardia (108 pulses per minute) and
decreased SpO2 (94%), otherwise vital signs were unremarkable.</li>
<li>Except for slightly low serum potassium (3.3 mmol/L) and low HGB
(11.3 g/dL), all lab results were generally normal on 2022-11-24.</li>
<li>The active prescription is working as intended.</li>
</ul>
</div>
<div id="section-103" class="section level3">
<h3>2022-10-04</h3>
<ul>
<li>The available data now argues for adjuvant chemotherapy in
mesenchymal chondrosarcoma, with little reliable data on craniofacial
lesions in particular. The optimal drug combination to be employed has
not been well-defined. (ref: Systemic treatment for primary malignant
sarcomas arising in craniofacial bones. Front Oncol. 2022;12:966073. <a href="doi:10.3389/fonc.2022.966073" class="uri">doi:10.3389/fonc.2022.966073</a>)</li>
<li>In mesenchymal chondrosarcoma, treatment with Ewing sarcoma-like
chemotherapy regimens may be considered, although data supporting its
use is even more limited given its rarity. (ref: Systemic Therapy for
Chondrosarcoma. Curr Treat Options Oncol. 2022;23(2):199-209. <a href="doi:10.1007/s11864-022-00951-7" class="uri">doi:10.1007/s11864-022-00951-7</a>)</li>
<li>It was reported that ifosfamide-doxorubicin may be more beneficial
in younger patients with &gt;5 cm, high-grade, soft-tissue-sarcoma of
the trunk or extremity in synovial-cell, dedifferentiated-liposarcoma,
myxofibrosarcoma, round-cell-liposarcoma,
undifferentiated-pleomorphic-sarcoma, and
undifferentiated-sarcoma-not-otherwise-specified. (ref: The role of
Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade,
locally advanced soft tissue sarcoma, a 14-year experience. Radiother
Oncol. 2021;165:174-178. <a href="doi:10.1016/j.radonc.2021.10.019" class="uri">doi:10.1016/j.radonc.2021.10.019</a>)</li>
<li>It was possible to treat soft tissue sarcoma using a regimen using a
daily dose of mesna equivalent to that of ifosfamide. (ref: Crossover
randomized comparison of intravenous versus intravenous/oral mesna in
soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res.
2003;9(16 Pt 1):5829-5834.)</li>
<li>TPR, blood pressure, and SpO2 during the hospital stay, as well as
lab data on 2022-09-29 were grossly stable or normal.</li>
</ul>
</div>
</div>
</div>
<div id="section-104" class="section level1">
<h1>701346384</h1>
<div id="section-105" class="section level2">
<h2>221124</h2>
<p>{expired}</p>
<p>[exam findings]</p>
<ul>
<li>2022-11-22 Embolization (TAE) - abdomen
<ul>
<li>IMP: Active bleeding of ileocecal branch of SMA s/p TAE.</li>
</ul></li>
<li>2022-11-16 EGD
<ul>
<li>Diagnosis:
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis</li>
<li>Gastric polyps, body</li>
</ul></li>
<li>Suggestion:
<ul>
<li>No active bleeder nor coffee ground material was noted during this
exam.</li>
<li>Biopsy of polyp was NOT done due to suspected GI bleed setting</li>
</ul></li>
</ul></li>
<li>2022-11-15 CT - abdomen
<ul>
<li>Clinical history: 37 y/o male patient with bloody stool twice today.
denied abodminal pain</li>
<li>Past Histories: brain tumor appendectomy 2 weeks ago.</li>
<li>With and without contrast enhancement CT of abdomen - whole:
<ul>
<li>Irregular fluid accumulation (9.7x4.1cm) in right lower abdomen with
air bubble retention, could be due to abscess formation.</li>
<li>Generalized low density over liver parenchyma, suggesting fatty
liver.<br />
</li>
<li>Right lower lung collapse.</li>
</ul></li>
<li>Impression:
<ul>
<li>RLQ abscess.</li>
<li>Fatty liver.</li>
<li>Right lower lung collapse.</li>
</ul></li>
</ul></li>
<li>2022-11-15 ECG
<ul>
<li>Sinus tachycardia with short PR</li>
<li>Possible Left atrial enlargement</li>
<li>Left axis deviation</li>
</ul></li>
<li>2022-11-08 SONO - abdomen
<ul>
<li>Imp: Mild fatty liver.</li>
</ul></li>
<li>2022-10-31 L-spine AP + Lat (including sacrum)
<ul>
<li>mild scoliosis of the L-spine</li>
<li>unremarkable change in the width of the bony spinal canal<br />
</li>
<li>compession fractures at L3, L2, L1,T12, T11 and T10 vertebral
bodies</li>
<li>mild decreased disc spaces in the upper L-spine discs</li>
</ul></li>
<li>2022-10-18 CXR (erect)
<ul>
<li>Enlarged cardiac shadow. Consolidation patches at bilateral lower
lung field. Bilateral pleural effusion.</li>
</ul></li>
<li>2022-10-18 CT - abdomen
<ul>
<li>Dilatatation of appendix. Fat stranding at RLQ with minimal air
density. Focal small bowel ileus.</li>
<li>Partial consolidation at bil. lungs.</li>
</ul></li>
<li>2022-08-09 MRI - brain
<ul>
<li>Known a case of left parietal-occipital GBMs S/P operative removal.
Still presence of several ill-defined mass lesions at the same areas.
Marked progression of these heterogeneous enhancing tumors as compared
with prior MRI (2022/05/10).<br />
</li>
<li>MR angiography of the brain shows normal intracranial vessel
including circle of willis.</li>
</ul></li>
<li>2022-06-09 CXR
<ul>
<li>Linear band opacity over Rtmid lung zone, residual consolidation or
atelectatic lung parenchyma</li>
<li>Fine recticular opacities at left midlung zone, residual
inflammatory change or fibrotic change</li>
</ul></li>
<li>2022-05-10 MRI - brain
<ul>
<li>Known a case of left parietal-occipital GBMs S/P operative removal.
Still presence of several ille-defined mass lesions at the same areas.
Progression of these heterogeneous enhancing tumors as compared with
prior MRI (2021/12/16).<br />
</li>
<li>MR angiography of the brain shows normal intracranial vessel
including circle of willis.</li>
</ul></li>
<li>2022-04-27 CXR
<ul>
<li>Extensive consolidation and ground glass opacity with
air-bronchograms over bilateral lungs mainly involing upper lobes, with
small Lt pleural effusion</li>
<li>Reduced lung volume</li>
</ul></li>
<li>2022-04-22 CT - lung
<ul>
<li>Consolidation over right upper lobe and left upper lobe and less
significantly at right lower lobe and left lower lobe is found.
Air-bronchogram is found. Pneumonia is considered.</li>
</ul></li>
<li>2022-04-21 CXR
<ul>
<li>Consolidations in bilateral parahilar regions, suspected pneumonia,
suggest clinical correlation and further study.</li>
<li>Mild blunting of costophrenic angle, left side, could be due to
pleural effusion.</li>
</ul></li>
<li>2022-02-14, 2022-02-07, 2022-02-04 CXR
<ul>
<li>Essential negative findings of the air way, mediastinum, heart,
lungs, pleura, diaphragm and chest walls.</li>
<li>Blunted costophrenic angles due to effusion, pleural change,
atelectatic lungs, etc.</li>
</ul></li>
<li>2022-02-01 CXR
<ul>
<li>Enlarged cardiac shadow. Increased haziness at left hemithorax.
Bilateral clear costophrenic angles.</li>
</ul></li>
<li>2022-02-01 CT - brain
<ul>
<li>Brain tumors and edema at left parietal and temporal lobes,
significantly increased in size and extent, causing brain swelling and
brain herniation. Condition in progression.</li>
</ul></li>
<li>2022-01-04 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (66 - 18) / 66 = 72.73%</li>
<li>Conclutions
<ul>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Normal chamber size</li>
<li>Trivial TR</li>
</ul></li>
</ul></li>
<li>2021-12-16 MRI - brain
<ul>
<li>malignant left T-Parietal brain tumor (wild type Glioblastoma),
significantly increase in size and extent as compared with MRI on
2021/11/4, possibly involving the scalp region.</li>
</ul></li>
<li>2021-12-14 CT - brain
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>multiple hypodense brain tumors with vasogenic edema at left
parietal and temporal lobes, the tumor size and extent of edema has
significantly increased and causing marked brain swelling and mass
effect. Minimal intratumoral hemorrhage is present.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>brain herniation with midline shift to right side and downward
transtentorial herniation.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>previous postoperative change with a burr hole at left frontal
skull, and left temporal-parietal skull craniotomy.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li>Brain tumors and edema at left parietal and temporal lobes,
significantly increased in size and extent, causing brain swelling and
brain herniation.</li>
</ul></li>
</ul></li>
<li>2021-12-13 SONO - abdomen
<ul>
<li>Hepatic hemangioma, right lobe</li>
</ul></li>
<li>2021-11-29 CT - brain
<ul>
<li>Post-op at left frontoparietal skull.</li>
<li>Left temporoparietal malignancy with mass effect and
progression.</li>
<li>Focal ICH in left parietal lobe.</li>
</ul></li>
<li>2021-11-08 Frozen section
<ul>
<li>Findings: multiple tumors in the left supratentorial brain.</li>
<li>Diagnosis: Tumor, brain, frozen section — Glioblastoma</li>
</ul></li>
<li>2021-11-08 Patho - brain/meninges (tumor)
<ul>
<li>Brain tumors, left supratentorial region, FS + craniotomy —
Glioblastoma, IDH-wild type</li>
<li>Microscopically, the sections show a picture of glioblastoma of the
brain tissue consisting of hypercellularity with striking pleomorphism,
hemorrhage, pseudopalisading necrosis and endothelial proliferation of
vessels.</li>
<li>Immunohistochemistry shows GFAP(+), IDH-1(-), P53 and Ki67:
increased activity and EGFR(+) for tumor.</li>
</ul></li>
<li>2021-11-04 CT - brain for navigator
<ul>
<li>Finding: A low density mass, about 36 mm x 32 mm x 30 mm, with
irregular peripheral enhacning rim and central necrotic chnage in left
parietofrontal lobe, associating with extensive perifocal edmea and
causing effacement of adjacent cortical sulci and mild midline shift to
right side.</li>
<li>IMP: Left parietofrontal necrotic tumor. D/D: metastasis,
abscess.</li>
</ul></li>
<li>2021-11-04 MRA - brain
<ul>
<li>Finding: multiple heterogeneous enhancing lesions in the left
temporal lobe and left parietal lobe with the largest one, about 37mm,
in the left parietal lobe. Moderate to severe perifocal edema was noted.
Heterogeneous enhancement was noted.</li>
<li>IMP: multiple tumors in the left supratentorial brain.</li>
</ul></li>
<li>2021-11-04 CT - brain
<ul>
<li>Finding: a nodular lesion, about 39mm, in the left parietal lobe
with moderate perifocal edema</li>
<li>IMP: a nodular lesion in the left parietal lobe.</li>
</ul></li>
</ul>
<p>[MedRec]</p>
<ul>
<li>2022-11-15 ~ 2022-11-24 POMR Metabolism and Endocrinology Zhang
JiaHui
<ul>
<li>Discharge diagnosis
<ul>
<li>Peritoneal abscess, pus culture yields Enterococcus faecium and
quinolone -resistant Escherichia coli.</li>
<li>Bacteremia</li>
<li>Sepsis with septic shcok</li>
<li>Acute respiratory failure s/p intubation on 2022/11/22</li>
<li>Low gastrointestinal bleeding with hypovolemic shock</li>
<li>Multiple organ failure with metabolic acidosis and disseminated
intravascular coagulation</li>
<li>Malignant neoplasm of parietal lobe</li>
</ul></li>
<li>CC
<ul>
<li>Bloody stool twice for one day.</li>
</ul></li>
<li>Present illness
<ul>
<li>A 37-year-old patient has medical history of left supratentorial
region Isocitrate dehydrogenase wild type Glioblastoma post left
temporo-parieto-occipital craniotomy with remove brain tumor on November
5th last year, with seizure, then the image showed left frontoparietal
skull and left temporoparietal malignancy with mass effect and
progression and focal intracerebral hemorrhage in left parietal lobe
were find after the operation. However, the brain lesion with brain
tumors and edema at left parietal and temporal lobes, which
significantly increased in size and extent, and causing brain swelling
and brain herniation in last December. Depression and chronic hepatitis
were also noted.</li>
<li>He received chemotherapy after the operation, then the chemotherapy
was changed to targeted therapy from this August to October because of
the brain cancer recurred in this August. The targeted therapy was
stopped due to acute appendicitis in this October, he underwent the
drainage of appendix with drainage device, percutaneous endoscopic
approach on October 18 this year. He has no allergic to food or drugs,
nor travel, occupation, contact or cluster recently.</li>
<li>He presented in the emergency room with the symptoms of bloody stool
twice today, with nausea and weakness and dissy and hypotension, poor
appetite and bilateral flank pain (left &gt; right ) were also noted. In
the emergency department, GCS was E4V5M6. No Murphy’s sign or McBurney’s
point tenderness. A blood tests showed leukocytosis with bandemia 10.6%,
anemia, elevated c-reactive protein and activated partial thromboplastin
time. Blood gas showed respiratory alkalosis and metabolic alkalosis.
Chest x ray showed patch density at right lower lobe. A computer
tomography of the abdomen revealed right lower abdomen abscess,
irregular fluid accumulation(9.7x4.1cm) with air bubble retention and
right lower lung collapse. A Sono-and CT-guide drainage was arranged and
a 8 Fr. pig-tail catheter was placed for drainage. Cefotaxime and
Pantoloc were given. He is hospitalized on 2022/11/15.</li>
</ul></li>
<li>Course of inpatient treatment
<ul>
<li>During the hospital stay, we use parenteral Cefotaxime for empirical
treatment of peritoneal abscess. Pig tail was indwelling. The pus
discharge is submitted for pus culture. NPO except medications, PPI
injection and electrolyte solution supplement due to suspect UGI
bleeding. We also addition hemostatic agent and vitamin K1 for provided
hemostatic. Panendoscopy was arranged, which report Reflux esophagitis
LA Classification grade A. Superficial gastritis, Gastric polyps, body.
Under excluded UGI bleeding, we give shift to oral PPI use, and try oral
intake. Analgesic for pain control. Alk-p, serum calcium and albumin
survey, excluded hypercalcemia.</li>
<li>Episode of fever up to 38.2 degree. Blood, uric acid and urine are
submitted for blood culture, urinalysis and gout survey. Pyuria was
excluded, but uric acid induce fever was considered, thus anti-gout
agent was addition for anti-inflammation effected. Blood transfusion
with LPRBC one unit for two days. Pus culture yields Enterococcus
faecium and quinolone -resistant Escherichia coli. Antibiotic was change
to Vancomycin and also was de-escalation of antibiotics Cefotaxime to
cefuroxime. Intermittent high fever and pig tail without drainage
amount, suspect pig tail. Contact radiology for pig tail revision, but
radiology suggestion consulted general surgey for surgical drainage
implacment. General surgey was conulted and phone contact VS
賴介文，suggest arrange non contrast or abdominal sonography for
peritoneal abscess follow up.</li>
<li>Sudden of tachycardia, BP drop and abdominal pain. Normal saline and
Dextran were hydration. Vasoconstriction pump use for maintain
hemodynamic stable. Short of breath, exertional dyspnea and desaturation
are noted. Inform family about patient critical condition and need
intubation. Family agree intubation. Thus, he received intubation with
fixed 24 cm with ventilator use. Tarry stool is noted, blood transfusion
with LPRBC 2 unit. Antibiotic treatment with Vancomycin plus Cefepime
for infection control. He will be transfered to MICU.</li>
<li>After transfer to ICU, ventialtor full supply and unstable of blood
pressure combine massive amount bloody stool passage was found. NPO with
adequate fluid for hydration and high dose PPI pump titration. Artery
line and neck CVC were placement. Shock status, Albumin iv infusion and
vasopressor agent with Levophed plus pitressin were titration. Ex-change
antiboltic to IV Cravit, Cubicin, Doripenem plus IV Metronidazole were
perscribed. Blood transfusion with LPRBC, FFP, Cryo and LRP were
infusion for hypovolemic shock. Emergent contect contect radiology for
TAE, impression of active bleeding of ileocecal branch of SMA s/p TAE.
Correct imbalance of electrolyte. Well explain prognosis condition and
highly mortalety rate to his family, they understood and refused any
invade procedule, DNR was signed.</li>
<li>However, unstable of blood pressure under high dose vasopressor
agent and poorly response with ventialtor high setting. The EKG reveal
bradycardia then asystole, immeasurable pulsation and dilated pupil with
inactive light reflex. The patient was prononcement expired at 12:29pm
in 2022-11-24.</li>
</ul></li>
</ul></li>
</ul>
<p>[consultation]</p>
<ul>
<li>2022-08-12 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This 37-year-old man patient is a case of Left supratentorial region
Isocitrate dehydrogenase wild type Glioblastoma post left
temporo-parieto-occipital craniotomy with remove brain tumor on
2021/11/05.</li>
<li>This time, for headache from 2022/08/09. Brain MRI on 2022/08/09
showed 1. Known a case of left parietal-occipital GBMs S/P operative
removal. Still presence of several ill-defined mass lesions at the same
areas. Marked progression of these heterogeneous enhancing tumors as
compared with prior MRI (2022/05/10). 2. MR angiography of the brain
shows normal intracranial vessel including circle of willis.</li>
<li>Now, for evaluate whole brain radiotherapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>Palliative RT might help with limited symptoms relief. CT-simulation
will be arranged on 20220815.</li>
<li>Plan to deliver 10~20 Gy/ 5~10 fx to the gross brain tumor. The
exact dose schedule depends on the dose distribution with normal brain
constraint considered after calculation.</li>
<li>RT will start around 20220817. Thank you very much.</li>
</ul></li>
</ul></li>
<li>2022-04-25 Dermatology
<ul>
<li>Q
<ul>
<li>Under the impression of bilateral pneumonia, he was admitted to our
ward for further management and treatment.<br />
</li>
<li>After admission, the patient has had right forearm herpes zoster
since 2 months ago and treatment at INF OPD. Due to right forearm
chronic erosion lesion, so we sincerly your help. TKS !!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from multiple group vesicles on R’t upper limb
for months.</li>
<li>Imp: Post herptic neuralgia</li>
<li>Suggestion:
<ul>
<li>Arrange Ne-Na laser</li>
<li>mycomb *2 tubes/bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-02 Neurosurgery
<ul>
<li>Q
<ul>
<li>headache and progressive consciousness change in recent 2 days</li>
<li>no fever, no uri s/s, no dyspnea, no abdominal pain, no diarrhea, no
tarry or bloody stool</li>
<li>2021/12/16 Brain MRI: malignant left T-Parietal brain tumor (wild
type Glioblastoma), significantly increase in size and extent as
compared with MRI on 2021/11/4, possibly involving the scalp
region.</li>
<li>2021/12/14-2022/01/14 hospital stay, discharge diagnoses
<ul>
<li>Malignant neoplasm of parietal lobe</li>
<li>Left supratentorial region Isocitrate dehydrogenase wild type
Glioblastoma post left temporo-parieto-occipital craniotomy with remove
brain tumor on 2021/11/05</li>
<li>Headache</li>
<li>Nausea with vomiting, unspecified</li>
<li>Nontraumatic intracranial hemorrhage, unspecified</li>
<li>Abnormal results of liver function studies</li>
<li>Constipation, unspecified</li>
</ul></li>
<li>Allergy: nil</li>
<li>Trauma hx: negative</li>
</ul></li>
<li>A
<ul>
<li>A case of 36 y/o male; GBM s/p op/ CCRT;</li>
<li>Confuse status and headache noted;</li>
<li>F/U brain CT showed left PO residual/ relapse tumor with mass
effect;</li>
<li>P: Control IICP/ IV hydration; further tumor excision?</li>
</ul></li>
</ul></li>
<li>2022-01-12 Plastic and Reconstructive Surgery
<ul>
<li>Q
<ul>
<li>Owing to wound poor healing, we need your expertise for further
management</li>
</ul></li>
<li>A
<ul>
<li>assessment
<ul>
<li>scalp defect with bone and plate exposure, no pus, no infection sign
now</li>
<li>patient is undergoing radiotherapy and chemotherapy now</li>
</ul></li>
<li>plan and suggestion:
<ul>
<li>conservative treatment first, surgical intervention is not suitable
for him due to C/T and R/T</li>
<li>caring wound with following method:
<ul>
<li>first day: prontosan bid (drip protosan gel into wound, then cover
with white gauze) (about 600NT$)</li>
<li>2nd day: duoderm gel bid (duoderm gel to fill the hole, then cover
with white gauze) (about 300NT$)</li>
<li>3rd day: Greenguard gel bid (greenguard fill the hole, then cover
with white gauze) (about2000NT$)</li>
<li>then coming back to first day treatment method, 2nd day method, 3rd
day method, and so on.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-30 Gastroenterology
<ul>
<li>Q
<ul>
<li>The 36 y/o man has brain tumor /p op. No HBV and HCV, but his liver
dysfunction without recovery, so we need your help for management.
Thanks!</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>ALT 442 -&gt; 181 -&gt; 295</li>
<li>Bil(T) 0.44</li>
<li>rGT 254(20211209)</li>
<li>AlkP 85(20211209)</li>
<li>20211213 abdominal echo: hemangioma</li>
<li>HbsAg(-)</li>
<li>Anti-HbsAb(+, low titer)</li>
<li>Anti-HbcAb(-)</li>
<li>Anti-HCV ab(-)</li>
<li>Anti-HAV ab IgM(-)</li>
<li>ceruloplasmin 0.128 g/L (Low)</li>
</ul></li>
<li>A
<ul>
<li>abnormal liver function, cause?</li>
</ul></li>
<li>P
<ul>
<li>Arrange cardiac sonography</li>
<li>Check ALP, rGT, TBI/DBI, PT, APTT, LDH to complete liver study</li>
<li>Regular/close monitor AST/ALT, TBI, PT, APTT, Ammonia, GGT, ALP</li>
<li>Avoid hepatic toxic agent if possible (or adjust dose), simplify
medication</li>
<li>Stronger Neo Minophagen use (self-paid) 5 amp QD 3~5 days</li>
<li>Check alpha 1 antitrypsin (blood), 24hr urinary copper, blood
copper</li>
<li>Consult ophthalmology for Kayser - Fleischer ring examination</li>
<li>Consider liver biopsy if his condition allows</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-16 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Now, for evaluate whole brain ratiotherapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>CT-simulation will be arranged today. Due to the multiple tumors are
still limited to Lt hemisphere, I’d consider partial instead of whole
brain irradation for possible dose escalation.</li>
<li>Plan to deliver 60 Gy/ 30 fx to the gross brain tumors and the
involved scalp region. RT will start around 20211220. Thank you very
much.</li>
</ul></li>
</ul></li>
<li>2021-11-30 Neurosurgery
<ul>
<li>Q
<ul>
<li>Headache, N/V since last night</li>
<li>No fever, no chills, no abdominal pain, no chest pain, no dyspnea,
no focal weakness, no diarrhea, no discharge from OP wound</li>
<li>NKDA</li>
<li>PHx: Glioblastoma s/p left temporo-parieto-occipital craniotomy with
remove brain tumor at parieto-occipital, Kocher EVD with ICP monitor
2021/11</li>
</ul></li>
<li>A
<ul>
<li>a case of headache</li>
<li>P.H. malignant GBM s/p</li>
<li>conscious clear</li>
<li>no focal neurologic deficits</li>
<li>brain CT Post-op at left frontoparietal skull. Left temporoparietal
malignancy with mass effect and progression. Focal ICH in left parietal
lobe.</li>
<li>Plan:
<ul>
<li>consult oncologist for admission and CCRT</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-15 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>Current problem: pathology showed Glioblastoma, IDH-wild type</li>
<li>We need your expertise for expertise for further management. Thanks
a lot!</li>
</ul></li>
<li>A
<ul>
<li>Accoring to NCCN guideline 2021, version2, CCRT (Temozolomide) is
indicated for GBM.</li>
<li>Plan:
<ul>
<li>We will discuss with family and patient</li>
<li>We may take over this case if the sugical condition is stable for
futher management.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-15 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Current problem: pathology showed Glioblastoma, IDH-wild type</li>
<li>We need your expertise for expertise for further management. Thanks
a lot!</li>
</ul></li>
<li>A
<ul>
<li>Adjuvant RT is indicated. CT-simulation will be arranged on
20211129.</li>
<li>Plan to deliver 60 Gy/ 30 fx to the preOP tumor bed and residual
tumors. RT will start around 20211201 or 20211202. Thank you very
much.</li>
</ul></li>
</ul></li>
<li>2021-11-15 Rehabilitation
<ul>
<li>Q
<ul>
<li>His brain tumor pathologic showed Glioblastoma.</li>
<li>We need your help to do speech therapy and other rehabilitation
program. Thank you very much.</li>
</ul></li>
<li>A
<ul>
<li>A 36-year-old man presented with progressive headache, dizziness,
nausea, vomiting and whole body weakness since last midnight. He denied
any past systemic disease and surgical history was sinusitis status post
operation about 10 years ago.</li>
<li>According to his and his family statement, he started to felt mild
discomfort with headache and dizziness last night and the symptoms
exacerbated in this early morning around 1 AM with severe headache,
dizzness, nausea, and whole body weakness. Thus, he was sent to this
emergency room very early in the morning. Laboratory studies showed no
abnormal finding except mild hypokalemia. Brain CT revealed a nodular
lesion about 39mm in the left parietal lobe, then MRI disclosed multiple
tumors in the left supratentorial brain. Therefore, under the impression
of left supratentorial brain tumor, he admitted for surgical
intervention. we were consulted for further rehabilitation.</li>
<li>PE
<ul>
<li>2021/11/15 05:30 T/P/R: 36.9 / 65bpm / 19bpm BP:108/67mmHg</li>
<li>height: 174.0 Body weight: 54.3 BMI:17.9</li>
<li>Consciousness: clear</li>
<li>Cognition: intact, oriented to time, person and place, could follow
orders</li>
<li>Speech: no aphasia, no obvious dysarthria</li>
<li>Swallowing: take general diet without choking</li>
<li>Sphincter: urinary and stool continence</li>
<li>MP: RUE/RLE: 4/3, LUE/LLE: 4/3</li>
<li>Functional status: could perform bed mobility min A</li>
<li>BADL: needs mod assistance</li>
<li>MRS: 4 (needs follow-up)</li>
</ul></li>
<li>Assessment
<ul>
<li>left parietal lobe glioblastoma post operation on 20211105</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: GYM first PT, OT rehabilitation
programs</li>
</ul></li>
<li>Goal: Ambulation with device CG</li>
</ul></li>
</ul></li>
<li>2021-11-04 Neurosurgery
<ul>
<li>Q
<ul>
<li>Severe headache since today</li>
<li>First time of this symptoms</li>
<li>Nausea, vomiting, dizziness, weakenss</li>
<li>No fever, no URI symptoms, no chest pain, no abdominal pain, no
trauma</li>
<li>Allergy: nil</li>
</ul></li>
<li>A
<ul>
<li>a case of progressive headache</li>
<li>conscious clear</li>
<li>brain CT a nodular lesion, about 39mm, in the left parietal lobe
with moderate perifocal edema</li>
<li>brain MRI multiple heterogeneous enhancing lesions in the left
temporal lobe and left parietal lobe with the largest one, about 37mm,
in the left parietal lobe. Moderate to severe perifocal edema.
Heterogeneous enhancement.</li>
<li>Plan: risk benefit of brain surgery well explained to family and
patient</li>
</ul></li>
</ul></li>
</ul>
<p>[radiotherapy]</p>
<ul>
<li>2021-12-20 ~ 2022-01-28 completed RT to the Lt hemisphere: 46 Gy/ 23
fx. to the residual brain tumor: 60 Gy/ 30 fx</li>
</ul>
<p>[chemoimmunotherapy]</p>
<ul>
<li>2022-10-12 - bevacizumab 10mg/kg 700mg 90min</li>
<li>2022-09-28 - bevacizumab 10mg/kg 700mg 90min</li>
<li>2022-09-12 - bevacizumab 10mg/kg 700mg 90min</li>
<li>2022-07-21 ~ 2022-07-26 - temozolomide 320mg QDAC 5 days</li>
<li>2022-06-23 ~ 2022-06-28 - temozolomide 320mg QDAC 5 days</li>
<li>2022-05-19 ~ 2022-05-24 - temozolomide 320mg QDAC 5 days</li>
<li>2022-04-19 ~ 2022-04-24 - temozolomide 320mg QDAC 5 days</li>
<li>2022-03-22 ~ 2022-03-27 - temozolomide 320mg QDAC 5 days</li>
<li>2022-02-24 ~ 2022-03-10 - temozolomide 120mg QDAC 14 days</li>
<li>2022-01-20 ~ 2022-02-10 - temozolomide 120mg QDAC 21 days</li>
</ul>
<div id="section-106" class="section level3">
<h3>==========</h3>
</div>
<div id="section-107" class="section level3">
<h3>2022-10-12</h3>
<ul>
<li><p>Following standard brain RT and TMZ for multiple glioblastomas,
the NCCN evidence blocks (2022-09-29 version 2.2002) recommends clinical
trials, surgery for symptoms of large lesion, alternating electric field
therapy, and palliative/best supportive care.</p></li>
<li><p>It has been reported in a review article that studies have been
conducted using intra-arterial delivery of chemotherapeutics for the
treatment of GBM, which may be considered as an optional last resort.
(ref: A systematic review on intra-arterial cerebral infusions of
chemotherapeutics in the treatment of glioblastoma multiforme: The
state-of-the-art. Front Oncol. 2022;12:950167. Published 2022 Sep 23. <a href="doi:10.3389/fonc.2022.950167" class="uri">doi:10.3389/fonc.2022.950167</a> )</p></li>
<li><p>In addition, there is also an article reported CAR T cell therapy
and its potential to be integrated into the therapeutic paradigm for
aggressive gliomas in the future. (ref: Clinical utility of CAR T cell
therapy in brain tumors: Lessons learned from the past, current evidence
and the future stakes [published online ahead of print, 2022 Oct 3]. Int
Rev Immunol. 2022;1-19. <a href="doi:10.1080/08830185.2022.2125963" class="uri">doi:10.1080/08830185.2022.2125963</a> )</p></li>
</ul>
</div>
</div>
</div>
<div id="section-108" class="section level1">
<h1>700361559</h1>
<div id="section-109" class="section level2">
<h2>221123</h2>
<ul>
<li>diagnosis - 2022-11-05 discharge note
<ul>
<li>Malignant neoplasm of biliary tract, unspecified</li>
<li>Malignant neoplasm of biliary tract, unspecified, sarcomatoid
carcinoma with biliary differentiation, CK(+), CK7(+), CK20(-), p63(-)
and Hepatocyte(-) with LN metastases and tumor seeding (
carcinomatosis), stage IV</li>
<li>Adeocarcinoma of the gallbladder with liver metastasis, lymph nodes
metastases, and tumor seeding (carcinomatosis),cT4 N2 M1, Stage:IVB</li>
<li>Urinary tract infection, site not specified</li>
<li>Hypoalbuminemia</li>
</ul></li>
<li>history - 2022-11-05 discharge note
<ul>
<li>HTN with medicine control for 20+ years</li>
<li>CAD with medicine control for 20+ years</li>
<li>BPH</li>
<li>Unclear liver disease, tumor or inflammation, since Aug 2021,
initial admission at ShuangHo Hospital that UTI also told.</li>
<li>Liver abscess drainage was performed at ward on 2022/05/22</li>
<li>COVID-19 infection on 2022/05/28</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-20, … CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
<li>Prominence of bilateral hilar shadows are noted, which may be
engorged central pulmonary vessels or adenopathy, please correlate
clinically and follow-up.</li>
</ul></li>
<li>2022-11-11 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Low voltage QRS</li>
<li>Nonspecific T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-11-11 KUB
<ul>
<li>Degenerative joint disease of lumbar spine with marginal
osteophytes.</li>
<li>Surgical clips retention over epigastric region.</li>
<li>Ileus with gas-filled distended bowel loops of the abdomen.<br />
</li>
</ul></li>
<li>2022-10-31 Abdomen
<ul>
<li>Spondylosis of the L-spine is noted.</li>
<li>Ascites is highly suspected.</li>
</ul></li>
<li>2022-10-18 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Sarcomatoid carcinoma with biliary
differentiation</li>
<li>The specimen submitted consists of three strips of yellow gray soft
tissue, labeled liver, measuring up to 0.6 x 0.1 x 0.1 cm. All for
section.</li>
<li>The sections show a picture of sheets of poorly differentiated,
polygonal and spindle-shaped neoplasic cells, arranged in short
fascicles. Neither glandular nor squamous differentiation can be
found.</li>
<li>IHC shows: CK(+), CK7(+), CK20(-), p63(-) and Hepatocyte(-). The
finding is consistent with sarcimatoid carcinoma with biliary
differentiation. Suggest clinic correlation.</li>
</ul></li>
<li>2022-10-17 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in both rib cages, some T- and L-spine,
sacrum, bilateral sternoclavicular junctions, shoulders, elbows, S-I
joints, hips, and knees.</li>
</ul></li>
<li>2022-07-22 CT - abdomen
<ul>
<li>History: liver abscess
<ul>
<li>20220517 CT：Multicystic lesion in Rt lobe liver 10cm suspected
abscess</li>
<li>A tumor 1.7cm in S6 with rim enhancement, suspected
cholangiocarcinoma 20220519 S/P drainage was performed.</li>
</ul></li>
<li>Indication: S5 tumor in progress.</li>
<li>Findings:
<ul>
<li>There is a heterogeneous lobulated soft tissue mass in the medial
subhepatic space, directly attached the gallbladder, measuring 4.8 cm in
size at the largest dimension.
<ul>
<li>Gallbladder cancer is highly suspected.</li>
</ul></li>
<li>There is an ill-defined hypodense mass lesion measuring 3 cm in S5
of the liver. During dynamic study, this mass shows poor contrast
enhancement in arterial phase and portal venous phase images, and mild
centropedal enhancement in delayed phase images
<ul>
<li>Metastasis is highly suspected.</li>
<li>The differential diagnosis include Cholangiocarcinoma.</li>
</ul></li>
<li>There are several enlarged nodes in the hepatoduodenal ligament that
are c/w metastatic nodes.
<ul>
<li>In addition, There are lobulated soft tissue lesions in the
periportal area of the liver hilum and ligamentum teres. Metastatic
nodes are highly suspected.</li>
</ul></li>
<li>There are several soft tissue nodules in RUQ omentum that are c/w
tumor seeding.
<ul>
<li>In addition, There are few enhancing soft tissue lesions in
bilateral lower pelvis that may be tumor seeding?</li>
</ul></li>
<li>Prior CT identified multicystic lesions in right hepatic lobe is
noted again, marked decreasing in size that is c/w liver abscess S/P
catheter drainage and antibiotics treatment with near complete
response.</li>
<li>Non-visualization of the spleen is noted. please correlate with
clinical condition.</li>
<li>Several gallstones are noted.</li>
<li>Others
<ul>
<li>There is no focal abnormality in the biliary system, pancreas, &amp;
both kidney.<br />
</li>
<li>There is no bowel wall thickening, and no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Adeocarcinoma of the gallbladder with liver metastasis, lymph nodes
metastases, and tumor seeding (carcinomatosis) is highly suspected.
<ul>
<li>According to American Joint Committee on Cancer(AJCC) staging
system, 8th edition for gallbladder cancer: T4 N2 M1, Stage:IVB</li>
</ul></li>
<li>A poor enhancing mass 3 cm in S5 liver is noted.</li>
<li>Metastasis is highly suspected.</li>
<li>The differential diagnosis include Cholangiocarcinoma.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-02 - irinotecan liposome 70mg/m2 125mg 1.5hr + leucovorin
400mg/m2 700mg 1hr + fluorouracil 2400mg/m2 4000mg 46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Fatal neutropenic sepsis occurred in 0.8% of patients receiving
irinotecan (liposomal). Severe or life-threatening neutropenic fever or
sepsis occurred in 3% and severe or life-threatening neutropenia
occurred in 20% of patients receiving irinotecan (liposomal) in
combination with fluorouracil and leucovorin.</li>
<li>When irinotecan is suspected of causing acute gastroenteritis,
UGT1A1 genotyping might be utilized to confirm the homozygous state
(homozygous UGT1A1*28).</li>
<li>Atropine 0.5mg SC is recommended as a premedication prior to the use
of irinotecan in the next chemotherapy if there is no
contraindication.</li>
</ul>
</div>
</div>
<div id="section-110" class="section level1">
<h1>700384079</h1>
<div id="section-111" class="section level2">
<h2>221122</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-16, -09-28, -08-29, -08-25 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-11-16 CT - abdomen
<ul>
<li>History: UGI bleeding
<ul>
<li>20220808 gastroscopy: One 25mm ulcer with elevated margin was noted
at AW side of bulb/SDA. Patho: duodenal adenocarcinoma</li>
<li>20220817 CT: duodenal adenocarcinoma or metastatic node with
superior mesenteric vein invasion? cT4N2M0, cstage: IIIB</li>
</ul></li>
<li>MD CT of the abdomen and pelvis was performed with 0.625 mm
collimation &amp; 5 mm slice thickness reconstruction. Oral and rectal
contrast was not given for bowel opacification. Bi-phasic dynamic CT
images were obtained during non-enhanced, arterial phase, and portal
venous phase scan following IV contrast injection through autoinjector.
Coronal reformated isotropic images were obtained in portal venous phase
scan.</li>
<li>Findings: Comparison: prior CT dated 2022/08/17.
<ul>
<li>Prior CT identified lobulated wall thickening in duodenal bulb
measuring 1.5 cm in wall thickness is noted again, increasing in size to
2.1 cm. The stomach shows marked distension that may be gastric outlet
obstruction?
<ul>
<li>Please correlate with gastroscopy.</li>
<li>In addition, There is a poor enhancing mass measuring 2.5 cm in the
medial aspect of the duodenal 2nd portion with direct invasion the
superior mesenteric vein is noted again, decreasing in size to 1.8 cm
that may be metastatic node S/P C/T with partial response .</li>
<li>The differential diagnosis include adenocarcinoma with exophytic
growth?</li>
<li>Prior CT identified two enlarged nodes in the hepatoduodenal
ligament are noted again, mild decreasing in size that are c/w
metastatic nodes S/P C/T with partial response.</li>
</ul></li>
<li>There are several gallstones.</li>
<li>There are few metalic coils implantation at the gastroduodenal
artery that are c/w TAE for prior GI bleeding.</li>
<li>Abdominal aorta shows atherosclerosis and mild intramural thrombus
formation.</li>
<li>There is no focal abnormality in the liver, biliary system,
pancreas, spleen &amp; both kidney.<br />
</li>
<li>There is no ascites.<br />
</li>
<li>There is no bowel obstruction.<br />
</li>
<li>The IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>Adenocarcinoma of the duodenal bulb shows mild increasing in size.
However, metastatic nodes show decreasing in size.</li>
</ul></li>
</ul></li>
<li>2022-08-23 All-RAS + BRAF mutations assay
<ul>
<li>All-RAS mutations assay
<ul>
<li>Detection range
<ul>
<li>KRAS codon 12, 13, 59, 61, 117, 146</li>
<li>NRAS codon 12, 13, 59, 61, 117, 146</li>
</ul></li>
<li>Results
<ul>
<li>There was no variant detected in the KRAS/NRAS gene.</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with RAS mutation may not benefit from the anti-EGFR antibody treatment.
Patients with no RAS mutation are more likely to have disease control by
using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
<li>BRAF mutations assay
<ul>
<li>Detection range
<ul>
<li>BRAF codon 600</li>
</ul></li>
<li>Results
<ul>
<li>There was no variant detected in the BRAF gene.</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with BRAF mutation may not benefit from the anti-EGFR antibody
treatment. Patients with no BRAF mutation are more likely to have
disease control by using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-23 CT - chest
<ul>
<li>Pancreatic cancer with suspect duodenal bulb and SMV invasion</li>
<li>MDCT (256-detector rows, GE Revolution, was performed with 0.625 0.5
mm collimation &amp; 2.5 mm (lung window), 5 mm (soft-tissue window),
slice thickness) of the chest and upper abdomen without &amp; with
contrast enhancement, coronal and sagittal reconstructed images
shows:</li>
<li>Findings
<ul>
<li>Lungs: minimal centrilobular nodules at posterobasal segment of
RLL.normal appearance of RUL, RML, and left lung.</li>
<li>Mediastinum and hila: no enlarged LN or mass.
<ul>
<li>the trachea and main bronchi are normallly identified without
endobronchial lesion.</li>
</ul></li>
<li>Vessels:
<ul>
<li>moderate calcified plaques of the LAD coronary artery.</li>
<li>Aorta: normal caliber, mild atherosclerotic change of aortic arch
and descending thoracic aorta/aortic root.</li>
<li>Central pulmonary arteries: normal caliber.</li>
</ul></li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: unremarkable.</li>
<li>Chest wall and visible lower neck: unremarkable.</li>
<li>Visible abdominal contents: Pancreatic head cancer with suspect
duodenal bulb and SMV invasion
<ul>
<li>multiple small gall bladder stones</li>
</ul></li>
<li>Visualized bones: multiple marginal spurs of vertebrae..</li>
</ul></li>
<li>Impression:
<ul>
<li>minimal bronchiolitis in RLL-S10. moderate LAD CAD.</li>
</ul></li>
</ul></li>
<li>2022-08-17 CT - abdomen
<ul>
<li>History: UGI bleeding
<ul>
<li>20220808 gastroscopy: One 25mm ulcer with elevated margin was noted
at AW side of bulb/SDA. Patho: duodenal adenocarcinoma</li>
</ul></li>
<li>MD CT of the abdomen and pelvis was performed with 0.625 mm
collimation &amp; 5 mm slice thickness reconstruction. Oral and rectal
contrast was not given for bowel opacification. Bi-phasic dynamic CT
images were obtained during non-enhanced, arterial phase, and portal
venous phase scan following IV contrast injection through autoinjector.
Coronal reformated isotropic images were obtained in portal venous phase
scan.</li>
<li>Findings:
<ul>
<li>There is lobulated wall thickening in duodenal bulb measuring 1.5 cm
in wall thickness.
<ul>
<li>Adenocarcinoma of the duodenal bulb is highly suspected.</li>
<li>In addition, There is a poor enhancing mass measuring 2.5 cm in the
medial aspect of the duodenal 2nd portion with direct invasion the
superior mesenteric vein that may be metastatic node.</li>
<li>The differential diagnosis include adenocarcinoma with exophytic
growth?</li>
<li>There are two enlarged nodes in the hepatoduodenal ligament that may
be metastatic nodes.</li>
</ul></li>
<li>There are several gallstones.</li>
<li>There are few metalic coils implantation at the gastroduodenal
artery that are c/w TAE for prior GI bleeding.</li>
<li>Abdominal aorta shows atherosclerosis and mild intramural thrombus
formation.</li>
<li>There is no focal abnormality in the liver, biliary system,
pancreas, spleen &amp; both kidney.
<ul>
<li>There is no ascites.<br />
</li>
<li>There is no bowel obstruction.<br />
</li>
<li>The IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Adenocarcinoma of the duodenal bulb is highly suspected.</li>
</ul></li>
</ul></li>
<li>2022-08-10 Embolization (TAE: trans arterial embolisation) - abdomen
<ul>
<li>TAE of duodenal hemorrhage via right common femoral artery puncture
using Seldinger technique revealed:
<ul>
<li>The necessarity and risks of the procedure was well explanined to
patient family before the angiography. The patient family understood the
risks of incomplete procedure, bleeding, infection, organ injury.
Questions were answered, and all wished to procedure. Informed consent
was obtained.</li>
<li>Under local anesthesia, a 4 Fr arterial sheath was inserted into
right common femoral artery smoothly.</li>
<li>Active bleeding of gastroduodenal artery.</li>
<li>We used microcatheter for superselective catheterization due to easy
spasm, tortuous, small size of bleeding artery.</li>
<li>TAE was performed using four microcoils (2-4-42mm x3 and 2-6-85mm
x1) plus some gelfoam pieces.</li>
<li>No procedure-related complication during the whole procedure. Remain
the arterial sheath (4 Fr) at right inguinal region. Thanks for your
further care.</li>
</ul></li>
<li>IMP: Active bleeding of gastroduodenal artery s/p TAE.</li>
</ul></li>
<li>2022-08-09 Patho - duodenum biopsy (malignancy)
<ul>
<li>Duodenum, AW side of bulb/SDA, biopsy — moderately differentiated
adenocarcinoma</li>
<li>Microscopically, it shows moderately differentiated adenocarcinoma
composed of proliferation of irregular neoplastic glands with stromal
invasion. The tumor shows nuclear hyperchromasia, pleomorphsim,
prominent nucleoli and increased N/C ratio.</li>
<li>Immunohistochemical stain — CK(+), CDX-2(+)</li>
</ul></li>
<li>2022-08-08 Panendoscopy
<ul>
<li>Diagnosis
<ul>
<li>Severe duodenal ulcer, Forrest classification type Ib, suspected
tumor, s/p hemostasis with APC and biopsy</li>
<li>Incomplete of stomach</li>
</ul></li>
<li>Suggestion
<ul>
<li>NPO and PPI pump for 3 days.</li>
<li>Due to anticipated prolonged NPO time, suggest TPN supply
<ul>
<li>Calories: 25kcal per ideal body weight</li>
<li>Protein: 1.5gm per ideal body weight</li>
</ul></li>
<li>Consult interventional radiologist and surgical department if
further bleeding.</li>
<li>Weaning ventilator ASAP</li>
</ul></li>
</ul></li>
<li>2022-08-04 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (74.7 - 17.0) / 74.7 = 77.24%
<ul>
<li>M-mode (Teichholz) = 77</li>
</ul></li>
<li>Conclusion:
<ul>
<li>Normal chamber size</li>
<li>Septal hypertrophy</li>
<li>Adequate LV and RV systolic function</li>
<li>Mild MR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
</ul></li>
<li>2022-08-01 Panendoscopy
<ul>
<li>Diagnosis
<ul>
<li>Superfical gastritis, antrum</li>
<li>Duodenal ulcer, junction of 1st and 2nd portion, LC side, Forrest
classification IIb</li>
</ul></li>
<li>Suggestion
<ul>
<li>NPO and give high dose PPI</li>
</ul></li>
</ul></li>
<li>2022-07-29 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right bundle branch block</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-04-19 SONO - abdomen
<ul>
<li>Fatty liver, mild to moderate</li>
<li>GB stone, multiple</li>
</ul></li>
<li>2021-01-27 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right bundle branch block</li>
</ul></li>
<li>2019-11-04 CPA, carotid phonoangiograph
<ul>
<li>Sonographic diagnosis:
<ul>
<li>Moderate atheromatous lesions in bil BIF and right proximal
ICA.</li>
<li>Normal extracranial carotid, vertebral, and intracranial basal
cerebral arterial flows; stenotic flow in left MCA, more severe over
proximal segment; resistant flow in right CCA and left ECA, suspect
distal stenosis, suggest clinical correlation and further
evaluation.<br />
</li>
<li>Poor temporal windows for left PCA and right ACA.</li>
<li>Normal left ophthalmic arterial flows; reverse flow in right
OA.</li>
<li>Suggest MRA (neck + intracranial arteries) for further study if no
contraindication.</li>
</ul></li>
</ul></li>
<li>2018-03-26 SONO - hepatobiliary
<ul>
<li>Fatty liver.</li>
<li>GB stone.</li>
</ul></li>
<li>2018-02-18 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right bundle branch block</li>
</ul></li>
<li>2017-07-04 Barium Enema (double contrast)
<ul>
<li>Double contrast study of LGI series revealed:
<ul>
<li>The contrast medium passage from anus to terminal ileum smoothly
without obstruction.</li>
<li>Redundancy of T-colon.</li>
<li>Much stool retention in colon.</li>
<li>Normal contour and mucosal pattern of the colon.</li>
<li>Normal haustration and peristalsis of the colon.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-24 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For neoadjuvant chemotherapy of pancreatic cancer suspected duodenal
invasion suspected SMV invasion</li>
<li>THis is a 56 y/o male with history of DM, hypertension under
medication control</li>
<li>He was admitted since 20220730 due to gastric ulcer with bleeding
complicated with hypovolemic shock s/p ETT intubation (extubated), EGD
hemostasis and active bleeding of gastroduodenal artery s/p TAE on
20220810. There was an incidental finding of duodenal neoplasm,
pathology revealed adenocarcinoma. CT revealed adenocarcinoma of the
duodenal bulb, suspect SMV invasion.</li>
<li>Further tumor biomarker study revealed CA-199 = 1089; while other
biomarkers were within normal range, pancreatic cancer suspected
duodenal bulb invasion was suspected.</li>
<li>Due to above, surgical intervention was not recommended in the first
place, suggested by GS Dr. Wu.</li>
<li>We sincerely need your expertise for chemotherapy evaluation and
management.</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>Abdominal CT show:
<ul>
<li>There is lobulated wall thickening in duodenal bulb measuring 1.5 cm
in wall thickness.</li>
<li>Adenocarcinoma of the duodenal bulb is highly suspected.</li>
<li>In addition, There is a poor enhancing mass measuring 2.5 cm in the
medial aspect of the duodenal 2nd portion with direct invasion the
superior mesenteric vein that may be metastatic node. The differential
diagnosis include adenocarcinoma with exophytic growth?</li>
<li>There are two enlarged nodes in the hepatoduodenal ligament that may
be metastatic nodes.</li>
</ul></li>
<li>Pathology: Duodenum, AW side of bulb/SDA, biopsy — moderately
differentiated adenocarcinoma.
<ul>
<li>Immunohistochemical stain — CK(+), CDX-2(+)</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Duodenum adenocarcinoma with SMV invastion, T4N2Mx, stage IIIB at
least</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Arrange chest CT, EUS for complete staging</li>
<li>For Locally unresectable duodenum cancer, systemic chemotherapy is
indicated (goal for down stage)</li>
<li>Arrange port A insertion if patient agree further chemotherapy and
check HbsAg, Anti Hbc, Anti HCV</li>
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-18 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>For duodenal adenocarcinoma</li>
<li>This is a 56 y/o male with history of DM, hypertension under
medication control</li>
<li>He was admitted since 07/30 due to gastric ulcer with bleeding
complicated with hypovolemic shock s/p ETT intubation (extubated), EGD
hemostasis and active bleeding of gastroduodenal artery s/p TAE on
08/10. There was an incidental finding of duodenal neoplasm, pathology
revealed adenocarcinoma. CT revealed adenocarcinoma of the duodenal
bulb, suspect SMV invasion.</li>
<li>We sincerely need your expertise for surgical intervention
evaluation and management.</li>
</ul></li>
<li>A
<ul>
<li>A case suspect of duodenal or pancreatic tumor</li>
<li>further op will arrange on 8/24</li>
<li>we will take over for this case on 8/22</li>
<li>Due to pancreatic neck ca with SMV invasion and tumor seeding is
impression</li>
<li>Suggest further neoadjuvant chemotherapy first for tumor down
stage</li>
</ul></li>
</ul></li>
<li>2022-08-11 Diagnostic Radiology
<ul>
<li>Q
<ul>
<li>For TAE (trans arterial embolisation)</li>
<li>The 57-year-old male patient, he has history of: 1. Type 2 diabetes
mellitus for years. 2. Hypertension for years. He was under regular
medical treatment in our GI and Family Medicine Department OPD in the
recent years. He is a bus driver who fainted once in the toilet during
his lunch break yesterday. This time, he complained of black stool for
about a week. And also has dizziness again and cold sweat after going to
the toilet last night.</li>
<li>At ER, his consciousness was clear. KUB showed: Increase bowel gas
and presence of ileus.The serum examination showed : glucose: 336 mg/dL;
BUN: 62 mg/dL; Creatinine: 1.83 mg/dL; WBC: 11.10 *10^3/uL; HGB: 8.8
g/dL. Under the impression of upper gastrointestinal bleeding, IV
Panzolec pump were given and he was admitted for further evaluation and
management. After admitted to ward, the EGD performed on 08/01 showed
gastric ulcer Forrest class IIb. His tarry stool passage mildly subsided
since then(no loosen nor sticky unshaped stool, hemoglobin level around
8.0-8.7) s/p PPI high dose pump and then Q12H since 08/05.</li>
<li>However, on 08/06, he was noted dizziness, bloody stool passage, the
discharge was postponed. Following Hb today revealed 6.4, EGD was
arranged this afternoon. Hematemesis with consciousness disturbance
developed when undergo anesthesia surveillance, with cold and wet skin,
tachycardia, pale appearance, suspect hypovolemic shock. ETT intubation
was performed to secure airway(Dormicum x1, Esmeron x1), foley catheter
and CVC were also inserted in the same time. Fluid resuscitated with N/S
500 cc and LPRBC 2U ST, vesopressor with levophed 2 amps in 500 N/S run
20 cc/hr, PPI pump with 5 amps in 500 N/S run 20 cc/hr. His family was
informed and fully understood current situation. After emergent
management, the patient’s condition was temporarily under control and
was transferred to MICU for further evaluation and management on
2022-08-08.<br />
</li>
<li>After transferred to MICU, on ventilator full support and blood
transfusion with LPRBC 4u, FFP 4u and cyro 10u stat. On vasopressor with
levophed titration(8/8-) and N/S 500ml challenge for unstable
hemodynamic condition. Arranged pandoscope immediately which report
showed Severe duodenal ulcer, Forrest classification type Ib, suspected
tumor, s/p hemostasis with APC and biopsy. Jusomin 5amp iv stat for
metabolic acidosis. Extubation on 8/9 and then on nasal cannula support.
However, fresh bloody around 200ml via NG tube was noted now, so we
contact GI who suggested If active bleeding, arrange TAE. Therefore, we
need your help for TAE examination. Thanks!!</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, TAE is
indicated.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-08 - gemcitabine 800mg/2 1600mg 30min + oxaliplatin 85mg/m2
160mg 2hr + leucovorin 300mg/m2 600mg 2hr + fluorouracil 2000mg/m2
4000mg 48hr</li>
<li>2022-10-25 - gemcitabine 800mg/2 1600mg 30min + oxaliplatin 85mg/m2
160mg 2hr + leucovorin 300mg/m2 600mg 2hr + fluorouracil 2000mg/m2
4000mg 48hr</li>
<li>2022-09-28 - gemcitabine 800mg/2 1600mg 30min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 300mg/m2 570mg 2hr + fluorouracil 2000mg/m2
3800mg 48hr</li>
<li>2022-09-13 - gemcitabine 800mg/2 1600mg 30min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 300mg/m2 570mg 2hr + fluorouracil 2000mg/m2
3800mg 48hr</li>
<li>2022-08-29 - gemcitabine 800mg/2 1600mg 30min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 300mg/m2 570mg 2hr + fluorouracil 2000mg/m2
3800mg 48hr</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>GOLF regimen ref:</li>
<li>Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic
Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary
Tumors. JOP. 2019;20(5):121-124;</li>
<li>Biweekly triple combination chemotherapy with gemcitabine,
oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and
active treatment for patients with inoperable pancreatic cancer. J
Chemother. 2008;20(1):119-125. <a href="doi:10.1179/joc.2008.20.1.119" class="uri">doi:10.1179/joc.2008.20.1.119</a>;</li>
<li>A novel biweekly multidrug regimen of gemcitabine, oxaliplatin,
5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with
advanced colorectal carcinoma. Br J Cancer. 2004;90(9):1710-1714. <a href="doi:10.1038/sj.bjc.6601783" class="uri">doi:10.1038/sj.bjc.6601783</a></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>The GOLF regimen was introduced as a neoadjuvant treatment since
late August 2022 with the aim of downstaging the tumor. The CT
(2022-11-16) revealed that the adenocarcinoma of the duodenal bulb
showed a mild increase in size and that the metastatic nodes displayed a
decrease in size. There appears to be a greater likelihood that this
will improve the feasibility of the surgery.</p></li>
<li><p>The decreased CA199 marker also served as a side evidence that
the regimen is still effective.</p>
<ul>
<li>2022-11-21 CA199 346.54 U/mL<br />
</li>
<li>2022-10-11 CA199 740.79 U/mL<br />
</li>
<li>2022-09-13 CA199 1286.58 U/mL</li>
</ul></li>
<li><p>Data available indicate stable vital signs, and there is no
problem with the active prescription.</p></li>
</ul>
</div>
</div>
<div id="section-112" class="section level1">
<h1>700568782</h1>
<div id="section-113" class="section level2">
<h2>221122</h2>
<ul>
<li>diagnosis - 2022-11-10 discharge note
<ul>
<li>Right breast invasive carcinoma with liver and bone metastasis,
cT4N1M1, stage IV. ECOG:0</li>
<li>Viral hepatitis B without hepatic coma</li>
<li>Upper Gastrointestinal Bleeding, vomit OB: 3+</li>
<li>Reflux esophagitis, lower esophagus, LA classification, grade B</li>
<li>Gastric ulcer</li>
<li>Superfical gastritis</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-21 CXR
<ul>
<li>Ground glass opacity in RLL.</li>
</ul></li>
<li>2022-11-10 Patho - stomach biopsy
<ul>
<li>Stomach, AW of antrum, biopsy — Non-atrophic chronic gastritis,
Helicobacter Pylori: NOT present</li>
</ul></li>
<li>2022-11-10 Panendoscopy
<ul>
<li>Reflux esophagitis, lower esophagus, LA classification, grade B</li>
<li>Superfical gastritis, antrum</li>
<li>Gastric ulcer, antrum, AW, s/p biopsy</li>
</ul></li>
<li>2022-11-08 CT - abdomen
<ul>
<li>Clinical history: 54 y/o female patient with breast cancer with
liver mets, elevated TBI and liver dysfunction.</li>
<li>Findings
<ul>
<li>Diffuse liver tumors in both lobes of the liver, suggesting liver
metastasis. Progression as compare with CT study on 20220505.</li>
<li>Presence of gallbladder stones.</li>
<li>Unremarkable change of the spleen, pancreas and both kidneys.</li>
<li>No enlarged lymph node in the paraaortic region.</li>
<li>Presence of ascites.</li>
<li>Bilateral pleural effusion with right lower lung collapse.</li>
<li>Diffuese osteoblastic and osteolytic lesions in the bones, could be
due to bone metastasis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Liver metastasis and ascites with progression.</li>
<li>Diffuse bone metastasis.</li>
<li>Bilateral pleural effusion with right lung collapse.</li>
<li>GB stones.</li>
</ul></li>
</ul></li>
<li>2022-11-07 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>ST &amp; T wave abnormality, consider anterior ischemia</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-11-05 KUB
<ul>
<li>Diffuse bony metastases of the lower T-spine, L-spine, sacrum, and
bilateral ilium.</li>
</ul></li>
<li>2022-11-05 CXR
<ul>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Osteoblastic bony metastases in the lower T-spine and L-spine are
noted after correlate with prior CT.</li>
</ul></li>
<li>2022-10-28 Whole body PET scan
<ul>
<li>Findings
<ul>
<li>There was increased FDG uptake in the some mediastinal lymph nodes
and in multiple focal areas in the liver.</li>
<li>There was increased FDG uptake in multipe bones including the skull,
mandible, multiple C-, T- and L-spines, sternum, bilateral multiple
ribs, bilateral clavicle, bilateral scapulae, sacrum, bilateral pelvic
bones, bilateral humeri and femurs.</li>
</ul></li>
<li>Impression
<ul>
<li>Glucose hypermetabolism in multiple focal areas in the liver and in
multipe bones as mentioned above, suggesting multiple liver and bone
metastases.</li>
<li>Glucose hypermetabolism in some mediastinal lymph nodes. Metastatic
lymph nodes should be considered.</li>
</ul></li>
</ul></li>
<li>2022-10-28 ENT Hearing Test
<ul>
<li>Tymp:
<ul>
<li>Bil type A.</li>
</ul></li>
<li>ART:
<ul>
<li>R’t contra absent.</li>
<li>L’t WNL.</li>
</ul></li>
<li>E-tube function test:
<ul>
<li>Bil poor.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 18 dB HL; LE 19 dB HL.</li>
<li>Bil WNL.</li>
</ul></li>
</ul></li>
<li>2022-10-27 Sonography of hepatobiliary system
<ul>
<li>Findings
<ul>
<li>Bil. liver tumors (up to 6.39cm).</li>
<li>Moderate amount ascites.</li>
<li>Gallbladder stones (0.65cm, 1.10cm).</li>
<li>Patency of PV, HVs, IVC and aorta in hepatic portion.</li>
<li>Normal appearance of pancreatic head. The other portions of pancreas
masked by gastric/bowel gas.<br />
</li>
<li>Normal appearance of spleen.</li>
<li>No evidence of pleural effusion.</li>
<li>Normal appearance of kidneys.</li>
</ul></li>
<li>IMP:
<ul>
<li>Bil. liver tumors (up to 6.39cm). Moderate amount ascites.
Gallbladder stones (0.65cm, 1.10cm).</li>
</ul></li>
</ul></li>
<li>2022-10-27 CXR
<ul>
<li>Consolidation at RLL.</li>
</ul></li>
<li>2022-05-09 Tc-99m MDP whole body bone scan
<ul>
<li>Highly suspected multiple bone metastases in multiple T- and
L-spine, sternum, bilateral multiple ribs, sacrum, bilateral S-I joints,
left ischium, bilateral humeri, and femurs.</li>
<li>Increased tracer uptake in the skull and hips, the nature is to be
determined, suggesting follow-up with bone scan in 3 months for
investigation.</li>
</ul></li>
<li>2022-05-05 CT - abdomen
<ul>
<li>Findings
<ul>
<li>S/P right breast operation.</li>
<li>Bil. liver metastases (up to 6.5cm). AP shunt at right hepatic lobe.
Bil. liver cysts (up to 2.6cm).</li>
<li>Multiple bony metastases.</li>
<li>Normal appearance of spleen, pancreas, adrenals and kidneys.</li>
<li>Tiny gallbladder stones (2-3mm).</li>
<li>Patency of portal vein.</li>
<li>No ascites, nor enlarged lymph node.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
<li>No abnormal density at bilateral basal lungs.</li>
</ul></li>
<li>IMP:
<ul>
<li>S/P right breast operation.</li>
<li>Multiple liver and bony metastases.</li>
</ul></li>
</ul></li>
<li>2022-03-18 SONO - abdomen
<ul>
<li>Metastasis 9 cm in S4 liver is highly suspected.
<ul>
<li>Please correlate with contrast enhanced dynamic CT.</li>
<li>Several hepatic cysts on both lobes.</li>
</ul></li>
<li>Two polyp-like lesion 1.29 cm and 0.86 cm in the gallbladder are
suspected.<br />
</li>
</ul></li>
<li>2022-01-18 Patho - breast biopsy (no need margin)
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Breast, right, partial mastectomy — Invasive carcinoma of no special
type, s/p CDK 4/6 inh + AI treatment</li>
<li>Resection margin: involved</li>
<li>Lymph node, right left axilla/ sentinel, lymphadenecomy — Not
received</li>
<li>AJCC 8 th edition, Pathology stage: Anatomic stage: ypStage IV,
ypT2Nx (if cM1)</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Breast: Size: 4.5 x 3.1 x 3.0 cm</li>
<li>Skin: Size: 4.1 x 1.3 cm.</li>
<li>Nipple: Not Included<br />
</li>
<li>Tumor: Size: 2.8 x 2.0 x 1.7 cm.</li>
<li>Resection Margin: involved</li>
<li>Lymph node: Not received</li>
<li>Representative sections are taken and labeled as: A1-6.</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>FOR INVASIVE CARCINOMA
<ul>
<li>Histologic type: Invasive carcinoma of no special type</li>
<li>Size of invasive carcinoma: 2.8 x 2.0 x 1.7 cm.</li>
<li>Histologic grade (Nottingham histologic score): grade II (score 7)
<ul>
<li>Tubule formation: score 3</li>
<li>Nuclear pleomorphism: score 3</li>
<li>Mitotic count: score 1</li>
</ul></li>
<li>Extent of tumor (required only if the structures are present and
involved)</li>
<li>Skin involvement: Absent; The immunohistochemical stain of CK7 is
negative.<br />
</li>
<li>Chest wall invasion deeper than pectoralis muscle: not received</li>
</ul></li>
<li>FOR DUCTAL CARCINOMA IN SITU
<ul>
<li>Tumor size (cm): several foci, measuring up to 0.5 x 0.25 cm,
intermix with invasive carcinoma.</li>
<li>Nuclear grade: 3</li>
<li>Architectural pattern: Non-comedo (solid and cribriform)</li>
<li>Tumor necrosis: Present</li>
</ul></li>
<li>Margins: Involved ( unspecified margin)</li>
<li>Nodal status: Not received
<ul>
<li>number of lymph node examined: Not received</li>
<li>number with macrometastases (&gt;2mm): Not received</li>
<li>number with micrometastases (&gt;0.2~2mm and/or &gt;200 cells): Not
received</li>
<li>number with isolated tumor cells (&lt;=0.2mm and &lt;=200 cells):
Not received</li>
</ul></li>
<li>Treatment Effect: Response to presurgical (neoadjuvant) therapy (if
patient received)
<ul>
<li>In the Breast: Probable or definite response to presurgical therapy
in the invasive carcinoma</li>
<li>In the Lymph nodes: No lymph nodes removed</li>
</ul></li>
<li>Lymphovascular invasion: present</li>
<li>Perineural invasion: present</li>
</ul></li>
<li>IMMUNOHISTOCHEMICAL STUDY
<ul>
<li>ER (Ab): Positive (strong, 80 %)</li>
<li>PR (Ab): DCIS: Positive (strong, 10%); IDC: Negative</li>
<li>HER-2/Neu (Ab): DCIS: Positive (3+); IDC: Equivocal (2+)
<ul>
<li>The HER2/NEU In-Situ Hybridization Test from Taipei Institute of
Pathology is NEGATIVE.</li>
<li>There is NO amplification of HER2 detected.</li>
</ul></li>
<li>Ki-67: &lt; 5%</li>
</ul></li>
</ul></li>
<li>2022-01-17 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible Left atrial enlargement</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
<li>2021-12-31 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver,mild</li>
<li>Suspected liver cyst,left</li>
<li>Liver tumors,bil.Propable metastases</li>
<li>Suspected GB polyp</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Please correlate with other image</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver, especially liver dome and S1 was diffcult to
approach and easy missed</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-09 Family Medicine
<ul>
<li>Q
<ul>
<li>This time, she has nasuea and vomit and poor intake, so she was
admission for supprtiva care ( IVF &amp; Bfluid ) on 11/5 22. Howevee,
the patient’s condition, liver function worse, and request the combine
hospice care, so we need your help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>54-year-old female, right breast cancer with liver and bone
metastasis</li>
<li>Consciousness clear, ECOG 2</li>
<li>We will arrange hospice combine care and follow her condition</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There was an increase in serum bilirubin (both direct and total),
AST, ALT, and ammonia as a result of poor liver function.</li>
<li>Presently, Baraclude (entecavir), Baogan (silymarin) and Lactul
Syrup (lactulose) are used to treat liver insufficiency symptoms.</li>
<li>Hospice combined care has been arranged.</li>
<li>Her edema in the lower extremities might be mitigated by the use of
albumin (2.8 g/dL 2022-11-05).</li>
</ul>
</div>
</div>
<div id="section-114" class="section level1">
<h1>700361615</h1>
<div id="section-115" class="section level2">
<h2>221121</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 4 items.</p>
<p>the 3 items are identified as following while the other 1 item
remains unknown.</p>
<ul>
<li>Broen (l-cysteine 20mg, bromelain 20000unit)</li>
<li>Acetal (acetaminophen 500mg)</li>
<li>Sodicon (dextromethorphan 15mg)</li>
</ul>
<p>The drug will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-116" class="section level1">
<h1>700952001</h1>
<div id="section-117" class="section level2">
<h2>221121</h2>
<ul>
<li>diagnosis 20221001 discharge
<ul>
<li>Infiltrating duct carcinoma of left breast, pT2N0M0 post MRM
(20131017), ER:positive (90%), PR:40%, Her2/neu:equivocal(2+, FISH
negative), P53(-), Ki-67 index 30%, bone metastases</li>
<li>Essential (primary) hypertension</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-18 KUB
<ul>
<li>Fecal material store in the colon.</li>
<li>Spondylosis of the L-spine is noted.</li>
<li>S/P total hip arthroplasty, left hip and the screw penetration into
the pelvis.</li>
</ul></li>
<li>2022-11-18 CXR
<ul>
<li>Spondylosis of the T-spine</li>
<li>Few nodular opacity projecting in the left upper and middle lung are
suspected. Please correlate with CT.</li>
<li>S/P partial Mastectomy, left.</li>
</ul></li>
<li>2022-10-25 L-spine AP + Lat (including sacrum)
<ul>
<li>Straightening alignment of lumbar spine. Degenerative change of the
spine with marginal spur formation. Status post left total hip
replacement.</li>
<li>Multiple geographic areas of sclerotic bone change in visible bones
with pedicle involvement, compatible with bone metastases.</li>
</ul></li>
<li>2022-10-25 Pelvis + Lt. Hip Lat
<ul>
<li>Status post left total hip replacement. Mild osteoarthritis change
of right hip joint with joint space narrowing (more at superior aspect),
subchondral sclerosis and marginal spur formation.</li>
</ul></li>
<li>2022-10-25 CXR
<ul>
<li>Ill-defined faint patch at LUL.</li>
<li>Degenerative change of the spine with marginal spur formation.</li>
</ul></li>
<li>2022-10-25 CT - brain
<ul>
<li>Brain atrophy.</li>
</ul></li>
<li>2022-10-25 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Left axis deviation</li>
</ul></li>
<li>2022-09-17 MRI - brain
<ul>
<li>Bony metastases at skull, clivus and C2 vertebral body.</li>
<li>Suspected metastases at pituitary stalk and gland.</li>
</ul></li>
<li>2022-09-16 CT - chest
<ul>
<li>Left breast cancer s/p MRM with bilateral lung meta, liver meta and
mediastinal lymphadenopathy, in progression.</li>
<li>Bone meta. Please correlate with bone scan study.</li>
</ul></li>
<li>2022-06-17 CT - chest
<ul>
<li>S/P mastectomy at left side.</li>
<li>Bilateral lung meta and mediastinal lymphadenopathy</li>
<li>Liver meta</li>
<li>Bone meta.</li>
</ul></li>
<li>2022-04-28 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20210702, more new bone
lesions are noted, suggesting multiple bone metastases in
progression.</li>
</ul></li>
<li>2022-02-05 CT - abdomen
<ul>
<li>S/P mastectomy at left side</li>
<li>Suspected bone meta at L1</li>
<li>S/p Total hip replacement over left side is found. The nails of the
S/p Total hip extends to pelvic cavity.</li>
</ul></li>
<li>2021-07-02 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200210, the lesions in
the left 10th costovertebral junction, L1 spine and sarum are new. Bone
metastases should be considered frist.</li>
<li>The lesion in the L5 spine is a little more evident. Either
degenerative spine disease in a little more severe status or bone
metastasis may show this picture. Please correlate with other clinical
findings for further evaluation.</li>
<li>Suspected benign lesions in the maxilla, L2 spine, right
sternoclavicular junction, bilateral shoulders, S-I joints and
knees.</li>
</ul></li>
<li>2021-05-14 SONO - abdomen
<ul>
<li>Fatty liver, mild to moderate</li>
<li>Suspected fatty infiltration of pancreas</li>
</ul></li>
<li>2020-02-10 Tc-99m MDP whole body bone scan
<ul>
<li>A hot spot at the left femoral head and neck, the nature is to be
determined, suggesting further investigation and follow-up with bone
scan in 3 months.</li>
<li>Suspected benign lesions in the maxilla, L2-5 spines, right
sternoclavicular junction, bilateral shoulders, S-I joints, and
knees.</li>
</ul></li>
<li>2020-02-07 Pelvis &amp; Lt. Hip Lat
<ul>
<li>Osteoporotic change at the left femoral head is noted.</li>
<li>Chip fracture or Marginal osteophyte formation at the lateral aspect
of left acetabulum is noted. please correlate with clinical condition or
CT.</li>
</ul></li>
<li>2018-03-09 Bone densitometry - spine
<ul>
<li>AP L-spines, BMD of L1-4 0.763 gms/cm2, about 2.1 SD below the peak
bone mass (76%) and 0.1 SD above the mean of age-matched women
(102%).</li>
<li>IMP: Osteopenia.</li>
</ul></li>
<li>2018-03-09 Bone densitometry - hip
<ul>
<li>Left hip, BMD is 0.530 gms/cm2, about 2.6 SD below the peak bone
mass (66%) and 0.7 SD below the mean of age-matched people (90%).</li>
<li>IMP: Osteoporosis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-20 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This 72-year-old woman had past history of 1) infilltrating duct
carcinoma of left breast, pT2N0M0, grade II ER: positive (90%), PR:40%,
Her2/neu:equivocal (2+)–FISH NEGATIVE , P53(-), Ki- 67 index: 30%. post
MRM (2013/10/17).</li>
<li>She received the chemotherapy with AC followed by hormone therapy on
2013 then was regularly followed up at ONC OPD. Bone scan on 2022/04/22
showed in comparison with the previous study on 2021/7/2, more new bone
lesions are noted, suggesting multiple bone metastases in
progression.Then she started the CDk4/6 inhibitor with Kisqali and
Femara from July 2022 to August 2022. Hold due to leukopenia and general
weakness.</li>
</ul></li>
<li>A
<ul>
<li>A: Infiltrating ductal carcinoma, grade II, of the left breast, ER:
positive (90%), PR:40%, Her2/neu:equivocal (2+, FISH: negative), stage
pT2N0(cM0), s/p MRM and chemotherapy, with multiple including liver and
bone metastases.</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: Bony metastases at skull, clivus, C2 vertebral body,
pituitary stalk and gland.
<ul>
<li>Goal: palliation</li>
<li>Treatment target and volume: whole brain including bony metastases
at skull, clivus, C2 vertebral body, pituitary stalk and gland.</li>
<li>Technique: 2D</li>
<li>Preliminary planning dose: 3000cGy/15 fractions of the whole brain
including bony metastases at skull, clivus, C2 vertebral body, pituitary
stalk and gland.</li>
</ul></li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and her family (husband and son). They
understand and agree to receive radiotherapy, The treatment planning of
radiotherapy will be started at 1030, 2022-09-28.</li>
</ul></li>
</ul></li>
<li>2022-09-08 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>20220819 Xgeva</li>
<li>However, gingiva swelling was noted today, we need your expertise
for further management, thanks</li>
</ul></li>
<li>A
<ul>
<li>For gingiva swelling</li>
<li>O:
<ul>
<li>Poor oral hygiene with lots of calculus was noted of full
mouth.</li>
<li>Tenderness and swelling of right chin was noted.</li>
<li>Abscess with sinus tract of right anterior mandible. Pus discharged
was noted. Residual root of 42 s/p RCF with gingiva inflammation was
noted</li>
<li>Breast cancer under Xgeva treatment</li>
</ul></li>
<li>A:
<ul>
<li>Periapical abscess with sinus tract of tooth 42</li>
</ul></li>
<li>P:
<ul>
<li>Explained the finding to patient and her family.</li>
<li>Periodontal emergency of right mandible.</li>
<li>Suggest systemic antibiotics treatment.</li>
<li>OPD follow up</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-07 ~ undergoing - Aromasin (exemestane)</li>
<li>2022-10-07 ~ undergoing - Afinitor (everolimus)</li>
<li>2022-03-25 ~ undergoing - Arimidex (anastrozole)</li>
<li>2021-09-10 ~ 2022-03-29 - Kisqali (ribociclib)</li>
<li>2021-07-16 ~ undergoing - Xgeva (denosumab)</li>
<li>2017-01-06 ~ 2022-03-XX - Femara (letrozole)</li>
</ul></li>
</ul>
<div id="section-118" class="section level3">
<h3>==========</h3>
</div>
<div id="section-119" class="section level3">
<h3>2022-11-21</h3>
<ul>
<li>The results of the uric acid lab showed an upward trend and
indicated an increased risk of renal damage. It may be possible to
consider Feburic (febuxostat 80mg) 0.5# QD without the need of adjusting
the dose based on the current level of liver function.
<ul>
<li>2022-11-18 Uric Acid 8.6 mg/dL<br />
</li>
<li>2022-10-31 Uric Acid 6.7 mg/dL<br />
</li>
<li>2022-09-30 Uric Acid 6.1 mg/dL</li>
</ul></li>
</ul>
</div>
<div id="section-120" class="section level3">
<h3>2022-10-26</h3>
<ul>
<li>Cell plasticity constitutes the ability of cancer cells to rapidly
reprogramme their gene expression repertoire, to change their behaviour
and identities, and to adapt to microenvironmental cues. These features
also directly contribute to tumour heterogeneity and are critical for
malignant tumour progression. (ref: Breast cancer as an example of
tumour heterogeneity and tumour cell plasticity during malignant
progression. Br J Cancer 125, 164–175 (2021). <a href="https://doi.org/10.1038/s41416-021-01328-7" class="uri">https://doi.org/10.1038/s41416-021-01328-7</a>). It is
likely that the available gene assay results “ER:positive (90%), PR:40%,
Her2/neu:equivocal(2+, FISH negative), P53(-), Ki-67 index 30%” were
obtained long ago (MRM in 2013). A new gene expression assay might be
beneficial.</li>
<li>The use of Aromasin (exemestane) and Afinitor (everolimus) has been
started since Oct 2022 after a CT image (Sep 2022) indicated that the
disease was in progress.</li>
<li>It does not appear that there is a problem with the active
prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-121" class="section level1">
<h1>700569043</h1>
<div id="section-122" class="section level2">
<h2>221118</h2>
<p>{drug identification}</p>
<p>It was requested that four drugs be identified.</p>
<p>The items identified are as follows:</p>
<ul>
<li>Lipanthyl Supra (fenofibrate 160mg)</li>
<li>Trajenta (linagliptin 5mg)</li>
<li>Crestor (rosuvastatin 10mg)</li>
<li>Bentomin (metformin 500mg)</li>
</ul>
<p>These drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-123" class="section level1">
<h1>701196725</h1>
<div id="section-124" class="section level2">
<h2>221118</h2>
<ul>
<li>diagnosis - 2022-11-04 discharge note
<ul>
<li>Colon adenocarcinoma with obstruction s/p right hemicolectomy on
2021/12/01, pT4aN2bcM0(7/15), G2, LVI(+), PNI(+), CRM(-), stage IVA with
liver metastasis s/p chemotherapy with Avastin(5mg/kg)(self
pay)/FOLFIRI(Campto 120mg/m2, LV 400mg/m2, 5FU 400mg/m2 and 2400mg/m2)
from 2022/03/18~2022/05/26 for 4 cycles, patient refuse therapy with
bilateral lungs, pleura, liver, peritoneal and retroperitoneal
metastases s/p palliative chemotherapy with FOLFIRI from 2022/09/12</li>
<li>Peptic ulcer, site unspecified, unspecified as acute or chronic,
without hemorrhage or perforation</li>
<li>Type 2 diabetes mellitus without complications</li>
<li>Chronic viral hepatitis B without delta-agent</li>
<li>Essential (primary) hypertension</li>
<li>Unspecified hemorrhoids</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-11-02 CT - abdomen
<ul>
<li>History:
<ul>
<li>20211120 CT:Dilatation of small bowel and collapse of colon, r/o
obstruction at ileocecal valve. Suspect wall thickening of terminal
ileum and Small bowel feces sign in distal ileum +.</li>
<li>20211124 colonoscopy: One ulcerative tumor with about 1/2
circumferential involvement at ICV and extending to A-colon.</li>
<li>20211201 S/P right hemicolectomy:pT4aN2b, if cM0, stage IIIC<br />
</li>
<li>20220712 CT：Peritoneal carcinomatosis, lung and liver
metastases.</li>
</ul></li>
<li>Findings:
<ul>
<li>Prior CT identified multiple hypodense masses on both hepatic lobes
are noted again, increasing in size and number that are c/w liver
metastases with progressive disease.</li>
<li>Prior CT identified few metastases on both lung are noted again,
mild increasing in size that is c/w progressive disease.</li>
<li>There is massive ascites and soft tissue nodules in the omentum and
mesentery that is c/w carcinomatosis. Please correlate with ascites
cytology.</li>
<li>S/P right hemicolectomy</li>
<li>Few small gallstones are noted.</li>
<li>There is no hyper-or hypodense lesion in the biliary system,
pancreas, spleen &amp; both kidney.</li>
<li>There is no lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
</ul></li>
<li>IMP:
<ul>
<li>Peritoneal carcinomatosis, lung and liver metastases show
progressive disease.</li>
</ul></li>
</ul></li>
<li>2022-09-27 All-RAS + BRAF mutations assay
<ul>
<li>All-RAS mutations assay
<ul>
<li>Detection range
<ul>
<li>KRAS codon 12, 13, 59, 61, 117, 146</li>
<li>NRAS codon 12, 13, 59, 61, 117, 146</li>
</ul></li>
<li>Results
<ul>
<li>Detected (KRAS codon 12 GGT&gt;GAT, p.G12D)</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with RAS mutation may not benefit from the anti-EGFR antibody treatment.
Patients with no RAS mutation are more likely to have disease control by
using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
<li>BRAF mutations assay
<ul>
<li>Detection range
<ul>
<li>BRAF codon 600: p.V600M, p.V600L, p.V600E, p.V600A, p.V600G,
p.V600K, p.V600R</li>
</ul></li>
<li>Results
<ul>
<li>There was no variant detected in the BRAF gene.</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with BRAF mutation maynot benefit from the anti-EGFR antibody treatment.
Patients with no BRAF mutation are more likely to have disease control
by using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-06 SONO - abdomen
<ul>
<li>Chronic liver parenchymal disease</li>
<li>c/w liver and lymph node metastasis</li>
<li>Ascites</li>
<li>Minimal pleural effusion</li>
</ul></li>
<li>2022-09-05 Patho - stomach biopsy
<ul>
<li>Esophagus, 25 cm to EC junction, biopsy — Ulcer, with no viable
tissues</li>
<li>Microscopically, it shows necrotic debris, granulation tissue,and
abundant lymphocytic and leukocytic infiltrate. No viable tissue is
seen.</li>
<li>Immunohisotchemical stain reveals CK(-), CD20(-), CD3(-),
LAC(focal+),and CMV(-).</li>
</ul></li>
<li>2022-09-05 Patho - stomach biopsy
<ul>
<li>Stomach, angle, biopsy — ulcer with Helicobacter infection</li>
<li>Microscopically, it shows ulcer with ulcerative debris, focal
intestinal metaplasia and leukocytic infiltrate.<br />
</li>
<li>Mild Helicobacter-like bacilli are seen.</li>
</ul></li>
<li>2022-09-02 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
<li>Increased pulmonary vasculature is found.</li>
</ul></li>
<li>2022-09-02 KUB
<ul>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>Stool impaction at the abdominal cavity is noted.</li>
</ul></li>
<li>2022-09-02 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis with ulceration, LA-D</li>
<li>Superficial gastritis, s/p CLO test</li>
<li>Gastric ulcer, angle, s/p biopsy*4</li>
<li>CLO test (+)</li>
</ul></li>
<li>Suggestion
<ul>
<li>PPI pump and algitab</li>
<li>Pursue pathology</li>
<li>GI OPD for HP eradication after discharge</li>
</ul></li>
</ul></li>
<li>2022-07-12 CT - abdomen
<ul>
<li>Findings
<ul>
<li>S/P colon operation.</li>
<li>A nodule (5.4mm) at LLL.</li>
<li>Some soft tissues in peritoneal cavity with ascites.</li>
<li>Multiple liver tumors.</li>
<li>Some calcifications in peritoneal cavity.</li>
<li>Normal appearance of spleen, pancreas, adrenals and kidneys.</li>
<li>Tiny gallbladder stones.</li>
<li>Intact bony structures.</li>
<li>No enlarged lymph node.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
</ul></li>
<li>IMP:
<ul>
<li>S/P colon operation. Peritoneal carcinomatosis, lung and liver
metastases.</li>
</ul></li>
</ul></li>
<li>2022-05-27 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Liver cirrhosis with borderline splenomegaly</li>
<li>Hepatic hypoechoic lesions, multiple, both lobe, suspected
metastases</li>
<li>Gallbladder polyp</li>
<li>Cholecystopathy</li>
<li>Small amount ascites</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study</li>
</ul></li>
</ul></li>
<li>2022-03-01 CT - abodmen, pelvis
<ul>
<li>Clinical history: 71 y/o male patient with cecal cancer s/p OP and
C/T.</li>
<li>Findings
<ul>
<li>S/P right colectomy with regional dirty mesentery fat plane, post-op
change? Suggest follow up.<br />
</li>
<li>There are several low density tumors (up to 1.4cm) in both lobes of
the liver, suspected liver metastasis.</li>
<li>Presence of gallbladder stone.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P right hemicolectomy with regional dirty mesentery fat plane,
post-op change? Suggest follow up.<br />
</li>
<li>Liver tumors, suspect liver metastasis.</li>
</ul></li>
</ul></li>
<li>2021-12-02 Patho - colon segmental resection for tumor
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Tumor, ascending colon, right hemicolectomy — Adenocarcinoma<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Resection margins, bilateral, ditto — Free from tumor<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Lymph node, mesocolic, dissection — Tumor metastasis (7/15) with
extracapsular extension (3/7)<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Appendix, right hemicolectomy — Tumor emboli present, but no direct
invasion<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>AJCC pathologic stage — pT4aN2b, if cM0, stage IIIC<br />
</li>
</ol></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li><ol style="list-style-type: decimal">
<li>Histology: adenocarcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histology Grade: G2-3: moderately to poorly differentiated<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Depth of invasion: visceral peritoneum and some tiny nodules at
ileal wall<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Angiolymphatic invasion: Present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Perineural invasion: Present<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Discontinuous extramural tumor extension: NOT identified<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Circumferential (radial) margin of rectosigmoid: NOT involved<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Lymph node metastasis, mesocolic: tumor metastasis (7/15)<br />
</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymph node metastasis, IMA / SMA: N/A<br />
</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Extranodal involvement: Present (3/7)<br />
</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Pathological TNM Stage: pT4aN2b<br />
</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>Type of polyp in which invasive carcinoma arose: N/A<br />
</li>
</ol></li>
<li><ol start="13" style="list-style-type: decimal">
<li>Additional pathologic findings: focal tumor necrosis<br />
</li>
</ol></li>
<li><ol start="14" style="list-style-type: decimal">
<li>TNM descriptors: N/A<br />
</li>
</ol></li>
<li><ol start="15" style="list-style-type: decimal">
<li>Tumor regression grading S/P CCRT: N/A</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-11-26 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (162 - 47) / 162 = 70.99%
<ul>
<li>Dilated LA, LV</li>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Thick IVS, Impaired LV relaxation</li>
<li>Mild MR,TR,AR</li>
</ul></li>
</ul></li>
<li>2021-11-25 Patho - colorectal polyp
<ul>
<li>Colon, ileocecal valve, biopsy — Adenocarcinoma, moderately
differentiated<br />
</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and MSH6(+).<br />
</li>
</ul></li>
<li>2021-11-24 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Suspect advanced colon cancer, ICV, s/p biopsy(A), terminal ileum
maybe involved.</li>
<li>Colon polyp, proximal T-colon, s/p cold polypectomy(B) and clip</li>
<li>Colon polyp, T-colon, s/p hot polypectomy(C) and clip</li>
<li>ICV stenosis.</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-11-23 Small bowel series
<ul>
<li>Small bowel dilatation, suspected partial obstruction at distal
small bowel. Suggest clinical correlation</li>
</ul></li>
<li>2021-11-20 CT - abdomen
<ul>
<li>Imaging Report Form for Colorectal Carcinoma</li>
<li>Impression ( Imaging stage ): T:T4(T_value) N:N2(N_value)
M:M0(M_value)</li>
</ul></li>
<li>2021-11-20 KUB
<ul>
<li>Dilatation of small bowel and collapse of colon, suspected
obstruction</li>
</ul></li>
<li>2021-11-20 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right bundle branch block</li>
</ul></li>
<li>2021-11-11 Abdomen - standing (diaphragm)
<ul>
<li>Stool retention in the colon</li>
</ul></li>
<li>2021-11-05 Small Intestinal Series
<ul>
<li>Normal haustration of the jejunum and ileum.</li>
<li>The peristasis of the small intestine is intact.</li>
<li>No evidence of stenotic or obstructive lesion in the study.</li>
<li>The transit time is 4 hours</li>
</ul></li>
<li>2021-11-04 Abdomen - standing (diaphragm)
<ul>
<li>Presence of ileus.</li>
</ul></li>
<li>2021-11-02 CT - abdomen
<ul>
<li>Dilated intestines and colon, suspected enterocolitis</li>
</ul></li>
<li>2021-11-02 KUB
<ul>
<li>Dilated bowel gas, suspect ileus. Degenerative change of the spine
with marginal spur formation. Calcified nodules in the pelvic cavity,
could be urinary bladder stone.</li>
</ul></li>
<li>2021-11-02 ECG (emergency)
<ul>
<li>Sinus tachycardia</li>
<li>Right bundle branch block</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>T wave abnormality, consider inferolateral ischemia</li>
</ul></li>
<li>2019-09-24 ECG
<ul>
<li>Right bundle branch block</li>
<li>Nonspecific T wave abnormality</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-11-25 Colon and Rectal Surgery
<ul>
<li>Q
<ul>
<li>This is a 70-year-old male patient with the underlying diseases DM,
HCVD under medicine control. This time, he is presented with LUQ
abdominal pain and fullness, nausea sensation, no stool passage, and
intermittent fever for 2 days .</li>
<li>He had ileus on 20211103, and AAD on 20211105 under small serious
normal. Under the impression of ileus again, he came to our ward to do
further management and examination.</li>
<li>On 20211120 abdominal CT, Small bowel dilatation, suspected
obstruction, Suspect wall thickening of terminal ileum with regional
lymphadenopathy.</li>
<li>On 20211124 colonscope found suspect advanced colon cancer, ICV, s/p
biopsy, terminal ileum maybe involved.</li>
<li>We had arranged him to do 2D heart echo and PFT.</li>
</ul></li>
<li>A
<ul>
<li>A: Tumor of cecum with partial obstruction</li>
<li>P: The operaion of right hemicolectomy is indicated</li>
</ul></li>
</ul></li>
<li>2021-11-22 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>This is his second-time intestinal ileus, so we would like to
consult your expertise for him. Does he need the surgery survey?</li>
</ul></li>
<li>A
<ul>
<li>A: ileus, suspected colonic lesion ot terminal ileum lesion with
mechanical obstruction</li>
<li>P: Please arrange colonoscopy to rule out colonic lesion ot terminal
ileum lesion. If no colonic lesion ot terminal ileum lesion, but
symptoms persisted, laparoscopy exam may be considered.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-17 - bevacizumab 5mg/kg 300mg 90min + irinotecan 150mg/m2
250mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 2400mg/m2
4200mg 46hr (Avastin + FOLFIRI, Q2WK)</li>
<li>2022-11-02 - bevacizumab 5mg/kg 300mg 90min + irinotecan 150mg/m2
250mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 2400mg/m2
4200mg 46hr (Avastin + FOLFIRI, Q2WK)</li>
<li>2022-10-17 - bevacizumab 5mg/kg 300mg 90min + irinotecan 150mg/m2
250mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 2400mg/m2
4200mg 46hr (Avastin + FOLFIRI, Q2WK)</li>
<li>2022-09-27 - irinotecan 150mg/m2 250mg 90min + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-09-12 - irinotecan 120mg/m2 200mg 90min + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-08-16 ~ 2022-08-30 - UFT (tegafur 100mg, uracil 224mg)/cap 2#
BID PO</li>
<li>2022-06-14 ~ 2022-08-09 - Xeloda (capecitabine 500mg/tab) 1# TID
PO</li>
<li>2022-05-26 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
220mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2
700mg 10min + fluorouracil 2400mg/m2 4400mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-04-25 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
220mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2
700mg 10min + fluorouracil 2400mg/m2 4400mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-03-18 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
220mg 90min + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2
700mg 10min + fluorouracil 2400mg/m2 4400mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-02-23 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2 700mg
10min + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFOX, Q2WK)</li>
<li>2022-02-09 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2 700mg
10min + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFOX, Q2WK)</li>
<li>2022-01-19 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2 700mg
10min + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFOX, Q2WK)</li>
<li>2022-01-05 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 85mg/m2
150mg 2hr + leucovorin 400mg/m2 700mg 2hr + fluorouracil 400mg/m2 700mg
10min + fluorouracil 2400mg/m2 4200mg 46hr (Avastin + FOLFOX, Q2WK)</li>
</ul></li>
</ul>
<div id="section-125" class="section level3">
<h3>==========</h3>
</div>
<div id="section-126" class="section level3">
<h3>2022-11-18</h3>
<ul>
<li>CT imaging on 2022-11-02 revealed peritoneal carcinomatosis and lung
and liver metastases and a progressive disease was present.</li>
<li>In the past two months, more than 10 kg of weight have been lost (63
kg 2022-11-17 &lt;- 74 kg 2022-09-22). The use of appetite stimulants
(e.g. megestrol) may be beneficial.</li>
<li>Based on the updated elevated bilirubin levels, there are no issues
associated with the irinotecan dose.</li>
</ul>
</div>
<div id="section-127" class="section level3">
<h3>2022-10-18</h3>
<ul>
<li>The patient with mCRC has received FOLFOX/FOLFIRI plus bevacizumab
since early 2022.</li>
<li>Regorafenib might be an option as a subsequent treatment if the
patient’s disease becomes resistant, and would be covered by the
national health insurance program without prior use of cetuximab or
panitumumab due to the detected KRAS mutation (2022-09-27 All-RAS + BRAF
mutations assay). Regorafenib does not require dosage adjustment in
patients with mild or moderate hepatic impairment (total bilirubin
1.79mg/dL 2022-10-11 &lt; 3 times ULN), closely monitor for adverse
effects. The drug can be administered orally 160 mg once daily for the
first 21 days of each 28-day cycle; continue until disease progression
or unacceptable toxicity.</li>
<li>Lonsurf (trifluridine/tipiracil) is also covered by NHI, however the
drug is not recommended for this patient due to his total bilirubin &gt;
1.5 times ULN.</li>
</ul>
</div>
<div id="section-128" class="section level3">
<h3>2022-09-28</h3>
<ul>
<li>The serum glucose level remains within acceptable limits with the
use of patient-carried Uformin (metformin), Amepiride (glimepiride), and
Januvia (sitagliptin).</li>
<li>Human albumin is used to treat hypoalbuminemia (3.2g/dL 2022-09-22)
associated with liver cirrhosis (ABD Sono 2022-09-06).</li>
<li>The total bilirubin level was 1.51mg/dL (above 1.5 x ULN,
2022-09-22); the treated dose of irinotecan was 150mg/m2 (2022-09-27),
not exceeding the recommended limit of 200mg/m2.</li>
</ul>
</div>
</div>
</div>
<div id="section-129" class="section level1">
<h1>701446396</h1>
<div id="section-130" class="section level2">
<h2>221118</h2>
<ul>
<li>diagnosis
<ul>
<li>Right ovarian cancer (Clear cell adenocarcinoma) pT1a pN0 ;
AJCC/FIGO pStage: IA, at least. post debulking surgery on
2022/08/26</li>
<li>Unspecified viral hepatitis B without hepatic coma.</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-09 SONO - breast
<ul>
<li>Diagnosis: Bil. fibroadenomas</li>
<li>Suggestion: regular OPD follow up</li>
<li>BI-RADS: 2. benign finding</li>
</ul></li>
<li>2022-11-02 Mammography
<ul>
<li>Impression: Dense breast. Probably benign calcifications in
bilateral breasts. Suggest clinical correlation and follow up.</li>
<li>BI-RADS: Category 2: benign findings.-annual screening.</li>
</ul></li>
<li>2022-08-29 Patho - soft tissue tumor, extensive resection
<ul>
<li>Ovarian Fallopian tube Peritoneum Cancer Checklist (Based on AJCC
8th ed. and FIGO 2014)</li>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Ovary, right, oophorectomy with frozen section (F2022-400) — Clear
cell adenocarcinoma, high grade.
<ul>
<li>IHC stains: Napsin-A (+), P53: (wild type), PAX-8 (+), CK20 (-), ER
(-, 0%)</li>
</ul></li>
<li>Ovary, left , salpingectomy (S2022-14311) — Free.</li>
<li>Fallopian tube, right, salpingectomy — Free</li>
<li>Fallopian tube, left, salpingectomy — free</li>
<li>Uterus, corpus, total hysterectomy — myoma; No malignancy.</li>
<li>Uterus, cervix, total hysterectomy — free</li>
<li>Omentume, omentectomy — free</li>
<li>Lymph node, dissection — free</li>
<li>pT1a pN0 (if cM0); AJCC/FIGO pStage: IA, at least.
<ul>
<li>NOTE: According to AJCC staging manual 2017 8th edition page 10.
“Pathologist should not report any M category unless appropriate for the
specimen evaluated. Only the managing physician can assign cM0 after
taking into account physical examination, image, and other information”.
However, the pathologists are ordered by this hospital adminstration
(including the chiefs of cancer committee, medical department and
radiation oncology) to assign the “cM” category, although pathologists
are not in the position of doing so.</li>
</ul></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION:
<ul>
<li>Histologic type: clear cell adenocarcinoma<br />
</li>
<li>Histologic grade: ghigh grade</li>
<li>Contralateral ovary involvement: absent</li>
<li>Tumor side ovarian surface involvement: absent</li>
<li>Contralateral ovary surface involvement: absent</li>
<li>Right tube involvement: absent<br />
</li>
<li>Left tube involvement: absent</li>
<li>In situ adenocarcinoma in right and/or left fallopian tube:
absent</li>
<li>Right adnexa soft tissue involvement: absent</li>
<li>Left adnexa soft tissue involvement: absent</li>
<li>Pelvic soft tissue involvement: absent</li>
<li>Uterine serosa involvement: absent</li>
<li>Omentum involvement: absent</li>
<li>Uterine Cervix involvement: absent</li>
<li>Endometrium involvement: absent</li>
<li>Myometrium involvement: absent</li>
<li>Appendix involvement: not received</li>
<li>Largest Extrapelvic Peritoneal Focus - none</li>
<li>Peritoneal/Ascitic Fluid-Negative for malignancy
(normal/benign)</li>
<li>Regional Lymph Nodes: - free</li>
<li>Other organs or specimens involvement: none.</li>
</ul></li>
</ul></li>
<li>2022-08-26 Frozen section
<ul>
<li>Preliminary diagnosis: right ovary: malignant</li>
</ul></li>
<li>2022-08-26 Patho - stomach biopsy
<ul>
<li>Gastric polyp, cardia, biopsy — Compatible with fundic gland
polyp</li>
</ul></li>
<li>2022-08-24 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible Left atrial enlargement</li>
<li>Septal infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-15 CT - abdomen
<ul>
<li>Findings
<ul>
<li>Cystic tumor, 13.8cm in the pelvic cavity, with soft tissue
component, suspected right ovarian malignancy.</li>
<li>Liver cyst, 0.77cm in S2.</li>
<li>Soft tissue tumor, 2.7cm in the uterine fundus region, suspected
uterine myoma.</li>
</ul></li>
<li>Imaging Report Form for Ovarian Carcinoma
<ul>
<li>Impression (Imaging stage): T:T1(T_value) N:N0(N_value)
M:M0(M_value) STAGE: Ia (Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-08-15 Gynecologic ultrasonography
<ul>
<li>Suspected pelvis mass: 109X75mm with papillary: 25x19mm</li>
<li>Suspected pelvis mass or uterine myoma: 98x77, RI: 0.47</li>
<li>Adenomyosis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-28 Chinese Medicine
<ul>
<li>Q
<ul>
<li>The 59 y/o woman has right ovarian cancer (Clear cell
adenocarcinoma) pT1a pN0 ; AJCC/FIGO pStage: IA, at least. post
debulking surgery on 2022/08/26. She was admitted for chemotherapy. She
asks for your help for assessment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-08-26 debulking surgery (total abdominal hysterectomy + bil
salpingo-oophorectomy + BPLND + partial omentectomy) + enterolysis
<ul>
<li>uterus and bil adnexa
<ul>
<li>Uterus: 12x8x5 cm</li>
<li>corpus – adenomyosis-like with some uterine myomas</li>
<li>cervix – seemed free of cancer invasion</li>
<li>right adnexa –</li>
<li>ROV 15x14cm tumor with large solid and cystic contents, containing
chocolate fluid 600 c.c</li>
<li>Frozen section of ROV–malignancy</li>
<li>right tube – np</li>
<li>left adnexa: normal-looking</li>
<li>bowels, omentum, liver– seemed free of cancer invasion</li>
<li>Bilateral pelvic iliac and obturator LNs was removed</li>
<li>left iliac LNs</li>
<li>left obturator LNs</li>
<li>right iliac LNs</li>
<li>right obturator LNs</li>
<li>CDS: no ascites (washing cytology was sent) but pelvic adhesion was
noted between right adnexa, pelvis, peritoneum and bowels s/p
enterolysis A 7mm JP drain was placed in CDS</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-17 paclitaxel 175mg/m2 268mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2022-10-27 paclitaxel 175mg/m2 268mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2022-10-06 paclitaxel 160mg/m2 240mg 3hr + carboplatin AUC 5 600mg
2hr (paclitaxel first time 160, next 175)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The lab results (2022-11-17) were grossly normal and should be
considered satisfactory for the scheduled chemotherapy.</li>
<li>The currently used [paclitaxel + cisplatin] regimen is preferable
since carboplatin produces equivalent response rates and survival
outcomes to cisplatin and is associated with less toxicity, while
paclitaxel is less myelosuppressive than docetaxel. There is, however, a
higher risk of neuropathy, myalgias, and weakness associated with
paclitaxel in comparison with docetaxel, which should be monitored
regularly.</li>
<li>The underlying condition of viral hepatitis B is appropriately
managed with Vemlidy (tenofvir alafenamide).</li>
</ul>
</div>
</div>
<div id="section-131" class="section level1">
<h1>701262855</h1>
<div id="section-132" class="section level2">
<h2>221117</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 6 items.</p>
<p>the 5 items are identified as following while the other 1 item
remains unknown.</p>
<p>Indershin (indomethacin 25mg) Anrokin (chlorzoxazone 200mg) Leflo
(levofloxacin 500mg) Ketofen (ketoprofen 50mg) Decan (dexamethasone
0.75mg)</p>
<p>The drugs were packaged as one dose in an opaque bag, which was
opened irreversibly. The checked drugs will not be returned to the ward
due to the possibility of contamination.</p>
</div>
</div>
<div id="section-133" class="section level1">
<h1>700399143</h1>
<div id="section-134" class="section level2">
<h2>221116</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-03, -10-30, -10-27 CXR
<ul>
<li>Massive right side Pleura effusion causing mediastinum shift to left
side.</li>
<li>There are patchy opacity on right lung and nodular opacity
projecting in left lung. Please correlate with CT.</li>
</ul></li>
<li>2022-10-27 CT - chest
<ul>
<li>Indication: Malignant neoplasm of right main bronchusLung cancer,
clinical trail</li>
<li>Findings
<ul>
<li>Huge soft tissue mass at right lung up to 16.cm with massive right
pleural effusion is found. In enlargement.</li>
<li>Left lung nodules are found up to 1.7cm in largest dimension is
found. In comparison with CT dated on 2022-09-12, the lesion enlarged
markedly.</li>
<li>Marked paraseptal Emphysematous change over both lungs more on upper
lobes is found.</li>
<li>Right axillary lymphadenopathy is found.</li>
</ul></li>
<li>Imp:
<ul>
<li>Huge right lung cancer with lung to lung meta, right axillary
lymphadenopathy, in progression.</li>
</ul></li>
</ul></li>
<li>2022-10-06 ROS1 FISH
<ul>
<li>Result
<ul>
<li>Number of invasive tumor cells counted: 50</li>
<li>Number of cells (%) classified as negative: 49 (98%)</li>
<li>Number of cells (%) classified as positive: 1 (2%)</li>
</ul></li>
<li>Interpretation
<ul>
<li>Rearrangement of ROS1 gene is NOT detected. Patients with NO ROS1
gene arrangement may not benefit from therapy with ROS1-targeted
inhibitors.</li>
</ul></li>
</ul></li>
<li>2022-10-06 ALK IHC
<ul>
<li>ALK immunostaining result: Negative</li>
<li>The immunostaining of the section slide labeled S2022-15576, using
ALK antibody D5F3 along with a Ventana autostainer system, revealed no
staining in tumor cells.</li>
</ul></li>
<li>2022-10-04 MRI - brain
<ul>
<li>No intracranial metastatic lesion.</li>
</ul></li>
<li>2022-09-27 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Mildly increased activity in some L-spines and sacrum. Degenerative
change may show this picture. Please correlate with other imaging
modalities for further evaluation.</li>
<li>Some hot and faint hot spots in bilateral rib cages. The nature is
to be determined (post-traumatic change? other nature?). Please follow
up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders and hips, compatible with
benign joint lesions.</li>
</ul></li>
<li>2022-09-22 PD-L1 (22C3)
<ul>
<li>PD-L1 immunostaining result</li>
<li>Tumor Proportion Score (TPS) assessment: &gt;= 50%</li>
<li>Tumor Proportion Score (TPS): 85%</li>
</ul></li>
<li>2022-09-22 EGFR mutation
<ul>
<li>Result: No mutation was detected at exons 18 (G719X), 19
(Deletions), 20 (T790M, S768I, Insertions), 21 (L858R, L861Q) of EGFR
gene in this specimen.</li>
</ul></li>
<li>2022-09-15 Patho - bronchus biopsy
<ul>
<li>Lung, RLL, CT-guide biopsy — poorly differentiated non-small cell
carcinoma, origin?</li>
<li>Sections show large pleomorphic tumor cells infiltrating in a
fibrotic stroma with marked tumor necrosis.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), CK5/6(-),
GATA3(+), CDX2(focal weak +), TTF-1(-), Napsin A(-), CD56(-), and
p40(-). Please correlate with the clinical presentation and image study
to exclude other tumor origin.</li>
</ul></li>
<li>2022-09-12 CT - chest
<ul>
<li>Imaging Report Form for Lung Carcinoma</li>
<li>Impression (Imaging stage): T:T4(T_value) N:N2(N_value)
M:M1a(M_value) STAGE:____(Stage_value)</li>
</ul></li>
<li>2022-09-12 CXR
<ul>
<li>Huge mass lesion over right lung. Suggest check CT scan.</li>
</ul></li>
<li>2022-08-01 T-spine AP + Lat.
<ul>
<li>Large patchy consolidation over RUL.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-11-03 - pembrolizumab 100mg 1hr</li>
<li>2022-10-31 - carboplatin AUC 2 300mg 2hr D1 + paclitaxel 80mg/m2
120mg 1hr D2</li>
</ul></li>
</ul>
<p>[assessment, not posted]</p>
<ul>
<li>There were no mutations or arrangements detected for EGFR, ALK, or
ROS1. There is a tumor proportion score of 85% greater than 50% for
PD-L1. In this case, the [carboplatin + paclitaxel + pembrolizumab]
regimen is appropriate.</li>
</ul>
</div>
</div>
<div id="section-135" class="section level1">
<h1>700016065</h1>
<div id="section-136" class="section level2">
<h2>221115</h2>
<ul>
<li>diagnosis - 20221114 admission note
<ul>
<li>Malignant neoplasm of esophagus, unspecified</li>
<li>Chronic viral hepatitis B without delta-agent</li>
<li>Chronic hepatitis, unspecified</li>
<li>Unspecified cirrhosis of liver</li>
</ul></li>
<li>past history - 20221114 admission note
<ul>
<li>HBV and alcohol related to liver cirrhosis, Episode hepatic
encephalopathy times on 2009</li>
<li>Hemorroid bleeding on 2009.05</li>
<li>Reflux esophagitis, gastric ulcer, duodenal ulcer and esophageal
varices history for years</li>
<li>CAD under medication treatment for months</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-11-08 SONO - abdomen
<ul>
<li>Cirrhosis of liver</li>
<li>Splenomegaly, mild</li>
<li>Poor echo window due to inter-position of colon between liver and
abdominal wall</li>
<li>Collateral vessels, splenic hilum</li>
</ul></li>
<li>2022-09-22 Miniprobe Endoscopic Ultrasound
<ul>
<li>Esophageal cancer, middle and lower esophagus, T3 (suspicioius N1)
Mx</li>
</ul></li>
<li>2022-09-21 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Faint hot spots in both rib cages, the nature is to be determined
(post-traumatic change or other nature ?), suggesting follow-up with
bone scan in 3 months for further evaluation.</li>
<li>Suspected benign lesions in the maxilla, mandible, some C-, T- and
L-spine, bilateral sternoclaviculr junctions, shoulders, S-I joints,
hips, and left knee.</li>
</ul></li>
<li>2022-09-06 Patho - esophageal biopsy
<ul>
<li>Esophagus, 30 cm below incisor, biopsy — modertaely differentiated
squampus cell carcinoma</li>
<li>Microscopically, section shows moderately differentiated squamous
cell carcinoma consisting of nests of squamous tumor cells in
infiltrative growth pattern. The tumor cells have abundant eosinophilic
cytoplasm, round to oval nuclei, prominent nucleoli, pleomorphism,
hyperchromasia, higher necleus to cytoplasm ratio and mitiotic
activity.</li>
</ul></li>
<li>2022-09-05 Panendoscopy
<ul>
<li>Esophageal cancer, middle esophagus, s/p biopsy</li>
<li>Advance esophageal lesion, middle and lower esophagus</li>
<li>Reflux esophagitis, lower esophagus, LA classification, grade B</li>
<li>Superfical gastritis, antrum</li>
</ul></li>
<li>2022-03-07 CT - abdomen
<ul>
<li>Indication
<ul>
<li>Alcoholic + HBV related, Liver cirrhous with hepatic
encephalopathy</li>
<li>2021/12/20: echo and lab stable, follow up 3 months later by lab and
CT</li>
</ul></li>
<li>Findings
<ul>
<li>Severe splenomegaly and Irregular hepatic surface with parenchymal
nodularity indicate liver cirrhosis.</li>
<li>Significant splenic varices formation with splenorenal shunt is also
noted.</li>
</ul></li>
<li>Imp
<ul>
<li>Liver cirrhosis with varices formation and splenorenal shunt</li>
<li>No evidence of hepatic tumor in the study.</li>
</ul></li>
</ul></li>
<li>2021-06-29 SONO - abdomen
<ul>
<li>Cirrhosis of liver</li>
<li>Splenomegaly, mild</li>
<li>Colleteral vessels, LUQ of abdomen</li>
</ul></li>
<li>2021-04-05 CT - abdomen
<ul>
<li>Liver cirrhosis with portal hypertension, left splenorenal shunt and
splenomegaly.</li>
<li>Much stool retention in colon.</li>
</ul></li>
<li>2020-05-06 CT - abdomen
<ul>
<li>Liver cirrhosis with splenomegaly and varices formation.</li>
<li>No evidence of hepatic tumor in the study.</li>
</ul></li>
<li>2019-11-19 SONO - abdomen
<ul>
<li>Cirrhosis of liver</li>
<li>Part of right lobe masked by gas</li>
<li>Splenomegaly, mild</li>
</ul></li>
<li>2019-08-27 SONO - abdomen
<ul>
<li>Cirrhosis of liver</li>
<li>Splenomegaly, mild</li>
<li>Spleno-renal shunt</li>
</ul></li>
<li>2019-05-31 CT - abdomen
<ul>
<li>Liver cirrhosis and portal hypertension.</li>
<li>Splenomegaly.</li>
</ul></li>
<li>2019-03-19 SONO - abdomen
<ul>
<li>Cirrhosis of liver</li>
<li>Splenomegaly, mild</li>
</ul></li>
<li>2018-07-05 CT - abdomen
<ul>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2017-08-02 CT - abdomen
<ul>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2017-02-17 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (118 - 31) / 118 = 73.73%
<ul>
<li>M-mode (Teichholz) = 73</li>
</ul></li>
<li>Septal hypertrophy with Gr I LV diastolic dysfunction; dilated
LA.</li>
<li>Normal LV and RV systolic function.</li>
<li>Mild MR; mild TR.</li>
<li>VPC bigeminy.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Metoclopramide is recommended to be given at a dose of 5 mg four
times daily (maximum dose: 20 mg) for patients with moderate or severe
hepatic impairment (Child-Pugh class B or C). The medication is
currently prescribed in both oral and IV forms, with a dose of 3.84mg PO
TIDAC and 10mg IVD PRNQ6H.</li>
<li>As far as morphine for patients with hepatic impairment is
concerned, the manufacturer’s labeling does not provide any dosage
adjustments. Pharmacokinetics remain unchanged in mild liver disease;
substantial extrahepatic metabolism may occur. There may be a need to
adjust the dosage in patients with cirrhosis due to increases in
half-life and AUC.</li>
<li>A dose adjustment is not required for any other drug in the active
prescription.</li>
</ul>
</div>
</div>
<div id="section-137" class="section level1">
<h1>700054842</h1>
<div id="section-138" class="section level2">
<h2>221115</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-09 CT - abdomen
<ul>
<li>Indication: liver mass</li>
<li>CC:
<ul>
<li>Nausea and diarrhea for 2 weeks. Dizziness.</li>
<li>Abdominal fullness and passage of black stools for 2 weeks.</li>
<li>Tea-colored urine was noted. Tense leg edema for 10 days.</li>
</ul></li>
<li>Past history:
<ul>
<li>An oral caner patient and received operations and RT since
2013/2/15. He has sleeping problem and abnormal taste in his mouth after
operation and RT. He quit betel nut chewing and smoking in his past
years. He had been received induction chemotherapy, operations and
adjuvant RT due to oral cancer at his left lower gum since 2011/11.</li>
</ul></li>
<li>This patient did not receive IV contrast administration. Small
visceral, intra-abdominal and retroperitoneal lesion may be difficult to
detect. Either vascular patency or organ pefusion status can not be
determined without IV contrast.</li>
<li>Findings:
<ul>
<li>There is hepatomegaly (the greatest cranial-caudal dimension
measuring 21.2 cm) and infiltrative hypodense masses on both hepatic
lobes.
<ul>
<li>Metastases on both hepatic lobes are highly suspected.</li>
<li>The tumor margin is hard to define in non-enhanced CT. Please
correlate with contrast enhanced dynamic CT or non-enhanced MRI.</li>
<li>In addition, There is minimal dilatation of right lobe inferior
segment IHDs that may be tumor compression.</li>
<li>Please correlate with serum alk-p and bilirubin level.<br />
</li>
</ul></li>
<li>There is a soft tissue lesion in left para-aortic space, 2.2 cm in
size that may be metastatic node (Srs:201 Img:26) .</li>
<li>There is ascites.</li>
<li>There is lack of subcutaneous fat that may be cachexia status and
hypoalbuminemia.</li>
<li>A renal cyst measuring 1.9 cm in right middle pole is noted.</li>
<li>There is no hyper-or hypodense lesion in the gallbladder, ,
pancreas, spleen &amp; left kidney.<br />
</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>IMP:
<ul>
<li>Metastases on both hepatic lobes are highly suspected.</li>
<li>Metastatic node in left para-aortic space 2.2 cm.</li>
<li>Ascites</li>
</ul></li>
</ul></li>
<li>2022-11-04 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Liver tumor, right lobe, suspicious HCC with main and right portal
vein encasement.</li>
<li>Liver hemangioma, S2</li>
<li>Renal cyst, right</li>
<li>Ascites, mild</li>
</ul></li>
<li>Suggestion
<ul>
<li>arrange liver dynamic CT and correlate with tumor markers.</li>
</ul></li>
</ul></li>
<li>2022-08-16 KUB and lateral L-spine
<ul>
<li>Degenerative change of the thoracic and lumbar spine with spurs
formation and narrowed intervertebral disc spaces.</li>
</ul></li>
<li>2019-05-28 MRI - nasopharynx
<ul>
<li>Post OP at left oral cavity and mandible, stationary.</li>
</ul></li>
<li>2018-08-03 MRI - nasopharynx
<ul>
<li>Prominent soft tissu in the right lower gingiva. Nature?</li>
</ul></li>
<li>2017-11-24 MRI - L-spine
<ul>
<li>mild retrolisthesis at L2-3.</li>
<li>herniated discs in the L2/3 and L3/4 discs</li>
<li>annulus tears in the L4/5 and L5/S1 discs</li>
</ul></li>
<li>2017-11-23 MRI - nasopharynx
<ul>
<li>Post flap reconstruction surgery at left anterior lower
buccal-gingival region, mandible and submental region with sof-tissue
tissue defect, and retention of surgical clips. As compared with
previous study on 2017/04/11, there was no interval change. No focal
mass or nodule.</li>
<li>Post LNs dissection with clips retention with metallic artifact
and/or soft tissue or muscle defect, left.</li>
</ul></li>
<li>2017-04-11 MRI - nasopharynx
<ul>
<li>Post flap reconstruction surgery at left anterior lower
buccal-gingival mandible regions with left neck LNs dissection. No
evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-139" class="section level1">
<h1>700312743</h1>
<div id="section-140" class="section level2">
<h2>221115</h2>
<p>{gastric signet-ring cell carcinoma}</p>
<ul>
<li>exam findings
<ul>
<li>2022-11-13 CXR
<ul>
<li>Consolidations in both lung fields</li>
<li>Normal heart size and configuration</li>
<li>Suspect left pleural effusion</li>
</ul></li>
<li>2022-11-09 SONO - chest
<ul>
<li>Finding
<ul>
<li>Left-side of thorax
<ul>
<li>Irregularly thickened pleurae was noted along with moderate free and
anaechoic effusion LLL consolidaiton and atelectasis</li>
</ul></li>
<li>Right-side of thorax
<ul>
<li>no pleural effusion</li>
<li>No active lung lesion</li>
</ul></li>
</ul></li>
<li>Echo diagnosis:
<ul>
<li>Pleural effusion, moderate, left</li>
<li>atelectasis, LLL</li>
<li>Pleural nodules, left</li>
</ul></li>
</ul></li>
<li>2022-11-08 Pelvis &amp; Lt. Hip Lat
<ul>
<li>Avascular necrosis of right femoral head is highly suspected. please
correlate with clinical condition and MRI.</li>
<li>There is no identifiable osteoblastic or osteolytic bony lesion
recognized in the current radiography. Please correlate with clinical
condition or CT.</li>
</ul></li>
<li>2022-11-08, -10-31 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-11-04 CT - chest
<ul>
<li>Bil. pleural effusion with adjacent lung collapse.</li>
<li>No evidence of pulmonary embolism.</li>
</ul></li>
<li>2022-10-28 Panendoscopy
<ul>
<li>Diagnosis
<ul>
<li>Esophageal mucosal oozing, s/p hemostasis with APC</li>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis, remnant stomach</li>
<li>c/w s/p antrectomy with B-II anastomosis</li>
</ul></li>
<li>Suggestion
<ul>
<li>High dose PPI * 3 days</li>
</ul></li>
</ul></li>
<li>2020-10-26 CT - abdomen
<ul>
<li>History:
<ul>
<li>20200729 BW loss 6 Kgs in recent 6 months, postprandial epigastric
discomfort and poor appetie for 3 months</li>
<li>20200729 Gastroscopy: Borrmann type II gastric cancer in the antrum.
CT staging: cT4aN2M0, cSTAGE:III</li>
<li>20200810 S/P subtotal gastrectomy: Tumor present at greater omentum.
Surgeon suggests tumor seeding and c/w distant metastasis. pT4aN3aM1,
pstage IV</li>
</ul></li>
<li>Indication: LUQ pain persist in recent months</li>
<li>Findings:
<ul>
<li>There is left side Pleura effusion with suggstive thickening at the
parietal pleura that may be pleura tumor seeding. Please correlate with
pleura biopsy and pleura effusion cytology.
<ul>
<li>In addition, There are multiple enlarged nodes in paratracheal
space, subaortic space, bilateral hilum and subcarina space that are c/w
metastatic nodes.</li>
</ul></li>
<li>S/P subtotal gastrectomy</li>
<li>Prior CT identified Mild soft tissue density lesion in the celiac
trunk surrounding area is noted again, stationary that may be normal
variation.
<ul>
<li>The differential diagnosis include metastatic nodes. Follow up is
indicated.</li>
</ul></li>
<li>There are several hepatic cysts in both lobes and the largest one
1.3 cm in size at S7.<br />
</li>
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, spleen &amp; both kidney.</li>
<li>There is no evidence of lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>There is left side Pleura effusion with suggstive thickening at the
parietal pleura that may be pleura tumor seeding. Please correlate with
pleura biopsy and pleura effusion cytology.</li>
<li>Metastatic nodes in the mediastinum are noted.</li>
</ul></li>
</ul></li>
<li>2022-10-12 Patho - pleural/pericardial biopsy
<ul>
<li>Pleura, left, biopsy — metastatic signet-ring cell carcinoma,
consistent with gastric origin</li>
<li>Section shows skeletal muscle fibers and fibroadipose tissue with
metastatic signet-ring cell carcinoma.</li>
<li>The immunojostochemical stains reveal CK(+), CDX2(+), Calretinin(-),
and TTF-1(-). The results are consistent with gastric origin.</li>
<li>The immunohistohcmeical of Her-2/neu (Ab) is done and shows Negative
(0).</li>
</ul></li>
<li>2022-10-11 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (89 - 27) / 89 = 69.66%
<ul>
<li>LVEF (%) = 70</li>
<li>M-mode (Teichholz) = 70</li>
</ul></li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>Impaired LV relaxation.</li>
<li>Normal RV systolic function.</li>
<li>Mild MR; moderate TR; mild PR; aortic valve sclerosis.</li>
<li>Possible mild pulmonary hypertension, estimated PASP: 36 mmHg.</li>
<li>Flat IVC and tachycardia; consider hypovolemia.</li>
<li>Left pleural effusion.</li>
</ul></li>
<li>2022-09-24 CT - abdomen
<ul>
<li>Indication
<ul>
<li>[ICD10CM] Malignant neoplasm of pyloric antrum</li>
<li>[ICD10CM] Malignant neoplasm of stomach, unspecified</li>
</ul></li>
<li>Findings
<ul>
<li>s/p partial gastrectomy.</li>
<li>The GB is well distended without soft tissue lesion</li>
<li>Minimal soft tissue mass around the celiac trunk is found. In
comparison with CT dated on 2022-07-18, the lesion is stationary.</li>
<li>The urinary bladder is well distended without soft tissue
lesion.</li>
<li>There is no evidence of destructive bone lesion.</li>
<li>Non-specific bowel gas at abdominal cavity is found.</li>
<li>Dilated CBD is found. Stationary.</li>
<li>Massive left pleural effusion is found.</li>
<li>Normal heart size.</li>
<li>The lung fields are clear.</li>
</ul></li>
<li>Imp:
<ul>
<li>s/p partial gastrectomy.</li>
<li>Minimal soft tissue mass around the celiac trunk is found. In
comparison with CT dated on 2022-07-18, the lesion is stationary.</li>
</ul></li>
</ul></li>
<li>2022-07-18 CT - abdomen
<ul>
<li>s/p subtotal gastrectomy.</li>
<li>Soft tissue mass surrounding the celiac trunk is found. In
comparison with CT dated on 2022-04-20, the soft tissue is stationary in
size and extention.</li>
<li>Increased intestinal gas is found. The intestines are wall dilated.
Post op. change is favored.</li>
</ul></li>
<li>2022-04-28 MRI - T-spine
<ul>
<li>The thoracic spine shows normal alignment and vertebral
contour.</li>
<li>The thoracic disk spaces show no disk bulging, extrusion or
protrusion.</li>
<li>The thoracic spinal cord shows normal size and signal intensity
without evidence of compressive edema, ischemia or myelomalacia. There
is no extrinsic compresson of the cord.</li>
<li>The neural foramina of the thoracic spine are patent. No impingement
is seen.</li>
</ul></li>
<li>2022-04-27 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the LUQ of abdomen, compatible with S/P
subtotal gastrectomy.<br />
</li>
<li>Glucose hypermetabolism in the soft tissue in the left supra-renal
region and in the pre-vertebral space of T12 spine, the nature is to be
determined (reactive nodes, metastatic lymph nodes or others ?),
suggesting further investigation.<br />
</li>
<li>Glucose hypermetabolism in the right submandibular lymph nodes, the
nature is to be determined also (reactive nodes or others ?), suggesting
further investigation.<br />
</li>
<li>No prominent abnormal focal FDG uptake is noted elsewhere.</li>
</ul></li>
<li>2022-04-25 SONO - abdomen
<ul>
<li>Findings
<ul>
<li>Anechoic nodules, 1.19x0.65cm and 1.29x0.96cm in left lobe,
1.2x0.68cm and 1.07x0.85cm in right lobe, suspected liver cysts.</li>
<li>Normal appearance of gallbladder without stone.</li>
<li>Patency of PV, HVs, IVC and aorta in hepatic portion.</li>
</ul></li>
<li>Impression
<ul>
<li>Liver cysts.</li>
</ul></li>
</ul></li>
<li>2022-04-20 CT - abdomen
<ul>
<li>S/P subtotal gastrectomy.</li>
<li>Prior CT identified Mild soft tissue density lesion in the celiac
trunk surrounding area is noted again, stationary that may be normal
variation.</li>
<li>The differential diagnosis include metastatic nodes.</li>
</ul></li>
<li>2022-03-31 MRI - L-spine
<ul>
<li>Thoracicolumbar spondylosis with diffuse spinal canal stenosis and
neuroforaminal narrowing, es T10-11-12 (with left OYL) and L4-5 (with Gr
I spondylolisthesis).</li>
</ul></li>
<li>2022-01-27 CT - abdomen
<ul>
<li>S/P gastric operation. No evidence of tumor recurrence.</li>
</ul></li>
<li>2022-01-26 Tc-99m MDP whole body bone scan
<ul>
<li>Faint hot spots in the left fronto-parietal region of skull and
right hip joint, respectively, the nature is to be determined
(post-traumatic change or other nature ?), suggesting follow-up with
bone scan in 3-6 months for investigation.</li>
<li>Suspected benign lesions in the maxilla, mandible, some T- and
L-spine, bilateral shoulders, and knees.</li>
</ul></li>
<li>2021-11-08 SONO - abdomen
<ul>
<li>Findings
<ul>
<li>Anechoic nodules, 1.22x0.7cm, 1.29x1.16cm and 1.14x0.98cm in left
lobe, 0.96x0.51cm and 1.47x0.85cm in right lobe, could be due to liver
cysts.</li>
<li>Normal appearance of gallbladder without stone.</li>
<li>Patency of PV, HVs, IVC and aorta in hepatic portion.</li>
</ul></li>
<li>Impression:
<ul>
<li>Liver cysts.</li>
</ul></li>
</ul></li>
<li>2021-08-16 CT - abdomen
<ul>
<li>S/P gastric operation. No evidence of tumor recurrence.</li>
<li>Liver cysts (up to 1.1cm).</li>
</ul></li>
<li>2021-03-09 CT - abdomen
<ul>
<li>s/p subtotal gastrectomy.</li>
<li>No evidence of recurrent/residual tumor in the study.</li>
</ul></li>
<li>2020-08-11 Patho - stomach subtotal/total (tumor)
<ul>
<li>Addendum:
<ul>
<li>Tumor present at greater omentum. Surgeon suggests tumor seeding and
compatible with distant metastasis in clinico-pathologic
conference.</li>
<li>AJCC pathologic staging is revised to pT4aN3aM1, stage IV</li>
</ul></li>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Stomach, subtotal gastrectomy — Signet-ring cell carcinoma<br />
</li>
<li>Margins, bilateral cutting ends, ditto — Free of tumor<br />
invasion<br />
</li>
<li>MCA, ditto — Free of tumor metastasis (0/1)<br />
</li>
<li>Greater omentum, omentectomy — Tumor present<br />
</li>
<li>Lymph node, LN 1, dissection — Negative for tumor metastasis
(0/1)<br />
</li>
<li>Lymph node, LN 3, ditto — Tumor metastasis (4/8) without
extracapsular extension (0/4)<br />
</li>
<li>Lymph node, LN 4, ditto — Tumor metastasis (3/6) with extracapsular
extension (2/3)<br />
</li>
<li>Lymph node, LN 5, ditto — Negative for tumor metastasis (0/4)<br />
</li>
<li>Lymph node, LN 6, ditto — Tumor metastasis (4/5) with extracapsular
extension (1/4)<br />
</li>
<li>Lymph node, LN 7, 8, 9,12, ditto — Negative for tumor metastasis
(0/3)<br />
</li>
<li>Lymph node, LN 11p, ditto — Negative for tumor metastasis
(0/1)<br />
</li>
<li>Lymph node, LN 14, ditto — Tumor metastasis (3/3) with extracapsular
extension (2/3)<br />
</li>
<li>AJCC Pathologic staging — pT4aN3a (if cM0), stage IIIB<br />
</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histologic type: Signet-ring cell carcinoma<br />
</li>
<li>Histologic grade: Grade 3<br />
</li>
<li>Depth of tumor invasion: visceral peritoneum<br />
</li>
<li>Lymph nodes: tumor metastasis (14/31) with extracapsular extension
(5/14) in total number<br />
</li>
<li>Omentum: Tumor present<br />
</li>
<li>AJCC Pathologic Staging: pT4aN3a<br />
</li>
<li>Bilateral Margins: Free of tumor invasion<br />
</li>
<li>Additional pathologic findings: intestinal metaplasia, focal mucin
production<br />
</li>
<li>Immunohistochemical stains: CK(+), Her2(-, Dako score 0) for tumor
cells<br />
</li>
<li>Perineural invasion: present<br />
</li>
<li>Lymphovascular space invasion: present<br />
</li>
</ul></li>
</ul></li>
<li>2020-08-04 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (112 - 35) / 112 = 68.75%
<ul>
<li>M-mode (Teichholz) = 69</li>
</ul></li>
<li>Dilated LA, Ao</li>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Thick IVS, Impaired LV relaxation</li>
<li>Mild TR, AR</li>
</ul></li>
<li>2020-07-29 Patho - stomach biopsy
<ul>
<li>Stomach, biopsy — Adenocarcinoma<br />
</li>
<li>Section shows fragments of gastric tissue infiltrated by isolated
neoplastic cells.</li>
</ul></li>
<li>2020-07-29 CT - abdomen
<ul>
<li>History and Indication:
<ul>
<li>BW loss 6 Kgs in recent 6 months, postprandial epigastric discomfort
and poor appetie for 3 months</li>
<li>2020/07/29 Gastroscopy: Borrmann type II gastric cancer in the
antrum. CT staging</li>
</ul></li>
<li>FINDINGS:
<ul>
<li>There is lobulated wall thickening in the gastric antrum and low
body and the maximal wall thickness measuring about 2.2 cm that is
compatible with adenocarcionoma.</li>
<li>There are at least 4 enlarged nodes in the dorsal aspect mesentery
of the perigastric antrum area (Srs:302, Img:38,43) that may be
metastatic nodes in station 4 and 6.</li>
<li>Ascites in the pelvis is noted, nature?</li>
</ul></li>
<li>Imaging Report Form for Gastric Carcinoma
<ul>
<li>Impression (Imaging stage): T:T4a(T_value) N:N2(N_value)
M:M0(M_value) STAGE:III (Stage_value)</li>
</ul></li>
</ul></li>
<li>2020-07-29 Panendoscopy
<ul>
<li>big gastric ulcers. A2, highly suspected gastric cancer Bormman type
II; antrum</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-17 ENT
<ul>
<li>Q
<ul>
<li>for hoarse throat days</li>
<li>This 67-year-old man, a patinet of gastric cancer with Gastric adeno
CA of antrum, cT4aN2N0 stage III, pT4aN3aM1, stage IV, s/p Op &amp;
HIPEC on 20200810 &amp; post-Op adjuvant CCRT wt 5-FU 24 hr QD x 5 per
wk x 6 plus R/T finishing in Oct 2020 &amp; post-CCRT adjuvant C/T wt
Oxaliplatin / HDFL IV Q2W x 11 finishing in May 2021. He was admitted
due to dyspnea S/P pig-tail drainage inserted. He complained of hoarse
throat for days. WE need expertise to evaluate his condition
thanks!</li>
</ul></li>
<li>A
<ul>
<li>Scope: smooth nasopharynx, oropharynx, hypopharynx. Fair vocal cord
movement.</li>
<li>Impression: favor functional dysphonia.</li>
<li>Plan: May give Broen-C 2# TID.</li>
<li>ENT OPD follow-up after discharge.</li>
</ul></li>
</ul></li>
<li>2022-08-12 Nephrology
<ul>
<li>Q
<ul>
<li>for hyponatremia,thanks</li>
<li>This 65-year-old male, a pt of gastric adeno CA of antrum, cT4aN2N0
stage III, pT4aN3aM1, stage IV, s/p Op &amp; HIPEC on 20200810, suffered
from initial presentation of marked weight loss of 6kg from Feb
2020.</li>
<li>Surgical pathology with stomach, subtotal gastrectomy (20200810)
proved signet-ring cell carcinoma.</li>
<li>Subtotal gastrectomy, BII anticolic anastomosis, D2 dissection, with
T-colectomy and HIPEC with oxaliplatin 360mg/m2 (650mg) 42C for 60 min,
on 20200810.</li>
<li>He was referred to our hemato-oncologic clinic on 20200901 for
post-Op adjuvant CCRT &amp; C/T.</li>
<li>We explain to pt &amp; his wife about the indication &amp; risk /
benefit of post-Op adjuvant CCRT wt 5-FU 24 hr QD x 5 per wk x 6 plus
R/T then post-CCRT adjuvant C/T wt Oxaliplatin / HDFL IV Q2W x 12.</li>
<li>HBsAg, anti-HCV (20200901): negative.</li>
<li>#1 R/T to gastric tumor bed on 9/14 20</li>
<li>#1 post-Op adjuvant CCRT wt 5-FU 24 hr QD x 5 per wk x 6 plus R/T on
9/16~9/18 20, #2 on 9/28 20, #3 on 10/12 20.</li>
<li>#1 post-Op adjuvant CCRT with Oxaliplatin / HDFL IV Q2W x 12 on
11/17 20, #2 on 12/14 20, #3 on 12/28 20, #4 on 1/11 21, #5 on 1/25 21,
#6 on 2/22 21, #7 on 3/15 21, #8 on 3/29 21, #9 on 4/12 21, #10 on 4/27
21, #11 on 5/11 21</li>
<li>The whole abdominal CT (3/9 21) showed s/p subtotal gastrectomy. No
evidence of recurrent/residual tumor in the study.</li>
<li>Painless gastroscopy (4/1 21): Erosive reflux esophagitis LA
Classification grade A</li>
<li>S/p subtotal gastrectomy with B-II anastomsis, superficial
gastritis, remnant stomach.</li>
<li>Followed CXR &amp; abd sono (11/8 21): negative but liver
cysts.</li>
<li>Followed Abd CT (8/16 21) (1/27 22) revealeds/p gastric Op. No
evidence of tumor recurrence.Liver cysts (up to 1.1cm).</li>
<li>Followed Abd CT (4/20 22)revealed s/p subtotal gastrectomy.Prior CT
identified Mild soft tissue lesion in the celiac trunk noted again,
stationary that may be normal variation. D/D include mets nodes.</li>
<li>PET scan (4/27 22) showed negative.</li>
<li>Followed Abd CT (7/18 22) revealed s/p subtotal gastrectomy.Soft
tissue mass at the celiac trunk, compared wt CT on 4/20 22, the soft
tissue is stationary in size and extention. c/o L lower chest wall pain.
Dr Wu did bone scan.</li>
<li>Bone scan (1/26 22) showed negative. (2/8 22).</li>
<li>He complained of back pain &amp; left lower abdominal discomfort, Dr
Wu consult Dr Chang for CCRT on 7/26 22. Palliative R/T to recurrnet
LAPs for 3500cGy/14 fractions is suggested for pain control. Suggest
concurrent chemotherapy.The radiotherapy started on 8/5 22</li>
<li>This time ,he was admitted for #1 CCRT wt 5-FU 24 hr QD x 5 per wk x
3 on 8/9 22</li>
<li>However, hyponatremia was noted during CCRT.3% NACL 15ml/hr was
administered. Followed the thyroid function and pending. We need your
epertise for further management,thanks</li>
</ul></li>
<li>A
<ul>
<li>This 65 years old male patient had underlying history of gastric
adeno CA of antrum, cT4aN2N0 stage III, pT4aN3aM1, stage IV, s/p
subtotal gastrectomy BII anticolic anastomosis, D2 dissection, with
T-colectomy and HIPEC on 20200810 , post-Op adjuvant CCRT. Consult for
hyponatremia.</li>
<li>Lab data:
<ul>
<li>WBC: 2.76, Hb: 11.9,Plt: 182</li>
<li>Na: 132-&gt; 128-&gt; 126-&gt; 125(8/9)-&gt; 115(8/12)</li>
<li>K: 4.3, Ca: 2.42, Albumin: 4.6, Ca: 2.14, Mg: 1.7</li>
<li>BUN: 16, Cre: 0.75</li>
<li>Uric acid: 1.6, T bil: 1.03, D bil: 0.21, GOT :31</li>
<li>E4V5M6, BW 67.15kg</li>
</ul></li>
<li>Assessment :
<ul>
<li>Severe acute hyponatremia</li>
</ul></li>
<li>Suggetsion:
<ul>
<li>Supplementation with 3% NS run 20ml per hr for one day</li>
<li>Follow up serum Na Q4hr and not more than 8-10mmol/L per day</li>
<li>Check plasma osmolality, urine osmolarity and urine Na, FeNa, Fe
uric acid (serum uric acid, urine uric acid, serum Cr, urine Cr) , TSH,
Free T4, ACTH, cortisol</li>
<li>We will follow up this case.</li>
</ul></li>
<li>Follow up (20220813)
<ul>
<li>Lab
<ul>
<li>Na: 117</li>
<li>Urine uric aicd : 21.7</li>
<li>Urine osmolarity: 377</li>
<li>Plasma osmolality : 236</li>
<li>Uric acid: 1.6</li>
</ul></li>
<li>Assessment: suspect SIADH</li>
<li>Suggestion:
<ul>
<li>Keep 3% NS 20ml per hr for 2 days</li>
<li>Fluid restriction</li>
<li>Follow up Na Q4h or Q6h</li>
<li>Lasix 1 amp IV st</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-08-10
<ul>
<li>Surgery
<ul>
<li>Subtotal gastrectomy with D2 LNdissection</li>
<li>mesocolon resection</li>
<li>HIPEC with Oxaliplatinum 360mg/M2 650 mg T 42 C for 60 mins</li>
<li>B-II anticolic anastomosis</li>
</ul></li>
<li>Finding
<ul>
<li>huge gastric ulcerative mass at greater cuvature with direct
invasion to moesocolon</li>
<li>small nodular seeding at greater omentum</li>
<li>ascite(-)</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-25 - irinotecan 160mg/m2 270mg 1.5hr + leucovorin 400mg/m2
670mg 1.5hr + fluorouracil 2800mg/m2 4700mg 46hr</li>
<li>2022-08-22 - fluorouracil 200mg/m2 350mg 24hr D1-D3 (CCRT)</li>
<li>2022-08-15 - fluorouracil 200mg/m2 350mg 24hr D1-D5 (CCRT)</li>
<li>2022-08-09 - fluorouracil 200mg/m2 350mg 24hr D1-D4 (CCRT)</li>
<li>2021-05-11 - oxaliplatin 85mg/m2 160mg 2hr + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5200mg 46hr</li>
<li>2021-04-27 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
740mg 2hr + fluorouracil 2800mg/m2 5200mg 46hr</li>
<li>2021-04-12 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5100mg 46hr</li>
<li>2021-03-29 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5100mg 46hr</li>
<li>2021-03-15 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5100mg 46hr</li>
<li>2021-02-22 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5100mg 46hr</li>
<li>2021-01-25 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
<li>2021-01-11 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
<li>2020-12-28 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 5000mg 46hr</li>
<li>2020-12-14 - oxaliplatin 70mg/m2 120mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 4900mg 46hr</li>
<li>2020-11-17 - oxaliplatin 70mg/m2 120mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 2800mg/m2 4900mg 46hr</li>
<li>2020-10-12 - fluorouracil 200mg/m2 350mg 24hr D1-D5 (CCRT)</li>
<li>2020-10-01 - fluorouracil 200mg/m2 350mg 24hr D1 (CCRT)</li>
<li>2020-09-28 - fluorouracil 200mg/m2 350mg 24hr D1-D3 (CCRT)</li>
<li>2020-09-15 - fluorouracil 200mg/m2 350mg 24hr D1-D4 (CCRT)</li>
<li>2020-08-10 - [cisplatin 360mg/m2 650mg + gentamicin 40mg + sodium
bicarbonate 7% 60mL] IP 1hr for HIPEC at OR</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>As the patient reported bilateral lower limb edema after taking
Lyrica (pregabalin), so the pregabalin has been held for the moment. As
part of discharge preparations, gabapentin could be prescribed as a
substitute for pregabalin for the patient’s neuropathic pain with less
than half the risk of edema. (ref: UpToDate)</li>
</ul>
</div>
</div>
<div id="section-141" class="section level1">
<h1>700900195</h1>
<div id="section-142" class="section level2">
<h2>221114</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-08 CT - brain
<ul>
<li>No ICH. Brain atrophy. Old left anterior basal ganglia lacunar
infarcts.</li>
</ul></li>
<li>2022-08-22 MRI - c-spine
<ul>
<li>Cervical spondylosis, retrolordotic change, subluxation, mild spinal
canal stenoses.</li>
</ul></li>
<li>2022-01-07 CT - c-spine
<ul>
<li>Cervical spinal kyphosis.</li>
<li>Degenerative spinal and disc disease.</li>
<li>Severe right C4-5, C5-6 neuroforaminal narrowing.</li>
</ul></li>
<li>2021-05-11 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (54 - 13) / 54 = 75.93%
<ul>
<li>M-mode (Teichholz) = 76</li>
</ul></li>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Grade 1 LV diastolic dysfunction</li>
<li>Mild AR, TR</li>
</ul></li>
<li>2021-05-11 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Following the last cholesterol total measurement in April 2021 (275
mg/dL), there has been no further follow-up. It might be beneficial to
collect the reading again to determine whether a statin agent is
required (Zulitor (pitavastatin 4mg) 1# QN has been used in the
past).</li>
</ul>
</div>
</div>
<div id="section-143" class="section level1">
<h1>701447350</h1>
<div id="section-144" class="section level2">
<h2>221114</h2>
<ul>
<li>exam findings
<ul>
<li>2022-10-31 Pelvis &amp; Bilat. Hip Lat
<ul>
<li>There is an osteolytic or osteopenic lesion in the lesser trochanter
of right femur. Please correlate with CT to R/O bony metastasis.</li>
</ul></li>
<li>2022-10-05 Tc-99m MDP whole body bone scan
<ul>
<li>A hot area in the right iliac bone and increased activity in the
sternum, malignancy with bone metastases should be considered,
suggesting further investigation.<br />
</li>
<li>Increased activity in the sacrum, left humerus, and left hip, the
nature is to be determined (bone mets or other nature ?), suggesting
follow-up with bone scan in 3 months for evaluation.</li>
<li>Suspected benign lesions in some C-, T- and L-spine, bilateral
shoulders, and right femoral trochanter.</li>
</ul></li>
<li>2022-10-04 Patho - liver biopsy
<ul>
<li>Liver, CT-guided biopsy — Adenocarcinoma, poorly differentiated,
compatible with cholangiocarcinoma</li>
<li>The sections show adenocarcinoma, poorly differentiated, composed of
nests of large pleomorphic neoplastic cells, arranged in solid pattern
with desmoplastic stromal reaction. Subtle glandular formation is
present.</li>
<li>IHC, tumor cells reveal: CK7(+), CK20(-), Hepa-1(-) and
Arginase-1(-).</li>
</ul></li>
<li>2022-09-14 CT - abdomen
<ul>
<li>Hepatocholangiocarcinoma is highly suspected. The differential
diagnosis include cholangiocarcinoma and metastases? Biopsy is
indicated.</li>
<li>Multiple metastatic nodes in hepatoduodenal ligament, para-aortic
space and para-cava space.</li>
<li>Bony metastases.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-02 Radiation Oncology
<ul>
<li>A
<ul>
<li>A: Intrahepatic cholangiocarcinoma with multiple metastases.</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: bone metastases.
<ul>
<li>Goal: palliation</li>
<li>Treatment target and volume: metastatic right ilium, sacrum, and
right lesser trochanter lesions</li>
<li>Technique: IMRT</li>
<li>Preliminary planning dose: 3000cGy/12 fractions of the metastatic
right ilium, sacrum, and right lesser trochanter lesions.</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and his wife. They understand and agree to
receive radiotherapy, The treatment planning of radiotherapy will be
started at 1330, 2022-11-07.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-10-28 Rheumatology
<ul>
<li>Q
<ul>
<li>This 64-year-old man, a patient of being diagnosed to have
HBV-related HCC several years ago (3-4 yrs) post TAE at SYKCC &amp;
bililary ca was diagnosed later and received further chemotherapy
(cisplatin and gemza x 7 times) and bone met S/P R/T x 6 times was noted
later. He was admitted for C/T. He complained of whole body skin rash
&amp; icthing did not improve for days. The ANA:1:80, IgE: 425. We need
expertise to evaluate his condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>History review was performed. Patient was admitted due to
HBV-related HCC &amp; for C/T. I was consulted for generalized itching
sensation.</li>
<li>RIA condition:
<ul>
<li>Allergic rhinitis Hx(+)</li>
<li>multiple small papules over four limbs</li>
<li>WBC/Hgb/PLT:4550/8.1/49K; Eosinophils:1.1%</li>
<li>IgE:425</li>
<li>ANA:1:80(s)</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Treatment as current your expert’s management.</li>
<li>Please check cryoglobulin, Panel 5 specific allergen test.</li>
<li>Keep allegra 1#BID &amp; add chlorpheniramine 1# prn HS.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-10-03 Dermatology
<ul>
<li>Q
<ul>
<li>for skin rash &amp; icthing over whole body</li>
<li>This 64-year-old man, Being diagnosed to have HBV-related HCC
several years ago (3-4 yrs) post TAE at SYKCC . Bililary ca was
diagnosed later and received further chemotherapy (cisplatin and gemza
)and bone met was noted later. The abdominal CT (9/14 22) showed
Hepatocholangiocarcinoma is highly suspected. The differential diagnosis
include cholangiocarcinoma and metastases? Biopsy is indicated.Multiple
metastatic nodes in hepatoduodenal ligament, para-aortic space and
para-cava space,Bony metastases. He complained of skin rash &amp;
icthing over whole body for days. We need expertise to evaluate his
condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from erythematous papules on limbs for 2 wks.
and dyskeratoticnails for yrs.</li>
<li>Imp:
<ul>
<li>Subacute dermatitis</li>
<li>Tinea unguim</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Please check CBC. ANA. TSH. IgE</li>
<li>Dexamethason * 1 /Qd</li>
<li>Topsym cream * 4 tubes/bid</li>
<li>Excelderm soln * 2 Bt/Bid</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-31 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
750mg 2hr + fluorouracil 2800mg/m2 5300mg 46hr</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-145" class="section level1">
<h1>700132355</h1>
<div id="section-146" class="section level2">
<h2>221110</h2>
<p>[assessment]</p>
<ul>
<li><p>The trough value of vancomycin was reported on 2022-11-10 at 25.4
mcg/mL.</p></li>
<li><p>A blood draw time of “2022-11-10 00:00” has been recorded, this
should be due to an invalid entry, please confirm that the concentration
is actually a “trough”.</p></li>
<li><p>Redraw the value if it is not truly a “trough”.</p></li>
<li><p>In the event that the value is a real “trough”, then it is
recommended to hold vancomycin and perform a renal function
test.</p></li>
</ul>
</div>
</div>
<div id="section-147" class="section level1">
<h1>700161803</h1>
<div id="section-148" class="section level2">
<h2>221103</h2>
<ul>
<li>exam findings
<ul>
<li>2022-11-02 CT - abdomen
<ul>
<li>Findings:
<ul>
<li>There are multiple enlarged lymph nodes in the gastrohepatic
ligament, hepatoduodenal ligament, celiac trunk, mesentery, para-aortic
space, para-cava space, and bilateral common iliac chain.
<ul>
<li>Metastatic nodes are highly suspected.</li>
<li>The differential diagnosis include lymphoma.</li>
<li>In addition, thrombosis in right superficial femoral vein is
noted.</li>
</ul></li>
<li>There is diffuse wall thickening at the low body and antrum of the
stomach. Please correlate with gastroscopy.</li>
<li>Prior CT identified a poor enhancing Soft tissue tumor, 4cm in the
uterus, is noted again, stationary. Myoma is suspected.
<ul>
<li>In addition, There is a homogeneous soft tissue mass measuring 2.8 x
1.8 cm in left adnexa, near the uterine fundus, that also may be
myoma.</li>
</ul></li>
<li>Bilateral renal cysts, up to 2.6cm.</li>
<li>There are massive bilateral Pleura effusion.</li>
</ul></li>
<li>Impression:
<ul>
<li>Multiple Metastatic nodes are highly suspected.
<ul>
<li>The differential diagnosis include lymphoma.</li>
<li>In addition, thrombosis in Rt superficial femoral vein is
noted.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-05-15 CT - abdomen
<ul>
<li>Imaging Report Form for Gastric Carcinoma
<ul>
<li>Impression (Imaging stage): T:T2(T_value) N:N0(N_value)
M:M0(M_value) STAGE:I(Stage_value)</li>
</ul></li>
</ul></li>
<li>2021-05-11 Patho - stomach biopsy
<ul>
<li>Stomach, GC-PW of middle body, biopsy — Adenocarcinoma, moderately
differentiated<br />
</li>
<li>The sections show a picture of tubular adenocarcinoma, moderately
differentiated, composed of gastric mucosal tissue with columnar to
cuboidal neoplastic cells, arranged in glandular and cribriform patterns
with desmoplastic reaction.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Low molecular weight heparin (LMWH) is probably superior to
unfractionated heparin (UFH) in reducing mortality in the initial
treatment of venous thromboembolism (VTE) in people with cancer
(2022-11-02 CT: thrombosis in right superficial femoral vein). Also,
there are additional advantages of LMWH related to subcutaneous
administration and outpatient management. (ref: Anticoagulation for the
initial treatment of venous thromboembolism in people with cancer.
Cochrane Database of Systematic Reviews 2021, Issue 12. Art. No.:
CD006649. DOI: 10.1002/14651858.CD006649.pub8). For most patients with
active malignancy and acute VTE who have a reasonable life expectancy
and adequate renal function (CrCl &gt;=30 mL/minute), LMWH is the
preferred agent for initial anticoagulation, rather than other
agents.</li>
</ul>
</div>
</div>
<div id="section-149" class="section level1">
<h1>701035130</h1>
<div id="section-150" class="section level2">
<h2>221103</h2>
<ul>
<li>diagnosis - 2022-11-02 adminssion note
<ul>
<li>Unspecified abdominal pain</li>
<li>Malignant neoplasm of unspecified part of left bronchus or lung</li>
<li>Malignant neoplasm of esophagus, unspecified</li>
<li>Chronic viral hepatitis C</li>
<li>Malignant neoplasm of upper lobe, left bronchus or lung</li>
<li>Malignant neoplasm of middle third of esophagus</li>
<li>Alcohol dependence, uncomplicated</li>
<li>Secondary malignant neoplasm of bone</li>
<li>Calculus of bile duct with cholangitis, unspecified, with
obstruction</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-10-06 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
<li>Increased activity around right hip prosthesis. The nature is to be
determined (infection or inflammation? other nature?). Please correlate
with other clinical findings.</li>
<li>Mildly increased activity in the right knee. Arthritis may show this
picture. Please also correlate with other clinical findings for further
evaluation and to rule out other possibilities.</li>
</ul></li>
<li>2022-10-05 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, left upper lobe, CT-guide biopsy — small cell carcinoma</li>
<li>Sections show large nests of small hyperchromatic tumor cells with
scanty cytoplasm and marked crushing artifact.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), TTF-1(-),
Napsin A(-), Synaptophysin(-), Chromogranin A(-), CK5/6(-), p40(-),
GATA3(focal +), SALL4(-), OCT4(-), and beta-hCG(-). The morphology is
the same as S2022-16555.</li>
</ul></li>
<li>2022-09-30 MRI - pancreas
<ul>
<li>History: 20220924 CC: abdomen pain
<ul>
<li>20220924 CT: A mass (2.6x5.4cm) at LUL and left pulmonary hilum.
Some LNs at mediastinum, hepatic hilum, and retroperitoneum. Some
hypodense lesions (up to 4.7cm) in both hepatic lobes.
<ul>
<li>Suspected lung cancer at LUL with LNs and liver metastases</li>
</ul></li>
<li>20220927 CA199: 19090 U/mL (&lt; 35), CEA and AFP: normal.</li>
<li>20220928 liver biopsy: neuroendocrine carcinoma</li>
</ul></li>
</ul></li>
<li>2022-09-28 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Poorly differentiated carcinoma,compatible
with neuroendocrine carcinoma</li>
<li>The sections show nests of medium to large-sized, poorly
differentiated neoplastic cells with marked apoptosis, in fibrous
stroma. Neither squamous nor glandular differentiation can be
identified.</li>
<li>IHC shows: CK(+), p40(-), TTF1(-), CD56 (+), and Synaptophysin(-).
The findings favor neuroendocrine carcinoma.</li>
</ul></li>
<li>2022-09-28 Patho - stomach biopsy (middle esophagus)
<ul>
<li>Labeled as “middle esophagus”, biopsy (B) — squamous cell
carcinoma.</li>
<li>IHC stains: CK5/6 (+), p63 (+).</li>
</ul></li>
<li>2022-09-26 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Liver tumors, favor metastatic tumors</li>
<li>liver parenchymal disease</li>
<li>mild GB wall thickening</li>
</ul></li>
<li>Suggestion
<ul>
<li>correlate with other image study such as contrast-enhanced CT scan
or MRI</li>
</ul></li>
</ul></li>
<li>2022-09-24 CT - chest
<ul>
<li>Suspected lung cancer at LUL with LNs and liver metastases. Suggest
tissue study.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-11-02 Family Medicine
<ul>
<li>Q
<ul>
<li>This is a 51-year-old man with past history of
<ul>
<li>Squamous cell carcinoma involved middle esopahgus</li>
<li>Nueroendocrine carcinoma of liver, poor differentiated, multiple
metastatic lymph nodes</li>
<li>Small cell carcinoma of lung</li>
<li>Tc99m: multiple bone metastasis<br />
</li>
<li>Left hip AVN, alcoholism related, s/p left THR in 2013 at WanFang
Hospital.</li>
<li>Left distal tibial fracture and lateral malleolar fracture by
trauma, s/p ORIF with plate fixation in 2017/07</li>
<li>Left THR acetabular component loosening, s/p left hip revision THR
in 2017/12</li>
<li>Right hip s/p bipolar hemiarthoplasty s/p infection, s/p ROI and
antibiotic cement beads insertion in 2020/04</li>
<li>Hepatitis C under Maviret treatment since 20221021.</li>
</ul></li>
<li>According to family, the patient developed chest tightness,
abdominal pain, and severe right knee pain for several days. Productive
cough with difficult swallowing were also noted. So he visited our ER
for help. He managed to talk oriently and was able to eat by himself
then.
<ul>
<li>Vital sign at ER revealed BP:117/76 mmHg; HR:102 bpm; BT:35.6
celsius degree; RR:18 /min ; GCS:E4V5M6. Laboratory data revealed
leukocytosis, elevated CRP and direct/total bilirubin. Icteric
appearance was noted. Cefataxime was prescribed at ER. However, he
became lethargy and confused this morning. Though his eyes opened
spontaneously, he could not answer questions properly or obey order.
Productive cough was also noted. Under the impression of (1) squamous
cell carcinoma involved middle esopahgus (2) Nueroendocrine carcinoma of
liver (3) Small cell carcinoma of lungs (4) altered mental status (5)
pneumonia, the patient was admitted for further evaluation and
management. Due to difficult swallowing and altermental status, NG tube
was inserted today.</li>
</ul></li>
<li>Considering the irreversible end stage cancers and his family
decided not to accept advanced treatment, we need your expertise for
this patient’s hospice care. Thank you very much!!</li>
</ul></li>
<li>A
<ul>
<li>After discussion, I decided to arrange hospice combine care for this
patient. Thanks for your consultation.</li>
<li>Current condition: 51 y/o Esophageal cancer, bone mets</li>
<li>Indication for hospice combine care: Advanced esophageal cancer</li>
</ul></li>
</ul></li>
<li>2022-10-03 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 51-year-old man, who was admitted for GI bleeding. PES was
done and his vital signs is stable now. Further investigation revealed
1. Esophageal Ca, r/o lung cancer and liver neuroendocrine carcnioma
were noted.</li>
<li>We would like to request your expertise upon further management of
the condition.</li>
</ul></li>
<li>A
<ul>
<li>This 51-year-old man was consulted and evaluated for liver tumor and
esophageal cancer.<br />
</li>
<li>History and medical records reviewed and patient interviewed at
bedside.</li>
<li>Recommendation:
<ul>
<li>lung biopsy to R/O small cell carcinoma of lung</li>
<li>chemotherpay with cisplatin based regimen is suggested after the
lung tumor pathology is elucidated.</li>
<li>check bone scan</li>
<li>suggest to consult the radiation oncologist for possible of
CCRT</li>
</ul></li>
<li>I will follow up this patient, Thank you for the referral.</li>
</ul></li>
</ul></li>
<li>2022-09-27 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This is a 51-year-old patient, he came to our ward since GI
bleeding.</li>
<li>On 20220924, chest x ray shows: Mass like lesion at left upper lobe
is found.</li>
<li>on 20220924, CT shows: A mass (2.6x5.4cm) at LUL abutting
mediastinum and left pulmonary hilum.</li>
<li>Meanwhile, abdominal sonography shows multiple liver tumors,
metastatic suspected.</li>
<li>We would like to consult to Dr. we wonder if there’s any advices, or
would you recommand surgical intervention for the patient?</li>
<li>Please insight us. Thanks for your time and reply.</li>
</ul></li>
<li>A
<ul>
<li>This 51-year-old man without chronic disease was admitted due to GI
bleeding and CXR showed incidental finding of lung tumor.
<ul>
<li>Chest CT revealed multiple liver hypodense tumor with LUL mass near
hilum with multiple LD at retroperitonium, and mediastinum. Therefore,
we were consulted for further evaalution and management.</li>
</ul></li>
<li>Lab:
<ul>
<li>CA19-9: 19090, AFP, CEA: normal</li>
<li>Anti-HCV: (+)</li>
<li>smoking, alcohol, and betel nut history: (+)</li>
<li>Panendoscopy revealed esophageal lesion post biopsy, GU post biopsy,
and DU scar.</li>
</ul></li>
<li>Impression:
<ul>
<li>Lung tumor with multiple liver tumor and LN with esophageal lesion,
primary origin?</li>
<li>Gastric ulcer, with esophageal lesion s/p biopsy</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Pending biopsy report</li>
<li>Could ask the interventional radiologist for CT guided biopsy (liver
tumor first due to lower risk) if negative findings of esophageal
lesion.
<ul>
<li>If interventional radiologist refuse, we could arrange bronchoscopy
to see whether we could approach the mass lesion.</li>
</ul></li>
<li>could also check other tumor marker - SCC for evaluation.</li>
<li>Treat Gi bleeding as your expertise.</li>
<li>We will closely follow up the patient.</li>
</ul></li>
<li>Thanks for your consultation</li>
</ul></li>
</ul></li>
<li>2022-09-26 Rehabiliation
<ul>
<li>A
<ul>
<li>Right knee:
<ul>
<li>No erythermatous change, no swelling, no heating, no tenderness over
his right knee</li>
<li>Lockman test: negative; McMurray test: Positive</li>
<li>Pain when flexion and extension ROM, relief after resting</li>
</ul></li>
<li>Right knee sonogram: mild effusion in suprapatellar</li>
<li>Assessment
<ul>
<li>Right knee internal derangement</li>
</ul></li>
<li>Plan
<ul>
<li>Arranged right knee sonogram (done, pending report)</li>
<li>Knee IA with low dose steriod injection</li>
<li>Please arrange right knee X-ray, and MRI</li>
<li>Please arrange rehab OPD after discharge for follow up if his right
knee is still pain</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Tube feeding is possible for all oral medications in the active
prescription.</li>
<li>It is recommended that the patient-carried medication Maviret
(glecaprevir 100mg + pibrentasvir 40mg) be taken with food (cum cibos)
and the frequency should be amended to QDCC.</li>
</ul>
</div>
</div>
<div id="section-151" class="section level1">
<h1>701458197</h1>
<div id="section-152" class="section level2">
<h2>221031</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 1 item.</p>
<p>the item is identified as Serenal (oxazolam 10mg/cap).</p>
<p>the drug will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-153" class="section level1">
<h1>701272100</h1>
<div id="section-154" class="section level2">
<h2>221028</h2>
<ul>
<li>diagnosis 2022-06-24 discharge
<ul>
<li>Pancreas adenocarcinoma, pT2N2(cM0); Stage III status post
pylorus-preserving pancreaticoduodenectomy with lymph node dissection on
2021/03/29 s/p concurrent chemoradiotherapy</li>
<li>Chronic viral hepatitis B without delta-agent</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-09 CT - abdomen
<ul>
<li>FINDINGS:
<ul>
<li>Prior CT identified several metastatic nodes in para-aortic space
and left common iliac chain are noted again, decreasing in size that may
be metastatic nodes S/P C/T with partial response .</li>
<li>S/P Whipple operation and S/P cholecystectomy.
<ul>
<li>Mild dilatation of the IHDs on both lobes are noted.</li>
<li>Please correlate with serum alk-p and bilirubin level.</li>
</ul></li>
<li>There is a poor enhancing lesion 1.1 cm in S6 liver that is c/w
cyst.<br />
</li>
<li>There is a enlarged node measuring 1.8 x 1.1 cm in the para-tracheal
space that may be metastatic node.</li>
</ul></li>
<li>IMP:
<ul>
<li>Metastatic nodes in para-aortic space and left common iliac chain
S/P C/T show partial response. Follow up is indicated.</li>
<li>Metastatic node in paratracheal space measuring 1.8 x 1.1 cm is
highly suspected.</li>
</ul></li>
</ul></li>
<li>2022-07-15 Tc-99m MDP whole body bone scan
<ul>
<li>Mildly increased activity in the lower C- and lower L-spines.
Degenerative change may show this picture.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?). Please follow up bone
scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, hips, knees and feet,
compatible with benign joint lesions.</li>
</ul></li>
<li>2022-06-21 SONO - neurology
<ul>
<li>Minimal atherosclerosis in bilateral CCA bifurcations.</li>
<li>Normal extracranial carotid, vertebral, and intracranial basal
cerebral arterial flows.</li>
</ul></li>
<li>2022-06-16 MRI - brain
<ul>
<li>No abnormal enhancing lesion within brain parenchyma.</li>
<li>Mild periventricular small vessel disease. NO acute ischemic
infarct.</li>
</ul></li>
<li>2022-05-25 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-05-25 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>There are several newly-developed nodes in para-aortic space and
left common iliac chain that may be metastatic nodes.</li>
<li>S/P Whipple operation and S/P cholecystectomy.</li>
<li>Mild pneumobilia on both lobes IHDs are noted.</li>
<li>There is a poor enhancing lesion 1.1 cm in S6 liver that is c/w
cyst.<br />
</li>
</ul></li>
<li>Imp:
<ul>
<li>There are several newly-developed nodes in para-aortic space and
left common iliac chain that may be metastatic nodes.</li>
</ul></li>
</ul></li>
<li>2022-03-28 Patho - soft tissue biopsy/simple excision (non lipoma)
<ul>
<li>Skin and soft tissue, abdominal wall #1, excision — Fat
necrosis</li>
<li>Soft tissue, abdominal wall #2, excision — Fat necrosis</li>
</ul></li>
<li>2022-03-01 Patho - soft tissue debridment
<ul>
<li>Labeled as “abdominal wall tumor around the scar region”, clinical
history of pancreatic ductal carcinoma, needle biopsy — fibrosis.</li>
<li>IHC stains: CD68 highlights many histiocytes. CK (-): no
carcinoma.</li>
</ul></li>
<li>2022-02-25 CT - abdomen, pelvis
<ul>
<li>S/P Whipple operation and S/P cholecystectomy. There is no evidence
of tumor recurrence.</li>
<li>Mild pneumobilia on both lobes IHDs are noted.</li>
</ul></li>
<li>2021-10-14 CT - abdomen, pelvis
<ul>
<li>Pancreatic cancer s/p operation. No evidence of tumor
recurrence.</li>
</ul></li>
<li>2021-07-27 MRI - MR Cholangiography, MRCP
<ul>
<li>Pancreatic cancer s/p operation. No evidence of tumor
recurrence.</li>
</ul></li>
<li>2021-07-07 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>S/P Whipple operation and S/P cholecystectomy.</li>
<li>There is mild fatty stranding and suspicious mild fluid collection
at the anastomosis area of the pancreaticojejunostomy that may be
post-operative change. The differential diagnosis include partial
leakage? please correlate with clinical condition.</li>
<li>There is a round, encapsulated lesion in the subcutaneous fat layer
of the midline incisional wound with a central area of predominantly fat
attenuation, a finding indicative of encapsulated fat necrosis.</li>
<li>Mild ascites in the pelvis is suspected.</li>
<li>Fatty liver, grade 4, is noted.</li>
</ul></li>
<li>IMP:
<ul>
<li>Post-operative change at the anastomosis area of the
pancreaticojejunostomy is suspected. The differential diagnosis include
partial leakage? please correlate with clinical condition.</li>
<li>Encapsulated Fat necrosis in the subcutaneous fat layer of the
incisional wound is suspected.</li>
</ul></li>
</ul></li>
<li>2021-03-30 Patho - gallbladder (benign lesion)
<ul>
<li>Gallbladder, cholecystectomy — Chronic cholecystitis<br />
</li>
<li>The sections show a picture of chronic cholecystitis, composed of
congestion, mild chronic inflammatory cells infiltration, mild mural
fibrosis, and scattered Rokitansky-Aschoff sinuses.</li>
</ul></li>
<li>2021-03-30 Patho - liver partial resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Lymph nodes, LN 7, 8, 9, 11p, 12, dissection — Metastatic
adenocarcinoma (1/18)<br />
</li>
<li>Lymph node, J1, dissection — Metastatic adenocarcinoma (1/1)<br />
</li>
<li>Lymph node, SMV, dissection — Metastatic adenocarcinoma (1/1)<br />
</li>
</ul></li>
</ul></li>
<li>2021-03-30 Patho - pancreas total/subtotal resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Pancreas, Whipple operation — Ductal adenocarcinoma, moderately
differentiated<br />
</li>
<li>Lymph nodes, regional, Whipple operation — Metastatic carcinoma
(8/44)<br />
</li>
<li>Pathologic Staging: pT2N2; Stage III if cM0<br />
</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>Specimen Type: Whipple operation<br />
</li>
<li>Venous (Large Vessel) Invasion: Absent<br />
</li>
</ul></li>
<li>microscopic examination Representative parts are taken for section
and labeled as: A1=
<ul>
<li>Histologic Type: Ductal adenocarcinoma<br />
</li>
<li>Histologic Grade: Moderately differentiated (G2)<br />
</li>
<li>Tumor Extension: Tumor invades peripancreatic soft tissue<br />
</li>
<li>Lymphvascular Invasion: Present</li>
</ul></li>
</ul></li>
<li>2021-03-12 Patho - pancreas biopsy
<ul>
<li>Labeled as “pancreatic tumor”, EUS guided FNA/B of Pancreas —
adenocarcinoma.</li>
<li>IHC stain: CK highlights small irregular infiltrative neoplastic
ducts.<br />
</li>
<li>Section shows cores of markedly necrotic tissue with atypical
mucinous gnads.</li>
</ul></li>
<li>2021-03-12 Cell block
<ul>
<li>cytologic diagnosis
<ul>
<li>Atypia</li>
</ul></li>
<li>gross description
<ul>
<li>32 cc, light orange, turbid<br />
</li>
</ul></li>
<li>microscopic description
<ul>
<li>Smears an cell block show scant atypical hyperchromatic epithelial
cells. The speicmen may not be representative for low cellularity.<br />
</li>
</ul></li>
</ul></li>
<li>2021-03-12 Endoscopic Ultrasonography, EUS
<ul>
<li>Diagnosis
<ul>
<li>Suspected Pancreatic head cancer s/p CH-EUS &amp; EUS/FNB</li>
<li>Pancreatic cystic lesions, pancreatic body, suspected IPMN</li>
<li>Peri-pancreatic lymphadenopathy</li>
<li>Shallow duodenal ulcer, bulb</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/u pathology</li>
<li>PPI use for ulcer</li>
</ul></li>
</ul></li>
<li>2021-03-11 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Pancreatic tumor, uncinate process</li>
<li>Pancreatic cystic lesions, body</li>
<li>Main pancreatic duct dilatation</li>
<li>Liver cysts, three, S3 and S6</li>
<li>Suspected renal stone, left kidney</li>
</ul></li>
<li>Suggestion
<ul>
<li>correlated wtih other images and tumor markers</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-15 ENT
<ul>
<li>Q
<ul>
<li>For dizziness when turn the neck for 1 week.</li>
<li>This 64-year-old female has past history of gastric ulcer. According
for her statement, she noted for pancreatic tumor for 3 years with
regular follow up at other hospital. However, health examination
revealed pancreatic lesion by abdomen MRI which showed a 2.2cm sized
progressive rim enhancing lesion is noted at uncinate process of the
pancreas, with high signal intensity on T2WI, diffusion restriction,
nature to be determined. suspect of pancreatic cancer, solid
pseudopapillary tumor. She came to our OPD for further management. EUS
was also performed and showed 1) R/o Pancreatic head cancer s/p biopsy.
2) Pancreatic cystic lesions, pancreatic body, r/o IPMN. 3)
Peri-pancreatic lymphadenopathy. 4) Shallow duodenal ulcer, bulb. Tumor
marker of CEA: 2.05ng/ml, CA-199: 469.32U/ml on 2021/03/16. She referred
to our GS OPD for further treatment.</li>
<li>Now, she is admitted for Abraxane and Gemcitabine on 2022-06-14, she
complaints dizziness when turn the neck for 1 week, so we need tour
help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>PE: Bil. Dix-Hallpike test negative, no spontaneous nor motional
nystagmus</li>
<li>According to her statement, favoring resolved BPPV, unspecific
ear</li>
<li>However, still have to r/o tumor metastasis</li>
<li>May prescribe Diphenidol for her remaining dizziness</li>
</ul></li>
</ul></li>
<li>2021-08-20 Infectious Disease
<ul>
<li>Q
<ul>
<li>This 63-year-old is a case of Pancreas adenocarcinoma, pT2N2(cM0);
Stage III status post pylorus-preserving pancreaticoduodenectomy with LN
dissection s/p CCRT. This time, for abdominal wound casr with pus in
2021/07 with antibiotic Metrozole 1# po QID and Amoxicillin 2# po Q8H
theraoy. But, Pus/C showed normal. Now, for evaluate antibiotic therapy.
Thank you.</li>
</ul></li>
<li>A
<ul>
<li>A 63-year-old woman of pancreas adenocarcinoma. Wound/pus culture
revealed no growth. The common infecting bacteria of deep wound
infection including Streptococci, Staphylococci, and gram
negative-negative enteric bacteria possible. MRSA has been reported to
account for up to 21% of nosocomial skin infections. Vancomycin
typically is the drug of choice for methicillin-resistant
coagulase-negative and coagulase-positive staphylococcal infections. It
is also useful against penicillin-resistant streptococcal infections.
Anti-microbiologic coverage as with parenteral Vancocin 500 mg or + -
(plus Fortum 1.0 gm) q12h is recommended.</li>
</ul></li>
</ul></li>
<li>2021-04-10 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For further chemotherapy</li>
<li>This 64 y/o female a case of pancreatic head cancer s/p PPPD + LND
on 20220329. The final pathology revealed ductal adenocarcinoma,
moderately differentiated, lymph nodes metastatic (8/44), Staging:
pT2N2M0; Stage III. Now, her condition improve and appetite fair. We
need your expertise for further chemotherapy. Thanks for your
times.</li>
</ul></li>
<li>A
<ul>
<li>A case MD pancreatic ductal adenocarinoma, post PPPD and LND,
pT2N2(8/44)M0, Stage III, was noted.</li>
<li>My suggestion would be:
<ul>
<li>The adjuvnat treatment is mandatory. May consider CCRT followed by
C/T</li>
<li>Please check HBV (HBs Ag, Anti-HBs Ab, Anti-HBc Ab) and HCV
(Anti-HCV) status during this admission, or I will check in my OPD</li>
<li>If possible, please check CA199/CEA, or I will check in my OPD</li>
<li>If MBD, please arrange my OPD</li>
<li>Please arrange Port-A if possible.</li>
</ul></li>
<li>Thanks for your consultation. Any problem, please let me know.</li>
</ul></li>
</ul></li>
<li>2021-04-09 Radiation Oncology
<ul>
<li>Q
<ul>
<li>For further radiotherapy</li>
<li>This 64 y/o female a case of pancreatic head cancer s/p PPPD + LND
on 20220329. The final pathology revealed ductal adenocarcinoma,
moderately differentiated, lymph nodes metastatic (8/44), Staging:
pT2N2M0; Stage III. We need your expertise for further radiotherapy.
Thanks for your times.<br />
</li>
</ul></li>
<li>A
<ul>
<li>The patient’s history was reviewed and patient was examined.</li>
<li>S:
<ul>
<li>For postoperative radiotherapy due to pancreatic cancer.</li>
<li>PI: Ductal adenocarcinoma, moderately differentiated of the
pancreas, pathologic Staging: pT2N2(cM0); Stage III, s/p PPPD with LN 5,
6,7,8,9,11p,12, 14a &amp; v dissection on 2021-03-29.<br />
</li>
<li>Family history: (father: prostate cancer, elder brother: esophageal
cancer)</li>
<li>Cancer site specific factors: Alcohol (-); Smoking (quit); Betel nut
(-).</li>
<li>Personal Hx: DM(-); HTN(-)</li>
<li>Other disease: (-)</li>
<li>Previous RT Hx: (-)</li>
</ul></li>
<li>O:
<ul>
<li>ECOG: 1</li>
<li>PE: neck and bil SCF: neg; abdomen: surgical scar and status during
drainage.</li>
<li>CXR (2021-03-09): Essential negative findings</li>
<li>Abd sono (2021-03-11): pancreatic tumor, uncinated process;
pancreatic cystic lesions, body; main pancreatic duct dilatation; liver
cysts, three, S3 and S6; suspected renal stone, left kidney.</li>
<li>CA199 (2021-03-16): 469.32</li>
<li>Operation (2021-03-29): PPPD with LN 5, 6,7,8,9,11p,12, 14a &amp; v
dissection.</li>
<li>Pathology (S2021-04713, 2021-04-01): 1. Lymph nodes, LN 7, 8, 9,
11p, 12, dissection — Metastatic adenocarcinoma (1/18). 2. Lymph node,
J1, dissection — Metastatic adenocarcinoma (1/1). 3. Lymph node, SMV,
dissection — Metastatic adenocarcinoma (1/1).</li>
<li>Pathology (S2021-04715, 2021-04-01): 1. Pancreas, Whipple operation
— Ductal adenocarcinoma, moderately differentiated. 2. Lymph nodes,
regional, Whipple operation — Metastatic carcinoma (8/44). 3. Pathologic
Staging: pT2N2; Stage III if cM0. Uncinate margin: Uninvolved by
invasive carcinoma, 1 mm from closest margin.<br />
</li>
</ul></li>
<li>A:
<ul>
<li>Ductal adenocarcinoma, moderately differentiated of the pancreas,
pathologic Staging: pT2N2(cM0); Stage III, s/p PPPD with LN 5,
6,7,8,9,11p,12, 14a &amp; v dissection.</li>
</ul></li>
<li>P:
<ul>
<li>Radiotherapy is indicated for this patient with the following
indicators: Staging: pT2N2(cM0); Stage III, and close margin.</li>
<li>Goal: curative</li>
<li>Treatment target and volume: pancreatic tumor bed, peripheral, to
regional lymphatic area.</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 4500cGy/25 fractiobns</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and her brother’s son. They understand and
agree to receive radiotherapy. The treatment planning of radiotherapy
will be started at 11AM, 2021-04-22.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-03-29
<ul>
<li>Surgery
<ul>
<li>PPPD with LN 5, 6, 7, 8, 9, 11p, 12, 14a &amp; v dissection</li>
</ul></li>
<li>Finding
<ul>
<li>2 x 2.0cm tumor at uncinate process with SMV partial invasion</li>
<li>multiple LN palpable at proximal SMA to J1</li>
<li>P-duct 3mm with soft pancreas</li>
<li>C-duct 1.0cm</li>
</ul></li>
</ul></li>
<li>2021-03-28
<ul>
<li>Surgery
<ul>
<li>Excision of subcut tumor 4 x 2 cm</li>
<li>and 1.5 x 1.0 cm at midline abdominal wound</li>
</ul></li>
<li>Finding
<ul>
<li>two subcut hard mass at upper mdiline laparotomy wound</li>
<li>4 cm and 1.5 cm</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-04-29 ~ 2021-06-02) - 4500cGy/25 fractions (15MV photon) of the
pancreatic tumor bed, peripheral, to regional lymphatic area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-19 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 30min</li>
<li>2022-10-05 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 30min</li>
<li>2022-09-28 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 30min</li>
<li>2022-09-14 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 30min</li>
<li>2022-09-07 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 150mg 30min</li>
<li>2022-08-24 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-08-17 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-08-03 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-07-20 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-07-13 - gemcitabine 800mg/m2 1200mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-06-29 - gemcitabine 1000mg/m2 1400mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-06-23 - gemcitabine 1000mg/m2 1400mg 30min + nab-paclitaxel
100mg/m2 140mg 30min</li>
<li>2022-02-09 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2022-01-18 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2022-01-03 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-12-16 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-12-01 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-11-16 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-11-03 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-10-15 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-09-30 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
85mg/m2 120mg 2hr + leucovorin 400mg/m2 550mg 48hr + fluorouracil
2800mg/m2 4000mg 48hr</li>
<li>2021-09-09 - gemcitabine 1000mg/m2 1600mg 30min + oxaliplatin
85mg/m2 130mg 2hr + leucovorin 400mg/m2 600mg 48hr + fluorouracil
2800mg/m2 4300mg 48hr</li>
<li>2021-08-24 - gemcitabine 800mg/m2 1100mg 30min + oxaliplatin 65mg/m2
100mg 2hr + leucovorin 200mg/m2 280mg 48hr + fluorouracil 2000mg/m2
2800mg 48hr</li>
<li>2021-07-19 - gemcitabine 1000mg/m2 1400mg 30min + oxaliplatin
65mg/m2 100mg 2hr + leucovorin 240mg/m2 350mg 48hr + fluorouracil
2400mg/m2 3500mg 48hr</li>
<li>2021-06-02 - gemcitabine 400mg/m2 600mg 30min (CCRT)</li>
<li>2021-05-27 - gemcitabine 400mg/m2 600mg 30min (CCRT)</li>
<li>2021-05-17 - gemcitabine 400mg/m2 600mg 30min (CCRT)</li>
<li>2021-05-07 - gemcitabine 400mg/m2 600mg 30min (CCRT)</li>
<li>2021-04-29 - gemcitabine 400mg/m2 700mg 30min (CCRT)</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>NCCN Pancreatic Adenocarcinoma 20210225 evidence blocks p35~36
<ul>
<li>neoadjuvant therapy
<ul>
<li>FOLFIRINOX or modified FOLFIRINOX +- subsequent chemoradiation</li>
<li>Gemcitabine + albumin-bound paclitaxel +- subsequent
chemoradiation</li>
<li>Only for known BRCA1/2 or PALB2 mutations
<ul>
<li>FOLFIRINOX or modified FOLFIRINOX +- subsequent chemoradiation</li>
<li>Gemcitabine + cisplatin (&gt;= 2-6 cycles) +- subsequent
chemoradiation</li>
</ul></li>
</ul></li>
<li>adjuvant therapy
<ul>
<li>preferred regimens
<ul>
<li>Modified FOLFIRINOX (category 1)</li>
<li>Gemcitabine + capecitabine (category 1)</li>
</ul></li>
<li>other recommended regimens
<ul>
<li>Gemcitabine (category 1)</li>
<li>5-FU + leucovorin (category 1)</li>
<li>Continuous infusion 5-FU</li>
<li>Capecitabine (category 2B)</li>
<li>Induction chemotherapy (gemcitabine, 5-FU + leucovorin, or
continuous infusion 5-FU) followed by chemoradiation</li>
<li>Induction chemotherapy (gemcitabine, 5-FU + leucovorin, or
continuous infusion 5-FU) followed by chemoradiation followed by
subsequent chemotherapy  - Gemcitabine followed by chemoradiation
followed by gemcitabine -Bolus 5-FU + leucovorin followed by
chemoradiation followed by bolus 5-FU + leucovorin -Continuous infusion
5-FU followed by chemoradiation followed by continuous infusion
5-FU</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-155" class="section level3">
<h3>==========</h3>
</div>
<div id="section-156" class="section level3">
<h3>2022-10-28</h3>
<ul>
<li>According to 2022-09-09 CT (compared to 2022-05-25 CT), the disease
has had a partial response to the current regimen started
2022-06-23.</li>
<li>Oxacillin (currently used) or cefalotin remain the drugs of choice
for treating uncomplicated cellulitis (of left lower limb) in regions
where community-acquired methicillin-resistant S. aureus is
infrequent.</li>
<li>The active prescription does not pose any problems.</li>
</ul>
</div>
<div id="section-157" class="section level3">
<h3>2022-06-15</h3>
<ul>
<li>2022-05-25 CT showed several newly-developed nodes in para-aortic
space and left common iliac chain that may be metastatic nodes.</li>
<li>CA199 levels time series showed the biomarker has roughly tripled in
the last six months.
<ul>
<li>2022-06-13 88.35 U/mL</li>
<li>2022-05-25 78.08 U/mL</li>
<li>2022-04-29 83.18 U/mL</li>
<li>2022-02-23 31.33 U/mL</li>
<li>2022-01-26 28.59 U/mL</li>
<li>2022-01-18 29.57 U/mL</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-158" class="section level1">
<h1>701457957</h1>
<div id="section-159" class="section level2">
<h2>221027</h2>
<p>{colon cancer}</p>
<ul>
<li>exam findings
<ul>
<li>2022-10-22 CXR
<ul>
<li>Tortuosity of the aorta with atherosclerotic change.</li>
<li>Increased infiltration over RLL. May be active infection.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Fasting blood sugar level is highly volatile (103 ~ 419 mg/dL).
Acute infections lead to difficulty in controlling blood sugar levels
and infectious diseases are more frequent and/or serious in patients
with diabetes mellitus. The patient has been prescribed biosynthetic
human insulin.</li>
<li>Despite improvements in renal function compared to 2022-10-24,
creatinine and BUN levels remain high (creatinine 2.33 mg/dL and BUN 55
mg/dL on 2022-10-27).</li>
<li>When there is no evidence of active bleeding, the pantoprazole
injection might be switched to an oral PPI.</li>
</ul>
</div>
</div>
<div id="section-160" class="section level1">
<h1>700014137</h1>
<div id="section-161" class="section level2">
<h2>221026</h2>
<p>{Extranodal NK/T-cell lymphoma, nasal type, Lugano stage II, PS:
0}</p>
<ul>
<li>initial presentation
<ul>
<li>2022-04
<ul>
<li>nasal stuffness and abscess discharge.</li>
<li>fever and weight loss about 4kg in 2 months and night sweats were
also noted.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-08-08 CMV viral load assay 39 IU/mL<br />
</li>
<li>Anti-HBc
<ul>
<li>2022-06-09 Reactive 7.68 S/CO<br />
</li>
</ul></li>
<li>EBV DNA PCR
<ul>
<li>2022-06-08 2724 copies/mL<br />
</li>
</ul></li>
<li>HBsAg
<ul>
<li>2022-06-01 Negative 0.517<br />
</li>
</ul></li>
<li>Anti-HCV
<ul>
<li>2022-06-01 Negative 0.0409</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-10-06 Sinoscopy
<ul>
<li>bil profuse otorrhea, L mucopus</li>
</ul></li>
<li>2022-09-19 Sinoscopy
<ul>
<li>nasal ca s/p CCRT</li>
</ul></li>
<li>2022-09-05 Nasopharyngoscopy
<ul>
<li>nasal cancer s/p CCRT</li>
<li>gr4 mucositis + mucopus</li>
</ul></li>
<li>2022-08-22 Sinoscopy
<ul>
<li>bil nasal synehiae (basal) + L IT synechiae lyzed after intranasal
injection + L nasal packing + post nasal septal R/T mucositis, gr 3</li>
<li>post R/T mucositis, ENT local treatment done</li>
</ul></li>
<li>2022-08-22 Pure Tone Audiometry, PTA
<ul>
<li>Tymp:
<ul>
<li>Bil grommet</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 50 dB HL; LE 56 dB HL.</li>
<li>bil mild to severe mixed type HL.</li>
<li>tinnitus(+)</li>
</ul></li>
</ul></li>
<li>2022-08-19 C-spine AP + Lat.
<ul>
<li>Degeneration and spondylosis of C-spine.</li>
</ul></li>
<li>2022-08-15 Nasopharyngoscopy
<ul>
<li>nasal ca under CCRT</li>
</ul></li>
<li>2022-08-02 Nasopharyngoscopy
<ul>
<li>crust and bloody discharge at bil nasal internal nasal valve and bil
nasal septum, covered with Surgicel, smooth OPx, HPx</li>
</ul></li>
<li>2022-07-31 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Left axis deviation</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-07-28 Pure Tone Audiometry, PTA
<ul>
<li>Tymp:
<ul>
<li>R’t type C; L’t type B.</li>
</ul></li>
<li>ART:
<ul>
<li>Bil absent.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 61 dB HL; LE 54 dB HL.</li>
<li>R’t mild to profound MHL.</li>
<li>L’t moderate to severe mixed type HL.</li>
</ul></li>
</ul></li>
<li>2022-07-21 Sinoscopy
<ul>
<li>much mucopus</li>
<li>no visible tumor</li>
</ul></li>
<li>2022-07-14 Nasopharyngoscopy
<ul>
<li>sinonasal lymphoma undergong CCRT</li>
</ul></li>
<li>2022-06-16 Sinoscopy
<ul>
<li>remove packing + R packing with Surgicel</li>
<li>2022/6/13 fiber = R nasal cancer, bleeing spontaneous (cancer+)
again after removal of nasal packing; thus, bil Merocel packing
again</li>
<li>intermittent L epistaxis noted for 2 months, went to ShuangHo
Hospital and Biopsy, NK/T-cell lymphoma, nasal type was diagnosed</li>
<li>went to our hospital for CCRT</li>
<li>Left epistaxis during admission, ENT was consulted, s/p L merocel
packing</li>
</ul></li>
<li>2022-06-16 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, moderate</li>
<li>Pancreas not shown</li>
<li>Suboptimal examination of liver due to poor echo window caused by
severe fatty infiltration</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver, especially liver dome and S1 was diffcult to
approach and easy missed</li>
<li>Because of poor echo window, infiltrative lesion or small lesion may
not be excluded completely. Please correlate with other image or follow
sono abd every 3-6 months.</li>
</ul></li>
</ul></li>
<li>2022-06-15 Nerve Conduction Velocity (NCV), Electromyography (EMG)
<ul>
<li>Findings
<ul>
<li>The ENoG study showed a facial CMAP amplitude ratio as 73%
(right/left) and prolonged distal latency in bilateral facial
nerves.</li>
<li>The results of blink reflex study were within normal limits.</li>
</ul></li>
<li>Conclusion
<ul>
<li>The above findings may suggest bilateral peripheral facial nerve
lesion, more severe in the right side, with demyelinating pattern.
Advise clinical correlation.</li>
</ul></li>
</ul></li>
<li>2022-06-13 Nasopharyngoscopy
<ul>
<li>smooth NPx, OPx, HPx</li>
</ul></li>
<li>2022-06-01 CT - lung/mediastinum/pleura
<ul>
<li>no abnormality in the chest and upper abdomen.</li>
</ul></li>
<li>2022-05-30 MRI - larynx
<ul>
<li>Findings
<ul>
<li>Extensive soft tissue tumor with T1-hypointensity, T2-hyperintensity
and vivid enhancement involving nasopharynx, soft palate, bilateral
nasal cavities, bilateral ethmoid and sphenoid sinsues, right maxillary
sinus wall, clivus and adjacent sphenoid bones.</li>
<li>No enlarged lymph node.</li>
<li>No abnormality at hypopharynx and larynx.</li>
<li>Diffuse mottled T2-hyperintensity filling in bilateral mastoid air
cells, indicating amstoiditis.</li>
<li>No abnormality at parotid, submandibular and sublingual glands.</li>
</ul></li>
<li>IMP:
<ul>
<li>Nasal-nasopharyngeal tumor with aforementioned involvement. D/D:
lymphoma, NPC.</li>
</ul></li>
</ul></li>
<li>2022-05-30 2D transthoracic echocardiography
<ul>
<li>Normal AV/MV with no AR/MR</li>
<li>Mild concentric LVH, normal LV wall motion</li>
<li>Preserved LV and RV systolic function</li>
<li>No PR, trivial TR, normal IVC size</li>
</ul></li>
<li>2022-05-30 EKG
<ul>
<li>Left axis deviation</li>
</ul></li>
<li>2022-05-28 CXR
<ul>
<li>Chest PA and Lat. LT view: Widening of the right upper mediastinum
is suspected. Please correlate with CT.</li>
</ul></li>
<li>2022-05-17 PET scan (at ShuangHo Hospital)
<ul>
<li>c/w lymphoma involving a NP, nasal cavity, ethmoid sinus, soft
palate.</li>
</ul></li>
<li>2022-05-03 Surgical pathology - nasal tumor biopsy (at ShuangHo
Hospital)
<ul>
<li>extranodal NK/T-cell lymphoma, nasal type.</li>
</ul></li>
<li>2018-02-21 Blink Reflex Studies
<ul>
<li>The ENoG study showed facial CMAP amplitude ratio as 74 %
(right/left). The blinking reflex study showed relatively prolonged
ipsilateral R1 and R2 latency when right side stimulation and relatively
prolonged contralateral R2 latency when left side stimulation. These
findings may suggest right facial nerve lesion.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-06-22 ~ 2022-08-08 - 2000cGy/10 fractions of the nasal -
nasopharyngeal, peripheral involved to bilateral neck nodal, and
5000cGy/25 fractions of the reduced nasal - nasopharyngeal, peripheral
involved area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-20 - carboplatin AUC 4 200mg/m2 300mg 2hr D1 + etoposide
67mg/m2 110mg 1hr D1-3 + ifosfamide 1000mg/m2 1700mg 4hr D1-3</li>
<li>2022-08-29 - carboplatin AUC 2 150mg/m2 260mg 2hr D1 + etoposide
67mg/m2 110mg 1hr D1-3 + ifosfamide 900mg/m2 1500mg 4hr D1-3 (full dose:
carboplatin 200mg/m2, etoposide 67mg/m2, ifosfamide 1000mg/m2)</li>
<li>2022-07-21 - carboplatin AUC 2 150mg/m2 270mg 2hr D1 + etoposide
67mg/m2 120mg 2hr D1-3 + ifosfamide 900mg/m2 1600mg 4hr D1-3<br />
</li>
<li>2022-06-08 - carboplatin AUC 2 150mg/m2 270mg 2hr D1 + etoposide
67mg/m2 120mg 2hr D1-3 + ifosfamide 900mg/m2 1600mg 4hr D1-3</li>
</ul></li>
<li>G-CSF
<ul>
<li>2022-09-06 Granocyte (lenograstim) 250mg QD SC OPD 2022-09-06</li>
<li>2022-08-03 Granocyte (lenograstim) 250mg QD SC IPD 2022-07-31</li>
</ul></li>
</ul>
<div id="section-162" class="section level3">
<h3>==========</h3>
</div>
<div id="section-163" class="section level3">
<h3>2022-10-26</h3>
<ul>
<li>Swelling around the eyes might be caused by inflammation resulting
from a variety of conditions, including infection, injury, and
allergies. If this is the case, some eye drops containing
steroid/antihistamine and/or antimicrobial might be beneficial.</li>
</ul>
</div>
<div id="section-164" class="section level3">
<h3>2022-08-30</h3>
<ul>
<li>Pure-tone audiometry 2022-08-22 RE 50 dB HL LE 56 dB HL &lt;-
2022-07-28 RE 61 dB HL LE 54 dB HL. There is no evidence of rapid
deterioration in hearing.</li>
<li>Tamsulosin has been prescribed. Please make sure that any possible
obstruction to the urinary tract has been eliminated or corrected before
beginning treatment with ifosfamide.</li>
</ul>
</div>
<div id="section-165" class="section level3">
<h3>2022-07-22</h3>
<ul>
<li>2022-06-15 electromyography suggested bilateral peripheral facial
nerve lesion, more severe in the right side, with demyelinating
pattern.</li>
<li>The neurology related adverse reaction incidences of the drugs in
current regimen:
<ul>
<li>carboplatin - Nervous system: Neurotoxicity (5%), peripheral
neuropathy (4% to 6%)</li>
<li>etoposide - Peripheral neuropathy (1% to 2%)</li>
<li>ifosfamide - Central nervous system: Brain disease (&lt;=15%),
central nervous system toxicity (&lt;=15%)</li>
</ul></li>
<li>Please monitor for newly developed neuropathy as usual.</li>
</ul>
</div>
<div id="section-166" class="section level3">
<h3>2022-06-09</h3>
<ul>
<li>There is no re-biopsy performed at our facility, in addition to our
imaging studies and pathology results from ShuangHo Hospital.</li>
<li>An EBV positive result (lab 2022-06-08 EBV DNA PCR 2724 copies/mL)
is consistent with NK/T-cell, nasal type. EBV-associated T- and NK-cell
lymphoproliferative disorders (LPD), including chronic active EBV
infection (CAEBV), can progress to aggressive NK-cell leukemia
(ANKL).</li>
<li>For extranodal NK/T-cell lymphomas, suggested treatment regimens can
be (ref <a href="https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2018/12/nhl-extranodalnk_0318_9414.pdf" class="uri">https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2018/12/nhl-extranodalnk_0318_9414.pdf</a>
)
<ul>
<li>combination chemotherapy regimen (asparaginase-based)
<ul>
<li>Modified SMILE (steroid [dexamethasone], methotrexate, ifosfamide,
pegaspargase, and etoposide) x 4-6 cycles for advanced stage</li>
<li>P-GEMOX (gemcitabine, pegaspargase, and oxaliplatin)</li>
<li>DDGP (dexamethasone, cisplatin, gemcitabine, pegaspargase)</li>
</ul></li>
<li>combined modality therapy
<ul>
<li>concurrent chemoradiation therapy: RT and 3 courses of DeVIC
(dexamethasone, etoposide, ifosfamide, and carboplatin) &lt;= currently
applied.</li>
<li>sequential chemoradiation: For stage I, II, modified SMILE x 2-4
cycles followed by RT</li>
<li>sandwich chemoradiation: P-GEMOX x 2 cycles followed by RT followed
by P-GEMOX x 2-4 cycles</li>
</ul></li>
</ul></li>
<li>CCRT using DeVIC is currently being applied during this hospital
stay.</li>
<li>Lab results 2022-06-08 indicated liver and kidney function, CBC, WBC
DC, electrolytes were grossly normal. TPR, PB is relatively stable.</li>
<li>There is a self-carried drug - amoxicillin 500mg PO Q8H - listed in
active prescription for the apical infection of tooth 26 and its
complicated extraction.</li>
</ul>
</div>
</div>
</div>
<div id="section-167" class="section level1">
<h1>701049370</h1>
<div id="section-168" class="section level2">
<h2>221025</h2>
<ul>
<li>diagnosis 20221003 discharge
<ul>
<li>B cell lymphoma, high grade, stage IV</li>
<li>Splenomegaly, not elsewhere classified</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-09-30 CXR
<ul>
<li>Fibrosis of left upper lung are suspected. Please correlate with
clinical history to R/O old inflammatory process.</li>
</ul></li>
<li>2022-09-19 Whole body PET scan
<ul>
<li>Glucose hypermetabolism lesions in bilateral cervical, bilateral
axillary, celiac chain, bilateral para-aortic space, and pre-vertebral
lymph nodes of lower T-spine, and spleen, highly suspected lymphoma with
involvement of lymph node regions on both sides of the diaphragm.</li>
<li>Glucose hypermetabolism lesions in T9-11 spines, highly suspected
lymphoma with involvement of bones and/or bone marrow.<br />
</li>
<li>Increased FDG uptake in bilateral pulmonary hilar and bilateral
mediastinal lymph nodes, probably reactive nodes (priority) or lymphoma
with involvement of lymph node regions, suggesting further
investigation.</li>
<li>B cell lymphoma, c-stage IV (AJCC 8th ed.), by this F-18 FDG PET
scan.</li>
</ul></li>
<li>2022-09-20 CXR
<ul>
<li>Interstitial pattern at LUL.</li>
</ul></li>
<li>2022-09-15 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Atypical lymphoid aggregates, favor
reactive</li>
<li>The sections show normocellular marrow (30%). The myeloid series
show good maturation. The megakaryocytes are normal in number and
morphology. Scattered interstitial, mixed small and large lymphoid cell
aggregates are present.</li>
<li>IHC, a mixture of CD3+ T and CD20+ B lymphocytes haphazardly
arranged with slightly B cell predominant are noted. The B cells also
show: BCL6(focal +), CD10(-), and CD23(-). The findings favor reactive
lymphoid aggregates. Suggest bone marrow smear evaluation and clinic
correlation.</li>
</ul></li>
<li>2022-09-01 Patho - fibrolipoma
<ul>
<li>Labeled as “right neck”, excisional biopsy — B cell lymphoma, high
grade.</li>
<li>Section shows lymph nodes with architecture obscured by large blasts
like neoplastic lymphoid cells (more than 15/HPFs) and scattered
centrocytes like cells.</li>
<li>IHC stains: CK (-), CD3 (focal+), CD20 (diffuse +), CD10 (+), bcl-2
(+), bcl-6 (+), MUM-1 (focal +, 10%), Ki-67: 60%, cyclin-D1:
(equivocal), c-myc (-). Vague lymphoid follicles are highlighted by IHC
stains. The pattern is suggestive of follicular lymphoma, grade 3A.</li>
</ul></li>
<li>2022-09-01 CT - abdomen
<ul>
<li>Thickening of right posterior pleura and prevertebral tissue at
T10-12.</li>
<li>Portal hypertension and splenomegaly.</li>
<li>Some LNs (up to 2.0cm) at retroperitoneum.</li>
</ul></li>
<li>2022-03-24 CT - abdomen
<ul>
<li>Thickening of right posterior pleura and prevertebral tissue at
T10-12.</li>
<li>Increased soft tissue at left pubic cavity.</li>
<li>Portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-12-21 Patho - soft tissue nontumor/mass/lipoma/degridement
<ul>
<li>Soft tissue mass, left pelvic cavity, CT-guide biopsy — Suggestive
of benign, reactive change<br />
</li>
<li>Microscopically, the sections show a picture of almost small to
medium-sized lymphocytes infiltration with monocytoid feature.<br />
</li>
<li>Immunohistochemistry shows CK(-), CD3, CD5 and CD43 (+, diffuse),
CD20(+, diffuse), CD10(+) for follicle, Bcl-2(-) for follicle, CD23(-)
and Cyclin-D1(-). According to all histopathologic findings, it is
suggestive of reavtive hyperplasia and less likely lymphoma. However,
repeat biopsy or excision is advised for further evaluation, if
malignancy is still suspected clinically.</li>
</ul></li>
<li>2021-12-13 CT - abdomen
<ul>
<li>Thickening of right posterior pleura and prevertebral tissue at
T9-12.</li>
<li>Increased soft tissue at left pubic cavity.</li>
<li>Portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-12-07 SONO - abdomen
<ul>
<li>Splenmegaly, marked</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-24 - rituximab 375mg/m2 600mg 8hr + cyclophosphamide
750mg/m2 1200mg 30min + doxorubicin 50mg/m2 50mg 30min + vincristine
1.4mg/m2 2mg 10min + prednisolone 60mg/m2 5mg/tab 18# 90mg QD D1-5</li>
<li>2022-09-30 - rituximab 375mg/m2 600mg 8hr + prednisolone 60mg/m2
5mg/tab 8# 40mg BID D1-5</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There is evidence of splenomegaly, portal hypertension, and high
bilirubin levels (direct and total), but the cause is not yet
known.</li>
<li>Interstitial pattern and/or fibrosis at LUL has been observed.
Rituximab has been associated with pulmonary disease and/or pulmonary
toxicity. It might be necessary to monitor the lung status on a regular
basis.</li>
<li>As far as the current prescription is concerned, there is no
problem.</li>
</ul>
</div>
</div>
<div id="section-169" class="section level1">
<h1>700141460</h1>
<div id="section-170" class="section level2">
<h2>221024</h2>
<ul>
<li>chemoimmunotherapy
<ul>
<li>2022-09-14 - irinotecan 150mg/m2 230mg 90min + leucovorin 400mg/m2
600mg 2hr + fluorouracil 2400mg 3600mg 46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Coxine (isosorbide-5-mononitrate) has been prescribed for the
patient’s high hs-Troponin I (241.8 pg/mL 2022-10-22) and CKMB (9.7
ng/mL 2022-10-22).</li>
<li>The most recent record of blood pressure was 100/52 (2022-10-24
08:41). The perfusion of vital organs, including the coronary arteries,
might be compromised by low blood pressure. Saline 0.9% 500mL IVD PRNQD
has been prescribed.</li>
<li>There is an impairment of renal function in the patient.
Hemodialysis will be arranged by a nephrologist.</li>
<li>Currently, the serum potassium level is within the normal range (3.5
mmol/L 2022-10-22)</li>
<li>The blood calcium concentration of this patient is frequently below
normal. The addition of some phosphate binders may be beneficial.
Phosphate binders are categorized as calcium-containing and
noncalcium-containing. Calcium-containing binders include calcium
carbonate and calcium acetate. Major noncalcium-containing binders
include sevelamer and lanthanum. Other agents include ferric citrate and
sucroferric oxyhydroxide.</li>
</ul>
</div>
</div>
<div id="section-171" class="section level1">
<h1>700511404</h1>
<div id="section-172" class="section level2">
<h2>221024</h2>
<ul>
<li>past history (2022-10-22 adminnote)
<ul>
<li>DM</li>
<li>Hypertension</li>
<li>Left breast cancer s/p OP</li>
<li>GERD</li>
<li>Constipation</li>
<li>Hyperthyroidism</li>
<li>Breast cancer s/p C/T (bil leg numbness)</li>
<li>Multiple myeloma IgA kappa + lambda biclonce /p Ixazomib since
2022/7-2022/8 and lenalidomide 1# QOD and dexamethasone since 2022/7 to
now.</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-12-02 CT - brain
<ul>
<li>A skull defect at left temporal region. Some lucent lesions in
skull.</li>
<li>Brain atrophy and lacunar infarct.</li>
</ul></li>
<li>2022-11-03 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably mild myocardial ischemia at the apex.</li>
<li>Mild reverse redistribution of radioactivity to the anteroapical
wall and posterior wall, either normal variant or myocardial ischemia
may show this picture.</li>
</ul></li>
<li>2022-11-03 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (124 - 49) / 124 = 60.48%
<ul>
<li>M-mode (Teichholz) = 60</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Trivial MR, mild AR, mild TR</li>
<li>Mild pulmonary hypertension</li>
<li>LV diastolic dysfunction, Gr 1</li>
<li>Preserved RV systolic function</li>
<li>Sinus rhythm at the exam</li>
</ul></li>
<li>2022-10-25 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — myeloma.</li>
<li>IHC stains: CD138: 60%; Kappa and Lambda light chains show a
predominant lambda sub-population. CD34: &lt;1 %; MPO: 30-40% (of the
nucleated cells).</li>
<li>Section shows piece(s) of bone marrow with 40 % cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes and increase in the number of plasmacytoid
cells. Megakaryocytes are adequate in number.</li>
</ul></li>
<li>2022-10-24 Abdomen
<ul>
<li>Spondylosis of the L-spine is noted.</li>
<li>Compression fracture of T12, L2, L4, and L5 are suspected.</li>
</ul></li>
<li>2022-10-22 CXR
<ul>
<li>Cardiomegaly and tortuosity of the thoracic aorta.</li>
<li>Widening of the mediastinum.</li>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-03-08 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Multiple myeloma</li>
<li>Microscopically, the bone marrow shows multiple myeloma
characterized by hypercellularity (90%), 2:3 of M:E ratio and a
proliferation of plasma cells (11~20%).</li>
<li>Immunohistocehmical stain reveals CD20(+, 15%), CD138(&gt;10%),
Kappa(-), Lambda(+), MPO(+), CD34(-), CD117(-) and CD71(+).</li>
</ul></li>
<li>2021-12-09 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae: free</li>
<li>EM: 8.3mm.</li>
</ul></li>
<li>2021-03-05 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — &lt;2% of CD138+ cells<br />
</li>
<li>Microscopically, it shows 30% of cellularity, 1:1 of M:E ratio,
occasional normal megakaryocytes and &lt;2% of CD138+ cells.<br />
</li>
<li>Immunohistochemical stain reveals CD138(&lt;2%), CD71(+), MPO(+),
CD117(-), CD34(-), CD20 (2~3%).<br />
</li>
</ul></li>
<li>2021-01-25 ENT Hearing Test
<ul>
<li>Reliabilty Fair</li>
<li>PTA
<ul>
<li>R’t : 58 dB HL</li>
<li>L’t : 50 dB HL</li>
<li>Bil mild to moderately severe SNHL</li>
</ul></li>
<li>Tymp
<ul>
<li>R’t : Type As</li>
<li>L’t : Type C</li>
</ul></li>
<li>ART
<ul>
<li>Bil absent.</li>
</ul></li>
</ul></li>
<li>2020-10-20 ENT Hearing Test
<ul>
<li>Tymp bil type As</li>
<li>ART bil contra and RE ipsi absent, LE ipsi reduced thretholds</li>
<li>E- tube function bil poor</li>
<li>PTA:
<ul>
<li>Reliability FAIR</li>
<li>Average RE 60 dB HL, LE 50 dB HL
<ul>
<li>RE mild to severe SNHL</li>
<li>LE mild to moderately severe SNHL</li>
</ul></li>
</ul></li>
<li>RE tinnirus</li>
</ul></li>
<li>2020-10-20 OVEMP
<ul>
<li>oVEMP (ocular vestibular-evoked myogenic potential)
<ul>
<li>Bil show no response</li>
</ul></li>
<li>cVEMP (cervical VEMP)
<ul>
<li>Bil show no response</li>
</ul></li>
</ul></li>
<li>2020-10-20 Electronystagmography, ENG
<ul>
<li>no abnormal nystagmus</li>
</ul></li>
<li>2020-09-28 C-spine Lat. flex. and ext.
<ul>
<li>Osteoporosis. Spondylosis, esp C5-6-7.</li>
</ul></li>
<li>2020-08-28 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Compatible with plasma cell myeloma with
partial remission<br />
</li>
<li>The sections show normocellular marrow (20%). M/E ratio = 3:1. The
myeloid cells show good maturation. The megakaryocytes are normal in
number and morphology.</li>
<li>IHC, scattered CD138+ plasma cells in interstitium, account for
&lt;5% of marrow cells with lambda light chain restriction and negative
for kappa light chain. Suggest further bone marrow smear evaluation and
clinic correlation.</li>
</ul></li>
<li>2020-04-13 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (112 - 44.1) / 112 = 60.63%
<ul>
<li>M-mode (Teichholz) = 60.6</li>
</ul></li>
<li>Adequate LV systolic function with no regional wall motion
abnormality at resting state</li>
<li>Mild aortic, mitral and tricuspid regurgitation</li>
<li>Dilated LA, thick IVS and LVPW</li>
<li>Impaired LV relaxation</li>
</ul></li>
<li>2020-04-09 Long bones series
<ul>
<li>Few osteopenic defects at bilateral radius, bilateral humerus,
bilateral femur, bilateral fibular and bilateral scapular are
suspected.</li>
</ul></li>
<li>2020-04-07 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — Myeloma.</li>
<li>IHC stains: CD138 (+, 85-90% of the nucleated cells), kappa (+,
80-90%), lambda (&lt;5%), MPO (&lt;5%), CD117 (&lt;1%)<br />
</li>
<li>Section shows one piece of bone marrow with 40-50% cellularity and a
predominant plasmacytoid cells.</li>
</ul></li>
<li>2020-04-06 Patho - bone exostosis
<ul>
<li>Soft tissue and bone, L5 body and right upper sacrum, CT-guided
biopsy — Plasma cell neoplasm, compatible with plasma cell myeloma<br />
</li>
<li>The sections show plasma cell neoplasm, composed of diffuse sheets
of neoplastic round cells with abundant basophilic cytoplasm and
eccentric nuclei. Occasional intranuclear inclusions (Dutcher body) can
be found.</li>
<li>IHC, the neoplastioc cells reveal: CD138(+), cytokeration(-), lambda
light chain(+), and kappa light chain(-). Suggest clinic
correlation.</li>
</ul></li>
<li>2020-04-01 SONO - nephrology
<ul>
<li>right adrenal tumor, nature to be determined</li>
</ul></li>
<li>2020-03-31 MRI - L-spine
<ul>
<li>Small L4/5 central HIVD.</li>
<li>L2 compression fracture.</li>
<li>Mass or nodule in anterior L5 body and right upper sacrum, suspected
multiple myeloma, metastases</li>
</ul></li>
<li>2019-06-05 Color Transcranial Sonographic, CPA (carotid
phonoangiograph)
<ul>
<li>Mild atheromatous lesions in bilateral ICAs and carotid
bifurcations.</li>
<li>Normal extracranial carotid, vertebral arterial flows.</li>
<li>Poor bilateral temporal windows for transcranial insonation.</li>
<li>Normal other intracranial and bilateral ophthalmic arterial
flows.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2020-04-10 Rehabiliation
<ul>
<li>Q
<ul>
<li>Being unable to sit up in bed</li>
</ul></li>
<li>A
<ul>
<li>Assessment
<ul>
<li>Multiple myeloma</li>
<li>Anemia</li>
<li>Hypercalcemia, improved</li>
<li>Hypertension</li>
<li>Diabetic mellitus (2020/3/13 HbA1c 6.6%)</li>
</ul></li>
<li>Plans
<ul>
<li>Please treat the myeloma and related back pain as your
expertise</li>
<li>Keep back brace use except when lying down</li>
<li>Rehabilitation programs: Bedside PT rehabilitation programs
<ul>
<li>Goal: better sitting/standing balance, ambulate with device under
support</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-04-10 Radiation Oncology
<ul>
<li>A
<ul>
<li>A: Multiple myeloma with L spine and sacrum involvement.</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: Multiple myeloma with low back pain.
<ul>
<li>Goal: palliation.</li>
<li>Treatment target and volume: L2~L5 and sacrum.</li>
<li>Technique: IMRT</li>
<li>Preliminary planning dose: 2800cGy/14 fractions.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-03-31 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For MRI showed Mass or nodule in anterior L5 body and right upper
sacrum, suspected multiple myeloma, metastases<br />
</li>
<li>This 73-year-old female with a past history of 1) DM 2) Hypertension
3) Left breast cancer s/p OP 4) Constipation, she had dizziness for half
years, under regular Neuro OPD follow up. She was admitted due to severe
low back pain, L-MRI showed Mass or nodule in anterior L5 body and right
upper sacrum, suspected multiple myeloma, metastases. We need your help
for further management, thanks a lot.</li>
</ul></li>
<li>A
<ul>
<li>This is a case of hypercalcemia. Mass over anterior L5 vertebral
body was noted. MRI sifggested D/D of myeloma and metastasis.</li>
<li>Suggest check immunoglobulin profile (IgG, A, M, kappa/lambda light
chain), tumor marker screening (CEA, CA199, CA153, CA125). We’ll follow
up this case, if there is abnormal immunoglobulin profile, we’ll make
diagnostic BM biopsy; otherwise, do tumor survey according tumor markers
and do tumor mass mass biopsy is suggested.</li>
</ul></li>
</ul></li>
<li>2020-03-31 Orthopedics
<ul>
<li>Q
<ul>
<li>for severe low back pain</li>
</ul></li>
<li>A
<ul>
<li>consult for low back pain radiation to bilateral buttock and lower
leg, weakness and paresthesia,unable to bear weight</li>
<li>Xray showed bil SI joint OAand decreased disc space and foramen of
L5-S1 level
<ul>
<li>suggest pain control (Arcoxia 1# QD or even Dynastat Q12H x 3 days
if severe pain + Mefno 1# QD + Neurontin 1# QD)</li>
<li>suggest L-spine MRI for further evaluation</li>
<li>contact me afteer MRI was done</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-03-24 Orthopedics
<ul>
<li>Q
<ul>
<li>Due to right lower back pain was noted for days, she also mentioned
she was her CVA husband main care giver, we would like to need your
visit to rule out orthologic disease. Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>S: low back pain, radiation to bil buttock and thigh</li>
<li>O: tenderness. knocking pain+, muscle spasm, SLRT-X: L5-S1 narrow,
bil SI arthritis</li>
<li>A: lumbar spondylosis, L5-S1 narrow, degeneration</li>
<li>P: Arcoxia 1# QD, Traumacet 1# bid, Neurontin 1# HS, use waist
support</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-21 ~ 2022-09-01 - Ninlaro (ixazomib) 3mg QWAC</li>
<li>2022-04-14 ~ 2022-11-25 - Revlimid (lenalidomide) 25mg QOD</li>
<li>2022-01-27 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2022-01-18 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2022-01-13 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2022-01-06 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-12-09 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-12-02 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-11-25 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-11-18 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-11-11 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-11-04 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-10-28 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-10-21 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-10-15 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-10-08 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-09-30 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-09-23 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-09-17 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-09-09 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-08-27 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-08-20 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-05-07 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-04-30 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-04-23 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-04-16 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-03-26 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-03-18 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-03-12 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-03-05 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-02-26 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-02-19 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-01-15 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2021-01-08 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-11-20 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-11-13 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-11-06 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-10-30 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-10-20 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-10-16 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-10-02 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-09-25 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-09-18 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-09-11 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-07-10 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-07-03 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-06-26 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-06-19 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-05-27 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-05-20 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-04-28 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-04-21 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-04-14 - Velcade (bortezomib) 1.3mg/m2 2mg SC</li>
<li>2020-05-13 ~ 2022-04-14 - Thado (thalidomide) 100mg QN</li>
<li>2020-07-03 ~ on and off - Xgeva (denosumab) 120mg Q1M SC</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>As the patient’s serum calcium levels have dropped into the normal
range, it may be appropriate to hold or discontinue Miacalcic
(calcitonin) if no other considerations exist.
<ul>
<li>2022-12-05 Ca (Calcium) 2.39 mmol/L<br />
</li>
<li>2022-12-04 Ca (Calcium) 2.74 mmol/L<br />
</li>
<li>2022-12-03 Ca (Calcium) 3.25 mmol/L<br />
</li>
<li>2022-12-02 Ca (Calcium) 3.25 mmol/L</li>
</ul></li>
<li>For it has been observed that multiple data points of blood sugar
levels exceeding 200 mg/dL since this hospitalization under current
metformin treatment, the initialization of basal insulin is
recommended.</li>
</ul>
</div>
</div>
<div id="section-173" class="section level1">
<h1>701120825</h1>
<div id="section-174" class="section level2">
<h2>221024</h2>
<ul>
<li>exam finding
<ul>
<li>2022-10-21 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Right atrial enlargement</li>
<li>Rightward axis</li>
<li>Possible Anterior infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-10-21 Nasopharyngoscopy
<ul>
<li>Tumor involving soft palate, bilateral palatine tonsil, tongue base,
epiglottis, supraglottic region and nasopharyngeal roof. Bilateral vocal
fold immobility with airway narrowing.</li>
</ul></li>
<li>2017-10-05 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a focal area in the left lower neck about
level IV. A metastatic lymph node may show this picture.</li>
<li>Asymmetric FDG uptake in bilateral tonsils with a little more FDG
uptake in the right tonsil. The nature is to be determined (inflammatory
process? other nature?). Please correlate with other clinical findings
for further evaluation.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions,
bilateral shoulders and right hip. Inflammatory process may show this
picture.</li>
</ul></li>
<li>2017-07-17 MRI - larynx
<ul>
<li>A nodule or LN with central necrosis in left lower neck, level
IV.</li>
</ul></li>
<li>2017-02-22 CT - neck, hypopharynx
<ul>
<li>several small lymph nodes in the right parotid space</li>
</ul></li>
<li>2016-04-23 CT
<ul>
<li>Post LNs dissection with soft tissue or muscle defect, right.</li>
<li>Small left neck LNs.</li>
<li>No obvious nasopharynx, oropharynx, hypopharynx or larynx
mass..</li>
<li>No obvious abnormal enhancement after contrast medium
administration.</li>
</ul></li>
<li>2015-04-23 pathology
<ul>
<li>Tonsil, right, biopsy — Negative for malignancy.</li>
<li>Lymph node, neck level I, right, neck dissection — Negative for
malignancy (0/2).</li>
<li>Salivary gland, submandibular, right, neck dissection — Negative for
malignancy.</li>
<li>Lymph node, neck level II, right, lymphadenectomy with frozen
section — Presence of metastatic carcinoma, in favor of non-keratinizing
sqaumous cell carcinoma, with extranodal extension(1/1).</li>
<li>Lymph node, neck level II, III and IV, right, neck dissection —
Negative for malignancy( 0/10).</li>
<li>Tissue labelled as “internal jugular vein”, right, neck dissection —
Negative for malignancy.</li>
<li>Soft tissue, sternocleidomastoid muscle, right, neck dissection —
Negative for malignancy.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-22 Family Medicine
<ul>
<li>Q
<ul>
<li>The 64 y/o woman has head and neck non-keratinizing sqaumous cell
carcinoma, with extranodal extension, regular at Mackey Hospital for
supportive care. Deu to dyspnea, so she sent to our ED. Family favor
hospice. We need your help. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>Dyspnea.</li>
<li>NOW with UFT 1# BID</li>
<li>Our share care would follow up.</li>
</ul></li>
</ul></li>
<li>2022-10-21 ENT
<ul>
<li>Q
<ul>
<li>The 64 y/o woman has head and neck non-keratinizing sqaumous cell
carcinoma, with extranodal extension, regular at Mackey for supportive
care. Due to suspect air obstruction, we need your help for
management.</li>
</ul></li>
<li>A
<ul>
<li>Oral cavity: trismus with &lt;1 FB.</li>
<li>Neck: stiffness, previous OP wound over right neck, an about 3cm
tumor over rigt post-auricular region.</li>
<li>Scope: Tumor involving soft palate, bilateral palatine tonsil,
tongue base, epiglottis, supraglottic region and nasopharyngeal roof.
Bilateral vocal fold immobility with airway narrowing.</li>
<li>Impression: Head and neck malignancy with diffuse involvement.</li>
<li>Plan: Since the patient has signed DNR consent, palliative therapy
is suggested for the patient.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2015-04-23
<ul>
<li>Surgery
<ul>
<li>Radical neck dissection, right</li>
<li>Tumor mapping with right tonsil biopsy</li>
</ul></li>
<li>Finding
<ul>
<li>Hypertrophy of lower pole of right tonsil, s/p biopsy.</li>
<li>4x4cm capsulized tumor at right neck level II, severe adhesion to
surrounding muscle and vessel, ruptured intra-operatively and some
serous flowed out, which was sent for culture. The tumor was sent for
frozen section. Frozen section = suspected squamous cell carcinoma</li>
<li>Lymphoareolar tissue at right level I, II, III, III as well as
internal jugular vein, SCM were dissected out and removed. Spinal
accessory nerve was preserved.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>2022-10-21 serum creatinine 0.39 mg/dL, eGFR 175, serum glucose 127
mg/dL. Glomerular hyperfiltration promoted by hyperglycemia? Muscle
loss?</li>
<li>Celebrex (celecoxib) should be limited as short as necessary to
prevent possible renal injury.</li>
</ul>
</div>
</div>
<div id="section-175" class="section level1">
<h1>701370027</h1>
<div id="section-176" class="section level2">
<h2>221024</h2>
<p>[assessment]</p>
<ul>
<li>eGFR was around 15 ~ 20 over the past half year (2022-04 ~ 2022-10),
and the medication dosage has been adjusted accordingly.</li>
<li>There is no restriction on the use of nasogastric tubes in the
administration of oral medications included in the active
prescription.</li>
</ul>
</div>
</div>
<div id="section-177" class="section level1">
<h1>700629294</h1>
<div id="section-178" class="section level2">
<h2>221022</h2>
<ul>
<li>exam finding
<ul>
<li>2022-10-22 CT - chest
<ul>
<li>No evidence of recurrent/residual tumor in the study</li>
</ul></li>
<li>2022-10-06 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae: free</li>
<li>EM: 4.7mm.</li>
</ul></li>
<li>2022-07-22 Patho - breast simple/partial mastectomy
<ul>
<li>DIAGNOSIS:
<ul>
<li>A. Breast, right partial mastectomy with frozen section
(F2022-337SA) — atypical ductal hyperplasia (ADH) with
microcalcifciation.
<ul>
<li>IHC stains: CK5/6 (+, focal rim staining) p63 (rim staining).</li>
</ul></li>
<li>B. Lymph node, sentinel, right, sentinel LN, s/p neoadjuvant
chemotherapy (F2022-337FSC) — negative for malignancy. Two focus of
fibrosis probably involuted lymph node after chemotherapy.</li>
<li>C. Breast, right, total mastectomy total mastectomy (S2022-11852) —
scleroscing adenosis, fibrocystic disease, and adenosis.</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A. Sections F2022-337FSA1-2 show breast tissue with atypica ductal
hyperplasia with microaclcification.
<ul>
<li>IHC stains: CK5/6 (+, focal rim staining) p63 (rim staining). Foci
of scleroscing adenosis, fibrocystic disease, and adenosis are
present.</li>
</ul></li>
<li>B. Sections F2022-337FSC1-2 show fibroadipose tissue with moderate
fibrosis.</li>
<li>C. Sections S2022-11852 show breast tissue with scleroscing
adenosis, fibrocystic disease, and adenosis are present.</li>
</ul></li>
</ul></li>
<li>2022-07-22 Patho - breast simple/partial mastectomy
<ul>
<li>Diagnosis
<ul>
<li>Breast, left, s/p neoadjuvant chemotherapy followed by total
mastectomy (S2022-11851) — no residual malignancy</li>
<li>Resection margin: free:</li>
<li>Lymph node, left, sentinel lymph node biopsy with frozen section
(F2022-337FSB) — free</li>
<li>yp T0 ypN0(sn) (if cM0)</li>
</ul></li>
<li>Gross Description
<ul>
<li>Procedure - mtotal mastectomy with senteinel lymph nodes.</li>
<li>Lymph node sampling - sentinel lymph node(s)</li>
<li>Specimen laterality - Left
<ul>
<li>Sections are taken and labeled as:
<ul>
<li>Tissue for frozen sections: F2022-337FSB: left sentinel lymph
nodes.</li>
<li>Tissue for formalifixation: S2022-11851A1-12: left breast.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Microscopic Description
<ul>
<li>For Invasive Carcinoma: no residual malignancy.</li>
<li>For Ductal Carcinoma In Situ: no DCIS</li>
<li>Margins: no residual malignancy</li>
<li>Nodal status: Negative (if lymph nodes are present in the specimen)
<ul>
<li>No. examined: 2</li>
<li>No. macrometastases (&gt;2 mm): 0</li>
<li>No. micrometastases (&gt;0.2 ~ 2 mm and/or &gt;200 cells): 0</li>
<li>No. isolated tumor cells (&lt;=0.2 mm and &lt;=200 cells): 0</li>
</ul></li>
<li>Treatment Effect: Response to presurgical (neoadjuvant) therapy (if
patient received)
<ul>
<li>In the Breast
<ul>
<li>No residual invasive carcinoma is present in the breast after
presurgical therapy</li>
</ul></li>
<li>In the Lymph nodes
<ul>
<li>No lymph node metastases and no prominent fibrous scarring in the
nodes</li>
</ul></li>
</ul></li>
<li>Immunohistochemical Study: result of biopsy specimen: S2021-19572
<ul>
<li>IHC stains (using blockS2021-19572): ER(+ , 100%, strongintensity),
PR(-), Her2/neu: positive(score=3+), Ki-67(70 %), p53(50%).</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-21 Frozen section
<ul>
<li>Preliminary diagnosis:
<ul>
<li>FSA1-2: right breast: irrregular duct. The possibility of malignancy
cannot be excluded. Will need IHC stain to determine the nature of these
ducts.</li>
<li>FSB: left sentinel LN s/p neoadjuvant therapy: free (0/2).</li>
</ul></li>
<li>ADDENDUM:
<ul>
<li>FSC1-2: right sentinel LN, s/p neoadjuvant chemotherapy: negative
for malignancy. Two focus of fibrosis probably involuted lymph node
after chemotherapy.</li>
</ul></li>
</ul></li>
<li>2022-07-21 Lymphoscintigraphy
<ul>
<li>The sentinel lymph node mapping was performed immediately after
injection of 0.5 mCi of Tc-99m phytate (s.c) above the left breast. The
sequential dynamic and static images over the chest revealed at least
one focal area of increased accumulation of radioactivity at the left
axilla.</li>
<li>IMPRESSION: Probably at least one sentinel lymph node at the left
axillary region.</li>
</ul></li>
<li>2022-07-07 Mammography
<ul>
<li>Impression:
<ul>
<li>Regression of left breast tumor (LIQ) and axillary lymph node.</li>
<li>Focal asymmetry in UOQ of right breast (posterior portion),
stationary.</li>
</ul></li>
<li>BIRADS 6</li>
</ul></li>
<li>2022-07-07 SONO - breast
<ul>
<li>Diagnosis
<ul>
<li>Bil. fibroadenomas as described</li>
<li>Left breast cancer</li>
</ul></li>
<li>BI-RADS:
<ul>
<li>6 - known biopsy-proven malignancy</li>
</ul></li>
</ul></li>
<li>2022-06-11 CT - lung/mediastinum/pleura
<ul>
<li>IMP: No evidence of lung metastases based on this CT study.</li>
</ul></li>
<li>2022-01-25 2D transthoracic echocardiography
<ul>
<li>LVEF(%) = 72</li>
</ul></li>
<li>2022-01-14 CT - abdomen, pelvis
<ul>
<li>Left breast cancer with left axillary lymph node metastasis is
highly suspected. please correlate with clinical condition.</li>
<li>The gallbladder shows mild irregular wall thickening and few stones
that may be chronic inflammation. The differential diagnosis include
gallbladder cancer.</li>
</ul></li>
<li>2021-12-28 Patho - breast biopsy
<ul>
<li>Breast, left, 5/2, core biopsy — Invasive carcinoma, no special
type, NST.</li>
<li>IHC stains (using blockS2021-19572): ER (+, 100%, strongintensity),
PR(-), Her2/neu: positive (score=3+), Ki-67(70 %), p53 (50%).</li>
</ul></li>
<li>2021-12-28 Patho - lymphnode biopsy
<ul>
<li>Lymph node, left, core biopsy — Invasive carcinoma, no special type,
NST.</li>
<li>IHC stains (using blockS2021-19571): ER (+, 100%, strongintensity),
PR(+, 30%, strong intensity), Her2/neu: positive (score=3+), Ki-67(90
%), p53 (60%).<br />
</li>
</ul></li>
<li>2021-12-28 SONO - breast
<ul>
<li>Bilateral breast irregular tumors, suspected malignancy, suggest
biopsy.</li>
<li>Enlarged left axillary lymph node, suspected lymph node
metastasis.</li>
<li>Suggest biopsy.<br />
</li>
<li>BI-RADS: Category 4c: highly suspicious abnormality-biopsy should be
considered.</li>
</ul></li>
<li>2021-12-18 Mammography
<ul>
<li>BI-RADS category 0, Need additional imaging evaluation.</li>
<li>Suggest ultrasound correlation for developing left breast nodules
and enlarged left axillary lymph node.</li>
</ul></li>
<li>2019-05-03 Mammography
<ul>
<li>Impression: No mammographic evidence of malignancy, suggest clinical
correlation and regular follow up.</li>
<li>BI-RADS: Category 1: negative.-annual screening.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-31 ENT
<ul>
<li>Q
<ul>
<li>for right ear pain and headache</li>
<li>This 58 year-old woman panient suffered from left breast mass in
2021/11. Breast SONO on 2021/12/28 showed bilateral breast irregular
tumors, suspected malignancy, suggest biopsy, enlarged left axillary
lymph node, suspected lymph node metastasis and suggest biopsy. Left
lymph node core biopsy showed invasive carcinoma, no special type, NST.
IHC stains (using block S2021-19571): ER (+ , 100%, strongintensity),
PR(+, 30%, strong intensity), Her2/neu: positive(score=3+), Ki-67(90 %),
p53 (60%). Left 5/2 breast core biopsy showed Invasive carcinoma, no
special type, NST. IHC stains (using block S2021-19572): ER (+ , 100%,
strongintensity), PR(-), Her2/neu: positive(score=3+), Ki-67(70 %), p53
(50%).</li>
<li>This time, she was admitted to ward for chemotherapy with AC(C4) on
2022/03/31, then she complaints right ear pain and headache for 3-4
days, so we need your help for survey evulation, thanks a lot.</li>
</ul></li>
<li>A
<ul>
<li>Eating on side(+, L) R otalgia with bil temple pain for 3 days.</li>
<li>PE:
<ul>
<li>Ear drum: bil intact</li>
<li>EAC: clean</li>
<li>TMJ: right TMJ tenderness when compression</li>
</ul></li>
<li>Imp: TMJ syndrome</li>
<li>Plan: Pain control</li>
</ul></li>
</ul></li>
</ul></li>
<li>surigcal operation
<ul>
<li>2022-07-21
<ul>
<li>Surgery
<ul>
<li>bilateral simple mastectomy and SLNB</li>
</ul></li>
<li>Finding
<ul>
<li>left breast cancer, HER-2 type, s/p neoadjuvant chemotherapy and
target therapy, tumor regression, SLNB: negative of malignancy</li>
<li>right breast tumor, excision for frozen pathology: irrregular duct.
The possibility of malignancy cannot be excluded. Will need IHC stain to
determine the nature of these ducts –&gt; do simple mastectomy and SLN
sampling</li>
</ul></li>
</ul></li>
<li>2018-07-05 PCS code 87003C
<ul>
<li>Benign neoplasm of skin of eyelid, including canthus</li>
<li>lid tumor, os</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-18 - Herceptin (trastuzumab) 600mg SC</li>
<li>2022-09-27 - Herceptin (trastuzumab) 600mg SC</li>
<li>2022-09-06 - Herceptin (trastuzumab) 600mg SC</li>
<li>2022-08-16 - Herceptin (trastuzumab) 600mg SC</li>
<li>2022-06-29 - Nolbaxol (docetaxel) 75mg/m2 140mg 1hr + Herceptin
(trastuzumab) 600mg SC (neoadjuvant)</li>
<li>2022-06-10 - Nolbaxol (docetaxel) 75mg/m2 140mg 1hr + Herceptin
(trastuzumab) 600mg SC (neoadjuvant)</li>
<li>2022-05-16 - Nolbaxol (docetaxel) 75mg/m2 140mg 1hr + Herceptin
(trastuzumab) 600mg SC (neoadjuvant)</li>
<li>2022-04-22 - Nolbaxol (docetaxel) 75mg/m2 140mg 1hr + Herceptin
(trastuzumab) 600mg SC (neoadjuvant)</li>
<li>2022-04-01 - Adriamycin (doxorubicin) 60mg/m2 110mg 10min + Endoxan
(cyclophosphamide) 600mg/m2 1100mg 1hr</li>
<li>2022-03-11 - Adriamycin (doxorubicin) 60mg/m2 110mg 10min + Endoxan
(cyclophosphamide) 600mg/m2 1100mg 1hr</li>
<li>2022-02-15 - Adriamycin (doxorubicin) 60mg/m2 110mg 10min + Endoxan
(cyclophosphamide) 600mg/m2 1100mg 1hr</li>
<li>2022-01-25 - Adriamycin (doxorubicin) 60mg/m2 110mg 10min + Endoxan
(cyclophosphamide) 600mg/m2 1100mg 1hr</li>
</ul></li>
</ul>
<div id="section-179" class="section level3">
<h3>==========</h3>
</div>
<div id="section-180" class="section level3">
<h3>2022-10-22</h3>
<ul>
<li>Trastuzumab administration (2022-04-22 ~ undergoing) might result in
subclinical and clinical cardiac failure. The incidence and severity
might be higher for patients received anthracycline-containing
chemotherapy regimens (doxorubicin 2022-01 ~ 2022-04). An update of 2D
transthoracic echocardiography is recommended (the most recent was
performed on 2022-01-25 prior to the introduction of doxorubicin).</li>
</ul>
</div>
<div id="section-181" class="section level3">
<h3>2022-05-17</h3>
<ul>
<li>The patient was diagnosed with breast cancer (ER+, PR (-, + lymph
nodes) Her2/neu 3+) and has been treated with
doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab.</li>
<li>The last CT performed on 2022-01-14 showed a thickening of the
gallbladder wall. Since gallbladder mets from breast cancer are rare, it
might be sufficient to follow the gallbladder on an annual basis.</li>
<li>Lab data on 2022-05-10 showed that liver and kidney function,
electrolytes and CBC were generally normal.</li>
<li>TPR readings remain stable during this hospital stay, no issues with
active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-182" class="section level1">
<h1>700269001</h1>
<div id="section-183" class="section level2">
<h2>221021</h2>
<ul>
<li>lab data
<ul>
<li>UGT1A1 6/7</li>
<li>Bilirubin total
<ul>
<li>2022-07-14 Bilirubin total 0.70 mg/dL<br />
</li>
<li>2022-06-16 Bilirubin total 1.30 mg/dL<br />
</li>
<li>2022-04-21 Bilirubin total 0.60 mg/dL<br />
</li>
<li>2022-04-07 Bilirubin total 0.98 mg/dL<br />
</li>
<li>2022-03-31 Bilirubin total 0.98 mg/dL<br />
</li>
<li>2022-03-22 Bilirubin total 1.18 mg/dL<br />
</li>
<li>2022-03-09 Bilirubin total 2.15 mg/dL<br />
</li>
<li>2022-02-24 Bilirubin total 1.44 mg/dL<br />
</li>
<li>2022-02-09 Bilirubin total 1.22 mg/dL<br />
</li>
<li>2022-01-26 Bilirubin total 1.27 mg/dL<br />
</li>
<li>2021-12-30 Bilirubin total 0.98 mg/dL<br />
</li>
<li>2021-12-25 Bilirubin total 0.78 mg/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-29 CT - abdomen, pelvis
<ul>
<li>Rectal cancer s/p operation. Minimal ascites in pelvic cavity.</li>
</ul></li>
<li>2022-07-15 Pure Tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 18 dB HL, LE 21 dB HL</li>
<li>bil normal to moderate SNHL</li>
</ul></li>
<li>2022-07-08 Pure Tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average R’t 13 dB HL, L’t 31 dB HL</li>
<li>R’t normal to mild SNHL.</li>
<li>L’t normal to moderately severe SNHL.</li>
<li>Tymp: Bil type A.</li>
<li>ART: R’t WNL.</li>
<li>L’t 500 Hz reduced thresholds.</li>
</ul></li>
<li>2022-07-01 Pure Tone Audiometry, PTA
<ul>
<li>Reliabilty Fair</li>
<li>R’t: 19 dB HL, WNL except 8k Hz</li>
<li>L’t: 45 dB HL, mild to moderately severe SNHL.</li>
</ul></li>
<li>2022-06-23 Hearing Test
<ul>
<li>Reliabilty Fair</li>
<li>PTA - Pure Tone Audiometry
<ul>
<li>R’t: 18 dB HL, normal to moderate SNHL</li>
<li>L’t: 46 dB HL, normal to moderately severe SNHL</li>
</ul></li>
<li>Tymp - Tympanogram
<ul>
<li>Bil Type A</li>
</ul></li>
<li>ART - Acoustic reflex threshold
<ul>
<li>R’t: Ipsi absent</li>
<li>L’t: Ipsi 500-1k Hz reduced, contra absent.</li>
</ul></li>
</ul></li>
<li>2022-05-23 Patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Tumor, lower rectum, Robotic Abdominal Perineal Resection — Residual
intramucosal adenocarcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Resection margins, ditto — Free of tumor</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Lymph nodes, mesocolic, dissection — Free of tumor metastasis
(0/8)</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>AJCC pathologic stage — ypTisN0, stage 0, if cM0</li>
</ol></li>
</ul></li>
<li>macroscopic examination
<ul>
<li>Tumor appearance: elevated mucosa</li>
<li>Depth of invasion grossly: lamina propria</li>
</ul></li>
<li>microscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Histology: residual intramucosal adenocarcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histology Grade: G1, well differentiated<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Depth of invasion: lamina propria</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Angiolymphatic invasion: not identified</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Perineural invasion: not identified</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Discontinuous extramural tumor extension: absent</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Circumferential (radial) margin of rectosigmoid: Not involved</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Lymph node metastasis, mesocolic: free of tumor metastasis
(0/8)</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymph node metastasis, IMA / SMA: N/A</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Extranodal involvement: N/A</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Pathological TNM Stage: ypTisN0</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>Type of polyp in which invasive carcinoma arose: N/A</li>
</ol></li>
<li><ol start="13" style="list-style-type: decimal">
<li>TNM descriptors: y<br />
</li>
</ol></li>
<li><ol start="14" style="list-style-type: decimal">
<li>Tumor regression grading S/P CCRT: grade 2 (rare residual
cancer)</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-05-23 SONO - abdomen
<ul>
<li>Liver calcification nodules (incomplete exam of liver)</li>
</ul></li>
<li>2022-05-19 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>RSR or QR pattern in V1 suggests right ventricular conduction
delay</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-04-07 CT - abdomen, pelvis
<ul>
<li>History and indication:
<ul>
<li>Rectal cancer s/p CCRT suspected low rectal cancer at anterior;
1.5*1.5 cm with ulceration and bleeding at 3 cm from AV</li>
</ul></li>
<li>IMP:
<ul>
<li>Mild regression of rectal cancer.</li>
</ul></li>
</ul></li>
<li>2022-04-07 Colonoscopy
<ul>
<li>Findings
<ul>
<li>The scope reach the S-colon.</li>
<li>Rectal cancer s/p CCRT with tumor regression at anterior wall, 4cm
from AV</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Rectal cancer s/p CCRT with tumor regression</li>
</ul></li>
</ul></li>
<li>2022-03-24 Cardiac Catheterization
<ul>
<li>Type of arrhythmia
<ul>
<li>WPW</li>
</ul></li>
<li>Ablation Diagnosis
<ul>
<li>Intermittent Wolff-Parkinson-White syndrome (iWPW), s/p successful
cryoablation of para-Hisian accessory pathway through non-coronary cusp
(NCC) approach</li>
</ul></li>
</ul></li>
<li>2022-03-14 SONO - abdomen
<ul>
<li>suspected liver parenchymal disease, mild fatty liver</li>
<li>liver calcification nodules</li>
</ul></li>
<li>2022-02-17 ECG
<ul>
<li>Sinus rhythm with frequent Premature ventricular complexes in a
pattern of bigeminy</li>
<li>Fusion complexes</li>
</ul></li>
<li>2022-01-28 Cardiopulmonary Exercise Testing
<ul>
<li>summary:
<ul>
<li>maximal exercise</li>
<li>normal exercise capacity ( VO2 99%, WR 118%)</li>
<li>normal stroke volume response during exercise</li>
<li>normal ventilatory function ( FVC 127%, FEV1 118%)</li>
<li>normal respiratory muscle strength (MIP 75%, MEP 89%)</li>
</ul></li>
<li>suggestions:
<ul>
<li>treat underlying condition</li>
<li>survey and treat cardiac function, refer to CV for EKG with ST-T
changes</li>
<li>arrange pulmonary rehab with exercise training</li>
</ul></li>
</ul></li>
<li>2022-01-12 CXR
<ul>
<li>A calcified spot at RUQ.</li>
</ul></li>
<li>2021-12-28 Patho - colon biopsy
<ul>
<li>Colon, dentate line to 8 cm AAV at anterior wall, biopsy —
Adenocarcinoma.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
</ul></li>
<li>2021-12-28 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Highly suspected rectal cancer, 1/4 circumference, from dentate line
to 8 cm AAV at anterior wall, s/p biopsy</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-12-27 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Colorectal Carcinoma</li>
<li>Impression (Imaging stage): T3N0M0, stage IIA</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-18 Psychosomatic Medicine
<ul>
<li>Q
<ul>
<li>This 57-year-old woman patient is a case of low rectal cancer
arising from dentate line with broad-based villous tumor up to 8 cm from
AV cT3N0M0; stage II. She was admitted for concurrent chemoradiotherapy.
For evaluate anxiety with insomnia therapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>Psychiatric impression:
<ul>
<li>depression and anxiety</li>
<li>suspected adjustment reaction with anxiety and depression</li>
</ul></li>
<li>Psychiatric history:
<ul>
<li>This 57-year-old woman patient is a case of low rectal cancer
cT3N0M0; stage II was diagnosed in December 2021. This time she was
admitted for concurrent chemoradiotherapy. We were consulted due to
anxiety and insomnia were noted.</li>
<li>According to the patient, she suffered from low mood, anxiety and
worry about the cancer treatement (enteroproctia, artificial anus).
surgical treatment, fearfulness, anticipatory anxiety, negative thought,
free floating anxiety, poor appetite and poor sleeplasting (1-2 hour),
suicide ideation before.</li>
<li>MSE: coherent and relevent speech, fair spontaneous speech, anxiety
and low mood, negative thinking, worrisome, denied panic like
attack.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>emotional support and empthy</li>
<li>may give Mirtapine (mirtazapine) 0.5# HS and alprazolam 0.5# prn if
anxiety</li>
<li>arrange psychiatric OPD (patient request W1 evening OPD)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-01-10 ~ 2022-02-23 - Concurrent radiotherapy 4500cGy/25
fractions of the pelvic and 5040cGy/28 fractions of the rectal tumor bed
area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-20 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-09-30 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-09-07 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-08-26 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-08-12 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-07-29 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-07-15 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr</li>
<li>2022-07-01 - oxaliplatin 65mg/m2 100mg 2hr + leucovorin 300mg/m2
450mg 2hr + 2400mg/m2 3500mg 46hr (oral mucostatis with ulcer with pain
for 2 weeks, upper and lower limbs numbness in 2022-06)   </li>
<li>2022-04-11 - oxaliplatin 85mg/m2 120mg 2hr + leucovorin 400mg/m2
600mg 2hr + fluorouracil 400mg/m2 600mg 10min + 2400mg/m2 3600mg
46hr</li>
<li>2022-03-09 - oxaliplatin 85mg/m2 120mg 2hr + leucovorin 400mg/m2
600mg 2hr + fluorouracil 400mg/m2 600mg 10min + 2400mg/m2 3600mg
46hr</li>
<li>2022-02-14 - Leucovorin 20mg/m2 10min D1~2 + 5-FU 400mg/m2 10min
D1~2; CCRT</li>
<li>2022-02-09 - Leucovorin 20mg/m2 10min D1~3 + 5-FU 400mg/m2 10min
D1~3; CCRT</li>
<li>2022-01-17 - Leucovorin 20mg/m2 10min D1~3 + 5-FU 400mg/m2 10min
D1~3; CCRT</li>
<li>2022-01-13 - Leucovorin 20mg/m2 10min D1~2 + 5-FU 400mg/m2 10min
D1~2; CCRT</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>All You Need to Know About UGT1A1 Genetic Testing for Patients
Treated With Irinotecan: A Practitioner-Friendly Guide ( <a href="https://ascopubs.org/doi/full/10.1200/OP.21.00624" class="uri">https://ascopubs.org/doi/full/10.1200/OP.21.00624</a> )
<ul>
<li>Irinotecan is an anticancer agent widely used for the treatment of
solid tumors, including colorectal and pancreatic cancers. Severe
neutropenia and diarrhea are common dose-limiting toxicities of
irinotecan-based therapy, and UGT1A1 polymorphisms are one of the major
risk factors of these toxicities.</li>
<li>In 2005, the US Food and Drug Administration revised the drug label
to indicate that patients with UGT1A1<em>28 homozygous genotype should
receive a decreased dose of irinotecan. However, UGT1A1</em>28 testing
is not routinely used in the clinic, and specific reasons include lack
of access to concise information on this wide issue as well as mixed
recommendations by regulatory and professional entities.</li>
<li>To assist oncologists in assessing whether and when to use UGT1A1
genetic testing in patients receiving irinotecan-based therapies, this
article provided (1) essential knowledge of UGT1A1 polymorphisms; (2) an
update on the impact of UGT1A1 polymorphisms on efficacy and toxicity of
contemporary irinotecan-based regimens; (3) dosing adjustments based
upon the UGT1A1 genotypes, and (4) recommendations from currently
available guidelines from the US and international scientific consortia
and major oncology societies.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>FOLFOX regimen has been modified by lowering oxaliplatin dose
(65mg/m2 &lt;- 85mg/m2) and skipping fluorouracil bolus since July 2022
due to mucositis and limb numbness observed in June 2022.</li>
<li>Oral mucositis is appropriately treated with Nincort Oral Gel
(triamcinolone) currently.</li>
<li>Duloxetine is recommended for the mitigation of chemotherapy-induced
peripheral neuropathy (ref: Prevention and Management of
Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult
Cancers: ASCO Guideline Update. Journal of Clinical Oncology 2020 38:28,
3325-3348)</li>
<li>Duloxetine for chemotherapy-induced peripheral neuropathy (off-label
use): Oral initial: 30 mg once daily for 1 week, then 60 mg once daily.
(ref: UpToDate)</li>
</ul>
</div>
</div>
<div id="section-184" class="section level1">
<h1>700514824</h1>
<div id="section-185" class="section level2">
<h2>221021</h2>
<p>[assessment]</p>
<ul>
<li>Since the patient began her hospital stay, her blood sugar levels
have exceeded 200 mg/dL in all data points ( with a record high 401
mg/dL) under current basal/bolus insulin therapy.</li>
<li>In this case, it is recommended to gradually increase the basal
insulin by 2 or 3 units and monitor the changes in blood sugar levels to
determine whether further adjustments are necessary.</li>
</ul>
</div>
</div>
<div id="section-186" class="section level1">
<h1>700999894</h1>
<div id="section-187" class="section level2">
<h2>221021</h2>
<ul>
<li>diagnosis
<ul>
<li>2022-10-18 discharge note
<ul>
<li>Right lower lobe lung cancer, adenocarcinoma, T2bN0M0, stage IIA,
status post operation, with recurrent rT4N2M1a, stage IVA with lung to
lung metastasis, ECOG 1, EGFRmutation: L858R (-), exon 19 (-), ALK(-),
ROS1(-)</li>
<li>Essential (primary) hypertension</li>
<li>Type 2 diabetes mellitus without complications</li>
<li>Insomnia, unspecified</li>
<li>Malignant neoplasm of lower lobe, right bronchus or lung</li>
<li>Chronic obstructive pulmonary disease</li>
<li>Chronic rhinitis</li>
</ul></li>
</ul></li>
<li>History
<ul>
<li>hypertension under regular control for 2-3years (at LMD)</li>
<li>RLL lung cancer,adenocarcinoma, pStage IIA, pT2bN0(cMx)s/p VATS RLL
lobectomy + RLND on 20170904, diagnosed on 20170908 ECOG:1; EGFR
mutation wild type; Alk negative; PDL1 &lt;1%.
<ul>
<li>post operation adjuvent chemotherapy:
<ul>
<li>immunotherapy Keytruda 20171006 ~ 20190603</li>
<li>chemotherapy with C1D1D8 Navelbine (20171007 and 20171031);</li>
<li>Gemzar total 6 cycle (20171030 ~ 20180501);</li>
<li>CDDP total 4 cycle (201761103, 20171127, 20180302, 20180503);</li>
<li>Vinorelbine total 6 cycle (20180528, 20180621, 20180726, 20180821,
20180914, 20181012)</li>
</ul></li>
<li>For lung cancer re-staging, the chest CT was performed, wich
multiple nodular lesions of varying sizes in both lungs shown, favor
recurrent lung tumor with lung to lung metastasis.
<ul>
<li>Brain MRI and whole body bone scane also done without brain or bone
metastasis.</li>
</ul></li>
<li>For tissue prove, thet thoracoscopic wedge or Partial resection of
the Lung on 20190315 and the pathogen disclosed Adenocarcinoma.
<ul>
<li>Therefore, the progression lung cancer pT2bN0 staage IIA -&gt;
rT2bN0M1a Stage IV was diagnosed.</li>
</ul></li>
<li>For progression lung cancer, we was re-challenge the chemotherapy to
immunotherapy C1 with Tecentriq (Atezolizumab), chemotherapy C1 Alimta,
C1 Avastin and C1 CDDP since 201904.</li>
<li>The chest film showed ill-defined nodular/masses lesions of varying
sizes in both lungs, recurrent lung cancer with lung to lung metastases,
in progression on 20220907.</li>
</ul></li>
<li>The lung cancer treatment regimen as below:
<ul>
<li>1st chemotherapy with C1 Alimta, C1 Avastin and C1 CDDP since
201904</li>
<li>2nd chemotherapy with C1 Docetaxel since 20220913.</li>
<li>immunotherapy C1 with Tecentriq since 201904, and changed to double
immunetherapy with C1 Nivo total 200mg (free) IVF on 20210304 and
Ipilmumab total 50mg (charge) IVF on 20210305.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-14 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-10-14 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-10-13 - Nolboxol (docetaxel) 25mg/m2 40mg 1hr</li>
<li>2022-09-15 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-09-14 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-09-13 - Nolboxol (docetaxel) 25mg/m2 40mg 1hr</li>
<li>2022-06-30 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-06-29 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-06-28 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-06-27 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-06-08 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-06-07 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-06-06 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-04-29 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-04-28 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-04-27 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-03-24 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-03-23 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-03-22 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-03-21 - Cyramza (ramucirumab) 10mg/mg 600mg 90min</li>
<li>2022-02-24 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-02-23 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-02-22 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-02-21 - Cyramza (ramucirumab) 10mg/mg 600mg 90min</li>
<li>2022-01-21 - Yervoy (ipilimumab) 50mg 30min</li>
<li>2022-01-20 - Opdivo (nivolumab) 200mg 1hr</li>
<li>2022-01-19 - Alimta (pemetrexed) 500mg/m2 900mg 10min</li>
<li>2022-01-19 - Cyramza (ramucirumab) 10mg/mg 600mg 90min</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-188" class="section level1">
<h1>701356390</h1>
<div id="section-189" class="section level2">
<h2>221021</h2>
<p>{breast cancer with brain mets}</p>
<ul>
<li>cheif complaint (2022-09-16 adminnote)
<ul>
<li>Gait disturbance within recent half month, headedness, headache,
poor memory, left hand tremor also noted.</li>
</ul></li>
<li>present illness (2022-09-16 adminnote)
<ul>
<li>The skin-sparing mastectomy with immediate breast reconstruction was
done on 2007-11-26.
<ul>
<li>The pathological report showed the diagnosis of Invasive Lobular
Carcinoma. The stage was pT2N0M0, Stage IIA, with ER (4+), PR (4+),
Her-2 IHC (1+).</li>
</ul></li>
<li>The adjuvant treatement was LHRH agonist (Zoladex) from 2007-12-27
to 2012-12-13.</li>
<li>The anti-estrogen, tamoxifen, was added from 2012-06-28 to
2013-01-10.</li>
<li>On 2018-03-21, she sustained a mass over left supraclavicular
area.</li>
<li>On 2018-03-26, the whle body bone scan showed the possibility of
bone mets over left anterior 1st and 2nd ribs.</li>
<li>The denosumab (XGEVA) was given from 2018-03-29 to now.</li>
<li>The palbociclib plus letrozole was given 2018-04-26 to
2018-11-06.</li>
<li>On 2018-06-27, the Chest CT scan revealed necrotized mass over the
left uper anterior mediastinum with direction invasion to left antirior
1st and 2nd ribs, which might explain the findings of increasing tracer
uptake in the whole body bone scan on 2018-06-27 and later on
2018-08-21.
<ul>
<li>It indicated the recurrence of invasive lobular carcinoma over
mediastinum, The treatment was at SD, based on the findings of CT on
2018-10-16.</li>
</ul></li>
<li>On 2018-10-26, the PET-CT demonstraged: 1. a huge hypermetabolic
mass wiht central necrosis, abunting anterior chest wall and possible
invsding sternum in the anterior mediastinum; 2. several hypermetaboic
nodes in the left supraclavicular, left para-sternal and left lower
pleura, indicating nodal metastases or pleural seeding.</li>
<li>The sono-guided biopsy on 2018-11-02 disclosed metastaic poorly
differentiated carcinoma, with ER (30%), PR (-), Her-2 (&lt;10%), Ki-67
(&lt;3%)</li>
<li>On 2018-12-25, the thyroid sonography revealed bilateral
multinodular gioter, without evident malignancy by aspiration cytology.
The weekly eribulin for 2 weeks every 3 weeks was given from 2018-11-07
to 2019-10-09.</li>
<li>The letrozole from hospital and palbociclib from outside hospital
were resumed from 2019-12-04 to now.</li>
<li>On 2019-03-14, the follow-up PET-CT showed marked regression of
prepericardial and left intercostal LAPs, mild regression of the
anterior mediastinal mass.</li>
<li>To maximize the anti-cancer effect, the radiotherapy to the anterior
mediastinal mass was given with 45 Gy/18Fx was given from 2019-04-02 to
2019-04-25.</li>
<li>On 2019-09-18, the follow-up PET-CT showed partial regression of the
anterior mediastinal mass and invisibility of those aforementioned
LAPs.</li>
<li>On 2020-04-01, the follow-up CT showed the metastases of mass and
LAP in PR.</li>
<li>On 2021-04-26, the follow-up PET-CT showed the metastases of mass
and LAP in PR.</li>
<li>She suffered from lower limbs weakness, and visited our ER on
2022-01-10. Brain CT on 2022/01/10 showed c/w brain metastasis and
midline shift, 8mm. Brain MRI on 2022-01-10 showed intra-axial lesions,
R/O brain metastasis.</li>
<li>Brain CT on 2022-01-12 showed multiple brain metasatses with mass
effect. S/P markers for stereostatic surgery. Stereotactic biopsy and
aspiration for right PO cystic lesion and left frontal deep tumor on
2022-01-13
<ul>
<li>CSF pathology suspicious for adenocarcinoma,</li>
<li>Brain pathology showed metastatic carcinoma, breast origin ,
<ul>
<li>Immunohistochemistry shows CK(+), GATA-3(+), ER(-), PR(-) and
HER2(2+, equivocal) for tumor cells, compatible with metastatic breast
carcinoma.</li>
</ul></li>
</ul></li>
<li>Abdominal CT on 2022-02-11 showed 1. S/P Mastectomy, left. There is
soft tissue swelling at the left upper anterior mediastinum, nature?
please correlate with clinical condition. 2. Detailed findings, please
see description.</li>
<li>Whole body bone scan on 2022-02-14 showed two hot spots in bilateral
fronto-parietal region of the skull, respectively, and increased
activity in the sternum, the nature is to be determined (post-traumatic
change, early bone mets or other nature ?).</li>
<li>Plan to deliver 30 Gy/ 10 fractions to the whole brain from
2022/01/24~2022/01/28 for 15 Gy/ 5 fractions.</li>
<li>Xgeva 1pc SC on 2022/01/27, 2022/02/24, 2022/03/24, 2022/04/19.</li>
<li>Received palliative chemotherapy with Q3W
Adriamycin(60mg/m2)/Cyclophosphamide(600mg/m2) on 2022/02/24(C1),
2022/03/16(C2), 2022/04/07(C3), 2022/04/27(C4), 2022/05/17(C5),
202206/07(6).</li>
<li>Chemotherapy with QW Docetaxel(35mg/m2) on 2022/06/30(C1),
2022/07/14(C2), 2022/07/28(C3), 2022/08/11(C4),2022/09/01(C5).</li>
<li>Brain MRI on 2022/08/10 showed 1.unremarkable change in the
intraventricular and extraventricular CSF spaces; 2.solid and
rim-enhnaincg lesions in the left frontal lobe, 22mm; left cindulate
gyrus,14.8mm; right cerebellar hemisphere, 5.7mm. right
parieto-occipito-temporal lobe, 42.3mm. The small one in the left
parietal lobe on the previous study on 20220510 was missing. The solid
nodule in the left frontal lobe was increased in size; 3. unremarkable
change in the skull base.</li>
<li>She suffered from gait disturbance within recent half month,
headedness, headache, poor memory, left hand tremor also noted. She came
to NS OPD for help on 2022/09/09.</li>
<li>Brain CT was done showed: 1.mild dilated intraventricular and
extraventricular CSF spaces, 2.two cystic lesions with fluid-fluid
levels, about 20mm and 9.4mm in the left frontal lobe and about 44mm in
the right parietotemporal lobe, 3.unremarkable change in the skull
base.</li>
<li>Now, she was admitted to ward for radiotherapy evaluate and change
chemotherapy regimen for disease progression.</li>
</ul></li>
<li>past history
<ul>
<li>Breast cancer s/p about 15 year ago, s/p OP and radiotherapy with
bone and lymph node metastases s/p chemotherapy with brain metastasis
s/p radiotherapy</li>
<li>Left lymph node s/p biospy, about 2 year ago. under Hormones and
Targeted Therapy. Re-follow CT show Left lymph node and clavicle
metastasis.</li>
<li>Hypertension for 10 years with Novrasc 1# po QD and Bisoprolol
1.25mg 1# po QD</li>
<li>Diabetes for 10 years with Glimet(glimepiride 2mg+metformin 500mg)
1# po QD.</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-10-20 CT - abdomen
<ul>
<li>Partial consolidation at LLL suspected pneumonia.</li>
<li>Colon diverticula. Fat stranding abutting S-colon suspected
diverticulitis.</li>
<li>Left ovary cyst (5.2cm).</li>
</ul></li>
<li>2022-10-07 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (99.8 - 21.7) / 99.8 = 58.82%
<ul>
<li>M-mode (Teichholz) = 78.3</li>
</ul></li>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Mild PR</li>
<li>Impaired LV relaxation</li>
</ul></li>
<li>2022-09-09 CT - brain
<ul>
<li>mild dilated intraventricular and extraventricular CSF spaces</li>
<li>two cystic lesions with fluid-fluid levels, about 20mm and 9.4mm in
the left frontal lobe and about 44mm in the right parietotemporal
lobe.</li>
<li>unremarkable change in the skull base</li>
</ul></li>
<li>2022-08-19 CT - chest
<ul>
<li>Left breast cancer with chest wall meta s/p left mastectomy, C/T and
R/T. The chest wall meta is stationary .</li>
</ul></li>
<li>2022-08-10 MRI - brain
<ul>
<li>multiple brain metastasis with some stationary; one missing ; the
solid one, increase in size.</li>
</ul></li>
<li>2022-08-01 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the skull, both rib cages, sternum,
lower L-spine, sacrum, bilateral shoulders, S-I joints, hips and
knees.</li>
</ul></li>
<li>2022-05-24 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2022/02/25, the previous
two hot spots in the skull are a little less evident. However, no
prominent change is noted in the lesions in the sternum.</li>
<li>Suspected benign lesions in lower L-spines, sacrum, bilateral
shoulders, S-I joints, hips and knees.</li>
</ul></li>
<li>2022-05-19 CT - chest
<ul>
<li>Left anterior chest wall soft tissue lesion. Stationary.</li>
<li>S/P mastectomy at left side.</li>
<li>Radiation pneumoniitis at left upper lobe</li>
</ul></li>
<li>2022-05-10 MRI - brain
<ul>
<li>At least 7 intra-axial lesions, mixed solid and cystic components,
in bilateral cerebral hemispheres and right cerebellar hemisphere. 5.6mm
of the largest one in right posterior temporal lobe. Enhancement of the
solid part after contrast administration.</li>
<li>compatible with breast cancer with brain metastases.</li>
</ul></li>
<li>2022-02-25 Ventricular ejaction fraction and wall motion study
<ul>
<li>The RVEF and LVEF were 63% and 65% respectively.</li>
<li>Normal wall motion of the LV.</li>
</ul></li>
<li>2022-02-24 transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (121 - 51.2) / 121 = 57.69%</li>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Thick IVS, Impaired LV relaxation</li>
<li>Mild PR,TR</li>
</ul></li>
<li>2022-02-14 Tc-99m MDP whole body bone scan
<ul>
<li>Two hot spots in bilateral fronto-parietal region of the skull,
respectively, and increased activity in the sternum, the nature is to be
determined (post-traumatic change, early bone mets or other nature ?),
suggesting follow-up with bone scan in 3 months for further
evaluation.</li>
<li>Suspected benign lesions in lower L-spine, sacrum, bilateral
shoulders, S-I joints, and hips.</li>
</ul></li>
<li>2022-02-11 CT - whole abdomen, pelvis
<ul>
<li>S/P Mastectomy, left.</li>
<li>There is soft tissue swelling at the left upper anterior
mediastinum, nature?</li>
</ul></li>
<li>2022-01-13 Patho - brain biopsy
<ul>
<li>Brain tumor, r’t frontal area, frozen section and biopsy -
Metastatic carcinoma, breast origin</li>
<li>IHC: CK(+), GATA-3(+), ER(-), PR(-) and HER2(2+, equivocal) for
tumor cells, compatible with metastatic breast carcinoma.
<ul>
<li>There is NO amplification of HER2 detected by FISH assay in Taipei
Institute of Pathology</li>
</ul></li>
</ul></li>
<li>2022-01-13 Frozen section
<ul>
<li>Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>2022-01-12 CT - Brain for navigator
<ul>
<li>Multiple brain metasatses with mass effect. S/P markers for
stereostatic surgery.</li>
</ul></li>
<li>2022-01-10 MRI - Brain for navigator
<ul>
<li>Intra-axial lesions, suspected brain metastasis</li>
</ul></li>
<li>2022-01-10 CT - Brain
<ul>
<li>c/w brain metastasis</li>
<li>Midline shift, 8mm</li>
</ul></li>
<li>2021-04-26 PET
<ul>
<li>metastases of mass and LAP in PR.</li>
</ul></li>
<li>2020-04-01 CT
<ul>
<li>metastases of mass and LAP in PR.</li>
</ul></li>
<li>2019-09-18 PET
<ul>
<li>partial regression of the anterior mediastinal mass and invisibility
of those aforementioned LAPs.</li>
</ul></li>
<li>2019-03-14 PET
<ul>
<li>marked regression of prepericardial and left intercostal LAPs, mild
regression of the anterior mediastinal mass.</li>
</ul></li>
<li>2018-12-25 Sonography - thyroid
<ul>
<li>bilateral multinodular gioter, without evident malignancy by
aspiration cytology.</li>
</ul></li>
<li>2018-11-02 Patho - sono-guided biopsy
<ul>
<li>metastaic poorly differentiated carcinoma</li>
<li>ER (30%), PR (-), Her-2 (&lt;10%), Ki-67 (&lt;3%)</li>
</ul></li>
<li>2018-10-26 PET
<ul>
<li>a huge hypermetabolic mass wiht central necrosis, abunting anterior
chest wall and possible invading sternum in the anterior
mediastinum</li>
<li>several hypermetaboic nodes in the left supraclavicular, left
para-sternal and left lower pleura, indicating nodal metastases or
pleural seeding.</li>
</ul></li>
<li>2018-10-16 CT
<ul>
<li>SD - stable disease</li>
</ul></li>
<li>2018-08-21, -06-27 Whole body bone scan
<ul>
<li>increasing tracer uptake</li>
<li>it indicated the recurrence of invasive lobular carcinoma over
mediastinum</li>
</ul></li>
<li>2018-06-27 CT - chest
<ul>
<li>necrotized mass over the left uper anterior mediastinum with
direction invasion to left antirior 1st and 2nd ribs</li>
</ul></li>
<li>2018-03-26 Whole body bone scan
<ul>
<li>possibility of bone mets over left anterior 1st and 2nd ribs.</li>
</ul></li>
<li>2018-03-21 Presentation
<ul>
<li>she sustained a mass over left supraclavicular area.</li>
</ul></li>
<li>2007-11-26 Patho - skin-sparing mastectomy
<ul>
<li>Invasive Lobular Carcinoma. The stage was pT2N0M0, Stage IIA,</li>
<li>IHC: ER (4+), PR (4+), Her-2 (1+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-13 Stereotactic biopsy and aspiration for right PO cystic
lesion and left frontal deep tumor; breast cancer history (+);
<ul>
<li>finding
<ul>
<li>OP 1:
<ul>
<li>Two pieces white-grayish soft tumor was harvest at left forntal deep
brain.</li>
<li>Frozen section: Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>OP 2:
<ul>
<li>Xanthochromic then light reddish fluid about 40cc was apirated at
right PO area.</li>
<li>sent for cytology/culture and CSF profile.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2007-11-26 skin-sparing mastectomy with immediate breast
reconstruction</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-07 medrec plan to deliver 30 Gy/ 10 fx to the whole
brain.</li>
<li>2022-01-24 ~ 2022-01-28 - the whole brain 15 Gy/ 5 fractions?</li>
<li>2019-04-02 ~ 2019-04-25 - 45 Gy/18Fx to the anterior mediastinal
mass</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-10-21 ~ 2022-10-24 - Granocyte (lenograstim) 250mg QD SC</li>
<li>2022-10-20 - G-CSF (filgrastim) 150mg ST SC</li>
<li>2022-10-07 - Lipo-Dox (liposome doxorubicin) 50mg/m2 80mg 2hr</li>
<li>2022-09-01 - Nolbaxol (docetaxel) 35mg/m2 50mg 1hr</li>
<li>2022-08-11 - Nolbaxol (docetaxel) 35mg/m2 50mg 1hr</li>
<li>2022-07-28 - Nolbaxol (docetaxel) 35mg/m2 50mg 1hr</li>
<li>2022-07-14 - Nolbaxol (docetaxel) 35mg/m2 50mg 1hr</li>
<li>2022-06-30 - Nolbaxol (docetaxel) 35mg/m2 50mg 1hr</li>
<li>2022-06-07 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2022-05-17 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2022-04-27 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2022-04-13 ~ 2022-04-15 - Granocyte (lenograstim) 250mg QD SC</li>
<li>2022-04-07 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2022-03-21 ~ 2022-03-23 - Granocyte (lenograstim) 250mg QD SC</li>
<li>2022-03-16 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2022-02-24 - cyclophosphamide 600mg/m2 900mg 1hr + doxorubicin
60mg/m2 90mg 1hr</li>
<li>2019-12-04 ~ undergoing ? palbociclib + letrozole</li>
<li>2018-11-07 ~ 2019-10-09 - weekly eribulin for 2 weeks every 3
weeks</li>
<li>2018-04-26 ~ 2018-11-06 - palbociclib + letrozole</li>
<li>2018-03-29 ~ on-and-off - Xgeva (denosumab)
<ul>
<li>2022-01-27, 2022-02-24, 2022-03-24, 2022-04-19, 2022-05-17,
2022-06-16, 2022-07-28, 2022-08-13, 2022-09-16</li>
</ul></li>
<li>2012-06-28 ~ 2013-01-10 - anti-estrogen tamoxifen</li>
<li>2007-12-27 ~ 2012-12-13 - LHRH (luteinising hormone releasing
hormone) agonist Zoladex (goserelin)</li>
</ul></li>
</ul>
<div id="section-190" class="section level3">
<h3>==========</h3>
</div>
<div id="section-191" class="section level3">
<h3>2022-10-21</h3>
<ul>
<li>Grade 4 neutropenia (2022-10-21 WBC 20 cells/uL) is observed. The
patient has been received lenograstim and filgrastim.</li>
<li>As the disease itself and its metastases evolve, their
characteristics are changing
<ul>
<li>2007-11-26 patho - mastectomy: ER(4+), PR(4+), Her2(1+).</li>
<li>2018-11-02 patho - sono-guided biopsy: ER(30%), PR(-),
Her2(&lt;10%), Ki-67(&lt;3%)</li>
<li>2022-01-13 patho - brain biopsy: CK(+), GATA-3(+), ER(-), PR(-) and
HER2(2+, equivocal)</li>
</ul></li>
<li>A brain MRI on 2022-08-10 revealed that a solid mass had increased
in size. Researchers have demonstrated that trastuzumab deruxtecan had a
high intracranial response rate in patients with active brain metastases
associated with HER2-positive breast cancer (ref: Trastuzumab deruxtecan
in HER2-positive breast cancer with brain metastases: a single-arm,
phase 2 trial. Nat Med 28, 1840–1847 (2022). <a href="https://doi.org/10.1038/s41591-022-01935-8" class="uri">https://doi.org/10.1038/s41591-022-01935-8</a>). Upon
confirmation that Her2 is positive, trastuzumab deruxtecan may be
considered as a treatment option.</li>
<li>The blood sugar level records showed a monotonic increase (331 &lt;-
265 &lt;- 208 mg/dL). In addition to current used Galvus Met (metformin
and vildagliptin), acarbose, glimepiride or basal insulin is
recommended. The SGLT2i would not be preferred for her since she
recently experienced a UTI event.</li>
</ul>
</div>
<div id="section-192" class="section level3">
<h3>2022-10-13</h3>
<ul>
<li>During this hospital stay, all data points of serum glucose before
meal were above 220mg/dL and a 368mg/dL peak record was observed.</li>
<li>Metformin/vildagliptin is currently being taken by the patient.
There is a recommendation to add alpha-glucosidase inhibitors, e.g.,
acarbose, SGLT-2 inhibitors, such as canagliflozin, dapagliflozin (use
SGLT2i if no more UTI concern), or a basal insulin therapy.</li>
</ul>
</div>
<div id="section-193" class="section level3">
<h3>2022-09-19</h3>
<ul>
<li><p>This patient had received doxorubicin/cyclophosphamide (<em>6,
2022-02-24 ~ 2022-06-07) and docetaxel (</em>5, 2022-06-30 ~
2022-09-01)</p></li>
<li><p>Brain MRI (2022-08-10) showed one solid mets increased in size
and brain CT (2022-09-09) showed mild dilated intraventricular and
extraventricular CSF spaces and two cystic lesions with fluid-fluid
levels, about 20mm and 9.4mm in the left frontal lobe and about 44mm in
the right parietotemporal lobe.</p></li>
<li><p>Pathology (2022-01-13) comfirmed breast cancer brain mets triple
negative. Neither trastuzumab and its biosimilars/ADC(antibody drug
conjugates) nor CDK4/6 inhibitors (e.g., ribociclib, palbociclib) might
likely to show effective.</p></li>
<li><p>National Health Insurance covers PARP (poly ADP-ribose
polymerase) inhibitors like olaparib and talazoparib for metastatic
triple negative breast cancer with BRCA1/2 mutations since
2022-08-01.</p></li>
<li><p>For patients with triple-negative brain metastases from breast
cancer (BCBM), two chemotherapy regimens seem to show specific CNS
activity:</p>
<ul>
<li>the anti-vascular endothelial growth factor agent bevacizumab plus
paclitaxel in a small Phase 2 study (70% ORR but only 6 patients with
triple negative MBC) and the microtubule inhibitor eribulin in case
reports.</li>
<li>A Phase 2 trial presented at ASCO 2013 highlighted a combination of
bevacizumab plus carboplatin in the treatment of BCBM. In this study, 38
patients were treated with bevacizumab plus carboplatin, and trastuzumab
was added if the tumour was HER2+. The composite brain ORR was 63% and
the global ORR was 45%.</li>
<li>For these HER2– patients, therefore, standard chemotherapy
comprising capecitabine, eribulin or carboplatin plus bevacizumab can be
used for progressive BM after local treatment.</li>
<li>ref: Bailleux, C., Eberst, L. &amp; Bachelot, T. Treatment
strategies for breast cancer brain metastases. Br J Cancer 124, 142–155
(2021). <a href="https://doi.org/10.1038/s41416-020-01175-y" class="uri">https://doi.org/10.1038/s41416-020-01175-y</a></li>
</ul></li>
</ul>
</div>
<div id="section-194" class="section level3">
<h3>2022-04-08</h3>
<ul>
<li>The patient has TNBC with brain mets and is being treated with
doxorubicin and cyclophosphamide as from late February 2022.</li>
<li>In lab results reported on 2022-04-06, liver and kidney functions
were normal, and no obvious abnormalities were noted in the CBC or WBC
levels.</li>
<li>If the current regimen fails to produce satisfactory outcome,
capecitabine might be a subsequential alternative.</li>
<li>Olaparib or talazoparib might be an optional add-on if the BRCA1/2
mutation germline sequencing result is positive.</li>
<li>Phase III KEYNOTE-355 trial demonstrated the benefits of
pembrolizumab added to chemotherapy in locally advanced or metastatic
triple-negative breast cancer.
<ul>
<li>Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced
or Metastatic Triple-Negative Breast Cancer.</li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/35348777/" class="uri">https://pubmed.ncbi.nlm.nih.gov/35348777/</a></li>
</ul></li>
</ul>
</div>
<div id="section-195" class="section level3">
<h3>2022-03-17</h3>
<ul>
<li>The patient has TNBC with brain mets and is being treated with
doxorubicin and cyclophosphamide as from late February 2022.</li>
<li>In the event that the results do not meet expectations, capecitabine
might be an alternative.
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/17611719/" class="uri">https://pubmed.ncbi.nlm.nih.gov/17611719/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16005228/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16005228/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/14650117/" class="uri">https://pubmed.ncbi.nlm.nih.gov/14650117/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16777702/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16777702/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16909414/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16909414/</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-196" class="section level1">
<h1>701450829</h1>
<div id="section-197" class="section level2">
<h2>221021</h2>
<ul>
<li>exam findings
<ul>
<li>2022-10-20 CT - abdomen
<ul>
<li>Cecal cancer with colostomy, peritoneal seeding, LNs, liver and lung
metastases. Compression fracture of T12.</li>
</ul></li>
<li>2022-10-20 KUB
<ul>
<li>Lumbar spondylosis.</li>
<li>T12 compression fracture.</li>
</ul></li>
<li>2022-10-20 CXR
<ul>
<li>Increase bilateral lung markings.</li>
<li>Mild cardiomegaly.</li>
<li>Thoracic spondylosis and scoliosis.</li>
<li>T12 compression fracture.</li>
</ul></li>
<li>2022-10-05 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (109 - 32.2) / 109 = 70.46%
<ul>
<li>M-mode (Teichholz) = 70.5</li>
</ul></li>
<li>Normal chamber size</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>Calcified mitral annulus with mild MR, mild TR and PR</li>
<li>AV sclerosis with mild AR , trivial AS</li>
<li>Possibly mild pulmonary HTN</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2022-10-04 ECG
<ul>
<li>Sinus rhythm with Fusion complexes</li>
<li>T wave abnormality, consider inferior ischemia</li>
</ul></li>
<li>2022-10-04 CXR
<ul>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2022-09-26 Patho - colon biopsy
<ul>
<li>Colon, hepatic flexure, biopsy — Adenocarcinoma, moderately
differentiated</li>
<li>The sections show a picture of adenocarcinoma, moderately
differentiated, composed of columnar neoplastic cells, arranged in
glandular and cribriform patterns with desmoplastic stromal
reaction.</li>
<li>IHC, tumor cells reveal: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li>2022-09-23 Colonoscopy
<ul>
<li>One tumor mass (4-5 cm in size) was noted in thehepatic flexure
withlumen narrowing (80 cm from anal verge).</li>
</ul></li>
<li>2022-09-16 CT - abdomen
<ul>
<li>History: Mild epigastric discomfort and fullness, acid reflux,
weight loss due to decrease intake, microcytic anemia was noted at OPD
post transfusion
<ul>
<li>20220915 sono: A 71.8x57.8 mm hypoechoic heterogeneous mass lesion
at the RT lobe liver. Suspected HCC</li>
<li>20220916 CA125: 97.2 U/mL (&lt;35), CA199: 1896 U/mL (&lt;35), AFP:
normal.</li>
</ul></li>
<li>Findings:
<ul>
<li>There is circumferrential asymmetrical wall thickening at the cecum,
proximal ascending colon, ileocecal valve, and terminal ileum with
irregular contour, measuring 4.7 x 6.8 cm in size.
<ul>
<li>Cecal cancer (T4a) is highly suspected. Please correlate with
colonoscopy.</li>
<li>In addition, there are several enlarged nodes in the adjacent
mescolon (T2a).</li>
</ul></li>
<li>There are heterogeneous poor enhancing masses in S5 and S6 of the
liver and the largest one measuring 8 cm in size. It is c/w liver
metastasis.
<ul>
<li>In addition, there are two soft tissue nodules in LLL and LUL of the
lung that are c/w lung metastases.</li>
<li>There are two small soft tissue nodule in the omentum of RMQ and
lower pelvis that may be tumor seeding (M1C).</li>
</ul></li>
<li>There is mild ascites in the cul-de-sac.</li>
<li>A renal cyst measuring 2.9 cm in left upper pole is noted.</li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T4a (T_value) N:N2a (N_value) M:M1c
(M_value) STAGE:IVC(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-09-15 Sonography - abdomen
<ul>
<li>hepatic tumor favor HCC</li>
<li>susp. parenchymal liver disease.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-21 Family Medicine
<ul>
<li>Q
<ul>
<li>The 85 y/o woman has ascending colon cancer with liver, peritoneal
seeding, LNs, liver and lung metastases, stage IVc (cT4aN2aM1c) status
post laparoscopy with loop-ileostomy on 20221006. Family need
information for hospice care. Thanks! 64749陳宣妃</li>
</ul></li>
<li>A
<ul>
<li>DNR(-) The patient is unaware of the situation?</li>
<li>Our share care would follow up.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-198" class="section level1">
<h1>700997286</h1>
<div id="section-199" class="section level2">
<h2>221020</h2>
<p>{ovarian cancer s/p debulking surgery}</p>
<ul>
<li>discharge diagnosis
<ul>
<li>2022-07-22
<ul>
<li>1: Ovarian cancer s/p Debulking surgery (bilateral
salpingo-oophorectomy + omentectomy + peritoneal tumor excision +
bilateral inguinal mass excision) on 2021/11/09, pT3cN0M1b, Stage IVB
s/p chemotherapy with Taxaol/Carboplatin(from 2021/12/15~2022/03/16 for
9 cycles), PD</li>
<li>2: Major depressive disorder, single episode, severe with psychotic
features</li>
<li>3: Delusional disorders</li>
<li>4: Hypomagnesemia</li>
</ul></li>
</ul></li>
<li>drug allergy
<ul>
<li>Ibuprofen Injection 100mg/ml,4ml/amp: angioedema</li>
<li>Voren 12.5mg/supp (diclofenac sodium): angioedema</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-04 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Progression of peritoneal/abdominal wall seeding, retroperitoneal
and pelvic recurrence.</li>
<li>Enlarged LNs (up to 2.1cm) at retroperitoneum and left inguinal
region.</li>
</ul></li>
<li>2022-06-10 Patho - lymph node region resection
<ul>
<li>Lymph node, left inguinal, excision — metastatic ovarian high-grade
serous adenocarcinoma (2/2)</li>
<li>Section shows pieces of lymph nodes with metastatic papillary tumor
cells.</li>
<li>The immunohistochemical stains reveal PAX8(+), WT-1(+), and p53
(aberrant expression).</li>
<li>The results are in favor of metastatic ovarian high-grade serous
adenocarcinoma.</li>
</ul></li>
<li>2022-06-02 ECG
<ul>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-04-25 ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
<li>Incomplete right bundle branch block</li>
<li>T wave abnormality, consider anterior ischemia</li>
<li>Prolonged QT</li>
</ul></li>
<li>2022-04-25 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>S/P hysterectomy. Some soft tissue masses in retroperitoneum and
pelvic cavity.</li>
<li>Enlarged LNs (up to 2.1cm) at retroperitoneum and left inguinal
region.</li>
<li>Some fluid at operative wound site.</li>
<li>Left renal stone (2mm).</li>
</ul></li>
<li>Impression
<ul>
<li>S/P hysterectomy. Recurrent tumors in retroperitoneum and pelvic
cavity. Enlarged LNs (up to 2.1cm) at retroperitoneum and left inguinal
region. Some fluid at operative wound site.</li>
</ul></li>
</ul></li>
<li>2022-04-14 2D transthoracic echocardiography
<ul>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild MR,TR,PR</li>
<li>Mild Pulmonary HTN</li>
</ul></li>
<li>2022-03-23 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Recurrent serous adenocacinoma in left inguinal area.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Metastatic nodes in para-aortic space, aortocaval space, Lt common
iliac chain, and Lt external iliac chain.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>There are lobulated cystic lesions in the pelvis and smuddgy
appearance of the omentum that may be residual tumor seeding
(carcinomatosis)?</li>
</ol></li>
</ul></li>
<li>2021-12-13 Pure Tone Audiometry, PTA
<ul>
<li>Reliabilty Fair</li>
<li>R’t : 15 dB HL</li>
<li>L’t : 10 dB HL</li>
<li>Bil WNL.</li>
</ul></li>
<li>2021-11-09 Patho - soft tissue tumor, extensive resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Ovary, right, salpingo-oophorectomy —- serous adenocarcinoma, high
grade.<br />
</li>
<li>Ovary, left, salpingo-oophorectomy —- serous adenocarcinoma, high
grade.</li>
<li>Fallopian tube, right, salpingo-oophorectomy —- serous
adenocarcinoma, high grade. By seeding.<br />
</li>
<li>Fallopian tube, left, salpingo-oophorectomy —- serous
adenocarcinoma, high grade. By seeding.<br />
</li>
<li>Uterus — absent – post hysterectomy<br />
</li>
<li>Omentume, omentectomy —- serous adenocarcinoma, high grade.<br />
</li>
<li>Douglous pouch mass, tumor excision — serous adenocarcinoma, high
grade.<br />
</li>
<li>Para-rectal mass, tumor excision — serous adenocarcinoma, high
grade.</li>
<li>Omentum mass x 2, tumor excision — serous adenocarcinoma, high
grade.</li>
<li>Right inguinal mass, tumor excision — serous adenocarcinoma, high
grade.<br />
</li>
<li>Left inguinal mass, tumor excision — serous adenocarcinoma, high
grade.<br />
</li>
<li>An addendum report of the consensus pathological stage will be
followed after tumor board meeting.<br />
</li>
<li>The consensus pathology tumor staging of gynecology tumor board
meeting on Nov. 18, 2021: pT3c pNx pM1b, FIGO stage: IVB.<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic type: serous adenocarcinoma<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic grade: high grade</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Contralateral ovary involvement: present<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Tumor side ovarian surface involvement: present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Contralateral ovary surface involvement: present<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Right tube involvement: present (on serosa)</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Left tube involvement: present (on serous and in parenchyma)<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>In situ adenocarcinoma in right and/or left fallopian tube:
absent</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Right adnexa soft tissue involvement: present<br />
</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Left adnexa soft tissue involvement: present<br />
</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Pelvic soft tissue involvement: present: 3). central pelvic mass;
4). Douglous pouch mass; 5). para-rectal mass x 2)</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>Uterine serosa involvement: non-applicable (previous hysterectomy;
no uterus received)<br />
</li>
</ol></li>
<li><ol start="13" style="list-style-type: decimal">
<li>Omentum involvement: present.<br />
</li>
</ol></li>
<li><ol start="14" style="list-style-type: decimal">
<li>Uterine Cervix involvement: not received<br />
</li>
</ol></li>
<li><ol start="15" style="list-style-type: decimal">
<li>Endometrium involvement: not received<br />
</li>
</ol></li>
<li><ol start="16" style="list-style-type: decimal">
<li>Myometrium involvement: not received<br />
</li>
</ol></li>
<li><ol start="17" style="list-style-type: decimal">
<li>Appendix involvement: not received<br />
</li>
</ol></li>
<li><ol start="18" style="list-style-type: decimal">
<li>Largest Extrapelvic Peritoneal Focus - Macroscopic (2 cm or
less)<br />
</li>
</ol></li>
<li><ol start="19" style="list-style-type: decimal">
<li>Peritoneal/Ascitic Fluid-Not submitted.<br />
</li>
</ol></li>
<li><ol start="20" style="list-style-type: decimal">
<li>Regional Lymph Nodes: No lymph nodes submitted<br />
</li>
</ol></li>
<li><ol start="21" style="list-style-type: decimal">
<li>Other organs or specimens involvement: present. 7). right inguinal
mass; 8). left inguinal mass.<br />
</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-09-22 Patho - ovary (tumor)
<ul>
<li>Pelvic mass, CT-guide biopsy — Adenocarcinoma</li>
<li>Microscopically, the sections show a picture of adenocarcinoma
characterized by pleomorphic and hyperchromatic tumor cells arranged in
papillary or soild pattern.</li>
<li>Immunohistochemistry shows CK7(+), CK20(-), PAX-8(+, focal), WT-1(+)
and calretinin(-) for tumor cells, serous carcinoma originating from
adnexa maybe first considered. Please check GYN condition and clinical
correlation is advised.</li>
</ul></li>
<li>2021-06-17 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. Some soft tissue masses (up to 6.2cm) in
peritoneal cavity (esp. pelvic cavity) suspected peritoneal seeding.
Suspected liver metastases.</li>
</ul></li>
<li>2021-05-13 Gynecologic ultrasonography
<ul>
<li>pelvis mass 57x50mm, RI:0.22, ATH</li>
<li>suspect pelvis mass</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-06 Plastic and Reconstructive surgery
<ul>
<li>Q
<ul>
<li>The 61 y/o woman has ovary cancer with recurrent tumors in
retroperitoneum and pelvic cavity. Enlarged LNs (up to 2.1cm) at
retroperitoneum and left inguinal region. Some fluid at operative wound
site. We confirm GYN, who suggested debridement, so we need your help.
Thanks!</li>
</ul></li>
<li>A
<ul>
<li>I will check on her next Monday. Thanks.</li>
</ul></li>
</ul></li>
<li>2022-05-05 Infectious Disease
<ul>
<li>Q
<ul>
<li>The 61 y/o woman has ovarian cancer with peritoneal sign and fistula
with fungating. Due to spiked fever noted, so we hold Tapimycin and
shift to Meropenam and Targocid for infection control. We need your
agree. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>keep present antibiotic Rx, and adjust to culture data later</li>
<li>monitor CRP</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-19 - topotecan 1.2mg/m2 1.5mg 90min D1-D5</li>
<li>2022-09-13 - topotecan 1.2mg/m2 1.5mg 90min D1-D5</li>
<li>2022-08-18 - topotecan 1.2mg/m2 1.5mg 90min D1-D5
<ul>
<li>topotecan dosing
<ul>
<li>package insert: Ovarian cancer and SCLC:
<ul>
<li>Initial Dose: The recommended dose of topotecan is 1.5 mg/m2 body
surface area/day administered by intravenous infusion over 30 minutes
daily for 5 consecutive days with a 3 week interval between the start of
each course.</li>
<li>Subsequent Dose: Preconditions: Neutrophil &gt;= 10^9/L, PLT &gt;=
100*10^9/L, HGB &gt;= 9 g/dL</li>
</ul></li>
<li>UpToDate: Ovarian cancer, metastatic: IV: 1.5 mg/m2/day for 5
consecutive days every 21 days, continue until disease progression or
unacceptable toxicity (ten Bokkel Huinink 2004) or (off-label dosing)
1.25 mg/m2/day for 5 days every 21 days until disease progression or
unacceptable toxicity or a maximum of 12 months (Sehouli 2011) or
(weekly administration; off-label dosing) 4 mg/m2 on days 1, 8, and 15
every 28 days until disease progression or unacceptable toxicity or a
maximum of 12 months (Sehouli 2011).</li>
</ul></li>
</ul></li>
<li>2022-07-21 - liposome doxorubicin 40mg/m2 50mg 1hr + carboplatin AUC
5 600mg 2hr</li>
<li>2022-06-22 - liposome doxorubicin 40mg/m2 50mg 1hr + carboplatin AUC
5 600mg 2hr</li>
<li>2022-04-14 - liposome doxorubicin 40mg/m2 50mg 1hr + carboplatin AUC
5 600mg 2hr</li>
<li>2022-03-16 - paclitaxel 80mg/m2 100mg 1hr + carboplatin AUC 2 220mg
2hr</li>
<li>2022-03-09 - paclitaxel 80mg/m2 100mg 1hr + carboplatin AUC 2 190mg
2hr</li>
<li>2022-02-23 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 190mg
2hr</li>
<li>2022-02-16 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 190mg
2hr</li>
<li>2022-01-19 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 280mg
2hr</li>
<li>2022-01-12 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 280mg
2hr</li>
<li>2022-01-05 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 280mg
2hr</li>
<li>2021-12-22 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 280mg
2hr</li>
<li>2021-12-15 - paclitaxel 80mg/m2 90mg 1hr + carboplatin AUC 2 280mg
2hr</li>
</ul></li>
<li>lab data
<ul>
<li>WBC
<ul>
<li>2022-10-19 WBC 7.13 *10^3/uL</li>
<li>2022-09-08 WBC 4.19 *10^3/uL Granocyte (lenograstim) 250mg SC
2022-09-20,21,22</li>
<li>2022-08-19 WBC 7.81 *10^3/uL Granocyte (lenograstim) 250mg SC
2022-08-25,26,27<br />
</li>
<li>2022-08-16 WBC 5.49 *10^3/uL<br />
</li>
<li>2022-08-09 WBC 1.92 *10^3/uL</li>
<li>2022-08-02 WBC 2.73 *10^3/uL<br />
</li>
<li>2022-07-21 WBC 4.34 *10^3/uL Granocyte (lenograstim) 250mg SC
2022-07-27,28,29</li>
<li>2022-07-14 WBC 3.21 *10^3/uL<br />
</li>
<li>2022-07-07 WBC 1.18 *10^3/uL<br />
</li>
<li>2022-06-22 WBC 9.33 *10^3/uL<br />
</li>
<li>2022-06-20 WBC 9.86 *10^3/uL<br />
</li>
<li>2022-06-02 WBC 10.30 *10^3/uL<br />
</li>
<li>2022-05-09 WBC 3.54 *10^3/uL<br />
</li>
<li>2022-05-02 WBC 7.09 *10^3/uL<br />
</li>
<li>2022-04-29 WBC 1.11 *10^3/uL Granocyte (lenograstim) 250mg SC
2022-04-29,30,2022-05-01,02</li>
<li>2022-04-25 WBC 2.31 *10^3/uL<br />
</li>
<li>2022-03-30 WBC 4.38 *10^3/uL<br />
</li>
<li>2022-03-16 WBC 4.55 *10^3/uL<br />
</li>
<li>2022-03-09 WBC 8.12 *10^3/uL<br />
</li>
<li>2022-02-23 WBC 3.27 *10^3/uL<br />
</li>
<li>2022-02-16 WBC 3.12 *10^3/uL<br />
</li>
<li>2022-02-09 WBC 2.45 *10^3/uL<br />
</li>
<li>2022-01-19 WBC 2.91 *10^3/uL<br />
</li>
<li>2022-01-12 WBC 3.56 *10^3/uL<br />
</li>
<li>2022-01-05 WBC 4.00 *10^3/uL<br />
</li>
<li>2021-12-22 WBC 5.48 *10^3/uL<br />
</li>
<li>2021-11-29 WBC 10.34 *10^3/uL<br />
</li>
<li>2021-11-10 WBC 10.67 *10^3/uL<br />
</li>
<li>2021-11-07 WBC 8.92 *10^3/uL<br />
</li>
<li>2021-10-04 WBC 6.82 *10^3/uL<br />
</li>
<li>2021-09-13 WBC 5.54 *10^3/uL<br />
</li>
<li>2021-08-05 WBC 6.03 *10^3/uL<br />
</li>
<li>2021-04-28 WBC 5.37 *10^3/uL</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Grade 2 neutropenia (ANC &lt;1.5 *10^3/uL) has not been observed
since mid-August 2022 as a result of the administration of G-CSF in late
August and September 2022.</li>
<li>The use of electrolyte supplements is appropriate in the treatment
of hypokalemia (3.1 mmol/L 2022-10-19) and hypomagnesemia (1.6 mg/dL
2022-10-19).</li>
</ul>
<p>2022-08</p>
<ul>
<li>WBC and regiemn:
<ul>
<li>2022-08-09 WBC 1.92 *10^3/uL &lt;– 2022-07-21 liposome doxorubicin +
carboplatin</li>
<li>2022-07-07 WBC 1.18 *10^3/uL &lt;– 2022-06-22 liposome doxorubicin +
carboplatin</li>
<li>2022-04-29 WBC 1.11 *10^3/uL &lt;– 2022-04-14 liposome doxorubicin +
carboplatin</li>
</ul></li>
<li>During the 2 to 3 weeks after receiving [liposome doxorubicin 40
mg/m2 + carboplatin AUC 5], severe neutropenia was observed, whereas
during the prior nine cycles of [paclitaxel 80 mg/m2 + carboplatin AUC
2], there was no such severe neutropenia observed.</li>
</ul>
</div>
</div>
<div id="section-200" class="section level1">
<h1>700335277</h1>
<div id="section-201" class="section level2">
<h2>221018</h2>
<p>{DLBCL, diffuse large B-cell lymphoma}</p>
<ul>
<li>past history
<ul>
<li>Systemic disease: CAD (coronary artery disease), 2VD s/p POBA (plain
old balloon angioplasty) + DES (drug eluting stent) at prox to mild LAD
(left anterior descending artery) and POBA to distal LCX (left
circumflex artery) on 20210906, paroxysmal atrial fibrillation and
atrial flutter, hypertension, benign prostatic hyperplasia  </li>
</ul></li>
<li>exam finding
<ul>
<li>2022-10-02 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-09-21 MRI - larynx
<ul>
<li>An enhancing lesion (9 mm) at C2 vertebral body. Stationary as
compared with MRI on 20220316. Suggest regular follow-up.</li>
</ul></li>
<li>2022-09-04 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Moderate voltage criteria for LVH, may be normal variant</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-08-22 CXR
<ul>
<li>Borderline cardiomegaly</li>
</ul></li>
<li>2022-08-08 ECG
<ul>
<li>Atrial flutter with variable A-V block</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-03 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
<li>2022-08-01, 2022-07-29, 2022-07-26 CXR
<ul>
<li>Borderline cardiomegaly</li>
</ul></li>
<li>2022-07-26 2D transthoracic echocardiography
<ul>
<li>LVEF(%) = 65</li>
<li>Conclusion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal LV systolic function with normal wall motion.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Concentric LVH, severely dilated LA; LV diastolic dysfunction Gr
2.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal RV systolic function.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Aortic valve sclerosis with no AS, moderate AR; moderate MR; mild to
moderate TR; mild PR.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Possible mild pulmonary hypertension, estimated PASP: 37 mmHg.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Mildly dilated ascending aorta.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-07-25 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Early repolarization</li>
</ul></li>
<li>2022-07-24 ECG
<ul>
<li>Atrial fibrillation with a competing junctional pacemaker</li>
</ul></li>
<li>2022-07-24 CXR
<ul>
<li>Essential negative findings of the air way, mediastinum, heart,
lungs, pleura, diaphragm and thoracic cage. Suggest clinical
correlation.</li>
</ul></li>
<li>2022-06-23 CXR
<ul>
<li>S/P port-A implantation. Otherwise, there is no significant
abnormality of the chest.</li>
</ul></li>
<li>2022-05-17 CXR
<ul>
<li>Elevation of both hemidiaphragms</li>
<li>Skin fold over Rt hemithorax</li>
<li>Crowding of vascular markings and/or reticular opacities over lung
fields</li>
</ul></li>
<li>2022-03-22 EKG
<ul>
<li>Normal sinus rhythm</li>
<li>Voltage criteria for left ventricular hypertrophy</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-03-16 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Hypercellularity (50%)</li>
<li>Microscopically, the bone marrow shows hypercellularity with
hemopoietic components accounting for about 50% of the marrow space, M/E
ration of 1~2: 1 and presence of trilineage component. Megakaryocytes
are occasionally seen.</li>
<li>Immunohistochemical stain reveals MPO(+), CD34(-),CD117(-),
CD138(&lt;5%), CD20 (focal+, &lt;3%), Bcl-2(-), Bcl-6(-), CD71(+).</li>
</ul></li>
<li>2022-03-14 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
</ul></li>
<li>2022-03-14 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal AV with moderate AR</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal MV with mild MR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>LV septal hypertrophy</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved LV and RV systolic function</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Mild PR, mild TR, normal IVC size</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Dilated LA</li>
</ol></li>
</ul></li>
<li>2022-02-24 Whole body PET scan
<ul>
<li>There was increased FDG uptake involving the left tonsil and some
left upper neck lymph nodes.</li>
<li>The FDG PET findings are compatible with lymphoma involving the left
tonsil and some left upper neck lymph nodes.</li>
</ul></li>
<li>2022-02-22 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
</ul></li>
<li>2022-02-16 Tc-99m MDP whole body bone scan
<ul>
<li>Several hot or faint hot spots in the left lower temporal region of
the skull, right rib cage, right S-I joint, L/3, and right acetabulum,
respectively, the nature is to be determined (post-traumatic change or
othr nature ?), suggesting further investigation and follow-up with bone
scan in 3 months.</li>
<li>Suspected benign lesions in some middle to lower C-spine, L4 spine,
L-S junction, bilateral shoulders, elbows, left knee, and left
foot.</li>
</ul></li>
<li>2022-02-14 Patho - tonsil and/or ademoid
<ul>
<li>Tonsil tumor, left, biopsy — Diffuse large B-cell lymphoma<br />
</li>
<li>Histology type: diffuse large B-cell lymphoma shows large atypical
lymphoid cells with nucleoli and focal tumor necrosis</li>
<li>Immunohistochemistry: CK(-), P16(-), P63(+, scatter), CD3(-),
CD20(+, diffuse), Bcl-2(+), CD30(-), CD10(-), Bcl-6(+), C-MYC(+, 20-30%)
tumor.</li>
</ul></li>
<li>2022-02-11 CT - neck
<ul>
<li>Imaging Report Form for Oropharynx Carcinoma</li>
<li>Impression (Imaging stage): T2N0M0, stage II</li>
</ul></li>
<li>2022-02-11 Neck Soft Tissue
<ul>
<li>Film(s) of neck soft tissue shows:
<ul>
<li>Degeneration and spondylosis of C-spine.</li>
<li>A calcified spot at left neck.</li>
</ul></li>
</ul></li>
<li>2022-02-11 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Otherwise normal ECG</li>
</ul></li>
<li>2022-02-11 Nasopharyngoscopy
<ul>
<li>smooth NPx, moderate obstruction at velum level, smooth OPx, HPx,
airway mild compromised</li>
</ul></li>
<li>2021-09-07 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Otherwise normal ECG</li>
</ul></li>
<li>2021-09-06 ECG
<ul>
<li>Sinus bradycardia with 1st degree A-V block</li>
</ul></li>
<li>2021-09-06 Cardiac Catheter
<ul>
<li>Intervention Summary
<ul>
<li>LAD P-M, Pre-DS = 70%
<ul>
<li>MLD/RVD=/3.5 mm mm → /3.5 mm, Post Balloon DS = 50%%.
<ul>
<li>Guiding catheter: Boston 6F CLS3.5.</li>
<li>Guide Wire: Terumo Runthrough Floopy.</li>
<li>Guide Wire2: Asahi SION BLUE.</li>
<li>Balloon: B Braun NSE alpha balloon. 3.5 X 13mm mm. Pressure: 12
atmospheres. 43 secs.</li>
<li>Balloon2: Abbott NC Trek. 3.5 X 20mm mm. Pressure: 9 atmospheres. 30
secs.</li>
<li>Balloon3: Medtronic NC Euphora. 4.0 X 12mm mm. Pressure: 22
atmospheres. 15 secs.</li>
<li>Stent: B Braun Coroflex ISAR DES. 3.5 X 28mm mm. Pressure: 14
atmospheres. 14 secs.</li>
<li>Stent-MLD/RVD=/3.5 mm Stent DS = 0% residual stenosis.</li>
</ul></li>
</ul></li>
<li>LCX-D, Pre-DS = 80%
<ul>
<li>MLD/RVD=/2.5mm mm → /2.5 mm, Post Balloon DS = 30%%.
<ul>
<li>Guiding catheter: Boston 6F CLS3.5.</li>
<li>Guide Wire: Terumo Runthrough Floopy.</li>
<li>Guide Wire2: Asahi SION BLUE.</li>
</ul></li>
</ul></li>
</ul></li>
<li>In conclusion: CAD DVDs/p PCI with DES for proximal to mid LAD and
POBA for distal LCX, successful</li>
<li>Recommendation: PCI for LAD and LCX</li>
</ul></li>
<li>2021-09-03 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Preserved LV and RV systolic function with normal wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated LA, grade 2 LV diastolic dysfunction</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mild AR, MR, TR</li>
</ol></li>
</ul></li>
<li>2021-09-01 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
</ul></li>
<li>2021-08-27 19:52 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-08-27 17:26 ECG
<ul>
<li>Atrial flutter with variable A-V block</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-08-01 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-05-31 ECG
<ul>
<li>Sinus bradycardia with 1st degree A-V block with Premature
supraventricular complexes</li>
</ul></li>
<li>2021-04-14 Vestibular Evoked Myogenic Potential, VEMP
<ul>
<li>oVEMP Interaural Amplitude Asymmetry ratio 22.78 %,WNL</li>
<li>cVEMP Interaural Amplitude Asymmetry ratio 8.98 %, WNL</li>
</ul></li>
<li>2021-04-06 C-spine AP + Lat.
<ul>
<li>Radiograph of the cervical spine (AP and lateral):
<ul>
<li>Osteoporosis.</li>
<li>Spondylosis, esp C4-5-6-7.</li>
</ul></li>
</ul></li>
<li>2020-07-28 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably mild to moderate myocardial ischemia with possible a
portion of severe ischemia at the inferolateral wall and posterior wall
and mild myocardial ischemia at the apical lateral wall.</li>
</ul></li>
<li>2020-07-17 CXR
<ul>
<li>Spondylosis of the T-spine</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2020-07-17 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>Borderline ECG</li>
</ul></li>
<li>2019-12-20 KUB
<ul>
<li>The psoas shadow is clear.</li>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>Increased intestinal gas is found.</li>
<li>Phlebolith at pelvic cavity is also found.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>2019-12-10 Surgical pathology Level III
<ul>
<li>Clinical diagnosis: Other cellulitis &amp; absess, leg, except
foot</li>
<li>Pathologic diagnosis
<ul>
<li>Benign</li>
<li>Skin and soft tissue, right lateral calf, regional fasciectomy —
necrotizing inflammation</li>
</ul></li>
</ul></li>
<li>2019-12-10 Surgical pathology Level III
<ul>
<li>Clinical diagnosis: Benign neoplasm of connective and other soft
tissue, unspecified</li>
<li>Pathologic diagnosis
<ul>
<li>Benign</li>
<li>Tumor, chest, excision — Neurofibroma</li>
</ul></li>
</ul></li>
<li>2017-11-14 Knee Bilat. standing
<ul>
<li>Moderate osteoarthritis of both knees with varus configuration</li>
<li>Ahlback calcification: grade 3, 3</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-29 Cardiology
<ul>
<li>Q
<ul>
<li>for hypertension poor control</li>
<li>This 78-year-old male, a pt of DLBCL, Lungano stage II, Dx in Feb
2022, suffered from initial presentation of enlarged neck near thyroid
in Jan 2022. He was admitted due to port-A infection for anti treatment.
Owing to hypertension poor control (SBP:200-206)/DBP(90) was noted
during admission. We need expertise to evaluate his condition
thanks!</li>
</ul></li>
<li>A
<ul>
<li>S:
<ul>
<li>He also suffered Zoaster with neuropathic pain in T4-6 dermatome
region from back to chest with large surface area, now in healing stage,
but neuropathic pain remains but can tolerate. He also has port A
removal site pain. He felt headache when in hypertension. He also has
mild right ankle joint pain but not inflammed on inspection.</li>
<li>Denied of chest and abdominal pain. shortness of breath.</li>
</ul></li>
<li>O
<ul>
<li>BP: near control till 20220627 then elevated upto 200/90 in
2022/06/27-28.</li>
<li>HR: average 70</li>
<li>Bed side BP during visit: 155/78-169/81</li>
<li>Current medication
<ul>
<li>po candesartan 1# qn</li>
<li>po atenolol 1# qd</li>
<li>po lasix 1# qd</li>
</ul></li>
<li>Lab
<ul>
<li>Renal and electrolyte : normal</li>
</ul></li>
</ul></li>
<li>Impression
<ul>
<li>Elevated blood pressure in prior HCVD patient suspected neuropathic
and post op pain related.</li>
<li>Port A infection with psuedomonas infection</li>
</ul></li>
<li>Suggestion
<ul>
<li>please add po norvasc 1# qd for BP and hold If SBP &lt; 140mmHg
(observe ankle swelling which could be worsen due to norvasc side
effect)</li>
<li>educate patient if home BP is relatively lower than 140mmHg. and
also, if recurrent zoaster infection, then visit dermatologist for UV
radiation that fasten healing and reduce neuropthic pain.</li>
<li>Adequate pain control.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-10 Dermatology
<ul>
<li>Q
<ul>
<li>For herpes zoter</li>
<li>This 78-year-old man, a patient of DLBCL (triple-hit lymphoma) at L
tonsil, Lungano stage II, IPI: 1, non-GCB subtype, Dx in Feb 2022,
suffered from initial presentation of enlarged neck near thyroid in Jan
2022 S/P C/T. He was admitted for C/T. He complained of pain &amp;
herpes zoter over right chest, armpit, back for 3 days. We need
expertise to evaluate his condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from grouped vesicels on R’t trunk for 3
days.</li>
<li>Imp: Herpes zoster</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Famvior 1 / Tid</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Lyrica * 1 /Bid</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>ZnO* 1 tube/bid</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-11 ENT
<ul>
<li>Q
<ul>
<li>Sore throat &gt; blood pressure or heartbeat is different from the
patient’s usual value, however hemodynamics is stable, tonsils are
suppuration, and there is no improvement after visiting local clinics.
<ul>
<li>throat pain noted for days</li>
<li>no fever</li>
<li>odynophagia(+)</li>
<li>no vomiting</li>
</ul></li>
<li>PH: HTN; Af ; CAD</li>
<li>NKA</li>
<li>s/p 2nd Moderna last Dec.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>Odynophagia, VAS 4-5 for a week.</li>
<li>Fever(-) Dypsnea(-)</li>
</ul></li>
<li>O
<ul>
<li>PE:
<ul>
<li>Oral: swelling of left tonsil with exudate, swelling of left soft
palate s/p aspiration(no pus)</li>
<li>Scope: smooth NPx, moderate obstruction at velum level, smooth OPx,
HPx, airway mild compromised</li>
</ul></li>
</ul></li>
<li>Imp: Suspect left peritonsillar abscess</li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>Neck CT with/without contrast (last meal: 20220211 11:40)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>OA to ENT, IV Curam + Genta</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Monitor airway</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>R-DA-EPOCH, Dose-adjusted EPOCH-R ([etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin] + rituximab). Titration up:
etoposide, doxorubicin, cyclophosphamide</li>
<li>2022-10-18 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 10mg/m2 17mg 24hr D1-4 + vincristine 0.4mg/m2
0.7mg 24hr D1-4 + cyclophosphamide 750mg/m2 1285mg 30min D5 +
prednisolone 60mg/m2 tmg/tab 20# QD D1-5</li>
<li>2022-09-19 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 10mg/m2 17mg 24hr D1-4 + vincristine 0.4mg/m2
0.7mg 24hr D1-4 + cyclophosphamide 750mg/m2 1285mg 30min D5 +
prednisolone 60mg/m2 tmg/tab 20# QD D1-5</li>
<li>2022-08-22 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 10mg/m2 17mg 24hr D1-4 + vincristine 0.4mg/m2
0.7mg 24hr D1-4 + cyclophosphamide 750mg/m2 1300mg 30min D5 +
prednisolone 60mg/m2 5mg/tab 20# QD D1-5</li>
<li>2022-07-26 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 9mg/m2 15mg 24hr D1-4 + cyclophosphamide
600mg/m2 1000mg 30min D5 + prednisolone 60mg/m2 5mg/tab 20# QD D1-5
(vincristine not available then)</li>
<li>2022-05-03 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 9mg/m2 15mg 24hr D1-4 + vincristine 0.4mg/m2
0.6mg 24hr D1-4 + cyclophosphamide 600mg/m2 1000mg 30min D5 +
prednisolone 60mg/m2 5mg/tab 20# QD D1-5</li>
<li>2022-04-12 - rituximab 375mg/m2 600mg 8hr + etoposide 50mg/m2 80mg
24hr D1-4 + doxorubicin 9mg/m2 15mg 24hr D1-4 + vincristine 0.4mg/m2
0.6mg 24hr D1-4 + cyclophosphamide 600mg/m2 1000mg 30min D5 +
prednisolone 60mg/m2 5mg/tab 20# QD D1-5</li>
<li>2022-03-17 - rituximab 375mg/m2 640mg 8hr + etoposide 40mg/m2 68mg
24hr D1-4 + doxorubicin 6mg/m2 10mg 24hr D1-4 + vincristine 0.4mg/m2
0.6mg 24hr D1-4 + cyclophosphamide 600mg/m2 1000mg 30min D5 +
prednisolone 60mg/m2 5mg/tab 20# QD D1-5</li>
</ul></li>
</ul>
<div id="section-202" class="section level3">
<h3>==========</h3>
</div>
<div id="section-203" class="section level3">
<h3>2022-09-19</h3>
<p>[drug identification]</p>
<p>One drug for identification.</p>
<ul>
<li>It is identified as Doudart (dustasteride 0.5mg + tamsulosin
0.4mg).</li>
<li>In men, it is used to treat the signs of an enlarged prostate.</li>
</ul>
<p>The drug will be sent back to ward by the in-hospital porter.</p>
</div>
<div id="section-204" class="section level3">
<h3>2022-08-23</h3>
<ul>
<li>During this hospitalization, the blood pressure was around
(180+-30)/(85+-10) with prescribed Norvasc (amlodipine 5mg) 1# QD,
Blopress (candesartan 8mg) 1# QN and self-carried Urosin (atenolol
100mg) QD. If HTN still becomes symptomatic, thiazide diuretics such as
Tricozide (trichlormethiazide 2mg/tab) 1# QD or Natrilix (indapamide
1.5mg/tab) 1# QD might be also considered.</li>
<li>Renal denervation is another BP-lowering strategy in hypertensive
patients with high CV risk, such as resistant or masked uncontrolled
hypertension, established ASCVD, intolerant or nonadherent to
antihypertensive drugs, or features indicative of neurogenic
hypertension after careful clinical and imaging evaluation (COR IIa, LOE
B).</li>
</ul>
</div>
<div id="section-205" class="section level3">
<h3>2022-07-25</h3>
<ul>
<li>There is a history of cardiovascular disease in the patient,
2022-03-14 2D transthoracic echocardiography showed: Mild PR, mild TR,
Dilated LA, grade 2 LV diastolic dysfunction.</li>
<li>There were elevated levels of hs-Troponin I and NT-proBNP in the lab
data that might indicate cardiovascular conditions.
<ul>
<li>hs-Troponin I
<ul>
<li>2022-07-24 58.3 pg/mL<br />
</li>
<li>2022-07-24 59.4 pg/mL<br />
</li>
<li>2022-02-11 36.3 pg/mL<br />
</li>
</ul></li>
<li>NT-proBNP
<ul>
<li>2022-07-24 847 pg/mL<br />
</li>
<li>2020-12-31 194 pg/mL<br />
</li>
</ul></li>
</ul></li>
<li>Doxorubicin was initialized at 6mg/m2 (2022-03-17) and titrated up
to 9mg/m2 (2022-04-12), this is a relatively conservative and robust way
of administration, last dose was administered on 2022-05-03.</li>
<li>Control of blood pressure was better than last hospitalization for
there was no event of a SBP exceeding 200 mmHg and/or a DBP exceeding
100 mmHg.</li>
</ul>
</div>
<div id="section-206" class="section level3">
<h3>2022-03-25</h3>
<p>[drug identification]</p>
<p>Two drugs need identification.</p>
<p>the 2 identified items has been shown as following:</p>
<ul>
<li>Duodart (tamsolosin 0.4mg, dutasteride 0.5mg)</li>
<li>Urosin (atenolol 100mg)</li>
</ul>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
</div>
<div id="section-207" class="section level1">
<h1>700805995</h1>
<div id="section-208" class="section level2">
<h2>221018</h2>
<p>{Endometrioid carcinoma, grade 2, of the uterine endometrium, AJCC
Pathologic stage — pT3aN1aM1, stage IVB / FIGO stage IVB, s/p
Laparoscopic gynecologic oncology staging surgery.}</p>
<ul>
<li>exam finding
<ul>
<li>2022-10-18 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (93 - 12) / 93 = 87.10%
<ul>
<li>LVEF (%) = 87</li>
<li>M-mode (Teichholz) = 87</li>
</ul></li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>LV diastolic dysfunction Gr 2.</li>
<li>Normal RV systolic function.</li>
<li>Mild MR; mild TR; aortic valve sclerosis</li>
</ul></li>
<li>2022-09-16 CXR
<ul>
<li>Scoliotic alignment of the thoracolumbar spine is noted.</li>
</ul></li>
<li>2022-09-16 Peripheral Vascular Test - AV fistula
<ul>
<li>adequate size of RUV</li>
</ul></li>
<li>2022-08-23 Patho - uterus with or without SO
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Endometrium, uterus, LSC staging surgery — Endometrioid carcinoma,
grade 2</li>
<li>Myometrium, uterus, ditto — Tumor invasion, more than half
thickness</li>
<li>Uterus, cervix, ditto — Free of tumor, 5.2 cm away from tumor</li>
<li>Ovary, right, ditto — Tumor invasion</li>
<li>Fallopian tube, right, ditto — Free of tumor</li>
<li>Ovary, left, ditto — Free of tumor</li>
<li>Fallopian tube, left, ditto — Free of tumor</li>
<li>Lymph node, left iliac, dissection — Free of tumor metastasis
(0/9)</li>
<li>Lymph node, left oburator, ditto — Tumor metastasis (1/6) with
extracapsular extension (1/1)</li>
<li>Lymph node, right iliac, ditto — Free of tumor metastasis (0/9)</li>
<li>Lymph node, right oburator, ditto — Free of tumor metastasis
(0/14)<br />
</li>
<li>Omentum, omentectomy — Tumor invasion</li>
<li>AJCC Pathologic stage — pT3aN1aM1, stage IVB / FIGO stage IVB</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology type: Endometrioid carcinoma</li>
<li>Histology grade: Grade 2</li>
<li>Depth of invasion: more than half thickness of myometrium</li>
<li>Lymphovascular invasion: Present</li>
<li>The cervical stroma involvement: Absent</li>
<li>Resection margins of the cervix: Free, 5.2 cm away from tumor</li>
<li>Additional pathologic findings: focal tumor necrosis and focal
squamous differentiation</li>
<li>Lymph nodes: tumor metastasis (1/38) with extracapsular extension
(1/1) in total number</li>
<li>Uterine cervix: Free of tumor, chronic cervicitis</li>
<li>L’t ovary: corpus albicans and free</li>
<li>R’t ovary: tumor invasion</li>
<li>Bilateral fallopian tubes: Free of tumor</li>
<li>Omentum: tumor invasion characterized by scant tumor measured less
than 0.1 cm with stromal inflammation. Immunohistochemistry of CK(+) for
tumor</li>
</ul></li>
</ul></li>
<li>2022-08-22 Body fluid cytology - ascites
<ul>
<li>diagnosis
<ul>
<li>Malignancy</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>40 cc grey-orange cloudy ascites<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The smears show lymphocytes, reactive mesothelial cells and some
hyperchromatic atypical epithelial cell clusters, compatible with
metastatic carcinoma. Clinical correlation and confirmatory biopsy is
advised.</li>
</ul></li>
</ul></li>
<li>2022-08-18 MRI - pelvis
<ul>
<li>Imaging Report Form for Endometrial Carcinoma</li>
<li>Imaging stage : T:T1b(T_value) N:N1a(N_value) M:M0(M_value) STAGE:
IIIc(Stage_value)</li>
<li>Imperssion: Uterine tumor with lymph nodes, suspected endometrial
malignancy with lymph nodes metastasis, cstage T1bN1aM0, IIIc.</li>
</ul></li>
<li>2022-08-08 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, D＆C — endometrioid adenocarcinoma, grade
1.</li>
<li>IHC stains: ER (+, 100% strong intensity), PR (+, 90%, strong
intensity), vimentin (+), P53 (wild type), Napsin-A (-), CK20 (-).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-08-08
<ul>
<li>Surgery
<ul>
<li>D&amp;C, theraputic and diagnostic, vaginal bleeding </li>
<li>Pathology: pending</li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: Anteversion, 7 cm.</li>
<li>Some endometrial tissue were curetted out.</li>
<li>Estimated blood loss: 10 mL</li>
<li>Blood transfusion: nil</li>
<li>Complication: nil.  </li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-09-28 ~ undergoing? 1980cGy/11 fractions of the pelvic
area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-17 - doxorubicin 50mg/m2 77mg 30min + cisplatin 50mg/m2 77mg
2hr (Q3W)</li>
<li>2022-09-21 - paclitaxel 160mg/m2 250mg 3hr + carboplatin AUC 5 490mg
2hr (Q3W, paclitaxel first 160mg/m2, full 175mg/m2)
<ul>
<li>After admission, she took pre-medication as Dorison 20mg at 20220920
2300 and 20220921 0500. She received Taxel (Initial 160mg/m2) and
Carboplatin AUC 5 on 20220921.</li>
<li>When the Taxel drip around 11 ml, she has dyspnea and mild SOB. We
stopped chemotherapy and IVF hydration.</li>
<li>Under the stable condition, she can be discharged on 20220922. OPD
follow up is arranged.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-209" class="section level1">
<h1>700866748</h1>
<div id="section-210" class="section level2">
<h2>221014</h2>
<ul>
<li>diagnosis
<ul>
<li>Adenocarcinoma, moderately differentiated, of the esophagus, EG
junction, stage IV, pT3N1(pM1), s/p thoracoscopic esophagectomy,
radiotherapy, UFUR, and TS-1, with left mediastinal lymph nodes
metastases and suspicious right lung metastases, s/p radiotherapy and
status during chemotherapy with brain metastases, s/p radiotherapy.</li>
<li>EG junction adenocarcinoma s/p adjuvant CCRT (4860 cGy and UFUR)
followed by adjuvant C/T with TS-1, with recurrent adenocarcinoma over
middle and lower third trachea, s/p palliative C/T of docetaxel with or
without 5-FU /Folinic Acid, s/p R/T with 5760 cGy, in progression, s/p
CAL056, with progression of lung metastasis s/p palliative C/T with
FOLFOX with brain metastasis s/p whole brain R/T and palliative C/T with
FOLFIRI from 2022/08/10</li>
<li>Chronic obstructive pulmonary disease, unspecified</li>
<li>Gout, unspecified</li>
<li>Insomnia, unspecified</li>
</ul></li>
<li>past history
<ul>
<li><ol style="list-style-type: decimal">
<li>Gout from 2002 to now</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Limping gait from 2006 to now</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Benign prostatic hyperplasia from 2010 to now</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Herniated Intervertebral Disc from 2010-06-10 to now</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Bilateral renal cysts from 2010-06-10 to now</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Mitral regurgitation Gr 1 from 2010-06-12 to now</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Tricuspid regurgitation Gr 1 from 2010-06-12 to now</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Degenerative change of the thoraco-lumbar spine with narrowed
intervertebral disc spaces and spurs formation from 2012-04-13 to
now</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Superimposed bilateral lumbosacral radiculopathy from 2013-08-26 to
now</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Spondylosis from 2013-09-03 to now</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Onychomycosis from 2017 to now</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>Obstruction sleep apnea from 2017-01-31 to now</li>
</ol></li>
<li><ol start="13" style="list-style-type: decimal">
<li>Fatty liver from 2017-01-13 to now</li>
</ol></li>
<li><ol start="14" style="list-style-type: decimal">
<li>Insomnia Gr 1 from 2017-02-07 to now</li>
</ol></li>
<li><ol start="15" style="list-style-type: decimal">
<li>Productive cough Gr 1 from 2017-06 to now</li>
</ol></li>
<li><ol start="16" style="list-style-type: decimal">
<li>Chronic obstructive pulmonary disease from 2017-07-14 to now</li>
</ol></li>
<li><ol start="17" style="list-style-type: decimal">
<li>Chronic allergic rhinitis Gr 1 from 2017-07-14 to 2020-10-21, Gr 2
from 2020-10-22 to now</li>
</ol></li>
<li><ol start="18" style="list-style-type: decimal">
<li>Gastroesophageal reflux disease Gr 2 from 2018-01-04 to now</li>
</ol></li>
<li><ol start="19" style="list-style-type: decimal">
<li>Hyperlipidemia Gr 1 from 2018-04-24 to now</li>
</ol></li>
<li><ol start="20" style="list-style-type: decimal">
<li>Hiatal hernia from 2018-10-16 to 2022-02-06</li>
</ol></li>
<li><ol start="21" style="list-style-type: decimal">
<li>Superficial gastritis from 2019-12-30 to 2022-02-06</li>
</ol></li>
<li><ol start="22" style="list-style-type: decimal">
<li>Marginal spurs of multiple vertebral bodies from 2020-07-28 to
now</li>
</ol></li>
<li><ol start="23" style="list-style-type: decimal">
<li>Esophageal shallow ulcers (above ECJ) from 2020-08-05 to now</li>
</ol></li>
<li><ol start="24" style="list-style-type: decimal">
<li>Hemoptysis, intermittently from 2021-08 to 2021-09-28</li>
</ol></li>
<li><ol start="25" style="list-style-type: decimal">
<li>Anemia Gr 1 from 2020-08-25 to now</li>
</ol></li>
<li><ol start="26" style="list-style-type: decimal">
<li>Atherosclerotic change of aortic arch from 2020-10-16 to now</li>
</ol></li>
<li><ol start="27" style="list-style-type: decimal">
<li>Bilateral carpal tunnel syndrome from 2020-11-17 to now</li>
</ol></li>
<li><ol start="28" style="list-style-type: decimal">
<li>Retrolordotic curve change of the spine 2020-11-23 to now</li>
</ol></li>
<li><ol start="29" style="list-style-type: decimal">
<li>Gallbladder stones from 2021-04-13 to now</li>
</ol></li>
<li><ol start="30" style="list-style-type: decimal">
<li>Reflux laryngitis from 2021-05-13 to now</li>
</ol></li>
<li><ol start="31" style="list-style-type: decimal">
<li>Mild posterior pericardial effusion from 2021-08-04 to now</li>
</ol></li>
<li><ol start="32" style="list-style-type: decimal">
<li>Bilateral pleura effusion from 2021-08-04 to now</li>
</ol></li>
<li><ol start="33" style="list-style-type: decimal">
<li>Platelet count decreased Gr 1 from 2021-12-14 to now</li>
</ol></li>
<li><ol start="34" style="list-style-type: decimal">
<li>Blood-stinged sputum, intermittently from 2022-01-28 to
now      </li>
</ol></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-15 Patho - bronchus biopsy
<ul>
<li>Lung, LB8 endobronchial tumor, bronchoscopic biopsy —
adenocarcinoma, consistent with metastatic tumor</li>
<li>Sections show neoplastic glandular cells infiltrating in a fibrotic
stroma with focal tumor necrosis.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), CDX2(focal
+), TTF-1(-), and Napsin A(-). The results are consistent with
metastatic adenocarcinoma from esophagogastric junction (cardiac cancer
of stomach).</li>
</ul></li>
<li>2022-09-15 Bronchoscopy
<ul>
<li>The nasal mucosa was hypertrophic.</li>
<li>The nasal lumen was severely narrowed.</li>
<li>The was copious mucoid nasal discharge retained in the nasal
cavity.</li>
<li>Mucosa of nasopharynx was hypertrophic .</li>
<li>Nasopharynx was severely narrowed.</li>
<li>Mucosa of pharynx cobble-stone in shape .</li>
<li>Movement of the both. vocal cord(s) was normal .</li>
<li>Bilateral arytenoid proceww was normal .</li>
<li>Trachea whole segment: patent and the mucosa was normal .</li>
<li>Main carina: sharp and movable on deep breathing.</li>
<li>Bilateral endobronchial trees:
<ul>
<li>Trachea: no tumor recur</li>
<li>RML/RLL carina submucosal lesion, without airway mucosal
invasion</li>
<li>RLL orifice two submucosal lesions, without airway mucosal
invasion</li>
<li>LB 8 endobronchial tumor with total occlusion</li>
</ul></li>
<li>Under fluoroscent bronchoscopy:
<ul>
<li>Trachea: no tumor recur</li>
<li>RML/RLL carina submucosal lesion, without airway mucosal
invasion</li>
<li>RLL orifice two submucosal lesions, without airway mucosal
invasion</li>
<li>LB8 endobronchial tumor with total occlusion, s/p biopsy</li>
</ul></li>
<li>After RB8 tumor biopsy by 15C biopsy forceps and snare-loop, tumor
bleeding was noted, electrocautery with 25W/25W to 35W/35W with
heat-probe was done for bleeding control.</li>
</ul></li>
<li>2022-08-11 MRI - brain
<ul>
<li>Known a case of EG junction adenocarcinoma s/p CCRT. One enhancing
nodular lesion (3.7cm) over right cerebellar lobe, favor a metastatic
lesion.</li>
<li>Prominent peritumoral edema.</li>
<li>The intracranial vessels are normally signal-void.</li>
<li>The paranasal sinuses and mastoid air cells are aerated.</li>
<li>The globes, optic nerve and extraoccular muscles are sketchyily
intact in the non-FatSat images.</li>
</ul></li>
<li>2022-07-08 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>Prior CT identified several metastases in both lung are noted again.
Most of then show stable in size. However, two metastases in RLL and LLL
of the lung show increasing in size.</li>
<li>Pleura reaction in bilateral posterior basal CP angle.</li>
<li>Few calcified gallstones are noted.</li>
<li>There are several renal cysts on both kidney and the largest one
measuring 3.6 cm in size at left middle pole.
<ul>
<li>In addition, both kidney show mild irregular contour that may be old
inflammatory process or normal variation.</li>
</ul></li>
<li>s/p distal esophagectomy, cardiectomy and esophagogastrostomy.
<ul>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
<li>There is no focal abnormality in the liver, biliary system,
pancreas, and spleen.
<ul>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>Impression
<ul>
<li>Prior CT identified several metastases in both lung are noted again.
Most of then show stable in size. However, two metastases in RLL and LLL
of the lung show increasing in size.</li>
</ul></li>
</ul></li>
<li>2022-06-16 Bronchial Washing
<ul>
<li>Positive for malignancy</li>
</ul></li>
<li>2022-06-15 CXR
<ul>
<li>Bilateral pleural effusions</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Coarse reticular opacities or Platelike lung atelectasis over Lt Rt
lower lung zones</li>
<li>Marginal spurs of multiple vertebral bodies.</li>
</ul></li>
<li>2022-04-08 CT - abdomen, pelvis
<ul>
<li>Lung metastases show mild increasing in size.</li>
</ul></li>
<li>2022-02-07 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis, LA-A (minimal)</li>
<li>Postoperative status of partial esophagectomy and gastric tube
reconstruction.</li>
<li>Much food residue retention in esophagus and stomach</li>
<li>Incomplete study</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD follow-up</li>
</ul></li>
</ul></li>
<li>2022-01-28 CT - abdomen, pelvis
<ul>
<li>Lung metastases show mild increasing in size.</li>
</ul></li>
<li>2022-01-06 Bronchoscopy
<ul>
<li>The nasal mucosa was hypertrophic.</li>
<li>The nasal lumen was severely narrowed.</li>
<li>The was copious mucoid nasal discharge retained in the nasal
cavity.</li>
<li>Mucosa of nasopharynx was hypertrophic .</li>
<li>Nasopharynx was severely narrowed.</li>
<li>Mucosa of pharynx cobble-stone in shape .</li>
<li>Movement of the both. vocal cord(s) was / werenormal .</li>
<li>Bilateral arytenoid proceww was normal .</li>
<li>Trachea whole segment: patent and the mucosa was normal.</li>
<li>Main carina: sharp and movable on deep breathing.</li>
<li>Bilateral endobronchial trees:
<ul>
<li>RML bronchus swelling and hyperremic, easy touch bleeding.</li>
<li>No visible endobronchial lesion</li>
</ul></li>
</ul></li>
<li>2021-11-22 CT - lung
<ul>
<li>bilateral lung and mediastinal metastases, slightly in progression
as compared with previous CT study on 20210804</li>
</ul></li>
<li>2021-08-04 CT - lung
<ul>
<li>consistent with bilateral lung and mediastinal metastases, in
progression as compared with previous CT study on 20210719</li>
</ul></li>
<li>2021-07-19 CT - abdomen
<ul>
<li>S/P gastric operation.</li>
<li>Small nodules at right lung suspected metastases.</li>
</ul></li>
<li>2021-04-13 CT - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Gastric cancer s/p partial gastrectomy. Suggest follow up.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Bilateral renal cysts.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>GB stones.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Old fractures at bilateral ribs.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Bilateral basal lung atelectasis.</li>
</ol></li>
</ul></li>
<li>2021-02-24 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Possible Inferior infarct, age undetermined</li>
</ul></li>
<li>2020-11-06 CT -lung
<ul>
<li>Gastric cancer s/p partial gastrectomy.</li>
<li>Right lower lobe and left lower lobe intrafissural nodule. Decreased
in size.</li>
<li>Right upper lobe tiny nodule. Stable.</li>
</ul></li>
<li>2020-09-03 Patho - trancheal biopsy
<ul>
<li>Lung, side ?, bronchoscopic biopsy — adenocarcinoma, poorly
differentiated, consistent with recurrence</li>
</ul></li>
<li>2020-08-07 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>Prominently increased activity in the L3-5 spines and L5-sacrum
junction. Severe degenerative change may show this picture. However,
please correlate with other imaging modalities for further evaluation
and to rule out other possibilities.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mildly increased activity in the lower C-spine, middle and lower
T-spines. Degenerative change is more likely.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Some faint hot spots in the sternum and bilateral rib cages. The
nature is to be determined (post-traumatic change? other nature?).
Please follow up bone scan for further evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, wrists and knees, compatible with benign
joint lesions.</li>
</ol></li>
</ul></li>
<li>2020-08-05 Patho - trancheal biopsy
<ul>
<li>Lung, ? side, bronchoscopic biopsy — adenocarcinoma, moderately
differentiated, in favor of recurrence</li>
<li>Sections show bronchail mucosa with neoplastic glandular cells
infiltrating in submucosa.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), CDX2(focal
+), TTF-1(-), and Napsin A(-). The results are in favor of recurrent
tumor.</li>
<li>The HER2/NEU In-Situ Hybridization Test report from Taipei Institute
of Pathology is NEGATIVE. There is NO amplication of HER2
detected.<br />
</li>
</ul></li>
<li>2020-08-04 Esophagography
<ul>
<li>s/p distal esophagectomy with esophagogastrostomy</li>
<li>High grade gastroesophageal reflex</li>
</ul></li>
<li>2020-07-28 CT - lung
<ul>
<li>recurrent gastric cancer as metastatic left mediastinal LAP and
suspect two metastatic Rt lung nodules.</li>
</ul></li>
<li>2019-08-01 Impedance Audiometry
<ul>
<li>Reliabilty Fair</li>
<li>PTA
<ul>
<li>R’t : 41 dB HL</li>
<li>L’t : 41 dB HL</li>
<li>Bil normal to severe SNHL</li>
</ul></li>
<li>Tymp
<ul>
<li>Bil Type B</li>
</ul></li>
<li>ART
<ul>
<li>Bil absent.</li>
</ul></li>
</ul></li>
<li>2019-04-01 CT - abdomen
<ul>
<li>s/p distal esophagectomy and cardiectomy with
esophagogastrostomy.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2016-12-12
<ul>
<li>VATS with subtotal esophagectomy, cardiectomy and jejunostomy</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2020-08-14 ~ 2020-09-28 - 5760 cGY/32Fx</li>
<li>2017-05-18 ~ 2017-06-27 - CCRT with 4860 cGy/27 fractions</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-06 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 4800mg 48hr</li>
<li>2022-09-21 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 4970mg 48hr</li>
<li>2022-09-07 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-08-24 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-08-10 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-07-20 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-07-06 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-06-01 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-05-18 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-05-04 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-04-20 - oxaliplatin 85mg/m2 175mg 2hr + leucovorin 300mg/m2
600mg 2hr + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2022-03-14 - investigational CAL056</li>
<li>2022-02-15 - investigational CAL056</li>
<li>2022-01-12 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2021-12-29 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5200mg 48hr</li>
<li>2021-12-15 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2000mg/m2 4300mg 48hr</li>
<li>2021-11-17 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2000mg/m2 4300mg 48hr</li>
<li>2021-11-03 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5200mg 48hr</li>
<li>2021-10-20 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5200mg 48hr</li>
<li>2021-10-06 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5200mg 48hr</li>
<li>2021-09-22 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5200mg 48hr</li>
<li>2021-09-08 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1-2 + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2021-08-25 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2400mg/m2 5000mg 48hr</li>
<li>2021-08-11 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-07-28 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-07-14 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-06-30 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-06-16 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-06-02 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-05-19 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-05-05 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 2000mg/m2 4000mg 48hr</li>
<li>2021-04-21 - docetaxel 35mg/m2 75mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-04-07 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-03-24 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-03-09 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-02-17 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-02-03 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2021-01-21 - docetaxel 30mg/m2 60mg 1hr + folinate 15mg/tab 1# QID
D1 + fluorouracil 1600mg/m2 3500mg 48hr</li>
<li>2020-12-25 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-11-27 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-11-20 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-11-05 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-10-30 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-10-16 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-10-08 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-10-02 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-09-17 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-09-10 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-08-25 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2020-08-19 - docetaxel 25mg/m2 54mg 1hr</li>
<li>2017-08-22 ~ 2018-05-07 - TS-1 (25 mg bid of
Tegafur/Gimeracil/Oteracil, 25 mg/7.25 mg/24.5 mg)</li>
<li>2017-05-18 ~ 2017-06-27 - UFUR (2 capsules bid of Tegafur/Uracil,
100 mg/224 mg), CCRT</li>
</ul></li>
</ul>
<div id="section-211" class="section level3">
<h3>==========</h3>
</div>
<div id="section-212" class="section level3">
<h3>2022-10-14</h3>
<ul>
<li>There is an underlying condition of COPD in this patient. The CXR
taken on 2022-10-13 showed ground glass opacities in both lungs. His
symptoms of SOB lasted for a week and he has been treated with tapimycin
(piperacillin + tazobactam) since 2022-10-13.</li>
</ul>
</div>
<div id="section-213" class="section level3">
<h3>2022-10-07</h3>
<ul>
<li>In the last two months, weight loss has exceeded 10 kilograms
(86.3kg 2022-10-06 &lt;- 99.1kg 2022-08-03) (due to reduced intake or
other factor?)</li>
<li>The underlying conditions of COPD, gout, and insomnia are managed
with appropriate medication and remain stable.</li>
</ul>
</div>
<div id="section-214" class="section level3">
<h3>2022-08-11</h3>
<ul>
<li>As indicated by CT findings of mildly growing lung metastases, the
lab tumor markers CEA and CA199 have slowly trended up since March 2022.
<ul>
<li>CEA
<ul>
<li>2022-07-19 5.77 ng/mL<br />
</li>
<li>2022-06-14 4.91 ng/mL<br />
</li>
<li>2022-05-17 4.13 ng/mL<br />
</li>
<li>2022-04-12 3.44 ng/mL<br />
</li>
<li>2022-03-14 2.81 ng/mL<br />
</li>
</ul></li>
<li>CA199
<ul>
<li>2022-07-19 38.82 U/mL<br />
</li>
<li>2022-06-14 29.36 U/mL<br />
</li>
<li>2022-05-17 23.62 U/mL<br />
</li>
<li>2022-04-12 12.43 U/mL<br />
</li>
<li>2022-03-14 9.06 U/mL<br />
</li>
</ul></li>
</ul></li>
<li>Curam 1000mg/tab (amoxicillin 875mg + clavulanic acid 125mg) 1# PO
BID has been prescribed since 2022-06-21. Either amoxicillin-clavulanate
or a respiratory fluoroquinolone (ie, levofloxacin or moxifloxacin) are
recommended for exacerbations of COPD patients who have risk factors for
poor outcomes (but no increased risk for Pseudomonas infection). Elderly
patients might be at increased risk of developing
amoxicillin-clavulanate-induced jaundice. Prolonged treatment might
increase the risk of hepatotoxicity.</li>
<li>There is a history of gout, mitral regurgitation, and tricuspid
regurgitation in the patient. A recent large RCT showed that in patients
with gout and major cardiovascular coexisting conditions, febuxostat was
noninferior to allopurinol with respect to rates of adverse
cardiovascular events. Allcause mortality and cardiovascular mortality
were higher with febuxostat than with allopurinol. ( <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1710895" class="uri">https://www.nejm.org/doi/full/10.1056/NEJMoa1710895</a> ).
Febuxostat is currently prescribed as equivalent daily dose of 20 mg (80
mg 0.5# QOD), which should reduce the risk of cardiovascular
events.</li>
</ul>
</div>
</div>
</div>
<div id="section-215" class="section level1">
<h1>700928671</h1>
<div id="section-216" class="section level2">
<h2>221014</h2>
<ul>
<li><p>lab data</p>
<ul>
<li>2021-12-14 Anti-HBs 7.30 mIU/mL<br />
</li>
<li>2021-12-13 HBsAg Nonreactive<br />
</li>
<li>2021-12-13 HBsAg (Value) 0.45 S/CO<br />
</li>
<li>2021-12-13 HBeAg Nonreactive<br />
</li>
<li>2021-12-13 HBeAg(Value) 0.326 S/CO<br />
</li>
<li>2021-12-13 Anti-HBe Reactive S/CO<br />
</li>
<li>2021-12-13 Anti-HBe Ratio 0.66 S/CO<br />
</li>
<li>2021-12-13 Anti-HBc Reactive<br />
</li>
<li>2021-12-13 Anti-HBc-Value 5.36 S/CO<br />
</li>
<li>2021-12-13 Anti-HBc IgM Nonreactive<br />
</li>
<li>2021-12-13 Anti-HBc IgM Value 0.12 S/CO</li>
</ul></li>
<li><p>exam findings</p>
<ul>
<li>2022-10-12 CXR
<ul>
<li>Port-A catheter inserted into cavo-atrial junction via right
subclavian vein.</li>
<li>small Rt hemithorax, elevation of hemidiaphgram and superior
convexity of major fissure due to post operative change of RUL
lobectomy</li>
<li>Subcutaneous emphysema in Rt chest wall neck in regression as
compared with the previous image</li>
<li>no right pneumothorax</li>
</ul></li>
<li>2022-09-26 Patho - lung total/lobe/segmental
<ul>
<li>PATHOLOGIC DIAGNOSIS:
<ul>
<li>Lung, right, upper lobe, lobectomy —- pleomorphic carcinoma with
squamous cell carcinoma</li>
<li>Lymph node, lobar, lymphadenectomy —- pleomorphic carcinoma,
metastatic (3/4)</li>
<li>Lymph node, right, group No.2+4, lymphadenectomy —- pleomorphic
carcinoma, metastatic (6/11)</li>
<li>Lymph node, right, group No.7, lymphadenectomy —- Negative for
malignancy (0/1)</li>
<li>Lymph node, right, group No.9, lymphadenectomy —- Negative for
malignancy (0/1)</li>
<li>Lymph node, right, group No.10, lymphadenectomy —- Negative for
malignancy (0/2)</li>
<li>Lymph node, right, group No.11, lymphadenectomy —- Negative for
malignancy (0/2)</li>
<li>Lymph node, right, group No.12, lymphadenectomy —- pleomorphic
carcinoma, metastatic (3/3)</li>
<li>AJCC 8th edition pTNM Pathology stage: pStage IVA, pT4N2(if cM1a(by
CT finding)) or pStage IIIB, pT4N2(if cM0)</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION:
<ul>
<li>Specimen:
<ul>
<li>Lung, size: 12 x 7 x 4.5 cm with a piece of parietal pleura,
measruing 3.3 x 3.0 cm</li>
<li>Lymph nodes, 6 bottles, group 2+4, 7, 9, 10, 11, 12; maximal size:
2.8 x 1.9 cm</li>
</ul></li>
<li>Tumor Site: Periphery</li>
<li>Tumor Size: Multiple (Number: several), Maximal one: 8.2 x 5.5 x 5.0
cm</li>
<li>Gross tumor patterns: poorly defined, Pleural retraction with
invasion to parietal pleura</li>
<li>Tissue for sections:
<ul>
<li>A1: bronchial and vascular resection margins; A2: parenchymal
resection margin; A3: lymph node, lobar; A4: lung with satellite tumor
nodules; A5: bronchus; A6-7: tumor with parietal pleura; A8-10: tumor;
B1-4: lymph node, group 2+4; C: lymph node, group 7; D: lymph node,
group 9; E: lymph node, group 10; F: lymph node, group 11; G: lymph
node, group 12.</li>
</ul></li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality: Separate tumor nodules of same histopathologic type
(intrapulmonary metastases) in same lobe</li>
<li>Histologic Type (select all that apply): Pleomorphic carcinoma with
squamous cell carcinoma; The immunohistochemical stains reveal CK7(-),
CK20(-), CK5/6(+), p40(+), TTF-1(-), Napsin A(-), CD56(-).</li>
<li>Histologic Grade: G3: Poorly differentiated</li>
<li>Spread Through Air Spaces (STAS): Present</li>
<li>Visceral Pleura Invasion: Present (PL2) with invasion to parietal
pleura</li>
<li>Lymphovascular Invasion (select all that apply): Present,
Lymphatic</li>
<li>Direct Invasion of Adjacent Structures (select all that apply):
Adjacent structures present and involved, Parietal pleura</li>
<li>Margins (select all that apply):All margins are uninvolved by
carcinoma
<ul>
<li>Distance of invasive carcinoma from closest margin (centimeters):
0.05 cm</li>
<li>Specify closest margin: Parietal pleura</li>
<li>Bronchial resection margin: 2.5 cm</li>
</ul></li>
<li>Treatment Effect: No known presurgical therapy</li>
<li>Regional Lymph Nodes: lobar: 3/4; group 2+4: 6/11; group 7: 0/1;
group 9: 0/1; group 10: 0/2; group 11: 0/2; group 12: 3/3.<br />
</li>
<li>Extranodal Extension: Present</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply): not applicable</li>
<li>Primary Tumor (pT): pT4: Tumor &gt;7 cm in greatest dimension;<br />
</li>
<li>Regional Lymph Nodes (pN): pN2: Metastasis in ipsilateral
mediastinal and/or subcarinal lymph node(s)</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case): if cM1a (by CT finding)</li>
</ul></li>
<li>Additional Pathologic Findings (select all that apply): None
identified</li>
</ul></li>
</ul></li>
<li>2022-09-20 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a large focal area in the upper lobe of
right lung, compatible with primary lung malignancy.</li>
<li>Glucose hypermetabolism in a smal focal area in the upper lobe of
right lung, compatible with a metastatic lesion.</li>
<li>Glucose hypermetabolism in the right pulmonary hilar region and in
some right lower paratracheal lymph nodes. Metastatic lymph nodes may
show this picture.</li>
<li>Glucose hypermetabolism in the right adrenal gland and in multiple
bones as mentioned above. Adrenal metastasis and multiple bone
metastases may show this picture.</li>
<li>Mild glucose hypermetabolism in the lower portion of the esophagus
and in a right supraclavicular lymph node. The nature is to be
determined (inflammation? other nature?). Please correlate with other
clinical findings for further evaluation.</li>
</ul></li>
<li>2022-09-14 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Lung Carcinoma</li>
<li>T4N2M1a AJCC8.0</li>
</ul></li>
<li>2022-09-01 MRI - nasopharynx
<ul>
<li>C/W oral cancer s/p operation without evidence of recurrence. Right
upper lung mass (67 mm), suspected infection or metastasis.</li>
</ul></li>
<li>2022-03-03 Patho - oral cancer (wide excision + lymph node)
<ul>
<li>Left buccal mucosa, partial lips and extraoral facial skin near lip
conner, s/p induction chemotherapy wide excision (S2022-3441H) with
frozen section (F2022-85) — Residual verrucous carcinoma.<br />
</li>
<li>Lymph node, left neck, dissection — Free</li>
<li>ypT2 ypN0 (if cM0); ypStage: II, at least.</li>
</ul></li>
<li>2022-03-01 MRI - nasopharynx
<ul>
<li>Markely regressed left buccal, oral commissure, upper lip tumors.
Regressed left level I LAP.</li>
<li>Tumor, left buccal mucosa, incisoinal biopsy — Compatible with
squamous cell carcinoma and ulcer</li>
<li>Microscopically, the sections show a picture of ulcer with dense
inflammation and atypical squamous epithelium with hyperkeratosis,
occasional mitoses and few isolated nests or buds in dense inflammatory
stroma. According to clinical (7 cm big mass), MRI (T4a) and
histopathologic findings, it is compatible with squamous cell carcinoma,
microinvasive. However, more advanced invasion can not excluded due to
limited specimen.</li>
<li>Immunohistochemistry shows CK5/6(+), CK(+, weakly), P16(-), P53(+,
focal) and P63(+) for tumor.</li>
</ul></li>
<li>2021-12-10 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the middle C-spine, L3 and L5 spines.
Degenerative change may show this picture. However, please correlate
with other imaging modalities for further evaluation and to rule out
other possibilities.</li>
<li>Increased activity in the maxilla. Dental problem may show this
picture.</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions and hips, compatible with benign joint
lesions.</li>
</ul></li>
<li>2021-12-10 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Left renal cyst</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study and clinical condition</li>
<li>Regular f/u</li>
</ul></li>
</ul></li>
<li>2021-12-09 MRI - nasopharynx
<ul>
<li>Imaging Report Form for Oral Cavity Carcinoma</li>
<li>Impression (Imaging stage): T:4a(T_value) N:1(N_value) M:0(M_value)
STAGE:IVA(Stage_value)</li>
</ul></li>
<li>2021-11-30 Patho - gingival/oral mucosa biopsy
<ul>
<li>Oral cavity, left buccal mucosa to lip commissure, incisional biopsy
— Verrucous carcinoma<br />
</li>
<li>Microscopically, it shows verrucous carcinoma composed of
club-shaped papillae and blunt intrastromal invagination of
well-differentiated squamous neoplasm with inflammatory infiltrate at
the submucosa. The tumor invades the stroma with a pushing.</li>
<li>IHC stain — p16(-)</li>
</ul></li>
</ul></li>
<li><p>consultation</p>
<ul>
<li>2022-03-18 Radiation Oncology
<ul>
<li>A
<ul>
<li>A: Squamous cell carcinoma and verrucous carcinoma of the left lip
commissure to left buccal area, stage cT4aN1M0 (IVA), s/p induction
chemotherapy and operation (Modified radical neck dissection of left
side. Wide excision of the malignant tumor at the left buccal mucosa,
partial lips and extraoral facial skin near lip conner. Complicated
tooth extraction of 7 teeth. Alvealoplasty of left and right maxilla.
Left ALT free flap reconstruction. ALT donor site closure using
fasciocutaneous rotational flap), stage ypT2N0(cM0).</li>
<li>P: According to HN tumor board (2022-03-18) conclusion:
postoperative CCRT is indicated for this patient with the following
indicators: skin sparing conservative surgery with cosmetic and function
preservation of his left lip commissure area.
<ul>
<li>Goal: curative</li>
<li>Treatment target and volume: left lip commissure, buccal tumor bed
to bilateral neck area.</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 5000cGy/25 fractions of the left lip
commissure, buccal tumor bed to bilateral neck, and 6600cGy/33 fractions
of the left lip commissure and buccal tumor bed.</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and his son. They understand and agree to
receive radiotherapy, The treatment planning of radiotherapy will be
started at 0830, 2022-03-24.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li><p>SOP</p>
<ul>
<li>2022-10-11 Radiation Oncology
<ul>
<li>A:
<ul>
<li>Squamous cell carcinoma and verrucous carcinoma of the left lip
commissure to left buccal area, stage cT4aN1M0 (IVA), s/p induction
chemotherapy and operation (Modified radical neck dissection of left
side. Wide excision of the malignant tumor at the left buccal mucosa,
partial lips and extraoral facial skin near lip conner. Complicated
tooth extraction of 7 teeth. Alvealoplasty of left and right maxilla.
Left ALT free flap reconstruction. ALT donor site closure using
fasciocutaneous rotational flap), stage ypT2N0(cM0), s/p CCRT.</li>
<li>Pleomorphic carcinoma with squamous cell carcinoma of the lung, RUL,
stage AJCC 8th edition pTNM. Pathology stage: pStage IVA, pT4N2(cM1b),
s/p VATS, RUL lobectomy + RLND.</li>
</ul></li>
<li>P:
<ul>
<li>Radiotherapy is indicated for this patient with the following
indicators: very close surgical margin</li>
<li>Goal: palliation</li>
<li>Treatment target and volume: primary lung tumor bed and regional
lymphatic area.</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 5400cGy/30 fractions of the primary lung
tumor bed and regional lymphatic area.</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and his sons. They understand and agree to
receive radiotherapy, The treatment planning of radiotherapy will be
started at 0830, 2022-10-19.</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>radiotherapy</p></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2022-05-16 - cisplatin 40mg/m2 70mg 2hr</li>
<li>2022-05-04 - cisplatin 40mg/m2 70mg 2hr</li>
<li>2022-04-21 - cisplatin 40mg/m2 70mg 2hr</li>
<li>2022-04-13 - cisplatin 40mg/m2 70mg 2hr</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 160mg in fluorouracil 900mg/m2 1600mg 22hr
(neoadjuvant)</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 160mg in fluorouracil 900mg/m2 1600mg 22hr
(neoadjuvant)</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 160mg in fluorouracil 900mg/m2 1600mg 22hr
(neoadjuvant)</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 170mg in fluorouracil 900mg/m2 1700mg 22hr
(neoadjuvant)</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 160mg in fluorouracil 900mg/m2 1600mg 22hr
(neoadjuvant)</li>
<li>2022-02-08 - docetaxel 36mg/m2 65mg 1hr + cisplatin 35mg/m2 65mg 3hr
+ leucovorin 90mg/m2 160mg in fluorouracil 900mg/m2 1600mg 22hr
(neoadjuvant)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pleomorphic carcinoma is a poorly differentiated non-small cell
carcinoma that contains at least 10% spindle and/or giant cells or a
carcinoma consisting only of spindle and giant cells.</li>
<li>There are no related molecular testing results available in HIS5
that might be considered, including: EGFR mutations, ALK, KRAS, ROS1,
BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2), PD-L1.</li>
<li>Hypercalcaemia (2022-10-14 3.86 mg/dL) and hyperuricemia (2022-10-14
8.7 mg/dL) are treated with allopurinol and zoledronic acid,
respectively.</li>
</ul>
</div>
</div>
<div id="section-217" class="section level1">
<h1>701394404</h1>
<div id="section-218" class="section level2">
<h2>221014</h2>
<p>{Gastric adenocarcinoma of antrum with gastric outlet obstruction
cT3N3bM1, stage IV, ECOG 1 status post laparoscoppic gastrojejunostomy
and Port-A implantation on 2022-06-16}</p>
<ul>
<li>last discharge diagnosis
<ul>
<li>1: Gastric adenocarcinoma of antrum with gastric outlet obstruction
cT3N3bM1, stage IV, ECOG 1 status post laparoscoppic gastrojejunostomy
and Port-A implantation on 2022-06-16</li>
<li>2: Postive of anti-HBc</li>
<li>3: Anemia</li>
<li>4: Hypertension</li>
<li>5: Hyperlipidemia</li>
<li>6: Hypoalbuminemia</li>
</ul></li>
<li>lab data
<ul>
<li>albumin
<ul>
<li>2022-07-08 2.9 g/dL</li>
<li>2022-06-21 2.8 g/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-10-13 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (34 - 14) / 34 = 58.82%
<ul>
<li>M-mode (Teichholz) = 58</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Septal hypertrophy</li>
<li>Trivial MR, trivial AR and mild TR and trivial PR</li>
<li>Mild to moderate pulmonary hypertension</li>
<li>Preserved RV systolic function</li>
<li>Tachycardia with E/A fusion at the exam.</li>
</ul></li>
<li>2022-10-12 KUB
<ul>
<li>marginal spurs of multiple vertebral bodies due to spondylosis.</li>
<li>Atherosclerosis of abdominal aorta and bilateral common and external
iliac arteries.</li>
<li>Abdominal ascites</li>
<li>interrupted lower body of gastric air column and scanty colonic
air</li>
<li>Normal shape and size of kidneys and spleen.</li>
<li>Normal appearance of psoas shadows</li>
</ul></li>
<li>2022-10-12 CXR
<ul>
<li>Thoracic aortic arch calcified atheriosclerotic plaque</li>
<li>Fullness and increased density of Rt infrhilum hila may be due to
lymphadenopathy</li>
<li>Normal heart size</li>
<li>Costophrenic angles are preserved</li>
</ul></li>
<li>2022-10-12 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-09-16 CT - abdomen
<ul>
<li>Findings:
<ul>
<li>There are several newly-developed poor enhancing masses on both
hepatic lobes that are c/w liver metastases.
<ul>
<li>The largest one measuring 4.3 cm in S3.</li>
</ul></li>
<li>There is mild ascites and soft tissue nodules in the omentum that
may be carcinomatosis.</li>
<li>Prior CT identified gastric wall thickening is noted again, mild
increasing in wall thickness.</li>
<li>Prior CT identified multiple metastatic nodes in the gastrohepatic
ligament, hepatoduodenal ligament, celiac trunk, para-aortic space and
para-cava space are noted again, mild increasing in size.</li>
<li>There is no focal lesion in both lung.
<ul>
<li>There are several enlarged nodes in paratracheal space.</li>
</ul></li>
<li>Few gallstones are noted and the largest one 1.6 cm.</li>
<li>There is no focal abnormality in the biliary system, pancreas,
spleen &amp; both kidney.
<ul>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Multiple liver metastases.</li>
<li>Carcinomatosis is highly suspected.</li>
</ul></li>
</ul></li>
<li>2022-06-16 Body fluid cytology - ascites
<ul>
<li>20 cc dark-brown turbid ascites — Atypia</li>
<li>The smears show lymphocytes, reactive mesothelial cells and few
atypical cells show enlarged and hypochromatic nuclei with degenerative
quality. Follow up.</li>
</ul></li>
<li>2022-06-15 Upper GI series
<ul>
<li>The contrast medium passage from oral cavity through esophagus to
stomach smoothly without obstruction.</li>
<li>Normal contour and mucosal pattern of the esophagus. S/P NG tube
indwelling.</li>
<li>Distention of stomach suspected outlet obstruction.</li>
</ul></li>
<li>2022-06-13 Patho - stomach biopsy
<ul>
<li>Stomach, antrum, biopsy — Adenocarcinoma.</li>
<li>IHC stains: CK highlights neoplastic cells. Her2/neu: negative
(score=0).</li>
<li>Section shows fragments of gastric tissue infiltrated by irregular
neoplastic glands.</li>
</ul></li>
<li>2022-06-11 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Gastric Carcinoma</li>
<li>Impression (Imaging stage): T3N3M1, stage IVB</li>
</ul></li>
<li>2022-06-11 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Highly suspected gastric cancer, Borrmann classification type III,
with suspected gastric outlet obstruction, s/p biopsy.</li>
<li>Reflux esophagitis LA Classification grade D</li>
<li>Incomplete study due to much coffee ground content and food
retention in stomach and gastric outlet obstruction</li>
</ul></li>
<li>Suggestion
<ul>
<li>PPI Q12H IV</li>
</ul></li>
</ul></li>
<li>2022-06-10 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific ST abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-13 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>This is a 67-year-old male with hx of HTN.</li>
<li>This time, he suffered from vomiting with black vomitus, dizziness,
and tarry stool for 2 days. Body weight loss ~15kg in 1-2 month was
noted. He was brought to our ER for help. At ER, the vital signs were
generally normal with tachycardia (HR 129bpm) with BP 117/58mmHg. Lab
study found Hb: 5.0g/dL, with stool OB: 2+, emergent blood transfuion
with LPRBC 4U was given, and anemia improved (Hb: 5.0 -&gt; 8.4 g/dL
with f/u Hb: 6.9 -&gt; 7.6). Abdome CT showed gastric cancer with
gastric outlet obstruction cstage: T3 N3b M1 (lack of detailed
description of metastasis).</li>
<li>Under the impression of Suspect gastric cancer, so he was admitted
for urther evaluation and management.</li>
<li>We need your expertise for further evaluation for the patient’s
condition of gastric cancer, and outlet obstruction, and future feeding
method.</li>
</ul></li>
<li>A
<ul>
<li>S: A 67-year-old male with hx of HTN. This time, he suffered from
vomiting with black vomitus, dizziness, and tarry stool for 2 days. Body
weight loss ~15kg in 1-2 month was noted. He was brought to our ER for
help. At ER, the vital signs were generally normal with tachycardia (HR
129bpm) with BP 117/58mmHg. Lab study found Hb: 5.0g/dL, with stool OB:
2+, emergent blood transfuion with LPRBC 4U was given, and anemia
improved (Hb: 5.0–＞8.4 g/dL with f/u Hb: 6.9-＞7.6). Abdome CT showed
gastric cancer with gastric outlet obstruction cstage: T3 N3b M1(lack of
detailed description of metastasis). Surgical evaluation is
consulted.</li>
<li>O: vital signs: stable, no fever
<ul>
<li>abdomen: soft, ovoid, decrease bowel sound, mild epigastric pain, no
Murphy’s sign<br />
</li>
<li>lab data: see chart</li>
</ul></li>
<li>A: gastric cancer with gastric outlet obstruction cstage: T3 N3b M1,
stage IV</li>
<li>P: Suggest neoadjuvant chemotherapy for down staging first.
<ul>
<li>If gastric outlet obstruction related poor oral intake and
malnutrition is noted, laparoscopic gastrojejunostomy may be
considered.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-16 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 67 year-old male who has the history of hypertension with
medication control. This time, he suffered from vomiting with black
vomitus, dizziness, and Tarry stool for 2 days. Body weight loss ~15kg
in 1-2 month, so he was brought to our ER for help. Under the impression
of gastric cancer, he was transfer to GS for surgery of
gastrojejunostomy on 2022/06/16. We need your help for neoadjuvant
chemotherapy. Thank you so much!!</li>
</ul></li>
<li>Q
<ul>
<li>Impression:
<ul>
<li>Suspect gastric cancer with gastric outlet obstruction cstage: T3
N3b M1, stage IV</li>
</ul></li>
<li>Suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>Pending pathology, if confirm gastric cancer, we will discuss with
patient about neoadjuvant chemotherapy for down staging.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Check anti Hbc, HbsAg, Anti HCV</li>
</ol></li>
</ul></li>
<li>s/p gastrojejunostomy on 2022/06/16.</li>
<li>Medical advice:
<ul>
<li>It will be possible to be cured only in the patient whose gastric
cancer is amenable to total surgical resection (R0 resection). The local
advanced gastric CA wt gastric outlet obstruction of this pt is deemed
not operably subjected to total surgical resection.</li>
<li>Pre-Op neoadjuvant C/T is indicated.
<ul>
<li>Pre-Op neoadjuvant C/T regimen may be: Oxaliplatin / HDFL or 5-FU /
LV / Oxaliplatin / Docetaxel ( FLOT ) IV Q2W x 3~4 cycles beofore /
after Op.</li>
</ul></li>
<li>If gastric tumor bleeding persists, may consider R/T to gastric
tumor to cease bleeding.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-16
<ul>
<li>Surgery
<ul>
<li><ol style="list-style-type: decimal">
<li>Laparoscopic gastrojejunostomy</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Port-A insertion, L’t after L’t cephalic vein
exploration        </li>
</ol></li>
<li>Post-OP Dx: gastric antrum Ca, cT3N3M1, stage IV, ECOG 1    </li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>We explore and identify the L’t cephaic vein &amp; use cutdown
method to insert the 7 Fr cathter into it. We also use intra-operative
EKG to check its position.        </li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hypertorphy and distension of stomach.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>No visible peritoneal wall tumor and enlarged lymph node was noted.
We collect ascites for cytology.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Gastric juice 2750 ml was decompressed.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-07-08 ~ undergoing - FOLFOX</li>
</ul></li>
</ul>
<div id="section-219" class="section level3">
<h3>==========</h3>
</div>
<div id="section-220" class="section level3">
<h3>2022-10-14</h3>
<ul>
<li>2022-10-13 2D transthoracic echocardiography showed adequate LV
systolic function with normal resting wall motion and preserved RV
systolic function.</li>
<li>It is possible that the rising levels of hs-Troponin I (366.4 &lt;-
226.8 &lt;- 134.4) are related to sepsis. The infection is currently
being managed with tapimycin (piperacillin + tazobactam).</li>
</ul>
</div>
<div id="section-221" class="section level3">
<h3>2022-07-11</h3>
<ul>
<li>This patient is taking two antiplatelet agents: aspirin, cilostazol
(antiplatelet agent; phosphodiesterase-3 enzyme inhibitor; vasodilator);
four antihypertensives: amlodipine (antianginal agent; antihypertensive;
calcium channel blocker), indapamide (thiazide diurectic),
spironolactone (antihypertensive; potassium sparing diurectic;
mineralocorticoid (aldosterone) receptor antagonists), ramipril
(angiotensin-converting enzyme (ACE) inhibitor; antihypertensive).</li>
<li>It was reported that salicylates and/or thiazides could enhance the
nephrotoxic effect of angiotensin-converting enzyme inhibitors, and
potassium-sparing diuretics may enhance the hyperkalemic effect of
angiotensin-converting enzyme inhibitors. According to lab data on
2022-07-08, renal function and serum potassium were normal.</li>
<li>Since the afternoon of 2022-07-09, blood pressure readings have
returned to normal, and no tachycardia has been observed since
2022-07-10. TPR and BP are stable currently.</li>
<li>Crestor (rosuvastatin calcium 10mg) QD might be an option if
hyperlipidemia is still a medical problem.</li>
</ul>
</div>
</div>
</div>
<div id="section-222" class="section level1">
<h1>700410422</h1>
<div id="section-223" class="section level2">
<h2>221012</h2>
<ul>
<li>exam findings
<ul>
<li>2022-09-13 CXR
<ul>
<li>distorted and small left hilum, small left hemithorax with decreased
vascular markings, and Lt shift of heart due to LLL lobectomy</li>
<li>Lt pleural effusion/thickening with loculation, stationary</li>
</ul></li>
<li>2022-07-21 MRI - brain
<ul>
<li>Known a case of lung. No metastatic lesion of brain parenchyma.</li>
</ul></li>
<li>2022-07-19 CT - chest
<ul>
<li>post op change in left hemithorax. decreased volume of left pleural
effusion compared with CT on 20220309.</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>no mediastinal or hilar enlarged lymph nodes.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2022-04-11 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the left lower and right upper lungs,
cancer s/p treatment with chronic inflammation may show this picture.
Please correlate with other clinical findings for further evaluation and
to rule out other possibilities.<br />
</li>
<li>Increased FDG uptake in the left aspect of the maxilla, probably
dental and/or gum problems.<br />
</li>
<li>Increased FDG uptake/accumulation in the colon and bilateral
ureters, physiological FDG uptake/accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake is noted elsewhere.</li>
</ul></li>
<li>2022-03-09 CT - chest
<ul>
<li>post op change in left hemithorax. increase in volume of moderate
left pleural effusion compared with CT on 20211208</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>no mediastinal or hilar enlarged lymph nodes.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2021-12-10 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20210728, no prominent
change is noted.</li>
<li>Suspected benign lesions in the maxilla, mandible, some L-spines,
bilateral shoulders, S-I joints, hips, and knees.</li>
</ul></li>
<li>2021-12-09 MRI - brain
<ul>
<li>No evident brain metastasis.</li>
</ul></li>
<li>2022-03-09 CT - chest
<ul>
<li>post op change in left hemithorax. stationary of moderate left
pleural effusion compared with CT on 20210916</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>no mediastinal or hilar enlarged lymph nodes.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2021-09-16 CT - chest
<ul>
<li>Left pleural effusion.</li>
<li>s/p left lower lobe lobectomy.</li>
</ul></li>
<li>2021-07-28 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the maxilla, mandible, L-spine,
bilateral shoulders, S-I joints, hips, and knees.</li>
</ul></li>
<li>2021-06-23 CT - chest
<ul>
<li>post op change in left hemithorax. slighlty increase in volume of
left pleural effusion compared with CT on 20210304.</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>suspect mild small airways disease in RLL.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2021-03-04 CT - chest
<ul>
<li>Ground glass pacthes at left lung with left pleural effusion. Recent
pneumonia is favored.</li>
</ul></li>
<li>2021-03-03 MRI - brain
<ul>
<li>no evidence of metastatic brain tumors</li>
</ul></li>
<li>2020-11-12 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in the left lower lung field.
Post-operative inflammation may show this picture. However, please
correlate with other clinical findings for further evaluation and to
rule out other possibilities.<br />
</li>
<li>Increased FDG uptake in the region about the left aspect of maxilla.
The nature is to be determined (some kind of dental and/or gum problem?
other nature?). Please also correlate with other clinical findings for
further evaluation.<br />
</li>
<li>Increased FDG uptake/accumulation in bilateral vocal cords and both
kidneys. Physiological FDG uptake/accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2020-11-11 MRI - brain
<ul>
<li>focal SI change in the splenium of the corpus callosum. Nature?</li>
</ul></li>
<li>2020-11-10 CT - chest
<ul>
<li>post op change in left hemithorax. increase in volume of left</li>
<li>pleural effusion compared with CT on 20200818.</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>suspect mild small airways disease in RLL.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2020-08-18 CT - chest
<ul>
<li>post op change in left hemithorax.</li>
<li>mild emphysema in left upper lung and RUL.</li>
<li>no new lung nodule or mass.</li>
</ul></li>
<li>2020-06-03 Patho - lung total/lobe/segmental
<ul>
<li>PATHOLOGIC DIAGNOSIS:
<ul>
<li>Lung, left, lower lobe, lobectomy —- Adenocarcinoma, moderately
differentiated, s/p CCRT and Immuotherapy<br />
</li>
<li>Lymph node, lobar, lymphadenectomy —- Negative for malignancy
(0/1)<br />
</li>
<li>Soft tissue, group No.7 lymph node, lymphadenectomy —- Negative for
malignancy (0/0)<br />
</li>
<li>Lymph node, group No.9, lymphadenectomy —- Negative for malignancy
(0/1)<br />
</li>
<li>Lymph node, group No.10, lymphadenectomy —- Negative for malignancy
(0/1)<br />
</li>
<li>Lymph node, group No.12, lymphadenectomy —- Negative for malignancy
(0/1)<br />
</li>
<li>AJCC 8th edition pTNM Pathology stage: ypStage IB, ypT2aN0(if
cM0)<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION:
<ul>
<li>Specimen:
<ul>
<li>Lung, size: 13.5 x 7.4 x 2.7 cm; 89.9 gm<br />
</li>
<li>Lymph nodes, 4 bottles, group 7, 9, 10, and 12; maximal size: 0.8 x
0.3 x 0.3 cm<br />
</li>
</ul></li>
<li>Tumor Site: Periphery<br />
</li>
<li>Tumor Size: Solitary: 2.1 x 2.0 x 1.8 cm<br />
</li>
<li>Gross tumor patterns: poorly defined, Pleural retraction<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality: Single tumor<br />
</li>
<li>Histologic Type (select all that apply): Invasive adenocarcinoma,
acinar predominant (60 %);
<ul>
<li>The immunohistochemical stains reveal CK(+) and TTF-1(+).<br />
</li>
<li>Other subtypes present (specify subtype(s), may also include
percentages): lepidic: 40%<br />
</li>
</ul></li>
<li>Histologic Grade: G2: Moderately differentiated<br />
</li>
<li>Spread Through Air Spaces (STAS): Not identified<br />
</li>
<li>Visceral Pleura Invasion: Present (PL2)<br />
</li>
<li>Lymphovascular Invasion (select all that apply): Present,
Lymphatic<br />
</li>
<li>Direct Invasion of Adjacent Structures (select all that apply): No
adjacent structures present<br />
</li>
<li>Treatment Effect: Greater than 10% residual viable tumor<br />
</li>
<li>Regional Lymph Nodes: lobar: 0/1; group 7: 0/0; group 9: 0/1; group
10: 0/1; group 12: 0/1<br />
</li>
<li>Extranodal Extension: Not identified<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) : y (posttreatment)
<ul>
<li>Primary Tumor (pT): pT2a: Invades visceral pleura (PL2);<br />
</li>
<li>Regional Lymph Nodes (pN): pN0: No regional lymph node
metastasis<br />
</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case): if cM0<br />
</li>
</ul></li>
</ul></li>
<li>Additional Pathologic Findings (select all that apply): None
identified</li>
</ul></li>
</ul></li>
<li>2018-05-23 Surgical pathology Level IV
<ul>
<li>Clinical diagnosis
<ul>
<li>Chronic airway obstruction (COPD), NEC;</li>
</ul></li>
<li>Pathological diagnosis
<ul>
<li>Soft tissue, neck, needle biopsy — adenocarcinoma, moderately
differentiated, metastatic, consistent with lung origin</li>
</ul></li>
<li>Specimen submitted in formalin consists of 2 strips of tan,
irregular tissue measuring up to 1.6 x 0.1 x 0.1 cm. All for section in
one cassette.</li>
<li>Sections show solid tumor nests, with focal glandular pattern,
infiltrating in a fibrotic stroma. No lymphoid tissue is seen.
<ul>
<li>The immunohistochemical stains reveal TTF-1(+) and Napsin A(+). The
results are supportive for metastatic lung adenocarcinoma.</li>
</ul></li>
</ul></li>
<li>2018-05-18 Surgical pathology Level IV
<ul>
<li>Indication: Localized swelling, mass and lump, neck; Fracture of
frontal skull and SAH; Unspecified open wound of scalp, initial
encounter; Hypovolemic shock; Unspecified open wound, right foot,
initial encounter; Screening for malignant neoplasms of oral cavity;
Enlargement of lymph nodes; Swelling, mass,or lump in head and
neck;</li>
<li>Pathological Diagnosis: Lymph node, left lower neck, sono-guide
biopsy — Metastatic adenocarcinoma, pulmonary origin</li>
<li>The specimen submitted consisted of 1 strip of lymph node tissue
measuring 1.2 cm in length, fixed in formalin. Grossly, it was grey in
color and soft in consistence. All embedded for sections in one
cassette.</li>
<li>Microscopically, the section shows a picture of metastatic
adenocarcinoma of the lymph node tissue characterized by nest or
tubular-arranged tumor cells infiltrated in parenchyma.</li>
<li>Immunohistochemical stains of CK(+), TTF-1(+); P40(-), Napsin-A(+)
and CD56(-) for tumor cells.
<ul>
<li>According to clinical information and above histopathologic
findings, it is consistent with metastatic adenocarcinoma of pulmonary
origin. Clinical correlation is advised.</li>
</ul></li>
</ul></li>
<li>2018-05-18 Neck sonography
<ul>
<li>Findings: Multiple LNs in bilateral neck, with size up to 1.37 cm in
length at right and 3.3 cm at left.</li>
<li>Imp: Multiple bilateral neck LNs.</li>
</ul></li>
</ul></li>
<li>SOP
<ul>
<li>2018-07-18
<ul>
<li>20180718 Apply Crizotinib for ALK inhibitor 1st line, maybe wait to
August admission for C/T with Alimta, Kytruda first, CCRT</li>
<li>A case of Lung cancer, adenocarcinoma, T2aN3M0, stage IIIB, with
left supraclavicular LAPs metastasis, ECOG 1, T2a: LLL mass N3:
bilateral mediastinal and left supraclavicular LAPs M0: no definite
brain, lung to lung metasatsis</li>
<li>EGFR mutation: L858R (-), exon 19 (-), PD-L1: 5%, ALK(+)</li>
<li>cough with sputum, chest tightness, dyspnea, rhinorrhea(-), nasal
congestion(-), post nasal dripping(-), acid regurgitation, DOE(+), body
weight loss(+), poor appetite(+) Past history: Family history of
malignancy(-) Smoking(+), 1ppd for 20 yrs, Allergic history:(-)
Traveling history:(-) PFT: Mild restriction without Significant response
to Bronchodilator</li>
<li>C1 Keytruda (2mg/kg) 100mg IVF on 20180620, C1 Alimta (500mg/m2)
800mg on 20180621, admission for 20180712 for Alimta, may add Keytruda
or Crizotinib</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-07-02 ~ 2018-07-30 - 5000cGy/20 fractions (14 MV photon) to LLL
tumor, mediastinal &amp; SCF LAPs.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-14 - Cyramza (ramucirumab) 500mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-08-17 - Cyramza (ramucirumab) 500mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-07-20 - Cyramza (ramucirumab) 500mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-05-05 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-04-06 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-03-08 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-02-17 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2022-01-04 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-12-07 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-11-15 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-10-12 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-09-15 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-08-18 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-07-27 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-06-23 - Cyramza (ramucirumab) 400mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-04-26 - Cyramza (ramucirumab) 200mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-03-29 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 + Opdivo
(nivolumab) 100mg 1hr D2</li>
<li>2021-03-02 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2021-02-02 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2021-01-11 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-12-09 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-11-10 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-10-13 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-09-15 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-08-18 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-07-21 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-06-22 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-05-25 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-04-27 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-03-31 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-03-05 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2020-02-12 - Cyramza (ramucirumab) 7.5mg/kg 200mg 1.5hr D1 +
Keytruda (pembrolizumab) 2mg/kg 100mg 30min D2</li>
<li>2019-09-06 ~ ?? - Cyramza (ramucirumab) 400mg</li>
<li>2018-06-21 - Alimta (pemetrexed) 500mg/m2 800mg</li>
<li>2018-06-20 ~ 2019-08-15 - Keytruda (pembrolizumab) 100mg
(C1-13)</li>
<li>2021-11-15 ~ 2022-07-25 - Alunbrig (brigatinib) 90mg/tap 1# QD</li>
<li>2020-09-14 ~ 2021-10-13 - Zykadia (ceritinib) 150mg/cap 1# QD</li>
<li>2019-08-28 ~ undergoing - Alecensa (alectinib) 150mg/cap 4#
BIDCC</li>
<li>2018-08-29 ~ 2019-07-25 - Xalkori (crizotinib) 250mg/cap 1# BID
<ul>
<li>alectinib, brigatinib, ceritinib, crizotinib are for ALK
rearrangement</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-224" class="section level1">
<h1>701116474</h1>
<div id="section-225" class="section level2">
<h2>221012</h2>
<p>[exam findings]</p>
<ul>
<li>2023-05-31 ECG
<ul>
<li>Sinus bradycardia with 1st degree A-V block</li>
</ul></li>
<li>2023-05-31 CXR
<ul>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Linear opacity projecting at right lower lung show stationary.</li>
</ul></li>
<li>2023-04-07 CT - abdomen
<ul>
<li>History: 65 y/o male with Mantle cell lymphoma with bone marrow
involvement, Lugano stage IV, MIPI: 6.4 points.</li>
<li>Indication: FU mantle cell lymphoma over both side of diaphragm</li>
<li>Findings: Comparison prior CT dated 2023/01/17.
<ul>
<li>Prior CT identified several enlarged nodes in bilateral inguinal
area noted again, stationary.</li>
<li>Prior CT identified infiltrative soft tissue lesions (confluent
enlarged nodes) in the retroperitoneum around the aortocaval region,
encasement of SMA/SMV and celiac trunk are noted again, stationary that
is c/w Mantle cell lymphoma S/P C/T with stable disease.</li>
<li>There is minimal pleura reaction in Rt CP angle.</li>
<li>There are several renal cysts on left kidney and the largest one
measuring 2.3 cm in size at left upper pole.</li>
</ul></li>
<li>Impression:
<ul>
<li>Mantle cell lymphoma S/P C/T show stable disease.</li>
</ul></li>
</ul></li>
<li>2023-01-17 CT - abdomen
<ul>
<li>History and indication: pain over Rt inguinal region with tenderness
for 2 days.</li>
<li>With and without-contrast CT of abdomen-pelvis revealed:
<ul>
<li>Enlarged LNs (up to 3.1cm) at bil. inguinal regions, RLQ, mesentery
and paraaortic region.</li>
<li>Left renal cyst (2.4cm).</li>
<li>Atherosclerosis of aorta, iliac, coronary arteries.</li>
</ul></li>
<li>IMP:
<ul>
<li>Enlarged LNs (up to 3.1cm) at bil. inguinal regions, RLQ, mesentery
and paraaortic region (stable condition).</li>
</ul></li>
</ul></li>
<li>2022-10-18 Patho - lymphnode biopsy
<ul>
<li>Soft tissue, lymph node? inguinal region, right, excision —
Granulation tissue</li>
</ul></li>
<li>2022-10-15 CT - abdomen
<ul>
<li>With and without contrast enhancement CT of abdomen–whole:
<ul>
<li>Infiltrative soft tissue in the retroperitoneum around the
aortocaval region and encasement of SMA/SMV and celiac trunk. Stationary
as compare with CT study on 2022-08-19.</li>
<li>Left renal cysts, up to 2.8cm.</li>
<li>Focal atelectasis in right lung and pleural thickening,
stationary.</li>
<li>There are lymph nodes in the mediastinum and right hilar
region.</li>
<li>Coronary artery calcifications.</li>
<li>Enlarged right inguinal lymph nodes. Cystic lesion(3.1cm) in right
inguinal region with subcutaneous infiltrates and skin thickening. R/O
abscess and cellulitis. DDx: lymph node necrosis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Clinical lymphoma s/p treatment.</li>
<li>Enlarged right inguinal lymph nodes. Cystic lesion in right inguinal
region with focal fatty infiltrates and skin thickening, r/o absces and
cellulitis. DDx: lymph node necrosis.</li>
<li>Focal atelectasis in ight lung and pleural thickening,
stationary.</li>
<li>Coronary artery calcifications.</li>
</ul></li>
</ul></li>
<li>2022-10-11 CXR
<ul>
<li>Blunted right costophrenic angle.</li>
<li>Ground glass opacity in RLL.</li>
</ul></li>
<li>2022-08-19 CT - abdomen
<ul>
<li>History: 65 y/o male with Mantle cell lymphoma with bone marrow
involvement, Lugano stage IV, MIPI: 6.4 points.</li>
<li>Indication: FU mantle cell lymphom over both side of diaphragm</li>
<li>Findings
<ul>
<li>Prior CT identified infiltrative soft tissue lesions (confluent
enlarged nodes) in the retroperitoneum around the aortocaval region,
encasement of SMA/SMV and celiac trunk are noted again, decreasing in
size that is c/w Mantle cell lymphoma S/P C/T with partial
response.</li>
<li>Prior CT identified enlarged lymph nodes in the paratracheal space
are noted againm, mild decreasing in size that is c/w mantle cell
lymphoma with mediastinum LNs involvement S/P C/T with partial
response.</li>
<li>There is minimal pleura effusion or reaction in Rt CP angle.</li>
<li>There are several renal cysts on left kidney and the largest one
measuring 2.3 cm in size at left upper pole.</li>
</ul></li>
<li>Impression:
<ul>
<li>Mantle cell lymphoma over both side diaphragm S/P C/T show partial
response.</li>
</ul></li>
<li>2022-05-17 CT - abdomen
<ul>
<li>Clinical history: 65 y/o male patient with Mantle cell lymphoma with
bone marrow involvement, Lugano stage IV, MIPI: 6.4 points.</li>
<li>Findings
<ul>
<li>Infiltrative soft tissue in the retroperitoneum around the
aortocaval region and encasement of SMA/SMV and celiac trunk. Relative
regression as compare with CT study on 2022-03-08.</li>
<li>Mild right pleural effusion. Focal atelectasis in right lung.</li>
<li>There are lymph nodes in the mediastinum and right hilar
region.</li>
<li>Coronary artery calcifications.</li>
</ul></li>
<li>Impression:
<ul>
<li>Clinical lymphoma, with mild regression, suggest follow up.</li>
<li>Mild right pleural effusion. Focal atelectasis in right lung.</li>
<li>Coronary artery calcifications.</li>
</ul></li>
</ul></li>
<li>2022-04-26 CXR
<ul>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Linear opacity projecting at right lower lung show stationary.</li>
</ul></li>
<li>2022-04-08 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — Mantle cell lymphoma</li>
<li>Sections show 20-30 % cellularity. The M/E ratio is about 3/1 - 4/1.
Megakaryocytes are found about 0-2/HPF. No increase of blasts is noted.
Several foci of aggregation of lympohid cells are seen.</li>
<li>The immunohistochemical stains reveal CD20(+), CD3(-), Cyclin D1(+).
The results are consistent with Mantle cell lymphoma.</li>
</ul></li>
<li>2022-03-08 CT - chest
<ul>
<li>Findings
<ul>
<li>Lungs: subsegmental opacities with extensive septal thickening and
peribronchovascular bundle thickening in Rt lung, RML and RLL
predominance, in regression as compared with previous CT study on 1/3. a
centrilobular nodule at lingula.</li>
<li>Mediastinum: extensive lymphadenopathy in visceral and Rt anterior
prevascular spaces, in regression.
<ul>
<li>Rt pericardial thickening.</li>
</ul></li>
<li>Hila: enlarged LN, Rt, in regression.</li>
<li>Vessels: extensive coronary arterial calcification
<ul>
<li>Aorta: normal caliber, mild atherosclerotic change of descending
thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
</ul></li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: small Rt pleural effusion with extensive thick parietal
thickening.</li>
<li>Chest wall and visible lower neck: residual small and slightly
enlarged LNs at Rt axilla and supraclavicular fossae, stationary.</li>
<li>Visible abdominal-pelvic contents: moderate splenomegaly.
<ul>
<li>regression of extensive confluent lympapathy in the para-aortic
region and msentery root, involving the pancreas, and discrete
lymphadopathies in both inguinal regions compared with CT on
20220103</li>
<li>a well-defined cystic lesion of water in density (27x34 mm) at Rt
inguinal region.</li>
<li>a small left renal cyst and wall thickening of.</li>
<li>the gallbladder. no focal lesion in the liver and adrenal
glands</li>
<li>Visualized bones: marginal spurs of vertebrae.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Mantle cell lymphoma in both sides of diaphgram, with regression of
lung involvement and slightly regression of extensive lymphadenopathy as
compared with CT on 20220103</li>
</ul></li>
</ul></li>
<li>2022-03-07 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy — B-cell lymphoma involvement</li>
<li>Microscopically, the sections show pictures of extensively crush
artifact of bone marrow tissue. The cellularity maybe increased.</li>
<li>Immunohistochemistry shows CD3(+, focal), CD20(+), CD5(+), CD34(-)
and cyclin-D1(-), compatible with B-cell lymphoma involvement, and
mantle cell lymphoma maybe first considered according to past history.
Clinical correlation is advised.</li>
</ul></li>
<li>2022-01-03 CT - chest
<ul>
<li>Mantle cell lymphoma in both sides of diaphgram, with progression of
lung involvement and slightly regression of extensive lymphadenopathy as
compared with CT on 20211002</li>
</ul></li>
<li>2021-11-03 SONO - chest
<ul>
<li>Pleural effusion, minimal, bilateral, organizing</li>
<li>Pleural thickening, bilateral</li>
</ul></li>
<li>2021-10-18 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (131 - 39) / 131 = 70.23%
<ul>
<li>M-mode (Teichholz) = 70</li>
</ul></li>
<li>Mild septal hypertrophy with Gr I LV diastolic dysfunction.</li>
<li>Mildly dilated LV with normal LV and RV systolic function.</li>
<li>Aortic valve sclerosis with mild AR.</li>
<li>Mild aoratic root calcification; dilated proximal ascending aorta
(38mm).</li>
</ul></li>
<li>2021-10-13 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, clinically: mantle cell lymphoma, biopsy —
Lymphoma involvement.</li>
<li>IHC stains: Cyclin-D1 (weak +).<br />
</li>
<li>Section shows piece(s) of bone marrow with 70% cellularity and with
a predominant small to intermediate size atypical lymphoid cells.</li>
</ul></li>
<li>2021-10-12 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma of low FDG uptake
involving multiple lymph nodes on both sides of the diaphragm as
mentioned above (at least stage III).</li>
<li>Mildly and diffusely increased FDG uptake in the bone marow of the
skeleton. The nature is to be determined (lymphoma involving the bone
marrow? bone marrow hyperplasia?). Please correlate with other clinical
findings for further evaluation.</li>
<li>Mildly increased FDG uptake in the right lower lung field and pleura
of right lower lung. Inflammation may show this picture. However, please
also correlate with other clinical findings for further evaluation and
to rule out other possibilities.</li>
</ul></li>
<li>2021-10-05 Patho - lymph node region resection
<ul>
<li>Lymph node, right inguinal, excision biopsy —- Mantle cell
lymphoma<br />
</li>
<li>Soft tissue, neck, excision — Consistent with mantle cell
lymphoma<br />
</li>
<li>Histology type: B-cell neoplasms, Mantle cell lymphoma Mantle cell
lymphoma — classic,<br />
</li>
<li>Immunohistochemical stain profiles: CD3(-), CD20(+), CD5(+),
CD10(-), BCL2(+), BCL6(-), Cyclin D1(+), Ki-67 is about 10-20%.</li>
</ul></li>
<li>2021-10-02 CT - chest
<ul>
<li>Probably lymphoma with mediasitinal, paraaortic, iliac and inguinal
lymphadenopathy</li>
<li>Pneumonia at right middle lobe and right lower lobe with bilateral
pleural effusion.</li>
<li>Hepatosplenomegaly.</li>
</ul></li>
</ul></li>
</ul>
<p>[chemoimmunotherapy]</p>
<ul>
<li><p>2023-05-30 - etoposide 500mg/m2 1000mg NS 50mL 2hr D1-4</p>
<ul>
<li>[dexamethasone 4mg + diphenhydramine 30mg + granisetron 2mg + NS
250mL] D1-4</li>
</ul></li>
<li><p>2022-06-02 - undergoing - Imbruvica (ibrutinib) 140mg/cap 4#
QD</p></li>
<li><p>2022-04-11 - rituximab 375mg/m2 700mg 6hr + cisplatin 100mg/m2
190mg 24hr D2 + cytarabine 2000mg/m2 3900mg 3hr Q12H D3</p></li>
<li><p>2022-03-11 - rituximab 375mg/m2 730mg 8hr + cyclophosphamide
750mg/m2 1466mg 30min + doxorubicin 50mg/m2 97mg 30min + vincristine
1.4mg/m2 2mg 10min + prednisolone 60mg/m2 50mg BID PO D1-5
(R-CHOP)</p></li>
<li><p>2022-02-08 - rituximab 375mg/m2 700mg 6hr + cisplatin 100mg/m2
190mg 24hr D2 + cytarabine 2000mg/m2 3900mg 3hr Q12H D3</p></li>
<li><p>2022-01-04 - rituximab 375mg/m2 738mg 8hr + cyclophosphamide
750mg/m2 1470mg 30min + vincristine 1.4mg/m2 2mg 10min + prednisolone
60mg/m2 50mg BID PO D1-5</p></li>
<li><p>2021-12-08 - cytarabine 2000mg/m2 3900mg 3hr Q12H D3</p></li>
<li><p>2021-12-07 - rituximab 375mg/m2 700mg 6hr + cisplatin 100mg/m2
190mg 24hr D2 + cytarabine 2000mg/m2 3900mg 3hr Q12H D3</p></li>
<li><p>2021-11-16 - rituximab 375mg/m2 730mg 8hr + cyclophosphamide
750mg/m2 1466mg 30min + doxorubicin 50mg/m2 97mg 30min + vincristine
1.4mg/m2 2mg 10min + prednisolone 60mg/m2 50mg BID PO D1-5</p></li>
<li><p>2021-10-19 - rituximab 375mg/m2 738mg 8hr + cyclophosphamide
750mg/m2 1470mg 30min + vincristine 1.4mg/m2 2mg 10min + prednisolone
60mg/m2 30mg BID PO D1-5</p></li>
</ul>
<div id="section-226" class="section level3">
<h3>==========</h3>
</div>
<div id="section-227" class="section level3">
<h3>2022-10-12</h3>
<ul>
<li><p>This mantle cell lymphoma patient had been treated with
R-CVP/R-CHOP/R-DHAP (until April 2022) and started receiving Bruton’s
tyrosine kinase inhibitor ibrutinib in early June 2022 and achieved a
partial response (2022-08-19 CT). As part of this hospitalization,
images will be updated.</p></li>
<li><p>The combination of ibrutinib and venetoclax (this is not covered
by National Health Insurance at present) has been shown to promote
responses in patients with relapsed or refractory mentle cell
lymphoma.</p>
<ul>
<li>ref:
<ul>
<li>Combining BTK inhibitors with BCL2 inhibitors for treating chronic
lymphocytic leukemia and mantle cell lymphoma. Biomark Res.
2022;10(1):17. Published 2022 Apr 4. <a href="doi:10.1186/s40364-022-00357-5" class="uri">doi:10.1186/s40364-022-00357-5</a></li>
<li>Dose-finding study of ibrutinib and venetoclax in relapsed or
refractory mantle cell lymphoma. Blood Adv. 2022;6(5):1490-1498. <a href="doi:10.1182/bloodadvances.2021005357" class="uri">doi:10.1182/bloodadvances.2021005357</a></li>
<li>Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle
cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J
Hematol Oncol. 2021;14(1):179. Published 2021 Oct 30. <a href="doi:10.1186/s13045-021-01188-x" class="uri">doi:10.1186/s13045-021-01188-x</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-228" class="section level1">
<h1>701306067</h1>
<div id="section-229" class="section level2">
<h2>221011</h2>
<ul>
<li>lab data
<ul>
<li>2022-09-12 Anti-HBs &gt;1000.00 mIU/mL<br />
</li>
<li>2021-10-04 ROS1 IHC specimen number S2021-11626<br />
</li>
<li>2021-10-04 ROS1 IHC 1+<br />
</li>
<li>2021-09-23 EGFR specimen number S2021-11626<br />
</li>
<li>2021-09-23 EGFR G719X not detected<br />
</li>
<li>2021-09-23 EGFR Exon19 del detected<br />
</li>
<li>2021-09-23 EGFR S768I not detected<br />
</li>
<li>2021-09-23 EGFR T790M not detected<br />
</li>
<li>2021-09-23 EGFR Exon20 ins not detected<br />
</li>
<li>2021-09-23 EGFR L858R not detected<br />
</li>
<li>2021-09-23 EGFR L861Q not detected<br />
</li>
<li>2021-09-23 PD-L1(22C3) specimen number S2021-11626<br />
</li>
<li>2021-09-23 PD-L1(22C3) TPS &gt;= 50%<br />
</li>
<li>2021-09-23 ALK IHC specimen number S2021-11626<br />
</li>
<li>2021-09-23 ALK IHC Negative</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-14 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2021/09/14, the old lesions
at the T10 and L1 spines are more evident; the right rib cage and left
S-I joint show stationary, and a new lesion at the sacrum is noted,
indicating metastatic bone disease in progression.<br />
</li>
<li>Suspected benign lesions at bilateral shoulders and hips.</li>
</ul></li>
<li>2022-09-12 CXR
<ul>
<li>A poorly defined nodule over Rt lower lobe due to tumor</li>
<li>Nodular opacitiy projecting over Lt lower lung zone due to nipple
shadow</li>
<li>pathological compression fracture of T9 vertebral body</li>
</ul></li>
<li>2022-09-01 MRI - brain
<ul>
<li>Findings: Multiple intra-axial enhancing lesions (all smaller than
10 mm) along cortical gyrus or corticomedullary junction of bilateral
frontal and temporal lobes, indicating metastases. Increased in number
as compared with MRI on 20220502.</li>
<li>IMP: Multiple brain metastases. Progressive change as compared with
MRI on 20200502.</li>
</ul></li>
<li>2022-08-02 CT - lung/mediastinum/pleura
<ul>
<li>stationary in size of primary RLL cancer with two small nodules in
the same lobe stationary as compared with CT on 2022/02/16</li>
<li>no locoregional recurrent breast tumor.</li>
</ul></li>
<li>2022-07-21 CXR
<ul>
<li>Patch density at bil. lungs.</li>
</ul></li>
<li>2022-07-21 SONO - abdomen
<ul>
<li>Findings: A hyperechoic nodule (1.40x2.08cm) at S7 of liver. Bil.
liver cysts (up to 2.0cm).</li>
<li>IMP: A hemangioma (1.40x2.08cm) at S7 of liver. Bil. liver cysts (up
to 2.0cm).</li>
</ul></li>
<li>2022-05-02 MRI - brain
<ul>
<li>Bifrontal and left temporal metastases.</li>
<li>Newly developing right frontal nodules. One lesion of left frontal
lobe, seems enlarged.</li>
</ul></li>
<li>2022-03-31 SONO - abdomen
<ul>
<li>Left liver cyst (2.48x2.70cm).</li>
<li>A hyperechoic nodule (1.53x1.57cm) in S6 of liver suspected
hemangioma.</li>
</ul></li>
<li>2022-02-16 CT - chest
<ul>
<li>decreased size of primary RLL cancer with two small nodules in the
same lobe and mediastinal LAP resolved compared with CT on
2021/9/18.</li>
<li>questionable left frontal brain nodule based on noncontrast CT
images.</li>
</ul></li>
<li>2021-12-15 SONO - abdomen
<ul>
<li>Liver cyst, S4 and S6</li>
<li>Liver tumor, suspicious hemangioma, S6</li>
<li>Accessory spleen</li>
<li>pancreatic tail masked by gas.</li>
</ul></li>
<li>2021-11-17 T-, L-spine AP + Lat
<ul>
<li>mild scoliosis of the L-spine.</li>
<li>Unremarkable change in the width of the bony spinal canal<br />
</li>
<li>mild anterior spur formation at the L-spine.</li>
<li>decreased disc spaces in the T-spine discs and the middle L-spine
discs..</li>
</ul></li>
<li>2021-09-18 MRI - brain
<ul>
<li>Left fronto-temporal metastases</li>
<li>Suspected Bil. cerebellar metastases.</li>
</ul></li>
<li>2021-09-14 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>In comparison with the previous study on 2021/07/26, the lesions in
the T10 spine, L1 spine and left S-I joint are more evident. Bone
metastases should be watched out.</li>
<li>Some new faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? bone metastases?). Please follow up
bone scan for further evaluation.</li>
</ul></li>
<li>2021-09-10 CT - chest
<ul>
<li>Indication
<ul>
<li>Right breast cancer proved by CNB on 20210707</li>
<li>20210628
<ul>
<li>Breast lump, right</li>
<li>self examination</li>
<li>palpable at right/ left breast: yes</li>
</ul></li>
</ul></li>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Spiculated mass at right lower lobe up to 3.5cm in largest dimension
is found. Lung cancer is suspected.</li>
<li>Some lymph nodes are found at paratracheal region.</li>
<li>No evidence of bilateral pleural effusion.</li>
<li>S/P mastectomy at right side.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Hepatic simple cysts at both lobes of liver up to 2.3cm at S1 and
1.5cm at S7/8.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp: left lower lobe lung cancer with medistinal lymph nodes,
T2aN2M0</li>
<li>Imaging Report Form for Lung Carcinoma
<ul>
<li>Impression (Imaging stage): T:T2(T_value) N:N2(N_value)
M:M0(M_value) STAGE:____(Stage_value)</li>
</ul></li>
</ul></li>
<li>2021-09-01 Patho - lung wedge biopsy
<ul>
<li>Lung, right, CT-guide biopsy — adenocarcinoma, moderately to poorly
differentiated, in favor of lung primary tumor<br />
</li>
<li>Sections show solid nests and neoplastic glandular cells
infiltrating in a fibrotic stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(focal +), Napsin A(focal
+), GATA3(focal weak +), Mammaglobin (-), ER(-), PR(-), and HER2(2+,
equivocal). The Ki-67 is about 50%. The results are in favor of primary
lung adenocarcinoma.<br />
</li>
</ul></li>
<li>2021-08-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (80.42 - 13.74) / 80.42 =
82.91%</li>
<li>LVEF = 65 (%)
<ul>
<li>M-mode (Teichholz) = 70.97</li>
</ul></li>
<li>Normal AV/MV with no AR/MR</li>
<li>Normal LV chamber size and wall thickness</li>
<li>Preserved LV and RV systolic function</li>
<li>No PR, mild TR, normal IVC size</li>
</ul></li>
<li>2021-08-23 Peripheral Vascular Test - vein, lower limbs
<ul>
<li>Clinical diagnosis: edema</li>
<li>Doppler study: (N = Normal, A = Abnormal, T = Thrombus)
<ul>
<li>Lower limbs R_CFV R_SFV R_PV R_PTV R_SV L_CFV L_SFV L_PV L_PTV
L_SV</li>
<li>Spontaneous signal A N N N N N N A N N</li>
<li>Respiratory changes A N N N N N N A N N</li>
<li>Cough response A N N N N N N A N N</li>
<li>Compression study A N N N N N N A N N</li>
</ul></li>
<li>Report:
<ul>
<li>Right side:
<ul>
<li>SVC: 16.3 mmHg ; 17.6 mmHg ;</li>
<li>MVO/SVC: 99 % ; 97 % ;</li>
<li>Average MVO/SVC: 98.00 %</li>
</ul></li>
<li>Left side:
<ul>
<li>SVC: 17.0 mmHg ; 17.0 mmHg ;</li>
<li>MVO/SVC: 100 % ; 100 % ;</li>
<li>Average MVO/SVC: 100.00 %</li>
</ul></li>
<li>Thrombus : None</li>
<li>Varicose vein : None</li>
</ul></li>
<li>Conclusion:
<ul>
<li>A perforator vein connecting the right PTV and LSV at middle lower
leg level, but no engorgement of LSV was noted. Increased venous return
flow velocity at right CFV. Tissue edema at right lower leg.</li>
<li>Mild venous reflux at left popliteal vein; mild veonus reflux at
left popliteal vein; a perforator vein connecting the left PTV and LSV
at middle lower leg level, but no engorgement of LSV was noted. Tissue
edema at left lower leg.</li>
<li>No evidence of venous thrombosis at bilateral lower limbs venous
systems.</li>
<li>The ratios of MVO and SVC of bilateral legs were within normal
limits.</li>
</ul></li>
</ul></li>
<li>2021-07-28 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the right lower lung, probably another
primary (priority) or secondary lung malignancy, suggesting biopsy for
further investigation.<br />
</li>
<li>Glucose hypermetabolism in the right SCF lymph nodes, bilateral
mediastinal lymph nodes, and right pulmonary hilar lymph nodes, probably
lung cancer with regional lymph nodes metastases, suggesting biopsy for
further investigation also.<br />
</li>
<li>Glucose hypermetabolism in the right rib cage, T10 and L1 spines,
and left iliac bone, probably lung cancer with multiple bone
metastases.<br />
</li>
<li>Increased FDG uptake at the initial end of A-colon, the nature is to
be determined (physiological uptake of FDG, polyp, or other nature ?),
suggesting colon fibroscopy for investigation.</li>
<li>Increased FDG uptake at the left shoulder, probably post-traumatic
change.</li>
<li>Right breast cancer s/p treatment, no evidence of residual tumor;
right lower lung cancer (if proved), cTxN3M1c, stage IVB (AJCC 8th ed.),
by this F-18 FDG PET scan.</li>
</ul></li>
<li>2021-07-27 Patho - breast simple/partial mastectomy
<ul>
<li>pathologic diagnosis
<ul>
<li>Breast, right, simple mastectomy — Invasive carcinoma of no special
type<br />
</li>
<li>Resection margin, breast, right, simple mastectomy — Free<br />
</li>
<li>Lymph node, sentinel, right axilla, SNLB — Negative for malignancy
(0/1)<br />
</li>
<li>AJCC 8 th edition, Pathology stage: pT2N0; Anatomic stage IIA;
Prognostic stage IIA if cM0</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Invasive carcinoma of no special type<br />
</li>
<li>Size of invasive carcinoma: 3.5 x 3.0 x 3.0 cm<br />
</li>
<li>Histologic grade (Nottingham histologic score): Grade 3 (score =
8)<br />
</li>
<li>Skin involvement: Absent</li>
<li>Ductal carcinoma in situ (DCIS): Present; Extensive DCIS:
Negative<br />
</li>
<li>Margins: Negative, Closest margin ( 2 mm from base margin)<br />
</li>
<li>Nodal status: Negative (sentinel 0/1)
<ul>
<li>number of lymph node examined: 1 (sentinel)<br />
</li>
<li>number with macrometastases (&gt;2mm): 0 (sentinel)<br />
</li>
<li>number with micrometastases (&gt;0.2~2mm and/or &gt;200 cells):
0<br />
</li>
<li>number with isolated tumor cells (&lt;=0.2mm and &lt;=200 cells):
0<br />
</li>
</ul></li>
<li>Treatment Effect: No presurgical neoadjuvant therapy received<br />
</li>
<li>Lymphovascular invasion: Presnt<br />
</li>
<li>Perineural invasion: Absent<br />
</li>
<li>Representative parts are taken for section and labeled: A1 = nipple,
A2-A4 = tumor + base margin, A5-A7 = tumor + skin, A8 = non-tumor.
F2021-000286 FSA= sentinel lymph node, FSB= skin.<br />
</li>
</ul></li>
<li>IMMUNOHISTOCHEMICAL STUDY (S2021-08728)
<ul>
<li>ER (Ab): Positive (strong, &gt;90%)<br />
</li>
<li>PR (Ab): Negative<br />
</li>
<li>HER-2/Neu (Ab): Equivocal (score= 2+)<br />
</li>
<li>Ki-67: 10%<br />
</li>
<li>p53: Positive<br />
</li>
</ul></li>
<li>IN-SITU HYBRIDIZATION (S2021-08728)
<ul>
<li>HER2/NEU In-Situ Hybridization: Neagtive.</li>
<li>There is NO amplification of HER2 detected</li>
</ul></li>
</ul></li>
<li>2021-07-27 Lymphoscintigraphy
<ul>
<li>The sentinel lymph node mapping was performed immediately after
injection of 0.5 mCi of Tc-99m phytate (s.c) above the right breast. The
sequential static images over the chest revealed a focal area of
increased accumulation of radioactivity at the right axilla.</li>
<li>IMPRESSION: Probably a sentinel lymph node at the right axillary
region.</li>
</ul></li>
<li>2021-07-26 CT - abdomen
<ul>
<li>A tumor (2.5cm) at RLL.</li>
<li>Retroversion of uterus.</li>
<li>Liver cysts (up to 2.3cm).</li>
</ul></li>
<li>2021-07-26 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the maxilla, a middle C- spine,T10 and
L3-4 spines, sacrum, bilateral shoulders, S-I joints, and hips.</li>
</ul></li>
<li>2021-07-26 SONO - abdomen
<ul>
<li>Hepatic tumor, S7</li>
<li>Hepatic cysts</li>
<li>Parenchymal liver disease</li>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2021-07-23 Mammography
<ul>
<li>S/P right mastectomy.</li>
<li>No mammographic evidence of malignancy, suggest clinical correlation
and regular follow up.</li>
<li>BI-RADS: Category 1: negative.</li>
</ul></li>
<li>2021-07-02 Patho - breast biopsy (no margin)
<ul>
<li>Breast, right, sono guide biopsy— invasive carcinoma of no special
type</li>
<li>Microscopically, the breast shows invasive carcinoma characterized
by proliferation of tumor cells with infiltrative growth pattern, ductal
differentiation and stromal fibrosis. The tumor cell shows
hyperchromatic nuclei, plemorphism and high N/C ratio.<br />
</li>
<li>IHC stain— ER:positive (strong, &gt; 90%), PR: negative, Her2/neu:
equivocal (2+), Ki-67 index: 10%, P53: positive<br />
</li>
<li>HER2/NEU In-Situ Hybridization — Neagtive: There is NO amplification
of HER2 detected.<br />
</li>
</ul></li>
<li>2021-07-02 SONO - breast
<ul>
<li>Right breast tumor, suspected malignancy.</li>
<li>Complex cystic tumor in right breast, 10’region.</li>
<li>Right axillary lymph node, suspected metastasis.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-30 Dermatology
<ul>
<li>Q
<ul>
<li>Consult for pressure sore with necrosis and of buttock</li>
<li>This 70-year-old woman had history of
<ul>
<li>Right breast cancer s/p simple mastectomy and SLNB on 20210727,
T2N3M1, Stage IV</li>
<li>Lung cancer, adenocarcinoma, cT2aN2M1c, stage IVB, with bone, brain
metastasis, ECOG 1, under Iressa since 20210915.</li>
</ul></li>
<li>Falling accidence for 2 times in 2022/07 (also Zoledronic acid).
Nausea with diarrhea for more weeks, suspect Iressa side effect.</li>
<li>Brain MRI on 2022-09-01 showed multiple brain metastases.
Progressive change as compared with MRI on 20200502.</li>
<li>Thus she was admitted to our chest ward for further exam with
treatment.</li>
<li>After admission, pressure sore with necrosis and of buttock was
noted, aerobic culture of pus grown Staphylococcus.</li>
<li>Wet dressing with diluted betaiodine (1:1) gauze BID not improve due
to nearly bed riddeen and poor nutrition.</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from one ulceration on L’t buttock for
days.</li>
<li>Imp: Bedsore</li>
<li>Suggestion:
<ul>
<li>Doxyclin 1 /Bid</li>
<li>Fuciden * 2 tube/bid</li>
<li>ZnO * 1 tube/bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-15 Infectious Disease
<ul>
<li>Q
<ul>
<li>Consultation for Zyvox</li>
</ul></li>
<li>A
<ul>
<li>Patient’s sacral pressure sore wound culture showed MSSA infection.
<ul>
<li>There is penicillin anaphylactic shock history that use of
penicillin should be avoided.</li>
<li>From the MSSA antibiogram, Baktar, Avelox, and Cipro all
susceptible.</li>
<li>Use of Zyvox should be not necessary.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>DC Zyvox.</li>
<li>Add oral Avelox or Cipro for coverage of bedsore MSSA
infection.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-12 Plastic and Reconstructive Surgery
<ul>
<li>Q
<ul>
<li>Consult for open wound of buttock</li>
<li>This 70-year-old woman had history of
<ul>
<li>Right breast cancer s/p simple mastectomy and SLNB on 2021-07-27,
T2N3M1, Stage IV</li>
<li>Lung cancer, adenocarcinoma, cT2aN2M1c, stage IVB, with bone, brain
metastasis, ECOG 1, under Iressa since 2021-09-15.</li>
</ul></li>
<li>Falling accidence for 2 times in 2022/07 (also Zoledronic acid).
Nausea with diarrhea for more weeks, suspect Iressa side effect.</li>
<li>Brain MRI on 2022-09-01 showed multiple brain metastases.
Progressive change as compared with MRI on 20200502. Thus she was
admitted to our chest ward for further exam with treatment.  </li>
<li>After admission, pressure sore with pus of buttock was noted,
aerobic and anarobic culture of pus was collect.</li>
<li>We need your professional expertise for help, thank you very
much.</li>
</ul></li>
<li>A
<ul>
<li>This is a case of pressure sore with necrosis and cellulitis of the
sacrum.</li>
<li>Suggestion
<ul>
<li>The conservative treatment
<ul>
<li>antibiotic use;</li>
<li>wet dressing with diluted betaiodine (1:1) gauze bid;</li>
<li>avoiding the supine position;</li>
<li>nutrition supportion</li>
</ul></li>
<li>and observation are suggested.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-12 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Consult for brain radiotherapy</li>
<li>This 70-year-woman had history of
<ul>
<li>Right breast cancer s/p simple mastectomy and SLNB on 2021-07-27,
T2N3M1, Stage IV</li>
<li>Lung cancer, adenocarcinoma, cT2aN2M1c, stage IVB, with bone, brain
metastasis, ECOG 1, under Iressa since 2021-09-15.</li>
</ul></li>
<li>Falling accidence for 2 times in 2022/07 (also Zoledronic acid).
Nausea with diarrhea for more weeks, suspect Iressa side effect. Brain
MRI on 2022-09-01 showed multiple brain metastases. Progressive change
as compared with MRI on 20200502.</li>
<li>Thus she was admitted to our chest ward for further exam with
treatment.  </li>
<li>Due to multiple brain metastasis, we need your professional
expertise for radiotherapy, thank you very much.</li>
</ul></li>
<li>A
<ul>
<li>Subjective:
<ul>
<li>History: This 70-year-woman had history of
<ul>
<li>Right breast cancer s/p simple mastectomy and SLNB on 2021/07/27,
cT2N3M1, Stage IV;</li>
<li>Lung cancer, adenocarcinoma, cT2aN2M1c, stage IVB, with bone, brain
metastasis, ECOG 1, under Iressa since 2021/09/15.</li>
</ul></li>
<li>Falling accidence was noted for 2 times in 2022/07 (also Zoledronic
acid). Nausea with diarrhea was noted for more weeks, suspect Iressa
side effect. Brain MRI on 2022-09-01 showed multiple brain metastases,
with progressive change as compared with MRI on 20200502. Poor intake
and dehydration due to nausea has been noted for weeks.<br />
</li>
<li>Previous RT: denied.</li>
<li>Other disease: as above.</li>
<li>Family history: denied.
<ul>
<li>Habit: Alcohol, denied; smoking: denied; betel nuts: denied.</li>
<li>Single. Caregiver: her friend. Job: nil. Mild economic stress.</li>
<li>Language: Taiwanese. Mandarin.</li>
<li>Religion: Buddism.</li>
</ul></li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2022/09/12: No palpable neck LNs.</li>
<li>Pathology, 2021/09/01: Lung, right, CT-guide biopsy —
adenocarcinoma, MD to PD, in favor of lung primary tumor. TTF-1(focal
+), Napsin A(focal +), GATA3(focal weak +), Mammaglobin (-), ER(-),
PR(-), and HER2(2+, equivocal). The Ki-67 is about 50%.</li>
<li>Images:
<ul>
<li>Brain MRI, 2022/05/02: Bifrontal and left temporal metastases. Newly
developing right frontal nodules. One lesion of left frontal lobe, seems
enlarged.</li>
<li>Brain MRI, 2022/09/01: Multiple intra-axial enhancing lesions (all
smaller than 10 mm) along cortical gyrus or corticomedullary junction of
bilateral frontal and temporal lobes, indicating metastases. Increased
in number as compared with MRI on 20220502. IMP: Multiple brain
metastases. Progressive change as compared with MRI on 20200502.</li>
<li>Chest CT, 2022/08/02: stationary in size of primary RLL cancer with
two small nodules in the same lobe stationary as compared with CT on
2022/02/16; no locoregional recurrent breast tumor.</li>
</ul></li>
</ul></li>
<li>Diagnosis: Lung cancer, adenocarcinoma, cT2aN2M1c, stage IVB, with
bone, brain metastasis, ECOG 1, under Iressa since 2021/9/15 with
progressive brain metastasis; ECOG 2; poor intake &amp;
dehydration.</li>
<li>Goal of radiotherapy: Palliative.</li>
<li>RT Plan:
<ul>
<li>Target &amp; Volume: Brain metastasis (n=15) with sparring of
hippocampus.</li>
<li>Technique: VMAT.</li>
<li>Dose &amp; Fractionation: 3960cGy/12 fractions.</li>
<li>Plan: Brain RT for 3960cGy/12 fractions is suggested for symptom
control. First fraction was prescribed smoothly on Sep 12, 15:00.
Possible radiation side effects are told to the patient and her friend.
Please prescribe adequate dose of dexamethasone and Famotidine to
prevent IICP during brain RT. IV fluids may be prescribed due to poor
intake &amp; dehydration.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-07-27 Simple mastectomy + SLNB    
<ul>
<li>right breast tumor 3cm, 1-2 oclock/1cm from nipple</li>
<li>axillary sentinel lymph node: 0/1</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-01-12, 2022-02-09 - zoltedronic acid 4mg IVD (for bone
mets)</li>
<li>2021-09-23 ~ undergoing - Iressa (gefitinib 250mg/tab) 1# QD</li>
<li>2021-09-22 ~ 2022-05-25 - Kisqali (ribociclib 200mg/tab) 2# QD</li>
<li>2021-08-11 ~ undergoing - Femara (letrozole 2.5mg/tab) 1# QD</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>The patient has been diagnosed with ER(+) PR(+) HER2(-) breast
cancer and has been treated with letrozole, an aromatase inhibitor, in
combination with the CKD4/6 inhibitor, ribociclib (2021-09-22 ~
2022-05-25).</p></li>
<li><p>She was also diagnosed with EGFR Exon19 deletion, PD-L1 TPS &gt;=
50% lung adenocarcinoma, and is currently undergoing the TKI gefitinib
(2021-09-23 ~ undergoing).</p></li>
<li><p>The use of atezolizumab might be an option for her subsequent
treatment, as her lung cancer is also characterized by PD-L1 TPS &gt;=
50%. (2021-09-23 S2021-11626)</p></li>
<li><p>Her bone mets were treated with zoltedronic acid (2022-01-12,
2022-02-09) and two falling accidents were noted in July 2022. In the
event that zoltedronic acid is not well tolerated by the patient, Xgeva
(denosumab 120mg SC) or romosozumab (currently not available at this
hospital) might be an alternative.</p></li>
</ul>
</div>
</div>
<div id="section-230" class="section level1">
<h1>700199371</h1>
<div id="section-231" class="section level2">
<h2>221007</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-13 Gynecologic ultrasonography
<ul>
<li>ATH + BSO</li>
<li>Suspected Lt adnexal cyst (26mmx22mm)</li>
<li>Suspected Rt mass? (39mmx30mm), RI:0.65</li>
</ul></li>
<li>2022-07-22 CT - abdomen
<ul>
<li>Local recurrent tumor 3.7 cm in left pelvis is suspected. please
correlate with clinical condition.</li>
<li>Metastatic node 3.1 cm in pre-cava space.
<ul>
<li>In addition, several metastatic nodes in para-aortic space and
para-cava space, bilateral common iliac chain, and bilateral inguinal
area are highly suspected.<br />
</li>
</ul></li>
</ul></li>
<li>2022-05-07 Gynecologic ultrasonography
<ul>
<li>ATH + BSO</li>
<li>Suspected Lt adnexal cyst (29mmx28mm)</li>
<li>Suspected Rt mass? (37mmx30mm)</li>
</ul></li>
<li>2022-04-27 CT - abdomen
<ul>
<li>Prior CT identified a soft tissue mass measuring 2.7 cm in left
pelvis is noted again, mild increasing in size to 2.9 cm. Follow up is
indicated.</li>
</ul></li>
<li>2022-01-27 CT - abdomen
<ul>
<li>S/P hysterectomy. A soft tissue tumor (2.7cm) at left pelvic cavity.
A cystic lesion (2.2x6.3cm) at left pelvic cavity.</li>
<li>Grade 4 fatty liver.</li>
</ul></li>
<li>2021-11-08 SONO - abdomen
<ul>
<li>Fatty liver.</li>
<li>Hypoechoic lesion, 1.72x0.93cm in pericholecystic region, suspected
focal fatty sparying. Suggest follow up.<br />
</li>
<li>Left renal cyst.</li>
</ul></li>
<li>2021-08-25 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the skull, maxilla, upper L-spine,
bilateral sternoclavicular junctions, shoulders, elbows, wrists, hands,
knees, and feet.</li>
</ul></li>
<li>2021-08-18 MRI - pelvis
<ul>
<li>S/P hysterectomy.<br />
</li>
<li>Suspected hematoma (1.5cm) around left aspect of vaginal stump,
suggest follow up.</li>
<li>Left pelvic cavity cystic lesion, suspected lymphocele, suggest
follow up.</li>
<li>Bone lesion in right sacrum, 1cm, bone metastasis? suggest bone scan
study.</li>
</ul></li>
<li>2021-05-17 MRI - pelvis
<ul>
<li>S/P hysterectomy.<br />
</li>
<li>Small peritoneal nodule (0.48cm) in lower pelvic cavity,
carcinomatosis? Suggest follow up.</li>
<li>Suspected hematoma (1.3cm) around left aspect of vaginal stump,
suggest follow up.</li>
<li>Suspected lymphocele in left pelvic cavity, suggest follow up.</li>
</ul></li>
<li>2020-10-31 Gynecologic ultrasonography
<ul>
<li>ATH + BSO</li>
<li>Suspected Lt adnexal cyst (58mmx42mm), no blood flow</li>
</ul></li>
<li>2020-09-17 Patho - uterus (with or without SO) neoplastic
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Endometrium, uterus, staging surgery — Endometrioid carcinoma, grade
2<br />
</li>
<li>Myometrium, uterus, ditto — Tumor invasion, more than half
thickness, leiomyomas<br />
</li>
<li>Cervix, uterus, ditto — Free of tumor invasion, Nabothian cyst<br />
</li>
<li>Ovary, left, ditto — Free of tumor invasion, hemorrhagic corpus
luteum<br />
</li>
<li>Fallopian tube, left, ditto — Free of tumor invasion<br />
</li>
<li>Ovary, right, ditto — Free of tumor invasion, hemorrhagic corpus
luteum<br />
</li>
<li>Fallopian tube, right, ditto — Free of tumor invasion<br />
</li>
<li>Lymph node, left external iliac, dissection — Tumor metastasis
(3/10) with extracapsular extension (3/3)<br />
</li>
<li>Lymph node, left oburator, ditto — Tumor metastasis (5/9) without
extracapsular extension (0/5)<br />
</li>
<li>Lymph node, right external iliac, ditto — Tumor metastasis (1/5)
without extracapsular extension (0/1)<br />
</li>
<li>Lymph node, right oburator, ditto — Tumor metastasis (2/12) without
extracapsular extension (0/2)<br />
</li>
<li>Lymph node, left para-aortic, ditto — Free of tumor metastasis
(0/7)<br />
</li>
<li>Parametrium, bilateral — Free of tumor<br />
</li>
<li>Cul-de sac tumor, excision — Endometrioid carcinoma<br />
</li>
<li>Serosal nodule, uterus — Endometrioid carcinoma<br />
</li>
<li>Vaginal stump — Free of tumor<br />
</li>
<li>AJCC Pathologic stage — pT3aN1a (if cM0), stage IIIC1 (FIGO stage
IIIC1)<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Operation Procedure: staging surgery (TAH, BSO and BPLND)<br />
</li>
<li>Specimens include: Uterus, bilateral ovaries and fallopian tubes,
pelvic LNs and cul-de sac tumor<br />
</li>
<li>Specimen size:
<ul>
<li>uterus: 15.2 x 12.3 x 7.5 cm in size, and 552 gm in weight contains
myomas and one serosal nodule<br />
</li>
<li>right ovary: 3.6 x 1.8 x 1.4 cm<br />
</li>
<li>left ovary: 3.4 x 2.2 x 1.2 cm<br />
</li>
<li>right tube: 6.5 cm in length; 0.6 cm in diameter<br />
</li>
<li>left tube: 6.9 cm in length; 0.7 cm in diameter<br />
</li>
</ul></li>
<li>Tumor site: endometrium, from fundus to endocervix<br />
</li>
<li>Tumor size: 11.6 x 8.3 x 4.2 cm<br />
</li>
<li>The myometrium: up to 3.2 cm in thickness<br />
</li>
<li>The cervix : mucoid cysts<br />
</li>
<li>Adnexa (bilateral): not invaded by tumor<br />
</li>
<li>Lymph nodes: left external iliac LNs; left obturator LNs; right
external iliac LNs, right obturator LNs and left para-aortic LNs<br />
</li>
<li>cul-de sac tumor: one small piece, 2.4 x 1.8 cm<br />
</li>
<li>Serosal nodule of uterus: 1.2 x 0.8 x 0.7 cm<br />
</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION<br />
</li>
<li>Histology type: Endometrioid carcinoma<br />
</li>
<li>Histology grade: Grade 2<br />
</li>
<li>Depth of invasion: More than half thickness of myometrium<br />
</li>
<li>Lymphovascular invasion: Present<br />
</li>
<li>The cervical stroma involvement:: absent<br />
</li>
<li>Resection margins of the cervix: Free, 3.2 cm away from tumor
cells<br />
</li>
<li>Additional pathologic findings: N/A<br />
</li>
<li>Lymph nodes: tumor metastasis (11/43) with extracapsular extension
(3/11) in total number<br />
</li>
<li>Vaginal stump: 0.8 cm, free<br />
</li>
<li>Immunohistochemistry: WT-1(-), ER(+), PR(+), PAX-8(+) and
vimentin(+, scatter) for tumor cells<br />
</li>
<li>Cul-de sac tumor: endometrioid carcinoma<br />
</li>
<li>Serosal nodule of uterus: Endometrioid carcinoma</li>
</ul></li>
<li>2020-08-28 MRI - pelvis
<ul>
<li>Findings
<ul>
<li>Diffuse soft tissue tumor, up to 8.8cm in the uterine cavity
(fundus, body to the eneocervical region), suspected endometiral
malignancy.</li>
<li>Soft tissue tumors in the cul-de-sac with ascites, suspected tubal
or ovarian involvement.</li>
<li>There are T2 hypointensity tumors, up to 1.8cm in the uterine
myometrium, suspected uterine myomas.</li>
<li>There are diffuse enlarged lymph nodes in bilateral obturator,
intenal, external and common iliac regions, could be due to metastatic
lymph nodes.</li>
<li>Non-enhancing nodules in bilateral kidneys, suspected renal
cysts.</li>
</ul></li>
<li>Imaging Report Form for Endometrial Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3(T_value) N:N1(N_value)
M:M0(M_value) STAGE: III (Stage_value)</li>
<li>Diffuse soft tissue tumors in the uterine cavity with diffuse
enlarged lymph nodes in the pelvic cavity, suspected endometrial
malignancy with lymph nodes metastasis.</li>
<li>Soft tissue tumors in the cul-de-sac with ascites, suspected tubal
or ovarian involvement. cstage T3N1M0.<br />
</li>
</ul></li>
</ul></li>
<li>2020-08-21 Patho - endometrium curretage/biopsy
<ul>
<li>Endometrium, uterus, D&amp;C — Adenocarcinoma</li>
</ul></li>
<li>2020-08-15 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae: free</li>
<li>Suspected endometrial hyperplasia</li>
<li>Uterine myoma</li>
</ul></li>
<li>2020-06-27 Gynecologic ultrasonography
<ul>
<li>Bilateral adnexae: free</li>
<li>EM: 22.6m</li>
<li>Uterine myoma</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-06 - docetaxel 75mg/m2 135mg 1hr + carboplatin AUC 5 550mg
2hr</li>
<li>2022-09-15 - bevacizumab 7.5mg/kg 570mg 1.5hr + docetaxel 75mg/m2
135mg 1hr + carboplatin AUC 5 550mg 2hr</li>
<li>2022-08-25 - bevacizumab 7.5mg/kg 570mg 1.5hr + docetaxel 75mg/m2
135mg 1hr + carboplatin AUC 5 550mg 2hr</li>
<li>2022-08-04 - bevacizumab 7.5mg/kg 590mg 1.5hr + docetaxel 60mg/m2
100mg 1hr + carboplatin AUC 5 560mg 2hr</li>
<li>2021-02-02 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2021-01-12 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2020-12-22 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2020-12-01 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2020-11-10 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 450mg
2hr</li>
<li>2020-10-20 - paclitaxel 160mg/m2 270mg 3hr + carboplatin AUC 5 450mg
2hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<p>Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano
RP. Anticoagulation Strategies in Patients With Cancer: JACC Review
Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336-1349. <a href="doi:10.1016/j.jacc.2019.01.017" class="uri">doi:10.1016/j.jacc.2019.01.017</a></p>
<p>Johnstone C, Rich SE. Bleeding in cancer patients and its treatment:
a review. Ann Palliat Med. 2018;7(2):265-273. <a href="doi:10.21037/apm.2017.11.01" class="uri">doi:10.21037/apm.2017.11.01</a></p>
<ul>
<li><p>There has been an observation of vaginal bleeding possibly caused
by bevacizumab. A transfusion might be necessary if there is a
significant loss of blood (which is not the case for this patient HGB
11.0 g/dL 2022-10-06).</p></li>
<li><p>Tranexamic acid has not been studied in advanced cancer, but it
reduces mortality due to bleeding by approximately one-third. A
reduction of approximately one-third in blood loss and transfusion
requirements has been seen in meta analyses of its use in elective
surgery as well.</p>
<ul>
<li>ref: Ker K, Edwards P, Perel P, et al. Effect of tranexamic acid on
surgical bleeding: Systematic review and cumulative meta-analysis. BMJ
2012;344:e3054.</li>
<li>ref: Ker K, Prieto-Merino D, Roberts I. Systematic review,
meta-analysis and meta-regression of the effect of tranexamic acid on
surgical blood loss. Br J Surg 2013;100:1271-9.</li>
</ul></li>
<li><p>No dose-response has been seen for tranexamic acid’s therapeutic
effect, and the recommended dose is 10 mg/kg per dose given
intravenously every 6-8 hours, with no benefit to doses above 1
gram.</p>
<ul>
<li>ref: Hunt BJ. The current place of tranexamic acid in the management
of bleeding. Anaesthesia 2015;70 Suppl 1:50-3, e18.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-232" class="section level1">
<h1>701453252</h1>
<div id="section-233" class="section level2">
<h2>221007</h2>
<p>Pancreatic cancer, adenocarcinoma, pT2N2M1, stage IV with liver mets
with Paclitaxel and Gemcitabine Gastric cancer, adenocarcinoma,
pT2N3aM0, stage IIIa Malignant neoplasm of unspecified site of left
female breast</p>
<ul>
<li>past history
<ul>
<li>Pancreatic cancer, adenocarcinoma, pT2N2M1, stage IV with liver
metastasis s/p pancreaticoduodenectomy, Level 3 mesopancreas dissection,
cholecystectomy and wedge biopsy of liver, laparotomy on 2021/01/19
&amp; s/p palliative chemotherapy with Paclitaxel and Gemcitabine</li>
<li>Gastric cancer, adenocarcinoma, pT2N3aM0, stage IIIa s/p totally
laparoscopic distal gastrectomy (TLDG) with D2 lymphadenectomy (LND) on
2018/07/16 &amp; s/p adjuvant chemotherapy + radiotherapy</li>
<li>Left breast cancer, intraductal papilloma with ductal carcinoma
in-situ, pTis, stage 0 s/p excision on 2018/11/30 &amp; s/p hormone
therapy with Femara since 2019/02/15 + radiotherapy till 2019/04/10</li>
<li>Peptic ulcer more than 10 years ago</li>
<li>Hypertension for years without medical control</li>
<li>Severe narrowing of left C5/6 and C6/7 neural foramina, caused by
protusion disc plus compressin of left C6 and C7 nerve roots, then left
upper and lower limbs muscle weakness</li>
</ul></li>
<li>op history
<ul>
<li>Left femur intertrochanteric displaced fracture, with posteromedial
involvement to lesser trochanter status post open reduction and internal
fixation with Gamma nail on 2022/09/23</li>
<li>s/p lumbar spine (L4/5) surgery in 2011 and s/p cervical spine (C3)
surgery in 2014</li>
<li>C/S in 1986.</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-10-06 CT - abdomen
<ul>
<li>Findings
<ul>
<li>S/P gastric and pancreas operation.</li>
<li>Heterogeneous density of liver with some poor enhancing
nodules.</li>
<li>Multiple nodules at bil. lungs. Left pleural effusion with adjacent
lung collapse.</li>
<li>Soft tissues in peritoneal cavity.</li>
<li>Mild dilatation of IHDs.</li>
<li>Massive ascites.</li>
<li>General subcutaneous edema.</li>
<li>Enlarged LNs at mediastinum, mesentery and retroperitoneum.</li>
</ul></li>
<li>Impression
<ul>
<li>S/P gastric and pancreas operation. In favor of peritoneal seeding,
LNs, lung and liver metastases. Ascites and pleural effusion.</li>
</ul></li>
</ul></li>
<li>2022-09-26 Patho - bone biopsy/curetting
<ul>
<li>Labeled as “breast cancer, suspected mets; left femur fracture”,
ORIF with Gamma nail — fractured bone tissue with no metastatic
carcinoma in this specimen.</li>
<li>IHC stains: CK (-), GATA-3 (-).</li>
</ul></li>
<li>2022-09-23 Pelvis-THR &amp; Lt. Hip Lat
<ul>
<li>Left femoral intertrochanteric fracture, s/p ORIF</li>
<li>Acceptable alignment</li>
</ul></li>
<li>2022-09-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (117 - 31) / 117 = 73.50%
<ul>
<li>M-mode (Teichholz) = 73.4</li>
</ul></li>
<li>Dilated LA</li>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild PR, TR</li>
<li>Mild Pulmonary HTN</li>
<li>Redundent mitral chordae tendinae</li>
</ul></li>
<li>2022-08-03 TS-1 (1-1); 08-24 (1-2)</li>
<li>2022-07-27 Abdominal CT
<ul>
<li>There is a 1.3cm nodule with enhanced wall and low density center in
S3 liver.</li>
<li>There are tiny nodules in bilateral lung base. Pneumobilia
noted.</li>
<li>There is a 1.0cm enlarged lymph node in paraaortic region.</li>
<li>stable disease.</li>
</ul></li>
<li>2022-07-25 Visit Yuli TzuChi hospital due to fall down on 20220721.
<ul>
<li>X-ray showed left medial curneiform, left 2~4th metatarsal base
linear fracture.</li>
</ul></li>
<li>2022-05-12 Onivyde + 5-Fu/LV (7); 05-25 (8); 06-08 CEA: 28, CA 19-9:
3676, Onivyde + 5-Fu/LV (9); 06-22 (10); 07-06 (11); 07-20 (12)</li>
<li>2022-04-21 CT - abdominal
<ul>
<li>Metastatic tumor in S3 liver is likely.</li>
<li>Pneumobilia.</li>
<li>Metastatic tumors in bilateral lung base is likely;</li>
<li>S/P L4-5 disc spacer implantation.</li>
<li>The liver tumor lesion was similar in size (1.2 cm -&gt; 1.5 cm). So
called lung lesions were very small (less than 0.5mm, need to follow
up).</li>
<li>Stable condition.</li>
</ul></li>
<li>2022-02-17 Onivyde + 5-Fu/LV (2); 03-03 (3); 03-17 (4); 03-31 (5);
04-14 (6)</li>
<li>2022-02-04 Onivyde + 5-Fu/LV (1), 80% dose, use TS-1 to replace CI
5-Fu (due to port-A on right thigh and relative need help in daily
activity due to chronic leg problem).</li>
<li>2022-01-17 Hb 7.8 g/dL -&gt; PRBC 2 u</li>
<li>2021-12-08 Gemzar + Nab Paclitaxel (6/D15); 12-16 (7/D1); 12-29
(7/D8); 111-01-05 (7/D15), CEA 10.5 ng/mL, CA 19-9: 414 U/mL</li>
<li>2021-11-30 CT - chest and abdominal
<ul>
<li>A 1.2 cm rim-enhancing nodular lesion in the S3 of liver, suspicious
metastasis. Tiny nodular opacity in lateral segment of RML of the
lung.</li>
<li>Discuss with patient about her condition and treatment options. Keep
current chemotherapy and suggest patient weekly chemotherapy first for
better efficacy. If patient can not return to clinics weekly, consider
change to 2nd line chemotherapy with Onivyde + 5-Fu/LV. She prefer to
keep current treatment because she also had some difficulty in using
continuous infusion.</li>
</ul></li>
<li>2021-08-18 Gemzar + Nab Paclitaxel (4/D1); 08-30 CEA 3.1 ng/mL, CA
19-9: 185 U/mL; 09-01 Gemzar + Nab Paclitaxel (4/D8); 09-15 (4/D15);
09-29 (5/D1); 10-11 CEA: 3.8 ng/mL, CA 19-9: 219.1 U/mL; 10-13 (5/D8);
10-27 (5D15); 11-10 (6/D1); 11-24 (6/D8); CEA 6.0 ng/mL, CA 19-9 294.7
U/mL</li>
<li>2021-08-04 CT - chest
<ul>
<li>A tiny nodular opacity in lateral segment of RML of the lung, less
than 3 mm in size, which was too small to be characterized.</li>
<li>A small L.N. in Lt. para-aortic retroperitoneum, showed decreased
nodal size compared with prior CT images on 2021/04/28.</li>
<li>Pneumobilia in the liver.</li>
</ul></li>
<li>2021-07-28 CXR
<ul>
<li>Opacity in right medial mid-lung.</li>
</ul></li>
<li>2021-05-12 SONO - breast
<ul>
<li>No evidence of local recurrence.</li>
</ul></li>
<li>2021-05-03 Gemzar + Nab Paclitaxel (1/D1); 05-19 (1/D8); 06-02
(1/D15); 06-16 (2/D1); 06-30 (2/D8), CEA 3.9 ng/mL, CA 19-9 307.9 U/mL;
07-14 (3/D15)</li>
<li>2021-04-28 CT - abdomen
<ul>
<li>Metastatic lymphadenopathy in paraaortic region.</li>
</ul></li>
<li>2021-02-18 TS-1 (1), 2 weeks on and 1 week off; 03-29 CEA 14.9
ng/mL, CA 19-9 4812 U/mL, 04-01 Gemzar (1/D1); 04-12 (1/D8)</li>
<li>2021-01-19 Open PD and partial hepatectomy
<ul>
<li>Pancreas, head, pancreaticoduodenectomy, ductal adenocarcinoma
(pT2N2); Liver, wedge biopsy, ductal adenocarcinoma, metastatic (x2);
Gallbladder, cholecystectomy, chronic cholecystitis with
cholesterolosis; Lymph node, regional, lymphadenectomy, adenocarcinoma,
metastatic (1/2); Lymph node, regional, ALN, lymphadenectomy,
adenocarcinoma, metastatic (4/9); CDX-2 (+), CK7 (-) and CK20 (-).</li>
<li>Pancreatic cancer with liver mets. Palliative IV chemotherapy with
Gemzar + Abraxane was suggested but she took TS-1 due to her preference
of oral chemotherapy after detailed discussion.</li>
</ul></li>
<li>2021-01-12 PES
<ul>
<li>GERD LA A</li>
</ul></li>
<li>2020-12-31 CT - chest
<ul>
<li>No active or space occupying lesion was found in the lung.</li>
<li>Increased soft tissue mass in hepatoduodenal ligament and portocaval
space of middle abdomen, associated with IHDs dilation, suspect
metastatic LAPs.</li>
</ul></li>
<li>2020-12-07 MRI - brain
<ul>
<li>old infarction.</li>
<li>no definite brain mets.</li>
</ul></li>
<li>2020-11-23 Mamography
<ul>
<li>Category 0 (according to ACR BI-RADS categories for mammographic
lesions): (a) From chart record: Received left breast intraductal
papilloma (IDP) excision on 2018-11-30, pathology revealed: intraductal
papilloma with ductal carcinoma in-situ (pTis). (b) Post operative
changes ofleft breast. (c) Benign calcification in left breast UOQ
(upper outer quadrant). (d) Recommend sonography as
complementation.</li>
</ul></li>
<li>2020-11-23 CT - abdominal
<ul>
<li>Slight more dilated biliary tree than before. Otherwise, stationary
status.</li>
</ul></li>
<li>2020-08-27 Chest/Abdomen CT
<ul>
<li>Post distal gastrectomy for gastric cancer as told.</li>
<li>No apparent radiological sign of local recurrence or distant
metastasis noted from present imaging scope.</li>
<li>Known post excision for left breast malignancy. Favor no apparent
recurrence.</li>
<li>Mild scars in LUL (left upper lung) lingular lobe.</li>
</ul></li>
<li>2020-03-10 PES at Yuli hospital
<ul>
<li>BII, GERD.</li>
</ul></li>
<li>2018-11-30 Patho
<ul>
<li>Breast, left, ductography and excision, intraductal papilloma with
ductal carcinoma in-situ (pTis).</li>
<li>ER (+++,98%), PR (+++,90%), Her-2/neu (0, negative), ki67 (+, 3%),
p63 (reduced myoepithelial cells) and CK5/6 (loss of expression in
DCIS)</li>
</ul></li>
<li>2018-11-30? SONO - breast
<ul>
<li>Scar at the LT breast. Several uneven size breast cysts, cystic
lesions and fibroadenomas noted in both breasts, favor benign findings.
No nipples retraction, bil. No abnormal lymphadenopathy in bilateral
axillary regions.</li>
<li>Chest X-ray: Mild emphysematous lungs but apparent active lung
lesion.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-24 Orthopedics
<ul>
<li>Q
<ul>
<li>left hip painful disability</li>
<li>no HI, no ILOC</li>
<li>NKDA</li>
<li>PH: gastric (stage III) and pancreatic cancer (stage IV) f/u at
HuaLien TzuChi Hospital s/p OP and C/T</li>
<li>OP hx: cervical and lumbar spondylosis s/p OP with left side
weakness and paresthesia</li>
</ul></li>
<li>A
<ul>
<li>68 y/o female
<ul>
<li>past history:
<ul>
<li>gastric (stage III) and pancreatic cancer (stage IV) f/u at HuaLien
TzuChi Hospital s/p operation (2018 and 2019) and chemotherapy</li>
<li>cervical spondylosis S/P anterior instrumentation of C3</li>
<li>Severe spinal stenosis at C5/6 level, caused by posterior central
disc protusion. Compression of cervical cord.</li>
<li>Severe narrowing of left C5/6 and C6/7 neural foramina, caused by
protusion disc. Compressin of left C6 and C7 nerve roots. =＞ Left upper
and lower limb muscle weakness</li>
<li>Lumbar spondylosis s/p instrumentation of L4/L5</li>
</ul></li>
<li>Allergy: NKDA</li>
<li>No current anti-platelet/anti-coagulation medication usage</li>
<li>NPO: since 0900</li>
<li>Subjective fall down at home last night, left hip painful swelling
and deformity
<ul>
<li>NO ILOC, no head/chest/abdomen trauma</li>
</ul></li>
<li>PE:
<ul>
<li>Inspection: Left hip flexion deformity</li>
</ul></li>
<li>Palpation: Left hip tenderness, aggravated when motion</li>
<li>Motion: difficult on LEFT hip motion</li>
<li>Distal sensation: intact</li>
<li>Circulation: Capillary refill time &lt;2sec, dorsalis pedis
pulse(+)</li>
<li>X-ray:
<ul>
<li>Left femoral intertrochanteric fracture, with posteromedial
involvement to lesser trochanter</li>
</ul></li>
</ul></li>
<li>Plan:
<ul>
<li>Arrange 2D cardiac echo for preoperative evaluation</li>
<li>Blood transfusion if Hb &lt;10 mg/dL</li>
<li>Pain control</li>
<li>High mortality risks of hip fracture (50% if non-operation in one
year; 20% if operation in one-year) had detail explained to family and
patient</li>
<li>Arrange ORIF with Gamma nail today</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>SOP
<ul>
<li>2022-09-28 Hemato-Oncology
<ul>
<li>Impression:
<ul>
<li>Pancreatic cancer, adenocarcinoma, pT2N2M1, stage IV with liver
mets</li>
<li>Gastric cancer, adenocarcinoma, pT2N3aM0, stage IIIa</li>
<li>Breast cancer, Tis, stage 0</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Explain to patient about the chemotherapy (Regimen: Abraxane +
Gemzar) for her pancreatic caner - benefit / side effects were informed.
Questions were all answered. She agreed with the chemotherapy. Breast
surgeon suggest hormone therapy (AI) + radiation for her breast cancer
in situ. Keep AI.</li>
<li>Educate patient about the side effects of chemotherapy, return to
clinic or ER if any discomfort.</li>
<li>Symptomatic treatment. Add H2 blocker for epigastric pain and
educate self care.</li>
</ul></li>
<li>Keep current chemotherapy and suggest patient keep weekly
chemotherapy first for better efficacy. Change to 2nd line chemotherapy
with Onivyde + 5-Fu/LV. Might need use TS-1 or UFUR to replace CI 5-Fu
(due to port-A on right thigh and relative need help in daily activity
due to chronic leg problem).</li>
<li>Explain to patient about her CT - stable disease. Keep TS-1 as
maintenance and also for her recent leg fracture. Consider change to
Cisplatin + 5-Fu if disease progression.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy 2022-10-06 ~ undergoing - TS-1</li>
</ul>
<p>[assessment]</p>
<ul>
<li>Following the administration of 10 units of human insulin, the blood
sugar level decreased from 404mg/dL to 155mg/dL.</li>
<li>Since the blood sugar level has returned to relative normal, current
‘insulin 10 units QD’ might be switched to PRN in order to prevent
hypoglycemia.</li>
<li>To determine the pattern of blood sugar levels, please continue to
monitor them.</li>
</ul>
</div>
</div>
<div id="section-234" class="section level1">
<h1>700972259</h1>
<div id="section-235" class="section level2">
<h2>221006</h2>
<p>{HCC with lung &amp; bone metastasis, suspected a large tumor at L5
vertebral body, R paravertebral / R perivertebral spaces}</p>
<ul>
<li>past history
<ul>
<li>Mitral valve prolapse,</li>
<li>Hepatitis B carrier,</li>
<li>Gastric ulcer,</li>
<li>chronic rhinitis s/p radiofrequency turbinoplasty on 20081202,</li>
<li>Duodenal ulcer induce peritonitis with pneumoperitonium post
Laparoscopic simple closure on 20090830,</li>
<li>HBV related liver cirrhosis, child A</li>
<li>Hepatocellular carcinomas, bilateral, cT3N0M0 stage IIIa, Barcelona
Clinc Liver Cancer stage B diagnosis on 20200107
<ul>
<li>1st TACE on 20200107 and 2nd TACE 20200206.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>AFP
<ul>
<li>2022-03-18 16.9 ng/mL</li>
<li>2022-03-07 12.2 ng/mL</li>
<li>2022-01-05 11.0 ng/mL</li>
<li>2021-11-23 24.6 ng/mL</li>
<li>2021-09-06 32.5 ng/mL</li>
<li>2021-06-22 49.7 ng/mL</li>
<li>2021-02-16 6.3 ng/mL</li>
<li>2020-12-29 3.2 ng/mL</li>
<li>2020-10-27 3.6 ng/mL</li>
<li>2020-10-27 3.9 ng/mL</li>
<li>2020-08-18 7.1 ng/mL</li>
<li>2020-04-20 3.2 ng/mL</li>
<li>2020-03-05 3.6 ng/mL</li>
<li>2020-02-05 2.7 ng/mL</li>
<li>2019-12-09 2.8 ng/mL</li>
<li>2019-09-16 3.0 ng/mL</li>
<li>2019-01-09 3.0 ng/mL</li>
<li>2018-05-28 12.7 ng/mL</li>
<li>2018-03-03 1.3 ng/mL</li>
<li>2017-12-04 2.1 ng/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-26 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-09-12 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Esophageal varices, F1Cb, Li-m, RCS(-), nipple sign(-)</li>
<li>Portal hypertensive gastropathy</li>
<li>Congestive duodenitis</li>
<li>Duodenal scars with bulb deformity</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue CLO test</li>
<li>OPD follow-up</li>
</ul></li>
</ul></li>
<li>2022-09-01 CT - abdomen
<ul>
<li>Bil. diffuse HCCs s/p TACE with viable tumors.</li>
<li>No evidence of tumor rupture.</li>
<li>Partial thrombosis of left portal vein.</li>
<li>Lung and bony metastases.</li>
</ul></li>
<li>2022-06-30 CT - abdomen
<ul>
<li>Bil. diffuse HCCs s/p TACE with viable tumors.</li>
<li>Partial thrombosis of left portal vein.</li>
<li>Lung and bony metastases.</li>
</ul></li>
<li>2022-06-30 Knee RT
<ul>
<li>There is no identifiable osteoblastic or osteolytic bony lesion
recognized in the current radiography.</li>
</ul></li>
<li>2022-06-30 Femur RT
<ul>
<li>There is no identifiable osteoblastic or osteolytic bony lesion
recognized in the current radiography.</li>
</ul></li>
<li>2022-06-16 MRI - pelvis
<ul>
<li>Findings
<ul>
<li>Mass lesions in L5 vertebral body, right sacral ala, right iliac
tuberosity, and right acetabulum. Enhancement after contrast
administration.</li>
<li>Post-OP change at L4-S1. Right neuroforaminal narrowing and lateral
recess effacement at L5-S1.</li>
<li>Multiple mass lesion in both hepatic lobes.</li>
</ul></li>
<li>Impression
<ul>
<li>c/w HCCs with bone metastasis, involving L5, sacrum, and right
pelvis</li>
</ul></li>
</ul></li>
<li>2022-03-08 CT - abdomen, pelvis
<ul>
<li>With and without contrast enhancement CT of abdomen – whole:
<ul>
<li>There are diffuse enhancing tumors in both lobes of liver, s/p TACE
with multiple viable tumors.</li>
<li>Unremarkable change of the spleen, pancreas and both kidneys.</li>
<li>No enlarged lymph node in the paraaortic region.</li>
<li>No ascites.</li>
<li>Post-op at L4-5 spine.</li>
<li>There is destructive bone lesion in right pelvis, paraspinal region,
L4/5 level, could be due to metastasis, progression.</li>
<li>Diffuse lung emphysema.</li>
<li>Right lower lung nodule, suspected lung metastasis. Stationary.</li>
</ul></li>
<li>Impression:
<ul>
<li>Diffuse HCCs s/p TACE with viable tumors.</li>
<li>Bone and spine metastasis in right pelvis, post-op at L4/5 level,
progression.</li>
<li>Stationary of RLL nodule, suspected lung metastasis.</li>
</ul></li>
</ul></li>
<li>2022-01-29 MRI - L-spine
<ul>
<li>Without- and with-contrast MRI of lumbar spine, including sagittal
T2W FSE, sagittal T1W, coronal STIR, axial T2W and axial T1W images (3
mm thickness for sagittal images and 4 mm thickness for the others)
reveal:
<ul>
<li>A huge poorly enhancing tumor involving L5 vertebral body, mainly
right part, intraspinal space and paraspinal region. S/P operation, TPSs
and prosthesis, with susceptibility artifacts.</li>
<li>Progressive tumor invasion into intraspinal space and along
anterolateral aspect along right iliac wing. General bulging disc,
hypertrophic yellow ligaments and enlarged facets causing mild spinal
canal stenosis at L1-2.</li>
<li>Gr I spondylolisthesis, end-plate degeneration, disc collapse with
general bulging, hypertrophic yellow ligaments, enlarged facets and
superimposed tumor invasion causing moderate spinal canal stenosis and
bilateral moderate to severe neuroforaminal narrowing at L4-5, more
severe on right side.</li>
<li>No intramedullary lesion.</li>
</ul></li>
<li>IMP:
<ul>
<li>L5 vertebral body metastasis, progressive change as compared with
MRI on 20211222.</li>
</ul></li>
</ul></li>
<li>2022-01-12 Patho - interveterbral disc
<ul>
<li>pathologic diagnosis
<ul>
<li>L5 spinal tumor, excision + frozen section — Metastatic
hepatocellular carcinoma<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Microscopically, the section shows a picture of metastatic
adenocarcinoma characterized by tumor cells with eosinophilic cytoplasm,
bile pigment, arranged in nest or pesudoglandular pattern, hemorrhage,
focal necrosis and bone invasion.<br />
</li>
<li>Immunohistochemical stains of CK7(-), CK20(-), Hepa-1(+),
arginase(-) and TTF-1(-) for tumor.</li>
<li>According to clinical information and above histopathologic
findings, it indicated a case of metastatic hepatocellular carcinoma,
grade 2</li>
</ul></li>
</ul></li>
<li>2022-01-07 CT - lung/mediastinum/pleura
<ul>
<li>HCC at both lobes of liver with stationary size and extension.</li>
<li>Tiny nodules at both lungs. Lung mets is favored. Stable.</li>
</ul></li>
<li>2022-01-06 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the L5 spine. Bone metastasis should be
watched out. Please correlate with other imaging modalities for further
evaluation.</li>
<li>Mildly increased activity in the lower T-spines. Degenerative change
may show this picture. However, please follow up bone scanto rule out
other possibilities.</li>
<li>A hot spot in the anterior aspect of left 2nd rib. The nature is to
be determined (post-traumatic change? other nature?). Please also follow
up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, right sternoclavicular
junction and bilateral hips, compatible with benign joint lesions.</li>
</ul></li>
<li>2022-01-05 Chest PA/AP view
<ul>
<li>S/P port-A implantation.</li>
<li>Several small nodular opacity projecting at right upper lung are
suspected. Follow up is indicated. Otherwise, Please correlate with
CT.</li>
</ul></li>
<li>2021-12-22 MRI - L-spine
<ul>
<li>suspected a large tumor at the right L5 vertebral body, right
paravertebral and right perivertebral spaces.</li>
<li>herniated disc in the L4/5 disc</li>
</ul></li>
<li>2021-11-29 CT - abdomen, pelvis
<ul>
<li>Bil. diffuse HCCs s/p TACE with viable tumors. Lung and bony
metastases.</li>
</ul></li>
<li>2021-09-07 CT - abdomen, pelvis
<ul>
<li>Diffuse HCCs s/p TACE with viable tumors, progression.</li>
<li>Bone metastasis, L-S.</li>
<li>Stationary RML nodule, 0.4cm. Diffuse bilateral lung emphysema.</li>
</ul></li>
<li>2021-06-01 CT - abdomen, pelvis
<ul>
<li>Liver cirrhosis with multiple HCC at both lobes of liver, the tumor
extension is stationary.</li>
<li>Right lower lobe nodule. Stable.</li>
</ul></li>
<li>2021-04-09 KUB
<ul>
<li>Fecal material store in the colon.</li>
<li>Disk space narrowing and Marginal osteophyte formation at right
lateral aspect of L4-5 is suspected. Please correlate with L-spine
lateral view.</li>
</ul></li>
<li>2021-02-16 CT - abdomen, pelvis
<ul>
<li>LIver cirrhosis with multiple HCC s/p TACE and targeted therapy with
tumor progression.</li>
</ul></li>
<li>2021-02-09 Abdominal Ultrasonography
<ul>
<li>Cirrhosis of liver</li>
<li>Hepatic tumor, multiple, probably hepatoma</li>
</ul></li>
<li>2020-10-20 CT - abdomen, pelvis
<ul>
<li>Liver cirrhosis wiht multiple HCC at both lobes of liver, in
progression.</li>
</ul></li>
<li>2020-09-29 Abdominal Ultrasonography
<ul>
<li>Cirrhosis of liver</li>
<li>Hepatic tumor, multiple, probably TAE effect of hepatoma(S3)</li>
</ul></li>
<li>2020-08-13 CT - abdomen, pelvis
<ul>
<li>Bil. HCCs s/p TACE with viable tumors (up to 2.0cm, increaed tumor
number but decreased tumor size).</li>
</ul></li>
<li>2020-04-24 Abdominal Ultrasonography
<ul>
<li>Liver cirrhosis</li>
<li>Hepatic tumors, favor HCC s/p TAE</li>
</ul></li>
<li>2020-04-23 CT - abdomen, pelvis
<ul>
<li>HCC s/p TACE</li>
<li>Tiny nodule at right middle lobe, intrafissural nodule is
considered.</li>
</ul></li>
<li>2020-03-05 CT - liver, spleen, biliary duct
<ul>
<li>Bil. HCCs s/p TACE with viable tumors (up to 2.5cm).</li>
<li>A nodule (3.7mm) in RML.</li>
</ul></li>
<li>2020-01-27 KUB
<ul>
<li>Bilateral clear psoas shadows. Unremarkable bowel gas pattern.
Radiopaque density at left upper abdomen, probably post-TAE at left
hepatic lobe. Degenerative change of the spine with marginal spur
formation.</li>
</ul></li>
<li>2020-01-14 Abdominal Ultrasonography
<ul>
<li>Cirrhosis of liver</li>
<li>Hepatic tumor, probably HCC post TAE effect</li>
<li>Pleural effusion, left</li>
</ul></li>
<li>2019-12-25 CT - liver, spleen, biliary duct
<ul>
<li>Multiple HCCs in S2-3 of the liver are highly suspected.<br />
</li>
<li>Three HCCs in S7, S4/5, and S4 are also suspected.</li>
<li>Please correlate with AFP.</li>
<li>AJCC 8th edition, CT staging of HCC: T3N0Mx</li>
</ul></li>
<li>2017-02-07 Abdominal Echo
<ul>
<li>Cirrhosis of liver</li>
<li>Calcified spot of liver</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-05 Radiological Diagnosis
<ul>
<li>Q
<ul>
<li>for TAE</li>
<li>This 69-year-old male, a pt of HBV carrier with liver cirrhosis,
hepatocellular carcinoma, bilateral with lung &amp; bone mets. He was
admitted due to right hip pain for 2 months ago and L-spine MRI showed
suspected a large tumor at the right L5 vertebral body, right
paravertebral and right perivertebral spaces.herniated disc in the L4/5
disc. We need expertise to evaluate his condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, TAE is
indicated.</li>
</ul></li>
</ul></li>
<li>2020-04-22 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This 68 year-old man had medical history with HBV carrier with liver
cirrhosis; PPU s/p simple closure ; GERD ; Hepatocellular carcinoma,
bilateral, cT3N0M0 stage IIIa, Barcelona Clinc Liver Cancer stage B,
status post 3rd Transcatheter arterial chemoembolization. Due to the 3/5
Abd CT showed Bil. HCCs s/p TACE with viable tumors (up to 2.5cm). A
nodule (3.7mm) in RML. He recevied TACE of HCCs at both hepatic lobes on
20200421. So we need you evaluation and suggestion of this patient.</li>
</ul></li>
<li>A
<ul>
<li>Objective
<ul>
<li>This 68 y/o male, a pt of HCC Dx in Dec 2019 s/p TACE x 3 on 1/7,
2/6, 4/21 20. Abd CT (3/5 20) showed Bil. HCCs s/p TACE with viable
tumors (up to 2.5cm). A nodule (3.7mm) in RML. Dz in progress seems to
be noted. AFP (4/20 20): 3.2</li>
<li>Albumin (4/20 20):4.2, Bil-T:0.54, PT:10.6, no ascites, no
encephalopathy, Child-Pugh classification: A.</li>
</ul></li>
<li>Suggestion
<ul>
<li>May do chest CT to evaluate the underlying lung mets.</li>
<li>If lung mets is confrimed, will suggest systemic therapy ( eg:
Nexavar or Lenvima ) with or w/o immunotherapy wt Nivolumab (Nivo is no
longer reimbursed by NHI since April 2020).</li>
<li>Palliative C/T offers little benefit to pt wt mets HCC &amp; rarely
recommended &amp; may be the last resort of Tx.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-11
<ul>
<li>Surgery
<ul>
<li>excision of malignant tumor lumbar 5</li>
<li>posterior spinal fusion with instrumentation</li>
<li>microscopy</li>
<li>fluoroscopy</li>
<li>CUSA</li>
</ul></li>
<li>Finding
<ul>
<li>lumbar 5 spinal metastatic lesion from malignant tumor of liver</li>
<li>after excision of the metastatic lumbar bone invasion, mesh and
autograft bone from adjacent spinal process for posterior spinal bone
fusion.</li>
<li>posterior spinal instrumentation was done by L4 and S1 bilateral
pedicle screws and rods.</li>
</ul></li>
</ul></li>
<li>2022-01-10 Embolization (TAE) - extremity
<ul>
<li>TAE of RIGHT sacral tumor via right common femoral artery puncture
using Seldinger technique.</li>
<li>IMP: A hypervascular tumor at RIGHT sacral region s/p TAE.</li>
</ul></li>
<li>2020-04-21 Embolization (TAE) - abdomen
<ul>
<li>TACE of bil. HCCs via right common femoral artery puncture using
Seldinger technique</li>
<li>IMP: HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2020-02-06 Embolization (TAE) - abdomen
<ul>
<li>TACE of bil. HCCs via right common femoral artery puncture using
Seldinger technique<br />
</li>
<li>IMP: HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2020-01-07 Embolization (TAE) - abdomen
<ul>
<li>TACE of left HCCs via right common femoral artery puncture using
Seldinger technique</li>
<li>IMP: HCCs at left hepatic lobe s/p TACE.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-09 ~ 2022-02-24 - 3600cGy/12 fractions (6 MV photon) to
para-L5 metastasis.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-10-05 - nivolumab 40mg 1hr + oxaliplatin 85mg/m2 135mg 2hr +
leucovorin 400mg/m2 640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min
D1-2 + fluorouracil 600mg/m2 960mg 22hr D1-2</li>
<li>2022-09-13 - oxaliplatin 85mg/m2 135mg 2hr + leucovorin 400mg/m2
640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min D1-2 + fluorouracil
600mg/m2 960mg 22hr D1-2</li>
<li>2022-08-30 - oxaliplatin 85mg/m2 135mg 2hr + leucovorin 400mg/m2
640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min D1-2 + fluorouracil
600mg/m2 960mg 22hr D1-2</li>
<li>2022-08-16 - oxaliplatin 85mg/m2 135mg 2hr + leucovorin 400mg/m2
640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min D1-2 + fluorouracil
600mg/m2 960mg 22hr D1-2</li>
<li>2022-08-02 - oxaliplatin 85mg/m2 135mg 2hr + leucovorin 400mg/m2
640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min D1-2 + fluorouracil
600mg/m2 960mg 22hr D1-2</li>
<li>2022-07-18 - oxaliplatin 85mg/m2 135mg 2hr + leucovorin 400mg/m2
640mg 2hr D1-2 + fluorouracil 400mg/m2 640mg 10min D1-2 + fluorouracil
600mg/m2 960mg 22hr D1-2</li>
<li>2022-06-29 - oxaliplatin 85mg/m2 139mg 2hr + leucovorin 200mg/m2
300mg 2hr D1-2 + fluorouracil 400mg/m2 650mg 10min D1-2 + fluorouracil
600mg/m2 980mg 22hr D1-2</li>
<li>2022-06-15 - oxaliplatin 85mg/m2 138mg 2hr + leucovorin 200mg/m2
300mg 2hr D1-2 + fluorouracil 400mg/m2 650mg 10min D1-2 + fluorouracil
600mg/m2 970mg 22hr D1-2</li>
<li>2022-05-30 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
650mg 2hr D1-2 + fluorouracil 400mg/m2 650mg 10min D1-2 + fluorouracil
600mg/m2 980mg 22hr D1-2</li>
<li>2022-04-28 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
650mg 2hr D1-2 + fluorouracil 400mg/m2 650mg 10min D1-2 + fluorouracil
600mg/m2 980mg 22hr D1-2</li>
<li>2022-04-15 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
650mg 2hr D1-2 + fluorouracil 400mg/m2 600mg 10min D1-2 + fluorouracil
600mg/m2 980mg 22hr D1-2</li>
<li>2022-03-31 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
650mg 2hr D1 + fluorouracil 400mg/m2 650mg 10min D1 + fluorouracil
2800mg/m2 4600mg 46hr D1-2</li>
<li>2022-03-18 - oxaliplatin 70mg/m2 100mg 2hr + leucovorin 400mg/m2
650mg 2hr D1 + fluorouracil 400mg/m2 650mg 10min D1 + fluorouracil
2800mg/m2 4600mg 46hr D1-2</li>
<li>2021-08-26 - cisplatin 40mg/m2 67mg 2hr + fluorouracil 1000mg/m2
3380mg 46hr</li>
<li>2021-08-10 - cisplatin 40mg/m2 67mg 2hr + fluorouracil 1000mg/m2
3340mg 46hr</li>
<li>2021-07-27 - cisplatin 40mg/m2 67mg 2hr + fluorouracil 1000mg/m2
3400mg 46hr</li>
<li>2021-07-10 - cisplatin 40mg/m2 68mg 2hr + fluorouracil 1000mg/m2
3400mg 46hr</li>
<li>2021-06-15 - cisplatin 40mg/m2 67mg 2hr + fluorouracil 1000mg/m2
3390mg 46hr</li>
<li>2021-05-31 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3380mg 46hr</li>
<li>2021-05-10 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3300mg 46hr</li>
<li>2021-04-23 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3340mg 46hr</li>
<li>2021-04-09 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3360mg 46hr</li>
<li>2021-03-25 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3360mg 46hr</li>
<li>2021-03-12 - cisplatin 40mg/m2 60mg 2hr + fluorouracil 1000mg/m2
3400mg 46hr</li>
<li>2020-12-05 ~ 2021-02 - Stivarga (regorafenib) 160mg QD</li>
<li>2020-06-02 ~ 2020-11 - Nexavar (sorafenib) 400mg BIDAC</li>
</ul></li>
</ul>
<div id="section-236" class="section level3">
<h3>==========</h3>
</div>
<div id="section-237" class="section level3">
<h3>2022-06-30</h3>
<ul>
<li>A slight increase in AFP has been observed
<ul>
<li>2022-03-18 16.9 ng/mL</li>
<li>2022-03-07 12.2 ng/mL</li>
<li>2022-01-05 11.0 ng/mL</li>
</ul></li>
<li>The use of sorafenib and regorafenib was conducted from 2020-06 to
2021-02, nivolumab could also be considered optionally.</li>
</ul>
</div>
<div id="section-238" class="section level3">
<h3>2022-05-31</h3>
<ul>
<li>This patient has been diagnosed with advanced HCC with spine mets
and suspected lung mets. He underwent excision of the malignant tumour
near L5 in January 2022, and a CT scan in March 2022 revealed the
progressive destruction of bone at right pelvis.</li>
<li>Previously, he has received sorafenib (2020-06 ~ 2020-10), rorafenib
(2020-12 ~ 2021-02), cisplatin with 5-Fu (2021-08 ~ 2021-02), and now
FOLFOX4 (since 2022-03). Additionally, he had 4 TAEs on 2020-01-07,
2020-02-06, 2020-04-21, and 2022-01-10 (sacral).</li>
<li>Multikinase inhibitors and first line systemic chemotherapy have
been tried. These treatments have been shown to be some effective in
published studies. ( <a href="https://pubmed.ncbi.nlm.nih.gov/33869060/" class="uri">https://pubmed.ncbi.nlm.nih.gov/33869060/</a> ) Despite some
studies showing a relatively limited efficacy of chemotherapy. ( <a href="https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-5173-0.pdf" class="uri">https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-5173-0.pdf</a>
)</li>
<li>There are several second line treatments for advanced HCC including
cabozantinib. ( <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863772/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863772/</a> )
However, these drugs are rarely covered by national health insurance
currently for advanced HCC.</li>
<li>The lab data on 2022-05-30 showed grossly normal results. No issue
with active prescription.</li>
</ul>
</div>
<div id="section-239" class="section level3">
<h3>2022-01-06</h3>
<p>[drug interaction]</p>
<p>Combination use of H2 antagonist (Famotidine) and PPI (Rabeprazole)
might enhance gastric acid suppression, might also increase the
potential risk of Clostridioides difficile infection. Ref:</p>
<ul>
<li><a href="https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.1665" class="uri">https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.1665</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246810/pdf/ciaa545.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246810/pdf/ciaa545.pdf</a></li>
</ul>
</div>
</div>
</div>
<div id="section-240" class="section level1">
<h1>700336877</h1>
<div id="section-241" class="section level2">
<h2>221005</h2>
<ul>
<li>exam findings
<ul>
<li>2022-10-03 KUB
<ul>
<li>S/P metalic autosuture at the rectum.</li>
<li>Few calcification projecting at left renal area are noted.</li>
</ul></li>
<li>2022-10-03 CXR
<ul>
<li>Patchy opacity projecting at left upper lung zone and multiple
nodular opacity projecting in both lung are noted that may be
metastases. Please correlate with CT.</li>
</ul></li>
<li>2022-09-30 SONO - nephrology
<ul>
<li>Bilateral renal stones</li>
<li>Right renal cyst</li>
</ul></li>
<li>2022-09-09 MRI - brain
<ul>
<li>Left frontal tumor with mass effect. Suspected high-grade
glioma.</li>
</ul></li>
<li>2022-09-07 CT - brain
<ul>
<li>an intra-axial tumor in the left frontal lobe. suspected GBM.</li>
<li>a large tumor in the left frontal region. Please correlate with
contrast-enhanced study or MRI.</li>
<li>12mm midline shift to the right side.</li>
</ul></li>
<li>2022-09-07 CXR
<ul>
<li>Patch density at LUL.</li>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-242" class="section level1">
<h1>700704174</h1>
<div id="section-243" class="section level2">
<h2>221005</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>past history
<ul>
<li>Type 2 diabetes mellitus was diagnosed for months.
<ul>
<li>Kludone MR 60mg 1# po BID</li>
<li>Galvus Met 1# po BID</li>
<li>Zulitor F.C 4mg 0.5# po QN</li>
</ul></li>
<li>Hepatitis B carrier, fatty liver for 10+ years under regular follow
up at NTUH
<ul>
<li>Baraclude 0.5mg 1# po QDAC</li>
</ul></li>
<li>History of operation:
<ul>
<li>Laparoscopic anterior resection and anastomosis-malignant on
2019/10/14.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>UGT1A1 showed 1:67</li>
<li>2022-06-15 P.jiroveci DNA (Bronchial washing) Undetectable</li>
<li>2022-06-13 Aspergillus Ag Negative<br />
</li>
<li>2022-06-13 Aspergillus Ag Value 0.09 Ratio<br />
</li>
<li>2022-06-09 MTBC PCR NOT DETECTED<br />
</li>
<li>2022-06-09 MTBC PCR Value &lt;131 CFU/ml<br />
</li>
<li>2022-06-06 Aspergillus Ag Negative<br />
</li>
<li>2022-06-06 Aspergillus Ag Value 0.11 Ratio<br />
</li>
<li>2022-06-06 Anti-ds DNA Antibody &lt;0.5 IU/ml<br />
</li>
<li>2022-06-06 Anti-cardiolipin-IgM 2.1 MPL U/mL<br />
</li>
<li>2022-06-06 Anti-Cardiolopin IgG 0.8 GPL-U/mL<br />
</li>
<li>2022-06-06 Anti-ENA Sm 2.0 EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA RNP 0.5 EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA(Jo-1) EliA U/ml<br />
</li>
<li>2022-06-06 Anti Jo-1 antibody &lt;0.3 EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA (Scl-70) EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA Scl-70 Ab &lt;0.6 EliA U/ml<br />
</li>
<li>2022-06-06 Anti ENA(Ro,La) EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA SS-A(Ro) 0.3 EliA U/ml<br />
</li>
<li>2022-06-06 Anti-ENA SS-B(La) &lt;0.3 EliA U/ml<br />
</li>
<li>2022-06-06 PR3 Negative IU/ml<br />
</li>
<li>2022-06-06 PR3 Value &lt;0.2 IU/ml<br />
</li>
<li>2022-06-06 MPO Negative<br />
</li>
<li>2022-06-06 MPO Value &lt;0.2 IU/ml<br />
</li>
<li>2022-06-06 ANA Negative<br />
</li>
<li>2022-06-04 Cryptococcus Ag Negative<br />
</li>
<li>2022-06-04 RF &lt;10 IU/mL<br />
</li>
<li>2022-06-03 LA1 39.5 sec<br />
</li>
<li>2022-06-03 LA2 34.0 sec<br />
</li>
<li>2022-06-03 LA1/LA2 ratio 1.0<br />
</li>
<li>HbA1c
<ul>
<li>2022-06-30 HbA1c 6.4 %<br />
</li>
<li>2022-04-07 HbA1c 6.9 %<br />
</li>
<li>2022-01-10 HbA1c 6.5 %<br />
</li>
<li>2021-11-11 HbA1c 8.2 %<br />
</li>
<li>2021-09-07 HbA1c 8.9 %<br />
</li>
<li>2021-04-12 HbA1c 7.5 %<br />
</li>
<li>2021-01-14 HbA1c 8.3 %<br />
</li>
<li>2020-10-22 HbA1c 6.6 %<br />
</li>
<li>2020-07-31 HbA1c 7.2 %<br />
</li>
<li>2020-05-07 HbA1c 8.1 %<br />
</li>
<li>2020-02-14 HbA1C 7.7 %<br />
</li>
<li>2019-10-06 HbA1C 10.7 %<br />
</li>
</ul></li>
<li>CEA
<ul>
<li>2022-06-24 CEA 7.40 ng/mL<br />
</li>
<li>2022-05-24 CEA 4.26 ng/mL<br />
</li>
<li>2022-04-15 CEA 2.44 ng/mL<br />
</li>
<li>2022-03-18 CEA 1.79 ng/mL<br />
</li>
<li>2022-02-16 CEA 2.21 ng/mL<br />
</li>
<li>2022-01-19 CEA 2.04 ng/mL<br />
</li>
<li>2021-12-22 CEA 2.49 ng/mL<br />
</li>
<li>2021-12-03 CEA 2.57 ng/mL<br />
</li>
<li>2021-11-16 CEA 3.33 ng/mL<br />
</li>
<li>2021-10-20 CEA 3.76 ng/mL<br />
</li>
<li>2021-09-28 CEA 2.28 ng/mL<br />
</li>
<li>2021-09-07 CEA 3.19 ng/mL<br />
</li>
<li>2021-07-16 CEA 2.98 ng/mL<br />
</li>
<li>2021-06-24 CEA 2.27 ng/mL<br />
</li>
<li>2021-06-02 CEA 3.22 ng/mL<br />
</li>
<li>2021-04-20 CEA 3.43 ng/mL<br />
</li>
<li>2021-03-09 CEA 8.40 ng/mL<br />
</li>
<li>2021-02-05 CEA 6.039 ng/ml<br />
</li>
<li>2020-11-06 CEA 1.313 ng/ml<br />
</li>
<li>2020-08-07 CEA 0.761 ng/ml<br />
</li>
<li>2020-04-15 CEA 1.183 ng/ml<br />
</li>
<li>2019-12-31 CEA 1.97 ng/mL<br />
</li>
<li>2019-10-04 CEA 2.38 ng/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-29 CXR
<ul>
<li>Linear and nodular infiltration over both lung are noted. please
correlate with clinical condition and CT to R/O lypmphangitic
carcinomatosis.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
</ul></li>
<li>2022-07-29 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>In comparison with the previous study on 2021/02/24, the previous
FDG avid lesion in the C7 spine is a little less evident. However, the
FDG avid lesions in the T1 spine, in some right paratracheal and
bilateral pulmonary hilar lymph nodes, in diffuse small focal areas in
bilateral lung fields and in bilateral adrenal glands are either new or
more evident. Multiple metastatic lesions should be considered
first.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Increased FDG uptake in the left aspect of mandible. Osteonecrosis
may show this picture. Please correlate with other clinical findings for
further evaluation and to rule out other possibilities.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased FDG uptake in the region about prostate. The nature is to
be determined. Please correlate with other clinical findings for further
evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased FDG uptake in the left shoulder, compatible with
arthritis.</li>
</ol></li>
</ul></li>
<li>2022-06-16 Nerve Conduction Velocity, NCV; Electromyography, EMG
<ul>
<li>Finding (Motor nerve conduction study)
<ul>
<li>Normal distal latency with reduced MNCV and normal CMAP amplitude in
the bilateral median nerves.</li>
<li>Normal distal latency with reduced MNCV and normal CMAP amplitude in
the bilateral ulnar nerves</li>
</ul></li>
<li>Conclusion
<ul>
<li>Sensorimotor demyelinating polyneuropathy with secondary axonal loss
(suspect chemotherapy superimposed with diabetes related). Please
correlate with the clinical presentations.</li>
</ul></li>
</ul></li>
<li>2022-06-09 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2022/03/10, the lesion in
the lower C-spine is slightly more evident, compatible with bone
metastasis in slight progression.</li>
<li>No prominent change is noted in other bone lesions. Suspected benign
lesions in bilateral rib cages, mandible, lower L-spine, bilateral
shoulders and knees.</li>
</ul></li>
<li>2022-06-10 Patho - lung transbronchial biopsy
<ul>
<li>Lung, LUL, bronchoscopic biopsy — metastatic adenocarcinoma,
consistent with colorectal origin</li>
<li>Sections show bronchial mucosa with neoplastic glandular cells
infiltrating in muscular layer.</li>
<li>The immunohistochemical stains reveal CK7(-), CK20(+), CDX2(+), and
TTF-1(-). The results are consistent with metastatic colorectal
adenocarcinoma.</li>
</ul></li>
<li>2022-06-08 Body fluid cytology - bronchial washing
<ul>
<li>Smears show histiocytes, benign bronchial cells and clusters of
atypical hyperchromatic cells with increased N/C ratio.</li>
<li>Malignancy is suspected.</li>
<li>Please correlate with the clinical presentation.</li>
</ul></li>
<li>2022-06-08 Patho - esophageal biopsy
<ul>
<li>EC junction, biopsy — squamous hyperplasia and moderate chronic
inflammation.</li>
</ul></li>
<li>2022-06-08 MRI - C-spine
<ul>
<li>IMP: Bony metastasis at C7 vertebral body, causing intrapsinal and
paraspinal involvement as described. Stationary or mild progression as
compared with MRI on 20220311.</li>
</ul></li>
<li>2022-06-08 Esophagogastroduodenoscopy (EGD)
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA grade A</li>
<li>Suspected Barett’s esophagus, s/p biopsy</li>
<li>Superficial gastritis, s/p CLO test</li>
<li>Duodenal ulcer scar, bulb</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue the result of pathology report and CLO test</li>
</ul></li>
</ul></li>
<li>2022-06-08 Bronchoscopy
<ul>
<li>Bronchoscopic diagnosis:
<ul>
<li><ol style="list-style-type: decimal">
<li>LUL acute bronchitis</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>No endobronchial lesion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Chronic hypertrophic rhinitis</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-07 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Post-op at the colon. Rim enhanced nodule (1.6cm) in left paracolic
region, stationary.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Suspected adrenal metastasis.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Diffuse bilateral lung interstitial infiltrates, suspected
lymphangitic carcinomatosis.</li>
</ol></li>
</ul></li>
<li>2022-05-31 CT - lung
<ul>
<li>pulmonary lypmphangitic carcinomatosis, metastatic adrenal tumors,
and metastatic Lt supraclavicular and Rt paratracheal LNs, in
progression compared with CT on 2022/03/09.</li>
</ul></li>
<li>2022-05-24 Walking 6 minutes
<ul>
<li>Conclusion
<ul>
<li>Obstructive ventilatory impairment with both large and small airway
involved,resulting dynamic hyperinflation.</li>
<li>Fluctuated O2 saturation at resting, with early and prolonged
desaturation during exercise, with SaO2 91% nadir</li>
<li>during exercise. Emphysema or DPLD with SAD was considered.</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Check and treat underlying small airway diseases</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>May try bronchodialtor targeting the small airways if
symptomatic</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Exercise training</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Breahing control wtih purse-lip breathing during exercise</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>f/u HRCT</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>f/u 6-12 months later</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-05-24 Pulmonary Function Test, PFT
<ul>
<li>Moderate obstructive ventilatory impairement, with both large and
small airway involved with partial reversibility</li>
<li>Low IC, TLC</li>
<li>No hyperinflation, no air-trapping.</li>
<li>Normal diffusion capacity</li>
<li>High airway resistance</li>
<li>Favor COPD, mainly chronic bronchitis</li>
</ul></li>
<li>2022-05-10 SONO - articular peripheral soft tissue
<ul>
<li>Impression And Suggestions:
<ul>
<li>Mild left shoulder supraspinatus tendiniti</li>
<li>Pain at terminal ranges of motion, compatible with left shoudler
adhesive capsulitis.</li>
</ul></li>
</ul></li>
<li>2022-05-09 CXR
<ul>
<li>Linear infiltration over both lung are noted. please correlate with
clinical symptom to rule out inflammatory process.</li>
</ul></li>
<li>2022-05-06 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Fatty liver, mild</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Renal cyst, left</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>pancreatic body masked by gas.</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>encourage exercise and diet adjustment.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-03-11 MRI - C-spine
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>General bulging disc with central disc protrusion, posterolateral
osteophytes and enlarged facets causing spinal canal stenosis and
bilateral neuroforaminal narrowing at C3-4-5-6, most severe at
C5-6.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Collapse of C7 vertebral body with T1- and T2-hypointensity and poor
enhancement. Similar intensity also noted in its spinous process,
indicating bony metastasis. Posterior bony displacement causing spinal
canal stenosis and cord compression also noted.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>No intramedullary abnormality.</li>
</ol></li>
</ul></li>
<li>IMP:
<ul>
<li>Bony metastasis at C7 vertebral body. Stationary as compared with
MRI on 20210726.</li>
</ul></li>
</ul></li>
<li>2022-03-10 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2021/11/24, no prominent
change is noted in the lesion in the lower C-spine, compatible with bone
metastasis in stationary status.</li>
</ul></li>
<li>2022-03-09 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Prior CT identified a rim enhancing lesion and fat component
measuring 1.9 x 1.7 cm in left paracolic gutter space is noted again,
stable in size and feature. Benign lesion is highly suspected. Follow up
is indicated.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Prior CT identified One enlarged node measuring 1.2 cm in aortocaval
space is not noted in the current CT.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Adenoma 1.3 cm and hyperplasia in left adrenal gland show
stationary.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>A renal cyst measuring 0.9 cm in left upper pole is noted.</li>
</ol></li>
</ul></li>
<li>Impression
<ul>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2021-11-24 Tc-99m MDP whole body bone scan
<ul>
<li>The lesion of increased tracer uptake in a lower C-spine comes to
less evident compared to the previous study on 2021-07-27, and no new
lesion of increased tracer uptake is noted, suggesting partial response
to current therapy.</li>
</ul></li>
<li>2021-11-23 MRI - C-spine
<ul>
<li><ol style="list-style-type: decimal">
<li>C7 metastasis, seems stationary</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Small C4/5/6 central HIVDs with combined spinal canal stenoses.</li>
</ol></li>
</ul></li>
<li>2021-11-19 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Prior CT identified a rim enhancing lesion and fat component
measuring 1.9 x 1.7 cm in left paracolic gutter space is noted again,
stable in size and feature. Benign lesion is highly suspected. Follow up
is indicated.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>One enlarged node measuring 1.2 cm in aortocaval space is
noted.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Adenoma 1.3 cm and hyperplasia in left adrenal gland show
stationary.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>A renal cyst measuring 0.9 cm in left upper pole is noted.</li>
</ol></li>
</ul></li>
<li>IMP:
<ul>
<li><ol style="list-style-type: decimal">
<li>One enlarged node 1.2 cm in aortocaval space is noted.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-08-25 SONO - abdomen
<ul>
<li>fatty liver, mild</li>
</ul></li>
<li>2021-07-28 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Prior CT identified a rim enhancing lesion and fat component
measuring 1.9 x 1.7 cm in left paracolic gutter space is noted again,
stable in size and feature. Benign lesion is highly suspected. Follow up
is indicated.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Prior CT identified several enlarged nodes in para-aortic space and
para-cava space are not noted again that may be metastatic nodes S/P C/T
show complete response.</li>
</ol></li>
</ul></li>
<li>2021-07-27 Tc-99m MDP whole body bone scan
<ul>
<li><ol style="list-style-type: decimal">
<li>Prominently increased activity in a lower C-spine. Bone metastasis
may show this picture.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mildly increased activity in the lower L-spines. Degenerative change
is more likely. Please correlate with other imaging modalities for
further evaluation.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?). Please follow up bone
scan for further evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders and knees, compatible with
benign joint lesions.</li>
</ol></li>
</ul></li>
<li>2021-07-26 MRI - C-spine
<ul>
<li>indication: Sigmoid cancer with lymph node metastasis s/p
Laparoscopic anterior resection and anastomosis-malignant on 2019/10/14,
pT3N2bM0, stage IIIC s/p adjuvant chemotherapy with tumor recurrence and
C7 spine metastasis, rcTxN0M1a, r-staging IVA</li>
<li>Bony metastasis at C7 vertebral body.</li>
</ul></li>
<li>2021-03-23 SONO - abdomen
<ul>
<li>probably fatty liver</li>
</ul></li>
<li>2021-03-17 MRI, C-spine:
<ul>
<li>bony spinal canal stenosis in the middle and lower C-spine.</li>
<li>degenerative change in the middle and lower C-spine disc spaces</li>
<li>a heterogeneous enhancing tumor at C7 vertebral body.<br />
</li>
<li>degerative change at lower C-spine facet joints.</li>
</ul></li>
<li>2021-03-09 sigmoidoscopy:
<ul>
<li>negative finding up to D-colon.</li>
<li>no evidence of local recurrence.</li>
</ul></li>
<li>2021-02-27 whole body PET scan:
<ul>
<li>a glucose hypermetabolic lesion in the rectal region, probably tumor
recurrence.<br />
</li>
<li>glucose hypermetabolic lesion at the C7 spine, probably tumor with
distant metastasis.</li>
<li>increased FDG uptake in bilateral pulmonary hilar regions and the
right shoulder, benign change is more likely.</li>
<li>s-colon cancer s/p treatment with tumor recurrence and C7 spine
metastasis, rcTxN0M1a, r-staging IVA (AJCC 8th edi.)</li>
</ul></li>
<li>2021-02-22 CT, abdomen:
<ul>
<li>tumor seeding in left paracolic gutter space is suspected. the
differential diagnosis include epiploic appendagitis or omentum
infarction.</li>
<li>metastatic nodes in para-aortic space and para-cava space are
suspected.</li>
</ul></li>
<li>2020-05-07 CT, abdomen, pelvis:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ without
interval change.</li>
<li>left adrenal nodule (1.3cm) without interval change.</li>
</ul></li>
<li>2020-05-07 sigmoidoscopy: no evidence of recurrence</li>
<li>2019-10-16 patho:
<ul>
<li>sigmoid colon, laparoscopic sigmoid colectomy - adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - positive for tumor metastasis
(8/18) with extracapsular extension (6/8)</li>
<li>AJCC pathologic stage - pT3N2bMx, stage IIIC at least B.</li>
</ul></li>
<li>2020-01-16 CT, abdomen:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ.</li>
<li>left adrenal nodule (1.3cm).</li>
</ul></li>
<li>2019-10-14 laparoscopic anterior resection and
anastomosis-malignant, finding:
<ul>
<li>sigmoid cancer 5<em>3</em>3cm near D-S junction with nearly total
obstruction</li>
<li>splenic flexure was fully mobilized</li>
</ul></li>
<li>2019-10-03 colonofiberoscopy: an ulcerative lesion with lumen
narrowing at 30 cm to 40 cm from anal verge and biopsy was done.
impression: suspicion of sigmoid colon tumor.</li>
<li>2019-10-03 CT, abdomen:
<ul>
<li>wall thickening of sigmoid colon, 4.4 cm in length, with perifocal
fat stranding.</li>
<li>sigmoid colon cancer T3N1MX.</li>
</ul></li>
<li>2019-09-20 screening for malignant neoplasm, colon: stool occult
blood test positive</li>
</ul></li>
<li>consultation
<ul>
<li>2022-10-05 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>for osteonecrosis of jaw evaluate</li>
<li>This 58-year-old man patient is a case of adenocarcinoma of sigmoid
with obstruction post laparoscopic anterior resection pT3N2bM0 stage
IIIC for twelfth FOLFOX6 adjuvant chmotherapy; ECOG: 1, and Xgavex
therapy, now, his tooth loss one, so we need your help for osteonecrosis
of jaw evaluate. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>The exam will be arranged today.</li>
</ul></li>
</ul></li>
<li>2021-09-13 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>This 57-year-old man patieitn is a case of Sigmoid cancer with LN
metas s/p Laparoscopic, pT3N2bM0, stage IIIC s/p C/T with recurrence and
boneas, rcTxN0M1a, r-staging IVA. He was admitted for chemotherapy with
Avastin(C8)/FOLFIRI(C5D1) from 2021/09/09~2021/09/11. This time, for
Type 2 diabetes mellitus with OHA control (Kludone MR 60mg 0.5# po QDAC,
Galvus Met 1# po BID, Tulip F.C 20mg 1# po QD), But, HbA1c
progression(20210412 showed 7.5%, 20210907 showed 8.9%). Now, for
evaluate Type 2 diabetes mellitus with OHA control therapy. Thank you.
    </li>
</ul></li>
<li>A
<ul>
<li>S: We were consulted for blood sugar control.</li>
<li>O
<ul>
<li>BH: 163 cm, BW: 63 Kg</li>
<li>Diet: DM diet 1800 kcal/day</li>
<li>Medication in OPD: Kludone 1# BID, GalvusMet 1# BID</li>
<li>Medication during hospitalization: same as above</li>
<li>PE: no cushingoid appearance</li>
<li>Na: 140, K: 4.0</li>
<li>AST/ALT: 13/7</li>
<li>BUN/Cr: 13/0.66 (eGFR: 132.23)</li>
<li>F/S:
<ul>
<li>Date 210909 210910</li>
<li>QDAC - 253</li>
<li>QLAC - -</li>
<li>QNAC 246</li>
<li>HS -</li>
</ul></li>
<li>Blood glucose: 238 mg/dL</li>
<li>HbA1c: 7.5 -&gt; 8.9</li>
<li>Urine ACR: 0.03</li>
<li>OPH OPD: in LMD (no record)</li>
<li>ACTH/cortisol (8am): 14.2/10.79 (2020/05)</li>
<li>PRA/aldo: 0.23/100 (2020/05)</li>
<li>Urine VMA/catecholamine: within normal range (2020/05)</li>
<li>DHEA-S: 198 (2020/05)</li>
<li>Testosterone: 343.59 (2020/05)</li>
<li>Abd. CT: (2021/07/28)
<ul>
<li><ol style="list-style-type: decimal">
<li>Adenoma 1.3 cm in left adrenal gland shows stationary.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hyperplasia of left adrenal gland is also noted.</li>
</ol></li>
</ul></li>
</ul></li>
<li>A:
<ul>
<li><ol style="list-style-type: decimal">
<li>Type 2 DM, poor control</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Left adrenal adenoma and hyperplasia</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Recurrent sigmoid CA</li>
</ol></li>
</ul></li>
<li>Suggestions:
<ul>
<li><ol style="list-style-type: decimal">
<li>Check F/S TIDAC + HS (please confirm timed quantification of each
meal)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>DC GalvusMet, Kludone</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Give Apidra 3U TIDAC and adjust with correction scales</li>
</ol>
<ul>
<li>F/S &lt; 080, Apidra hold</li>
<li>F/S 081~100, Apidra -2U</li>
<li>F/S 201~250, Apidra +1U</li>
<li>F/S 251~300, Apidra +2U</li>
<li>F/S &gt; 300, Apidra +3U</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Give Tresiba 8U HS and adjust as below</li>
</ol>
<ul>
<li>F/S QDAC &lt; 100 (for 1 day), Tresiba -2U</li>
<li>F/S QDAC &gt; 150 (for consecutive 3 days), Tresiba +2U (each
adjustment is for the day)</li>
</ul></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Adrenal incidentaloma survey is not feasible for now (steroid use on
20210909 and will be discharged on 20210912). We will arrange in OPD
later.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Adrenal gland malignancy or metastasis should be ruled out: check
DHEA-S</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Meta-OPD F/U, contact us if any problem</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-04-21 Neurology
<ul>
<li>Q
<ul>
<li>Vertigo was noted since 2021/3 post chemotherapy, we need your help
for further management, thanks a lot.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>Persistent transient vertigo episodes aggravate by lying down or
fast head movement and relieved by avoiding head movement for about 1
month. Minimal tinnitus without ear infection also present. Headache,
limb weakness or clumsiness was denied. Vertigo association with body
position change is also denied</li>
</ul></li>
<li>O
<ul>
<li>Consciouenss: clear, E4V5M6</li>
<li>Language: normal</li>
<li>Visual field: normal</li>
<li>EOM: free , no nystagmus</li>
<li>HINTs exam: intact</li>
<li>Pupil: 3.0/3.0 mm, Light reflex: +/+</li>
<li>Face: symmetrical</li>
<li>Muscle power: full</li>
<li>DTR: ++/++</li>
<li>Coordination: FNF &amp; HKS intact, no truncal titubation</li>
<li>BabinskI sign: down/down</li>
<li>Sensory: decrease pinprick distal finger and toes</li>
<li>Gait: intact</li>
</ul></li>
<li>Impression:
<ul>
<li>BPPV, suspected chemotherapy side effect</li>
</ul></li>
<li>Plan
<ul>
<li><ol style="list-style-type: decimal">
<li>Meclizine 25mg 1# BID or Diphenidol 25mg 1# tid</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>May arrange MRA brain with/without contrast to rule out brain
metastasis</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-04-20 ENT
<ul>
<li>Q
<ul>
<li>Vertigo was noted since 2021/3 post chemotherapy, we need your help
for further management, thanks a lot.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>Vertigo for 1 month.</li>
<li>Spinning(+), imbalance(-) neck soreness(-), headache(-) hearing loss
(-) tinnitus(+, mild, R, jijijiao) Recent URI(-)</li>
<li>Duration: secs</li>
<li>Aggravates: when lying down</li>
<li>Reliever : remain still</li>
<li>Association : nausea(-) vomiting(-)</li>
</ul></li>
<li>PE
<ul>
<li>Ear drum: intact</li>
<li>VFT
<ul>
<li>No spontaneous, positional, positioning nystagmus</li>
<li>finger nose finger: ok</li>
<li>Rapid alternative movement: ok</li>
<li>Romberg test: ok</li>
<li>Steping test: ok</li>
<li>Tandem gait: ok</li>
</ul></li>
<li>Dix-Hallpike test: left geotropic torsional nystagmus s/p Epley
maneuver</li>
</ul></li>
<li>Imp: L p-BPPV</li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>Educated patient about BPPV</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>ENT OPD f/u if s/s persist</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-03-16 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>Now, for Xgavex therapy, for evaluate tooth for prevention ONJ.
Thank you.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>After examining the patient’s dental condition based on panoramic
film and intraoral examination, retained root of tooth 16 and apical
lesion of tooth 37 was noted.</li>
</ul></li>
<li>O:
<ul>
<li><ol style="list-style-type: decimal">
<li>Retained root of tooth 16</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Apical periodontitis of tooth 36 with percussion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Benign looking calcification of right mandibluar angle</li>
</ol></li>
</ul></li>
<li>A:
<ul>
<li><ol style="list-style-type: decimal">
<li>Retained root of tooth 16</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Chronic apical lesion of tooth 36</li>
</ol></li>
</ul></li>
<li>P:
<ul>
<li><ol style="list-style-type: decimal">
<li>Explain the findings to the patient</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Suggest dental extraction of retained root of tooth 16 and dental
root canal treatment of tooth 36</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-03-15 Dentistry
<ul>
<li>Q
<ul>
<li>Now, for Xgavex therapy, for evaluate tooth for prevention ONJ.
Thank you.</li>
</ul></li>
<li>A
<ul>
<li>Intra-oral examination, a gum boil over lower left molar area is
noted .</li>
<li>Further root canal therapy or extraction mightbe necessary , suggest
consult the oral sergery section for sure.</li>
</ul></li>
</ul></li>
<li>2021-03-15 Neurosurgery
<ul>
<li>Q
<ul>
<li>Whole body PET scan on 2021/02/24 showed: 1. A glucose
hypermetabolic lesion in the rectal region, probably tumor recurrence.
2. Glucose hypermetabolic lesion at the C7 spine, probably tumor with
distant metastasis. Now, for evaluate C7 spine metastasis therapy. Thank
you.</li>
</ul></li>
<li>A
<ul>
<li>Suggest arrange C-spine MRI with and without enhancement for further
evaluation.</li>
<li>Radiotherapy for the suspected metastatic lesion of cervical spine
is also the treatment of option.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-25 - irinotecan 120mg/m2 180mg 90min + leucovorin 300mg/m2
450mg 2hr + fluorouracil 300mg/m2 450mg 10min + fluorouracil 2000mg/m2
3000mg 46hr</li>
<li>2022-08-02 - irinotecan 150mg/m2 200mg 90min + leucovorin 400mg/m2
600mg 2hr + fluorouracil 400mg/m2 600mg 10min + fluorouracil 2400mg/m2
3700mg 46hr</li>
<li>2022-07-11 - bevacizumab 5mg/kg 300mg + irinotecan 150mg/m2 220mg
90min + leucovorin 400mg/m2 680mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 3800mg 46hr</li>
<li>2022-06-15 - irinotecan 120mg/m2 200mg 90min + leucovorin 400mg/m2
650mg 2hr + fluorouracil 400mg/m2 650mg 10min + fluorouracil 2400mg/m2
4000mg 46hr</li>
<li>2021-11-19 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-10-26 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-10-04 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-09-09 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-08-18 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-07-23 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-06-30 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 650mg 2hr + fluorouracil 400mg/m2 650mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-06-07 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 680mg 2hr + fluorouracil 400mg/m2 680mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-05-13 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 680mg 2hr + fluorouracil 400mg/m2 680mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-04-20 - bevacizumab 5mg/kg 400mg + irinotecan 150mg/m2 250mg
90min + leucovorin 400mg/m2 680mg 2hr + fluorouracil 400mg/m2 680mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-04-02 - bevacizumab 5mg/kg 400mg + irinotecan 120mg/m2 230mg
90min + leucovorin 400mg/m2 680mg 2hr + fluorouracil 400mg/m2 680mg
10min + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-03-18 - irinotecan 120mg/m2 200mg 90min + leucovorin 400mg/m2
680mg 2hr + fluorouracil 400mg/m2 680mg 10min + fluorouracil 2400mg/m2
4000mg 46hr</li>
<li>2020-04-13 - oxaliplatin 85mg/m2 144mg 2hr + leucovorin 400mg/m2
678mg 2hr + fluorouracil 2800mg/m2 4748mg 40hr</li>
<li>2020-03-30 - oxaliplatin 85mg/m2 143mg 2hr + leucovorin 400mg/m2
675mg 2hr + fluorouracil 2800mg/m2 4737mg 40hr</li>
<li>2020-03-16 - oxaliplatin 85mg/m2 144mg 2hr + leucovorin 400mg/m2
678mg 2hr + fluorouracil 2800mg/m2 4750mg 40hr</li>
<li>2020-03-02 - oxaliplatin 85mg/m2 143mg 2hr + leucovorin 400mg/m2
673mg 2hr + fluorouracil 2800mg/m2 4700mg 40hr</li>
<li>2020-02-17 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
669mg 2hr + fluorouracil 2800mg/m2 4684mg 40hr</li>
<li>2020-02-03 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
680mg 2hr + fluorouracil 2800mg/m2 4750mg 40hr</li>
<li>2020-01-15 - oxaliplatin 85mg/m2 140mg 2hr + leucovorin 400mg/m2
669mg 2hr + fluorouracil 2800mg/m2 4600mg 40hr</li>
<li>2021-04-02 ~ undergoing - Xgeva (denosumab) 120mg SC
(self-paid)</li>
<li>2021-12-02 ~ 2022-06-13 - Xeloda (capecitabine) 500mg BID</li>
<li>2021-03-18 ~ 2021-11-19 - FOLFIRI, + avastin (bevacizumab) since
2021-04-02</li>
<li>2019-11-04 ~ 2020-04-13 - FOLFOX (7 times)</li>
</ul></li>
</ul>
<div id="section-244" class="section level3">
<h3>==========</h3>
<p>[not posted?]</p>
<ul>
<li>no IHC stains (MSI, MMR) from patho report, no
KRAS/NRAS/BRAF/HER2/NTRK found.</li>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior
resection.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in
Feb~Mar 2021 showed spine metastasis. the startup FOLFOX might not work
anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the
former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for
evaluating osteonecrosis of the jaw, ONJ.</li>
</ul></li>
<li>patients with the UGT1A1 7/7 genotype may be at increased risk for
developing GI toxicity and myelosuppression. dose reduction should be
considered in this setting.</li>
<li>the treatments are followed the NCCN guidelines, no issue
found.</li>
</ul>
</div>
<div id="section-245" class="section level3">
<h3>2022-10-05</h3>
<ul>
<li>The patient has been experiencing coughing with sticky sputum and
shortness of breath over the past week. He is currently being treated
with imipenem-cilastatin. A CXR performed on 2022-09-29 revealed
infiltration of both lungs and blunted costal-phrenic angles. The
results of previous PET and CT images suggested the presence of
pulmonary lymphomatic carcinomatosis.</li>
<li>Blood sugar levels during this hospital stay remained acceptable,
however HbA1c slightly increased during the last quarter (2022-09-22
7.0% &lt;- 2022-06-30 6.4%).</li>
<li>There has been a loss of more than 15 kilograms in the last five
months (2022-10-04 49.7kgw &lt;- 2022-05-06 66kgw; 2022-10-05 albumin
2.9g/dL). An increase in intake should be beneficial for this
patient.</li>
</ul>
</div>
<div id="section-246" class="section level3">
<h3>2022-08-04</h3>
<ul>
<li><p>2022-07-29 Whole body PET scan showed the FDG avid lesions in the
T1 spine, in some right paratracheal and bilateral pulmonary hilar lymph
nodes, in diffuse small focal areas in bilateral lung fields and in
bilateral adrenal glands are either new or more evident.</p></li>
<li><p>In recent months, CEA lab data showed an increasing trend</p>
<ul>
<li>2022-07-21 CEA 8.47 ng/mL<br />
</li>
<li>2022-06-24 CEA 7.40 ng/mL<br />
</li>
<li>2022-05-24 CEA 4.26 ng/mL<br />
</li>
<li>2022-04-15 CEA 2.44 ng/mL<br />
</li>
<li>2022-03-18 CEA 1.79 ng/mL</li>
</ul></li>
<li><p>F/S blood sugar level were 200 +- 20 mg/dL, body weight loss:
57kg &lt;- 66kg (2022-06), empagliflozin 25mg QDPC or canagliflozin
100mg QDAC might be an optional add-on.</p></li>
</ul>
</div>
<div id="section-247" class="section level3">
<h3>2022-07-12</h3>
<ul>
<li>HbA1c trend shows that blood sugar level control is improving.
<ul>
<li>2022-06-30 6.4 %<br />
</li>
<li>2022-01-10 6.5 %<br />
</li>
<li>2021-11-11 8.2 %<br />
</li>
<li>2021-09-07 8.9 %<br />
</li>
<li>2019-10-06 10.7 %<br />
</li>
</ul></li>
<li>TPR, BP, SpO2 were stable except for asymptomatic slight tachycardia
(114 pulse/min).</li>
<li>No issue with active prescription.</li>
</ul>
<p>[visiting the patient]</p>
<ul>
<li>I visited the patient at approximately 13:25 2022-07-12.</li>
<li>The patient stated:
<ul>
<li><ol style="list-style-type: decimal">
<li>Despite various visits to the orthopaedic and rehabilitation OPD,
the pain in the left shoulder and arm has not improved. (morphine
mitigates the pain)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>It is difficult for him to sleep well at night because he feels hot.
With earlier chemotherapy, this is not the case.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>During chemotherapy, he still feels nauseated, but after returning
home, the nausea has improved and is tolerable.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>He has nonproductive coughs, and sometimes feels “stagnant” when
breathing, and he cannot speak too fast or too long.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>He feels that his physical strength is not as good as before, so he
does not want to exercise or even walk as he once did.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>When morphine was used at night, the pain became less severe and the
sleep became more restful. He asked if it would be possible overdose or
become addicted to morphine by taking it.</li>
</ol></li>
</ul></li>
<li>I explained to the patient:
<ul>
<li><ol style="list-style-type: decimal">
<li>Morphine is not likely to cause overdose or addiction based on the
current dosage and usage.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>I encourged the patient to maintain a regular exercise regimen in
order to keep muscle strength.</li>
</ol></li>
</ul></li>
<li>No other medication-related questions raised by the patient.</li>
<li>It appeared that his lung function was gradually deteriorating.
Regular follow-up might be necessary.</li>
</ul>
</div>
<div id="section-248" class="section level3">
<h3>2021-07-26</h3>
<p>[colon cancer]</p>
<ul>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior
resection on 2019-10-14 inhibited the tumor for 1+ year.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in
Feb~Mar 2021 showed spine metastasis, meaning the startup FOLFOX might
not work anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the
former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for
evaluating osteonecrosis of the jaw, ONJ.</li>
<li>the slight elevated CEA and CA199 in 2021 July probably hinted a
decreasing response to the current treatment.</li>
</ul></li>
<li>MMR proficient, pembrolizumab or novolumab might not be
indicated.</li>
<li>EGFR(+), cetuximab or panitumumab might be indicated.</li>
<li>BRAF V600E lab data not found, vemurafenib, dabrafenib, encorafenib
might not be indicated.</li>
<li>regorafenib might be indicated for the next-line treatment (after
having 5-FU, OX, IRI based chemo regimen and anti-VEGF agent while KRAS
wild type, under the scope of benefits of NHI).</li>
</ul>
<p>[type 2 DM]</p>
<ul>
<li>lab data showed serum glucose (AC) ranging 142~191mg/dL, HbA1c
6.6~8.3% since May 2020.</li>
<li>prescribed anti-DM agents such as metformin, gliclazide,
vildagliptin were listed in PharmaCloud, could be set as ‘self-carried’
items if needed.</li>
</ul>
<p>[dyslipidemia]</p>
<ul>
<li>triglyceride, cholesterol total lab data were within normal range
these months, no special issue found.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>no IHC stains (MSI, MMR) from patho report, no
KRAS/NRAS/BRAF/HER2/NTRK found.</li>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior
resection.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in
Feb~Mar 2021 showed spine metastasis. the startup FOLFOX might not work
anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the
former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for
evaluating osteonecrosis of the jaw, ONJ.</li>
</ul></li>
<li>the treatments are followed the NCCN guidelines, no issue
found.</li>
</ul>
</div>
<div id="section-249" class="section level3">
<h3>2021-03-15</h3>
<p>[felt fatigue in prior chemo]</p>
<ul>
<li><p>visiting the patient at 09:47 on 2021-03-15, he is wide awake,
this patient has not been administrated chemo regimen yet since this
admission, in prior to the chemo course, consultations for C7 spinal
segment and ONJ are arranged (based on his PET scan outcome).</p></li>
<li><p>he says he felt fatigue after chemo been started 2-3 days in the
prior course.</p></li>
<li><p>HbA1c 8.3% and serum glucose (AC) 191mg/dL reported on
2021-01-14, no newer data available, could be followed up if
necessary.</p></li>
</ul>
</div>
</div>
</div>
<div id="section-250" class="section level1">
<h1>700856538</h1>
<div id="section-251" class="section level2">
<h2>221005</h2>
<ul>
<li>lab data
<ul>
<li>2022-03-18 EGFR基因突變檢測<br />
</li>
<li>2022-03-18 EGFR specimen number S2022-3327<br />
</li>
<li>2022-03-18 EGFR G719X not detected<br />
</li>
<li>2022-03-18 EGFR Exon19 del detected<br />
</li>
<li>2022-03-18 EGFR S768I not detected<br />
</li>
<li>2022-03-18 EGFR T790M not detected<br />
</li>
<li>2022-03-18 EGFR Exon20 ins not detected<br />
</li>
<li>2022-03-18 EGFR L858R not detected<br />
</li>
<li>2022-03-18 EGFR L861Q not detected<br />
</li>
<li>2022-03-16 PD-L1 (22C3) specimen number S2022-3327<br />
</li>
<li>2022-03-16 PD-L1 (22C3) TPS &lt; 1%<br />
</li>
<li>2022-03-14 Anti-HCV Nonreactive<br />
</li>
<li>2022-03-14 Anti-HCV Value 0.05 S/CO<br />
</li>
<li>2022-03-14 HBsAg Nonreactive<br />
</li>
<li>2022-03-14 HBsAg (Value) 0.34 S/CO<br />
</li>
<li>2022-03-14 Anti-HBs 23.31 mIU/mL<br />
</li>
<li>2022-03-14 P.jiroveci DNA (Quality) Positive<br />
</li>
<li>2022-03-09 Aspergillus Ag Value 0.15 Ratio</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-28 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2022/07/07, the lesion in
the lower T-spine is a little less evident, indicating response to
current therapy or benign lesion in resolution.</li>
<li>Suspected benign lesions in the skull, bilateral rib cages,
L5-sacrum junction, bilateral shoulders, hips, knees, and right
foot.</li>
</ul></li>
<li>2022-09-27 CT - chest
<ul>
<li>Dx: Right middle lobe Lung cancer, adenocarcinoma, T4N1M1c with
brain, bone metastasis, ECOG 1,</li>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>s/p RML lobectomy with surgical staple line over anterior lung
region, along anterior major fissure.</li>
<li>a 6mm nodule in LUL and a 3mm nodule in RUL.</li>
</ul></li>
<li>Mediastinum and hila: no enlarged LN or mass.</li>
<li>Vessels:
<ul>
<li>Aorta: normal appearance of thoracic aorta and central pulmonary
arteries.</li>
<li>Heart: normal in size of cardiac chambers.</li>
</ul></li>
<li>Pleura: a small loculated effusion along anterior Rt major
fissure</li>
<li>Chest wall and visible lower neck: unremarkable.</li>
<li>Visible abdominal contents:
<ul>
<li>normal appearance of gallbladder. no focal lesion in visible portion
of the liver, spleen, both adrenal glands, pancreas, and kidney. no
enlarged lymph node.</li>
</ul></li>
<li>Visualized bones: no destructive lytic or blastic change even at T9
spinal process depicted on 2022/03/09 MRI exam.
<ul>
<li>nonenhanced axial brain CT shows: no space taking in the brain.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>post op change in Rt lung. LUL 6mm nodule and RUL 3mm nodule.</li>
</ul></li>
</ul></li>
<li>2022-09-26 CXR
<ul>
<li>increased density over of Rt hilar shadow s/p RML lobectomy with
surgical staple line over perihilar lung region</li>
<li>Rt phrenic peak</li>
</ul></li>
<li>2022-07-07 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2022/03/03, the lesion in
the lower T-spine is a little more evident.</li>
<li>Bone metastasis should be watched out. Please correlate with other
imaging modalities for further evaluation.</li>
</ul></li>
<li>2022-07-06 MRI - brain
<ul>
<li>no evidence of brain metastasis.</li>
</ul></li>
<li>2022-07-05 CT - chest
<ul>
<li>post op change in Rt lung. no abnormal new nodule or mass in both
lungs.</li>
</ul></li>
<li>2022-03-09 MRI - T-spine
<ul>
<li>Bony metasatsis at spinous process of T9 vertebral body. (due to a
lung cancer in RLL?)</li>
</ul></li>
<li>2022-03-08 Patho - lung total/lebe/segmental
<ul>
<li>Pathologic Diagnosis:
<ul>
<li>Lung, right, middle lobe, lobectomy —- Adenocarcinoma, poorly
differentiated</li>
<li>Lung, right, upper lobe, wedge resection —- Adenocarcinoma, by
direct invasion</li>
<li>Lymph node, group No.2+4, lymphadenectomy —- Negative for malignancy
(0/2)</li>
<li>Lymph node, group No.7, lymphadenectomy —- Negative for malignancy
(0/1)</li>
<li>Lymph node, group No.9, lymphadenectomy —- Negative for malignancy
(0/1)</li>
<li>AJCC 8th edition pTNM Pathology stage: pStage IVA, pT3N0M1a</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality:Separate tumor nodules of same histopathologic type
(intrapulmonary metastases) in same lobe<br />
</li>
<li>Histologic Type (select all that apply): Invasive adenocarcinoma,
solid predominant (60 %);
<ul>
<li>The immunohistochemical stains reveal TTF-1(+), CDX2(focal weak +),
CD56(focal +), and p40(-).</li>
<li>Other subtypes present (specify subtype(s), may also include
percentages): acinar: 30%; micropapillary: 10%.<br />
</li>
</ul></li>
<li>Histologic Grade: G3: Poorly differentiated</li>
<li>Spread Through Air Spaces (STAS): Not identified</li>
<li>Visceral Pleura Invasion: Present (PL2)</li>
<li>Lymphovascular Invasion (select all that apply): Present, Lymphatic
and Venous</li>
<li>Direct Invasion of Adjacent Structures (select all that apply): No
adjacent structures present</li>
<li>Margins (select all that apply): All margins are uninvolved by
carcinoma
<ul>
<li>Distance of invasive carcinoma from closest margin (centimeters):
0.2 cm</li>
<li>Specify closest margin:
<ul>
<li>RML: bronchial resection margin</li>
<li>RUL: wedge resection margin: 0.3 cm<br />
</li>
</ul></li>
</ul></li>
<li>Treatment Effect: No known presurgical therapy</li>
<li>Regional Lymph Nodes: group 2+4: 0/2; group 7: 0/1; group 9:
0/1</li>
<li>Extranodal Extension: Not identified</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply): absent
<ul>
<li>Primary Tumor (pT): pT3: separate tumor nodule(s) in the same lobe
as the primary</li>
<li>Regional Lymph Nodes (pN): pN0: No regional lymph node
metastasis</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case): pM1a: Separate tumor nodule(s) in contralateral lobe;
tumor with pleural or pericardial nodules or malignant pleural (or
pericardial) effusion</li>
</ul></li>
</ul></li>
<li>Additional Pathologic Findings (select all that apply): None
identified</li>
</ul></li>
</ul></li>
<li>2022-03-04 MRI - brain
<ul>
<li>Brain metastases, right frontal periventricular white matter and
right frontal cortex.</li>
</ul></li>
<li>2022-03-04 Cardiopulmonary Exercise Testing
<ul>
<li>Conclusion
<ul>
<li>submaximal exercise</li>
<li>low exercise capacity (VO2 52%, WR 77%)</li>
<li>low stroke volume response during exercise</li>
<li>slow HR response</li>
<li>small airway disease (FVC 86%, FEV1 77%, MMEF 53%)</li>
<li>normal respiratory muscle strength (MIP 84%, MEP 96%)</li>
</ul></li>
<li>Suggestion:
<ul>
<li>treat underlying condition</li>
<li>survey and treat cardiac function</li>
<li>small airway disease, give bronchodilator</li>
<li>arrange pulmonary rehab with exercise training</li>
</ul></li>
</ul></li>
<li>2022-03-03 Tc-99m MDP whole body bone scan
<ul>
<li>Prominently increased activity in the lower T-spine. The nature is
to be determined. Please correlate with other imaging modalities for
further evaluation and to rule out the possibility of bone
metastasis.</li>
<li>Mildly increased activity in the L5-sacrum junction. Degenerative
change may show this picture.</li>
<li>Some faint hot spots in the skull and bilateral rib cages
(post-traumatic change? other nature?). Please follow up bone scan for
further evaluation.</li>
<li>Increased activity in bilateral shoulders, hips and knees,
compatible with benign joint lesions.</li>
</ul></li>
<li>2022-03-02 Patho - lung transbronchial biopsy
<ul>
<li>Lung, RML, CT-guide biopsy — adenocarcinoma, poorly
differentiated</li>
<li>Sections show solid nests and acinar glandular cells infiltrating in
a fibrotic stroma with focal tumor necrosis.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), TTF-1(+),
CDX2(focal +), p40(-), and CD56(focal +). The results are supportive for
the diagnosis.</li>
</ul></li>
<li>2022-03-02 CXR
<ul>
<li>A well defined mass (36 mm) over RML, favor a malignant tumor</li>
<li>Rt apicolateral pneumothorax s/p transthoracic needle biopsy of RML
nodule.</li>
</ul></li>
<li>2022-02-07 CT - abdomen, pelvis
<ul>
<li>History and indication:
<ul>
<li>A case of rectal carcinoid (NET) s/p TAMIS local excision</li>
</ul></li>
<li>Findings
<ul>
<li>A pathcy density (4.5cm) at RML with pericardial invasion. Some
nodules at bil. lungs.</li>
<li>S/P rectal operation.</li>
<li>Right renal angiomyolipoma (3.0cm).</li>
<li>Left adrenal nodule (7mm).</li>
<li>Right liver cyst (4mm).</li>
<li>Metastases in spine.</li>
<li>Normal appearance of spleen, pancreas.</li>
<li>Normal appearance of gallbladder.</li>
<li>Patency of portal vein.</li>
<li>No ascites, nor enlarged lymph node.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
</ul></li>
<li>Imaging Report Form for Lung Carcinoma
<ul>
<li>Impression (Imaging stage): T: T3 (T_value) N: N0(N_value) M: M1c
(M_value) STAGE: IVB (Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-02-07 Sigmoidoscopy
<ul>
<li>Diagnosis
<ul>
<li>Post OP scar, rectum</li>
<li>Mixed hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-01-04 CT - abdomen
<ul>
<li>S/P rectal operation.</li>
<li>Right renal angiomyolipoma (3.0cm).</li>
<li>Left adrenal nodule (7mm).</li>
<li>A nodule (23mm) at RML.</li>
</ul></li>
<li>2019-11-04 CT - abdomen
<ul>
<li>S/P rectal operation.</li>
<li>Right renal angiomyolipoma (3.0cm).</li>
<li>Left adrenal nodule (7mm).</li>
<li>A small nodule (3mm) at RLL.</li>
</ul></li>
<li>2019-10-28 Sigmoidfiberscopy
<ul>
<li>Normal mucosal appearance without focal lesion from rectum to near
splenic flexure colon (60cm AAV).</li>
<li>Previous surgical scar at middle rectum was seen and is fine.</li>
</ul></li>
<li>2019-07-05 Surgical pathology level V
<ul>
<li>Rectum, transanal minimally invasive surgery with local excision —
Neuroendocrine tumor, G1 (carcinoid)</li>
<li>Pathologic Stage: pT1bNx(cMx); Stage I if N0 and cM0</li>
<li>The sections show following features:
<ul>
<li>Histologic type and grade: Neuroendocrine tumor, G1
(carcinoid)<br />
</li>
<li>Mitotic rate: &lt;2 mitosis/10 high power fields<br />
</li>
<li>Ki-67 labeling index: &lt;3%<br />
</li>
<li>Tumor extension: Tumor invades the submucosa<br />
</li>
<li>Margins: All margins are uninvolved by tumor
<ul>
<li>Distance of tumor from closest margin: 2 mm<br />
</li>
</ul></li>
<li>Lymphvascular invasion: Not identified<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>IHC: Synaptophysin(+), chromogranin A(-), Ki-67= 1%<br />
</li>
</ul></li>
</ul></li>
<li>2019-06-24 CT - abdomen
<ul>
<li>A hepatic cyst 5 mm in S8 is suspected. Please correlate with
sonography.</li>
<li>An angiomyolipoma 3.2 x 2.5 cm in right kidney lower pole.</li>
<li>Submucosal lesion 1 cm in the rectum is suspected.</li>
</ul></li>
<li>2019-06-24 Sigmoidfiberscopy
<ul>
<li>Indication: SMT at rectum was noted</li>
<li>Findings: The scope was advanced to 30cm AAV. A hard submucosal
tumor, 1.5cm in size is locted at low rectum (8cm AAV, right lateral
site).</li>
<li>Diagnosis: A hard submucosal tumor, 1.5cm in size is locted at low
rectum (8cm AAV, right lateral site).</li>
<li>Suggestion: TAMIS local excision</li>
</ul></li>
<li>2019-06-03 Miniprobe Endoscopic Ultrasound
<ul>
<li>Pre-EUS diagnosis
<ul>
<li>Rectal SMT 　　- Endoscopic Findings</li>
<li>A hemispherical lesion with intact mucosa at middle rectal, at the
level of 10 cm AAV. 　　- EUS Findings EUS using miniprobe 2R showed a
slightly hyperechoic tumor arising from deep mucosa or submucosa, sized
11.2 mm. The consistency of the tumor was elastic firm, and there was no
pillow sign. 　　- Diagnosis</li>
<li>Rectal submucosal tumor, nature indeterminate 　　- Comment</li>
<li>Recommend ESD or transanal surgery for en-blac resection of the
tumor.</li>
</ul></li>
</ul></li>
<li>2019-05-04 Bone densitometry - Hip
<ul>
<li>Left hip, BMD is 0.574 gms/cm2, about 2.1 SD below the peak bone
mass (72%) and 1.6 SD below the mean of age-matched people (76%).</li>
<li>IMP: Osteopenia</li>
</ul></li>
<li>2019-05-03 SONO - abdomen
<ul>
<li>diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst, S6.</li>
</ul></li>
<li>suggestion
<ul>
<li>encourage exercise and diet control</li>
</ul></li>
</ul></li>
<li>2019-05-03 Flow-volume curve
<ul>
<li>Mild restrictive ventilatory impairment</li>
</ul></li>
<li>2019-05-03 Colon fiberoscopy
<ul>
<li>Findings
<ul>
<li>A 1 cm SMT was noted at 10 cm.</li>
<li>The scope was inserted to cecum smoothly. Some liquid stool was
noted in the colon.</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Internal hemorrhoid, mild</li>
<li>Submucosal tumor, rectum</li>
</ul></li>
</ul></li>
<li>2018-04-18 Gynecologic ultrasonography
<ul>
<li>S/P lapacoscopy</li>
<li>Bilateral ovarian cyst, Suspected endometrioma</li>
<li>Uterine myoma</li>
<li>Mild Adenomyosis</li>
</ul></li>
<li>2018-01-10 Gynecologic ultrasonography
<ul>
<li>Mild Adenomyosis</li>
<li>Bilateral ovarian cyst (endometrioma)</li>
</ul></li>
<li>2017-10-18 Gynecologic ultrasonography
<ul>
<li>Mild Adenomyosis</li>
<li>Lov cyst</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-31 Chinese Medicine
<ul>
<li>Q
<ul>
<li>This 49-year-old woman who with past history of
<ul>
<li><ol style="list-style-type: decimal">
<li>significant of rectal cancer status post transanal microscopic
surgery on 2019/07/04</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Right middle lobe Lung cancer, adenocarcinoma, T4N1M1c with brain,
bone metastasis, ECOG 1,</li>
</ol>
<ul>
<li>EGFR mutation: L858R (-), exon 19 (+), ALK(), PD-L1: &lt;1%
diagnosed on 2022-03-22, with Giotrif since 20220325. The lung cancer
treatment regimen as below:
<ul>
<li>1st chemotherapy with TKIs with Giotrif since 2022-03-25.</li>
<li>Angiogenesis inhibitor C1 Cyramza since 2022-03-22.<br />
</li>
</ul></li>
</ul></li>
</ul></li>
<li>Tracing back the past history, she was referred to chest surgery
department because of a pathcy density (4.5cm) noted at RML under
abdominal CT on 2022/02/07. According to herself, she received regular
outpatient clinic follow up in colorectal department after ectal
surgery, and on this February, he was found to have a pathy dendity
under abdominal CT. Therefore, she was referred to chest surgery
department for further evaluation. On admission, she made no specific
complaint. No obvious illnes was told. Physical examination showed no
obvious heart murmur. Breath sounds were clear. Chest movements were
symmetric. Abdomen was soft, No tenderness nor rebounding pain was
observed. Under the impression of solitary lung nodule, she was admitted
for further survey.  </li>
<li>Mutation report reveal Exon 19 deteced, TKI with Afatinib 30mg 1#
QDAC was prescribed. Arrange Angiogenesis inhibitor C1 Ramu 500mg on
2022-03-22, C2 Cyaramza 500mg (charge) on 2022-04-20. There were no
fever or chills, no short of breath, no chest pain. Under diagnosis of
Lung cancer, adenocarcinoma, T4N1M1c with brain, bone metastasis, she
was admitted for on schdule for chemotherapy .     </li>
<li>For cancer fatigue, we sincerly your help.</li>
</ul></li>
<li>A
<ul>
<li>Treatment
<ul>
<li>1st chemotherapy with TKIs with Giotrif since 20220325.</li>
<li>Angiogenesis inhibitor C1 Cyramza since 2022-03-22.
<ul>
<li>C2 Cyaramza 500mg (charge) on 2022-04-20.</li>
<li>C3 Cyaramza 500mg (charge) on 2022-07-02.</li>
<li>C4 Cyaramza 500mg chemotherapy on 2022-08-03.</li>
</ul></li>
</ul></li>
<li>Past history
<ul>
<li>Rectal cancer status post transanal microscopic surgery on
2019/07/04</li>
<li>Right middle lobe Lung cancer, adenocarcinoma, T4N1M1c with brain,
bone metastasis, ECOG 1, EGFR mutation: L858R (-), exon 19 (+), ALK(),
PD-L1: &lt;1% diagnosed on 2022-03-22, with TKIs with Giotrif since
20220325.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-07 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>for Cortisol; 0.53 ug/dL 
<ul>
<li>Free-T4 0.83 ng/dL            </li>
<li>TSH 0.249 uIU/mL          <br />
</li>
<li>ACTH &lt;5.0 pg/mL  </li>
</ul></li>
<li>History: Hyperthyroidism, Goiter, rectal carcinoid (NET) s/p TAMIS
local excision</li>
</ul></li>
<li>A
<ul>
<li>This 49-year-old female was a case of right middle lobe lung
adenocarcinoma, T4N1M1c with brain, bone metastasis, ECOG 1, was
admitted for following up and chemotherapy. We were consulted for low
cortisol level and abnormal TFT.</li>
<li>O:
<ul>
<li>BW: 56.1 kg</li>
<li>HR: 65-100</li>
<li>Possible related medication: dexamethasone, clobestasol</li>
<li>AST/ALT: 13/16</li>
<li>BUN/Cr: 11/0.64</li>
<li>Na: 143, K: 4.0</li>
<li>TSH/FT4: 0.249/0.83</li>
<li>T3: unavailable</li>
<li>ACTH/Cortisol: &lt; 5.0/0.53</li>
<li>ECG: normal sinus rhythm (2022/03)</li>
</ul></li>
<li>A:
<ul>
<li>Physiological response of steroid use.</li>
<li>Abnormal TFT, DDx: sick euthyroid syndrome, secondary
hypothyroidism</li>
</ul></li>
<li>Suggestions:
<ul>
<li>No need of any supplement of steroid or thyroxine</li>
<li>Check T3 and complete pituitary function (IGF-1, FSH/LH, E2,
prolactin) in the next lab.</li>
<li>Contact us if needed. I’d like to follow up this patient.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-07 Dermatology
<ul>
<li>Q
<ul>
<li>for paronychia.</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered erytehamtous patches on bil palme-soles for
days.</li>
<li>Imp: Hand foot sym</li>
<li>Suggestion:
<ul>
<li>Sinpharderm * 1 tubes/bid</li>
<li>Topsym cream * 4 tubes/bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-09 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>For chemotherapy and target therapy</li>
<li>This 49-year-old patient with underlying stage 4 lung cancer has
brain metastasis. She had received video assisted thoracoscopic right
middle lobe lobectomy on 2022/03/07. We need your help to evaluate if
she could receive chemotherapy. Thank you!</li>
</ul></li>
<li>Impression:
<ul>
<li>Lung cancer, adenocarcinoma, T4N1M1c, stage IVB, with bone, brain
metastasis</li>
</ul></li>
<li>Suggestion:
<ul>
<li>EGFR mutation test</li>
<li>Bone RT if severe bone pain</li>
<li>We will take over this case after chest tube removed</li>
</ul></li>
</ul></li>
<li>2022-03-08 Radiation Oncology
<ul>
<li>Q
<ul>
<li>For radiotherapy</li>
</ul></li>
<li>A
<ul>
<li>S: For radiotherapy due to lung adenocarcinoma with brain
metastasis.
<ul>
<li>PI: The patient is a case of adenocarcinoma of the lung, RML, with
brain metastasis, s/p 3D VATS, RML lobectomy + RUL wedge + RLND on
2022-03-07. Referred for radiotherapy due to brain metastases.<br />
</li>
<li>Family history: (-)</li>
<li>Cancer site specific factors: Alcohol (-); Smoking (-); Betel nut
(-).</li>
<li>Personal Hx: DM(-); HTN(-)</li>
<li>Other disease: carcinoid tumor of rectum (?)</li>
<li>Previous RT Hx: (-)</li>
</ul></li>
<li>O: ECOG: 1
<ul>
<li>PE: neck and bil SCF: neg; chest: status on chest tube
drainage.</li>
<li>CT scan of abdomen (2022-2-7): A pathcy density (4.5cm) at RML. Some
nodules at bil. lungs. Lung cancer should be ruled out. S/P rectal
operation. Right renal angiomyolipoma (3.0cm). Left adrenal nodule
(7mm).</li>
<li>CXR (2022-03-01): A well defined mass (36 mm) over Rt central
midlung zone, RML, favor a malignant tumor. Nodular opacitiy projecting
over tLt lower lung zone due to nipple shadow. Normal shape and size of
heart. Costophrenic angles are preserved</li>
<li>Bone scan (2022-03-03): Prominently increased activity in the lower
T-spine. The nature is to be determined. Please correlate with other
imaging modalities for further evaluation and to rule out the
possibility of bone metastasis.</li>
<li>MRI of brain (2022-03-04): Brain metastases, right frontal
periventricular white matter and right frontal cortex.</li>
<li>Pathology (S2022-03327, 2022-3-4): Lung, RML, CT-guide
biopsy—adenocarcinoma, poorly differentiated</li>
<li>Operation (2022-03-07): 3D VATS, RML lobectomy + RUL wedge + RLND.
Finding:
<ul>
<li>One tumor lesion was noted over RML, size about 2.0cm in diameter
which invade across the horizontal fissure to RUL s/p RML lobectomy +
RUL wedge.</li>
<li>visceral and parietal pleura tumor seeding</li>
<li>abolished bronchioarterial plane which has been devided
together.</li>
<li>stiff, enlarge and not well-capsuled subcarina and paratrachea lymph
node suspected metastasis.</li>
<li>one 24 Fr. straight chest tubes were inserted via right 8th
ICS.</li>
</ul></li>
</ul></li>
<li>A: Adenocarcinoma of the lung, RML, with brain metastasis, s/p 3D
VATS, RML lobectomy + RUL wedge + RLND.</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: brain metastasis
<ul>
<li>Goal: palliation</li>
<li>Treatment target and volume: metastatic brain tumors</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 3000cGy/10 fractions of the metastatic
brain tumors</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and her brother. They understand and would
like to receive radiotherapy, The treatment planning of radiotherapy
will be started at 1500, 2022-3-11.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-18 ~ undergoing - Giotrif (afatinib) 30mg/tab 1# QOD</li>
<li>2022-09-26 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-08-29 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-08-02 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-07-08 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-04-20 - Cyramza (ramucirumab) 500mg 1.5hr</li>
<li>2022-03-22 - Cyramza (ramucirumab) 500mg 1.5hr</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-252" class="section level1">
<h1>700504868</h1>
<div id="section-253" class="section level2">
<h2>221004</h2>
<ul>
<li><p>lab data</p>
<ul>
<li>2022-06-30 EGFR specimen number S2022-09386<br />
</li>
<li>2022-06-30 EGFR G719X not detected<br />
</li>
<li>2022-06-30 EGFR Exon19 del not detected<br />
</li>
<li>2022-06-30 EGFR S768I not detected<br />
</li>
<li>2022-06-30 EGFR T790M detected<br />
</li>
<li>2022-06-30 EGFR Exon20 ins not detected<br />
</li>
<li>2022-06-30 EGFR L858R detected<br />
</li>
<li>2022-06-30 EGFR L861Q not detected<br />
</li>
<li>2022-05-30 ASMA Positive ; 1:80<br />
</li>
<li>2022-05-30 AMA Positive ; 1:20<br />
</li>
<li>2022-05-26 Factor IX assay 78.2 %<br />
</li>
<li>2022-05-26 Factor VIII assay 103.4 %<br />
</li>
<li>2022-05-26 Cryoglobulin Negative<br />
</li>
<li>2022-05-23 ANA Speckled 1:80<br />
</li>
<li>2022-05-23 Von willebrand factor 224.8 %<br />
</li>
<li>2022-05-21 PR3 Negative IU/ml<br />
</li>
<li>2022-05-21 PR3 Value &lt;0.2 IU/ml<br />
</li>
<li>2022-05-21 MPO Negative<br />
</li>
<li>2022-05-21 MPO Value &lt;0.2 IU/ml<br />
</li>
<li>2022-05-21 Anti-ENA SS-A(Ro) 89 EliA U/ml<br />
</li>
<li>2022-05-21 Anti-ENA SS-B(La) 0.3 EliA U/ml<br />
</li>
<li>2022-05-21 Anti-ds DNA Antibody 0.8 IU/ml<br />
</li>
<li>2022-05-21 Anti-Cardiolopin IgG 1.9 GPL-U/mL<br />
</li>
<li>2022-05-21 Anti-cardiolipin-IgM 62 MPL U/mL<br />
</li>
<li>2022-05-21 Anti-ENA Sm 2.2 EliA U/ml<br />
</li>
<li>2022-05-21 Anti-ENA RNP 0.6 EliA U/ml<br />
</li>
<li>2022-05-19 RF 364.8 IU/mL<br />
</li>
<li>2022-05-19 C3 118.3 mg/dL<br />
</li>
<li>2022-05-19 C4 &lt;8 mg/dL<br />
</li>
<li>2022-05-19 IgG (blood) 1143 mg/dL<br />
</li>
<li>2020-08-05 PD-L1(22C3) specimen number S2020-09426<br />
</li>
<li>2020-08-05 PD-L1(22C3) TPS &gt;= 1% and &lt;50%<br />
</li>
<li>2020-07-30 ROS1 specimen number S2020-09426<br />
</li>
<li>2020-07-30 ROS1 not detected<br />
</li>
<li>2020-07-27 ALK IHC specimen number S2020-09426<br />
</li>
<li>2020-07-27 ALK IHC Negative<br />
</li>
<li>2020-07-24 EGFR specimen number S2020-09426<br />
</li>
<li>2020-07-24 EGFR G719X Not detected<br />
</li>
<li>2020-07-24 EGFR Exon19 del Not detected<br />
</li>
<li>2020-07-24 EGFR S768I Not detected<br />
</li>
<li>2020-07-24 EGFR T790M Not detected<br />
</li>
<li>2020-07-24 EGFR Exon20 ins Not detected<br />
</li>
<li>2020-07-24 EGFR L858R detected<br />
</li>
<li>2020-07-24 EGFR L861Q Not detected<br />
</li>
<li>2020-07-09 Anti-HCV NONREACTIVE<br />
</li>
<li>2020-07-09 Anti-HCV Value 0.06 S/CO<br />
</li>
<li>2020-07-09 HBsAg NONREACTIVE<br />
</li>
<li>2020-07-09 HBsAg (Value) 0.13 S/C value<br />
</li>
<li>2020-07-09 Anti-HBs 14.17 mIU/mL</li>
</ul></li>
<li><p>exam finding</p>
<ul>
<li>2022-10-03 KUB
<ul>
<li>Compression fracture of T11-L2.</li>
<li>Stool retention in the bowel.</li>
</ul></li>
<li>2022-09-25 CXR
<ul>
<li>Lt pleural thickening?</li>
<li>increased opacity over Lt lower hemithorax with obliteration of
hemidiaphgram and Lt shift of heart</li>
<li>a poorly defined nodular opacity at RUL, and subtle LUL nodule,
stationary</li>
<li>Osteoblastic metastasis in many vertebrae</li>
<li>Mild dextroscoliosis of the T-spine<br />
</li>
<li>mild cardiomegaly</li>
</ul></li>
<li>2022-09-26 SONO - chest
<ul>
<li>No pleural effusion.</li>
<li>Left lower lung consolidation.</li>
</ul></li>
<li>2022-09-16 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2022/05/16, all the
previous bone lesions are more eivdent and some new bone lesions are
noted, suggesting multiple bone metastases in progression.</li>
</ul></li>
<li>2022-09-15 MRI - T-spine
<ul>
<li>Known a case of lung cancer. Abnormal enhancing lobulated mass
lesion (&gt;4.2cm) over left lateral mass of T2-T3-T4 and spinous
process, causing severe spinal stenosis and compression of thoracic
cord. Abnormal marrow enhancement of T2-T3 vertebral bodies. Compatible
with metastases.</li>
<li>Also abnormal enhancing lesions over T9 &amp; T12 spinous
process.</li>
<li>Also abnormal marrow enhancement of T12 and L1 vertebral bodies.
Favor metastatic lesions.</li>
</ul></li>
<li>2022-09-14 Eelectroencephalogram, EEG
<ul>
<li>This EEG study recorded background alpha rhythm (8-9 Hz) and plenty
beta activity with occasional transient diffuse slow waves.</li>
<li>No epileptiform discharge. Please correlate with clinical
features</li>
</ul></li>
<li>2022-09-14 Nerve Conduction Velocity (NCV) and Electromyography
(EMG)
<ul>
<li>Finding
<ul>
<li>MNCV: difficult access to right hand due to IV site. delayed CMAPs
onset latency of bilateral peroneal nerves; slow motor conduction
velocity of left median, bilateral ulnar nerves across elbow, bilateral
peroneal and left tibial nerves</li>
<li>SNCV: slow sensory conduction velocity of bilateral ulnar and right
median nerves</li>
<li>F-wave: delayed responses of bilateral peroneal and tibial
nerves</li>
<li>H-reflex: delayed responses of bilateral lower limbs</li>
<li>Thermal quantitative sensory test showed abnormal warm and cold
threshold in left lower limb</li>
</ul></li>
<li>Conclusion
<ul>
<li>This NCV study suggested bilateral lumbosacral radiculopathy,
bilateral ulnar neuropathy across elbow and bilateral median distal
neuropathy.</li>
<li>Thermal quantitative sensory test suggested small fiber
neuropathy.</li>
<li>Please correlate with clinical features.</li>
</ul></li>
</ul></li>
<li>2022-09-13 Humerus Lt
<ul>
<li>avalsion fracture of proximal humerus, involving greater tuberosity,
with suspect combined radiolucency</li>
</ul></li>
<li>2022-09-07 CXR
<ul>
<li>Lt pleural thickening with minimal pleural effusion</li>
<li>large LLL retrocardiac tumor opacity and a poorly defined nodular
opacity at RUL, and subtle LUL nodule, stationary</li>
<li>Osteoblastic metastasis in many vertebrae</li>
<li>Mild dextroscoliosis of the T-spine<br />
</li>
<li>mild cardiomegaly</li>
</ul></li>
<li>2022-08-12 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Soft tissue mass at left lower lobe up to 7.5cm with attachment with
parietal and visceral pleura is found. In comparison with CT dated on
2022-04-26, the lesion is stationary.</li>
<li>Several irregular shaped patch/mass at right upper lobe and other
lobes. Stable.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>Mild left pleural effusion is found.</li>
<li>Calcified coronary arteries is found.</li>
<li>Small lymph nodes are found at both sides of the mediastinum.</li>
</ul></li>
<li>Imp
<ul>
<li>LEFT LOWER LOBE lung cancer with lung to lung meta. Mediastinal
lymphadenopathy and bone meta. These lesions are stationary.</li>
</ul></li>
</ul></li>
<li>2022-08-05 MRI - brain
<ul>
<li>Indication: Lung cancer, LLL, adenocarcinoma, cT4N2M1c, with brain
metastasis, with TKI Giotrif since 2020/07/16, Cyramza C1 since
2020/08/05 with disease progression and brain metastasis (n＝3); ECOG
＝1. s/p Brain RT on 2022/6/01.</li>
<li>Findings
<ul>
<li>multiple enhancing nodules at the left frontal cortex, left
occipital cortex, and right anterior insula, compatible with brain
metastases. Most of the tumors are stationary or smaller. But the one at
left anterior frontal lobe is enlarged (1.3m) with increased extent of
vasogenic edema.</li>
<li>mild brain atrophy with prominent sulci, fissures and dilated
ventricles.</li>
<li>multiple nonspecific hyperintense patches in T2WI at bilateral
periventricular white matter, leukoaraiosis is considered.</li>
<li>no midline shift nor brain herniation.</li>
<li>no abnormal bright up on DWI.</li>
<li>unremarkable skull base and calvarial vault.</li>
</ul></li>
<li>Impression:
<ul>
<li>Multiple brain metastases, the one at left anterior frontal lobe is
enlarged (1.3cm).</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
</ul></li>
<li>2022-06-09 Patho - bronchus biopsy
<ul>
<li>Lung, left, CT-guide biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show neoplastic acinar glandular cells infiltrating in a
fibrotic stroma with focal tumor necrosis.</li>
</ul></li>
<li>2022-06-08 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesions in the left lower lung as well as
left pleural effusion, compatible with the primary lung cancer with
malignant pleural effusion.<br />
</li>
<li>Glucose hypermetabolic lesions in several lung lobes, highly
suspected lung cancer with lung to lung metastases.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral pulmonary hilar and
mediastinal lymph nodes, highly suspected lung cancer with regional
lymph nodes metastases.<br />
</li>
<li>Glucose hypermetabolic lesions in the left adrenal region and
multiple skeleton as above-mentioned, highly suspected lung cancer with
distant metastases.</li>
<li>Increased FDG uptake in the right lobe of the thyroid gland,
probably lung cancer with thyroid metastasis or another primary cancer
of thyroid, suggesting further investigation.<br />
</li>
<li>Left lower lung cancer with left pleura, bilateral lung lobes,
bilateral regional lymph nodes, left adrenal and multiple bone mets,
cT4N3M1c, stage IVB (AJCC, 8th ed.), by this F-18 FDG PET scan.<br />
</li>
</ul></li>
<li>2022-05-16 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2021/12/24, two lesions in
the left 11th costovertebral junction and in a upper T-spine are new,
and the nature is to be determined, suggesting follow-up with bone scan
in 3-6 months for investigation.<br />
</li>
<li>Other lesions in the posterior aspect of the left 8th and 9th ribs,
respectively, T12 spine, L3 spine, right femoral trochanter, bilateral
shoulders, and S-I joints show slightly less evident.</li>
</ul></li>
<li>2022-05-14 MRI - brain
<ul>
<li>Enlarged bi-frontal cortical/subcortical nodules with increased
perifocal edema at right, another small residual nodule in left anterior
part, artifact? stationary.</li>
</ul></li>
<li>2022-04-26 CT - chest
<ul>
<li>LLL cancer T4N3M1b, increase in size of priamry tumor and stationary
of lung to lung metastatic lesion, left pleura and spine metastases, but
newly developed left ribs metastasis as compared with previous CT study
on 2021/12/23.</li>
</ul></li>
<li>2021-12-24 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2020/12/23, the lesions in
the posterior aspect of the left 8th and 9th ribs, some middle and lower
T-spines and L3 spine are a little more prominent. Bone metastases in a
little more progression should be watched out. Please correlate with
other clinical findings for further evaluation.<br />
</li>
<li>No prominent change is noted in other bone lesions.</li>
</ul></li>
<li>2021-12-23 CT - chest
<ul>
<li>left lower lobe lung cancer with lung to lung meta and lumbar spine
meta. stationary.</li>
</ul></li>
<li>2021-12-22 MRI - brain
<ul>
<li>Regressed Small bi-frontal cortical nodules, a residual nodule in
left or artifact?</li>
</ul></li>
<li>2021-08-26 CT - chest
<ul>
<li>Left lower lobe mass with enlargement. Either tumor progression or
mucus impaction is suspected. Suggest contrast enhanced study.</li>
<li>Right upper lobe and right lower lobe and left lower lobe nodules.
Stationary. cT4N3M1b.</li>
</ul></li>
<li>2021-03-11 CT - chest
<ul>
<li>right upper lobe and left lower lobe lung cancer with lung to lung
and bone meta. Stable. cT4N3M1b.</li>
</ul></li>
<li>2020-12-23 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2020/07/15, one faint hot
spot in the posterior aspect of the left 8th rib comes to less evident,
but the other faint hot spot in the post. aspect of the left 9th rib
becomes more prominent, suggesting bone mets with mixed response to
current therapy.<br />
</li>
<li>Increased activity in the T12 spine shows more evident compared with
the previous study on 2020/07/15, the nature still is to be determined
(bone mets, DJD, or other nature ?), suggesting follow-up with bone scan
in 3 months for further evaluation.</li>
<li>Suspected benign lesions in L3 spine, bilateral shoulders and S-I
joints.</li>
</ul></li>
<li>2020-12-24 CT - chest
<ul>
<li>Left lower lobe lung cancer with lung to lung meta and bone meta.
T4N3M1b, in regression.</li>
</ul></li>
<li>2020-09-29 CT - chest
<ul>
<li>LLL cancer T4N3M1b, significant in regression of lung tumors
and</li>
<li>metastatic mediastinal and hilar LAP, but stationary of left pleural
and spine metastases as compared with previous CT study on
2020/07/13.</li>
</ul></li>
<li>2020-07-15 Tc-99m MDP whole body bone scan
<ul>
<li>A hot spot in the posterior aspect of the left 8th rib and a faint
hot spot in the post. aspect of the left 9th rib, malignancy with bone
mets may be considered.</li>
<li>Increased activity in the T12 spine and L3 spine, the nature is to
be determined (bone mets, DJD, or other nature ?), suggesting follow-up
with bone scan in 3 months for further evaluation.</li>
<li>Suspected benign lesions in bilateral shoulders and S-I joints.</li>
</ul></li>
<li>2020-07-14 MRI - brain
<ul>
<li>Small bifrontal cortical nodules, favor metastases.</li>
</ul></li>
<li>2020-07-13 Patho - lung transbronchial biopsy
<ul>
<li>Lung, ? side, needle biopsy—adenocarcinoma, moderately
differentiated<br />
</li>
<li>Sections show solid nests and glandular tumor cells infiltrating in
a fibrotic stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(+), Napsin A(+), p40(-),
and CD56(-). The results are supportive for the diagnosis.</li>
</ul></li>
<li>2020-07-13 CT - chest
<ul>
<li>Findings
<ul>
<li>Lungs and large airways:
<ul>
<li>an irregular, large, soft-tissue tumor (at least 70 mm in largest
dimension) in LLL, involving the hilum, inferior pulmonary artery and
vein, and adjacent mediastinum and pericardium.</li>
<li>multiple nodular lesions of varying sizes in bilateral lungs up to
36 mm at RUL due to lung to lung metastasis.</li>
</ul></li>
<li>Mediastinum and hila: metastatic LAPs in stations 5, 7, and left
10.</li>
<li>Vessels: mild coronary arterial calcification
<ul>
<li>Aorta: normal caliber, extensive atherosclerotic change of aortic
arch and descending thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>LLL cancer T4N3M1b, stage IVA.</li>
</ul></li>
</ul></li>
<li>2020-07-09 SONO - chest
<ul>
<li>Left side moderate amount of pleural effusion, 600cc serosangious
fluid was aspirated for analysis.</li>
<li>Pleural biopsy was not done due to INR:2.51.</li>
</ul></li>
<li>2020-07-01 CXR
<ul>
<li>Several nodular opacity projecting in the both upper lung are
suspected. Please correlate with CT.</li>
<li>Massive left side Pleura effusion is suspected.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
</ul></li>
</ul></li>
<li><p>consultation</p>
<ul>
<li>2022-09-28 Rehabilitation
<ul>
<li>Q
<ul>
<li>for bedside rehabilitation</li>
<li>This 76-year-old woman was a case with past hsitory of Rheumatoid
arthritis and hypertension and a case of Lung cancer, adenocarcinoma,
T4N2M1C, stage IVB with brain, bone, lung to lung metastasis, ECOG 1,
diagnosedand on 2020-08; T4: LLL mass with bilateral lung to lung; N2:
right mediastinal LAPs; M1C: brain, bone, lung to lung metasatsis; EGFR
mutation: L858R (+), exon19(-), ALK(-).</li>
<li>Tracing back the past history, she suffered from cough productive of
whitish sputum for many months, chest tightness and exertional dyspnea
for 2-3 months. She visited our chest OPD for help, chest x-ray films
and showed Several nodular opacity projecting in the both upper lung are
suspected. massive left side Pleura effusion is suspected, than was
arranged admission on 2020-07-17.</li>
<li>After admissin, arranged sonography of chest, left side moderate
amount of pleural effusion, 600cc serosangious fluid was aspirated for
analysis. The 2nd chest echo on 20200710 displayed L’t pleural effusion,
lung mass s/p pigtail insertion. Arranged CT guiding biopsy on 20200713
and pathology disclosed non-small cell lung cancer initially, then
adenocarcioma was confirmed after speciall stain. Brain MRI was done and
disclosed small bifrontal cortical nodules, favor metastases. Whole body
bone scan also done 20200715 and disclosed multiple bone metastases in
the left rib and spine. The lung cancer, adenocarcinoma, T4N2M1C, stage
IVB with brain, bone, lung to lung metastasislung cancer stage was
T4N3M1b, stage IV was diagnosed.</li>
<li>We well explained the treatment to the lung cancer and after
disscussion with her familes member, TKI with Giotrif was prescried
since 2020-07-16. EGFR: T790M detected and L858R detected. change TKI to
Tagrisso (2022-07-13 ~ ).</li>
<li>This time, she suffered from Severe Chest and back pain for one
week, other symptoms included cough, hemoptysis, dyspnea on exertion,
nausea, poor appetite and body weight loss. Under the impression of Lung
cancer, adenocarcinoma, T4N2M1C, stage IVB with brain, bone, lung to
lung metastasis, she was admitted for pain control and
radiotherapy.</li>
</ul></li>
<li>A
<ul>
<li>I have called NP for more clinical information. The patient suffered
from lower limbs weakness and numbness due to suspected T-spine mets
after admission.
<ul>
<li>T spine MRI findings:
<ul>
<li>Known a case of lung cancer. Abnormal enhancing lobulated mass
lesion (&gt;4.2cm) over left lateral mass of T2-T3-T4 and spinous
process, causing severe spinal stenosis and compression of thoracic
cord. Abnormal marrow enhancement of T2-T3 vertebral bodies. Compatible
with metastases.</li>
<li>Also abnormal enhancing lesions over T9 &amp; T12 spinous
process.</li>
<li>Also abnormal marrow enhancement of T12 and L1 vertebral bodies.
Favor metastatic lesions.</li>
</ul></li>
<li>He could walk on admission, but was bed-ridden or wheelchair bounded
now.
<ul>
<li>MP over lower limbs</li>
<li>Before 20220911: 5/5</li>
<li>On 20220912: 2/2</li>
<li>After 20220913: 0/0</li>
</ul></li>
<li>Due to lower limbs weakness and numbness, we were consulted for
further rehabilitation training.</li>
</ul></li>
<li>PE
<ul>
<li>2022/09/28 12:40 T/P/R: 38.0C / 95bpm / 20bpm BP:120/59mmHg</li>
<li>height: 163.5 Body weight: 57.6 BMI:21.5</li>
<li>Consciousness: clear</li>
<li>Cognition: intact, oriented to time, person and place, could follow
orders</li>
<li>Speech: no aphasia, no obvious dysarthria</li>
<li>Swallowing: take general diet without choking</li>
<li>Sphincter: Foley+, stool incontinent; preserve anal sensation and
contraction</li>
<li>MP: R L</li>
<li><pre><code>  (C5) Deltoid/Biceps            5         4</code></pre></li>
<li><pre><code>  (C6) Wrist extensor            5         4</code></pre></li>
<li><pre><code>  (C7) Triceps                   5         4</code></pre></li>
<li><pre><code>  (C8) Flex. dig. profundus      5         5</code></pre></li>
<li><pre><code>  (T1) Hand intrinsics           5         5 </code></pre></li>
<li><pre><code>  (L2) Iliopsoas                 0         0</code></pre></li>
<li><pre><code>  (L3) Quadriceps                0         0</code></pre></li>
<li><pre><code>  (L4) Tibialis ant.             0         0</code></pre></li>
<li><pre><code>  (L5) Ext. hallu. longus        0         0</code></pre></li>
<li><pre><code>  (S1) Gastrocnemus              0         0</code></pre></li>
</ul></li>
<li>AP and LAT. views of left humerus show: avalsion fracture of
proximal humerus, involving greater tuberosity, with suspect cpmbined
radiolucency
<ul>
<li>-&gt; left arm sling protection</li>
</ul></li>
<li>Sensory: bilateral lower limbs numbness below T10</li>
<li>Functional status: could sit-up under maxA</li>
<li>BADL: eating and grooming minA; toileting, bathing, and dressing
needs maxA</li>
<li>DTR: decrease in bilateral lower limbs</li>
<li>Barbinski: positive/negative</li>
<li>MRS: 5 (need followed up)</li>
</ul></li>
<li>Assessment
<ul>
<li>Lung cancer, adenocarcinoma, T4N2M1C, stage IVB with brain, bone,
lung to lung metastasis, ECOG 1</li>
<li>Malignant pleural effusion</li>
<li>hypertension</li>
<li>Chronic obstructive pulmonary disease</li>
<li>Encounter for antineoplastic immunotherapy</li>
<li>T-spine mets, T2-4, T9, T12-L1</li>
<li>SCI, ASIA B, level T9</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT, OT rehabilitation programs</li>
<li>Goal: improve ADL, muscle power and endurance</li>
</ul></li>
</ul></li>
<li>2022-09-28 Infectious Disease
<ul>
<li>A
<ul>
<li>The patinet is case of adenocarcinoma, T4N2M1C, stage IVB with
brain, bone, lung to lung metastasis.</li>
<li>S/C: oxacillin-resistatant Stapylococcus capitis</li>
<li>Agree with your use of zyvox. Please adjust antibiotic according to
culture results and clinical conditions.</li>
</ul></li>
</ul></li>
<li>2022-09-16 Radiation Oncology
<ul>
<li>Q
<ul>
<li>for L spine lesions, arrange radiotherapy</li>
</ul></li>
<li>A
<ul>
<li>This patient has suffered from lower limb weakness, constipation and
urine difficulty since last Saturday. Falling accidence with avalsion
fracture of proximal humerus, involving greater tuberosity happened on
last Saturday, too.</li>
<li>MRI of spine on 20220915 showed abnormal enhancing lobulated mass
lesion (&gt;4.2cm) over left lateral mass of T2-T3-T4 and spinous
process, causing severe spinal stenosis and compression of thoracic
cord. Abnormal marrow enhancement of T2-T3 vertebral bodies, which is
compatible with metastases. Also abnormal enhancing lesions over T9
&amp; T12 spinous process &amp; abnormal marrow enhancement of T12 and
L1 vertebral bodies are norted; metastatic lesions are all favored.</li>
<li>Palliative RT to T2-4 spines had been prescribed on 20220908 to
20220909, for 600cGy/2 fractions, and was interrupted after avalsion
fracture of proximal humerus was noted. I have started RT to T2-4 spines
at 3 pm today, and treatment will be continued next week. Please keep
dexamethsone use during spine RT and increase dose if necessary. The
recovery of muscle power may not be complete because the dueration of
spinal cord compression.</li>
</ul></li>
</ul></li>
<li>2022-09-13 Neurology
<ul>
<li>Q
<ul>
<li>for numbness of lower limbs for 2-3 days</li>
</ul></li>
<li>A
<ul>
<li>According to the patient’s statement, she was able to walk last week
when admission. However she suffered from progressive lower limbs
weakness and numbnesss since admission. Left lower limb was worse than
the right. In addition, she complained of abnormal sensation below
nipple and urinary difficulty. Middle back and chest diffuse pain was
also noted since last week. Hands numbness was also noted.
<ul>
<li>NE E4V5M6</li>
<li>CNs: intact</li>
<li>MP upper &gt;4/&gt;4, lower 3/2-3</li>
<li>DTR 2+/2+</li>
<li>sensation: below nipple parethesia with distal prominence, normal
proprioception</li>
<li>FNF: no dsymetria</li>
</ul></li>
<li>brain MRI in 2022/08: Multiple brain metastases, the one at left
anterior frontal lobe is enlarged (1.3cm).
<ul>
<li>impression: bilateral lower limbs numbness and weakness with urinary
retention. suspect myelopathy below T4, suspected new organic brain
lesion</li>
</ul></li>
<li>suggestion:
<ul>
<li>Do T-spine MRI with/without contrast enhancement (including whole
spine saggital view) if feasible</li>
<li>consider to repeat brain MRI if negative spine MRI findings</li>
<li>do NCV (upper /lower limb motor and sensory nerve conduction study,
F-wave, H-reflex) and QST to survey possible polyneuropathy</li>
<li>EEG should be considered if seizure or nonconvulsive seizure was
suspected</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-09-12 Orthopedics
<ul>
<li>Q
<ul>
<li>Painful limitation of left shoulder was noted due to slipping (fall
down) at the toilet tonight. Left humoral head fracture was noted on
X-ray. So, we would like to request your expertise for further
management. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>Left shoulder pain after falling down tonight</li>
<li>X-ray : Left proximal humerus GT avulsion fracture
<ul>
<li>Adequate pain control</li>
<li>Arm sling protection</li>
<li>Check left shoulder X-ray after R/T tomorrow</li>
<li>Explain the current condition and further management to the patient
and family</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-16 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Consult for brain radiotherapy</li>
<li>This 76-year-old woman was a case with past history of Rheumatoid
arthritis and hypertension, she was not regular control. A case of Lung
cancer, adenocarcinoma, T4N2M1C, stage IVB with brain, bone, lung to
lung metastasis, ECOG 1, diagnosedand on 2020-08; T4: LLL mass with
bilateral lung to lung; N2: right mediastinal LAPs; M1C: brain, bone,
lung to lung metasatsis. EGFR mutation: L858R (+), exon 19 (-), ALK
(-).</li>
<li>The lung cancer treatment regimen as below:
<ul>
<li>1st chemotherapy with TKI Giotrif since 2020-07-16, added Cyramza C1
since 2020-08-05.<br />
</li>
</ul></li>
<li>This time, she admission for chemotheapy with C15-6 Cyramza (2 vial
free).</li>
<li>After admission, for lung cancer survey, brain MRI was complete that
show enlarged bi-frontal cortical/subcortical nodules with increased
perifocal edema at right, another small residual nodule in left anterior
part.</li>
</ul></li>
<li>A
<ul>
<li>Subjective:
<ul>
<li>History: This 76-year-old woman was a case of lung cancer,
adenocarcinoma, cT4N2M1c, stage IVB with brain, bone, lung to lung
metastasis, ECOG 1, diagnosed on 2020-08; EGFR mutation: L858R (+), exon
19 (-), ALK(-), under 1st target therapy with TKI Giotrif since
2020-07-16, added Cyramza C1 since 2020-08-05. This time, she was
admitted for chemotherapy with C15-6 Cyramza (2 vial free). After
admission, brain MRI showed enlarged bi-frontal cortical/subcortical
nodules with increased perifocal edema at right, another small residual
nodule in left anterior part.
<ul>
<li>Previous RT: s/p RT to pelvis and vaginal stump in 2016.</li>
<li>Other disease: Rheumatoid arthritis and hypertension.</li>
<li>Family history: denied.</li>
</ul></li>
<li>Habit: Alcohol: denied; Smoking: denied; betel nut: denied.</li>
<li>Widow. Caregiver: her sons (n=3). Job: housewife. Mild or no
economic stress.。</li>
<li>Language: Mandarin. Taiwanese.</li>
<li>Religion: buddism.</li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2022/05/16: No SCF LNs.</li>
<li>Pathology, 2020/07/13: Lung, needle biopsy—adenocarcinoma, moderated
differentiated.</li>
<li>Images:
<ul>
<li>Chest CT on 2022/04/26: LLL cancer T4N3M1b, increase in size of
primary tumor and stationary of lung to lung metastatic lesion, left
pleura and spine metastases, but newly developed left ribs metastasis as
compared with previous CT study on 2021/12/23.</li>
<li>Brain MRI, 2022/05/14: Enlarged bi-frontal cortical/subcortical
nodules with increased perifocal edema at right, another residual nodule
in left or artifact, stationary. After IV contrast administration shows
well or heterogenous enhancement of those nodules or tumors. Imp:
Enlarged bi-frontal cortical/subcortical nodules with increased
perifocal edema at right, another small residual nodule in left anterior
part.</li>
</ul></li>
</ul></li>
<li>Diagnosis: Lung cancer, LLL, adenocarcinoma, cT4N2M1c, stage IVB
with brain, bone, lung to lung metastasis, ECOG 1, diagnosed on 2020/08;
EGFR mutation: L858R (+), exon 19 (-), ALK(-), under 1st target therapy
with TKI Giotrif since 2020/07/16, Cyramza C1 since 2020/08/05 with
disease progression and brain metastasis (n=3); ECOG =1.</li>
<li>Suggest:
<ul>
<li>Radiotherapy.</li>
<li>Goal: Palliative.</li>
<li>RT Plan may be designed as the following one:
<ul>
<li>Target &amp; Volume: Metastatic brain tumors (n=3).</li>
<li>Technique: VMAT &amp; IGRT (OBI).</li>
<li>Dose &amp; Fractionation: 3960cGy/12 fractions.</li>
</ul></li>
</ul></li>
<li>Plan:
<ul>
<li>Palliative R/T is suggested for tumor control. Possible toxicity
(malaise, IICP &amp; hair loss) is told. CT simulation is arranged on
May 16 15:30pm. Treatment will be started on Wednesday if feasible.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-10-28 Dermatology
<ul>
<li>Q
<ul>
<li>For Pyogenic granuloma on R’t toenail for wks, severe painful</li>
<li>After admission, under the ANC: 4541 /uL. Chemotherapy C10 Cyramza
total 200mg were done smoothly respectly on 20211027 and kept TKI with
giotrif 30 mg/tab 1 tab PO QDAC continued given for lung cancer control.
There were no nausea, vomiting, SOB or chest pain after chemotherapy.
Only mild general malaise was mentioned and improved after bed reset and
medica treatment.</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from multiple granulation on bil fingeres and
toenails for days</li>
<li>Imp: Pyogenic granuloma</li>
<li>Suggestion:
<ul>
<li>Arrange liq N2 Tx</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li><p>chemoimmunotherapy</p></li>
<li><p>Tagrisso - osimertinib 80mg/tab 1# QD PO</p>
<ul>
<li>2022-07-13 ~ undergoing</li>
</ul></li>
<li><p>Cyramza - ramucirumab (NSCLC recommended dose in package insert:
in combination with erlotinib, 10mg/kg Q2W IVD 60min)</p>
<ul>
<li>2022-09-20 - ramucirumab 200mg 15hr</li>
<li>2022-05-13 - ramucirumab 200mg 15hr</li>
<li>2022-03-15 - ramucirumab 200mg 15hr</li>
<li>2022-02-17 - ramucirumab 200mg 15hr</li>
<li>2021-12-21 - ramucirumab 200mg 15hr</li>
<li>2021-11-23 - ramucirumab 200mg 15hr</li>
<li>2021-10-27 - ramucirumab 200mg 15hr</li>
<li>2021-04-13 - ramucirumab 200mg 15hr</li>
<li>2021-03-02 - ramucirumab 200mg 15hr</li>
<li>2021-01-19 - ramucirumab 200mg 15hr</li>
<li>2020-12-22 - ramucirumab 200mg 15hr</li>
<li>2020-11-25 - ramucirumab 200mg 15hr</li>
<li>2020-10-27 - ramucirumab 200mg 15hr</li>
<li>2020-09-28 - ramucirumab 200mg 15hr</li>
<li>2020-09-03 - ramucirumab 200mg 15hr</li>
<li>2020-08-05 - ramucirumab 200mg 15hr</li>
</ul></li>
<li><p>Giotrif - afatinib 30mg/tab 1# QDAC PO</p>
<ul>
<li>2020-07-16 ~ 2022-07-13</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There has been an active problem with hemoptysis since 2022-09-07.
Ramucirumab is associated with an increased risk of hemorrhage and GI
hemorrhage. Various exclusion criteria in some non-small cell lung
cancer trials included a recent history of gross hemoptysis, evidence of
major airway or blood vessel involvement or intratumor cavitation; the
risk of pulmonary hemorrhage in patients with such criteria is not
known. Monitoring should be conducted on a continuous basis.</li>
<li>The use of ramucirumab has also been associated with hypertension
(incidence 16% to 25%). This patient’s blood pressure level never
exceeded 125mmHg during the last seven days of hospitalization.
Hypertension appears to be less of a problem.</li>
<li>Lab results
<ul>
<li>2020-07-24 EGFR L858R detected =&gt; afatinib - 2020-07-16 ~
2022-07-13</li>
<li>2022-06-30 EGFR T790M detected =&gt; osimertinib - 2022-07-13 ~
undergoing</li>
</ul></li>
<li>It has been reported that sequential afatinib and osimertinib
demonstrated encouraging activity in patients with EGFR
mutation-positive NSCLC and acquired T790M. Activity was observed across
all subgroups, including patients with poor ECOG PS or brain metastases.
ECOG PS and incidence of brain metastases remained stable prior to, and
after, afatinib treatment. (ref: Sequential afatinib and osimertinib in
patients with EGFR mutation-positive NSCLC and acquired T790M: A global
non-interventional study (UpSwinG). Lung Cancer. 2021;162:9-15. <a href="doi:10.1016/j.lungcan.2021.09.009" class="uri">doi:10.1016/j.lungcan.2021.09.009</a>)</li>
</ul>
</div>
</div>
<div id="section-254" class="section level1">
<h1>700040696</h1>
<div id="section-255" class="section level2">
<h2>221003</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-26 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Liver cyst, small, S8</li>
<li>Parenchymal renal disease and renal cyst, bilateral, c/w ESRD</li>
<li>pancreas and spleen masked by gas.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Semi-annual ultrasound follow up.</li>
</ul></li>
</ul></li>
<li>2022-08-03 CT - abdomen
<ul>
<li>History
<ul>
<li>20220331 gastroscopy: One huge lumen-protruding ulcerative tumor
with mucosa friability at LC side of antrum involving the angularis. The
pylorus seems to be spared. IMP: Highly suspected gastric cancer,
Borrmann type III, antrum LC, angularis involved.</li>
<li>20220401 CT:gastric cancer, cT3N2M1?, cSTAGE:IVB</li>
<li>20220413 s/p radical subtotal gastrectomy with en bloc distal
pancreatectomy:Adenocarcinoma of gastric antrum with pancreas invasion,
pT4bN1(cM0) stage IIIB</li>
</ul></li>
<li>Indication: FU</li>
<li>Findings:
<ul>
<li>S/P subtotal gastrectomy
<ul>
<li>Prior CT identified One enlarged node measuring 1.5 x 1 cm in right
lower pelvis is noted again, stationary. Follow up is indicated.</li>
</ul></li>
<li>Prior CT identified three enhancing round-shaped lymph nodes in left
inguinal area (size: &lt; 5 mm) are noted again, stationary. Follow up
is indicated.
<ul>
<li>In addition, there are several ovoid-shaped enlarged nodes with
fatty hilum that are c/w benign reactive nodes.</li>
</ul></li>
<li>There are several small poor enhancing lesions in both hepatic lobes
and the largest one 1.4 cm in S2 that may be cysts. Please correlate
with sonography.</li>
<li>Both kidney show small size, few cysts, and thin parenchyma that are
c/w ESRD.</li>
</ul>
<ol start="5" style="list-style-type: decimal">
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, and spleen.</li>
</ol></li>
<li>IMP:
<ul>
<li>S/P subtotal gastrectomy. There is no evidence of tumor
recurrence.<br />
</li>
<li>Prior CT identified One enlarged node measuring 1.5 x 1 cm in right
lower pelvis is noted again, stationary. Follow up is indicated.</li>
</ul></li>
</ul></li>
<li>2022-07-02 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Increased pulmonary vasculature is found.</li>
</ul></li>
<li>2022-05-27 CXR
<ul>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
<li>Increased lung markings on both lower lung are noted. Please
correlate with clinical condition.</li>
</ul></li>
<li>2022-04-13 Patho - stomach subtotal/total (tumor)
<ul>
<li>Diagnosis
<ul>
<li>Stomach, antrum, radical subtotal gastectomy — adenocarcinoma,
poorly differentiated; AJCC 8th edition: pStage IIIB, pT4bN1(if cM0) or
pStage IV, pT4bN1(if cM1: by CT-finding)</li>
<li>Pancreas, body, en block distal pancreatectomy — adenocarcinoma, by
direct invasion</li>
<li>Duodenum, radical subtotal gastectomy — negative for malignancy</li>
<li>Omentum, omentectomy — negative for malignancy</li>
<li>Lymph node, group 1, dissection — negative for malignancy (0/4)</li>
<li>Lymph node, group 3, dissection — negative for malignancy (0/3)</li>
<li>Lymph node, group 4, dissection — adenocarcinoma, metastatic (1/
4)</li>
<li>Lymph node, group 5, dissection — negative for malignancy (0/1)</li>
<li>Lymph node, group 6, dissection — negative for malignancy (0/3)</li>
<li>Lymph node, group 7, 8, 9, 11p, 12, dissection — adenocarcinoma,
metastatic (1/ 9)</li>
<li>Lymph node, group 14v, dissection — negative for malignancy
(0/1)</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Adenocarcinoma, Lauren classification of
adenocarcinoma: Intermediate type (tubular)</li>
<li>Histologic Grade: G3: Poorly differentiated,<br />
</li>
<li>Tumor Extension: Tumor invades adjacent structures/organs(specify):
pancreas<br />
</li>
<li>Margins
<ul>
<li>Proximal margin: uninvolved by invasive carcinoma: 3.4 cm</li>
<li>Distal margin: uninvolved by invasive carcinoma: 1.1 cm</li>
<li>Radial margin: uninvolved by invasive carcinoma: 0.1 cm</li>
<li>Pancreatic resection margin: 0.7 cm</li>
</ul></li>
<li>Lymphovascular Invasion: present<br />
</li>
<li>Perineural Invasion: present<br />
</li>
<li>Regional Lymph Nodes: please see diagnosis<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply) :absent<br />
</li>
<li>Primary Tumor (pT): pT4b: Tumor invades adjacent
structures/organs</li>
<li>Regional Lymph Nodes (pN): pN1: Metastasis in one or two regional
lymph nodes</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case): if cM0 or cM1(CT-finding)</li>
</ul></li>
<li>Additional Pathologic Findings
<ul>
<li>Intestinal metaplasia: present</li>
<li>Low-grade dysplasia: present</li>
<li>High-grade dysplasia: absent</li>
<li>Helicobacter pylori-type gastritis: absent</li>
<li>Autoimmune atrophic chronic gastritis: absent<br />
</li>
<li>Polyp(s): absent<br />
</li>
</ul></li>
<li>A Schwannoma, measuring 0.2 x 0.1 cm, is seen in muscularis propria
of pylorus.</li>
<li>The immunohistochemical stains reveal S-100(+), SMA(-), CD34(-),
Desmin(-) and CD117(-).</li>
</ul></li>
</ul></li>
<li>2022-04-12 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the antrum of the stomach, compatible
with primary gastric malignancy.</li>
<li>Glucose hypermetabolism in the region about the lower end of the
esophagus. The nature is to be determined (inflammatory process? other
nature?). Please correlate with other clinical findings for further
evaluation.</li>
<li>Mild glucose hypermetabolism in a focal area in the right lower
pelvis, possibly more benign in nature. However, please follow up other
imaging modalities for further evaluation and to rule out the
possibility of malignnacy or metastasis of low FDG uptake.</li>
<li>Increased FDG accumulation in the colon and rectum. Physiological
FDG accumulation is more likely.</li>
</ul></li>
<li>2022-04-08 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (121 - 51.2) / 121 = 57.69%</li>
<li>Adequate LV systolic function with no regional wall motion
abnormality at resting state</li>
<li>Mild tricuspid regurgitation, trivial aortic and mitral
regurgitation</li>
<li>Impaired LV relaxation</li>
<li>Dilated LA, LV hypertrophy</li>
</ul></li>
<li>2022-04-07 Colonoscopy
<ul>
<li>Colon polyp, Paris classification 0-IIa, sigmoid colon, s/p cold
polypectomy and Sureclip*2</li>
<li>Diverticulum, ascending colon</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>2022-03-31 CXR
<ul>
<li>Increase bilateral lung markings.</li>
<li>Thoracic spondylosis.</li>
</ul></li>
<li>2022-03-31 ECG
<ul>
<li>Sinus rhythm with occasional Premature ventricular complexes</li>
<li>Left ventricular hypertrophy with repolarization abnormality</li>
</ul></li>
<li>2022-03-31 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA grade A</li>
<li>Highly suspected gastric cancer, Borrmann type III, antrum LC,
angularis involved, s/p biopsy*6 pieces<br />
</li>
</ul></li>
<li>2022-03-30 Peropheral Vascular Test - AV fistula
<ul>
<li>clinical diagnosis: S/P left radiocephalic AV fistula, interval
duplex F/U</li>
<li>S/P left radiocephalic AV fistula, VF at inflow radial artery
655-738 ml/min, anastomotic diameter 6.0x10.8 mm, juxta-anastomotic
segment 7.1 mm, proximal cephalic vein aneurysmal formation 23.2 mm
without thrombus within, then cephalic vein 7.0 mm with PS 68 cm/s,
A-puncture site diameter 10.8 mm (depth 2.4 mm), intervening segment 3.0
mm (relatively reduced) with mosaic flow pattern and pressure build-up
PS 201.6 cm/s, Vpuncture site 8.9 mm (depth 2.2mm), cubitobasilic vein
6.0mm, upper arm basilic vein 6.2mm, continuous flow pattern over
draining basiloaxillary vein indicating no overt outflow
obstruction</li>
<li>Recommendation: Preemptive PTA to stenotic cubital cephalic vein to
avoid further aneurysmal formation of upstream cephalic vein</li>
<li>Suggestion: PTA</li>
</ul></li>
<li>2021-11-03 Peropheral Vascular Test - AV fistula</li>
<li>2021-02-24 Peropheral Vascular Test - AV fistula</li>
<li>2020-09-30 Peropheral Vascular Test - AV fistula</li>
<li>2018-09-03 Impedance audiometry
<ul>
<li>Tymp: R’t type B, L’t type A.</li>
<li>ART: Bil absent.</li>
<li>PTA
<ul>
<li>Reliability: fair</li>
<li>Average: R’t 69 dB HL.</li>
<li>R’t moderate to profound mixed type HL (BC 1k &amp; 4k Hz masking
dilemma).</li>
<li>L’t severe to profound mixed type HL.</li>
</ul></li>
</ul></li>
<li>2017-05-11 CT - abdomen
<ul>
<li>Atrophy of kidneys with cysts (1.3-2.4cm). Bil. hydronephrosis and
hydroureter. Distention of urinary bladder.</li>
</ul></li>
<li>2017-03-04 SONO - Nephrology
<ul>
<li>Finding:
<ul>
<li>Size Shape
<ul>
<li>R’t: 8.68 cm, uneven surface</li>
<li>L’t: 8.98 cm, uneven surface</li>
</ul></li>
<li>Cortex
<ul>
<li>R’t: Echogenicity: increased; Thickness: decreased</li>
<li>L’t: Echogenicity: increased; Thickness: decreased</li>
</ul></li>
<li>Pyramid:
<ul>
<li>R’t: prominent</li>
<li>L’t: prominent</li>
</ul></li>
<li>Sinus
<ul>
<li>Not Dilated</li>
</ul></li>
<li>Cyst
<ul>
<li>R’t: cortical, single,0.9cm in the middle kidney</li>
<li>L’t: cortical, parapelvic, multiple</li>
<li>L’t: cortical, parapelvic, multiple, 3 cystic lesions, the largest
one is 2.5 cm in the middle kidney</li>
</ul></li>
<li>Stone
<ul>
<li>None</li>
</ul></li>
<li>Mass
<ul>
<li>None</li>
</ul></li>
</ul></li>
<li>Interpretation
<ul>
<li>Bilateral small kidneys with chronic parenchymal changes.</li>
<li>Bilateral renal cysts.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-06 Urology
<ul>
<li>Q
<ul>
<li>For evaluation of possible bladder cancer</li>
<li>This is a 66 y/o man who was admitted to our hospital due to UGI
bleeding.</li>
<li>Abdominal CT on 20220401 revealed T3N2M1?, Stage:III or IVB.</li>
<li>We suspect the involvement of the bladder due to thickening of the
bladder wall and enlargement of lymph nodes near the bladder.</li>
<li>Please kindly assist to evaluate the patient and advise us on the
management of the condition.</li>
</ul></li>
<li>A
<ul>
<li>I have visit this patient and his family. The studies were
checked.</li>
<li>After recheck the CT scan, the right pelvic nodule could be right
distal ureter in my opinion.</li>
<li>Due to no hydronephrosis, smooth bladder wall and no gross
hematuria, cancer from urinary tract is not likely.</li>
<li>Please check urine cytology 3 sets in different days first.
Cystoscopy or ureteroscopic exams could be the next step if abnormal
finding.</li>
<li>Otherwise you may treat his gastric cancer first. Uro. clinic follow
up is indicated. Thanks for your consultation.</li>
</ul></li>
</ul></li>
<li>2022-03-31 Nephrology
<ul>
<li>Q
<ul>
<li>This is 66 y/o man who has underlying disease of
<ul>
<li>ESRD under H/D W246</li>
<li>Otitis media, unspecified, left ear</li>
<li>Sensorineural hearing loss, bilateral</li>
<li>AKI with obstructive uropathy s/p temporary HD and transurethral
incision of bladder neck was done at WanFang Hospital</li>
</ul></li>
<li>The patient was admitted due to upper GI bleeding.</li>
<li>We need you to arrange him to accept hemodialysis on QW246</li>
</ul></li>
<li>A
<ul>
<li>We will arrrange HD QW246. Please prescribe EPO 5000U qW4 if
Hb&lt;11.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-13
<ul>
<li>Surgery
<ul>
<li>radical subtotal gastectomy with en block distal pancreatectomy</li>
<li>D2 LN dissection</li>
</ul></li>
<li>Finding
<ul>
<li>distal gastric ulcerative mass with direct invasion to pancreas
body</li>
<li>multiple LN was noted</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-05-24 ~ 2022-06-?? - RT to the stomach and adjacent lymphatic
drainage area: 16.2 Gy/ 9 fx.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-15 - oxaliplatin 85mg/m2 110mg 2hr + leucovorin 400mg/m2
540mg 2hr + fluorouracil 2400mg 3250mg 46hr (adjuvant FOLFOX)</li>
<li>2022-08-31 - oxaliplatin 85mg/m2 110mg 2hr + leucovorin 400mg/m2
550mg 2hr + fluorouracil 2400mg 3280mg 46hr (adjuvant FOLFOX)</li>
<li>2022-08-31 - oxaliplatin 80mg/m2 110mg 2hr + leucovorin 400mg/m2
550mg 2hr + fluorouracil 2400mg 3300mg 46hr (adjuvant FOLFOX)</li>
<li>2022-08-31 - oxaliplatin 70mg/m2 70mg 2hr + leucovorin 400mg/m2
540mg 2hr + fluorouracil 2400mg 3200mg 46hr (adjuvant FOLFOX)</li>
<li>2022-06-27 - fluorouracil 200mg/m2 280mg 24hr D1-3 (adjuvant
CCRT)</li>
<li>2022-06-20 - fluorouracil 200mg/m2 280mg 24hr D1-5 (adjuvant
CCRT)</li>
<li>2022-06-13 - fluorouracil 200mg/m2 290mg 24hr D1-5 (adjuvant
CCRT)</li>
<li>2022-06-08 - fluorouracil 200mg/m2 290mg 24hr D1-3 (adjuvant
CCRT)</li>
<li>2022-05-30 - fluorouracil 200mg/m2 290mg 24hr D1-3 (adjuvant
CCRT)</li>
<li>2022-05-26 - fluorouracil 200mg/m2 290mg 24hr D1-2 (adjuvant
CCRT)</li>
</ul></li>
</ul>
<div id="section-256" class="section level3">
<h3>==========</h3>
</div>
<div id="section-257" class="section level3">
<h3>2022-10-03</h3>
<p>[drug identification]</p>
<p>requesting drug identification for 3 items.</p>
<p>the 2 items are identified as following while the other 1 item
remains unknown.</p>
<ul>
<li>Vemlidy (tenofovir 25mg)</li>
<li>U-Cal (calcium carbonate 500mg)</li>
<li>Folic acid 5mg</li>
</ul>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
<div id="section-258" class="section level3">
<h3>2022-05-30</h3>
<p>[drug identification]</p>
<p>Total 3 drugs for identification.</p>
<p>The 2 identified items has been shown as following while the other 1
items still remain unknown:</p>
<ul>
<li>A-Cal (calcium carbonate, CaCO3, 500mg)</li>
<li>Folic acid 5mg</li>
</ul>
<p>These drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
</div>
<div id="section-259" class="section level1">
<h1>700054037</h1>
<div id="section-260" class="section level2">
<h2>221003</h2>
<ul>
<li>diagnosis
<ul>
<li>Left pyriform sinus cancer, cT2N0M0, stage II status post
laryngomicrosurgery on 2019-3-11 and complicated extraction of tooth*13
on 2019-03-13</li>
<li>Left tongue cancer, pT3N0M0, stage III, status post left tongue
cancer excision and left neck dissection on 2019-02-22</li>
<li>Hypopharyngeal squamous cell carcinoma, moderately differentiated
s/p laryngomicrosurgery on 2022-05-11, pT3N0M0, stage III and
Tracheostomy + Port-A implantation on 2022-05-18</li>
<li>Carrier of viral hepatitis B</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-11 PD-L1 (22C3)
<ul>
<li>Tumor Proportion Score (TPS) assessment: TPS &lt; 1%</li>
</ul></li>
<li>2022-08-11 PD-L1 28-8 IHC
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percent of PD-L1 expression in tumor cells (TC): &lt; 1%</li>
</ul></li>
<li>2022-08-11 PD-L1 (SP142)
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana) - S2022-8227
<ul>
<li>Tumor type: Squamous cell carcinoma</li>
<li>Tumor location: Hypopharynx</li>
<li>Testing assay: SP142 Assay (Ventana)</li>
<li>Testing platform: BenchMark XT</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit</li>
<li>Control slide result: Pass,<br />
</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells):
Yes,<br />
</li>
</ul></li>
<li>Result:
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>Tumor cell (TC) staining assessment: TC category: TC &lt; 1%<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: upper-alpha">
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC &lt; 1%</li>
</ol></li>
</ul></li>
<li>Note:
<ul>
<li><ol style="list-style-type: decimal">
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-08-04 Nasopharyngoscopy
<ul>
<li>smooth nasopharynx and oropharynx; regression of hypopharyngeal
swelling compared to the previous study; thin mucosa over right
arytenoid cartilage; right vocal cord fixation; fair left vocal cord
movement.</li>
</ul></li>
<li>2022-07-28 MRI - larynx
<ul>
<li>Tongue cancer Stage IV, post chemotherapy * 3 cycles</li>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P opeation at left part of oral tongue and left neck.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P tracheosotmy.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Diffuse swelling at hypopharynx, mild regession as comapred with MRI
on 20220505.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>No enlarged lymph node.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No abnormality at nasopharynx, oropharynx and larynx.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Mild hypertrophic degeneration of C-spine.</li>
</ol></li>
</ul></li>
<li>IMP:
<ul>
<li>Post-operation change at left part of oral tongue without evidence
of recurrence. Less swelling of the hypopharynx, as compared with MRI on
20220505. Suggest regular follow-up.</li>
</ul></li>
</ul></li>
<li>2022-05-25 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Cannot rule out Inferior infarct, age undetermined</li>
</ul></li>
<li>2022-05-25 CXR
<ul>
<li>S/P tracheostomy</li>
<li>S/P port-A implantation.</li>
</ul></li>
<li>2022-05-20 Tc-99m DMP whole body bone scan
<ul>
<li>In comparison with the previous study on 2019/02/14, no prominent
change is noted in the lesions in the middle C-spine, lower T- and lower
L-spines. Degenerative change may show this picture.</li>
<li>No prominent change is noted in the previous faint hot spot in the
right temporal area of the skull, possibly more benign in nature.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture. Please correlate with other clinical findings for
further evaluation.</li>
<li>Increased activity in bilateral shoulders and knees, compatible with
benign joint lesions.</li>
</ul></li>
<li>2022-05-19 Patho - stomach biopsy
<ul>
<li>Duodenum, 2nd portion, biopsy — Compatible with ulcer</li>
<li>Microscopically, the sections show a picture of mucosal erosion with
inflammatory cells infiltrate, compatible with ulcer. Follow up</li>
</ul></li>
<li>2022-05-12 Patho - larynx biopsy
<ul>
<li>Hypopharynx, right, biopsy — Squamous cell carcinoma, moderately
differentiated</li>
<li>Section shows a piece of squamous mucosa with infiltration of nests
of neoplastic squamous cells.</li>
<li>The immunohistochemical stain of p16 is positive.</li>
</ul></li>
<li>2022-05-12 Patho - larynx biopsy
<ul>
<li>Esophagus, right, upper, posterior wall, biopsy — Squamous cell
carcinoma, moderately differentiated</li>
<li>Section shows a piece of squamous mucosa with nests of neoplastic
squamous cells in submucosa.</li>
<li>The immunohistochemical stain of p16 is positive.</li>
</ul></li>
<li>2022-05-05 MRI - larynx
<ul>
<li>The current study was compared to the prior one obtained on
2021/11/02.</li>
<li>Markedly enhancing mucosal thickening and swollen change of larynx
and hypopharyngeal space. Suggest clinical correlation.</li>
<li>Post operative appearance in or at the area of left tongue, no focal
mass or nodule.</li>
<li>Post LNs dissection with clips retention with metallic artifact
and/or soft tissue or muscle defect, left.</li>
<li>Normal appearance of both mastoid air-cells.</li>
<li>The bilateral parotid and submandibular glands enhance as before. It
is consistent with post-radiation inflammation.</li>
<li>Clear appearacne of all paranasal sinuses.</li>
</ul></li>
<li>2021-11-02 MRI - larynx
<ul>
<li>Findings
<ul>
<li>Post operative appearance in or at the area of left tongue, no focal
mass or nodule.</li>
<li>Post LNs dissection with clips retention with metallic artifact
and/or soft tissue or muscle defect, left.</li>
<li>No evident abnormal enlarged lymph node in the visible neck.</li>
<li>Heterogeneous soft tissue in the right vocal cord, posterior wall of
the bilaeral hypopharynx, righy hypopharynx and bilateral aryepiglottic
folds, more on the right side, seems in progression.<br />
</li>
<li>After IV contrast administration shows well or heterogenous
enhancement of the mass or tumor.</li>
</ul></li>
<li>IMP:
<ul>
<li>Post OP at left tongue with left neck dissection. No local
recurrence, no neck LAP</li>
<li>Seems in progression of bil. hypopharynx, larynx masses? need
clinical check, partially due to post R/T effect?<br />
</li>
</ul></li>
</ul></li>
<li>2021-07-15 MRI - larynx
<ul>
<li>Findings
<ul>
<li>s/p left neck lymph node dissection</li>
<li>heterogeneous enhancing soft tissue in the right vocal cord,
posterior wall of the bilaeral hypopharynx, righy hypopharynx and
bilateral aryepiglottic folds, more on the right side.</li>
<li>no neck LAP.</li>
<li>unremarkable change in the tongue.</li>
<li>unremarkable change at the skull base</li>
</ul></li>
<li>IMP:
<ul>
<li>suspected tumors in the bilateral hypopharynx and right vocal
cord.</li>
</ul></li>
</ul></li>
<li>2019-02-22 Surgical pathology Level VI
<ul>
<li>pathologic diagnosis
<ul>
<li>Tongue, left, excision — Squamous cell carcinoma, moderately
differentiated</li>
<li>AJCC Pathologic staging — pT3N0Mx, stage III at least</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Squamous cell carcinoma with focal salivary gland
invasion</li>
<li>Histologic Grade: G2: moderately differentiated</li>
<li>Microscopic Tumor Extension: 1.2 cm in thickness</li>
</ul></li>
</ul></li>
<li>2019-02-18 Surgical pathology Level IV
<ul>
<li>pathologic diagnosis
<ul>
<li>Tumor, left pyriform sinus, biopsy — Squamous cell carcinoma</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Microscopically, the sections show a picture of squamous cell
carcinoma characterized by some solid tumor nests show enlarged,
hyperchromatic and pleomorphic nuclei infiltrate in the stroma with
scant keratin formation.</li>
<li>Immunohistochemistry shows CK5/6(+); P63(+) and CK(+) for tumor
cells.</li>
</ul></li>
</ul></li>
<li>2019-02-15 Upper G-I panendoscopy
<ul>
<li>Diagnosis: suspect larynx lesion</li>
<li>Suggestion: suggest further study to check cancer or precancer
lesion at larynx</li>
</ul></li>
<li>2019-02-14 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the middle C-spine, lower T- and lower
L-spines. Degenerative change may show this picture. Please correlate
with other imaging modalities for further evaluation.</li>
<li>A faint hot spot in the right temporal area of the skull. The nature
is to be determined (post-traumatic change? other nature?). Please
follow up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders and knees, compatible with
benign joint lesion.</li>
</ul></li>
<li>2019-02-14 MRI - larynx
<ul>
<li>Left tongue CA, T3N0Mx stage III. Left pyriform sinus CA, T1N0Mx,
stage I.</li>
</ul></li>
<li>2019-01-29 Surgical pathology Level IV
<ul>
<li>Tongue, lower, left, biopsy — Squamous cell carcinoma, p16(-)</li>
<li>The sections show a picture of squamous cell carcinoma, composed of
nests of moderately differentiated neoplastic squamous cells with
stromal invasion and desmoplastic reaction. Subtle keratin formation is
present.</li>
<li>IHC: p16(-).</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-16 Hemato-Oncology
<ul>
<li>Impression:
<ul>
<li>Squamous cell carcinoma, moderately differentiated, of the left oral
tongue, s/p wide excision and left neck dissection, stage pT3N0(cM0),
stage III, s/p radiotherapy.</li>
<li>Squamous cell carcinoma of the left pyriform sinus, stage cT2N0M0
(tumor board conclusion), s/p radiotherapy, with relapse.</li>
<li>HBV</li>
</ul></li>
<li>Suggestion:
<ul>
<li>If sugical intervention is not feasible, CCRT is indicated. We would
like to perform chemotherapy for this case.</li>
<li>Please arrange Port-A insertion for him.</li>
</ul></li>
</ul></li>
<li>2022-05-13 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This is a 54 y/o male patient with history of 1. Left oral tongue,
SCC, moderately differentiated s/p wide excision and left neck
dissection, stage pT3N0(cM0), stage III, s/p radiotherapy on 2019-05-20.
2. Left pyriform sinus SCC, stage cT2N0M0, Completion of radiotherapy on
2019-05-20, and HBV.</li>
<li>He was regularly followed up at our hospital. At Dr. Su’s OPD on
2022/05/03, PE showed no obivious palpable neck LN. Nasopharyngoscopy
revealed posterior hypopharyngeal tumor with involvement of right
pyriform sinus apex, with suspected esophageal involvement, and right
vocal palsy. He was admitted underwent LMS tumor mapping on 20220511.
The whole procedure performed smoothly. However, dyspnea noted since
20220512, we check nasopharyngoscope revealed right vocal palsy.</li>
<li>Hypopharyngeal cancer was suspected, but the pathology data
pending.</li>
<li>It was explained by Dr. Wanfu Su that a tracheostomy was necessary
in order to maintain a patent airway, and because the previous dose of
radiotherapy had reached its upper limit, a total laryngectomy would be
needed. Therefore, chemoradiotherapy may be indicated for the patient.
Consult to determine this possibility.</li>
</ul></li>
<li>A
<ul>
<li>S: For discussion the salvage treatment modality.</li>
<li>A:
<ul>
<li>Squamous cell carcinoma, moderately differentiated, of the left oral
tongue, s/p wide excision and left neck dissection, stage pT3N0(cM0),
stage III, s/p radiotherapy.</li>
<li>Squamous cell carcinoma of the left pyriform sinus, stage cT2N0M0
(tumor board conclusion), s/p radiotherapy, with relapse.</li>
</ul></li>
<li>P:
<ul>
<li>According to HN tumor board (2022-05-13) conclusion, salvage surgery
including tracheostomy is recommended.</li>
<li>The patient already received full dose radiotherapy before, further
radiotherapy of previous irradiated area with low dose CCRT without
surgery is only palliative and may be not effective. The possible
effects of re-irradiation were well explained to the patient and his
family. The patient would like to go back for consideration including
neoadjuvant chemotherapy and then make a decision.</li>
<li>Please also consult medical oncologist.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-18
<ul>
<li>Surgery
<ul>
<li>Tracheosotmy</li>
</ul></li>
<li>Finding
<ul>
<li>Insertion of Shiley #6.</li>
</ul></li>
<li>Procedure
<ul>
<li>The patient was in supine position with neck hyperextended. Skin was
disinfected and draped as usual. Local anesthesia with Bosmin-rinsed
Xylocaine was injected into the subcutaneous tissue and the pretracheal
area layer by layer. A vertical skin incision was made in the midline of
lower neck. Subcutaneous tissue, fascia and strap muscles were
seperated, then the thyroid gland was seen and hooked upwards with
thyroid hooks. The tracheal rings were cut in longitudinal direction. A
oval-shaped window was made at the 2 nd to 3 rd rings. A Shiley #6
cuffed tracheostomy tube was inserted. The patient tolerated the above
procedure well.</li>
</ul></li>
</ul></li>
<li>2022-05-11
<ul>
<li>Surgery
<ul>
<li>Laryngomicrosurgery for tumor mapping      </li>
</ul></li>
<li>Finding
<ul>
<li>upper esophageal posterior wall mass</li>
<li>hypopharyngeal (postcricoid) tumor, with right AE fold
involvement</li>
</ul></li>
<li>Procedure
<ul>
<li>The patient lay in supine position and general anesthesia was set up
via EGTA. The neck was slightly extended with shoulder-roll. Rigid
laryngoscope was applied gently with fixation of chest support.
Microscope was use for the microlaryngoscopic procedure. Upper
esophageal posterior wall mass and postcricoid tumor, with right AE fold
involvement. Compression with Bosmin-rinsed cotton balls was used for
hemostasis and removed thereafter. The patient standed the whole
procedure well.   </li>
</ul></li>
</ul></li>
<li>2019-03-13
<ul>
<li>Diagnosis
<ul>
<li>Deep caries of multiple teeth</li>
</ul></li>
<li>PCS
<ul>
<li>92014C</li>
</ul></li>
<li>Finding
<ul>
<li>Multiple deep caries and retained roots of tooth
11,12,13,14,16,18,21,22,23,27,36,37 and 38.</li>
</ul></li>
<li>Procedure
<ul>
<li>Patient was on a supine position and anesthetized through nasal
endotracheal tube in the usual method.</li>
<li>Patient head was draped and nasal endotracheal tube was secured at
the patient’s forehead area.</li>
<li>Patient’s mouth was soaked with aqueous b-iodine solution.</li>
<li>Patient’s mouth, lower face, neck and shoulder areas were
disinfected with aqueous b-iodine solution</li>
<li>Patient’s body and head, except operation fields, were draped in the
usual manner with 2-layer sterilized sheets.</li>
<li>Excess aqueous b-iodine solution in
patient<code>s mouth was suctioned and a 4*8 gauze was placed at the patient</code>s
throat to prevent fluid from entering patient’s airway.</li>
<li>Several cartridges of 1.8ml local anesthetic solution containing
with 0.01mg epinephrine were injected into the operation fields for
local hemostasis.</li>
<li>Complicated extraction of of tooth
11,12,13,14,16,18,21,22,23,27,36,37 and 38 was done carefully</li>
<li>Primary closure of the surgical wound with 3-0 and 4-0 Vicryl</li>
<li>After all the procedures were done, plenty of N/S was used to
irrigate the oral cavity.</li>
<li>Patient regained consciousness smoothly and gradually after the
operation was completed.</li>
</ul></li>
</ul></li>
<li>2019-03-11
<ul>
<li>Diagnosis
<ul>
<li>Hypopharyngeal CA, Lt.</li>
</ul></li>
<li>PCS
<ul>
<li>66032B</li>
</ul></li>
<li>Finding
<ul>
<li>FK oral retractor failed to approach left hypopharynx</li>
<li>LMS approach for tumor mapping, pyriform sinus posterior wall biopsy
done</li>
</ul></li>
<li>Procedure
<ul>
<li>The patient lay in supine position and general anesthesia was set up
via EGTA. The neck was slightly extended with shoulder-roll. FK oral
retractor was used first but failed to approach left hypopharynx. Rigid
laryngoscope was applied gently with fixation of chest support.
Microscope was use for the microlaryngoscopic procedure. left pyriform
sinus posterior wall tumor mapping done by microforcep. Compression with
Bosmin-rinsed cotton balls was used for hemostasis and removed
thereafter. The patient standed the whole procedure well.</li>
</ul></li>
</ul></li>
<li>2019-02-22
<ul>
<li>Diagnosis
<ul>
<li>left tongue cancer</li>
</ul></li>
<li>PCS
<ul>
<li>71013A</li>
</ul></li>
<li>Finding
<ul>
<li>1.7x1.5x1.2cm tumor at the junction of left mouth floor and ventral
tongue, excision with adequate safty margin.</li>
<li>Excision of left neck lymph nodes from level I to level IV.</li>
<li>IJV, SAN and SCM were preserved well.</li>
</ul></li>
<li>Procedure
<ul>
<li>He was in supine position with neck hyperextended. General
anesthesia was set via nasal endotracheal tube. Then he was disinfected
and draped as usual. The skin incision with neck and lower lip extension
was made. The left side skin flaps were developed in the subplatysmal
plane as far as the midline neck anteriorly, trapezius muscle laterally,
clavicle inferiorly, and mandible superiorly. After the flaps were
completely elevated, the SCM muscle was dissected out, then the whole
lymphoareolar tissue with the lymph nodes were dissected carefully off
the carotid artery sheath. Several lymph nodes were noted at level IV,
III,II, The internal jugular vein, vagus nerve and spinal accessory
nerve were identified and preserved, One JP ball was inserted for
drainage and the wound was closed in 2 layers. Thee the oral cavity was
disinfected and irrigated. The tumor invaded the junction of mouth floor
and left ventral tougue. The whole tongue and mouth floor was removed as
a whole with adequate safty margin. After hemostasis, the tongue was
sutured anteriorposteriorly, NG tube was inserted for feeding.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-30 - docetaxel 60mg/m2 100mg 1hr D1 + cisplatin 60mg/m2
100mg 24hr D1 + fluorouracil 750mg/m2 1300mg 24hr D1-5</li>
<li>2022-09-01 - docetaxel 60mg/m2 100mg 1hr D1 + cisplatin 60mg/m2
100mg 24hr D1 + fluorouracil 750mg/m2 1300mg 24hr D1-5</li>
<li>2022-08-10 - docetaxel 60mg/m2 100mg 1hr D1 + cisplatin 60mg/m2
100mg 24hr D1 + fluorouracil 750mg/m2 1300mg 24hr D1-5</li>
<li>2022-07-15 - docetaxel 60mg/m2 100mg 1hr D1 + cisplatin 60mg/m2
100mg 24hr D1 + fluorouracil 750mg/m2 1300mg 24hr D1-5</li>
<li>2022-06-23 - docetaxel 60mg/m2 100mg 1hr D1 + cisplatin 60mg/m2
100mg 24hr D1 + fluorouracil 750mg/m2 1300mg 24hr D1-5</li>
<li>2022-06-09 - docetaxel 35mg/m2 60mg 1hr D1 + cisplatin 30mg/m2 50mg
2hr D1 + fluorouracil 2000mg/m2 3500mg 46hr</li>
<li>2022-06-02 - docetaxel 35mg/m2 60mg 1hr D1 + cisplatin 30mg/m2 50mg
2hr D1 + fluorouracil 2000mg/m2 3500mg 46hr</li>
</ul></li>
</ul>
<p>[note]</p>
<p>Locally advanced squamous cell carcinoma of the head and neck ( <a href="https://www.uptodate.com/contents/locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-approaches-combining-chemotherapy-and-radiation-therapy" class="uri">https://www.uptodate.com/contents/locally-advanced-squamous-cell-carcinoma-of-the-head-and-neck-approaches-combining-chemotherapy-and-radiation-therapy</a>
)</p>
<ul>
<li>Systemic Therapy Regimen
<ul>
<li>Agents with proven activity in squamous cell head and neck cancer
that are most commonly included in either induction or concurrent
chemotherapy regimens include the platinum compounds (cisplatin,
carboplatin), fluorouracil, and taxanes (docetaxel, paclitaxel).</li>
<li>Induction chemotherapy - Multiple clinical trials have established
that three drug combinations of cisplatin, fluorouracil, plus a taxane
are the preferred approach for induction chemotherapy.
<ul>
<li>Initial clinical trials found that cisplatin and fluorouracil (PF;
cisplatin, 100 mg/m2, and fluorouracil, 1000 mg/m2/day continuous
24-hour infusion for five days) given every three weeks as induction
chemotherapy induced higher rates of complete response and better
survival compared with two cycles of an earlier cisplatin and
bleomycin-based regimens or regimens using two cycles of cisplatin with
shorter infusions of fluorouracil.</li>
<li>Subsequent randomized trials found that the addition of a taxane
(docetaxel, paclitaxel) to PF induction chemotherapy enhanced the
effectiveness of induction chemotherapy used with radiation therapy (RT)
alone or with RT plus concurrent chemoradiation. In contrast, a small
randomized trial in larynx/hypopharynx cancer did not show a benefit
from the addition of cetuximab to induction chemotherapy that included
docetaxel and cisplatin followed by accelerated RT with or without
concurrent cetuximab.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Nincort Oral Gel (triamcinolone) is used for the treatment of
chemotherapy-induced oral ulcers, while Baraclude (entecavir) is
utilized for the treatment of HBV infections.</li>
<li>The laboratory results on 2022-09-27 were grossly normal except for
a slight pancytopenia.</li>
</ul>
<p>chemotherapy induced oral ulcer is treated with Nincort Oral Gel
(triamcinolone) and hepatitis B is surpressed using Baraclude
(entecavir)</p>
</div>
</div>
<div id="section-261" class="section level1">
<h1>700358478</h1>
<div id="section-262" class="section level2">
<h2>221003</h2>
<p>{Adenocarcinoma of splenic flexure colon with obstruction, and liver,
lung, bone metastasis with carcinomatosis, cT3N2bM1c, stage IVC status
post colostomy on 2021-10-06}</p>
<ul>
<li>exam findings
<ul>
<li>2022-09-01, -08-15 Nerve Conduction Velocity (NCV) and
Electromyography (EMG)
<ul>
<li>Findings
<ul>
<li>The NCV study showed slowing sensory conduction velocity in
bilateral ulnar nerves. The F wave study showed prolonged latency in
left tibial nerve. The H reflex study showed both prolonged.</li>
</ul></li>
<li>Conclusion
<ul>
<li>The above findings suggest bilateral ulnar neuropathy and bilateral
lumbosacral radiculopathy. Advise clinical correlation.</li>
</ul></li>
</ul></li>
<li>2022-08-16 MRI - brain
<ul>
<li>Known a case of colon cancer. No metastatic lesion of brain
parenchyma.</li>
<li>Moderate periventricular small vessel disease. NO acute ischemic
infarct.</li>
<li>Prominence of cerebral cortical sulci, gyri atrophy and
proportionate ventricular dilatation.</li>
<li>MR angiography of the brain shows atherosclerotic change of
intracranial and carotid vessels.</li>
<li>Short segmental moderate stenosis of left distal ICA (cavernous
segment).</li>
</ul></li>
<li>2022-07-14 CT - abdomen, pelvis
<ul>
<li>S/P colon operation. Mild decreased size of lung and liver
metastases. Multiple bony metastases.</li>
<li>Enlargement of prostate. Mild dilatation of abdominal aorta (3.8cm)
with mural thrombus.</li>
</ul></li>
<li>2022-06-27 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>multiple randomly distributed pulmonary nodules of varying sizes (up
to 13mm at lingula, lower lobes predominance) due to metastases.</li>
<li>extensive, bilateral upper lobe predominant, centrilobular
emphysema, in the lungs. and subpleural paraseptal emphysema</li>
<li>minimal fibrosis in paravertebral region of RLL, related to
osteophytes of spine.</li>
</ul></li>
<li>Mediastinum and hila: no enlarged LN or mass.</li>
<li>Vessels: moderate coronary arterial calcification</li>
<li>Aorta: normal caliber, mild atherosclerotic change of aortic arch
and descending thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: no effusion or nodule.</li>
<li>Chest wall and visible lower neck: diffuse blastic change in bones
of thoracic cage, with focal expansile blastic change of left 5th
rib.</li>
<li>Visible abdominal contents: small metastatic lesions in the
liver.</li>
</ul></li>
<li>Impression:
<ul>
<li>colon cancer with lung, liver, and bones metastases, in progression
of lung metastases compared with CT on 2022/04/15</li>
</ul></li>
</ul></li>
<li>2022-06-16 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is suspected.
Please correlate with CT.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-04-16 Chest AP - portable
<ul>
<li>S/P port-A implantation.</li>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is suspected.
Please correlate with CT.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-04-15 CT - abdomen, pelvis
<ul>
<li>Splenic flexure colon cancer with multiple metastatic nodes in the
adjacent omentum and mesentery, multiple metastases in the liver, lung
and bone S/P C/T show partial response.</li>
<li>RCC 2.4 cm at left kidney lower pole shows stationary.</li>
<li>The differential diagnosis include angiomyolipoma (lipid-poor).
Follow up is indicated.</li>
</ul></li>
<li>2022-03-31 Chest PA erect view
<ul>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is suspected.
Please correlate with CT.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-03-11 Bronchial dilation test
<ul>
<li>Moderate obstructive ventilatoryimpairment without significant
reversibility</li>
<li>FEV1/FVC = 45%, FVC = 96%, FEV1 = 54%</li>
</ul></li>
<li>2022-03-10 Chest PA
<ul>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is
suspected.</li>
</ul></li>
<li>2022-01-19 CT
<ul>
<li>Findings:
<ul>
<li>Prior CT identified lobulated segmental wall thickening in the
splenic flexure colon is noted again, mild decreasing in size.
<ul>
<li>In addition, prior CT identified multiple metastatic nodes in the
surrounding mesentery and omentum are noted again, decreasing in
size.</li>
</ul></li>
<li>Prior CT identified mutliple metastases on both hepatic lobes are
noted again, decreasing in size.
<ul>
<li>The size of S5 metastasis in prior and current CT is measured 3.1 cm
and 2.5 cm, respectively.</li>
</ul></li>
<li>Prior CT identified mutliple metastases on both lung are noted
again, decreasing in size.
<ul>
<li>The size of LUL metastasis in prior and current CT is measured 2 cm
and 1.5 cm, respectively.</li>
</ul></li>
<li>Prior CT identified multiple osteoblastic bony metastases in the
L-spine and bilateral ilium are noted again, increasing density that may
be bony metastases with progressive disease.</li>
<li>Prior CT suspected renal cell carcinoma measuring 2 cm in left
kidney lower pole is noted again, stable in size.
<ul>
<li>The differential diagnosis include angiomyolipoma (lipid-poor).</li>
</ul></li>
<li>Abdominal aorta aneurysm measuring 3.3 cm in diameter with
atherosclerotic change and mural thrombosis is noted.
<ul>
<li>Right common iliac artery also shows aneurysm 1.7 cm in diameter
with mild mural thrombus formation.</li>
</ul></li>
<li>Adenoma 0.9 cm in left adrenal gland it noted.</li>
</ul></li>
<li>Impression:
<ul>
<li>Splenic flexure colon cancer with multiple metastatic nodes in the
adjacent omentum and mesentery, and multiple metastases in the liver and
lung S/P C/T show partial response.</li>
<li>Multiple bony metastases show more osteoblastic change.</li>
<li>RCC 2 cm at left kidney lower pole shows stationary. The
differential diagnosis include angiomyolipoma (lipid-poor). Follow up is
indicated.</li>
</ul></li>
</ul></li>
<li>2021-09-29 CT
<ul>
<li>Findings:
<ul>
<li>There is lobulated segmental wall thickening in the splenic flexure
colon measuring 1.7 cm in wall thickness, causing lumen narrowing that
is compatible with adenocarcinoma with impending obstruction.
<ul>
<li>In addition, there are multiple metastatic nodes in the surrounding
mesentery and omentum, and the largest one 2.2 cm.</li>
</ul></li>
<li>There are mutliple poor enhancing masses on both hepatic lobes and
the largest one measuring 3.1 cm in S5 that are compatible with liver
metastases.</li>
<li>There are several osteoblastic change of the L-spine and bilateral
ilium that are compatible with bony metastases.</li>
<li>Abdominal aorta aneurysm measuring 3.3 cm in diameter with
atherosclerotic change and mural thrombosis is noted.
<ul>
<li>Right common iliac artery also shows aneurysm 1.7 cm in diameter
with mild mural thrombus formation.</li>
</ul></li>
<li>There are few small soft tissue nodules in both lower lung that are
compatible with lung metastases.</li>
<li>There is a well-defined heterogeneous poor enhancing mass measuring
2 cm in left kidney lower pole that may be RENAL CELL CARCINOMA. The
differential diagnosis include metastasis.
<ul>
<li>Please correlate with contrast enhanced dynamic CT or MRI.</li>
</ul></li>
<li>Adenoma 0.9 cm in left adrenal gland it noted.</li>
<li>Imaging stage: T3N2bM1c stage IVC</li>
</ul></li>
</ul></li>
<li>2021-09-28 Patho - Colon biopsy
<ul>
<li>Colon, splenic flexure, biopsy - Adenocarcinoma, moderately
differentiated</li>
<li>The secvtions show a picture of adenocarcinoma, composed of columnar
neoplastic cells, arranged in glandular patterns with desmoplastic
stromal reaction.</li>
<li>IHC, tumor cells reveal: EGFR(-), MLH1(+), PMS2(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li>2021-09-23 CT
<ul>
<li>Imaging stage: T4N2M1</li>
<li>Imp: Colon cancer at splenic flexure with liver, lung and bone
mets.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-13 Neurology
<ul>
<li>Q
<ul>
<li>This 73 year-old man patient is a case of Colon cancer with
obstruction and splenic, liver, lung and bone metastases, T3N2bM1b,
stage IVB s/p T loop colostomy on 2021/10/06 s/p chemotherapy with
FOLFIRI/Avastin, SD. He was admitted for palliative chemotherapy with
Avastin(C16)/FOLFIRI(C10D1) from 2022/08/12~2022/08/14.</li>
<li>This time, dizziness with bilateral lower limbs weakness for 2
months. Now, for evaluate examination of dizziness with bilateral lower
limbs weakness. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>The patient had chronic unsteady gait.
<ul>
<li>Cranial nerve: intact</li>
<li>motor: intact</li>
<li>sensory: intact</li>
<li>Romberg (+)</li>
<li>FNF: bilateral dysmetria</li>
</ul></li>
<li>Imp:
<ul>
<li>suspect cerebellar dysfunction + suspected peripheral sensory nerve
disease</li>
</ul></li>
<li>P:
<ul>
<li>Arrange brain MRI with/without contrast if no contraindication.</li>
<li>Arrange NCV upper and lower limbs (motor + sensory + F + H)</li>
<li>Try suzin 1# HS</li>
<li>Check TSH, Free T4, ANA, HbA1C, Anti SSA/SSB, Vit B12, folic
acid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-14 Thoracic Medicine
<ul>
<li>Underlying disease:
<ul>
<li>Colon cancer with multiple lung meta, ribs mets, bone mets,
cT3N2M1c, stage IV</li>
<li>Heavy smoking (quited), with COPD, centrilocular emphysema, PFT
showed: moderate obstruction, involving both large and small sized
airways</li>
<li>Baseline hypoxemia, room air SaO2 only 94%</li>
<li>Old TB with LUL calcinfied granuloma.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Favor chest tight due to (1) rib mets with pain, (2) COPD, (3)
abdominal distension with diaphragm dysfunction, (4) possibly GERD</li>
<li>Add Foster 2 puff BID, spiriva 2 puff HS (from
Adult-Aerochamber)</li>
<li>Self-paid Adult-Aerochamber recommended</li>
<li>Try Topaal for GERD</li>
<li>Pain relief</li>
<li>Avoid constipation</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-06 T loop colostomy
<ul>
<li>Splenic flexure colon cancer with obstruction, and liver, lung, bone
metastasis with carcinomatosis, cT3N2bM1c, stage IVC</li>
<li>RUQ stoma with stent</li>
</ul></li>
<li>2017-12-11 Biopsy prostate (punch)
<ul>
<li>Prostatic hyperplasia with urinary retention</li>
<li>Finding
<ul>
<li>DRE: stiffness Rt&gt; Lt but not hard nodule, may be huge
adenoma</li>
<li>Hypertrophy of prostate with high bladder neck, enlarged median
lobe</li>
<li>Moderate trabeculation of bladder</li>
<li>intraoperative impression: prostate volume &gt;100cc</li>
<li>52g retrieved</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2022-09-30 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4500mg 46hr</li>
<li>2022-09-07 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-08-26 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-08-12 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-07-28 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-07-14 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-06-29 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4700mg 46hr</li>
<li>2022-06-16 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4500mg 46hr</li>
<li>2022-06-01 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4500mg 46hr</li>
<li>2022-05-13 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
300mg 90min + leucovorin 400mg/m2 750mg 2hr + 5-Fu 400mg/m2 750mg 10min
+ 5-Fu 2400mg/m2 4500mg 46hr</li>
<li>2022-04-27 - irinotecan 180mg/m2 90min + leucovorin 400mg/m2 2hr +
5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2 46hr</li>
<li>2022-04-15 - irinotecan 180mg/m2 90min + leucovorin 400mg/m2 2hr +
5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2 46hr</li>
<li>2022-03-29 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2022-03-14 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2022-02-22 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2022-01-19 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2022-01-04 - bevacizumab 5mg/kg 400mg 90min + irinotecan 180mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2021-12-22 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2021-12-09 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2021-11-25 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2021-11-12 - bevacizumab 5mg/kg 400mg 90min + irinotecan 150mg/m2
90min + leucovorin 400mg/m2 2hr + 5-Fu 400mg/m2 10min + 5-Fu 2400mg/m2
46hr</li>
<li>2021-10-26 - irinotecan 120mg/m2 90min + leucovorin 400mg/m2 2hr +
5-Fu 300mg/m2 10min + 5-Fu 2400mg/m2 46hr
<ul>
<li>Ref UpToDate - FOLFIRI plus bevacizumab chemotherapy for metastatic
colorectal cancer</li>
</ul></li>
</ul></li>
</ul>
<div id="section-263" class="section level3">
<h3>==========</h3>
</div>
<div id="section-264" class="section level3">
<h3>2022-10-03</h3>
<ul>
<li>Irinotecan has been reported with following adverse drug reactions
and incidences: dizziness (15% to 21%), drowsiness (9%).</li>
<li>Neurology studies on 2022-09-01 showed slowing sensory conduction
velocity in bilateral ulnar nerves and prolonged latency in left tibial
nerve.</li>
<li>A walking stick is being prepared by the Discharge Planning Service
Center.</li>
</ul>
</div>
<div id="section-265" class="section level3">
<h3>2022-09-08</h3>
<ul>
<li>It is recommended to prescirbe the patient-carried diphenidol
(25mg/tab) 1# TIDPC (currently TID) according to the package
insert.</li>
</ul>
</div>
<div id="section-266" class="section level3">
<h3>2022-06-30</h3>
<ul>
<li>2022-06-27 CT showed lung mets in progression, however tumor markers
decreased slightly (CEA: 2022-06-24 2235 ng/mL &lt;- 2022-06-14 2447
ng/mL; CA199: 2022-06-24 3344 U/mL &lt;- 2022-06-14 3614 U/mL).</li>
<li>Lung mets have been developed. Oxaliplatin is rarely associated with
pulmonary toxicity. For patients with unexplained pulmonary symptoms,
oxaliplatin is recommended to be withheld until interstitial lung
disease or pulmonary fibrosis is excluded.
<ul>
<li>Oxaliplatin-induced Pulmonary Toxicity: A Rare but Serious
Complication. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188452/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188452/</a></li>
<li>Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal
Malignancies: Two Case Reports and Review of the Literature. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441996/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441996/</a></li>
<li>Pulmonary Fibrosis Secondary to Oxaliplatin Treatment: From Rarity
to Reality: A Case Study and Literature Review. <a href="https://link.springer.com/article/10.1007/s40487-020-00127-z" class="uri">https://link.springer.com/article/10.1007/s40487-020-00127-z</a></li>
</ul></li>
</ul>
</div>
<div id="section-267" class="section level3">
<h3>2022-06-17</h3>
<ul>
<li>A partial response was seen on the CT image of 2022-04-15 (compared
to 2022-01-19), however some biomarker levels have continued to
rise.</li>
<li>Biomarkers time series:
<ul>
<li>CEA
<ul>
<li>2022-06-14 2447 ng/mL</li>
<li>2022-05-25 2039 ng/mL</li>
<li>2022-04-27 2063 ng/mL</li>
<li>2022-03-30 3132 ng/mL</li>
<li>2022-02-16 1956 ng/mL</li>
<li>2022-01-18 771 ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2022-06-14 3614 U/mL</li>
<li>2022-05-25 2383 U/mL</li>
<li>2022-04-27 2758 U/mL</li>
<li>2022-03-30 2837 U/mL</li>
<li>2022-02-16 2376 U/mL</li>
<li>2022-01-18 1089 U/mL</li>
</ul></li>
</ul></li>
<li>The creatinine level on 2022-06-14 increased to 1.43 mg/dL slightly
above ULN and a record high, which might need to be kept in check.</li>
<li>SpO2 96%, TPR, BP were stable since this hospitalization. No issue
with active prescription.</li>
</ul>
</div>
<div id="section-268" class="section level3">
<h3>2022-06-02</h3>
<ul>
<li>During the past five months, the patient’s body weight has increased
by more than ten kilograms (84.2 kgw 2022-06-01 &lt;- 71.5 kgw
2022-01-05), and insomnia remained on the patient’s medical problem list
in recent hospital stays even when lorazepam has been prescribed. The
use of steroids (both systemically and inhalationally) can result in
these side effects.
<ul>
<li>Steroid-Induced Sleep Disturbance and Delirium: A Focused Review for
Critically Ill Patients. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357890/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357890/</a></li>
<li>Steroid-induced mental disorders in cancer patients: a systematic
review. <a href="https://doi.org/10.2217/fon-2017-0306" class="uri">https://doi.org/10.2217/fon-2017-0306</a></li>
</ul></li>
<li>Pharmacotherapy should not be the sole treatment of insomnia.
Cognitive behavioral therapy for insomnia (CBT-I) is the preferred
first-line treatment for chronic insomnia in adults. The evidence base
is stronger for CBT-I than for medications. When used, medications
should be combined with healthy sleep habits and CBT-I, when appropriate
and available.
<ul>
<li>The effectiveness of non-pharmacological sleep interventions for
people with chronic pain: a systematic review and meta-analysis. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092772/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092772/</a></li>
</ul></li>
</ul>
</div>
<div id="section-269" class="section level3">
<h3>2022-04-28</h3>
<ul>
<li>Recent two consecutive CT scans have indicated a partial response of
splenic flexure colon cancer to the current regimen. However, there is
an enlarged tumor on the lower pole of the left kidney that might need
to be addressed (2.4cm 2022-04-15 &lt;- 2.0cm 2022-01-19, a 20% increase
in diameter in 3 months).</li>
<li>The CEA and CA199 levels on 2022-04-27 fell to 2063ng/mL (from
3132ng/mL on 2022-03-30) and 2758U/mL (from 2837U/mL on 2022-03-30),
which were both positive signs.</li>
<li>In three months, the body weight increased by ten kilograms (81.2
kgw 2022-04-27 &lt;- 71.5 kgw 2022-01-05). According to lab data on
2022-04-27, liver and kidney function, serum electrolytes, and blood
cell counts were all within normal ranges. Cachexia is still a
diagnosis.</li>
<li>The current chemotherapy regimen FOLFIRI plus bevacizumab is
generally well tolerated by the patient and respiratory symptoms have
been managed with corresponding medication.</li>
</ul>
</div>
<div id="section-270" class="section level3">
<h3>2022-04-15</h3>
<ul>
<li>Currently there are no new CT images (last 2022-01-19) or CEA or
CA199 readings (last 2022-03-30) since the last hospitalization.</li>
<li>Lab results on 2022-04-12 concerning liver function, renal function,
serum electrolytes, and blood cell counts were grossly normal.</li>
<li>The current chemotherapy regimen FOLFIRI is generally well tolerated
by the patient and respiratory symptoms have been managed with
corresponding medication.</li>
</ul>
</div>
<div id="section-271" class="section level3">
<h3>2022-03-30</h3>
<ul>
<li>The evidences were inconsistent, with CT images (2022-01-19) showing
improvement and lab data readings (CEA from 869 to 3132 ng/mL, CA199
from 1089 to 2837 U/mL, since 2022) showing deterioration, following T
loop colostomy (2021-10-06) and FOLFIRI plus bevacizumab (since mid Nov
2021).</li>
<li>pMMR (colon biopsy pathology 2021-09-28), certain kind of drugs
e.g. nivolumab or pembrolizumab might not be preferred.</li>
<li>Cetuximab or panitumumab may be appropriate in this patient with a
left-sided tumor if the RAS WT is confirmed.</li>
<li>When BRAF V600E mutation is proven, then BRAF inhibitors,
e.g. encorafenib, dabrafenib + trametinib, could also be considered
optionally.</li>
</ul>
</div>
<div id="section-272" class="section level3">
<h3>2022-02-17</h3>
<ul>
<li>CT images on 2022-01-19 showed some improvement based on decreasing
in mass size and/or density, CEA and CA199 data revealed the same trend
p/s colostomy and FOLFIRI treatment, however both the lab readings
doubled within just a month could hint the disease is acquiring
resistence after 4 months treatment.</li>
<li>pMMR, certain kind of drugs e.g. nivolumab or pembrolizumab might
not be preferred.</li>
<li>if RAS WT proven, cetuximab or panitumumab might be applicable for
this left-sided tumor patient.</li>
</ul>
</div>
</div>
</div>
<div id="section-273" class="section level1">
<h1>701179785</h1>
<div id="section-274" class="section level2">
<h2>221003</h2>
<p>{vancomycin trough concentration}</p>
<ul>
<li><p>There was a trough concentration of 9.4 mg/L recorded on
2022-10-03 in this patient treated with U-Vanco (vancomycin) 1000mg QW15
(based on his renal function) since 2022-09-25.</p></li>
<li><p>It appeared to be effective (CRP 15.84mg/dL 2022-10-03 &lt;=
29.58mg/dL 2022-09-22) when vancomycin was used, however, it is
recommended that serum vancomycin trough concentrations should always be
kept above 10 mg/L to avoid resistance development. For a pathogen with
an MIC of 1 mg/L, the minimum trough concentration would have to be at
least 15 mg/L to generate the target AUC (Area under the curve): MIC of
400. (ref: Therapeutic monitoring of vancomycin in adult patients: a
consensus review of the American Society of Health-System Pharmacists,
the Infectious Diseases Society of America, and the Society Of
Infectious Diseases Pharmacists. Clin Biochem
Rev. 2010;31(1):21-24.)</p></li>
<li><p>Changing the current administration frequency from QW15 to QW135
is recommended to increase the concentration to at least 10 mg/L. Thank
you!</p></li>
</ul>
</div>
</div>
<div id="section-275" class="section level1">
<h1>700052326</h1>
<div id="section-276" class="section level2">
<h2>220930</h2>
<ul>
<li><p>BH 172, BW 109.2, BMI 36.9</p></li>
<li><p>past history</p>
<ul>
<li>3-V coronary artery disease
<ul>
<li>s/p PTCA with stenting for 2 times in 2005-10 &amp; 2006-02 at
Cardinal Tien Hospital;</li>
<li>s/p PTCA with stenting for LAD instent restenosis in 2006-08 at TPE
TCH;</li>
<li>s/p PTCA with bare-metal stenting for RCA and LAD on
2011-09-28;</li>
<li>s/p PTCA with stenting for middle RCA and PL branch on
2012-02-08;</li>
<li>s/p PTCA with stenting for D1 &amp; LAD on 2012-09-05.</li>
<li>2VD with LAD-D1 and RCA stenosis on 2015-06-01, Medical treatment
was suggested due to no severe stenosis or occlusion was found.</li>
</ul></li>
<li>Hypertensoin under medical control for 10+ years</li>
<li>Hyperlipidemia under statin control for 10+ years</li>
<li>Type II DM for years</li>
<li>Old left radial liniar fracture</li>
<li>Diverticulitis of ascending colon and local perforation with
conservation treatment on 2022-01.</li>
</ul></li>
<li><p>family history</p>
<ul>
<li><ol style="list-style-type: decimal">
<li>Father died of acute myocardial infarction at age 64, hypertension
with diabetes.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Grandfather and younger brother: heart disease, unknown type.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mother: hypertension.    </li>
</ol></li>
</ul></li>
<li><p>lab data</p>
<ul>
<li>CEA
<ul>
<li>2022-09-27 CEA 6.67 ng/mL<br />
</li>
<li>2022-08-30 CEA 9.69 ng/mL<br />
</li>
<li>2022-08-03 CEA 14.95 ng/mL<br />
</li>
<li>2022-07-05 CEA 20.39 ng/mL<br />
</li>
<li>2022-06-07 CEA 22.12 ng/mL<br />
</li>
<li>2022-05-04 CEA 27.26 ng/mL<br />
</li>
<li>2022-04-01 CEA 39.36 ng/mL<br />
</li>
<li>2022-03-25 CEA 38.05 ng/mL<br />
</li>
</ul></li>
<li>All-RAS
<ul>
<li>2022-04-29 Detected
<ul>
<li>KRAS codon 12 GGT &gt; GCT, p.G12A
<ul>
<li>The current study and treatment guidelines indicate that patients
with RAS mutation may not benefit from the anti-EGFR antibody
treatment.</li>
<li>Patients with no RAS mutation are more likely to have disease
control by using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>BRAF
<ul>
<li>2022-04-29 Not Detected
<ul>
<li>There was no variant detected in the BRAF gene
<ul>
<li>The current study and treatment guidelines indicate that patients
with BRAF mutation may not benefit from the anti-EGFR antibody
treatment.</li>
<li>Patients with no RAS mutation are more likely to have disease
control by using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li><p>exam finding</p>
<ul>
<li>2022-08-31 CT - abdomen
<ul>
<li>History:
<ul>
<li>Recurrent RUQ pain for times, intermittent</li>
<li>20220111 CT: Diverticulitis of ascending colon with perforation and
abscess s/p medication (0111~0120) and LGI bleeding (0124~0126)</li>
<li>20220401 CEA: 39.36 ng/mL (&lt; 5).</li>
<li>20220401 CT: Locally advanced ascending colon cancer with abscess
and partial obstruction, carcinomatosis s/p exploratory laparotomy with
right hemicolectomy on 2022/04/06, pT4aN2bM1c, Stage IVC</li>
</ul></li>
<li>Findings:
<ul>
<li>S/P right hemicolectomy</li>
<li>Prior CT identified multiple enlarged nodes in celiac trunk,
hepatoduodenal ligament, mesentery, para-aortic space, para-cava space,
bilateral common iliac chain, bilateral external iliac chain and
bilateral interal iliac chain are noted again, mild decreasing in size
that are c/w metastatic nodes (non-regional) S/P C/T with partial
response.</li>
<li>A hepatic cyst measuring 1.3 x 0.7 cm in S3 is noted.</li>
</ul></li>
<li>Impression:
<ul>
<li>Non-regional metastatic nodes S/P C/T show partial response.</li>
<li>Detailed findings, please see description.</li>
</ul></li>
</ul></li>
<li>2022-05-11 Chest XR
<ul>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Normal size of heart.</li>
<li>Clear both lung field.</li>
</ul></li>
<li>2022-04-08 Chest XR
<ul>
<li>Right catheterization to SVC in position.</li>
<li>S/P NG tube indwelling.</li>
<li>Ground glass opacities in bil. lungs.</li>
<li>S/P operation.</li>
</ul></li>
<li>2022-04-07 Patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>Ascending colon, right hemicolectomy — Adenocarcinoma, poorly
differentiated, with abscess formation<br />
</li>
<li>Resection margins, right hemicolectomy — Free<br />
</li>
<li>Lymph nodes, mesocolic, right hemicolectomy — Metastatic
adenocarcinoma (7/14)<br />
</li>
<li>Pathology stage: pT4aN2b(cM1a); Stage IVA</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Adenocarcinoma with abscess formation<br />
</li>
<li>Histology Grade: Poorly differentiated<br />
</li>
<li>Depth of invasion: Pericolic soft tissue</li>
<li>Angiolymphatic invasion: Present and extensive</li>
<li>Perineural invasion: Present<br />
</li>
<li>Tumor cell budding: High<br />
</li>
<li>Margins
<ul>
<li>Proximal and distal margins: Uninvolved</li>
<li>Circumferential (radial) margin: Uninvolved</li>
</ul></li>
<li>Lymph node metastasis, mesocolic: Metastatic adenocarcinoma
(7/14)</li>
<li>Extranodal involvement: Present</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT): pT4a (Tumor invades through serosa)</li>
<li>Regional Lymph Nodes (pN): pN2b (seven or more regional lymph nodes
are positive)</li>
<li>Distant Metastasis (pM): cM1a</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Not identified</li>
<li>Additional pathologic findings: Two tubulovillous adenoma and tumor
emboli in submucosal vascular channels</li>
<li>Tumor regression grading S/P CCRT: N/A</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(focal +), MSH2(+), MSH6(+)</li>
<li>Appendix: Submucosal abscess and granulation tissue</li>
</ul></li>
</ul></li>
<li>2022-04-07 Chest XR
<ul>
<li>S/P ET tube inserted in position with cuff inflation.</li>
<li>Right catheterization to SVC in position.</li>
<li>S/P NG tube indwelling.</li>
<li>Right pleural effusion.</li>
<li>Ground glass opacity in bilateral lower lungs.</li>
</ul></li>
<li>2022-04-04 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>Wall thickening of A-colon with adjacent fat stranding and regional
LAP. Enlarged LNs at mediastinum and along aorta/ IVC and bil. iliac
vessels.</li>
<li>Grade 4 fatty liver.</li>
<li>Normal appearance of spleen, pancreas, adrenals and kidneys.</li>
<li>Distention of gallbladder.</li>
<li>Intact bony structures.</li>
<li>Minimal ascites.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
<li>Atherosclerosis of coronary arteries.</li>
<li>Partial atelectasis at right basal lung.</li>
</ul></li>
<li>Impression:
<ul>
<li>Wall thickening of A-colon with adjacent fat stranding and regional
LAP. Enlarged LNs at mediastinum and along aorta/IVC and bil. iliac
vessels.</li>
<li>Grade 4 fatty liver.</li>
<li>Distention of gallbladder.</li>
</ul></li>
</ul></li>
<li>2022-04-03 Electrocardiography, ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
<li>Moderate voltage criteria for LVH, may be normal variant</li>
<li>Anteroseptal infarct</li>
<li>T wave abnormality, consider lateral ischemia</li>
</ul></li>
<li>2022-04-01 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>There is lobulated enhancing wall thickening at the ascending colon
that may be adenocarcinoma. The differential diagnosis include
diverticulitis. Please correlate with colonoscopy. In addition, there
are multiple enlarged nodes in right side mesocolon (the largest one
measuring 2.8 cm) and mesentery root that may be metastatic nodes?</li>
<li>There are multiple enlarged nodes in celiac trunk, hepatoduodenal
ligament, para-aortic space, para-cava space, bilateral common iliac
chain, bilateral external iliac chain and bilateral interal iliac chain.
Metastatic nodes (non-regional) are highly suspected.</li>
<li>There is symmetrical wall thickening of the ascending colon with
surrounding fatty stranding and free gas bubbles that is c/w prior acute
diverticulitis with perforation and abscess S/P treatment with residual
change. In addition, The free gas bubbles show directly attached right
transverse abdominis muscle that may be muscle invasion.</li>
<li>A hepatic cyst measuring 1.3 x 0.7 cm in S3 is noted.</li>
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, spleen &amp; both kidney.</li>
<li>There is no evidence of ascites.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.</li>
</ul></li>
<li>Impression:
<ul>
<li>Adenocarcinoma of the proximal ascending colon with lymph nodes
metastases is highly suspected.</li>
<li>If ascending colon cancer is finally proved by pathology. According
to American Joint Committee on Cancer(AJCC) staging system, 8th edition
for colon cancer: T4a N2b M1a, Stage:IVA</li>
</ul></li>
</ul></li>
<li>2022-01-25 Sigmoidoscopy
<ul>
<li>Indication：Blood in the stool</li>
<li>Premedication: Buscopan 20mg + Alfentanil 0.25mg IV</li>
<li>Anesthesia: No anesthesia</li>
<li>The scope reach the sigmoid colon. Multiple diverticula at S
colon</li>
<li>Internal hemorrhoid was noted.</li>
<li>Diagnosis
<ul>
<li>Diverticulosis, S colon</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-01-11 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>Wall edema at ascending colon with pericolonic fatty infiltrates and
fluid, suspected ascending colon diverticulitis.</li>
<li>There are outpouching lesions in the sigmoid colon, suggesting
sigmoid diverticulosis.</li>
<li>Presence of gallbladder sludge.</li>
<li>Liver cyst, 1.3cm in left lobe liver.</li>
<li>Unremarkable change of the spleen, pancreas and both kidneys.</li>
<li>There are multiple enlarged lymph nodes in the paraaortic region and
common iliac and obturator regions. suspected lymphoma.</li>
</ul></li>
<li>Impression:
<ul>
<li>Colon diverticulosis.</li>
<li>Suspected ascending colon diverticulitis, suggest clinical
correlation.</li>
<li>Multiple enlarged lymph nodes in the paraaortic region and common
iliac and obturator regions. Suspected lymphoma. Suggest further
study.</li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Imaging stage: T4aN2M1a, stage IVA</li>
</ul></li>
</ul></li>
<li>2021-11-12 Myocardial perfusion SPECT with persantin
<ul>
<li>The Tl-201 stress myocardial perfusion SPECT performed after
intravenous injection 60 mg of dipyridamole revealed markedly decreased
perfusion of radioactivity to the apex, inferoapical wall and anterior
wall and mildly to moderately decreased perfusion of radioactivity to
the septum, inferolateral wall and posterior wall. The Tl-201
redistribution myocardial perfusion SPECT revealed partial reperfusion
of radioactivity to the apex, inferoapical wall and anterior wall and
reperfusion of radioactivity to the septum, inferolateral wall and
posterior wall.</li>
<li>IMPRESSION: Probably severe myocardial ischemia with possible a
portion of infarction at the apex, inferoapical wall and anterior wall
and mild to moderate myocardial ischemia at the septum, inferolateral
wall and posterior wall.</li>
</ul></li>
<li>2021-11-12 2D transthoracic echocardiography
<ul>
<li>Mildly abnormal LV systolic function with hypokinesia to akinesia of
mid-anterior to apical segments</li>
<li>Dilated LA and LV</li>
</ul></li>
<li>2021-10-26 Electrocardiography, ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Anteroseptal infarct, age undetermined</li>
</ul></li>
<li>2017-11-10 Renal ultrasound
<ul>
<li>Bilateral parenchymal renal disease.</li>
</ul></li>
</ul></li>
<li><p>consultation</p>
<ul>
<li>2022-04-09 Infectious Disease
<ul>
<li>Findings:
<ul>
<li>Consultation for Finibax antibiotic</li>
<li>A-colon cancer with local abscess and partial obstruction case.</li>
<li>Fever persists for nearly one week despite Brosym use.</li>
<li>Serial CxR film shows newly developed right pleural effusion and LLL
infiltrates, which hard to say pneumonia or not.</li>
<li>No significant culture report available yet.</li>
<li>White count 15110 yesterday and CRP level up to 26 today.</li>
<li>Brosym is replaced by Finibax ysterday.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Continue Finibax for 5 days first.</li>
<li>Check drainage fluid and blood culture report.</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>multiteam</p>
<ul>
<li>2022-04-07 Social Service
<ul>
<li>Reason: Economic issues such as medical care, nursing care, daily
necessities, etc.</li>
<li>Processing status: open</li>
<li>Family status: 20220406 Talk with the case brother
<ul>
<li>The case is unmarried. After the stent was installed in the heart in
2013, he is unemployed and his last job is a car salesman.</li>
<li>The family has a history of heart disease. His grandfather, his
father, his elder brother and his elder sister all died of heart
disease. The mother of the case is 84 years old and has four sons and
two daughters. The case is ranked fifth, and they are twin brothers. The
second brother of the case, married and living in Linkou, was estranged
from the case’s family and did not provide assistance. The second sister
of the case is married and works as a general electronics company
operator. The brother-in-law of the second sister is a bus driver. The
two have a son. The nephew of the case is married and has a young
son.</li>
<li>The case does not have labor insurance and private insurance, and
the house is owned by the case and the case brother.</li>
<li>The younger brother is a Reha bus driver with a monthly income of
about 33,000 yuan. After the case fell ill, the second sister assisted
in taking out medical insurance and had a heart stent installed in our
hospital. The case and the mother’s living expenses all depend on the
younger brother’s income. .</li>
</ul></li>
<li>Main Issue: Economic Issue</li>
</ul></li>
<li>2022-04-06 PreOp Evaluation
<ul>
<li>Fever before operations: No  </li>
<li>CNS：Consciousness: Clear and alert  </li>
<li>Respiratory system: Lung disease: No</li>
<li>Breathing sound: Clear</li>
<li>Cardiovascular System: Cardiovascular disease: Yes</li>
<li>Diabetes mellitus: Yes, Good control</li>
<li>Malignant neoplasm: No</li>
<li>Bleeding tendency: Nil  </li>
<li>Other infectious disease: No</li>
<li>Plavix discontinued for 3 months   </li>
</ul></li>
</ul></li>
<li><p>surgical operation</p>
<ul>
<li>2022-04-06
<ul>
<li>Surgery
<ul>
<li>EXP LAP with right hemicolectomy</li>
</ul></li>
<li>Finding
<ul>
<li>A colon tumor with invasion to right side abdominal wall, with
abscess, invade to gerota fascia, colohepatic ligment and partial
obstruction.</li>
<li>Enlarge LN over ileocecal artery</li>
<li>Tumor invasion to ileum.</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>radiotherapy</p>
<ul>
<li>2022-06-28 ~ 2022-07-22 CCRT 5000cGy/25 fractions (15 MV photon) to
PA &amp; pelvic LAPs</li>
</ul></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2022-09-29 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 75mg/m2
170mg 2hr + leucovorin 400mg/m2 900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr
D1-2</li>
<li>2022-09-13 - bevacizumab 5mg/kg 300mg 90min + oxaliplatin 85mg/m2
190mg 2hr + leucovorin 400mg/m2 900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr
D1-2</li>
<li>2022-08-30 - oxaliplatin 85mg/m2 190mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr D1-2</li>
<li>2022-08-18 - oxaliplatin 85mg/m2 190mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr D1-2</li>
<li>2022-08-05 - oxaliplatin 75mg/m2 170mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr D1-2</li>
<li>2022-07-22 - oxaliplatin 75mg/m2 170mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr D1-2</li>
<li>2022-07-07 - oxaliplatin 75mg/m2 170mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2700mg 24hr D1-2</li>
<li>2022-06-23 - oxaliplatin 65mg/m2 150mg 2hr + leucovorin 400mg/m2
900mg 2hr + 5-Fu 1200mg/m2 2800mg 24hr D1-2</li>
<li>2022-06-09 - leucovorin 400mg/m2 950mg 2hr + 5-Fu 1200mg/m2 2800mg
24hr D1-2</li>
<li>2022-05-26 - leucovorin 400mg/m2 950mg 2hr + 5-Fu 1200mg/m2 2800mg
24hr D1-2</li>
</ul></li>
</ul>
<div id="section-277" class="section level3">
<h3>==========</h3>
</div>
<div id="section-278" class="section level3">
<h3>2022-09-30</h3>
<ul>
<li>A mild pancytopenia was observed on 2022-09-27, but the scheduled
chemotherapy should not be suspended</li>
<li>The underlying conditions T2DM and HTN appeared to be under control
during this hospitalization.</li>
<li>A downward trend in CEA levels has been observed, which is
encouraging and suggests the current regimen is working.
<ul>
<li>2022-09-27 CEA 6.67 ng/mL<br />
</li>
<li>2022-08-30 CEA 9.69 ng/mL<br />
</li>
<li>2022-08-03 CEA 14.95 ng/mL<br />
</li>
<li>2022-07-05 CEA 20.39 ng/mL<br />
</li>
<li>2022-06-07 CEA 22.12 ng/mL<br />
</li>
<li>2022-05-04 CEA 27.26 ng/mL<br />
</li>
<li>2022-04-01 CEA 39.36 ng/mL</li>
</ul></li>
</ul>
</div>
<div id="section-279" class="section level3">
<h3>2022-08-31</h3>
<ul>
<li>In patients with renal failure (acute or chronic), the renal
clearance of metformin is decreased, and there is an associated risk of
lactic acidosis. Some patients who receive intravenous contrast may
experience a deterioration of renal function (contrast-induced
nephropathy). Intravenous studies using a single dose of metformin in
normal subjects show that metformin is excreted as unchanged drug in the
urine and does not undergo hepatic metabolism (no metabolites have been
identified in humans) or biliary excretion. The patient does not appear
to have renal impairment (2022-08-30 creatinine 0.59 mg/dL, eGFR 154.55,
BUN 12 mg/dL). For CT scanning, metformin might be temporarily held,
although the risk of lactic acidosis is less likely to occur in this
patient.</li>
<li>Dapagliflozin is primarily glucuronidated to become the inactive
3-O-glucuronide metabolite (60.7%). The metabolites are mainly inactive,
although dapagliflozin is not recommended in patients with a creatinine
clearance below 45mL/min and is contraindicated in patients with
creatinine clearance below 30mL/min, temporarily hold the drug for CT
scanning could be a preventive option which might be over aversion to
the risk.</li>
</ul>
</div>
<div id="section-280" class="section level3">
<h3>2022-08-19</h3>
<ul>
<li>There was a study demonstrated that empirically eliminating 5-FU
bolus and LV from first line palliative therapy with mFOLFOX6 in mCRC
resulted in no significant difference in median PFS or OS. Despite
reduced growth factor utilization, the non-bolus arm demonstrated a
favorable safety profile with less treatment-related hematologic grade
&gt;= 3 AE. It suggested consideration of empirically eliminating 5-FU
bolus and LV from the mFOLFOX6 regimen to avoid additive toxicities
without negatively impacting efficacy. Reference: Impact of empirically
eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients
with metastatic colorectal cancer (mCRC) receiving first-line treatment
with mFOLFOX6. DOI: 10.1200/JCO.2020.38.15_suppl.4022 Journal of
Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4022-4022. <a href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4022" class="uri">https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4022</a></li>
<li>Because this patient is receiving a 5-FU-bolus-removed regimen,
leucovorin might also be removed or reduced to no more than
200mg/m2.</li>
</ul>
</div>
<div id="section-281" class="section level3">
<h3>2022-07-25</h3>
<ul>
<li>The patient was admitted to receive his scheduled FOLFOX
regimen.</li>
<li>Cardiovascular adverse reactions reported for oxaliplatin include
chest pain (5%), edema (10%), flushing (3%), peripheral edema (5%), and
thromboembolism (2%); and for fluorouracil, angina pectoris, cardiac
arrhythmia, cardiac failure, cerebrovascular accident, ischemic heart
disease, local thrombophlebitis, myocardial infarction, vasospasm, and
ventricular ectopy.</li>
<li>For this patient with a history of previous myocardial infarction
and chronic ischemic heart disease, oxaliplatin is titrated up from 65
mg/m2 to 75 mg/m2 (still less than the standard 85 mg/m2), and the 5-Fu
bolus is skipped.</li>
<li>QT prolongation and ventricular arrhythmias have been reported after
oxaliplatin. ECG monitoring is recommended if therapy is initiated in
patients with heart failure, bradyarrhythmias, coadministration of drugs
known to prolong the QT interval, and electrolyte abnormalities. There
is no abnormality in the serum potassium level (2022-07-19), which was
3.5 mmol/L. Earlier ECG 2022-04-03 showed: 1) Anteroseptal infarct; 2) T
wave abnormality, consider lateral ischemia.</li>
<li>CEA and CA199 keep declining since April 2022. 2022-07-05 CEA 20.39
ng/mL (&lt;- 38) , CA199 12.38 U/mL (&lt;- 20).</li>
<li>The patient’s blood sugar level fluctuates between 89 and 147 mg/dL,
never exceeding 150 mg/dL during this hospitalization. There is no need
to adjust his hypoglycemic agents urgently.</li>
<li>TPR, BP, SpO2 readings were relatively stable. No issue with active
prescription. It might be necessary to follow up with an ECG and/or
cardiac ultrasound on a regular basis.</li>
</ul>
</div>
<div id="section-282" class="section level3">
<h3>2022-06-10</h3>
<ul>
<li>The patient was admitted to receive his scheduled FOLFOX
regimen.</li>
<li>CEA and CA199 keep declining since April 2022.</li>
<li>Other lab results (2022-06-07) indicated that the readings were
grossly normal.</li>
<li>No issue with active prescription.</li>
</ul>
</div>
<div id="section-283" class="section level3">
<h3>2022-05-27</h3>
<ul>
<li>This is an economically disadvantaged patient who has been
unemployed for many years and relies on relatives for financial support.
He was diagnosed with stage IV A-colon cancer with mets in the first
quarter of 2022, underwent right hemicolectomy in April of that year and
was subsequently admitted to receive his first FOLFOX treatment.</li>
<li>TPR, BP, (2022-05-27) lab results (2022-05-26) were generally not
bad. Self-carried items in active prescription are used to treat
underlying health conditions.</li>
<li>The patient has a KRAS mutation (2022-04-29 detected) and may not
benefit from anti-EGFR antibody treatment.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-284" class="section level1">
<h1>700943429</h1>
<div id="section-285" class="section level2">
<h2>220929</h2>
<ul>
<li>past history
<ul>
<li>The patient had cervical cancer stage I s/p for 6 years ago</li>
<li>history of operation: laparoscopic cervical resection and myoma
resection for 6 years ago</li>
<li>Denied recent traveling history</li>
<li>Blood transfusion history: NIL</li>
<li>Regular medications or herb：no     </li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-24 Patho - stomach subtotal/tatal (tumor)
<ul>
<li>Diagnosis
<ul>
<li>Stomach, antrum, laparoscope radical subtotal gastectomy —- Poorly
cohesive carcinoma, non-signet-ring cell type</li>
<li>Duodenum, laparoscope radical subtotal gastectomy —- Negative for
malignancy</li>
<li>Margin: free</li>
<li>Lymph node, group 1, dissection —- Negative for malignancy
(0/4)</li>
<li>Lymph node, group 3, dissection —- Metastatoc carcinoma (3/7)</li>
<li>Lymph node, group 4, dissection —- Negative for malignancy
(0/9)</li>
<li>Lymph node, group 5, dissection —- Metastatic carcinoma (1/1)</li>
<li>Lymph node, group 6, dissection —- Negative for malignancy
(0/13)</li>
<li>Lymph node, group 7, 8, 9, 11, 12, dissection —- Negative for
malignancy (0/13)</li>
<li>Lymph node, group 14v, dissection —- Negative for malignancy
(0/2)</li>
<li>AJCC 8 th edition p T N M Pathology stage: pStage IIIA, pT3N2(if
cM0)</li>
</ul></li>
<li>Gross Description:
<ul>
<li>Procedure: laparoscope radical subtotal gastectomy</li>
<li>Specimen size: Greater curvature: 11.5 cm, Lesser curvature: 8.5 cm,
Duodenum: 0.5 cm</li>
<li>Tumor site: (check that apply): Antrum, lesser curvature</li>
<li>Tumor size: 2.0 x 1.5 cm</li>
<li>Gross configuration: Type III: Ulcerated with poorly defined
infiltrative margins</li>
<li>Sections are taken and labeled as:
<ul>
<li>A1-2: proximal resection margin;</li>
<li>A3: distal resection margin;</li>
<li>A4: stomach, non-tumor;</li>
<li>A5-8: tumor;</li>
<li>B: lymph node, group 1;</li>
<li>C: lymph node, group 3;</li>
<li>D1-2: lymph node, group 4;</li>
<li>D3: omentum;</li>
<li>E: lymph node, group 5;</li>
<li>F: lymph node, group 6;</li>
<li>G1-2: lymph node, group 7, 8, 9, 11, 12;</li>
<li>H: lymph node, group 14v.</li>
</ul></li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Lauren classification of adenocarcinoma: Diffuse
type (WHO(2019) poorly cohesive carcinoma, non-signet-ring cell type);
The immunohistochemical stains reveal CK(+) and Her-2/neu (Ab): Negative
(0)</li>
<li>Histologic Grade: G3: Poorly differentiated, undifferentiated</li>
<li>Tumor Extension: Tumor penetrates the subserosal connective tissue
without invasion of the visceral peritoneum or adjacent structures</li>
<li>Margins
<ul>
<li>Proximal margin: uninvolved by invasive carcinoma: 2.9 cm</li>
<li>Distal margin: uninvolved by invasive carcinoma: 4.5 cm</li>
<li>Radial margin: uninvolved by invasive carcinoma: 0.2 cm</li>
</ul></li>
<li>Lymphovascular Invasion: present<br />
</li>
<li>Perineural Invasion: present<br />
</li>
<li>Regional Lymph Nodes: please see diagnosis<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply): absent<br />
</li>
<li>Primary Tumor (pT): pT3: Tumor penetrates the subserosal connective
tissue without invasion of the visceral peritoneum or adjacent
structures</li>
<li>Regional Lymph Nodes (pN): pN2: Metastasis in three to six regional
lymph node</li>
<li>Distant Metastasis (pM) (required only if confirmed pathologically
in this case): if cM0</li>
</ul></li>
<li>Additional Pathologic Findings
<ul>
<li>Intestinal metaplasia: present</li>
<li>Low-grade dysplasia: present</li>
<li>High-grade dysplasia: present</li>
<li>Helicobacter pylori-type gastritis: absent</li>
<li>Autoimmune atrophic chronic gastritis: absent<br />
</li>
<li>Polyp(s): absent</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-10 Doppler color flow mapping
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (80 - 17) / 80 = 78.75%
<ul>
<li>M-mode (Teichholz) = 77</li>
</ul></li>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Grade 1 LV diastolic dysfunction</li>
<li>Mild MR, TR</li>
</ul></li>
<li>2022-05-27 CT - abdomen
<ul>
<li>History:
<ul>
<li>Epigastric fullness for days, Fasting epigastralgia</li>
<li>Belching and acid reflux, nausea(+), Decreased appetite(+), Weight
loss(+)</li>
<li>20220518 gastroscopy: A 2-3cm A2 ulcer was noted at angle, s/p
biopsy, path:Intramucosal adenocarcinoma and gastric ulcer</li>
</ul></li>
<li>Findings:
<ul>
<li>There is mild wall thickening at the gastric low body-antrum,
measuring 0.9 cm in wall thickness.Please correlate with gastroscopy.
<ul>
<li>In addition, There is no enlarged node in the perigastric area.</li>
</ul></li>
<li>There are several enhancing lesions in the uterus, the largestone
measuring 5 cm in size, that may be myomas. Please correlate with GYN.
sonography.</li>
<li>There is no focal lesion in both lung and mediastinum.</li>
</ul></li>
<li>Imaging Report Form for Gastric Carcinoma
<ul>
<li>Impression (Imaging stage): T:T2 (T_value) N:N0 (N_value) M:M0
(M_value) STAGE:I(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-05-18 Patho - stomach biopsy
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Stomach, angle, biopsy — Intramucosal adenocarcinoma and gastric
ulcer</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>The specimen submitted consists of multiple small pieces of
gray-white soft tissue, labeled angle of stomach, measuring up to 0.4 x
0.2 x 0.2 cm. All for section.</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>The sections show intramucosal adenocarcinoma, composed of gastric
mucosal tissue with columnar to cuboidal neoplastic cells, arranged in
glandular and cribriform patterns with focal stromal invasion. Gastric
ulcer with necrosis and inflammatory exudate can be identified
also.</li>
</ul></li>
</ul></li>
<li>2022-05-18 SONO - abdomen
<ul>
<li>gallbladder polyp</li>
</ul></li>
<li>2021-12-22 Patho - colorectal polyp
<ul>
<li>Intestine, large, cecum, (A), biopsy removal — tubular adenoma</li>
<li>Intestine, large, transverse colon, (B), polypectomy —tubular
adenoma<br />
</li>
<li>Intestine, large, transverse colon, (C), polypectomy —tubular
adenoma</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-23
<ul>
<li>Surgery
<ul>
<li>laparoscope radical subtotal gastectomy with D2 LN dissection</li>
</ul></li>
<li>Finding
<ul>
<li>2 x 1.8 cm ulcerative mass at antrum lesser curvature</li>
<li>regional LN at LN 3, 5 &amp; 8</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-28 - oxaliplatin 85mg/m2 110mg 2hr + leucovorin 400mg/m2
500mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</li>
<li>2022-09-12 - oxaliplatin 85mg/m2 110mg 2hr + leucovorin 400mg/m2
500mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</li>
<li>2022-08-29 - oxaliplatin 85mg/m2 110mg 2hr + leucovorin 400mg/m2
500mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</li>
<li>2022-08-15 - oxaliplatin 70mg/m2 90mg 2hr + leucovorin 400mg/m2
500mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-286" class="section level1">
<h1>700192852</h1>
<div id="section-287" class="section level2">
<h2>220928</h2>
<p>{Primary peritoneal serous carcinoma (omentum, ileum, colon, appendix
involvement), pT3cN0M0, FIGO stage IIIC s/p Optimal (R1) debulking
surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY + CYTOLOGY) + CUSA +
Right hemicolectomy (Terminal ileum + Appendix + ascending/transverse
colon resection) on 20210111.}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>CA125
<ul>
<li>2022-07-19 CA-125 669.52 U/ml<br />
</li>
<li>2022-06-13 CA-125 957.5 U/mL<br />
</li>
<li>2022-06-10 CA-125 1194.15 U/ml<br />
</li>
<li>2022-05-27 CA-125 1918.48 U/ml<br />
</li>
<li>2022-04-22 CA-125 823.98 U/ml<br />
</li>
<li>2022-02-11 CA-125 85.56 U/ml<br />
</li>
<li>2020-12-29 CA-125 254.73 U/ml<br />
</li>
<li>2020-12-11 CA-125 394.4 U/mL<br />
</li>
<li>2018-09-08 CA 125 8.2 U/mL<br />
</li>
</ul></li>
<li>CA199
<ul>
<li>2022-07-19 CA-199 451.52 U/ml<br />
</li>
<li>2022-06-10 CA-199 551.82 U/ml<br />
</li>
<li>2022-05-27 CA-199 480.27 U/ml<br />
</li>
<li>2022-02-09 CA-199 66.817 U/ml<br />
</li>
<li>2020-12-29 CA-199 371.190 U/ml<br />
</li>
<li>2020-12-11 CA-199 166.87 U/mL<br />
</li>
<li>2018-09-10 CA-199 9.123 U/ml</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-09 SmallIntestine
<ul>
<li>Segmental dilatation of proximal small bowel, suspected partial
obstruction</li>
</ul></li>
<li>2022-07-11 Abdomen standing
<ul>
<li>S/P nasogastric tube insertion</li>
<li>Few segment of bowel in the middle abdomen show air-fluid
level.</li>
</ul></li>
<li>2022-06-17 Small Intestinal Series
<ul>
<li>Dilated haustration of the jejunum and ileum and stomach as well as
the doudenum is found.</li>
<li>The peristasis of the small intestine is retarded.</li>
<li>The transit time is 24 hours.</li>
<li>Imp: Paralytic ileus with delayed peristasis.</li>
</ul></li>
<li>2022-06-15 CT - abdomen, pelvis
<ul>
<li>Tumor seeding in the proximal jejunum induce bowel obstruction is
highly suspected.</li>
<li>Carcinomatosis.</li>
<li>Metastatic nodes in the mesentery and para-aortic space.</li>
<li>Tumor seeding at the sigmoid colon and terminal ileum at the pelvis
show stationary.</li>
</ul></li>
<li>2022-04-27 Small Intestine
<ul>
<li>Some indentation at bowel loop.</li>
<li>The passage time is about 4 hours.</li>
</ul></li>
<li>2022-04-25 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Suspected peritoneal seeding and liver/lung metastases.</li>
<li>Wall thickening of S-colon.</li>
</ul></li>
<li>2022-04-22 Patho - stomach biopsy
<ul>
<li>Stomach, pyloric ring, biopsy — ulcer with Helicobacter
infection</li>
</ul></li>
<li>2022-04-22 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis
<ul>
<li>Gastric ulcer, H2, pyloric ring, s/p biopsy</li>
<li>Suboptimal study due to much food residue in stomach and duodenum,
probable due to bowel obstruction below 2nd portion</li>
<li>Reflux esophagitis LA Classification grade A</li>
</ul></li>
<li>Suggestion
<ul>
<li>NG decompression</li>
<li>Small bowel series</li>
</ul></li>
</ul></li>
<li>2022-04-15 KUB
<ul>
<li>Stool retention in the bowel.</li>
</ul></li>
<li>2022-04-01 KUB
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-01-21 Patho - soft tissue debridment
<ul>
<li>Ileum, exploratory laparotomy with segmental bowel resection with
end to end anastomosis — benign perforated ileum with external tumor
seeding and muscular invasion as well as necrotic acute inflammatory
exudates containing tumor nests.
<ul>
<li>One of three peri-ileal lymph nodes (1/3) show tumor metastasis (2 x
1 mm).</li>
<li>IHC stains: CK20 (-): non-intestinal origin, PAX-8 (+), WT-1 (+),
Napsin-A (-), p53 (aberrant type): compatible with serous
carcinoma.</li>
</ul></li>
<li>Labeled as ‘cut end 2’, exploratory laparotomy with segmental bowel
resection with end to end anastomosis — Free.</li>
<li>Labeled as ‘cut end’, exploratory laparotomy with segmental bowel
resection with end to end anastomosis — Free.</li>
<li>Labeled as ‘peritoneum tumor’, excision — serous carcinoma (4 x 3
mm).
<ul>
<li>IHC stains: CK20 (-), PAX-8 (+), WT-1 (+), Napsin-A (-), p53
(aberrant type).<br />
</li>
</ul></li>
</ul></li>
<li>2022-01-20 CT - abdomen, pelvis
<ul>
<li>Pneumoperitoneum. Focal wall thickening of ileum suspected
malignancy.</li>
</ul></li>
<li>2021-01-11 Pathology at VGHTPE
<ul>
<li>Recurrence from primary peritoneal serous carcinoma (omentum, ileum,
colon, appendix involvement), pT3cN0M0, FIGO stage IIIC, s/p Optimal
(R1) debulking surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY +
CYTOLOGY) + CUSA + Right hemicolectomy (Terminal ileum + Appendix +
ascending/transverse colon resection)</li>
<li>PAX-8 (+), WT-1 (+), Napsin-A (-), p53 (aberrant type)</li>
</ul></li>
<li>2020-12-25 Small Intestinal Series
<ul>
<li>Normal haustration of the jejunum and ileum.</li>
<li>The peristasis of the small intestine is intact.</li>
<li>No evidence of stenotic or obstructive lesion in the study.</li>
<li>The transit time is 120 minutes.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>2020-12-11 Gynecologic ultrasonography
<ul>
<li>Suspected Lt ovarian cyst</li>
<li>Uterine myoma</li>
</ul></li>
<li>2020-12-01 KUB
<ul>
<li>Stool retention in the bowel.</li>
</ul></li>
<li>2020-08-19 CT - abdomen, pelvis
<ul>
<li>Infectious colitis is suspected.</li>
<li>Please correlate with stool routine and culture, or
colonoscopy.</li>
</ul></li>
<li>2019-04-01 SONO - breast
<ul>
<li>Right breast cyst and fibroadenoma. Suggest follow up.</li>
<li>BI-RADS2. benign finding</li>
</ul></li>
<li>2018-09-08 EKG
<ul>
<li>Sinus bradycardia with Premature atrial complexes</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2018-09-08 SONO - breast
<ul>
<li>Suspected right breast tumor</li>
<li>Right fibroadenoma as described</li>
<li>Suggestion: tissue study</li>
<li>BI-RADS: suspicious abnormality, biopsy should be considered</li>
</ul></li>
<li>2018-09-08 Mammography
<ul>
<li>Dense breast. No mammographic evidence of malignancy, suggest
clinical correlation and regular follow up.</li>
<li>BI-RADS: Category 1: negative.-annual screening.</li>
</ul></li>
<li>2018-09-08 Low-dose CT - lung cancer screening
<ul>
<li>Lungs: Nodular lesion at left upper lobe up to 4.7mm in largest
dimension.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-15 General and Gastrointestinal Surgery
<ul>
<li>A
<ul>
<li>She suffered from had acute abdomen pain with fever due to ca
involved small bowel with perforation and adhesions status post op 4
months ago</li>
<li>P.E showed soft abdomen, no muscle guarding, no local tendderness
but severe abdomen distention</li>
<li>tumor markers and image studies in favor of cancer metastasis</li>
<li>Further C/T or immonotherapy is idicated</li>
<li>Give PN if oral feeding can not proceed</li>
</ul></li>
</ul></li>
<li>2022-02-09 thoracic surgery
<ul>
<li>Q
<ul>
<li>This 60 year-old female had past history of 1) Myomectomy 20 years
ago. 2) Primary peritoneal serous carcinoma (omentum, ileum, colon,
appendix involvement), pT3cN0M0, FIGO stage IIIC, s/p Optimal (R1)
debulking surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY + CYTOLOGY) +
CUSA + Right hemicolectomy (Terminal ileum + Appendix +
ascending/transverse colon resection) on 20210111. This time, she
suffered from abdomen pain since 20220120 morning. She was brought to
our ER, her consciousness remained E4V5M6. KUB showed calcification in
LUQ, suspected left renal stone. Abdomen CT revealed pneumoperitoneum
due to hollow organ perforation and carcinomatosis. After GS was
consulted and suggested emergency survey was indicated. She underwent
Exp. lap. with primary repair, lysis of adhesions, segmental bowel
resection with end to end anastomosis excision of peritoneal tumor and
multiple drainage on 20220120.</li>
<li>We need your expertise in evaluation and performing CVC insertion to
facilitate TPN infusion in the immediate future.</li>
</ul></li>
<li>A
<ul>
<li>I will arrange central venous catheterization. Thanks for your
consultation.</li>
</ul></li>
</ul></li>
<li>2022-01-20 gastroenterological surgery
<ul>
<li>Q
<ul>
<li>abdomenial pain VAS 4-7, no fever, nausea +, no diarrhea, deny tarry
or bloody stool</li>
<li>PH: peritoneal cancer s/p op in Jan 2021 at Taipei Veterans General
Hospital</li>
<li>allergy: aspirin</li>
<li>s/p 2 doses of covid vaccine</li>
</ul></li>
<li>A
<ul>
<li>Acute left abdominal pain with fever with chillness for days</li>
<li>P.E showed diffuse local tenderness with muscle guarding esp left
abdomen</li>
<li>Lab and CT in favor of pneumoperitoneum due to hollow organ
perforation and carcinomatosis</li>
<li>Emergency op is indicated</li>
</ul></li>
</ul></li>
</ul></li>
<li>past history
<ul>
<li>Myomectomy 20 years ago.</li>
<li>Primary peritoneal serous carcinoma (omentum, ileum, colon, appendix
involvement), pT3cN0M0, FIGO stage IIIC s/p Optimal (R1) debulking
surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY + CYTOLOGY) + CUSA +
Right hemicolectomy (Terminal ileum + Appendix + ascending/transverse
colon resection) on 20210111.</li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-20
<ul>
<li>Surgery
<ul>
<li>Exp. lap. with primary repair,lysis of adhesions,segmental bowel
resection with end to end anastomosis excision of peritoneal tumor and
multiple drainage.</li>
</ul></li>
<li>Finding
<ul>
<li>Bowel perforation of upper jejunum, 1.5cm in diameter, cause?</li>
<li>Severe adhesions and desmoplastic reaction over lower abdomen with
focal or segmental bowel ischemic chnage and serosal tear</li>
<li>Multiple small nodules ove peritoneum and mesencary</li>
<li>A lot of turbid fluid over intraabdominal spaces, 100ml in
amount</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-09 - pembrolizumab 200mg 1.5hr</li>
<li>2022-08-23 - liposome doxorubicin 40mg/m2 50mg 2hr</li>
<li>2022-08-16 - pembrolizumab 200mg 1.5hr</li>
<li>2022-07-26 - pembrolizumab 200mg 1.5hr + liposome doxorubicin
40mg/m2 57mg 2hr</li>
<li>2022-07-05 - pembrolizumab 200mg 1.5hr</li>
<li>2022-06-28 - liposome doxorubicin 40mg/m2 50mg 2hr</li>
<li>2022-06-15 - pembrolizumab 200mg 1.5hr</li>
<li>2022-05-30 - liposome doxorubicin 40mg/m2 57mg 2hr</li>
<li>2022-05-24 - pembrolizumab 200mg 1.5hr</li>
<li>2022-05-03 - pembrolizumab 200mg 1.5hr + liposome doxorubicin
40mg/m2 57mg 2hr</li>
</ul></li>
</ul>
<div id="section-288" class="section level3">
<h3>==========</h3>
</div>
<div id="section-289" class="section level3">
<h3>2022-06-27</h3>
<ul>
<li>Hyperphosphatemia (7.5mg/dL 2022-06-26) might possibly due to tumor
lysis syndrome?</li>
<li>The hyperphosphatemia usually resolves within 6 to 12 hours if
kidney function is intact. If kidney function is intact (creatinine 0.48
mg/dL, BUN 12 mg/dL 2022-06-26), phosphate excretion can be increased by
saline infusion, although this can further reduce the serum calcium
concentration by dilution.</li>
</ul>
</div>
<div id="section-290" class="section level3">
<h3>2022-04-25</h3>
<ul>
<li>Lab data on 2022-04-21, liver and kidney functions, serum
electrolytes and blood cell counts were grossly normal, however the
ca125 level of 823 U/mL was a record high.</li>
<li>The use of a platinum based regimen, specifically
paclitaxel/carboplatin Q3W, is recommended for serous carcinoma of
either low grade or high grade. The addition of bevacizumab can also be
considered.</li>
<li>Acid reflux remains an active issue since 2022-04-22. Some H2
antagonists or PPIs may provide some relief. The prescription for
pantoprazole 40mg IVD QD has been made.</li>
<li>This patient is allergic to aspirin, which is not currently
prescribed.</li>
</ul>
</div>
</div>
</div>
<div id="section-291" class="section level1">
<h1>700695787</h1>
<div id="section-292" class="section level2">
<h2>220927</h2>
<ul>
<li>past history
<ul>
<li>Hypertension</li>
<li>Hyperlipidemia</li>
<li>Type II Diabetes Mellitus</li>
<li>Chronic kidney disease, stage III</li>
<li>Benign Prostatic Hyperplasia</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-26 CXR
<ul>
<li>Ground glass opacity in bilateral lower lungs.</li>
<li>Cardiomegaly.</li>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2022-09-26 CT - abdomen
<ul>
<li>Splenomegaly with some low attenuations suspected infarcts.</li>
<li>Partial consolidation at LLL. Left pleural effusion.</li>
<li>Mild distention of left renal pelvis.</li>
<li>Some LNs (up to 1.1cm) at retroperitoneum.</li>
<li>Gallbladder stone (0.7cm).</li>
<li>Cardiomegaly.</li>
</ul></li>
<li>2022-06-20 SONO - nephrology
<ul>
<li>Left hydronephrosis</li>
<li>Left renal stone</li>
<li>Bilateral renal cysts</li>
</ul></li>
<li>2022-05-09 Effective renal plasma flow, ERPF
<ul>
<li>The ERPF values of the right kidney and the left kidney are 154.5
ml/min and 79.1 ml/min, respectively (normal reference range of ERPF:
&gt; 150 ml/min in each kidney for adults). There is decreased renal
plasma flow to the left kidney.</li>
<li>Delayed radiotracer washout from the right kidney is noted,
indicating obstructive uropathy in the right kidney.</li>
<li>It is indeterminate for obstructive uropathy of the left kidney
because of diminished left renal function. Please correlate with other
clinical findings for further evaluation.</li>
</ul></li>
<li>2022-04-27 Intravenous pyelogram, IVP
<ul>
<li>No evidence of urolithiasis.</li>
</ul></li>
<li>2022-03-28 SONO - nephrology
<ul>
<li>Parenchymal renal disease with enlarged parenchyma, bilateral,
suspect diabetic nephropathy</li>
<li>Hydronephrosis, left</li>
<li>Simple cyst, bilateral</li>
</ul></li>
<li>2021-10-18 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Voltage criteria for left ventricular hypertrophy</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Currently, there are antiglycemic agents (Januvia, sitagliptin
100mg, PO QD; Loditon, metformin 850mg, PO BID) on the active
prescription list. On 2022-09-26, a blood glucose level of 300mg/dL was
recorded prior to dinner. The use of Dibose (acarbose 100mg/tab,
available in stock) 1# TID might be initialized if two or more
consecutive data points exceed 200mg/dL.</li>
</ul>
</div>
</div>
<div id="section-293" class="section level1">
<h1>700811991</h1>
<div id="section-294" class="section level2">
<h2>220927</h2>
<ul>
<li>lab data
<ul>
<li>2022-09-09 Anti-HBc Reactive<br />
</li>
<li>2022-09-09 Anti-HBc-Value 4.74 S/CO<br />
</li>
<li>2022-09-09 Anti-HBs 8.30 mIU/mL<br />
</li>
<li>2022-08-25 HBsAg Negative<br />
</li>
<li>2022-08-25 HBsAg Value 0.538<br />
</li>
<li>2022-08-25 Anti-HCV Negative<br />
</li>
<li>2022-08-25 Anti-HCV Value 0.0352</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-16 CXR
<ul>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2022-08-30 All-RAS + BRAF mutations assay
<ul>
<li>All-RAS mutations assay
<ul>
<li>Detection range
<ul>
<li>KRAS codon 12, 13, 59, 61, 117, 146</li>
<li>NRAS codon 12, 13, 59, 61, 117, 146</li>
</ul></li>
<li>Results
<ul>
<li>Detected (KRAS codon 12 GGT&gt;GTT, p.G12V)</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with RAS mutation may not benefit from the anti-EGFR antibody treatment.
Patients with no RAS mutation are more likely to have disease control by
using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
<li>BRAF mutations assay
<ul>
<li>Detection range
<ul>
<li>BRAF codon 600</li>
</ul></li>
<li>Results
<ul>
<li>There was no variant detected in the BRAF gene.</li>
</ul></li>
<li>Interpretation
<ul>
<li>The current study and treatment guidelines indicate that patients
with BRAF mutation maynot benefit from the anti-EGFR antibody treatment.
Patients with no BRAF mutation are more likely to have disease control
by using anti-EGFR antibody treatment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-28 Standing KUB
<ul>
<li>Degeneration and spondylosis of L-S spine.</li>
</ul></li>
<li>2022-08-25 Patho - colon segmental resection for tumor
<ul>
<li>Diagnosis:
<ul>
<li>Intestine, large, sigmoid colon, left hemicolectomy — Moderately
differentiated adenocarcinoma</li>
<li>Proximal anastomosis: Negative for malignancy<br />
</li>
<li>Distal anastomosis: Negative for malignancy<br />
</li>
<li>Lymph node, regiona, dissection — Metastatic adenocarcinoma
(4/18)</li>
<li>AJCC 8th edition pathology stage: T3N2a( cM1); AJCC stage IVA, at
least</li>
</ul></li>
<li>Gross Description:
<ul>
<li>Procedure: Left hemicolectomy</li>
<li>Tumor Site: Sigmoid colon</li>
<li>Tumor Size: 4.8x 3.5 cm.<br />
</li>
<li>Macroscopic Tumor Perforation: Not identified</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Adenocarcinoma</li>
<li>Histologic Grade: G2: Moderately differentiated</li>
<li>Tumor Extension: Tumor invades through the muscularis propria into
pericolorectal tissue</li>
<li>Margins:
<ul>
<li>Proximal margin: Uninvolved</li>
<li>Distal margin: Uninvolved</li>
<li>Radial or Mesenteric Margin: Involved</li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Perineural Invasion: Not identified</li>
<li>Tumor Budding:
<ul>
<li>Number of tumor buds in 1 “hotspot” field (specify total number in
area = 0.785 mm2)</li>
<li>Intermediate score (5-9)</li>
</ul></li>
</ul></li>
<li>Type of Polyp in Which Invasive Carcinoma Arose: Not identified</li>
<li>Tumor Deposits: Not identified
<ul>
<li>Specify number of deposits: N/A</li>
</ul></li>
<li>Regional Lymph Nodes
<ul>
<li>Number of Lymph Nodes Involved/Examined: 4 / 18, with extranodal
extension</li>
</ul></li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition):
<ul>
<li>TNM Descriptors (required only if applicable) (select all that
apply)
<ul>
<li>m (multiple primary tumors) r (recurrent) y (posttreatment)</li>
</ul></li>
<li>Primary Tumor (pT):
<ul>
<li>pT3: Tumor invades through the muscularis propria into
pericolorectal tissues</li>
</ul></li>
<li>Regional Lymph Nodes (pN):
<ul>
<li>pN2a: Four to six regional lymph nodes are positive</li>
</ul></li>
<li>Distant Metastasis (pM):
<ul>
<li>N/A</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (108 - 33) / 108 = 69.44%
<ul>
<li>M-mode (Teichholz) = 69</li>
</ul></li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>LV diastolic dysfunction Gr 2.</li>
<li>Normal RV systolic function.</li>
<li>Mild MR; mild TR; aortic valve sclerosis.</li>
</ul></li>
<li>2022-08-23 Flow Volume Curve
<ul>
<li>Mild obstructive pulmonary function impairment</li>
</ul></li>
<li>2022-08-22 CXR
<ul>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2022-08-22 CT - abdomen
<ul>
<li>History
<ul>
<li>73 y/o 2022-07-17 abdominal pain off and on for a period of
time</li>
<li>PI : diarrhea (-) constipation (-) BW loss (-) appetite : good,
relieving factor (-)</li>
<li>PHx : HTN (+) DM (+) Op. (+) prostate hypertrophy CAD s/p
stenting</li>
</ul></li>
<li>Imp
<ul>
<li>Suspected colon cancer at rectosigmoid colon with lung meta and
regional lymph nodes</li>
</ul></li>
<li>Impression (Imaging stage): T:T3(T_value) N:N2(N_value)
M:M1(M_value)</li>
</ul></li>
<li>2022-08-11 Patho - colon biopsy
<ul>
<li>R-S junction, 20 cm AAV, biopsy — Adenocarcinoma, moderately
differentiated</li>
<li>The sections show adenocarcinoma, moderately differentiated,
composed of columnar neoplastic cells, arranged in glandular,
cribriform, and papillary patterns with desmoplastic stromal
reaction.</li>
<li>IHC, tumor cells reveal: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li>2022-08-10 Colonoscopy
<ul>
<li>Suspected colon cancer, 20cm AAV, s/p biopsy</li>
<li>Internal hemorrhoid</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-26 - irinotecan 120mg/m2 150mg 90min + leuocovrin 300mg/m2
450mg 2hr + fluorouracil 2400mg/m2 3700mg 46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pathology performed in late August 2022 revealed the disease to be
characterized by pMMR, EGFR(+), KRAS codon 12 mutations, without BRAF
mutations.
<ul>
<li>pMMR =&gt; it would be less prominent in the effect of pembrolizumab
or nivolumab +- ipilimumab.</li>
<li>mutated RAS =&gt; the effect of anti-EGFR antibody treatment (e.g.,
panitumumab, cetuximab) might be mitigated.</li>
<li>lack of BRAF codon 600 mutatation =&gt; encorafenib might not be the
choice.</li>
</ul></li>
<li>The blood pressure appears to be under control (with bisoprolol and
nicorandil); however, the blood sugar appears to be a little higher
(with metformin and vildagliptin). The addition of a hypoglycemic agent
is not urgently required yet.</li>
</ul>
</div>
</div>
<div id="section-295" class="section level1">
<h1>700155901</h1>
<div id="section-296" class="section level2">
<h2>220926</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-13, -09-06, 09-02, 08-24, 08-19, 08-10, 08-05 CXR
<ul>
<li>Blunting of bilateral costal-phrenic angle is noted, which may be
due to pleura effusion ?</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-08-05, -07-11 Abdomen - standing (diaphragm)
<ul>
<li>Increase soft tissue density of the right lower abdomen is noted
that is c/w local recurrent tumor after correlate with prior CT on
20220625.</li>
<li>Spondylosis with scoliosis of the L-spine with convex to left
side</li>
</ul></li>
<li>2022-07-14 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (93 - 23) / 93 = 75.27%
<ul>
<li>M-mode (Teichholz) = 75</li>
</ul></li>
<li>Dilated LA</li>
<li>Adequate LV, RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild PR, TR</li>
</ul></li>
<li>2022-07-11 KUB
<ul>
<li>Increase soft tissue density of the RLQ abdomen is suspected. Please
correlate with CT for further evaluation.</li>
<li>Ascites is suspected.</li>
</ul></li>
<li>2022-07-11 Patho - uterus with or without SO
<ul>
<li>DIAGNOSIS: Tissue, pelvic, biopsy — malignant tumor, high-grade</li>
<li>Microscopically, it shows mlaignant tumor composed of high-grade
tumor cells arranged in solid architacture and focal glandular
differentiation. The tumor shows nuclear hyperchromasia, pleomorphism,
and mitotic activity.</li>
<li>Immunohistochemical stain reveals CK (focal +), PXA-8(+), WT-1(-),
CK20(-).</li>
</ul></li>
<li>2022-07-05 Gynecologic ultrasonography
<ul>
<li>Suspected pelvis mass: (1) 197x122mm (2) 64x41mm</li>
<li>Ascites (+)</li>
</ul></li>
<li>2022-06-25 CT - abodmen
<ul>
<li>S/P hysterectomy with minimal ascites. Some recurrent tumors (up to
13.3cm) in peritoneal cavity.</li>
</ul></li>
<li>2022-02-18 SONO - abdomen
<ul>
<li>Two hepatic cysts in S6/7 and S5 are suspected. Follow up is
indicated.</li>
<li>S/P cholecystectomy.</li>
</ul></li>
<li>2022-02-04 CT - abdomen
<ul>
<li>History:
<ul>
<li>Endometrial carcinosarcoma S/P hysterectomy and adjuvant chemo and
radiotherapy</li>
</ul></li>
<li>Impression
<ul>
<li>There are two poor enhancing lesion measuring 0.4 cm in S6/7 and 0.6
cm in S5 and of the liver that may be metastases or cysts? Please
correlate with sonography and MRI.</li>
</ul></li>
</ul></li>
<li>2021-10-15 MRI - pelvis
<ul>
<li>S/P hysterectomy and oophorectomy. Suggest follow up.</li>
<li>Suspected R/O left renal cyst.</li>
</ul></li>
<li>2021-09-02 Pure tone audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 28 dB HL / LE 30 dB HL</li>
<li>bil normal to moderate SNHL</li>
</ul></li>
<li>2021-07-22 Gynecologic ultrasonography
<ul>
<li>ATH + BSO</li>
<li>no obvious uterine or ovarian lesion</li>
</ul></li>
<li>2021-07-12 Patho - uterus with or without SO
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Uterus, endometrium, staging surgery — carcinosarcoma, poorly
differentiated<br />
</li>
<li>Uterus, myometrium, staging surgery — Involved by carcinosarcoma
(&lt; 1/2 thickness) — intramural myomas<br />
</li>
<li>Uterus, cervix, staging surgery — endocervical polyp<br />
</li>
<li>Ovary and fallopian tubes, right, staging surgery — Involved by
carcinosarcoma<br />
</li>
<li>Ovary and fallopian tubes, left, staging surgery — Negative for
malignancy<br />
</li>
<li>Lymph node, left iliac, dissection — Negative for malignancy
(0/2)<br />
</li>
<li>Lymph node, left obturator, dissection — Negative for malignancy
(0/4)<br />
</li>
<li>Lymph node, right iliac, dissection — Negative for malignancy
(0/2)<br />
</li>
<li>Lymph node, right obturator, dissection — Negative for malignancy
(0/5)<br />
</li>
<li>Lymph node, left paraaortic, dissection — Negative for malignancy
(0/1)<br />
</li>
<li>Lymph node, right paraaortic, dissection — Negative for malignancy
(0/3)<br />
</li>
<li>Omentum, omentectomy— Positive for carcinosarcoma<br />
</li>
<li>AJCC 8th edition Pathology stage: pT3aN0M1; FIGO IVB, AJCC stage
IVB<br />
</li>
<li>Additional Pathologic Findings — Carcinosarcoma with heterologous
rhabdomyosarcomatous differentiation (S2021-08805)<br />
</li>
<li>Ancillary Studies: IHC stain — vimentin( +), ER(-), PR:+(moderate,
60%), CK(+), SMA (-)<br />
</li>
</ul></li>
</ul></li>
<li>2021-07-06 MRI - pelvis
<ul>
<li>Imaging Report Form for Endometrial Carcinoma
<ul>
<li>Impression (Imaging stage) : T:T1(T_value) N:N0(N_value)
M:M0(M_value) STAGE:Ia(Stage_value)</li>
</ul></li>
<li>Impression:
<ul>
<li>Prominent soft tissue in the uterine cavity, suspected endometrial
malignancy, if proven malignancy, cstage T1aN0M0.</li>
<li>Utereine myoma.</li>
<li>Enhancing lesion in right ischial bone, suggest bone scan
correlation.</li>
</ul></li>
</ul></li>
<li>2021-07-06 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, endometrial curettage — Carcinosarcoma with
heterologous rhabdomyosarcomatous differentiation<br />
</li>
<li>IHC: CK(+ for epithelial component), Vimentin(+ for sarcomatous
component), Desmin(+ for rhabdomyoblasts), and Myogenin(+ for
rhabdomyoblasts).<br />
</li>
</ul></li>
<li>2021-07-05 Gynecologic ultrasonography
<ul>
<li>bilateral adnexae: free</li>
<li>endometrial hyperplasia: 51.4mm (RI: 0.24)</li>
</ul></li>
<li>2021-03-13 SONO - nephrology
<ul>
<li>a 0.61cm hyperecholic lesion without acoustic shadow in the cortex
of middle portion, left kidney, suspect hypercalcification lesion</li>
<li>Interpretation: Bilateral parenchymal renal disease</li>
<li>A calcification lesion, left kidney</li>
</ul></li>
<li>2020-05-07 SONO - nephrology
<ul>
<li>Left renal stones.</li>
<li>Parenchymal renal disease.</li>
</ul></li>
<li>2019-08-22 SONO - abdomen
<ul>
<li>Mild fatty liver. S/P cholecystectomy. Suspected left renal
angiomyolipoma</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>The blood pressure and blood sugar levels are within the normal
range.</p></li>
<li><p>Human albumin 20g QD, furosemide 20mg QD, and spironolactone 25mg
BID are currently being used to control patient edema.</p></li>
<li><p>Blood pressure and blood sugar are grossly in normal
range.</p></li>
<li><p>Human albumin 20g QD, furosemide 20mg QD, spironolactone 25mg BID
are currently applied to cope with the patients edema.</p></li>
</ul>
</div>
</div>
<div id="section-297" class="section level1">
<h1>700316910</h1>
<div id="section-298" class="section level2">
<h2>220926</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-25 CT - abdomen
<ul>
<li>Rectal cancer s/p operation.</li>
<li>Bony metastases at sacrum and pelvic bones with adjacent tructures
invason causing left hydronephrosis/hydroureter. Multiple LNs, liver and
lung metastases. General subcutaneous edema.</li>
</ul></li>
<li>2022-09-25 KUB
<ul>
<li>Bony destruction of sacrum and pelvic bones.</li>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-09-25 CXR
<ul>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2022-07-14 CXR
<ul>
<li>Patch density at right lower lung zone.</li>
</ul></li>
<li>2022-07-14 KUB
<ul>
<li>Degeneration of bony structures.</li>
<li>Some lucent lesions in bony structures.</li>
<li>Deformity of right pubic bone.</li>
<li>Stool retention in bowl.</li>
</ul></li>
<li>2022-07-14 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>T wave abnormality, consider inferolateral ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-12-10 Peripheral Vascular Test - vein, lower limbs
<ul>
<li>Clinical diagnosis: left leg edema, pelvic cancer</li>
<li>Doppler study: (N = Normal, A = Abnormal, T = Thrombus)
<ul>
<li>Lower limbs R_CFV R_SFV R_PV R_PTV R_SV L_CFV L_SFV L_PV L_PTV
L_SV</li>
<li>Spontaneous signal N N N N N N N N N N<br />
</li>
<li>Respiratory changes N N N N N A A A A A</li>
<li>Cough response N N N N N N N N N N</li>
<li>Compression study N N N N N N N N N N</li>
<li>Right Left N N N N N N N N N N</li>
</ul></li>
<li>Report:
<ul>
<li>Thrombus : None</li>
<li>Varicose vein : None</li>
</ul></li>
<li>Right side:
<ul>
<li>SVC: 11.3 mmHg ; 12.7 mmHg ;</li>
<li>MVO/SVC: 89 % ; 83 % ;</li>
<li>Average MVO/SVC: 86 %</li>
</ul></li>
<li>Left side:
<ul>
<li>SVC: 8.0 mmHg ; 10.3 mmHg ;</li>
<li>MVO/SVC: 75 % ; 66 % ;</li>
<li>Average MVO/SVC: 70 %</li>
</ul></li>
<li>Conclusion:
<ul>
<li>There was no evidence of DVT detecetd at both lower limbs venous
system.</li>
<li>Loss of respiratory change of venous flow at left CFA, PFA, SFA and
popliteal vein, consider left iliofemoral venous stenosis or
obstruction. A large perforator vein anastomosed the left PTV and left
LSV at left lower calf level was detected.</li>
<li>Bilateral saphenofemoral venous junction (LSV) and saphenopopliteal
venous junction (SSV) were competent without venous reflux.</li>
<li>The measured MVO/SVC at right thigh was normal (86%). However, the
measured MVO/SVC ratio at left thigh was 70%, compatible with left
iliofemoral venous stenosis or obstruction.</li>
</ul></li>
</ul></li>
<li>2021-11-15 MRI - L-spine
<ul>
<li>Findings
<ul>
<li>Large area of Bone destructions at S1-2-3, mainly at left, with
neuroformen impingement.</li>
<li>No evident bony destructive lesion at T-spine.</li>
<li>Normal cord size and signal intensity.</li>
</ul></li>
<li>Impression
<ul>
<li>Favor large area of sacral bone metastases.</li>
</ul></li>
</ul></li>
<li>2021-11-15 CT - abdomen
<ul>
<li>Rectal cancer s/p operation. Bony metastases at sacrum with adjacent
tructures invason causing left hydronephrosis/hydroureter. Multiple lung
metastases.</li>
</ul></li>
<li>2021-11-15 KUB + L-spine Lat
<ul>
<li>increased air in nondistended loops of small bowel over abdomen and
pelvic</li>
<li>large osteolytic change at sacrum especially left side due to
metastasis, in progression as compared with previous images on
20210714.</li>
</ul></li>
<li>2021-03-02 CT - abdomen
<ul>
<li>Post-op at the colon.</li>
<li>Destructive lesion in the sacrum, suspected metastasis.</li>
<li>RLL nodule, suspected lung metastasis.</li>
<li>Gallbladder stones.</li>
<li>Suspected liver cysts.</li>
</ul></li>
<li>2021-01-05 CT - abdomen
<ul>
<li>Recurrent colon cancer at sacrum. Suggest further treatment.</li>
</ul></li>
<li>2020-10-13 CT - abdomen
<ul>
<li>No evidence of recurrent tumor in the study.</li>
</ul></li>
<li>2020-08-20 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Increased activity in the sacrum and adjacent left S-I joint. Bone
metastasis should be considered. Please correlate with other imaging
modalities for further evaluation.</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular juntions and knees, compatible with benign joint
lesions.</li>
</ul></li>
<li>2020-08-18
<ul>
<li>Subtle osteolytic lesion in the left side 1st and 2nd sacrum is
noted that is compatible with bony metastasis after correlate with prior
CT on 2020-04-28 and MRI on 2020-07-17 from TSGH. Please correlate with
clinical condition.</li>
</ul></li>
<li>2020-07-21 CT - chest
<ul>
<li>a tiny RUL-S3 perifussural nodule, stationary, favor an
intrapulmonary LN. no mediastinal tumor.</li>
</ul></li>
<li>2020-04-28 CT - abdomen
<ul>
<li>Post-op at the colon. Suggest follow up.</li>
<li>GB stones.</li>
<li>Liver cysts.</li>
</ul></li>
<li>2020-02-04 SONO - abdomen
<ul>
<li>Mild fatty liver.</li>
<li>There are several hepatic cysts in both lobes and the largest one is
measured about 1.7 cm in size at S6.</li>
<li>A gallstone measuring 0.64 cm.</li>
</ul></li>
<li>2019-10-29 CT - abdomen
<ul>
<li>Clinical history:
<ul>
<li>57 y/o male patient with rectal CA, ypT3N1b (3/12) cM0, stage IIIB
Dx in July 2017 at ShuangHo Hospital s/p CCRT at ShuangHo Hospital &amp;
s/p Op in Oct 2017 by Dr Xiao GuangHong, s/p post-Op adjuvant
Oxaliplatin (self-paid) / HDFL IV Q2W x 12 finishing in May 2018,
Rectum, laparoscopic LAR (20171025): AdenoCA, MD, LNs, mesorectal,
dissection: Metastatic adenocarcinoma (3/12) Pathology stage:
ypT3N1b(cM0), stage IIIB.</li>
<li>Rectal cancer, cT3N1M0; stage III s/p CCRT at 10 cm from AV at
ShuangHo Hospital</li>
</ul></li>
<li>Impression
<ul>
<li>Post-op at the colon. suggest follow up.</li>
<li>Liver cysts.</li>
<li>GB stone.</li>
</ul></li>
</ul></li>
<li>2019-08-08 CT - chest
<ul>
<li>Pleura traction at right upper lobe, right upper lobe nodule. These
two findigs are stationary.</li>
</ul></li>
<li>2019-07-30 SONO - abdomen
<ul>
<li>Mild fatty liver.</li>
<li>There are several hepatic cysts in both lobes and the largest one is
measured about 1.7 cm in size at S6.</li>
<li>A gallstone measuring 0.86 cm and a polyp 0.21 cm.</li>
</ul></li>
<li>2019-05-07 CT - abdomen
<ul>
<li>No evidence of recurrent tumor in the study.</li>
<li>Cystic duct stone.</li>
</ul></li>
<li>2019-02-12 CT - chest
<ul>
<li>The peripheral tiny nodule at RUL is pleural fat protrudining and
indenting the lung.</li>
<li>no interval change of a tiny nodule (about 2mm) at RUL.</li>
</ul></li>
<li>2018-08-14 SONO - hepatobiliary
<ul>
<li>Small hepatic cysts, up to 1.28 cm. A gallstone.</li>
</ul></li>
<li>2018-05-29 CT - chest
<ul>
<li>Tiny nodules (2.2mm, 3.6mm) at RUL.</li>
</ul></li>
<li>2018-05-24 CT - abdomen
<ul>
<li>S/P operation.</li>
<li>Liver cysts (0.5-1.6cm).</li>
<li>Gall stone (6mm).</li>
</ul></li>
<li>2017-10-26 Surgical pathology Level VI
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Rectum, laparoscopic LAR — Adenocarcinoma, moderately
differentiated</li>
<li>Resection margins: Free<br />
</li>
<li>Lymph nodes, mesorectal, dissection — Metastatic adenocarcinoma
(3/12)<br />
</li>
<li>Pathology stage: ypT3N1b(cM0), stage IIIB</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology: Adenocarcinoma</li>
<li>Histology Grade: Moderately differentiated</li>
<li>Depth of invasion: To perirectal soft tissue</li>
<li>Angiolymphatic invasion: Not identified</li>
<li>Perineural invasion: Not identified</li>
<li>Discontinuous extramural tumor extension: Not identified</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 10 mm from
the margin</li>
<li>Lymph node metastasis, mesorectal: Metastatic adenocarcinoma
(3/12)</li>
<li>Extranodal involvement: Not identified<br />
</li>
<li>Pathological TNM Stage: ypT3N1b(cMx)<br />
</li>
<li>Type of polyp in which invasive carcinoma arose: Not identified</li>
<li>Additional pathologic findings: None identified</li>
<li>TNM descriptors: y (Post-treatment)<br />
</li>
<li>Tumor regression grading S/P CCRT: Grade 2 (partial response)</li>
<li>Proximal and distal margins: Free of tumor</li>
<li>IHC for mismatch repair proteins:
<ul>
<li>MSH6: Intack nuclear expression</li>
<li>PMS2: Intack nuclear expression</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-28 bil. lumbar sympathetic block
<ul>
<li>pain management procedural note
<ul>
<li>The patient lay prone on a radiolucent table with a pillow under the
upper abdomen.</li>
<li>The site of vertebral bodies were marked out with the X-ray beam in
the postero-anterior axis.</li>
<li>The double end-plate at border of L2 vertebral body was corrected by
angling the intensifier.</li>
<li>The X-ray beam was gently rotated obliquely away from the spine,
until the edge of the transverse process along the border of vertebral
body.</li>
<li>A mark was made.</li>
<li>After local anesthetic infiltration, a 22G, 150 mm long needle was
inserted along the X-ray beam.</li>
<li>The angle of the needle was adjusted to obtain tunnel view, and the
needle was poised to contact the anteriolateral border of the vertebral
body.</li>
<li>Contrast medium was injected to assure the proper needle tip
position in both P-A and lateral X-ray views.</li>
<li>Then 5 ml of 0.5% buivacaine  was injected.</li>
<li>The other targeted sites were proceeded in the same manner.</li>
<li>complication nil    </li>
<li>blood loss &lt;1ml </li>
</ul></li>
</ul></li>
<li>2018-06-06 Closure of enterostomy or Colostomy (loop or
double-barrel)
<ul>
<li>PCS code: 73020C</li>
<li>Finding
<ul>
<li>Loop ileostomy at Right abdomen</li>
</ul></li>
</ul></li>
<li>2017-10-25 Restorative proctectomy with colo-analanastomosis
<ul>
<li>PCS code: 74213B</li>
<li>Finding
<ul>
<li>Rectal cancer s/p CCRT with tumor shrinkage remaining a scar at 6 cm
from AV</li>
<li>Narrow pelvis</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-05-31 - bevacizumab 5mg/kg 400mg 1.5hr + irinotecan 170mg/m2
330mg 90min + leucovorin 400mg/m2 770mg 2hr + fluorouracil 2800mg/m2
5400mg 46hr</li>
<li>2021-03-16 - irinotecan 170mg/m2 330mg 90min + leucovorin 400mg/m2
770mg 2hr + fluorouracil 2800mg/m2 5400mg 46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The addition of a PPI might be beneficial in the event of stool OB
4+ (2022-09-25) and suspicion of GI bleeding.</li>
<li>A temporary hold on NSAIDs (diclofenac, patient-carried) may also be
an option in this situation.</li>
<li>Diclofenac adverse reactions and incidences - Gastrointestinal:
nausea (3% to 14%), abdominal pain (4% to 7%), constipation (8%),
diarrhea (6%), duodenal ulcer, dyspepsia (2%), flatulence (2% to 3%),
gastric ulcer, gastrointestinal hemorrhage, gastrointestinal
perforation, heartburn, upper abdominal pain (3%), vomiting (3% to
6%).</li>
</ul>
</div>
</div>
<div id="section-299" class="section level1">
<h1>700377487</h1>
<div id="section-300" class="section level2">
<h2>220926</h2>
<p>{multiple myeloma}</p>
<ul>
<li>exam finding
<ul>
<li>2022-09-23 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (80 - 32) / 80 = 60%</li>
<li>Normal LV systolic function with abnormal septal wall motion due to
RV pressure overload.</li>
<li>Hypertrophic cardiomyopathy without outflow tract obstruction,
dilated LA; LV diastolic dysfunction Gr 3 (restrive pattern).</li>
<li>Dilated RA and RV; Impaired RV systolic function with free wall
hypokinesia.</li>
<li>Mild to moderate MR; moderate to severe TR.</li>
<li>Possible moderate pulmonary hypertension, estimated PASP: 40 mmHg
(systemic systolic pressure: 95mmHg).</li>
<li>Engorgement of IVC with poor inspiratory collapse, consider fluid
overload.</li>
<li>Dilated aortic root and ascending aorta.</li>
<li>Minimal pericardial effusion.</li>
</ul></li>
<li>2022-09-22 CXR
<ul>
<li>Ground glass opacity in RLL.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Cardiomegaly.</li>
<li>Widening of mediastinum.</li>
</ul></li>
<li>2022-09-15 L-spine 4 views (including sacrum)
<ul>
<li>mild spondylolisthesis at L4-5</li>
<li>Unremarkable change in the width of the bony spinal canal<br />
</li>
<li>mild anterior spur formation at the L-spine</li>
<li>moderate decreased disc space in the L4/5 disc</li>
<li>Unremarkable change in the paravertebral region</li>
<li>compression fractures at L1, T12 and T11 vertebral bodies</li>
</ul></li>
<li>2022-08-18 Uroflow
<ul>
<li>Q max: fair</li>
<li>flow pattern: normal</li>
</ul></li>
<li>2022-08-18 Bladder Sosography
<ul>
<li>PVR: 11.35mL (postvoided residual)</li>
</ul></li>
<li>2022-07-21 Transrectal Ultrasound of Prostate, TRUS-P
<ul>
<li>Findings
<ul>
<li>Prostate
<ul>
<li>Size of prostate: 3(T)cm x 4.6(L)cm x 4.6(AP)cm = 34cc</li>
<li>Size of adenoma: 2(T)cm x 2.4(L)cm x 3.4(AP)cm = 0.9cc</li>
</ul></li>
</ul></li>
<li>Seminal vesicles：
<ul>
<li>L
<ul>
<li>Size：L’t1.7 x 0.6 cm</li>
<li>Vas deferens：Normal</li>
<li>Cyst：No</li>
<li>Abscess：No</li>
<li>Tumor：No</li>
</ul></li>
<li>R
<ul>
<li>Size：R’t1.5 x 0.4 cm</li>
<li>Vas deferens：Normal</li>
<li>Cyst：No</li>
<li>Abscess：No</li>
<li>Tumor：No</li>
</ul></li>
</ul></li>
<li>Diagnosis
<ul>
<li>Benign prostatic hyperplasia</li>
</ul></li>
</ul></li>
<li>2022-06-30 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Prominence of right hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
<li>Increased lung markings on both lower lung are noted. Please
correlate with clinical condition.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
</ul></li>
<li>2022-06-18 SONO - Nephrology
<ul>
<li>Chronic parenchymal renal disease.</li>
<li>Right renal cysts, cortical and parap</li>
</ul></li>
<li>2022-06-17 SONO - abdomen
<ul>
<li>Parenchymal liver disease</li>
<li>Gallbladder stones</li>
<li>Cholecystopathy</li>
<li>Bilateral renal cysts</li>
<li>Splenomegaly</li>
<li>Splenic hyperechoic lesion, nature? suspected hemangioma</li>
<li>Minimal ascites</li>
<li>Bilateral pleural effusion</li>
</ul></li>
<li>2022-06-15 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (91 - 21) / 91 = 76.92%
<ul>
<li>M-mode (Teichholz) 77</li>
</ul></li>
<li>Dilated LA,Ao,RA,RV,PA,IVC</li>
<li>Biventricular hypertrophy</li>
<li>Poor RV systolic function</li>
<li>Adequate LV systolic function, abnormal septal wall motion due to RV
failure</li>
<li>Impaired LV relaxation</li>
<li>Moderate MR,PR</li>
<li>Severe TR</li>
<li>Minimal amount pericardial effusion, No tamponade, No pericardial
constriction at present</li>
<li>Paroxysmal atrial fibrillation or MAT rhythm</li>
</ul></li>
<li>2022-06-14 ECG
<ul>
<li>Atrial fibrillation with rapid ventricular response</li>
<li>Left axis deviation</li>
<li>Anterior infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-05-06 Ultrasound of male genital organs
<ul>
<li>Scrotal soft tissue edema</li>
<li>Enlarged Right epididymis without vascularity, epididymitis was not
likely</li>
</ul></li>
<li>2022-05-01 KUB
<ul>
<li>Blunted right costophrenic angle.</li>
<li>Degeneration and spondylosis of L-S spine.</li>
</ul></li>
<li>2022-05-01 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Left axis deviation</li>
<li>Anteroseptal infarct, age undetermined</li>
</ul></li>
<li>2022-02-14 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (111 - 35) / 111 = 68.47%
<ul>
<li>M-mode (Teichholz) 68</li>
</ul></li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Moderate MR, moderate TR and trivial PR</li>
<li>Dilated LA, septal hypertrophy</li>
<li>Preserved RV systolic function</li>
<li>Dilated aortic root</li>
</ul></li>
<li>2022-02-14 SONO - chest
<ul>
<li>Bilateral trivial pleural effusion (right &gt; left).</li>
</ul></li>
<li>2022-02-10 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Prominence of right hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
</ul></li>
<li>2022-02-09 MRI - retroperitoneum
<ul>
<li>History: both lower legs edema Suspected Retroperitoneum
lesion?</li>
<li>Past Hx: multiple myeloma</li>
<li>Findings
<ul>
<li>There is a newly-developed soft tissue mass measuring 3.8 x 2.5 cm
in the lower pole of spleen with exophytic growth, showing hypointensity
on T1WI, mild hyperintensity on both T2WI and DWI. However, there is no
signal drop on ADC.
<ul>
<li>Please correlate with contrast enhanced dynamic MRI to R/O
extramedullary plasmacytoma or angiosarcoma.</li>
</ul></li>
<li>There is no retroperitoneal lesion and no extrinsic compression
lesion in the IVC, bilateral iliac vein, and bilateral femoral vein.
<ul>
<li>The IVC, iliac vein, and femoral vein show no filling defect.</li>
</ul></li>
<li>There is periportal lucency and gallbladder wall edema that may be
hypoalbuminemia.
<ul>
<li>In addition, There is edematous change in the subcutaneous fat layer
of anterior abdominal wall, bilateral flank area and pre-sacral space
that also may be due to hypoalbuminemia. please correlate with clinical
condition.</li>
</ul></li>
<li>There is mild ascites in perihepatic and perisplenic space.</li>
<li>Mild bilateral Pleura effusion are noted.</li>
<li>There is a diverticulum measuring 2.6 cm in the medial aspect of
duodenum 2nd portion, near the ampulla of Vater area. Please correlate
with clinical condition.</li>
<li>There are several renal cysts on both kidney and the largest one
measuring 1 cm in size at right upper pole.<br />
</li>
<li>There are few gallstones and the size &lt; 1.5 cm.</li>
<li>There is no focal abnormality in the biliary system and
pancreas.<br />
</li>
<li>There is no evidence of lymphadenopathy.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>IMP:
<ul>
<li>Splenic mass,nature? Please correlate with contrast enhanced dynamic
MRI to R/O extramedullary plasmacytoma or angiosarcoma.<br />
</li>
<li>There is no retroperitoneal lesion and no extrinsic compression
lesion in the IVC, bilateral iliac vein, and bilateral femoral vein. The
IVC, iliac vein, and femoral vein show no filling defect.</li>
</ul></li>
</ul></li>
<li>2022-01-26 Peripheral Vascular Test - vein, lower limbs
<ul>
<li>Doppler study: (N = Normal, A = Abnormal, T = Thrombus)
<ul>
<li>Lower limbs R_CFV R_SFV R_PV R_PTV R_SV L_CFV L_SFV L_PV L_PTV
L_SV</li>
<li>Spontaneous signal N N N N A N N N N A</li>
<li>Respiratory changes N N N N N N N N N N</li>
<li>Cough response N N N N N N N N N N</li>
<li>Compression study N N N N N N N N N N</li>
<li>Right Left N N N N N N N N N N</li>
</ul></li>
<li>Report:
<ul>
<li>Right side:
<ul>
<li>SVC: 11.8 mmHg ; 14.2 mmHg ;</li>
<li>MVO/SVC: 90 % ; 86 % ;</li>
<li>Average MVO/SVC: 88 %</li>
</ul></li>
<li>Left side:
<ul>
<li>SVC: 8.6 mmHg ; 10.9 mmHg ;</li>
<li>MVO/SVC: 100 % ; 91 % ;</li>
<li>Average MVO/SVC: 95 %</li>
</ul></li>
</ul></li>
<li>Conclusion:
<ul>
<li>No venous thormbosis at bilateral deep and superficial venous
system</li>
<li>No varicose vein at both GSV/SSV with mild venous reflux reponse
with sponteanous reversal flow</li>
<li>Marked interstititla edema at both calf site, plese correlate with
serum albumin level or renal function</li>
<li>The MVO/SVC ratio showed no significant venous obstruction at iliac
iven or IVC level</li>
</ul></li>
</ul></li>
<li>2022-01-25, -01-24 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Prominence of right hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
</ul></li>
<li>2022-01-24 ECG
<ul>
<li>Left axis deviation</li>
<li>Anteroseptal infarct , age undetermined</li>
<li>Prolonged QT</li>
<li>Non-specific intra-ventricular conduction delay</li>
</ul></li>
<li>2021-10-07 Patho - bone marrow biopsy
<ul>
<li>Clinical finding: R/I MM recurrence</li>
<li>Ciinical diagnosis: C90.00 Multiple myeloma not having achieved
remission</li>
<li>DIAGNOSIS: Bone marrow, rigth ileum, biopsy — Multiple myeloma<br />
</li>
<li>Microscopically, it shows 90% cellularity of bone marrow with
diffuse proliferation of plasma cells admixed with some myeloid and
erythroid cells and occsaional megakaryocytes. No blast is seen. It is
compatible with multiple myeloma.<br />
</li>
<li>Immunohistochemical stain reveals CD138(diffuse +), MPO(foal+),
CD71(focal+), Kappa chain (-), lambda chain (+), CD34(-), CD117(-),
TdT(-),and CD20(-).</li>
</ul></li>
<li>2021-08-16 SONO - nephrology
<ul>
<li>slightly enlargement of both kidneys</li>
<li>right renal cysts</li>
<li>gall stones? &gt; 3 stones</li>
<li>spleen tumor?</li>
</ul></li>
<li>2021-07-23 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably mild myocardial ischemia at the apex.</li>
<li>Reverse redistribution of radioactivity to the basal lateral wall,
either normal variant or myocardial ischemia may show this picture.</li>
</ul></li>
<li>2021-07-21 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (98.3 - 35.3) / 98.3 = 64.09%
<ul>
<li>M-mode (Teichholz) 64.1</li>
</ul></li>
<li>Dilated aortic root</li>
<li>Thickening of IVS</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>Mild MR, AR, TR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2021-07-19 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Left anterior fascicular block</li>
<li>Septal infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2018-12-13 Surgical pathology Level IV
<ul>
<li>Clinical diagnosis
<ul>
<li>Multiple myeloma, without mention of remission; Anemia,
unspecified.</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Bone marrow, side? biopsy — Multiple myeloma</li>
</ul></li>
<li>Sections show 80-100 % cellularity. There are diffuse interstitial
infiltrates and aggregates with immature plasma cells. The plasma cells
accounts for about 80-100% of all nucleated cells. Megakaryocytes are
found about 0-5/HPF. No increase of blasts is noted. There are no
granulomas, nor foreign malignant cells.</li>
<li>Immunohistochemical stains reveal CD138(+), CD20(-), Kappa light
chain(-), and Lambda light chain (+). The Ki-67 is &lt; 1%.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-15 Cardiology
<ul>
<li>Q
<ul>
<li>for heart failure &amp; dyspnea</li>
<li>This 64-yera-old man, a patient of multiple myeloma S/P C/T. He was
admitted due to dyspnea &amp; heart failure and acute hepatitis. Fever
37.9 degree C without chills was noted at home.</li>
<li>pt is taking Houttuynia cordata for 2 days and both lower legs edema
and laboratory showed NT-pro BNP: &gt; 25000, hs-Troponin I:1571,
CK-MB:128. We need expertise to evaluate his condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>This is a 64 years old man who has HBV carrier under entecavir,
multiple myeloma and this time was admitted for acute kidney injury,
acute hepatitis, acute heart failure. He is taking of herbal
medication.</li>
<li>We were consulted for acute on chornic heart failure.</li>
<li>S:
<ul>
<li>self complaint bilateral lower limbs edema, SOB just after receiving
immuno-target therapy (new) in Feb 2022</li>
<li>no Chest tightness, no PND, no orthopnea</li>
</ul></li>
<li>P/E:
<ul>
<li>Conjunctiva : pale</li>
<li>Chest : coarse breathing sounds,</li>
<li>Heart : no audible murmur</li>
<li>Extremities : 4+ pitting edema up to scrotum</li>
</ul></li>
<li>Vital sign
<ul>
<li>BT: 36.8 RR: 18 BP: 90/60 HR: 80 SpO2: 99% under NC 3L/m</li>
<li>Chest : coarse breathing sounds</li>
<li>Heart : tachycardia</li>
<li>Extremities: 4+ pitting edema up to scrotum</li>
</ul></li>
<li>Labs
<ul>
<li>Hb: 8.6 MCV: 105</li>
<li>WBC: 22k CRP: 9 neutrophil:81%, band : 5.1%</li>
<li>PLT: 61</li>
<li>Albumin : 3.2 Globulin : 5.3<br />
</li>
<li>T.bilirubin : 1.09 (05/30) –&gt; 2.19 (06/14)</li>
<li>GOT: 19 –&gt;2472 ; GPT: 9 –&gt; 1630</li>
<li>INR: 1.24 –&gt; 1.92</li>
<li>BUN: 30 (05/30) –&gt; 60 (06/14)</li>
<li>Cr: 1.88–&gt; 3.80</li>
<li>NT-proBNP: 6013–&gt; &gt;25000</li>
<li>hsTrop : 182 —&gt;1040 ; CPK/CKMB: 1571/12.8</li>
<li>Na/K: 129/6.0</li>
</ul></li>
<li>Urine analysis : pyuria; bacteriuria</li>
<li>CXR: cardiomegaly</li>
<li>2022/06/15 Echocardiography:
<ul>
<li>LVEF 77%, LV:45/24, IVS/PW:19/14, LA:50, dilated LA,Ao,RA,RV,PA,IVC,
biventricular hypertrophy, poor RV systolic function, adequate LV
systolic function, abnormal septal wall motion due to RV failure,
impaired LV relaxation, moderate MR,PR, severe TR, minimal amount
pericardial effusion, No tamponade, No pericardial cons</li>
</ul></li>
<li>MRI (02/2022) –&gt; RA/RV dilatation.</li>
<li>EKG:
<ul>
<li>Af</li>
<li>Poor R wave progression</li>
<li>Q-wave in antero-septal leads.</li>
</ul></li>
<li>Previous immune and target therapy history
<ul>
<li>Daratumumab</li>
<li>Bortezomib</li>
</ul></li>
<li>Impression
<ul>
<li>Heart failure with preserved EF, H2FPEF score: 6,</li>
<li>Acute on chronic renal failure with oliguria.</li>
<li>Proxysmal Af with CHADVASC score 1 point</li>
<li>Acute hepatits, etiology? congestive liver, acute HBV reactivation
or herbal medication related</li>
<li>Urinary tract infection under brosym</li>
<li>Macrocytic anemia</li>
</ul></li>
<li>Suggestion
<ul>
<li>Restrict salt and water intake</li>
<li>Push up IV lasix dosage to increase urine output, such as IV lasix
2amp Q8H or Q6H.</li>
<li>Consult nephrologist for acute on chronic renal failure with
oliguria. This might be the major etiology of generalized edema.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-04 Infectious Disease
<ul>
<li>Q
<ul>
<li>For redness, swelling, pain, and blisters on the inner thighs,
suspected cellulitis</li>
<li>This 64-year-old man, a patient of multiple myeloma, IgG Lambda Dx
in Sep 2010 at our H S/P C/T. He was admitted due to pain at thights. He
complained of redness, swelling, pain, and blisters on the inner thighs
since 20220427. We need expertise to evaluate his condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>64-year-old multiple myeloma male patient has bilateral medial thigh
and scrotal cellulitis with severe sepsis.
<ul>
<li>Blood culture showed raoultella ornithinolytica bacteremia on May
1.</li>
<li>Under ceftazidime use, there is clinical improvement with
defervescence, more stable vital signs and partial resolution of local
erythema and swelling.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Continue ceftazidime.</li>
<li>Add ciprofloxacin 400mg iv qd as combination therapy.</li>
<li>Arrange scrotal echo.</li>
<li>Needle aspiration of bullae fluid and send for bacterial culture
(maintain bullae skin intact).</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-17 Infectious Disease
<ul>
<li>A
<ul>
<li>This 64-yera-old man, a patient of multiple myeloma S/P C/T. The
blood culture yielded Serratia marcescens S/P Tapimycin for 7 days. but
repeat blood culture via port-A later fever with chills on 20220217
morning. Cr: 1.87</li>
<li>Suggestion:
<ul>
<li>Agree with your use of finibax for Serratia marcescens
bacteremia.</li>
<li>Consider to remove the Prot-A if persistent fever.</li>
<li>Arrange CV-echo to exlcude endocaridits.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-14 Nephrology
<ul>
<li>Q
<ul>
<li>for both lower legs edema R/O nephrotic syndrome</li>
<li>This 64-year-old man, a patient of Multiple myeloma not having
achieved remission S/P C/T. He was admitted due to dyspnea &amp; both
lower legs edema. Owing to dyspnea &amp; both lower legs edema
progression were noted and high NT-proBNP (5207) and Albumin 2.7–&gt;3.2
post Albumin support. We need expertise to evaluate his condition
thanks!</li>
</ul></li>
<li>A
<ul>
<li>This 64 years old male patient of MM not having achieved remission.
He was admitted to Dyspnea and lower leg edema progression. Consult for
nephrotic syndrome.</li>
<li>Lab data :
<ul>
<li>Albumin: 3.2, BUN:22, cre:1.65</li>
<li>Na: 142, K: 4.3, Uric acid: 5.6, LDH: 179</li>
<li>PE: slight dyspena under nasal 3 L, Bilateral lower limb edema
+++</li>
<li>Chest echo : bilateral pleural effusion (rt&gt;lt)</li>
<li>Cardiac echo :LVEF: 68%, normal resting wall motion</li>
<li>MRI retroperitonium : splenic mass, no retroperitoneal lesion</li>
</ul></li>
<li>Impression:
<ul>
<li>Nephrotic syndrome? due to multiple myeloma?</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Check urine for analysis</li>
<li>Check UPCR, UACR, lipid profile</li>
<li>Keep albumin + diuretic</li>
<li>Check ANA, ANCA, antiGBM, antidsDNA, C3, C4, HBV, HCV, syphilis,
cryoglobulin, serum free light chain, IgA, IgM, IgE</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-11 Cardiology
<ul>
<li>Q
<ul>
<li>for high NT-proBNP &amp; suspected heart failure</li>
</ul></li>
<li>A
<ul>
<li>PMH: case of multiple myeloma s/p Daratumumab QW plus Bortezomib /
Dexa</li>
<li>S: shortness of breath for 3 days, bilateral lower limbs edema noted
for about half month. coincide with target therapy. denied of chest pain
or discomfort.
<ul>
<li>P/E:
<ul>
<li>2 consecutive days fever</li>
<li>abdominal type respiration, N/C support 5L/m</li>
<li>chest : reduced breathing sounds over bilateral lower lungs fields,
inspiratory crackles</li>
<li>heart : regular heart beats, apical systolic murmur</li>
<li>Extremities : 4+ pitting edema</li>
</ul></li>
<li>Labs
<ul>
<li>PCT:5.27, Blood culture: GNB</li>
<li>pro BNP: 5200</li>
<li>BUN/Cr: 27/1.59</li>
</ul></li>
<li>I/O: +380+loss
<ul>
<li>albumin : 2.7–&gt;3.3 (albumin supplement)</li>
</ul></li>
<li>Current medication
<ul>
<li>po aldactone 1#bid</li>
<li>iv tapimycin</li>
</ul></li>
<li>Recent medication
<ul>
<li>albumin + iv lasix</li>
</ul></li>
<li>EKG:
<ul>
<li>2022/01/24 QS wave in V1-3, poor R wave progression</li>
</ul></li>
<li>CXR: bilateral pleural effusion (right&gt;left) + perihilar
congestion</li>
<li>Echo (07/21) :EF: 65%</li>
</ul></li>
<li>Impression
<ul>
<li>heart failure with educed or preserved LVEF(?) or noncardiogenic
lung edema</li>
<li>GNB sepsis</li>
<li>Multiple myeloma</li>
<li>prior hypoalbuminemia 2.7 –&gt;3.3</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Arrange 2D echography to assess the LV function deterioration or
not</li>
<li>Restrict salt and water intake, Iv lasix use with keep negative I/O
balance, record BW. To precise record I/O, consider foley insertion</li>
<li>maintain serum albumin level at upper limit at least 3.5 mg/dL to
avoid lower level of oncotic pressure</li>
<li>Chest echo and thorcacocentesis if possible.</li>
<li>F/u electrolyte and renal function<br />
</li>
<li>Treat sepsis first and underlying as your expertise.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-01-26 - daratumumab 16mg/kg 1300mg 4hr</li>
<li>2022-01-21 - bortezomib 1.3mg/m2 2.5mg SC 5min</li>
<li>2022-01-18 - daratumumab 18mg/kg 1296mg 7hr + bortezomib 1.3mg/m2
2.5mg SC 10min</li>
<li>2022-01-15 - bortezomib 1.3mg/m2 2.5mg SC 5min</li>
<li>2022-01-12 - daratumumab 8mg/kg 631mg 4hr</li>
<li>2022-01-11 - daratumumab 600mg 4hr + bortezomib 1.3mg/m2 2.5mg SC
1hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>2022-09-23 2D transthoracic echocardiography showed dilated RA and
RV, impaired RV systolic function and possible moderate pulmonary
hypertension.</li>
<li>Vasoreactive patients with pulmonary arterial hypertension may
benefit from high dose calcium channel blockers, although this treatment
may cause hypotension as an adverse reaction. (ref: <a href="https://doi.org/10.1093/eurheartj/ehac237" class="uri">https://doi.org/10.1093/eurheartj/ehac237</a> ) The
patient’s recent blood pressure reading is approximately 100/75. Adding
CCB immediately would not be recommended at this time.</li>
</ul>
</div>
</div>
<div id="section-301" class="section level1">
<h1>700813596</h1>
<div id="section-302" class="section level2">
<h2>220922</h2>
<p>{adenocarcinoma of rectosigmoid, not completed}</p>
<ul>
<li>exam finding
<ul>
<li>2022-08-08, -08-04 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
</ul></li>
<li>2022-06-16 Whole body PET scan
<ul>
<li>Multiple glucose hypermetabolic lesions in the right and left lobes
of the liver, compatible with multiple liver metastases.</li>
<li>Multiple glucose hypermetabolic lesions in the abdominal left and
right paraaortic areas. Multiple lymph node metastases should be
considered first.</li>
<li>Increased FDG accumulation in both kidneys and bilateral ureters.
Physiological FDG accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2022-06-04 CT - abdomen
<ul>
<li>Colon cancer s/p operation. Multiple liver metastases (mild
progression).</li>
</ul></li>
<li>2022-01-14 CT - abdomen
<ul>
<li>Three liver metastases S/P C/T show complete response.</li>
<li>Two liver metastase S/P C/T show stable disease.</li>
</ul></li>
<li>2021-09-03 CT - abdomen
<ul>
<li>Five newly-developed liver metastases are suspected.</li>
<li>Please correlate with sonography and MRI.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-303" class="section level1">
<h1>701353650</h1>
<div id="section-304" class="section level2">
<h2>220921</h2>
<p>[subjective]</p>
<ul>
<li>bloody stool since 2021-02</li>
<li>tenesmus since 2021-03</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-07-14 Sigmoidoscopy
<ul>
<li>Rectal cancer s/p OP with anastomostic leakage, with healing</li>
</ul></li>
<li>2022-07-08 CT - abdomen
<ul>
<li>There is no focal wall thickening at the rectum. Please correlate
with colonoscopy.</li>
<li>S/P ileostomy at RMQ abdominal wall.</li>
</ul></li>
<li>2022-05-09 Patho - colon segmental resection for tumor
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Tumor, rectum, Robotic assisted TaTME (s/p CCRT) — Adenocarcinoma,
residual</li>
<li>Resection margins, ditto — Free from tumor</li>
<li>Lymph nodes, mesocolic, dissection — Tumor metastasis (11/17) with
extracapsular extension (2/11)</li>
<li>AJCC pathologic stage — ypT3N2b, stage IIIC, if cM0</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology: adenocarcinoma</li>
<li>Histology Grade: G2, moderately differentiated<br />
</li>
<li>Depth of invasion: pericolonic fat</li>
<li>Angiolymphatic invasion: present</li>
<li>Perineural invasion: present</li>
<li>Discontinuous extramural tumor extension: absent</li>
<li>Circumferential (radial) margin of rectosigmoid: not involved</li>
<li>Lymph node metastasis, mesocolic: tumor metastasis (11/17)</li>
<li>Lymph node metastasis, IMA / SMA: N/A</li>
<li>Extranodal involvement: present (2/11)</li>
<li>Pathological TNM Stage: ypT3N2b</li>
<li>Type of polyp in which invasive carcinoma arose: N/A</li>
<li>TNM descriptors: y<br />
</li>
<li>Tumor regression grading S/P CCRT: G3</li>
</ul></li>
</ul></li>
<li>2022-04-12 CT - abdomen
<ul>
<li>Mild regression of rectal cancer.</li>
</ul></li>
<li>2022-04-12 Sigmoidoscopy
<ul>
<li>Findings:
<ul>
<li>Rectal cancer s/p CCRT at 5 cm from AV , (right lateral ~ left
anterior)</li>
<li>DRE: relative fixed (DRE = digital rectal examination)</li>
</ul></li>
<li>Diagnosis:
<ul>
<li>Rectal cancer s/p CCRT with significant tumor regression</li>
</ul></li>
</ul></li>
<li>2022-01-28 Cardiopulmonary Exercise Testing
<ul>
<li>conclusions
<ul>
<li>maximal exercise/ submaximal exercise</li>
<li>normal exercise capacity ( VO2 102%, WR 114%)</li>
<li>normal stroke volume response during exercise</li>
<li>normal ventilatory function ( FVC 99%, FEV1 103%)</li>
<li>normal respiratory muscle strength (MIP 95%, MEP 73%)</li>
</ul></li>
<li>suggestions:
<ul>
<li>treat underlying condition</li>
<li>arrange pulmonary rehab with exercise training for his CCRT with
decline of activity</li>
</ul></li>
</ul></li>
<li>2021-12-29 CT
<ul>
<li>Findings
<ul>
<li>There is wall thickening at the rectum measuring 2 cm in wall
thickness that is c/w adenocarcinoma.
<ul>
<li>In addition, at least six enlarged lymph nodes in the perirectal
space and adjacent mesocolon are noted.</li>
</ul></li>
<li>There are several hepatic cysts in left lobe and the largest one 3.7
cm in size at S2/4.</li>
</ul></li>
<li>Impression (Imaging stage): T3N2aM0, stage IIIB</li>
</ul></li>
<li>2021-12-24 Patho - colon biopsy
<ul>
<li>Rectum , 4 cm from AV, biopsy - Adenocarcinoma.</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-06
<ul>
<li>Surgery
<ul>
<li>Robotic assisted TaTME</li>
</ul></li>
<li>Finding
<ul>
<li>Rectal cancer s/p CCRT with tumor regression</li>
<li>Tumor location : 5 cm from Av   </li>
<li>Anastomosis using circular staple CDH 33 at dentate line</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-01-13 ~ 2022-02-25 - 4500cGy/25 fractions of the pelvic and
5040cGy/28 fractions of the rectal tumor bed area</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-20 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 400mg/m2 700mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-09-01 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 400mg/m2 700mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-08-18 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
700mg 2hr + fluorouracil 400mg/m2 700mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-08-04 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 430mg/m2 730mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-07-21 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 430mg/m2 730mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-07-05 - oxaliplatin 85mg/m2 155mg 2hr + leucovorin 400mg/m2
730mg 2hr + fluorouracil 430mg/m2 730mg 10min + fluorouracil 2400mg
4375mg 46hr</li>
<li>2022-06-21 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
750mg 2hr + fluorouracil 430mg/m2 750mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-04-15 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
750mg 2hr + fluorouracil 430mg/m2 750mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-03-25 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
750mg 2hr + fluorouracil 430mg/m2 750mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-03-09 - oxaliplatin 85mg/m2 150mg 2hr + leucovorin 400mg/m2
750mg 2hr + fluorouracil 430mg/m2 750mg 10min + fluorouracil 2400mg
4300mg 46hr</li>
<li>2022-02-18 - leucovorin 20mg/m2 35mg 10min D1 + fluorouracil
400mg/m2 700mg 10min D1 (CCRT)</li>
<li>2022-02-16 - leucovorin 20mg/m2 35mg 10min D1-D3 + fluorouracil
400mg/m2 700mg 10min D1-D3 (CCRT)</li>
<li>2022-01-18 - leucovorin 20mg/m2 35mg 10min D1 + fluorouracil
400mg/m2 700mg 10min D1 (CCRT)</li>
<li>2022-01-17 - leucovorin 20mg/m2 35mg 10min D1 + fluorouracil
400mg/m2 700mg 10min D1 (CCRT)</li>
<li>2022-01-12 - leucovorin 20mg/m2 35mg 10min D1-D3 + fluorouracil
400mg/m2 700mg 10min D1-D3 (CCRT)</li>
</ul></li>
</ul>
<div id="section-305" class="section level3">
<h3>==========</h3>
</div>
<div id="section-306" class="section level3">
<h3>2022-09-21</h3>
<p>In the last three months, both AST and ALT have increased.</p>
<p>Oxaliplatin has been associated with hepatotoxicity, including
elevated transaminases and alkaline phosphatases. Peliosis, nodular
regenerative hyperplasia or sinusoidal abnormalities, perisinusoidal
fibrosis, and veno-occlusive lesions have been detected on liver biopsy.
Patients with portal hypertension or increased liver function tests,
which cannot be attributed to liver metastases, should be evaluated for
hepatic vascular disorders.</p>
</div>
<div id="section-307" class="section level3">
<h3>2022-02-17</h3>
<ul>
<li>current treatment introduced just about a month, have to wait and
see the response.</li>
<li>available CEA, CA199 readings never outranged normal limits, might
not sensible enough for this patient.</li>
<li>Zoloft (sertraline 50mg QD) and Rivotril (clonazepam 0.5mg HS) are
prescribed for the anxiety.</li>
<li>no drug allergy recorded in database, no issue with current
medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-308" class="section level1">
<h1>700382077</h1>
<div id="section-309" class="section level2">
<h2>220920</h2>
<ul>
<li>lab data
<ul>
<li>2022-09-19 Varicella-zoster virus PCR Undetectable<br />
</li>
<li>2022-09-15 EB VCA IgG Positive Ratio<br />
</li>
<li>2022-09-15 EB VCA IgG Value 6.3 Ratio<br />
</li>
<li>2022-09-14 EB VCA IgM Negative Ratio<br />
</li>
<li>2022-09-14 EB VCA IgM Value 0.2<br />
</li>
<li>2022-09-14 VZV IgM Negative Ratio<br />
</li>
<li>2022-09-14 VZV IgM Value 0.1 Ratio<br />
</li>
<li>2022-09-12 RPR/VDRL Nonreactive<br />
</li>
<li>2022-09-12 HBsAg Nonreactive<br />
</li>
<li>2022-09-12 HBsAg (Value) 0.28 S/CO<br />
</li>
<li>2022-09-12 Anti-HBc Reactive<br />
</li>
<li>2022-09-12 Anti-HBc-Value 3.65 S/CO<br />
</li>
<li>2022-09-12 Anti-HCV Nonreactive<br />
</li>
<li>2022-09-12 Anti-HCV Value 0.06 S/CO<br />
</li>
<li>2022-09-12 CMV IgM Nonreactive<br />
</li>
<li>2022-09-12 CMV IgM Value 0.19 Index<br />
</li>
<li>2022-09-12 CMV_IgG Reactive<br />
</li>
<li>2022-09-12 CMV_IgG Value 87.1 AU/mL<br />
</li>
<li>2022-09-12 HIV Ab-EIA Nonreactive<br />
</li>
<li>2022-09-12 Anti-HIV Value 0.07 S/CO<br />
</li>
<li>2022-09-12 Anti HTLV I/II Nonreactive<br />
</li>
<li>2022-09-12 Anti HTLV I/II Value 0.07 S/CO</li>
</ul></li>
</ul>
<div id="section-310" class="section level3">
<h3>==========</h3>
</div>
<div id="section-311" class="section level3">
<h3>2022-09-13</h3>
<ul>
<li><p>Hyperuricemia is noted (serum uric acid readings have been around
9mg/dL in 2022), allopurinol or febuxostat might be indicated.</p></li>
<li><p>Febuxostat differs from allopurinol in a number of ways:</p>
<ul>
<li>It is not a purine base analog; because of the non-purine structure,
febuxostat inhibits both reduced and oxidized forms of xanthine oxidase
and has minimal effects on other enzymes involved in purine and
pyrimidine metabolism.</li>
<li>Dose adjustment is not needed in patients with mild to moderate
renal impairment.</li>
<li>There are fewer drug-drug interactions with febuxostat than with
allopurinol.</li>
<li>It is quite a bit more expensive than allopurinol, at least partly
because allopurinol is available as a generic preparation.</li>
</ul></li>
<li><p>Feburic (febuxostat 80mg/tab) 0.5# QD is recommended.</p></li>
<li><p>In the last half year, serum creatinine readings have been around
2 mg/dL, indicating altered kidney function. (170cm, 78kg -&gt; eGFR
40mL/min/1.73m2, CrCl 40~45mL/min)</p></li>
<li><p>Fluconazole for candidiasis, prophylaxis - Hematologic malignancy
patients or hematopoietic cell transplant (HCT) recipients who do not
warrant mold-active prophylaxis: Oral 400 mg once daily. If the CrCl
value is less than 50 mL/minute, the dosage is recommended to be reduced
by 50%. The current dose is 300mg per day, which is less than 400mg, so
no urgent adjustment is necessary.</p></li>
<li><p>As phenytoin is an inducer of CYP3A4 and P-glycoprotein and
apxaban is metabolized predominantly by CYP3A4 and a P-gp substrate, the
former may decrease the serum concentration of the latter.</p></li>
<li><p>Another direct oral anticoagulant Lixiana (edoxaban) undergoes
minimal CYP metabolism (still an p-gp substrate) might be an alternative
to Eliquis (apixaban). Edoxaban can be administered 30mg once daily for
patients with CrCl 15 to 50 mL/minute.</p></li>
<li><p>As dexlansoprazole’s pharmacokinetics are not expected to be
altered in patients with renal impairment, dose adjustment is not likely
to be necessary.</p></li>
</ul>
</div>
</div>
</div>
<div id="section-312" class="section level1">
<h1>701192939</h1>
<div id="section-313" class="section level2">
<h2>220920</h2>
<ul>
<li>exam findings
<ul>
<li>2022-09-19 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the L5 spine and sacrum, the nature is to be
determined (post-traumatic change, DJD or other nature ?), suggesting
follow-up with bone scan in 3 months for further evaluation.</li>
<li>Suspected benign lesions in both rib cages, some T- and L-spine,
bilateral shoulder, S-I joints, and hips.</li>
</ul></li>
<li>2022-09-15 CT - chest
<ul>
<li>Esophageal cancer at lower third with tumor regression. However,
extensve miliary lung meta is found which progressed signficantly.</li>
<li>Mediastinal lymphadenopathy, stable.</li>
</ul></li>
<li>2022-09-13 CXR
<ul>
<li>There are multiple nodular opacity projecting in both lung that are
c/w metastases after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Pleura thickening in bilateral apical lung area.</li>
</ul></li>
<li>2022-08-09 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Pleura thickening in bilateral apical lung area.</li>
</ul></li>
<li>2022-06-15 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P feeding jejunostomy at left upper pelvis.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P drainage tube insertion via right upper abdominal wall and the
tip located at left pelvis.</li>
</ol></li>
</ul></li>
<li>2022-06-09 CXR
<ul>
<li>Port-A catheter inserted into cavo-atrial junction via left
subclavian vein.</li>
<li>Thoracic aortic arch calcified atheriosclerotic plaque</li>
<li>biapical fibrothoraces</li>
<li>reticular opacities over RUL based on plain image</li>
</ul></li>
<li>2022-06-07 MRI - brain
<ul>
<li>No brain nodule or metastasis.</li>
</ul></li>
<li>2022-06-06 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesions in the middle esophagus, compatible
with the primary esophageal cancer.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral mediastinal space and
celiac chain lymph nodes, highly suspected cancer with regional lymph
nodes involvement, suggesting biopsy for investigation.<br />
</li>
<li>Glucose hypermetabolic lesions in the left pulmonary hilar region
and left supraclavicular fossa, probably reactive nodes or metastatic
lymph nodes, suggesting further investigation.<br />
</li>
<li>Increased FDG accumulation in bilateral kidneys and ureters,
probably physiological uptake of FDG.<br />
</li>
<li>Middle esophageal cancer, cTxN3M0, stage IVA (AJCC, 8th ed.), by
this F-18 FDG PET scan.<br />
</li>
</ul></li>
<li>2022-06-04 CT
<ul>
<li>Imaging Report Form for Esophageal Carcinoma</li>
<li>Impression (Imaging stage): T3N2M0</li>
</ul></li>
<li>2022-06-02 Patho - esophageal biopsy
<ul>
<li>DIAGNOSIS:
<ul>
<li>A. Labeled as “Esophagus, 40 cm from incisor”, biopsy (A)— squamous
mucosa with high grade dysplasia.</li>
<li>B. Labeled as “Esophagus, 35-38 cm from incisor”, biopsy (B)—
squamous cell carcinoma, moderately differentiated. IHC stains: p40 (+),
CK5/6 (+), Ki-67: 90%.</li>
<li>C. Labeled as “Esophagus, 20 cm from incisor”, biopsy (C)— squamous
mucosa with low grade dysplasia.</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A. Section shows squamous mucosa with high grade dysplasia.</li>
<li>B. Section shows squamous cell carcinoma, moderately differentiated.
<ul>
<li>IHC stains: p40 (+), CK5/6 (+), Ki-67: 90%. Muscularis propria is
not present in this biopsy specimen.</li>
</ul></li>
<li>C. Section shows squamous mucosa with low grade dysplasia.</li>
</ul></li>
</ul></li>
<li>2022-06-02 2D transthoracic echocardiography
<ul>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild MR</li>
</ul></li>
<li>2022-06-01 ECG
<ul>
<li>first degree AV block</li>
</ul></li>
<li>2022-02-11 Patho - esophageal biopsy
<ul>
<li>Esophagus, 28 cm below the incisor, biopsy — High-grade dysplasia
<ul>
<li>The sections show a picture of high-grade dysplasia, composed of
squamous epithelim with basal cells proliferation, and atypical cell
extends up into upper third of the epithelium. Suggest follow up.</li>
</ul></li>
<li>Esophagus, 32-35 cm below the incisor, biopsy — Squamous cell
carcinoma, moderately differentiated.
<ul>
<li>The sections show a picture of squamous cell carcinoma, composed of
nests of moderately differentiated neoplastic squamous cells with
pelomorphic nuclei and stromal invasion. Ulcer and granulation tissue
are present.</li>
</ul></li>
</ul></li>
<li>2022-02-10 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA grade A</li>
<li>Esophageal tumor, middle esophagus, suspected esophageal cancer,
post biopsy (A)</li>
<li>Esophageal mucosal lesion, upper esophagus, s/p biopsy (B)</li>
<li>Superficial gastritis</li>
<li>Gastric angiodysplasia, low body, GC site</li>
</ul></li>
<li>Suggestion
<ul>
<li>Refer to chest surgeon</li>
</ul></li>
</ul></li>
<li>2022-02-10 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Suspected fatty infiltration of pancreas</li>
<li>Suboptimal examination of liver due to poor echo window</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver, especially liver dome and S1 was diffcult to
approach and easy missed</li>
<li>Because of poor echo window, infiltrative lesion or small lesion may
not be excluded completely. Please correlate with other image or follow
sono abd every 3-6 months.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-08 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This 72-year-old male patient with underlying reflux esophagitis (LA
grade A) were noted complained dysphagia since 2022-02. Under the
impression of esophageal cancer, he was admitted for complete cancer
staging and port-A catheter implanation and laparoscopic jejunostomy on
20220609. The disgnosis was esophageal squamous cell carcinoma with
mediastinal lymphadenopathy, cT3N3M0, stage IVA. However, the patient
wants to discahrge after the surgery done on 20220609 due to personal
reason. We recommend CCRT to be arranged during OPD f/u. As a reason, we
need your expertise to evaluate this patient and arranged radiotherapy
for him. Thank you very much for your kind help!</li>
</ul></li>
<li>A
<ul>
<li><ol style="list-style-type: decimal">
<li>Subjective:</li>
</ol>
<ul>
<li>I. Previous RT: denied.</li>
<li><ol start="2" style="list-style-type: upper-roman">
<li>Other disease: reflux esophagitis (LA grade A).</li>
</ol></li>
<li><ol start="3" style="list-style-type: upper-roman">
<li>Family history: denied.</li>
</ol>
<ul>
<li>A. Habit: Alcohol: wine and beer for 40 yr; Smoking: 2 PPD for 40
yr; betel nut: 80#/day for 40 yr.</li>
<li>B. Married. Caregiver: his son (n=2), daughter (n=1), wife. Job:
Labor. Mild economic stress.</li>
<li>C. Language: Taiwanese. Mandarin.</li>
<li>D. Religion: Buddism.</li>
</ul></li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Objective:</li>
</ol>
<ul>
<li>I. General Condition-ECOG: 1.</li>
<li><ol start="2" style="list-style-type: upper-roman">
<li>PE, 2022/06/08: No palpable SCF LNs.</li>
</ol></li>
<li><ol start="3" style="list-style-type: upper-roman">
<li>Pathology, 2022/02/21: Esophagus, 32-35 cm below the incisor, biopsy
— Squamous cell carcinoma, moderately differentiated; 28 cm below the
incisor, biopsy — High-grade dysplasia.</li>
</ol></li>
<li><ol start="4" style="list-style-type: upper-roman">
<li>2022/06/02: A. Labeled as “Esophagus, 40 cm from incisor”, biopsy
(A) — squamous mucosa with high grade dysplasia. B. Labeled as
“Esophagus, 35-38 cm from incisor”, biopsy (B) — squamous cell
carcinoma, moderately differentiated. IHC stains: p40 (+), CK5/6 (+),
Ki-67: 90%. C. Labeled as “Esophagus, 20 cm from incisor”, biopsy (C) —
squamous mucosa with low grade dysplasia.</li>
</ol></li>
<li>V. Images:
<ul>
<li>A. PES, 2022/02/20: One ulcerative mucosa lesion with elevated
margin and mucosal nodularity/irregularity was noted at middle
esophagus, 32-35cm below the incisor, R/O esophageal cancer: s/p biopsy
for eight pieces(A). One slightly elevated mucosa lesion with nodularity
was noted at upper esophagus, about 28cm below the incisor, s/p biopsy
for multiple pieces(B).</li>
<li>B. EUS, 2022/06/02: EUS with UM-25R to the main lesion (35-38 cm)
showed hypoechoic lesion involve 4th layer of esophageal wall with 1.7
cm in max thickness. EUS to the lesion at 30 cm lesion revealed a
hypoechoic area at 2nd layer of esophageal wall measured 0.26 cm. No
change in others lesions. At least 9 para esophageal lymph nodes were
detected by EUS. Dx: Esophageal cancer, 35-38 cm, T3N3Mx, s/p biopsy.
Rule out dysplastic esophageal lesion, 40 cm, s/p biopsy. Rule out
dysplasitc esophageal lesion, 20 cm, s/p biopsy .</li>
<li>C. Chest CT, 2022/06/04: Minimal bronchiectatic change over right
lower lobe with peribronchovascular infiltration is found. Mild
bilateral apical pleural thickening is noted. Long segmental wall
thickening at middle to lower esophagus is found up to 6.7cm in largest
dimension. Some mediastinal lymphadenopathy is noted at both sides.
(n＝5) There are also some calcified lymph nodes at bilateral
mediastinum. No evidence of bilateral pleural effusion. IMP: cT3N2.</li>
<li>D. Brain MRI, 2022/06/07: negative.</li>
<li>E. PET, 2022/06/06: There were focal or nodular lesions of increased
FDG uptake in the middle esophagus (SUVmax early: 26.58, delay: 46.59),
bilateral mediastinal space (SUVmax early: 6.55, delay: 11.68), left
pulmonary hilar region (SUVmax early: 5.00, delay: 7.65), left
supraclavicular fossa (SUVmax early: 3.13, delay: 6.78), and celiac
chain lymph nodes (SUVmax early: 4.69, delay: 5.54).IMP: cN3M0.</li>
</ul></li>
</ul></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Diagnosis: Esophageal cancer, L/3, MD squamous cell carcinoma, cT3N3
(cM0), with paraesophageal and perigastric LAP metastasis at least,
scheduled port-A catheter implantation and laparoscopic jejunostomy on
06/09; ECOG =1.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Suggest: Radiotherapy.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Goal: Curative (pre-operative).</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>RT Plan may be designed as the following one:</li>
</ol>
<ul>
<li>I. Target &amp; Volume: esophageal tumor, LAPs.</li>
<li><ol start="2" style="list-style-type: upper-roman">
<li>Technique: VMAT and IGRT (OBI).</li>
</ol></li>
<li><ol start="3" style="list-style-type: upper-roman">
<li>Dose &amp; Fractionation: 5040cGy/28 fractions, with concurrent
chemotherapy.</li>
</ol></li>
</ul></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Plan: CCRT is suggested for tumor control. Possible toxicity
(esophagitis, pneumonitis) is told. CT simulation is arranged on June 14
15:30pm. Treatment will be started 2-3 days later. Diet education and
psychological support is given.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-08 Hemato-Oncology
<ul>
<li>A
<ul>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>lower third esophageal squamous cell carcinoma with mediastinal
lymphadenopathy, cT3N3M0, stage IVA</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Please check HbsAg, AntiHbc, Anti HCV</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Arrange port A insertion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>We will discuss with patient about further treatment. Arrange our
OPD after discharge.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-02 Gastroenterology
<ul>
<li>A
<ul>
<li>EUS for esophageal SCC staging is indicated.</li>
<li>Already arrange EUS on 20220602 10:30.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-06-17 ~ 2022-07-25 - 4680cGy/26 fractions (15 MV photon) to
stomach, anastomosis and regional lymphatics (CCRT)</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-07-29 cisplatin 60mg/m2 100mg 4hr + fluorouracil 800mg/m2
1300mg 24hr D1-4</li>
<li>2022-07-01 cisplatin 60mg/m2 100mg 4hr + fluorouracil 800mg/m2
1300mg 24hr D1-4
<ul>
<li>ref: U2D - Trimodality therapy with cisplatin plus fluorouracil
chemotherapy with concurrent radiotherapy followed by surgery for
esophageal and esophagogastric junction cancer</li>
</ul></li>
</ul></li>
</ul>
<div id="section-314" class="section level3">
<h3>==========</h3>
</div>
<div id="section-315" class="section level3">
<h3>2022-07-29</h3>
<ul>
<li>In active prescriptions, all oral drugs can be administered by
nasogastric tube.</li>
<li>It is recommended to monitor for hearing loss prior to (each dose
of, if possible) cisplatin; audiometry as clinically indicated.</li>
<li>An assessment of neurologic function prior to each course of
chemotherapy might be beneficial.</li>
<li>There is no issue with the active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-316" class="section level1">
<h1>701345085</h1>
<div id="section-317" class="section level2">
<h2>220920</h2>
<p>{Mucinous adenocarcinoma of the sigmoid colon with uterus invasion,
stage pT4bN2bM0, stage IIIC, s/p LAR in 2017, with local regional
recurrence s/p concurrent chemoradiotherapy}</p>
<ul>
<li>exam finding
<ul>
<li>2022-09-15 CT - abdomen, pelvis
<ul>
<li>Colon cancer s/p operation with local recurrence and adjacent
structures invasion (stable).</li>
<li>Some LNs (up to 1.4cm) at pelvic cavity and paraaortic region
(stable).</li>
<li>Grade 5 fatty liver.</li>
</ul></li>
<li>2022-04-28 CT - abdomen, pelvis
<ul>
<li>Colon cancer s/p operation.</li>
<li>Increased soft tissues in pelvic cavity suspected tumor
recurrence.</li>
<li>Some LNs (up to 1.4cm) at paraaortic region c/w metastases.</li>
<li>Grade 5 fatty liver.</li>
</ul></li>
<li>2022-01-19 CT - abdomen, pelvis
<ul>
<li>History and Indication:
<ul>
<li>2017/07 at CGMH keelung: Mucinous adenocarcinoma of the sigmoid
colon with direct invasion the uterus, pT4bN2b (8/61).</li>
<li>2021/09 at CGMH keelung: Adenomyosis s/p subtotal hysterectomy +
right oophrectomy, and appendectomy.</li>
<li>2021/11 at CGMH keelung: Pelvic tumor with colonic obstruction s/p
T-loop colostomy 2021/11/02</li>
</ul></li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P LAR with autosuture retention over the sigmoid colon.</li>
</ol>
<ul>
<li>Wall thickening in the rectosigmoid colon, below and beyond
autosuture, is noted that may be local recurrent adenocarcinoma of the
colon. Please correlate with colonoscopy.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>prior MRI identified ill-defined soft tissue mass in the uterine
cervix area and left adnexa is noted again, stable in size.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Prior MRI identified multiple enlarged nodes in the perirectal
space, left interal iliac chain, left common iliac chain, para-aortic
space and para-cava space ar noted again, stable in size.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>S/P colostomy at right transverse colon.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>The uterus shows enlarged in size and mild heterogeneous density.
please correlate with clinical condition.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>There is no focal lesion in both lung and mediastinum.</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, pancreas, spleen &amp; right kidney.<br />
</li>
</ol>
<ul>
<li>There is no evidence of ascites.<br />
</li>
<li>There is no bowel wall thickening, and no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>IMP:
<ul>
<li><ol style="list-style-type: decimal">
<li>Local recurrent colon cancer in the rectosigmoid, below and beyond
prior autosuture, is highly suspected. Please correlate with
colonoscopy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Local recurrent rectosigmoid cancer with uterine cervix area and
left adnexa involvement show stable in size.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Multiple metastatic lymph nodes show stable in size.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-12-09 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Mass lesion, lower abdomen, c/w tumor recurrence</li>
<li>Hydronephrosis, bilateral, suspected mass effect due to tumor</li>
<li>Incomplete study of liver</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please corelated with other images.</li>
</ul></li>
</ul></li>
<li>2021-11-19 Cardiopulmonary Exercise Testing, CPX
<ul>
<li>summary:
<ul>
<li>low exercise capacity (VO2 57%, WR 71%)</li>
<li>normal stroke volume response during exercise</li>
<li>slow HR response, 68%</li>
<li>normal ventilatory function (FVC 93%, FEV1 102%)</li>
<li>low respiratory muscle strength (MIP 108%, MEP 54%)</li>
</ul></li>
<li>suggestions:
<ul>
<li>treat underlying condition</li>
<li>survey and treat slow HR response, such as thyroid function or
drugs</li>
<li>arrange pulmonary rehab with exercise training</li>
</ul></li>
</ul></li>
<li>2021-11-05 MRI - pelvis
<ul>
<li>History and Indication:
<ul>
<li>2017/07 at CGMH keelung: Mucinous adenocarcinoma of the sigmoid
colon with direct invasion the uterus, pT4bN2b (8/61).</li>
<li>2021/09 at CGMH keelung: Adenomyosis s/p subtotal hysterectomy +
right oophrectomy, and appendectomy.</li>
<li>2021/11 at CGMH keelung: Pelvic tumor with colonic obstruction s/p
T-loop colostomy 2021/11/02</li>
</ul></li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There is an ill-defined soft tissue mass in the uterine cervix area
and left adnexa measuring 6.6 x 5.5 cm in size, showing mild
hyperintensity on both T2WI and DWI, and mild enhancement, causing mild
left hydroureteronephrosis and delayed contrast excretion of left kidney
that may be local tumor recurrence with distal ureter invasion induce
obstructive uropathy. Please correlate with retrograde pyelography.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P LAR with autosuture retention over the sigmoid colon.</li>
</ol>
<ul>
<li>Wall thickening in the sigmoid colon, just beyond autosuture, is
noted that may be left adnexa mass with sigmoid colon invasion? Please
correlate with colonoscopy.</li>
<li>The differential diagnosis include local tumor recurrence of the
sigmoid colon with outward extension, left adnexa and uterine
invasion?<br />
</li>
</ul></li>
<li><ol start="3" style="list-style-type: decimal">
<li>There are multiple enlarged nodes in the perirectal space, left
interal iliac chain, left common iliac chain, para-aortic space and
para-cava space that are c/w metastatic nodes.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>S/P colostomy at right transverse colon.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>The uterus shows enlarged in size and heterogeneous hypointensity on
T2WI at right lateral aspect of the body and fundus that may be
adenomyosis.</li>
</ol>
<ul>
<li>However, the left lateral aspect of the uerine body and fundus shows
heterogeneous mild hyperintensity on T2WI and DWI, and contrast
enhancement that may be tumor invasion?</li>
</ul></li>
<li><ol start="6" style="list-style-type: decimal">
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, pancreas, spleen &amp; right kidney.</li>
</ol>
<ul>
<li>There is no evidence of ascites.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
</ul></li>
<li>IMP:
<ul>
<li><ol style="list-style-type: decimal">
<li>Local tumor recurrence at the uterine cervix area and left adnexa
with direct sigmoid colon invasion and left distal ureter invasion
induce obstructive uropathy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Multiple metastatic lymph nodes.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor invasion in left lateral aspect of the uterine body and fundus
are highly suspected.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-11-02 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Rectal tumor, with lumen stenosis nearing obstruction, 10cm above
anal verge, s/p biopsy</li>
<li>Mixed hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication：
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-09-22 PET (CGMH Keelung)
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Main tumor status: rectum (SUV 2.18, score 2)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Regional LN status: not found</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Distant site status: uterine mass (SUV 3.83, score 2)</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Compatible with recurrent colon cancer in post-operative status,
tentative stage rT0N0M0 (AJCC 2017).</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Rectum lesion, probably bowel physiological uptakes.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Uterine lesion, uterine myoma may show this picture.</li>
</ol></li>
</ul></li>
<li>Suggesstion:
<ul>
<li>Please correlate with other image and clinical findings.</li>
</ul></li>
<li>Comment: Score 0 = normal; Score 1 = benign lesion; Score 2 =
equivocal lesion; Score 3 = possible malignancy; Score 4 = high
probability of malignancy</li>
</ul></li>
<li>2021-09-22 Pathology (CGMH Keelung)
<ul>
<li>biopsy date 2021/09/10</li>
<li>DX:
<ul>
<li>Uterus, endometrium, uncomplicated subtotal hysterectomy —-
Proliferative phase</li>
<li>Uterus, myometrium, uncomplicated subtotal hysterectomy —-
Adenomyosis</li>
<li>Fallopian tube, bilateral, prophylactic salpingectomy —- No
pathological diagnosis made.</li>
</ul></li>
</ul></li>
<li>2021-09-22 Pathology (CGMH Keelung)
<ul>
<li>biopsy date 2021/09/10</li>
<li>DX:
<ul>
<li>Appendix, appendectomy —- Mucinous adenocarcinoma, in favor of
metastatic mucinous adenocarcinoma of colorectal origin (Reference:
S2017G-09314 and S2017G-10251)</li>
</ul></li>
<li>GROSS D:
<ul>
<li>The specimen submitted is an appendix measuring 8.0 cm in length and
1.5 cm in maximal diameter, fixed in formalin. The external surface is
smooth. The cut surface reveals a narrowed lumen filled with mucoid
material. The wall is markedly thickened with a mucoid appearance. The
mesoappendix is not inflamed. Sections of the tip portion and
representative cross sections are taken.</li>
</ul></li>
<li>MICRO D:
<ul>
<li>Sections of appendix show nearly totally infiltrated by a mucinous
adenocarcinoma. Based on the history, metastatic mucinous and
signet-ring cell adenocarcinoma is favored.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-11-02
<ul>
<li>Surgery
<ul>
<li>T loop colostomy        </li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>Pelvic tumor with colonic obstruction, suspected rectal cancer</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilation of colon and severe adhesion around midline laparotomy</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>RUQ stoma with stent</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Previous surgery:</li>
</ol>
<ul>
<li>&lt;1&gt; Sigmoid mucinous adenocarcinoma, pT4bN3a s/p LAR on
2017</li>
<li>&lt;2&gt; Adenomytosis s/p total hysterectomy with right
salpingo-oophorectomy, appendectomy on 2021/09, appendix pathology:
metastatic Sigmoid mucinous adenocarcinoma</li>
</ul></li>
</ul></li>
<li>Procedure
<ul>
<li>The patient was placed in supine position and general endotracheal
anesthesia was induced. The abdomen was prepped and draped in standard
sterile fashion. The ostomy site was marked about halfway between the
umbilicus and right costal margin, 3 to 5 cm lateral to the linea alba.
A short transverse incision was made over the previously marked ostomy
site in the right upper quadrant. This was deepened through the
subcutaneous tissues and hemostasis was achieved with electrocautery.
The anterior rectus sheath was encountered and cut, exposing the rectus
muscle. This was opened by muscle-splitting in a direction parallel to
the rectus muscle. Hemostasis was achieved. The posterior sheath and
peritoneum were identified and incised, and then the peritoneum was
entered. The massive distended transverse colon was immediately
encountered. The omentum was swept cephaled and the transverse colon was
delivered into the incision. A window was created under the colon by
dividing the mesentery adjacent to the colon wall with clamps and
ligating with 3-0 silk ties. Hemostasis was checked. A plastic bridge
was placed at this point. Moist pads were placed and the colon was
opened along a taenia. Succus and air were aspirated. The colostomy was
matured with multiple interrupted mucocutaneous suture of 4-0 monopril.
The colostomy was well formed and viable. A colostomy bag was placed.
The patient tolerated the procedure well and was taken to the POR in
stable condition.  </li>
</ul></li>
</ul></li>
<li>2021-09
<ul>
<li>Operation: subtotal hysterectomy + R’t oophrectomy,
appendectomy.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-11-22 ~ 2021-12-30 - 4500cGy/25 fractions (15 MV photon) of the
pelvic to paraaortic area</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-25 ~ undergoing - FOLFIRI + bevacizumab</li>
<li>2022-02-08 ~ 2022-04-28 - FOLFIRI (5 times)</li>
<li>2021-11-22 ~ 2021-12-20 - FL (400mg/m2, CCRT) (2 times)</li>
<li>2017 ~ ???? - adjuvant chemothoerapy 12 times.</li>
</ul></li>
</ul>
<p>                                   </p>
</div>
</div>
<div id="section-318" class="section level1">
<h1>701390560</h1>
<div id="section-319" class="section level2">
<h2>220920</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-01 CTA - chest
<ul>
<li>Left pleural effusion. MIld</li>
<li>No evidence of pulmonary embolism nor aortic dissection is
found.</li>
<li>Right renal cyst. 9.3cm</li>
</ul></li>
<li>2022-07-28 Pure Tone Audiometry
<ul>
<li>PTA:</li>
<li>Reliability FAIR</li>
<li>Average RE 6 dB HL / LE 6 dB HL</li>
<li>bil WNL</li>
</ul></li>
<li>2022-07-01 CXR
<ul>
<li>s/p right chest tube in place, its tip directed superiorly
projecting over 4th intercostal space</li>
<li>expansion of Rt lung with platelike lung atelectasis over Rt lower
lung zone</li>
</ul></li>
<li>2022-06-29 Patho - thymus tumor
<ul>
<li>diagnosis
<ul>
<li>Thymus, excision — Squamous cell carcinoma of thymus, poorly
differentiated,
<ul>
<li>AJCC 8th edition: pStage IVA, pT1aNxM1a</li>
</ul></li>
<li>F2022-00304 - Pericardium, biopsy — Thymic squamous cell carcinoma,
metastatic</li>
</ul></li>
<li>microscopic description
<ul>
<li>Sections show sheets of poorly differentiated carcinoma infiltrating
in fibrous stroma. Focal squamous cell differentiation is seen.
<ul>
<li>The immunohistochemical stains reveal CD5(+), CD20(-), p40(+),
CD117(+), CK19(+), TdT(-), CD56(equivocal), and
Synaptophysin(equivocal). The in situ hybridization for EBER is
negative. The results are in favor of thymic squamous cell carcinoma.
The tumor has invaded to the peripheral thymus tissue. The tumor capsule
is focally ruptured.</li>
</ul></li>
<li>F2022-00304 - Section shows fibrous tissue with metastatic
carcinoma.
<ul>
<li>The immunohistochemical stains reveal CD5(+), CD20(-), p40(+),
CD117(+), CK19(+), and TdT(-). The results are consistent with
metastatic thymic squamus cell carcinoma.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-29 Frozen Section
<ul>
<li>Preliminary diagnosis: Pericardium, biopsy — metastatic tumor</li>
</ul></li>
<li>2022-06-28 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Left axis deviation</li>
</ul></li>
<li>2022-05-18 CT at Cathay General Hospital
<ul>
<li>Anterior mediastinal tumor, size about 5.0cm in diameter, anoterior
to aortic root.</li>
<li>suspected thymoma.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-29 VATS excision of mediastinal tumor and PP window.
<ul>
<li>One mass lesion was noted over anterior mediastinum, anterior to
ascending aorta, size about 5.0cm in diameter. Multiple pleural military
lesions over left pleural cavity and pericardium.</li>
<li>Frozen section of pericardial nodule: carcinoma.</li>
<li>One 24 Fr. straight chest tube was inserted via right 7th ICS.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-07-29 ~ 2022-09-06 - at 4500cGy/25 fractions of the thymus
tumor bed area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-19 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 6 600mg
2hr</li>
<li>2022-08-25 - cisplatin 40mg/m2 65mg 2hr (CCRT)</li>
<li>2022-08-18 - cisplatin 40mg/m2 65mg 2hr (CCRT)</li>
<li>2022-08-11 - cisplatin 40mg/m2 65mg 2hr (CCRT)</li>
<li>2022-08-04 - cisplatin 40mg/m2 65mg 2hr (CCRT)</li>
<li>2022-07-29 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>Losartan might be held temperately due to a drop in blood
pressure (2022-09-20 09:21 96/56mmHg).</p></li>
<li><p>Blood glucose levels were elevated (2022-09-20 06:40 236 mg/dL).
If the reading remains high over the next two days, then antiglycemic
interventions might be necessary.</p></li>
</ul>
</div>
</div>
<div id="section-320" class="section level1">
<h1>700823225</h1>
<div id="section-321" class="section level2">
<h2>220919</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-29 CXR
<ul>
<li>Enlargement of cardiac silhouette.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side<br />
</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
</ul></li>
<li>2022-06-09 Whole body PET scan
<ul>
<li>In comparison with the previous study on 2021/12/08, the glucose
hypermetablism in the confluent right neck and right supraclavicular
lymph nodes (Deauville score 5) are a little more evident. However, no
prominent glucose hypermetablism was noted in the previous FDG avild
lesions in the tonsils and left neck lymph nodes.<br />
</li>
<li>Mild glucose hypermetablism in the right hip joint, compatible with
arthritis.<br />
</li>
<li>Increased FDG accumulation in the colon and both kidneys.
Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2022-06-08 CT - neck
<ul>
<li>Progressive enlargement of LAP of right neck and regression of LAP
at left neck, as compared with CT scna on 20211127.</li>
</ul></li>
<li>2022-06-08 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (112 - 36) / 112 = 67.86%</li>
<li>Indeterminated LV filling pressure; impaired RV relaxation.</li>
<li>Normal LV and RV systolic function.</li>
<li>Mild MR; mild TR.</li>
<li>Thick epicardial fat.</li>
</ul></li>
<li>2022-06-07 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Right bundle branch block</li>
<li>T wave abnormality, consider inferior ischemia</li>
</ul></li>
<li>2022-06-07 CXR
<ul>
<li>Enlargement of cardiac silhouette.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side<br />
</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion?</li>
</ul></li>
<li>2021-12-09 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (70 - 26) / 70 = 62.88%</li>
<li>Normal LV systolic function with normal wall motion.</li>
<li>Concentric LVH, dilated LA; LV diastolic dysfunction Gr 1.</li>
<li>Normal RV systolic function.</li>
<li>Aortic valve sclerosis with trivial AS; mild MR; mild TR; mild
PR.</li>
<li>Small pericardial effusion without tamponade and constriction
sign.</li>
</ul></li>
<li>2021-12-08 Whole body PET scan
<ul>
<li>Glucose hypermetablic lesions in bilateral lateral walls of
oropharynx (Deauville score 5), compatible with the primary
lymphoma.<br />
</li>
<li>Glucose hypermetablic lesions in bilateral cervical lymph nodes,
right SCF and ICF lymph nodes (Deauville score 5), highly suspected
lymphoma with lymph node regions involvement.<br />
</li>
<li>Glucose hypermetablic lesions in a right axilla lymph node
(Deauville score 2) and right hip joint (Deauville score 3), probably
benign in nature.</li>
</ul></li>
<li>2021-12-07 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Right bundle branch block</li>
</ul></li>
<li>2021-12-06 CXR
<ul>
<li>Cardiomegaly.</li>
<li>Tortuous thoracic aorta.</li>
<li>No mediastinal widening.</li>
<li>Obliteration of left CP angle.</li>
<li>Scoliosis and spondylosis of T-L spine.</li>
</ul></li>
<li>2021-12-06 Patho - gingival/oral mucosa biopsy
<ul>
<li>Oropharynx, left, punch biopsy — Diffuse large B-cell lymphoma, GCB
type<br />
</li>
<li>Section shows squamous mucosa with ulcer and infiltration of large
pleomorphic tumor cells.</li>
<li>The immunohistochemical stains reveal CK(-), LCA(+), CD3(-),
CD20(+), CD10(+), BCL2(-), BCL6(+), MUM1(+), CyclinD1(-), CD56(-),
p63(-), and p16(-). The Ki-67 is about 80%. The results are in favor of
GCB type of diffuse large B-cell lymphoma.</li>
</ul></li>
<li>2021-12-03 Nasopharyngoscopy
<ul>
<li>L oropharyngeal cancer with bil neck mets</li>
</ul></li>
<li>2021-11-29 Lymph Node Aspiration
<ul>
<li>indication: suspect L oropharyngeal cancer with neck mets</li>
<li>Malignancy, positive for carcinoma</li>
</ul></li>
<li>2021-11-29 Pure Tone Audiometry, PTA
<ul>
<li>Tymp bil type C</li>
<li>ART bil absent</li>
<li>PTA:
<ul>
<li>Reliability FAIR</li>
<li>Average RE 59 dB HL // LE 69 dB HL</li>
<li>RE mild to profound SNHL</li>
<li>LE moderate to profound SNHL</li>
</ul></li>
</ul></li>
<li>2021-11-27 CT - neck
<ul>
<li>Enlarged lymph nodes at both sides of neck with left palatine
lesion. Oropharyngeal cancer with bialetral metastatic LAPs should be
first considered until proved otherwise.</li>
</ul></li>
<li>2021-11-26 Nasopharyngoscopy
<ul>
<li>huge firm level II NM (infection was told and repeated pus
aspiration at 中和LMD)</li>
<li>fiber = L tonsillar granular tumor with touch bleeding, ENT local tx
done</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-07 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>For dental evaluation</li>
<li>A case of oropharyngeal tumor with bilateral metastatic LAPs</li>
<li>This is a 80 y/o female patient denied systemic disease. This time,
she was admitted for cancer work up due to left oropharyngeal tumor with
bilateral metastatic LAPs. The left oropharyngeal biopsy pathologic
report was pending, but the pathologic report of left neck LN revealed
positive for malignancy. Neck CT disclosed enlarged LN at both sides of
neck with left palatine lesion. Oropharyngeal cancer with bialetral
metastatic LAPs should be first considered until proved otherwise. Due
to left oropharyngeal cancer with bil. metastatic LAPs impressed, we
need your expertise for pre-RT dental evaluation. Thank you very
much!!</li>
</ul></li>
<li>A
<ul>
<li>This is a 80 y/o female who suffered from Oropharyngeal cancer.</li>
<li>O: No obvious tooth decay or residual root is noted</li>
<li>P:
<ul>
<li>Teach her how to do home care and OHI (oral hygiene
instruction)</li>
<li>Suggest scaling at LDC regularly</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-322" class="section level1">
<h1>700999537</h1>
<div id="section-323" class="section level2">
<h2>220919</h2>
<p>[Chief Complaint] for chemotherapy
                                        </p>
<p>[Present Illness] This 46-year-old female patient had invasive
carcinoma of no special type with focal micropapillay pattern of the
right breast cancer, pT2N1M0, stage IIB, ER (postive, +++95%), RP
(postive, +++80%), Her-2/Neu(equivocal, 2+), s/p MRM and ALND on
2017/11/30, post chemotherapy with AC 4 times since 106/12-107/03/13.
Adjuvant chemotherapy with Taxotere on 108/04/04-6/6 and
radiotheratpy.</p>
<p>On 2020/12/01, microinvasive carcinoma of the left breast, AJCC 8 th
edition, Pathology stage: pT1miN0; Anatomic stage IA; Prognostic stage
IA if cM0. Margins: Negative, Closest margin (7 mm from deep margin). ER
(Ab): Positive (60%, moderate intensity), PR (Ab): Negative, HER-2/Neu
(Ab): Positive (score= 3+), s/p left partial mastectomy and sentinel
lymph node biopsy, radiotherapy (Radiotherapy with 5000cGy/25 ractions
of the left breast, and 6000cGy/30 fractions of the left breast tumor
bed (scar) area), and status during endocrine therapy.</p>
<p>Followed CT on 2022/1/28 which revealed Four Metastases on both
hepatic lobes are highly suspected. Her-2 overexpressed liver metastases
were confirmed after liver biopsy. Bone scan revealed a hot spot in the
left humeral head, some faint hot spots in bilateral rib cage, upper
T-spine, L2-3 spines, lower L-spine, sacrum, bilateral sternoclavicular
junctions, upper portion of the sternum, shoulders, and knees in
whole-body survey.</p>
<p>Then she recevied C1 Herceptin, Perjenta (840mg) for loading dose on
2022/2/14, Taxotere on 2022/2/15. C2 Herceptin, Perjenta on 2022/3/7
Taxotere on 2022/3/8. C3 Herceptin, Perjenta on 2022/3/28 Taxotere on
2022/3/29. C4 Herceptin and Perjenta on 2022/4/18,Taxotere on 2022/4/19.
Followed CT of chest was performed on 5/2 revealed almost resolution of
metastatic hepatic tumors (with a small residual lesion in S6) compared
with abdominal CT on 1/28.minimal nonspecific RML inflammation and
subtle small nodules inlower lobes of lungs, susggest f/u. Chemotherapy
with C5 Herceptin + Perjenta (420mg) on 2022/5/9.Taxotere on 2022/5/10.
C6 Herceptin + Perjenta (420mg) on 2022/5/30.Taxotere on 2022/5/31 C7
Herceptin + Perjenta (420mg) on 2022/6/20.Taxotere on 2022/6/21 C8
Herceptin + Perjenta (420mg) on 2022/7/11.Taxotere on 2022/7/12.</p>
<p>Followed up CT of chest on 2022/8/8 revealed 1.almost resolution of
metastatic hepatic tumors (with a small residual low lesion in S6)
compared with CT on 5/4 and 2.two small nodules in Rt lung still
visualized, susggest f/u.</p>
<p>C9Herceptin + Perjenta (420mg) on 2022/8/29 and Taxotere on
2022/8/30</p>
<p>This time, she was admitted for chemotherapy on 2022/9/18.</p>
<ul>
<li>past history
<ul>
<li>disease
<ul>
<li>right breast cancer, cT2N0M0,stage II</li>
<li>HBV</li>
</ul></li>
<li>operation
<ul>
<li>partial mastectomy and sentinel lymphnode biopsy on 2017-11-30</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-08 CT - chest
<ul>
<li>indication: breast ca with liver metastases</li>
<li>findings:
<ul>
<li>Lungs: two centrilobular nodules at peripheral of RUL and RLL.</li>
<li>Mediastinum and hila: no enlarged LN or mass.</li>
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: unremarkable.</li>
<li>Chest wall and visible lower neck: s/p Rt mastectomy.</li>
<li>Visible abdominal-pelvic contents:
<ul>
<li>liver: small residual low attenuated lesion in S6 and no more
visible tumors in other segments. many small hepatic cysts also are
visible.</li>
<li>a gall bladder stone, 1.4 cm.</li>
<li>unremarkable of the spleen, both adrenal glands, pancreas, and both
kidneys. no enlarged lymph node.</li>
</ul></li>
<li>Visualized bones: unremarkable</li>
</ul></li>
<li>Impression:
<ul>
<li>almost resolution of metastatic hepatic tumors (with a small
residual low lesion in S6) compared with CT on 20220504.</li>
<li>two small nodules in Rt lung still visualized, susggest f/u.</li>
</ul></li>
</ul></li>
<li>2022-07-20 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Liver tumor, right lobe</li>
<li>Liver cysts</li>
<li>GB stone</li>
</ul></li>
<li>Suggestion
<ul>
<li>Remission (at least partial) of hepatic metastasis was noted
compared to previous echo study. Correlate with CT scan if clinically
indicated</li>
</ul></li>
</ul></li>
<li>2022-05-04 CT - chest
<ul>
<li>Impression:
<ul>
<li>almost resolution of metastatic hepatic tumors (with a small
residual lesion in S6) compared with abdominal CT on 20220128.</li>
<li>minimal nonspecific RML inflammation and subtle small nodules in
lower lobes of lungs, susggest f/u.</li>
</ul></li>
</ul></li>
<li>2022-03-18 Nasopharyngoscopy
<ul>
<li>findings: smooth NPx, oropharynx, hypopharynx; Bil. ant. nasal
septum blood clot</li>
<li>conclusion: epistaxis</li>
</ul></li>
<li>2022-02-11 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2017/11/22, the hot spot in
the left humeral head and some faint hot spots in bilateral rib cage are
new. The nature is to be determined (post-traumatic change? bone
metastases? other nature?). Please correlate with other clinical
findings for further evaluation.</li>
<li>The lesions in the L2-3 spines, lower L-spine and sacrum are
slightly more evident. Degenerative spine disease in a little more
severe status may show this picture. However, please follow up bone scan
for further evaluation and to rule out other possibilities.</li>
<li>No prominent change is noted in the hot spot in the left temporal
region of the skull.</li>
</ul></li>
<li>2022-01-28 CT - abdomen
<ul>
<li>Four Metastases on both hepatic lobes are highly suspected.</li>
<li>The differential diagnosis include HCCs and cholangiocarcinoma.</li>
<li>Please correlate with AFP, CEA, CA199 and CA153.</li>
</ul></li>
<li>2022-01-19 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Hepatic tumors, probable metastatic tumors</li>
<li>Liver cyst</li>
<li>GB stone</li>
</ul></li>
<li>Suggestion
<ul>
<li>Further investigation of hepatic metastasis</li>
</ul></li>
</ul></li>
<li>2021-11-05 Gynecologic ultrasonography
<ul>
<li>uterine myoma</li>
</ul></li>
<li>2021-07-14 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst</li>
</ul></li>
</ul></li>
<li>2021-01-13 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst</li>
<li>GB stone</li>
</ul></li>
</ul></li>
<li>2020-11-30 Patho - breast mastectomy with regional lymph nodes
<ul>
<li>pathologic diagnosis
<ul>
<li>Breast, left, partial mastectomy — Microinvasive carcinoma<br />
</li>
<li>Resection margin, breast, left, partial mastectomy — Free<br />
</li>
<li>Lymph node, sentinel, left axillary, SLNB — Negative for malignancy
(0/2)<br />
</li>
<li>AJCC 8 th edition, Pathology stage: pT1miN0; Anatomic stage IA;
Prognostic stage IA if cM0<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Microinvasive carcinoma<br />
</li>
<li>Size of invasive carcinoma: 0.1 x 0.1 x 0.1 cm<br />
</li>
<li>Histologic grade (Nottingham histologic score): Only microinvasion
present (Not graded)<br />
</li>
<li>Tumor Focality: Three foci of microinvasive carcinoma<br />
</li>
<li>Skin involvement: Absent<br />
</li>
<li>Ductal carcinoma in situ: Present, intermediate grade<br />
</li>
<li>Size of DCIS: 1.0 x 0.8 x 0.7 cm<br />
</li>
<li>Margins: Negative, Closest margin (7 mm from deep margin)<br />
</li>
<li>Nodal status (sentinel): Negative (0/2)
<ul>
<li>number of lymph node examined: 2<br />
</li>
<li>number with macrometastases (&gt;2mm): 0<br />
</li>
<li>number with micrometastases (&gt;0.2~2mm and/or &gt;200 cells):
0<br />
</li>
<li>number with isolated tumor cells (&lt;=0.2mm and &lt;=200 cells):
0<br />
</li>
</ul></li>
<li>Treatment Effect: No presurgical neoadjuvant therapy received<br />
</li>
<li>Lymphovascular invasion: Absent<br />
</li>
<li>Perineural invasion: Absent<br />
</li>
</ul></li>
<li>immunohistochemical study
<ul>
<li>ER (Ab): Positive (60%, moderate intensity)<br />
</li>
<li>PR (Ab): Negative<br />
</li>
<li>HER-2/Neu (Ab): Positive (score= 3+)<br />
</li>
<li>Ki-67: 15%<br />
</li>
<li>p63: Loss of myoepithelial cells in invasive component</li>
</ul></li>
</ul></li>
<li>2020-11-26 Lymphoscintigraphy
<ul>
<li>The sentinel lymph node mapping was performed immediately after
injection of 0.5 mCi of Tc-99m phytate (s.c) above the left breast. The
sequential static images over the chest revealed two focal areas of
increased accumulation of radioactivity at the left axilla.</li>
<li>Impression: Probably twp sentinel lymph nodes at the left axillary
region.</li>
</ul></li>
<li>2020-11-13 Patho - breast biopsy
<ul>
<li>Breast tumor, left (12, 1.5), core needle biopsy — Ductal carcinoma
in situ, intermediate grade<br />
</li>
<li>Microscopically, the sections show a picture of ductal carcinoma in
situ, intermediate grade characterized by some dilated ducts fill with
intermediate grade atypical epithelial cells without necrosis and
preserved outer myoepithelial cells.</li>
<li>Immunohistochemistry of CK5/6 and P63 show preserved myoepithelial
cell;
<ul>
<li>ER(strong, diffusely), PR(+, 1-5%);</li>
<li>Her2/neu(+, Dako score 3+).</li>
<li>Besides, microcalcification is also noted in non-tumor breast
tissue.</li>
</ul></li>
</ul></li>
<li>2020-08-28 Gynecologic ultrasonography
<ul>
<li>uterine myoma</li>
</ul></li>
<li>2020-07-13 Mammography
<ul>
<li>Indication: Right breast cancer status post mastectomy on
2017-11-30</li>
<li>Final assessment: BI-RADS category 2, Benign finding.</li>
</ul></li>
<li>2020-07-13 SONO - breast
<ul>
<li>S/P right mastectomy.</li>
<li>Right chest wall hypoechoic tumor, suggest follow up.</li>
<li>Developed left breast 12’ region hypoechoic tumor, 0.78x0.47cm, may
consider biopsy.</li>
<li>BIRADS 4a</li>
</ul></li>
<li>2019-11-15 SONO - breast
<ul>
<li>Left fibroadenomas</li>
<li>S/P right breast operation</li>
<li>BI-RADS: 2. benign finding</li>
</ul></li>
<li>2017-11-30 Surgical pathology Level VI
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Breast, right, radical mastectomy — Invasive carcinoma of no special
type with focal micropapillay pattern</li>
<li>Resection margin: Free</li>
<li>Lymph node, right axilla, lymphadenecomy — Metastatic carcinoma
(3/11)<br />
</li>
<li>Pathology stage: pT2N1(cM0), stage IIB</li>
</ul></li>
<li>IMMUNOHISTOCHEMICAL STUDY (Reference: S2017-18231)
<ul>
<li>ER (Ab): Positive (+++ 95%)</li>
<li>PR (Ab): Positive (+++ 80%)</li>
<li>HER-2/Neu (Ab): Equivocal (2+)
<ul>
<li>FISH STUDY (Reference: S2017-18231) Her2/neu Dual probe FISH: NO
amplification</li>
</ul></li>
<li>Ki-67: 60%</li>
<li>p53: pOSITIVE (70%)</li>
</ul></li>
</ul></li>
<li>2017-11-30 Frozen section
<ul>
<li>Malignant female breast neoplasm, upper-outer quadrant;</li>
<li>Sentinel lymph nodes, frozen section — Metastatic invasive carcinoma
(2/4)</li>
</ul></li>
<li>2017-11-30 Lymphoscintigraphy
<ul>
<li>Probably one sentinel lymph node at the right axillary region.</li>
</ul></li>
<li>2017-11-18 SONO - hepatobiliary
<ul>
<li>Gallbladder stone (1.25cm).</li>
</ul></li>
<li>2017-11-06 Surgical pathoogy Level IV
<ul>
<li>Clinical diagnosis: Lump or mass breast;</li>
<li>Diagnosis
<ul>
<li>Breast, right, core biopsy — Infiltrating ductal carcinoma.</li>
<li>IHC stains: E-cadherin (+), ER (+,), PR: (+), Her2/neu: equivocal
(score=2+), Ki-67: 60%, p53: 70%.
<ul>
<li>Her2/neu Dual probe FISH: NO amplification. (sent out test by Taipei
Institute of pathology.)</li>
</ul></li>
</ul></li>
</ul></li>
<li>2017-08-05 Mammography
<ul>
<li>Regional plemorphic microcalcifications noted in inner upper portion
of right breast(posterior third), suggest biopsy.</li>
<li>BI-RADS: Category 4b: intermediate suspicion-biopsy should be
considered.</li>
</ul></li>
<li>2017-08-05 Bone densitometry - hip
<ul>
<li>osteopenia</li>
</ul></li>
<li>2017-08-05 Flow-volume curve
<ul>
<li>mild lung restriction</li>
</ul></li>
<li>2017-08-05 Colon fiberoscopy
<ul>
<li>Colitis with ulcer, sigmoid colon, s/p biopsy</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>2017-08-05 Upper GI panendoscopy
<ul>
<li>Reflux esophagitis, lower esophagus, LA clasification grade A 　　-
Rule out Barrett’s esophagus, s/p biopsy 　　- Ectopic gastric mucosa,
upper esophagus 　　- Superficial gastritis, antrum</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-324" class="section level1">
<h1>700065031</h1>
<div id="section-325" class="section level2">
<h2>220916</h2>
<p>{Olfactory Neuroblastoma}</p>
<ul>
<li>lab data
<ul>
<li>2022-04-13
<ul>
<li>Anti-HBc Reactive<br />
</li>
<li>Anti-HBc-Value 5.56 S/CO<br />
</li>
<li>Anti-HBs 861.40 mIU/mL<br />
</li>
<li>HBsAg Nonreactive</li>
<li>HBsAg Value 0.00 IU/mL</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.07 S/CO<br />
</li>
</ul></li>
<li>2022-04-02
<ul>
<li>Protein, total 6.6 g/dL<br />
</li>
<li>Albumin 47.1 %<br />
</li>
<li>Alpha-1 4.1 %<br />
</li>
<li>Alpha-2 13.1 %<br />
</li>
<li>Beta 17.9 %<br />
</li>
<li>Gamma 17.8 %<br />
</li>
<li>M-peak Negative<br />
</li>
<li>A/G Ratio 0.9<br />
</li>
<li>Haptoglobin 351 mg/dL (30~200)<br />
</li>
</ul></li>
<li>2022-04-01
<ul>
<li>B2-microglobulin 4.89 mg/L<br />
</li>
</ul></li>
<li>2022-03-31
<ul>
<li>Ferritin 1475.4 ng/mL<br />
</li>
<li>Fe (Iron-bound) 35 ug/dL<br />
</li>
<li>TIBC 271 ug/dL</li>
<li>UIBC 236 ug/dL</li>
<li>DBI/TBI 21.21 %</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-14 CT - brain
<ul>
<li>no acute intracranial hemorrhage</li>
<li>mucosal thickening in the right nasopharyngeal roof</li>
<li>increased soft tissue in the anterior skull base of the sphenoidal
sinus and lateral walls of the bilateral ethoidal sinuses.</li>
</ul></li>
<li>2022-09-13 Nasopharyngoscopy
<ul>
<li>Rt malignancy optic nerve tumor s/p op and CCRT. uneven NPX.</li>
</ul></li>
<li>2022-09-03 Nasopharyngoscopy
<ul>
<li>Scope: smooth NPx, oropharynx, larynx, hypopharynx</li>
<li>There’s no nasal septum</li>
<li>diffuse prominent vessels with oozing over left inferior turbinate
and left lateral nasal wall</li>
<li>crust and necrotic tissue over right lateral nasal wall</li>
<li>s/p surgicel covered over left inferior turbinate and left lateral
nasal wal</li>
</ul></li>
<li>2022-08-15 Acoustic radiation force impulse, ARFI
<ul>
<li>results
<ul>
<li>Median 1.75 m/s</li>
<li>IQR 0.14 m/s</li>
<li>IQR/Median 7.9 %</li>
<li>Metavir Score ：F2</li>
</ul></li>
<li>ref
<ul>
<li>degree of liver fibrosis, NHI def; Device ref value (LOGIQ E10)</li>
<li>F0 ARFI &lt; 1.3 m/s F0 ARFI &lt; 1.35 m/s</li>
<li>F1 1.3 &lt;= ARFI &lt; 1.5 m/s F1 1.35 ~ 1.66 m/s</li>
<li>F2 1.5 &lt;= ARFI &lt; 1.81 m/s F2 1.66 ~ 1.77 m/s</li>
<li>F3 1.81 &lt;= ARFI &lt; 1.98 m/s F3 1.77 ~ 1.99 m/s</li>
<li>F4 1.98 &lt;= ARFI F4 1.99 &lt; ARFI</li>
</ul></li>
</ul></li>
<li>2022-08-15 SONO - abdomen
<ul>
<li>Parenchymal liver disease</li>
<li>Hepatic cysts, bilateral lobes</li>
<li>Parenchymal renal disease and renal cysts, both</li>
<li>Splenomegaly, moderate</li>
<li>Ascites, minimal</li>
</ul></li>
<li>2022-07-29 SONO - kidney
<ul>
<li>Bilateral chronic change of both kidneys.</li>
<li>Bilateral renal cysts.</li>
</ul></li>
<li>2022-07-25 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Right bundle branch block</li>
</ul></li>
<li>2022-07-20 MRI - nasopharynx
<ul>
<li>suspected tumor recurrence in the lateral walls of the bilateral
ethoidal sinuses.</li>
<li>focal mucosal thickening in the right nasopharynx</li>
</ul></li>
<li>2022-07-18 CT - abdomen
<ul>
<li>complete regression of right 12th rib soft tissue lesion is
found.</li>
<li>hepatic and renal cysts</li>
</ul></li>
<li>2022-04-13 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
</ul></li>
<li>2022-04-11 Pure Tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 33 dB HL // LE 38 dB HL</li>
<li>RE normal to severe SNHL (Sensorineural hearing loss)</li>
<li>LE normal to profound SNHL (Sensorineural hearing loss)</li>
</ul></li>
<li>2022-03-30 Patho - soft tissue biopsy / simple excision (non lipoma)
<ul>
<li>Soft tissue, right 12th rib, biopsy — Small blue round cell tumor,
compatible with metastatic neuroblastoma</li>
<li>Microscopically, the sections show a picture of small blue round
cell tumor with apoptosis and focal tumor necrosis.</li>
<li>Immunohistochemistry shows CK(-), LCA(-), CD56(+), S-100(-),
synaptophysin (-) and chromogranin-A(-) for tumor.</li>
<li>According to above histopathologic finding and patient’s past
history, it is compatible with metastatic olfactory neuroblastoma.
Clinical correlation is needed.</li>
</ul></li>
<li>2022-03-30 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease, suspected early cirrhosis</li>
<li>Liver cyst, S7</li>
<li>Bilateral renal cysts</li>
<li>Splenomegaly</li>
</ul></li>
<li>Suggestion
<ul>
<li>Ultrasound follow up</li>
</ul></li>
</ul></li>
<li>2022-03-28 CT - abdomen, pelvis
<ul>
<li>Soft tissue lesion encasing right 12th rib is found. Nature? Suggest
contrast enhanced study.</li>
</ul></li>
<li>2022-03-26 CT - abdomen, pelvis
<ul>
<li>Diverticulosis in the A-colon and cecum.</li>
</ul></li>
<li>2022-03-26 CT - brain
<ul>
<li>bone destruction in the walls of the right maxillary sinus and right
ethmoidal sinus, anterior skull base.</li>
<li>increased soft tissue in the bilateral frontal, bilateral ethmoidal
and bilateral maxillary sinuses.</li>
</ul></li>
<li>2022-03-26 Nasopharyngoscopy
<ul>
<li>Scope: Right pulsatile nasal tumor with oozing, nature?</li>
<li>Left nose: also some soft tissue or blood clot with oozing</li>
</ul></li>
<li>2020-11-13 Patho - paranasal biopsy
<ul>
<li>Diagnosis
<ul>
<li>A. Labeled as “right nasal tumor”, biopsy — malignant round blue
cell tumor.
<ul>
<li>IHC stains: CK (-), CD56 (+), granzyme B (-), CD3 and CD20: no
predominant sub-population; p16 (-), EBV(-), CD99 (-). feature
suggestive of olfactory neuroblastoma, high grade.<br />
</li>
</ul></li>
<li>B. Labeled as “right nasopharynx tumor tumor”, biopsy — malignant
round blue cell tumor.
<ul>
<li>IHC stains: CK (-), CD56 (+), granzyme B (-), CD3 and CD20: no
predominant sub-population; p16 (-), EBV(-), CD99 (-). feature
suggestive of olfactory neuroblastoma, high grade.<br />
</li>
</ul></li>
</ul></li>
<li>Microscopic Description
<ul>
<li>A. Section shows benign respiratory eoithelium lined tissue with
irregular nests of large round blue cells demonstrating marked crush
artifact and small amount of neurofibrillary-like structure.
<ul>
<li>Mitosis is 0-1/HPF.</li>
</ul></li>
<li>B. Section shows benign respiratory eoithelium lined tissue with
irregular nests of large round blue cells demonstrating marked crush
artifact and small amount of neurofibrillary-like structure.
<ul>
<li>Mitosis is 0-1/HPF.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-11-09 MRI - nasopharynx
<ul>
<li>IMP: D/D: NPC, Inverted palliloma with SCC.</li>
</ul></li>
<li>2020-11-06 Nasopharyngoscopy
<ul>
<li>Epistaxis</li>
<li>Right chronic sinusitis with polyposis</li>
<li>Right nasal tumor with unknown etiology</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-03 ENT
<ul>
<li>Q
<ul>
<li>epigastaxis at bilateral nostril since tonight after
nose-picking</li>
<li>Denied trauma</li>
<li>2020-12 LinKou CGMH diagnosed Olfactory Neuroblastoma</li>
<li>Hx of epistaxis</li>
<li>NKA</li>
<li>PH: HT, Rt malignancy optic nerve tumor s/p op and CCRT last Dec. at
CGMH</li>
<li>2022-02-25 CT 1. No contrast extravasation (CE), neither
pseudoaneurysm (PSA) 2. Hyperemic area lateral to the left pterygoid
plate could be acute inflammation change or tumor vessels. 3. S/P change
with soft tissue thickening surround the anterior skull base and fovea
ethmoidale. 4. Thickening of mucoperiosteum of paranasal sinus,
suggestive of chronic sinusitis. 5. Bone destrction/errsion of the right
maxillary antral walls, right ethmoid lateral wall and roof. 6.
Effacement of the bil. nasopharyngeal recess. 7. A score 2 LN at left
neck zone II 8. Left mastoid focal mastoiditis at lower part. 9. No
definite active lesion in the scanned lungs and intracranial cavity;
IMP: 1. S/P change with soft tissue thickening surround the anterior
skull base and fovea ethmoidale. 2. No contrast extravasation (CE),
neither pseudoaneurysm (PSA)</li>
</ul></li>
<li>A
<ul>
<li>S: Bil. epistaxis since this evening
<ul>
<li>According to the patient and medical record:</li>
<li>Right olfactory neuroblastoma s/p op and CCRT at CGMH in
2020/12</li>
<li>massive epistaxis history in 2022/02, TAE was suggested by CGMH but
not done</li>
<li>intermittent epistaxis since then</li>
<li>under chemotherapy due to metastatic neuroblastoma (Rib) since
2022/04 (Dr. Xia HeXiong), but hold recently due to impaired renal and
marrow function</li>
</ul></li>
<li>O:
<ul>
<li>oral cavity and oropharynx: mild blood clots over post. pharyngeal
wall</li>
<li>Scope: smooth NPx, oropharynx, larynx, hypopharynx</li>
<li>There’s no nasal septum</li>
<li>diffuse prominent vessels with oozing over left inferior turbinate
and left lateral nasal wall</li>
<li>crust and necrotic tissue over right lateral nasal wall</li>
</ul></li>
<li>A:
<ul>
<li>epistaxis</li>
</ul></li>
<li>Plan:
<ul>
<li>s/p surgicel covered over left inferior turbinate and left lateral
nasal wall</li>
<li>ENT OPD f/u and suggest back to CGMH for further treatment amd
management</li>
<li>treat anemia, electrolyte imbalace (Na, K), prolonged APTT, impaired
renal function as your expertise</li>
<li>supportive care</li>
<li>Education done: if bleeding again, keep head downward and mouth
open, if persistent bleeding, back to hospital soon</li>
<li>Observation for bleeding at ER at least for 1 hour</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-01 Nephrology
<ul>
<li>Q
<ul>
<li>He was admitted of hematuria since 20220725. We follow laboratory
data revealed elevated renal function was found (Cre 4.6mg/dL, BUN
43mg/dL), suspect chemotherapy side effects or another cause?</li>
<li>We also arranged kidney echo, report showed 1. Bilateral chronic
change of both kidneys. 2. Bilateral renal cysts. Now, he still has dark
urine today. We need your expertise and evaluation! Thanks a lot!
NP楊采諭/VS陳亨翔</li>
</ul></li>
<li>A
<ul>
<li>Subj/Obj
<ul>
<li>This 51-year-old man patient suffered from right neck mass with mild
nasal oozing in 2020/11. Nasopharynx MRI on 2020/11/10 showed NPC,
Inverted palliloma with SCC. Right nasal tumor bipsy on 2021/11/13 and
pathology showed olfactory neuroblastoma. Right supraomothyoid neck
dissection on 2020/12/10. Endoscopic caniofacial ersection, bilateral
nasoseptal flap for skull base reconstruction, facia lata transfer on
2020/12/15.</li>
<li>Chemotherapy with EP (VP-16 60mg/m2, CDDP 60mg/m2) from
2021/01/07~2021/3/13 for 3 cycles. VMAT radiotherapy from
2021/01/25~2021/03/19 for 6996 cGy/33 fractions. He is also received
chemotherapy with EP (Etoposide 80mg/m2 x3, CDDP 25mg/m2 x3) on
2022/4/13(C1), on 2022/5/9(C2), 2022/06/02(C3), 2022/6/24(C4),
2022/07/15(C5).</li>
<li>This time, he suffers from fever to 39.5C at home, and his grandson
was confirmed case with COVID-19 virus infection before. He also has
dark urine since this morning. He came to our emergency for help. At the
ER, laboratory data revealed hematuria and bacteriuria (bacteria:2+
/HPF, Leucocyte Ester:1+, Sediment-RBC: &gt;=100 /HPF), elevated CRP
(7.89 mg/dL).</li>
<li>WBC 2.21, Hb 8.5, Plt 19, Na 142, K 2.9 BUN 43, Cr 1.2 -&gt;
4.6</li>
</ul></li>
<li>Impression
<ul>
<li>AKI stage 3, due to sepsis or chemotherapy related</li>
<li>Neutropenic fever</li>
<li>thromocytopenia suspect chemotherapeutic agents induced</li>
<li>Hematuria suspect thrombocytopenia related</li>
</ul></li>
<li>Suggestion
<ul>
<li>check FeNa, urine Na, urine osmo</li>
<li>arrange renal echo</li>
<li>adequate hydration</li>
<li>avoid nephrotoxic agents</li>
<li>record I/O and body weight QD</li>
<li>recheck urinalysis</li>
<li>correct thrombocytopenia</li>
<li>follow up renal function , electrolytes and total CO2</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-31 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This 51-year-old male has past history of
<ul>
<li><ol style="list-style-type: decimal">
<li>Right malignancy optic nerve tumor under operation and CCRT</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hypertension under medication control.</li>
</ol></li>
</ul></li>
<li>This time, he was admitted with a chief complaint of right waist
soreness for two weeks. The sumptom got worsen thus he came to our ER
for help.</li>
<li>At ER, laboratory data revealed elevation CRP (9.08 mg/dL),
Lymphocyte: 9.3 %, normalcytic anemia of HB 8.7 g/dL and impaired renal
function of creatinine 1.94 mg/dL.</li>
<li>Abdomen CT revealed soft tissue lesion encasing right 12th rib is
found.</li>
<li>Under the impression of 1) suspect soft tissue lesion of right 12th
rib, 2) Hematuria, he was admitted to INF ward for further evaluation
and treatment on 2022/03/28.</li>
<li>During hospitalization, laboratory data revealed uric acid: 10.1
mg/dL, LDH: 2172 U/L. We need your expertise to evaluate, sincerely
thanks.</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>Soft tissue lesion encasing right 12th rib</li>
<li>Hematuria, cause to be determined</li>
<li>Right olfactory neuroblastoma, high grade s/p operation and CCRT at
CGMH</li>
<li>Hypertension</li>
<li>CKD</li>
</ul></li>
<li>Suggestion:
<ul>
<li>pending soft tissue biopsy result</li>
<li>check Ca, total bilirubin/direct bilirubin, haptoglobin, serum
eletropheresis (protein EP), Beta-2 microglobulin, check urine
cytology</li>
<li>may apply CGMH medical history (olfactory neuroblastoma) if patient
want to treat in our hospital</li>
<li>thanks for your consultation, we would like to follow up this case.
If there is any problem, please feel free to let us known.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-09 ~ undergoing - etoposide + carboplatin</li>
<li>2022-04-13 - etoposide</li>
<li>2021-01-07 ~ 2021-03-13 - etoposide (3 times)</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Tumors that show good differentiation are generally easy to
diagnose, but identification of the diagnostic, morphological features
is difficult when a tumor is poorly differentiated, therefore, no
definitive diagnosis may be possible. Differential diagnosis of small
round cell tumors is particularly difficult due to their
undifferentiated or primitive character. (Round Cell Tumors:
Classification and Immunohistochemistry. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686981/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686981/</a>
)</li>
<li>For sinonasal undifferentiated carcinoma (SNUC) with neuroendocrine
features, small cell, high-grade olfactory esthesioneuroblastoma, or
sinonasal neuroendocrine carcinoma (SNEC) histologies, systemic therapy
should be a part of the overall treatment. Consider a clinical trial and
referral to a major medical center that specializes in these diseases.
(Head and Neck Cancers NCCN Evidence Blocks Version 1.2022 - February
14, 2022. p.109)
<ul>
<li>Carboplatin/etoposide +- concurrent RT</li>
<li>Cisplatin/etoposide +- concurrent RT</li>
<li>Cyclophosphamide/doxorubicin/vincristine (followed by RT-based
treatment) (category 2B)</li>
</ul></li>
</ul>
<div id="section-326" class="section level3">
<h3>==========</h3>
</div>
<div id="section-327" class="section level3">
<h3>2022-06-27</h3>
<ul>
<li>The patient has recurrent small blue round cell tumor, olfactory
neuroblastoma, high grade, with metastatic lesion around the right 12th
rib. He is receiving etoposide + carboplatin chemotherapy for his
disease.</li>
<li>The patient’s HGB has been low several times since this May. Lab
data also showed high haptoglobin (351 mg/dL 2022-04-02) and high
ferritin (1475.4 ng/mL 2022-03-31).
<ul>
<li>2022-06-21 HGB 6.4 g/dL<br />
</li>
<li>2022-06-14 HGB 6.8 g/dL<br />
</li>
<li>2022-05-04 HGB 5.5 g/dL<br />
</li>
</ul></li>
<li>Anemia, which can impair functional status, is commonly seen in
patients with cancer as a complication of both the illness and its
treatment with chemotherapy. The incidence of anemia increases
significantly with age. Hb levels can be raised with either ESAs or RBC
transfusions.
<ul>
<li>ESAs are indicated for patients who have mildly to moderately
symptomatic chemotherapy-associated anemia who have no other potentially
correctable causes of the anemia, an Hb level &lt;=10 g/dL prior to
therapy, and no contraindications to the use of an ESA (eg, prior
history of thromboses, surgery, prolonged periods of immobilization or
limited activity, or uncontrolled hypertension).</li>
<li>RBC transfusion is recommended for patients whose clinical condition
indicates the need for immediate correction of the Hb level (eg,
severely symptomatic, cardiopulmonary compromise, and need for a rise in
Hb before the two to four weeks or more that it may take for ESAs to
take effect), and for patients who have established general risk factors
for thromboembolic events or uncontrolled hypertension and thus are poor
candidates for ESAs.</li>
</ul></li>
</ul>
</div>
<div id="section-328" class="section level3">
<h3>2022-08-12</h3>
<p>[Angiotensin-Converting Enzyme Inhibitors / Angiotensin II Receptor
Blockers]</p>
<ul>
<li>Hypertension is observed (SBP 165 +- 20 during this hospital
stay).</li>
<li>Blood creatinine level remains above 4mg/dL since end of July.
2022-08-12 Cre 4.33 =&gt; eGFR 15, CrCl 17.</li>
<li>Sevikar (amlodipine 5mg + olmesartan 20mg) 1# QD and Tritace
(ramipril 10mg) 1# QD have been prescribed. Ramipril is an
angiotensin-converting enzyme inhibitor and olmesartan is an angiotensin
II receptor blocker.</li>
<li>Studies showed that the combination of an ACE inhibitor and an ARB
can lead to worse renal outcomes. Reference: Misra S, Stevermer JJ. ACE
inhibitors and ARBs: one or the other - not both - for high-risk
patients. J Fam Pract. 2009;58(1):24-27.</li>
<li>Recommendation
<ul>
<li><ol style="list-style-type: decimal">
<li>DC Tritace</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Replace Sevikar with Norvasc (amlodipine 5mg) 1# QD, mild to severe
kidney impairment: no dosage adjustment necessary</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Start administering Entresto (sacubitril 97mg + valsartan 103mg) 36
hours after the last dose of Tritace. Initial 0.5# QD for eGFR &lt;30
mL/minute/1.73m2 patients.</li>
</ol></li>
</ul></li>
</ul>
</div>
<div id="section-329" class="section level3">
<h3>2022-08-16</h3>
<ul>
<li>Coadministration of angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers may enhance their adverse or toxic
effects. US labeling states that concurrent use of telmisartan and
ramipril is specifically not recommended. Canadian labeling states that
irbesartan and eprosartan are contraindicated for use with ACE
inhibitors in patients with diabetic nephropathy, and Canadian labeling
for ramipril/hydrochlorothiazide states use with angiotensin II receptor
antagonists (ARBs) is contraindicated in patients with diabetes with end
organ damage, moderate to severe renal impairment (GFR less than 60
mL/min), hyperkalemia, or hypotensive congestive heart failure. It is
not clear if any other combination of an ACE inhibitor and an ARB would
be any safer. If such a combination must be used, monitor patients extra
closely for a greater-than-expected response to the combination,
including monitoring of blood pressure, renal function, and potassium
concentrations.</li>
<li>Atanaal (nifedipine 5mg/cap) 2# TIDAC is listed in active
prescription. Adapine (nifedipine 30mg/tab) 1# QD might be a better
alternative since it has a prolonged release mechanism, which may result
in less fluctuation in concentration.</li>
</ul>
</div>
<div id="section-330" class="section level3">
<h3>2022-09-15</h3>
<ul>
<li>Poor liver and kidney function. Since the end of July 2022, the
serum creatinine level has remained above 4 mg/dL, while the BUN level
has followed the same trend and reached 90 mg/dL on 2022-09-14. A high
AST/ALT ratio is noted, as AST reached 139 U/L and ALT remained at 13
U/L (2022-06-14).</li>
<li>PLT has decreased to 62<em>10^3/uL (2022-09-15) from 167</em>10^3/uL
(2022-09-02). Thrombocytopenia is a common complication in liver disease
and can adversely affect the treatment, limiting the ability to
administer therapy and delaying planned procedures because of an
increased risk of bleeding. There is a history of epistaxis in this
patient and he tends to pick his nose frequently.</li>
<li>Hepatic encephalopathy might be the cause of the patient’s
diminished expression and hearing ability, which is currently being
treated with LACTUL (lactulose).</li>
<li>The use of ramipril (in the active prescription currently) in
patients with ascites (in case if it develops) due to cirrhosis or
refractory ascites should be avoided; however, if the use cannot be
avoided, monitor blood pressure and renal function carefully to ensure
that renal failure does not occur rapidly (AASLD [Runyon 2013]).</li>
</ul>
<p>[drug identification]</p>
<ul>
<li>Total 2 drugs for identification.</li>
<li>The 1 identified items has been shown as following while the other 1
items still remain unknown:
<ul>
<li>Through (sennoside 12mg) tab: Laxative, Stimulant
<ul>
<li>Indication: Constipation
<ul>
<li>Relieves occasional constipation (irregularity); generally causes
bowel movement in 6 to 12 hours</li>
</ul></li>
</ul></li>
</ul></li>
<li>These drugs will be sent back to ward by the in-hospital
porter.</li>
</ul>
</div>
<div id="section-331" class="section level3">
<h3>2022-09-16</h3>
<ul>
<li>Tritace (ramipril) is a member of angiotensin-converting enzyme
inhibitors (ACEI) and Sevikar (amlodipine + olmesartan) contains a
member of angiotensin II receptor blockers (ARB). Angiotensin II
Receptor Blockers may enhance the adverse/toxic effect of
Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor
Blockers may increase the serum concentration of Angiotensin-Converting
Enzyme Inhibitors. Coadministration of these two medications is not
recommended. Adapine (nifedepine 30mg) 1# QD might be an alternative to
replace Sevikar.</li>
</ul>
</div>
</div>
</div>
<div id="section-332" class="section level1">
<h1>700129413</h1>
<div id="section-333" class="section level2">
<h2>220916</h2>
<ul>
<li>present illness
<ul>
<li>2022-09-15 adminnote
<ul>
<li>The 75-year-old female who has history of hypertension and
hyperlipidemia with medication control, regular follow-up at Taipei City
Hospital YangMing Branch for years.</li>
<li>According the patient, she suffered from many bruises noted after
lifting heavy objects about three weeks ago, she went to the Clinic for
help. At Clinic, the lab showed thrombocytopenia, so she was transferred
to NTUH and steoid therapy (30 mg/day, NTUH 20220722). Due to the
personal reason, so she came to our Hematology Oncology OPD for help and
steoid therapy increase dose to 60 mg/day since 20220803. But it seemed
not change the platelet count much. The medication was changed to
dexamethasone at last visit.</li>
<li>She regular follow-up Hematology Oncology OPD, then the lab of
platelet level lower (Plt: 3000/uL), add Danzol on 2022/09/07.</li>
<li>This time, she is admitted for mabthera therapy (low dose 100
mg/week). According the family, the patient’s sugar poor control, so
regular follow-up Metabolism OPD, and the patient suffered from fatigue,
weakness and appetite change, lethargy for one week, then worsening
symptoms and consciousness drowsy since this morning. And suspect a
tooth is shaking noted, and bleeding noted last night.</li>
</ul></li>
</ul></li>
<li>past history
<ul>
<li>hypertension and hyperlipidemia with medication control, regular
follow-up at Taipei City Hospital YangMing Branch for years.</li>
</ul></li>
<li>VsNote
<ul>
<li>2022-09-15
<ul>
<li>A patient of ITP with platelet count 3 k/cumm at OPD (current
medication with steroid, CSA and Danazol)</li>
<li>Admitted for low dose Mabthera.</li>
<li>She was found with drowsy and slow response, no headache, corena
with LR (+), bilateral.</li>
<li>On touch Glucose &gt; 500</li>
<li>Assessment
<ul>
<li>Suspected ICH (arrange emergency brain C.T.) (ICH = Intracranial
Hemorrhage)</li>
<li>Suspected HHNK (aggressive surgar control with RI) (HHNK =
hyperglycemic hyperosmolar nonketotic coma)</li>
</ul></li>
</ul></li>
</ul></li>
<li>diagnosis
<ul>
<li>2022-09-15 adminnote
<ul>
<li>Immune thrombocytopenic purpura</li>
<li>Essential (primary) hypertension</li>
<li>Hyperlipidemia, unspecified</li>
<li>Type 2 diabetes mellitus without complications</li>
<li>Liver disease, unspecified</li>
<li>Other specified diseases of liver</li>
<li>Constipation, unspecified</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-15 ECG
<ul>
<li>Sinus tachycardia</li>
<li>ST &amp; T wave abnormality, consider inferolateral ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-22 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Liver cyst, left lobe</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please survey hepatitis B and hepatitis C</li>
</ul></li>
</ul></li>
<li>2022-08-16 Patho - bone marrow biopsy
<ul>
<li>The sections show normocellular marrow (25%). M/E ratio = 10:1 in
CD71 stain. The myeloid cells show good maturation with neutrophilia.
The megakaryocytes are increased in number and left shift. No increased
CD34+ blasts. Suggest further bone marrow smear evaluation and clinic
correlation.</li>
</ul></li>
<li>2022-08-15 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
</ul></li>
<li>2022-08-15 CXR
<ul>
<li>A nodular opacity projecting in the left lower lung is suspected.
Follow up is indicated. Otherwise, Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
</ul></li>
</ul>
<p>[not completed]</p>
<ul>
<li>F/S records and administered insulin units
<ul>
<li>Date QDAC basal bolus QLAC bolus QNAC bolus HS</li>
<li>Unit mg/dL unit unit mg/dL unit mg/dL unit</li>
<li>2022-09-17 184 12 7 - - - -</li>
<li>2022-09-16 157 12 7 256 8 141<br />
</li>
<li>2022-09-15 435</li>
</ul></li>
<li>F/S records and administered insulin units
<ul>
<li>Date QDAC basal bolus QLAC bolus QNAC bolus HS</li>
<li>Unit mg/dL unit unit mg/dL unit mg/dL unit</li>
<li>2022-07-20 184 12 7 - - - -</li>
<li>2022-07-19 157 12 7 256 8 141 7</li>
<li>2022-07-18 277 12 7 360 7 316 7</li>
<li>2022-07-17 105 12 7 301 7 361 7</li>
<li>2022-07-16 265 12 7 274 7 179 7</li>
<li>2022-07-15 060 0 0 280 7 186 7 (QDPC 190 mg/dL, after taking
sugar)</li>
<li>2022-07-14 189 12 7 281 7 319 7</li>
<li>2022-07-13 - - - - - 376 7</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Blood sugar levels are poorly controlled. The 2022-09-14 Metabolism
and Endocrinology OPD prescribed oral hypoglycemic agents - Galvus Met
1# BID and Relinide 1# TIDAC15 might be added to the active medication
list as patient-carried items (hold Galvus temporally for the scheduled
brain CT due to its metformin content).</li>
</ul>
</div>
</div>
<div id="section-334" class="section level1">
<h1>701361745</h1>
<div id="section-335" class="section level2">
<h2>220915</h2>
<p>[tube feeding]</p>
<p>The capsule of Nexium (esomeprazole 40mg/tab) should be opened and
the small granules poured into drinking water before tube feeding can
begin.</p>
</div>
</div>
<div id="section-336" class="section level1">
<h1>700883303</h1>
<div id="section-337" class="section level2">
<h2>220914</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-08-01 CT - abdomen
<ul>
<li>Findings
<ul>
<li>s/p LAR with autosuture retention.</li>
<li>Infra-renal aortic aneurysm up to 3.1cm in largest dimension is
found.</li>
<li>Low density area at both lobes of liver are found up to 12.1cm at
right lobe. LIver meta is considered. In comparison with CT dated on
2022-04-15, the metastastic lesions are stationary.</li>
<li>Some lymphadenopathy are found at hepatic hilum and retroperitoneal
region.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
<li>Herniation of the small intestines at RLQ is found. No strangulation
is found.</li>
<li>There is stone at dependent portion of GB. GB stone(s) are
noted.</li>
<li>Visible chest
<ul>
<li>Diffuse nodular lesions (n&gt;50) are found at both lungs.
Stable.</li>
<li>Calcified coronary arteries is found.</li>
<li>Borderline heart size is found.</li>
<li>There is no evidence of destructive bone lesion.</li>
<li>Suggest clinical correlation</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>s/p LAR.</li>
<li>Metastatic lesions at both lobes of liver and both lungs. Stationary
in size and numbers.</li>
</ul></li>
</ul></li>
<li>2022-04-15 CT - abdomen
<ul>
<li>Multiple metastases on both hepatic lobes and Multiple metastatic
nodes in the celiac trunk, hepatoduodenal ligament, mesentery and
para-aortic space S/P C/T show stable disease .</li>
</ul></li>
<li>2022-01-07 CT - abdomen, pelvis
<ul>
<li>finding
<ul>
<li>Prior CT idenified multiple metastases on both hepatic lobe are
noted again, mild decreasing in size (the largest one measuring 13 cm
(the largest dimension) at S4 and residual right lobe at prior CT and
12.6 cm in current CT).</li>
<li>Prior CT identified multiple metastatic nodes in the celiac trunk,
hepatoduodenal ligament, mesentery and para-aortic space are noted
again, mild decreasing in size.</li>
</ul></li>
<li>impression
<ul>
<li>Multiple metastases on both hepatic lobes and multiple metastatic
nodes in the celiac trunk, hepatoduodenal ligament, mesentery and
para-aortic space S/P C/T show partial response.</li>
</ul></li>
</ul></li>
<li>2021-08-25 CT - abdomen, pelvis
<ul>
<li>finding
<ul>
<li>Prior CT idenified multiple metastases on both hepatic lobe are
noted again, mild decreasing in size (the largest one measuring 16.6 cm
in the largest dimension at S4 and residual right lobe at prior CT and
13 cm in current CT).</li>
<li>Prior CT identified multiple metastatic nodes in the celiac trunk,
hepatoduodenal ligament, mesentery and para-aortic space are noted
again, mild decreasing in size.</li>
</ul></li>
<li>impression
<ul>
<li>Multiple metastases on both hepatic lobes and Multiple metastatic
nodes in the celiac trunk, hepatoduodenal ligament, mesentery and
para-aortic space S/P C/T show partial response.</li>
</ul></li>
</ul></li>
<li>2021-05-21 MRA - brain
<ul>
<li>IMP: No evidence of brain metastasis. Old ischemic insults as
descibed. Intracranial artherosclerosis. General brain atrophy.</li>
</ul></li>
<li>2021-05-20 CT - abdomen, pelvis
<ul>
<li>IMP: Rectal cancer s/p operation. Right abdominal wall hernia. Mild
decreased size of liver and LNs metastases.</li>
</ul></li>
<li>2021-02-17 CT - abdomen, pelvis
<ul>
<li>Multiple metastases on both hepatic lobes and the largest one
measuring 16.6 cm at S4 and residual right lobe.</li>
<li>Multiple metastatic nodes in the celiac trunk, hepatoduodenal
ligament, mesentery and para-aortic space.</li>
</ul></li>
<li>2019-10-28 M-mode Echo
<ul>
<li>Dilated LA and LV; Mildly abnormal LV sytstolic function with global
hypokinesia</li>
<li>Septal hypertrophy</li>
<li>Trivial MR, mild AR, trivial TR and trivial PR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2019-10-24 CT - brain
<ul>
<li>Impression: Brain atrophy with old left basal ganalia lacunar brain
infarcts. Arteriosclerosis.</li>
</ul></li>
<li>2018-07-02 Whole body PET scan
<ul>
<li>At least five glucose hypermetablic lesions in both lobes of the
liver, rectal cancer with liver mets should be considered.<br />
</li>
<li>At least two glucose hypermetablic lesions in the LLQ and RLQ of
abdomen, rectal cancer with tumor seeding should be considered,
suggesting further investigation.</li>
<li>Mild glucose hypermetabolism in the mediastinal lymph node and left
SCF lymph node, reactive change may show such a picture.</li>
<li>Rectal cancer s/p treatment, cTxNxM1b-1c, stage IVB-IVC (AJCC, 8th
ed.), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2018-06-28 CT - abdomen
<ul>
<li>S/P operation with liver metastases.</li>
<li>Gall stones (3-10mm).</li>
<li>Small bowel ileus.</li>
</ul></li>
<li>2018-06-15 CT - abdomen
<ul>
<li>Post-op at the colon and liver.</li>
<li>Liver metastasis.</li>
<li>Prominent soft tissue density in RLQ around the terminal ileum,
suspected tumor seeding. Suggest follow up.</li>
</ul></li>
<li>2018-02-20 CT - abdomen
<ul>
<li>Compatible with rectal cancer with liver meta s/p op. over liver and
rectum. No focal tumor is found.</li>
</ul></li>
<li>2017-11-15 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Possible liver cyst with calcification</li>
<li>Possible surgical artefact in liver dome</li>
<li>GB sludge ball with marked distention of GB</li>
<li>Poor postprandial contraction of GB, suggestive of obstruction of
GB</li>
</ul></li>
<li>Suggestion
<ul>
<li>Refer to GS for evaluation of cholecystectomy</li>
</ul></li>
</ul></li>
<li>2017-10-30 Abdominal Ultrasonography
<ul>
<li>GB stones with distended GB, with cholecystopathy; equivocal
echo</li>
<li>Murphy sign</li>
<li>Possible cystic duct stone</li>
<li>Dilated bilateral IHD</li>
<li>Suboptimal examination of liver and CBD</li>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2017-10-29 CT - abdomen
<ul>
<li>Distal CBD stone (6mm) with biliary obstruction. Gall stones
(7-11mm).</li>
</ul></li>
<li>2017-07-28 CT - abdomen
<ul>
<li>Rectal CA wtih liver metastasis, s/p operation</li>
<li>Increased perirectal soft tissue.</li>
</ul></li>
<li>2017-07-06 CT - lung/pleura
<ul>
<li>Fracture of right clavicle, 4th-9th ribs with pneumothorax and
subcutaneous emphysema. Right hemothorax.</li>
<li>Gall stones (8-10mm).</li>
</ul></li>
<li>2017-04-21 Surgical pathology Level VI
<ul>
<li>pathological diagnosis
<ul>
<li>Large intestine, rectum, LAR — Adenocarcinoma, moderately
differentiated<br />
</li>
<li>Resection margins: Free of tumor</li>
<li>Lymph nodes, mesorectal, LAR — Metastatic adenocarcinoma
(4/34)<br />
</li>
<li>Liver, S7, S5 and S3, partial hepatectomy — Metastatic
adenocarcinoma (see path: S2017-05994)</li>
<li>Pathology stage: Stage IV (pT3N2aM1)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: Moderately differentiated</li>
<li>Depth of invasion: Perirectal soft tissue</li>
<li>Angiolymphatic invasion: Present; Extramural venous invasion:
Present<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 1.5 mm from
the margin</li>
<li>Lymph node metastasis, mesorectal: Metastatic adenocarcinoma
(4/34)</li>
<li>Extranodal involvement: Present<br />
</li>
</ul></li>
</ul></li>
<li>2017-04-21 Surgical pathology Level V
<ul>
<li>Liver, S7, S5, S3 &amp; S3, segmental hepatectomy + partial
hepatectomy — Metastatic adenocarcinoma, colorectal origin</li>
</ul></li>
<li>2017-04-18 M-mode Echo
<ul>
<li>Dilated LA and LV</li>
<li>Thick IVS and LVPW</li>
<li>Normal LV and RV contractility</li>
<li>LV Grade 1 diastolic dysfunction</li>
<li>Mild AR, mild MR</li>
</ul></li>
<li>2017-04-13 CT - abdomen
<ul>
<li>Rectal cancer with LNs and liver metastases</li>
<li>Cstage T3N2aM1a</li>
</ul></li>
<li>2017-04-06 Surgical pathology Level IV
<ul>
<li>Rectum, biopsy — Adenocarcinoma. IHC stain of EGFR (+).</li>
<li>IHC stains: PMS2 (+), MSH6 (+), using tissue block
(S2017-5995T1)</li>
</ul></li>
<li>2017-04-05 Colonoscopic polypectomy
<ul>
<li>Endoscopic examination of rectum and colon was done and the scope
has been inserted up to the level of cecum. One 8 mm Is polyp is noted
at A-colon 70 cm from anal verge, polypectomy done (A), another similar
lesion is seen at the 30 cm, polypectomy (B) done. An annular uclerative
tumor mass nearly occupying the whole circumferential lumen is noticed
at the rectum 7 cm to the anus, Bx done.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-05-20 Neurology
<ul>
<li>The patient presented with acute left limbs weakness with right side
deviation of gait since 3 days ago. He denied limbs numbness, slurred
speech, facial asymmetry.</li>
<li>Impression
<ul>
<li>recurrent right subcortical stroke or left cerebellar stroke</li>
</ul></li>
<li>Suggestion
<ul>
<li>Arrange MRA brain with/without contrast, EKG</li>
<li>Keep bokey</li>
<li>Normal saline Hydration</li>
<li>Keep SBP&lt;220 or DBP&lt;120 mmHg in acute stroke</li>
<li>Check D-dimer for rule out Trousseau’s syndrome.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimuunotherapy
<ul>
<li>2022-09-13 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-08-24 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-07-29 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-07-08 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-05-11 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-04-14 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-03-15 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-02-15 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-01-25 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2022-01-05 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-12-14 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-11-18 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-10-25 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-10-06 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-09-13 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-08-26 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-08-06 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-07-22 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-06-21 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-05-21 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-05-04 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-04-21 - bevacizumab 5mg/kg 300mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-03-31 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
<li>2021-03-04 - bevacizumab 5mg/kg 200mg 90min + irinotecan 120mg/m2
200mg 90min + leucovorin 300mg/m2 500mg 2hr + fluorouracil 300mg/m2
500mg 10min + fluorouracil 2400mg/m2 4000mg 46hr (Avastin + FOLFIRI,
Q2WK)</li>
</ul></li>
</ul>
<div id="section-338" class="section level3">
<h3>==========</h3>
</div>
<div id="section-339" class="section level3">
<h3>2022-09-14</h3>
<ul>
<li><p>CEA lab data</p>
<ul>
<li>2022-08-19 CEA 2066.02 ng/mL<br />
</li>
<li>2022-07-22 CEA 1882.44 ng/mL<br />
</li>
<li>2022-06-15 CEA 1801.03 ng/mL<br />
</li>
<li>2022-05-03 CEA 1288.14 ng/mL<br />
</li>
<li>2022-04-06 CEA 1470.23 ng/mL<br />
</li>
<li>2022-02-11 CEA 864.46 ng/mL<br />
</li>
<li>2021-12-28 CEA 740.59 ng/mL<br />
</li>
<li>2021-11-09 CEA 555.92 ng/mL<br />
</li>
<li>2021-09-29 CEA 525.75 ng/mL</li>
</ul></li>
<li><p>According to CT scan impressions, the disease had responded to
the current treatment (bevacizumab + FOLFIRI) introduced in early March
2021 and remains stable in the recent half year. However, CEA readings
have also increased over the past 12 months.</p></li>
<li><p>Upon confirmation that the disease has acquired resistance,
regorafenib might be considered as a subsequent treatment
option.</p></li>
<li><p>The underlying condition HTN appears to be well controlled during
this hospitalization. There are no updated hyperlipidemia lab results
available for the past two years that could be ordered if clinically
indicated.</p></li>
</ul>
</div>
<div id="section-340" class="section level3">
<h3>2022-04-15</h3>
<ul>
<li>Recent CT images (2021-08-25, 2022-01-07) showed partial resonses,
however lab data showed elevated biomarker levels (CEA 1470ng/mL
2022-04-06 from 525 2021-09-29, CA199 1087U/mL 2022-04-07 from 465
2021-08-19).</li>
<li>Current chemotherapy regimen, FOLFIRI plus bevacizumab, has been in
use since 2021-03-04 and it should be still effective according to above
mentioned exam results.</li>
<li>Lab results on 2022-04-06 concerning liver function, renal function,
serum electrolytes, and blood cell counts were grossly normal.</li>
<li>Hypertension is one of the underlying health conditions that is well
managed based on the TPR records during this hospital stay with the
prescribed Sevikar (amlodipine + olmesartan).</li>
<li>Hyperlipidemia is also listed as a diagnosis and treated with
Crestor (rosuvastatin) currently, however, there is no follow up lab
data for more than six months. It is recommended that a blood lipid test
be performed.</li>
</ul>
</div>
<div id="section-341" class="section level3">
<h3>2021-06-21</h3>
<p>[Rectal Cancer]</p>
<p>initial presentation</p>
<ul>
<li>2017-04-07 tenesmus with bloody stool for more than 1 year.</li>
</ul>
<p>definite diagnosis</p>
<ul>
<li>2017-04-07 diagnosed with rectal cancer.</li>
</ul>
<p>disease extent</p>
<ul>
<li>2017-04-14 proved adenocarcinoma of low rectum with right liver
metastasis, cT3N2M1a, stage IVa, suggest LAR with protective ileostomy
and partial hepatectomy.</li>
<li>2017-04-21 pT3N2aM1(4/34), stage IVa, with rectal anastomotic leak
s/p debridement. RAS WT.</li>
<li>2018-07-05 PET showed liver metastases and may peritoneal seeding,
stage IVb-c</li>
</ul>
<p>treatment</p>
<ul>
<li>2017-06-23 mFOLFOX6 started</li>
<li>2017-08-18 hold chemotherapy due to chest contusion injury and
cholecystitis</li>
<li>2017-11-07 closure of colostomy on 2017-10-19</li>
<li>2018-02-27 refused adjuvant therapy</li>
<li>2021-03-04 Avastin with FOLFIRI Q2WK started</li>
</ul>
<p>effect and side effect</p>
<ul>
<li>2018-06-26 CT showed suspected liver metastases</li>
<li>2018-06-28 small bowel obstruction to ER</li>
<li>2021-02-17 CT, ABD:
<ul>
<li>Multiple metastases on both hepatic lobes and the largest one
measuring 16.6 cm at S4 and residual right lobe.</li>
<li>Multiple metastatic nodes in the celiac trunk, hepatoduodenal
ligament, mesentery and para-aortic space.</li>
</ul></li>
<li>2021-05-20 CT, ABD:
<ul>
<li>Rectal cancer s/p operation. Right abdominal wall hernia. Mild
decreased size of liver and LNs metastases.</li>
</ul></li>
<li>CEA (ng/mL)
<ul>
<li>2021-05-19 2259</li>
<li>2021-04-26 1870</li>
<li>2021-03-29 3623</li>
<li>2021-01-29 3951</li>
</ul></li>
<li>CBC 2021-05-21 WBC, RBC, PLT all in acceptable range.</li>
</ul>
<p>ongoing problem</p>
<p><thrombosis></p>
<p>Objective:</p>
<ul>
<li>2019-10-24 CT, Brain: Brain atrophy with old left basal ganalia
lacunar brain infarcts. Arteriosclerosis.</li>
<li>2021-05-21 MRA, Brain:
<ul>
<li>No evidence of brain metastasis. Old ischemic insults. Intracranial
artherosclerosis. General brain atrophy.</li>
</ul></li>
<li>2021-05-20 D-dimer 1291ng/mL(FEU)</li>
<li>bokey (aspirin, 100mg QD) in active medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>biomarker hint increased probability of inappropriate blood
clots.</li>
<li>no related clinical symptom recorded.</li>
<li>Trousseau’s syndrome not been concluded yet.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>keep following up clinical signs indicating the syndrome.</li>
</ul>
<p><hypertension></p>
<p>Objective:</p>
<ul>
<li>BP 141/93 at 10:55 on 06-21 (this is the only record for now during
this hospitalization)</li>
<li>sevikar (amlodipine 20mg, olmesartan 5mg) 0.5 tab QD in active
medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>too few data points to tell the trend.</li>
<li>preliminary interpretation: BP still in acceptable range.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>keep monitor BP and collect more data points</li>
</ul>
<p><hyperlipdemia></p>
<p>Objective:</p>
<ul>
<li>Cholesterol total 110mg/dL (2020-07-08)</li>
<li>Triglyceride 51mg/dL (2020-07-08), 91mg/dL (2019-10-25)</li>
<li>crestor (rosuvastatin 10mg) QD in active medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>gathered data showed the stable condition.</li>
<li>no new lab data since 2020 Aug.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>update lab data.</li>
</ul>
</div>
</div>
</div>
<div id="section-342" class="section level1">
<h1>701432687</h1>
<div id="section-343" class="section level2">
<h2>220914</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-29 KUB
<ul>
<li>Post-op with metallic wire retention in upper abdomen.</li>
<li>No disernible calcification along bilateral urotracts based on this
study, suggest clinical correlation.</li>
</ul></li>
<li>2022-08-25 CT - abdomen
<ul>
<li>Indication
<ul>
<li>Adenocarcinoma of pancreas with peritoneal seeding, cT3NxM1, stage
IV s/p laparoscopic Op wt peritoneal tumor excision on 20220803 &amp;
s/p laparoscopic gastrojejunostomy on 20220624 at Taipei City Hospital
ZhongXing Branch.</li>
</ul></li>
</ul></li>
<li>2022-08-04 Patho - peritoneum biopsy
<ul>
<li>diagnosis
<ul>
<li>FsA: peritoneum 1, biopsy— Metastatic adenocarcinoma, moderately
differentiated</li>
<li>FsB: peritoneum 2, biopsy— Aggregation of foamy histiocytes with
focal metastatic adenocarcinoma</li>
</ul></li>
<li>microscopic description
<ul>
<li>A: Section shows fibroadipose tissue with metastatic moderately
differentiated adenocarcinoma. The immunohistochemical stains reveal
CK7(+), CK20(-), CDX2(focal +), WT-1(-), and Calretinin(focal weak +).
The results are consistent with pancreatic origin. Please correlate with
the clinical presentation and image study to exclude other origin.</li>
<li>B: Section shows fibroadipose tissue with aggregation of foamy
histicoytes and multinucleated giant cells. Focal metastatic moderately
differentiated adenocarcinoma is seen.</li>
</ul></li>
</ul></li>
<li>2022-08-03 Frozen Section
<ul>
<li>Preliminary diagnosis:
<ul>
<li>FsA: peritoneum 1, biopsy— Metastatic adenocarcinoma</li>
<li>FsB: peritoneum 2, biopsy— Aggregation of foamy histiocytes with
focal metastatic adenocarcinoma</li>
</ul></li>
</ul></li>
<li>2022-07-26 Upper GI series
<ul>
<li>UGI series revealed obstruction of duodenum, 3rd portion.</li>
</ul></li>
<li>2022-07-26 Patho- pancreas biopsy
<ul>
<li>Labeled as “pancreas”, clinically: 1.8 cm pancreatic uncinate
process mass on MRI, needle biopsy — bland pancreatic acinar tissue and
bland islet tissue. Please repeat biopsy.</li>
<li>IHC stains: CA19-9 (+), CK19 (+), synaptophysin (- to equivocal),
CD56 (- to equivocal), Ki-67: &lt;5%.</li>
</ul></li>
<li>2022-07-25 Endoscopic Ultrasonography, EUS
<ul>
<li>Pancreatic tumor, uncinate process, s/p EUS-FNA with ROSE</li>
<li>s/p gastroenterostomy</li>
</ul></li>
<li>2022-07-23 MRI - brain
<ul>
<li>No metastatic lesion over left cerebellar lobe.</li>
</ul></li>
<li>2022-07-21 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (75 - 25) / 75 = 66.67%</li>
<li>Adequate LV systolic function with normal resting wall motion</li>
<li>Dilated LA; LV diastolic dysfunction, Gr 1</li>
<li>Trivial MR, trivial TR and trivial PR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2022-07-20 Whole body PET scan
<ul>
<li>The pancreatic tumor at ucinate process shown on the previous
abdomen MRI reveals glucose hypermetabolism, and the nature is to be
determined (pancreatic head malignancy, lymphoma, or others ?),
suggesting biopsy for investigation.<br />
</li>
<li>Glucose hypermetabolism in the muscle layer of the right umbilical
region, the nature is to be determined also (post-traumatic change,
lymphoma, or others ?), suggesting biopsy for investigation.<br />
</li>
<li>Probably reactive nodes in the right mediastinum and bilateral
pulmonary hilar regions.</li>
<li>Inhomogenously increased FDG uptake in the left cerebellum, the
nature is to be determined (normal variants, lymphoma, or other nature
?). Please correlate with other clinical findings for further
evaluation.</li>
<li>Probably physiological uptake of FDG in the colon.</li>
</ul></li>
<li>2022-07-19 Flow volume loop
<ul>
<li>poor performance</li>
<li>mild restrictive ventilatory impairment</li>
</ul></li>
<li>2022-07-12 MRI - pancreas
<ul>
<li>History and indication:
<ul>
<li>Duodenum obstruction suspected P-head tumor</li>
<li>Addendum Imaging Report Form for Pancreatic Carcinoma</li>
<li>Impression (Imaging stage) : T:T1c(T_value) N:N0(N_value)
M:M0(M_value) STAGE:IA(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-07-11 Endoscopic Ultrasonography, EUS
<ul>
<li>Suspicious pancreatic head (uncinate process) tumor or duodenal
tumor with duodenal obstruction, s/p biopsy (A)</li>
<li>Enlarged major papilla, suspected tumor involvement, s/p biopsy
(B)</li>
<li>Suspect GB polyp</li>
<li>S/p gastrojejunostomy</li>
<li>GERD LA Gr.A</li>
</ul></li>
<li>2022-07-08 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
</ul></li>
<li>2022-07-08 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-08-03
<ul>
<li>Surgery
<ul>
<li>laparoscopic examination</li>
<li>excision of peritoneal tumor, malignancy</li>
</ul></li>
<li>Finding
<ul>
<li>ascites(-)</li>
<li>multiple small seeding tumors over right paracolic gutter, frozen
section: adenocarcinoma</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-13 - gemcitabine 700mg/m2 1000mg 30min + carboplatin AUC 4
200mg 2hr + fluorouracil 1500mg/m2 2000mg 46hr (Due to economic
difficulties, the self-paid FOLFIRINOX shifted to Gemzar + PF)</li>
<li>2022-08-24 - oxaliplatin 60mg/m2 90mg 2hr + irinotecan 150mg/m2
220mg 1.5hr + leucovorin 400mg/m2 590mg 2hr + fluorouracil 2400mg/m2
3500mg 46 (pre-Op neoadjuvant FOLFIRINOX, 5-FU initialized at a lower
dose)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li><p>Serum uric acid lab data</p>
<ul>
<li>2022-09-13 Uric Acid 10.1 mg/dL<br />
</li>
<li>2022-09-01 Uric Acid 9.0 mg/dL<br />
</li>
<li>2022-08-11 Uric Acid 4.8 mg/dL<br />
</li>
</ul></li>
<li><p>There is a history of gout in this patient, and his serum uric
acid level is elevated. One option might be to prescribe Feburic
(febuxostat 80mg) 0.5# QD for at least seven days.</p></li>
<li><p>Lab data: serum creatinine (2022-09-13 2.14 mg/dL &lt;-
2022-09-01 1.20 mg/dL), BUN (2022-09-13 39 mg/dL &lt;- 2022-09-01 23
mg/dL). The patient’s renal function is declining.</p></li>
<li><p>Male, age 58, 160cm, 45kg =&gt; BMI 17.6kg/m2, CrCl 24mL/min,
eGFR 32~38mL/min/1.73m2</p></li>
<li><p>As this patient is mildly thin, an increase in intake is
recommended in order to prevent malnutrition and build up some reserve
for future treatment.</p></li>
<li><p>The use of carboplatin has been associated with renal adverse
reactions, including decreased creatinine clearance (27%), and increased
blood urea nitrogen (14% to 22%). In the next chemotherapy cycle, it
might be an option to reduce the dose.</p></li>
</ul>
</div>
</div>
<div id="section-344" class="section level1">
<h1>701432850</h1>
<div id="section-345" class="section level2">
<h2>220914</h2>
<p>{not completed}</p>
<ul>
<li>exam finding
<ul>
<li>2022-09-12 CXR
<ul>
<li>Port-A catheter inserted its tip projecting over carina via left
subclavian vein.</li>
<li>enlarged cardiac silhoutte may be due to dilated cardiac chamber
(LAD) and prominent cardiophrenic angle mediastinal fat pad/ supine
position</li>
<li>Dilation of pulmonary trunk</li>
<li>Rt and Lt subpulmonary effusion</li>
<li>hazy increased opacities over both lungs with poor defination of
perihilar and lower lobes vessels</li>
</ul></li>
<li>2022-09-08 Visceral Angiography over 2 vessels
<ul>
<li>DSA of celiac trunk, SMA and IMA via right common femoral artery
puncture revealed:
<ul>
<li>A tumor stain at splenic flexure of colon.</li>
<li>No evidence of active bleeding.</li>
</ul></li>
</ul></li>
<li>2022-09-08 CXR
<ul>
<li>Port-A catheter inserted its tip projecting over carina via left
subclavian vein.</li>
<li>enlarged cardiac silhoutte may be due to dilated cardiac chamber
(LAD) and prominent cardiophrenic angle mediastinal fat pad/ supine
position</li>
<li>Dilation of pulmonary trunk</li>
<li>Rt and Lt subpulmonary effusion</li>
<li>reticular opacities over both lungs</li>
<li>Elevation of both hemidiaphragms</li>
</ul></li>
<li>2022-09-07 Patho - colon biopsy
<ul>
<li>Colorectum, splenic flexure, biopsy — Adenocarcinoma.</li>
</ul></li>
<li>2022-09-06 CXR
<ul>
<li>appropriately positioned gastric tube</li>
<li>Port-A catheter inserted its tip projecting over carina via left
subclavian vein.</li>
<li>Thoracic aortic arch calcified atheriosclerotic plaque</li>
<li>enlarged cardiac silhoutte may be due to dilated cardiac chamber
(LAD) and prominent cardiophrenic angle mediastinal fat pad/ supine
position</li>
<li>Dilation of pulmonary trunk</li>
<li>Rt and Lt subpulmonary effusion</li>
<li>reticular opacities over both lungs may be due to interstitial lung
edema</li>
</ul></li>
<li>2022-09-06 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (111 - 41.6) / 111 = 62.52%</li>
<li>Thickened AV with mild AR</li>
<li>Normal MV with mild MR</li>
<li>Concentric LVH, normal LV wall motion</li>
<li>Preserved LV and RV systolic function</li>
<li>Mild PR, mild TR, normal IVC size</li>
<li>Moderate pulmonary hypertension</li>
</ul></li>
<li>2022-09-05 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific T wave abnormality</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-09-05 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Prominence of bilateral hilar shadows are noted, which may be
engorged central pulmonary vessels or adenopathy, please correlate
clinically and follow-up.</li>
<li>Linear infiltration over right and left lower lung zone is noted.
please correlate with clinical symptom to rule out inflammatory
process.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
</ul></li>
<li>2022-08-06 SONO - Nephrology
<ul>
<li>No significant abnormality from echography for both kidneys</li>
<li>Urinary retention, suspected neurogenic bladder</li>
</ul></li>
<li>2022-07-19 SONO - chest
<ul>
<li>Bilateral thorax: minimal amount pleural effusion; thoracocentesis
was not performed due to high risk of complications.</li>
</ul></li>
<li>2022-07-18 SONO - abdomen
<ul>
<li>parenchymal renal disease, both</li>
<li>pleural effusion, bilateral</li>
</ul></li>
<li>2022-07-15 CT - lung
<ul>
<li>Findings
<ul>
<li>Diffuse nodularity at bilateral upper lobes is found. suspected
colon cancer meta.</li>
<li>Increased pulmonary vasculature is found.</li>
<li>Patent airway is found.</li>
<li>There is no evidence of mediastinal LAP</li>
<li>There is moderate bilateral pleural effusion.</li>
<li>Extensive bilateral chest wall soft tissue swelling is found.
suspected hypoalbuminemia related.</li>
</ul></li>
<li>Imp:
<ul>
<li>Diffuse nodularity at bilateral upper lobes is found. suspected
colon cancer meta.</li>
<li>Bilateral moderate pleural effusion and chest wall swelling is
found.</li>
</ul></li>
</ul></li>
<li>2022-07-14 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion in the left upper abdomen. Colon
malignancy near the splenic flexure should be watched out. Please
correlate with other clinical findings for further evaluation.</li>
<li>A glucose hypermetabolic lesion in the midline pelvic region about
sigmoid colon. The nature is to be determined (inflammatory process?
malignancy? other nature?). Please also correlate with other clinical
findings for further evaluation.</li>
<li>Increased FDG uptake in bilateral neck muscles. Physiological FDG
uptake is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2022-07-12 Patho - colorectal polyp
<ul>
<li>Colon, transverse, biopsy — Adenocarcinoma.</li>
<li>IHC stains: EGFR (+); PMS2 (loss), MSH6 (+), MSH2(+), MLH1
(loss).</li>
</ul></li>
<li>2022-07-11 Colonoscopy
<ul>
<li>Probable colon cancer with partial obstruction, proximal T colon,
s/p biopsy(A)</li>
<li>Suspect colon polyp with focal malignant change, Paris
classification 0-Ip, RS junction, s/p biopsy(B)</li>
<li>S/p right hemicolectomy</li>
</ul></li>
<li>2022-07-08 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific T wave abnormality</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-12 Cardiology
<ul>
<li>Q
<ul>
<li>For adjusted BP medication</li>
<li>This 60 years old female patient had underlying history of DM,
hypertension, CHF, CKD stage 5, Right distal foot wet gangrene with
local heat s/p BK and Colon cancer under chemotherapy.</li>
<li>Hospitalization, shock status with bleeding tedency. transferred to
ICU for monitoring.</li>
<li>During ICU course, anti-hypertensive agents are combine with to
control BP. however, Blood pressure are out of control.</li>
<li>We need your spcecialist to adjusted BP medication. Thanks.</li>
</ul></li>
<li>A
<ul>
<li>For this patient, the present treatment have reaches to maximal dose
of anti-HTN agents</li>
<li>only catapress 1 bid can be used for BP control</li>
<li>For dilysis patient, some patient has intractable hypertension
despite of current regimen</li>
<li>You can ask nephrologist to increase the ultrafiltration amount,
which might contribute the BP lowering effect</li>
<li>The target BP is set as 140-150 mmHg</li>
<li>If all treatment is effective, you will ask patient or family to buy
minoxidil. minoxidil is relatively powerful for BP control.</li>
</ul></li>
</ul></li>
<li>2022-09-09 Radiation Oncology
<ul>
<li>Q
<ul>
<li>passage bloody stool around 210g suspected tumor bleeding, so we
need your help for evaluation. Thanks!!</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings,
angiography is indicated.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<p><hypertension></p>
<ul>
<li><p>The patient’s blood pressure has been around 190(+-10)/90(+-10),
despite taking the following antihypertensive agents as part of the
active prescription:</p>
<ul>
<li>Chenday (labetalol 25mg) 0.5# PRNQ12H</li>
<li>Apresoline (hydralazine 50mg) 1# Q6H</li>
<li>Sevikar (amlodipine 5mg + olmesartan 20mg) 1# BID</li>
<li>Doxaben (doxazosin 4mg) 1# Q12H</li>
<li>Syntrend (carvedilol 25mg) 1# BID</li>
</ul></li>
<li><p>Clonidine can be used for chronic hypertension as an alternative
agent. It is not recommended for initial management but may be
considered as additional therapy for resistant hypertension in patients
who do not respond adequately to combination therapy with preferred
agents (ACC/AHA [Whelton 2018]). We have in stock Catapres (clonidine
0.075mg) currently. Oral form immediate release: Initial 0.1 mg twice
daily; increase dose in increments of 0.1 mg/day at weekly intervals
based on response and tolerability; usual dose range: 0.2 to 0.6 mg/day
in 2 divided doses. The manufacturer’s labeling includes a maximum daily
dose of 2.4 mg; however, doses &gt;0.6 mg/day are generally not
used.</p></li>
<li><p>In an alternative attempt to lower the blood pressure, currently
used Sevikar might also be replaced with Adapine (nifedipine 30mg) 1#
BID and Micardis (telmisartan 80mg) 1# QD.</p></li>
<li><p>Minoxidil (not available in stock) can also act as an alternative
adjunctive agent. It should be reserved for patients with resistant
hypertension who do not respond adequately to an optimized 4-drug
regimen, ideally consisting of a thiazide-like diuretic (eg,
chlorthalidone) and a mineralocorticoid-receptor antagonist (eg,
spironolactone). It can be used in combination with a beta-blocker to
prevent reflex tachycardia. Fluid retention may occur and may require
additional diuretic therapy (ACC/AHA [Whelton 2018]; Brook 2022). Oral
form initial: 5 mg once daily, increase dose gradually in intervals of
&gt;= 3 days; usual effective dose: 10 to 40 mg/day in 1 to 3 divided
doses; maximum dose: 100 mg/day in 1 to 3 divided doses. During therapy,
if supine diastolic pressure is reduced &lt;30 mm Hg, administer total
daily dose once daily; if supine diastolic pressure is reduced &gt;30 mm
Hg, administer in divided doses (ACC/AHA [Whelton 2018]; manufacturer’s
labeling).</p></li>
</ul>
</div>
</div>
<div id="section-346" class="section level1">
<h1>701207878</h1>
<div id="section-347" class="section level2">
<h2>220913</h2>
<p>{MDS, RAEB-1}</p>
<ul>
<li>present illness
<ul>
<li>This 29-year-old man with past history of PMH of depression,
insomnia, acute pancreatitis s/p treatment, GERD. His last dose of COVID
vaccination was AZ in November 2021.</li>
<li>He was admitted due to chest pain and chest tightness which then
accidently discovered thrombocytopenia and anemia on 20220217.</li>
</ul></li>
<li>past history
<ul>
<li>acute pancreatitis</li>
<li>GERD</li>
<li>depression, insomnia</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-14 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, post iliac creast, biopsy — Refractory anemia with
excess blasts (RAEB-1)</li>
<li>Microscopically, the bone marrow shows hypercellularity with
hemopoietic components accounting for about 80~90% of the marrow space,
and M/E ration of 2-3:1. Megakaryocytes are midly increased in quantity.
Focal excess of blast (5%-9%) is noted and highlighted by CD117 and
CD34.</li>
<li>Immunohistochemical stain reveals MPO(+), CD71(+), CD138(&lt;3%),
CD20(&lt;5%), CD10(focal+), TdT(-) and CD68(diffuse +).</li>
<li>NOTE: Please correlate with flowcytometry, peripheral blood and
molecular cytogenetic study.</li>
</ul></li>
<li>2022-02-17 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Compatible with myelodysplastic syndrome.</li>
<li>The sections show hypercellular marrow (90%). The M/E ratio = 2:1.
Erythroid hyperplasia with megaloblastoid changes in CD71 stain. The
megakaryocyte is slightly decreased in number and a few small
megakaryocytes can be found. The MPO+ myeloid cells shows left shift and
scattered immature myeloid cells in interstitium are present. An
increase in CD68+ monocytes (10%), no CD34+ blasts, and increased CD117+
immature cells constitue 20% of marrow cells are evident. The finding is
compatible with myelodysplastic syndrome. Suggest bone marrow smear
evaluation and clinic correlation.</li>
</ul></li>
<li>2020-12-17 CT - abdomen, pelvis
<ul>
<li>Grade C pancreatitis.</li>
<li>Grade 4 fatty liver.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-06-13
<ul>
<li>EB VCA IgG Positive Ratio<br />
</li>
<li>EB VCA IgG Value 5.6 Ratio<br />
</li>
<li>VZV IgG Positive Index<br />
</li>
<li>VZV-G Value 2.7 Index<br />
</li>
</ul></li>
<li>2022-06-10
<ul>
<li>RPR/VDRL Nonreactive<br />
</li>
</ul></li>
<li>2022-06-10
<ul>
<li>CMV_IgG Reactive<br />
</li>
<li>CMV_IgG Value 179.4 AU/mL<br />
</li>
<li>CMV IgM Nonreactive<br />
</li>
<li>CMV IgM Value 0.16 Index<br />
</li>
<li>HIV Ab-EIA Nonreactive<br />
</li>
<li>Anti-HIV Value 0.05 S/CO<br />
</li>
<li>Anti HTLV I/II Nonreactive<br />
</li>
<li>Anti HTLV I/II Value 0.08 S/CO<br />
</li>
</ul></li>
<li>2022-04-15
<ul>
<li>HLA A-high rsolution 11:01</li>
<li>HLA A-high rsolution -<br />
</li>
<li>HLA B-high rsolution 13:01</li>
<li>HLA B-high rsolution 35:01</li>
<li>HLA C-high rsolution 03:03</li>
<li>HLA C-high rsolution 03:04</li>
<li>HLA DR-high rsolution 09:01</li>
<li>HLA DR-high rsolution 14:05</li>
</ul></li>
<li>2022-03-04
<ul>
<li>JAK2-single site mutation Undetectable<br />
</li>
<li>FLT3-D835 mutation Undetectable<br />
</li>
</ul></li>
<li>2022-03-03
<ul>
<li>BCR/abl Undetectable</li>
</ul></li>
<li>2022-02-24
<ul>
<li>FLT3/ITD mutation Undetectable<br />
</li>
<li>NPM1 mutation Undetectable<br />
</li>
<li>ANA Negative<br />
</li>
</ul></li>
<li>2022-02-23
<ul>
<li>LA1 35.2 sec<br />
</li>
<li>LA2 34.7 sec<br />
</li>
<li>LA1/LA2 ratio 1.0<br />
</li>
<li>Anti-ds DNA Antibody &lt;0.5 IU/ml<br />
</li>
<li>Anti-ENA Sm 0.7 EliA U/ml<br />
</li>
<li>Anti-ENA RNP &lt;0.3 EliA U/ml<br />
</li>
<li>Anti-Cardiolopin IgG &lt;0.5 GPL-U/mL<br />
</li>
<li>Anti-cardiolipin IgM 2.0 MPL U/mL<br />
</li>
<li>Anti-β2-glycoprotein-I Ab &lt;0.6 U/mL<br />
</li>
<li>RF &lt;10 IU/mL<br />
</li>
<li>C3 135.1mg/dL<br />
</li>
<li>C4 30.8 mg/dL<br />
</li>
<li>Direct Coomb Test Negative</li>
<li>Indirect Coomb Test Negative</li>
</ul></li>
<li>2022-02-18
<ul>
<li>MPO stain Positive(3+)<br />
</li>
<li>CAE stain Positive<br />
</li>
<li>ANAE stain Negtive<br />
</li>
<li>CD2 NA<br />
</li>
<li>CD3 0.38<br />
</li>
<li>CD4 NA<br />
</li>
<li>CD5 0.32<br />
</li>
<li>CD7 48.01</li>
<li>CD8 NA<br />
</li>
<li>CD10 1.24<br />
</li>
<li>CD11b 20.93</li>
<li>CD13 93<br />
</li>
<li>CD14 1.14<br />
</li>
<li>CD15 NA<br />
</li>
<li>CD16 4.2<br />
</li>
<li>CD19 11.63</li>
<li>CD19/kappa NA<br />
</li>
<li>CD19/Lambda NA<br />
</li>
<li>CD20 0<br />
</li>
<li>CD23 NA<br />
</li>
<li>CD25 NA<br />
</li>
<li>CD33 99<br />
</li>
<li>CD34 2.11<br />
</li>
<li>CD38 NA<br />
</li>
<li>CD56 0.06<br />
</li>
<li>CD103 NA<br />
</li>
<li>CD117 72.82</li>
<li>CD138 NA<br />
</li>
<li>FMC7 NA<br />
</li>
<li>HLA-DR 91.75</li>
<li>MPO NA<br />
</li>
<li>TdT NA<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.38 S/CO<br />
</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.08 S/CO<br />
</li>
<li>Anti-HBc Nonreactive<br />
</li>
<li>Anti-HBc-Value 0.11 S/CO<br />
</li>
<li>Anti-HBc IgM Nonreactive<br />
</li>
<li>Anti-HBc IgM Value 0.10 S/CO<br />
</li>
<li>Anti-HBs 0.00 mIU/mL</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-15 ~ undergoing - azacitidine</li>
</ul></li>
</ul>
<div id="section-348" class="section level3">
<h3>==========</h3>
</div>
<div id="section-349" class="section level3">
<h3>2022-09-13</h3>
<ul>
<li>Time serial serum creatinine, cyclosporine trough concentration and
cyclosporine daily dose log:
<ul>
<li>Date // cre // trough // cyclosporine daily dose</li>
<li>2022-09-12 1.83 163.7 200mg = 100mg 1# BID, PO</li>
<li>2022-09-11 200mg = 100mg 1# BID, PO</li>
<li>2022-09-10 200mg = 100mg 1# BID, PO</li>
<li>2022-09-09 1.41 200mg = 100mg 1# BID, PO</li>
<li>2022-09-08 200mg = 100mg 1# BID, PO</li>
<li>2022-09-07 1.20 200mg = 100mg 1# BID, PO</li>
<li>2022-09-06 200mg = 100mg 1# BID, PO</li>
<li>2022-09-05 1.11 193.8 200mg = 100mg 1# BID, PO</li>
<li>2022-09-04 200mg = 100mg 1# BID, PO</li>
<li>2022-09-03 200mg = 100mg 1# BID, PO</li>
<li>2022-09-02 200mg = 100mg 1# BID, PO</li>
<li>2022-09-01 69.1 200mg = 100mg 1# QD + 100mg 1# BID first dose,
PO</li>
<li>2022-08-31 0.94 50mg = 25mg 2# QD, PO</li>
<li>2022-08-30 50mg = 25mg 2# QD, PO</li>
<li>2022-08-29 0.93 50mg = 25mg 2# QD, PO</li>
<li>2022-08-28 50mg = 25mg 2# QD, PO</li>
<li>2022-08-27 50mg = 25mg 2# QD, PO</li>
<li>2022-08-26 1.22 50mg = 25mg 2# QD, PO</li>
<li>2022-08-01 109.6 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-31 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-30 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-29 0.68 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-28 0.74 118.3 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-27 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-26 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-25 0.85 126.9 100mg = 100mg 1# QD, PO</li>
<li>2022-07-24 100mg = 100mg 1# QD, PO</li>
<li>2022-07-23 0.83 100mg = 100mg 1# QD, PO</li>
<li>2022-07-22 100mg = 100mg 1# QD, PO</li>
<li>2022-07-21 0.77 487.1 200mg = 100mg 1# BID, PO</li>
<li>2022-07-20 200mg = 100mg 1# BID, PO</li>
<li>2022-07-19 200mg = 100mg 1# BID, PO</li>
<li>2022-07-18 0.82 220.0 200mg = 200mg QD, IVD</li>
<li>2022-07-17 200mg = 200mg QD, IVD</li>
<li>2022-07-16 200mg = 200mg QD, IVD</li>
<li>2022-07-15 0.73 162.0 200mg = 200mg QD, IVD</li>
<li>2022-07-14 200mg = 200mg QD, IVD</li>
<li>2022-07-13 0.71 200mg = 200mg QD, IVD</li>
<li>2022-07-12 200mg = 200mg QD, IVD</li>
<li>2022-07-11 0.80 172.6 200mg = 200mg QD, IVD</li>
<li>2022-07-10 200mg = 200mg QD, IVD</li>
<li>2022-07-09 200mg = 200mg QD, IVD</li>
<li>2022-07-08 0.67 200mg = 200mg QD, IVD</li>
<li>2022-07-07 82.7 180mg = 180mg QD, IVD</li>
<li>2022-07-06 180mg = 180mg QD, IVD</li>
<li>2022-07-05 150mg = 150mg QD, IVD</li>
<li>2022-07-04 0.65 77.0 150mg = 150mg QD, IVD</li>
<li>2022-07-03 150mg = 150mg QD, IVD</li>
<li>2022-07-02 150mg = 150mg QD, IVD</li>
<li>2022-07-01 0.59 130mg = 130mg QD, IVD</li>
<li>2022-06-30 130mg = 130mg QD, IVD</li>
<li>2022-06-29 0.56 130mg = 130mg QD, IVD</li>
<li>2022-06-28 130mg = 130mg QD, IVD</li>
</ul></li>
</ul>
</div>
<div id="section-350" class="section level3">
<h3>2022-09-07</h3>
<ul>
<li><p>Alprazolam is metabolized by the enzyme CYP3A4 and the antifungal
drugs itraconazole, ketoconazole, posaconazole, and voriconazole are
strong inhibitors of this enzyme, which can increase the serum
concentration of alprazolam.</p></li>
<li><p>Each member of the azole class exhibits a unique spectrum of
activity, although fluconazole, itraconazole, voriconazole,
posaconazole, and isavuconazole all demonstrate similar activity against
most Candida species. (ref: Pappas PG, et al. Clinical Practice
Guideline for the Management of Candidiasis: 2016 Update by the
Infectious Diseases Society of America. Clin Infect Dis.
2016;62(4):e1-e50. <a href="doi:10.1093/cid/civ933" class="uri">doi:10.1093/cid/civ933</a> )</p></li>
<li><p>While fluconazole is a less strong (i.e. moderate) CYP3A4
inhibitor than voriconazole, it might be a suitable substitute for
voriconazole if no other considerations are taken into account.
Additionally, a change from 2# to 1# of alprazolam might also be
considered.</p></li>
</ul>
</div>
<div id="section-351" class="section level3">
<h3>2022-09-06</h3>
<ul>
<li><p>On 2022-09-05, blood was drawn about one hour before the time of
administration for cyclosporine TDM. It is recommended that blood be
drawn within half an hour of the time of administration. As of the
latest monitoring result, the level is 193.8 ng/mL, which is generally
considered to be within the reasonable range (100 to 400 ng/mL). Based
on changes in serum creatinine, renal function appears to be slowly
declining (but still within normal range). It might take less time to
achieve a concentration greater than 400ng/mL by consecutive daily doses
of 200mg than it did in mid-July. A retest is recommended after three
days to determine if the dose should be adjusted.</p></li>
<li><p>Time serial serum creatinine, cyclosporine trough concentration
and cyclosporine daily dose log:</p>
<ul>
<li>Date // cre // trough // cyclosporine daily dose</li>
<li>2022-09-06 200mg = 100mg 1# BID, PO</li>
<li>2022-09-05 1.11 193.8 200mg = 100mg 1# BID, PO</li>
<li>2022-09-04 200mg = 100mg 1# BID, PO</li>
<li>2022-09-03 200mg = 100mg 1# BID, PO</li>
<li>2022-09-02 200mg = 100mg 1# BID, PO</li>
<li>2022-09-01 69.1 200mg = 100mg 1# QD + 100mg 1# BID first dose,
PO</li>
<li>2022-08-31 0.94 50mg = 25mg 2# QD, PO</li>
<li>2022-08-30 50mg = 25mg 2# QD, PO</li>
<li>2022-08-29 0.93 50mg = 25mg 2# QD, PO</li>
<li>2022-08-28 50mg = 25mg 2# QD, PO</li>
<li>2022-08-27 50mg = 25mg 2# QD, PO</li>
<li>2022-08-26 1.22 50mg = 25mg 2# QD, PO</li>
<li>2022-08-01 109.6 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-31 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-30 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-29 0.68 150mg = 100mg 1# QD + 25mg 1# BID, PO</li>
<li>2022-07-28 0.74 118.3 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-27 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-26 125mg = 100mg 1# QD + 25mg 1# QD, PO</li>
<li>2022-07-25 0.85 126.9 100mg = 100mg 1# QD, PO</li>
<li>2022-07-24 100mg = 100mg 1# QD, PO</li>
<li>2022-07-23 0.83 100mg = 100mg 1# QD, PO</li>
<li>2022-07-22 100mg = 100mg 1# QD, PO</li>
<li>2022-07-21 0.77 487.1 200mg = 100mg 1# BID, PO</li>
<li>2022-07-20 200mg = 100mg 1# BID, PO</li>
<li>2022-07-19 200mg = 100mg 1# BID, PO</li>
<li>2022-07-18 0.82 220.0 200mg = 200mg QD, IVD</li>
<li>2022-07-17 200mg = 200mg QD, IVD</li>
<li>2022-07-16 200mg = 200mg QD, IVD</li>
<li>2022-07-15 0.73 162.0 200mg = 200mg QD, IVD</li>
<li>2022-07-14 200mg = 200mg QD, IVD</li>
<li>2022-07-13 0.71 200mg = 200mg QD, IVD</li>
<li>2022-07-12 200mg = 200mg QD, IVD</li>
<li>2022-07-11 0.80 172.6 200mg = 200mg QD, IVD</li>
<li>2022-07-10 200mg = 200mg QD, IVD</li>
<li>2022-07-09 200mg = 200mg QD, IVD</li>
<li>2022-07-08 0.67 200mg = 200mg QD, IVD</li>
<li>2022-07-07 82.7 180mg = 180mg QD, IVD</li>
<li>2022-07-06 180mg = 180mg QD, IVD</li>
<li>2022-07-05 150mg = 150mg QD, IVD</li>
<li>2022-07-04 0.65 77.0 150mg = 150mg QD, IVD</li>
<li>2022-07-03 150mg = 150mg QD, IVD</li>
<li>2022-07-02 150mg = 150mg QD, IVD</li>
<li>2022-07-01 0.59 130mg = 130mg QD, IVD</li>
<li>2022-06-30 130mg = 130mg QD, IVD</li>
<li>2022-06-29 0.56 130mg = 130mg QD, IVD</li>
<li>2022-06-28 130mg = 130mg QD, IVD</li>
</ul></li>
</ul>
</div>
<div id="section-352" class="section level3">
<h3>2022-07-29</h3>
<p>[recommended cyclosporine daily dose to maintain a stable and
reasonable trough concentration]</p>
<ul>
<li>Time serial cyclosporine daily dose and its trough concentration
log:
<ul>
<li>Date // trough conc ng/mL // cyclosporine daily dose mg</li>
<li>2022-07-29 200mg ~ 100mg BID</li>
<li>2022-07-28 118.3 100mg ~ 100mg QD</li>
<li>2022-07-27 100mg ~ 100mg QD</li>
<li>2022-07-26 100mg ~ 100mg QD</li>
<li>2022-07-25 126.9 100mg ~ 100mg QD</li>
<li>2022-07-24 100mg ~ 100mg QD</li>
<li>2022-07-23 100mg ~ 100mg QD</li>
<li>2022-07-22 100mg ~ 100mg QD</li>
<li>2022-07-21 487.1 200mg ~ 100mg BID</li>
<li>2022-07-20 200mg ~ 100mg BID</li>
<li>2022-07-19 200mg ~ 100mg BID</li>
<li>2022-07-18 220.0 200mg ~ 200mg QD</li>
<li>2022-07-17 200mg ~ 200mg QD</li>
<li>2022-07-16 200mg ~ 200mg QD</li>
<li>2022-07-15 162.0 200mg ~ 200mg QD</li>
<li>2022-07-14 200mg ~ 200mg QD</li>
<li>2022-07-13 200mg ~ 200mg QD</li>
<li>2022-07-12 200mg ~ 200mg QD</li>
<li>2022-07-11 172.6 200mg ~ 200mg QD</li>
<li>2022-07-10 200mg ~ 200mg QD</li>
<li>2022-07-09 200mg ~ 200mg QD</li>
<li>2022-07-08 200mg ~ 200mg QD</li>
<li>2022-07-07 82.7 180mg ~ 180mg QD</li>
<li>2022-07-06 180mg ~ 180mg QD</li>
<li>2022-07-05 150mg ~ 150mg QD</li>
<li>2022-07-04 77.0 150mg ~ 150mg QD</li>
<li>2022-07-03 150mg ~ 150mg QD</li>
<li>2022-07-02 150mg ~ 150mg QD</li>
<li>2022-07-01 130mg ~ 130mg QD</li>
<li>2022-06-30 130mg ~ 130mg QD</li>
<li>2022-06-29 130mg ~ 130mg QD</li>
<li>2022-06-28 130mg ~ 130mg QD</li>
</ul></li>
<li>According to the above records, 175 mg per day is more likely to
maintain a trough concentration within a reasonable and relatively
stable range.</li>
</ul>
</div>
<div id="section-353" class="section level3">
<h3>2022-07-22</h3>
<p>[cyclosporine concentration]</p>
<ul>
<li>On 2022-07-21, the cyclosporine trough concentration in this patient
reached a record high of 487 ng/mL, which is generally considered to be
above the normal range.</li>
<li>The following adverse reactions and incidences have been reported
with systemic use of the drug. Percentages indicate the highest
frequency, regardless of indication or dosage. Monitoring these signs
might be helpful.
<ul>
<li>Cardiovascular: Hypertension (13% to 53%)</li>
<li>Endocrine &amp; metabolic: Hirsutism (21% to 45%)</li>
<li>Gastrointestinal: Gingival hyperplasia (4% to 16%)</li>
<li>Genitourinary: Urinary tract infection (21%)</li>
<li>Infection: Viral infection (16%)</li>
<li>Nervous system: Headache (2% to 15%)</li>
<li>Neuromuscular &amp; skeletal: Tremor (21% to 55%)</li>
<li>Renal: Nephrotoxicity (25% to 38%)</li>
</ul></li>
<li>In the hospital, capsules containing 100mg and 25mg are
available.</li>
<li>The recommended dose for oral administration is 100mg for one day
followed by 150mg (100mg + 2 x 25mg) for the next two or three days,
followed by another TDM to determine whether it is necessary to titrate
the dose up to 175mg per day.</li>
</ul>
</div>
<div id="section-354" class="section level3">
<h3>2022-07-19</h3>
<p>[cyclosporine trough concentration]</p>
<ul>
<li>A trough concentration of 220 ng/mL of cyclosporine was observed on
2022-07-18, which is considered adequate; however, the concentration
momentum remains upward.</li>
</ul>
</div>
<div id="section-355" class="section level3">
<h3>2022-07-15</h3>
<p>[post-transplant immunization</p>
<ul>
<li>Hematopoietic cell transplant (HCT) recipients should be immunized
against a number of pathogens such as pneumococcus, Haemophilus
influenzae, tetanus, and others once they are likely to mount an immune
response.</li>
<li>Most live virus vaccines are avoided altogether during the first 24
months following HCT.</li>
<li>Certain ones (eg, measles, mumps, and rubella vaccine) are indicated
24 months following HCT in patients who do not have active
graft-versus-host disease and who are not receiving immunosuppressive
agents.</li>
</ul>
<p>[cyclosporine trough concentration]</p>
<p>As of 2022-07-14, the trough concentration of cyclosporine was 162
ng/mL, which is considered to be an acceptable level.</p>
</div>
<div id="section-356" class="section level3">
<h3>2022-07-13</h3>
<p>[Cyclosporine trough concentration follow-up]</p>
<ul>
<li>Cyclosporine trough concentration on 2022-07-11 reached 172.6 ng/mL,
which was within the range of 100 to 400 ng/mL where the majority of
individuals demonstrate optimal responses.</li>
</ul>
</div>
<div id="section-357" class="section level3">
<h3>2022-07-08</h3>
<p>[Cyclosporine (ciclosporin) concentration]</p>
<ul>
<li>There appears to have been an error in entering the time of blood
collection as 2022-07-07 00:00 by the system, and the concentration of
ciclosporin was recorded as 82.7 ng/mL.</li>
<li>Ciclosporin has been titrated up to 200 mg per day (2020-07-05 09:15
150mg, 2020-07-06 09:17 180mg, 2020-07-07 09:14 180mg, 2020-07-08 08:38
200mg).</li>
<li>It should be expected that the new dose (200 mg QD) will reach a
steady state at blood levels of more than to 100 ng/mL. This can be
checked next Monday (2022-07-11) by TDM.</li>
</ul>
</div>
<div id="section-358" class="section level3">
<h3>2022-07-07</h3>
<p>[cyclosporine trough concentration]</p>
<ul>
<li>Most individuals display optimal response to cyclosporine with
trough whole blood levels 100 to 400 ng/mL. The trough concentration on
2022-07-04 was 77 ng/mL with 150mg IVD administered each day. Please
recheck the clinical response to determine if dosage needs to be
adjusted.</li>
</ul>
</div>
<div id="section-359" class="section level3">
<h3>2022-06-14</h3>
<p>Dosage of ATG as part of the conditioning regimen in allogeneic PBSCT
from matched sibling donors in patients with hematologic
malignancies</p>
<ul>
<li>As can be seen, 4.5~6mg/kg of ATG was used in allogeneic PBSCT from
siblings who had been matched, specifically:
<ul>
<li>ATG plus CsA, MTX, and MMF for GVHD prophylaxis with the following
details: 3 mg/kg CsA continuous intravenous drip, started on day 21,
changed to orally when GI function recovered with a dose of 5 mg/kg
administered as 2 divided doses, and CsA trough concentration maintained
at 200-300 ng/mL; 15 mg/m2 MTX on day 1 and 10 mg/m2 MTX on days 3, 6,
and 11; 0.25 g MMF twice a day, starting on day 21 and continuing to day
30 for 1 month; and 4.5 mg/kg ATG divided in day 23, day 22, and day 21.
<ul>
<li>ref: Antithymocyte Globulin for Matched Sibling Donor
Transplantation in Patients With Hematologic Malignancies: A
Multicenter, Open-Label, Randomized Controlled Study. <a href="https://pubmed.ncbi.nlm.nih.gov/32650683/" class="uri">https://pubmed.ncbi.nlm.nih.gov/32650683/</a></li>
<li>ref: Antithymocyte Globulin for Matched Sibling Donor
Transplantation in Patients With Hematologic Malignancies (letter to the
editor). <a href="https://pubmed.ncbi.nlm.nih.gov/33104439/" class="uri">https://pubmed.ncbi.nlm.nih.gov/33104439/</a></li>
</ul></li>
<li>rATG was administered to 40 patients at an intravenous dose of 5
mg/kg divided over day 5 and day 4 before graft infusion.
<ul>
<li>ref: Reduced risk of chronic GVHD by low-dose rATG in adult matched
sibling donor peripheral blood stem cell transplantation for hematologic
malignancies. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944670/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944670/</a></li>
</ul></li>
<li>an ATG dose &lt;6 mg/kg is sufficient for GVHD prophylaxis, while
higher doses impair disease control and outcome.
<ul>
<li>ref: Impact of antithymocyte globulin doses in reduced intensity
conditioning before allogeneic transplantation from matched sibling
donor for patients with acute myeloid leukemia: a report from the acute
leukemia working party of European group of Bone Marrow Transplantation.
<a href="https://pubmed.ncbi.nlm.nih.gov/29330391/" class="uri">https://pubmed.ncbi.nlm.nih.gov/29330391/</a></li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="section-360" class="section level3">
<h3>2022-05-19</h3>
<ul>
<li>This 29-year-old male was diagnosed with MDS, RAEB-1 during Feb, Mar
2022 and has been receiving azacitidine since April 2022.</li>
<li>There is also a possibility of acute leukemia, the patient has been
admitted for further evaluation.</li>
<li>The underlying diseases are treated with corresponding drugs. No
issue with current medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-361" class="section level1">
<h1>700065931</h1>
<div id="section-362" class="section level2">
<h2>220912</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-09 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-09-09 Neck soft tissue
<ul>
<li>Increased prevertebral soft tissu thickness. Please correlate with
CT.</li>
</ul></li>
<li>2022-09-09 CXR
<ul>
<li>Lung markings: increased density in the right lower lung field.</li>
<li>blurred right hemidiaphram</li>
<li>blunting right costophrenic angle 2022-09-01 Nasopharyngoscopy</li>
<li>Findings
<ul>
<li>blood clot at left anterior nasal cavity, bloody discharge at left
nasopharynx, bi nasopharynx smooth, multiple whitish spots coating on
hypopharynx and supraglottis, favor candidiasis; supraglottis mild
edema</li>
</ul></li>
<li>Conclusion
<ul>
<li>NPC s/p treatment</li>
<li>Suspected pharynx and larynx candidiasis</li>
</ul></li>
</ul></li>
<li>2022-08-31 CXR
<ul>
<li>There is diffuse osteoblastic bony metastases in the T-spine and
L-spine?</li>
</ul></li>
<li>2022-08-25 Patho - lymph node region resection
<ul>
<li>Labeled as “right axillary lymph nodes”, clinical history of
nasopharyngeal carcinoma, dissection — metastatic poorly differentiated
squamous cell carcinoma (10/10).</li>
<li>IHC stains: CK5/6 (+), p40 (+), p16 (-), EBV (-).</li>
</ul></li>
<li>2022-08-25 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>Nasopharynx: smooth</li>
<li>Larynx and hypopharynx: epiglottis and bi arytenoid and bi false
cord edema, airway small but adequate</li>
</ul></li>
<li>Conclusion
<ul>
<li>supraglottic edema, suspected RT and intubation trauma related</li>
</ul></li>
</ul></li>
<li>2022-08-22 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Highly suspected cancer with multiple bone metastases in the
sternum, both rib cages, scapulae, and several T- and L-spine.</li>
<li>Increased tracer uptake in the sacrum, bilateral multiple pelvic
bones, S-I joints, and bilateral femurs, bone metastases should be
considered, suggesting follow-up with bone scan in 3 months for
investigation.</li>
</ul></li>
<li>2022-08-19 CXR
<ul>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
</ul></li>
<li>2022-08-18 SONO - chest
<ul>
<li>Diagnosis:
<ul>
<li>Pleural effusion, milk like, favor chylothorax.</li>
<li>Chest echography was performed first. The suitable intercostal space
was selected and located.</li>
<li>Catheter was inserted with negative pressure smoothly.</li>
<li>Right side pleural effusion was drawn smoothly.</li>
<li>Watch out BP after tapping.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Send pleural effusion for examination about cytology (cell block),
biochemistry, culture, Gram stain, cell count, and TB exam. TB PCR. TG
and amylase.</li>
</ul></li>
</ul></li>
<li>2022-08-17 CT - lung
<ul>
<li>occlusion of Rt IJV, subclavian and innominate vein, with pleural
effusion.</li>
<li>bony metastasis and suspect metastatic LNs in axillary regions and
mediastinum.</li>
</ul></li>
<li>2022-08-17 CXR
<ul>
<li>reticular opacities at LUL due to fibrotic change</li>
<li>extensive consolidation over Rt lower lobe and possibly increased
opacity over Lt retrocardiac lower lobe</li>
<li>mild enlarged cardiac silhoutte</li>
<li>widening of Rt paratracheal stripe</li>
</ul></li>
<li>2022-08-17 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-07-25 MRI - nasopharynx
<ul>
<li>No local NPx tumor recurrence.</li>
<li>Post OP/RT in right parotid gland, with soft tissue swelling and
well post contrast enhancement, stationary</li>
<li>Sternal notch and chest wall lesion, more likely infection,
improved, but seems extending to the mediastinum.<br />
</li>
</ul></li>
<li>2022-07-18 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis</li>
<li>Gastric subepithelial leison (SEL), antrum AW</li>
</ul></li>
<li>Suggestion
<ul>
<li>No evident esophageal lesion on endsocopy</li>
<li>Consider EUS study for the gastric SEL</li>
</ul></li>
</ul></li>
<li>2022-07-06 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesions disappear in soft tissues in the
suprasternal notch and presternal area compared with the previous study
on 2022-01-21, indicating response to current therapy. However, glucose
hypermetabolism becomes more evident in the lower portion of the
esophagus, and the nature is to be determined (inflammation or other
nature?). Please correlate with other clinical findings for further
evaluation.</li>
<li>Suspected benign lesions in the left aspect of maxilla, in bilateral
axillary lymph nodes, and in the proximal portion of right femoral
shaft.</li>
<li>Mild glucose hypermetabolism in bilateral shoulders, compatible with
arthritis.</li>
<li>No abnormally increased FDG uptake is evidently delineated
elsewhere.</li>
</ul></li>
<li>2022-06-10 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Fibrosis of left upper lung is noted. Please correlate with clinical
history to rule out old inflammatory process.</li>
</ul></li>
<li>2022-05-23 Nasopharyngoscopy
<ul>
<li>NPC s/p treatment</li>
<li>No evidence of tumor recurrence at nasopharynx</li>
</ul></li>
<li>2022-03-10 Nasopharyngoscopy
<ul>
<li>NPC s/p treatment</li>
<li>No evidence of tumor recurrence at nasopharynx</li>
<li>Lower neck/upper chest wall recurrence under CCRT</li>
</ul></li>
<li>2022-01-26 Patho - lymphnode biopsy
<ul>
<li>Tissue, lower neck, subcutaneous, biopsy — Nasopharyngeal carcinoma,
non-keratinizing and undifferentiated<br />
</li>
<li>The specimen submitted consists of 9 tissue fragments measuring up
to 0.7x 0.6x 0.3 cm in size, fixed in formalin. Grossly, they are
grayish and solid.</li>
<li>Microscopically, it shows nasopharyngeal carcinoma characterized by
diffuse sheets or syncytia of non-keratinizing invasive carcinoma
infiltrated by lymphoplasmacytic cells.The tumor shows nuclear
hyperchromasia, pleomorphism and high N/C ratio.</li>
<li>Immunohistochemical stain reveals CK(+), P40(+), and p16(-).</li>
</ul></li>
<li>2022-01-21 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in the soft tissues in the suprasternal
notch and presternal area, in a right axillary lymph node, in two left
axillary lymph nodes and in the lower portion of the esophagus. The
nature is to be determined (inflammation? other nature?). Please
correlate with other clinical findings for further evaluation.</li>
<li>Mild glucose hypermetabolism in the proximal portion of right
femoral shaft. The nature is to be determined (post-traumatic change?
other nature?). Please also correlate with other clinical findings for
further evaluation.</li>
<li>Mild glucose hypermetabolism in a focal area in the left aspect of
maxilla. Dental problem is more likely.</li>
<li>Mild glucose hypermetabolism in bilateral shoulders, compatible with
arthritis.</li>
</ul></li>
<li>2022-01-03 SONO - articular peripheral soft tissue
<ul>
<li>Finding:
<ul>
<li>Heterogeneous hypoechoic poor-defined mass noted over the
subcutaneous layer of left SCM at sternal head area, without increased
signal under power Doppler.</li>
</ul></li>
<li>Impression And Suggestions:
<ul>
<li>A poor-defined subcutaneous soft tissue mass, located superficial to
the left SCM, sternal head, without increased signal under power
Doppler.</li>
</ul></li>
</ul></li>
<li>2021-12-07 MRI - nasopharynx
<ul>
<li>No local nasopharynx tumor recurrence.</li>
<li>Post OP/RT in right parotid gland, with soft tissue swelling and
well post contrast enhancement, need follow up.</li>
<li>Sternal notch and chest wall lesion, more likely infection.</li>
</ul></li>
<li>2021-12-07 SONO - abdomen
<ul>
<li>A hepatic hemangioma or calcification 0.31 cm in S8.</li>
<li>A gallbladder polyp 2.3 mm is highly suspected.<br />
</li>
</ul></li>
<li>2021-08-17 MRI - nasopharynx
<ul>
<li>No nasopharynx tumor recurrence.</li>
<li>Post OP/RT in right parotid gland, with soft tissue swelling and
well post contrast enhancement, need follow up.</li>
<li>Chronic mastoiditis.</li>
</ul></li>
<li>2021-06-24 Pure tone audiometry
<ul>
<li>Tymp RE type B, LE type C</li>
<li>PTA:
<ul>
<li>Reliability FAIR</li>
<li>Average RE 35 dB HL / LE 20 dB HL</li>
</ul></li>
<li>RE normal to severe MHL</li>
<li>LE normal to severe SNHL</li>
</ul></li>
<li>2021-04-22 Patho - salivary gland resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Parotid gland, right, parotidectomy — Lymphoepithelial carcinoma
involving margins.</li>
<li>Superior margin to?, excision — Lymphoepithelial carcinoma involving
margin<br />
</li>
<li>Tissue around trigus, excision — benign parotid gland<br />
</li>
<li>Deep lobe of parotid, excision — Lymphepithelial carcinoma involving
margin.<br />
</li>
</ul></li>
<li>microscopic description
<ul>
<li>Both salivary lymphoepithelial carcinoma and nasopharyngeal
lymphoepithelial carcinoma have the same morphology.</li>
</ul></li>
</ul></li>
<li>2021-04-20 EKG
<ul>
<li>Sinus tachycardia with occasional Premature ventricular
complexes</li>
<li>Left axis deviation</li>
<li>Inferior infarct, age undetermined</li>
</ul></li>
<li>2021-04-16 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Esophageal ulcer, ECJ, s/p biopsy</li>
<li>Reflux esophagitis LA Classification grade B</li>
<li>Duodenal shallow ulcers, bulb</li>
<li>Duodenal ulcer scar, bulb</li>
<li>Gastric erosion, antrum, LC</li>
<li>Gastric subepithelial lesion, antrum, AW-GC</li>
<li>Superficial gastritis, s/p CLO test</li>
</ul></li>
<li>Suggestion
<ul>
<li>Persue biopsy result</li>
</ul></li>
</ul></li>
<li>2021-04-08 Whole body PET scan
<ul>
<li>Some mild glucose hypermetabolic lesions in the right parotid gland.
The nature is to be determined (metastases/malignancy of low FDG uptake?
other nature?). Please correlate with other clinical findings for
further evaluation.</li>
<li>A glucose hypermetabolic lesion in the lower portion of the
esophagus. The nature is to be determined (inflammation? other nature?).
Please also correlate with other clinical findings for further
evaluation.</li>
<li>Mild glucose hypermetabolism in bilateral shoulders, compatible with
arthritis.</li>
</ul></li>
<li>2021-03-26 Pathology - lymph node
<ul>
<li>Malignancy</li>
<li>R’t parotid nodules: one wet and one dry smears show lymphocytes,
acinar clusters, and some atypical epithelial clusters with enlarged
nuclei and prominent nucleoli, suggestive of carcinoma, and metastatic
maybe first considered according to past history.</li>
</ul></li>
<li>2021-02-22 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatement without local reurrence. However, progressive
enlargement of right parotid lesions is noted. Suggest further
evaluation. Left mastoiditis.</li>
</ul></li>
<li>2021-02-22 SONO - abdomen
<ul>
<li>Fatty liver.</li>
<li>Gallbladder polyps.</li>
</ul></li>
<li>2020-08-06 MRI - nasopharynx
<ul>
<li>No nasopharynx tumor recurrence.</li>
<li>Several small nodulated lesions in right parotid gland, stationary
in sizes.</li>
</ul></li>
<li>2020-02-04 MRI - nasopharynx
<ul>
<li>No nasopharynx tumor recurrence.</li>
<li>Several small nodulated lesions in right parotid gland, stationary
in sizes.</li>
</ul></li>
<li>2019-06-14 MRI - nasopharynx
<ul>
<li>Several small lymph nodes in the right parotid gland, stationary in
sizes.</li>
</ul></li>
<li>2019-02-19 MRI - nasopharynx
<ul>
<li>NPC, post CCRT. No local tumor recurrence. No neck LAP. A right
parotid gland nodule or LN.</li>
</ul></li>
<li>2018-08-02 MRI - nasopharynx
<ul>
<li>NPC, post CCRT. No local tumor recurrence. No neck LAP.</li>
</ul></li>
<li>2018-04-10 MRI - nasopharynx
<ul>
<li>NPC s/p CCRT with post treatment change.</li>
<li>Chronic maxillary sinusitis and left mastoiditis.</li>
</ul></li>
<li>2017-11-20 MRI - nasopharynx
<ul>
<li>NPC s/p CCRT with post treatment change.</li>
<li>Chronic maxillary sinusitis and left mastoiditis.</li>
</ul></li>
<li>2017-08-16 MRI - nasopharynx
<ul>
<li>NPC s/p CCRT with tumor regression.</li>
</ul></li>
<li>2017-02-23 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the nasopharyngeal roof, compatible with
primay nasopharyngeal malignancy.</li>
<li>Glucose hypermetabolism in bilateral retropharyngeal lymph nodes,
bilateral neck level II-V lymph nodes and bilateral supraclavicular
lymph nodes. Lymph node metastases may show this picture.</li>
<li>Mild glucose hypermetabolism involving the right shoulder, right
sternoclavicular junction and left hip, compatible with benign joint
lesion such as arthritis.</li>
</ul></li>
<li>2017-02-17 MRI - nasopharynx
<ul>
<li>Tumor location/size
<ul>
<li>Bilateral nasopharyngeal roof</li>
<li>Size (largest dimension): 34 mm</li>
</ul></li>
<li>Tumor invasion:
<ul>
<li>T1 (nasopharynx)</li>
</ul></li>
<li>Neck lymph node:
<ul>
<li>Retropharynx: Rt(+)/Lt(+); Supraclavicular: Rt(+)/Lt(+)</li>
<li>Level I: Rt(-)/Lt(-); Level II: Rt(+ab)/Lt(+ab); Level III:
Rt(-)/Lt(+ab); Level IV: Rt(-)/Lt(-); Level V: Rt(+ab)/Lt(+ab); Lvele
VI: Rt(-)/Lt(-); Level VII: Rt(-)/Lt(-)
<ul>
<li>-: short axis&lt;10 mm,</li>
<li>a: short axis&gt;=10 mm;</li>
<li>b: long axis &gt;= 15 mm,</li>
<li>c: cluster of &gt;= 3 nodes with short axis &gt;= 7 mm,</li>
<li>e: extracapsular spread,</li>
<li>n: necrosis</li>
</ul></li>
</ul></li>
<li>Distant metastasis in this study:
<ul>
<li>No or equivocal</li>
</ul></li>
<li>Imaging stage according to AJCC 7th edition:
<ul>
<li>nasopharyngeal tumor.</li>
</ul></li>
<li>Impression:
<ul>
<li>nasopharyngeal tumor, suspected lymphoma or others.</li>
</ul></li>
</ul></li>
<li>2017-02-15 Surgical pathology Level IV
<ul>
<li>Nasopharynx, biopsy — Nasopharyngeal carcinoma, non-keratinizing and
undifferentiated (WHO type 2b)</li>
<li>IHC stain — CK(+)</li>
<li>Microscopically, section shows nasopharyngeal carcinoma
characterized by diffuse sheets or syncytia of non-keratinizing invasive
carcinoma closely infiltrated by prominent lymphoplasmacytic cells.
Nuclei are vesicular with indistinct cell margins, prominent
eosinophilic nucleolus and scattered mitotic figures. Desmoplasia is
absent or minimal.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-25 ENT
<ul>
<li>Q
<ul>
<li>This 59-year-old man with past history of
<ul>
<li>Nasopharyngeal carcinoma, cT1N3bM0, stage IVB s/p CCRT and adjuvant
chemotherapy with PF on 2017; Recurrence nasopharyngeal carcinoma over
subcutaneous tissue of lower neck, rcT0N0M1, stage IVC, s/p CCRT on
2022/03/18 and adjuvant chemotherapy with PF three times again since
2022/04~2022/06.</li>
<li>Lymphoepithelial carcinoma of Right parotid with peri-salivary gland
tissue invasion, pT3cN0M0, s/p parotidectomy with positive and CCRT on
2021/04~2021/07</li>
<li>Hypothyroidism under thyroxin control.</li>
</ul></li>
<li>This time, he had face/neck and chest wall swelling, orthopnea
(cough at night), distended neck veins, collateral circulation, swelling
over bilateral axillas and dyspnea for several weeks.</li>
<li>Under the impression of SVC syndrome, he is admitted to our ward for
further evaluation and management.</li>
<li>20220817 Chest CT:
<ul>
<li>Occlusion of Rt IJV, subclavian and innominate vein, with pleural
effusion</li>
<li>Bony metastasis and suspect metastatic LNs in axillary regions and
mediastinum</li>
</ul></li>
<li>S
<ul>
<li>He was regularly followed up at your ward, and he would arrange to
follow your ward again on 20220822.</li>
<li>He had done right axillary LN dissection on 20220824. He was found
the foreign on his throat, when he was inbutation for operation.</li>
<li>He also complained that he was hard to swollen in recent several
days.</li>
</ul></li>
<li>We would like to consult your expertise for recurrent NPC further
evaluation and management. Thanks in advance and have a nice day.</li>
</ul></li>
<li>A
<ul>
<li>SOB after intubation.</li>
<li>Scope:
<ul>
<li>Nasopharynx: smooth</li>
<li>Larynx and hypopharynx: epiglottis and bi arytenoid and bi false
cord edema, airway small but adequate</li>
</ul></li>
<li>Imp: Supraglottic edema, suspected RT and intubation trauma
related</li>
<li>Plan:
<ul>
<li>IV steroid for 5-7 days, monitor airway</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-19 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>We would like to consult your expertise for his axillary LN biopsy
further evaluation and management.</li>
</ul></li>
<li>A
<ul>
<li>Due to suspected that bilateral axillary LN metastasis and related
SVC syndrome. Axillary LN biopsy is consulted.</li>
<li>O:
<ul>
<li>vital signs: stable, no fever</li>
<li>PE: no central vein stenosis<br />
</li>
<li>lab data: see chart</li>
</ul></li>
<li>A: suspected that bilateral axillary LN metastasis</li>
<li>P: I will arrange axillary LN biopsy, R’t on 20220824</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-26
<ul>
<li>Surgery
<ul>
<li>Lower neck and chest wall mass incisinal biopsy        </li>
</ul></li>
<li>Finding
<ul>
<li>Lower neck and chest wall swelling and induration</li>
</ul></li>
</ul></li>
<li>2021-04-21
<ul>
<li>Surgery
<ul>
<li>Parotidectomy. right</li>
</ul></li>
<li>Finding
<ul>
<li>Several indurated nodules over right parotid gland</li>
<li>Sacrificed of right greater auricular nerve</li>
</ul></li>
</ul></li>
<li>2020-12-24
<ul>
<li>Surgery
<ul>
<li>total excision</li>
</ul></li>
<li>Finding
<ul>
<li>skin tumor</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-08-25 ~ 2022-09-05 - 2100cGy/7 fractions (6 MV photon) to low
pelvis &amp; hips.</li>
<li>2022-03-16 ~ 2022-03-18 - boost 1050cGy/3 fractions to lower neck
and pre-sternal soft tissue tumor due to slow regression</li>
<li>2022-02-15 ~ 2022-03-15 - 6000cGy/20 fractions (6 MV photon) to
lower neck and pre-sternal soft tissue tumor</li>
<li>2021-05-24 ~ 2021-07-05 - 6000cGy/30 fractions (6 MV photon) to Rt
parotid bed and regional lymphatics</li>
<li>2017-03-08 ~ 2017-04-26 - 7140cGy/34 fractions (6 MV photon) to NPX
&amp; neck LAPs
<ul>
<li>Cisplatin: 2017-03-10, 2017-03-16, 2017-03-23, 2017-03-30,
2017-04-06, 2017-04-13, 2017-04-20, 2017-04-24.</li>
<li>Radiation mucositis, grade 2; pharyngitis, grade 2; dermatitis,
grade 2; N/V, grade 0; esophagitis, grade 1.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-31 - cisplatin 80mg/m2 130mg 2hr D1 + gamcitabine 1250mg/m2
2100mg 30min D1</li>
<li>2022-06-10 - cisplatin 80mg/m2 140mg 3hr D1 + fluorouracil 1000mg/m2
1790mg 24hr D1-4 (PF Q4W)</li>
<li>2022-05-06 - cisplatin 80mg/m2 140mg 3hr D1 + fluorouracil 1000mg/m2
1790mg 24hr D1-4 (PF Q4W)</li>
<li>2022-04-07 - cisplatin 80mg/m2 140mg 3hr D1 + fluorouracil 1000mg/m2
1800mg 24hr D1-4 (PF Q4W)</li>
<li>2022-03-16 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2022-03-09 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2022-03-02 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2022-02-23 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2022-02-16 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-06-30 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-06-23 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-06-16 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-06-09 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-06-02 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
<li>2021-05-26 - cisplatin 30mg/m2 50mg 2hr D1 (cisplatin weekly,
CCRT)</li>
</ul></li>
</ul>
<p>[assessment, not posted]</p>
<ul>
<li>An elevated level of D-dimer has been observed.
<ul>
<li>2022-09-12 D-dimer 3998.90 ng/mL(FEU)<br />
</li>
<li>2022-09-07 D-dimer 2014.01 ng/mL(FEU)<br />
</li>
<li>2022-08-26 D-dimer 2846.63 ng/mL(FEU)<br />
</li>
<li>2022-08-23 D-dimer 3582.31 ng/mL(FEU)<br />
</li>
<li>2022-08-19 D-dimer 4672.59 ng/mL(FEU)</li>
</ul></li>
<li>In patients with VTE and cancer (cancer associated thrombosis [CAT])
there is a higher risk for recurrence as well as a higher risk for major
bleeding than in patients with VTE without cancer. Because DOACs have
not been compared head-to-head among patients with cancer, apixaban or
LMWH may be the preferred option in patients with luminal GI
malignancies who place higher value on avoiding GI major bleeding,
whereas others may elect the convenience of oncedaily DOAC therapy
(edoxaban or rivaroxaban). However, LMWH has the potential advantages of
bypassing the GI system in patients with nausea or mucositis and may be
more easily dose-adjusted in patients with thrombocytopenia due to
cancer therapy.
<ul>
<li>ref: Stevens SM, et al. Executive Summary: Antithrombotic Therapy
for VTE Disease: Second Update of the CHEST Guideline and Expert Panel
Report. Chest. 2021;160(6):2247-2259. <a href="doi:10.1016/j.chest.2021.07.056" class="uri">doi:10.1016/j.chest.2021.07.056</a></li>
<li>Executive Summary - <a href="https://journal.chestnet.org/action/showPdf?pii=S0012-3692%2821%2901507-5" class="uri">https://journal.chestnet.org/action/showPdf?pii=S0012-3692%2821%2901507-5</a></li>
</ul></li>
<li>Eliquis (apixaban) has been introduced since 2022-09-01. (Superior
Vena Cava Syndrome suspected? 2022-08-17 CT).</li>
</ul>
</div>
</div>
<div id="section-363" class="section level1">
<h1>701346860</h1>
<div id="section-364" class="section level2">
<h2>220907</h2>
<p>[objective]</p>
<ul>
<li>past history
<ul>
<li>DM(-), HTN(-)</li>
<li>Arrhythmia/tachycardia s/p ablative surgery at WanFang Hospital</li>
<li>Facial herpes zoster reactivation s/p medical therapy neurotin and
methylcobalamin</li>
<li>Appendectomy and neck mass excision 40 years ago</li>
</ul></li>
<li>lab data
<ul>
<li>2021-12-30 Anti-HBs 254.35 mIU/mL<br />
</li>
<li>2021-12-30 Anti-HBc Reactive<br />
</li>
<li>2021-12-30 Anti-HBc-Value 4.38 S/CO<br />
</li>
<li>2021-12-30 HBsAg Nonreactive<br />
</li>
<li>2021-12-30 HBsAg (Value) 0.68 S/CO<br />
</li>
<li>2021-12-30 Anti-HCV Nonreactive<br />
</li>
<li>2021-12-30 Anti-HCV Value 0.05 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-07-15 CT - abdomen, pelvis
<ul>
<li>History: Endometrium serous adenocarcinoma, high grade, T1N0M0,
stage I s/p Staging surgery (ATH + BSO + bilateral pelvic lymphnode
dissection + paraaortic lyphnode dissection) on 2021/12/22 s/p
concurrent chemoradiotherapy</li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P hysterectomy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Disc space narrowing at L5/S1.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li></li>
</ol>
<ul>
<li>There is no focal abnormality in the liver, gallbladder, biliary
system, pancreas, spleen &amp; both kidney.</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-02-24 Hearing Test
<ul>
<li>PTA, Pure-tone Audiometry
<ul>
<li>Reliability FAIR</li>
<li>Average R’t 23 dB HL // L’t 21 dB HL</li>
<li>Bil normal to moderately severe SNHL</li>
</ul></li>
</ul></li>
<li>2022-01-27 KUB
<ul>
<li>Diffuse bowel dilatation with barium retention. Stationary.</li>
</ul></li>
<li>2022-01-21 KUB
<ul>
<li>Diffuse small bowel dilatation.</li>
<li>Retention of barium in the bowel loops.</li>
</ul></li>
<li>2022-01-19 Small intestine
<ul>
<li>Small bowel ileus.</li>
<li>The passage time is more than 24 hours.</li>
</ul></li>
<li>2022-01-02 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. Small bowel ileus and the transtitional zone.</li>
<li>Distention of stomach.</li>
</ul></li>
<li>2022-01-02 EKG
<ul>
<li>Sinus rhythm with short PR</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
<li>2021-12-22 Patho - uterus (with or without SO) neoplastic
<ul>
<li>Pathologic diagnosis
<ul>
<li>Uterus, endometrium, staging surgery — Serous carcinoma,
high-grade<br />
</li>
<li>Uterus, myometrium, total hysterectomy
<ul>
<li>— Involved by serous carcinoma (&lt; 1/2 thickness)<br />
</li>
<li>— Intramural myoma<br />
</li>
</ul></li>
<li>Uterus, cervix, total hysterectomy
<ul>
<li>— Endocervix involved by tumor<br />
</li>
<li>— Cervical stromal not involvement<br />
</li>
<li>— Free of cervical margin<br />
</li>
</ul></li>
<li>AJCC 8th edition Pathology stage: pT1aN0(if cM0); FIGO IA; AJCC
stage IA</li>
</ul></li>
<li>Microscopic Examination
<ul>
<li>Histology type: Serous carcinoma<br />
</li>
<li>Histology grade: High-grade<br />
</li>
<li>Depth of invasion: 2 mm (invade &lt;1/2 thickness of the myometrial
wall)<br />
</li>
</ul></li>
</ul></li>
<li>2021-12-10 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, EM sampling — serous adenocarcinoma, high
grade</li>
<li>IHC stains: p53 (aberrant type), WT-1 (+), CK20 (-), PAX-8 (-), ER
(-, 0%), PR (-, 0%).<br />
</li>
</ul></li>
<li>2021-12-09 Gynecologic ultrasonography
<ul>
<li>Endometrial hyperplasia(EM:30.1mm), suspected endometrial
malignancy</li>
<li>thickness of the posterior wall: 0.47cm</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-20 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>This is a 71 y/o female, G5P3AA2 (NSD*3) with the past history of
cardiac arrhythmia s/p ablative surgery. She is just discharged from our
hospital due to endometrial cancer pT1aN0(if cM0); FIGO IA s/p staging
surgery (ATH + BSO + bilateral pelvic lymphnode dissection + paraaortic
lyphnode dissection) on 2021/12/22 and subsequently admitted again due
to post-operative ileus. However, she suffered from abdominal fullness
since yesterday morning and had colicky abdominal pain. She recalled
only eating pumpkin porridge yesterday morning. She vomited once this
early morning at 2AM. She denied diarrhea, fever, coffee ground or
bloody emesis. Because of the severe discomfort, she was brought to our
ER. At the ER, KUB showed presence of ileus. Thus, primperan was given
and she was kept on NPO. Due to the above problem, she is admitted for
further management and close observation.</li>
<li>Abdominal to pelvis CT showed S/P hysterectomy. Small bowel ileus
and the transtitional zone. Distention of stomach. As a result, we need
your help and expertise for assessment and management of her ileus.</li>
</ul></li>
<li>A
<ul>
<li>Assessment
<ul>
<li>Ms. Chen had been found with postoperative intestinal obstruction.
Small bowel series disclosed small bowel obstructin.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please keep NPO, iv fluid, and maybe NG decompression if
vomiting</li>
<li>F/u KUB subsequently</li>
<li>Surgical intervention is preserved only if peritonitis or failed
conservative treatment.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-05 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>This is a 71 y/o female, G5P3AA2 (NSD*3) with the past history of
cardiac arrhythmia s/p ablative surgery. This time, she is just
discharged from our hospital due to endometrial cancer pT1aN0(if cM0);
FIGO IA s/p staging surgery (ATH + BSO + bilateral pelvic lymphnode
dissection + paraaortic lyphnode dissection) on 2021/12/22. However, she
suffered from abdominal fullness last night and felt nausea but did not
vomit. She recalled only eating steamed bun and vegetables. Because of
the severe discomfort, she was brought to our ER. At the ER, KUB showed
presence of ileus. Blood exam showed mildly elevated WBC 11K, band form
1.9%, CRP 0.42. Empiric antbiotics of Brosym was given. Abdominal CT
showed S/P small bowel ileus and distention of stomach. Thus, NG
decompression (2150/day), dulcolax 1# prnq4h and primperan was given and
she was kept on NPO use. Due to the above problem, she is admitted for
further management and close observation.</li>
</ul></li>
<li>A
<ul>
<li>Assessment
<ul>
<li>Mrs. Chen had received operation and discharged recently. However,
intestinal obstruction is suspicious. PE showed soft palpation.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please keep current treatment and f/u KUB subsequently</li>
<li>Conservative treatment at first</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-31 Radiation Oncology
<ul>
<li>S:
<ul>
<li>For postoperative radiotherapy due to serous carcinoma of the
uterine endometrium.</li>
<li>PI: This 71-year-old woman, G5P3AA2, menopausal at 50 years old. She
had history of cardiac arrhythmia s/p ablative surgery. MRI of pelvis
(2021-12-13) showed lobulated tumor, 5.8cm in the uterine cavity (body),
suspected endometrial malignancy . She then noted fresh red vaginal
spotting again on 2021/12/17. She underwent staging surgery (ATH + BSO +
bilateral pelvic lymphnode dissection + paraaortic lyphnode dissection)
on 12/22/2021.</li>
<li>Family history: (-)</li>
<li>Cancer site specific factors: Alcohol (-); Smoking (-); Betel nut
(-).</li>
<li>Personal Hx: DM(-); HTN(-)</li>
<li>Allergy(-)</li>
<li>Travel hx(-)</li>
<li>Other disease: heart disease</li>
<li>Previous RT Hx: (-)</li>
</ul></li>
<li>O:
<ul>
<li>ECOG: 0</li>
<li>PE: neck and bil SCF: neg; abdomen: a longitudinal surgical scar;
bil low limbs: no edema.</li>
<li>MRI of pelvis (2021-12-13): Lobulated tumor, 5.8cm in the uterine
cavity (body), suspected endometrial malignancy. Unremarkable change of
the liver, spleen, pancreas and both kidneys. No enlarged lymph node in
the paraaortic region. Minimal ascites in the pelvic cavity. Bulging
disc at L5-S1. Impression: Lobulated tumor in the uterus, suspected
endometrial malignancy. If proven malignancy, T1N0M0. Post-op proven
endometrial malignancy.</li>
<li>CXR (2021-12-21): No active lung lesion. No cardiomegaly.</li>
<li>Operation (2021-12-22): Staging surgery (ATH + BSO + bilateral
pelvic lymphnode dissection + paraaortic lyphnode dissection)</li>
<li>Ascites (N2021-04522, 2021-12-23): neg.</li>
<li>Pathology (S2021-19117, 2021-12-28):
<ul>
<li>Uterus, endometrium, staging surgery — Serous carcinoma,
high-grade.</li>
<li>Uterus, myometrium, total hysterectomy — Involved by serous
carcinoma (&lt;1/2 thickness) — Intramural myoma.</li>
<li>Uterus, cervix, total hysterectomy — Endocervix involved by tumor —
Cervical stromal not involvement — Free of cervical margin.</li>
<li>AJCC 8th edition Pathology stage: pT1aN0(if cM0); FIGO IA; AJCC
stage IA.</li>
<li>Lymphovascular Invasion: Present</li>
</ul></li>
<li>CXR (2021-12-31): No active lung lesion. Normal heart size and
contour. S/P port-A insertion via left subclavian vein.</li>
</ul></li>
<li>A:
<ul>
<li>Serous carcinoma, high-grade, of the uterine endometrium, AJCC 8th
edition Pathology stage: pT1aN0(cM0); FIGO IA; AJCC stage IA, s/p
staging surgery (ATH + BSO + bilateral pelvic lymphnode dissection +
paraaortic lyphnode dissection).</li>
</ul></li>
<li>P: Systemic therapy and vaginal brachytherapy is indicated for this
patient with the following indicators: serous carcinoma, high-grade, of
the uterine endometrium, stage: pT1aN0(cM0); FIGO IA
<ul>
<li>Goal: curative</li>
<li>Treatment target and volume: vaginal cuff mucosa surface</li>
<li>Technique: IVRT</li>
<li>Preliminary planning dose: 600cGy to vaginal cuff mucosa surface x 5
fractions by IVRT.<br />
</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and her daughter. They understand and
would like to receive radiotherapy, The treatment planning of
radiotherapy will be started at 1530, 2022-1-21.</li>
</ul></li>
</ul></li>
<li>2021-12-31 Hemato-Oncology
<ul>
<li>this 71 year old woman is a case of endometrium serous
adenocarcinoma, high grade, pstageIA.</li>
<li>for invasive stageIA case, systemic therapy is indicated.</li>
<li>we will discuss with patient for systemic chemotherapy (self pay
palitaxel 175mg/m2 + self pay carboplatin AUC target 6) Q3W.</li>
<li>arrange our OPD after discharge.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-22 Staging surgery (ATH + BSO + bilateral pelvic lymphnode
dissection + paraaortic lyphnode dissection)</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-22 ~ 2022-04-12 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and another 1200cGy/3 fractions of the vaginal cuff mucosa area
by IVRT.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-06 - paclitaxel 175mg/m2 210mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-08-16 - paclitaxel 175mg/m2 210mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-07-14 - paclitaxel 175mg/m2 210mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-06-24 - paclitaxel 175mg/m2 210mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-06-07 - paclitaxel 175mg/m2 210mg 3hr + carboplatin AUC 5 300mg
2hr (paclitaxel 240mg -&gt; 210mg for leukocytopenia)</li>
<li>2022-04-25 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-03-30 - cisplatin 40mg/m2 60mg 3hr (CCRT)</li>
<li>2022-03-23 - cisplatin 40mg/m2 60mg 3hr (CCRT)</li>
<li>2022-03-16 - cisplatin 40mg/m2 60mg 3hr (CCRT)</li>
<li>2022-03-09 - cisplatin 40mg/m2 60mg 3hr (CCRT)</li>
<li>2022-03-02 - cisplatin 40mg/m2 60mg 3hr (CCRT)</li>
<li>2022-02-24 - cisplatin 40mg/m2 55mg 3hr (CCRT)</li>
</ul></li>
</ul>
<div id="section-365" class="section level3">
<h3>==========</h3>
</div>
<div id="section-366" class="section level3">
<h3>2022-09-07</h3>
<ul>
<li>Leukocytopenia is anticipated to be mitigated as a result of
reducing the dosage of Paclitaxel and adding G-CSF.</li>
</ul>
</div>
<div id="section-367" class="section level3">
<h3>2022-08-17</h3>
<ul>
<li>There is no evidence of tumor recurrence found by 2022-07-15
CT.</li>
</ul>
</div>
<div id="section-368" class="section level3">
<h3>2022-06-08</h3>
<ul>
<li>According to lab results on 2022-06-02, WBC, RBC, and HGB were
slightly lower, however this should not affect the chemotherapy.</li>
<li>The D-dimer reading gradually decreased to near normal levels, which
might be considered as a good sign
<ul>
<li>2022-05-30 674.30 ng/mL(FEU)</li>
<li>2022-05-05 774.52 ng/mL(FEU)</li>
<li>2022-02-22 907.50 ng/mL(FEU)</li>
<li>2022-02-15 1010.02 ng/mL(FEU)</li>
<li>2022-01-21 1793.51 ng/mL(FEU)</li>
<li>2022-01-08 3883.44 ng/mL(FEU)</li>
</ul></li>
<li>Chronic viral hepatitis B as well as constipation are currently
treated with Baraclude (entecavir) and magnesium oxide,
respectively.</li>
<li>BP 141/68 (2022-06-07 15:50) -&gt; 102/58 (2022-06-07 20:48), please
keep track of its drop rate.</li>
</ul>
</div>
<div id="section-369" class="section level3">
<h3>2022-04-26</h3>
<ul>
<li>The patient has endometrial serous carcinoma of high grade, s/p
surgery on 2021-12-22, and CCRT during late February to the end of March
in 2022. She has been administered paclitaxel + carboplatin as of this
hospital stay.</li>
<li>The CBC and WBC results reported on 2022-04-20 and liver and kidney
function, serum electrolytes reported on 2022-04-13 were grossly normal.
Chronic viral hepatitis B is managed with Baraclude (entecavir) 0.5mg
QDAC.</li>
<li>For those with human epidermal growth factor receptor
2-overexpressing (HER2 data not found yet), addition of trastuzumab to
current chemotherapy might be considered optionally.</li>
</ul>
</div>
</div>
</div>
<div id="section-370" class="section level1">
<h1>700513871</h1>
<div id="section-371" class="section level2">
<h2>220906</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-18 Fluid cytology - dialysate
<ul>
<li>after IP: 10cc, yellow, turbid</li>
<li>Smears show neutrophils, lymphocytes, and atypical, pleomorphic
hyperchromatic cells.</li>
<li>Malignancy is favored.</li>
</ul></li>
<li>2022-08-15 Fluid cytology - dialysate
<ul>
<li>before IP: 13 cc, light-yellow, clear</li>
<li>Smears show necrotic debris, neutrophils, lymphocytes, and clusters
of pleomorphic cells.</li>
<li>Malignancy is favored.</li>
</ul></li>
<li>2022-08-12 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-05-23 Fluid cytology - ascites
<ul>
<li>after IP C/T: adenocarcinoma, degenerated;</li>
<li>Many lymphocytes, mesothelial cells, and few degenerated
adenocarcinoma cells present.</li>
</ul></li>
<li>2022-05-16 Patho - peritoneum biopsy
<ul>
<li>Peritoneum tumor, laparoscopic excision — Metastatic
poorly-differentiated carcinoma</li>
<li>Microscopically, the sections shows a poorly-preserved specimen with
almost crush artifact and only a few pleomorphic, patternless,
well-preserved tumor cells, which immunohistochemistry of CK(-),
PAX-8(+, focal), WT-1(-, cytoplasmic staining) and P53 does not have
aberrant expression. However, PAX-8 IHC stain is mainly used for renal
carcinoma, thyroid carcinoma and gynecologic carcinoma. According to
radiologic findings, metastatic poorly-differentiated carcinoma with
gynecologic origin should be first considered. Clinical correlation is
advised.</li>
</ul></li>
<li>2022-05-11 Flow volume loop
<ul>
<li>moderate restrictive impairment</li>
</ul></li>
<li>2022-05-11 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Sub-optimal echo window</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal AV with mild AR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal MV with no MR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Concentric LVH</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Preserved LV and RV systolic function</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Mild PR, mild TR, normal IVC size</li>
</ol></li>
</ul></li>
<li>2022-05-10 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>A focal area of increased FDG uptake in the midline lower pelvic
region about uterus. Malignancy of the uterus should be watched out.
Please correlate with other clinical findings for further
evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Multiple glucose hypermetabolic lesions in the abdominal and pelvic
cavities and a glucose hypermetabolic lesion in the midline anterior
lower abdominal wall, compatible with multiple metastatic lesions.
Please also correlate with other clinical findings for further
evaluation.</li>
</ol></li>
</ul></li>
<li>2022-05-09 Cell block
<ul>
<li>Peritoneal carcinomatosis with ascites.</li>
<li>The smears and cell block show lymphocytes, reactive mesothelial
cells and some pleomorphic atypical cell clusters, suggestive of
malignancy, but uncertain origin due to limited ICC stains.
Immunocytochemistry shows PAX-8(-), WT-1(-, cytoplasmic staining),
ER(-), CD10(-) and P53(+) for pleomorphic cell. Confirmatory biopsy is
advised for further evaluation.</li>
</ul></li>
<li>2022-05-09 Gynecologic ultrasonography
<ul>
<li><ol style="list-style-type: decimal">
<li>Suspected Ascites:(+)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Endometrial thickening.(Em:2.14), endometrial (+fluid)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Suspected endometrial mass</li>
</ol></li>
</ul></li>
<li>2022-05-06 Patho - esophageal biopsy
<ul>
<li>Esophagus, 23cm below incisors, s/p biopsy — benign squamous mucosa
with abundant granular cytoplasm, suggestive of glycogenosis.</li>
</ul></li>
<li>2022-05-06 Patho - colorectal polyp
<ul>
<li>Colon, descending colon, post Biopsy removal — Hyperplastic
polyp</li>
</ul></li>
<li>2022-05-05 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Peritoneal carcinomatosis with ascites.</li>
</ul></li>
<li>2022-05-04 Fluid cytology - ascites
<ul>
<li>Smears show atypical hyperchromatic and pleomorphic tumor
cells.<br />
</li>
<li>Malignancy is favored. Please correlate with the clinical
presentation.</li>
</ul></li>
<li>2022-05-03 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Parenchymal liver diseae</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Ascites, moderate amount</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hepatic cyst</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li>abdominal paracentesis</li>
</ul></li>
</ul></li>
<li>2018-03-31 CT - abdomen
<ul>
<li>Right UVJ stone (4.5mm) with obstructive uropathy. Right renal
stones (2-4mm).</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-20 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>for neoadjuvant chemotherapy with IP + systemic</li>
<li>This 77 y/o female patient has the history of hypertension. This
time, due to mild epigastric pain and abdominal fullness were noted.
Abdominal sonography was done that showed ascites. Abdominal
paracentesis was done and the analysis showed exudate; abdominal
sonography showed 1.Prob. Liver cirrhosis 2.Ascites, moderate amount
3.hepatic cyst.</li>
<li>Abdominal CT showed Peritoneal carcinomatosis with ascites. Ascites
cytology showed Smears show atypical hyperchromatic and pleomorphic
tumor cells. Malignancy is favored. Further whole body PET was performed
and showed 1) A focal area of increased FDG uptake in the midline lower
pelvic region about uterus. Malignancy of the uterus should be watched
out. Please correlate with other clinical findings for further
evaluation. 2) Multiple glucose hypermetabolic lesions in the abdominal
and pelvic cavities and a glucose hypermetabolic lesion in the midline
anterior lower abdominal wall, compatible with multiple metastatic
lesions. Please also correlate with other clinical findings for further
evaluation.</li>
<li>Laparoscopic exam was performed on 20220516 and operation finding
showed peritoneal carinomatosis including 4 quadrant and small bowel
mesentry. PCI: 13/39. laparoscope intraabdominal tumor excision with
biopsy was performed and pathology pending. We need your help for
further management for neoadjuvant IP + systemic chemotherapy. Thanks
for your time!!</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Peritoneal carcinomatosis and malignant ascites, origin unkown, s/p
laparoscope intraabdominal tumor excision, PD tube inserted and Port-A
insert on 20220516</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>HTN</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Keep best supportive care and nutrition support.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Pending pathology result. We will discuss with patient about further
neoadjuvant IP + systemic chemotherapy.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Thanks for your consultation. We wound like to follow up this case.
If there is any problem, please feel free to let us known.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-09 Obstetrics and Gynecology
<ul>
<li>Q
<ul>
<li>Tumor maker with CA 125 showed 476.8 U/ml. So we need you evaluation
and suggestion of this patient.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>77 y/o, female, G2P2(C/S)</li>
<li>Hx: Admitted due to abdominal fullness</li>
</ul></li>
<li>O:
<ul>
<li>CA125: 485</li>
<li>sono: uterus: AVF: 57x37mm, endometrial mass 20x19mm, EM:21.4mm</li>
<li>bilaterla adnexa free</li>
<li>Abdominal CT showed Peritoneal carcinomatosis with ascites.</li>
<li>Ascites cytology showed Smears show atypical hyperchromatic and
pleomorphic tumor cells.</li>
</ul></li>
<li>IMP:
<ul>
<li>Peritoneal carcinomatosis and malignant ascites, origin unknown</li>
</ul></li>
<li>P:
<ul>
<li>Please informed us the result of cell block</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-06 Obstetrics and Gynecology
<ul>
<li>A
<ul>
<li>CT of pelvis/abdomen report not mention about GYN lesion</li>
<li>no adnexa mass; UT : myoma?</li>
<li>might check CEA/CA125/CA199 first</li>
<li>suggest ascites sent for cell block to check the origin of
malignancy</li>
<li>Please connect us, if GYN origin likely by cell block, thank
you.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-09-06 - paclitaxel 50mg/m2 80mg IVD 3hr + carboplatin AUC 2
100mg IVD 2hr + docetaxel 30mg/m2 40mg IP 1hr + carboplatin 100mg IP 1hr
+ gentamicin 40mg IP + NaHCO3 70mg/mL 40mL IP</li>
<li>2022-08-16 - paclitaxel 50mg/m2 87mg IVD 3hr + carboplatin AUC 2
100mg IVD 2hr + decetaxel 30mg/m2 40mg IP 1hr + carboplatin 100mg IP 1hr
+ gentamicin 40mg IP + NaHCO3 70mg/mL 40mL IP</li>
<li>2022-06-17 - paclitaxel 50mg/m2 87mg IVD 3hr + carboplatin AUC 2
100mg IVD 2hr + decetaxel 30mg/m2 40mg IP 1hr + carboplatin 100mg IP 1hr
+ gentamicin 40mg IP + NaHCO3 70mg/mL 40mL IP</li>
<li>2022-05-19 - paclitaxel 50mg/m2 87mg IVD 3hr + carboplatin AUC 2
120mg IVD 2hr + decetaxel 30mg/m2 40mg IP 1hr + carboplatin 120mg IP 1hr
+ gentamicin 40mg IP + NaHCO3 70mg/mL 40mL IP</li>
</ul></li>
</ul>
<div id="section-372" class="section level3">
<h3>==========</h3>
</div>
<div id="section-373" class="section level3">
<h3>2022-09-06</h3>
<ul>
<li>2022-09-05 creatinine 2.62, CrCl 15mL/min, eGFR 18.8.</li>
<li>febuxostat for patient with CrCl &lt;30 mL/minute: Initial: 20 to 40
mg once daily (manufacturer’s labeling; expert opinion). Observational
studies in patients with hyperuricemia have reported safety and
tolerability of 60 and 80 mg/day; a careful titration may be considered
in patients unresponsive to standard doses. The recommended dose is 0.5#
(40mg) QD if no other clinical considerations exist.</li>
<li>entecavir for patient with CrCl 10 to &lt;30 mL/minute: Administer
30% of usual indication-specific dose daily. Alternatively, administer
the usual indication-specific dose every 72 hours. There is no urgent
need to adjust the dosage of Baraclude as it is currently prescribed as
0.5mg 1# QOD.</li>
<li>furosemide for patient with eGFR &lt;=30 mL/minute/1.73m2: Higher
doses may be required to achieve desired diuretic response due to
decreased secretion into the tubular fluid. However, single doses
&gt;160 to 200 mg IV (or oral equivalent) are unlikely to result in
additional diuretic effect</li>
</ul>
</div>
<div id="section-374" class="section level3">
<h3>2022-08-15</h3>
<ul>
<li>As a result of renal impairment, drug doses have been adjusted.
There is no issue with active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-375" class="section level1">
<h1>700563751</h1>
<div id="section-376" class="section level2">
<h2>220906</h2>
<ul>
<li>diagnosis
<ul>
<li>2022-09-02 discharge
<ul>
<li>1: suspect left breast cancer with left axillary LNs and hepatic
metastases</li>
<li>2: Dyspnea, unspecified</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>HBV, HCV
<ul>
<li>2022-09-02 HBsAg (NuMe) Negative<br />
</li>
<li>2022-09-02 HBsAg Value (NuMe) 0.443<br />
</li>
<li>2022-09-02 Anti-HCV (NuMe) Negative<br />
</li>
<li>2022-09-02 Anti-HCV Value (NuMe) 0.0345<br />
</li>
<li>2022-09-01 HBsAg Nonreactive<br />
</li>
<li>2022-09-01 HBsAg (Value) 0.25 S/CO<br />
</li>
<li>2022-09-01 Anti-HCV Nonreactive<br />
</li>
<li>2022-09-01 Anti-HCV Value 0.09 S/CO<br />
</li>
<li>2022-08-30 Anti-HBc Nonreactive<br />
</li>
<li>2022-08-30 Anti-HBc-Value 0.95 S/CO</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-02 Patho - breast biopsy
<ul>
<li>Breast, left, core biopsy — Invasive carcinoma, no special type,
NST.</li>
<li>IHC stains: ER (+, 40%, intermediate intensity), PR(-, 0%, ),
Her2/neu: positive (score=3+), Ki-67(25 %), CK5/6 (-), p63 (-).</li>
<li>Section shows fragments of breast tissue with irregular neoplastic
ducts infiltration.</li>
</ul></li>
<li>2022-09-02 SONO - breast
<ul>
<li>Left breast tumor with diffuse microcalcifications, suspected
malignancy, suggest biopsy.</li>
<li>Enlarged left axillary lymph nodes, suspected metastatic lymph
nodes.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy - appropriate
action should be taken.</li>
</ul></li>
<li>2022-09-02 Mammography
<ul>
<li>Left breast microcalcifications with axillary lymph nodes, suspected
malignancy with lymph nodes metastasis.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy - appropriate
action should be taken.</li>
</ul></li>
<li>2022-09-01 Patho - stomach biopsy
<ul>
<li>Stomach, low body, biopsy — Chronic gastritis, H pylori present</li>
</ul></li>
<li>2022-09-01 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis, s/p random biopsy at low body, GC</li>
</ul></li>
<li>2022-08-30 CTA - chest
<ul>
<li>indication
<ul>
<li>Dyspnea for 2 wks</li>
</ul></li>
<li>findings
<ul>
<li>Lung: a suspect ground-glass nodule at posterior RUL (5mm) and a
lobular opacity at peripheral of LUL</li>
<li>Chest wall and visible lower neck: small and enlarged LNs at Lt
axilla. abnormal enhancing mass in left breast. a well-defined Rt
thyroid nodule 10mm</li>
<li>Visible abdominal contents: mild ascities at RUQ of abdomen.
hepatomegaly with ill-defined hypodense lesions in both lobes.</li>
</ul></li>
<li>impression
<ul>
<li>Lt breast cancer with left axillary LNs and hepatic metastases.</li>
<li>no pulmonary embolism.</li>
<li>LUL lobular opacity and RUL GGO 5mm, nature to be determined,
suggest follow up. (GGO: ground glass opacity)</li>
</ul></li>
</ul></li>
<li>2022-08-30 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Possible Left atrial enlargement</li>
</ul></li>
<li>2022-08-30 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There is no anti-HBc test result available yet, HBV immune status
remains unknown. ( <a href="https://med.stanford.edu/content/dam/sm/liver/documents/resources/guides/cdc_pub.pdf" class="uri">https://med.stanford.edu/content/dam/sm/liver/documents/resources/guides/cdc_pub.pdf</a>
)</li>
<li>The immunization of susceptible patients should be strongly
considered at the time of cancer diagnosis. (ref: Torres HA, etc.
Reactivation of hepatitis B virus and hepatitis C virus in patients with
cancer. Nat Rev Clin Oncol 2012; 9:156-66; <a href="PMID:22271089" class="uri">PMID:22271089</a>; <a href="http://dx.doi.org/10.1038/nrclinonc.2012.1" class="uri">http://dx.doi.org/10.1038/nrclinonc.2012.1</a> )</li>
<li>All unvaccinated patients with cancer aged 19 to 59 years and those
&gt;=60 years old with risk factors (eg, diabetes mellitus, chronic
liver disease, hepatitis C, hemodialysis, and other risk factors) should
receive the hepatitis B vaccine. (ref: Murthy N, etc. Advisory Committee
on Immunization Practices Recommended Immunization Schedule for Adults
Aged 19 Years or Older - United States, 2022. MMWR Morb Mortal Wkly
Rep. 2022;71(7):229-233. Published 2022 Feb 18. <a href="doi:10.15585/mmwr.mm7107a1" class="uri">doi:10.15585/mmwr.mm7107a1</a> ). As with other vaccines,
cancer patients may have suboptimal response to the hepatitis B vaccine.
Regimens that include doubling the standard antigen dose or
administering additional doses may increase response rates but, given
the limited data with these alternative regimens, this approach cannot
be routinely recommended.</li>
</ul>
</div>
</div>
<div id="section-377" class="section level1">
<h1>700137025</h1>
<div id="section-378" class="section level2">
<h2>220905</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-02 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (93 - 28) / 93 = 69.89%
<ul>
<li>Preserved LV and RV systolic function with normal wall motion</li>
<li>Grade 1 LV diastolic dysfunction</li>
<li>Mild TR and moderate sclerotic AS (TR = tricuspid regurgitation; AS
= aortic stenosis)</li>
</ul></li>
</ul></li>
<li>2022-08-20 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>S/P NG tube placement.</li>
<li>Osteopenia of the bony structure is noted.</li>
<li>Increased pulmonary vasculature is found.</li>
</ul></li>
<li>2022-08-18 Patho - colorectal polyp
<ul>
<li>Intestine, large, hepatic flexure to A-colon, biopsy— signet ring
cell carcinoma</li>
<li>Microscopically, it shows signet ring cell carcinoma composed of
proliferation of malignant tumor cells arranged in solid architecture,
and signet-ring cell diffferentiation.</li>
<li>Immunohistochemical stain— EGFR(+), MLH1(+), MSH2(+), MSH6(+),
PMS2(-)</li>
</ul></li>
<li>2022-08-17 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Colon ulcerative mass, hepatic flexure to A-colon, s/p biopsy</li>
<li>Pseudopolyps, T-colon</li>
<li>Melanosis coli</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please pursue pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-08-16 Patho - stomach biopsy
<ul>
<li>Stomach, antrum, biopsy — Ulcer with chronic inflammation, H pylori
NOT present</li>
</ul></li>
<li>2022-08-13 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Colorectal Carcinoma</li>
<li>Impression (Imaging stage): T:4a(T_value) N:1b(N_value)
M:____(M_value) STAGE:IIIB(Stage_value)</li>
</ul></li>
<li>2022-08-13 CXR
<ul>
<li><ol style="list-style-type: decimal">
<li>Unremarkable change in the visible trachea</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal cardiac size; mediastinal widening</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Lung markings: small patches in the left upper lung field and right
middle lung fields.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Normal bilateral hemidiaphrams</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Blunting bilateral costophrenic angles</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Unremarkable change in bilateral clavicles</li>
</ol></li>
</ul></li>
<li>2022-07-26 CT - brain
<ul>
<li>No acute infarct, No ICH. Brain atrophy. Atherosclerosis.</li>
</ul></li>
<li>2022-07-26 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Incomplete right bundle branch block</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-07-13 Percutaneous transluminal angioplasty, PTA
<ul>
<li>clinical diagnosis:
<ul>
<li>AVF dysfunction</li>
</ul></li>
<li>Indication
<ul>
<li>The patient was referred with swelling of left arm and left forearm.
The procedure was explained in detail to the patient and family. Risks,
complications and alternative treatments were reviewed. Written consent
was obtained.</li>
</ul></li>
<li>Approach
<ul>
<li>Percutaneous access was performed through the av shunt fistula where
a 6F sheath was inserted.</li>
</ul></li>
<li>Procedure
<ul>
<li>The patient was taken to the cardiac catheterization laboratory in
the TZU CHI Taipei Hospital. Heart institute and prepared in the usual
sterile fashion. The contrast material used was Omnipaque 350 50cc. The
patient was treated with dormicum (Dosage=1.5 mg).</li>
</ul></li>
<li>Finding Summary
<ul>
<li>Left Radio cephalic AVF, draining axillary vein : 91% stenosis. AV
fistula.</li>
<li>Left Radio cephalic AVF, draining basilic vein : 75% stenosis. AV
fistula.</li>
</ul></li>
<li>Intervention Summary
<ul>
<li>Left Radio cephalic AVF, draining axillary vein, Pre-DS = 91%
<ul>
<li>MLD/RVD=0.65/7.18 mm → 6.08/7.13 mm, Post-DS = 15%.</li>
<li>Guide Wire: Terumo Radifocus 0.035 150cm.</li>
<li>Balloon: Boston Mustang. 8.0 X 60 mm. Pressure: 8 atmospheres.</li>
</ul></li>
<li>Left Radio cephalic AVF, drainig basilic vein, Pre-DS = 75%
<ul>
<li>MLD/RVD=1.69/6.87 mm → 6.31/6.84 mm, Post-DS = 8%.</li>
<li>Guide Wire: Terumo Radifocus 0.035 150cm.</li>
<li>Balloon: Bard Conquest. 7.0 X 40 mm. Pressure: 6 atmospheres.</li>
</ul></li>
</ul></li>
<li>In conclusion :
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P PTA for left radiocephalic AVF, draining axillary vein,
successful, from 91% to 15% residual stenosis</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P PTA for left radiocephalic AVF, draining basilic vein,
successful, from 78% to 5% residual stenosis</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-07-11 MRA - brain
<ul>
<li>Brain atrophy.</li>
</ul></li>
<li>2022-07-11 CXR
<ul>
<li>Elevation of both hemidiaphragms</li>
<li>Tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch and D-aorta</li>
<li>mild enlarged cardiac silhoutte due to prominent pericardial fat/
prominent cardiophrenic angle mediastinal fat pad</li>
<li>Clean lung fields based on plain image</li>
<li>Costophrenic angles are preserved</li>
<li>marginal spurs of multiple vertebral bodies</li>
<li>Joint space narrowing at bilateral glenohumeral joints, may be
inflammatory arthritis</li>
</ul></li>
<li>2022-07-11 CT - brain
<ul>
<li>Brain atrophy. Atherosclerosis.</li>
</ul></li>
<li>2022-06-24 Peropheral Vascular Test - AV fistula
<ul>
<li>clinical diagnosis: AVF dysfunction</li>
<li><ol style="list-style-type: decimal">
<li>Access type: Native</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Site:Left radiocephalic AVF</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Clinical problem: Swelling of left forearm and left arm</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Age of vascular access:</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Result:</li>
</ol>
<ul>
<li>The venous Duplex study revealed a left radiocephalic AVF. The
cephalic veinw as patent, with aneursymal dilatation at the cannulation
sites. The venous diameter at A cannulation site and V cannulation site
were 21.5mm and 14.7~10.2mm. Upstream draining basilic vein was patent.
Upstream draining cephalic vein at left arm level was patent but with
vessel tortousity.</li>
<li>The estimated flow volume measuerd at the feeding radial artery was
877 ml/min.</li>
<li>The measured MVO/SVC ratio at right amr level was 100%, indicated no
significant right central vein stenosis or occlusion.
<ul>
<li>Right side:
<ul>
<li>SVC: 1.3 mmHg ;</li>
<li>MVO/SVC: 100 % ;</li>
</ul></li>
</ul></li>
<li>Suggestion:
<ul>
<li>Left central vein stenosis or oclusion is highly suspected according
to the physical examination and clinical presentation.</li>
<li>IV DSA and PTA prn is recommended. However, her family refused
further IV DSA study.</li>
</ul></li>
</ul></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Suggestion: PTA</li>
</ol></li>
</ul></li>
<li>2022-06-13 CXR
<ul>
<li>Cardiomegaly and tortuosity of the thoracic aorta.</li>
<li>Widening of the mediastinum.</li>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
<li>Osteopenic change.</li>
</ul></li>
<li>2022-03-26 CXR
<ul>
<li>Elevation of both hemidiaphragms may be due to expiratory
phase.</li>
<li>Tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch and D-aorta</li>
<li>mild enlarged cardiac silhoutte due to prominent pericardial fat/
prominent cardiophrenic angle mediastinal fat pad</li>
<li>Clean lung fields based on plain image</li>
<li>Costophrenic angles are preserved</li>
<li>marginal spurs of multiple vertebral bodies</li>
</ul></li>
<li>2022-01-08 ECG
<ul>
<li>Sinus rhythm with sinus arrhythmia with occasional Premature
ventricular complexes</li>
<li>Otherwise normal ECG</li>
</ul></li>
<li>2021-12-01 CT - abdomen
<ul>
<li>History and Indication: 89 y/o, 2021/11/29 coming here due that she
is told to have abnormal liver fucntion test with elevated ALP &amp;
GGT, so request CT study</li>
<li>Hx of ESRD on HD since 2007-05-09</li>
<li>MD CT (Revolution) of the abdomen and pelvis was performed with
0.625 mm collimation &amp; 5 mm slice thickness reconstruction. Oral and
rectal contrast was not given for bowel opacification. Tri-phasic
dynamic CT images were obtained during non-enhanced, arterial phase,
portal venous phase, and delayed phase scan following IV contrast
injection through autoinjector. Coronal reformated isotropic images were
obtained in portal venous phase scan.</li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There is asymmetrical wall thickening at distal ascending colon,
near hepatic flexure, that may be adenocarcinoma. Please correlate with
colonoscopy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Both kidney show small size and thin parenchyma that are c/w
ESRD.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Two small gallstones are noted.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>The liver shows mild irregular contour that may be early cirrhosis?
please correlate with clinical condition.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Compression fracture of L1 vertebral body. Mild Disc space narrowing
with marginal osteophyte formation and vacuum phenomenon from L2 to
S1.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Hyperplasia of bilateral adrenal gland are noted.</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>There is no focal abnormality in the biliary system, pancreas, and
spleen.<br />
</li>
</ol>
<ul>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.<br />
</li>
<li>There is no focal lesion over the mesentery and omentum.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Adenocarcinoma of the distal ascending colon is suspected. Please
correlate with colonoscopy.</li>
</ul></li>
</ul></li>
<li>2021-10-22 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>GB polyps</li>
<li>C/W ESRD</li>
<li>Fatty infiltration of pancreas</li>
<li>Suboptimal exam of liver due to poor echo window</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study and clinical condition</li>
<li>Regular f/u</li>
</ul></li>
</ul></li>
<li>2021-05-07 CT - coronary artery calcium socre, without contrast
<ul>
<li>Nonenhanced ECG-gated CT for calcium scoring was obtained using
64-slice multidetector row CT scanner showed:
<ul>
<li><ol style="list-style-type: decimal">
<li>Calcification of the coronary arteries. (LAD＝17, LCX＝4, RCA＝55).
Total calcium score＝76</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Unremarkable of the pericardium.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The heart size is normal. Calcified aortic valve and mitral valve is
found.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>The visible lung fields are intact.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>There is no evidence of mediastinal LAP at visible field.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Patent airway at the examing field.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-05-03 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (73 - 19) / 73 = 73.97%</li>
<li><ol style="list-style-type: decimal">
<li>Normal LV systolic function with normal wall motion.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Concentric LVH; LV diastolic dysfunction Gr 1.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal RV systolic function.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Aortic valve calcification with moderate AS (AVA(Doppler) = 1.07 cm²
, Mean aortic pressure = 10 mmHg), mild AR; mild MR; mild TR; mild
PR</li>
</ol>
<ul>
<li>Note: Aortic regurgitation (AR); Pulmonary regurgitation (PR);
Mitral regurgitation (MR); Tricuspid regurgitation (TR)</li>
</ul></li>
</ul></li>
<li>2021-02-10 Pure Tone Audiometry, PTA
<ul>
<li>Tymp:
<ul>
<li>R’t perforation; L’t type A.</li>
</ul></li>
<li>ART:
<ul>
<li>R’t ipsi CNT, contra absent.</li>
<li>L’t ipsi absent, contra CNT.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 85 dB HL; LE 41 dB HL.</li>
<li>R’t moderately severe to profound mixed type HL.</li>
<li>L’t mild to moderately severe SNHL.</li>
</ul></li>
</ul></li>
<li>2021-02-05 CT - brain
<ul>
<li>Brain atrophy. Suspected empty sella.</li>
</ul></li>
<li>2021-02-01 Myocardial perfusion SPECT with persantin
<ul>
<li><ol style="list-style-type: decimal">
<li>Probably normal variant or mild stress-induced ischemia in apical
anteroseptal wall, basal inferior wall, and basal inferoseptal wall of
LV.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>No post-stress dilatation of LV.</li>
</ol></li>
</ul></li>
<li>2020-10-30 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (51.9 - 14.4) / 51.9 = 72.25%</li>
<li><ol style="list-style-type: decimal">
<li>Eccentric LVH.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal RV &amp; LV systolic function. No regional wall motion
abnormalities.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Impaired LV relaxation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Calcified aortic valve, with moderate aortic stenosis (AVA 1.16
cm2).</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Mild tricuspid regurgitation.</li>
</ol></li>
</ul></li>
<li>2019-02-11 Doppler flowmetry - perivasculary
<ul>
<li><ol style="list-style-type: decimal">
<li>Access type: native</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Site: left AVF</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Clinical problem: difficult to gain hemostasis</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Age of vascular access:</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Result:</li>
</ol>
<ul>
<li>Left radiocephalic fistual with aneurysmal dilatation at arterial
and vein cannulation site</li>
<li>Vessel size =16-18.4 mm, outflwo cephalic vein at forearm is very
tortuous and duplicated ,</li>
<li>Vein cannulation site = 10.2-10.9 mm, juxta-area =6.8 mm , only
small draining vein at cephalci vein junction</li>
<li>Estiamted volume flow from feeding brachial artery =1250-1320
ml/min</li>
<li>Adjust needle cannulation site</li>
</ul></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Suggestion: Clinical follow up</li>
</ol></li>
</ul></li>
<li>2019-01-02 Bone densitometry - spine
<ul>
<li>L-spines BMD (AP view) performed by DXA revealed:
<ul>
<li>AP L-spines, BMD of L1-4 0.757 gms/cm2, about 2.4 SD below the peak
bone mass (74%) and 0.4 SD above the mean of age-matched people
(110%).</li>
<li>Other detailed data described in the attached reports.</li>
</ul></li>
<li>IMP: osteopenia</li>
</ul></li>
<li>2018-02-14 Doppler color flow mapping, M-mode Echo
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal chamber size</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal LV and RV contractility</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Impaired LV relaxation</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Aortic valve calcification with mild AS</li>
</ol></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-09-02 Nephrology
<ul>
<li>Q
<ul>
<li>for H/D QW 2.4.6</li>
<li>This 89-year old woman, a patient of A- colon of signet ring cell
carcinoma, Immunohistochemical stain — EGFR(+), MLH1(+), MSH2(+),
MSH6(+), PMS2(-). She was admitted for staging work-up. We need
expertise to evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>We will arrrange HD QW246.</li>
<li>Please prescribe EPO 5000U QW4 if Hb &lt;11.</li>
</ul></li>
</ul></li>
<li>2022-08-18 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>She was admitted for suspect UGIB (Upper Gastrointestinal Bleeding).
This time, for loose upper dentures. So we need you evaluation and
suggestion of this patient.</li>
</ul></li>
<li>A
<ul>
<li>For evaluation of mobility of upper bridge</li>
<li>Hx:
<ul>
<li><ol style="list-style-type: decimal">
<li>epilepsy 2. ESRD 3. HCVD 4. Parkinsonism 5. Hypothyroidism.</li>
</ol></li>
</ul></li>
<li>O:
<ul>
<li><ol style="list-style-type: decimal">
<li>Mibility of 12xx22 was noted.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Poor cooperation was noted.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Poor oral hygiene was noted.</li>
</ol></li>
</ul></li>
<li>A: Periodontitis of tooth 12, 22</li>
<li>P:
<ul>
<li><ol style="list-style-type: decimal">
<li>Explain the current finding to patient</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Suggest reevulation of extraction on OPD after her general condition
is stable.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-15 Nephrology
<ul>
<li>Q: Regular HD day 2,4,6 was noted, we need your evaluation and
arranged Hemodialysis</li>
<li>A: We will arrrange HD QW246. Please prescribe EPO 5000U qW4 if Hb
&lt;11.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Evista (raloxifene) might decrease the absorption of Eltroxin
(levothyroxine). It is recommended to shift Evista from QD to QL or QN.
Or monitor for reduced effects of levothyroxine (ie, signs and symptoms
of hypothyroidism) and reduced serum concentrations of thyroxine if
raloxifene and levothyroxine are concomitantly administered.</li>
<li>Takepron (lansoprazole) should not be ground, but soaked in water
and tube-fed with small granules.</li>
<li>Keppra (levetiracetam) could be administered 500 mg to 1 g every 24
hours (currently 250mg BID in active prescription); a supplemental dose
of 250 to 500 mg is recommended post each hemodialysis session
(currently HD QW246). (ref: Bahte SK, Hiss M, Lichtinghagen R, Kielstein
JT. A missed opportunity - consequences of unknown levetiracepam
pharmacokinetics in a peritoneal dialysis patient. BMC Nephrol.
2014;15:49. <a href="doi:10.1186/1471-2369-15-49" class="uri">doi:10.1186/1471-2369-15-49</a>.)</li>
<li>Midodrine 2mg QW246 is used to prevent hypotension caused by
hemodialysis; the patient’s blood pressure during this hospitalization
was essentially acceptable.</li>
</ul>
</div>
</div>
<div id="section-379" class="section level1">
<h1>700912048</h1>
<div id="section-380" class="section level2">
<h2>220905</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-01 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Compatible with sarcomatoid carcinoma with
nearly total tumor necrosis</li>
<li>The sections show sheets of spindle to polygonal tumor cells with
pleomorphic nuclei and nearly total tumor necrosis.</li>
<li>IHC shows following features: CK(-), CK7(-), Vimentin(+),
Hepatocyte(-) and Arginase-1(-).</li>
</ul></li>
<li>2022-07-27 CT - abdomen
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There are several poor enhancing masses on both hepatic lobes and
the largest one measuring 7.1 cm in S2/3.</li>
</ol>
<ul>
<li>HCCs are highly suspected.</li>
<li>The differential diagnosis include cholangiocarcinoma.</li>
<li>There are filling defects in the right atrium, IVC, left hepatic
vein, both lobes and main trunk portal vein, splenic vein, and superior
mesenteric vein that may be tumor thrombosis?</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>The liver shows irregular contour and atrophy of segment 4 that is
consistent with cirrhosis.</li>
</ol>
<ul>
<li>A hepatic cyst measuring 1.5 cm in S6 is noted.</li>
</ul></li>
<li><ol start="3" style="list-style-type: decimal">
<li>S/P cholecystectomy, splenectomy and hysterectomy.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li>HCCs on both hepatic lobes are highly suspected.</li>
<li>The differential diagnosis include cholangiocarcinoma.</li>
<li>Biopsy is indicated.</li>
<li>There are filling defects in the right atrium, IVC, left hepatic
vein, both lobes and main trunk portal vein, splenic vein, and superior
mesenteric vein that may be tumor thrombosis?</li>
</ul></li>
</ul></li>
<li>2022-07-25 SONO - abdomen
<ul>
<li>Hepatic tumors, bilateral lobes, suspected HCC</li>
<li>Hepatic cyst, right lobe</li>
<li>Parenchymal liver disease</li>
<li>Main portal vein and splenic vein thrombosis</li>
</ul></li>
<li>2022-01-25 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Spondylosis of the T-spine</li>
<li>Increased lung markings on both lower lung are noted. Please
correlate with clinical condition.</li>
</ul></li>
<li>2021-12-16 Polysomnography, PSG
<ul>
<li>Conclusion:
<ul>
<li>RDI: 40.6/hr</li>
<li><ol style="list-style-type: decimal">
<li>Severe obstructive sleep apnea syndrome with moderate desaturation
during sleep.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Sleep efficiency: poor</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>CPAP is indicated for this case, pressure: 9cmH2O</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-11-07 Polysomnography, PSG
<ul>
<li>Conclusion:
<ul>
<li>RDI: 40.6/hr</li>
<li><ol style="list-style-type: decimal">
<li>Severe obstructive sleep apnea syndrome with moderate desaturation
during sleep.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Sleep efficiency: poor</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Refer to ENT/OS for upper airway evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Non-Supine position would be better</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Evaluate heart function.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Body weight reduction.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>CPAP is indicated for this case</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-10-29 CXR
<ul>
<li>elongated and tortuosity of thoracic aorta</li>
<li>moderate enlarged cardiac silhoutte due to prominent pericardial
fat/prominent mediastinal fat pad</li>
</ul></li>
<li>2021-03-09 Cardiac Catheterization
<ul>
<li>In conclusion
<ul>
<li><ol style="list-style-type: decimal">
<li>Patent coronary artery</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>LVEF 77.5% and LVEDP 28mmHG, favor diastolic heart failure.</li>
</ol></li>
</ul></li>
<li>Recommendation
<ul>
<li>DC anti-PLT agent.</li>
</ul></li>
</ul></li>
<li>2021-02-05 Myocardial perfusion SPECT with persantin
<ul>
<li><ol style="list-style-type: decimal">
<li>Probably moderate to severe myocardial ischemia at the anteroapical
wall and anteroseptal wall.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mild reverse redistribution of radioactivity to the lateral wall,
either normal variant or myocardial ischemia may show this picture.</li>
</ol></li>
</ul></li>
<li>2021-01-21 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with normal resting wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated LA, concentric LVH; diastolic dysfunction, Gr 1</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Trivial MR, trivial TR and trivial PR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Mild pulmonary hypertension</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Preserved RV systolic function</li>
</ol></li>
</ul></li>
<li>2021-01-19 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — Negative for malignancy or
dysplasia.</li>
<li>IHC stains: CD117: 1%, CD34: 1%. MPO: 40-50%, CD61: 2-5%; CD71:
25-30%.</li>
</ul></li>
<li>2019-09-16 SONO - abdomen
<ul>
<li>poor echo window: please see discription</li>
<li>fatty liver, moderate (incomplete exam of liver)</li>
<li>poor visualization of pancreas/spleen/ vessels</li>
<li>GB sac not seen</li>
</ul></li>
<li>2019-08-13 SONO - abdomen
<ul>
<li>Fatty liver, mild</li>
<li>Hepatic cyst</li>
<li>Invisible GB</li>
<li>Pleural effusion, left</li>
<li>Minimal left subphrenic fluid collection, post drainage</li>
<li>Pancreas not shown</li>
</ul></li>
<li>2019-08-07 CT - abdomen
<ul>
<li>Left pleural effusion with adjacent lung collapse.</li>
<li>S/P splenectomy.</li>
<li>An encapsulated fluid collection (5.8x9.7cm) at left subphrenic
region.</li>
</ul></li>
<li>2019-08-06 Echo for abdomen
<ul>
<li>Fatty liver, mild</li>
<li>Fluid collection, LUQ of abdomen</li>
<li>Pleural effusion, left</li>
<li>Hepatic cyst</li>
<li>Postcholecystectomy</li>
</ul></li>
<li>2019-08-06 Doppler color flow mapping, M-mode Echo
<ul>
<li>Septal hypertrophy. Dilated LA.</li>
<li>Normal RV &amp; LV systolic function. No regional wall motion
abnormalities.</li>
<li>Impaired LV relaxation.</li>
<li>Mild mitral regurgitation.</li>
<li>Mild tricuspid regurgitation.</li>
</ul></li>
<li>2019-05-17 Surgical Pathology Level IV
<ul>
<li>clinical diagnosis
<ul>
<li>Splenomegaly; Thrombocytopenia, unspecified; Unspecified endocrine
disorder; Corticoadrenal insufficiency;</li>
</ul></li>
<li>pathologic diagnosis
<ul>
<li>Bone marrow, biopsy— negative for malignancy</li>
</ul></li>
<li>Microscopically, it shows normal cellularity (50%), 2:1 of M:E
ration, mature trilineage compnents and presence of occasional
megakaryocytes.</li>
<li>Immunohistochemical stain reveals CD34(-), CD117(-), MPO(+),
CD61(focal+) and CD71(+).</li>
</ul></li>
<li>2018-09-28 Surgical Pathology Level III
<ul>
<li>clinical diagnosis
<ul>
<li>Caculus of gallbladder with acute cholecystitis without mention of
obstruction;</li>
</ul></li>
<li>pathologic diagnosis
<ul>
<li>Gallbladder, laparoscopic cholecystectomy —- Chronic cholecystitis
and cholelithiasis</li>
</ul></li>
<li>Section shows gallbladder mucosal tissue with invaginated sinus
mucosa, marked chronic inflammation and pigmented stone fragments.</li>
</ul></li>
<li>2018-07-23 Multiple Sleep Test
<ul>
<li>diagnosis
<ul>
<li>mild OSAS (AHI 14)</li>
</ul></li>
<li>suggest
<ul>
<li>lateral posture during sleeping</li>
<li>body weight reduction</li>
<li>f/u PSG one year later</li>
</ul></li>
</ul></li>
<li>2018-06-21 H Reflex
<ul>
<li>Comments
<ul>
<li>MNCV: normal</li>
<li>SNCVL normal</li>
<li>F-wave: normal</li>
<li>H-reflex: normal.</li>
</ul></li>
<li>Conclusion
<ul>
<li>This is a normal lowerl limb NCV study.</li>
<li>Please correlate with clinical features.</li>
</ul></li>
</ul></li>
<li>2018-05-29 Sialoscintigraphy
<ul>
<li>Impression
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal uptake function of bilateral parotid glands and impaired
uptake function of bilateral submandibular glands.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>The tracer excretion after acid stimulation was fair to good at four
main salivary glands.</li>
</ol></li>
</ul></li>
<li>Comment
<ul>
<li>Salivery gland uptake: normal &gt; 0.25%, 0.2%–0.25% (mild), 0.15% -
0.2% (moderate), 0.1%-0.15% (marked), and &lt;0.1% (severe).</li>
</ul></li>
</ul></li>
<li>2018-05-24 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver,severe</li>
<li>Propable chronic liver parenchymal disorders (Please correlate with
liver function test)</li>
<li>Suspected GB stone</li>
<li>Splenomegaly</li>
<li>Suboptimal examination of liver due to poor echo window caused by
liver</li>
<li>Fatty change</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Please correlate with other image</li>
<li>Follow liver function test and AFP</li>
<li>Part of liver,especially liver dome was diffcult of approach</li>
<li>Because of fatty liver change and poor echo window,infiltrative
lesion or small lesion may not be excluded completely. Please correlate
with other image or follow sono abd every 3-6 months</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-03 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>The 57 y/o woman has IPT s/p sleenectomy and cholangiocarcinoma was
diagnosis this time, due to massive thrombosis (CT: filling defects in
the right atrium, IVC, left hepatic vein, both lobes and main trunk
portal vein, splenic vein, and superior mesenteric vein that may be
tumor thrombosis.) and protal vein thrombosis, so we need your help for
surgical assessment.</li>
</ul></li>
<li>A
<ul>
<li>S: The 57 y/o woman has IPT /p sleenectomy on 1080725 and
cholangiocarcinoma was diagnosis this time, due to massive thrombosis
(CT: filling defects in the right atrium, IVC, left hepatic vein, both
lobes and main trunk portal vein, splenic vein, and superior mesenteric
vein that may be tumor thrombosis.) and protal vein thrombosis. Surgical
intervention is consulted.</li>
<li>O: vital signs: stable, no fever
<ul>
<li>abdomen: soft, flat, normal bowe sound, no tenderness</li>
</ul></li>
<li>A: bilateral liver cholangiocarcinoma with IVC and Portal vein
thombosis,</li>
<li>P: Surgical intervention is not suggested due to impossible en-bloc
resection</li>
</ul></li>
</ul></li>
<li>2022-07-28 Radiation Oncology
<ul>
<li>Q
<ul>
<li>for arrange CT quiding liver biopsy</li>
<li>This is a 57-year-old woman with past medical hostories of: 1)
Adrenocortical insufficiency; 2) Hypertensive heart disease with heart
failure; 3) Idiopathic Thrombocytopenic Purpura s/p splenectomy; 4) Type
2 DM; 5) COPD; 6) Type 2 DM; 7) Severe obstructive sleep apnea syndrome
with moderate desaturation during sleep.</li>
<li>She regular at chest/CV/Meta/Oncology OPD follow up.</li>
<li>This time, she suffered from poor appetite, body weight loss about
10Kg/6 months. She visited to our Chest OPD regular follow up. Blood
test was done that showed abnormal liver functions. She was refer to our
GI OPD for management. At GI OPD, hepatitis markers with HBsAg, Anti HCV
were follow up that showed negative finding. Autoimmune hepatitis
profile with IgG, ANA, ASMA, AMA, IgG4 that showed ANA 1:160. Abdominal
sonography was performed which revealed hepatic tumors, bilateral lobes,
suspected HCC; hepatic cyst, right lobe; parenchymal liver disease and
main portal vein and splenic vein thrombosis. Explained this condition
to herself, she understood. Under the impression of Suspect HCC. She was
admitted to our GI ward for management and further survey.<br />
</li>
<li>Now, due to abdominal CT showed suspect HCCs on both hepatic lobes
with right atrium, IVC, left hepatic vein, both lobes and main trunk
portal vein, splenic vein, and superior mesenteric vein thrombosis. The
differential diagnosis include cholangiocarcinoma.</li>
<li>We need your further survey for liver biopsy.</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, biopsy is
indicated.</li>
</ul></li>
</ul></li>
<li>2022-07-28 Dermatology
<ul>
<li>Q
<ul>
<li>After admission, she complained about severe lower legs redness (LMD
diagnosis: Vasculitis) but now symptoms intensify. Now, we need your
further survey. Thanks a lot!!!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from brownish patches on bil legs for
months.</li>
<li>Imp: Stasis Dermatitis</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Sinpharderma 1 tube/bid</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Topsym cream 4 tubes/bid</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-381" class="section level3">
<h3>==========</h3>
</div>
<div id="section-382" class="section level3">
<h3>2022-08-04</h3>
<ul>
<li><p>Patients with acute portal vein thrombosis should be started on
low molecular weight heparin to achieve rapid anticoagulation, with a
switch to an oral anticoagulant (warfarin or possibly a direct-acting
oral anticoagulant [DOAC]) once the patient’s condition has stabilized
and no invasive procedures are planned.</p></li>
<li><p>Patients with chronic portal vein thrombosis when treated with
anticoagulation, enoxaparin is more often used rather than warfarin
because of its shorter duration of action, less variability in
anticoagulation, decreased need for monitoring, and decreased difficulty
when managing patients around the time of liver transplantation. An
alternative is to use an oral anticoagulant.</p></li>
<li><p>If warfarin is used, goal INR can be set as 2 to 3. (2022-08-03
INR 1.24)</p></li>
<li><p>Enoxaparin (in active prescription now) used for venous
thromboembolism treatment in patients with active cancer:</p>
<ul>
<li>Months 1 to 6: SUBQ: Initial: 1 mg/kg every 12 hours (this patient
is 80 kgw =&gt; 80mg Q12H) or 1.5 mg/kg once daily (120mg QD; now 60mg
Q12H in active prescription) for a total duration of 3 to 6 months.
Twice-daily dosing may be more efficacious than once-daily dosing based
on post hoc data (60mg Q12H is better than 120mg QD).</li>
<li>Maintenance beyond 6 months: considering continuing anticoagulation
beyond 6 months in select patients due to the persistent high risk of
recurrence in those with active cancer; consider risk versus benefit of
bleeding and recurrence.</li>
<li>No issue with active prescription.</li>
</ul></li>
<li><p>Direct oral anticoagulant (DOAC) therapy is an alternative to
enoxaparin or warfarin for treating chronic portal vein thrombosis.</p>
<ul>
<li>The patient has good renal function (2022-08-03 Cre 0.53, eGFR 126),
so, except for edoxaban (CrCl &gt;95 mL/minute: edoxaban use is not
recommended due to increased risk of ischemic stroke compared to
warfarin), any of dabigatran, rivaroxaban, apixaban, or betrixaban might
be a candidate for treatment.</li>
<li>In the case of Child-Pugh B or C, both rivaroxaban and betrixaban
are contraindicated, so dabigatran or apixaban might be a better
alternative, even if the patient has a slightly deteriorated liver
function. (reference: <a href="https://www.ahajournals.org/doi/10.1161/JAHA.120.017559" class="uri">https://www.ahajournals.org/doi/10.1161/JAHA.120.017559</a>
)</li>
<li>Dabigatran has not been studied in patients with active cancer (ACCP
[Stevens 2021]; ASCO [Key 2020]).</li>
<li>Apixaban might be used in patients with active cancer (eg,
metastatic disease or receiving chemotherapy) (ACCP [Stevens 2021];
Agnelli 2020; Leader 2020; McBane 2019).</li>
</ul></li>
<li><p>Apixaban oral 10 mg twice daily for certain duration followed by
5 mg twice daily.</p>
<ul>
<li>Optimal duration of therapy is unknown and is dependent on many
factors, such as presence of provoking events, patient risk factors for
recurrence and bleeding, and individual preferences.</li>
<li>Provoked venous thromboembolism: 3 months (provided provoking risk
factor is no longer present).</li>
<li>Unprovoked venous thromboembolism or provoked venous thromboembolism
with a persistent risk factor: &gt;=3 months depending on risk of venous
thromboembolism (VTE) recurrence and bleeding.</li>
<li>All patients receiving indefinite therapeutic anticoagulation with
no specified stop date should be reassessed at periodic intervals.</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-383" class="section level1">
<h1>701269412</h1>
<div id="section-384" class="section level2">
<h2>220905</h2>
<ul>
<li>diagnosis
<ul>
<li>2022-08-19 discharge
<ul>
<li>1: Malignant neoplasm of extrahepatic bile duct</li>
<li>2: Cholangitis</li>
<li>3: Obstruction of bile duct</li>
<li>4: Essential (primary) hypertension</li>
<li>5: Enlarged prostate with lower urinary tract symptoms</li>
</ul></li>
</ul></li>
<li>past history
<ul>
<li><ol style="list-style-type: decimal">
<li>Cholangiocarcinoma T3N2M1, stage IV (Diagnosed on 20220728, Liver
and peritoneum mets)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hypettension</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Duodenal ulcer</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Nasal cavity benign neoplasm s/p OP</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>BPH</li>
</ol></li>
</ul></li>
<li>lab data
<ul>
<li>CA199
<ul>
<li>2022-09-05 CA199 &gt;19090.00 U/mL<br />
</li>
<li>2022-07-22 CA199 &gt;19680.00 U/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-05 SONO - abdomen
<ul>
<li>Diagnosis (Poor echo window, Pancreas and CBD masked by bowel)
<ul>
<li>Parenchymal liver disease</li>
<li>Liver tumor (6.89cm and 3.69cm), rigth lobe</li>
<li>Dilated bilateral IHD</li>
<li>Gallbladder sludge</li>
<li>s/p biliary stent.</li>
<li>Ascites, moderate</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlated with other image study</li>
</ul></li>
</ul></li>
<li>2022-09-03 CT - abdomen
<ul>
<li>Indication
<ul>
<li>cholangiocarcinoma with Liver and peritoneum metachest tighness,
malnutrition with elevation of bilirubin and ALT level suspected tumor
progress and further mets</li>
</ul></li>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Progression of mass lesion around gallbladder and CBD. Infiltration
lesions in S8 of liver.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilation of IHDs. s/p biliary stent.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Progression of peritoneal carcinomatosis.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Progression of ascites.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No bony destructive lesion on these images.</li>
</ol></li>
</ul></li>
<li>Impression
<ul>
<li>c/w cholangiocarcinoma with liver and peritoneum metastasis, in
progression;</li>
<li>DDx: gallbladder cancer</li>
</ul></li>
</ul></li>
<li>2022-09-02 Ascites tapping
<ul>
<li>About 3000ml brown asictes was drained.</li>
</ul></li>
<li>2022-08-17 CXR
<ul>
<li>Patchy opacity projecting in the right upper lung is suspected.
Please correlate with CT.</li>
</ul></li>
<li>2022-08-17 Ascites tapping
<ul>
<li>About 3000ml yellow cloudy asictes was drained.</li>
</ul></li>
<li>2022-08-15 Body fluid cytology - ascites
<ul>
<li>Smears show lymphocytes, reactive mesothelial cells, and atypical
hyperchromatic cells with prominent nucleoli.</li>
<li>Malignancy is suspected.</li>
</ul></li>
<li>2022-08-12 SONO - abdomen
<ul>
<li>Parenchymal liver disease</li>
<li>Liver tumor (0.3cm and 2.7cm), rigth lobe, unknwon etiology.</li>
<li>GB tumor</li>
<li>Prominent left IHD</li>
<li>suspicious, peritoneal carcinomatosis</li>
<li>pancreas masked by bowel.</li>
<li>Ascites, severe.</li>
</ul></li>
<li>2022-08-12 Ascites tapping
<ul>
<li>About 3000ml yellow nontransparent asictes was drained.</li>
</ul></li>
<li>2022-08-11 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Left axis deviation</li>
<li>Septal infarct, age undetermined</li>
</ul></li>
<li>2022-08-11 CXR
<ul>
<li>Patchy opacity projecting in the right upper lung is suspected.
Please correlate with CT.</li>
</ul></li>
<li>2022-07-28 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Adenocarcinoma, moderately differentiated,
compatible with cholangiocarcinoma</li>
<li>The sections show a picture of adenocarcinoma, composed of nests,
cords, and single large pleomorphic neoplastic cells in fibrous stroma.
Focal glandular differentiation is present.</li>
<li>IHC shows: CK7(+), CK19(+), CK20(-), and Hepatocyte(focal +). The
finding is compatible with cholangiocarcinoma.</li>
</ul></li>
<li>2022-07-27 Endoscopic ultrasound guided fine needle biopsy, EUS-FNB
<ul>
<li>Suspect gall bladder cancer with biliary obstruction, s/p CH-EUS and
EUS FNB</li>
</ul></li>
<li>2022-07-25 Endoscopic Retrograde CholangioPancreatography, ERCP
<ul>
<li>After standard sphincterotomy, one plastic biliary stents with
Boston Scientific 7 Fr. 12 cm are placed for free drainage.</li>
<li>diagnosis: Biliary duct stricture s/p EST &amp; plastic stents
(Boston Scientific 7 Fr. 12 cm)</li>
<li>suggestion: f/u amylase &amp; lipase</li>
</ul></li>
<li>2022-07-23 CT - abdomen
<ul>
<li>indication: Jaundice</li>
<li>Imp:
<ul>
<li>Soft tissue mass at distal CBD and cystic duct with obliterating
biliary tree with dilated IHDs and CBD, cholangiocarcinoma is
favored.</li>
<li>Liver mets and diffuse cancerous peritonitis is found. Suggest
tissue proof.</li>
</ul></li>
<li>Imaging Report Form for Cholangiocarcinoma
<ul>
<li>Impression (Imaging stage) : T:T3(T_value) N:N2(N_value)
M:M1(M_value)</li>
</ul></li>
</ul></li>
<li>2022-07-23 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>GB tumor</li>
<li>Bil IHDS &amp; CHD dilatation</li>
<li>Parenchymal liver disease</li>
<li>Ascites, trivial amount</li>
</ul></li>
<li>Suggestion
<ul>
<li>CECT study</li>
</ul></li>
</ul></li>
<li>2022-07-22 CXR
<ul>
<li>Compression fracture of T spine.</li>
</ul></li>
<li>2022-07-22 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Left axis deviation</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-02 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This 66 year-old male has the histories of 1. Hypettension. 2.
Duodenal ulcer. 3. Nasal cavity benign neoplasm post biopsy. He was
regullar follow up at GI LMD. He ever came to GI LMD due to body weight
lose 6kgs for a year and tea colored urine, clay stool and poor appetite
for a week. Blood analysis showed no leukocytosis (9.42*10^3/uL), but
left shift (SEG: 80.3 %), elevated hepatobiliary enzyme (AST:148
U/L,ALT:327 U/L, TBI:12.19mg/dl, r-GT:390 U/L,ALP:317 IU/L). HBsAg and
Anti-HCV were nonreactive. Abdominal CT was performed on 20220723 and
reported cholangiocarcinoma T3N2M1, stage IV. Liver biopsy pathology
showed Cholangiocarcinoma. So we need you evaluation and suggestion of
this patient. Thank you very much ~</li>
</ul></li>
<li>A
<ul>
<li>Recommendation:</li>
<li>palliative chemotherapy maybe helpful for this patient</li>
<li>port-A implantation if patient agree chemotherapy</li>
</ul></li>
</ul></li>
<li>2022-08-01 Urology
<ul>
<li>Q
<ul>
<li>This time, he sufferred from dysuria. So we need you evaluation and
suggestion of this patient. Thank you very much ~</li>
</ul></li>
<li>A
<ul>
<li>The patient reported urinary frequency with small amount. U/A is
clean.</li>
<li>He had OAB (overactive bladder, may due to disease or medication
realted) and we will prescribed antimuscarinic for him.</li>
<li>If symptoms did not improved may contact further evaluation</li>
</ul></li>
</ul></li>
<li>2022-07-28 Radiation Oncology
<ul>
<li>Q</li>
<li>Abdominal CT was performed on 20220723 and reported
cholangiocarcinoma T3N2M1, stage IV. We need arrange CT Guide Biopsy of
liver, thank you~</li>
<li>A</li>
<li>According to the clinical condition and imaging findings, biopsy is
indicated.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-12 - fluorouracil 1000mg/m2 1500mg 22hr D1-5 + cisplatin
100mg/m2 150mg 3hr D2</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-385" class="section level1">
<h1>701370041</h1>
<div id="section-386" class="section level2">
<h2>220905</h2>
<ul>
<li>exam finding
<ul>
<li>2022-09-03 CXR
<ul>
<li>Left lower lung infiltrates.</li>
<li>Borderline cardiomegaly.</li>
<li>Tortuous thoracic aorta with intimal calcification.</li>
<li>Thoracic spondylosis.</li>
</ul></li>
<li>2022-07-25, -07-21 CXR
<ul>
<li>small Lt pleural effusion and Rt subpulmonary effusion</li>
<li>Linear band subsegmental atelectasis at Lt lung base</li>
<li>Tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch and D-aorta<br />
</li>
<li>appropriately positioned gastric tube</li>
</ul></li>
<li>2022-07-20 CT - abdomen, pelvis
<ul>
<li>History: bloody stool</li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There is segmental circumferrential wall thickening at the sigmoid
colon, measuring 5.5 cm in length and 1.6 cm in maximal wall thickness.
Adenocarcinoma is highly suspected.</li>
</ol>
<ul>
<li>In addition, There is a soft tissue mass measuring 4 cm in width at
the adjacent mesocolon that may be exophytic tumor or metastatic
node?</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>There is a poor enhancing lesion measuring 5.3 cm in left kidney
lower pole with suggestive central soft tissue nodular component that
may be cyst or cystic tumor? Please correlate with sonography and
contrast-enhanced dynamic CT.<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>There are bilateral Pleura effusion (more severe on left side) and
passive atelectasis in left posterior basal lung.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>S/P nasogastric tube insertion</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>There is mild ascites in right perihepatic space, left para-colic
gutter space, and pelvis. please correlate with clinical condition or
ascites cytology.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>The urinary bladder shows small size, mild wall thickening., gas
content and S/P Foley’s catheter insertion.</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Disc space narrowing with marginal osteophyte formation and vacuum
phenomenon of L3-4, L4-5 and L5-S1.</li>
</ol></li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3 (T_value) N:N1a (N_value) M:M0
(M_value) STAGE:IIIB(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-07-19 Patho - colon biopsy
<ul>
<li>Colon, 18 cm to 22 cm from anal verge, biopsy — Adenocarcinoma,
moderately differentiated<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>The immunohistochemical stains reveal EGFR(+), PMS2(+), MLH1(+),
MSH2(+), and MSH6(+).</li>
</ul></li>
<li>2022-07-19 CXR
<ul>
<li>appropriately positioned gastric tube<br />
</li>
<li>enlarged cardiac silhoutte</li>
<li>mixed crowding of vascular markings and reticular opacities
over</li>
<li>left lower lung zone?</li>
</ul></li>
<li>2022-07-18 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Highly suspected colon cancer, with mild oozing, 18cm to 22cm AAV,
s/p biopsy.</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
<li>CRS consultation</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-07-13 ECG (ICU)
<ul>
<li>note: low data quality</li>
<li>Sinus tachycardia</li>
<li>Incomplete right bundle branch block</li>
<li>ST elevation consider inferior injury or acute infarct</li>
<li>ECG interpretation of ACS is based on presence of symptoms and ST
elevation in Inferior leads with Reciprocal ST depression in Anterior
leads and T-wave inversion in Septal leads</li>
</ul></li>
<li>2022-07-12 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (81.3 - 28.0) / 99.3 = 65.56%</li>
<li><ol style="list-style-type: decimal">
<li>Sub-optimal echo window</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal AV/MV with no AR/MR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Concentric LVH</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved LV and RV systolic function</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No PR/TR, dilated IVC</li>
</ol></li>
</ul></li>
<li>2022-07-08 CT - brain
<ul>
<li>A soft tissue tumor (1.5cm) at left CP angle cistern r/o
meningioma.</li>
<li>Brain atrophy. Sinusitis.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-15 Dermatology
<ul>
<li>Q
<ul>
<li>At ONC ward, vital signs stable and we will explained the current
condition to patient and family.Radiothist was consulted for
radiotherapy and started on 2022/08/12.</li>
<li>However, his skin rash was noted during hospitalization. we need
your expertise further management, thanks</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from mutiple erytheamtous patches on trunk and
4 limbs for days.</li>
<li>IMp: Tinea corporis</li>
<li>Suggestion: Zalain cream * 2 tubes/bid</li>
</ul></li>
</ul></li>
<li>2022-08-05 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This is a 81 years old male with uderlying disease of DM, HTN,
dementia. He was admission due to suffered from a consciousness change
since 20220707. Palpitations, shortness of breath, dyspnea, pyuria,
spiky fever and generalized malaise for 2 days were noted. Then the
patient was brought to our ER for help. Con’s: E2V2M4, O2 saturation:
87%. The laboratory data showed leukcoytosis and elevated of CRP level,
acute kidney injury was also noted BUN 143 / Cr 5.5. The urinlyais
showed UTI picture, the CXR film showed bilateral infiltration, under
the impression of sepsis, pneumonia and UTI related, then he was
admission to INF ward for further management on 2022-07-10. At ward, NG
insert for prevent chocking. The antibiotic Avelox plus Tapimycin on
2022/07/11. We discuss with families, they decided DNR except
medication. Due to unstable hemodynamic condition, he was transferred to
MICU for further treatment on 2022/07/11.</li>
<li>&lt; MICU course 20220711-0728 &gt; At MICU, we kept the antibiotics
of Tapimycin (20220711-0720) and Ciproxin (20220712-0719). NRM was
changed to V-M 12L/min and the patient was tolerant. We added inhalation
medication for COPD. Cardiac echo was arranged and showed normal wall
motion. Cardiologist was consulted for AF control. Diltiazem and Plavix
were suggested. For weak cough function and much sputum, VEST was
arranged (20220716-0726). Hypernatramia was improved after adequate IV
and oral water. The patient’s respiratory pattern was getting smoother
under treatment. However, brick-red stool was noted since 20220717
night. Plavix was hold. Sidmoidoscopy revealed erosion with oozing, susp
tumor bleeding. Thus we consulted CRS then abdominal CT was suggested.
We also explained to his family about the condition, they favor
conservative treatment. The abdominal CT showed Sigmoid adenocarcinoma,
cT3N1aM0, stage IIIB. We added Albumin and lasix for generalized edema
and kept I/O negative. Less brick-red stool noted thus NG diet was
given. Antibiotic was shifted to Curam (20220721~). Under stable
condition, he was transferred back to ordinary ward on July 27,
2022.</li>
<li>&lt; Ward course 7/28~ &gt; After he was transferred to our ward, we
kept Curam for prophylactic treatment. Smooth respiratory under nasal
cannula used. We consulted Oncology for colon cancer evaluation and
management. Intermittent brick-red stool and black stool passage under
Transamin iv treatment. L-PRBC transfusion was done for Anemia. The
general condition was improvment and stationary. Today, he will be
transferred to the oncology ward and taken over by oncologist chief
Chang for further cancer further management on Aug 03, 2022. At ONC
ward, vital signs stable and we explianed the current condition to
patient and family, they agree the radiotherapy therapy. We need your
expertise for radiotherapy evaluation, thanks.</li>
</ul></li>
<li>A
<ul>
<li>This 81 y/o male sufferred from bloody stool. The abdominal CT
showed Sigmoid adenocarcinoma, cT3N1aM0, stage IIIB. Due to poor general
condition, surgery or chemotherapy is not feasible, according to his
daughter.</li>
<li>Palliative RT for bleeding control and obstruction prevention is
indicated. Plan to deliver 45 Gy/ 25 fx to the pelvis. Then boost the
rectal tumor and LAPs to 54 Gy/ 30 fx. However, due to he’s bed-ridden
now, his daughter will ask if he can stay at the ward during the whole
radiotherapy course. If he can, CT-simulation will be arranged
accordingly. Thank you very much.</li>
</ul></li>
</ul></li>
<li>2022-07-18 Colon and Rectal Surgery
<ul>
<li>Q
<ul>
<li>Episodes of bloody stool passaged and Hgb drop was noted, LPRBC 2U
*2 days(20220717-0718) and sigmoidoscopy of 20220718 which showed
suepected cancer with bleeding related (about 20cm AAV). We need your
expert to evaluate his condition. Thank a lot!</li>
</ul></li>
<li>A
<ul>
<li>wait sigmoidoscopy report</li>
<li>Blood transfusion and resuscitation as needed</li>
<li>suggest CT to evlaution if cancer is highly suspected.</li>
</ul></li>
</ul></li>
<li>2022-07-13 Cardiology
<ul>
<li>Q:
<ul>
<li>We need your expertise for evaluation and suggestion of elevated
hsTnI and AF medication. Thanks a lot!</li>
<li>hs-Troponin I                      
<ul>
<li>2022-07-08 21:39 11899.3 pg/mL          </li>
<li>2022-07-09 00:11 13997.4 pg/mL          </li>
<li>2022-07-09 06:57 12819.3 pg/mL          </li>
<li>2022-07-09 20:18 11471.6 pg/mL       - A</li>
</ul></li>
<li>This is a 81 years old man who was admitted for urosepsis with
pneumonia. Has consent for DNR. We were consulted for elevated trop and
Af</li>
<li>Cardiac echo 20220713 EF: 65%
<ul>
<li><ol style="list-style-type: decimal">
<li>Sub-optimal echo window</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal AV/MV with no AR/MR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Concentric LVH</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved LV and RV systolic function</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No PR/TR, dilated IVC</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-07 Orthopedics
<ul>
<li>Q
<ul>
<li>fell down on the groung</li>
<li>lower back pain, bil hip pain, right knee pain</li>
<li>could not weight bearing</li>
<li>ILOC (-), head injury (-)</li>
<li>Allergy: -</li>
<li>Past history: dementia, DM, HTN</li>
<li>Exposure (TOCC): denied</li>
<li>Trauma hx: denied</li>
</ul></li>
<li>A
<ul>
<li>81 y/o M</li>
<li>A: right knee pain and right ankle pain, suspected patella and ankle
fracture</li>
<li>P: long leg splint and OPD follow-up</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Na (2022-09-04 132 mmol/L &lt;- 2022-09-03 126 mmol/L), K
(2022-09-04 3.9 mmol/L &lt;- 2022-09-03 6.1 mmol/L). Hyperkalemia and
hyponatremia have been alleviated.</li>
<li>In spite of the fact that AKI in July has improved, kidney function
has decreased over the past week. (Cre 2022-09-03 1.35 mg/dL &lt;-
2022-08-24 1.03 mg/dL, BUN 2022-09-03 33 mg/dL &lt;- 2022-08-24 27
mg/dL)</li>
<li>If the patient’s kidney function deteriorates, the dose of
tranexamic acid, Fylin (pentoxifylline), Glucophage (metformin), and
Feburic (febuxostat) listed in active prescription might need to be
adjusted.</li>
</ul>
</div>
</div>
<div id="section-387" class="section level1">
<h1>701431395</h1>
<div id="section-388" class="section level2">
<h2>220905</h2>
<p>{Lung cancer at right lower lung, adenocarcinoma, with multiple brain
metastasis, cT4N0M1b, stage IV, with mukltiple brain metastasis, PD-L1:
TC &lt; 1%, IC &lt; 1%, TPS &lt; 1 %, EGFR E19 deletion and T790M
(+)}</p>
<ul>
<li>lab data
<ul>
<li>2022-07-07 HBsAg Nonreactive<br />
</li>
<li>2022-07-07 HBsAg (Value) 0.29 S/CO<br />
</li>
<li>2022-07-07 Anti-HBs 263.06 mIU/mL</li>
<li>2022-07-07 Anti-HCV Nonreactive<br />
</li>
<li>2022-07-07 Anti-HCV Value 0.20 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-09-02, -08-29 CXR
<ul>
<li>Patchy opacity of the right lower lung zone and several nodular
opacity projecting at both lung are noted that may be primary lung
cancer with lung to lung metastases. Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
<li>Patchy consolidation of the right middle lung zone is suspected.
Please correlate with clinical condition or CT.</li>
</ul></li>
<li>2022-08-26 KUB
<ul>
<li>S/P wires projecting at the midline abdominal and pelvic wall.</li>
<li>Fecal material store in the colon.</li>
<li>Compression fracture of T12 vertebral body.</li>
</ul></li>
<li>2022-08-24 MRI - C-spine
<ul>
<li>heniated discs in the C3/4, C4/5, C5/6 and C6/7 discs, more on the
C6/7 disc.</li>
<li>spinal canal stenosis at the middle and lower C-spine.</li>
</ul></li>
<li>2022-08-22 MRI - L-spine
<ul>
<li>After IV contrast administration shows well or heterogenous
enhancement at C4,5 bodies, metastases?</li>
</ul></li>
<li>2022-08-22 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible Left atrial enlargement</li>
<li>Poor wave progression V1~4</li>
<li>Nonspecific T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-07-26 PD-L1 IHC
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percentage of 28-8 expressing tumor cells (%TC): 0%</li>
</ul></li>
<li>2022-07-26 PD-L1 22C3
<ul>
<li>Tumor Proportion Score (TPS) category: TPS &lt; 1%</li>
</ul></li>
<li>2022-07-26 PD-L1 (SP142)
<ul>
<li>Result:
<ul>
<li>Tumor cell (TC) staining assessment: TC category: TC &lt; 1%</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC &lt; 1%</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
<li>2022-07-26 ROS1 FISH
<ul>
<li>ROS1 fluorescent-in-situ hybridization report - rearrangement of
ROS1 gene is NOT detected. Patient with NO ROS1 gene arrangement may not
benefit from therapy with ROS1-targeted inhibitors.</li>
</ul></li>
<li>2022-07-26 EGFR mutation
<ul>
<li>Two mutations were detected at exon 19 (Del) and exon 20 (T790M) of
EGFR gene in this specimen.</li>
</ul></li>
<li>2022-07-12 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>Mildly increased activity in the lower C-spine, lower T-spine and
L5-sacrum junction. Degenerative change is more likely.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>A faint hot spot in the anterior aspect of left 1st rib. The nature
is to be determined (post-traumatic change? other nature?). Please
follow up bone scan for further evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders, left wrist, bilateral
hips and right knee, compatible with benign joint lesions.</li>
</ol></li>
</ul></li>
<li>2022-07-11 Patho - lung wedge biopsy
<ul>
<li>Lung, right, CT-guide biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show acinar glandular cells infiltrating in a fibrotic
stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(+) and Napsin A(+). The
results are supportive for the diagnosis.</li>
</ul></li>
<li>2022-07-09 CXR
<ul>
<li>Patchy opacity of the right lower lung zone and several nodular
opacity projecting at both lung are noted that may be primary lung
cancer with lung to lung metastases. Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
</ul></li>
<li>2022-07-09 MRI - brain
<ul>
<li>Multiple bil. brain and upper left brain stem metastases, more
prominent at left cerebellum and left frontal lobe.</li>
</ul></li>
<li>2022-07-07 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible Left atrial enlargement</li>
<li>Poor wave progression V1~4</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-26 Rehabilitation
<ul>
<li>A
<ul>
<li>Due to 4 limbs weakness, we were consulted for bedside PT
rehabilitation programs.</li>
<li>MP:
<ul>
<li>RUL/RLL: 4/3 LUL/LLL: 4/3 (before Radiotherapy, MP was 2-3/3;
4/3)</li>
</ul></li>
<li>Functional status: needs min assistance</li>
<li>BADL: needs miin assistance</li>
<li>Assessment
<ul>
<li>Lung cancer at right lower lung, adenocarcinoma</li>
<li>HTN</li>
<li>HIVD, heniated discs in the C3/4, C4/5, C5/6 and C6/7 discs, more on
the C6/7 disc.</li>
</ul></li>
<li>Plan
<ul>
<li>arrange rehab OPD after discharge for further Rehabilitation
programs: PT rehabilitation programs</li>
</ul></li>
<li>Goal: improve endurance and muscle strength</li>
</ul></li>
<li>2022-08-30 supplement
<ul>
<li>The discharge plan was posponed due to unstable condition and fever.
We were consulted today for arrangement of rehab training.</li>
<li>Fever 38.1-38.3’C with chillness was noted when I visited.</li>
<li>Consciousness: intact</li>
<li>Cognition: intact, oriented, could follow orders</li>
<li>Mobility: lying on bed due to discomfort and general weakness.</li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: improve endurance and muscle strength</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-24 Radiation Oncology
<ul>
<li>Q
<ul>
<li>Brain MRI (20220709): Multiple bil. brain and upper left brain stem
metastases, more prominent at left cerebellum and left frontal lobe.
Consult radiation oncology for CT-guide biopsy at right lung the report
showed RLL lung mass, s/p CT-guided biopsy. Minimal pneumothorax on
20220709. The biopsy report showed adenocarcinoma, moderately
differentiated, immunohistochemical stains reveal TTF-1(+) and Napsin
A(+), PD-L1: TC &lt; 1%, IC &lt; 1%, TPS &lt; 1 %, EGFR E19 deletion and
T790M (+). And received radiotherapy with dose: 660cGy/2 fractions (6 MV
photon) to brain metastasis, 2022/07/29-2022/08/01, then RT dose:
2310cGy/7 fractions (6 MV photon) to brain metastasis,
2022/08/01-2022/08/08, RT dose: 3960cGy/12 fractions (6 MV photon) to
brain metastasis, 2022/08/08- 2022/08/15, the targeted therapy as
Afatinib 1tab QOD since 2022/08/09.</li>
<li>This time, she came to radiation oncology OPD foloow-up, then
complaints bilateral lower limbs weakness and lethargy for two weeks,
and suspect intramedullary metastasis and spinal cord compression, so
she was transferred to our ER for help. At ER, followed-up chest X-ray
showed a mass lesion in right lower lung zone, the L-spine MRI
(20220822) showed: no obvious spinal cord mass or nodule. After IV
contrast administration shows well or heterogenous enhancement at C4,5
bodies, metastases? we already arrange the C-spine MRI on 20220824. So
we need your help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>Past Hx: HTN(-); no DM.</li>
<li>Initial presentation with clonus over right side.</li>
<li>Lung nodule noted in 2022-04; Brain CT on 2022-06-16: multiple bran
metastasis.</li>
<li>Rt hemiweakness for 1-2 months.</li>
<li>2022/07/11 PATHO-Lung wedge biopsy: adenocarcinoma, moderately
differentiated.</li>
<li>immunohistochemical stains reveal TTF-1(+) and Napsin A(+), PD-L1:
TC &lt; 1%, IC &lt; 1%, TPS &lt; 1 %; EGFR Exon 19 deletion and T790M
(+).</li>
<li>2022/07/12 bone scan: 1. Mildly increased activity in the lower
C-spine, lower T-spine and L5-sacrum junction. Degenerative change is
more likely. 2. Increased activity in the maxilla and mandible. Dental
problem may show this picture. 3. A faint hot spot in the anterior
aspect of left 1st rib. The nature is to be determined (post-traumatic
change? other nature?).</li>
<li>2022/07/09 MRI: Brain: Multiple bil. brain and upper left brain stem
metastases, more prominent at left cerebellum and left frontal
lobe.</li>
<li>She has suffered from bilateral lower limbs weakness and lethargy
for two weeks.</li>
<li>C-T-L spine MRI on 20220822: T-L spines: No obvious spinal cord mass
or nodule. Presence of anterior wedge deformity or body collapse of the
thoracic or lumbar spine due to compression fracture at T12, old. No
evident tumor like bony destructive lesion. Presence of
spondylolisthesis at L5/S1 was found.</li>
<li>C-Spine: No obvious spinal cord mass or nodule. After IV contrast
administration shows well or heterogenous enhancement at C4,5 bodies,
metastases?</li>
<li>C spine MRI with contrast, 20220824: high SI change on T2WI in the
C6-7 cord; degeerative change in the C-spine disc spaces; moderate
decreased disc spaces in the C3/4, C4/5, C5/6 and C6/7 discs. Herniated
discs in the C3/4, C4/5, C5/6 and C6/7 discs caused mild anterior
indentation on the C3-4, C4-5 and C5-6 cord; severe indentation on the
C6-7 cord and moderate left C6-7 foraminal stenosis. Unremarkable change
in the bone marrow signal intensity. Degenerative change in the C-spine
facet joints. IMP: 1. heniated discs in the C3/4, C4/5, C5/6 and C6/7
discs, more on the C6/7 disc. 2. spinal canal stenosis at the middle and
lower C-spine.</li>
</ul></li>
<li>Imp: Lung cancer, RLL, adenocarcinoma, with multiple brain
metastasis, cT4N0M1b, with multiple brain metastasis, ECOG =2;
<ul>
<li>s/p brain RT for 3960cGy/12 fx, 2022/7/29 to 8/15;</li>
<li>under targeted therapy as Afatinib 1tab QOD since 2022/08/15.</li>
<li>Herniated discs in the C3/4, C4/5, C5/6 and C6/7 discs caused mild
anterior indentation on the C3-4, C4-5 and C5-6 cord; severe indentation
on the C6-7 cord and moderate left C6-7 foraminal stenosis.</li>
</ul></li>
<li>Plan: Please consult Rehabilitation &amp; NS for further evaluation.
I will F/U this patient at my OPD and arrange follow-up brain MRI for
her. Thanks very much for your consultation.</li>
</ul></li>
</ul></li>
<li>2022-07-08 Radiation Oncology
<ul>
<li>Q
<ul>
<li>For lung CT-guide biopsy</li>
<li>The 89 y/o woman has hypertension with Sevikar control at Central
Clinic &amp; Hospital. She also has rectal cancer in age 60 at Central
Clinic &amp; Hospital, stage unknown.</li>
<li>She has SOB and fatigue noted in 2022-04, check CXR showed nodule at
Central Clinic &amp; Hospital, and then took some bronchodilator and
anti-cough medicine control. Suddenly unable to lift right hand during
meal time on 20220612 and sent to Central Clinic &amp; Hospital for
help.</li>
<li>The brain CT showed brain metastasis. She denied BW loss within 3
months. Now, she need family support for walk. She came to our neuro OPD
and refered to ONC OPD on 20220630. Under the impression of suspect lung
cancer with brain mets, so she was admitted on 20220707.</li>
</ul></li>
<li>A
<ul>
<li>This 89-year-old patient is a case of right lung mass, suspected
malignancy. CT-guided biopsy is indicated.</li>
<li>Please chek platelet, PT, and aPTT before this procedure. We will
inform the risk of insufficient specimen, pneumothorax, hemorrhage,
infection, and air embolism to the patient and the family.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-08-08 ~ 2022-08-15 - 3960cGy/12 fractions (6 MV photon) to
brain metastasis</li>
<li>2022-08-01 ~ 2022-08-08 - 2310cGy/7 fractions (6 MV photon) to brain
metastasis</li>
<li>2022-07-29 ~ 2022-08-01 - 660cGy/2 fractions (6 MV photon) to brain
metastasis</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-09 ~ Giotrif (afatinib 30mg/tab) 1# QOD</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>2022-08-30 blood culture result Escherichia coli is currently
treated with flomoxef with no issue.</li>
<li>2022-08-30 semifluid stool OB 2+, HGB has been declining (2022-09-05
9.8 g/dL &lt;- 2022-08-22 11.8 g/dL). Possible GI bleeding is treated
with pantoprazole 40mg IVD QD currently.</li>
<li>BUN/creatinine ratio increases due to a low serum creatinine level
(2022-09-05 0.28 mg/dL &lt;- 2022-07-07 0.63 mg/dL) along with a normal
BUN level (2022-09-05 17 mg/dL). This elevation in the BUN-to-creatinine
ratio is one of the suggestive clinical signs of decreased kidney
perfusion (semifluid stool, two to five bowel movements per day in late
Aug, volume depletion?).</li>
<li>The downtrend in serum creatinine might also be related to muscle
loss and/or malnutrition (2022-09-05 albumin 2.8 g/dL).</li>
<li>2D transthoracic echocardiography for heart and flow volume loop and
volume time curve for lung were recommended since afatinib is reported
relating to cardiovascular and pulmonary toxicity, baseline
establishment might be necessary. An ECG recorded on 2022-08-22
indicated possible left atrial enlargement, which might be due to mitral
stenosis, mitral regurgitation, or aortic stenosis, which could also be
examined with heart doppler sonography.</li>
<li>Under Apidra, the blood sugar level remains between 130 and 220
during this hospitalization, there is no urgent need to adjust the
dose.</li>
</ul>
</div>
</div>
<div id="section-389" class="section level1">
<h1>700463704</h1>
<div id="section-390" class="section level2">
<h2>220902</h2>
<ul>
<li>present illness
<ul>
<li><ol style="list-style-type: decimal">
<li>Hepatitis B carrier,</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hepatocellular carcinoma, pT2NxMx, stage II, BLCL A, Child-pugh A
s/p S5 segmentectomy with cholecysectomy on 2013/02/01,</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Recurrent HCC s/p S8 segmentectomy, rpT3N0M0,s tage IIIA on
2020/07/08.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Recurrent HCC s/p TACE 7 times on 2015/11/5 ~ 2021/11/26.</li>
</ol></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-22 CXR
<ul>
<li>Mass lesions in both lung zones</li>
<li>Right pleural effusion</li>
</ul></li>
<li>2022-08-08 CT - chest
<ul>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>multiple nodules of variable sizes throughout both lungs due to
metastases, with relaxation atelectasis of RLL and RML.</li>
<li>moderate Rt pleural effusion.</li>
<li>further increase in size of a large metastatic tumor at Rt anterior
chest wall involving adjacent mediastinum as compared with the previous
CT on 20220611.</li>
</ul></li>
<li>HCC, s/p many surgical resections. further progression of recurrent
tumors in both hepatic lobes with tumor thrombi in left portal
vein.</li>
<li>unremarkable of the spleen, pancreas, both kidneys, and both adrenal
glands. no ascites or emlarged lymph nodes.</li>
</ul></li>
<li>Impression:
<ul>
<li>recurrent HCC with lung and chest wall metastases, further in
progression as compared with the previous CT on 2022/06/11.</li>
</ul></li>
</ul></li>
<li>2022-08-04 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>Mildly increased activity in some L-spines. Degenerative change may
show this picture.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Some faint hot spots in bilateral rib cages and increased activity
in the sternum. The nature is to be determined. Please correlate with
other clinical findings and follow up bone scan for further
evaluation.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulsers, sternoclavicular
junctions and hips, compatible with benign joint lesions.</li>
</ol></li>
</ul></li>
<li>2022-06-11 CT - abdomen
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>HCC, s/p operation. Progression of recurrent tumors in both hepatic
lobes.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Tumor thrombi in left portal vein.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Right chest wall mass lesion, in progression.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>No ascites, nor extraluminal free air.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No bony destructive lesion on these images.</li>
</ol></li>
</ul></li>
<li>Impression
<ul>
<li>Recurrent HCCs, in progression</li>
<li>Left portal vein thrombosis</li>
<li>Right chest wall metastasis, in progression</li>
</ul></li>
</ul></li>
<li>2022-06-11 CXR
<ul>
<li>Focal upward bulging of right diaphragm is noted. please correlate
with clinical condition or CT.</li>
</ul></li>
<li>2022-04-01 Patho - pleural/pericardial biopsy
<ul>
<li>Labeled as “R superior chest wall tumor”, CT-guided biopsy — poorly
differentiated carcinoma.</li>
<li>IHC stains: CK (+), GATA-3 (+), mammoglobin (-), E-cadherin (-),
hepatocyte (-), Arginase-1 (-), AFP (-), ER (-), PR (-), Her2/neu:
negative (score = 0), Ki-67: 90%.</li>
<li>Section shows soft tissue with infiltration of trabeculae of poorly
differentiated carcinoma.</li>
</ul></li>
<li>2022-04-01 CXR
<ul>
<li>Focal upward bulging of right diaphragm is noted. please correlate
with clinical condition or CT.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
</ul></li>
<li>2022-03-21 CT - chest
<ul>
<li>Findings
<ul>
<li>Lungs: subtle mosaic attenuation in both lower lobes and posterior
both Lt upper lobe. old calcified LN in the left anterior prevascular
space, sequela of previous TB infection</li>
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: no effusion or nodule.</li>
<li>Chest wall: Rt thyroid lobe calcification 11 mm.
<ul>
<li>a well-defined soft-tissue mass with cystic and solid components
(16x27x16 mm) at Rt paramedian superior anterior chest wall (beneath the
pectoralis msucle).</li>
</ul></li>
<li>Visible abdo &gt; S/P resection of right lobe liver.
<ul>
<li>poor enhancing iInfiltrative tumor in left lobe liver and enhancing
tumor (2 cm) in S7 liver due to recurrent HCCs.</li>
<li>Presence of central portal venous thrombosis.</li>
</ul></li>
<li>unremarkable of the spleen, adrenal glands, pancreas, and
kidneys.</li>
<li>Visualized bones: unremarkable.evaluation.</li>
</ul></li>
<li>Impression:
<ul>
<li>Rt superior anterior chest wall mass, metastatic tumor or a primary
intercostal chest lesion.</li>
</ul></li>
</ul></li>
<li>2022-02-26 CT - abdomen
<ul>
<li>Findings
<ul>
<li>S/P resection of right lobe liver.</li>
<li>Infiltrative tumor in left lobe liver, enhancing tumor (2cm) in S7
liver, could be due to recurrent HCCs.</li>
<li>Presence of portal venous thrombosis, progression.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P resection of right lobe liver.</li>
<li>Recurrent HCCs with progression of portal venous thrombosis.</li>
</ul></li>
</ul></li>
<li>2022-01-10 MRI - liver, spleen
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There are two ill-defined masses, measuring 2.4 cm in S7 dome and
3.1 x 2.7 cm in S4 of the liver. During dynamic study, two masses show
contrast enhancement in arterial phase images and no significant
evidence of contrast washout in portal venous phase and delayed phase
images.</li>
</ol>
<ul>
<li>HCCs are highly suspected.</li>
<li>In addition, The S4 lesion shows hypointensity on T1WI and it
directly connected with left portal vein thrombosis.</li>
<li>Recurrent HCC at S4 with directly invasion causing portal vein tumor
thrombsis is highly suspected.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Prior CT suspected Two ill-defined poor enhancing area in left lobe
liver are not noted in the current MRI that are c/w flow artifacts.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Prior CT identified an ill-defined enhancing lesion measuring 2.9 x
2.6 cm in S2/3 of the liver at arterial phase images is not noted in the
current MRI and the mechanism may be hyperemia (compensatory increased
arterial flow in arterial phase images secondary to portal vein
thrombosis).<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>The liver shows irregular contour and atrophy of segment 4 that is
consistent with cirrhosis.</li>
</ol>
<ul>
<li>There is mild esophageal varices that may be portal
hypertension.</li>
</ul></li>
<li><ol start="5" style="list-style-type: decimal">
<li>S/P cholecystectomy. S/P partial resection of S5 and S8 of the
liver.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Two recurrent HCCs on S7 dome and S4 are suspected.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Recurrent HCC at S4 causing left lobe portal vein tumor thrombosis
is highly suspected.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-01-05 CT - abdomen
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There are three ill-defined iso-hypodense lesion, measuring 2.4 cm
in S7 dome, 2.9 x 2.6 cm in S2/3, and 3.2 x 2.6 cm in S4, of the liver.
During dynamic study, all masses show contrast enhancement in arterial
phase images and Eqivocal contrast washout in portal venous phase and
delayed phase images.<br />
</li>
</ol>
<ul>
<li>HCCs are highly suspected.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Two ill-defined poor enhancing area in left lobe liver are suspected
and non-enhancement of left portal vein.</li>
</ol>
<ul>
<li>Please correlate with MRI to R/O infiltrative type HCCs with tumor
thrombosis in left portal vein.</li>
</ul></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The liver shows irregular contour and atrophy of segment 4 that is
consistent with cirrhosis.</li>
</ol>
<ul>
<li>There is mild esophageal varices that may be portal
hypertension.</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>S/P cholecystectomy. S/P partial resection of S5 and S8 of the
liver.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Three recurrent HCCs on both hepatic lobes are suspected.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Infiltrative type HCCs at left hepatic lobe with tumor thrombosis in
left portal vein are suspected.</li>
</ol></li>
<li>Please correlate with MRI.</li>
</ul></li>
</ul></li>
<li>2021-10-04 MRI - liver, spleen
<ul>
<li>Findings
<ul>
<li>HCC s/p operation and TACE. Some small marginal enhancing nodules
(up to 1.7cm) in both hepatic lobes.</li>
</ul></li>
<li>IMP:
<ul>
<li>HCC s/p operation and TACE. Some small marginal enhancing nodules
(up to 1.7cm) in both hepatic lobes c/w tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2021-09-29 SONO - abdomen
<ul>
<li>Hepatic tumor suspected HCC (inconspicuous)</li>
<li>Liver cirrhosis</li>
<li>post cholecystectomy</li>
</ul></li>
<li>2021-08-14 CT - abdomen
<ul>
<li>Findings
<ul>
<li>s/p cholecystectomy and S5 resetion.</li>
<li>Hypervascular hepatic tumor at S4 of liver up to 1.94cm in largest
dimension. Suggest closely follow up.</li>
<li>The portal vein and IVC are patent.</li>
<li>Another low density lesion at dome about 2.0cm in largest dimension.
HCC?</li>
<li>Irregular hepatic surface with parenchymal nodularity indicate liver
cirrhosis. Suggest clinical correlation</li>
</ul></li>
<li>Imp:
<ul>
<li>Suspected hepatic tumors at S4 and S5 of liver. Suggest correlate
with other findings.</li>
</ul></li>
</ul></li>
<li>2021-06-11 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>A hypoechoic lesion 1.49 cm in S2/3 of the liver is noted that may
be tumor or fat sparing area. Please correlate with contrast enhanced
dynamic CT or MRI.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P partial resection of S7-8 of the liver and cholecystectomy.</li>
</ol></li>
</ul></li>
<li>2021-03-08 MRI - liver, spleen
<ul>
<li>HCC s/p operation and TACE without enhancing tumor.</li>
</ul></li>
<li>2021-03-08 SONO - abdomen
<ul>
<li>Liver lesion, nature?</li>
<li>Liver cirrhosis, mild fatty liver</li>
<li>Post cholecystectomy</li>
<li>Fatty pancreas</li>
</ul></li>
<li>2021-02-01 MRI - liver, spleen
<ul>
<li>HCC s/p operation and TACE. A recurrent HCC (1.8cm, srs8, img23) at
liver dome.</li>
</ul></li>
<li>2020-11-28 CT - abdomen
<ul>
<li>Liver cirrhosis with HCC s/p S5 and S8 op. with borderline enhanced
region at S7 just near previous TACE region. Suggest closely follow
up.</li>
</ul></li>
<li>2020-09-08 SONO - abdomen
<ul>
<li>S/P cholecystectomy and partial resection of S7-8 of the liver.</li>
</ul></li>
<li>2020-07-09 Patho - liver partial resection
<ul>
<li>pathologic diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Liver, S8, segmental hepatectomy — Hepatocellular carcinoma,
recurrent<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Pathologic Staging: rpT3Nx; Stage IIIA at least</li>
</ol></li>
</ul></li>
<li>microscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic Type: Hepatocellular carcinoma, trabecular type with
focal intratumoral fibrosis<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic Grade: Poorly differentiated (G3)<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor Necrosis: Present<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Tumor Capsule: Encapsulated with focal infiltrative border<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Tumor Extension: Tumor confined to liver<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Large Vessel Invasion: Not identified<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Small Vessel Invasion: Present<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Perineural Invasion: Not identified<br />
</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Pathologic Staging (rpTNM): Stage IIIA at least (rpT3Nx)<br />
</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Margins<br />
</li>
</ol>
<ul>
<li>10.1 Parenchymal Margin: Free, 1.6 cm from closest margin<br />
</li>
<li>10.2 Hepatic Capsule: Uninvolved by invasive carcinoma<br />
</li>
</ul></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Additional Pathologic Findings: Small cell and large cell
changes<br />
</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>Hepatitis (specify type): Hepatitis B<br />
</li>
</ol></li>
<li><ol start="13" style="list-style-type: decimal">
<li>Ishak Modified HAI Grading: Score=3 (interphase hepatitis = 1/4,
confluent necrosis = 0/6, focal necrosis = 0/4, portal inflammation =
2/4) (Corresponding Metavir A1, mild activity)<br />
</li>
</ol></li>
<li><ol start="14" style="list-style-type: decimal">
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)<br />
</li>
</ol></li>
<li><ol start="15" style="list-style-type: decimal">
<li>Fatty Change: Present (10%)</li>
</ol></li>
</ul></li>
</ul></li>
<li>2020-05-30 CT - abdomen
<ul>
<li>Hepatic tumor at dome, recurrent HCC is considered.</li>
</ul></li>
<li>2020-05-23 SONO - abdomen
<ul>
<li>Liver tumor: suspect HCC</li>
<li>Liver cirrhosis, mild fatty liver</li>
<li>post cholecystectomy</li>
</ul></li>
<li>2020-02-14 SONO - abdomen
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>Status post partial resection of S5/8 of the liver.</li>
</ol>
<ul>
<li>The residual liver shows normal in size and echogenicity without
focal lesion.<br />
</li>
<li>Portal vein flow: patent.</li>
<li>Bile ducts: not dilated.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Status post cholecystectomy.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The pancreatic head and body shows normal in size and texture.</li>
</ol>
<ul>
<li>The pancreatic tail is obscured by overlying bowel gas.</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>The spleen shows normal in size and echogenicity without focal
lesion.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Abdominal aorta and IVC show unremarkable finding.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>There is no evidence of para-aortic lymphadenopathy or ascites.</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Both kidney show normal echopattern and size.</li>
</ol>
<ul>
<li>There is no evidence of stone or hydronephrosis.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P cholecystectomy and partial resection of S5/8 of the liver.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Otherwise, no significant abnormal finding is noted.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2019-10-05 CT - abdomen
<ul>
<li>HCC s/p operation and TACE without viable tumor.</li>
</ul></li>
<li>2019-08-26 SONO - abdomen
<ul>
<li>HCC, Status post partial right segmentectomy (S5/8)</li>
<li>Liver tumors?</li>
<li>Liver cirrhosis</li>
<li>Status post cholecystectomy</li>
</ul></li>
<li>2019-06-08 CT - abdomen
<ul>
<li>HCC s/p operation and TACE without viable tumor.</li>
</ul></li>
<li>2019-03-04 SONO - abdomen
<ul>
<li>Liver cirrhosis</li>
<li>Status post cholecystectomy</li>
<li>Status post partial right segmentectomy (S5/8)</li>
</ul></li>
<li>2018-12-01 CT - abdomen
<ul>
<li>HCC s/p operation and TACE without viable tumor.</li>
</ul></li>
<li>2018-09-07 SONO - abdomen
<ul>
<li>Suspected chronic liver parenchyma disease (Please correlate with
liver function)</li>
<li>Suspected early cirrhosis</li>
<li>C/w partial segmentectomy,right liver</li>
<li>S/p cholecystectomy</li>
<li>Suboptimal examination of liver due to poor echo window</li>
</ul></li>
<li>2018-07-16 SONO - abdomen
<ul>
<li>Liver cirrhosis</li>
<li>Liver nodules?</li>
<li>Status post cholecystectomy</li>
</ul></li>
<li>2018-06-16 CT - abdomen
<ul>
<li>Liver cirrhosis.</li>
<li>HCC s/p wedge resecion. No local recurrence</li>
</ul></li>
<li>2018-03-17 CT - abdomen
<ul>
<li>HCC s/p operation and TACE with minimal viable tumor.</li>
</ul></li>
<li>2018-01-08 SONO - abdomen
<ul>
<li>HCC s/p segmentectomy</li>
<li>Liver lesions, nature?</li>
<li>Parenchymal liver disease</li>
<li>Status postcholecystectomy</li>
</ul></li>
<li>2017-12-23 CT - abdomen
<ul>
<li>HCC s/p operation and TACE. A residual HCC (1.5cm) at S8 of
liver.</li>
</ul></li>
<li>2017-09-30, 2017-07-08, 2017-04-15 SONO - abdomen
<ul>
<li>liver cirrhosis/ incomplete exam of liver</li>
<li>GB sac not seen</li>
</ul></li>
<li>2017-01-24 SONO - abdomen
<ul>
<li>Liver cirrhosis</li>
<li>Post cholecystectomy</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-07-08
<ul>
<li>Surgery
<ul>
<li>S8 resection</li>
<li>adhesivelysis</li>
</ul></li>
<li>Finding
<ul>
<li>S8 recurrent tumor 5.5 x 5.0 x 3.5 cm</li>
<li>severe adhesion of liver and T-colon and diaphragm due to previous
operation</li>
<li>mild liver cirrhosis</li>
</ul></li>
</ul></li>
<li>2014-03-27 Hemorrhoidectomy
<ul>
<li>Hemorrhoids with a papillar lesion at 7 oclock position, another at
3 oclock position.</li>
</ul></li>
<li>2013-02-01 S5 segmentectomy with cholecysectomy</li>
</ul></li>
<li>Transarterial Chemoembolization, TACE
<ul>
<li>2022-01-14 Embolization (TAE, TACE) - doxorubicin</li>
<li>2021-11-26 Embolization (TAE, TACE) - doxorubicin</li>
<li>2021-02-18 Embolization (TAE, TACE) - doxorubicin</li>
<li>2020-06-09 Embolization (TAE, TACE) - doxorubicin</li>
<li>2018-04-13 Embolization (TAE, TACE)</li>
<li>2018-01-19 Embolization (TAE, TACE)</li>
<li>2016-09-02 Embolization (TAE, TACE)</li>
<li>2015-11-05 Embolization (TAE, TACE)</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-15 - cisplatin 40mg/m2 80mg 2hr + fluorouracil 2000mg/m2
4000mg 22hr (2002-08-08 CT progressive disease)</li>
<li>2022-08-01 - oxaliplatin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-07-18 - oxaliplatin 85mg/m2 160mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-07-04 - oxaliplatin 85mg/m2 160mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-06-20 - oxaliplatin 85mg/m2 160mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-06-06 - oxaliplatin 80mg/m2 150mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-05-23 - oxaliplatin 70mg/m2 140mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 2400mg/m2 4800mg 46hr</li>
<li>2022-03-19 ~ 2022-05-10 - sorafenib 200mg/tab 2 BIDAC</li>
<li>2022-03-11 - nivolumab 100mg 1hr</li>
<li>2022-02-08 - nivolumab 100mg 1hr</li>
<li>2022-01-14 - nivolumab 100mg 1hr</li>
<li>2021-12-03 ~ 2021-12-31 - sorafenib 200mg/tab 1 BIDAC</li>
<li>2021-02-26 ~ 2021-10-26 - sorafenib 200mg/tab 1 BIDAC</li>
<li>about one year, when? - lenvatinib</li>
</ul></li>
</ul>
<div id="section-391" class="section level3">
<h3>==========</h3>
</div>
<div id="section-392" class="section level3">
<h3>2022-09-02</h3>
<ul>
<li>Cisplatin was introduced during the last hospital stay (2022-08-15),
but there are no hearing test records (e.g. pure tone audiometry)
available. Prior to accumulating too much dose, it is recommended to
obtain a baseline measurement.</li>
</ul>
</div>
<div id="section-393" class="section level3">
<h3>2022-08-23</h3>
<ul>
<li>Apresoline (hydralazine) and Sevikar (amlodipine + olmesartan)
reduced blood pressure from 181/108 (2022-08-22 19:46) to 153/87
(2022-08-23 08:44).</li>
<li>If cellulitis of lower limbs is still a diagnosis, then parenteral
antibiotics without an indication for MRSA in higher risk patients could
be:
<ul>
<li>cefazolin 1 to 2 g IV Q8H</li>
<li>oxacillin 1 to 2 g IV Q4H</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-394" class="section level1">
<h1>700994233</h1>
<div id="section-395" class="section level2">
<h2>220901</h2>
<ul>
<li>family history
<ul>
<li>mother: cervical cancer</li>
<li>father: parkinson’s disease</li>
</ul></li>
<li>lab data
<ul>
<li>2022-08-25 Anti-HBc Reactive<br />
</li>
<li>2022-08-25 Anti-HBc-Value 5.79 S/CO<br />
</li>
<li>2022-08-25 Anti-HBs 58.45 mIU/mL<br />
</li>
<li>2022-08-19 HBsAg Nonreactive<br />
</li>
<li>2022-08-19 HBsAg (Value) 0.42 S/CO<br />
</li>
<li>2022-08-19 Anti-HCV Nonreactive<br />
</li>
<li>2022-08-19 Anti-HCV Value 0.09 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-26 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, EUS-FNB — Adenocarcinoma, pancreatobiliary type, moderately
differentiated</li>
<li>The sections show a picture of adenocarcinoma, pancreatobiliary
type, moderately differentiatrf, composed of liver tissue with nests,
cords, and single cuboidal to low columnar neoplastic cells with
glandular differentiation in fibrous stroma. Intracellular and
extracellular mucin secretion can be found.</li>
<li>IHC shows: CK7(+), CA19-9(+), CK20(-), and CDX2(-).</li>
</ul></li>
<li>2022-08-26 Needle Aspiration Cytology - pancreas
<ul>
<li>Indication: suspected pancreas cancer with liver metastasis, T3N2M1,
stage IV</li>
<li>Pathologic diagnosis: pancreatic tumor, suspicious for
malignancy</li>
</ul></li>
<li>2022-08-26 Endoscopic Ultrasonography, EUS
<ul>
<li><ol style="list-style-type: decimal">
<li>Pancreatic body tumor, s/p CH-EUS &amp; EUS/FNB (B)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Liver tumor, favor metastatic lesion, s/p CH-EUS &amp; EUS/FNB
(A)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Suspected SMV thrombus or tumor direct invasion to SMV</li>
</ol></li>
</ul></li>
<li>2022-08-22 CT - abdomen
<ul>
<li>Findings
<ul>
<li>A poor enhancing tumor (2.7x4.7cm) in pancreatic body and tail with
adjacent fat stranding.</li>
<li>Multiple liver tumors.</li>
<li>Some soft tissues in peritoneal cavity with ascites.</li>
<li>Some LNs at retroperitoneum.</li>
</ul></li>
<li>Imaging Report Form for Pancreatic Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3(T_value) N:N2(N_value)
M:M1(M_value) STAGE:IV(Stage_value)</li>
</ul></li>
</ul></li>
<li>2022-08-19 Esophagogastroduodenoscopy, EGD
<ul>
<li>erosive esophagitis LA Classification grade A</li>
<li>superficial gastritis, post CLO test</li>
<li>gastric erosions, multiple, whole stomach</li>
</ul></li>
<li>2022-08-19 SONO - abdomen
<ul>
<li>Liver tumors, multiple, nature?</li>
<li>Parenchymal live disease</li>
<li>Borderline splenomegaly</li>
<li>Minimal ascites</li>
<li>Gall stones</li>
</ul></li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>2022-09-01 Pilian (cyproheptadine 4mg/tab) 1# TID - off-label:
Decreased appetite secondary to chronic disease; Serotonin syndrome;
Spasticity associated with spinal cord damage
<ul>
<li>Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A
Multicenter, Randomized, Double-blind, Placebo-controlled Study - <a href="https://sci-hub.se/10.1016/j.clinthera.2021.08.001" class="uri">https://sci-hub.se/10.1016/j.clinthera.2021.08.001</a></li>
<li>Cyproheptadine: Drug information - <a href="https://www.uptodate.com/contents/cyproheptadine-drug-information" class="uri">https://www.uptodate.com/contents/cyproheptadine-drug-information</a>
(2022-09-01)
<ul>
<li>Dosing: Adult
<ul>
<li>Appetite, decreased secondary to chronic disease
<ul>
<li>Appetite, decreased secondary to chronic disease (off-label use):
Oral: Initial: 2 mg 4 times per day for 1 week, then 4 mg 4 times per
day (Homnick 2004; Homnick 2005).</li>
</ul></li>
<li>Serotonin syndrome, moderate
<ul>
<li>Serotonin syndrome (serotonin toxicity), moderate (off-label use):
<ul>
<li>Note: Reserve for patients with agitation despite discontinuation of
serotonergic agent(s), adequate sedation (eg, with a benzodiazepine),
and supportive care (Boyer 2005; Sun-Edelstein 2008).</li>
<li>Oral: Initial: 12 mg once followed by 2 mg every 2 hours until
clinical response. Maintenance: 4 to 8 mg every 6 hours as needed.
Maximum dose: 32 mg/day (Boyer 2005; Sun-Edelstein 2008).</li>
</ul></li>
</ul></li>
<li>Dosage adjustment for concomitant therapy: Significant drug
interactions exist, requiring dose/frequency adjustment or avoidance.
Consult drug interactions database for more information.</li>
</ul></li>
<li>Dosing: Kidney Impairment: Adult
<ul>
<li>No dosage adjustment provided in manufacturer’s labeling. However,
elimination is diminished in renal insufficiency.</li>
</ul></li>
<li>Dosing: Hepatic Impairment: Adult
<ul>
<li>No dosage adjustment provided in manufacturer’s labeling.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-396" class="section level1">
<h1>701037871</h1>
<div id="section-397" class="section level2">
<h2>220830</h2>
<p>{hypopharynx squamous cell carcinoma, cT3N1M0}</p>
<ul>
<li>diagnosis
<ul>
<li>2022-08-16 discharge diagnosis
<ul>
<li>1: Squamous cell carcinoma, posterior wall of hypopharynx, cT3N1M0,
stage III status post port-A catheter implantation, tracheostomy, and
laparoscopic gastrostomy and on 2022-07-21</li>
<li>2: Ventral hernia status post repair of ventral hernia on
2022-08-04</li>
<li>3: Bilateral pleural effusion status post left pigtail catheter
insertion on 2022-07-26, and right pigtail catheter insertion on
2022-07-27</li>
<li>4: Liver S6 hemangioma</li>
<li>5: Subcutance emphysema</li>
<li>6: Occlusion and stenosis of right middle cerebral artery</li>
<li>7: Atrial fibrillation</li>
<li>8: Type 2 diabetes mellitus without complications</li>
<li>9: Pyuria( urine culture no growth on 2022-07-24)</li>
<li>10: Systemic lupus erythematosus</li>
<li>11: Hypertension</li>
<li>12: Hyperlipidemia</li>
<li>13: Diarrhea, unspecified</li>
<li>14: Insomnia, unspecified</li>
<li>15: Gout, unspecified</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-26 SONO - chest
<ul>
<li><ol style="list-style-type: decimal">
<li>left side small amount of pleural effusion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>right side moderate amount of pleural effusion over dependent
portion, 400cc serosangious fluid was aspirated for analysis.</li>
</ol></li>
</ul></li>
<li>2022-08-24 CXR
<ul>
<li>left shoulder: Prior arthroplasty</li>
<li>Port-A catheter inserted into SVC via left subclavian vein.</li>
<li>enlarged cardiac silhoutte; old fracture of multiple Lt ribs<br />
</li>
<li>Rt greater than Lt bilateral pleural effusions</li>
<li>Consolidation and volume reduce over Rt upper lobe</li>
<li>Tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch and D-aorta</li>
</ul></li>
<li>2022-08-24 CT - brain
<ul>
<li>Old cerebral infarcts. Mild general brain atrophy. Hypopharyngeal
tumor.</li>
</ul></li>
<li>2022-08-24 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-08-12 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>S/P endotracheal intubation with the tip beyond the carina</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Linear infiltration over right and left lower lung zone is noted.
please correlate with clinical symptom to rule out inflammatory
process.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion?</li>
</ul></li>
<li>2022-08-02 CT - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P gastrostomy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Bilateral chest wall subcutaneous emphysema.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Liver tumors, r/o hemangiomas.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Dense calcification in right lobe liver.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Bilateral pleural effusion with basal lung atelectasis.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>L2-3 compression fractures.</li>
</ol></li>
</ul></li>
<li>2022-07-29 CXR
<ul>
<li>enlarged cardiac silhoutte; old fracture of multiple Lt ribs<br />
</li>
<li>Subcutaneous emphysema in the right and left neck and chest wall in
regression</li>
<li>bilateral pleural effusions s/p pigtail drains placement</li>
</ul></li>
<li>2022-07-19 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>Glucose hypermetabolism in the posterior wall of the hypopharynx,
compatible with primary hypopharyngeal malignancy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Glucose hypermetabolism in some focal areas in the right
retropharyngeal and right neck level II areas. Metastatic lymph nodes
may show this picture. Please correlate with other clinical findings for
further evaluation.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions.
Inflammatory process may show this picture.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased FDG accumulation in both kidneys and bilateral ureters.
Physiological FDG accumulation is more likely.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ol></li>
</ul></li>
<li>2022-07-15 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (107 - 38) / 107 = 64.49%</li>
<li><ol style="list-style-type: decimal">
<li>Preserved LV systolic function with normal wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated LA, LV and RV hypertrophy</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>c/w RHD with multiple valve involvement (RHD: rheumatic heart
disease)</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Mild MR, TR and moderate to severe AR</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Impaired RV systolic function</li>
</ol></li>
</ul></li>
<li>2022-07-14 Patho - esophageal biopsy
<ul>
<li>Hypopharynx, posterior wall, biopsy — Compatible with squamous cell
carcinoma and ulcer</li>
<li>Microscopically, the sections show a picture of high grade dysplasia
of squamous epithelium with focal squamous cell carcinoma in situ, ulcer
with inflammatory exudate and necrotic debris, and inflamed, scant
stroma with focal epithelial budding or few isolated nest, compatible
with squamous cell carcinoma, moderately differentiated.</li>
<li>Immunohistochemistry of P16 (-), CK(+), P63(+) and P53(+, diffuse)
for tumor. Clinical correlation is advised.</li>
</ul></li>
<li>2022-07-13 CT - neck
<ul>
<li>Thickening wall with enhancement at hypopharynx more severe at right
side, suspected hypopharyngeal malignancy, suggest further study.</li>
</ul></li>
<li>2022-07-13 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Nonspecific ST and T wave abnormality</li>
</ul></li>
<li>2022-07-13 CXR
<ul>
<li>Increase bilateral lung markings.</li>
<li>Mild cardiomegaly.</li>
<li>Tortuous thoracic aorta with intimal calcification.</li>
<li>Thoracic spondylosis.</li>
<li>Post-op at left proximal humerus.</li>
<li>Old fractures at left ribs.</li>
</ul></li>
<li>2022-07-13 Neck soft tissue
<ul>
<li>No radiopaque foreign body noted.</li>
<li>No evidence of prevertebral soft tissue swelling.</li>
</ul></li>
<li>2022-07-13 Nasopharyngoscopy
<ul>
<li>smooth NPx, OPx, bulging of R arytenoid (unable to see vocal cord,
NBI+), mild saliva pooling at HPx</li>
</ul></li>
<li>2022-07-13 Esophagogastroduodenoscopy, EGD
<ul>
<li>Findings
<ul>
<li>Ulcerative change of the mucosa at the posterior wall of hypopharynx
with easy touched bleeding with edematous change of the surrounding
mucosa. Even the fine-caliber endoscopy couldn’t pass the upper
esophageal sphincter.</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Suspect hypopharynx or esophageal malignancy with obstuction of
esophagus, s/p biospy</li>
</ul></li>
<li>Suggestion
<ul>
<li>neck to chect CT scan</li>
<li>monitor her respiratory condition, the risk of apsiration is high.
consider intubation if the bleeding persisted</li>
</ul></li>
</ul></li>
<li>2022-06-11 CT - lung
<ul>
<li>Suspected bil. bronchiolitis.</li>
</ul></li>
<li>2022-06-11 Abdomen - supine (diaphragm)
<ul>
<li>S/P NG tube indwelling.</li>
<li>Compression fracture of L1-3.</li>
</ul></li>
<li>2022-06-11 MRA - brain
<ul>
<li>Brain atrophy with multiple old lacunar brain infarcts.</li>
</ul></li>
<li>2022-06-11 ECG
<ul>
<li>Atrial fibrillation with rapid ventricular response</li>
<li>LVH with ST T changes</li>
</ul></li>
<li>2022-06-10 CXR
<ul>
<li>elongated and tortuosity of thoracic aorta and diffuse calcified
atherosclerotic change at aortic arch and D-aorta. dilated ascending
aorta</li>
<li>mild enlarged cardiac silhoutte due to dilated cardiac chamber (LAD)
and prominent cardiophrenic angle mediastinal fat pad</li>
<li>coliosis of the spine</li>
<li>Lt shoulder prior hemiarthroplasty</li>
<li>old fracture of many Lt ribs</li>
<li>Compression fracture of L1-L3 vertebral bodies</li>
</ul></li>
<li>2022-05-16 Swallowing video fluoroscopy
<ul>
<li>Abnormal contour of hypopharynx.</li>
<li>Easy chocking during swallowing.</li>
</ul></li>
<li>2022-05-12 Nasopharyngoscopy
<ul>
<li>smooth NPx, OPx, HPx, R vocal palsy, mild saliva pooling at HPx</li>
</ul></li>
<li>2022-05-05 Neurosonology
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild (to moderate) atheromatous lesions in bilateral CCA
bifurcations; mild atheromatous lesions in bilateral middle to distal
CCA.s</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Poor bilateral temporal windows for transcranial insonation.</li>
</ol></li>
</ul></li>
<li>2020-12-15 Knee Bilat. standing
<ul>
<li>Osteoarthritis change of both knees with joint space narrowing and
marginal spur formation. Osteopenia of visible bones. Loose bodies in
the right knee joint.</li>
</ul></li>
<li>2020-09-17 ECG
<ul>
<li>Atrial flutter with variable A-V block</li>
<li>ST &amp; T wave abnormality, consider inferior ischemia</li>
</ul></li>
<li>2020-07-30 CXR
<ul>
<li>cardioemgaly; and mediastinal widening</li>
<li>s/p post-OP change in the left humeral bone; and fractures in the
left middle ribs.</li>
</ul></li>
<li>2020-07-13 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (128 - 50) / 128 = 60.94%</li>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with normal resting wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>RHD with mild MR; dilated LA (RHD: rheumatic heart disease)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Aortic valve calcification with mild to moderate AS; moderate
AR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>mild MR, trivial TR</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Preserved RV systolic function</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Atrial fibrillation at the exam</li>
</ol></li>
</ul></li>
<li>2020-05-26 Neurosonology
<ul>
<li><ol style="list-style-type: decimal">
<li>Moderate (to severe) atheromatous lesions in R CCＡbifurcation; mild
(to moderate) atheromatous lesions in R proximal CCA, L distal CCA to
CCA bifurcation; mild atheromatous lesions in L middle CCA, R middle to
distal CCA, R ICA, R ECA and R subclavian artery.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Poor bilateral temporal windows for transcranial insonation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Normal bilateral ophthalmic arterial flows</li>
</ol></li>
</ul></li>
<li>2018-06-19 CT - brain
<ul>
<li>Lacunar infarcts, brain atrophy, and intracranial
arteriosclerosis</li>
</ul></li>
<li>2018-06-06 Color Transcranial Doppler Sonographic diagnosis:
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild (to moderate) atheromatous lesions in bilateral CCA
bifurcations; mild atheromatous lesions in bilateral distal CCAs and
right subclavian artery. Irregular heart beats.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Poor bilateral temporal windows for transcranial insonation.</li>
</ol></li>
</ul></li>
<li>2018-06-06 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (103 - 35.6) / 103 = 65-44%
<ul>
<li>Dilated LA</li>
<li>Septal hypertrophy</li>
<li>Adequate LV and RV performance</li>
<li>AV sclerosis with moderate AR ; mild AS</li>
<li>Calcified mitral annulus and mitral valve with mild to moderate MR;
mild TR and PR</li>
<li>Possibly mild pulmonary HTN</li>
<li>No regional wall motion abnormalities</li>
<li>Atrial fibrillation</li>
</ul></li>
</ul></li>
<li>2018-06-05 MRA - brain
<ul>
<li>recent lacunar infarct, Rt thalamus.</li>
<li>Multiple old lacunar infarcts, deep cerebral hemisphere and pons.
Intracranial ICAs and VAs atherosclerosis.</li>
<li>Brain atrophy.</li>
<li>Bilateral subcortical and periventricular white matter change
(leukoaraiosis).</li>
</ul></li>
<li>2018-06-05 CT - brain
<ul>
<li>A recent infarct in right centrum semiovale</li>
<li>Lacunar infarcts, brain atrophy, and intracranial
arteriosclerosis</li>
</ul></li>
<li>2018-06-05 ECG
<ul>
<li>Atrial fibrillation</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-02 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>The 76 year-old female with the underlying of
<ul>
<li><ol style="list-style-type: decimal">
<li>HTN</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>SLE</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>type II diabetes mellitus</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Atrial flutter</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Old CVA of right side</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Dysphagia had problem of swollow.</li>
</ol></li>
</ul></li>
<li>The patient had had difficulty in swallowing for 2 months. She
visited OPD today for changing of nasogastric tube. She can not restore
the new NG tube after the old one removed. The she brought to our ER and
ENT with the trying of re-on NG tube but in vain. The CT revealed
thickening wall with enhancement at hypopharynx more severe at right
side, suspected hypopharyngeal malignancy. So she was admitted to our
ward for further management and survey. Panendoscopy show suspect
hypopharynx or esophageal malignancy with obstuction of esophagus, s/p
biospy. Pathology show Hypopharynx squamous cell carcinoma, cT3N1M0.
Then tracheostomy, prot-A and gastrostomy were performed on 2022/07/21.
Post operation, she was admitted to SICU for intensive care. After
treatment, we started try collar mask trainning, and tried over night
well since 2022-07-29. Under stable hemodynamic status, she was
transferred to ward for care on 2022-08-01.</li>
<li>Further CCRT will be arranged, so we need consult you for pre-RT
dental evaluation and management. Thank you very much.</li>
</ul></li>
<li>A
<ul>
<li>we are consulted for dental evaluation prior to definitive CCRT for
hypopharyngeal cancer.</li>
<li>As she depends on oxygen treatment via tracheostomy. Bedside
physical examination was done.</li>
<li>No periodontal disease of full mouth or deep carious teeth were
noticed.</li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>Explain the findings to the patient and her daughter</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Oral hygiene reinforcement</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-02 Relabilitation
<ul>
<li>Q
<ul>
<li>Since esophageal malignancy was also suspected accoring to the
report of upper gastrointestinal endoscopy, CS was consulted for
evaluation of gastrostomy or jejunostomy. With the impression of
hypopharyngeal tumor, the patient was admitted for further evaluation
and management.<br />
</li>
</ul></li>
<li>A
<ul>
<li>Due to deconditioning, we were consulted for bedside PT
rehabilitation programs.</li>
<li>Premorbid status
<ul>
<li>wheelchair bound<br />
</li>
<li>heavy hygeiene: maximal assistance</li>
</ul></li>
<li>Physical examination
<ul>
<li>2022/08/01 20:11 T/P/R: 36.9℃ / 87bpm / 19bpm BP:114/54mmHg</li>
<li>Body weight: 58</li>
<li>Consciousness: E4VTM6</li>
<li>Cognition: mostly intact; could follow orders</li>
<li>Speech: could not speak due to tracheostomy</li>
<li>Swallowing: Gastrostomy (+)</li>
<li>Sphincter: Foley (+), stool incontinence</li>
<li>MP:
<ul>
<li>RUL3 LUL3</li>
<li>RLL2 LLL2</li>
</ul></li>
<li>Functional status: needs max assistance</li>
<li>BADL: needs max assistance</li>
</ul></li>
<li>Assessment
<ul>
<li><ol style="list-style-type: decimal">
<li>Squamous cell carcinoma, s/p tracheostomy, prot-A and gastrostomy on
2022/07/21</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>HTN</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>SLE</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>type II diabetes mellitus</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Atrial flutter</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Old CVA of right side<br />
</li>
</ol></li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-20 Radiation Oncology
<ul>
<li>Q
<ul>
<li>We would like to consult your expertise on arrangement of CCRT for
the patient, thank you!</li>
</ul></li>
<li>A
<ul>
<li>S: For CCRT due to hypopharyngeal carcinoma.
<ul>
<li>PI: The patient with the underlying of 1. HTN 2. SLE 3. type II
diabetes mellitus 4. Atrial flutter 5. Old CVA of right side 6.
Dysphagia. She can not restore the new NG tube after the old one
removed. The she brought to our ER and ENT with the trying of re-on NG
tube but in vain. The CT scan revealed thickening wall with enhancement
at hypopharynx more severe at right side, r/o hypopharyngeal malignancy.
Referred for CCRT.</li>
<li>Family history: (-)</li>
<li>Cancer site specific factors: Alcohol (quit); Smoking (-); Betel nut
(-).</li>
<li>Personal Hx: DM(-); HTN(-)</li>
<li>Allergy(-)</li>
<li>Travel Hx(-)</li>
<li>Other disease: SLE</li>
<li>Previous RT Hx: (-)</li>
</ul></li>
<li>O:
<ul>
<li>ECOG: 1</li>
<li>PE: neck and bil SCF: neg.</li>
<li>CXR (2022-7-13): Increase bilateral lung markings. Mild
cardiomegaly. Tortuous thoracic aorta with intimal calcification.
Thoracic spondylosis. Post-op at left proximal humerus. Old fractures at
left ribs.</li>
<li>UGI endoscopy (2022-7-13): Suspect hypopharynx or esophageal
malignancy with obstuction of esophagus, s/p biopsy.</li>
<li>CT scan of neck (2022-7-13): Thickening wall with enhancement at
hypopharynx more severe at right side, r/o hypopharyngeal malignancy,
suggest further study.</li>
<li>Pathology (S2022-11210, 2022-7-18): Hypopharynx, posterior wall,
biopsy — Compatible with squamous cell carcinoma and ulcer.
Immunohistochemistry of P16 (-), CK(+), P63(+) and P53(+, diffuse) for
tumor.</li>
<li>PET (2022-7-19): 1.Glucose hypermetabolism in the posterior wall of
the hypopharynx, compatible with primary hypopharyngeal malignancy.
2.Glucose hypermetabolism in some focal areas in the right
retropharyngeal and right neck level II areas. Metastatic lymph nodes
may show this picture.</li>
</ul></li>
<li>A: Squamous cell carcinoma of the hypopharynx, p16(-), stage
cT4aN2bM0 (IVA).</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: advanced stage hypopharyngeal carcinom
<ul>
<li>Goal: curative</li>
<li>Treatment target and volume: hypopharyngeal tumor to bilateral
neck</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 5000cGy/25 fractions of the
hypopharyngeal tumor to bilateral neck, and 7000cGy/35 fractions of the
hypopharyngeal tumor bed to right neck involved nodal lesions.</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient and her son. They understand and agree to
receive radiotherapy, The treatment planning of radiotherapy will be
started 1330, 2022-7-27.</li>
<li>Please consult Dental department for pre-RT dental evaluation and
management.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-15 Cardiology
<ul>
<li>Q
<ul>
<li>After admitted, she was diffcultly swallowing, nutrition supplement
under PPN, we will arrange operation with gastrostomy on next W1. The
patient recevid Digoxin and Eliquis for Atrial flutter and Old CVA. We
need your help for anti-coagulation therapy. Thank you very much!!</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This is a 76 years old lady who was admitted for hypopharynx more
severe at right side, suspected hypopharyngeal malignancy. We were
consulted for anticoagulant medication.</li>
</ul></li>
<li>O
<ul>
<li>BP 140/63 HR 84</li>
<li>Heart: IRRHB with systolic murmur, Gr II</li>
<li>EKG: Permenant Af</li>
<li>CxR borderline cardiomegaly</li>
</ul></li>
<li>As patient is undergoing to receive head and neck operation, a major
operation with high bleeding risk procedure (2 days risk of major bleed
2-4%)</li>
<li>current problems
<ul>
<li><ol style="list-style-type: decimal">
<li>Atrial fibrillation</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>History of mitral valve stenosis and aortic stenosis</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>diffcultly swallowing; suspected hypopharyngeal malignancy</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Suspected CAD (because of coronary artery calcification by chest
CT)</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>becauase of patient could not swallowing, she stop Eliquis. maybe
shift to enoxaparin 50mg SC Q12H for prevent AF related stroke and for
possible CAD.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>If patient operation, please stop enoxaparin for one dose (stop
enoxaparin 12 hours)</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Arrange 2D echo because of hx of AS. MS, and possible CAD</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>check BW QD and consider check I/O if pulmonary edema</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>difficulty in swallowing might lead to dehydration, now on TPN, it
still risk of fluid overload, maybe check CxR prn if dyspnea or
Q3~4Days</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>if AF HR&gt;110, amiodarone IV is indication.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-14 Thoracic Surgery
<ul>
<li>A
<ul>
<li>Hpopharyngeal tumor was seen and biopsy was done.</li>
<li>Since sophageal malignancy could not be ruled out, I will arrange
admission for further evaluation and management.</li>
</ul></li>
</ul></li>
<li>2022-07-13 ENT
<ul>
<li>A
<ul>
<li>Dysphagia, unable to swallow.</li>
<li>Scope: smooth NPx, OPx, bulging of R arytenoid (unable to see vocal
cord, NBI+), mild saliva pooling at HPx</li>
<li>Imp: Hypopharynx tumor, suspect malignancy</li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>Pending esophageal biopsy</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Gastrostomy for nutrition, patient’s family member agreed</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>ENT OPD f/u for esophageal biopsy report, futher tx if proved
malignancy</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-08-04 Repair of ventral hernia</li>
<li>2022-07-21 Port-A catheter implantation, tracheostomy, and
laparoscopic gastrostomy
<ul>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>A 7.0-French Polysite port inserted through left cephalic vein
toward superior vena cava for about 20cm long.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>The port implanted at upper chest below lateral 1/3 of left
clavicle.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tracheostomy tube: 7.0mm ID Rota-Trach Tracheostomy Tube.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Gastrostomy tube: Cook PEG-24-PULL-S.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Percutaneous endoscopic gastrostomy converted to laparoscopic
gastrostomy due to incapability of the upper gastrointestinal endoscope
to pass the esophagus.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>One liver tumor noted over S6, suspected hemangioma (in GS doctor’s
opinion).</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Estimated blood loss: 10ml.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2018-06-13 L3 compression fracture
<ul>
<li>Compression of with collapse of the body height 60%</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-08-12 ~ - at 1000cGy/5 fractions of the hypopharyngeal tumor to
bilateral neck.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-24 - cisplatin 30mg/m2 45mg 2hr (CCRT)</li>
<li>2022-08-17 - cisplatin 30mg/m2 45mg 2hr (CCRT)</li>
<li>2022-08-12 - cisplatin 30mg/m2 45mg 2hr (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>For the patient’s underlying heart condition, Eliquis (apixaban 5mg)
1# BID had been prescribed by our OPD for routine refilling prior to
this hospital stay. The drug is recommended and can also be administered
with nasogastric tube.</li>
</ul>
</div>
</div>
<div id="section-398" class="section level1">
<h1>700945739</h1>
<div id="section-399" class="section level2">
<h2>220826</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-26 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>A glucose hypermetabolic lesion in the pancreatic head. Primary
malignancy in the pancreatic head may show this picture. Please
correlate with other clinical findings for further evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mild glucose hypermetabolism in some abdominal paraaortic lymph
nodes. Either inflammatory process or metastatic lymph nodes of low FDG
uptake may show this picture.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>A mild glucose hypermetabolic lesion in the upper lobe of left lung.
The nature is to be determined (inflammation? primary lung malignancy or
lung metastasis of low FDG uptake? other nature?). Please also correlate
with other clinical findings for further evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Mild glucose hypermetabolism in the midline anterior abdominal wall,
compatible with post-operative inflammation.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Increased FDG accumulation in the colon, both kidneys and bilateral
ureters. Physiological FDG accumulation is more likely.</li>
</ol></li>
</ul></li>
<li>2022-08-05 Patho - gallbladder (benign lesion)
<ul>
<li>Gallbladder, laparoscopic cholecystectomy — Chronic cholecystitis
and cholelithiasis</li>
</ul></li>
<li>2022-08-04 CXR
<ul>
<li>S/P right pig-tail catheter indwelling.</li>
<li>S/P operation.</li>
<li>S/P NG tube indwelling.</li>
<li>Right catheterization to SVC in position.</li>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Ground glass opacity in bilateral lower lungs.</li>
</ul></li>
<li>2022-07-28 Flow Volume Loops
<ul>
<li>Mild restrictive ventilatory impairment</li>
</ul></li>
<li>2022-07-28 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (81 - 33) / 81 = 59.26%</li>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with normal resting wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Trivial MR and trivial TR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>LV diastolic dysfunction, Gr 1</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved RV systolic function</li>
</ol></li>
</ul></li>
<li>2022-07-26 MRI - pancreas
<ul>
<li>Imaging Report Form for Pancreatic Carcinoma</li>
<li>Impression (Imaging stage) : T:T2(T_value) N:N1(N_value)
M:M0(M_value) STAGE:IIB(Stage_value)</li>
</ul></li>
<li>2022-07-23 CT - abdomen
<ul>
<li>Findings
<ul>
<li>A poor enhancing tumor (3.0cm) at pancreatic head with biliary
obstruction and p-duct dilatation. Some small LNs at
retroperitoneum.</li>
<li>Grade 4 fatty liver.</li>
<li>Right renal angiomyolipoma (1.2cm).</li>
<li>Distention of gallbladder with stones (2-4mm).</li>
</ul></li>
<li>IMP:
<ul>
<li>Suspected pancreatic head cancer with biliary obstruction and p-duct
dilatation. Grade 4 fatty liver. Right renal angiomyolipoma (1.2cm).
Gallbladder stones (2-4mm).</li>
</ul></li>
</ul></li>
<li>2022-07-23 SONO - abdomen
<ul>
<li>Fatty liver, moderate</li>
<li>GB stone, mutliple</li>
<li>Dilated CBD</li>
</ul></li>
<li>2022-04-11 Patho - stomach biopsy
<ul>
<li>Gastric polyp, body, biopsy — Compatible with fundic gland
polyp</li>
</ul></li>
<li>2022-04-08 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA grade ASuperficial gastritis</li>
<li>Gastric polyps, body and fundus, s/p biopsy</li>
</ul></li>
<li>2022-04-08 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Fatty liver, severe</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>GB stone</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Renal tumor, suspicious angiomyolipoma of the right kidney</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Renal calcinosis, left</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>pancreatic body masked by gas</li>
</ol></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-400" class="section level1">
<h1>700876297</h1>
<div id="section-401" class="section level2">
<h2>220825</h2>
<p>{Rt breast cancer with Rt axillary LNs, lungs, and liver
metastases}</p>
<p>[objective]</p>
<ul>
<li>Lab findings
<ul>
<li>2022-05-27 Patho - breast mastectomy with regional lymph nodes
<ul>
<li>pathologic diagnosis
<ul>
<li>Tumor, R’t breast, MRM —- Invasive carcinoma of no special type with
focal ductal carcinoma in situ, high grade</li>
<li>Resection margins, ditto — Free, closest margin 0.1 cm from
base</li>
<li>Skin, R’t breast, MRM — Skin ulcer with tumor</li>
<li>Nipple, R’t breast, MRM — Free from tumor</li>
<li>Lymph nodes, R’t level I/II, dissection — Tumor metastasis (2/18)
without extracapsular extension (0/2)</li>
<li>AJCC Pathologic Anatomic Stage — ypT4bN1a, cM1, Stage IV and
Prognostic Stage — Stage IV</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Invasive carcinoma of no special type with focal
ductal carcinoma in situ, high grade with focal tumor necrosis</li>
<li>Size of invasive carcinoma: multiple foci measured up to 5.1 x 2.5
cm</li>
<li>Histologic grade (Nottingham histologic score): Grade III (score 9)
including [(A) Tubule formation: score 3; (B) Nuclear pleomorphism:
score 3 and (C) Mitotic count: score 3]</li>
<li>Margins: Free, closest margin 0.1 cm from base</li>
<li>Nodal status: tumor metastasis (2/18)</li>
<li>Treatment Effect: post C/T (y)</li>
<li>Lymphovascular space invasion: present</li>
<li>Perienural invasion: present</li>
</ul></li>
</ul></li>
<li>2022-05-11 MRI - c-spine
<ul>
<li>Findings
<ul>
<li>Lower vertebral body height, end-plate degeneration, disc collapse
with general bulging, posterolateral osteophytes and enlarged facets
causing mild canal stenosis and left moderate neuroforaminal narrowing
at C5-6-7.</li>
<li>No intramedullary abnormality.</li>
</ul></li>
<li>IMP:
<ul>
<li>Cervical spondylosis, esp C5-6-7 with left neuroforaminal
narrowing.</li>
</ul></li>
</ul></li>
<li>2022-05-05 CT - lung/mediastinum/pleura
<ul>
<li>Chest CT with and without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>Abnormal skin thickening and nodular lesion up to 1.1cm at right
breast is found. In comparison with CT dated on 2022-01-07, marked
regression is found.</li>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Small lymph nodes are found at right axillary region. In
regression.</li>
<li>Fibrotic change at left upper lobe is found. In regression.</li>
<li>Patent airway is found.</li>
<li>There is no evidence of mediastinal LAP</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Very low density lesion with marginal enhancement at S4 of liver is
found. Liver meta is considered. In regression.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Right breast cancer with right axillary lymph nodes, lung meta and
liver meta. All of the tumor activity regression.</li>
</ul></li>
</ul></li>
<li>2022-05-05 SONO - breast
<ul>
<li>Diagnosis
<ul>
<li>Bil. fibroadenomas</li>
<li>Right breast cancer</li>
</ul></li>
</ul></li>
<li>2022-05-05 Mammography
<ul>
<li>Mammography of bilateral breasts with craniocaudal (CC) and
mediolateral oblique (MLO) views shows:
<ul>
<li>Composition: The breast tissue is heterogeneously dense, and this
may decrease the sensitivity of mammography.</li>
<li>Ill-defined mass density at right upper breast, associated with
nipple retraction and skin thickening, compatible with breast
cancer.</li>
<li>No definite enlarged axillary lymph node.</li>
</ul></li>
<li>Final assessment:
<ul>
<li>BI-RADS category 6, Known Biopsy-proven malignancy. Surgical
excision should be considered when clinically appropriate.</li>
<li>Right breast cancer.</li>
<li>BI-RADS: 6. known biopsy-proven malignancy</li>
</ul></li>
</ul></li>
<li>2022-01-17 CT - lung/mediastinum/pleura
<ul>
<li>Rt breast cancer with Rt axillary LNs, lungs, and liver metastases,
in regression compared with CT on 20211104.</li>
</ul></li>
<li>2021-11-04 CT - lung/mediastinum/pleura -Right huge breast cancer
with lung meta. Sacrum invasion and liver mets. Stationary.</li>
<li>2021-10-15 CT - abdomen - liver, spleen, biliary duct, pancreas
<ul>
<li>Right breast cancer with right axillary lymph nodes and lung
metastases.</li>
<li>One metastasis or primary lung cancer in LUL of the lung is
suspected.</li>
<li>One liver metastasis is highly suspected.</li>
</ul></li>
<li>2021-10-15 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Increased activity in the lower L-spines and bilateral S-I joints.
Degenerative change may show this picture.</li>
<li>Increased activity in the maxilla. Dental problem may show this
picture.</li>
<li>Some faint hot spots in the anterior aspect of bilateral rib cages.
The nature is to be determined (post-traumatic change? other
nature?).</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, elbows, wrists, hips and knees, compatible
with benign joint lesions.</li>
</ul></li>
<li>2021-10-11 Patho - breast, right, core biopsy; lymph node, right
axillary, core biopsy
<ul>
<li>Invasive carcinoma, no special type, NST.</li>
<li>IHC stains (using lymph node tissue block S2021-14022):
<ul>
<li>ER (+, 90%, strong intensity),</li>
<li>PR (+, 90%, strong intensity, breast mass; +, 50%, strong intensity,
lymphonode biopsy),</li>
<li>Her2/neu: positive(score=3+),</li>
<li>Ki-67 (90%),</li>
<li>E-cadherin (+).</li>
</ul></li>
</ul></li>
<li>2021-10-11 SONO - breast
<ul>
<li>Right breast tumor with enlarged axillary lymph nodes, suspected
right breast malignancy, suggest follow up.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy - appropriate
action should be taken.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-24 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-08-03 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-07-13 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-06-20 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-04-18 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-03-22 - trastuzumab 600mg SC 5min + pertuzumab 420mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-03-02 - trastuzumab 600mg SC 5min + pertuzumab 840mg 1hr +
docetaxel 75mg/m2 120mg 1hr</li>
<li>2022-02-07 - docetaxel 60mg/m2 98mg 1hr</li>
<li>2022-01-07 - doxorubicin 60mg/m2 95mg 10min + cyclophosphamide
600mg/m2 950mg 1hr (AC)</li>
<li>2021-12-17 - doxorubicin 60mg/m2 95mg 10min + cyclophosphamide
600mg/m2 950mg 1hr (AC)</li>
<li>2021-11-26 - doxorubicin 60mg/m2 95mg 10min + cyclophosphamide
600mg/m2 950mg 1hr (AC)</li>
<li>2021-11-26 - doxorubicin 50mg/m2 80mg 10min + cyclophosphamide
600mg/m2 950mg 1hr (AC)</li>
</ul></li>
</ul>
<div id="section-402" class="section level3">
<h3>==========</h3>
</div>
<div id="section-403" class="section level3">
<h3>2022-06-21</h3>
<ul>
<li>The ongoing THP (docetaxel + trastuzumab + pertuzumab) since early
March 2022 appears to be effective according to a CT scan on 2022-05-05
that all of the tumor activity regression.</li>
<li>On the basis of the lab results reported on 2022-06-20, the patient
is expected to be able to tolerate the current regimen as in the
past.</li>
<li>The patient’s TPR, BP, and SpO2 remain stable since being
hospitalized, except for intermittent episodes of tachycardia.</li>
</ul>
</div>
<div id="section-404" class="section level3">
<h3>2022-03-23</h3>
<ul>
<li>As compared to the CT images taken on 2021-11-04, the CT images
taken on 2022-01-17 have revealed a partial response to the disease
under AC (doxorubicin + cyclophosphamide) regimen administrated during
early November 2021 to early January 2022</li>
<li>Currently, the patient receives THP (docetaxel + trastuzumab +
pertuzumab) since early March 2022.</li>
<li>Before the administration of the THP regimen, studies of the heart
(echocardiography, 2021-11-05) and lung (CT, 2022-01-17) have been
performed to obtain baseline information. Estimated LVEF 61% (based on
the echocardiography) and no obvious abnormal laboratory readings were
reported on 2022-03-23.</li>
</ul>
</div>
<div id="section-405" class="section level3">
<h3>2022-02-08</h3>
<ul>
<li>endocrine therapy e.g. tamoxifen might be preferred to aromatase
inhibitors</li>
<li>trastuzumab, pertuzumab might also be considered if no
contraindications</li>
</ul>
</div>
</div>
</div>
<div id="section-406" class="section level1">
<h1>700374742</h1>
<div id="section-407" class="section level2">
<h2>220823</h2>
<ul>
<li>diagnosis
<ul>
<li>2022-07-26 discharge diagnosis
<ul>
<li>1: Malignant neoplasm of middle third of esophagus</li>
<li>2: tonsillar fossa tumor with lateral pterygoid muscle with lateral
nasopharynx invasion, any node(s) and clinically overt ENE, T4bN3bM0,
STAGE:IVB
<ul>
<li>TPF for head and neck cancer</li>
</ul></li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Magnesium
<ul>
<li>2022-07-21 Mg (Magnesium) 1.2 mg/dL<br />
</li>
<li>2022-06-30 Mg (Magnesium) 2.7 mg/dL<br />
</li>
<li>2022-06-27 Mg (Magnesium) 1.2 mg/dL<br />
</li>
<li>2022-06-06 Mg (Magnesium) 2.0 mg/dL<br />
</li>
<li>2022-06-02 Mg (Magnesium) 1.4 mg/dL<br />
</li>
<li>2022-05-18 1.5 mg/dL</li>
<li>2022-04-29 2.2 mg/dL</li>
<li>2022-04-28 1.2 mg/dL</li>
<li>2022-04-13 1.4 mg/dL</li>
<li>2022-03-17 1.5 mg/dL</li>
<li>2022-03-14 1.5 mg/dL</li>
<li>2021-11-05 1.6 mg/dL</li>
<li>2021-11-03 1.3 mg/dL</li>
<li>2021-10-25 1.4 mg/dL</li>
<li>2021-10-18 1.6 mg/dL</li>
<li>2021-10-04 1.6 mg/dL</li>
<li>2021-09-27 1.5 mg/dL</li>
<li>2020-06-08 1.7 mg/dL<br />
</li>
<li>2020-06-03 1.8 mg/dL<br />
</li>
<li>2020-05-30 1.8 mg/dL<br />
</li>
<li>2020-05-29 2.1 mg/dL<br />
</li>
<li>2020-05-28 1.5 mg/dL<br />
</li>
</ul></li>
<li>CEA
<ul>
<li>2022-04-28 10.607 ng/ml</li>
<li>2022-02-23 4.299 ng/ml</li>
<li>2021-12-01 3.934 ng/ml</li>
<li>2020-08-11 2.202 ng/ml</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-07-22 MRI - nasopharynx
<ul>
<li><ol style="list-style-type: decimal">
<li>Right tonsillar cancer size enlarged, which invades right soft
palate and extends laterally to encase right proximal ICA (internal
carotid artery) and ECA (external carotid artery).</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Right neck lymphadenopathy with ENE (extranodal extension),
enlarged.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Post-irradiation change with/without tumor involvement, right
lateral nasopharynx, right lateral pterygoid and temporalis
muscles.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Progressively swelling of right AE fold (aryepiglottic fold,
杓狀會厭皺襞).</li>
</ol></li>
</ul></li>
<li>2022-07-21 CXR
<ul>
<li>Scoliosis of the T-spine with convex to right side.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>A nodular opacity projecting in the right upper lung is suspected.
Please correlate with CT.</li>
<li>Emphysematous change of both lung field</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-03-16 MRI - nasopharynx
<ul>
<li>The current study was compared to the prior one obtained on
20210924.</li>
<li>Knwon a case of right tonsillar cancer S/P treatment. Still mild
mucosal thickening of right palatine fossa. Also swollen change of right
A-E fold with enhancement. Suggest clinical correlation to rule out
inflammatory change or recurrence.</li>
<li>Right mastoiditis.</li>
<li>The bilateral parotid and submandibular glands enhance as before. It
is consistent with post-radiation inflammation.</li>
<li>Clear appearacne of all paranasal sinuses.</li>
</ul></li>
<li>2022-03-15 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200605, the lesions in
the lower T-spines and some L-spines are stationary. Degenerative change
may show this picture.</li>
<li>Some new faint hot spots in the posterior aspect of right rib cage.
The nature is to be determined (post-traumatic change? other nature?).
Please correlate with the clinical history and follow up bone scan for
further evaluation.</li>
<li>No prominent change is noted in the previous faint hot spots in the
skull and the lesion in the right femoral shaft, possibly more benign in
nature.</li>
<li>Increased activity in bilateral shoulders, right sternoclavicular
junction, bilateral hips and right knee, compatible with benign joint
lesions.</li>
</ul></li>
<li>2022-03-09 Nasopharyngoscopy
<ul>
<li>rt arytenoid swelling, limited airway, suggest tracheostomy</li>
<li>rt tonsil and mouth floor, p16(-), ct2N2bM0, stage IVa + esophagus
ca</li>
</ul></li>
<li>2022-02-22 SONO - abdomen
<ul>
<li>A polyp 4.5 mm and multiple stones (&lt; 6 mm) of the gallbladder
are noted.</li>
</ul></li>
<li>2022-01-12 SONO - head and neck, soft tissue
<ul>
<li>right neck mass, suspected malignancy</li>
<li>right neck level II, large, heterogenous mass lesion (tender+), s/p
FNA</li>
</ul></li>
<li>2021-11-30 MRI - larynx
<ul>
<li>Regressed right tonsil CA, stationary of right carotid and posterior
cervical LAPs with central necrotic change.</li>
</ul></li>
<li>2021-09-30 CT - lung/mediastinum/pleura
<ul>
<li>Consolidation over posterior segment of right upper lobe.</li>
<li>No evidence of metastatic lesion in the current study.</li>
</ul></li>
<li>2021-09-28 Patho - gingival/oral mucosa biopsy
<ul>
<li>Observed
<ul>
<li>Hx of R tonsil + mouth floor, esophageal ca s/p incomplete
CCRT<br />
</li>
<li>Mouth floor lesion</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Labeled as ‘mouth floor lesion’, biopsy — squamous cell
carcinoma.<br />
</li>
<li>Section shows squamous cell carcinoma.</li>
</ul></li>
</ul></li>
<li>2021-09-28 L-N aspiration
<ul>
<li>R level V LAP, 3*3cm, firm, hard - squamous cell carcinoma</li>
</ul></li>
<li>2020-10-23 Patho - esophageal biopsy
<ul>
<li>Esophagus, 30 cm below incisor, biopsy - squamous cell
hyperplasia</li>
</ul></li>
<li>2020-10-05 CT - lung/mediastinum/pleura
<ul>
<li>RUL infection D/D includes TB or bacteria severe emphysema and
fibrotic change in lower lobes.</li>
</ul></li>
<li>2020-07-28 Patho - esophageal biopsy
<ul>
<li>A. Labeled as “the lesion needed to ablate is localized at the 19 cm
to 35 cm. Random Bx is done (A) as marking at the 19 cm.”, biopsy —
squamous mucosa with low grade dysplasia and necrosis.<br />
</li>
<li>B. Labeled as ‘There is some ablated esophageal tumor tissue
retrieved for patho exam (B)’, biopsy - benign squamous mucosa with
moderate acute inflammation.</li>
</ul></li>
<li>2020-06-30 Patho - tonsil biopsy
<ul>
<li>A. Right side tonsil, frozen section + tonsillectomy — Squamous cell
carcinoma, moderately differentiated
<ul>
<li>IHC: CK5/6(+); P16(-), HPV(-) and P63(+) for tumor cells.</li>
</ul></li>
<li>B. Mouth floor tumor, above wharton’s duct, FS + excision — Squamous
cell carcinoma, moderately differentiated characterized by epithelial
hyperplasia with high grade dysplasia and focal stromal invasion.</li>
</ul></li>
<li>2020-06-30 Frosen section
<ul>
<li>A. Right side tonsil, frozen section — Squamous cell carcinoma<br />
</li>
<li>B. Mouth floor, ditto — Mild to focal moderate dysplasia</li>
</ul></li>
<li>2020-06-29 CT - neck
<ul>
<li>imaging reort form for oropharynx carcinoma</li>
<li>Imaging stage: T2N2bM0, stage IVA</li>
</ul></li>
<li>2020-06-24 Nasopharyngoscopy
<ul>
<li>Rt NP cyst, Rt tonsils with induration, mouth floor tumor?,
hypopharynx cyst.</li>
</ul></li>
<li>2020-06-09 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism involving the middle portion of the
esophagus, compatible with primary esophageal malignancy of low FDG
uptake. However, no prominent abnormal focal FDG uptake was noted in the
lower portion of the esophagus.</li>
<li>Mild glucose hypermetabolism in the right tonsil and stomach. The
nature is to be determined (inflammatory process? other nature?).</li>
<li>Mildly increased FDG uptake in the right anterior neck muscle.
Either physiological FDG uptake or mild inflammation may show this
picture.</li>
</ul></li>
<li>2020-06-08 Miniprobe Endoscopic Ultrasound
<ul>
<li>Esophageal cancer, middle esophagus, EUS estimated stage
T1b~T2N1Mx</li>
<li>Suspected early esophageal cancer, lower esophagus, EUS estimated
stage T1bN1Mx</li>
</ul></li>
<li>2020-06-06 CT - lung/mediastinum/pleura
<ul>
<li>u/3 thoracic esophageal cancer T? no evidence of mediastinal
invasion, no LAP (N0) and M0.</li>
<li>diffuse emphysema, could be related to smoking and fibrotic change
in LLL, RLL, and LUL, sequela of prior infection?</li>
<li>moderate 3V-CAD.</li>
</ul></li>
<li>2020-06-01 Patho - esophageal biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>A. Lower esophagus, biopsy — High grade dysplasia at least,
suspicious for malignancy<br />
</li>
<li>B. Middle esophagus, biopsy — Squamous cell carcinoma, moderately
differentiated</li>
</ul></li>
<li>microscopic examination
<ul>
<li>A. Lower esophagus: thick epithelium shows high grade dysplasia and
few subepithelial connective tissue without tumor invasion. It is still
suspicious for malignancy. Repeat biopsy is advised for further
evaluation.<br />
</li>
<li>B. Middle esophagus: squamous cell carcinoma, moderately
differentiated characterized by thick epithelium with high grade
dysplasia and a few tumor nests infiltrated in inflamed stroma.
<ul>
<li>IHC: CK5/6(+); P16(-), HPV(-), CD34(equivocal) and P63 (+) for tumor
cells.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-09-30 Radiation Oncology
<ul>
<li>This 53-year-old man previously:
<ul>
<li>MDSCC of Rt tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa, s/p
CCRT</li>
<li>MDSCC of esophagus M/3, p16(-). cT1b~T2N1M0</li>
</ul></li>
<li>2020-06-06 ~ 2020-09-09 RT to the bil. neck, Rt tonsil, LAPs: 50y/
25fx. The whole esophagus and adjacent lymphatic drainage area: 45y/
25fx. Postponed since 2020-09-10 because he wanted to take a rest.</li>
<li>This time, he suffered from tonsillar fossa tumor with Lateral
pterygoid muscle with lateral nasopharynx invasion, Any node(s) and
clinically overt ENE, T4bN3bM0, stage IVB. FNA were performed on
2021-09-27. The Labeled as ‘mouth floor lesion’, biopsy (2021-09-29)
proved squamous cell carcinoma.</li>
<li>Palliative CCRT is indicated. Plan to deliver at least 50 Gy/ 25 fx
to the Rt tonsillar tumor, LAPs, and Rt neck level I~III. However, after
explanation, he is still afraid of the side effects, such as mucositis
or xerostomia, and still need more time to consider whether to have
radiotherapy. If he makes up his mind to have radiotherapy, please
inform us so we can make arrangement for him. Thank you very much.</li>
</ul></li>
<li>2021-09-28 ENT
<ul>
<li>PHx: R tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa;
Esophagus cancer, M/3, p16(-), cT1b-T2N1M0 with incomplete CCRT tx</li>
<li>Oral: mouth floor whitish lesion s/p biopsy</li>
<li>Neck: right level V induration s/p FNA</li>
<li>Imp:
<ul>
<li>Right neck mass, suspect malignancy</li>
<li>Mouth floor lesion, suspect malignancy</li>
</ul></li>
<li>Plan:
<ul>
<li>Pending pathology report</li>
<li>If unsatisfactory, may consider arrange right neck LAP biopsy under
LA</li>
</ul></li>
</ul></li>
<li>2021-09-22 ENT
<ul>
<li>Local finding: a 3-4 cm indurated non-movable mass with tenderness
over R neck level V. A wart-like lesion over midline of floor of
mouth.</li>
<li>Scope: smooth nasopharynx, oropharynx and hypopharynx. Medialization
of right lateral pharyngeal wall. Patent airway.</li>
<li>Neck CT a rim-enhanced irregular mass over R level V, increase in
size compared to previous study in 2020-06.</li>
<li>Neck sono: a heterogenous mass over R neck level V.</li>
<li>Impression: Suspect nodal metastasis with or withour necrosis; Mouth
floor lesion. Poor nutrition and dehydration.</li>
<li>Plan: Admission to Oncology IPD for supportive treatment and further
cancer work-up was suggested.</li>
<li>NG placement is suggested.</li>
</ul></li>
<li>2020-10-27 Radiation Oncology
<ul>
<li>This 52 y/o male patient was diagnosed with
<ul>
<li>MDSCC of Rt tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa</li>
<li>MDSCC of esophagus M/3, p16(-). cT1b~T2N1M0</li>
</ul></li>
<li>s/p incomplete CCRT [20200806 ~ RT to the bil. neck, Rt tonsil,
LAPs: 50y/ 25fx. The whole esophagus and adjacent lymphatic drainage
area: 45y/ 25fx. Postponed since 20200910 because he wanted to take a
rest.]</li>
<li>He was admitted due to poor nutrition and pneumonia.</li>
<li>To resume CCRT is indicated for double cancer treatment. However,
after discussion, he refused to resume CCRT right now and said he will
come back for further treatment when he feels better.</li>
</ul></li>
<li>2020-05-30 Nephrology
<ul>
<li>This 51 y/o man of chronic alcoholism presented with hypokalemia,
hypomagnesemia, and hypocalcemia.</li>
<li>PE revealsed severe malnutrition with muscle wasting. The ABG was
not remarkable.</li>
<li>Hypo-K, hypo-Mg and hypo-Ca are commonly seen in patients with
alcoholism and malnutrition, probably due to chronic low intake.</li>
<li>This triple electrolyte deficiency is not related to renal tubular
dysfunction. Only IV or oral supplements with these electrolytes are
needed.<br />
</li>
<li>I will follow up this patient.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-07-27 Endoscopic radiofrequency ablation with Barrx 360 express
RFA cathether</li>
<li>2020-06-30 Right side tonsil tumor, wide excision; Mouth floor
tumor, above wharton’s duct, excision</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-06 ~ 2021-10-29 RT to the Rt neck LAPs and tonsilar tumor:
36 Gy/ 18 fx</li>
<li>2020-08-06 ~ 2020-09-09 RT to the bil. neck, Rt tonsil, LAPs: 50y/
25fx. The whole esophagus and adjacent lymphatic drainage area: 45y/
25fx.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-07-22 - docetaxel 40mg/m2 59mg 1hr + cisplatin 40mg/m2 59mg 2hr
+ fluorouracil 1000mg/m2 2980mg 46hr</li>
<li>2022-06-27 - docetaxel 40mg/m2 59mg 1hr + cisplatin 40mg/m2 59mg 2hr
+ fluorouracil 1000mg/m2 2980mg 46hr</li>
<li>2022-06-02 - docetaxel 40mg/m2 58mg 1hr + cisplatin 40mg/m2 58mg 2hr
+ fluorouracil 1000mg/m2 2900mg 46hr</li>
<li>2022-05-18 - docetaxel 40mg/m2 58mg 1hr + cisplatin 40mg/m2 58mg 2hr
+ fluorouracil 1000mg/m2 2900mg 46hr</li>
<li>2022-04-29 - docetaxel 40mg/m2 59mg 1hr + cisplatin 40mg/m2 59mg 2hr
+ fluorouracil 1000mg/m2 2990mg 46hr</li>
<li>2022-04-14 - docetaxel 40mg/m2 58mg 1hr + cisplatin 40mg/m2 58mg 2hr
+ fluorouracil 1000mg/m2 2920mg 46hr (cisplatin 40 &lt;- 50)</li>
<li>2022-03-17 - docetaxel 40mg/m2 60mg 1hr + cisplatin 50mg/m2 79mg 2hr
+ fluorouracil 3170mg/m2 2920mg 46hr (TPF - <a href="https://pubmed.ncbi.nlm.nih.gov/20878112/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20878112/</a> for head and
neck cancer)</li>
<li>2021-11-03 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2021-10-25 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2021-10-18 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2021-10-07 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2020-09-01 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2020-08-25 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2020-08-18 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
<li>2020-08-11 - cisplatin 40mg/m2 60mg 2hr (CCRT)</li>
</ul></li>
</ul>
<div id="section-408" class="section level3">
<h3>==========</h3>
</div>
<div id="section-409" class="section level3">
<h3>2022-08-23</h3>
<ul>
<li>Weight loss 17 kgw during the past 6 months (2022-08-22 37 kgw &lt;-
2022-03-14 54 kgw), 173 cm, BMI = 12.4 kg/m2, severe thinness. The
patient has a history of alcoholism, malnutrition and hypomagnesemia are
suspected. NAKO NO.5 has been prescribed.</li>
<li>Hyperuricemia is observed (2022-08-22 blood uric acid 9.3 mg/dL),
Euricon (benzbromarone 50mg/tab) 1# QD might be considered.</li>
</ul>
</div>
<div id="section-410" class="section level3">
<h3>2022-06-06</h3>
<ul>
<li>The patient was diagnosed with stage IVB esophageal cancer in June
2020, and he underwent partial CCRT in September of the following year.
Following the last dose of cisplatin received at the beginning of
November of 2021, the patient started receiving TPF on 2022-03-17.</li>
<li>Last images in March 2022 revealed mild mucosal thickening in the
right palatine fossa, and the lesions in the lower T-spine and some
L-spine areas have remained stationary, An update image studye might be
helpful.</li>
<li>A steady rise in the CEA level has been observed:
<ul>
<li>2022-04-28 10.607 ng/ml</li>
<li>2022-02-23 4.299 ng/ml</li>
<li>2021-12-01 3.934 ng/ml</li>
<li>2020-08-11 2.202 ng/ml</li>
</ul></li>
<li>Hypomagnesia has been noted since 2020-05, possibly caused by
undernutrition (BMI 15), electrolyte supplements may be beneficial (MgO
500g PO BID and Nako No.5 500mL IVD BID have been prescribed).</li>
</ul>
</div>
<div id="section-411" class="section level3">
<h3>2022-05-19</h3>
<ul>
<li>This patient was diagnosed with stage IVB esophageal cancer, he had
surgery in June, July 2020, and incomplete CCRT the following September.
After receiving the last dose of cisplatin in early November of 2021,
the patient began receiving TPF on 2022-03-17.</li>
<li>Images in March 2022 revealed mild mucosal thickening in the right
palatine fossa, and the lesions in the lower T-spine and some L-spine
areas have remained stationary. A slow pace of progress might be
likely?</li>
<li>CEA level continues to rise steadily, lab data:
<ul>
<li>2022-04-28 10.607 ng/ml</li>
<li>2022-02-23 4.299 ng/ml</li>
<li>2021-12-01 3.934 ng/ml</li>
<li>2020-08-11 2.202 ng/ml</li>
</ul></li>
<li>Records available in the hospital indicated that blood magnesium
levels were almost always below the lower limit of normal. He was found
to have been an alcohol dependent for years. The patient with BMI 15
(height of 175 cm, weight of 46 kg) might be undernourished. It is
common to observe hypomagnesemia in patients suffering from alcoholism
and malnutrition. The need for a lifestyle change cannot be
overstated.</li>
<li>The components of the current regimen contain 5-Fu and cisplatin,
which might also cause a low magnesium level. If hypomagnesemia becomes
symptomatic, MgSO4 injection might be considered.</li>
</ul>
</div>
<div id="section-412" class="section level3">
<h3>2022-04-29</h3>
<ul>
<li>After receiving last cisplatin in early November of 2021, this
patient began receiving TPF from 2022-03-17.</li>
<li>Lab data results: serum Mg 1.2 mg/dL (2022-04-28), CEA 10.607 ng/ml
(2022-04-28) &lt;- 4.299 (2022-02-23) &lt;- 3.934 (2021-12-01) &lt;-
2.202 (2020-08-11).</li>
<li>CEA is increasing in trend, which needs to be addressed.</li>
<li>Hypomagnesemia is frequently a result of magnesium depletion, which
is often caused by gastrointestinal or renal losses.
<ul>
<li>One of the main dose-limiting side effects of fluoropyrimidines such
as FU (and its oral prodrugs capecitabine and ftorafur-uracil [UFT]) is
diarrhea.</li>
<li>It is also possible that renal loss could be caused by medications
such as diuretics (loop and thiazide), antibiotics (aminoglycoside,
amphotericin, pentamidine), calcineurin inhibitors, cisplatin,
antibodies targeting epidermal growth factor (EGF) receptors (cetuximab,
panitumumab, matuzumab), which are not prescribed currently. (5-FU and
cisplatin are in recent regimen.)</li>
<li>Alcoholism is also a cause of renal loss. According to the
consultation with mental health clinic 2020-05-30, the patient might be
alcohol dependent.</li>
<li>The use of MgSO4 injection might be considered if there are no
contraindications.</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-413" class="section level1">
<h1>700929934</h1>
<div id="section-414" class="section level2">
<h2>220819</h2>
<p>{DLBCL stage IV}</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-06 Automated perimetry
<ul>
<li>clinical diagnosis: glaucoma</li>
<li>Report: VF on 06/06/2022 (od) tunnel vision only (os) arcuate
scotoma, MD -26.03/-6.48 dB</li>
</ul></li>
<li>2022-06-02 CT - abdomen, pelvis
<ul>
<li>Finding
<ul>
<li>Some enlarged LNs at retroperitoneum along aorta and IVC.</li>
<li>Wall edema of rectum.</li>
<li>A small cystic lesion (0.6cm) at pancreatic tail.</li>
<li>A calcified nodule (0.5cm) at RML. Right minimal pleural
effusion.</li>
<li>Gallbladder stones (2-6mm).</li>
<li>Atherosclerosis of aorta, iliac arteries.</li>
</ul></li>
<li>IMP:
<ul>
<li>Some enlarged LNs at retroperitoneum along aorta and IVC suspected
lymphoma.</li>
<li>Gallbladder stones (2-6mm). Wall edema of rectum.</li>
</ul></li>
</ul></li>
<li>2022-05-24 Patho - bone marrow biopsy - negative for malignancy
<ul>
<li>Bone marrow, iliac, clinically: DLBL, biopsy — Negative for
malignancy.</li>
<li>IHC stains: CD3: &lt;2%; CD20: &lt;2 %; bcl-2: &lt;2%, bcl-6: (-);
MUM-1: (-) (of the nucleated cells).</li>
<li>Section shows piece(s) of bone marrow with 50% cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
is no malignancy present.</li>
</ul></li>
<li>2022-05-21 CT - brain
<ul>
<li>Brain atrophy</li>
</ul></li>
<li>2022-05-21 Micro-sonography
<ul>
<li>glaucoma od &gt; os</li>
<li>229/224um, no sub RPE infiltration ou</li>
<li>54/82um, VCDR 0.82/0.58, IS thining</li>
<li>GCC loss od</li>
</ul></li>
<li>2022-05-21 Optical Coherence Tomography
<ul>
<li>c/d: 0.9 od, 0.4 os, media clear, no infiltration noted ou</li>
</ul></li>
<li>2022-05-18 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in lymph nodes from head to bilateral upper
thighs, compatible with lymphoma with involvement of lymph node regions
on both sides of the diaphragm.<br />
</li>
<li>Glucose hypermetabolism in the left upper lung pleura, right lower
lung, left lobe of the liver, spleen, several C-, T- and L-spine,
sacrum, and bilateral iliac bones, highly suspected lymphoma with
diffuse involvement of multiple extralymphatic organs.</li>
<li>Diffuse large B-cell lymphoma, stage IV (AJCC, 8th ed.), by this
F-18 FDG PET scan.</li>
</ul></li>
<li>2022-05-16 CXR
<ul>
<li>Boderline cardiomegaly</li>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-05-10 Patho - lymph node region resection
<ul>
<li>Lymph node, right level Ib, excisional biopsy — Diffuse large B-cell
lymphoma<br />
</li>
<li>Histology type: diffuse large B-cell lymphoma with atypical large
lymphoid cells with nucleoli and totally effacement of nodal
architecture</li>
<li>Immunohistochemistry: CK(-), CD3(-), CD20(+), Bcl-2(+), CD30(-),
CD10(-), Bcl-6(+, focal), C-MYC(-, &lt;30%) , Ki-67: 80% for tumor</li>
</ul></li>
<li>2022-05-06 CT - neck
<ul>
<li>Finding
<ul>
<li>Multiple enlarged, homogeneously enhancing lymph nodes at bilateral
level I, II, III, IV, V, as well as bilateral mediastinum. There are
multiple enlarged lymph nodes in bilateral parotid glands as well.
Lymphoma should first be considered.</li>
<li>Bilateral symmetric pharyngeal mucosa.</li>
<li>Normal size and normal enhancement pattern of bilateral
submandibular glands.</li>
</ul></li>
<li>Impression
<ul>
<li>Consider lymphoma. Suggest further evaluation.</li>
</ul></li>
</ul></li>
<li>2022-05-05 Nasopharyngoscopy
<ul>
<li>smooth NPx, OPx, HPx</li>
</ul></li>
<li>2017-10-12 Pure Tone Audiometry, PTA
<ul>
<li>R’t: mild to profound mixed type HL</li>
<li>L’t: mild to severe mixed type HL</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Anti-HBc 2022-05-21 Reactive, 8.51 S/CO</li>
<li>HBsAg 2022-05-16 Reactive, 4785.50 S/CO</li>
<li>Anti-HCV 2022-05-16 Nonreactive 0.07 S/CO</li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-20 Ophthalmology
<ul>
<li>Objective
<ul>
<li>BV of right eye &gt; left eye for over 1 year</li>
<li>recently diagnosed DLBCL with initial presentation of bilateral
sunmadibular gland enlargement</li>
<li>phx: DM, HTN under bokey</li>
<li>ophx: glaucoma under combigan for 1 year</li>
<li>BCVA OD 0.3(0.5x+0.75/-2.0x85) OS 0.5(0.6x+1.25/-0.75x75)</li>
<li>PT: 20/19 mmHg</li>
<li>pupil: 3.5 mm+/+, 3mm+/+, rapd + od</li>
<li>EOM: full and free</li>
<li>Lid: lago os , imcomplete blinjing os</li>
<li>conj: pterygium at 3 o’c od, np os</li>
<li>K: cl od, inf spk os</li>
<li>AC: deep and clear ou</li>
<li>Lens: NS 2+ OD＞OS</li>
<li>F’d: c/d: 0.9 od, 0.4 os, media clear, no infiltration noted ou</li>
</ul></li>
<li>Assessment:
<ul>
<li>glaucoma od &gt; os</li>
<li>lagophthalmos os due to left CN 7 palsy</li>
</ul></li>
<li>Plan
<ul>
<li>combigan 1gtt bid ou + sinomin 1gtt qid os + duratears qid os</li>
<li>we will arrange OCT and VF later for optic neuropahty od</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-07-29 - rituximab 375mg/m2 690mg 8hr D1 + cyclophosphamide
750mg/m2 1378mg 30min D2 + doxorubicin 50mg/m2 91mg 30min D2 +
prednisolone 60mg/m2 5mg/tab 11tab BID D2-6 (R-CHOP, vincristine not
avaliable then)</li>
<li>2022-07-07 - rituximab 375mg/m2 690mg 8hr D1 + cyclophosphamide
750mg/m2 1378mg 30min D2 + doxorubicin 50mg/m2 91mg 30min D2 +
vincristine 1.4mg/m2 2mg 10min D2 + prednisolone 60mg/m2 5mg/tab 11tab
BID D2-6 (R-CHOP)</li>
<li>2022-06-16 - rituximab 375mg/m2 690mg 8hr D1 + cyclophosphamide
750mg/m2 1378mg 30min D2 + doxorubicin 50mg/m2 91mg 30min D2 +
vincristine 1.4mg/m2 2mg 10min D2 + prednisolone 60mg/m2 5mg/tab 11tab
BID D2-6 (R-CHOP)</li>
<li>2022-05-25 - rituximab 375mg/m2 690mg 8hr D1 + cyclophosphamide
750mg/m2 1380mg 30min D2 + vincristine 1.4mg/m2 2mg 10min D2 +
prednisolone 60mg/m2 5mg/tab 10tab BID D2-4 (R-COP)</li>
</ul></li>
</ul>
<div id="section-415" class="section level3">
<h3>==========</h3>
</div>
<div id="section-416" class="section level3">
<h3>2022-08-19</h3>
<ul>
<li>TPR, BP were stable during this hospital stay.</li>
<li>Blood sugar 2022-08-18 17:10 236 mg/dL, 2022-08-19 08:21 249 mg/dL.
If diabetes is confirmed, since the patient has normal kidney function
(based on 2022-08-18 laboratory results), then metformin 500mg BID could
be considered.</li>
</ul>
</div>
<div id="section-417" class="section level3">
<h3>2022-05-30</h3>
<ul>
<li>Diffuse large B-cell lymphoma involving both sides of the diaphragm,
stage IV (PET 2022-05-18), no evidence of involvement of the central
nervous system yet (CT 2022-05-21).</li>
<li>BCL2(+), BCL6(+), however C-MYC less than 30% (pathology
2022-05-10), might not be regarded as a ‘double/triple hit’ lymphoma.
LDH 384U/L, anti-HBc reactive (2022-05-21), HBsAg reactive (2022-05-16).
No anti-HBs, IgM anti-HBc, Epstein-Barr virus results were found.</li>
<li>RCHOP might be indicated in patients with DLBCL. For patients who
are too frail to withstand even R-mini-CHOP, treatment with a systemic
steroid, with or without rituximab, might improve the patient’s
performance status (PS) and enable subsequent treatment with R-mini-CHOP
or single chemotherapeutic agents.
<ul>
<li>S-GPT/ALT, S-GOT/AST were both slightly elevated (2022-05-20).
Cyclophosphamide, doxorubicin, and vincristine dosages may need to be
adjusted for preexisting liver dysfunction (not applicable to this
patient at present).</li>
<li>As the patient has ‘Three Hypers’ and borderline cardiomegaly as
well as increased interstitial lines in both lungs (CXR 2022-05-16),
decreased cardiopulmonary function could be expected. LVEF should be
evaluated prior to initiation of RCHOP. Dose alterations should be
considered for LVEF &lt;50%, and doxorubicin therapy is contraindicated
in patients with LVEF &lt;30% at initiation.</li>
</ul></li>
<li>HBsAg(+), anti-HBc(+), elevated ALT, AST levels suggest infection
with HBV. Antiviral prophylaxis might be considered prior to initiating
rituximab treatment.</li>
<li>HR (102 -&gt; 65 pulse/min) and SBP (142 -&gt; 92mmHg) have fallen
sharply 2022-05-23 08:45 which should be addressed. Amlodipine and/or
valsartan might be temporarily suspended.</li>
</ul>
</div>
</div>
</div>
<div id="section-418" class="section level1">
<h1>701196422</h1>
<div id="section-419" class="section level2">
<h2>220817</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-17 CXR
<ul>
<li>Bilateral pleural effusion.</li>
<li>Ground glass opacities in bil. lungs.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Intact bony structure(s).</li>
</ul></li>
<li>2022-08-16 MRI - brain
<ul>
<li>Multiple bilateral cerebellar, cerebral and left upper brain stem
metastases, with slight regression in cerebelli and cerebral
hemispheres, but seems stationary or mild progression in left upper
brain stem when compared with 2022/06/07 MRI.</li>
</ul></li>
<li>2022-08-16 SONO - chest
<ul>
<li>symptom: dyspnea</li>
<li>indication: effusion</li>
<li>clinical diagnosis
<ul>
<li>right breast ca</li>
<li>bilateral pleural effusion</li>
</ul></li>
<li>Echo Diagnosis
<ul>
<li>Left thorax: moderate amount pleural effusion s/p drainage of 860
cc, serosanguinous pleural effusion.</li>
<li>Right thorax: small amount pleural effusion; thoracocentesis was not
performed due to high risks of complications.</li>
</ul></li>
</ul></li>
<li>2022-08-15 CXR
<ul>
<li>Bilateral pleural effusion.</li>
<li>Ground glass opacities in bil. lungs.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Compression fracture of T12.</li>
</ul></li>
<li>2022-08-15 2D transthoracic echocardiography
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (30.9 - 11.9) / 30.9 = 61.49%</li>
<li><ol style="list-style-type: decimal">
<li>Normal AV with no AR</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal MV with mild MR</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal LV chamber size and wall thickness</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved LV and RV systolic function</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>No PR, trivial TR, normal IVC size</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Large amount of left pleural effusion, right side deviation of heart
and poor para-sternal window</li>
</ol></li>
</ul></li>
<li>2022-07-25 CXR
<ul>
<li>Bilateral pleural effusion.</li>
<li>Focal calcification of left pleura.</li>
<li>Compression fracture of spine.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Ground glass opacities in bil. lungs.</li>
</ul></li>
<li>2022-07-25 SONO - chest
<ul>
<li>Echo diagnosis: Bilateral pleural effusion (Left: small and Right:
small to moderate), post left diagnostic thoracentesis and bilateral
therapeutic thoracentesis.</li>
</ul></li>
<li>2022-07-04 CXR
<ul>
<li>Bilateral pleural effusion.</li>
<li>Ground glass opacities in bil. lungs.</li>
<li>Multiple nodules at bil. lungs.</li>
<li>Compression fracture of spine.</li>
</ul></li>
<li>2022-07-04 SONO - chest
<ul>
<li>Echo diagnosis: Bilateral pleural effusion (Left: minimal and Right:
moderate to massive), s/p right diagnostic and therapeutic
thoracentesis.</li>
</ul></li>
<li>2022-06-13 SONO - chest
<ul>
<li>Echo diagnosis: Bilateral pleural effusion (Left: minimal to small
and Right: moderate to massive), post right diagnostic and therapeutic
thoracentesis.</li>
</ul></li>
<li>2022-06-07 MRI - brain
<ul>
<li>Clinical information: Lt breast advanced ca with spine mets</li>
<li>DCIS (Ductal Carcinoma in Situ) was told after CNB (core needle
biopsy) at Taipei Medical University Hospital on 2015-08-11 without
treatment.</li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>Numerous intra-axial faintly enhancing lesions with perifocal edema
in bilateral cerebral and cerebellar hemispheres, and midbrian and brain
stem, with the largest one about 20 mm at right occipital lobe.
Increased in size and number of these metastatic lesions, as compared
with MRI on 20220302.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Multifocal peritumoral edema.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-02 SONO - abdomen
<ul>
<li>Gallbladder stones (0.37-0.99cm).</li>
<li>Splenomegaly.</li>
<li>Right pleural effusion.</li>
</ul></li>
<li>2022-06-02 CT - lung/mediastinum/pleura
<ul>
<li>Residual breast tumor at right side with lung meta, bone mets,
stationary.</li>
<li>Bilateral massive pleural effusion.</li>
</ul></li>
<li>2022-04-18 CXR
<ul>
<li>Bilateral pleural effusion.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Compression fracture of T12.</li>
<li>Ground glass opacities in bil. lungs.</li>
</ul></li>
<li>2022-03-11 CT - lung/mediastinum/pleura
<ul>
<li>Compatible with breast cancer with lung and bone mets, the lung mets
is stationary.</li>
<li>Bilateral pleural effusion with stationary extension.</li>
</ul></li>
<li>2022-03-11 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Prior sonography identified An ill-defined hypoechoic lesion 3.19 cm
in S7 liver is noted again, mild decreasing in size to 2.86 cm. Follow
up is indicated.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Several gallstone are noted.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The spleen shows enlarged in size (long axis: 13.2 cm).</li>
</ol></li>
</ul></li>
<li>2022-03-02 MRI - brain
<ul>
<li>C/W multiple brain metastases, progressive change as compared with
MRI on 20211108.</li>
</ul></li>
<li>2022-01-24 CXR
<ul>
<li>Lung markings: opacification in the bilateral lower lung fieldl
small nodular lesions in the bilatearl lung fields.</li>
<li>blurred bilateral hemidiaphrams</li>
<li>blunting bilateral costophrenic angles</li>
</ul></li>
<li>2022-01-24 Neck
<ul>
<li>increased density in the C2 vertebral body. Nature?</li>
</ul></li>
<li>2022-01-24 Nasopharyngoscopy
<ul>
<li>Multiple petechiae were found at posterior pharyngeal wall and
arytenoid</li>
<li>No active bleeder and foreign body was found</li>
</ul></li>
<li>2021-12-23 CT - abdomen
<ul>
<li>S/P left breast operation.</li>
<li>Multiple bony metastases.</li>
<li>Some nodules at bil. lungs. Bil. pleural effusions.</li>
<li>Splenomegaly.</li>
</ul></li>
<li>2021-12-06 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Irregular hypoechoic lesion, 3.19x2.68cm in S7 liver,
progression.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>GB stone.</li>
</ol></li>
</ul></li>
<li>2021-12-02 Patho - intradermal nervus
<ul>
<li>Skin, trunk, total excision — Invasive carcinoma, no special type,
NST.</li>
<li>IHC stains: ER (-, 0%), PR(-, 0%), Her2/neu: positive (score=3+),
Ki-67 (30%), GATA-3 (+).<br />
</li>
<li>Section shows skin tissue with irregular neoplastic ducts
infiltration. Margins free (0.1 cm from closest side margin and 0.3 cm
from deep margin.</li>
</ul></li>
<li>2021-11-08 MRI - brain
<ul>
<li>C/W multiple brain metastases, regression in sizi and number as
compared with MRI on 20210508, but with progressive white matter edema
in right posterior temporal-occipital lobe.</li>
</ul></li>
<li>2021-09-24 CT - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Multiple bony metastases.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Flow artifact in S7 liver.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Splenomegaly and a hemangioma 1.2 cm in the spleen.</li>
</ol></li>
</ul></li>
<li>2021-08-31 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200908, some new bone
lesions are noted and some previous bone lesions are more evident. The
scintigraphic findings suggest multiple bone metastases in
progression.</li>
</ul></li>
<li>2021-08-31 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>Prior sonography identified An ill-defined hypoechoic lesion 2.48 cm
in S7 liver is noted again, mild decreasing in size to 2.18 cm. Follow
up is indicated.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>A gallstone 1.45 cm is suspected.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The spleen shows enlarged in size (long axis: 13.35 cm).</li>
</ol></li>
</ul></li>
<li>2021-08-03 MRI - brain
<ul>
<li><ol style="list-style-type: decimal">
<li>Brain metastases, slight regression in right hippocampus, bil.
cerebellar hemispheres and left IAC.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Seems stationary of bil. cerebral nodules.</li>
</ol></li>
</ul></li>
<li>2021-06-08 CT - lung
<ul>
<li>breast ca with lung, pleura, and bones metastasis, in regression of
pleural effusion and stationary of lung and bony metastases as compared
with previous CT study 2021/03/22</li>
</ul></li>
<li>2021-06-08 SONO - abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>An ill-defined hypoechoic lesion 2.48 cm in S7 liver is noted that
may be tumor or pseudolesion? Please correlate with contrast enhanced
dynamic CT or MRI.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>A gallstone 1.79 cm is suspected.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The spleen shows prominence in size (long axis: 11.38 cm).</li>
</ol></li>
</ul></li>
<li>2021-05-08 MRI - brain
<ul>
<li>Brain metastases, progression in right hippocampus, bil. cerebellar
hemispheres and left IAC.</li>
</ul></li>
<li>2021-03-22 SONO - breast
<ul>
<li><ol style="list-style-type: decimal">
<li>Right breast tumors, suspected malignancy with axillary lymph node
metastasis.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Right breast skin thickening.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Left breast tumor, suspected fibroadenoma. Suggest follow up.</li>
</ol></li>
<li>BI-RADS 6. known biopsy-proven malignancy</li>
</ul></li>
<li>2021-03-22 CT - lung
<ul>
<li>breast ca with lung, pleura, and bones metastasis, in prgression of
lung and pleural metastases as compared with previous CT study
2020/12/22</li>
</ul></li>
<li>2021-01-27 MRI - brain
<ul>
<li>multiple brain metastasis, decrease in sizes and numbers.</li>
</ul></li>
<li>2020-12-22 CT - lung
<ul>
<li>breast ca with lung, pleura, and bones metastasis, stationary of as
compared with previous CT study 2020/09/11.</li>
</ul></li>
<li>2020-10-28 MRI - brain
<ul>
<li>multiple brain metastasis, increase in sizes and numbers.</li>
</ul></li>
<li>2020-09-11 CT - lung
<ul>
<li>Compatible with left breast cancer with lung and bone mets.</li>
<li>Enhanced breast nodules at right side, in regression.</li>
</ul></li>
<li>2020-09-08 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases. In
comparison with the previous study on 2019/09/27, most of the previous
bone lesions are less evident except some bone lesions in the left S-I
joint and right femur are a little more evident.</li>
</ul></li>
<li>2020-08-06 T-L spine AP+ Lat.
<ul>
<li>Pathologic compression fracture of T8,9,12, and L1,5</li>
<li>Blastic metastasis of bony structures</li>
</ul></li>
<li>2020-07-22 MRI - brain
<ul>
<li>multiple brain metastasis, decrease in sizes and numbers.</li>
</ul></li>
<li>2020-06-19 CT - lung
<ul>
<li>Compatible with breast cancer over both sides with lung, bone meta
and pleural effusion. The main mass at left breast and right bresat
tumors decreased in size.</li>
<li>The lung meta regressed.</li>
</ul></li>
<li>2020-06-19 SONO - abdomen
<ul>
<li>A hypoechoic nodule (1.59x1.66cm) at S7 of liver.</li>
<li>Gallbladder stones (0.51-0.92cm).</li>
<li>Splenomegaly.</li>
</ul></li>
<li>2020-06-19 SONO - breast
<ul>
<li>Left breast cancer</li>
<li>Bil. fibroadenomas</li>
<li>Suspected right breast tumor (#1)</li>
</ul></li>
<li>2020-04-20 MRI - brain
<ul>
<li>Numerous brain metastases.</li>
</ul></li>
<li>2020-03-11 CT - lung
<ul>
<li>breast ca with lung, pleura, and bones metastasis, in regression of
lung metastasis and primary tumors, but in progression of bones
metastasis as compared with previous CT study.</li>
</ul></li>
<li>2020-03-03 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal chamber size</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal LV and RV contractility</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mitral valve prolapse, mild MR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Mild TR</li>
</ol></li>
</ul></li>
<li>2020-03-03 SONO - abdomen
<ul>
<li>Fatty liver, mild to moderate</li>
<li>Suspect focal liver lesion or fatty liver related change, S7/8</li>
<li>Gall stone</li>
<li>Splenomegaly</li>
<li>Bilateral pleural effusion</li>
</ul></li>
<li>2019-10-31 CXR
<ul>
<li>Ground glass opacities in bil. lungs.</li>
<li>Bilateral pleural effusion.</li>
</ul></li>
<li>2019-10-27 CXR
<ul>
<li>Diffuse nodules in bilateral lungs.</li>
<li>Consolidations in bilateral lungs.</li>
<li>Progression of right pleural effusion as compare with CXR on
2019-10-22.</li>
<li>No cardiomegaly.</li>
<li>Compression fractures at lower T-spine.</li>
</ul></li>
<li>2019-10-22 CXR
<ul>
<li>Ground glass opacities and nodules in bil. lungs.</li>
</ul></li>
<li>2019-10-21 CXR
<ul>
<li>Presence of nodules at bil. lungs</li>
<li>Bilateral pleural effusion.</li>
</ul></li>
<li>2019-10-04 M-mode Echo
<ul>
<li>LVEF = (LVEDV - LVESV) / LVEDV = (80 - 25) / 80 = 68.75%</li>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Limited echo window due to breast Ca wound</li>
</ul></li>
<li>2019-10-01 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>The FDG PET findings are compatible with left breast malignancy with
right breast, multiple lung, liver, bone and lymph node metastases as
mentioned above. Please correlate with other clinical findings for
further evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>A small focal area of increased FDG uptake in the left hemisphere of
the cerebellum. A metastatic lesion can not be ruled out.</li>
</ol></li>
</ul></li>
<li>2019-09-27 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
<li>2019-09-26 CT - lung
<ul>
<li>Left breast cancer with skin invasion.</li>
<li>Mediastinal lymphadenopathy and right breast, diffuse bone and lung
mets.</li>
</ul></li>
<li>2019-09-24 MRI - T-spine
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild scoliosis of thoracicolumbar vertebral column.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Diffuse osteolytic lesions with abnormal soft tissue intensity and
compression involving T2-12 and L1-4 vertebral bodies (visible in these
images), with collapse of T3 and T12 vertebral body, and compromise of
neuroforamina at T11-T12-L1 levels.</li>
</ol></li>
</ul></li>
<li>Imp:
<ul>
<li>Diffuse bony and lung metastases as aforementioned.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-14 Neurology
<ul>
<li>Q
<ul>
<li>no blurred vision aura before visual defect, seeing things white,
lasts 30 minutes and recovered spontaneously</li>
</ul></li>
<li>A
<ul>
<li>This 43 y/o woman has a history of breast cancer with bone and brain
metastatsis. She complained of left visual field defect noted since this
morning. The symptom may fluctuate but the patient claimed that she may
not pay attention to it. Frequent dizziness was also noted for a few
days. I was consulted for further evaluation.</li>
<li>O
<ul>
<li>NE E4V5M6 cachexia</li>
<li>CNs: left homonymous hemianopia</li>
<li>MP: &gt;4</li>
<li>sensation: intact</li>
<li>FNF: no dysmetria</li>
<li>brain MRI in 2022/06: multiple metastases, bilateral occpital lobes
involvement and right side worse</li>
</ul></li>
<li>impression:
<ul>
<li>visual field defect caused by metastatses</li>
</ul></li>
<li>suggestion:
<ul>
<li>control underlying disease progression</li>
<li>neurology OPD follow-up for EEG and VEP study</li>
<li>consider antiseizure medication after evaluation or clinical seizure
witnessed.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-08-14 Ophthalmology
<ul>
<li>Q
<ul>
<li>no blurred vision aura before visual defect, seeing things white,
lasts 30 minutes and recovered spontaneously</li>
</ul></li>
<li>A
<ul>
<li>S: Left homonymous side photopsia for 2-3 hrs, painless, with
persistent left VF defect now
<ul>
<li>Deneid fever</li>
<li>Lab data : pancytopenia</li>
<li>phx: breast caner with lung, bone, liver, LN, skin and brain mets
with right occipital lobe involved</li>
<li>ophx: denied</li>
<li>nka</li>
</ul></li>
<li>O:
<ul>
<li>VAcNC: OD 20/70 OS 20/100</li>
<li>IOP:14/16mmHg</li>
<li>pupil: 3mm+/+, 3mm+/+, no rapd</li>
<li>EOM: full and free</li>
<li>Confrontation test: left homonymous hemianopia</li>
<li>Red desaturation test: intact ou</li>
<li>conj: np ou</li>
<li>K: cl ou</li>
<li>AC: shallow/clear ou</li>
<li>Lens: cl ou</li>
<li>fundus : c/d: 0.7 margin clear, vessels perfusion ok, no break
ou</li>
</ul></li>
<li>A:
<ul>
<li>Left homonymous hemianopia c/w brain metastasis with right occipital
lobe</li>
</ul></li>
<li>P:
<ul>
<li>Control underlying disease + correct pancytopenia</li>
<li>Consider further brain image as your expertise</li>
<li>oph opd f/u for VF if condition stable, if bv/pain/neurologic
defect/any symptom worsen, come back earlier</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-19 Ophthalmology
<ul>
<li>Q
<ul>
<li>Patient complained of suspected glaucoma at our ophthalmic clinic
and would like to seek expertise from ophthalmic doctor.</li>
</ul></li>
<li>A
<ul>
<li>S: left homonymous side photopsia and transient vision loss
recently, and prolonged duration today, improving now</li>
<li>O
<ul>
<li>phx: breast ca with brain mets with right occipital lobe
involved</li>
<li>ophx: enlarged cupping ou</li>
<li>BCVA: OD 0.4(0.8x0/-1.0x95) OS 0.6(1.0x-0.25/-0.5x70)</li>
<li>PT: 16/14 mmHg</li>
<li>pupil: 3mm+/+, 3mm+/+, no rapd</li>
<li>EOM: full and free, nystagmus in lateral gaze ou with fast pahse to
lateral</li>
<li>confrontation test: inf temp VFD os?</li>
<li>conj: np ou</li>
<li>K: cl ou</li>
<li>AC: shallow/clear ou</li>
<li>LEns: cl ou</li>
<li>c/d: 0.7 inf notch od?, margin clear</li>
</ul></li>
<li>A:
<ul>
<li>favor occipital seizure</li>
</ul></li>
<li>P:
<ul>
<li>explain current condition and no fundus exam due to shallow AC to
the patient, opd f/u for OCT and VF test(111/4/18) for preglaucoma and
occipital lobe mets</li>
<li>if the symptoms prolong or persist, if any neurologic sign show up,
come back eariler</li>
<li>opd f/u on W2</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-24 ENT
<ul>
<li>Q
<ul>
<li>CC.hemoptysis one time this morning</li>
<li>foreign body sensation in throat</li>
<li>throat pain(-), dizziness(-)</li>
<li>Onset: ate drug</li>
<li>Px. breast cancer under therapy treatment</li>
<li>TOCC: nil</li>
<li>vaccine: denied</li>
</ul></li>
<li>A
<ul>
<li>Subjective:
<ul>
<li>hemoptysis one time this morning</li>
<li>foreign body sensation in throat</li>
<li>No hemoptysis and lump sensation now.</li>
</ul></li>
<li>Scope:
<ul>
<li>Multiple petechiae were found at posterior pharyngeal wall and
arytenoid</li>
<li>No active bleeder and foreign body was found</li>
</ul></li>
</ul></li>
<li>Plan:
<ul>
<li>Treat her thrombocytopenia as your expertise</li>
<li>Please give Broen-C TID</li>
</ul></li>
</ul></li>
<li>2020-10-24 ENT
<ul>
<li>Q
<ul>
<li>fever for 3 days with sore throat and greenish rhinorrhea</li>
<li>denied chest pain, SOB, abd pain, diarrhea, dysuria</li>
</ul></li>
<li>A
<ul>
<li>Water’s view: fluid accumulation over bilateral maxillary
sinuses.</li>
<li>Local finding: no neck tenderness; fair mouth opening; no enlarged
tonsils; injected posterior oropharyngeal wall; erythematous abrasive
change over philtrum; yellowish crust with some blood clot in bilateral
nasal cavity.</li>
<li>Scope: blood clot with yellowish mucus discharge over bilateral
nasal cavity with post-nasal dripping; erosive change over nasopharynx,
suspect post-RT change; smooth oropharynx and hypopharynx, erythematous
change of epiglottis; patent airway; sputum noted in trachea.</li>
<li>Impression: acute nasopharyngitis and acute sinusitis, suspected
pneumonia.</li>
</ul></li>
<li>Plan:
<ul>
<li>Suggest admission to department of infecious disease or oncology for
intravenous antibiotic treatment.</li>
<li>Please prescribe Broen-C, cough mixture, allegra, and biomycin
ointment (for the philtrum wound) as symptomatic treatment.</li>
<li>Culture of nasal discharge was done.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-08-16 - Enhertu (fam-trastuzumab deruxtecan-nxki) 5.4mg/kg
200mg 90min</li>
<li>2022-07-25 - Kadcyla (ado-trastuzumab) 3.6mg/kg 120mg 90min</li>
<li>2022-07-04 - Kadcyla (ado-trastuzumab) 3.6mg/kg 120mg 90min</li>
<li>2022-06-13 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-05-23 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-05-02 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-04-11 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-03-16 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-02-23 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2022-01-19 - Kadcyla (ado-trastuzumab) 3.6mg/kg 120mg 90min</li>
<li>2021-12-29 - Kadcyla (ado-trastuzumab) 120mg 90min</li>
<li>2021-11-29 - Kadcyla (ado-trastuzumab) 3.6mg/kg 100mg 90min</li>
<li>2021-10-27 - Kadcyla (ado-trastuzumab) 3.6mg/kg 120mg 90min</li>
<li>2021-09-08 - Kadcyla (ado-trastuzumab) 3.6mg/kg 150mg 90min</li>
<li>2021-08-18 - Kadcyla (ado-trastuzumab) 150mg 90min</li>
<li>2021-07-28 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-07-07 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-06-16 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-05-26 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-05-05 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-04-14 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-03-24 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-03-03 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-02-10 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2021-01-20 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-12-30 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-12-09 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-11-18 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-10-27 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-10-07 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-09-16 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-08-26 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-08-05 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-07-15 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-06-24 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-06-03 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-05-06 - Herceptin (trastuzumab) 600mg SC 5min</li>
<li>2020-04-15 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-03-25 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr</li>
<li>2020-03-04 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr + docetaxel 60mg/m2 82mg 1hr + carboplatin
AUC 6 300mg 2hr</li>
<li>2020-02-03 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr + docetaxel 60mg/m2 80mg 1hr + carboplatin
AUC 6 300mg 2hr</li>
<li>2020-01-06 - Herceptin (trastuzumab) 600mg SC 5min + Perjeta
(pertuzumab) 420mg IVD 1hr + docetaxel 75mg/m2 100mg 1hr + carboplatin
AUC 6 300mg 2hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>During this hospitalization, the patient is receiving her first dose
of Enhertu.</li>
<li>2022-08-15 2D transthoracic echocardiography prior to having Enhertu
showed baseline LVEF = (LVEDV - LVESV) / LVEDV = (30.9 - 11.9) / 30.9 =
61.49%</li>
<li>Hypoalbuminemia is observed (2022-08-17 2.4 g/dL, normal 3.5 ~ 5.7).
For humans, deruxtecan plasma protein binding is approximately 97% and
the blood-to-plasma ratio is approximately 0.6, in vitro. Low albumin
might potentially increase unbound deruxtecan concentration.</li>
<li>Enhertu is classified as having a moderate emetic risk according to
the NCCN guidelines, premedication palonosetron has been administered as
the antiemetic agent.</li>
<li>Recommended antiemetics for days 2-4: (reference: Rugo HS, Bianchini
G, Cortes J, Henning JW, Untch M. Optimizing treatment management of
trastuzumab deruxtecan in clinical practice of breast cancer [published
online ahead of print, 2022 Aug 11]. ESMO Open. 2022;7(4):100553. <a href="doi:10.1016/j.esmoop.2022.100553" class="uri">doi:10.1016/j.esmoop.2022.100553</a> )
<ul>
<li>1st cycle:
<ul>
<li>dexamethasone 4mg or 8mg daily +- metoclopramide 10mg PO TID or</li>
<li>5-HT3 RA [e.g. granisetron (1-2 mg PO QD or 0.1 mg/kg IV QD)]</li>
</ul></li>
<li>Subsequent cycles:
<ul>
<li>If adequate, repeat above.</li>
<li>If not (e.g. grade &gt;= 1 for &gt;= 3 days), give
<ul>
<li>aprepitant (80mg PO) + 5-HT3 RA +- dexamethasone (8mg) or</li>
<li>dexamethasone (8mg QD) +- metoclopramide (10mg PO TID)</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-420" class="section level1">
<h1>700887906</h1>
<div id="section-421" class="section level2">
<h2>220816</h2>
<ul>
<li>lab data
<ul>
<li>Creatinine
<ul>
<li>2022-07-22 Creatinine 2.24 mg/dL<br />
</li>
<li>2022-07-15 Creatinine 2.53 mg/dL<br />
</li>
<li>2022-07-12 Creatinine 4.16 mg/dL<br />
</li>
<li>2022-06-21 Creatinine 2.03 mg/dL<br />
</li>
<li>2022-05-30 Creatinine 2.20 mg/dL<br />
</li>
<li>2022-05-09 Creatinine 1.69 mg/dL<br />
</li>
<li>2022-04-30 Creatinine 2.07 mg/dL<br />
</li>
<li>2022-04-27 Creatinine 1.98 mg/dL<br />
</li>
<li>2022-04-21 Creatinine 1.49 mg/dL<br />
</li>
<li>2022-04-18 Creatinine 1.75 mg/dL<br />
</li>
<li>2022-04-16 Creatinine 3.63 mg/dL<br />
</li>
<li>2022-04-15 Creatinine 3.95 mg/dL<br />
</li>
<li>2022-04-14 Creatinine 2.33 mg/dL<br />
</li>
<li>2022-04-12 Creatinine 1.86 mg/dL<br />
</li>
<li>2022-02-28 Creatinine 1.81 mg/dL<br />
</li>
<li>2022-02-15 Creatinine 1.65 mg/dL<br />
</li>
<li>2021-11-10 Creatinine 1.93 mg/dL<br />
</li>
<li>2021-09-23 Creatinine 2.35 mg/dL<br />
</li>
<li>2021-07-08 Creatinine 2.21 mg/dL<br />
</li>
<li>2021-04-08 Creatinine 1.77 mg/dL<br />
</li>
<li>2021-01-11 Creatinine 2.05 mg/dL<br />
</li>
<li>2020-11-05 Creatinine 1.74 mg/dL<br />
</li>
<li>2020-09-01 Creatinine 1.7 mg/dL<br />
</li>
<li>2020-08-21 Creatinine 2.1 mg/dL<br />
</li>
<li>2020-08-20 Creatinine 2.2 mg/dL<br />
</li>
<li>2020-08-14 Creatinine 3.1 mg/dL<br />
</li>
<li>2020-08-12 Creatinine 2.2 mg/dL<br />
</li>
<li>2020-08-04 Creatinine 1.8 mg/dL<br />
</li>
<li>2020-07-10 Creatinine 1.7 mg/dL<br />
</li>
<li>2020-06-15 Creatinine 1.7 mg/dL<br />
</li>
<li>2020-06-15 Creatinine 1.7 mg/dL<br />
</li>
<li>2020-05-29 Creatinine 1.9 mg/dL<br />
</li>
<li>2020-04-11 Creatinine 1.8 mg/dL<br />
</li>
<li>2020-04-09 Creatinine 1.6 mg/dL<br />
</li>
<li>2020-02-14 Creatinine 1.5 mg/dL<br />
</li>
<li>2020-02-07 Creatinine 1.4 mg/dL<br />
</li>
<li>2020-02-04 Creatinine 1.4 mg/dL<br />
</li>
<li>2020-01-07 Creatinine 1.5 mg/dL</li>
</ul></li>
</ul></li>
<li>exam findings
<ul>
<li>2022-07-22 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
</ul></li>
<li>2022-07-19 MRI - liver, spleen
<ul>
<li>Multiple liver tumors suspected metastases.</li>
<li>S/P left nephrectomy. S/P right PCN.</li>
<li>A soft tissue nodule (1.5cm) at umbilical region suspected tumor
seeding.</li>
<li>Some LNs at retroperitoneum.</li>
</ul></li>
<li>2022-07-15 CT - abdomen, pelvis
<ul>
<li>Multiple liver tumors suspected metastases.</li>
<li>S/P left nephrectomy and cystectomy. S/P right PCN.</li>
<li>A soft tissue nodule (1.5cm) at umbilical region suspected tumor
seeding.</li>
<li>Some LNs at retroperitoneum.</li>
</ul></li>
<li>2022-07-15 KUB
<ul>
<li>S/P right pig-tail catheter indwelling.</li>
</ul></li>
<li>2022-07-12 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
</ul></li>
<li>2022-05-30 KUB
<ul>
<li>S/P PCN catheter drainage, right side.</li>
<li>Lumbar spondylosis.</li>
</ul></li>
<li>2022-05-30 CXR
<ul>
<li>Increased bilateral lung markings.</li>
</ul></li>
<li>2022-05-21 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P left nephrectomy and cystectomy. S/P PCN drainage, right
side.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Enlarged lymph nodes in right lower abdome around IVC, suspected
metastatic lymph nodes.</li>
</ol></li>
</ul></li>
<li>2022-05-20 SONO - nephrology
<ul>
<li>s/p left nephrectomy</li>
</ul></li>
<li>2022-05-09 PD-L1 (SP142)
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana)
<ul>
<li>Tumor type: Infiltrating urothelial carcinoma, high-grade</li>
<li>Tumor location: Prostate</li>
<li>Testing assay: SP142 Assay (Ventana)</li>
<li>Testing platform: BenchMark ULTRA</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit</li>
<li>Control slide result: [ V ] Pass, [ ] Fail</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells): [ V ]
Yes, [ ] No</li>
</ul></li>
<li>Result:
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>Tumor cell (TC) staining assessment:</li>
</ol>
<ul>
<li><ol style="list-style-type: decimal">
<li>TC category: TC &lt; 1%</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Percentage of PD-L1 expressing tumor cells (%TC): &lt; 1%
(optional)</li>
</ol></li>
</ul></li>
<li><ol start="2" style="list-style-type: upper-alpha">
<li>Tumor-infiltrating immune cell (IC) staining assessment:</li>
</ol>
<ul>
<li><ol style="list-style-type: decimal">
<li>IC category: IC &lt; 1%</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Proportion of tumor area occupied by PD-L1 expressing
tumor-infiltrating immune cells (% IC): &lt; 1% (optional)</li>
</ol></li>
</ul></li>
</ul></li>
<li>Note:
<ul>
<li><ol style="list-style-type: decimal">
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-04-15 Patho - urinary bladder partial/total resection
<ul>
<li>PATHOLOGIC DIAGNOSIS:
<ul>
<li><ol style="list-style-type: decimal">
<li>Urinary bladder, Robotic-assisted radical cystoprostatectomy ( s/p
TURBT) — Urothelial carcinoma in situ — No residual papillary urothelial
carcinoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Prostate, RARC — Involved by infiltrating urothelial carcinoma,
high-grade (at prostatic stroma) — Positive for tumor at apex
margin</li>
</ol></li>
<li>3, Seminal vesicles, bilateral, RARC — Negative for malignancy</li>
<li><ol start="4" style="list-style-type: decimal">
<li>Ureter, right, RARC — Negative for malignancy<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Ureter, left, RARC — Negative for malignancy<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Lymph node, right common iliac, dissection —- Negative for
malignancy (0/1)</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Lymph node, right internal iliac, dissection —- Negative for
malignancy (0/2)</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Lymph node, left external iliac, dissection —- Negative for
malignancy (0/1)</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymph node, rleft external iliac, dissection —- Negative for
malignancy (0/3)</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Vas deferens, left, RARC — Negative for malignancy<br />
</li>
</ol></li>
<li><ol start="11" style="list-style-type: decimal">
<li>Vas deferens, right, RARC — Negative for malignancy<br />
</li>
</ol></li>
<li><ol start="12" style="list-style-type: decimal">
<li>AJCC 8th edition Pathology stage: pT4aN0(if cM0); AJCC pathologic
stage IIIA</li>
</ol></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION (for urinary bladder):
<ul>
<li><ol style="list-style-type: decimal">
<li>Histological type, Urothelial: Papillary urothelial carcinoma,
invasive</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histological grade: For urothelial carcinoma, other variants, or
divergent differentiation: High grade</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-04-13 2D transthoracic echocardiography
<ul>
<li>Normal chamber size</li>
<li>Thickening of IVS</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>AV sclerosis with trivial AR, mild MR, TR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2022-04-12 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
</ul></li>
<li>2022-04-08 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>In comparison with the previous study on 2020/08/18, the lesions in
the middle and lower C-spines are a little more evident. Degenerative
change in a little more severe status may show this picture. However,
please correlate with other imaging modalities for further evaluation
and to rule out other possibilities.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>No prominent change is noted in the lesions in the lower T-spine,
some L-spines, L5-sacrum junction, compatible with degenerative
change</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>The previous some faint hot spots in bilateral rib cages are
stationary, probably more benign in nature.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, left elbow, bilateral wrists, knees and
ankles. Benign joint lesions are more likely.</li>
</ol></li>
</ul></li>
<li>2022-03-01 Patho - urinary bladder TURBT
<ul>
<li>DIAGNOSIS:
<ul>
<li>A: Urinary bladder, TURBT — Non-invasive papillary urothelial
carcinoma, high grade — Muscularis proria present without tumor</li>
<li>B: Urinary bladder, deep cut, TURBT — Negative for malignancy —
Muscularis proria present without tumor</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A: Section shows high grade papillary urothelial carcinoma with
focal cauterized artifact. No subepithelial invasion is found. Focal
muscular layer is seen without tumor.<br />
</li>
<li>B: Section shows smooth muscular tissue without tumor.</li>
</ul></li>
</ul></li>
<li>2022-02-28 CT - abdomen, pelvis
<ul>
<li>Wall thickening of urinary bladder.</li>
</ul></li>
<li>2021-09-24 Patho - urinary bladder TURBT
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Urianry bladder, “tumor”, left, TURBT — Non-invasive papillary
urothelial carcinoma, high-grade<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Urinary bladder, “deep cut”, TURBT — Non-invasive papillary
urothelial carcinoma, high-grade<br />
</li>
</ol></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic type: Papillary urothelial carcinoma, non-invasive<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic grade: High-grade<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor configuration: Papillary<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Muscularis propria: Present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Lymphovascular invasion: Not identified<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Microscopic tumor extension: Tumor is non-invasive<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Specimen labeled “deep cut”: Non-invasive papillary urothelial
carcinoma, high-grade<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Additional pathologic findings: Necrotizing inflammation</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-07-09 Patho - urinary bladder TURBT
<ul>
<li>DIAGNOSIS:
<ul>
<li><ol style="list-style-type: decimal">
<li>Urinary bladder, “tumor”, TUR-BT — Infiltrating urothelial
carcinoma, high-grade — Muscularis propria present and no tumor
involvement<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Urinary bladder, “deep cut”, TUR-BT — Negative for malignancy —
Muscularis propria present and no tumor involvement</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-04-09 urinary bladder biopsy
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Urianry bladder, “tumor”, lateral wall, left, TURBT — Non-invasive
papillary urothelial carcinoma, high-grade<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Urinary bladder, “tumor base”, TURBT — Free<br />
</li>
</ol></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic type: Papillary urothelial carcinoma, non-invasive<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic grade: High-grade<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor configuration: Papillary<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Muscularis propria: Present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Lymphovascular invasion: Not identified<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Microscopic tumor extension: Tumor is non- invasive<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Specimen labeled “tumor base”: Free of tumor<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Additional Pathologic findings: Necrotizing granulomatous
inflammation</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-02-01 MRI - lower abdomen
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P left nephrectomy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Focal mucosal thiekening at urinary bladder base, suggest cystoscope
correlation.</li>
</ol></li>
</ul></li>
<li>2021-01-12 Patho - urinary bladder TURBT
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Urianry bladder, “bladder tumor”, TURBT — Non-invasive papillary
urothelial carcinoma, high-grade<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Urinary bladder, “tumor base”, TURBT — Free<br />
</li>
</ol></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic type: Papillary urothelial carcinoma, non-invasive<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic grade: High-grade<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor configuration: Papillary and flat<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Muscularis propria: Present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Lymphovascular invasion: Not identified<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Microscopic tumor extension: Tumor is non-invasive<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Specimen labeled “tumor base”: Free of tumor</li>
</ol></li>
</ul></li>
</ul></li>
<li>2020-11-06 Patho - urinary bladder TURBT
<ul>
<li>DIAGNOSIS:
<ul>
<li>A. Urinary bladder, bladder tumor, TURBT — Urothelial carcinoma (low
grade) invading submucosa. Muscularis propria present and not invaded.
<ul>
<li>IHC stain: GATA-3 (+), SMA (highlights +, muscle layer).<br />
</li>
</ul></li>
<li>B. Urinary bladder, tumor base, TUR-BT — Free. Muscularis prorpia
present and not invaded.<br />
</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A. Section shows multiple pieces of low grade invasive carcinoma,
invading submucosa. Muscularis propria present and not invaded.
<ul>
<li>IHC stain: GATA-3 (+), SMA (highlights +, muscle layer).<br />
</li>
</ul></li>
<li>B. Section show musculkaris propria and free of malignancy.</li>
</ul></li>
</ul></li>
<li>2020-08-28 MRI - kidney, adrenals
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P Lt nephrectomy. There is no evidence of tumor recurrence.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>There is mild wall thickening in left lateral aspect of the urinary
bladder. Please correlate with cystoscopy.</li>
</ol></li>
</ul></li>
<li>2020-08-18 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>In comparison with the previous study on 2019/10/22, the lesions in
the middle and lower C-spines, lower T-spine, some L-spines and
L5-sacrum junction are either stationary or a little less evident.
Degenerative change may show this picture.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>The previous some faint hot spots in bilateral rib cages are a
little less evident, probably more benign in nature.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, left elbow, bilateral wrists, knees and
ankles. Benign joint lesions are more likely.</li>
</ol></li>
</ul></li>
<li>2020-08-11 Patho - urinary bladder TURBT
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Bladder tumor, posterior wall, TURBT — Invasive papillary urothelial
carcinoma, high grade<br />
</li>
</ol>
<ul>
<li>Muscularis propria, ditto — Absent<br />
</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Tumor base — Free from tumor<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Previous scar at left U/O — Chronic cystitis, compatible with
scar<br />
</li>
</ol>
<ul>
<li>Muscularis propria, ditto — Present<br />
</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Previous TURBT scar at 5 o’clock bladder neck — Ulcer with
fibrosis<br />
</li>
</ol>
<ul>
<li>Muscularis propria, ditto — Absent<br />
</li>
</ul></li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li><ol style="list-style-type: decimal">
<li>Bladder tumor at posterior wall: invasive papillary urothelial
carcinoma, high grade characterized by the pleomorphic tumor cells
arranged in papillary or nest growth pattern with subepithelial
invasion. Immunohistochemistry shows GATA-3(+), Uroplakin-II(+, scatter)
and CK20(-) for tumor cells. Besides, Muscularis propria is absent in
the limited specimen.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Tumor base: muscularis propria only and free from tumor.<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Previous scar at left U/O: chronic cystitis, compatible with scar.
Besides, muscularis propria is present and free from tumor.<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Previous TURBT scar at 5 o’clock bladder neck: ulcer with stromal
fibrosis. Muscularis propria is absent.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2020-05-29 Patho - urinary bladder TURBT
<ul>
<li>DIAGNOSIS:
<ul>
<li>A. Urinary bladder, “1. bladder tumornear UO”, TURBT — Urothelial
carcinoma (high grade), invading muscularis propria.
<ul>
<li>IHC stains: CK20 (diffuse +, whole layer), CD44 (-), SMA highlights
muscularis propria with tumor invasion.<br />
</li>
</ul></li>
<li>B. Urinary bladder, “2. bladder tumor at the prostatic urethra”,
TURBT — Urothelial carcinoma (high grade), invading submucosa.<br />
</li>
<li>C. Urinary bladder, “3. deep cut of bladder tumor near UO”, TURBT —
free, muscularis propria present and not invaded.<br />
</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A. Section shows multiple pieces of urothelial carcinoma composed of
papillary structures lined by urothelial cells with enlarged,
hyperchromatic nuclei, high N/C ratio and mitoses up to 3/HPF. Tumor
invades muscularis propria. IHC stains: CK20 (diffuse +, whole layer),
CD44 (-), SMA highlights muscularis propria with tumor invasion.<br />
</li>
<li>B. Section shows urothelial carcinoma (high grade), invading
submucosa.<br />
</li>
<li>C. Section shows soft tissue with no tumor, muscularis propria
present and not invaded.</li>
</ul></li>
</ul></li>
<li>2020-04-13 Patho - kidney partial/total resection
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li><ol style="list-style-type: decimal">
<li>Renal calyx, left, nephroureterectomy — Invasive papillary
urothelial carcinoma, high-grade<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Renal pelvis, ditto — Free of tumor<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Renal parenchyma, ditto — Tumor invasion<br />
</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Renal hilum, ditto — Tumor emboli present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Perinephric fat, ditto — Free of tumor invasion<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Gerota’s fascia, ditto — Free of tumor invasion<br />
</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Ureter, ditto — Non-invasive papillary urothelial carcinoma,
high-grade<br />
</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Ureter cutting end＆ bladder cuff, ditto — Free of tumor<br />
</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Lymph node, dissection — Free of tumor including hilum (0/1) and
peri-renal fat (fat only)<br />
</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>AJCC Pathologic Staging — ypT3N0 (if cM0), stage III</li>
</ol></li>
</ul></li>
</ul></li>
<li>2020-02-24 MRI - kidney, adrenals
<ul>
<li>Left renal caliceal tumor, regression as compare with CT study on
2019-07-17.</li>
</ul></li>
<li>2019-10-24 Effective renal plasma flow (ERPF)
<ul>
<li><ol style="list-style-type: decimal">
<li>The ERPF of the right kidney was 161.3 ml/min, and the ERPF of the
left kidney was 80.8 ml/min (normal reference range of ERPF: &gt; 150
ml/min in each kidney for adults).</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>After furosemide administration, the radiotracer washout was smooth
from bilateral kidneys, indicating no definite evidence of obstructive
hydronephrosis. Please correlate with other clinical findings for
further evaluation.</li>
</ol></li>
</ul></li>
<li>2019-10-22 Whole body bone scan with SPECT
<ul>
<li><ol style="list-style-type: decimal">
<li>Increased activity in the middle and lower C-spines, lower T-spine
and L5-sacrum junction. Degenerative change may show this picture.
Please correlate with other imaging modalities for further
evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?). Please follow up bone
scan for further evaluation.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, elbows wrists, knees and ankles. Benign
joint lesion is more likely.</li>
</ol></li>
</ul></li>
<li>2019-10-04 Surgical pathology Level IV
<ul>
<li>DIAGNOSIS:
<ul>
<li>Kidney, left upper calyceal, biopsy —Non-invasive papillary
urothelial carcinoma, high grade</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>Section shows high grade papillary urothelial carcinoma. No
subepithelial invasion is found. Please correlate with the clinical
presentation and further examination is suggested.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-15 Urology
<ul>
<li>A
<ul>
<li>S
<ul>
<li>This 68-year-old male had history of
<ul>
<li><ol style="list-style-type: decimal">
<li>Bladder urothelial carcinoma,cT2N0M0 s/p TUR-BT for 8 times on
2020/05/29, 2020/08/10, 2020/11/06, 2020/11/06, 2021/01/12, 2021/04/09,
2021/07/09, 2021/09/24, 2022-03-01 s/p intravesical chemotherapy, s/p
gemcitabine + carboplatin, s/p radiotherapy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Left renal pelvis urothelial carcinoma, ypT3N0cM0, stage III s/p
neoadjuvant chemotherapy and laparoscopic nephroureterectomy with
bladder cuff resection on 2020/4/10; Recurrent tumor found in right side
by cystoscopy on 2022/02/16</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Chronic kidney disease.   </li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Bladder cancer s/p robotic-assisted radical cystectomy and right
PCND on 2022/04/18, 2022/06/21; Urothelial cell carinoma, pT4aN0M0 stage
IIIA.</li>
</ol></li>
</ul></li>
<li>He was just diacharged from our hospital due to dislodgement of
right PCN. Revision of right PCN was done on 7/13. Severe right flank
pain was noted for one day. The pain was associated with
respiration.</li>
<li>He denied fever/chillness, nor turbid urine from PCN bag.</li>
</ul></li>
<li>O
<ul>
<li>PE: right flank tenderness, no rebound pain, no muscle guarding</li>
<li>Lab data:
<ul>
<li>WBC 14.54k without bandemia (N/L: 85.6/6.2%), Hb 8.8 g/dL; Plt 303
k/uL</li>
<li>creatinine: 2.53 (improved) CRP 12.4 mg/dL</li>
<li>U/A clear; leuckocyte esterase 1+; NIT -; RBC 10-19/HPF;WBC 6-9/HPF;
bac 1+/HPF</li>
</ul></li>
<li>Abdominal CT: no urinoma, no fat stranding of right kidney,
suspected new lesion at liver and a tumor above umbilicus</li>
</ul></li>
<li>Imp:
<ul>
<li>UTI, metastatic UC</li>
</ul></li>
<li>Suggestion:
<ul>
<li>antibiotics treatment with cephalexin and pain control with regular
tramacet</li>
<li>OBS for one night and OPD follow up</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-15 Nephrology
<ul>
<li>Q
<ul>
<li>For hemodialysis evaluation</li>
<li>The 63 year-old male patient this admission impression of bladder
cancer, he received of: 1. RARC + pelvic LN dissection; 2. Right PCN on
20220414. Post operation then transfer to SICU for care. RIght PCN
dysfunction was found, PCN re-do was done, The CRE: 2.33-&gt;3.95. we
need your help for this patient under hemodialysis evaluation, Thanks a
lot.</li>
</ul></li>
<li>A
<ul>
<li>Consult for HD evaluation</li>
<li>O
<ul>
<li>WBC:16.95, Band: 13.3, CRP::7.91</li>
<li>BUN/Cre: 32/1.86(4/12)-&gt;24/2.33(4/14)-&gt;34/3.95(4/15)</li>
<li>PH: 7.39, PCO2: 38, PO2:169, HCo3:23.0</li>
<li>Na: 143, K:3.9, Ca:1.89</li>
<li>U/O:273ml</li>
</ul></li>
<li>Impression:
<ul>
<li>Acute kidney injury stage 2 related to obstructive uropathy</li>
</ul></li>
<li>Suggestion
<ul>
<li>No emergent HD indication.</li>
<li>Follow up U/O and renal function, ABG, electrolyte</li>
<li>If persistant oliguria, refractory metabolic acidosis, hyperkalemia,
fluid overload, we will arrange HD</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-15 Radiological Diagnosis
<ul>
<li>Q
<ul>
<li>for right PCN dusfunction ( Arrange antegrade pyelography )</li>
<li>The 69 year-old male patient this admission impression of bladder
cancer, he received of: 1. RARC + pelvic LN dissection; 2. Right PCN on
20220414. Post operation then tranfer to SICU for care. However, rigth
PCN dysfunction was found. bed side echo showed rigth hydronephrosis, we
need your help for this patient under antegrade pyelography examination,
Thank`s a lot.</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, PCN is
indicated.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-14
<ul>
<li><ol style="list-style-type: decimal">
<li>RARC + pelvic LN dissection</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Right PCN</li>
</ol></li>
</ul></li>
<li>2022-03-01 TURBT</li>
<li>2021-09-24 Trnasurethral resection of bladder tumor</li>
<li>2021-07-09 TURBT</li>
<li>2021-01-12 TURBT + flexible URS of right ureter</li>
<li>2020-11-06 TURBT + Right URS and DBJ insertion</li>
<li>2020-08-10 TURBT</li>
<li>2020-05-29 TURBT</li>
<li>2020-04-10 Laparoscopic transperitoneal nephroureterectomy + bladder
cuff resection left</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-09 - vinblastine 3mg/m2 2mg 10min + doxorubicin 30mg/m2 40mg
24hr + carboplatin AUC 4 200mg 2hr
<ul>
<li>due to high blood creatinine level, MVAC (methotrexate (hold) +
vinblastine + doxorubicin + cisplatin (changed to carboplatin))</li>
</ul></li>
<li>2022-07-12 - pembrolizumab 100mg 30min</li>
<li>2022-06-21 - pembrolizumab 100mg 30min</li>
<li>2022-05-30 - pembrolizumab 100mg 30min</li>
<li>2022-03-03 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-11-10 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2021-11-03 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2021-10-20 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-10-13 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2021-10-02 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2021-09-24 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-08-25 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-08-18 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2021-08-11 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2021-08-04 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-07-28 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2021-07-21 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2021-07-09 - mitomycin-C 30mg/m2 1hr intravesical</li>
<li>2021-06-02 - gemcitabine 1000mg 1hr intravesical</li>
<li>2021-05-26 - gemcitabine 1000mg 1hr intravesical</li>
<li>2021-05-15 - gemcitabine 1000mg 1hr intravesical</li>
<li>2021-05-03 - gemcitabine 1000mg 1hr intravesical</li>
<li>2021-04-24 - gemcitabine 2000mg 1hr intravesical</li>
<li>2021-04-17 - gemcitabine 1000mg 1hr intravesical</li>
<li>2021-04-09 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2021-03-10 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2021-02-24 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2021-02-03 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2021-01-27 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2021-01-20 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2021-01-13 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-12-23 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2020-12-16 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-12-09 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-12-02 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-11-25 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-11-17 - Bacillus Calmette-Guerin live attenuated vaccine,
intravesical</li>
<li>2020-11-06 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-10-14 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-10-07 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-09-30 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-09-23 - cisplatin 30mg/m2 1hr intravesical</li>
<li>2020-09-16 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2020-09-08 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2020-08-21 - gemcitabine 1000mg/m2 30min + carboplatin 280mg
4hr</li>
<li>2020-08-11 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2020-07-28 - gemcitabine 1000mg 1hr intravesical</li>
<li>2020-07-11 - cisplatin 35mg/m2 3hr IVD</li>
<li>2020-07-10 - gemcitabine 1000mg/m2 30min + cisplatin 35mg/m2
3hr</li>
<li>2020-06-24 - gemcitabine 1000mg/m2 30min</li>
<li>2020-06-16 - cisplatin 35mg/m2 3hr IVD</li>
<li>2020-06-15 - gemcitabine 1000mg/m2 30min + cisplatin 35mg/m2
3hr</li>
<li>2020-05-30 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2020-04-09 - doxorubicin 30mg/m2 1hr intravesical</li>
<li>2020-02-25 - gemcitabine 1000mg/m2 30min</li>
<li>2020-02-18 - gemcitabine 1000mg/m2 30min</li>
<li>2020-02-07 - gemcitabine 1000mg/m2 30min + cisplatin 70mg/m2
3hr</li>
<li>2020-01-21 - gemcitabine 1000mg/m2 30min</li>
<li>2020-01-14 - gemcitabine 1000mg/m2 30min</li>
<li>2020-02-07 - gemcitabine 1000mg/m2 30min + cisplatin 70mg/m2
3hr</li>
</ul></li>
</ul>
<div id="section-422" class="section level3">
<h3>==========</h3>
</div>
<div id="section-423" class="section level3">
<h3>2022-08-16</h3>
<ul>
<li>2022-08-16 stool OB 4+ with tranexamic acid and pantoprazole
administrated.</li>
<li>Naproxen might be held temporarily for NSAIDs cause an increased
risk of serious gastrointestinal adverse events, including bleeding,
ulcers, and perforations of the stomach and intestines.</li>
</ul>
</div>
<div id="section-424" class="section level3">
<h3>2022-07-26</h3>
<ul>
<li>2022-07-22 CFP 19.28 mg/dL, Ceftriaxone 200mg QD IVD has been
administrated. 2022-07-23 urine culture showed after 48 hours &lt; 1000
CFU/mL, body temperature touched 39.4 degree 2022-07-26 09:43.</li>
<li>CrCl is 25 mL/min, no dose adjustment is needed for the drugs in
active prescription.</li>
<li>If recent extended spectrum beta-lactamase (ESBL) isolated, then
meropenem or imipenem might be an option.</li>
</ul>
</div>
</div>
</div>
<div id="section-425" class="section level1">
<h1>701393637</h1>
<div id="section-426" class="section level2">
<h2>220816</h2>
<ul>
<li>past history
<ul>
<li>essential thromobocythemia under hydroxyurea &amp; anagrelide for
yrs &amp; spleen infartion s/p lower molecular heparin since 2019-04,
now no more LMWH &amp; hydroxyurea &amp; anagrelide Tx.</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-15 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Possible Left atrial enlargement</li>
<li>Nonspecific T wave abnormality</li>
</ul></li>
<li>2022-08-15 Transfer
<ul>
<li>transferred from Cardinal Tien Hospital (2022-08-15) due to sepsis
&amp; pneumonia, anemia R/O GI bleeding, thrombocytopenia and left pevic
fracture S/O ORIF (Open reduction internal fixation) on 20220805 and
antibiotic with Mepem/Fluco was given for sepsis blood culture
(Yeast-like and Cryptococcus neoformans (ARD), peumonia (sputum culture:
acinetobacter pittii) and fungemia.</li>
</ul></li>
<li>2022-08-14 CT - brain (at Cardinal Tien Hospital?)
<ul>
<li>no definite brain lesion.</li>
</ul></li>
<li>2022-08-11 CT - chest (at Cardinal Tien Hospital?)
<ul>
<li>mild bilateral pleural effusion</li>
</ul></li>
<li>2022-08-02 SONO - abdominal (at Cardinal Tien Hospital?)
<ul>
<li>splenomegaly (17.5 cm)</li>
</ul></li>
<li>2022-08 Culture (at Cardinal Tien Hospital)
<ul>
<li>blood culture Yeast-like and Cryptococcus neoformans (ARD),</li>
<li>peumonia (sputum culture: Acinetobacter pittii) and fungemia.</li>
</ul></li>
<li>2022-07-16 CXR
<ul>
<li>Increased infiltration in both lungs</li>
<li>Borderline enlarged cardiac sihoutte</li>
</ul></li>
<li>2022-07-16 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>Nonspecific ST abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-07-04 JAK2 single site mutation
<ul>
<li>target: JAK2 gene (p.V617F)</li>
<li>presence of mutation</li>
</ul></li>
<li>2022-06-20 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-06-20 SONO - abdomen
<ul>
<li>Right renal cyst.</li>
</ul></li>
<li>2022-03-21 CT - abdomen (at Cardinal Tien Hospital?)
<ul>
<li>splenomegaly.</li>
</ul></li>
<li>2022-03-11 Bone marrow (at ChangHua Christian Hospital)
<ul>
<li>JAK2 V617F.</li>
<li>hypocellular marrow with fibrosis.</li>
<li>Gr II myelofibrosis by reticulin &amp; trichrome stain.</li>
<li>No BCR/ABL fusion gene.</li>
<li>No occult mets carcinoma cell found by cytokeratin immunostain.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-08-15 Infectious Disease
<ul>
<li>Q
<ul>
<li>This 70-year-old woman, intermitent fever with chills S/P ABX
treatment at Cardinal Tien Hospital. She was transferred to our hospital
on 20220518.</li>
<li>The blood culture yielded yeast-like &amp; sputum culture:
Acinetobater pittii moderate. We need expertise to evaluate her
condition thanks!</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>High serum osmolality 320 mOsm/Kg (2022-08-15), hydration with 0.45%
NaCl 500mL BID.</li>
<li>Antimicrobial meropenem and fluconazole have been prescribed for
Acinetobacter pittii and Cryptococcus neoformans respectively.</li>
<li>2022-08-15 PLT 41 *10^3/uL. In the case of active bleeding, patients
with thrombocytopenia should be transfused with platelets immediately to
maintain platelet counts above 50,000/microL in most bleeding
situations, including disseminated intravascular coagulation (DIC).</li>
<li>Drug dosages in active prescriptions have been adjusted in
accordance with the patient’s current renal function (2022-08-15
creatinine 1.21 mg/dL).</li>
<li>There are no issues with the medication at present.</li>
</ul>
</div>
</div>
<div id="section-427" class="section level1">
<h1>701007135</h1>
<div id="section-428" class="section level2">
<h2>220815</h2>
<p>{oropharyngeal cancer}</p>
<ul>
<li>exam finding
<ul>
<li>2022-08-12 CT - abdomen, pelvis
<ul>
<li>Few stones in the distal CBD, causing mild dilatation of the
proximal CBD, CHD, and IHDs, are suspected. Please correlate with
ERCP.</li>
</ul></li>
<li>2022-08-12 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
<li>Emphysematous change over both lungs.</li>
<li>Osteopenia of the bony structure is noted.</li>
</ul></li>
<li>2022-07-13 Percutaneous gall bladder drainage
<ul>
<li>Distention of the gallbladder (by US images). S/P NG tube
indwelling.</li>
</ul></li>
<li>2022-07-12 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Gallbladder sludge</li>
<li>CBD dilatation</li>
<li>Cholecystopathy</li>
<li>Fatty liver, mild</li>
<li>Renal stone, right kidney</li>
<li>Small amount ascites</li>
<li>Bilateral pleural effusion</li>
</ul></li>
<li>Suggestion
<ul>
<li>correlated with liver function test and clinical symptoms</li>
</ul></li>
</ul></li>
<li>2022-07-08 ECG
<ul>
<li>Paroxysmal Atrial fibrillation</li>
<li>Low voltage QRS</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-07-06 2D transthoracic echocardiography
<ul>
<li>Conclusion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Dilated RV with preserved RV systolic function; cor pulmonale?</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Preserved LV systolic function.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Moderate TR.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Sinus tachycardia.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-07-05 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Right renal stone.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>GB stones.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Bilateral pleural effusion and ascites.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Fatty liver.</li>
</ol></li>
</ul></li>
<li>2022-07-04 CT - abdomen, pelvis
<ul>
<li>Dilated, swelling of the intestines with increased intestinal gas is
found. Gastrogenteritis is favored.</li>
<li>Right renal staghorn stone.</li>
<li>Gallstone.</li>
</ul></li>
<li>2022-07-04 ECG
<ul>
<li>Undetermined rhythm</li>
<li>Marked ST abnormality, possible inferior subendocardial injury</li>
<li>Abnormal ECG</li>
<li>Left axis deviation</li>
<li>ST depression, consider subendocardial injury</li>
</ul></li>
<li>2019-12-30 CXR
<ul>
<li>Increased lung volumes.</li>
<li>Subsegmental ground glass opacity over Rt peripheral upper lung
zone</li>
<li>Tortousity of thoracic aorta</li>
</ul></li>
<li>2019-03-29 CT - brain
<ul>
<li>Swelling of right frontal scalp.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-12 Radiological Diagnosis
<ul>
<li>Q
<ul>
<li>The 73 years old male had history of 1). renal stone S/P ESWL for
five times at MMH, 2). GU, DU, gastritis. 3). Oropharyngeal cancer
diagnosis on 2022-05. 4). COVID-19 infection on 20220426. According to
the statement of ER and family record. He was a heavy drinker/smoker
before. Denied any systemic past history before diagnosis oropharyngeal
cancer. This time he suffered from SOB on 20220704. Therefore his wife
call 119 and sent to our ER for evalutation. At ER, he denied fever,
N/V, constipation, diarrhea. COVID-19 infection positive on 20220426.
Abdominal CT showed 1. Right renal stone. 2. Bilateral pleural effusion
and ascites. 3. Fatty liver. Under impress of 1). Severe sepsis with
septic shock 2). AKI 3). R/O GI bleeding. He was admitted to our MICU
for further treatment.</li>
<li>After admission to our MICU, empirical antibiotic with cefepime was
administered for sepsis control. Hypercapenia respiratroy failure
episode intubation was on 20220705. Due to intermittent fever still
episode, we change to Doripenem plus Targocid on 20220706. NPO and PPI
plus adequate IVF for GI bleeing. Bloodtransfusion LRP and FFP for
correct thrombocytopenia and abnormal coagulation. Inotropic with
levohped plus albumin for shock. Unbalane electrolye was correct.
Sedative medication with Fentanyl plus ativan. However KP pneumonia was
diagnosis, keep doripenem use.Abdomen echo was performed, that report
showed CBD dilatation.</li>
<li>For GB stone with CBD dilatation, so we need your help for PTGBD
evaluation. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, PTGBD is
indicated.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-429" class="section level1">
<h1>700020247</h1>
<div id="section-430" class="section level2">
<h2>220812</h2>
<p>{Cholangiocarcinoma, pT4N0cM0, s/p S5 segmentectomy with lymph node
dissection and cholecystectomy on 2020-01-13, with T11-12 metastasis and
compression fracture s/p radiotherapy to T spine in 2020-04}</p>
<ul>
<li>Past History
<ul>
<li>Medical history
<ul>
<li><ol style="list-style-type: decimal">
<li>Hypertension</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Sick sinus syndrome (brady-tachy syndrome) post DDDR pacemaker in
2020/07</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Atrial fibrillation under amiodarone and Rivaroxaban</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Goiter</li>
</ol></li>
</ul></li>
<li>Surgical history
<ul>
<li><ol style="list-style-type: decimal">
<li>Hemorrhoids, Grade III post hemorrhoidectomy on 2015/10/02</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Cholangiocarcinoma, pT4N0cM0, s/p S5 segmentectomy with lymph node
dissection and cholecystectomy on 2020/01/13, with T11-12 metastasis and
compression fracture s/p radiotherapy to T spine on
2020/04/01-2020/04/15 under partial response        </li>
</ol></li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-12 MRI - upper abdomen
<ul>
<li>History and indication:
<ul>
<li>20210712 CT: recurrent CCC 2.6 cm at S6, S/P surgery</li>
<li>20191219 CT: CCC 2.6 cm at S5 with gallbladder invasion S/P op.</li>
</ul></li>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>S/P partial resection of S5 and S6 of the liver.</li>
</ol>
<ul>
<li>A hepatic cyst measuring 1 cm in S5 is noted.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>S/P cholecystectomy.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>There are several renal cysts on both kidney and the largest one
measuring 1.6 cm in size at right middle pole.</li>
</ol>
<ul>
<li>Both kidney show small size that may be chronic renal disease.
Please correlate with renal function.</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Compression fracture of T10-11.</li>
</ol>
<ul>
<li>Mild Disc space narrowing with marginal osteophyte formation and
vacuum phenomenon of L4-5 and L5-S1.</li>
</ul></li>
<li><ol start="5" style="list-style-type: decimal">
<li>There is no hyper-or hypodense lesion in the biliary system,
pancreas, and spleen.</li>
</ol>
<ul>
<li>There is no ascites or lymphadenopathy.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
</ul></li>
</ul></li>
<li>IMP:
<ul>
<li>S/P partial resection of S5 and S6 of the liver.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-07-15 Tc-99m MDP whole body bone scan
<ul>
<li><ol style="list-style-type: decimal">
<li>As compared with the previous study on 2021-04-19, the lesion in the
lower T-spine is a little less evident.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>No prominent change is noted in other bone lesions, possibly more
benign in nature.</li>
</ol></li>
</ul></li>
<li>2022-06-30 ECG
<ul>
<li>Atrial-paced rhythm with prolonged AV conduction</li>
<li>Prolonged QT</li>
</ul></li>
<li>2022-06-28 SONO - abdomen
<ul>
<li>S/P cholecystectomy and partial resection of S5/6/8 liver.</li>
<li>Several renal cysts on both kidney and the largest one is measured
about 3.4 cm in size at right middle pole.</li>
</ul></li>
<li>2022-04-13 MRI - upper abdomen
<ul>
<li>S/P partial resection of S5 and S6 of the liver.</li>
<li>There is no evidence of tumor recurrence.</li>
</ul></li>
<li>2022-03-24 CT - abdomen, pelvis
<ul>
<li>S/P liver operation. A poor enhancing tumor (1.4cm) in S6 of
liver.</li>
<li>Renal and liver cysts (up to 3.7cm).</li>
</ul></li>
<li>2022-03-10 SONO - abdomen
<ul>
<li>S/P right liver operation. S/P cholecystectomy. Bil. renal
cysts.</li>
</ul></li>
<li>2022-01-10 CT - abdomen, pelvis
<ul>
<li>S/P partial resection of S5 and S6 of the liver.</li>
<li>Please correlate with contrast enhanced dynamic CT or MRI.</li>
</ul></li>
<li>2021-08-06 Patho - liver partial resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S6, segmentectomy — Intrahepatic cholangiocarcinoma,
recurrent<br />
</li>
<li>Pathologic Staging: rpT3Nx; Stage IIIA if cM0<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Intrahepatic cholangiocarcinoma, recurrent</li>
<li>Histologic Grade: Moderately differentiated (G2)</li>
<li>Tumor Growth Pattern: Mass-forming</li>
<li>Tumor Necrosis: Present</li>
<li>Tumor Extension: Tumor perforating the visceral peritoneum<br />
</li>
<li>Perineural Invasion: Present<br />
</li>
<li>Pathologic Staging: rpT3Nx; Stage IIIA if cM0<br />
</li>
<li>Margins
<ul>
<li>Parenchymal Margin: Free, 1.2 cm from closest margin<br />
</li>
<li>Hepatic Capsule: Involved by invasive carcinoma<br />
</li>
</ul></li>
<li>Non-neoplastic liver: Mild portal inflammation, portal fibrosis, and
mild fatty change (5%)<br />
</li>
</ul></li>
</ul></li>
<li>2021-07-12 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P liver operation. A recurrent tumor (2.6cm) in S6 of liver.</li>
</ul></li>
<li>2021-07-02 SONO - abdomen
<ul>
<li>S/P cholecystectomy and partial resection of S5-8 liver.</li>
<li>There is an ill-defined hypoechoic lesion 2.33 x 1.67 cm in S6 of
the liver.</li>
<li>Recurrent cholangiocarcinoma is highly suspected. Please correlate
with contrast enhanced dynamic MRI.</li>
<li>Several renal cysts on both kidney and the largest one is measured
about 3.34 cm in size at right middle pole.</li>
</ul></li>
<li>2021-04-29 MRI - liver, spleen
<ul>
<li>Imp: s/p S5 resection with post op. change.</li>
<li>No evidence of recurrent/residual tumor in the study.</li>
</ul></li>
<li>2021-04-19 Tc-99m MDP whole body bone scan
<ul>
<li>Increased radioactivity at the T10-11 spines is old and comes to
less prominent compared with the previous study on 2020-04-29,
indicating partial response to current therapy.</li>
<li>Suspected benign lesions in the maxilla, mandible, lower L-spine,
bilateral shoulders, sternoclavicular junctions, wrists, hips and
knees.</li>
</ul></li>
<li>2021-03-09 CT - abdomen, pelvis
<ul>
<li>Suspected band like heterogenoeous hyperemic change at S5/S8 of
liver is found. In comparison with CT dated on 2020-11-27, the lesion is
stationary.</li>
</ul></li>
<li>2020-11-27 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Biloma in S5/8 of the liver show decreasing in size.</li>
<li>Two ovoid-shaped soft tissue lesions 1.5 x 1 cm and 1.3 x 0.8 cm in
LLL of lung at lung window setting are noted that may be focal
atelectasis with granuloma?</li>
<li>The differential diagnosis include metastases.</li>
<li>Follow up chest CT is indicated.</li>
</ul></li>
<li>2020-07-01 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Biloma in S5/8 of the liver is highly suspected.</li>
<li>Follow up is indicated.</li>
</ul></li>
<li>2020-01-14 Patho - liver partial resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S5, segmentectomy — Cholangiocarcinoma, large duct type<br />
</li>
<li>Lymph nodes, LN 12 and LN 8+7, dissection — No lymph node
found<br />
</li>
<li>Gallbladder, cholecystectomy — Involved by carcinoma<br />
</li>
<li>Pathologic Staging: pT4Nx; Stage IIIB at least<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologica Type: Cholangiocarcinoma, large duct type<br />
</li>
<li>Histologic Grade: G2 ( Moderately differentiated)<br />
</li>
<li>Tumor Growth Pattern: Mass-forming<br />
</li>
<li>Tumor Extension: Tumor invades gallbladder<br />
</li>
<li>Gall bladder margin: Uninvolved by invasive carcinoma<br />
</li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Perineural Invasion: Present<br />
</li>
<li>Regional Lymph Nodes: No lymph nodes found<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)<br />
</li>
<li>Non-neoplastic liver: Mild portal inflammation and portal
fibrosis<br />
</li>
</ul></li>
</ul></li>
<li>2019-12-27 Surgical pathology Level V
<ul>
<li>Liver, CT-guided biopsy — Adenocarcinoma, moderately differentiated,
compatible with cholangiocarcinoma</li>
</ul></li>
<li>2019-12-23 Abdominal Ultrasonography
<ul>
<li>Hepatic tumor, right lobe, favor malignancy, r/o abscess</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2020-01-15 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>For left pleural effusion</li>
<li>The male patient this admission impression of HCC, he was received
of S5 resection on 20200113, post operation then transfer to SICU for
care. The CXR showed left pleural effusion, we need your help for this
patient chest echo examination and chest tapping.</li>
</ul></li>
<li>A
<ul>
<li>The chest sono on 2020-Jan-15 showed (1) consolidation over left
lower lung field (2) minimal amount pleural effusion over right thorax.
Thus, thoracocentesis was not perforemd.</li>
</ul></li>
</ul></li>
<li>2020-01-09 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>This 80 years old man has the histories of
<ul>
<li><ol style="list-style-type: decimal">
<li>Lumbosacral spondylosis without myelopathy</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Neuralgia,neuritis,and radiculitis,unspecified</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Sick sinus syndrome (brady-tachy syndrome) post pacemaker on
2009/06/08</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Atrial fibrillation</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Hemorrhoids, Grade III post hemorrhoidectomy on 2015/10/02.</li>
</ol></li>
</ul></li>
<li>This time, he suffered from fever (BT up to 39C) for 2 days, chills,
epigastric pain about two days. The abdominal CT with contrast was done
which revealed A poor enhancing lesion (2.6cm) in S5 of liver. DDX:
early phase abscess, hypovascular tumor; Suspected hemangiomas (3mm,
8mm) at right heaptic lobe; Renal cysts (up to 3.1cm) and tiny
gallbladder stones (1-2mm). CXR showed borderline heart size
enlargement. Abdominal sonography was done which revealed hepatic tumor,
right lobe, favor malignancy, suspected abscess. The tumor markers
(CA19-9 3096.87 IU/mL; CEA 14.43ng/mL), the liver biopsy was arranged on
2019/12/27 and pathology reported Liver, CT-guided biopsy —
Adenocarcinoma, moderately differentiated, compatible with
cholangiocarcinoma. Chest CT showe T10-T11 spondylodiscitis and favor
left lung infection with pleural effusion. no metastatic lung nodule.
liver tumor, cholangiocarcinoma.</li>
<li>We need your expertise for surgical intervention of
cholangiocarcinoma. Thanks.</li>
</ul></li>
<li>A
<ul>
<li>This case with liver tumor with cholangiocarcinoma was
impressed.</li>
<li>Suggest:
<ul>
<li><ol style="list-style-type: decimal">
<li>consult CV for heart and pacemaker evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>arrange cardiopulmonary function</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>we will arrange operation after data report</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-08-05
<ul>
<li>Surgery
<ul>
<li>S6 resection</li>
<li>IOE</li>
</ul></li>
<li>Finding
<ul>
<li>severe intraabd adhesion due to last hepatectomy</li>
<li>2 x 1.8 x 1.5 cm well define tumor at S6 with retroperitoenal
invasion</li>
</ul></li>
</ul></li>
<li>2020-01-13
<ul>
<li>Surgery
<ul>
<li>S5 segmentectomy</li>
<li>cholecystectomy</li>
<li>hepato-duodenal ligament LN dissection</li>
<li>intraoperative echo</li>
<li>laparoscope</li>
</ul></li>
<li>Finding
<ul>
<li>4.5 x 4.0 x 2.5 cm tumor at S5 with GB invasion</li>
<li>no obvious LN was noted at station 12 and 8</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2020-04-01 ~ 2020-04-15 - 3000cGy/10 fractions (6 MV photon) to
T8-12 rib, Rt 9th rib.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-10 - gemcitabine 1000mg/m2 1700mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
<li>2022-07-12 - gemcitabine 1000mg/m2 1700mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
<li>2022-06-13 - gemcitabine 1000mg/m2 1700mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
<li>2022-05-16 - gemcitabine 1000mg/m2 1700mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
<li>2022-04-26 - gemcitabine 1000mg/m2 1700mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
<li>2022-04-11 - gemcitabine 900mg/m2 1500mg 30min + carpoplatin AUC 3
150mg 2hr + fluorouracil 1000mg/m2 3400mg 46hr</li>
</ul></li>
</ul>
<div id="section-431" class="section level3">
<h3>==========</h3>
</div>
<div id="section-432" class="section level3">
<h3>2022-08-12</h3>
<ul>
<li>There has been a slow decline in tumor markers in the past six
months, which might indicate that the treatment is having a positive
impact.
<ul>
<li>CEA
<ul>
<li>2022-08-12 5.525 ng/ml<br />
</li>
<li>2022-08-12 5.962 ng/ml<br />
</li>
<li>2022-06-21 8.350 ng/mL<br />
</li>
<li>2022-04-12 6.903 ng/ml<br />
</li>
<li>2022-03-09 10.570 ng/mL<br />
</li>
</ul></li>
<li>CA199
<ul>
<li>2022-08-12 209.425 U/ml<br />
</li>
<li>2022-08-12 242.735 U/ml<br />
</li>
<li>2022-06-21 235.360 U/mL<br />
</li>
<li>2022-04-12 273.730 U/ml<br />
</li>
<li>2022-03-09 300.520 U/mL<br />
</li>
</ul></li>
</ul></li>
<li>Blood creatinine level around 2 mg/dL since April 2022 =&gt; eGFR 35
mL/min/1.73m2, CrCl 25 mL/min. Adjustments have been made to the
following items:
<ul>
<li>rivaroxaban for patients with atrial fibrillation, nonvalvular (to
prevent stroke and systemic embolism), CrCl 15 to 50 mL/minute: 15 mg
once daily with the evening meal (AHA/ACC/HRS January 2014; AHA/ACC/HRS
January 2019).</li>
<li>nebivolol for patients CrCl &lt;30 mL/minute: Initial: 2.5 mg once
daily; if initial response is inadequate, may increase cautiously.</li>
<li>spironolactone for patients eGFR 30 to 50 mL/minute/1.73 m2:
Initial: 12.5 mg once daily or every other day; may double the dose
every 4 weeks if serum potassium remains &lt;5 mEq/L and renal function
is stable, up to a maximum target dose of 25 mg/day (ACCF/AHA Yancy
2013).</li>
</ul></li>
</ul>
</div>
<div id="section-433" class="section level3">
<h3>2022-07-13</h3>
<ul>
<li>BH 160 cm, BW 68.6 kgw (2022-07-12), creatinine level around 2 mg/dL
since April 2022 =&gt; eGFR 32.1 ~ 39.0 mL/min/1.73m2, CrCl 22.9 ~ 28.0
mL/min.
<ul>
<li>As with creatinine, BUN displayed a similar trend.</li>
</ul></li>
<li>Options for adjusting the dose of the current regimen for patients
with kidney impairment
<ul>
<li>Carboplatin:
<ul>
<li>The manufacturer’s labeling recommends the following dosage
adjustments for single-agent therapy
<ul>
<li>Baseline CrCl 41 to 59 mL/minute: Initiate at 250 mg/m2 and adjust
subsequent doses based on bone marrow toxicity.</li>
<li>Baseline CrCl 16 to 40 mL/minute: Initiate at 200 mg/m2 and adjust
subsequent doses based on bone marrow toxicity.</li>
<li>Baseline CrCl &lt;=15 mL/minute: There are no dosage adjustments
provided in the manufacturer’s labeling.</li>
</ul></li>
<li>Aronoff 2007 (for dosing based on mg/m2)
<ul>
<li>GFR &gt;50 mL/minute: No dosage adjustment is necessary.</li>
<li>GFR 10 to 50 mL/minute: Administer 50% of the usual dose.</li>
<li>GFR &lt;10 mL/minute: Administer 25% of the usual dose.</li>
</ul></li>
</ul></li>
<li>Gemcitabine
<ul>
<li>Discontinue if severe renal toxicity or hemolytic uremic syndrome
occur during gemcitabine treatment.</li>
</ul></li>
</ul></li>
<li>The current dose of carboplatin is 150mg, which should remain within
the acceptable range.</li>
</ul>
</div>
<div id="section-434" class="section level3">
<h3>2022-05-17</h3>
<ul>
<li>No abnormalities in TPR. Lab data on 2022-05-16 showed general
normal readings except for elevated blood creatinine (1.66 mg/dL) and
BUN (47 mg/dL).</li>
<li>No issue with active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-435" class="section level1">
<h1>700064846</h1>
<div id="section-436" class="section level2">
<h2>220812</h2>
<ul>
<li>exam finding
<ul>
<li>2022-07-01 CXR
<ul>
<li>tortousity of thoracic aorta and calcified atherosclerotic change at
aortic arch</li>
<li>mild enlarged cardiac silhoutte due to prominent cardiophrenic angle
mediastinal fat pad</li>
<li>reticular opacities at RUL due to fibrotic change</li>
</ul></li>
<li>2022-06-08 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Few linear and nodular infiltrations in both lung are noted. please
correlate with clinical condition.</li>
<li>S/P metalic autosuture at right upper lung.</li>
</ul></li>
<li>2022-04-18 CT - abdomen, pelvis
<ul>
<li>Colon cancer s/p RAR without recurrent/residual tumor in the
study.</li>
<li>s/p right upper lobe wedge resection.</li>
<li>Hepatic simple cysts..</li>
</ul></li>
<li>2021-11-08 KUB
<ul>
<li>Surgical stiches and clips over abdomen</li>
<li>Suspect left renal stone</li>
</ul></li>
<li>2021-10-25 Patho - lung total/lobe/segmental
<ul>
<li>Lung, right upper lobe, VATS RUL wedge resection — Interstitial
fibrosis</li>
<li>Microscopically, sections show Interstitial fibrosis characterized
by stromal fibrosis with intervening vessels and focal deposition of
pigment-laden histiocytes. The lung elsewhere shows is not
remarkable.<br />
</li>
<li>Immunohistochemical stain reveals CK(-)</li>
</ul></li>
<li>2021-10-22 Patho - colon segmental resection for tumor
<ul>
<li>indication: Adenocarcinoma of ascending colon, cT3N0M1a (lung mets,
but RUL frozen show fribrosis) s/p L-right hemicolectomy<br />
</li>
<li>pathologic diagnosis
<ul>
<li>Large intestine, ascending colon, SILS Right-hemicolectomy —
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Resection margins: free<br />
</li>
<li>Lymph node, mesocolic, dissection — Negative for malignancy
(0/16)<br />
</li>
<li>Lymph node, IMA / SMA, dissection — N/A.<br />
</li>
<li>Appendix: Negative for malignancy<br />
</li>
<li>Pathology stage: pT3N0 (if cM0); AJCC stage IIA</li>
</ul></li>
</ul></li>
<li>2021-10-21 CXR
<ul>
<li>Ground glass opacity in right lung.</li>
</ul></li>
<li>2021-10-21 Frozen section - lung
<ul>
<li>Lung, RUL, frozen section— Fibrosis</li>
</ul></li>
<li>2021-09-28 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>A glucose hypermetabolic lesion in the middle portion of the
ascending colon, compatible with primary colon malignancy. However, no
prominent FDG uptake was noted in the soft tissue nodule in the upper
lobe of right lung delineated in the chest CT scan. Please follow up
chest CT scan for further evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>A glucose hypermetabolic lesion in the left upper abdomen just
between the stomach and left lobe of the liver. A metastatic lymph node
should be watched out.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>A small glucose hypermetabolic lesion in the vertebral body of T10
spine only in the delayed imaging. Please follow up other imaging
modalities for further evaluation and to rule out the possibility of
early bone metastasis.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Glucose hypermetabolism in some right upper neck level II lymph
nodes. The nature is to be determined (inflammation? other nature?).
Please correlate with other clinical findings for further
evaluation.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Mild glucose hypermetabolism in right pulmonary hilar region.
Inflammation may show this picture.</li>
</ol></li>
</ul></li>
<li>2021-09-22 CT
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There is soft tissue nodule 6 mm in RUL of the lung that may be
metastasis. The differential diagnosis include primary lung cancer or
lung parenchyma lymph node.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>There is mild wall thickening at the posterior aspect of the middle
ascending colon measuring 1 cm in wall thickness that may be
adenocarcinoma. Please correlate with colonoscopy.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Fatty liver, grade 4-5, is noted. There are few small poor enhancing
lesions on both hepatic lobes that may be cysts? The largest one
measuring 0.6 cm in S6. Please correlate with sonography.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Two small calcified renal stones in left lower pole are noted. A
renal cyst measuring 3 cm in left lower pole is noted.</li>
</ol></li>
</ul></li>
<li>Imaging Report Form for Colorectal Carcinoma
<ul>
<li>Impression (Imaging stage): T:T3 N:N0 M:M1a; stage:IVA</li>
</ul></li>
</ul></li>
<li>2021-09-13 Patho - colon biopsy
<ul>
<li>Colon, middle ascending?/cecum?, 110 cm from anal verge, biopsy (A)
— Adenocarcinoma.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2 (+), MLH1 (+).</li>
</ul></li>
<li>2021-09-13 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>One ulcerative mass was noted in the middle ascending colon s/p
biopsy</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Two polyps was noted in the ascending colon and sigmoid s/p
polypectomy and clipped</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
</ul></li>
<li>2021-09-13 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis</li>
<li>Gastric ulcer, antrum, PW</li>
<li>Gastric erosion, antrum, AW</li>
<li>Duodenal erosion, bulb, LC</li>
<li>Post self-paid CLO test</li>
</ul></li>
<li>Suggestion
<ul>
<li>PPI use</li>
<li>Persue CLO test result</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-22 Dermatology
<ul>
<li>Q
<ul>
<li>This 59-year-old man patient is a case of Adenocarcinoma of A-colon,
cT3N0M1a (0.6cm RLL nodule, suspected metastasis and liver nodules),
stage IVa. He was admitted for chemotherapy with FOLFOX (C2D15).</li>
<li>This time, for right back of thigh mole and right foot thumb
onychomycosis. Now, for evaluate right back of thigh mole and right foot
thumb onychomycosis therapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>S: This patient suffered from dyskeratotic nails on bil sole for
yrs</li>
<li>Imp: Tinea unguim</li>
<li>Suggestion:
<ul>
<li>Excelderm soln (sulconazole) *4 BT/Bid</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-11 - oxalipaltin 50mg/m2 100mg 24hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr (oxa 24hr &lt;- 2hr)</li>
<li>2022-07-21 - oxalipaltin 75mg/m2 150mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-06-06 - oxalipaltin 75mg/m2 150mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-05-06 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-04-15 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-03-25 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-03-02 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-02-10 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-01-21 - oxalipaltin 85mg/m2 170mg 2hr + leucovorin 400mg/m2
800mg 2hr + fluorouracil 400mg/m2 800mg 10min + fluorouracil 2400mg/m2
4800mg 46hr</li>
<li>2022-01-07 - oxalipaltin 85mg/m2 165mg 2hr + leucovorin 400mg/m2
775mg 2hr + fluorouracil 400mg/m2 775mg 10min + fluorouracil 2400mg/m2
4660mg 46hr</li>
<li>2021-12-17 - oxalipaltin 85mg/m2 165mg 2hr + leucovorin 400mg/m2
775mg 2hr + fluorouracil 400mg/m2 775mg 10min + fluorouracil 2400mg/m2
4660mg 46hr</li>
<li>2021-11-26 - oxalipaltin 85mg/m2 165mg 2hr + leucovorin 400mg/m2
775mg 2hr + fluorouracil 400mg/m2 775mg 10min + fluorouracil 2400mg/m2
4660mg 46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient was found to have pulmonary fibrosis in Oct 2021
(pathology and frozen section).</li>
<li>Studies have found that oxaliplatin is associated with pulmonary
toxicity, and some of those suggested that the drug should be withheld
for unexplained pulmonary symptoms until interstitial lung disease or
pulmonary fibrosis are ruled out.</li>
</ul>
</div>
</div>
<div id="section-437" class="section level1">
<h1>700928517</h1>
<div id="section-438" class="section level2">
<h2>220812</h2>
<ul>
<li>exam finding
<ul>
<li>2022-07-11 CT - abdomen, pelvis
<ul>
<li>Presacral soft tissue mass, in enlargement. Rectal cancer
progression is favored.</li>
<li>One growing low density at S8 of liver is found. Liver mets is
hightly suspected.</li>
</ul></li>
<li>2022-05-25 Patho - colon resection
<ul>
<li>intestine, large, proximal transverse colon, revision of T colon
colostomy — compatible with prolapse of colon</li>
</ul></li>
<li>2022-05-17 ECG
<ul>
<li>Right bundle branch block</li>
<li>Left anterior fascicular block</li>
<li>Bifascicular block</li>
</ul></li>
<li>2022-05-17 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Preserved LV and RV systolic function with normal wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated AsAo, LA and LV, grade 1 LV diastolic dysfunction</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Moderate to severe AR</li>
</ol></li>
</ul></li>
<li>2022-03-05 CT - abdomen, pelvis
<ul>
<li>indication: Recurrent rectal cancer with impending obstruction s/p T
loop colostomy on 2021/12/08 and concurrent chemoradiotherapy</li>
<li>Soft tissue mass at presacral space, in enlargement.</li>
<li>Liver low density lesions. Simple cysts are favored.</li>
</ul></li>
<li>2021-12-07 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Right bundle branch block</li>
<li>Left anterior fascicular block</li>
</ul></li>
<li>2021-11-23 Patho - colon biopsy
<ul>
<li>Rectum tumor, 6-7 cm above anal verge, biopsy — Adenocarcinoma<br />
</li>
<li>Immunohistochemistry shows CDX-2(+); MLH1(+), MSH2(+), MSH6(+) and
PMS2(+) for tumor.</li>
</ul></li>
<li>2021-11-22 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Probable rectal cancer with recurrence, 6-7cm above AV, s/p biopsy
for multiple pieces</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
</ul></li>
<li>2021-11-19 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Local recurrent tumor in the rectal fossa is suspected.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hemangioma 0.8 x 0.5 cm in S8 of the liver is suspected. Please
correlate with sonography or MRI.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Adenoma 2.8 x 2 cm of left adrenal gland is suspected. Please
correlate with clinical condition and MRI.</li>
</ol></li>
</ul></li>
<li>2021-05 CT - abdomen (at Far Eastern Memorial Hospital)
<ul>
<li>liver and adrenal mets.</li>
</ul></li>
<li>2021-02 CT - abdomen (at Far Eastern Memorial Hospital)
<ul>
<li>decreased size of liver mets but mildly increased size of
para-aortic LAP.</li>
</ul></li>
<li>2020-08 CT - abdomen (at Far Eastern Memorial Hospital)
<ul>
<li>recurrence over liver and para-aortic LAP.</li>
</ul></li>
<li>2020-01 CT (at Far Eastern Memorial Hospital)
<ul>
<li>local recurrence over distal rectum involved with seminal
vesicle.</li>
</ul></li>
<li>2017
<ul>
<li>recurrence of liver was noted, and he received the surgical
intervention with segmentectomy of liver S3 on 2017-06-09.</li>
</ul></li>
<li>2014 initial presentation
<ul>
<li>indicental finding of rectal mass, liver mets was noted. without
LAR, pT4bN1bM0, Stage III, s/p 1 dose of adjuvant chemotherapy.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-28 Colon and Rectal Surgery
<ul>
<li>Q
<ul>
<li>The 73 y/o man has rectal cancer, cT4bN1bM0, Stage III with many
times of recurrence s/p LAR (ypT3N0) s/p chemotherapy. He was admitted
for salvage CCRT. Fever noted and suspect anal fistula with pus
formation, so we need your help for management. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>Tumor recurrence with fistula formation</li>
<li>minimal abscess now</li>
<li>Need keep fistula opening by AgNO3 and empiric antibiotics
treatment</li>
</ul></li>
</ul></li>
<li>2021-12-27 Urology
<ul>
<li>Q
<ul>
<li>The 73 y/o man has recurrent rectum cacner under CCRT now. Due to
dysuria, so we need your help for management. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>Initial presentation: 2014, rectal cancer,cT4bN1bM0, Stage III with
many times of recurrence s/p LAR (ypT3N0), many times of
chemotherapy</li>
<li>He was admitted for salvage CCRT.</li>
<li>Chief complaint: weak stream, intermittency, abdominal straining,
and nocturia (2-3/per night) in recent 1 months, no sense of incomplete
voiding</li>
</ul></li>
<li>O
<ul>
<li>U/A: clear</li>
<li>TPV from CT: about 50 ml</li>
<li>PE: suspected an anal fistula with pus formation</li>
</ul></li>
<li>Suggestion:
<ul>
<li>check PSA</li>
<li>arange UFR/PVR on 12/29 morning</li>
<li>also consult CRS for management of anal fistula</li>
<li>precribe harnalidge QD</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-08 T loop colostomy (at Far Eastern Memorial Hospital)</li>
<li>2020-06-19 LAR, ypT3N0</li>
<li>2017-06-09 surgical intervention with segmentectomy of liver S3
(which hospital ?)</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-12-20 ~ 2022-01-10 - 4000cGy/16 fractions (15 MV photon) to
recurrent rectal tumor</li>
<li>2020-03-11 ~ 2021-04-15 - 4500cGy/25 fx (at Far Eastern Memorial
Hospital)</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-11 - irinotecan 150mg/m2 240mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 3900mg 46hr</li>
<li>2022-07-29 - irinotecan 150mg/m2 240mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 3900mg 46hr</li>
<li>2022-07-19 - irinotecan 150mg/m2 250mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2022-03-01 - irinotecan 150mg/m2 250mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2022-02-07 - irinotecan 150mg/m2 250mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2022-01-12 - irinotecan 120mg/m2 200mg 90min + leucovorin 300mg/m2
500mg 2hr + fluorouracil 2400mg/m2 4000mg 46hr</li>
<li>2021-12-30 - leucovorin 20mg/m2 30mg 10min D1-2 + fluorouracil
400mg/m2 650mg 10min D1-2 (CCRT)</li>
<li>2021-12-22 - leucovorin 20mg/m2 30mg 10min D1-2 + fluorouracil
400mg/m2 650mg 10min D1-2 (CCRT)</li>
<li>2021-03-04 ~ 2021-05-09 - cetuximab plus FOLFOX (Oxa 85 mg/m2, LV
300 mg/m2, no bolus 5-FU, 5-FU 2600 mg/m2) for 4 doses (at Far Eastern
Memorial Hospital)
<ul>
<li>the patient refused the further course of chemtoherapy due to
intoleralbe side effect of mucositis, diarrhea, constipation, nausea and
vomiting, and folliculitis over head.</li>
</ul></li>
<li>2020-08-18 ~ 2020-10-27 - FOLFOX * 5 (at Far Eastern Memorial
Hospital)</li>
<li>2020-03-11 ~ 2020-04-15 - weekly HDFL* 6 (CCRT) (at Far Eastern
Memorial Hospital)</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>When giving FOLFOX/FOLFIRI and skipping 5FU bolus, do you still give
leucovorin?
<ul>
<li><a href="https://www.themednet.org/when-giving-folfox-folfiri-and-skipping-5fu-bolus-do-you-still-give-leucovorin" class="uri">https://www.themednet.org/when-giving-folfox-folfiri-and-skipping-5fu-bolus-do-you-still-give-leucovorin</a></li>
</ul></li>
<li>Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and
leucovorin (LV) in patients with metastatic colorectal cancer (mCRC)
receiving first-line treatment with mFOLFOX6
<ul>
<li><a href="https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4022" class="uri">https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.4022</a></li>
</ul></li>
<li>Impact of Empirically Eliminating 5-Fluorouracil Bolus and
Leucovorin in Patients with Metastatic Colorectal Cancer Receiving
First-Line Treatment with mFOLFOX6
<ul>
<li><a href="https://britishjournalofcancerresearch.com/wp-content/uploads/2020/06/BJCR-162.pdf" class="uri">https://britishjournalofcancerresearch.com/wp-content/uploads/2020/06/BJCR-162.pdf</a></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The 5-FU bolus is skipped since the patient has been refused
treatment at Far Eastern Memorial Hospital in first half of 2021 due to
intolerance of side effects.</li>
<li>Vital signs and lab data during this hospitalization were generally
normal.</li>
<li>There is no issue with active prescription.</li>
</ul>
</div>
</div>
<div id="section-439" class="section level1">
<h1>701391524</h1>
<div id="section-440" class="section level2">
<h2>220811</h2>
<ul>
<li>exam findings
<ul>
<li>2022-07-26 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-07-21 ECG
<ul>
<li>Right superior axis deviation</li>
<li>Anterior infarct, age undetermined</li>
<li>Nonspecific T wave abnormality</li>
</ul></li>
<li>2022-07-21 Gynecologic ultrasonography
<ul>
<li>Suspected Mild Adenomyosis</li>
</ul></li>
<li>2022-07-21 Pure-tone Audiometry, PTA
<ul>
<li>Reliabilty Fair</li>
<li>R’t : 13 dB HL</li>
<li>L’t : 19 dB HL</li>
<li>Bil WNL.</li>
</ul></li>
<li>2022-07-07 ECG
<ul>
<li>Sinus rhythm with 1st degree A-V block</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-06-23 MRI - brain
<ul>
<li>No evidenec of intracranial lesion.</li>
</ul></li>
<li>2022-06-23 Miniprobe Endoscopic Ultrasound
<ul>
<li>Endoscopic findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Multiple patchy esophageal lesion were noted from 42cm to 20cm.
Under ME-NBI, brownish lesion with IPCL B1-2. Under lugol
chromoendoscopy, multiple lugol voiding lesions were noted. Pink color
sign (+)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>One raised and nodular mucosa lesion was noted at 28cm. Under
ME-NBI, IPCL B-3 with large AVA was noted. Mucosa break &lt;5mm was
noted at EC junction.</li>
</ol></li>
</ul></li>
<li>EUS findings
<ul>
<li>Using EUS-DP- 25R, EUS showed a hypoechoic mucosal lesion with
blurred 3rd layer at the lesion site. At least 3 lymph nodes were
noted.</li>
</ul></li>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Esophageal cancer, at least cT1bN2, middle esophagus</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Rule out dysplastic esophageal lesion, diffuse middle and lower
esophagus</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Reflux esophagitis</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-22 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Esophageal Carcinoma</li>
<li>Impression (Imaging stage): T0N0M0</li>
</ul></li>
<li>2022-06-20 Patho - tonsil and/or adenoid
<ul>
<li>Palatine tonsil, right, tonsillectomy
<ul>
<li>— Well differentiated squamous cell carcinoma</li>
<li>— Margin free of tumor</li>
</ul></li>
<li>Microscopically, section shows well differentiated squamous cell
carcinoma consisting of nests and sheets of tumor cells in infiltrative
growth pattern with squamous differentiation and areas of dyskeratosis.
The tumor cells have eosinophilic cytoplasm, round to oval nuclei,
prominent nucleoli, pleomorphism, hyperchromasia, higher necleus to
cytoplasm ratio and mitiotic activity. The margin is free of tumor and
1~2 mm of closest margin distance.</li>
</ul></li>
<li>2022-06-15 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>A glucose hypermetabolism lesion in the left palatine tonsil,
compatible with the primary tonsil cancer.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Another glucose hypermetabolism lesion in the right palatine tonsil,
the nature is to be determined, suggesting biopsy for
investigation.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Glucose hypermetabolism lesions in bilateral level III cervical
lymph nodes, cancer with regional lymph nodes mets should be
considered.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>A glucose hypermetabolism lesion in the left lower pelvis, the
nature is to be determined also (urine, Gyn problems, or other nature
?), suggesting further investigation.<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Increased FDG uptake in bilateral kidneys and colon, probably
physiological uptake of FDG.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Left palatine tonsil cancer, cTxN2cM0, stage IVA at least (AJCC 8th
ed.), by this F-18-FDG PET/CT scan.</li>
</ol></li>
</ul></li>
<li>2022-06-15 Patho - esophageal biopsy
<ul>
<li>Diagnosis
<ul>
<li>Esophagus, 28 cm below incisor, biopsy — well differentiated
squamous cell carcinoma</li>
</ul></li>
<li>Microscopically, section shows well differentiated squamous cell
carcinoma consisting of sheets of squamous tumor cells with areas of
dyskeratosis and focal stromal invasion. The tumor cells have abundant
eosinophilic cytoplasm, round to oval nuclei, prominent nucleoli,
pleomorphism, hyperchromasia, higher necleus to cytoplasm ratio and
mitiotic activity.</li>
</ul></li>
<li>2022-06-15 Patho - esophageal biopsy
<ul>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Esophaus, 33 cm below incisor, biopsy— severe dysplasia, at
least</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Esophaus, 40 cm below incisor, biopsy— mild dysplasia</li>
</ol></li>
</ul></li>
<li>Microscopically, section A shows severe dysplasia with squmoaus
cells hyperplasia, nuclear hyperchromais and pleomorphism. There is no
stromal component for evaluation of invasion. Section B shows mild
dysplasia of squamous cells.</li>
</ul></li>
<li>2022-06-14 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Esophageal hyperemic patch, 33cm below the incisor (specimen A) and
40cm below the incisor (specimen B), s/p biopsy</li>
<li>Esophageal mucosa lesion, 28 below the insicor, s/p biopsy (C)</li>
<li>Superficial gastritis, s/p CLO test</li>
<li>Gastric erosions, prepyloric antrum</li>
<li>Duodenitits</li>
<li>Suspicious pseudodiverticulum, bulb</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue CLO test and biopsy result</li>
</ul></li>
</ul></li>
<li>2022-06-13 MRI - larynx
<ul>
<li>Imaging Report Form for Oropharynx Carcinoma</li>
<li>Impression (Imaging stage): T2N2cM0, stage IVA</li>
</ul></li>
<li>2022-06-13 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Biatrial enlargement</li>
<li>Right superior axis deviation</li>
<li>Right ventricular hypertrophy</li>
</ul></li>
<li>2022-06-02 Patho - tonsil biopsy
<ul>
<li>Labeled as “left oropharynx”, biopsy — squamous cell carcinoma, well
differentiated.</li>
<li>IHC stains: p16 (-), p40 (+), CK5/6 (+).</li>
</ul></li>
<li>2022-06-02 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>Oral cavity and oropharynx: an ulceration at L tonsillar fossa(esp L
palatopharyngeal arch), a granular bulging at left velum posterior part
visible from nasopharynx</li>
<li>Nasopharynx: fair via mirror/scope</li>
</ul></li>
<li>Diagnosis
<ul>
<li>left oropharyngeal lesion</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-441" class="section level3">
<h3>==========</h3>
</div>
<div id="section-442" class="section level3">
<h3>2022-08-11</h3>
<ul>
<li>Renal function: female, age 45, weight 65, creatinine 4.43 =&gt;
CrCl 16 mL/min, eGFR 12 mL/min/1.73m2.</li>
<li>Levocetirizine elimination route: 168 hours post dose an average of
85.4% of a radiolabeled dose was recovered with an average of 80.8% in
the urine and 9.5% in the feces. Levocetirizine for CrCl 10 to 30
mL/minute: 2.5 mg twice weekly (every 3 or 4 days).</li>
</ul>
</div>
<div id="section-443" class="section level3">
<h3>2022-08-02</h3>
<ul>
<li>Recent creatinine level trend
<ul>
<li>2022-07-30 6.03 mg/dL<br />
</li>
<li>2022-07-29 5.80 mg/dL<br />
</li>
<li>2022-07-27 4.69 mg/dL<br />
</li>
<li>2022-07-25 2.31 mg/dL<br />
</li>
<li>2022-07-21 0.79 mg/dL<br />
</li>
</ul></li>
<li>Suspected AKI. Calculated CrCl based on Cockcroft-Gault formula is
13 mL/min, and eGFR by MDRD equation is approximate 8
mL/min/1.73m2.</li>
<li>For patients with kidney impairment:
<ul>
<li>Cefepime for CrCl 11 to 29 mL/min: max 1 g every 12 hourse or 2 g
every 24 hours, no dose adjustment is needed.</li>
<li>Cimetidine for GFR &lt;10 mL/min: 300 mg every 8 to 12 hours, no
dose adjustment is needed.</li>
<li>Levocetirizine for CrCl 10 to 30 mL/minute: 2.5 mg twice weekly
(every 3 or 4 days). The current dose form is 5mg per tablet, which is
difficult to administer to meet the aforementioned. Allegra
(fexofenadine 60mg/tab, available in stock) is an alternative that is
recommended at a dose of #1 QD.</li>
</ul></li>
</ul>
</div>
<div id="section-444" class="section level3">
<h3>2022-07-27</h3>
<ul>
<li>Nasogastric tubes can be used to administer all oral medications in
active prescriptions.</li>
<li>Ascorbic acid included in Lyo-povigent inj may improve the
absorption of iron supplement (ferrous sodium citrate) from the
stomach.</li>
</ul>
</div>
</div>
</div>
<div id="section-445" class="section level1">
<h1>700353371</h1>
<div id="section-446" class="section level2">
<h2>220810</h2>
<ul>
<li>past history
<ul>
<li>Diabetes mellitus for years under regular OHA control.</li>
<li>Hypertension for years under regular medication control.  </li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-05 Pure Tone Audiometry, PTA
<ul>
<li>Reliabilty Fair to Poor</li>
<li>PTA</li>
<li>R’t : 30 dB HL, normal to moderately severe SNHL</li>
<li>L’t : 34 dB HL, normal to severe mixed type HL.</li>
</ul></li>
<li>2022-07-26 CT - neck
<ul>
<li>Imaging Report Form for Hypopharynx Carcinoma</li>
<li>Impression (Imaging stage): T:T2/T4, N:N2C, M:M0, stage IVA</li>
</ul></li>
<li>2022-07-20 Patho - larynx biopsy
<ul>
<li>DIAGNOSIS:
<ul>
<li>A: Hypopharynx, pyriform sinus, right, biopsy — Squamous cell
carcinoma, moderately differentiated</li>
<li>B: Oropharynx, soft palate, right, biopsy — Chronic
inflammation</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>A: Section shows squamous mucosa with invasive squamous cell
carccinoma. The immunohistochemical stains reveal CK(+) and p63(+).</li>
<li>B: Section shows squamous mucosa with chronic inflammation. No
invasive tumor is seen.</li>
</ul></li>
</ul></li>
<li>2022-07-19 CXR
<ul>
<li>Tortuosity of the aorta with atherosclerotic change.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-07-14 Nasopharyngoscopy
<ul>
<li>smooth NPx, oropharynx, right pyriform sinus yellowish granular
tumor, saliva pooling</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-19 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>This 71-year-old man has history of diabetes mellitus and
hypertension over 2 years under regular medication control. The patient
suffered from left mouth floor cyst suspect ranula noted in 2012-02,
right buccal erythroplakia with mild uneven surface s/p biopsy on
20120325, the patho revealed minimal chronic inflammation.</li>
<li>This time, throat foreign body sensation, dysphagia, easy chocking
and trismus 1.5 fingers were complained for 2 weeks. He came to our ENT
OPD for help. Physical examination revealed trimus (1.5FB), soft palate
fibrosis, right buccal and R soft palate erythroplakia with mild uneven
surface, right pyriform sinus yellowish granular tumor, saliva
pooling.</li>
<li>Under the impression of right oropharyngeal tumor and right oral
lesion suspect malignancy, He was admission for lesion biopsy. We
request your consultatio for dental evaluation.</li>
</ul></li>
<li>A
<ul>
<li>This is a 71 y/o male who suffered from right oropharyngeal tumor
and right oral lesion suspect malignancy.</li>
<li>O:
<ul>
<li><ol style="list-style-type: decimal">
<li>Poor oral hygiene was noted</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Severe bone loss of tooth 27 47 and 44-33 was noted. No mobility was
noted</li>
</ol></li>
</ul></li>
<li>A:
<ul>
<li>Sever periodontits of toooth 27 47 and 44-33.</li>
</ul></li>
<li>P:
<ul>
<li><ol style="list-style-type: decimal">
<li>Take panoramic film for tooth evaluation</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Suggest conservative treatment or tooth 27 47 extraction before
further treatment</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>OHI and teach him how to do home care</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-07-20
<ul>
<li>Surgery
<ul>
<li>Laryngomicrosurgery        </li>
<li>Biopsy of oral mucosa</li>
<li>Rigid esophagoscopy</li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>Right pyriform sinus medial wall and anterior wall granular
tumor</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Rigid esophagoscopy: 18cm from incisor, free of tumor</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Erythroplakia at right soft palate and right retromolar trigone</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Removal of teeth #27,47</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-08 - docetaxel 30mg/m2 55mg 1hr + cisplatin 40mg/m2 75mg 2hr
+ fluorouracil 2000mg/m2 3850mg 48hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>TPR were relatively stable during this hospitalization.</li>
<li>In general, blood pressure is well controlled, except for a
transient episode of hypotension on 2022-08-09.</li>
<li>Blood sugar levels fluctuated between 100 mg/dL and 200 mg/dL, no
urgent intervention is required.</li>
<li>Metoclopramide and chlorpromazine are independently associated with
development of extrapyramidal symptoms (EPS) and neuroleptic malignant
syndrome (NMS). The former is administered as TIDAC and the latter is
administered as PRNHS, these two are not administered simultaneously,
thus minimizing the risk.</li>
<li>There is no issue with the active prescription.</li>
</ul>
</div>
</div>
<div id="section-447" class="section level1">
<h1>700515879</h1>
<div id="section-448" class="section level2">
<h2>220805</h2>
<p>{Right upper lung adenocarcinoma, moderately differentiated with bone
metastasis, stage IV}</p>
<ul>
<li>diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Malignant neoplasm of unspecified part of unspecified bronchus or
lung</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Lung cancer with bone metastasis, stage IV</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Essential (primary) hypertension</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Pure hypercholesterolemia</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Chronic viral hepatitis B without delta-agent</li>
</ol></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-08-05 Pure Tone Audiometry, PTA
<ul>
<li>PTA</li>
<li>Reliability FAIR</li>
<li>Average RE 29 dB HL; LE 50 dB HL.</li>
<li>R’t normal to severe SNHL.</li>
<li>L’t mild to severe SNHL.</li>
</ul></li>
<li>2022-07-11 PD-L1 IHC S2022-10376
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percent of PD-L1 expression in tumor cell (TC): &lt; 1%</li>
</ul></li>
<li>2022-07-08 PD-L1 22C3 S2022-10376
<ul>
<li>Tumor Proportion Score (TPS): &lt; 1%</li>
</ul></li>
<li>2022-07-08 PD-L1 SP142 S2022-10376
<ul>
<li>Tumor cell (TC) staining assessment: TC &lt; 1%
<ul>
<li>Percentage of PD-L1 expressing tumor cells (%TC): 0%</li>
</ul></li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC &lt; 1%
<ul>
<li>Proportion of tumor area occupied by PD-L1 expressing
tumor-infiltrating immune cells (% IC): 0%</li>
</ul></li>
<li>Note:
<ul>
<li><ol style="list-style-type: decimal">
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-07-08 EGFR mutation testing S2022-10376
<ul>
<li>No mutation was detected at exons 18 (G719X), 19 (Deletions), 20
(T790M, S768I, Insertions), 21 (L858R, L861Q) of EGFR gene in this
specimen.</li>
</ul></li>
<li>2022-07-08 ROS1 Fluorescent-in-situ hybridization S2022-10376
<ul>
<li>Rearrangement of ROS1 gene is NOT detected.</li>
</ul></li>
<li>2022-07-08 ALK IHC S2022-10376
<ul>
<li>Immunostaining using ALK antibody D5F3 revealed no staining of tumor
cells.</li>
</ul></li>
<li>2022-06-29 Pathology - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show acinar glandular cells infiltrating in a fibrotic
stroma.</li>
<li>The immunohistochemical stains reveal TTF-1(+) and Napsin A(+). The
results are supportive for the diagnosis.</li>
</ul></li>
<li>2022-06-28 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Lung Carcinoma</li>
<li>Impression (Imaging stage): T4N3M1c</li>
</ul></li>
<li>2022-06-21 CXR
<ul>
<li>Patchy opacity projecting at right upper lung zone was noted, which
might be bronchogenic carcinoma. Please correlate with CT.</li>
<li>Spondylosis of the T-spine</li>
</ul></li>
<li>2022-09-16 CT - abdomen, pelvis
<ul>
<li>S/P colon operation. A small nodule (5mm) at LUQ suspected tumor
seeding. Lung and bony metastases.</li>
</ul></li>
<li>2022-06-09 MRI - L-spine
<ul>
<li>Diffuse bony metastases involving T10-S4 vertebral column and bony
pelvis as described. Lumbar spondylosis with diffuse spinal canal
stenosis and neuroforaminal narrowing, esp L4-5 (with left HIVD).
Post-operation change at L4-5.</li>
</ul></li>
<li>2019-07-31 L-spine AP + Lat. (including sacrum)
<ul>
<li><ol style="list-style-type: decimal">
<li>post-OP change from L4 to L5; and mild scoliosis of the
L-spine.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>moderate to severe decreased disc spaces in the L2/3 and L3/4 discs;
and mild decreased disc space in the L1/2 disc.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>mild anterior and posterior spur formation in the L-spine</li>
</ol></li>
</ul></li>
<li>2019-07-05 Doppler Flowmetry (perivasculary)
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild atherosclerosis of bil. infrapopliteal arteries without
significant stenosis</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>All triphasic flow spectrum from bil. CFA, PFA, SFA and popliteal
arteries downstream to bil. PTA, ATA and DPA.</li>
</ol></li>
</ul></li>
<li>2019-06-28 MRI - L-spine
<ul>
<li>Lumbar spondylosis with spinal canal stenosis and neuroforaminal
narrowing, most severe on left side at L4-5.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Molecular and/or biomarker analyses were performed on this lung
adenocarcinoma patient in order to identify gene alterations. The
purpose of this is to identify potentially effective targeted therapies,
as well as to avoid therapies that are unlikely to provide clinical
benefits. However, the performed test results showed that PD-L1 TC &lt;
1% &amp; IC &lt; 1%, no EGFR mutation detected, no ROS1 rearrangement
detected, no immunostained ALK. An initial treatment option might be a
regimen based on carboplatin or cisplatin.</li>
<li>Underlying condition HTN is well controlled during this
hospitalization.</li>
</ul>
</div>
</div>
<div id="section-449" class="section level1">
<h1>700529765</h1>
<div id="section-450" class="section level2">
<h2>220805</h2>
<ul>
<li>exam finding
<ul>
<li>2022-08-04 KUB
<ul>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-08-04 CXR
<ul>
<li>Presence of ileus.</li>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2022-08-03 KUB
<ul>
<li>There is fecal materials impaction in the course of colons.</li>
<li>Local ileus.</li>
</ul></li>
<li>2022-06-21 CXR
<ul>
<li>Enlarged heart shadow with tortuous aorta.</li>
<li>Multiple nodules and masses in bilateral lungs, consider metastases,
enlarging.</li>
<li>Bilateral clear costophrenic angles.</li>
</ul></li>
<li>2022-06-21 Ribs Bilat
<ul>
<li>Multiple nodules and masses in both lungs, consider metastases,
enlarging.</li>
<li>No definite displaced rib fracture. Clinical correlation is
advised.</li>
</ul></li>
<li>2022-06-21 CT - brain
<ul>
<li>Brain atrophy. No ICH.</li>
</ul></li>
<li>2022-06-21 ECG
<ul>
<li>Sinus rhythm with premature atrial complexes</li>
<li>T wave abnormality, consider anterior ischemia</li>
<li>Prolonged QT</li>
</ul></li>
<li>2021-10-12 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>T wave abnormality, consider anterior ischemia</li>
</ul></li>
<li>2021-10-12 CT - abdomen, pelvis
<ul>
<li>Hx of rectal ca without Tx. Only receiving chinese medicine</li>
<li>Diffsue wall thickening of the rectum up to 7.5cm in length and
swelling of the sigmoid colon and descending colon is found. Rectal
cancer with colitis at sigmoid colon is considered.</li>
<li>Lung mets.</li>
</ul></li>
<li>2021-10-12 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
<li>Nodular lesion at right upper lobe and right lower lobe is
found.</li>
<li>Osteopenia of the bony structure is noted.</li>
</ul></li>
<li>2020-08-04 CT - lung/mediastinum/pleura
<ul>
<li>RLL solid nodule (15-mm) (in favor an another primary lung
cancer).</li>
<li>Lingula tiny nodule, nature to be determined.</li>
</ul></li>
<li>2020-08-04 Patho - colon biopsy
<ul>
<li>Large intestine, rectum, biopsy — Adenocarcinoma, moderately
differentiated<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>The immunohistochemical stains reveal EGFR(+), PMS2(+), MLH1(+),
MSH2(+), and MSH6(+).</li>
</ul></li>
<li>2020-08-04 SONO - abdomen
<ul>
<li>Hepatic cyst, multiple</li>
<li>GB stone, mutiple</li>
<li>Renal cyst, bilateral</li>
</ul></li>
<li>2020-08-03 Sigmoidoscopy
<ul>
<li>Diagnosis
<ul>
<li>Rectal cancer with partial obstruction, s/p Bx</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2020-08-03 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade A</li>
<li>Superficial gastritis</li>
</ul></li>
<li>Suggestion
<ul>
<li>PPI treatment</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-10-14 Family Medicine
<ul>
<li>Q
<ul>
<li>for combine hospice care</li>
<li>This 78 year-old female patient who has rectal cancer, Stage IV on
2020/08, then she refusioned the surgery treatment, chemotherapy,
radiotherapy.</li>
<li>This time, she suffered from watery diarrhea many times for one
month due to the use of folk herbal recipes, then the symptom of waterly
diarrhea progression, and poor intake, abdomen pain noted, so she was
brought our ER for help.</li>
<li>The patient still refusion chemotherapy, radiotherapy, but want to
combine hospice care, so we need your help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>Indication: rectal cancer, Stage I</li>
<li>Patient refuses cancer treatment and has no specific complaint while
I visited.</li>
<li>We will arrange share to follow up.</li>
<li>She can visit FM OPD for symptom control after discharge.</li>
</ul></li>
</ul></li>
<li>2020-08-04 Colorectal Surgery
<ul>
<li>Q
<ul>
<li>This 78 y/o female patient denied any systemic history before. She
suffered from abdominal fullness and difficult stool passage for 4 days.
She visited HoPing Hospital for help where suspected colon cancer by
abdomen CT exam. High level of CRP 29 was noted. The patient then
transfered to our OPD for personal reason. Denied fever, cough, chest
pain, tarry stool passage, oliguria, nor limbs edema. The physical
examination showed pink conjuctiva and soft abdomen. CEA on 20200729
31.7 ng/mL. Going to obtain routine blood test and further
management.</li>
<li>Sigmoid scope showed rectal cancer with partial obstruction, s/p Bx;
internal hemorrhoid. We would like to need your visit for professional
help. Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>I’ve visited this case.</li>
<li>This 78 y/o fenmale patient suffered from abdominal distension and
no stool passage for 4 days and then rectal cancer with obstruction was
diagnosed.</li>
<li>Stool passage (+) now and no more abdominal distension.</li>
<li>I’ve explained the necessity of surgical treatment, the patient
denied any discomfort and ask for discharge today.</li>
<li>The risk of re-obstruction was told.</li>
<li>Suggest OPD F/U</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient refused to receive surgery, chemotherapy,
radiotherapy.</li>
<li>Elevated CRP (2022-08-04 11.68 &lt;- 2022-08-03 8.57), normal WBC
(2022-08-04 7.13). Brosym (cefoperazone/sulbactam) is prescribed.</li>
<li>All the oral drugs in active prescription can be administered with
nasogastric tube without issues.</li>
</ul>
</div>
</div>
<div id="section-451" class="section level1">
<h1>700642355</h1>
<div id="section-452" class="section level2">
<h2>220805</h2>
<p>{ovarian cancer, pT3aN0cM0, FIGO stage IIIA2}</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-08 SONO - abdomen
<ul>
<li>Hydronephrosis, right</li>
</ul></li>
<li>2022-04-07 Patho - uterus with or without SO non-neoplastic/prolapse
<ul>
<li>Ovarian/ Fallopian tube/ Peritoneum Cancer Checklist</li>
<li>Diagnosis:
<ul>
<li>F2022-00147:
<ul>
<li>Ovary, left, oophorectomy —- Mucinous carcinoma</li>
<li>Ovary, right, oophorectomy —- Mucinous carcinoma</li>
<li>Fallopian tube, left, salpingectomy —- Not found</li>
<li>Fallopian tube, right, salpingectomy —- Negative for malignancy</li>
</ul></li>
<li>S2022-05776
<ul>
<li>Uterus, corpus, total hysterectomy —- Negative for malignancy —-
Leiomyoma</li>
<li>Uterus, endometrium, total hysterectomy —- Negative for
malignancy</li>
<li>Uterus, cervix, total hysterectomy —- Negative for malignancy</li>
<li>Omentum, omentectomy —- Extravasated mucin present</li>
</ul></li>
<li>AJCC 8th edition: pStage IIIA2, pT3aN0 (if cM0); FIGO Stage
IIIA2</li>
</ul></li>
<li>Gross description:
<ul>
<li>Procedure: ATH + BSO + Cytoreduction surgery + infracolic
omentectomy + LN dissection<br />
</li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Mucinous carcinoma with abundant extravasated
mucin; The immunohistochemical stains reveal PAX8(-), WT-1(-), PR(-),
and p53(wild type).<br />
</li>
<li>Histologic Grade: G2: Moderately differentiated</li>
<li>Implants (required for advanced stage serous/seromucinous borderline
tumors only): Not sampled</li>
<li>Other Tissue/ Organ Involvement (select all that apply): bilateral
adnexal soft tissue and omentum: extravasated acellular mucin
present</li>
<li>Largest Extrapelvic Peritoneal Focus (required only if applicable):
omentum: Microscopic</li>
<li>Peritoneal/Ascitic Fluid: N2022-01327: Negative for malignancy<br />
</li>
<li>Regional Lymph Nodes: left iliac: 0/3; left obturator: 0/5; right
iliac: 0/0; right obturator: 0/6; left para-aortic: 0/1; right
para-aortic: 0/0.<br />
</li>
<li>Additional Pathologic Findings: A leiomyoma is seen.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-06 Frosen Resection
<ul>
<li>FsA: Ovary, left, oophorectomy — mucinous adenocarcinoma</li>
<li>FsB: Ovary, right, oophorectomy — mucinous adenocarcinoma</li>
</ul></li>
<li>2022-04-01 Patho - stomach biopsy
<ul>
<li>Stomach, antrum, biopsy — Chronic gastritis, H pylori NOT
present</li>
</ul></li>
<li>2022-03-29 Mammography
<ul>
<li>Impression: Dense breast. No mammographic evidence of malignancy,
suggest clinical correlation and regular follow up.</li>
<li>BI-RADS: Category 1: negative. - annual screening.</li>
</ul></li>
<li>2022-03-28 CT - abdomen, pelvis
<ul>
<li>Right hydronephrosis and hydroureter.</li>
<li>A cystic lesion (11.4cm) at left adnexa with septation suspected
mucinous tumor. A tumor (5.9cm) at uterus suspected myoma.</li>
</ul></li>
<li>2022-03-28 Gynecologic ultrasonography
<ul>
<li>pelvis mass: 116x111mm</li>
</ul></li>
<li>2017-07-03 MRI - nasopharynx
<ul>
<li>Findings
<ul>
<li>Multiple ovoid and round nodular lesions in Rt level III, IV, Vab
(the largest lesion 21mmx20mm)</li>
<li>An heterogeneous enhancing mass, lobulated in contour (heterogeneous
hyperintensity on T2WI. mixed hyper-and intermediate intensity on T1WI)
in the lower neck and thoracic inlet, which is inseparable from adjacent
thyroid gland.</li>
</ul></li>
<li>Impression:
<ul>
<li>In favor of thyroid cancer with neck LNs metastasis.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-28 Obstetrics and Gynecology
<ul>
<li>Impression and plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>Huge ovarian mass, left side 116x111 mm, suspect malignancy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Uterine myoma: 69x43 mm</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Survey tumor marker CEA, CA125, CA199, AFP, SCC, D-dimer</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>surigcal operation
<ul>
<li>2022-04-06
<ul>
<li>Operation
<ul>
<li><ol style="list-style-type: decimal">
<li>Enterolysis</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Excision of intraabdominal malignant tumor</li>
</ol></li>
</ul></li>
<li>Finding
<ul>
<li>s/p lower midline incision scar with severe adhesion of small bowel
to abdominal wall and lower pelvic cavity.</li>
<li>Several mucinous nodules were removed</li>
<li>Washing cytology: ascites*1</li>
</ul></li>
</ul></li>
<li>2022-04-06
<ul>
<li>Surgery
<ul>
<li>Right hydronephrosis and hydroureter.A cystic lesion (11.4cm) at
left adnexa with septation suspected mucinous tumor.</li>
<li>Left ovarian tumor (11.4 cm), suspected malignancy.</li>
<li>Frozen: mucinous adenocarcinoma</li>
<li>Debulking surgery (ATH + BSO + Cytoreduction surgery + infracolic
omentectomy + LN dissection)     - Finding</li>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: enlarged, 8cm, tense contact with bladder, peritoneum dut to
tumor mass accupied .</li>
<li>Adnexa:
<ul>
<li>LOV: 11.4x10x8cm , rupture during the operation , smooth
surface.</li>
<li>ROV: 2x2x2 cystic mass , capsule not intact.</li>
<li>Fallopian tube: bilateral grossly normal</li>
</ul></li>
<li>CDS: invisible due to tumor mass occupied</li>
<li>Ascites: bloody , minimal</li>
<li>Bilateralpelvic lymph nodes: normal(-), enlarged(-),
indurated(-)</li>
<li>Omentum: grossly normal</li>
<li>Optimal debulking surgery was achieved.</li>
<li>Residue tumor: almost no residual tumors, maximal diameter &lt; 1
cm, over rectum and peritonealwall.</li>
<li>Estimated blood loss:1000 ml</li>
<li>Blood transfusion: 4U</li>
<li>Complication: NIL</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-04 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2022-07-13 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2022-06-02 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 600mg
2hr</li>
<li>2022-05-12 - paclitaxel 160mg/m2 210mg 3hr + carboplatin AUC 5 600mg
2hr</li>
</ul></li>
</ul>
<div id="section-453" class="section level3">
<h3>==========</h3>
</div>
<div id="section-454" class="section level3">
<h3>2022-06-27</h3>
<ul>
<li>The body temperature was no higher than 37 degrees since the night
of 2022-06-25 after administration of Tapimycin (piperacillin 4g,
tazobactam 0.5g) IVD Q6H since 2022-06-24.</li>
</ul>
</div>
</div>
</div>
<div id="section-455" class="section level1">
<h1>700653751</h1>
<div id="section-456" class="section level2">
<h2>220805</h2>
<p>{newly diagnosed with Endometrioid adenocarcinoma T1BN0M0 stage IB
s/p Laparoscopic gynecologic oncology staging surgery}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>Uric Acid
<ul>
<li>2022-06-29 8.6 mg/dL</li>
<li>2022-03-22 9.7 mg/dL<br />
</li>
<li>2022-02-14 8.2 mg/dL<br />
</li>
<li>2021-09-28 10.2 mg/dL<br />
</li>
<li>2021-04-21 9.8 mg/dL<br />
</li>
</ul></li>
<li>Hepatitis
<ul>
<li>2022-02-24
<ul>
<li>Anti-HBs 97.17 mIU/mL Reactive</li>
<li>Anti-HBc Nonreactive 0.53 S/CO<br />
</li>
<li>Anti-HCV Nonreactive 0.04 S/CO<br />
</li>
<li>HBsAg Nonreactive 0.29 S/CO</li>
</ul></li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-04-28 2D transthoracic echocardiography
<ul>
<li>Dilated LA</li>
<li>LV apical and septal hypertrophy</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>AV sclerosis with mild AR, mild MR and TR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2022-03-16 Pure tone audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average R’t 31 dB HL // L’t 35 dB HL</li>
<li>Bil normal to moderately severe SNHL.</li>
</ul></li>
<li>2022-02-16 Patho - uterus (with or without SO) neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, endometrium, laparoscopic staging surgery — Endometrioid
adenocarcinoma, grade 3<br />
</li>
<li>Uterus, myometrium, LSC staging surgery — Involved by adenocarcinoma
(more than half thickness)<br />
</li>
<li>Uterus, cervix, LSC staging surgery — Negative for malignancy</li>
<li>Ovaries and fallopian tubes, bilateral, LSC staging surgery —
Negative for malignancy</li>
<li>Lymph node, left iliac, dissection — Negative for malignancy
(0/4)<br />
</li>
<li>Lymph node, left obturator, dissection — Negative for malignancy
(0/6)</li>
<li>Lymph node, right iliac, dissection — Negative for malignancy (soft
tissue only)<br />
</li>
<li>Lymph node, right obturator, dissection — Negative for malignancy
(0/6)</li>
<li>AJCC 8th edition Pathology stage: pT1bN0(if cM0); FIGO IB; AJCC
stage IB</li>
</ul></li>
<li>IHC: p53(wild type), p16(-), ER: positive (moderate, 40%), PR:
positive (moderate, 40%)</li>
</ul></li>
<li>2022-02-11 MRI - pelvis
<ul>
<li>Soft tissue tumor in the uterine cavity, suspected endometrial
malignancy, cStage T1bN0M0.</li>
<li>Suspected right ovarian cyst.</li>
</ul></li>
<li>2022-02-10 Gynecologic ultrasonography
<ul>
<li>suspected endometrial hyperplasia</li>
<li>suspected rt ovarian cyst</li>
</ul></li>
</ul></li>
<li>past history
<ul>
<li>Hypertension since 2003.</li>
<li>Angina pectoris, years ago, and myocardia ischemia with patent
coronary artery with myocardial bridge at middle LAD by cardiac
catheterization in 2015. Now under Apixaban treatment.</li>
<li>Obstructive sleep apnea for years.</li>
<li>Diabetes mellitus, type II, under OHAs treatment.</li>
<li>Hyperlipidemia.</li>
<li>Chronic Af under medication treatment. </li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-16
<ul>
<li>Surgery
<ul>
<li>Laparoscopic gynecologic oncology staging surgery        </li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: normal size, smooth surface, papillary mass in uterus
cavity, myometrium invasion depth &lt;1/2</li>
<li>Bilateral adnexa: grossly normal</li>
<li>Bilateral pelvic lymph nodes: normal(-), enlarged(+),
indurated(+)</li>
<li>CDS: free</li>
<li>Adhesion between omentum and pelvic wall was noted</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-17 ~ 2022-05-05 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and another 1200cGy/3 fractions of the vaginal cuff mucosa
surface by IVRT.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-08-04 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 270mg
2hr</li>
<li>2022-07-08 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 270mg
2hr</li>
<li>2022-06-17 - paclitaxel 175mg/m2 240mg 3hr + carboplatin AUC 5 270mg
2hr</li>
<li>2022-05-24 - paclitaxel 175mg/m2 300mg 3hr + carboplatin AUC 5 300mg
2hr</li>
<li>2022-04-19 - carboplatin AUC 4 300mg 2hr (due to cisplatin caused
high creatinine level)</li>
<li>2022-03-23 - cisplatin 50mg/m2 80mg 24hr (NCCN 20211104 Uterine
Neoplasms p32 ENDO-D 1/4 - carboplatin + paclitaxel)</li>
</ul></li>
</ul>
<div id="section-457" class="section level3">
<h3>==========</h3>
</div>
<div id="section-458" class="section level3">
<h3>2022-08-05</h3>
<ul>
<li>After a switch from cisplatin to carboplatin in April 2022, the
blood creatinine level has returned to normal since late June 2022.</li>
<li>According to available records, the level of blood uric acid was
above the normal range for more than 12 months.
<ul>
<li>2022-06-29 8.6 mg/dL</li>
<li>2022-03-22 9.7 mg/dL<br />
</li>
<li>2022-02-14 8.2 mg/dL<br />
</li>
<li>2021-09-28 10.2 mg/dL<br />
</li>
<li>2021-04-21 9.8 mg/dL<br />
</li>
</ul></li>
<li>For patients at a high risk of an adverse cardiovascular event or
have a history of a previous cardiovascular adverse event, an initial
trial of a uricosuric agent rather than febuxostat is recommended,
benzbromarone 50mg/tab 1# PO QD might be considered.</li>
</ul>
</div>
<div id="section-459" class="section level3">
<h3>2022-06-20</h3>
<ul>
<li>An increase in S-GPT/ALT has been noted (2022-06-14 114 U/L &lt;-
2022-05-31 9 U/L). The same trend could be seen in S-GOT/AST (2022-06-14
25 U/L &lt;- 10 U/L)
<ul>
<li>Paclitaxel has been associated with serum aminotransferase
elevations in 7% to 26% of patients, but values greater than 5 times the
upper limit of normal (ULN) in only 2% of those receiving the highest
doses. ( <a href="https://www.ncbi.nlm.nih.gov/books/NBK548093/" class="uri">https://www.ncbi.nlm.nih.gov/books/NBK548093/</a> )</li>
<li>Mild and transient elevations in serum aminotransferase levels are
found in up to one-third of patients taking carboplatin. However,
clinically apparent acute liver injury from carboplatin is extremely
rare and the characteristics of such injury have not been well defined.
( <a href="https://www.ncbi.nlm.nih.gov/books/NBK548565/" class="uri">https://www.ncbi.nlm.nih.gov/books/NBK548565/</a> )</li>
</ul></li>
<li>The underlying condition Three-Hypers which are currently managed
through oral medication and Metabolism OPD follow-up, however patient’s
SBP was 91~191 and blood sugar was 123~490, both with high volatility.
In terms of HbA1c, LDL, and Triglyceride, the last test results were
dated in December 2021.</li>
</ul>
</div>
<div id="section-460" class="section level3">
<h3>2022-05-24</h3>
<ul>
<li>This patient was diagnosed with endometrioid adenocarcinoma in early
2022, had staging surgery in February 2022, received CCRT between March
and early May 2022, and begins to receive carboplatin/paclitaxel.</li>
<li>Most recent lab data reported on 2022-05-12 showed slightly
decreased blood cell counts. BUN and Creatinine levels were improving
(BUN 22 (2022-05-12) &lt;- 47 (2022-04-28); Creatinine 1.28 (2022-05-12)
&lt;- 1.76 (2022-04-28)).</li>
<li>The patient also has “Three-Hypers” which are managed through oral
medication (prescribed as self-carried items in active order currently)
and Metabolism OPD follow-up, however, in terms of HbA1c, LDL, and
Triglyceride, the last test results date back to December 2021 and might
need to be updated.</li>
</ul>
</div>
<div id="section-461" class="section level3">
<h3>2022-04-19</h3>
<ul>
<li>The patient has been recently diagnosed with endometrioid
adenocarcinoma stage IB s/p laparoscopic gynecologic oncology staging
surgery, and is receiving EBER since 2022-03-17 and cisplatin since
2022-03-23.</li>
<li>Lab data on 2022-04-19 and 2022-04-12 were grossly normal. Cardiac
conditions are managed with corresponding drugs. TPR readings are
normal. There is no information on blood sugar levels during this
hospital stay yet.</li>
</ul>
</div>
</div>
</div>
<div id="section-462" class="section level1">
<h1>700516604</h1>
<div id="section-463" class="section level2">
<h2>220801</h2>
<ul>
<li>exam finding
<ul>
<li>2022-07-30 CXR
<ul>
<li>Ground glass opacities in bil. lungs.</li>
</ul></li>
<li>2022-07-30 KUB
<ul>
<li>Stool retention in the bowel.</li>
<li>Degeneration and spondylosis of L-S spine.</li>
</ul></li>
<li>2022-07-21 CXR
<ul>
<li>lung markings: consolidation in the right lower lung field; focal
increased density in the right middle lung field.</li>
<li>blurred right hemidiaphram</li>
<li>blunting bilateral costophrenic angles</li>
</ul></li>
<li>2022-07-14 Paracentesis
<ul>
<li>Ascites tapping: 3000mL orange ascites</li>
</ul></li>
<li>2022-07-08 Paracentesis
<ul>
<li>Ascites tapping: 3000mL bloody ascites</li>
</ul></li>
<li>2022-06-25 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
</ul></li>
<li>2022-06-14 CT, CTA - chest
<ul>
<li>Finding
<ul>
<li>Filling defects of bilateral pulmonary arteries, lobar and segmental
branches.</li>
<li>Dilatation of right ventricle and pulmonary trunk.</li>
<li>Small amount of pleural effusion.</li>
<li>Liver cirrhosis and ascites.</li>
<li>Increased para-aortic soft tissue density.</li>
</ul></li>
<li>Impression
<ul>
<li>Pulmonary embolism, lobar and segmental branches</li>
</ul></li>
</ul></li>
<li>2022-06-14 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Rightward axis</li>
<li>Low voltage QRS of precordial leads</li>
<li>T wave abnormality, consider inferolateral ischemia</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-06-07 CT - abdomen, pelvis
<ul>
<li>Pancreatic head cancer s/p operation. Partial thrombosis of
IVC.</li>
<li>General subcutaneous edema. Small amount ascites. Bil. pleural
effusions.</li>
<li>Small patchy densities (0.5cm, 0.6cm) at LLL.</li>
<li>A poor enhancing nodule (2.3cm) at S6 of liver.</li>
<li>Some LNS at retroperitoneum with SMV encasement.</li>
</ul></li>
<li>2022-03-26 ECG
<ul>
<li>Sinus tachycardia</li>
<li>T wave abnormality, consider anterior ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-03-10 CT - abdomen, pelvis
<ul>
<li>Pancreatic head cancer s/p operation.</li>
<li>Bil. pleural effusions. A small patchy density (1.0cm) at LLL
suspected metastases.</li>
<li>A poor enhancing nodule (2.2cm) at S6 of liver suspected
metastases.</li>
<li>Some LNS at retroperitoneum.</li>
</ul></li>
<li>2022-03-10 CXR
<ul>
<li>Increased lung markings on left lower lung with blurring of left
medial diaphragm is noted. Please correlate with clinical
condition.<br />
</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion ?</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Spondylosis of the T-spine</li>
</ul></li>
<li>2022-02-18 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Dilated RA and RV</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Adequate LV systolic function with normal wall motion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mild to moderate TR and PR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Thick IVS</li>
</ol></li>
</ul></li>
<li>2022-02-14 SONO - vein
<ul>
<li><ol style="list-style-type: decimal">
<li>Circumferential venous thrombosis at right ostial to proximal SFV
with adequate recanalization, no venous thrombosis at right CFV, PFV,
middle to distal SFV, popliteal vien, PTV and LSV.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>No venous thrombosis at left lower limb venous systems.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Venous arterialization waveforms at bilateral CFVs, consider iliac
compression syndrome.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>No significant venous refluxes at bilateral lower limbs venous
systems.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>The ratios of MVO and SVC of bilateral legs were within normal
limits.</li>
</ol></li>
</ul></li>
<li>2022-02-11 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Preserved LV and RV systolic function with normal wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Concentric LVH, grade 1 LV diastolic dysfunction</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Mild AR, MR, PR, mild to moderate TR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Pulmonary hypertension</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Presence of thrombus in IVC</li>
</ol></li>
</ul></li>
<li>2022-02-10 CT, CTA - chest
<ul>
<li>INFERIOR VENA CAVA thrombus with pulmonary embolism and bialteral
upper lobe patch.</li>
<li>Pancreatic cancer in the abdominal cavity with stable
condition.</li>
<li>Left lower lobe nodule. stable.</li>
</ul></li>
<li>2021-10-27 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>A newly-developed soft tissue nodule 4 mm in LLL of the lung is
noted that may be metastasis? Follow up is indicated.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Metastasis at the mesentery with superior mesenteric artery and vein
encasement is suspected. please correlate with clinical condition and
tumor marker.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Metastasis or partial volume effect 0.9 cm in the pelvis is
suspected?</li>
</ol></li>
</ul></li>
<li>2021-06-19 CT - abdomen, pelvis
<ul>
<li>s/p subtotal gastrectomy.</li>
<li>s/p pancreatic head resection.</li>
<li>Some soft tissue mass around the SMA and SMV is found. In comparison
with CT dated on 2021-01-22, the lesion is stationary.</li>
</ul></li>
<li>2021-01-22 CT - abdomen, pelvis
<ul>
<li><ol style="list-style-type: decimal">
<li>Metastasis at the mesentery with superior mesenteric vein encasement
is suspected. please correlate with clinical condition, tumor marker,
and MRI.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Metastasis or partial volume effect 0.9 cm in the pelvis is
suspected?</li>
</ol></li>
</ul></li>
<li>2020-04-15 Esophagogastroduodenoscopy, EGD
<ul>
<li>Gastric bleeding prob anasmtomotic site bleeding s/p APC</li>
<li>Reflux esophagitis LA Classification grade A</li>
<li>s/p whipple operation</li>
<li>incomplete study</li>
</ul></li>
<li>2020-04-09 Patho - pancreas total/subtotal resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Pancreas, head, pancreatico-duodenectomy —- Adenocarcinoma,
moderately differentiated;
<ul>
<li>AJCC 8th edition: ypStage IIB, ypT3N1(if cM0), s/p pre-op
neoadjuvant treatment<br />
</li>
</ul></li>
<li>Small intestine, duodenuma, pancreatico-duodenectomy —-
Adenocarcinoma, by direct invasion<br />
</li>
<li>Portal vein, segmental resection —- Adenocarcinoma, by direct
invasion<br />
</li>
<li>Common bile duct, pancreatico-duodenectomy —- Negative for
malignancy<br />
</li>
<li>Stomach, pyloric, partial gastrectomy —- Negative for
malignancy<br />
</li>
<li>Gallbladder, cholecystectomy —-chronic cholecystitis —-
cholelithiasis</li>
<li>Lymph nodes
<ul>
<li>Lymph node, group 5, 6, 8, 9, 12, 13, 14, dissection —- Negative for
malignancy (0/6)<br />
</li>
<li>Lymph node, cystic, dissection —- Negative for malignancy
(0/1)<br />
</li>
<li>Lymph node, lesser curvature, dissection —- Negative for malignancy
(0/3)<br />
</li>
<li>Lymph node, greater curvature, dissection —- Negative for malignancy
(0/16)<br />
</li>
<li>Lymph node, peri-CBD, dissection —- Negative for malignancy
(0/3)<br />
</li>
<li>Lymph node, peri-pancreas, dissection —- Adenocarcinoma, metastatic
(1/6)<br />
</li>
</ul></li>
</ul></li>
<li>microscopic examination
<ul>
<li><ol style="list-style-type: decimal">
<li>Histologic Type: Ductal adenocarcinoma<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Histologic Grade (ductal carcinoma only): G2: Moderately
differentiated<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Margins</li>
</ol>
<ul>
<li>Margins: free, closest margin: 0.1 mm; Posterior retroperitoneal
(radial) margin<br />
</li>
<li>Distal pancreatic margin: 1.2 cm<br />
</li>
<li>Common bile duct margin: 2.5 cm<br />
</li>
<li>Gastric margin: 9 cm<br />
</li>
<li>Small intestinal margin: 16 cm<br />
</li>
</ul></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Lymphovascular invasion: Present<br />
</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Perineural Invasion: Present<br />
</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pathologic Staging (pTNM)<br />
</li>
</ol>
<ul>
<li>Primary Tumor (pT): pT3: Tumor ＞ 4 cm<br />
</li>
<li>Regional Lymph Nodes (pN): pN1: Metastasis in one to three regional
lymph nodes<br />
</li>
<li>Specify: group 5, 6, 8, 9, 12, 13, 14: 0/6; cystic: 0/6; cystic:
0/1; lesser curvature: 0/3; greater curvature: 0/16; peri-CBD: 0/3;
peri-pancreas: 1/6<br />
</li>
<li>Distant Metastasis (pM): if cM0<br />
</li>
</ul></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Additional Pathologic Findings: Tumor, invasion to portal vein and
duodenum is seen.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2020-04-06 Lung flow volume curve
<ul>
<li>Mild restrictive pulmonary function impairment</li>
</ul></li>
<li>2022-04-06 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with no regional wall motion
abnormality at resting state</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mild aortic, mitral and tricuspid regurgitation</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Thick IVS and LVPW</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Atheroma on ascending aorta</li>
</ol></li>
</ul></li>
<li>2020-03-27 CT - lung/mediastinum/pleura
<ul>
<li>Finding
<ul>
<li>Visible abdomen
<ul>
<li>Soft tissue mass at pancreatic head about 4.1cm in largest dimension
is found. In comparison with MRI dated on 2019-12-10, the lesion
progressed.</li>
<li>The GB is well distended without soft tissue lesion</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Pancreatic head cancer, cT4N0M0, in progression.</li>
</ul></li>
</ul></li>
<li>2019-12-27 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Septal hypertrophy with indeterminate LV filling pressure and
impaired RV relaxation; moderately dilated LA.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dilated LV with normal LV and RV systolic function.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>AV sclerosis with mild AR; mild MR.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>ild aortic root calcification with multiple protruding non-mobile
atheromas (5-6 mm of thickness).</li>
</ol></li>
</ul></li>
<li>2019-12-12 Surgical pathology Level V
<ul>
<li>clinical diagnosis
<ul>
<li>Malignant pancreas neoplasm, part NOS;</li>
</ul></li>
<li>pathologic diagnosis
<ul>
<li>Pancreatic head, EUS/FNB — Adenocarcinoma</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>The specimen submitted consists of mutiple small pieces of
gray-white soft tissue, labeled pancreatic head, measuring up to 3.5 x
0.1 x 0.1 cm. All for section.</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show a picture of adenocarcinoma, composed of well to
moderately differentiated polygonal to columnar neoplastic cells with
occasional pleomorphic nuclei, arranged in papillary and duct-like
structures. Desmoplastic stromal reaction and extensive tumor necrosis
are evident.</li>
</ul></li>
</ul></li>
<li>2019-12-11 Electronic Endoscopic Ultrasonography, EUS
<ul>
<li>position: pancreas</li>
<li>symptoms: elevated CA 19-9 and a 3-4 cm mass at the peri-panc head
area 　　- Pre-EUS diagnosis: Suspected pancreatic cancer 　　-
Endoscopic Findings: The major papilla looks normal.<br />
　　- EUS Findings
<ul>
<li>A 3.8x3.1 cm hyperechoic heterogeneous mass with one longitudinal
cystic lesion within this tumor seen at the pancreatic head
portion.</li>
<li>The mass revealed multiple small hypoechoic lesions inside. The MPD
is not dilated. The vessels were not encased. The CBD measured about 8
mm in diameter. 　　- Diagnosis</li>
<li>Pancreatic tumor, head, S/P EUS/FNB perhaps SCN</li>
</ul></li>
</ul></li>
<li>2019-12-10 MRI, MR cholangiography, MRCP
<ul>
<li>Imaging Report Form for Pancreatic Carcinoma</li>
<li>T4N0M0, stage III based on this MRI study</li>
</ul></li>
<li>2019-11-29 SONO - abdomen
<ul>
<li>diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>GB stone.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>pancreatic neck cystic lesion.</li>
</ol></li>
</ul></li>
<li>suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>Visit GI/GS OPD if symptom revealed</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>consider EUS for pancreatic cystic lesion</li>
</ol></li>
</ul></li>
</ul></li>
<li>2019-11-28 CPA - carotid phonoangiograph
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild atheromatous lesions in bilateral CCA bifurcatios, right ICA,
right ECA and left CCA.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Adequate total VA flow volume (108 ml/min).</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased RI in right VA, indicating distal stenosis.</li>
</ol></li>
</ul></li>
<li>2019-11-28 Bone densitometry - hip
<ul>
<li>Hip BMD performed by DXA revealed:
<ul>
<li>Hip, BMD is 0.551 gms/cm2, about 2.4 SD below the peak bone mass
(69%) and 0.2 SD below the mean of age-matched people (97%).</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-04 Family Medicine
<ul>
<li>Q
<ul>
<li>for share care or hospice care</li>
<li>This 75 y/o female, a pt of pancreatic head CA, ypStage IIB, ypT3N1
cM0, Dx in Dec 2019, s/p pre-op neoadjuvant C/T wt FOLFIRINOX IV Q2W x 4
finishing in March 2020 &amp; s/p pancreatico-duodenectomy on 20200408
&amp; post-Op adjuvant CCRT wt 5-FU 24 hr QD x 5 per wk x 6 plus R/T
from 20200608 to 20200704 &amp; s/p post-Op adjuvant C/T wt FOLFIRINOX
IV Q2W x 8 from July 2020 to Jan 2021 &amp; palliative C/T Abraxane
100mg / m2 + Gem 900mg/m2 D1 &amp; 8 Q3W x 13 since 2021-02 to
2022-05.</li>
<li>Owing to disease progression noted and we explained her poor
condition to her family and DNR was consented. We need expertise to
evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>75 y/ o lady advanced pancrease ca.</li>
<li>DNR + ECOG 3~4</li>
<li>GI bleeding pulmonism embolim</li>
<li>Our share care would follow up. Thanks for consultation.</li>
</ul></li>
</ul></li>
<li>2022-06-16 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For evaluation of current condition and the future treatment plan of
pancreatic cancer</li>
<li>This is a 75 y/o patient with pancreatic head cancer who is
currently hospitalized for the treatment of recurrent pulmonary
embolism.</li>
<li>Please kindly assist to evaluate the patient and advise if she can
proceed with palliative chemotherapy, and if DNR is a viable option
should her condition worsen during the course of current treatment.</li>
</ul></li>
<li>A
<ul>
<li>Impression
<ul>
<li><ol style="list-style-type: decimal">
<li>Recurrent pulmonary embolism, favor cancer related</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Pancrease Adenocarcinoma, ypStage IIB, ypT3N1 cM0, Dx in Dec 2019,
s/p pre-op neoadjuvant C/T wt FOLFIRINOX IV Q2W x 4 finishing in March
2020 &amp; s/p pancreatico-duodenectomy on 4/8 20 &amp; post-Op adjuvant
CCRT wt 5-FU 24 hr QD x 5 per wk x 6 plus R/T from 6/8 20 to 7/4 20
&amp; s/p post-Op adjuvant C/T wt FOLFIRINOX IV Q2W x 8 from July 2020
to Jan 2021 &amp; palliative C/T Abraxane 100mg / m2 + Gem 900mg/m2 D1
&amp; 8 Q3W x 13 since 2021.02 to May 2022. Suspected recurrent with
liver and LLL meta and Some LNS at retroperitoneum with SMV encasement.
(abdominal 20200310 amd 20200607 CT), apply 3rd lines palliative
chemotherapy with Onivyde (80mg/m2, give 120mg, IVF Q2W x 6) plus
HDFL.</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>Thanks for your consultation. We will see the patient and discuss
with further treatment.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Treat pulmonary embolism as your expertise. May consider check other
etiology of hypercoagulation although we favor cancer related</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-14 Cardiology
<ul>
<li>Q
<ul>
<li>dyspnea on exertion for 3 days, desaturation was found yesterday at
home</li>
<li>no chest pain, no odynophagia, no GI symptoms, no skin rash, no
dysuria</li>
<li>Went hema opd today for chemotherapy f/u, transferred to covid-19
opd for suspected covid-19</li>
<li>20220607 CT Pancreatic head cancer s/p operation. Partial thrombosis
of IVC; General subcutaneous edema. Small amount ascites. Bil. pleural
effusions. Small patchy densities (0.5cm, 0.6cm) at LLL. A poor
enhancing nodule (2.3cm) at S6 of liver. Some LNS at retroperitoneum
with SMV encasement.</li>
<li>PHx: pancreatic cancer, HTN, pulmonary embolism</li>
<li>NKDA</li>
<li>2022-02-11
<ul>
<li>1: Acute pulmonary embolism, bilateral</li>
<li>2: Acute respiratory failure with hypoxia</li>
<li>3: Inferior vena cava thrombus with pulmonary embolism and bialteral
upper lobe patch.</li>
<li>4: Circumferential venous thrombosis at right ostial to proximal
Superficial femoral vein. with adequate recanalization</li>
<li>5: pancreatic cancer of adenocarcinoma , ypStage IIB, ypT3N1 cM0
post operation and concurrent chemoradiotherapy</li>
<li>6: Pneumonia, bilateral lung by sputum culture grewed mix flora</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>Lab Hb 10.2, WBC 6660, PLT 191k, Cre 0.90, K 4.2, ALT 23, CRP 1.97,
NTproBNP 5397, hsTnI 131.5, CKMB 1.6, INR 1.68, Ddimer 7534</li>
<li>CXR 20220614 borderline heart size</li>
</ul></li>
<li>Impression
<ul>
<li>Pulmonary embolism, bilateral, noted since 2022/02, –&gt; still
residual thrombi</li>
<li>Pancreatic head cancer, IVC thrombosis</li>
<li>Ascites, increasing than before (by CT images comparision)</li>
<li>right lower limb DVT in 2022/02</li>
</ul></li>
<li>Suggestion
<ul>
<li><ol style="list-style-type: decimal">
<li>Keep NOAC as OPD Or give clexane 1mg/kg sc Q12h</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>If unstable hemodynamic status or desaturation is concerned, May
book ICU care.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Pulmonary embolism treatment effect is related to underlying cancer
status</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-29 Dermatology
<ul>
<li>Q
<ul>
<li>Under the impression of left leg cellulitis. She was admitted to
Infection’s ward for further evaluation and treatment on 20220326. For
bilateral leg scaly and vesicle lesions, we need ypur expertsie on
evaluation or some suggestion. Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from some erytheamtous papules on bil legs for
days.</li>
<li>Imp: Pigmented purpuric dermatosus</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Sinpharderm * 1 tube/bid</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Topsym cream * 3 tubes/bid</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-10 Cardiology
<ul>
<li>A
<ul>
<li>I was consulted for pulmonary embolism</li>
<li>O
<ul>
<li>CT scan documented</li>
<li>Cr 0.8</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>ICU admission</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Clexan 1mg/kg Q12H SC if no contraindication</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-10 Gastroenterology
<ul>
<li>A case of pancreatic cancer who request post-op nutrition support.
<ul>
<li>General appearance: ill looking</li>
<li>GI tract: Whipple on 20220408</li>
<li>Feeding: Sip water with NG decompression</li>
<li>Allergy: NKA</li>
<li>Past history: DM</li>
<li>Nutrition assessment:
<ul>
<li>BH 148cm BW 55.6kg</li>
<li>IBW 48.2kg 115% IBW, BMI 25.4, ABW 50kg</li>
<li>BEE (based on ABW) 1070kcal, TEE 1670kcal</li>
</ul></li>
<li>Lab data: GOT 160, GPT 232, K 3.5<br />
</li>
<li>20220409 Blood sugar: 408-310-262-218-204</li>
</ul></li>
<li>According to the patient’s present conditions, parenteral nutrition
will be suitable for nutrition supply. We will follow this case for
adjustment of optimal nutrition support.</li>
<li>PN use suggestion
<ul>
<li>DC YF5 1000ml QD （RI 10U each bottle）</li>
<li>DC SMOFkabiven peri 1440ml QD</li>
<li>SMOFkabiven central 1477ml QD, 61.5ml/hr</li>
<li>Lyo-Povigent 4ml/QD（add in TPN）</li>
<li>Addaven 10ml/QD（add in TPN）</li>
<li>RI 26U/QD（add in TPN）</li>
<li>KCL 5ml/QD（add in TPN）</li>
</ul></li>
<li>Items to be monitored when in PN use
<ul>
<li><ol style="list-style-type: decimal">
<li>Do not mix other drugs with TPN</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Check BW QW5 and record I/O Q8H</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Check one touch Q6H*2days, if stable QD check</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Please control BS &lt;200 mg/dl with RI sliding scale</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>QW1 check CBC/DC</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>QW1 check BUN. Cr. AST. ALT. T/D Bil. TG. ALP. rGT. Na. K. Cl. Ca.
P. Mg. Zinc. Alb. Prealbumin or Transferrin</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>if TPN is not sufficient, use YF5 or D10W</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-30 - nal-paclitaxel 125mg/m2 180mg 0.5hr + gemcitabine
1000mg/m2 1300mg 0.5hr</li>
<li>2022-05-10 - nal-paclitaxel 125mg/m2 180mg 0.5hr + gemcitabine
1000mg/m2 1300mg 0.5hr</li>
<li>2022-04-26 - nal-paclitaxel 125mg/m2 180mg 0.5hr + gemcitabine
1000mg/m2 1300mg 0.5hr</li>
<li>2022-04-12 - nal-paclitaxel 125mg/m2 180mg 0.5hr + gemcitabine
1000mg/m2 1300mg 0.5hr</li>
<li>2022-03-22 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1300mg 0.5hr</li>
<li>2022-01-18 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2022-01-04 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-12-21 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-12-07 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-11-23 - nal-paclitaxel 125mg/m2 160mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-10-19 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-10-12 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-09-14 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-09-07 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-08-24 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-08-17 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-08-03 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-07-20 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-05-18 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-05-11 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1250mg/m2 1700mg 0.5hr</li>
<li>2021-04-27 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-04-20 - nal-paclitaxel 125mg/m2 170mg 0.5hr + gemcitabine
1000mg/m2 1400mg 0.5hr</li>
<li>2021-04-06 - nal-paclitaxel 100mg/m2 140mg 0.5hr + gemcitabine
900mg/m2 1200mg 0.5hr</li>
<li>2021-03-30 - nal-paclitaxel 100mg/m2 140mg 0.5hr + gemcitabine
900mg/m2 1200mg 0.5hr</li>
<li>2021-03-16 - nal-paclitaxel 100mg/m2 140mg 0.5hr + gemcitabine
900mg/m2 1200mg 0.5hr</li>
<li>2021-02-23 - nal-paclitaxel 100mg/m2 140mg 0.5hr + gemcitabine
900mg/m2 1200mg 0.5hr</li>
<li>2021-01-08 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3950mg 46hr</li>
<li>2020-12-18 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3900mg 46hr</li>
<li>2020-11-24 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3900mg 46hr</li>
<li>2020-10-30 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3920mg 46hr</li>
<li>2020-10-08 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3920mg 46hr</li>
<li>2020-09-18 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 550mg 2hr + fluorouracil 2800mg/m2
3870mg 46hr</li>
<li>2020-08-24 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 570mg 2hr + fluorouracil 2800mg/m2
4000mg 46hr</li>
<li>2020-07-29 - oxaliplatin 40mg/m2 50mg 2hr + irinotecan 150mg/m2
200mg 90min + leucovorin 400mg/m2 570mg 2hr + fluorouracil 2800mg/m2
4000mg 46hr</li>
<li>2020-06-29 - fluorouracil 225mg/m2 320mg D1-5 (CCRT)</li>
<li>2020-06-26 - fluorouracil 225mg/m2 320mg D1 (CCRT)</li>
<li>2020-06-22 - fluorouracil 225mg/m2 320mg D1-3 (CCRT)</li>
<li>2020-06-15 - fluorouracil 225mg/m2 320mg D1-5 (CCRT)</li>
<li>2020-06-08 - fluorouracil 225mg/m2 320mg D1-5 (CCRT)</li>
<li>2020-03-09 - oxaliplatin 60mg/m2 90mg 2hr + leucovorin 400mg/m2
600mg + irinotecan 90mg/m2 100mg 2hr + fluorouracial 1200mg/m2 3400mg
46hr</li>
<li>2020-02-18 - oxaliplatin 60mg/m2 90mg 2hr + leucovorin 400mg/m2
600mg + irinotecan 90mg/m2 100mg 2hr + fluorouracial 1200mg/m2 3400mg
46hr</li>
<li>2020-02-04 - oxaliplatin 60mg/m2 90mg 2hr + leucovorin 400mg/m2
600mg + irinotecan 90mg/m2 100mg 2hr + fluorouracial 1200mg/m2 3400mg
46hr</li>
<li>2020-01-07 - oxaliplatin 60mg/m2 90mg 2hr + leucovorin 400mg/m2
600mg + irinotecan 90mg/m2 100mg 2hr + fluorouracial 1200mg/m2 3600mg
46hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Ceftriaxone for this CrCl &gt;15 mL/min patient, no dosage
adjustment is necessary.</li>
<li>In patients (with community-acquired pneumonia in the absence of
neutropenia and immunosuppressive therapy) requiring hospital admission,
monotherapy with a respiratory fluoroquinolone or combination therapy
with a macrolide plus either ceftriaxone, cefotaxime, or ertapenem is
recommended.</li>
<li>2022-08-01 eGFR 31.79.
<ul>
<li>For patients with eGFR 30 to 50 mL/minute/1.73 m2, spironolactone is
recommended to be initialized at 12.5 mg once daily or every other day;
may double the dose every 4 weeks if serum potassium remains &lt;5 mEq/L
and renal function is stable, up to a maximum target dose of 25
mg/day.</li>
</ul></li>
<li>2022-08-01 Creatinine 1.67 mg/dL. The following oral tranexamic acid
adjustments are based on a usual recommended dose of 10 to 15 mg/kg or 1
to 1.5 g 3 to 4 times daily.
<ul>
<li>Serum creatinine &gt;=1.4 to &lt;2.8 mg/dL (&gt;=120 to &lt;250
micromol/L): Administer usual dose twice daily.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-464" class="section level1">
<h1>701432312</h1>
<div id="section-465" class="section level2">
<h2>220801</h2>
<p>{lung adenocarcinoma and esophageal adenocarcinoma}</p>
<p>[Past History]</p>
<ul>
<li>past history
<ul>
<li>C5/6 disc herniation s/p OP on 2021/10/21 and TIA in 2022/03</li>
<li>LLL adenocarcinoma s/p VATS segmentectomy on 2022/06/21</li>
<li>DM(+) in 2021/05
<ul>
<li>Galvus Met 50mg &amp; 500mg 1# po QD</li>
</ul></li>
<li>HTN(+) in 2010
<ul>
<li>Pravafen 40mg &amp; 160mg 1# po QN</li>
<li>Exforge F.C 5mg &amp; 160mg 1# po QD</li>
<li>Bokey 1# po QD</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-07-15 Anti-HBc Reactive<br />
</li>
<li>2022-07-15 Anti-HBc-Value 2.41 S/CO</li>
<li>2022-07-15 Anti-HBs 5.12 mIU/mL<br />
</li>
<li>2022-07-15 HBsAg Nonreactive<br />
</li>
<li>2022-07-15 HBsAg Value 0.00 IU/mL<br />
</li>
<li>2022-07-15 Anti-HCV Nonreactive<br />
</li>
<li>2022-07-15 Anti-HCV Value 0.09 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-21 CT - lung
<ul>
<li>LLL cacner, cT2bN1M1a, stage IVA</li>
<li>Esophagus (Lower 1/3), cT3N3M0, stage IVA.</li>
</ul></li>
<li>2022-06-10 Pathology
<ul>
<li>esophagus endoscopic biopsy — adenocarcinoma, poorly differentiated,
primary or secondary,</li>
<li>the esophagus lower third, endoscopic biopsy showed metastatic
adenocarcinoma, poorly differentiated, suspicious for gastric or
intestinal origin.</li>
</ul></li>
<li>2022-05-31 Whole body PET scan
<ul>
<li>LLL tumor and lower esophageal tumor.</li>
</ul></li>
<li>2022-05-24 Whole body bone scan
<ul>
<li>no bone metastasis.</li>
</ul></li>
<li>2022-05-23 CT - brain
<ul>
<li>no brain metastasis.</li>
</ul></li>
<li>2022-05-19 Pathology
<ul>
<li>LLL tumor CT Guide biopsy — adenocarcinoma, poorly differentiated,
lung origin.</li>
</ul></li>
<li>2022-05 CT at DaLin TzuChi Hospital
<ul>
<li>a distal esophageal tumor and another LLL lung tumor</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-21 VATS LLL S10 segmentectomy + mediastinum lymph node
dissection
<ul>
<li>pathology showed Adenosquamous carcinoma, poorly differentiated,
pT2aN2</li>
<li>ICH stains showed CDX2 (EPR2764Y/Zeta, 100X), TTF-1 (SPT24/Leica,
250X), P40 (polyclonal/Zytomed, 100X).</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-07-21 ~
<ul>
<li>Plan to deliver 4500 cGy/ 25 fx to the L/2 esophagus and adjacent
lymphatic drainage area.</li>
<li>Then boost the esophageal tumor and celiac LAPs to 5040 cGy/ 28
fx.</li>
<li>The preOP (lung ca.) tumor bed: around 5600 cGy/ 28 fx.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-07-26 - paclitaxel 50mg/m2 80mg 3hr D1 + carboplatin AUC2 150mg
2hr D2</li>
<li>2022-07 plan
<ul>
<li>adjuvant therapy for lung ca.</li>
<li>neo-adjuvant therapy for eso. ca</li>
</ul></li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>HBV ref: <a href="https://cdn.who.int/media/docs/default-source/searo/hiv-hepatitis/training-modules/08-hbv-serological-markers.pdf" class="uri">https://cdn.who.int/media/docs/default-source/searo/hiv-hepatitis/training-modules/08-hbv-serological-markers.pdf</a>
<ul>
<li>HBV serological markers
<ul>
<li>HBsAg (hepatitis B surface antigen)
<ul>
<li>Hallmark of infection</li>
<li>Positive in the early phase of acute infection and persists in
chronic infection</li>
<li>Quantification of HBsAg is a potential alternative marker of
viraemia and it is also used to monitor the response to antiviral
treatment</li>
</ul></li>
<li>Anti-HBc IgM (hepatitis B core antibody)
<ul>
<li>IgM subclass of anti-HBc and observed during acute infection (used
to differentiate between acute and chronic HBV infection)</li>
<li>Might become positive during severe exacerbation of chronic
infection</li>
</ul></li>
<li>Anti-HBc (total)
<ul>
<li>Develops around 3 months after infection (most constant marker of
infection)</li>
<li>Total anti-HBc (IgM, IgA and IgG) indicates resolved infection</li>
</ul></li>
<li>HBeAg (hepatitis B e antigen)
<ul>
<li>Viral protein usually associated with high viral load and high
infectivity</li>
</ul></li>
<li>Anti-HBe (hepatitis B e antibody)
<ul>
<li>Antibody to HBeAg usually indicates decreasing HBV DNA</li>
<li>But present in the immune-control and immune-escape phases</li>
</ul></li>
<li>Anti-HBs (hepatitis B surface antibody)
<ul>
<li>Neutralizing antibody that confers protection from infection</li>
<li>Recovery from acute infection (with anti-HBc IgG)</li>
<li>Immunity from vaccination</li>
</ul></li>
</ul></li>
<li>Hepatitis B surface antigen and antibody
<ul>
<li>HBsAg
<ul>
<li>First marker to appear following HBV infection</li>
<li>Positivity indicates presence of virus in a person’s body</li>
<li>Acute infection: Disappears within 6 months</li>
<li>Chronic infection: Persists for several years (lifelong in
most)</li>
<li>Measurement of HBsAg concentration is being tried as a potential
alternative marker of viremia and to monitor response to treatment, but
still not well accepted</li>
</ul></li>
<li>Anti-HBs
<ul>
<li>Antibody to HBsAg</li>
<li>Is a neutralizing antibody and confers protection from
infection</li>
<li>Appears following clearance of acute infection</li>
<li>Does not develop in those who have chronic infection</li>
<li>Also develops in response to hepatitis B vaccine</li>
<li>Presence indicates immunity following acute infection or
vaccination</li>
<li>Anti-HBs titre &gt;10 mIU/mL is considered to be protective</li>
<li>Persists for several years (often lifelong) after infection, but
disappears in a few years after immunization</li>
</ul></li>
</ul></li>
<li>Hepatitis B core antigen and antibody
<ul>
<li>HBcAg
<ul>
<li>An internal component of the virus</li>
<li>Present in the nucleus of infected cells</li>
<li>But, does not appears in infected person’s blood</li>
<li>Not tested in clinical settings</li>
<li>Hepatitis B vaccine does not contain this antigen</li>
</ul></li>
<li>Anti-HBc
<ul>
<li>Develops in all those who get HBV infection, whether acute or
chronic</li>
<li>Does not develop after immunization</li>
<li>Two types IgM and IgG</li>
</ul></li>
<li>IgM anti-HBc
<ul>
<li>Appears following acute infection, and persists for up to ~6
months</li>
<li>Hence: presence indicates recent (acute) infection</li>
<li>Occasionally, detectable (in low amount) during severe exacerbation
of chronic infection</li>
</ul></li>
<li>IgG (or Total) anti-HBc
<ul>
<li>Develops soon after IgM anti-HBc</li>
<li>Most constant marker of exposure (current or past infection)</li>
<li>Positive total anti-HBc (IgG, IgM) with negative IgM anti-HBc in
HBsAg negative indicates resolved infection</li>
</ul></li>
</ul></li>
<li>Hepatitis B e-antigen and antibody
<ul>
<li>HBeAg
<ul>
<li>Produced in cells where virus is actively replicating, and is
secreted into the plasma</li>
<li>Usually its presence indicates high viral load and high
infectivity</li>
<li>Its absence indicates lower viral load, lower HBV DNA level. But, in
some, may be absent despite high viral load (due to viral mutation)</li>
<li>Associated with high risk of HBV transmission following exposure,
such as needle-stick injury, mother-to-child transmission, etc</li>
</ul></li>
<li>Anti-HBe
<ul>
<li>Indicates host immune response against HBeAg</li>
<li>Usually associated with reduced viral replication, lower HBV DNA
titer and reduced infectivity</li>
<li>But also present in those in HBeAg-negative viral mutation</li>
</ul></li>
<li>HBV DNA
<ul>
<li>Direct and accurate marker of HBV replication</li>
<li>Serum level seems to correlate with the risk of disease
progression</li>
<li>Used to decide need for anti-viral drugs</li>
<li>Also used to monitor efficacy of anti-viral drug treatment</li>
<li>Unit: almost 5 copies = 1 IU</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Double malignancies: 1) LLL adenocarcinoma s/p VATS LLL S10
segmentectomy and mediastinum lymph node dissection on 2022-06-21; 2)
Esophageal (lower 1/3) adenocarcinoma.</li>
<li>Documented treatment plan: adjuvant therapy for lung ca. and
neo-adjuvant therapy for eso. ca.</li>
<li>Carboplatin and paclitaxel are drugs that can be used in regimens
for both lung cancer and esophageal cancer. NCCN guidelines describe
regimens containing these two drugs:
<ul>
<li>For NSCLC: carboplatin AUC 6 day 1, paclitaxel 200mg/m2 day 1, every
21 days for 4 cycles.</li>
<li>For Eso ca: carboplatin AUC 2 day 1, paclitaxel 50mg/m2 day 1,
weekly for 5 weeks.</li>
</ul></li>
<li>The latter (lower doses with higher frequency administration) is
initialized on 2022-07-26.</li>
<li>Underlying conditions including T2DM and HTN.
<ul>
<li>There is good control of blood sugar levels during this
hospitalization.</li>
<li>A number of data points between 2022-07-29 and 2022-07-31 showed
hypotension events (SBP &lt; 100, DBP &lt; 60). If the hypotension
occurs again, please hold Exforge (amlodipine + valsartan)
temporarily.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-466" class="section level1">
<h1>701341214</h1>
<div id="section-467" class="section level2">
<h2>220729</h2>
<p>{prevent the patient from potential drug interaction: Dasatinib /
Inhibitors of the Proton Pump (PPIs and PCABs)}</p>
<ul>
<li>Pantoprazole (PPI) might decrease the serum concentration and
efficacy of dasatinib (both drugs were prescribed as QD administratered
and the latter is listed as an self-carried item in active
prescription).</li>
<li>It is recommended not to administer proton pump inhibitors (PPIs) or
potassium-competitive acid blockers (PCABs) with dasatinib.
Coadministration of these agents and dasatinib might reduce dasatinib
concentrations and efficacy.</li>
<li>Please consider antacids taken 2 hours before or after dasatinib
administration if acid-reducing therapy is needed. As an example, shift
dasatinib from QD to QN.</li>
</ul>
</div>
</div>
<div id="section-468" class="section level1">
<h1>700370302</h1>
<div id="section-469" class="section level2">
<h2>220727</h2>
<ul>
<li>Thrombocytopenia is treated with eltrombopag.</li>
</ul>
</div>
</div>
<div id="section-470" class="section level1">
<h1>701433496</h1>
<div id="section-471" class="section level2">
<h2>220727</h2>
<ul>
<li>exam findings
<ul>
<li>2022-07-22 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Prominence of bilateral hilar shadows are noted, which may be
engorged central pulmonary vessels or adenopathy, please correlate
clinically and follow-up.</li>
<li>Hypoinflation of both lung is noted.</li>
</ul></li>
<li>2022-07-18 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Prominence of bilateral hilar shadows are noted, which may be
engorged central pulmonary vessels or adenopathy, please correlate
clinically and follow-up.</li>
<li>Hypoinflation of both lung is noted.</li>
<li>A nodular opacity projecting in the left upper lung is suspected.
Follow up is indicated. Otherwise, Please correlate with CT.</li>
</ul></li>
<li>2022-07-21 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Hepatic tumors, multiple, bilateral lobe, suspected metastasis</li>
<li>Gall stones</li>
<li>Splenic cysts</li>
<li>Small amount ascites</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study</li>
</ul></li>
</ul></li>
<li>2022-07-18 Patho - colon biopsy
<ul>
<li>DIAGNOSIS:
<ul>
<li>Colon, SD junction, biopsy — Adenocarcinoma, moderately
differentiated<br />
</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>The immunohistochemical stains reveal EGFR(+), PMS2(+), MLH1(+),
MSH2(+), and MSH6(+).</li>
</ul></li>
</ul></li>
<li>2022-07-18 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Probable colon cancer with partial obstruction, 35cm AAV, probable
at SD junction, s/p biopsy</li>
<li>Incomplete study, poor colon preparation.</li>
</ul></li>
<li>Suggestion
<ul>
<li>F/U pathology report</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-07-15 ECG
<ul>
<li>Sinus tachycardia with Premature supraventricular complexes</li>
<li>Low voltage QRS</li>
<li>Borderline ECG</li>
</ul></li>
<li>2022-04-27 CT (Cardinal Tien Hospital)
<ul>
<li><ol style="list-style-type: decimal">
<li>consider sigmoid colon malignancy, involving length is approximately
6.2cm, imaging staging favored T4bN1bM1b if pathological proven
malignancy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Multiple hepatic and splenic tumors, like metastases.</li>
</ol></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-20 Colorectal Surgery
<ul>
<li>Q
<ul>
<li>This 88 y/o female has history of DM, HTN under medical control and
suspect colon cancer with liver metastases associated chronic diarrhea
for one month under symptom control. This time, according to the
families, the patient was found with fever and chillness for one day, so
she was sent to our ER for help on 20220712, vital signs showed
BP:121/57; PR:107; BT:38.5; RR:19; EKG showed Sinus rhythm with
Premature atrial complexes; PE showed unremarkable. Lab showed Covid-19
rapid screen: positive, WBC:14.92, Neutrophil:81.7%, CRP:7.9, Lactic
acid:3.1, hs-TnI:114.2, Hb:6.5, MCV:70fL, RDW-CV:22.3%, Na:133, K:2.7,
BUN/Cr:19/1.01, U/A with bacteria:1+ but without pyuria; CXR showed both
lower lobes infiltration.</li>
<li>So, under impression of 1.) Sepsis, favor Covid-19 infection with
secondary bacterial pneumonia; 2.) suspect colon cancer with liver
metastases for one month; 3.) Severe microcytic Anemia, she is admitted
to our isolation ward for further care on 20220712. - After admission,
empirical antibiotic with Brosym, steroid agent with Decan injection
were given for pneumonia treatment since 20220712. Urine culture showed
mixed growth. Pending one set of blood culture and sputum culture.
Antivirus agent with Remdesivir injection since 7/13-7/17 for treatment.
We consulted Hospice for colon cancer terminal on 7/13. We consulted
Oncologist for colon cancer terminal survey on 7/15. DNR was signed on
7/15. She is transfer to Oncologist ward for survey on 20220715.</li>
<li>At ONC ward, we had explained the current condition to family (third
daughter-in-law).</li>
<li>CT of abdominal was performed on 20220427 at Cardinal Tien Hospital
revealed 1) consider sigmoid colon malignancy, involving length is
approximately 6.2cm, imaging staging favored T4bN1bM1b if pathological
proven malignancy. 2) Multiple hepatic and splenic tumors, like
metastases.</li>
<li>Colonscopy was arrange on 20220718 showed A huge ulcerative tumor
with partial obstruction of the colon was noted at 35cm AAV, probable at
SD junction, s/p biopsy. We need your expertise for evaluation,
thanks.</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>Abdomen: soft, mild distended, no tenderness, no peritoneal
sings</li>
<li>pass flatus(+)</li>
<li>diarrhea(+)</li>
<li>SOB(+)</li>
</ul></li>
<li>A: S-colon cancer with multiple metastases of liver and spleen,
stage IVb (incurable)</li>
<li>P:
<ul>
<li><ol style="list-style-type: decimal">
<li>Diverting colostomy (under general anesthesia) may be considered if
total obstruction symptoms/signs developing</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Surgical and anesthesia risk is very high due to very old age and
terminal cancer stage and comorbidities</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>We had discussed her disease condition to her family and she can
understand</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Suggest hospice and palliative treatment</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-07-15 Hemato-Oncology
<ul>
<li>A
<ul>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Suspect colon cancer? AAD (Against Advise Discharge) from Cardinal
Tien Hospital</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>DM, HTN under medical control</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>We had phone call her daughter-in-law and discuss with further care.
They agree arrange colonscopy for tissue proof (for apply IC Cards for
Severe Illness) after transfer to ordinary ward.</li>
</ol>
<ul>
<li>In addition, Daughter-in-law agreed to go to Cardinal Tien Hospital
to apply for medical records and image CD after transfer to ordinary
ward.</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Thanks for your consultation.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Nasogastric tubes can be used to administer all oral medications in
active prescriptions.</li>
<li>The patient has applied for hospice care.</li>
<li>F/S recorded low blood sugar levels
<ul>
<li>2022-07-26 06:19 56 mg/dL</li>
<li>2022-07-26 06:18 60 mg/dL</li>
<li>2022-07-21 06:24 50 mg/dL</li>
</ul></li>
<li>A hypoglycemic event is more likely to occur in the early morning,
and it should be observed if there is a difference in carbohydrate
intake or consumption from the night before to the next day.</li>
</ul>
</div>
</div>
<div id="section-472" class="section level1">
<h1>700301518</h1>
<div id="section-473" class="section level2">
<h2>220726</h2>
<ul>
<li>diagnosis
<ul>
<li>67 y/o male, a pt of NSCLC at LLL wt lung to lung mets &amp; liver,
&amp; adrenal mets &amp; L neck LNs mets Dx in Dec 2021.</li>
<li>suffered from initial presentation of L neck LN enlargement at level
II &amp; III since Oct 2021.</li>
<li>This is a 67 year old man who has the history of liver cirrhosis,
acute cholecystitis s/p cholecystectomy, old CVA with right hemiparesis,
and non-small-cell lung cancer at left lower lung with lung to lung mets
&amp; liver, &amp; adrenal mets &amp; L neck LNs mets Dx in Dec
2021</li>
</ul></li>
<li>lab data
<ul>
<li>2022-01-10 PD-L1 Immunostaining Result (28-8)
<ul>
<li>Labeled as: S21-18526</li>
<li>Tumor type: Head and neck cancer, squamous cell carcinoma</li>
<li>Tumor cell (TC) staining assessment: TC &gt;= 50%</li>
<li>Percentage of 28-8 expressing tumor cells (%TC): 65%</li>
</ul></li>
<li>2021-12-30 PD-L1 Immunostaining Result (22C3)
<ul>
<li>Labeled as: S2021-18526</li>
<li>Tumor Proportion Score (TPS) assessment: TPS &gt;= 50%</li>
<li>Tumor Proportion Score (TPS): 55%</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-07-25 CXR
<ul>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Multiple nodules at bil. lungs.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Atherosclerosis of the aorta.</li>
<li>S/P operation with retention of surgical clips.</li>
<li>Old frcture of bil. ribs.</li>
<li>Suggest clinical correlation.</li>
</ul></li>
<li>2022-07-04 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Lungs:
<ul>
<li>significant inecrease in size of LLL anteromedial basal tumor (71mm
in longest axial dimension) and increase in size and number of multiple
nodules of variable sizes in both lungs as compared with CT on
2022/03/28</li>
<li>centrilobular emphysema in both upper lobes</li>
</ul></li>
<li>Mediastinum and hila: enlarged LN at Rt paratracheal space, and
subcarina
<ul>
<li>Vessels: moderate coronary arterial calcification</li>
<li>Aorta: normal caliber, extensive atherosclerotic change of aortic
arch and descending thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber. .</li>
<li>Heart: normal in size of cardiac chambers.</li>
</ul></li>
<li>Pleura: minimal effusion.</li>
<li>Chest wall and visible lower neck: progression of enlarged left neck
LAPs, level II-III-IV compared with CT on 2022/03/28</li>
<li>Visible abdominal contents: s/p cholecystectomy. pneumobilia in left
lobe liver and increase in size and numbers of ill-defined heterogeneous
tumors in liver and Rt adrenal tumor compared with CT on 2022/03/28.
<ul>
<li>unremarkable of the pancreas, and kidneys. bile ducts: dilatation of
CBD and CHD. mild splenomegaly.</li>
<li>no enlarged lymph node.</li>
</ul></li>
<li>Extensive atherosclerotic change of the abdominal aorta.</li>
<li>Visualized bones: extensive spondylosis.old fracture of many Lt ribs
and Rt and Lt clavicles.</li>
</ul></li>
<li>Impression:
<ul>
<li>LLL cancer T4N3M1c, in progression as compared with previous CT
study on 2022/03/28</li>
</ul></li>
</ul></li>
<li>2022-07-04 CXR + Lat. LT
<ul>
<li>S/P port-A implantation.</li>
<li>Primary lung cancer in LLL become smaller in size.</li>
<li>Few nodular opacity projecting in the left lower lung are noted.
Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Old fracture of bilateral clavicle and left ribs.</li>
<li>Spondylosis of the T-spine</li>
</ul></li>
<li>2022-06-06 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>poor echo window: please see discription</li>
<li>Liver tumor: (suspected HCC?)</li>
<li>Liver cirrhosis (incomplete exam of liver), splenomegaly</li>
<li>GB sac not seen</li>
<li>pancreas not shown</li>
</ul></li>
<li>Suggestion
<ul>
<li>suggest further imaging study</li>
</ul></li>
</ul></li>
<li>2022-05-03 KUB
<ul>
<li>s/p cholecystectomy</li>
<li>Unremarkable psoas shadows</li>
<li>Degenerative change of the lumbar spine</li>
<li>s/p right total hip replacement</li>
</ul></li>
<li>2022-05-03 CXR
<ul>
<li>Mass lesions in both lung fields</li>
<li>Bilateral clavicle and rib old fractures</li>
</ul></li>
<li>2022-05-03 ECG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2022-05-03 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>No active bleeder nor coffee ground material was noted during this
exam.</li>
<li>Suboptimal study due to food residual retention</li>
<li>Reflux esophagitis LA Classification grade A (minimal)</li>
<li>Superficial gastritis</li>
</ul></li>
<li>Suggestion
<ul>
<li>2nd look endoscopy is warranted if active bleeding sign or persisted
tarry stool.</li>
</ul></li>
</ul></li>
<li>2022-03-28 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>Lungs:</li>
</ol>
<ul>
<li>decrease in size of LLL anteromedial basal tumor (33 mm in longest
axial dimension) and multiple nodules of variable sizes in both lungs,
and resolution of LLL GGO as compared with CT on 2021/12/06.</li>
<li>centrilobular emphysema in both upper lobes</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mediastinum: regression of enlarged LN at Rt paratracheal
space.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hila: no enlarged LN.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Vessels: moderate coronary arterial calcification Aorta: normal
caliber, extensive atherosclerotic change of aortic arch and descending
thoracic aorta. Central pulmonary arteries: normal caliber.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Heart: normal in size of cardiac chambers.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pleura: no effusion.</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Chest wall and visible lower neck: regression of enlarged left neck
LAPs, level II-III-IV.</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Visible abdominal contents: s/p cholecystectomy. pneumobilia in left
lobe liver and increase in size an ill-defined heterogeneous tumor in S6
(76x85 mm) and stationary of a 16 mm Rt adrenal tumor. unremarkable of
the spleen, pancreas, and kidneys. bile ducts: dilatation of CBD and
CHDno enlarged lymph node.</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Extensive atherosclerotic change of the abdominal aorta.</li>
</ol></li>
<li><ol start="10" style="list-style-type: decimal">
<li>Visualized bones: extensive spondylosis.old fracture of many Lt ribs
and Rt and Lt clavicles.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li>LLL cancer T4N3M1c, regression of primary LLL tumor and metastatiuc
lung tumors, stationary of Rt adrenal tumor, and metastatic LAP at
mediastinum and neck, but increase in size ofmetastatic hepatic tumor as
compared with previous CT study on 2021/12/06</li>
</ul></li>
</ul></li>
<li>2022-03-14 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>poor echo window: please see discription</li>
<li>Liver tumor: (suspected HCC?)</li>
<li>Liver cirrhosis (incomplete exam of liver), mild splenomegaly</li>
<li>GB sac not seen</li>
</ul></li>
<li>Suggestion
<ul>
<li>suggest further imaging study</li>
</ul></li>
</ul></li>
<li>2021-12-24 PD-L1 (SP142)
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana)
<ul>
<li>S2021-19387
<ul>
<li>Tumor type: squamous cell carcinoma<br />
</li>
<li>Tumor location: soft tissue, right neck<br />
</li>
<li>Testing assay: SP142 Assay (Ventana)<br />
</li>
<li>Testing platform: BenchMark XT<br />
</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit<br />
Control slide result: Pass,<br />
Adequate tumor cells present (&gt;=50 viable tumor cells): Yes,<br />
</li>
</ul></li>
<li>Result:
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>Tumor cell (TC) staining assessment:<br />
</li>
</ol>
<ul>
<li><ol style="list-style-type: decimal">
<li>TC category: TC &lt; 1%<br />
</li>
</ol></li>
</ul></li>
<li><ol start="2" style="list-style-type: upper-alpha">
<li>Tumor-infiltrating immune cell (IC) staining assessment:<br />
</li>
</ol>
<ul>
<li><ol style="list-style-type: decimal">
<li>IC category: IC &lt; 1%<br />
</li>
</ol></li>
</ul></li>
</ul></li>
<li>Note:
<ul>
<li><ol style="list-style-type: decimal">
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.<br />
</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-13 Patho - lymphnode biopsy
<ul>
<li>DIAGNOSIS:
<ul>
<li>Soft tissue, left neck, sono-guide biopsy — squamous cell carcinoma,
moderately differentiated, origin?<br />
</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>Sections show solid sheets of hyperchromatic tumor cells
infiltrating in a fibrotic stroma. No keratinization is seen.</li>
<li>The immunohistochemical stains reveal p40(+), TTF-1(-), Napsin A(-),
and CD56(-). No lymphoid tissue is seen.</li>
<li>Please correlate with the clinical presentation and image study for
tumor origin.</li>
</ul></li>
</ul></li>
<li>2021-12-07 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>A prominent glucose hypermetabolic lesion in the lower lobe of left
lung. Primary lung malignancy should be considered. Please correlate
with other clinical findings for further evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Glucose hypermetabolism in multiple left neck level II to V lymph
nodes and in the right pulmonary hilar region, compatible with
metastatic lymph nodes.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Glucose hypermetabolism in multiple focal area in bilateral lung
fields, in some focal areas in the liver and in some bones as mentioned
above, suggesting multiple liver, lung and bone metastases.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Mild glucose hypermetabolism in the right adrenal gland. The nature
is to be determined (adrenal hyperplasia or adenoma? other nature?).
Please also correlate with other clinical findings for further
evaluation.</li>
</ol></li>
</ul></li>
<li>2021-12-06 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Lung Carcinoma</li>
<li>Impression (Imaging stage): T:T4(T_value), N:N3(N_value),
M:M1c(M_value), STAGE:IVB</li>
</ul></li>
<li>2021-11-13 CT - neck
<ul>
<li>Multiple enlarged left neck LAPs, level II-III-IV.</li>
<li>Left carotid artery encasement by the LAPs were found.</li>
<li>No obvious nasopharynx, oropharynx, hypopharynx or larynx mass.</li>
</ul></li>
<li>2021-11-01 L-N aspiration
<ul>
<li>DIAGNOSIS:
<ul>
<li>Left neck mass— Carcinoma<br />
</li>
</ul></li>
<li>MICROSCOPIC DESCRIPTION:
<ul>
<li>Smears show cohesive atypical tumor cells with nuclear
hyperchromasia, pleomorphism and high N/C ratio.</li>
</ul></li>
</ul></li>
<li>2021-10-29 SONO - head and neck soft tissue
<ul>
<li>Clinical impression/intent: left multiple neck mass (level 2-4)</li>
<li>Sonographic impression: left multiple neck mass with extra-capusular
extension, suspected metastasis.</li>
</ul></li>
<li>2021-04-05 MRI - MR Cholangiography, MRCP
<ul>
<li>S/P cholecystectomy. A filling defect at distal CBD (1.4cm) with
biliary dilatation suspected stone.</li>
<li>Splenomegaly.</li>
<li>Dilatation of p-duct (5.1mm).</li>
</ul></li>
<li>2021-03-15 CT - abdomen, pelvis
<ul>
<li>S/P cholecystectomy.</li>
<li>Suspected cholangitis and distal CBD stone.</li>
</ul></li>
<li>2021-01-09 Hip joints bilat.
<ul>
<li>S/P right THR without evidenced prothesis loosening.</li>
</ul></li>
<li>2021-01-09 CT - abdomen, pelvis
<ul>
<li>Suspected distal CBD stone (4mm). Mild dilatation of IHD
(intrahepatic duct) suspected cholangitis. Liver cirrhosis with
splenomegaly.</li>
</ul></li>
<li>2021-01-08 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2020-10-05 SONO - neurology
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild (to moderate) atheromatous lesions in R CCA bifurcation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Relatively smaller caliber with decreased flow in R cervical VA
compared with L VA.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Poor bilateral temporal windows for transcranial insonation.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Suspicious mass lesion in left thyroid gland.</li>
</ol></li>
</ul></li>
<li>2019-05-10 Cardiac ultrasound, M-mode Echo, Doppler color flow
mapping
<ul>
<li><ol style="list-style-type: decimal">
<li>Adequate LV systolic function with normal resting wall motion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Septal hypertrophy; LV diastolic dysfunction, Gr 1</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Trivial MR and mild TR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Preserved RV systolic function</li>
</ol></li>
</ul></li>
<li>2019-05-09 Bronchodilator Test, Flow-volume curve
<ul>
<li>Moderate restrictive ventilatory impairment</li>
<li>Not significant bronchodilator reversibility</li>
</ul></li>
<li>2019-05-08 CT - abdomen
<ul>
<li>Distal CBD stone with biliary tree obstruction.</li>
<li>Liver cirrhosis.</li>
</ul></li>
<li>2019-05-08 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>Patent airway is found.</li>
<li>Senile fibrotic change is noted at lung fields.</li>
</ul></li>
<li>2018-05-28 Hip joints RT
<ul>
<li>S/p Total hip replacement over right side.</li>
<li>The alignment of the bony structure after procedure is
satisfactory.</li>
</ul></li>
<li>2018-05-22 MRA - brain
<ul>
<li>Brain atrophy with multiple old lacunar brain infarcts.</li>
<li>Old hemorrhage in left thalamus. Abnormal signal intensity in
bilateral middle cerebellar peduncles, nature to be determined.</li>
</ul></li>
<li>2018-05-21 Color transcranial Doppler, Dopscan, Carotid
phonoangiograph (CPA)
<ul>
<li><ol style="list-style-type: decimal">
<li>Mild to moderate atheromatous lesions in R CCA bifurcation; mild
atheromatous lesions in L CCA bifurcation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Poor bilateraltemporal windows for transcranial insonation.</li>
</ol></li>
</ul></li>
<li>2018-05-16 CT - brain
<ul>
<li>Brain atrophy and old infarcts.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-20 - cisplatin 60mg/m2 1.5hr</li>
<li>2022-05-30 - cisplatin 60mg/m2 1.5hr</li>
<li>2022-05-09 - cisplatin 60mg/m2 1.5hr</li>
<li>2022-04-11 - cisplatin 60mg/m2 1.5hr</li>
<li>2022-03-21 - gemcitabine 1000mg/m2 30min</li>
<li>2022-03-07 - gemcitabine 1000mg/m2 30min + cisplatin 60mg/m2
1.5hr</li>
<li>2022-02-14 - gemcitabine 1000mg/m2 30min</li>
<li>2022-02-07 - gemcitabine 1000mg/m2 30min + cisplatin 60mg/m2
1.5hr</li>
<li>2022-01-17 - gemcitabine 1000mg/m2 30min</li>
<li>2022-01-04 - gemcitabine 1000mg/m2 30min + cisplatin 50mg/m2
1.5hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Lab data 2022-07-26: Procalcitonin (PCT) 1.73ng/mL, CRP
21.88mg/dL</li>
<li>The initial empiric therapy for fever and neutropenia in high-risk
patients could be cefepime, imipenem/cilastatin,
piperacillin/tazobactam, and ceftazidime. The administration of
ceftazidime 2000mg Q8H IVD has been ongoing since 2022-07-26. Results of
blood and urine cultures have not yet been released.</li>
<li>If atypical bacteria are suspected, azithromycin, doxycycline, or
fluoroquinolones might be an optional add-on. The use of fluconazole as
a prophylactic measure might also be considered for anticipated
mucositis.</li>
</ul>
</div>
</div>
<div id="section-474" class="section level1">
<h1>701164228</h1>
<div id="section-475" class="section level2">
<h2>220726</h2>
<ul>
<li>diagnosis
<ul>
<li>1: Endometroid carcinoma, FIGO grade 3, of the uterine endometrium,
AJCC 8 th edition, Pathology stage: pT3aN0(cM0); stage IIIA; FIGO stage
IIIA, s/p staging on 2022-02-07.</li>
<li>2: Right breast Invasive carcinoma post breast conserving therapy,
pT2N1a(sn)M0, stage IIB,</li>
<li>3: Chronic viral hepatitis B without delta-agent</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-22 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, marked</li>
<li>Liver cysts</li>
<li>Chronic kidney disease with renal calcifications</li>
<li>Left renal stone</li>
<li>(suboptimal echo window)</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD follow-up</li>
</ul></li>
</ul></li>
<li>2022-02-08 Patho - uterus (with or without SO) neoplastic
<ul>
<li>Pathologic Diagnosis
<ul>
<li>Uterus, endometrium, ATH — Endometroid carcinoma, FIGO grade 3</li>
<li>Fallopian tube, right, BSO — Involved by carcinoma</li>
<li>Lymph nodes, pelvic and para-aortic, bilateral, BPLND + PALND —
Negative for malignancy (0/39)</li>
<li>AJCC 8 th edition, Pathology stage: pT3aN0; stage IIIA; FIGO stage
IIIA; if cM0</li>
</ul></li>
<li>Macroscopic Examination
<ul>
<li>Procedure: ATH + BSO + omentectomy + BPLND + para-aortic LN
dissection</li>
</ul></li>
<li>Microscopic Examination
<ul>
<li>Histologic Type: Endometroid carcinoma</li>
<li>Histologic Grade: FIGO grade 3</li>
<li>Adenomyosis: Not identified</li>
<li>Depth of Tumor Invasion: Tumor invading more than half of
myometrium</li>
<li>Cervical Stromal Involvement: Not identified</li>
<li>Other Tissue/Organ Involvement: Tumor involving right fallopian
tube</li>
<li>Peritoneal/Ascitic Fluid: Not submitted</li>
<li>Margins: Uninvolved by carcinoma
<ul>
<li>Distance of invasive carcinoma from closest margin: 1.5 cm</li>
</ul></li>
<li>Lymphvascular Invasion: Present</li>
<li>Regional Lymph Nodes: All lymph nodes negative for tumor cells
(0/39)</li>
<li>AdditionalPathologic Findings
<ul>
<li>Cervix: Chronic cervicitis with squamous metaplasia</li>
<li>Myometrium: Leiomyoma</li>
<li>Ovary, right: No remarkable change</li>
<li>Ovary, left: No remarkable change</li>
<li>Fallopian tube, left: Chronic salpingitis</li>
<li>Omentum: No remarkable change</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-08 Cytology - ascites
<ul>
<li>ASCITES: suspicious for malignancy<br />
</li>
<li>Smears show lymphoid cells, and few suspicious cells with
elongated</li>
</ul></li>
<li>2022-01-17 MRI - pelvis
<ul>
<li>suspected endometrial malignancy with lymph nodes metastasis
(paraaortic region).
<ul>
<li>right parametrial soft tissue tumors, parametrial lymph nodes
metastasis or tumor seeding? cstage T3N2M0.</li>
</ul></li>
<li>uterine tumors, suspected myomas.</li>
<li>suspected liver cysts.</li>
</ul></li>
<li>2022-01-06 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, TCR — Endometrioid adenocarcinoma<br />
</li>
<li>Microscopically, sections show endometrioid adenocarcinoma
characterized by proliferation of neoplastic ells arranged in
cribrinform to solid architecture and invasive growth pattern with tumor
necrosis. The tumor shows eosinophilic cytoplasm, nuclear
hyperchromasia, pleomoephism, loss of polarity, prominent nuleoli and
mitoses.<br />
</li>
<li>Immunohistochemical stain reveals p16(patchy positive), p53(wild
type), CK7(+), CK20(-) and vimentin(+).</li>
</ul></li>
<li>2021-12-31 Gynecologic ultrasonography
<ul>
<li>Uterine myoma</li>
<li>Uterine mass: 27x23mm, no blood flow</li>
</ul></li>
<li>2021-11-09 SONO - abdomen
<ul>
<li>Bil. liver cysts (up to 1.0cm).</li>
</ul></li>
<li>2021-11-09 SONO - breast
<ul>
<li>Right fibroadenomas</li>
<li>s/p right breast operation</li>
<li>benign</li>
</ul></li>
<li>2021-05-07 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200316, no prominent
change is noted in the lesions in the lower L-spines. Degenerative spine
diseases may show such a picture.</li>
<li>Increased radiotracer uptake in maxilla and mandible, Dental lesions
may show this picture.</li>
<li>Probably degenerative change in bilateral shoulders,
sternoclavicular junctions, sacroiliac joints, knees, ankles and both
feet.</li>
<li>No prominent bone abnormality was noted elsewhere.</li>
</ul></li>
<li>2021-03-16 Mammography
<ul>
<li>Post-op with breast tissue reduction in right breast.</li>
<li>Benign calcifications in bilateral breasts.</li>
</ul></li>
<li>2021-03-16 SONO - breast
<ul>
<li>Operation scar at right UOQ breast.</li>
<li>Probably right breast fibroadenomas, stationary.</li>
</ul></li>
<li>2021-03-02 Gynecologic ultrasonography
<ul>
<li>uterine myoma</li>
</ul></li>
<li>2020-12-08 SONO - breast
<ul>
<li>Operation scar at right UOQ breast.</li>
<li>Probably right breast fibroadenomas.</li>
</ul></li>
<li>2020-03-18 SONO - breast
<ul>
<li>Breast tissue reduction in right breast, could be due to post-op
change.</li>
<li>Benign calcifications in bilateral breasts.</li>
</ul></li>
<li>2020-03-16 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20190114, the previously
noted faint hot spots in bilateral rib cages had disappeared, indicating
benign in nature.</li>
<li>Mildly and non-focally increased radiotracer uptake in lower
L-spine, degenerative spine diseases may show such a picture.</li>
<li>Increased radiotracer uptake in maxilla and mandible, suggesting
dental lesions.</li>
<li>Probably degenerative change in shoulders, sternoclavicular
junctions, sacroiliac joints, knees, and ankles.</li>
<li>No definite evidence of osteoblastic skeletal metastasis by this
bone scan.</li>
</ul></li>
<li>2019-02-12 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in the right breast. The nature is to
be determined (post-operative inflammation? other nature?). Please
correlate with other clinical findings for further evaluation.</li>
<li>Mild glucose hypermetabolism in bilateral shoulder joints,
compatible with benign joint lesion such as arthritis.</li>
<li>Mildly increased FDG accumulation in the colon. Physiologic FDG
accumulation is more likely.</li>
</ul></li>
<li>2019-01-22 Pathology Level VI
<ul>
<li>Pathologic diagnosis
<ul>
<li>Breast, right, partial mastectomy — Invasive carcinoma of no special
type (90%) with focal mucinous carcinoma (10%)<br />
</li>
<li>Resection margin: Free of carcinoma<br />
</li>
<li>Lymph node, right axillary sentinel, lymphadenecomy — Metastatic
carcinoma (1/1)<br />
</li>
<li>Pathology stage: pT2N1a(sn)(cMx); Anatomic stage IIB, Prognostic
stage IB</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic grade (Nottingham histologic score): Grade I (score=
5)<br />
</li>
<li>Tumor necrosis: Present<br />
</li>
<li>Nodal status (Sentinel): Positive (1/1)</li>
<li>Treatment Effect: No presurgical neoadjuvant therapy received<br />
</li>
<li>Lymphovascular invasion: Absent<br />
</li>
<li>Perineural invasion: Absent<br />
</li>
</ul></li>
<li>Immunohistochemical study (S2019-00163)
<ul>
<li>ER (Ab): Positive (90%)</li>
<li>PR (Ab): Positive (90%)</li>
<li>HER-2/Neu (Ab): Negative (score=0)</li>
<li>Ki-67: &lt;5%</li>
<li>p53: &lt;2%.</li>
</ul></li>
</ul></li>
<li>2019-01-04 Surgical pathology Level IV
<ul>
<li>Breast, right, 10 o’clock/3cm, SONO guided core biopsy — Invasive
carcinoma.</li>
<li>IHC: ER (+, 90%), PR: (+, 90%), Her2/neu: negative (score=0); Ki-67:
&lt;5%, p53: &lt;2%.</li>
</ul></li>
<li>2019-01-03 SONO - breast
<ul>
<li>Highly suspicious of malignancy, with sonographic negative axillary
LNs, suspected carcinoma, cT2N0.</li>
<li>BI-RADS: 5-Highly Suggestive of Malignancy (&gt;95% malignant)
Appropriate Action Should Be Taken.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-02-26 Urology
<ul>
<li>Q
<ul>
<li>For on D-J catheterization.</li>
<li>This 51-year-old female with endometrial cancer  was admitted for staging surgery at 20220207. </li>
<li>We need your evaluation of her condition for inserted D-J
catheterization. Thanks for your help!</li>
</ul></li>
<li>A
<ul>
<li>MRI showed lymph node and mild dialation of right renal pelvis.</li>
<li>We will stand by for this procedure</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-07 Endometrial cancer - Staging surgery (ATH + BSO + lymph
node dissection + infracolic omentectomy)        
<ul>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: normal size, tense contact with bladder, peritoneum due to
tumor mass accupied .</li>
<li>Adnexa:
<ul>
<li>LOV: 3x2x2cm, capsule intact, smooth surface.</li>
<li>ROV: 3x3x3cm, capsule intact, smooth surface.</li>
<li>Fallopian tube: bilateral grossly normal</li>
</ul></li>
<li>CDS: invisible due to tumor mass occupied</li>
</ul></li>
<li>2022-01-06 Transcervical resection polypectomy      
<ul>
<li>One endometrial polyp from low segemtn of uterus, with stalk from
5o’clock of direction</li>
</ul></li>
<li>2019-01-21 right breast cancer - BCT + SLND</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-09 ~ 2022-04-28 - 4500cGy/25 fractions of the pelvic, and
another 1200cGy/3 fractions of the vaginal cuff mucosa surface by
IVRT.</li>
<li>2019-08-27 ~ 2019-10-17 - 5000cGy/25 fractions of the right breast
to right SCF, and 6000cGy/30 fractions of the right breast tumor bed
(scar) area.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-08-15 - paclitaxel 175mg/m2 360mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-07-25 - paclitaxel 175mg/m2 360mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-07-04 - paclitaxel 175mg/m2 360mg 3hr + carboplatin AUC 5 500mg
2hr</li>
<li>2022-06-08 - paclitaxel 175mg/m2 360mg 3hr + carboplatin AUC 5 450mg
2hr</li>
<li>2022-04-20 - paclitaxel 175mg/m2 360mg 3hr + carboplatin AUC 5 450mg
2hr</li>
<li>2022-03-18 - paclitaxel 175mg/m2 330mg 3hr + carboplatin AUC 5 450mg
2hr</li>
<li>2021-03-02 ~ 2021-05-18 - Medrone (medroxyprogesterone acetate)
5mg/tab 1# QD PO</li>
<li>2019-08-13 ~ undergoing - Femara (letrozole) 2.5mg/tab 1# QD PO
(Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase
inhibitor first described in the literature in 1990. It is a third
generation aromatase inhibitor like exemestane and anastrozole, meaning
it does not significantly affect cortisol, aldosterone, and
thyroxine)</li>
<li>2019-02-25 ~ 2019-08-05 - (pegylated liposomal) doxorubicin +
cyclophosphamide</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Taxane derivatives: When administered as sequential infusions,
taxane derivatives (docetaxel, paclitaxel) should be administered before
the platinum derivatives (carboplatin, cisplatin) to limit
myelosuppression and to enhance efficacy.</li>
</ul>
<div id="section-476" class="section level3">
<h3>==========</h3>
</div>
<div id="section-477" class="section level3">
<h3>2022-07-26</h3>
<ul>
<li>RBCs were 2.75<em>10</em>6/uL and HGBs were 7.8g/dL on 2022-07-25.
2U of LPRBC (Leukocyte-poor RBC) had been transfused on the night of
2022-07-25.</li>
</ul>
</div>
<div id="section-478" class="section level3">
<h3>2022-06-09</h3>
<ul>
<li>In this patient, endometrial cancer has been diagnosed following ATH
+ BSO + lymph node dissection + infracolic omentectomy on 2022-02-07.
The patient is receiving treatment with paclitaxel + carboplatin from
2022-03-18. Before that, the right breast invasive carcinoma was treated
with partial mastectomy on 2019-01-21, followed by doxorubicin +
cyclophosphamide from 2019-02-25 to 2019-08-05, followed by letrozole
from 2019-08-13.</li>
<li>Lab data reported on 2022-06-08 indicated that liver and kidney
functions, serum electrolytes, and blood cell counts were grossly
normal.</li>
</ul>
</div>
<div id="section-479" class="section level3">
<h3>2022-04-21</h3>
<ul>
<li>This patient has been diagnosed with endometrial cancer s/p ATH +
BSO + lymph node dissection + infracolic omentectomy on 2022-02-07 and
is being treated with paclitaxel + carboplatin since 2022-03-18. Prior
to that, right breast invasive carcinoma was treated with partial
mastectomy on 2019-01-21, followed by doxorubicin + cyclophosphamide
from 2019-02-25 to 2019-08-05, then letrozole since 2019-08-13.</li>
<li>Lab data reported on 2022-04-20 showed that liver and kidney
function, serum electrolytes, and blood cell counts were grossly
normal.</li>
</ul>
</div>
</div>
</div>
<div id="section-480" class="section level1">
<h1>700341500</h1>
<div id="section-481" class="section level2">
<h2>220722</h2>
<p>{colon cancer with liver mets}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>Creatinine
<ul>
<li>2022-07-21 1.62 mg/dL</li>
<li>2022-07-06 1.59 mg/dL</li>
<li>2022-06-12 1.85 mg/dL</li>
<li>2022-05-27 1.84 mg/dL</li>
<li>2022-04-30 1.67 mg/dL</li>
<li>2022-04-22 1.55 mg/dL</li>
<li>2022-03-30 1.66 mg/dL</li>
<li>2022-03-17 1.46 mg/dL</li>
<li>2022-03-01 1.81 mg/dL</li>
<li>2022-02-25 1.90 mg/dL</li>
<li>2022-02-22 1.68 mg/dL</li>
<li>2022-02-10 1.25 mg/dL</li>
<li>2022-02-07 1.30 mg/dL</li>
<li>2022-01-20 1.31 mg/dL</li>
<li>2022-01-15 1.55 mg/dL</li>
<li>2022-01-06 1.51 mg/dL</li>
<li>2021-12-20 1.35 mg/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-29 SONO - abdomen
<ul>
<li>Chronic liver parenchymal disease</li>
<li>Hepatic tumors C/W metastatic liver tumors</li>
</ul></li>
<li>2022-05-27 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Borderline cardiomegaly</li>
<li>Bamboo spine is noted that is c/w ankylosing spondylitis.</li>
</ul></li>
<li>2022-05-02 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>Several low density lesions are found at both lobes of liver up to
4.35cm in largest dimension. In comparison with CT dated on 2021-12-21,
these lesions decreased in size</li>
<li>Filling defect at infrarenal aorta is found. r/o thrombus
formnation. The lesion could also be found at previous CT.</li>
<li>Enlarged left adrenal gland is found. Metastasis is considered. In
regression.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>Mild thrinkage of the sigmoid colon mass is found.</li>
<li>The urinary bladder is well distended without soft tissue
lesion.</li>
<li>No definite inguinal or pelvic sidewall LAP</li>
<li>Ankylosis of the thoracolumbar spine is found.</li>
</ul></li>
<li>Imp:
<ul>
<li>Sigmoid colon cancer with liver and left adrenal mets, all of the
tumor activity regressed and decreased in size.</li>
<li>Infra-renal aortic thrombus formation with stable size. suspected
chronic thrombus formation. Suggest further treatment.</li>
</ul></li>
</ul></li>
<li>2022-02-23 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Voltage criteria for left ventricular hypertrophy</li>
<li>Anteroseptal infarct, age undetermined</li>
<li>T wave abnormality, consider inferolateral ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-02-23 2D transthoracic echocardiography
<ul>
<li>Dilated LA and LV</li>
<li>Septal hypertrophy</li>
<li>Poor LV systolic function</li>
<li>Adequate RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>AV sclerosis with mild AR, mild MR and TR</li>
<li>Hypokinesis of anteroseptal, anterior, apical and inferioposterior
wall</li>
</ul></li>
<li>2022-02-22 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Minimal voltage criteria for LVH, may be normal variant</li>
<li>Anterior infarct, age undetermined</li>
<li>T wave abnormality, consider lateral ischemia</li>
</ul></li>
<li>2022-02-22 Cardiac catheterization
<ul>
<li>In conclusion: Coronary artery disease, 1VD, m-LAD; Syntax score 9
s/p POBA and stenting with Boston SYNERGY Drug-eluting stent. 4.0 X 48
mm for proximal LAD to middle LAD.</li>
<li>Recommendation: Patient had take PPI and gastritis history, shift
ticagrelor to clopiodgrel later.</li>
</ul></li>
<li>2021-12-23 Patho - colorectal polyp
<ul>
<li>A. Colon, transverse colon, s/p hot snare polypectomy (E) -
Tubulovillous adenoma with low grade dysplasia.</li>
<li>B. Colon, 10cm to 20cm AAV, s/p biopsy (F) - Adenocarcinoma.
<ul>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).<br />
</li>
</ul></li>
</ul></li>
<li>2021-12-23 Colonoscopy
<ul>
<li>Colon polyp, transverse colon, s/p EMR and clipping.</li>
<li>Highly suspected colon cancer, 1-cm to 20cm AAV, s/p biopsy.</li>
<li>Colon polyps, s/p polypectomy and biopsy, at least four residue
polyps not polypectomized.</li>
</ul></li>
<li>2021-12-21 CT - abdomen - liver, spleen, biliary duct, pancreas
<ul>
<li>Suspected rectosigmoid cancer with liver and left adrenal
metastasis.</li>
<li>Small right lung nodule, suspected lung metastasis.</li>
<li>Right renal stones. Left middle ureteral stone with
hydronephrosis.</li>
</ul></li>
<li>2021-12-17 Abdominal ultrasound
<ul>
<li>Parenchymal liver disease, suspected liver cirrhosis.</li>
<li>Hepatic tumors, HCC with portal vein invasion or metastatic tumor
with vessel compression were suspected.</li>
<li>Left hydronephrosis, mild</li>
<li>Splenomegaly</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-02-24 Rehabilitation
<ul>
<li>A
<ul>
<li>Assessment
<ul>
<li>ST elevation myocardial infarction, 1-vessel coronary artery
disease, s/p balloon angioplasty and drug eluting stenting on 2022/02/22
-colon cancer</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT cardiopulmonary rehabilitation
programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
<li>May arrange PM&amp;R OPD follow-up for further phase 2 cardiac
rehabilitation program as needed</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-22 Cardiology
<ul>
<li>This 69 y/o male is a case of colon CA. He admitted due to chest
pain. EKG ST elevation, anterior wall</li>
<li>bed side 2D anteroseptal, anterior and apex hypokinesia</li>
<li>Past history:
<ul>
<li>colon CA</li>
</ul></li>
<li>impression
<ul>
<li>STEMI, onset &lt;12 hours</li>
</ul></li>
<li>Suggestion
<ul>
<li>Dual anti-PLT therapy (aspirin 3# po STAT and brilinta 2# po STAT;
then spirin 1# po QD and brilinta 1# po QD) and anticoagulation (such as
heparin 4000U stat)</li>
<li>We explain the indication of primary percutaneous coronary
intervention in order to save life, but also potential risks of PCI
including stroke around 1/1000.</li>
<li>Arrange admission to MICU</li>
</ul></li>
</ul></li>
<li>2021-12-24 Colorectal Surgery
<ul>
<li>Q
<ul>
<li>for management of favor colon cancer with liver, lung and adrenal
mets</li>
<li>This 68 y/o male due to Liver tumor, HCC with right portal vein
invasion or metastatic tumor with vessel compression were suspected. He
was admitted to our GI ward for management and further survey.</li>
<li>After admission, Colonscopy was done that showed Highly suspected
colon cancer, 10cm to 20cm AAV, s/p biopsy.</li>
<li>Now, we will be pending pathology and need your management of favor
colon cancer with liver, lung and adrenal mets. Thanks a lot!!!</li>
</ul></li>
<li>A
<ul>
<li>I’ve visited this case. The patient was a case of colon cancer with
multiple liver, lung, adrenal metastasis</li>
<li>O
<ul>
<li>Oral intake : well</li>
<li>Appetite: good</li>
<li>Stool passage: Normal</li>
<li>No obstruction sign</li>
</ul></li>
<li>IMP：Colon cancer with multiple metastasis</li>
<li>Suggestion:
<ul>
<li>Consult Oncology for palliative chemotherapy + target therapy</li>
<li>Surgery will be reserved for obstruction for the patient</li>
<li>Thanks for your consultation</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-23 Urology
<ul>
<li>Q
<ul>
<li>Now, abdominal CT was done that showed Left middle ureteral stone
with mild hydronephrosis.</li>
</ul></li>
<li>A
<ul>
<li>Due to stone impaction with renal insufficiency, URSL with short
term DBJ insertion (7 days) is indicated.</li>
<li>Treating stone may yield better renal function for chemotherapy in
the future.</li>
<li>I will discuss with him after colonscopy</li>
<li>Adrenal tumor was seen. Metastasis is suspected.</li>
<li>Thanks for your consultation</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-20 ~ undergoing - bevacizumab 5mg/kg 90min + irinotecan
180mg/m2 90min + leucovorin 400mg/m2 2hr + 5-Fu 2800mg/m2 46hr (FOLFIRI
plus bevacizumab)</li>
<li>2022-01-20 - bevacizumab 5mg/kg 90min + irinotecan 160mg/m2 90min +
leucovorin 400mg/m2 2hr + 5-Fu 2800mg/m2 46hr</li>
<li>2022-01-06 - irinotecan 160mg/m2 90min + leucovorin 400mg/m2 2hr +
5-Fu 2800mg/m2 46hr</li>
</ul></li>
</ul>
<div id="section-482" class="section level3">
<h3>==========</h3>
</div>
<div id="section-483" class="section level3">
<h3>2022-07-22</h3>
<ul>
<li>2022-07-21 Creatinine 1.62 mg/dL, 171 cm, 74 kg, 69 years old =&gt;
CrCl 45 mL/min, eGFR 49 mL/min. There is no need to adjust doses in the
active prescription.</li>
</ul>
</div>
<div id="section-484" class="section level3">
<h3>2022-07-07</h3>
<ul>
<li>Following the administration of FOLFIRI plus bevacizumab since
2022-01-20, CT scan on 2022-05-02 revealed that all tumor activity had
regressed and decreased in size.</li>
<li>Under daily taking of aspirin and clopidogrel, an infra-renal aortic
thrombus of stable size was also demonstrated on 2022-05-02 CT.</li>
<li>TPR, BP signs during this hospitalizaion and lab data on 2022-07-06
were grossly normal except for creatinine 1.59 mg/dL. Chemotherapy
should be able to proceed as scheduled.</li>
</ul>
</div>
<div id="section-485" class="section level3">
<h3>2022-03-18</h3>
<ul>
<li>As reported by the laboratory on 2022-03-17, the patient has normal
liver function, but decreased renal function (creatinine 1.46 mg/dL),
slightly low RBC (3.92*10^6/uL) and HGB (11.3 g/dL) readings.</li>
<li>The patient is currently receiving FOLFIRI plus bevacizumab, and no
reports of diarrhea were found in the nursing notes during this hospital
stay.</li>
<li>5-FU has been associated with cardiac toxicity including myocardial
infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac
failure, sudden death, ECG changes, and cardiomyopathy. There is no
recommended dose for resumption of FU administration following
development of cardiac toxicity.
<ul>
<li>reference:
<ul>
<li><a href="https://www.uptodate.com/contents/image/print?imageKey=ONC%2F76300" class="uri">https://www.uptodate.com/contents/image/print?imageKey=ONC%2F76300</a></li>
<li><a href="https://www.uptodate.com/contents/fluoropyrimidine-associated-cardiotoxicity-incidence-clinical-manifestations-mechanisms-and-management" class="uri">https://www.uptodate.com/contents/fluoropyrimidine-associated-cardiotoxicity-incidence-clinical-manifestations-mechanisms-and-management</a></li>
<li><a href="https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-7-212" class="uri">https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-7-212</a></li>
<li><a href="https://www.frontiersin.org/articles/10.3389/fcvm.2021.713694/full" class="uri">https://www.frontiersin.org/articles/10.3389/fcvm.2021.713694/full</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-486" class="section level1">
<h1>701084563</h1>
<div id="section-487" class="section level2">
<h2>220722</h2>
<p>{Small Lymphocytic Lymphoma}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>BUN
<ul>
<li>2022-07-21 BUN 60 mg/dL<br />
</li>
<li>2022-07-13 BUN 41 mg/dL<br />
</li>
<li>2022-07-08 BUN 56 mg/dL<br />
</li>
<li>2022-07-06 BUN 56 mg/dL<br />
</li>
<li>2022-07-04 BUN 52 mg/dL<br />
</li>
<li>2022-06-27 BUN 32 mg/dL<br />
</li>
<li>2022-06-22 BUN 24 mg/dL<br />
</li>
<li>2022-06-10 BUN 19 mg/dL<br />
</li>
<li>2022-06-01 BUN 18 mg/dL<br />
</li>
</ul></li>
<li>Procalcitonin (PCT)
<ul>
<li>2022-07-21 Procalcitonin(PCT) 4.53 ng/mL<br />
</li>
<li>2022-07-13 Procalcitonin(PCT) 0.43 ng/mL<br />
</li>
<li>2022-06-23 Procalcitonin(PCT) 0.82 ng/mL<br />
</li>
<li>2022-06-01 Procalcitonin(PCT) 0.40 ng/mL<br />
</li>
<li>2022-04-21 Procalcitonin(PCT) 1.76 ng/mL<br />
</li>
</ul></li>
<li>2022-03-22 BCR-abl mutation undetectable</li>
<li>2022-03-16 bone marrow
<ul>
<li>FLT3-D835 mutation undetectable</li>
<li>FLT3/ITD mutation undetectable</li>
<li>NPM1 mutation undetectable</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-07-20 CXR
<ul>
<li>Ground glass opacities in bil. lungs.</li>
</ul></li>
<li>2022-07-14 Patho - paranasal biopsy
<ul>
<li>Nasal septum, left, biopsy — Necrotic tissues with candidiasis</li>
<li>Microscopically, it shows necrotic debris with granulation tissue,
leukocytic infiltrate and presence of bacterial clumps and fungal
hyphae. No viable tissue is seen.</li>
</ul></li>
<li>2022-07-14 Nasopharyngoscopy
<ul>
<li>Nasal lesions</li>
</ul></li>
<li>2022-07-13 Nasopharyngoscopy
<ul>
<li>Ulceration at L buccal, L retromolar trigone, L soft palate, blood
clot with whitish</li>
</ul></li>
<li>2022-07-12 MRI - nasopharynx
<ul>
<li>Enlarged left posterior cervical and bil. supraclavicular LNs as
indicated on axial fat sat T2WI when compared with 2021/09/08,
2021/03/23 MRI studies.</li>
</ul></li>
<li>2022-07-08, -07-04 CXR
<ul>
<li>Nodular opacities projecting in both lung are suspected. Please
correlate with CT.</li>
<li>Right pleura effusion is noted.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-06-27 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Dilated LA and LV; severely abnormal LV systolic function with
global hypokinesia</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Minimal pericardiac effusion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Moderate to severe MR, mild to moderate TR</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>LV diastolic dysfunction, Gr 1</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Impaired RV systolic function</li>
</ol></li>
</ul></li>
<li>2022-06-23 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific T wave abnormality</li>
<li>Poor wave progression V1~3</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-03-08 Patho - lymph node region resection
<ul>
<li>Lymph node, right neck, excision - Small lymphocytic lymphoma</li>
<li>IHC: CD20(+), CD23(+), CD3(-), CD5(+) and CD10(-).</li>
<li>According to above histopathologic findings and past history, it is
consistent with small lymphocytic lymphoma.</li>
</ul></li>
<li>2022-03-04 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in bilateral axillary lymph nodes, bilateral
supra and infraclavicular lymph nodes, bilateral neck lymph nodes and
abdominal lymph nodes, suggesting recurrent lymphoma involving multiple
lymph node regions on the both sides of the diaphragm (stage III).</li>
<li>Increased FDG accumulation in both kidneys, bilateral ureters and
colon. Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2022-03-03 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Small lymphocytic lymphoma /
chronic lymphocytic leukemia<br />
</li>
<li>IHC: CD20(+), CD3(-), CD23(+), CD34(-), CD117(-), CD61 showed
adequate megakaryocyte with focal mononucleation and hyposegmentation,
MPO and CD71 showed marked hypoplasia of both myeloid and erythroid
series.</li>
</ul></li>
<li>2021-12-21 SONO - abdomen
<ul>
<li>Two gallbladder polyp or sludge (2.2 mm).<br />
</li>
<li>A renal cyst measuring 1 cm in left lower pole is noted.</li>
</ul></li>
<li>2021-09-28 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs, seems stationary.</li>
<li>Markedly regression in other neck LNs found, stationary.</li>
</ul></li>
<li>2021-07-06 SONO - abdomen
<ul>
<li>Two gallbladder polyp or sludge (&lt; 2 mm).<br />
</li>
<li>A renal cyst measuring 0.89 cm in left lower pole is noted.</li>
</ul></li>
<li>2021-03-23 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs, stationary.</li>
<li>Markedly regression in other neck LNs found, stationary.</li>
</ul></li>
<li>2020-12-29 SONO - abdomen
<ul>
<li>A gallbladder polyp 2.5 mm.<br />
</li>
<li>A renal cyst measuring 0.93 cm in left lower pole is noted.</li>
</ul></li>
<li>2020-10-06 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs.</li>
<li>Markedly regression in other neck found.</li>
<li>Chronic bil. paranasal sinusitis.</li>
</ul></li>
<li>2020-05-11 MRI - brain
<ul>
<li>Subacute ICH at left anterior frontal base. No evidence of brain
metastasis.</li>
</ul></li>
<li>2020-05-06 CT -brain
<ul>
<li>localized SAH in the bilateral inferior frontal regions.</li>
</ul></li>
<li>2020-04-16 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - Compatible with B-cell lymphocytosis</li>
<li>B-cell proliferation in focal area, arranged in interstitial
pattern, which immunohistochemistry shows CD3 and CD5: similar pattern,
CD23: almost (-), CD20(+), Cyclin-D1(-), MPO(+) for myeloid series,
CD71(+) for erythroid series, CD61(+) for megakaryocytes and CD117(+)
for blast.. According to all above histopathologic findings, it is
compatible with B-cell lymphocytosis due to lack aberrant
expression.</li>
</ul></li>
<li>2020-04-08 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in bilateral axillary lymph nodes,
supraclavicular lymph nodes, and cervical lymph nodes, suggesting
lymphoma with tumor recurrence in multiple lymph node regions.<br />
</li>
<li>Glucose hypermetabolism in the spleen and bilateral inguinal lymph
nodes, the nature is to be determined. Please correlate with clinical
findings and keep follow up to exclude the possibility of tumor
recurrence in these regions.</li>
<li>B-cell lymphoma s/p treatment with tumor recurrence, rc-stage II, at
least (AJCC 8th ed.), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2020-03-27 Patho - lymphnode biopsy
<ul>
<li>Lymph node, right neck, excision - Small lymphocytic lymphoma<br />
</li>
<li>IHC: CD20(+), CD23(+, focal), CD3(-), CD5(+, focal), Bcl-2(+).</li>
<li>According to above histopathologic findings and past history, it is
consistent with small lymphocytic lymphoma.<br />
</li>
<li>Reference: S2014-05750 Lymph node, neck, excisional biopsy - Chronic
lymphocytic leukaemia / small lymphocytic lymphoma</li>
</ul></li>
<li>2020-03-19 MRI - larynx
<ul>
<li>lymphoma with extensive neck lymphadenopathy.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-13 ENT
<ul>
<li>Q
<ul>
<li>For chronic rhinosinusitis</li>
<li>This 64-year-old female has the medical history of congestive heart
failure, and chronic lymphocytic leukemia, small lymphocytic lymphoma
(CLL/SLL) diagnosed in 2014/04.</li>
<li>She was admitted for progressively enlarging bilateral axillary
lymph node. She was orginally under Venetoclax treatment. However, the
treatment was paused recently due to low WBC count.</li>
<li>Her current conditions are stable. However, she complained of
headache (forehead headache), facial apin and facial fullness in these
days. We have arranged nasopharynx MRI for her. Yet, no obvious
discharge or foreign body was seen over bilateral maxillary sinuses. We
need your help for further survey for chronic sinusitis! Thank you!</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>Facial pain, oral ulcer VAS 2~3 for 10+ days.</li>
<li>Previous epistaxis (+)</li>
<li>Hx of CLL/SLL</li>
</ul></li>
<li>PE:
<ul>
<li>Nose: ulceration at L nasal septum</li>
<li>Scope: Ulceration at L buccal, L retromolar trigone and L soft
palate, blood clot with whitish lesion on bil nasal septum and middle
turbinate</li>
</ul></li>
<li>Imp:
<ul>
<li><ol style="list-style-type: decimal">
<li>Impending destruction of nasal septum, suspect CLL/SLL related</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Suspect fungal infection of nasal cavity, or previous epistaxis
related</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Stomatitis, related to previous chemotherapy</li>
</ol></li>
</ul></li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>ENT OPD f/u nasal condition for further local tx</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>L nasal septal ulcerative tissue sent for pathology</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Oralog for oral ulcer</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-23 Cardiology
<ul>
<li>Q
<ul>
<li>This is a 64-year-old female with history of chronic lymphocytic
leukemia, small lymphocytic lymphoma (CLL/SLL) diagnosed in 2014/04, Ann
Arbor stage IV (BM involved), s/p R-CHOP x 2 (ceased in 2014-06, due to
rapid progression), Bendamustin/Rituximab (BR) x 7 (finished in 2014-12,
with CR).</li>
<li>Recurrent CLL/SLL at bil. axillary LNs, supraclavicular LNs, and
cervical LNs was found, s/p BR Q3W x 5 (finished in Aug 2020-08).</li>
<li>Third time recurrent CLL/SLL confirmed in 2022/03 involving multiple
lymph node regions at diaphragm stage III, with right neck lymph nodes
biopsy confirmed SLL.</li>
<li>Thus, she underwent another session of chemotherapy with BR since
2022/03/21, C2 on 2022/04/25, C3 on 2022/06/01. After last cycle, the
patient was noted to be pancytopenic with 11K of PLT, Hb 7.3, WBC 530 on
the first revisit of hematology OPD. Blood transfusion with LRP 2U +
LPRBC 1U were given and GCSF x 5 days was administered. The patient was
then sent home with relatively stable condition. The patient also
suffered from hemorrhoid, and went to LMD with medication use
currently.</li>
<li>This time, the patient came to Dr. Wan’s OPD for help on 2022-06-22
with complaint of rapid progression of bilateral axillary lymph node
swelling with heat and mild pain for 10 days. Mild dyspnea was also
noted. The patient was thus referred to ER for emergent care. At ER,
vital signs showed BT 37.6, BP 109/63mmHg; HR:134BPM; RR:20, with 94%
spO2 under room air. Lab study found pancytopenia with Hb 5.9, PLT 6K
WBC 6.86K with ANC 274. Emergent blood transfusion with LPRBC 4U + LRP
1U was given with dexamethasone and GCSF ST. The patient was then
admitted to our ward for further evaluation and management.</li>
<li>After admission, neutropenic fever was noted. Abx of tapimycin was
given. Due to CLL, rituximab, endoxan and prednisolon was given. High
fever was noted in this morning with HR up to 150bpm. Bedside EKG showed
sinus tachycardia without ST-T change. Troponin I was 1192.9 pg/ml. She
only complained about mild dyspnea with fever and chillness. There was
no typical chest pain. Follow-up EKG and troponin still showed sinus
tachy with troponin upto 1495.9 pg/ml. We need your expertise for
further evaluation and managment. Thanks!</li>
<li>Dx: CLL, neutropenic fever, UTI</li>
<li>For elevated troponin I from 1192.9 -&gt; 1495.9</li>
</ul></li>
<li>Q
<ul>
<li>S
<ul>
<li>This 64 y/o female patient is a case of CLL s/p C/T with
pancytopenia. She was admitted for further treatment. PRBC 4U and PLT 3U
were administered in the past 1 day. She complained of marked dyspnea
today. Othropnea was also noticed. Elevated cardiac markers were
detcted. Now we are consulted.</li>
</ul></li>
<li>O
<ul>
<li>BP:119/76 mHg; HR:124</li>
<li>Consciousness: clear and acute ill looking</li>
<li>Chest: bilateral basal rales heard</li>
<li>Heart: RHB with tachycardia, grade 1~2/6 SM at LLSB</li>
<li>20220623 EKG: sinus tachycardia with HR 135 BPM, nonspecific T wave
abnormality</li>
<li>20220622 sugar: 115, Cr: 0.51, AST/ALT: 26/42, CRP: 18.44, NTproBNP:
4105, hsTroponi-I: 1192 -&gt; 1495</li>
<li>Hb:5.9 -&gt; 8.4 -&gt; 9.9</li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>CLL s/p C/T with pancytopenia</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Acute pulmonary edema, suspected myocardial failure or fluid
overload due to blood transfusion and large IV fluid administeration, or
combination of these factors</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Suspected chemotherapy related cardiac toxicity with myocardial
failure</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Acute pulmaonry edema is prefered according to the physical
examination. Please give IV lasix 1amp stat and 1amp Q12H. Arrange CXR
stat.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>The patient has no past histyory of HTN, DM or smoking. She also
denied past history of effort related angina. Acute MI with elevated
cardiac markers is not likely. The elvated hsTroponin-I was possible due
to demand ischemia (because of severe anemia), or myocardial failure due
to chemotherapy. Please arrange echocardiography to evaluate LV
function.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-23 Family Medicine
<ul>
<li>Q
<ul>
<li>Due to progressed CLL, DNR was agreed by patient and family. We need
your expertise for share care. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>64 y/o lady CLL</li>
<li>DNR +<br />
</li>
<li>Our share care would follow up.</li>
<li>Thanks for consultation.</li>
</ul></li>
</ul></li>
<li>2022-03-03 General and Gastrointestinal Surgery
<ul>
<li>Q
<ul>
<li>This time, she has nasal and gums ulcer with swelling at first and
then multiple LNs enlarged over bilateral neck, supraclavicle and
axillary in Chinese New Year and fatigue in recently days. She denied
night sweat or BW loss. Due to leukocytosis and higher LDH, so she was
admitted for management.</li>
<li>Due to swollen lymph nodes at right neck, so we need your help for
lymphadenectomy and biopsy, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>S: R’t neck lymph node excision is consulted.</li>
<li>O: vital signs: stable, no fever
<ul>
<li>PE: multiple enlarged lymph nodes over bilateral lateral neck</li>
<li>lab data: see chart</li>
</ul></li>
<li>A: Chronic lymphocytic leukaemia / small lymphocytic lymphoma,
suspect recurrence</li>
<li>P: I will right neck LN biopsy on 3/8</li>
</ul></li>
</ul></li>
<li>2020-12-12 Neurology
<ul>
<li>Q
<ul>
<li>Patient’s mouth twisted to the right</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>NE E4V5M6<br />
</li>
<li>CNs: left peripheral facial palsy</li>
<li>MP: full</li>
<li>sensation: intact</li>
<li>FNF: no dysmetria</li>
<li>gait: steady</li>
<li>brain CT: no ICH</li>
</ul></li>
<li>impression: left bell palsy</li>
<li>plan:
<ul>
<li>give prednisolone 1mg/kg QD, famotidine 1# QD for 4 days (till W2
OPD)</li>
<li>give kentamin 1# BID, and duratea ointment</li>
<li>neurology OPD follow-up on W2</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-05-08 ENT
<ul>
<li>Q
<ul>
<li>for severe dizziness &amp; sudden onest of syncope on 5/6 night
&amp; 5/7 night about 10-20 sec</li>
<li>This 61-year-old female, a patinet of small B cell lymphoma S/P C/T.
She was admitted for C/T with BR on 5/5-5/6 20. Sudden onest of vomiting
&amp; dizziness was developed on 5/6 20 afternoon at 18:15 pm. The brain
CT (5/6 20) showed localized SAH in the bilateral inferior frontal
regions. We need expertise to evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>S: vertigo when postion change</li>
<li>O: dix-hallpike: left rotational nystagmus</li>
<li>A: suspected left BPPV</li>
<li>P:
<ul>
<li>left Epley (done)</li>
<li>symtpomatic treatment</li>
<li>ENT OPD f/u</li>
<li>please survey other cause of syncope</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-05-07 Neurosurgery
<ul>
<li>Q
<ul>
<li>For localized SAH in the bilateral inferior frontal regions
evaluation</li>
<li>This 61-year-old female, a patinet of small B cell lymphoma S/P C/T.
She was admitted for C/T with BR on 5/5-5/6 20. Sudden onest of vomiting
&amp; dizziness was developed on 5/6 20 afternoon at 18:15 pm. The brain
CT (5/6 20) showed localized SAH in the bilateral inferior frontal
regions.We need expertise to evaluate her condition. thanks!</li>
</ul></li>
<li>A
<ul>
<li>S/O
<ul>
<li>61 y/o female</li>
<li>Head trauma owing to an accidental fall last night. No loss of
consciousness.</li>
<li>c/o headache and dizziness.</li>
<li>Consciousness clear.</li>
<li>Head CT scan: minimal anterior interhemispheric SAH.</li>
</ul></li>
<li>A/P
<ul>
<li>Rx:</li>
<li>No neurosurgery is indicated.</li>
<li>Neuro monitoring and treatment for about 3 days.</li>
<li>Symptomatic treatment.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-08 Excision of r’t neck tumor</li>
<li>2020-03-27 Excisional biopsy, right neck enlarged LAP</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>unknown - venetoclax</li>
<li>2022-06-23 rituximab 375 mg/m2 10hr</li>
<li>2022-06-02 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2022-04-25 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2022-03-21 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2022-03-18 ~ 2022-03-23 - hydroxyurea 500 mg BID</li>
<li>2022-03-11 ~ 2022-03-18 - cyclophosphamide 50 mg BID</li>
<li>2020-08-03 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2020-07-07 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2020-06-16 rituximab 375 mg/m2 6hr D1 + bendamustine 100 mg/m2 90
min D1-2</li>
<li>2020-05-26 rituximab 375 mg/m2 10hr D1 + bendamustine 70 mg/m2 90
min D1-2</li>
<li>2020-05-05 rituximab 375 mg/m2 10hr D1 + bendamustine 70 mg/m2 90
min D1-2</li>
<li>2014-07 ~ -12 - rituximab + bendamustin (CR)</li>
<li>2014-05 ~ -06 - R-CHOP, ceased due to rapid progression</li>
</ul></li>
</ul>
<div id="section-488" class="section level3">
<h3>==========</h3>
</div>
<div id="section-489" class="section level3">
<h3>2022-07-22</h3>
<ul>
<li>According to UpToDate, cardiovascular adverse reactions of rituximab
are Cardiac disorder (5% to 29%), flushing (5% to 14%), hypertension (6%
to 12%), peripheral edema (8% to 16%), and a cardiovascular adverse
reaction of bendamustine is Peripheral edema (13%).</li>
<li>It is recommended to have cardiac ultrasound routinely when the
patient is undergoing treatment since she has a history of heart
failure, abnormal ECG, and edema. The most recent 2D transthoracic
echocardiography was done on 2022-06-27.</li>
</ul>
</div>
<div id="section-490" class="section level3">
<h3>2022-07-21</h3>
<ul>
<li>Tapimycin (piperacillin + tazobactam) is adequate for ground glass
opacities in bil. lungs (2022-07-20 CXR). No dose adjustment is needed
based on 2022-07-21 lab data.</li>
</ul>
</div>
<div id="section-491" class="section level3">
<h3>2022-03-22</h3>
<ul>
<li>For this patient with recurrent SLL, the r’t neck tumor was excised
on 2022-03-08.</li>
<li>The patient is receiving bendamustine and rituximab, the same
regimen used from May to August of 2020.</li>
<li>There were no detectable mutations in any of the following genes:
BCR-abl (2022-03-22), FLT3-D835, FLT3/ITD, and NPM1 (2022-03-16).</li>
<li>There is no del(17p), TP53 mutation status, CpG-stimulated karyotype
or IGHV mutation status found in lab data.</li>
</ul>
</div>
</div>
</div>
<div id="section-492" class="section level1">
<h1>700077356</h1>
<div id="section-493" class="section level2">
<h2>220720</h2>
<p>{left pyriform sinus cancer, cT2N2bMx, stage IVA, brain mets}</p>
<ul>
<li>exam finding
<ul>
<li>2022-07-13 Electroencephalography, EEG
<ul>
<li>Findings
<ul>
<li><ol style="list-style-type: decimal">
<li>the posterior background activities are at 10 Hz, symmetric and
responsive to eye opening</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>photic stimulation showed symmetric photo-driving response</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>hyperventilation study was not done</li>
</ol></li>
</ul></li>
<li>EEG classification: normal</li>
<li>Interpretation: normal</li>
</ul></li>
<li>2022-07-12 Pure-tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 29 dB HL; LE 29 dB HL.</li>
<li>R’t normal to moderate SNHL.</li>
<li>L’t normal to moderately severe SNHL.</li>
</ul></li>
<li>2022-06-23 Patho - larynx biopsy
<ul>
<li>Left pyriform sinus medial wall, LMS for tumor mapping — Moderately
differentiated squamous cell carcinoma</li>
<li>IHC stain — p16(-)</li>
</ul></li>
<li>2022-06-23 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>Glucose hypermetabolism in the left pyriform sinus, compatible with
primary hypopharyngeal malignancy. Please correlate with other clinical
findings for further evaluation.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Glucose hypermetabolism in multiple left neck level IV and Vb lymph
nodes, suggesting multiple ipsilateral lymph node metastases.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Increased FDG accumulation/uptake in bilateral masseter muslces,
both kidneys, bilateral ureters and colon. Physiological FDG
accumulaion/uptake is more likely.</li>
</ol></li>
</ul></li>
<li>2022-06-22 Frozen section
<ul>
<li>initial diagnosis: Pyriform sinus, left, frozen section — squamous
cell carcinoma</li>
</ul></li>
<li>2022-06-22 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Cirrhosis of liver with splenomegaly</li>
<li>Liver cyst</li>
<li>Portal hypertension</li>
<li>Chronic calcified pancreatitis with pancreatic duct dilatation</li>
<li>Subpleural consolidation of LLL with minimal pleural effusion</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD follow-up</li>
</ul></li>
</ul></li>
<li>2022-06-22 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Hypopharyneal tumor</li>
<li>Suspected Barett’s esophagus, C3M5</li>
<li>Reflux esophagitis LA grade A</li>
<li>Cervical inlet patches</li>
<li>Superficial gastritis</li>
<li>Suspected cascade stomach</li>
</ul></li>
<li>Suggestion
<ul>
<li>Biopsy was NOT done due to anticoagulation.</li>
</ul></li>
</ul></li>
<li>2022-06-16 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>bi nasal cavity and middle meatus clear; smooth nasopharynx; normal
vocal function: granular tumor at left</li>
<li>pyriform sinus and left AE fold and left arytenoid</li>
</ul></li>
<li>Summary:
<ul>
<li>left pyriform sinus and left supraglottis tumor, favor
malignancy</li>
</ul></li>
</ul></li>
<li>2022-05-30 MRI - nasopharynx
<ul>
<li>Imaging Report Form for Hypopharynx Carcinoma</li>
<li>Impression (Imaging stage): T2N2bMx, stage IVA</li>
</ul></li>
<li>2021-03-11 MRI - nasopharynx
<ul>
<li>He had buccal cancer of left side 2013-10. abnormal mass-like
fibrotic soft tissue overgrowth with ugly surface is noted at the left
buccal mucosa.</li>
<li>IMP:
<ul>
<li><ol style="list-style-type: decimal">
<li>focal mucosal thickening in the left upper and posterior
buccogingival mucosa. Nature?</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>prominent right oropharyngeal tonsil. Nature?</li>
</ol></li>
</ul></li>
</ul></li>
<li>2019-03-01 MRI - nasopharynx
<ul>
<li>Indication:
<ul>
<li>S: He is an oral cancer patient and received operations. He has poor
liver function and lower bleeding control at this moment (waiting for
liver transplantation).</li>
<li>O: Fungus infection at the left buccal mucosa is noted. leukoplakia
on the left tongue border near #36 with mild ulceration is noted.
surgical defect at the left buccal mucosa and tuberosity with fibrotic
soft tissue overgrowth with ugly surface are present</li>
<li>A:
<ul>
<li><ol style="list-style-type: decimal">
<li>SCC of left buccal mucosa (pT1N0M0) s∕p OP (2013-10)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Trismus and fungus infection</li>
</ol></li>
</ul></li>
<li>P:
<ul>
<li><ol style="list-style-type: decimal">
<li>BUN: normal</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>arrange MRI with contrast to evaluate undermining tumor status</li>
</ol></li>
</ul></li>
</ul></li>
<li>MRI of the head and neck in multiplanar projections, multisequence
imaging acquisition without and with IV Gd-DTPA administration shows:
<ul>
<li><ol style="list-style-type: decimal">
<li>Post operation change at left buccal region with abscence of
subamandibular gland. No focal mass or nodule.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Post left neck lymph nodes dissection .</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>No evident abnormal enlarged lymph node in the visible neck.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>No abnormal enhancement in the tongue.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>A right maxillary retension cyst up to 1.7cm.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>No abnormal signal intensity of the mandible.</li>
</ol></li>
</ul></li>
<li>IMP:
<ul>
<li>post op change at left buccal region.</li>
<li>no recurrent tumor.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-07-12 Neurology
<ul>
<li>Q
<ul>
<li>This 46-year-old man patient is a case of Left piryform sinus
cancer, cT2N2bM0, stage IVA. He was admited for prepare chemotherapy.
Alcoholic cirrhosis of liver without ascites, child A with
Encephalopathy on 2022/07/11 after admitted. He was to Taipei Mackay
Hospital with brain CT on 2022/07/11 showed no brain metastasis.</li>
<li>Now, for evaluate Alcoholic cirrhosis of liver without ascites,
child A with Encephalopathy examination and therapy. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>seizure as hypnopompic twitching of limbs</li>
<li>similar attack as alcohol withdrawal seizure before</li>
<li>NE: aware, fluent speech, normal cranial nerves, no obvious focal
weakness</li>
</ul></li>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>sleep related seizure or sleep related movement disorders</li>
</ol></li>
</ul></li>
<li>Suggest:
<ul>
<li><ol style="list-style-type: decimal">
<li>EEG might be arranged</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Rivotril might be added as (0.5mg) 1-2# HS</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>I would like to follow up this patient.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-24 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>This 46-year-old man has history of type 2 diabetes mellitus with
medication control and alcoholic cirrhosis of liver without ascites,
child A wait for liver transplantation. He had personal history of
smoking, betel nut chewing and drink wine for over 15 years, quitted
betel nut and drink 8 years ago. He had left buccal cancer, pT1N0M0,
stage I, status post operation on 2013/10/07 at our hospital by OS
Dr.Xia. He regular follow at Dr.Xia OPD.</li>
<li>This time, left pyriform sinus cancer, cT2N2bMx, stage IVA was
diagnosed, induction chemotherapy was indicated. We request your
consultation for dental evaluation.</li>
</ul></li>
<li>A
<ul>
<li>Currently, no emergency treatment or prophylactic dental extraction
is needed. Please arrange routine dental follow up after patient’s
finished the cancer treatment .</li>
</ul></li>
</ul></li>
<li>2022-06-23 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For induction chemotherapy for left pyriform sinus cancer, cT2N2bMx,
stage IVA evaluation (Hx: DM, liver cirrhosis, child A)</li>
<li>Neck MRI followed on 2022/05/30 which revealed left pyriform sinus
cancer, cT2N2bMx, stage IVA. He then was transferred to our ENT OPD. At
OPD, scope showed granular tumor at left pyriform sinus and left AE
fold. Several enlarged LN at left neck level IV and Vb, the largest one
around 3cm at left Vb. Admission for laryngomicrosurgery biopsy and
further examination was suggested, and the patient agreed after thorough
consideration. Therefore, under the impression of left pyriform sinus
cancer, the patient was admitted.</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>left pyriform sinus cancer, SCC, cT2N2bMx, stage IVA</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Diabetes mellitus</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Liver cirrhosis, child A</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Induction chemotherapy is indicated. Thanks for your consultation.
We will see the patient and discuss with patient.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Please check anti Hbc</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Arrange port A insertion</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-06-22
<ul>
<li>Surgery
<ul>
<li>Laryngomicrosurgery with esophagoscopy for tumor mapping</li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>Left pyriform sinus medial wall tumor</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Smooth mucosal over posterior pharyngeal wall, postcricoid region,
and cervical esophagus</li>
</ol></li>
</ul></li>
</ul></li>
<li>2013-10-07
<ul>
<li>Surgery
<ul>
<li><ol style="list-style-type: decimal">
<li>Wide excision of left buccal malignant lesion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Extraction of teeth of #27,#28,#37 and #38</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Supraomohyoid neck dissection, left</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Skin graft at the left buccal mucosa (donnor side is left
thigh)</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>OBTURATOR BY USE OF Buccal stent fixation</li>
</ol></li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>Unhealed ulcerative lesion at the left buccal mucsoa about 1.5 cm in
diameter.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>the tooth attrition by #27 is noted.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>malposition of #27,#28,#37 and #38</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-07-20 - docetaxel 30mg/m2 1hr + cisplatin 30mg/m2 24hr + 5-Fu
1600mg/m2 48hr</li>
<li>2022-07-14 - docetaxel 30mg/m2 1hr + cisplatin 30mg/m2 24hr + 5-Fu
1600mg/m2 48hr</li>
</ul></li>
</ul>
<div id="section-494" class="section level3">
<h3>==========</h3>
</div>
<div id="section-495" class="section level3">
<h3>2022-07-20</h3>
<ul>
<li>There are three oral hypoglycemic drugs - Forxiga (dapagliflozin
10mg), Amamet (glimepiride 2mg + metformin 500mg), Lodiglit
(pioglitazone 15mg + metformin 850mg), as well as a long-acting insulin
- Tujeo - used as the basal dose.</li>
<li>F/S records and administered insulin units
<ul>
<li>Date QDAC basal QLAC basal</li>
<li>Unit mg/dL unit mg/dL unit</li>
<li>2022-07-20 NA 16 - -</li>
<li>2022-07-19 231 16 - -</li>
<li>2022-07-18 254 16 - -</li>
<li>2022-07-17 241 16 - -</li>
<li>2022-07-16 193 16 - -</li>
<li>2022-07-15 164 16 - -</li>
<li>2022-07-14 189 16 - -</li>
<li>2022-07-13 154 16 - -</li>
<li>2022-07-12 237 - 176 16</li>
</ul></li>
<li>According to the patient, 2022-07-19, he was well-tolerated with
last chemotherapy that had been started on 2022-07-14, with the
exception of somewhat oral mucosal pain just developed. He also had good
appetite during those post-therapy days, so he consumed more than usual
and the serum glucose levels increased since 2022-07-17.</li>
<li>The basal dose might be increased by 1 units if the glucose level
still keeps above 200 mg/dL and his intake remains unchanged. In the
event of hypoglycemia caused by a sulfonylurea - glimepiride, adjustment
by only one unit should a precautionary measure.</li>
<li>Newly developed oral candidiasis is treated with oral suspension
Mycostatin (nystatin).</li>
<li>The patient has alcoholic cirrhosis history with normal AST/ALT,
bilirubin (total and direct) levels (2022-07-20), the doses of the
chemotherapy regimen were adequate.</li>
</ul>
</div>
<div id="section-496" class="section level3">
<h3>2022-07-12</h3>
<ul>
<li>The self-carried items Cardiolol (propranolol) and warfarin should
be indicated for cardiovascular conditions, the current panel does not
provide a cardiovascular diagnosis or condition yet.</li>
<li>Hx: type 2 DM. 2022-07-12 06:05 blood sugar level was 237 mg/dL.
2022-06-21 lab serum glucose AC 299 mg/dL.
<ul>
<li>Toujeo (insulin glargine) was prescribed by another hospital or
clinic for this patient and could be considered to include it as a
self-carried drug item for in-hospital use.</li>
<li>There are three oral hypoglycemic agents - Forxiga (dapagliflozin
(SGLT2i) 10mg), Amamet (glimepiride (Sulfonylureas) 2mg + metformin
500mg), Lodiglit (pioglitazone (thiazolidinedione, TZD) 15mg + metformin
850mg) in active prescription.
<ul>
<li>If liver dysfunction becomes significant, please check for lactic
acidosis. Liver disease is considered a risk factor for the development
of lactic acidosis during metformin therapy.</li>
<li>Lodiglit contains pioglitazone. Pioglitazone should be use with
caution if baseline liver tests are abnormal. If liver injury is
suspected (eg, fatigue, jaundice, dark urine), please interrupt therapy,
measure serum liver tests, and investigate possible etiologies.</li>
</ul></li>
<li>HbA1c might be checked.</li>
</ul></li>
<li>Consideration of dose adjustment for patients with impaired liver
function, possible regimen might be: gemcitabine/cisplatin,
docetaxel/cisplatin/5-FU
<ul>
<li>5-Fu. The following adjustments have been suggested:
<ul>
<li>Bilirubin &gt;5 mg/dL: Avoid use (Floyd 2006).</li>
<li>Hepatic impairment (degree not specified): Administer &lt;50% of
dose, then increase if toxicity does not occur (Koren 1992).</li>
</ul></li>
<li>Docetaxel
<ul>
<li>Hepatic impairment dosing adjustment specific for gastric or head
and neck cancer:
<ul>
<li>AST/ALT &gt;2.5 to &lt;=5 times ULN and alkaline phosphatase
&lt;=2.5 times ULN: Administer 80% of dose.</li>
<li>AST/ALT &gt;1.5 to &lt;=5 times ULN and alkaline phosphatase &gt;2.5
to &lt;=5 times ULN: Administer 80% of dose.</li>
<li>AST/ALT &gt;5 times ULN and /or alkaline phosphatase &gt;5 times
ULN: Discontinue docetaxel.</li>
</ul></li>
<li>The following adjustments have also been used (Floyd 2006):
<ul>
<li>Transaminases 1.6 to 6 times ULN: Administer 75% of dose.</li>
<li>Transaminases &gt;6 times ULN: Use clinical judgment.</li>
</ul></li>
</ul></li>
<li>Cisplatin
<ul>
<li>It undergoes nonenzymatic metabolism and predominantly renal
elimination. Dosage adjustment is likely not necessary.</li>
</ul></li>
<li>Gemcitabine
<ul>
<li>Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m2; may
escalate if tolerated.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-497" class="section level1">
<h1>701003664</h1>
<div id="section-498" class="section level2">
<h2>220720</h2>
<p>{cervical cancer, adenocarcinoma, cT1bN1MB, FIGO stage IIIB}</p>
<ul>
<li>exam finding
<ul>
<li>2022-07-14 KUB
<ul>
<li>S/P double J catheter insertion, left side urinary tract.</li>
<li>S/P clips projecting at right pelvis.</li>
<li>Ascites is noted. Please correlate with CT.</li>
<li>Segmental dilatation of bowel in the middle abdomen is noted. Please
correlate with CT.</li>
</ul></li>
<li>2022-06-23 ECG
<ul>
<li>Sinus tachycardia</li>
<li>ST &amp; T wave abnormality, consider inferior ischemia</li>
<li>ST &amp; T wave abnormality, consider anterior ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-06-23 KUB
<ul>
<li>S/P left side double J catheter insertion.</li>
<li>S/P operation with retention of surgical clips.</li>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-06-10 2D transthoracic echocardiography
<ul>
<li>Adequate LV,RV systolic function with normal wall motion</li>
<li>Impaired LV relaxation</li>
<li>Mild PR</li>
</ul></li>
<li>2022-06-03 CT - brain
<ul>
<li>No evidence of intracranial hemorrhage.</li>
</ul></li>
<li>2022-06-03 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>ST &amp; T wave abnormality, consider anterior ischemia</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-05-18 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Nonspecific ST and T wave abnormality</li>
</ul></li>
<li>2022-05-17 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>left abdominal wall mass, suspected tumor recurrence</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>intestinal obstruction, DDx: carcinomatosis or adhesion</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>right inguinal LAPs</li>
</ol></li>
</ul></li>
<li>Suggestion
<ul>
<li>refer to GYN</li>
</ul></li>
</ul></li>
<li>2018-09-26 Gynecologic ultrasonography
<ul>
<li>suspected Rt corpus luteum cyst</li>
</ul></li>
<li>2018-09-23 CT - abdomen
<ul>
<li>Right hydronephrosis and hydroureter</li>
<li>Right distal ureter lesion; DDx: tumor invasion, post-RT change</li>
<li>Heterogeneous enhancing lesions in both lobes of liver. Suggest
dynamic CT or sonography correlation.</li>
</ul></li>
<li>2018-04-04 Surgical pathology level V
<ul>
<li>clinical diagnosis
<ul>
<li>Mucous polyp of cervix; Subacute and chronic vaginitis;</li>
</ul></li>
<li>pathological diagnosis
<ul>
<li>Uterus, cervic, LEEP conization
<ul>
<li>— Well to moderately differentiated adenocarcinoma</li>
<li>— carcinoma in situ</li>
<li>— margin inadequate (&lt; or = 1mm of closest margin diatnce).</li>
</ul></li>
<li>IHC satin — p16(+), CEA(focal+), vimentin (-)</li>
</ul></li>
<li>microscopic description
<ul>
<li>It shows adenocarcinoma composed of prolieration of neoplastic
glands lined by atypical cells and infiltrative growth pattern. The
tumor shows hyperchromatic nuclei, plemorphism and promine tnucleoli. It
also shows carcinoma in sit characterized by atypical cells replacing
the fuul-thickness of the cervical epithelium with glandular
involvement. The margin is inadequate (&lt; or = 1mm of closest margin
diatnce).</li>
</ul></li>
</ul></li>
<li>2018-04-04 Surgical pathology level IV
<ul>
<li>clinical diagnosis
<ul>
<li>Mucous polyp of cervix; Subacute and chronic vaginitis;</li>
</ul></li>
<li>pathological diagnosis
<ul>
<li>Uterus, endocervix, ECC — Mild glandular dysplasia</li>
</ul></li>
<li>microscopic description
<ul>
<li>It shows endocervical mucosal tissue fragments with focal mild
glandular dysplasia.</li>
</ul></li>
</ul></li>
<li>2018-02-27 MRI - pelvis
<ul>
<li>Imaging Report Form for Cervical Carcinoma</li>
<li><ol style="list-style-type: decimal">
<li>Soft tissue tumor in right cervical region (fornix), suspected
cervical malignancy, cstage T1N0Mx.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Prominent density in the uterine cavity, suggest further study.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Uterine myoma.</li>
</ol></li>
</ul></li>
<li>2018-02-14 Surgical pathology level IV
<ul>
<li>Screening for malignant neoplasms of cervix; Mucous polyp of
cervix;</li>
<li>Diagnosis
<ul>
<li>Uterus, cervix, clinically R/O cervical cancer — Adenocarcinoma in
situ (AIS), at least.</li>
<li>NOTE: Since invasive malignancy is suspected clinically, further
work up is advised.</li>
</ul></li>
<li>Microscopic description
<ul>
<li>Section shows pieces of adenocarcinoma in situ (AIS), at least, with
papillary structures lined by epithelium demonatrsting elongated nuclei,
occasional nuclear pleomorphism, and many mitoses. Occasional cribriform
pattern glands are found.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-27 Chinese Medicine
<ul>
<li>Q
<ul>
<li>This 42-year-old woman patient is a case of Cervical cancer,
adenocarcinoma, cT1bN1MB, FIGO stage IIIB,
<ul>
<li>s/p Robotic radical trachelectomy + pelvic lymphadectomy on
2018/04/23 at Far Eastern Memorial Hospital with pelvic recurrence and
compression to lower part of right ureter and right ovary s/p Robotic
pelvic adhesiolysis, pelvic mass biopsy, right salpingo-oophorectomy and
left ovary suspension on 2018/11 at Far Eastern Memorial Hospital</li>
<li>s/p salvage CCRT with 6 cycles of chemotherapy with Cisplatin
40mg/m2 &amp; pelvic radiotherapy (6000cGy/30fx) (2018/12~2019/02) at
Far Eastern Memorial Hospital s/p radial trachelectomy and left ovarian
transposition on 2019/05/31 at Far Eastern Memorial Hospital with left
upper abdominal wall port site metastases,</li>
<li>s/p excision of abdomnal wall tumor on 2020/7/09, 2020/11/24,
2021/03/16 s/p systemic chemotherapy with 6 cycles of Cisplatin 50mg/m2
+ Paclitaxel 175 mg/m2 + Bevacizumab 15mg/kg at Far Eastern Memorial
Hospital (2021/03~?)</li>
<li>s/p left abdominal radiotherapy for the port-site metastatses x 10
times at Koo Foundation Sun Yat-Sen Cancer Center (2022/02~).</li>
</ul></li>
<li>This time, ileus with nauseas with vomiting admitted for further
treatment. Now, for evaluate Comprehensive protocol of integrated
Chinese and western medicine (ICWM). Thank you.</li>
</ul></li>
<li>A
<ul>
<li>past history
<ul>
<li>2018/07/27 Uterine myoma</li>
</ul></li>
<li>2022-04 CT at KFSYSCC
<ul>
<li>Clinical History and Indications Metastatic Cervical adenocarcinoma:
<ul>
<li><ol style="list-style-type: lower-alpha">
<li>Larger of the lower abdominal wall lesion. R/I metastasis; and
peritoneal / bowel wall invasion suspected. Right inguinal lymph node
(8.6 mm), larger.</li>
</ol></li>
<li><ol start="2" style="list-style-type: lower-alpha">
<li>Dilatation of small bowel, which may related to adhesion or
peritoneal carcinomatosis.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-27 lab data
<ul>
<li>S-GPT/ALT = 249 U/L;</li>
<li>S-GOT/AST = 112 U/L;</li>
<li>Albumin = 2.8 g/dL;</li>
<li>BUN = 20 mg/dL;</li>
<li>Bilirubin direct = 0.25 mg/dL;</li>
<li>eGFR = 90.07;<br />
</li>
<li>WBC = 1.52 *10^3/uL;</li>
<li>RBC = 3.68 *10^6/uL;</li>
<li>HGB = 10.0 g/dL;</li>
<li>PLT = 50 *10^3/uL;<br />
</li>
<li>Neutrophil = 65.0 %;</li>
</ul></li>
<li>Plan
<ul>
<li>By using acupuncture to improve the symptom of intestinal
obstruction</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-22 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This 42-year-old woman,G0P0, sex(+), with medical/surgical history
of
<ul>
<li><ol style="list-style-type: decimal">
<li>Cervical cancer, adenocarcinoma, cT1bN1MB, FIGO stage IIIB, - s/p
Robotic radical trachelectomy + pelvic lymphadectomy on 2018/04/23 at
FEMH</li>
</ol>
<ul>
<li>with pelvic recurrence and compression to lower part of right ureter
and right ovary, s/p Robotic pelvic adhesiolysis, pelvic mass biopsy,
right salpingo-oophorectomy and left ovary suspension on 2018/11 at
FEMH</li>
<li>s/p salvage CCRT with 6 cycles of chemotherapy with Cisplatin
40mg/m2 &amp; pelvic radiotherapy (6000cGy/30fx) (2018/12~2019/02) at
FEMH</li>
<li>s/p radial trachelectomy and left ovarian transposition on
2019/05/31 at FEMH</li>
<li>with left upper abdominal wall port site metastases, s/p excision of
abdomnal wall tumor on 2020/7/09, 2020/11/24, 2021/03/16</li>
<li>s/p systemic chemotherapy with 6 cycles of Cisplatin 50mg/m2
+Paclitaxel 175 mg/m2 + Bevacizumab 15mg/kg at FEMH (2021/03~?)</li>
<li>s/p left abdominal radiotherapy for the port-site metastatses x 10
times at KFSYSCC (2022/02~)<br />
</li>
</ul></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Bilateral lower ureteral stricture with bilateral
hydronephrosis,</li>
</ol>
<ul>
<li>s/p bilateral DBJ insertion since 2018/04</li>
<li>s/p left ureterolysis + right ureteroneocystostomy with psoas hitch
and Boari flap on 2019/05/31</li>
</ul></li>
</ul></li>
<li>This time, abdominal discomfort (intermittent cramping pain) and
body weight loss (8kg) were noted since 2022/03/26.
<ul>
<li>Abdominal CT scan showed
<ul>
<li><ol style="list-style-type: lower-alpha">
<li>Larger of the lower abdominal wall lesion. R/I metastasis; and
peritoneal / bowel wall invasion suspected;</li>
</ol></li>
<li><ol start="2" style="list-style-type: lower-alpha">
<li>Dilatation of small bowel, which may related to adhesion or
peritoneal carcinomatosis.</li>
</ol></li>
</ul></li>
<li>Blood drawn on 2022/04/25 showed CA153 17.2, CA199 655.1 and CA125
137.3.</li>
<li>She visited to our GI hospital on 2022/05/17 where sonography showed
<ul>
<li><ol style="list-style-type: decimal">
<li>Left abdominal wall mass, suspected tumor recurrence</li>
</ol></li>
<li>2.Intestinal obstruction, DDx: carcinomatosis or adhesion</li>
<li>3.Right inguinal LAPs.</li>
</ul></li>
</ul></li>
<li>Under the impression of cervical adenocarcinoma suspected metastasis
and recurrence, she was then referred to Prof. Huang and admission to
our ward for further evaluation and management, we need your expertise
for further evaluation and management.
<ul>
<li>s/p salvage CCRT with 6 cycles of chemotherapy with Cisplatin
40mg/m2 &amp; pelvic radiotherapy (6000cGy/30fx) (2018/12~2019/02) at
FEMH</li>
<li>s/p systemic chemotherapy with 6 cycles of Cisplatin 50mg/m2
+Paclitaxel 175 mg/m2 + Bevacizumab 15mg/kg at FEMH (2021/03~?)</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>For recurrent or metastasis cervical cancer, systemic chemotherapy
is indicated. We will discuss with patient about further systemic
chemotherapy.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-07-09, 2020-11-24, 2021-03-16
<ul>
<li>with left upper abdominal wall port site metastases, s/p excision of
abdomnal wall tumor</li>
</ul></li>
<li>2019-05-31 at FEMH
<ul>
<li>radial trachelectomy and left ovarian transposition</li>
<li>left ureterolysis + right ureteroneocystostomy with psoas hitch and
Boari flap</li>
</ul></li>
<li>2018-11-?? at FEMH
<ul>
<li>Robotic pelvic adhesiolysis, pelvic mass biopsy, right
salpingo-oophorectomy and left ovary suspension</li>
</ul></li>
<li>2018-09-23
<ul>
<li>Diagnosis
<ul>
<li>Right hydronephrosis</li>
</ul></li>
<li>PCS code
<ul>
<li>28020C</li>
</ul></li>
<li>Finding
<ul>
<li>Right lower ureter stricture 4cm proximal to ureteral orifice</li>
<li>External compression was clinically suspected</li>
<li>6Fr 24cm DBJ was inserted</li>
</ul></li>
</ul></li>
<li>2018-04-23 at FEMH
<ul>
<li>Robotic radical trachelectomy + pelvic lymphadectomy</li>
</ul></li>
<li>2018-04-04
<ul>
<li>Diagnosis
<ul>
<li>Mucous polyp of cervix</li>
</ul></li>
<li>PCS code
<ul>
<li>81031C</li>
</ul></li>
<li>Finding
<ul>
<li><ol style="list-style-type: decimal">
<li>Cervix:papillary lesion oner right external OS</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Three strips2<em>1</em>1, 1<em>1</em>1,0.5*0.5 cm strip of cervix
were electrocauterized.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Estimated blood loss:50ml</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Complication: nil</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02 ~ ? at KFSYSCC
<ul>
<li>left abdominal radiotherapy for the port-site metastatses x 10
times</li>
</ul></li>
<li>2018-12 ~ 2019-02 at FEMH
<ul>
<li>salvage CCRT with 6 cycles of chemotherapy with Cisplatin 40mg/m2
&amp; pelvic radiotherapy (6000cGy/30fx)</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-13, 2022-07-04 - topotecan 0.75mg/m2 30min D1-3 + cisplatin
25mg/m2 24hr D1-2</li>
<li>2021-03 ~ ? at FEMH - 6 cycles of cisplatin 50mg/m2 + paclitaxel 175
mg/m2 + bevacizumab 15mg/kg</li>
<li>2018-12 ~ 2019-02 at FEMH - 6 cycles of chemotherapy with cisplatin
40mg/m2 for CCRT</li>
</ul></li>
<li>chemotherapy regimen reference
<ul>
<li>Efficacy and Safety Evaluation of the Various Therapeutic Options in
Locally Advanced Cervix Cancer: A Systematic Review and Network
Meta-Analysis of Randomized Clinical Trials
<ul>
<li><a href="https://www.clinicalkey.com/service/content/pdf/watermarked/1-s2.0-S0360301618338185.pdf" class="uri">https://www.clinicalkey.com/service/content/pdf/watermarked/1-s2.0-S0360301618338185.pdf</a></li>
</ul></li>
<li>Comparison of the efficacy among multiple chemotherapeutic
interventions combined with radiation therapy for patients with cervix
cancer after surgery: A network meta-analysis
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564785/pdf/oncotarget-08-49515.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564785/pdf/oncotarget-08-49515.pdf</a></li>
</ul></li>
</ul></li>
</ul>
<div id="section-499" class="section level3">
<h3>==========</h3>
</div>
<div id="section-500" class="section level3">
<h3>2022-07-20</h3>
<ul>
<li>I visited the patient and her mother at approximately 16:45 on
2022-07-19.</li>
<li>As compared with the experience at FEMH/KFSYSCC, the patient
tolerates the current regimen well for less nausa and vomiting.</li>
<li>The patient is concerned that the treatment will adversely affect
her kidney function. According to the recent lab results, I told her
that there is no problem with her kidney function.</li>
</ul>
</div>
<div id="section-501" class="section level3">
<h3>2022-07-19</h3>
<p>[BFluid - the amount of electrolyte can be added]</p>
<p>A supplement to my explanation after answering the nurse’s call this
morning about the compatibility of B Fluid with KCl.</p>
<ul>
<li>Each 1000 mL BFluid solution contains (after mixing)
<ul>
<li>Electrolytes mEq/L, max amount to be added
<ul>
<li>Na+ 35 115</li>
<li>K+ 20 40</li>
<li>Ca++ 5 5</li>
<li>Mg++ 5 16</li>
<li>HPO4– 10 10</li>
<li>insulin 0 10~20 (IU)</li>
</ul></li>
</ul></li>
<li>The addition of other drugs to BFluid is not recommended except for
electrolytes and regular insulin.</li>
<li>Within the limits of the amount, KCl is compatible with B Fluid. It
contains 20mEq K+ in the prescribed 0.298% KCl 500mL.</li>
</ul>
</div>
</div>
</div>
<div id="section-502" class="section level1">
<h1>701381642</h1>
<div id="section-503" class="section level2">
<h2>220720</h2>
<p>{Thymic cancer, squamous cell carcinoma, cT4N2M1b, stage IVB, with
malignant pleural effusion, bone and lung metastasis}</p>
<ul>
<li>exam finding
<ul>
<li>2022-07-19 SONO - thorax
<ul>
<li>Echo diagnosis
<ul>
<li>Left thorax: organized pleural effusion</li>
<li>Right thorax: moderate amount, yellowish pleural effusion s/p
insertion of 14 Fr. pig-tail catheter and fixed at 15cm.</li>
</ul></li>
</ul></li>
<li>2022-07-16 CXR
<ul>
<li>Total white-out of left lung is noted that may be massive pleura
effusion?</li>
<li>Right pleura effusion.</li>
<li>Several nodular opacity projecting in the right lung are noted that
are c/w lung to lung metastases. Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Metastasis in right 5th rib is suspected.</li>
</ul></li>
<li>2022-07-14 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific ST and T wave abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-07-14 SONO - thorax
<ul>
<li>Symptoms: dyspnea improved</li>
<li>Indication: effusion, LUL</li>
<li>Clinical Diagnosis
<ul>
<li>Thymic cancer with persited left side pleural effusion, LUL
consolidation with airbronchogram. localized pleural effusion, with LUL
consolidation.</li>
</ul></li>
<li>Procedure &amp; Finding
<ul>
<li>The patient was in sitting upright posture while the chest
echography was performed using 3.75-mHz convex probe.</li>
<li>Left-side of thorax
<ul>
<li>Pleura positive Pleura Line thin</li>
<li>Effusion: Echogenicity clear localized</li>
<li>Size 1-2-ICS, Left upper lung, fixed, with LUL consolidation,
collapse.</li>
<li>Left lower back pleural thickening with fixed, organization of
pleural effusion or parietal pleural involvement.</li>
</ul></li>
<li>Right-side of thorax:
<ul>
<li>Pleura negative Pleura Line</li>
</ul></li>
</ul></li>
<li>Special Procedure: Nil</li>
<li>Echo diagnosis:
<ul>
<li>Left side:
<ul>
<li>Size 1-2-ICS, Left upper lung, fixed, with LUL consolidation,
collapse.</li>
<li>Left lower back pleural thickening with fixed, organization of
pleural effusion or parietal pleural involvement.</li>
</ul></li>
</ul></li>
<li>Removal of pig tail tube due to obstruction by debri.</li>
<li>Pig tail re-insertion was not safe because of a little pleural
effuion only.</li>
<li>Suggestion:
<ul>
<li>CxR follow up 3-7 days. or chest echography if SOB develope
again.</li>
</ul></li>
</ul></li>
<li>2022-06-24 CXR
<ul>
<li>Patchy opacity projecting at left upper lung zone with lung volume
decrease and air-bronchogram was noted. Please correlate with CT.</li>
<li>Several nodular opacity projecting in the right lung are noted that
are c/w lung to lung metastases. Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Left pleura effusion S/P pigtail catheter implantation.</li>
<li>S/P port-A implantation.</li>
<li>Metastasis in right 5th rib is suspected.</li>
</ul></li>
<li>2022-06-20 CXR
<ul>
<li>Patchy opacity projecting at left upper lung zone with lung volume
decrease was noted. Please correlate with CT.</li>
<li>Several nodular opacity projecting in the right lung are noted that
are c/w lung to lung metastases. Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Left pleura effusion S/P pigtail catheter implantation.</li>
<li>S/P nasogastric tube insertion</li>
<li>S/P port-A implantation.</li>
<li>Metastasis in right 5th rib is suspected.</li>
</ul></li>
<li>2022-06-16 CXR
<ul>
<li>appropriately positioned gastric tube</li>
<li>Port-A catheter inserted into RA via right subclavian vein.</li>
<li>LUL lobar consolidaition with air-bronchogram</li>
<li>consolidation over Lt lower lung with enlarged hilum</li>
<li>nodular/patchy opacities in Rt lung in progression</li>
<li>enlarged cardiac silhoutte</li>
<li>Rt pleural effusion</li>
<li>Lt pleural effusion s/p pigtail drain placement</li>
</ul></li>
<li>2022-06-16 CXR
<ul>
<li>appropriately positioned gastric tube</li>
<li>approriately positioned endotracheal tube in place</li>
<li>Port-A catheter inserted into RA via right subclavian vein.</li>
<li>LUL lobar consolidaition with air-bronchogram</li>
<li>extensive consolidation over Lt lower lung with enlarged hilum</li>
<li>nodular/patchy opacities in Rt lung</li>
<li>enlarged cardiac silhoutte</li>
<li>Rt pleural effusion</li>
<li>Lt pleural effusion s/p pigtail drain placement</li>
</ul></li>
<li>2022-06-09 CXR
<ul>
<li>Port-A catheter inserted into RA via right subclavian vein.</li>
<li>LUL lobar consolidaition with air-bronchogram</li>
<li>extensive consolidation over Lt lower lung with enlarged hilum</li>
<li>nodular/patchy opacities in Rt lung</li>
<li>enlarged cardiac silhoutte</li>
<li>Rt pleural effusion</li>
<li>appropriately positioned gastric tube</li>
<li>approriately positioned endotracheal tube in place</li>
<li>regression Lt pleural effusion s/p pigtail drain placement</li>
</ul></li>
<li>2022-06-06 CXR
<ul>
<li>Port-A catheter inserted into RA via right subclavian vein.</li>
<li>LUL lobar consolidaition with air-bronchogram</li>
<li>extensive consolidation over Lt lower lunbg with enlarged hilum</li>
<li>numerous nodules/parchy opacities of variable sizes in Rt lung due
to metastases</li>
<li>enlarged cardiac silhoutte</li>
<li>bilateral pleural effusions</li>
<li>appropriately positioned gastric tube</li>
<li>approriately positioned endotracheal tube in place</li>
<li>regression Lt pleural effusion s/p pigtail drain placement</li>
</ul></li>
<li>2022-06-02 SONO - chest
<ul>
<li>Clinical Diagnosis
<ul>
<li>Thymic cancer stage 4</li>
<li>Left side pleural effusion</li>
</ul></li>
<li>Procedure &amp; Finding
<ul>
<li>The patient was in supine posture while the chest echography was
performed using 3.75-mHz convex probe.
<ul>
<li>Left-side of thorax
<ul>
<li>Pleura positive Pleura Line thin</li>
<li>Effusion: Echogenicity clear extending from the posterior to the
anterior</li>
<li>Size 1-2-ICS</li>
</ul></li>
<li>Right-side of thorax</li>
</ul></li>
</ul></li>
<li>Echo diagnosis:
<ul>
<li>Left side mild to moderate pleural effusion s/p pig-tail insertion,
seroanguinous, drowsy</li>
</ul></li>
</ul></li>
<li>2022-06-02 2D transthoracic echocardiography
<ul>
<li>Normal chamber size</li>
<li>Small pericardial effusion</li>
<li>Adequate LV and RV systolic function</li>
<li>AV sclerosis with mild AR, mild MR, TR and PR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2022-05-31 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Nonspecific T wave abnormality</li>
</ul></li>
<li>2022-05-30 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Low voltage QRS</li>
<li>Poor wave progression</li>
<li>Abnormal ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-16 Nephrology
<ul>
<li>Q
<ul>
<li>This 45y/o female was a case of Thymic cancer, squamous cell
carcinoma, cT4N2M1b, stage IVB, with malignant pleural effusion, bone
and lung metastasis. Regular in NTUH follow-up.</li>
<li>According to the statement of the patient families and ER medical
record. She ever fever, suspected community-acquired pneumonia, status
post Unasyn 3/29-4/8 under Augmentin. This time. she had suffered from
palpitations, dyspnea, spiky fever and generalized malaise for 2 days,
the symptoms became to worsen. Therefore she was sent to our ER.</li>
<li>At ER, spiky fever up to 38.1degree, Acetamol iv infusion and
adequate fluid iv infusion were given. Elevation of breathing work and
saturation around 80%, the patient refused invade procedule, NIPPV
placement and steroid with solu-cortef 50mg iv injection. The chest
films disclosed of bilateral pneumonia with massive plerual effusion,
empiric antiboltic with Tapimycin was perscribed. Bordelrine blood
pressure around SBP 95-99mmHg, Albumin 50ml IVD loading and fluid iv
infusion for hydration.</li>
<li>Under the impression of sepsis and bilateral pneumonia with massive
plerual effusion combine impending respiratory failure. She was admitted
to our ICU for further observation and management.</li>
<li>Due to the very low creatinine level, electrolyte unbalance, short
stature, we have check Aldosterone and PRA (plasma renin activity)
according to the suggestion of endocrinologist and we need your
expertise of further evaluation and management of the very low
creatinine level, electrolyte unbalance, short stature. Thanks!</li>
</ul></li>
<li>Q
<ul>
<li>Impression
<ul>
<li>Low creatinine due to low muscle mass, or cachexia related</li>
<li>Mg deficiency suspect nutritional deficiency related</li>
</ul></li>
<li>Suggestion
<ul>
<li>Check 24h Cr</li>
<li>Nutrition supplement</li>
</ul></li>
<li>Thank you very much for your consultation.</li>
</ul></li>
</ul></li>
<li>2022-06-15 Metabolism and Endocrinology
<ul>
<li>c-peptide &lt; 0.02 ng/mL<br />
</li>
<li>very poor beta cell function,</li>
<li>high risk for DKA and sugar unstable as same as DM type 1</li>
<li>please check Anti-GAD (GAD Ab, Glutamic Acid Decarboxylase
Autoantibodies test), (self-paid item) to rule in DM type 1</li>
<li>re-on basal insulin with bolus insulin to control blood sugar</li>
<li>please check insulin Ab - –</li>
<li>very low Cr, electrolyte unbalance, short stature</li>
<li>glomerular hyperfiltration?</li>
<li>please check Aldosterone and PRA (plasma renin activity)</li>
<li>please Consult Nephrologist</li>
<li>may consult Pediatrics Dr. Tsai to rule out genetic disorder</li>
<li>please consult Oncologist</li>
</ul></li>
<li>2022-06-13 Gastroenterology
<ul>
<li>Q
<ul>
<li>We need your expertise for entecavir use before the chemotherapy
use. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>Entecavir would be prescribed.</li>
<li>Indication: HbsAg(+) or HbsAg(-) while anti-Hbc(+) plus chemotherapy
(1 wk before C/T unitl 6 mo after C/T)</li>
</ul></li>
</ul></li>
<li>2022-06-09 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>Due to the poor control hyperglycemia condition, we need your
expertise of further evaluation and management of medication control
under insulin use. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>BW: 43.2</li>
<li>Diet: NG, DM diet 1800 kcal/day</li>
<li>Medication in OPD: Metformin, Trajenta, NovoRapid, Toujeo</li>
<li>Medication during hospitalization: RI TIDAC, Toujeo, Metformin</li>
<li>Na: 132, K: 4.1</li>
<li>ALT: 7</li>
<li>BUN/Cr: 13/0.35 (eGFR: 213.07)</li>
<li>F/S (finger stick):
<ul>
<li>date 06-07 06-08 06-09</li>
<li>QDAC 277 357 281 -&gt; RI 16u</li>
<li>QLAC 466 328 272 -&gt; RI 16u</li>
<li>QNAC 240 393 91 -&gt; Hold RI</li>
<li>HS 072 054 308</li>
</ul></li>
<li>HbA1c: 6.5</li>
<li>Urine ACR: unavailable</li>
<li>OPH OPD: nil</li>
</ul></li>
<li>A:
<ul>
<li>Type 2 DM, poor controlled</li>
</ul></li>
<li>Suggestions:
<ul>
<li><ol style="list-style-type: decimal">
<li>Avoid all OADs at this moment (DC Metformin during infection
status)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>RI 14U QDAC (before first meal), 12U QLAC (before third meal), 10U
QNAC (before fifth meal) with correction scales -&gt; switch to apidra
low dose before each feeding</li>
</ol>
<ul>
<li>F/S &lt; 080，RI hold</li>
<li>F/S 081~090，RI -4U</li>
<li>F/S 091~100，RI -3U</li>
<li>F/S 101~110，RI -2U</li>
<li>F/S 111~120，RI -1U</li>
<li>F/S 201~250，RI +1U</li>
<li>F/S 251~300，RI +2U</li>
<li>F/S 301~350，RI +3U</li>
<li>F/S 351~400，RI +4U</li>
<li>F/S &gt; 400，RI +5U</li>
</ul></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hold Toujeo temporarily</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Check urine ACR</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Contact us if needed. I’d like to follow up this patient. - –</li>
</ol></li>
</ul></li>
<li>low body weight 42-43 kg</li>
<li>sugar unstable under RI 12u tidac and basal insulin<br />
</li>
<li>Switch RI tidac to apidra before each feeding</li>
<li>Please call Dr. Hu QD or QOD to adjust insulin dosage if sugar poor
control</li>
<li>Please check blood sugar and C-peptide to evaluate beta cell
function</li>
<li>Fluoroquinolones may increase the risk of hypoglycemia, please
closely monitor finger stick and hypoglycemia</li>
<li>consider switch Toujeo to Tresiba<br />
</li>
</ul></li>
</ul></li>
<li>2022-06-03 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>Due to Thymic cancer, squamous cell carcinoma, cT4N2M1b, stage IVB,
with malignant pleural effusion, bone and lung metastasis. Regular in
NTUH follow-up. Patient family stated that NTUH had thought to apply
oral targeted drugs, need your evluation help and check targeted drugs,
thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li><ol style="list-style-type: decimal">
<li>Bilateral pneumonia with respiratory failure s/p endo with
ventilation</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Thymic cancer, squamous cell carcinoma, cT4N2M1b, stage IVB, with
malignant pleural effusion, bone and lung metastasis</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Treat sepsis and respiratory failure as your expertise, best
supportive care</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Have the patient family to bring medical records from NTUH</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-01 Infectious Diseases
<ul>
<li>Antibiotic therapy should be adjusted according to the results of in
vitro sensitivity testing.</li>
<li>NO treatment for colonization. Do NOT use steroid.</li>
<li>Antimicrobiologic coverage with parental Finibax 500 mg q8h is
recommended.</li>
</ul></li>
<li>2022-05-31 Family Medicine
<ul>
<li>Q
<ul>
<li>This consultation is for critically ill hospice care.</li>
<li>After admission, elevation of breathing work with paradoxical
movement used and desaturation were found. We have informed prognosis
and intubation indication with treatment programs to his hunsband, he
understood and decided aggresive treatment. Due to these resasons, we
sincerely need your expertise for critically ill hospice care.
Thanks!</li>
</ul></li>
<li>A
<ul>
<li>Patient has received intubation and just undergoes aggressive
treatment.</li>
<li>We will arrange share care to F/U her prognosis.</li>
<li>We could arrange transfer if necessary.</li>
<li>Indication: Thymic cancer, squamous cell carcinoma, cT4N2M1b, stage
IVB</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-13 ~ undergoing - cisplatin 20mg/m2 24hr + 5-Fu 2000mg/m2
24hr + leucovorin 200mg/m2 24hr (weekly)</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Thymomas and Thymic Carcinomas, NCCN EB, Version 2.2022 - May 4,
2022, p13
<ul>
<li>Principles of systemic therapy - first-line combination chemotherapy
regimens
<ul>
<li>Thymoma
<ul>
<li>Preferred (Other Recommended for Thymic Carcinoma)
<ul>
<li>CAP1
<ul>
<li>Cisplatin 50 mg/m2 IV day 1</li>
<li>Doxorubicin 50 mg/m2 IV day 1</li>
<li>Cyclophosphamide 500 mg/m2 IV day 1</li>
<li>Administered every 3 weeks</li>
</ul></li>
</ul></li>
<li>Other Recommended for Thymic Carcinoma and Thymoma
<ul>
<li>CAP with prednisone
<ul>
<li>Cyclophosphamide 500 mg/m2 IV on day 1;</li>
<li>Doxorubicin, 20 mg/m2/day IV continuous infusion on days 1-3;</li>
<li>Cisplatin 30 mg/m2 days 1-3;</li>
<li>Prednisone 100 mg/day days 1-5;</li>
<li>Administered every 3 weeks</li>
</ul></li>
<li>ADOC
<ul>
<li>Doxorubicin 40 mg/m2 IV day 1;</li>
<li>Cisplatin 50 mg/m2 IV day 1;</li>
<li>Vincristine 0.6 mg/m2 IV day 3;</li>
<li>Cyclophosphamide 700 mg/m2 IV day 4</li>
<li>Administered every 3 weeks</li>
</ul></li>
<li>PE
<ul>
<li>Cisplatin 60 mg/m2 IV day 1;</li>
<li>Etoposide 120 mg/m2/day IV days 1-3;</li>
<li>Administered every 3 weeks</li>
</ul></li>
<li>Etoposide/ifosfamide/cisplatin5
<ul>
<li>Etoposide 75 mg/m2 on days 1-4;</li>
<li>Ifosfamide 1.2 g/m2 on days 1-4;</li>
<li>Cisplatin 20 mg/m2 on days 1-4</li>
<li>Administered every 3 weeks</li>
</ul></li>
</ul></li>
</ul></li>
<li>Thymic Carcinoma
<ul>
<li>Preferred (Other Recommended for Thymoma)
<ul>
<li>Carboplatin/paclitaxel
<ul>
<li>Carboplatin AUC 6</li>
<li>Paclitaxel 200 mg/m2</li>
<li>Administered every 3 weeks</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>Principles of systemic therapy - second-line chemotherapy regimens
(subsequent therapy)
<ul>
<li>Thymoma
<ul>
<li>Other Recommended
<ul>
<li>Etoposide</li>
<li>Everolimus</li>
<li>5-FU and leucovorin</li>
<li>Gemcitabine +- capecitabine</li>
<li>Ifosfamide</li>
<li>Octreotide (including LAR) +/- prednisone</li>
<li>Paclitaxel</li>
<li>Pemetrexed</li>
</ul></li>
</ul></li>
<li>Thymic Carcinoma
<ul>
<li>Other Recommended
<ul>
<li>Everolimus</li>
<li>5-FU and leucovorin</li>
<li>Gemcitabine +- capecitabine</li>
<li>Lenvatinib</li>
<li>Paclitaxel</li>
<li>Pembrolizumab</li>
<li>Pemetrexed</li>
<li>Sunitinib</li>
</ul></li>
<li>Useful in Certain Circumstances
<ul>
<li>Etoposide</li>
<li>Ifosfamide</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-504" class="section level3">
<h3>==========</h3>
</div>
<div id="section-505" class="section level3">
<h3>2022-07-20</h3>
<ul>
<li>F/S records and administered insulin units
<ul>
<li>Date QDAC basal bolus QLAC bolus QNAC bolus</li>
<li>Unit mg/dL unit unit mg/dL unit mg/dL unit</li>
<li>2022-07-20 184 12 7 - - - -</li>
<li>2022-07-19 157 12 7 256 8 141 7</li>
<li>2022-07-18 277 12 7 360 7 316 7</li>
<li>2022-07-17 105 12 7 301 7 361 7</li>
<li>2022-07-16 265 12 7 274 7 179 7</li>
<li>2022-07-15 060 0 0 280 7 186 7 (QDPC 190 mg/dL, after taking
sugar)</li>
<li>2022-07-14 189 12 7 281 7 319 7</li>
<li>2022-07-13 - - - - - 376 7</li>
</ul></li>
<li>According to the patient’s mother last evening, she had been feeling
weaker these two days and had also reduced her calorie intake. In spite
of the high blood sugar levels before lunch these days, there is no
urgent need to adjust the insulin dose for her recent low intake at this
time.</li>
</ul>
</div>
<div id="section-506" class="section level3">
<h3>2022-07-18</h3>
<ul>
<li>Insulins in active prescription
<ul>
<li>Apidra 100U/mL (insulin glulisine) 7 unit SC TIDAC
<ul>
<li>onset 5~15min, max 30~90min, duration 3~5hr</li>
</ul></li>
<li>Tresiba FlexTouch 100U/mL (insulin degludec) 12 unit SC QDAC
<ul>
<li>onset 1hr, no apparent peak, duration &gt;24hr</li>
</ul></li>
</ul></li>
<li>F/S records
<ul>
<li>Date QDAC QLAC QNAC HS</li>
<li>2022-07-18 277 360 - -</li>
<li>2022-07-17 105 301 361 NA</li>
<li>2022-07-16 265 274 179 NA</li>
<li>2022-07-15 060 280 186 NA (QDPC 190, after taking sugar)</li>
<li>2022-07-14 189 281 319 NA</li>
<li>2022-07-13 NA NA 376 NA</li>
</ul></li>
<li>On 2022-07-15 morning before breakfast, hypoglycemia was observed,
but it is unclear what transpired between 7/14 bedtime and the
event.</li>
<li>Last week I noted that the patient’s staple food was porridge, and
her snack was bread, which are easy to raise blood sugar levels, and her
each meal might not be taken in similar quantity, thus complicating
blood sugar control.</li>
<li>As there was a hypoglycemia event last week, the basal dose can be
kept as usual, however, the F/S readings remain high these days. It is
recommended that the QLAC bolus be increased by +2U, and the QNAC bolus
by +1U.</li>
</ul>
</div>
<div id="section-507" class="section level3">
<h3>2022-07-15</h3>
<ul>
<li>There were no visual problems perceived by the patient when I
visited her 09:10 2022-07-15. As there is no ophthalmology OPD record
found, it would be recommended to consult Oph if diabetic retinopathy is
suspected.</li>
</ul>
</div>
<div id="section-508" class="section level3">
<h3>2022-07-14</h3>
<ul>
<li>CNS depressants alprazolam, brotizolam, lorazepam, oxazolam were
prescribed as HS co-administered, adverse/toxic effect might be
enhanced.</li>
<li>The half-life of each item (short to long): brotizolam (3.5 ~ 8 hr),
oxazepam (5 ~ 15 hr), alprazoalm (6 ~ 12 hr), lorazepam (10 ~ 20 hr), it
may be considered to remove drugs that have similar effect time.</li>
</ul>
</div>
</div>
</div>
<div id="section-509" class="section level1">
<h1>700034769</h1>
<div id="section-510" class="section level2">
<h2>220719</h2>
<ul>
<li>lab data
<ul>
<li>Creatinine
<ul>
<li>2022-07-19 1.80 mg/dL</li>
<li>2022-07-11 2.25 mg/dL</li>
<li>2022-07-05 2.31 mg/dL</li>
<li>2022-06-28 2.04 mg/dL</li>
<li>2022-06-13 2.31 mg/dL</li>
<li>2022-05-28 2.23 mg/dL</li>
<li>2022-05-17 2.29 mg/dL</li>
<li>2022-05-05 2.47 mg/dL</li>
<li>2022-05-03 2.40 mg/dL</li>
<li>2022-04-29 2.94 mg/dL</li>
<li>2022-04-28 2.11 mg/dL</li>
<li>2022-04-25 1.90 mg/dL</li>
<li>2022-04-17 1.70 mg/dL</li>
<li>2022-04-15 2.03 mg/dL</li>
<li>2022-03-29 1.84 mg/dL</li>
<li>2022-03-21 2.16 mg/dL</li>
<li>2022-03-17 1.99 mg/dL</li>
<li>2022-03-16 1.77 mg/dL</li>
<li>2022-03-15 1.95 mg/dL</li>
<li>2022-03-01 1.68 mg/dL</li>
<li>2022-02-21 1.73 mg/dL</li>
<li>2022-02-15 1.78 mg/dL</li>
<li>2022-02-07 1.30 mg/dL</li>
<li>2022-01-24 1.40 mg/dL</li>
<li>2022-01-17 1.38 mg/dL</li>
<li>2022-01-14 1.45 mg/dL</li>
<li>2022-01-11 1.35 mg/dL</li>
<li>2022-01-03 1.11 mg/dL</li>
<li>2021-12-28 1.41 mg/dL</li>
<li>2021-12-21 1.41 mg/dL</li>
<li>2021-12-16 1.52 mg/dL</li>
<li>2021-12-14 1.36 mg/dL</li>
<li>2021-12-06 1.11 mg/dL</li>
<li>2021-11-26 1.07 mg/dL</li>
<li>2021-10-05 1.44 mg/dL</li>
<li>2021-09-07 1.22 mg/dL</li>
<li>2021-07-13 1.25 mg/dL</li>
<li>2021-03-23 1.13 mg/dL</li>
<li>2021-01-26 1.07 mg/dL</li>
<li>2020-10-06 1.18 mg/dL</li>
<li>2020-09-04 1.20 mg/dL</li>
</ul></li>
<li>BUN
<ul>
<li>2022-07-19 44 mg/dL</li>
<li>2022-07-11 31 mg/dL</li>
<li>2022-06-28 38 mg/dL</li>
<li>2022-05-28 34 mg/dL</li>
<li>2022-05-05 28 mg/dL</li>
<li>2022-05-03 33 mg/dL</li>
<li>2022-04-29 46 mg/dL</li>
<li>2022-04-28 32 mg/dL</li>
<li>2022-04-25 43 mg/dL</li>
<li>2022-04-17 28 mg/dL</li>
<li>2022-04-15 35 mg/dL</li>
<li>2022-03-16 34 mg/dL</li>
<li>2022-02-21 27 mg/dL</li>
<li>2022-02-07 20 mg/dL</li>
<li>2022-01-24 23 mg/dL</li>
<li>2022-01-03 25 mg/dL</li>
<li>2021-12-28 36 mg/dL</li>
<li>2021-12-06 23 mg/dL</li>
<li>2021-11-26 19 mg/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-20 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2022-05-28 CT - lung/mediastinum/pleura
<ul>
<li>Finding
<ul>
<li>Chest:
<ul>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Wedge shaped interstitial opacity over left upper lobe is found. The
lesion is new. Recent inflammation is considered.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Left renal stone is found.</li>
<li>The spleen, liver, pancreas and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is stone at dependent portion of GB. GB stone(s) are
noted.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Gallstones.</li>
<li>No evidence of lymphadenopathy in the study.</li>
<li>Wedge shaped interstitial opacity over left upper lobe is found. The
lesion is new. Recent inflammation is considered.</li>
</ul></li>
</ul></li>
<li>2022-04-28 ECG
<ul>
<li>Left ventricular hypertrophy with QRS widening</li>
</ul></li>
<li>2022-02-24 Renal SONO (Nephrology)
<ul>
<li>Bilateral renal cysts, cortical and parapelvic ones.</li>
</ul></li>
<li>2022-02-16 CT - neck
<ul>
<li>no evidence of left neck nodular leions.</li>
</ul></li>
<li>2021-12-18 Renal SONO (Nephrology)
<ul>
<li>Parenchymal renal disease</li>
<li>Bilateral renal cysts</li>
<li>Left renal stone</li>
</ul></li>
<li>2021-11-29 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac crest, biopsy — Negative for malignancy</li>
<li>Microscopically, it shows 40% of marrow cellularity, with 3:2 of M:E
ratio, presence of trilineage cellular component and occasional
megakaryocytes.<br />
</li>
<li>Immunohistochemical stain reveals CD34(-), CD117(-), CD20(-),
CD138(&lt; 5%), MPO(+), CD71(+), Bcl-2(-) and Bcl-6(+).</li>
</ul></li>
<li>2021-12-01 2D transthoracic echocardiography
<ul>
<li>Heart size: Dilated LA, AoR</li>
<li>Thickening: IVS, LVPW</li>
</ul></li>
<li>2021-11-26 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Voltage criteria for left ventricular hypertrophy</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-11-17 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the left neck lymph nodes and bilateral
axillary lymph nodes comes to less evident compared with the previous
study on 2017-08-18, indicating response to current therapy.<br />
</li>
<li>Glucose hypermetabolism in the left thyroid bed, the nature is to be
determined (functioning nodule of thyroid, inflammatory process or other
nature ?). Please correlate with other clinical findings for further
evaluation.</li>
<li>Glucose hypermetabolism in bilateral pulmonary hilar lymph nodes,
reactive nodes or physiologic FDG uptake is more likely.</li>
</ul></li>
<li>2021-11-08 Patho - lymphnode biopsy
<ul>
<li>Lymph node, left neck, excisional biopsy— Diffuse large B-cell
lymphoma, non-GCB (c-myc +)<br />
</li>
<li>Immunohistochemical stain profiles: CD23(focal+), CD20(+), CD10(-),
Ki-67 index: 20%, Bcl-2(+), c-myc (+, &gt;30%), MUM1(+), Bcl-6(+),
cyclin D1(-), CD3 (immunoreactive at background T cell).<br />
</li>
<li>Reference: S2017-12983</li>
</ul></li>
<li>2021-11-02 Nasopharyngoscopy
<ul>
<li>Findings
<ul>
<li>smooth NPx, oropharynx, hypopharynx, no tumor found</li>
</ul></li>
<li>Diagnosis
<ul>
<li>lymphoma s/p treatment</li>
</ul></li>
</ul></li>
<li>2021-10-20 CT - lung/mediastinum/pleura
<ul>
<li>Findings - comparison made with previous CT dated on 2021/04/13
<ul>
<li><ol style="list-style-type: decimal">
<li>Lungs: a 14 mm cyst at S10 of RLL, otherwise normal appearance of
bilateral lungs.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mediastinum: no enlarged LN or mass.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hila: no enlarged LN.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance..</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Heart: normal in size of cardiac chambers. midseptal hypertrophy of
IVS.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pleura and pericardium: no effusion or thickening</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Chest wall and visible neck: multiple small lymph nodes in bilateral
axillary regions and visible neck, stationary.</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Visible abdominal contents: a tiny Lt renal stone 2 mm. multiple
small liver cysts up to 1.5 cm. many gall bladder stones. unremarkable
of the spleen, adrenal glands, pancreas, and Rt kidney. no enlarged
LN.</li>
</ol></li>
</ul></li>
<li>IMP:
<ul>
<li>no mass or enlarged lymphadenopathy in visible neck, mediastinum and
axillary regions, and abdomen.</li>
</ul></li>
</ul></li>
<li>2021-04-13 CT - lung/mediastinum/pleura
<ul>
<li>Findings - comparison made with previous CT dated on 2020/10/27
<ul>
<li><ol style="list-style-type: decimal">
<li>Lungs: a 14 mm cyst at S10 of RLL, otherwise normal appearance of
bilateral lungs.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mediastinum: no enlarged LN or mass.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hila: no LAP.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Heart: normal in size of cardiac chambers. midseptal hypertrophy of
IVS.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pleura and pericardium: no effusion or thickening</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Chest wall and visible neck: multiple small lymph nodes in bilateral
axillary regions and posterior triangles of visible neck.</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Visible abdominal contents:</li>
</ol>
<ul>
<li>a tiny Lt renal stone 2 mm. multiple small liver cysts up to 1.5 cm.
gall bladder stones.</li>
<li>unremarkable of the spleen, adrenal glands, pancreas, and Rt
kidney.</li>
<li>no mass or lymphadenopathy in visible neck, mediastinum and axillary
regions, and abdomen.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-10-27 CT - lung/mediastinum/pleura
<ul>
<li>Findings - comparison: prior CT dated on 2019/01/17
<ul>
<li><ol style="list-style-type: decimal">
<li>Lungs and large central airways: normal appearance of bilateral
lungs.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mediastinum: no LAP or mass.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hila: no LAP.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Heart: normal in size of cardiac chambers.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pleura, pericardium: no effusion or thickening</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Chest wall and neck: multiple small lymph nodes in bilateral
axillary regions and posterior triangles of visible neck.</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Visible abdominal-pelvis contents:</li>
</ol>
<ul>
<li>a tiny Lt renal stone. multiple liver cysts up to 1.5cm</li>
<li>gall bladder stones.</li>
<li>unremarkable of the spleen, adrenal glands, pancreas, and Rt kidney.
U-bladder and small and large bowels are grossly unremarkbale.</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>no mass or LAP in visible, mediastinum and axillary regions.</li>
</ul></li>
</ul></li>
<li>2020-06-10 CT - neck
<ul>
<li>multiple bilateral lymph nodes in the neck spaces.</li>
</ul></li>
<li>2019-11-14 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Suspected chronic liver parenchyma disease(Please correlate with
liver function)</li>
<li>Suspected liver cyst, left</li>
<li>Suspected GB stones</li>
<li>Pancreas not shown</li>
<li>Suboptimal examination of liver due to poor echo window</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Follow liver function test and AFP</li>
<li>Because of poor echo window, infiltrative lesion or small lesion may
not be excluded completely. Please correlate with other image or follow
sono abd every 3-6 months</li>
</ul></li>
</ul></li>
<li>2019-05-20 SONO - abdomen
<ul>
<li>Parenchymal liver disease</li>
<li>GB stones</li>
<li>Liver cysts</li>
<li>Renal cyst, right side</li>
<li>Fatty infiltration of pancreas</li>
</ul></li>
<li>2019-01-17 CT - lung/pleura
<ul>
<li>Findings - comparison: prior CT on 2018/08/27
<ul>
<li><ol style="list-style-type: decimal">
<li>Lungs and large airways: normal appearance of bilateral lungs. as
compared with previous CT study.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Mediastinum: no LAP or mass.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hila: no LAP.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Vessels: the vascular markings and great vessels in the lung, hila,
and mediastinum are normal in distribution and appearance..</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Heart: normal in size.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Pleura: no effusion or thickening</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Chest wall and neck: no enlarged lymph nodes.</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Visible abdominal contents:</li>
</ol>
<ul>
<li>a tiny Lt renal stone. multiple liver cysts up to 1.5cm</li>
<li>gall bladder stones.</li>
<li>unremarkable of the spleen, adrenal glands, pancreas, and Rt
kidney</li>
<li>bile ducts: No dilatation.</li>
<li>no enlarged lymphadenopathy.</li>
</ul></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Visualized bones: unremarkable.</li>
</ol></li>
</ul></li>
<li>Impression:
<ul>
<li>no recurrent neck lymphadenopathy.</li>
<li>no lesion in mediastinum and axillary regions.</li>
</ul></li>
</ul></li>
<li>2018-08-27 CT - lung/pleura
<ul>
<li>Impression:
<ul>
<li>Bilateral axillary non-specific lymph nodes</li>
</ul></li>
</ul></li>
<li>2018-05-03 CT - lung/pleura
<ul>
<li>Impression:
<ul>
<li>3mm calcified granuloma in basal segments of LLL.</li>
<li>No LAPs in neck, chest and abdomen. gallstones. a 2mm left renal
stone.</li>
</ul></li>
</ul></li>
<li>2018-01-03 CT - lung/pleura
<ul>
<li>Impression:
<ul>
<li>Nonspecific micronodules in LLL.</li>
<li>No LAPs in chest and abdomen. gallstones.</li>
</ul></li>
</ul></li>
<li>2017-09-04 CXR
<ul>
<li>Borderline heart size enlargement.</li>
<li>Mild tortuosity of thoracic aorta. No mediastinal widening.</li>
<li>Presence of increased lung infiltrations.</li>
</ul></li>
<li>2017-08-19 SONO - abdomen
<ul>
<li>fatty liver, mild/ incomplete exam of liver</li>
<li>liver cysts</li>
<li>gallstones</li>
<li>gallbladder polyps, suspect adenomyomatosis of GB wall</li>
</ul></li>
<li>2017-08-18 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Left ventricular hypertrophy with QRS widening</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2017-08-18 Whole body PET scan
<ul>
<li>Glucose hypermetabolism involving a confluent left neck level II-III
lymph node, compatible with lymphoma.</li>
<li>Mild glucose hypermetabolism in bilateral axillary lymph nodes and
glucose hypermetabolism in the left aspect of the nasopharynx. The
nature is to be determined (inflammatory process? other nature?). Please
correlate with other clinical findings for further evaluation.</li>
<li>Glucose hypermetabolism in the right upper anterior chest wall in
linear shape. Post-operative inflammation may show this picture.</li>
<li>Increased FDG uptake in bilateral neck muscles. Physiologic FDG
uptake is more likely.</li>
</ul></li>
<li>2017-08-09 Surgical pathology Level IV
<ul>
<li>Lymph node, left neck, core needle biopsy —– Diffuse large B cell
lymphoma.</li>
<li>IHC stains: CK(-), CD3 (-), CD20 (+), bcl-2 (+), bcl-6 (+), CD10
(+), cyclin D1 (-), CD23 (-), c-myc (+, 100%).</li>
<li>Histology type: B-cell neoplasms; Diffuse large B-cell lymphoma</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-03 Cardiology
<ul>
<li>Q
<ul>
<li>The 69 y/o man recurrent lymphoma case, he has history of focal
segmental glomerulosclerosis (UACR 783, Proteinuria 2+).</li>
<li>Due to SBP need keep &lt; 130/80mmHg, his Exforge 5/160 1# bid, but
can’t control, so we need your help for anti-hypertension drugs
assassment. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>EKG showed NSR, LVH</li>
<li>Cardiac echo showed preserved LV function dilated LA Ao and LVH</li>
<li>please add doxaben 1 qd for BP control</li>
<li>If BP remained higher, indapamide 1 qd aslo can be
administrated</li>
</ul></li>
</ul></li>
<li>2021-12-02 Nephrology
<ul>
<li>Q
<ul>
<li>The 69 y/o man is a recurrent diffuse large B cell lymphoma case, he
has past history of proteinuria and s/p biopsy at WanFang H (pathology
report did not bring).</li>
<li>Due to urinalysis showed PRO 2+, so we need your help for
management. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>Lab data:
<ul>
<li>U/A : clear yellow, SG: 1.013, PH: 5.5, Nit: -, Glu: -, Pro:2+, Ket
:-, uro &lt;1.5, Ob:- , RBC: 0-2, WBC: 0-5, bacteria:-</li>
<li>WBC: 5.9, Hb: 13.4, Plt: 176</li>
<li>BUN: 19,cre: 1.07, ALKP: 80, LDH: 194</li>
<li>Na: 140, K: 3.9, Albumin: 4.0, uric acid: 5.8</li>
<li>PE: edema-</li>
<li>Renal biopsy: FSGS (focal segmental glomerulosclerosis)</li>
</ul></li>
<li>Impression:
<ul>
<li>Proteinuria caused by FSGS</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Check UACR</li>
<li>Keep Steroid 1mg/kg per day</li>
<li>DC ACEI</li>
<li>Esclate dose of ARB till BP control &lt; 130/80mmHg</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-02
<ul>
<li>Surgery
<ul>
<li>Double lumen catheter insertion (RIJV approach, 16cm)</li>
</ul></li>
<li>Finding
<ul>
<li>Adequate size of RIJV</li>
</ul></li>
<li>Procedure
<ul>
<li>Under LA, supine, disinfection and well drapped.</li>
<li>Under sonography guidance, puncture into RIJV then wiring into
RA</li>
<li>tunnel through RIJV puncture site, dilator insertion    </li>
<li>insert D/L</li>
<li>check flow, Hemostasis</li>
<li>secure the cath.  </li>
</ul></li>
</ul></li>
<li>2021-11-08
<ul>
<li>Surgery
<ul>
<li>Excision of left neck lymph nodes      </li>
</ul></li>
<li>Finding
<ul>
<li>Several enlarged lymph nodes at left neck level V, size around
1~2cm, two of them was removed for pathology pathology and TB
culture/PCR</li>
<li>The spinal acccessory nerve was exposed at the operative field and
well preserved</li>
</ul></li>
<li>Procedure
<ul>
<li>The patient was in supine position with neck hyperextended and
turned to the right side. Skin was disinfected and draped as usual.
Local anesthesia with Bosmin-rinsed Xylocaine was injected into the
subcutaneous tissue around the enlarged lymph noded after marked with
the pen. A horizontal incision parallel to the skin crease was made. The
subcutaneous tissue was cut through. Several enlarged lymph nodes at
left neck level V, size around 1~2cm, two of them was bluntly dissected
from its surrounding tissue and removed for pathology and TB
culture/PCR. No obvious adhesion was noted. The spinal acccessory nerve
was exposed at the operative field and well preserved. After hemostasis,
the wound was closed with 2 layers. The patient tolerated the procedure
well.  </li>
</ul></li>
</ul></li>
<li>2017-08-18
<ul>
<li>Diagnosis
<ul>
<li>Lymphoma</li>
</ul></li>
<li>PCS
<ul>
<li>47080B</li>
</ul></li>
<li>Finding
<ul>
<li>We identify the cephaic vein &amp; use cutdown method to insert the
7 Fr cathter into it. We also use intra-operative C-arm to check its
position.</li>
</ul></li>
<li>Procedure
<ul>
<li>Under loca lanethesia, 3cm incision was made over R’t subclavicular
region, outer 1/3. Superficial fascia was opened and the cephalic vein
was found from upper border of the pectoralis major muscle. The cephalic
vein was dissected and then pulled out with 3-0 silks over proximal and
distal portions respectively. The lumen was opened by a scissor and the
catheter was inserted into proximal lumen for 16 cm in length. The silks
were tied so that the catheter was fixed in the proximal lumen and the
distal end was ligated. After hemostasis and testing the function of the
port-A, wound was closed layer by layer.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-19 - etoposide</li>
<li>2021-12-08 ~ 2022-03-04 - R-DHAP (4 times)</li>
</ul></li>
</ul>
<div id="section-511" class="section level3">
<h3>==========</h3>
</div>
<div id="section-512" class="section level3">
<h3>2022-07-19</h3>
<ul>
<li>Creatinine dropped to 1.8 mg/dL and BUN rose to 44 mg/dL, it would
appear that there has not been a obvious decline in renal function and
that some dehydration might possibly be present. (the latter is diarrhea
caused?)
<ul>
<li>Creatinine
<ul>
<li>2022-07-19 1.80 mg/dL</li>
<li>2022-07-11 2.25 mg/dL</li>
<li>2022-07-05 2.31 mg/dL</li>
<li>2022-06-28 2.04 mg/dL</li>
<li>2022-06-13 2.31 mg/dL</li>
<li>2022-05-28 2.23 mg/dL</li>
<li>2022-05-17 2.29 mg/dL</li>
<li>2022-05-05 2.47 mg/dL</li>
<li>2022-05-03 2.40 mg/dL</li>
</ul></li>
<li>BUN
<ul>
<li>2022-07-19 44 mg/dL</li>
<li>2022-07-11 31 mg/dL</li>
<li>2022-06-28 38 mg/dL</li>
<li>2022-05-28 34 mg/dL</li>
<li>2022-05-05 28 mg/dL</li>
<li>2022-05-03 33 mg/dL</li>
</ul></li>
</ul></li>
<li>CrCl 35~40 mL/min, eGFR 38~45 mL/min/1.73m2, please check the
following items in active prescription for patient’s clinical need
<ul>
<li>fluconazole
<ul>
<li>CrCl &lt;=50 mL/minute: reduce normal dose by 50%.</li>
</ul></li>
<li>levofloxacin
<ul>
<li>CrCl 20 to &lt;50
<ul>
<li>If usual recommended dose is 500 mg every 24 hours: 500 mg initial
dose, then 250 mg every 24 hours</li>
<li>If usual recommended dose is 750 mg every 24 hours: 750 mg every 48
hours</li>
</ul></li>
</ul></li>
<li>nystin
<ul>
<li>There are no dosage adjustments provided in the manufacturer’s
labeling.</li>
</ul></li>
<li>entecavir
<ul>
<li>CrCl 30 to &lt;50 mL/minute: administer 50% of usual
indication-specific dose daily. alternatively, administer the usual
indication-specific dose every 48 hours.</li>
</ul></li>
<li>pentoxifylline
<ul>
<li>CrCl &gt;=30 mL/minute: there are no dosage adjustments provided in
the manufacturer’s labeling. however, exposure to one of
pentoxifylline’s the active metabolites (metabolite V) is increased with
renal impairment; use with caution.</li>
<li>Aronoff 2007: CrCl 10-50 mL/minute: 400 mg every 12 to 24 hours</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="section-513" class="section level3">
<h3>2022-07-12</h3>
<p>[visiting]</p>
<ul>
<li>I visited the patient at approximately 13:10 2022-07-12.</li>
<li>In spite of the upcoming transplant operation, the patient was still
a bit nervous, which is believed to be a psychological reaction to the
uncertainty of the future. In addition, he stated that he would actively
cooperate with the doctor to receive treatment.</li>
<li>The patient was also concerned about whether or not the renal
function will be maintained in the future. My explanation to him was
that our medication are adjusted in accordance with his renal
function.</li>
<li>No other medication-related questions raised by the patient.</li>
</ul>
</div>
<div id="section-514" class="section level3">
<h3>2022-07-11</h3>
<p>Dose adjustment recommendation for the scheduled PBSCT in this
impaired renal function patient</p>
<ul>
<li>The patient was diagnosed with stage III CKD on 2021-12-18 at
Nephrology OPD.</li>
<li>The level of creatinine in his blood gradually increased between
2021Q4 and 2022Q1, and has remained slightly above 2 mg/dL since April
2022. Similar trends were observed in blood BUN.</li>
<li>2022-07-11 creatinine 2.25 mg/dL -&gt; eGFR 29.1 ~ 35.2
mL/min/1.73m2, CrCl 28.1 ~ 34.0 mL/min</li>
<li>As the patient has scheduled an autologous PBSCT for his NHL, let us
go over the doses of items listed in the regimen:
<ul>
<li>BuCyE
<ul>
<li>busulfan
<ul>
<li>no dosage adjustments provided in the manufacturer’s labeling</li>
</ul></li>
<li>cyclophosphamide
<ul>
<li>CrCl 10 to 29 mL/minute: administer 75% of normal dose</li>
</ul></li>
<li>etoposide
<ul>
<li>CrCl 15 to 50 mL/minute: administer 75% of normal dose</li>
</ul></li>
</ul></li>
<li>premedication
<ul>
<li>phenytoin
<ul>
<li>primarily metabolized by the liver to inactive metabolites with
&lt;5% of active drug excreted unchanged in the urine</li>
<li>no dosage adjustment necessary for any degree of kidney
dysfunction</li>
</ul></li>
<li>fluconazole
<ul>
<li>CrCl &lt;= 50 mL/minute: reduce dose by 50%</li>
</ul></li>
<li>levofloxacin
<ul>
<li>CrCl 20 to &lt;50: if usual recommended dose is 500 mg every 24
hours, 500 mg initial dose, then 250 mg every 24 hours</li>
</ul></li>
<li>palonosetron
<ul>
<li>no dosage adjustment is necessary.</li>
</ul></li>
<li>granisetron
<ul>
<li>no dosage adjustment necessary</li>
</ul></li>
<li>betamethasone
<ul>
<li>no dosage adjustments provided in the manufacturer’s labeling</li>
</ul></li>
<li>mannitol
<ul>
<li>contraindicated in severe renal impairment. Use caution in patients
with underlying renal disease.</li>
</ul></li>
</ul></li>
</ul></li>
<li>The purchase order for busulfan has been sent and confirmed. In the
event that a drug does not meet the schedule, the staff in the medicine
storeroom will inform the updated status immediately.</li>
</ul>
</div>
</div>
</div>
<div id="section-515" class="section level1">
<h1>701431525</h1>
<div id="section-516" class="section level2">
<h2>220719</h2>
<p>[assessment]</p>
<ul>
<li>Cardinal Tien Hospital provided a diagnosis of “epigastric pain” on
2022-06-11. In addition to functional dyspepsia, if there are known
cardiac risk factors, symptoms suggestive of angina (e.g., shortness of
breath, exertional symptoms) might be evaluated.</li>
<li>This patient is admitted for bone marrow aspiration and biopsy.</li>
</ul>
</div>
</div>
<div id="section-517" class="section level1">
<h1>700846672</h1>
<div id="section-518" class="section level2">
<h2>220718</h2>
<p>{T-cell lymphoma with bone invasion, stage IV}</p>
<ul>
<li>past history
<ul>
<li>Pneumonia and meningitis in ShuangHo Hospital</li>
<li>Unknown neurology problem in ShuangHo Hospital</li>
<li>Depression</li>
<li>GERD</li>
<li>Lung benign nodule s/p OP</li>
<li>Viral hepatitis B</li>
<li>Chronic obstructive pulmonary disease</li>
<li>Polymyositis with respiratory involvement, anti-SAE1 and anti-MDA5
Antibodies positive</li>
</ul></li>
<li>lab data
<ul>
<li>blood B2-Microglobulin (609-2366 ng/mL)
<ul>
<li>2022-07-07 4691 ng/mL</li>
<li>2022-06-11 2559 ng/mL</li>
<li>2022-05-21 4000 ng/mL</li>
<li>2022-04-02 3073 ng/mL</li>
<li>2022-03-23 6077 ng/mL</li>
<li>2022-02-21 2376 ng/mL</li>
<li>2021-12-29 4427 ng/mL</li>
</ul></li>
<li>Erythrocyte sedimentation rate, ESR (2-15 mm/hr)
<ul>
<li>2021-12-28 55 mm/hr</li>
<li>2021-09-27 72 mm/hr</li>
<li>2021-09-08 56 mm/hr</li>
<li>2021-09-02 60 mm/hr</li>
<li>2021-04-05 38 mm/hr</li>
<li>2021-01-25 42 mm/hr</li>
<li>2021-01-05 34 mm/hr</li>
<li>2020-12-09 55 mm/hr</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-22 CXR
<ul>
<li>Patchy opacity projecting at right lower lung zone was noted. Please
correlate with CT.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura thickening?</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-05-10 2D transthoracic echocardiography (prior to doxorubicin)
<ul>
<li>Normal AV with no AR</li>
<li>Normal MV with mild MR</li>
<li>Concentric LVH</li>
<li>Preserved LV and RV systolic function</li>
<li>No PR, no TR, normal IVC size</li>
</ul></li>
<li>2022-04-16 KUB
<ul>
<li>Calcification in left pelvic cavity, could be due to granuloma.</li>
<li>Non-specific bowel gas pattern.</li>
<li>Clear margin of bilateral psoas muscles.</li>
<li>Lumbar spondylosis.</li>
</ul></li>
<li>2022-03-23 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>Prior CT identified lobulated soft tissue mass in RLL of the lung
with calcifications component measuring 6 cm in the largest dimension is
noted again, stable in size.</li>
<li>Fibrotic infiltrates in RUL of the lung show stationary.</li>
<li>Presence of small gallbladder stone.</li>
<li>Suspected liver cysts, up to 0.6cm in S4.</li>
<li>Tiny left renal stone.</li>
<li>There is no focal abnormality in the liver, biliary system,
pancreas, spleen &amp; right kidney.</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass. There
is no focal lesion over the mesentery and omentum.</li>
</ul></li>
<li>Impression:
<ul>
<li>Prior CT identified lobulated soft tissue mass in RLL of the lung
with calcifications component measuring 6 cm in the largest dimension is
noted again, stable in size. please correlate with clinical
condition.</li>
</ul></li>
</ul></li>
<li>2021-12-07 CT - abdomen, pelvis
<ul>
<li>RLL tumor with right upper lung nodules, c/w lymphoma.</li>
<li>Lymph nodes in mediastinum and right hilar region, suspected
lymphoma involvement.</li>
<li>GB stones.</li>
<li>RUL fibrotic infiltrates.</li>
</ul></li>
<li>2021-12-03 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>S/P nasogastric tube insertion</li>
<li>S/P autosuture projecting at right upper lung.</li>
<li>Patchy opacity projecting at right lower lung zone was noted. Please
correlate with CT.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura thickening?</li>
</ul></li>
<li>2021-12-02 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, left buttock, biopsy — Positive for T-cell
lymphoma<br />
</li>
<li>Microscopically, it shows bone marrow tissue with presence of
aggregations and scattered T-cell type lymphomatous cells. The
trilineage marrow components are not remarkable.<br />
</li>
<li>Immunohistochemical stain reveals CD3(+), CD20(-), CD136(&lt; 5%),
MPO(+), CD71(+), CD34(-) and CD117(-).</li>
</ul></li>
<li>2021-11-30 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion in the posterior aspect of the lower
lobe of right lung, compatible with lymphoma.</li>
<li>A glucose hypermetabolic lesion in the posterior aspect of the upper
lobe of right lung and some glucose hypermetabolic lesions in the lower
lobe of right lung and right pulmonary hilar region. Lymphoma should be
watched out. Please correlate with other clinical findings for further
evaluation.</li>
<li>Increased FDG uptake in the muslces in bilateral neck regions,
proximal portions of bilateral upper arms, left anterior and posterior
upper chest regions and bilateral lower pelvic regions. Physiological
FDG uptake due to increased muscle tension or inflammation in these
mucles may show this picture. Please also correlate with other clinical
findings for further evaluation and to rule out other
possibilities.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2021-11-29 CXR
<ul>
<li>RLL mass consolidation</li>
<li>Reticulonodular opacities in in both lungs due to bronchiolitis</li>
</ul></li>
<li>2021-11-22 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, RLL, CT-guide biopsy — malignant T-cell lymphoma</li>
<li>Sections show alveolar lung tissue with diffuse infiltration of
small lymphocytes and interstitial fibrosis.</li>
<li>The immunohistochemical stains reveal CK(-), CD3(+), CD20(-),
CD43(+), CD10(-), CD56(-), Cyclin D1(-). The number of CD8 positive
lymphocytes is more than CD4 positive lymphocytes. The results are in
favor of malignant T-cell lymphoma. Please correlate with the clinical
presentation and lab study.</li>
</ul></li>
<li>2021-11-18 Electroencephalography, EEG
<ul>
<li>Findings
<ul>
<li>there are continuous slowing at 3-4 Hz bilaterally</li>
<li>photic stimulation showed no photo-driving response</li>
<li>hyperventilation study was not done</li>
</ul></li>
<li>EEG classification: abnormal significance II, bilaterally continuous
slowing, 3-4 Hz.</li>
<li>Interpretation: this EEG study showed moderate diffuse
encephalopathy</li>
</ul></li>
<li>2021-11-16 CT - lung/mediastinum/pleura
<ul>
<li>Comparison made with previous CT dated on 2021/08/19
<ul>
<li>Lungs:
<ul>
<li>In comparison with the previous study on the lesion is increasing in
size</li>
<li>further increase in size a large RLL mass-like consolidation with
air bronxhograms containing coarse staple line and progression of
lobular areas of consolidation and centrilobular nodular and branching
opacities (especially in LLL) in both lungs of as compared with previous
CT study on 20210819.</li>
<li>extensive centrilobular emphysema subpleural paraseptal
emphysema</li>
</ul></li>
<li>Mediastinum: no enlarged LN or mass. old calcified LN in Rt visceral
space, sequela of previous TB infection</li>
<li>Hila: no enlarged LN.</li>
<li>Vessels: mild coronary arterial calcification.</li>
<li>Aorta: normal caliber, atherosclerotic change of aortic arch and
descending thoracic aorta.</li>
<li>Central pulmonary arteries: normal caliber.</li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: small Rt effusion.</li>
<li>Chest walleck: unremarkable.</li>
<li>Visible abdominal contents: no abnormal density in visible portion
of liver, spleen, adrenal glands, pancreas, and kidney.</li>
<li>Visualized bones: marginal spurs of vertebrae.</li>
</ul></li>
<li>Impression:
<ul>
<li>progressive increase in size a large RLL mass-like consolidation and
bilateral lung infection (especially in LLL) as compared with previous
CT study on 20210819.</li>
</ul></li>
</ul></li>
<li>2021-08-19 CT - lung/mediastinum/pleura
<ul>
<li>Chest CT without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>s/p right upper lobe and right lower lobe op. Soft tissue like
change at right lower lobe section area is found. In comparison with CT
dated on 2021-04-24, the lesion decresed in size.</li>
<li>Patent airway is found.</li>
<li>Some tree in bud appearance at residual right lung is found.</li>
<li>One new nodlar lesion at right lower lobe up to 0.88cm in largest
dimension. Recent inflammation is favored but follow up is
suggested.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
<li>Suggest clinical correlation</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Post op. change of right upper lobe and right lower lobe</li>
<li>Tree in bud appearance at right lung, repeated inflammation is
favored.</li>
<li>New nodular lesion at right lower lobe, suggest closely follow
up.</li>
</ul></li>
</ul></li>
<li>2021-07-24 CXR
<ul>
<li>Increased infiltration in right lung zone</li>
<li>Surgical stiches over right chest</li>
<li>Blunting of right CP angle</li>
</ul></li>
<li>2021-04-24 CT - lung/mediastinum/pleura
<ul>
<li>Chest CT without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>s/p op. over right upper lobe and right lower lobe</li>
<li>Some fibrotic change and tree in bud appearance at right upper
lobem, right lower lobe is found.</li>
<li>Calcified coronary arteries is found.</li>
<li>Dense calcified lymph nodes are found in the mediastinum.</li>
<li>No evidence of bilateral pleural effusion.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
<li>Suggest clinical correlation</li>
</ul></li>
</ul></li>
<li>Imp: post op. change at right upper lobe and right lower lobe</li>
</ul></li>
<li>2021-04-16 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst, small, S8</li>
<li>calcified spot of liver, S6</li>
<li>suspicious, GB stone</li>
<li>pancreatic tail masked by gas.</li>
</ul></li>
<li>Suggestion
<ul>
<li>encourage exercise and diet adjustment.</li>
</ul></li>
</ul></li>
<li>2020-12-30 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease, mild</li>
<li>Hepatic calcification, S6</li>
<li>Hepatic cyst, S4</li>
<li>GB polyp or stone (suboptimal study due to non-fasting status)</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD follow-up</li>
</ul></li>
</ul></li>
<li>2020-12-30 Brinchodilator Test
<ul>
<li>moderate restrictive impairment; non-significant bronchodilator
response</li>
</ul></li>
<li>2020-10-21 MRI - brain
<ul>
<li>old insults in the bilateral basal ganglia.</li>
</ul></li>
<li>2020-10-20 MRI - c-spine
<ul>
<li>C3/4, C5/6 HIVDs.</li>
<li>No abnormal bony destruction.</li>
<li>No abnormal fluid collection.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-11-26 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 64 year-old male patient presented to our emergency
department due to fever. He has the following past medical history:
<ul>
<li><ol style="list-style-type: decimal">
<li>HBV</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Peptic ulcer</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>depression</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Polymyositis with respiratory involvement, anti-SAE1 and anti-MDA5
Antibodies positive</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Pneumonia, with respiratory failure</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>COPD(2020/11/25)</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>recurrent pneumonia with respiratory failure s/p prior intubation
months ago</li>
</ol></li>
</ul></li>
<li>Apart from mild grade fever, his family members reported that he has
excessive sputum. Physical examination showed positive rhonchi and
tachypnea. Laboratory data did not reveal leukocytosis but U/A with mild
sign of urinary tract infection with mild elevated CRP(2.90). CXR showed
RML pneumonia.</li>
<li>Under the impression of recurrent pneumonia and prerenal AKI
(suspected dehydration induced), he is admitted to our ward for
treatment.</li>
<li>According to the CT image revealed progressive increase in size a
large RLL mass-like consolidation and bilateral lung infection
(especially in LLL) as compared with previous CT study on 2021/08/19.
Arranged the CT guide biopsy, result malignant T-cell lymphoma. For
maligant T-cell lymphoma, we are consulted.</li>
</ul></li>
<li>A
<ul>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Arrange PET for further work up</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Bone marrow aspiration and biopsy is indicated (suspected bone
marrow involvement). We will discuss with patient and family.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>After image survey, Lumbar punture is indicated in this case.
(suspected T cell lymphoma with CNS involvement). We will discuss with
patient and family.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Arrange 2D heart echo for future anthracycline base
chemotherapy</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>please complete baseline LDH, uric acid. (watch for tumor lysis
after chmoetherapy), moreover, please check HbsAg, Anti-Hbs,Anti-Hbc,
Anti-HCV</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Thanks for your consultation, we wound take over this case if you
agree.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-17 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This time, we arranged the chest CT result progressive increase in
size a large RLL mass-like consolidation and bilateral lung infection
(especially in LLL) as compared with previous CT study on 2021/08/19.
OPD medicines (Plavix) was hold since 2021/11/17 for prepare CT guide
biopsy. We need your expertise and evaluate. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>This 64-year-old male patient is a case of RLL lung mass, suspected
malignancy. CT-guided biopsy is indicated. Please check platelet, PT,
and aPTT before this procedure. We will inform the risk of insufficient
specimen, pneumothorax, hemorrhage, infection, and air embolism to the
patient and the family.</li>
</ul></li>
</ul></li>
<li>2021-11-16 Neurology
<ul>
<li>Q
<ul>
<li>Family complaint the patient conscious drowsy since 2021/11/14. We
need your expertise and evaluate. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>O
<ul>
<li>Consciousness: GCS E3V1M5</li>
<li>Cranial nerve: pupil 2+/2+, VF intact, EOM: move freely; no facial
palsy, on NG</li>
<li>Motor: &gt;3/&gt;3</li>
<li>sensory of limbs: symmetric</li>
<li>Chest CT: progressive increase in size a large RLL mass-like
consolidation and bilateral lung infection (especially in LLL) as
compared with previous CT study on 2021/08/19.</li>
<li>Lab: Cr: 0.86 =&gt; 3.42, CRP: 2.9</li>
</ul></li>
<li>Impression:
<ul>
<li>Conscious disturbance due to infection, AKI and respiratory
failure</li>
<li>Polymyositis with respiratory involvement, anti-SAE1 and anti-MDA5
Antibodies</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Please check CPK, Ca, Mg, P, TSH, Free T3, T4, Anti TPO and anti
thyroglobulin Ab, 8AM Cortisol, ACTH, B12, Folic acid.</li>
<li>Arrange EEG</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-07-02 Infectious Disease
<ul>
<li>Q
<ul>
<li>This is a 63 year old man who was admitted to our hospital because
of fever and dyspnea for several days. The patient had underlying
polymyisitis, COPD and old CVA on regular OPD follow up at our hospital.
Several days prior to admission to our hospital, the patient developed
fever and dyspnea. He denied having diarrhea, change in the sense of
smell or taste. On 2021/06/27, the patient was brought to our ER to seek
medical attention.</li>
<li>Blood test showed elevated levels of CRP, lactate and WBC, while CXR
revealed ground glass opacities in both lungs. Sputum culture on
2021/06/30 showed CRAP. In the following days, his fever off and on
wihtout regression under the treatemtns of brosym.</li>
<li>Cr: 2.56 mg/dL</li>
</ul></li>
<li>A
<ul>
<li><ol style="list-style-type: decimal">
<li>Zavicefat for CRPA is indicated.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Agree with your use of colimycin inhalation.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2021-06-28 Infectious Disease
<ul>
<li>Q
<ul>
<li>Blood test showed elevated levels of CRP, lactate and WBC, while CXR
revealed ground glass opacities in both lungs.</li>
</ul></li>
<li>A
<ul>
<li>Antibiotics with brosym and cravit is suggested.</li>
</ul></li>
</ul></li>
<li>2021-01-05 Rehabilitation
<ul>
<li>Q
<ul>
<li>In addition to unable to stand, we sincerely ask for your expert and
ambulation training.</li>
</ul></li>
<li>A
<ul>
<li>Premorbid status
<ul>
<li>Walk and BADL ID</li>
</ul></li>
<li>Physical examination
<ul>
<li>Consciousness: E4V5M6</li>
<li>Cognition: mostly intact</li>
<li>Speech: mostly intact</li>
<li>Swallowing: oral feeding</li>
<li>Sphincter: continence</li>
<li>MP: UE: 5/5; hip and knee: 3/3; ankle: 0/0</li>
<li>Functional status: bed mobility under min A</li>
<li>BADL: feeding, grooming ID; others under mod-max A</li>
</ul></li>
<li>Assessment
<ul>
<li>polymyositis with respiratory involvement with positive anti-SAE1
and anti-MDA5 antibodies</li>
<li>depression</li>
<li>GERD</li>
<li>COPD</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: improve lower extrimities endurance and muscle strength,
improve transfer skills</li>
<li>Prescribe bilateral posterior AFO for him to prevent ankle
contracture</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-10-23 Rehabilitation
<ul>
<li>Q: We need your help for arrange rehabilitation. Thank a lot!</li>
<li>A
<ul>
<li>2020-10-01 NCV
<ul>
<li>mixed type sensorimotor polyneuropathy with bilateral lower cervical
and lumbosacral radiculopathy.</li>
</ul></li>
<li>Premorbid status
<ul>
<li>Unknown</li>
</ul></li>
<li>Physical examination
<ul>
<li>Consciousness: E4VTM6</li>
<li>Cognition: could follow orders</li>
<li>Speech: tracheostomy</li>
<li>Swallowing: NG (+)</li>
<li>Sphincter: Foley (+), stool in diaper</li>
<li>MP: UE: 4/4, LE:2/2</li>
<li>Functional status: bed rest</li>
<li>BADL: needs max assistance</li>
</ul></li>
<li>Assessment
<ul>
<li>generalized weakness especially at LEs, with difficulty weaning,
suspect uncertain GBS (AMSAN), paraneoplastic polyneuropathy, critical
illness polyneuropathy, inherited polyneuropathy, CIDP, MG</li>
<li>depression</li>
<li>Peptic ulcer</li>
<li>benign right lung nodule</li>
</ul></li>
<li>Plans
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-10-16 Rheumatology and Immunology
<ul>
<li>Q
<ul>
<li>This 63 year old man had
<ul>
<li><ol style="list-style-type: decimal">
<li>Pneumonia over bilateral (2020/09/03 Sp/C: CRPA)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IHCA s/p CPCR s/p ET s/p extubation on 2020/09/11. Re-intubation on
2020/09/15; s/p Tr. on 2020/10/12</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Pulmonary TB s/p anti-TB agent since 2020/08/06</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Lower limbs weakness; suspected ALS or MG</li>
</ol></li>
</ul></li>
<li>2020/10/02 Neurologist: generalized weakness with difficulty
weaning, suspect uncertain GBS (AMSAN), paraneoplastic polyneuropathy,
critical illness polyneuropathy, inherited polyneuropathy, CIDP, MG,
Check autoantibodies SAE1 positive and MDA5 positive. He accepted pulse
therapy medason 80mg Q8H*2day 2020/10/16-17. (Medason -
methylprednisolone sodium succinate buffered 3%)</li>
<li>Due to Antibody-positive (SAE1) and anti-MDA5 antibodies positive
consult evaluation. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>History review &amp; physical examination were performed. Due to
positive MDA5 &amp; pulmonary fibrosis, inflammatory myopathy can’t be
ruled out.</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Treatment as current your expert’s management.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Please check muscle enzyme, arrange EMG if no contraindication.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Consider immunotherapy if no infectious contraindication.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Please inform me again if there are any informative reports.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-10-10 Anesthesiology
<ul>
<li>Q
<ul>
<li>for anesthesi evaluation</li>
<li>Hx: Depression, GERD</li>
<li>This is a 63 year-old male was admitted for impression of Pneumonia.
Due to difficulted weaning of ventilator, CS was consulted and arrange
tracheostomy on 2020/10/12 on call. We need your help for anesthesia
evaluation.</li>
</ul></li>
<li>A
<ul>
<li>Current problem:
<ul>
<li><ol style="list-style-type: decimal">
<li>respiratory failure s/p ETT intubation, failure to weaning</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>TB s/p medication use</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>depression/ GERD</li>
</ol></li>
</ul></li>
<li>Plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>ASA: III</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Arrange GA with current ETT`</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>please treat the patient’s current respiratory infection and TB
under your expertise</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>post-op ICU care</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>inform the patient’s daughter about increasing risk of desaturation,
hypotension, shock and bleeding during surgery</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-10-10 Thoracic Surgery
<ul>
<li>Q
<ul>
<li>In our hospital, PE showed right lung crackle sound. Lab data showed
WBC 28140 with neutrophil 92%. Influenza screen was negative. CXR showed
conslidation in the right lung field and mild blunting of right
costophrenic angle. Under the impression of pneumonia with TB suspected,
he is admitted for treatment and further evaluation.</li>
<li>After admission, he was treated with Brosym and TB medicins.
Desaturation was noted on 2020/09/01, we changed the nasal canula to
simple mask and saturation back to 94%. Blood culture was done too. CXR
on 20200901 showed pneumonia progression, so we added Targocid. Sputum
culture was collected on 20200902. Diamox (acetazolamide) 1# TID was
added for 2 days on 20200902 due to metabolic akalosis. On 20200903
midnight, loss of consciousness with dyspnea was noted. Hypercapnic
respiratory failure and septic shock was impressed. Assystole also
occured, s/p CPCR for 1 min. Intubation was also done. And he was
transfer to ICU for further care.</li>
<li>After transferred to ICU, he received inotropic agents, anti-TB
agent with Akurit4 plus vit B6 since 20200806. However, fever developed
was happened, discontinued Targocid (20200903~0910) and Mepem
(20200903~0907), ex-change to Fortum (0907-0913) plus Colimycin
IV(0907-0914) for sputum culture revealed CRPA. Adequate IV fluid for
polyuria and albumin transfusion for hypoalbuminemia. Episode of
persisted fever was also note and still S/C yiled CRPA, ex-change
antibiotic to Mepem since 0913 was prescribed. Ventilator weaning then
extubation on 20200911 under Mask full supply. But, weakness of cough
reflex and elevation breathing work and desaturation were also note,
re-intubation on 20200915 with ventilator supply. IV Colimycin since
20200916 was added for fever and S/C yiled CRPA, shifted to INHL on
20200922. Lower limbs weakness consider HIVD relate. Added Plavix for
old CVA. RCC was consculted due to ventilator difficlut weaning and
bedside rehabilitation, but hold scheduled due to fever and
hematuria.</li>
<li>Arrange lower NCV study for persist lower limbes weakness,that
report showed mixed type sensorimotor polyneuropathy with bilateral
lower cervical and lumbosacral radiculopathy.</li>
<li>For difficult weaning ventilator ,so we need your help for
tracheostomy evaluation. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>I will arrange tracheostomy for this patient after explained about
risk and benefit next Monday. Thanks for your consultaiton.</li>
</ul></li>
</ul></li>
<li>2020-10-02 Neurology
<ul>
<li>A
<ul>
<li>S
<ul>
<li>For persisted lower limb waeaknss and difficulty weaning, we were
consulted for further evaluation.</li>
<li>According to the statment of his family, he complained of right
chest/axillary pain (stabbing, intermittent with progressing frequency
and intensity) over 10+ years. Before he was admited to ShuangHo
Hospital this July, he complained of distal numbness with pain for a
while. His wife mentioned of easily awakenend during sleep with limbs
movment for 30 years, profuse sweating upon movmenet for many years were
also menetioned. Weight loss about 20 kg within a year, with decreased
appetite and altered taste. Denied urine retention, changed urine color,
costipation, tachycardia, choking, dysarthria, tremor or other
involuntary movements, travel or contact history.<br />
</li>
<li>From ShuangHo Hospital medical records, polyneuropathy was impressed
with EMG myopathic findings. In addition, porphyria was highly suspected
from positive finding in screening test and the result should be
persuit.</li>
<li>2020-10-01 NCV: mixed type sensorimotor polyneuropathy with
bilateral lower cervical and lumbosacral radiculopathy.</li>
</ul></li>
<li>O
<ul>
<li>Personal Hx:
<ul>
<li>denied toxic exposure history (contacted with acetone 20 years
ago),</li>
<li>smoking (+, 1 PPD for 40 years)</li>
<li>alcohol 3-4 times per week/beer*10 bot, quit recently</li>
<li>denied family hx</li>
</ul></li>
<li>NE: E4VTM6, cachexia, could answer by hand writing and gesture</li>
<li>EOM: free, no limitations</li>
<li>Nuchal rigidity : + (?)</li>
<li>CNS: noraml light reflex, symmetry CN5 sensations, normal pursuit
and saccade, nystagmus (-), diplopia (-, intermittent as the patient
stated)</li>
<li>Msucle atrophy and wasting</li>
<li>tone: soft and symmetric<br />
</li>
<li>power:
<ul>
<li>UE R/L: 3-4</li>
<li>LE R/L: Prox3Dis2/Prox3Dis2</li>
</ul></li>
<li>DTR:
<ul>
<li>UE R/L: 2+/2+</li>
<li>LE R/L: -/-</li>
</ul></li>
<li>Babinski: no response/no response</li>
<li>Sensation: bilateral lower limbs decreased with allodynia (?)</li>
</ul></li>
<li>Impression: generalized weakness with difficulty weaning, suspect
uncertain GBS (AMSAN), paraneoplastic polyneuropathy, critical illness
polyneuropathy, inherited polyneuropathy, CIDP, MG</li>
<li>Suggestion:
<ul>
<li>check ACHR antibody to rule out MG and check Fabry disease serum
check-up</li>
<li>persuit porphyria result</li>
<li>consider to repeat CSF study including self-paid exam including
paraneoplastic autoantibiodies (the fee was about NT 30000)</li>
<li>consider to repeat tumor marker survey if CSF study repeated</li>
<li>Contact us if any questions and thank you for consultation.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2020-09-24 Gastroenterology
<ul>
<li>A
<ul>
<li>Treat pneumonia</li>
<li>Survey the etiology elevated CA125 in “Male” patient (?)</li>
<li>Elective panendoscopy and colonoscopy after transfer to general ward
under stable condition</li>
</ul></li>
</ul></li>
<li>2020-09-18 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This time, due to ventilator diffcilut weaning, need your evaluation
ventilator traning, thanks a lot!</li>
</ul></li>
<li>A
<ul>
<li>After transfer to ICU, he received inotropic agents, antiTB agent
with Akurit4 plus vit B6 since 20200806. However, fever developed,
antibiotic with Targocid (teicoplanin) 9/3~9/10 and Mepem (meropenem)
9/3~9/7 shift to Fortum (ceftazidime) + colimcyin IV form (9/7~)for
sputum culture revealed CRPA, blood transfusion for anemia. adequate IV
fluid for polyuria and albumin transfusion for hypoalbuminemia.
Ventilator weaning then extubation on 2020/09/11 under Mask full supply.
But, weakness of cough reflex and elevation breathing work and
desaturation were also note, re-intubation on 2020/09/15 with ventilator
supply.</li>
<li>Transfer to RCC next week if bed available</li>
</ul></li>
</ul></li>
<li>2020-09-03 Infectious Disease
<ul>
<li>Q
<ul>
<li>A 64 y/o male under the diagnosis of progressing pneumonia with
septic shock + ARDS s/p ETT +MV and CPCR for 1 min despite under
Targocid + Brosym. Long term hospitalization(transfered from ShuangHo
Hospital), VAP first considered, but atypical pneumonia is also
considered due to prolong disease course. Mepem + Cravit for septic
shock and atypical coverage, thank you!</li>
</ul></li>
<li>A
<ul>
<li>Consultation for Mepem antibiotic.</li>
<li>S/O
<ul>
<li>A 63-yeara-old suspect pulmonary TB male patient has severe
both-lung pneumonia with pneumonia progression despite Brosym and
anti-TB medications.</li>
<li>Persistent fever is noted during hospitalization, followed by
respiratory failure and severe sepsis.</li>
<li>White count up to 29130 this early morning, with high CRP level
29.46 and hyperlactatemia.</li>
<li>Sputum culture shows normal flora only.</li>
<li>Brosym is replaced by Mepem, Cravit, and Targocid now.</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Continue the present antibiotic regimen for one week first.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Send sputum for TB-PCR and check serum fungal Aspergillus and
Cryptococcal antigen titer.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-10 ~ undergoing - CHOP (cylcophosphamide + doxorubicin +
vincristine + prednisolone)</li>
<li>2021-12-06 ~ 2022-03-22 - COP (cylcophosphamide + vincristine +
prednisolone)</li>
<li>2021-09-27 - Rituximab</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li><p>The disease should be subtype Peripheral T-cell lymphoma (PTCL),
not otherwise specified (NOS)?</p></li>
<li><p>T-Cell Lymphomas NCCN EB Version 2.2022 - March 7, 2022, p13</p>
<ul>
<li>For PTCL-NOS histologies, preferred regimens (alphabetical order)
<ul>
<li>Brentuximab vedotin + CHP (cyclophosphamide, doxorubicin, and
prednisone) for CD30+ histologies</li>
<li>CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide,
prednisone)</li>
<li>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)</li>
<li>Dose-adjusted EPOCH (etoposide, prednisone, vincristine,
cyclophosphamide, doxorubicin)</li>
</ul></li>
</ul></li>
<li><p>Restage after 3-4 cycles with PET/CT (preferred) or C/A/P CT scan
with contrast</p></li>
<li><p>Recommended Adult Immunization Schedule — United States, 2012 (
<a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm" class="uri">https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm</a>
)</p>
<ul>
<li>Pneumococcal polysaccharide (PPSV) vaccination
<ul>
<li>Vaccinate all persons with the following indications:
<ul>
<li>age 65 years and older without a history of PPSV vaccination;</li>
<li>adults younger than 65 years with chronic lung disease (including
chronic obstructive pulmonary disease, emphysema, and asthma); chronic
cardiovascular diseases; diabetes mellitus; chronic liver disease
(including cirrhosis); alcoholism; cochlear implants; cerebrospinal
fluid leaks; immunocompromising conditions; and functional or anatomic
asplenia (e.g., sickle cell disease and other hemoglobinopathies,
congenital or acquired asplenia, splenic dysfunction, or splenectomy [if
elective splenectomy is planned, vaccinate at least 2 weeks before
surgery]);</li>
<li>residents of nursing homes or long-term care facilities; and</li>
<li>adults who smoke cigarettes.</li>
</ul></li>
<li>Persons with asymptomatic or symptomatic HIV infection should be
vaccinated as soon as possible after their diagnosis.</li>
<li>When cancer chemotherapy or other immunosuppressive therapy is being
considered, the interval between vaccination and initiation of
immunosuppressive therapy should be at least 2 weeks. Vaccination during
chemotherapy or radiation therapy should be avoided.</li>
</ul></li>
</ul></li>
</ul>
<div id="section-519" class="section level3">
<h3>==========</h3>
</div>
<div id="section-520" class="section level3">
<h3>2022-07-18</h3>
<p>[to be discussed]</p>
<ul>
<li>This patient has a history of COPD, polymyositis involving the
respiratory system, would be more susceptible to respiratory infections.
No Pneumococcal vaccination records found in HIS5. Locally available
pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide
vaccines (PPV) are not live attenuated vaccines.</li>
<li>As long as prior vaccination has not been received and there is no
contraindication, vaccination could be an option when the disease is
relatively stable. ( <a href="https://www.cdc.gov.tw/File/Get?q=66HT6AZdVjKmPmyJ9OclbE7fSUNF8o6T2nY3X4twcs645z0sPVYF-Bs9hyzud3ouyA0NF3_ytXiBg8vfMLUoeu1uOfFQUFxf9Ng_s1D2kkA2xEAnPozcYeqUsprymjFpcqOVZOxJeW8xojXUSe2bgA" class="uri">https://www.cdc.gov.tw/File/Get?q=66HT6AZdVjKmPmyJ9OclbE7fSUNF8o6T2nY3X4twcs645z0sPVYF-Bs9hyzud3ouyA0NF3_ytXiBg8vfMLUoeu1uOfFQUFxf9Ng_s1D2kkA2xEAnPozcYeqUsprymjFpcqOVZOxJeW8xojXUSe2bgA</a>
)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>Nexium (esomeprazole) must not be ground. Please open the capsure
and pouring out the small granules and dissolved them in adequate
drinking water prior to tube feeding.</li>
</ul>
</div>
<div id="section-521" class="section level3">
<h3>2022-06-02</h3>
<ul>
<li>The pathology reports (2021-11-22, 2021-12-02) did not specify CD30,
ALK (anaplastic lymphoma kinase) or ALCL (anaplastic large cell
lymphoma) subtype information.</li>
<li>If CD30 is confirmed positive, brentuximab vedotin may prove
beneficial.</li>
<li>Past history of polymyositis has been linked to an increased
incidence of cancer. reference:
<ul>
<li>Risk of Malignancy in Dermatomyositis and Polymyositis. <a href="https://pubmed.ncbi.nlm.nih.gov/27534779/" class="uri">https://pubmed.ncbi.nlm.nih.gov/27534779/</a></li>
<li>Cancer risk in dermatomyositis: a meta-analysis of cohort studies.
<a href="https://pubmed.ncbi.nlm.nih.gov/25721032/" class="uri">https://pubmed.ncbi.nlm.nih.gov/25721032/</a></li>
<li>Polymyositis/dermatomyositis and malignancy risk: a metaanalysis
study. <a href="https://pubmed.ncbi.nlm.nih.gov/25448790/" class="uri">https://pubmed.ncbi.nlm.nih.gov/25448790/</a></li>
</ul></li>
<li>Low HGB level (8.7 g/dL 2022-06-01) combined with underlying COPD
might limit ventilation and/or oxygenation, please be aware of low
oxygen symptoms.</li>
</ul>
</div>
</div>
</div>
<div id="section-522" class="section level1">
<h1>701150775</h1>
<div id="section-523" class="section level2">
<h2>220714</h2>
<p>{pancreatic neck adenocarcinoma,cT1cNXM1, stageIV, with
retroperitoneal spread status post Roux-en-Y hepatico-jejunostomy and
cholecystectomy}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-03-30 CT - abdomen, pelvis
<ul>
<li>pancreatic neck cancer with vessel encasement and lymph nodes
metastases show mild decreasing in size.</li>
</ul></li>
<li>2022-01-26 CT - abdomen, pelvis
<ul>
<li>pancreatic neck cancer with vessel encasement, lymph nodes
metastases, and lung metastases.</li>
</ul></li>
<li>2022-01-06 Patho - F2022-00006
<ul>
<li>soft tissue, retroperitoneal, biopsy - metastatic adenocarcinoma,
consistent with pancreas origin</li>
<li>section shows fibroadipose tissue and nerve bundles with metastatic
adenocarcinoma. perineural invasion is seen.</li>
<li>IHC: CK7(+), CK20(-), and CK19(+).</li>
<li>the morphology and immunohistochemical stains are consistent with
pancreas origin.</li>
</ul></li>
<li>2021-12-14 Patho -</li>
<li>2021-12-03 Endoscopic Ultrasonography, EUS
<ul>
<li>pancreatic genu tumor s/p CH-EUS &amp; EUS/FNB</li>
<li>lymphadenopathy, beside hepatic hilum</li>
<li>reflux esophagitis LA classification grade A</li>
</ul></li>
<li>2021-12-02 Ultrasound - abdomen
<ul>
<li>pancreastic head tumor with lymphadenopathy</li>
<li>GB sludge with distension</li>
<li>CBD dilatation</li>
<li>fatty liver, mild</li>
</ul></li>
<li>2021-11-30 MRI - pancreas
<ul>
<li>a faint enhancing tumor (1.2cm) at pancreatic body with distal
p-duct dilatation.</li>
<li>some LNs around celiac trunk and proximal SMA.</li>
<li>dilatation of biliary tree suspected distal CBD lesion.</li>
<li>inhomogeneous intensity of pancreatic head.</li>
</ul></li>
<li>2021-11-25 CT - abdomen, pelvis
<ul>
<li>suspected pancreatic body cancer with distal pancreatic duct
dilatation.</li>
<li>T4N1M0</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01 ~ ongoing: FOLFIRINOX
<ul>
<li>FOL: folinic acid (leucovorin), a vitamin B derivative that enhances
the effects of 5-fluorouracil (5-FU);</li>
<li>F: fluorouracil, a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops DNA synthesis;</li>
<li>IRIN: irinotecan, a topoisomerase inhibitor, which prevents DNA from
uncoiling and duplicating; and</li>
<li>OX: oxaliplatin, a platinum-based antineoplastic agent, which
inhibits DNA repair and/or DNA synthesis.</li>
</ul></li>
</ul></li>
</ul>
<div id="section-524" class="section level3">
<h3>==========</h3>
</div>
<div id="section-525" class="section level3">
<h3>2022-07-14</h3>
<ul>
<li>ALT (2022-07-13) was 117 U/L, the dose of irinotecan has been
reduced to 150 mg/m2.</li>
</ul>
</div>
<div id="section-526" class="section level3">
<h3>2022-04-20</h3>
<ul>
<li>FOLFIRINOX is a chemotherapy regimen that is used to treat advanced
pancreatic cancer. The patient is undergoing the regimen since Jan
2022.</li>
<li>2022-03-30 updated CT images showed a mild decrease in the size of
the tumor, indicating that current treatment is working. However, CA-199
(137U/mL 2022-04-06) remained above the upper limit of normal, and
should be noted.</li>
<li>S-GPT/ALT elevated since late March (126U/L 2022-04-19), if
bilirubin also elevates up to 1.5mg/dL, then the dosage of irinotecan
should be lowered.</li>
<li>Some targeted therapeutic agents might be an option if no
contraindication
<ul>
<li>pembrolizumab for MSI-H or dMMR cases.</li>
<li>larotrectinib/entrectinib for NTRK gene fusion positive cases.</li>
</ul></li>
</ul>
</div>
<div id="section-527" class="section level3">
<h3>2022-02-15</h3>
<ul>
<li>FOLFIRINOX is a chemotherapy regimen for treatment of advanced
pancreatic cancer. the patient is on this regemen, which is made up of
the following four drugs:
<ul>
<li>FOL: folinic acid (leucovorin), a vitamin B derivative that enhances
the effects of 5-fluorouracil (5-FU);</li>
<li>F: fluorouracil, a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops DNA synthesis;</li>
<li>IRIN: irinotecan, a topoisomerase inhibitor, which prevents DNA from
uncoiling and duplicating; and</li>
<li>OX: oxaliplatin, a platinum-based antineoplastic agent, which
inhibits DNA repair and/or DNA synthesis.</li>
</ul></li>
<li>some targeted therapeutic agents might be considered if no
contraindication
<ul>
<li>pembrolizumab for MSI-H or dMMR cases.</li>
<li>larotrectinib/entrectinib for NTRK gene fusion positive cases.</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-528" class="section level1">
<h1>701374548</h1>
<div id="section-529" class="section level2">
<h2>220714</h2>
<p>{DLBCL}</p>
<ul>
<li>lab data
<ul>
<li>2022-05-24 HBsAg(核醫) Negative<br />
</li>
<li>2022-05-24 HBsAg Value(核醫) 0.399<br />
</li>
<li>2022-05-23 Anti-HBs 0.14 mIU/mL<br />
</li>
<li>2022-05-23 Anti-HBc Nonreactive<br />
</li>
<li>2022-05-23 Anti-HBc-Value 0.15 S/CO<br />
</li>
<li>2022-05-23 Anti-HCV Nonreactive<br />
</li>
<li>2022-05-23 Anti-HCV Value 0.06 S/CO</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-21 2D transthoracic echocardiography
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal LV systolic function with normal wall motion.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal LV diastolic function.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Normal RV systolic function.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Typical mitral valve prolapse (bileaflet) with trivial MR; mild
TR.</li>
</ol></li>
</ul></li>
<li>2022-05-26 Whole body PET scan
<ul>
<li><ol style="list-style-type: decimal">
<li>Glucose hypermetabolism in the right inferior buccal region,
compatible with diffuse large B-cell lymphoma.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Increased FDG accumulation in bilateral kidneys, probably
physiological uptake of FDG.<br />
</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Diffuse large B-cell lymphoma, stage I (AJCC, 8th ed.), by this F-18
FDG PET scan.</li>
</ol></li>
</ul></li>
<li>2022-05-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — No evidence of lymphoma involvement</li>
<li>The sections show normocellular marrow (35%). M/E ratio = 5:1. The
myeloid cells show good maturation with mild neutrophilia. The
megakaryocytes are normal in number and morphology. The erythoid
precursors are not remarkable.</li>
<li>IHC, scattered small CD3+ T-cells and CD20+ B lymphocytes in
interstitium and no lymphoid aggregates can be found. There is no
evidence of lymphoma involvment in the sections examined. Suggest
further bone marrow smear evaluation and clinic correlation.</li>
</ul></li>
<li>2022-05-18 Patho - salivary gland biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li><ol style="list-style-type: decimal">
<li>Tumor, R’t buccal mucosa, excision — Diffuse large B-cell
lymphoma</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Residual tumor, ditto — Diffuse large B-cell lymphoma and reactive
lymph nodes</li>
</ol></li>
</ul></li>
<li>microscopic examination
<ul>
<li>Main tumor: diffuse large B-cell lymphoma shows medium to large
atypical lymphoid cells with mitoses and occasional nucleoli.
<ul>
<li>Immunohistochemistry shows CD3(-), CD20(+), cyclin-D1(+, focal ),
Bcl-2(+), CK(-), CD10(-), Bcl-6(+), C-MYC(-) and Ki-67: 80% for
tumor.</li>
<li>According to all above histopathologic findings, it indicates a case
of diffuse large B-cell lymphoma.</li>
</ul></li>
<li>Residual tumor: one node showed diffuse large B-cell lymphoma as
well as two reactive lymph nodes.</li>
</ul></li>
</ul></li>
<li>2022-05-17 MRI - nasopharynx
<ul>
<li>Clinical information: suspected adenoma of right mandible.</li>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>One well-defined mass lesion (5.0cm in length) over right mandibular
space, showing high-signal intensity on T2WI and homogeneous
enhancement. Favor a soft tissue lesion. Suggest tissue proof.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Normal appearance of both mastoid air-cells.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Clear appearacne of all paranasal sinuses.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-05-16 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible left atrial enlargement</li>
</ul></li>
<li>2022-05-16 CxR
<ul>
<li>No cardiomegaly</li>
<li>No active lung lesion</li>
<li>Normal bony contour</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-23 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>For evaluation and further management of diffuse large B-cell
lymphoma</li>
<li>This is a 40-year-old female suffering from a painless mass over
right lower face and was admitted on 2022/05/16 for surgical
management.</li>
<li>According to her statement, she noted a painless mass at her right
lower face about 6 months and the tumor was growing rapidly within past
few months, she came to our OS OPD for help on 2022/04/26. Physical
examination showed a mobile, painless lump at the right
buccal-retromolar area, about 3.5 cm in size. No sensory change or
numbness was complained by the patient. Under the impression of adenoma
of right mandible, she underwent excision of oral tumor under general
anesthesia on 2022/05/18. Post-operatively, mild sensory disturbance
over right chin was reported by the patient. However, the pathological
report showed diffuse large B-cell lymphoma of right mandible. Thus, we
need your expertise for further evaluation and management. Thanks for
your time.</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>right buccal diffuse large B-cell lymphoma</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Arrange PET scan for staging and port A insertion</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Please check HbsAg, Anti-Hbc, Anti-HCV, LDH</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>We will arrange bone marros aspiration and biopsy on 2022/05/24</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>After above was done, please arrange our hematology OPD</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Thanks for your consultation.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-22 ~ undergoing - R-CHOP (Rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>DLBCL stage I, PS 0, IPI score 0; lab data on 2022-07-13 and TPR,
BP, SpO2 during this hospitalization were generally normal.</li>
<li>R-CHOP treatment has been provided to the patient since 2022-06-22
without any known issue.</li>
</ul>
</div>
</div>
<div id="section-530" class="section level1">
<h1>701359667</h1>
<div id="section-531" class="section level2">
<h2>220708</h2>
<p>{Endometrium neuroendocrine carcinoma, pT2pN0M0, FIGO stage II s/p
Staging surgery(ATH + BSO + omentectomy + LN dissection) on
2022/02/14}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-26 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>S/P hysterectomy.</li>
<li>Left renal stone (3mm).</li>
<li>Atherosclerosis of aorta, iliac arteries.</li>
</ul></li>
<li>IMP:
<ul>
<li>S/P hysterectomy.</li>
<li>No evidence of tumor recurrence.</li>
</ul></li>
</ul></li>
<li>2022-03-07 Pure tone audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 43 dB HL; LE 111 dB HL.</li>
<li>R’t mild to moderately severe SNHL.</li>
<li>L’t moderately severe to profound mixed type HL.</li>
</ul></li>
<li>2022-02-14 Patho - uterus with or without SO non-neoplastic/prolapse
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Uterus, endometrium, total hysterectomy — Neuroendocrine
carcinoma.</li>
<li>Uterus, myometrium, total hysterectomy — Neuroendocrine carcinoma.
Invading &gt; 1/2 thickness of the myometrium and 0.4 cm from serosal
surface.</li>
<li>Uterus, cervix, total hysterectomy — Neuroendocrine carcinoma.
Invading endocervix.</li>
<li>Ovaries and fallopian tubes, bilateral, BSO — Free</li>
<li>Lymph node, bilateral pelvic and para-aortic, dissection —
Free<br />
</li>
<li>pT2 pN0 (if cM0) AJCC 8th edition Pathology FIGO stage: II, at
least.<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Operation Procedure: Staging surgery(ATH + BSO + omentectomy + LN
dissection)<br />
</li>
<li>Specimens include: uterus, bilateral adnexae, bilateral pelvic and
para-aortic lymph nodes.</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology type: Large cell neuroendocrine carcinoma</li>
<li>Histology grade: high grade.</li>
<li>Depth of invasion: invade &gt; 1/2 thickness of the myometrial
wall<br />
</li>
<li>Uterine Serosa Involvement - Not identified</li>
<li>Cervical Stromal Involvement - Present</li>
<li>Other Tissue/ Organ Involvement - Not identified</li>
<li>Bilateral, ovary: free</li>
<li>Bilateral, fallopian tube: free</li>
<li>Omentum: free</li>
<li>Margins (required only if cervix and/or parametrium/paracervix is
involved by carcinoma)
<ul>
<li>Ectocervical/Vaginal Cuff Margin: Free 2.5 cm away</li>
</ul></li>
</ul></li>
<li>Parametrial/Paracervical Margin: Free
<ul>
<li>Lymphovascular Invasion: Present</li>
<li>Regional Lymph Nodes: free</li>
<li>Ancillary Studies - S2022-02021: IHC stains: CD56 (+), Ki-67:
30-40%, p40 (-), WT-1 (-), vimentin (focal +), p16: &lt;70%.</li>
</ul></li>
</ul></li>
<li>2022-02-11 Whole body PET scan
<ul>
<li>A prominent glucose hypermetabolic lesion in the uterus, compatible
with primary endometrial malignancy.</li>
<li>A small focal area of mildly increased FDG uptake in the right
lateral aspect of the pelvic cavity. The nature is to be determined (a
metastatic lymph node of low FDG uptake? other nature such as
inflammation?). Please correlate with other imaging modalities for
further evaluation.</li>
<li>Increased FDG accumulation in both kidneys, right ureter and
intestine. Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2022-02-09 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, D&amp;C — Neuroendocrine carcinoma.</li>
<li>IHC stains: CD56 (+), Ki-67: 30-40%, p40 (-), WT-1 (-), vimentin
(focal +), p16: &lt;70%.</li>
<li>Section show(s) piece(s) of markedly necrotic tissue with
infiltration of sheets, nests, and trabeculae of round blue neoplastic
cells demonstrating pleomorphic nuceli.</li>
</ul></li>
<li>2022-02-07 MRI - pelvis
<ul>
<li>Suspected endometrial malignancy, cstage T1bN2M0. IIIc.</li>
<li>Uterine myoma, in cervical region.</li>
</ul></li>
<li>2022-02-04 Gynecologic ultrasonography
<ul>
<li>Endometrial thickening (EM:43.8mm)</li>
<li>Uterine myoma</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-26 Chromogranin A 52.1 ng/mL<br />
</li>
<li>2022-02-24
<ul>
<li>Anti-HBs 9.49 mIU/mL<br />
</li>
<li>Anti-HBc Reactive<br />
</li>
<li>Anti-HBc-Value 4.50 S/CO<br />
</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.02 S/CO<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.35 S/CO<br />
</li>
</ul></li>
<li>2022-02-13
<ul>
<li>Blood type ABO B<br />
</li>
<li>RH(D) Positive</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-14
<ul>
<li>Surgery
<ul>
<li>Diagnosis: endometrial malignancy, staging surgery. suspected
endometrial malignancy, cstage T1bN2M0. III</li>
<li>Operation: Staging surgery (ATH + BSO + omentectomy + LN dissection)
    - Finding</li>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: normal size, tense contact with bladder, peritoneum dut to
tumor mass accupied.</li>
<li>Adnexa:
<ul>
<li>LOV: 3x2x2cm, grossly normal</li>
<li>ROV: 2x2x2cm, grossly normal</li>
<li>Fallopian tube: bilateral grossly normal</li>
<li>CDS: mild adhesion</li>
<li>Ascites: 10 ml</li>
<li>Bilateralpelvic lymph nodes: normal(-), enlarged(-), indurated(+,
right para aortic area)</li>
<li>Omentum: grossly normal</li>
<li>Liver: grossly normal and smooth</li>
<li>Appendix: not seen</li>
<li>After the operation, optimal debulking surgery was achieved.</li>
<li>Residue tumor: R0, No residual tissued left as we seen.</li>
<li>Estimated blood loss: 400ml</li>
<li>Blood transfusion: nil</li>
<li>Complication: nil</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-09
<ul>
<li>Surgery
<ul>
<li>Diagnosis: MRI reported suspect EM malignancy, cstage T1bN2M0</li>
<li>Operation: Diagnostic dilatation and curettage for pathology     -
Finding</li>
<li>Uterus: anteversion/retroversion, sounding: 8 cm, dilatation to
Hegar No. 9.</li>
<li>Some endometrial tissus was curetted from endometrial cavity.</li>
<li>Estimated blood loss: 3 ml , Blood transfusion: nil, Complication:
nil.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2022-03-18 ~ - 4500cGy/25 fractions of the pelvic area.</li>
</ul></li>
<li>Chemoimmunotherapy
<ul>
<li>2022-03-09 ~ undergoing - etoposide + cisplatin</li>
</ul></li>
</ul>
<div id="section-532" class="section level3">
<h3>==========</h3>
</div>
<div id="section-533" class="section level3">
<h3>2022-05-03</h3>
<ul>
<li>Estrogen receptor (ER) testing is recommended in the settings of
stage III, stage IV, and recurrent disease.</li>
<li>HER2 immunohistochemistry (IHC) testing is recommended for possible
treatment of advanced-stage or recurrent serous endometrial carcinoma or
carcinosarcoma.</li>
<li>Consider HER2 IHC testing in TP53-aberrant endometrial carcinoma
regarless of histotyping.</li>
<li>Molecular analysis of endometrial carcinoma has identified four
clinically significant molecular subgroups with differing clinical
prognoses: POLE mutations, microsatellite instability-high (MSI-H), copy
number low, and copy number high.</li>
<li>Ancillary studies for POLE mutations, mismatch repair (MMR)/MSI, and
aberrant p53 expression are encouraged to complement morphologic
assessment of histologic tumor type.</li>
<li>Universal testing of endometrial carcinomas for MMR proteins is
recommended (MSI testing if results equivocal).</li>
<li>Consider NTRK gene fusion testing for metastatic or recurrent
endometrial carcinoma.</li>
</ul>
</div>
</div>
</div>
<div id="section-534" class="section level1">
<h1>700900252</h1>
<div id="section-535" class="section level2">
<h2>220701</h2>
<p>{Pancreatic adenocarcinoma, T4N1M0, stageIII}</p>
<ul>
<li>lab data
<ul>
<li>Glucose (serum)
<ul>
<li>2022-06-30 218 mg/dL</li>
<li>2022-06-04 172 mg/dL</li>
<li>2022-05-31 279 mg/dL</li>
<li>2022-03-25 120 mg/dL</li>
<li>2022-01-21 126 mg/dL</li>
<li>2021-11-25 112 mg/dL</li>
<li>2020-08-21 113 mg/dL</li>
<li>2020-08-06 115 mg/dL</li>
</ul></li>
<li>Mg (Magnesium) (1.9~2.7)
<ul>
<li>2022-06-30 1.3 mg/dL</li>
<li>2022-06-21 1.8 mg/dL</li>
<li>2022-06-17 1.8 mg/dL</li>
<li>2022-06-11 1.2 mg/dL</li>
<li>2022-06-09 2.7 mg/dL</li>
<li>2022-06-07 1.3 mg/dL</li>
<li>2022-05-31 1.6 mg/dL</li>
<li>2022-05-24 1.6 mg/dL</li>
<li>2022-04-07 2.1 mg/dL</li>
<li>2022-01-24 1.9 mg/dL</li>
</ul></li>
<li>Albumin
<ul>
<li>2022-06-30 3.2 g/dL</li>
<li>2022-06-21 2.6 g/dL</li>
<li>2022-06-17 2.5 g/dL</li>
<li>2022-06-11 2.5 g/dL</li>
<li>2022-06-07 2.6 g/dL</li>
<li>2022-05-31 3.5 g/dL</li>
<li>2022-05-24 3.3 g/dL</li>
<li>2022-05-12 3.3 g/dL</li>
<li>2022-04-28 4.3 g/dL</li>
<li>2022-04-25 4.1 g/dL</li>
<li>2022-04-19 3.5 g/dL</li>
<li>2022-04-14 4.0 g/dL</li>
<li>2022-04-07 3.7 g/dL</li>
<li>2022-03-26 3.9 g/dL</li>
<li>2022-01-24 3.2 g/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-20 2D transthoracic echocardiography, TTE
<ul>
<li>Findings
<ul>
<li>Heart size: Dilated LA, AsAo (35 mm); (LA volume: 65 ml, LA volume
index: 50 ml/m2)</li>
<li>Mitral E/A = 83 / 115 cm/s (E/A ratio = 0.72); Dec.time = 174 ms;
Heart rate = 94 bpm</li>
<li>Septal MA e’/a’ = 5.4 / 12.2 cm/s; Septal E/e’ = 15.5 ;</li>
<li>Lateral MA e’/a’ = 8.8 / 18.4 cm/s; Lateral E/e’ = 9.5 ;</li>
<li>Calcified lestions: aortic root</li>
<li>IVC size 13 mm with inspiratory collapse &gt;50%</li>
</ul></li>
<li>Conclusion:
<ul>
<li>Indeterminated LV filling pressure and impaired RV relaxation;
severely dilated LA.</li>
<li>Normal LV and RV systolic function.</li>
<li>Mild aortic valve sclerosis with mild AR; mild MR; mild TR; mild
PR.</li>
<li>Dilated proximal ascending aorta (35mm); prominent aortic root
calcification with protruding atheroma (7.5 mm of thickness).</li>
<li>No vegetation was found by TTE study.</li>
</ul></li>
</ul></li>
<li>2022-06-15 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Borderline cardiomegaly</li>
</ul></li>
<li>2022-06-13 Pure Tone Audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 36 dB HL // LE 36 dB HL</li>
<li>RE normal to moderately severe SNHL (sensorineural hearing
loss)</li>
<li>LE normal to moderate SNHL (sensorineural hearing loss)</li>
</ul></li>
<li>2022-06-04 CXR
<ul>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-06-04 KUB
<ul>
<li>Degenerative joint disease of lumbar spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-06-04 ECG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2022-05-09 Cholangiography
<ul>
<li>Cholangiography via PTCD catheter administration revealed:
<ul>
<li>S/P cholecystojejunostomy.</li>
<li>Obstruction of distal CBD.</li>
<li>Patency of the catheter.</li>
</ul></li>
</ul></li>
<li>2022-04-19 Patho - pancreas biopsy
<ul>
<li>Diagnosis
<ul>
<li>Pancreas, biopsy — chronic inflammation and fibrosis</li>
<li>F2022-00175
<ul>
<li>FsA: Soft tissue, SMA root, biopsy — negative for malignancy</li>
<li>FsB: Pancreas, biopsy — chronic inflammation and fibrosis
<ul>
<li>Lymph node, site?, excision — metastatic adenocarcinoma (1/1)</li>
</ul></li>
</ul></li>
</ul></li>
<li>Microscopic description
<ul>
<li>Section shows pancreatic tissue with infiltration of chronic
inflammatory cell and fibrosis. No invasive tumor is found. The
immunohistochemical stain of CK reveals no invasive tumor.</li>
<li>F2022-00175
<ul>
<li>FsA: Section shows fibroadipose tissue without malignancy. The
immunohistochemical stain of CK reveals no invasive tumor.</li>
<li>FsB: Section shows a piece of pancreatic tissue and a lymph node.
The pancreatic tissue reveals infiltration of chronic inflammatory cell
and fibrosis. No invasive tumor is found. The immunohistochemical stain
of CK reveals no invasive tumor. Metastatic adenocarcinoma is seen in
the lymph node. The immunohistochemical stain of CK is positive.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-18 Frozen section
<ul>
<li>Preliminary diagnosis:
<ul>
<li>FsA: Soft tissue, SMA root, biopsy — negative for malignancy</li>
<li>FsB: Pancreas, biopsy — in favor of reactive change
<ul>
<li>Lymph node, site?, excision — metastatic adenocarcinoma (1/1)</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Percutaneous gall bladder drainage
<ul>
<li>Distention of the gallbladder (by CT images).</li>
<li>Under local anesthesia, sono- and fluoroscopy guiding, a 8 Fr
pig-tail catheter was inserted into the gallbladder smoothly.</li>
</ul></li>
<li>2022-04-06 2D transthoracic echocardiography, TTE
<ul>
<li>Findings
<ul>
<li>Heart size: Dilated LA; AsAo (33mm); (LA volume: 60 ml, LA volume
index: 47 ml/m2)</li>
<li>Thickening: LVPW</li>
<li>Mitral E/A = 80 / 117 cm/s (E/A ratio = 0.68); Dec.time = 222 ms;
Heart rate = 87 bpm</li>
<li>Septal MA e’/a’ = 5.4 / 9.3 cm/s; Septal E/e’ = 14.7 ;</li>
<li>Lateral MA e’/a’ = 8.3 / 16.9 cm/s; Lateral E/e’ = 9.6 ;</li>
<li>IVC size 12 mm with inspiratory collapse &gt;50%</li>
</ul></li>
<li>Conclusion:
<ul>
<li>Indeterminated LV filling pressure and impaired RV relaxation;
moderately dilated LA.</li>
<li>Normal LV and RV systolic function.</li>
<li>Aortic valve sclerosis with trivial AR; trivial MR; trivial TR; mild
PR.</li>
<li>Mildly dilated proximal ascending aorta (33mm).</li>
</ul></li>
</ul></li>
<li>2022-03-31 Patho - pancreas biopsy
<ul>
<li>Tumor, pancreas, EUS FNA biopsy — Adenocarcinoma</li>
<li>Microscopically, the sections show a picture of blood, fibrin
material, glandular or nest tumor cells with enlarged, hyperchromatic
nuclei and nucleoli embedded in some fibrous stroma and focal mucin
secretion, compatible with adenocarcinoma, moderately
differentiated.</li>
</ul></li>
<li>2022-03-31 Fine needle aspiration biopsy - pancreas
<ul>
<li>Smears show clusters of papillary atypical hyperchromatic
cells.<br />
</li>
<li>Malignancy is favored. Please correlate with the clinical
presentation.</li>
</ul></li>
<li>2022-03-31 Endoscopic Ultrasonography, EUS
<ul>
<li>Using EUS-UCT 260 showed
<ul>
<li>1.) dilatation of CBD up to 9.6mm filled with hyperechoic
material</li>
<li>2.) distented GB full of hyperechoic material.</li>
<li>3.) a 22*20mm hypoechoic lesion at pancreatic head region</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Pancreatic head tumor with CBD obstruction, s/p EUS-FNA + ROSE</li>
</ul></li>
<li>Suggestion
<ul>
<li>pursue pathological result</li>
</ul></li>
</ul></li>
<li>2022-03-30 MRI - pancreas
<ul>
<li>Findings:
<ul>
<li><ol style="list-style-type: decimal">
<li>There is an ill-defined homogeneous mass measuring 2 x 1.4 cm in the
pancreatic head, causing bile duct, galbladder and pancreatic duct
dilatation, and it showing hypointensity on T1WI and iso-intensity on
both T2WI and DWI. During dynamic study, this tumor shows relative poor
enhancement at arterial phase, portal-venous phase and delayed phase
images.</li>
</ol>
<ul>
<li>Adenocarcinoma of the pancreatic head is highly suspected.</li>
<li>Please correlate with EUS.</li>
</ul></li>
<li>There are symmetrical soft tissue lesions encompass the celiac trunk
and superior mesenteric artery that may be metastases?</li>
<li>There are few enlarged nodes in hepatoduodenal ligament and
aortocaval space.</li>
<li>Abdominal aorta shows atherosclerosis, ectasia 2.8 cm and mild
intramural thrombus formation.</li>
</ul></li>
<li>IMP:
<ul>
<li>Adenocarcinoma of the pancreatic head is highly suspected.</li>
</ul></li>
</ul></li>
<li>2022-03-28 CT - abdomen
<ul>
<li>Imaging Report Form for Pancreatic Carcinoma</li>
<li>Impression (Imaging stage): T1cN1M0, stage IIB</li>
</ul></li>
<li>2022-03-25 CXR
<ul>
<li>Tortous aorta with calcification is noted.</li>
</ul></li>
<li>2022-03-25 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Gallbladder stone and sludge</li>
<li>CBD dilatation</li>
<li>MPD dilatation</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study</li>
</ul></li>
</ul></li>
<li>2022-01-24 CT - abdomen
<ul>
<li>Fat stranding along celiac trunk, common hepatic artery, splenic
artery and proximal SMA.</li>
<li>A vascular blush at right hepatic lobe.</li>
</ul></li>
<li>2021-12-24 Patho - colon biopsy
<ul>
<li>Colon, transverse, biopsy — tubular adenoma with low grade
dysplasia</li>
</ul></li>
<li>2021-11-29 CTA - pelvis
<ul>
<li>History and indication: endometrial CA s/p ATH at VGH without
F/U</li>
<li>S/P hysterectomy. No evidence of tumor recurrence.</li>
</ul></li>
<li>2021-11-29 SONO - abdomen
<ul>
<li>Diagnosis
<ul>
<li>Fatty liver, mild</li>
<li>Hepatic calcified lesion, S5</li>
<li>Slightly dilatation of MPD, body</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image study and clinical condition</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-14 Infectious Disease
<ul>
<li>A
<ul>
<li>This is a case of pancreatic adenocarcinoma and neutropenic
fever.</li>
<li>2022/06/08 B/C: yeast-like.</li>
<li>Agree with your use of mycamine as antifungal treatment. Keep one
anti-fungal agent is suggested.</li>
<li>Please f/u the final B/C results and adjust it according to the
susceptibility.</li>
<li>Please check recheck B/C 3~5 days later.</li>
</ul></li>
</ul></li>
<li>2022-04-28 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This 66-year-old woman has past history of
<ul>
<li>1). Endometrial cancer s/p op and chemotherapy more than 20 years
ago,</li>
<li>2). hypertension,</li>
<li>3). abdominal pain suspect with partial intestinal obstrucion
related in 2014/11/14.</li>
</ul></li>
<li>This time, she suffered from water diarrhea right after oral intake
for 2+ months and fever with chills for 2 days. She was admitted to GI
ward with the initial diagnosis of infectious gastroenteritis.</li>
<li>Abdominal MRI with MRCP was performed on 3/30 and revealed
adenocarcinoma of the pancreatic head being highly suspected. EUS/FNAB
on 3/31 and pathology revealed Adenocarcinoma. GS was consulted and the
surgeon had well explain to families. PPN was added since 4/01. Follwed
up abdomen echo revealed gall bladder distension, dilatation of CBD and
bilateral IHD. PTGBD was done for bilitary tract obstruction drainage on
4/08. She was transferred to GS ward on 2022/04/14.</li>
<li>After transferred to GS ward, with stable condition after
pancreatitis subsided, she was scheduled to receive Whipple’s operation.
During operation, a &gt;2cm pancreatic head tumor with SMA &amp; SMV
invasion and multiple enlarged LNs over SMA root were noted. Pancreatic
tumor biopsy was done and the enlarged LN was harvested. The frozen
section showed positive of malignancy of LN. After informing the family,
GJ byass, cholecystojejunostomy were done instead.</li>
<li>The patient was currently with stable condition and would start full
liquid diet today.</li>
<li>We needed your expertise for further management. Thank you!</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>Pancreatic adenocarcinoma, T4N1M0, stageIII s/p 20220418 GJ byass,
cholecystojejunostomy, excision of intraabdominal tumor</li>
<li>During operation, a &gt;2cm pancreatic head tumor with SMA &amp; SMV
invasion and multiple enlarged LNs over SMA root were noted.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>For unresectable disease at surgery and local advanced disease,
systemic therapy is indicated. We will discuss with patients later.
<ul>
<li>if good performance: FOLFIRINOX, or Gemcitabine + albumin-bound
paclitaxel</li>
<li>if poor performance status, may consider gemcitabine alone or
capecitabine.</li>
</ul></li>
</ul></li>
<li>If patient agrees, we take over this case.</li>
</ul></li>
</ul></li>
<li>2022-04-01 General and Gastrointestinal Surgery
<ul>
<li>A
<ul>
<li>suggest:
<ul>
<li>please D/D ductal adenocarcinoma or NET</li>
<li>nutrition support with PPN or TPN for 1-2 weeks</li>
<li>check PFT and 2D echo</li>
<li>we will f/u this case</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-25 Psychosomatic medicine
<ul>
<li>Q
<ul>
<li>Anxiety was noted. So we need you evaluation and suggestion of this
patient. Thank you very much</li>
</ul></li>
<li>A
<ul>
<li>I. Psychiatric impression:
<ul>
<li>Anxiety state</li>
<li>Watery diarrhea, cause to be determined</li>
<li>suspected somatic symptom disorder</li>
</ul></li>
<li><ol start="2" style="list-style-type: upper-roman">
<li>Clinical course and presentation:</li>
</ol>
<ul>
<li>This 66 years old female had medical history of
<ul>
<li>1). Endometrial cancer s/p op and chemotherapy more than 20 years
ago,</li>
<li>2). hypertension,</li>
<li>3). abdominal pain suspect with partial intestinal obstrucion
related in 2014/11/14.</li>
</ul></li>
<li>This time, she suffered from persistent watery diarrhea since 4
months ago, and had detailed GI examination done at our hospital but in
vain.</li>
<li>The patient claimed to have fair appetite, diarrhea after eating,
fair sleep but notable distress feeling to her somatic symptoms.</li>
<li>Death thinking would occur but denied proper suicidal plans. Her
body weight had decreased around 13 kg in recent 4 months.</li>
<li>According to the observation of the medical team, the patient often
refrained from oral intake probably due to diarrhea.</li>
<li>She admitted to have fear of cancer relapse or some unknown medical
disease despite reassurance by doctors.</li>
<li>She also claimed to be easily anxious, she was ever admitted to NTUH
psy department for unknown psychiatric diagnosis, and lost
follow-up.</li>
<li>She had been taking alprazolam from our GI department and told to
have good response.</li>
</ul></li>
<li><ol start="3" style="list-style-type: upper-roman">
<li>Suggestion:</li>
</ol>
<ul>
<li>Sulpiride 1# HS</li>
<li>Alprazolam 1# PRNBID</li>
<li>Treat underlying reason for diarrhea, re-assurance of exam
results</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-18
<ul>
<li>Surgery
<ul>
<li>GJ byass</li>
<li>cholecystojejunostomy</li>
<li>excision of intraabdominal tumor, malignancy</li>
</ul></li>
<li>Finding
<ul>
<li>pancreatic head tumor, &gt;2cm</li>
<li>multiple enlarged LNs over group 15</li>
<li>SMA and SMV invasion</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-10 ~ undergoing - gemcitabine + cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Hypomagnesimia (2022-06-30 1.3 mg/dL) could be caused by
gastrointestinal loss (chemotherapy induced diarrhea, panceas disease)
or renal loss (cisplatin, loop diuretic furosemide). Magnesium sulfate
10% 20mL IVD QD has been prescribed.</li>
<li>The level of serum albumin was around 2.5 g/dL for most of June. BW
41 kg, BH 150 cm (2022-06-30); BMI 18.2 kg/m2, mild thinness. It is
recommended to eat more to prevent malnutrition.</li>
<li>It should be noted that blood sugar readings fluctuate at high
levels even after insulin was administered.</li>
<li>Both TPR and BP were stable during this hospital stay.</li>
</ul>
</div>
</div>
<div id="section-536" class="section level1">
<h1>701358791</h1>
<div id="section-537" class="section level2">
<h2>220630</h2>
<ul>
<li>present illness
<ul>
<li>In the case of this 41-year-old female, she was diagnosed with
endometrial adenocarcinoma IA Grade 2 and High grade endometrial stromal
sarcoma (ESS), stage IIB post-hysterectomy at MacKay Memorial Hospital
in 2021-08, where she was offered C/T &amp; R/T for post-operative
treatment, however, she hesitated and sought a second opinion at NTUH.
The patient had a CT in 2021-10 at NTUH for tumor staging. However, she
did not return to the clinic for the results.</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-28 CXR
<ul>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Ground glass opacity in right lung.</li>
</ul></li>
<li>2022-06-13 Renal ultrasound (Nephrology)
<ul>
<li><ol style="list-style-type: decimal">
<li>Normal right kidney except for a suspected AML, middle pole</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Left hydronephrosis</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Tumor compression of the left kidney</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>PCN in the left renal pelvis</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Mass lesion in the pelvic region</li>
</ol></li>
</ul></li>
<li>2022-06-04 CT - abdomen, pelvis
<ul>
<li>Recurrent endometrial cancer with LNs and lung metastases.</li>
<li>S/P bil. PCN.</li>
<li>Splenomegaly.</li>
</ul></li>
<li>2022-06-04 KUB + L-spine Lat
<ul>
<li>S/P bil. pig-tail catheters indwelling.</li>
</ul></li>
<li>2022-06-04 Electrocardiogram, ECG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2022-05-24 KUB
<ul>
<li>S/P bil. pig-tail catheters indwelling.</li>
</ul></li>
<li>2022-05-06 PCN - pigtail revision
<ul>
<li>Obstruction of left PCN catheter.</li>
<li>Revision of the catheter smoothly.</li>
</ul></li>
<li>2022-05-06 KUB
<ul>
<li>The psoas shadow is clear.</li>
<li>Increased density in the abdominal cavity is found.</li>
<li>Stool impaction at the abdominal cavity is noted.</li>
<li>Scoliotic alignment of the lumbar spine is found.</li>
<li>Calcified dot(s) is found at left paravertebral region, ureter
stone(s) is most likely.</li>
</ul></li>
<li>2022-04-28 KUB
<ul>
<li><ol style="list-style-type: decimal">
<li>s/p pigtail insertion in the bilateral uper abdomen.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>increased density in the lower abdomen. Nature?</li>
</ol></li>
</ul></li>
<li>2022-04-28 Electrocardiogram, ECG
<ul>
<li>Sinus tachycardia with Premature atrial complexes</li>
<li>Nonspecific ST abnormality</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-04-12 Patho - lymphnode biopsy
<ul>
<li>Soft tissue, pelvis, left, CT guided biopsy — sarcoma, high
grade.</li>
<li>IHC stains: vimentin (+), CD10 (-), CK (-), CK7 (-), CK20 (-).</li>
<li>Section shows cores of soft tissue with infiltration of epithelioid
and spindle shaped neoplastic cells.</li>
</ul></li>
<li>2022-04-08 CT - abdomen, pelvis
<ul>
<li>Local recurrent endometrial sarcoma with lymph nodes and lung
metastases is highly suspected.</li>
</ul></li>
<li>2022-04-08 Tc-99m MDP whole body bone scan
<ul>
<li>Some faint hot spots in the skull and bilateral rib cages. The
nature is to be determined (post-traumatic change? other nature?).
Please follow up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, bilateral elbows, S-I
joints, hips and knees. Benign joint lesions are more likely.</li>
</ul></li>
<li>2022-04-06 CT - abdomen
<ul>
<li>Ovarian cancer with lymph nodes metastases and lung metastais is
highly suspected. Please correlate with CA125 and contrast-enhanced
CT.</li>
<li>Splenomegaly is noted, nature? Please correlate with clinical
condition.</li>
</ul></li>
<li>2022-04-06 Gynecologic ultrasonography
<ul>
<li>ATH</li>
<li>Bilateral kidney hydronephsis</li>
<li>Suspected pelvis mass &gt; 30 cm</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-28 Urology
<ul>
<li>Q
<ul>
<li>ER Examination: 3.
<ul>
<li>Medical device problems &gt; acute peripheral severe pain
(8-10)</li>
<li>The patient reported pain in the right waist and obstruction of the
right renal drainage tube for 3 days</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>Ultrasound showed right hydronephrosis, combined with new left foot
swelling and bilateral waist and back skin swelling, water moved to
extravascular dehydration</li>
<li>The problem may not be solved by simply changing the tube, and there
may be other factors to consider</li>
<li>A swelling on the left foot may indicate aggravation of the
condition despite the patient’s pain and shortness of breath, and the
patient hopes for active treatment</li>
<li>I will perform change Pigtail with c-arm+ contrast medium</li>
<li>Do blood test CXR for suspect infection and renal failure</li>
</ul></li>
</ul></li>
<li>2022-05-27 Urology
<ul>
<li>Q
<ul>
<li>Bilateral hydronephrosis S/P Percutaneous Nephrostomy (PCN)
<ul>
<li>right Percutaneous Nephrostomy revision on 20220523.</li>
<li>left Percutaneous Nephrostomy revision on 20220506.</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>drainage function seems fine</li>
<li>no ecchymosis or leakage now</li>
<li>urine from right PCN is clear</li>
<li>there is no need of change Pigatail now</li>
<li>change of pigtail now may still be ainful</li>
<li>plan add morphine or other pain killer</li>
</ul></li>
</ul></li>
<li>2022-04-19 Dermatology
<ul>
<li>Q
<ul>
<li>Newly erupted itchy skin rash at bilateral popliteal regions,
elbows, axillary cavity, inguinal regions, metacarpophalangeal joints
were noted for one day. So, we need your expertise on evaluation or some
sugggestion. Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered from multiple erytheamtous papules-plaques on
bil legs after 2 dose BNT vaccine for months.</li>
<li>Imp: Vasculitis</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Please check CBC/DC, ANA,TSH, C3/C4, ASLO, Anti-HBsAg, Anti-HCV</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Zaditen 1 / Bid</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Xyzal * 1 Hs</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>SInpharderm * 1 tube/bid</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Topsym cream * 6 tubes/bid</li>
</ol></li>
</ul></li>
<li>Thanks!</li>
</ul></li>
</ul></li>
<li>2022-04-13 Cardiology
<ul>
<li>Q
<ul>
<li>This 41y/o female was diagnosed with Endometrial endometrioid
adenocarcinoma IA Grade 2 and High grade endometrial stromal
sarcoma(ESS), stage IIB s/p hysterectomy in 2021/08 in MacKay Memorial
Hospital.</li>
<li>This time was admitted to our Onco’s ward under impression of
suspect local recurrent endometrial stromal sarcoma with lymphnode and
lung metastasis and obstructive uropathy with UTI.</li>
<li>After admission, high blood pressure levels were found but the
patient denied history of HTN. For suspect newly diagnosed HTN, we need
your expertise for evaluation or some suggestion or OPD f/u. Thank you
very much!</li>
</ul></li>
<li>A
<ul>
<li>I was consulted for elevated hospitalized BP.</li>
<li>A
<ul>
<li>avg. 160-200 mmHg</li>
<li>EKG: LVH, sinus</li>
<li>Taking steroid, hydralazine now</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Add amlodipine 1pc QD; keep hydralazine</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Pain/anxiety relief</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Treat underlying diseases</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Urology
<ul>
<li>A
<ul>
<li>S
<ul>
<li>This time, the the patient had progressive low back pain, poor
appetite with body weight loss (20Kg) in these 2-3 months.</li>
</ul></li>
<li>O
<ul>
<li>Abdomen CT: pelvic mass with lymph nodes metastases and lung
metastais; external compression/invasion to left ureter and bilateral
hydronephrosis.</li>
</ul></li>
<li>A
<ul>
<li>Bilateral ureteral catheterization +/- left pigtail insertion is
indicated.</li>
<li>We’ve visited the patient and discussed with the patient about the
further treatment plan.</li>
<li>Current treatment plan is not well established, pathology report of
the pelvic mass is need.</li>
</ul></li>
<li>P
<ul>
<li>Please contact us when pathology is done. Thank you.</li>
<li>Urine retention is noted from 2 CT scans. Foley insertion is
recommended.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Rheumatology and Immunology
<ul>
<li>Q
<ul>
<li>For vasculitis-like skin rashes noted at the four limbs and APS not
be excluded , we need your expertise on evaluation or some suggesion.
Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>Diffuse skin purpura over four limb for several months, no active
joint pain, after vaccination?</li>
<li>O
<ul>
<li>Cr 0.89</li>
<li>ALT 6</li>
<li>CRP 8.97</li>
<li>urnie protein-, ob+</li>
</ul></li>
<li>Suggestion
<ul>
<li>suspected r/o vasculitis, may check ANA, anti-SSA, SSB, SM/RNP,
DSDNA, ANCA, anti-cardiolipin IG/IGM, B2glycoprotein 1, lupus
anticoagulation, C3/C4</li>
<li>may keep prednisolone 1#bid.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-06 Obstetrics and Gynecology
<ul>
<li>A
<ul>
<li>S
<ul>
<li>G0, SEX(-), TOCC(-)</li>
<li>PH: s/p hystectomy</li>
<li>Personal history:
<ul>
<li>Endometrial endometrioid adenocarcinoma IA Grade 2 =＞ s/p
hysterectomy (2021/08 op at MacKay H)</li>
<li>High grade endometrial stromal sarcoma, ESS, IIB, s/p hysterectomy
(2021/08 op at MacKay H, without CT/RT)</li>
<li>Vasculitis under medication of fexofenadine, prenisolone, and
MgO</li>
</ul></li>
<li>Family history: denied</li>
</ul></li>
<li>O
<ul>
<li>CT:
<ul>
<li>Ovarian cancer with lymph nodes metastases and lung metastais is
highly suspected.</li>
<li>Please correlate with CA125 and contrast-enhanced CT.</li>
</ul></li>
<li>Lab data: Cre = 0.89, eGFR = 74</li>
<li>PE: no pitting edema, no swelling over bilateral legs.</li>
<li>Echo:
<ul>
<li>Pelvic mass &gt; 30 cm, suspected ESS with bilateral
hydronephrosis</li>
</ul></li>
</ul></li>
<li>Impression and plan:
<ul>
<li><ol style="list-style-type: decimal">
<li>OPD follow up for suspect endometrial stromal sarcoma with lymph
node and lung mets.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Please check CA125, CA199, CEA</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Pain control</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>please consult urology for bilateral hydronephrosis being
noted.</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surigcal operation
<ul>
<li>2022-04-13 Percutaneous Nephrostomy</li>
<li>2022-04-12 Percutaneous Nephrostomy</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-20 ~ undergoing - paclitaxel + carboplatin</li>
</ul></li>
</ul>
<div id="section-538" class="section level3">
<h3>==========</h3>
</div>
<div id="section-539" class="section level3">
<h3>2022-06-30</h3>
<ul>
<li>There is severe pain a number of times after PCN, which could be
caused by the renal drainage tube. Unbalanced drainage amount recorded,
2022-06-29 right PCN 900 and left PCN was 0. It may be worthwhile to
investigate the underlying causal factors.</li>
<li>Several months of sinus tachycardia have been observed, which could
have been caused by hydralazine. In addition to acting as an
antihypertensive, ivabradine may also lower heart rate, which might be
worth considering.</li>
</ul>
</div>
<div id="section-540" class="section level3">
<h3>2022-05-20</h3>
<ul>
<li>The patient was diagnosed with high grade endometrial stromal
sarcoma in August 2021 and has been treated with paclitaxel +
carboplatin since April 2022.</li>
<li>Lab data reported on 2022-05-19 showed grossly normal. No issue with
active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-541" class="section level1">
<h1>701072376</h1>
<div id="section-542" class="section level2">
<h2>220629</h2>
<p>{cholangiocarcinoma, recurrenct, liver and lung mets, s/p colon
cancer}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>HGB
<ul>
<li>2022-06-28 7.9 g/dL</li>
<li>2022-06-09 8.0 g/dL</li>
<li>2022-05-29 8.9 g/dL</li>
<li>2022-05-13 8.3 g/dL</li>
<li>2022-04-26 9.4 g/dL</li>
<li>2022-04-25 8.9 g/dL</li>
<li>2022-04-22 8.2 g/dL</li>
<li>2022-04-07 9.3 g/dL</li>
<li>2022-03-29 10.9 g/dL</li>
<li>2022-03-22 11.1 g/dL</li>
<li>2022-03-11 11.0 g/dL</li>
<li>2022-02-23 12.6 g/dL</li>
<li>2022-02-18 12.5 g/dL</li>
<li>2021-12-17 13.8 g/dL</li>
<li>2021-11-01 12.5 g/dL</li>
<li>2021-03-20 14.1 g/dL</li>
<li>2021-03-19 15.5 g/dL</li>
</ul></li>
<li>Creatinine
<ul>
<li>2022-06-28 1.91 mg/dL</li>
<li>2022-06-21 1.79 mg/dL</li>
<li>2022-06-09 1.43 mg/dL</li>
<li>2022-05-29 1.79 mg/dL</li>
<li>2022-05-13 1.68 mg/dL</li>
<li>2022-04-25 1.24 mg/dL</li>
<li>2022-04-22 2.17 mg/dL</li>
<li>2022-04-07 1.62 mg/dL</li>
<li>2022-03-29 1.44 mg/dL</li>
<li>2022-03-22 1.29 mg/dL</li>
<li>2022-03-11 1.36 mg/dL</li>
<li>2022-02-23 1.23 mg/dL</li>
<li>2022-02-18 1.13 mg/dL</li>
<li>2022-01-20 1.04 mg/dL</li>
<li>2021-12-17 1.41 mg/dL</li>
<li>2021-11-03 1.11 mg/dL</li>
<li>2021-11-01 1.40 mg/dL</li>
<li>2021-09-16 1.17 mg/dL</li>
<li>2021-08-16 1.40 mg/dL</li>
<li>2021-03-19 2.11 mg/dL</li>
<li>2021-03-02 1.30 mg/dL</li>
<li>2020-12-08 1.27 mg/dL</li>
<li>2020-09-15 1.40 mg/dL</li>
<li>2020-03-25 1.30 mg/dL</li>
<li>2020-02-21 1.30 mg/dL</li>
</ul></li>
</ul></li>
<li>exam findings
<ul>
<li>2022-06-09, 2022-05-29 Electrocardiogram, ECG
<ul>
<li>Sinus bradycardia with sinus arrhythmia</li>
</ul></li>
<li>2021-12-21 CT
<ul>
<li>S/P right lobectomy and cholecystectomy. S/P colostomy.</li>
<li>Multiple recurrent tumors in the liver and peritoneal seeding, lymph
nodes metastasis, bilateral lung metastasis. (recurrent
cholangiocarcinoma or colon malignancy?)</li>
</ul></li>
<li>2021-11-16 CT
<ul>
<li>recurrent cholangiocarcinoma in left hepatic lobe with lung and Rt
cardiophenic angle LNs metastases. small airways disease in lungs
too.</li>
</ul></li>
<li>2021-09-01 Myocrdial perfusion SPECT with persantin
<ul>
<li>Mildly improved myocardial perfusion to LV compared with the
previous study on 2020-06-02, indicating resposne to current
therapy.</li>
<li>There is still mild myocardial ischemia at the basal inferolateral
wall and apical inferolateral wall (LCx territory) of LV. 3. No
dilatation of LV is noted.</li>
</ul></li>
<li>2021-06-02 Myocrdial perfusion SPECT with persantin
<ul>
<li>Probably mild to moderate myocardial ischemia with possible a small
portion of severe ischemia at the inferoapical wall and inferolateral
wall and mild myocardial ischemia at the inferoseptal wall and posterior
wall.</li>
</ul></li>
<li>2021-03-25 MRI - L-spine
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>herniated discs in the L2/3, L3/4, and L4/5 discs.</li>
</ul></li>
<li>2019-05-21 CT
<ul>
<li>Recurrent cholangiocarcinoma or artifact 1.8 cm in S4 of the liver
is suspected. Please correlate with AFP, CEA, and MRI.</li>
</ul></li>
<li>2018-08-07 SONO - Hepatobiliary
<ul>
<li>Post right hepatectomy. Poor defined gallbladder.</li>
</ul></li>
<li>2018-03-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, intrahepatic bile ducts, S5, right lobectomy -
Cholangiocarcinoma
<ul>
<li>Pathologic Staging (AJCC): pT2N0(cMx); Stage II if cM0</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Cholangiocarcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Tumor Growth Pattern: Mass-forming<br />
</li>
<li>Microscopic Tumor Extension: Tumor confined to hepatic
parenchyma<br />
</li>
<li>Small Vessel Invasion (L): Present<br />
</li>
<li>Additional Pathologic Findings: Cirrhosis<br />
</li>
<li>Hepatitis: Chronic hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score = 4 (interphase hepatitis = 1/4,
confluent necrosis = 0/6, focal necrosis = 1/4, portal inflammation =
2/4) (Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)</li>
<li>Fatty Change: Present (5%)</li>
<li>IHC for tumor cells: CK7(+), Hepa-1(-), Arginase(-)</li>
</ul></li>
</ul></li>
<li>2018-02-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, c;inical histroy of colorectal adenocarcinoma,
neele biopsy - Adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK7(+), CK20(-), CDX-2(-): dis-favor colorectal origin;</li>
<li>Hepatocyte(-), Arginase(-): dis-favor hepatocellular carcinoma.</li>
<li>CK19(+): favor cholangiocarcinoma.</li>
</ul></li>
</ul></li>
<li>2018-01-19 CT
<ul>
<li>Irregular low density(around 2.4cm) in right lobe liver, suspected
liver metastasis.</li>
<li>Post-op with colostomy in left abdomen.</li>
</ul></li>
<li>2017-07-12 Tc-99m MDP whole body bone scan
<ul>
<li>A new lesion in a middle C-spine in comparison with the previous
study on 2013-07-17, the nature is to be determined (DJD, post-traumatic
change or other nature ?), suggesting follow-up.</li>
<li>Significantly increased radioactivity in the mandilbe, dental
problems may show this picture.</li>
<li>Suspected benign lesions in the maxilla, bilateral sternoclavicular
junctions, L-S junction, bilateral shoulders, bilateral knees, and
bones/joints of right foot.</li>
</ul></li>
<li>2017-07-12 CT
<ul>
<li>Suspect small airway disease in lower lobes of lung.</li>
<li>Gallstones.</li>
</ul></li>
<li>2007-10-26 Patho
<ul>
<li>rectal adenocarcinoma pT2N1M0 s/p abdominal perineal resection.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-11-02 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This 70-year-old male patient had past history of:
<ul>
<li><ol style="list-style-type: decimal">
<li>Smoking for about 40-50 years, has quit for 2 years.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Rectal adenocarcinoma, pT2N1M0 s/p abdominal perineal resection on
2007/10/26.</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Hypertension for more then 10 years and diabetes for 5 years with
medical control.</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Ileus for times since 2012/08/06.</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Right hip osteoarthritis s/p total hip replacement on
2013/12/25.</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Right knee osteoarthritis s/p TKR on 2018/01/25 at Chang Hua
Hospital of MOHW</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>Right cholangiocarcinoma, pT2N0M0; Stage II s/p right lobectomy +
lymph node dissection + cholecystectomy on 2018/03/22.</li>
</ol></li>
</ul></li>
<li>He was under regular medical treatment in our CV, Neurology, Meta
OPD in the recent years.<br />
</li>
<li>According to patients and his daughter, he complained of dyspnea
after walking about 50 meters in the recent 1 years. The symptoms lasted
for 5~10 minutes and subsided after rest. So, we arranged 2D
transthoracic echocardiography on 2021/09/01, which showed EF 80%; 1.
Septal and RV hypertrophy with Gr I LV diastolic dysfunction and
impaired RV relaxation.; 2. Normal LV and RV systolic function.; 3. Mild
aortic valve sclerosis. Tl-201 stress myocardial perfusion scan on
2020/06/02, which showed: probably mild to moderate myocardial ischemia
with possible a small portion of severe ischemia at the inferoapical
wall and inferolateral wall and mild myocardial ischemia at the
inferoseptal wall and posterior wall. We arrange CAG on 2021/11/02.
Therefore, we need your expertise to evaluate his condition and make
further comments. Thank you very much!</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This 70 y.o male was a case of rectal adenocarcinoma, right
cholangiocarcinoma and HTN. This time, he was admitted due to
progressive dyspnea and suspected CAD. Now, we were consulted for
further evaluation about possible lung disease.</li>
<li>Smoking: 1 ppd for 40-50 years and quit for 2 years</li>
</ul></li>
<li>O
<ul>
<li>2021-08-24 CXR: mild cardiomegaly, LLL retrocardiac opacity r/o
consolidation or other etiology</li>
<li>2021-10-19 PFT: FEF 25-75% &lt;60%, suspected small airway disease
with significant bronchodilator response</li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>please follow up CXR, if LLL retrocardiac opacity still presented,
Chest CT was indicaded</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>please arrange Pulmonary provocation test for small airway disease
(suspected underline asthma or airway hypersensitivity)</li>
</ol></li>
</ul></li>
<li>We will like to f/u this case if data complete</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-03-23
<ul>
<li>Surgery: tumors excision</li>
<li>Finding: multiple granulomatous polyps formation around the
colostomy</li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2022-04-07 - 5-FU + carboplatin + gemcitabine</li>
<li>2022-02-23 ~ 2022-03-22 - 5-FU + cisplatin + gemcitabine</li>
</ul></li>
</ul>
<div id="section-543" class="section level3">
<h3>==========</h3>
</div>
<div id="section-544" class="section level3">
<h3>2022-06-29</h3>
<ul>
<li>2022-06-28 RBC 2.3 *10^6/uL, HGB 7.9 g/dL, MCV 105.7 fL =&gt; could
be macrocytic anemia. Kentamin (B1, B6, B12) has been prescribed.</li>
<li>Gemcitabine could also induce macrocytosis. Gemcitabine related
anemia incidence: 68%, grade 3 7%, grade 4 1%. This drug has been used
since 2022-02-23. It could have accelerated the decline in HGB levels,
however, there might also be other causal underlying conditions, as the
decline has been documented since March 2021.</li>
<li>There is an obvious downward trend of HGB with a monthly drop of
-0.5 g/dL.
<ul>
<li>2022-06-28 7.9 g/dL</li>
<li>2022-06-09 8.0 g/dL</li>
<li>2022-05-29 8.9 g/dL</li>
<li>2022-05-13 8.3 g/dL</li>
<li>2022-04-26 9.4 g/dL</li>
<li>2022-04-25 8.9 g/dL</li>
<li>2022-04-22 8.2 g/dL</li>
<li>2022-04-07 9.3 g/dL</li>
<li>2022-03-29 10.9 g/dL</li>
<li>2022-03-22 11.1 g/dL</li>
<li>2022-03-11 11.0 g/dL</li>
<li>2022-02-23 12.6 g/dL</li>
<li>2022-02-18 12.5 g/dL</li>
<li>2021-12-17 13.8 g/dL</li>
<li>2021-11-01 12.5 g/dL</li>
<li>2021-03-20 14.1 g/dL</li>
<li>2021-03-19 15.5 g/dL</li>
</ul></li>
<li>It is also possible for capecitabine-based regimens to cause anemia
(72% to 80%, grades 3 or 4 &lt;=3%)</li>
</ul>
</div>
<div id="section-545" class="section level3">
<h3>2022-04-08</h3>
<ul>
<li>The serum creatinine level rises from 1.04mg/dL (2022-01-04) to
1.62mg/dL (2022-04-07), which should be addressed.</li>
<li>In the new regimen used during this hospital stay, cisplatin was
substituted for carboplatin, which might mitigate renal toxicity.</li>
</ul>
</div>
<div id="section-546" class="section level3">
<h3>2022-03-23</h3>
<ul>
<li>Since late February 2022, the patient has been receiving 5-FU +
cisplatin + gemcitabine. No issue with current medication.</li>
<li>If a patient is not a candidate for a clinical trial or one is not
available, and if S-1 is not available, gemcitabine plus cisplatin is
recommended as a first-line regimen for patients with a good performance
status. Another reasonable, possibly better tolerated option is
gemcitabine plus oxaliplatin (GEMOX). Gemcitabine plus nanoparticle
albumin-bound paclitaxel (nabpaclitaxel) might also be considered.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/systemic-therapy-for-advanced-cholangiocarcinoma" class="uri">https://www.uptodate.com/contents/systemic-therapy-for-advanced-cholangiocarcinoma</a></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-547" class="section level1">
<h1>701136097</h1>
<div id="section-548" class="section level2">
<h2>220629</h2>
<p>{right ovarian cancer, pT1c3N0 if cM0, FIGO IC3 s/p Op on
20200720}</p>
<ul>
<li>lab data
<ul>
<li>Mg (Magnesium)
<ul>
<li>2022-06-28 1.5 mg/dL<br />
</li>
<li>2022-06-01 1.7 mg/dL<br />
</li>
<li>2022-04-26 1.5 mg/dL<br />
</li>
<li>2022-03-29 1.8 mg/dL<br />
</li>
<li>2022-03-07 1.9 mg/dL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-04-08 CXR
<ul>
<li>Cardiomegaly is noted.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>S/p port-A placement with its tip at RA</li>
<li>The lung fields are clear.</li>
<li>Clear bilateral costophrenic angle is noticed.</li>
<li>Patent airway is found.</li>
</ul></li>
<li>2022-04-08 Electrocardiogram
<ul>
<li>Normal sinus rhythm</li>
<li>ST &amp; T wave abnormality, consider inferior ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-03-09 Body Fluid Cytology - ascites
<ul>
<li>pathologic diagnosis
<ul>
<li>Before IP C/T: Atypia<br />
</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>11 cc pink clear ascites<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The smears show some lymphocytes, reactive mesothelial cells and few
atypical cells in necrotic debris show hyperchromatic nuclei and
degenerative quality. Follow up</li>
</ul></li>
</ul></li>
<li>2022-02-17 Electrocardiogram
<ul>
<li>Normal sinus rhythm</li>
<li>T wave abnormality, consider inferior ischemia</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-01-04 Patho - ovary (tumor)
<ul>
<li>diagnosis
<ul>
<li>Peritoneal nodule, right, debulking surgery — High-grade serous
carcinoma, seeding<br />
</li>
<li>Subdiaphramatic, right, debulking surgery — High-grade serous
carcinoma, seeding<br />
</li>
<li>Omentum, debulking surgery — High-grade serous carcinoma,
seeding<br />
</li>
<li>Transverse colon, debulking surgery — High-grade serous carcinoma,
seeding<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show serous carcinoma composed of irregular branching
of neoplastic papillae lined by high-grade tumor cells with tumor
necrosis and fibrous stroma. The tumor shows nclar hyperchromasia,
pleomorphism, prominent nucleoli and mitotic activity.<br />
</li>
<li>Immunohistochemical stain reveals CK7(+), WT-1(+), CK20(-) and
PAX-8(+).</li>
</ul></li>
</ul></li>
<li>2021-12-31 Colonoscopy
<ul>
<li>Diagnosis
<ul>
<li>Poor colon preparation</li>
<li>Internal hemorrhoid</li>
</ul></li>
<li>Suggestion
<ul>
<li>Repeat colonoscopy under good colon preparation if needed</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-12-10 CT - lung/mediastinum/pleura
<ul>
<li>Imp: No evidence of pulmonary mets.</li>
<li>Liver metastasis. Statinoary.</li>
<li>Splenic hilar mets. Stable.</li>
</ul></li>
<li>2021-11-23 Mammography
<ul>
<li>Impression:
<ul>
<li>Dense breast. No mammographic evidence of malignancy, suggest
clinical correlation and regular follow up.</li>
</ul></li>
<li>BI-RADS: Category 1: negative. - annual screening.</li>
</ul></li>
<li>2021-11-18 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Peritoneal seeding and liver metastases.</li>
</ul></li>
<li>2021-11-16 CXR
<ul>
<li>No active lung lesion.</li>
<li>Borderline cardiomegaly.<br />
</li>
<li>Thoracic spondylosis.</li>
</ul></li>
<li>2021-08-25 SONO - Abd for follow-up
<ul>
<li>A homogeneous hyperechoic nodule 0.9 cm in S6 of the liver is noted
that may be hemangioma? Follow up is indicated.</li>
<li>A renal cyst measuring 0.76 cm in right upper pole is noted.</li>
</ul></li>
<li>2021-08-10 CT - abdomen, pelvis
<ul>
<li>Imp: s/p ATH and BSO. No evidence of recurrent/residual tumor in the
current study.</li>
</ul></li>
<li>2021-02-23 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy and oophorectomy. Suggest follow up.</li>
<li>Renal cysts.</li>
<li>Right adrenal nodule, suspected adrenal adenoma.</li>
</ul></li>
<li>2020-07-20 Patho - uterus (with or without SO) neoplastic
<ul>
<li>Ovarian Fallopian tube Peritoneum Cancer Checklist (Based on AJCC
8th ed. and FIGO 2014)<br />
</li>
<li>pathologic diagnosis
<ul>
<li>Ovary, right, debulking surgery —- high-grade serous carcinoma<br />
</li>
<li>Ovary, left, debulking surgery —- high-grade serous carcinoma<br />
</li>
<li>Fallopian tube, right, debulking surgery —- high-grade serous
carcinoma<br />
</li>
<li>Fallopian tube, left, debulking surgery —- high-grade serous
carcinoma<br />
</li>
<li>Uterus, corpus, ebulking surgery —- intramural leiomyomas<br />
</li>
<li>Uterus, cervix, debulking surgery —- negative for malignancy<br />
</li>
<li>Omentume, debulking surgery —- negative for malignancy<br />
</li>
<li>Lymph node, left iliac, dissection — negative for malignancy
(0/7)<br />
</li>
<li>Lymph node, left obturator, dissection — negative for malignancy
(0/6)<br />
</li>
<li>Lymph node, right iliac, dissection — negative for malignancy
(0/7)<br />
</li>
<li>Lymph node, right obturator, dissection — negative for malignancy
(0/12)<br />
</li>
<li>Lymph node, left paraaortic, dissection — negative for malignancy
(0/8)<br />
</li>
<li>Lymph node, left paraaortic, dissection — negative for malignancy
(0/8)<br />
</li>
</ul></li>
<li>pTNM stage: pT1c3N0(If cM0); FIGO IC3<br />
</li>
<li>microscopic examination 1. Histologic type: serous carcinoma
<ul>
<li>Histologic grade: high grade<br />
</li>
<li>Contralateral ovary involvement: present<br />
</li>
<li>Tumor side ovarian surface involvement: present<br />
</li>
<li>Contralateral ovary surface involvement: present<br />
</li>
<li>Right tube involvement: present<br />
</li>
<li>Left tube involvement: present<br />
</li>
<li>In situ adenocarcinoma in right and/or left fallopian tube:
absent<br />
</li>
<li>Right adnexa soft tissue involvement: absent<br />
</li>
<li>Left adnexa soft tissue involvement: absent<br />
</li>
<li>Pelvic soft tissue involvement: absent<br />
</li>
<li>Uterine serosa involvement: absent<br />
</li>
<li>Omentum involvement: absent<br />
</li>
<li>Uterine Cervix involvement: absent<br />
</li>
<li>Endometrium involvement: absent<br />
</li>
<li>Myometrium involvement: absent<br />
</li>
<li>Appendix involvement: not received<br />
</li>
<li>Largest Extrapelvic Peritoneal Focus (required only if applicable):
N/A<br />
</li>
<li>Peritoneal/Ascitic Fluid - Malignant (positive for malignancy)
(N20202-02181)<br />
</li>
<li>Regional Lymph Nodes: Negative for metastasis: (0/ 48)<br />
</li>
<li>Other organs or specimens involvement: absent<br />
</li>
</ul></li>
</ul></li>
<li>2020-07-20 Body Fluid Cytology - ascites
<ul>
<li>pathologic diagnosis
<ul>
<li>Positive for malignancy<br />
</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>33 cc red turbid ascites<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The smears show lymphocytes, mesothelial cells &amp; many
hyperchromatic atypical cell clusters, compatible with malignant tumor.
Clinical correlation and confirmatory biopsy is advised.</li>
</ul></li>
</ul></li>
<li>2020-07-20 Frozen section
<ul>
<li>Ovary, right, frozen section— malignant tumor</li>
<li>IHC stain — WT-1(+), CK7(+), CK20(-), vimentin(-)</li>
</ul></li>
<li>2020-07-17 CT - abdomen, pelvis
<ul>
<li>Findings
<ul>
<li>There is a well-defined lobulated soft tissue mass measuring 9.8 x
7.3 x 10 cm in right pelvis with suggestive mild fat and calcification
component and it shows directly attached the uterus. Teratocarcinoma of
right ovary is highly suspected. The differential diagnosis include
serous carcinoma. Please correlate with clinical condition and MRI.</li>
<li>There is another soft tissue lesion 3.3 x 2.4 cm in left adnexa that
may be left ovarian cyst or cystic tumor.</li>
<li>There are three Uterine myoma 3.5 cm, 3.2 cm, and 1 cm.</li>
<li>Ascites in abdomen and pelvis is noted. In addition, soft tissue
lesions in the omentum is suspected that may be tumor seeding? Please
correlate with ascites cytology.</li>
<li>A renal cyst measuring 1.3 cm in left upper pole is noted.</li>
</ul></li>
</ul></li>
<li>2019-05-07 Surgical pathology Level IV
<ul>
<li>Uterus, cervix, biopsy — Mild dysplasia (CIN I)</li>
<li>Uterus, endocervix, ECC — Mild dysplasia (CIN I)</li>
</ul></li>
<li>2019-08-06 2Gynecologic ultrasonography
<ul>
<li>Uterine myoma</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-03
<ul>
<li>Surgery
<ul>
<li>Right diaphragmatic tumor resection and repair</li>
</ul></li>
<li>Finding
<ul>
<li>Table consultation.</li>
<li>Two tumors about 3.0cm x 2.0cm x1.0cm in size respectively over
right diaphragm.</li>
</ul></li>
<li>Procedure
<ul>
<li>Part of right diaphragm was resected by electrocautery. Lung injuury
was prevented during dissection. The 2 tumors were removed
together.</li>
<li>The diaphragmatic defect was closed by interrupted No.2 Silk. No
more defected was detected by palpation.</li>
</ul></li>
</ul></li>
<li>2020-07-20
<ul>
<li>Surgery
<ul>
<li>Cystoscopy and bilateral ureter catheter insertion</li>
</ul></li>
<li>Finding
<ul>
<li>normal bladder mucosa</li>
<li>huge posterior indentation</li>
<li>no bladder tumor was seen</li>
</ul></li>
</ul></li>
<li>2020-07-20
<ul>
<li>Surgery
<ul>
<li>Diagnosis
<ul>
<li>Right ovarian tumor suspected malignancy s/p debulking surgery.</li>
</ul></li>
<li>Operation
<ul>
<li>Debulking surgery (ATH + BSO + Cytoreduction surgery + infracolic
omentectomy + BPLND)     - Finding</li>
</ul></li>
<li>Right ovarian tumor, suspected malignancy.</li>
<li>Frozen: malignancy</li>
</ul></li>
</ul></li>
<li>2019-06-26
<ul>
<li>Dysplasia of cervix (uteri)</li>
<li>Finding
<ul>
<li>Uterus: Anteversion, 9 cm.</li>
<li>Scanty endocervical and some endometrial tissue were curetted
out.</li>
<li>Estimated blood loss: 15 mL, Blood transfusion: nil, complication:
nil.</li>
</ul></li>
<li>Procedure: Fractional dilatation and curettage
<ul>
<li>Put the patient on lithotomy position.</li>
<li>Douching, skin disinfection and skin draping as usual.</li>
<li>Sounding: Anteversion, 9 cm.</li>
<li>Cervical dilatation to Hegar No. 7.</li>
<li>Curette endocervical canal and uterine cavity.</li>
<li>Pack the vagina with a piece of gauze</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-10 ~ undergoing - docetaxel + carboplatin + gentamicin (+
bevacizumab since 2022-03-08)</li>
<li>2021-12-31 - liposome doxorubicin + carboplatin</li>
<li>2020-09-12 ~ 2021-01-27 - paclitaxel + carboplatin</li>
</ul></li>
</ul>
<p>[note]</p>
<ul>
<li>Causes of magnesium depletion (2022-06-29 <a href="https://www.uptodate.com/contents/hypomagnesemia-causes-of-hypomagnesemia" class="uri">https://www.uptodate.com/contents/hypomagnesemia-causes-of-hypomagnesemia</a>
)
<ul>
<li>Gastrointestinal losses
<ul>
<li>Diarrhea, malabsorption and steatorrhea, and small bowel bypass
surgery</li>
<li>Acute pancreatitis</li>
<li>Medications
<ul>
<li>PPIs</li>
</ul></li>
<li>Genetic disorders
<ul>
<li>Intestinal hypomagnesemia with secondary hypocalcemia</li>
</ul></li>
</ul></li>
<li>Renal losses
<ul>
<li>Medications
<ul>
<li>Diuretics (loop and thiazide)</li>
<li>Antibiotics (aminoglycoside, amphotericin, pentamidine)</li>
<li>Calcineurin inhibitors</li>
<li>Cisplatin</li>
<li>Antibodies targeting epidermal growth factor (EGF) receptor
(cetuximab, panitumumab, matuzumab)</li>
</ul></li>
<li>Volume expansion</li>
<li>Uncontrolled diabetes mellitus</li>
<li>Alcoholism</li>
<li>Hypercalcemia</li>
<li>Acquired tubular dysfunction
<ul>
<li>Recovery from acute tubular necrosis</li>
<li>Postobstructive diuresis</li>
<li>Post-kidney transplantation</li>
</ul></li>
<li>Genetic disorders
<ul>
<li>Bartter/Gitelman syndrome</li>
<li>Familial hypomagnesemia with hypercalciuria and
nephrocalcinosis</li>
<li>Autosomal dominant isolated hypomagnesemia (Na-K-ATPase gamma
subunit, Kv1.1 and cyclin M2 mutations)</li>
<li>Autosomal recessive isolated hypomagnesemia (EGF mutation)</li>
<li>Renal malformations and early-onset diabetes mellitus (HNF1-beta
mutation)</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-549" class="section level3">
<h3>==========</h3>
</div>
<div id="section-550" class="section level3">
<h3>2022-06-29</h3>
<ul>
<li>The serum magnesium level has declined over the past four months.
The last dose of cisplatin was dated on 2022-04-27. In PharmaCloud,
there are no records for loop diuretics, thiazide diuretics, or PPIs.
Diarrhea, malabsorption or steatorrhea?</li>
<li>Magnesium level time series
<ul>
<li>2022-06-28 1.5 mg/dL</li>
<li>2022-06-01 1.7 mg/dL</li>
<li>2022-04-26 1.5 mg/dL</li>
<li>2022-03-29 1.8 mg/dL</li>
<li>2022-03-07 1.9 mg/dL</li>
</ul></li>
<li>The laboratory results on 2022-06-28 were considered acceptable for
the continuation of the palliative chemotherapy.</li>
</ul>
</div>
<div id="section-551" class="section level3">
<h3>2022-06-02</h3>
<ul>
<li>This is a 59 y/o female with high-grade serous carcinoma accompanied
by peritoneal seeding and liver mets underwent debulking surgery on
2020-07-20 and right diaphragmatic tumor resection on 2022-01-03.</li>
<li>Her treatment regimens have included paclitaxel and carboplatin
(2020-09 ~ 2021-01), liposome doxorubicin and carboplatin (2021-12) as
well as the current regimen of docetaxel, carboplatin, and bevacizumab
since the first quarter of 2022.</li>
<li>The laboratory results on 2022-06-01 were considered acceptable for
the continuation of the palliative chemotherapy. Lenograstim 250 mcg SC
will be administered following chemotherapy on 2022-06-03.</li>
</ul>
</div>
</div>
</div>
<div id="section-552" class="section level1">
<h1>701342752</h1>
<div id="section-553" class="section level2">
<h2>220629</h2>
<p>{intra-hepatic cholangiocarcinoma with lung and right adrenal
mets}</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-29 ECG
<ul>
<li>Normal sinus rhythm</li>
<li>Possible Inferior infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-04-08 Cathay General Hospital Discharge Summary
<ul>
<li>intra-hepatic cholangiocarcinoma with lung and right adrenal mets,
cT4N1M1, post Nivolumab, Gemcitabine and TS-1 cycle 6 with progression
in lung mets, post PHDFL cycle 1</li>
<li>hepatitis B virus carrier. HTN. CKD.</li>
</ul></li>
<li>2022-04-01 CT - abdomen (Cathay General Hospital)
<ul>
<li>Related main clinical history: Large liver tumor s/p biopsy with
adenocarcinoma diagnosed favored intrahepatic cholangiocarcinoma.</li>
</ul></li>
<li>2022-03-11 CT - chest (Cathay General Hospital)
<ul>
<li>multiple lung metastasis. s/p treatment follow up.</li>
<li>progression in number and size of bilateral lung nodules and
bilateral lower pleural tickening.</li>
<li>findings:
<ul>
<li>Stationary upto nearly 14cm right hepatic poor contrast enhancing
tumor invading right suprarenal region.</li>
<li>Multiple varying size upto nearly 3.5cm bilateral hepatic
tumors.</li>
<li>Obliteration of right adrenal gland by right hepatic tumor
invasion.</li>
<li>Peritoneum &amp; mesentery: Mild increased ascites.</li>
<li>Lymph nodes: Stationary hepatic hilar, periceliac and aortocaval
LAP.</li>
</ul></li>
<li>impression:
<ul>
<li>Previous similar study on 2021/12/31.</li>
<li>Stationary upto n nearly 14cm right hepatic hypovascular tumor
invading right suprarenal and adrenal gland.</li>
<li>Multiple varying size upto nearly 3.5cm bilateral hepatic
tumors.</li>
<li>Mild increased ascites.</li>
<li>Stationary hepatic hilar, periceliac and aortocaval LAP.</li>
</ul></li>
</ul></li>
<li>2021-12-31 Follow-up abdominal + pelvis CT and chest CT
<ul>
<li>liver tumor intra-abdominal and left supraclavicular fossa LN
metastasis and bilateral lung metastasis.</li>
<li>mild ascites.</li>
</ul></li>
<li>2021-12-27 Patho - liver biopsy (Cathay general hospital)
<ul>
<li>Cholangiocarcinoma</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Tumour of the biliary tract with metastatic disease to the lungs and
adrenals. Earlier this year, carboplatin and HDFL were administered and
severe adverse effects were reported. There had been six cycles of
Nivolumab, Gemcitabine, and TS-1 prior to that.</li>
<li>Unresectable and metastatic biliary tract cancer is commonly treated
with these regimens:
<ul>
<li>5-fluorouracil + oxaliplatin</li>
<li>5-fluorouracil + cisplatin</li>
<li>Capecitabine + cisplatin</li>
<li>Capecitabine + oxaliplatin</li>
<li>Gemcitabine + albumin-bound paclitaxel</li>
<li>Gemcitabine + capecitabine</li>
<li>Gemcitabine + oxaliplatin</li>
<li>Gemcitabine + cisplatin + albumin-bound paclitaxel</li>
</ul></li>
<li>In the discharge summary from Cathay general hospital, no info is
found regarding what kind of severe adverse effects caused by
carboplatin/HDFL. Gemcitabine as a single agent might be worth
considering.</li>
<li>It is possible to extend the options in the event that a particular
gene pattern is approved:
<ul>
<li>NTRK gene fusion positive: entrectinib, larotrectinib</li>
<li>MSI-H/dMMR/TMB-H: pembrolizumab</li>
<li>FGFR2 fusion or rearrangements: pemigatinib, infigratinib</li>
<li>IDH1 mutation: ivosidenib</li>
<li>BRAF-V600E mutation: dabrafenib + trametinib</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-554" class="section level1">
<h1>700520713</h1>
<div id="section-555" class="section level2">
<h2>220628</h2>
<ul>
<li>exam finding
<ul>
<li>2022-06-27 CXR
<ul>
<li>General osteoporosis</li>
<li>Multilevel compression fracture of T-L spine</li>
</ul></li>
<li>2022-06-27 ECG
<ul>
<li>Sinus tachycardia</li>
<li>Left axis deviation</li>
<li>Inferior infarct, age undetermined</li>
<li>ST &amp; T wave abnormality, consider lateral ischemia</li>
<li>Prolonged QT</li>
</ul></li>
<li>2022-06-14 CT - abdomen, pelvis
<ul>
<li>S/P gastrectomy.</li>
<li>No evidence of tumor recurrence.</li>
</ul></li>
<li>2022-05-24 SONO - abdomen
<ul>
<li>Normal sonographic study of the hepatobiliary system.</li>
</ul></li>
<li>2022-05-24 CXR
<ul>
<li>Patchy opacity projecting in the right upper medial lung or
mediastinum shows stationary. Follow up is indicated.<br />
</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
</ul></li>
<li>2022-04-12 CT - brain
<ul>
<li>Imp: Brain atrophy.</li>
</ul></li>
<li>2022-01-25 CT - abdomen, pelvis
<ul>
<li>S/P subtotal gastrectomy.</li>
</ul></li>
<li>2021-11-23 Bone densitometry - spine
<ul>
<li>Osteoporosis</li>
</ul></li>
<li>2021-11-09 T- L-spine AP + Lat.
<ul>
<li>Compression fracture of T7, T10, T12 and L4.</li>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2021-07-20 Patho - stomach subtotal/total (tumor)
<ul>
<li>pathologic diagnosis
<ul>
<li>Stomach, anastomosis area, radical total gastrectomy —-
Adenocarcinoma, poorly differentiated, s/p subtotal gastrectomy about 30
years ago<br />
</li>
<li>Small intestine, duodenum, radical total gastrectomy —-
Adenocarcinoma, by direct invasion —- Neuroendocrine tumor,</li>
<li>G1 Soft tissue, anterior abdominal wall, excision —- Adenocarcinoma,
by direct invasion<br />
</li>
<li>Omentum,radical total gastrectomy —- Negative for malignancy<br />
</li>
<li>Lymph node, lesser curvature, group 1, 3, 5, 7, 8, 9, 11p, 12a,
dissection —- Adenocarcinoma, metastatic (2/14)<br />
</li>
<li>Lymph node, greater curvature, group 2, 4, 6, 14v, dissection —-
Adenocarcinoma, metastatic (4/16)<br />
</li>
<li>AJCC 8 th edition pTNM Pathology stage:
<ul>
<li>Adenocarcinoma: pStage IIIB, pT4bN2 (if cM0)<br />
</li>
<li>Neuroendocrine tumor: pStage I, pT1N0 (if cM0)</li>
</ul></li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Adenocarcinoma, Lauren classification of
adenocarcinoma: Intestinal type<br />
</li>
<li>Histologic Grade : G3: Poorly differentiated, undifferentiated<br />
</li>
<li>Tumor Extension: Tumor invades adjacent structures/organs (specify)
abdominal wall soft tissue<br />
</li>
<li>Lymphovascular Invasion: present<br />
</li>
<li>Perineural Invasion: present<br />
</li>
<li>Regional Lymph Nodes: lesser curvature: 2/14; greater curvature:
4/16<br />
</li>
<li>The immunohistochemical stains reveal CD56(+) and Synaptophysin(+).
The Ki-67 is &lt; 3%.</li>
<li>Intestinal metaplasia: present<br />
</li>
<li>Low-grade dysplasia: present<br />
</li>
<li>High-grade dysplasia: absent<br />
</li>
<li>Helicobacter pylori-type gastritis: absent<br />
</li>
<li>Autoimmune atrophic chronic gastritis: absent<br />
</li>
<li>Polyp(s): absent</li>
</ul></li>
</ul></li>
<li>2021-06-30 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Findings:
<ul>
<li>S/P subtotal gastrectomy with suggestive BI anastomosis?please
correlate with clinical history.</li>
<li>There is a lobulated wall thickening lesion in the stomach, beyond
anastomosis area, that is compatible with adenocarcinoma. The fat plane
between the gastric lesion, pancreatic body and abdominal wall shows
obliteration that may be directly attached or invasion?</li>
<li>There are six enlarged nodes in the gastrohepatic ligament and
adjacent omentum area that may be metastatic nodes.</li>
</ul></li>
<li>Imaging Report Form for Gastric Carcinoma</li>
<li>Impression (Imaging stage): T:T4b(T_value) N:N2(N_value)
M:M0(M_value) STAGE:IVA (Stage_value)</li>
</ul></li>
<li>2021-05-13 Patho - stomach biopsy
<ul>
<li>Stomach, Remnant gastric cancer, s/p biopsy — Adenocarcinoma.<br />
</li>
<li>IHC stains: CK highlights neoplastic cells. Her2/neu: negative
(score=0).<br />
</li>
<li>Section shows fragments of gastric tissue infiltrated by irregular
neoplastic glands.</li>
</ul></li>
<li>2021-05-13 SONO - abdomen
<ul>
<li>Hepatic tumor prob. hemangioma</li>
<li>Susp. parenchymal liver disease</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-07-13 Gastroenterology</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Lab data (2022-06-27) low K (2.3 mmol/L), high NT-proBNP (2561
pg/mL), high hs-Troponin I (561.5 pg/mL), high WBC (13.64 *10^3/uL)
-&gt; underlying cardiac conditions? following EKG indicated inferior
infarct and lateral ischemia.</li>
<li>pH 7.475, pCO2 22.8 mmHg, HCO3 16.4 mmol/L (2022-06-27) -&gt;
Hyperventilation to mitigate hypoperfusion of the heart?</li>
<li>no issue with active prescription.</li>
</ul>
</div>
</div>
<div id="section-556" class="section level1">
<h1>701378989</h1>
<div id="section-557" class="section level2">
<h2>220627</h2>
<ul>
<li>lab data
<ul>
<li>2022-06-27 PD-L1 22C3 S22-9396
<ul>
<li>Tumor type: Lung cancer</li>
<li>2022-06-27 Tumor Proportion Score (TPS): 60%</li>
</ul></li>
<li>2022-06-22 PD-L1 28-8 S22-9396
<ul>
<li>Tumor type: Lung cancer</li>
<li>Tumor Cell (TC) staining assessment: TC &lt; 1%</li>
<li>Percentage of 28-8 expressing tumor cells (%TC): 0%</li>
</ul></li>
<li>2022-05-27
<ul>
<li>Protein, total 5.8 g/dL<br />
</li>
<li>Albumin 52.9 %<br />
</li>
<li>Alpha-1 5.2 %<br />
</li>
<li>Alpha-2 13.4 %<br />
</li>
<li>Beta 16.1 %<br />
</li>
<li>Gamma 12.4 %<br />
</li>
<li>M-peak Negative<br />
</li>
<li>A/G Ratio 1.10<br />
</li>
<li>IgG/A/M Kappa/Lambda No Paraprotein</li>
</ul></li>
<li>2022-05-26
<ul>
<li>B2-Microglobulin 3379 ng/mL<br />
</li>
</ul></li>
<li>2022-05-25
<ul>
<li>SCC 1.6 ng/mL<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.52 S/CO<br />
</li>
<li>Anti-HBc Reactive<br />
</li>
<li>Anti-HBc-Value 3.74 S/CO<br />
</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.16 S/CO<br />
</li>
<li>Anti-HBc IgM Nonreactive<br />
</li>
<li>Anti-HBc IgM Value 0.12 S/CO</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-24 CXR
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
<li>Patchy opacity of the right lower lung zone was noted, which might
be bronchogenic carcinoma. Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P pigtail catheter implantation at right CP angle.</li>
<li>Spondylosis of the T-spine</li>
</ul></li>
<li>2022-06-15 Pathologic Report for PD-L1 (SP142) Assay (Ventana)
<ul>
<li>S2022-9396
<ul>
<li>Tumor type: adenocarcinoma</li>
<li>Tumor location: lung</li>
<li>Testing assay: SP142 Assay (Ventana)</li>
<li>Testing platform: BenchMark XT</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit</li>
<li>Control slide result: Pass,</li>
<li>Adequate tumor cells present (&gt;= 50 viable tumor cells):
Yes,</li>
</ul></li>
<li>Result:
<ul>
<li><ol style="list-style-type: upper-alpha">
<li>Tumor cell (TC) staining assessment: TC category: TC &lt; 1%</li>
</ol></li>
<li><ol start="2" style="list-style-type: upper-alpha">
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC &lt; 1%</li>
</ol></li>
</ul></li>
<li>Note:
<ul>
<li><ol style="list-style-type: decimal">
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ol></li>
</ul></li>
</ul></li>
<li>2022-06-15 Tc-99m MDP whole body bone scan
<ul>
<li>Highly suspected cancer with multiple bone metastases in the skull,
both rib cages, sternum, some C-, T- and L-spine, sacrum, bilateral
pelvic bones, and bilateral femoral trochanters.</li>
<li>Increased activity in the maxilla and bilateral shoulders, probably
post-traumatic change or bone mets.</li>
</ul></li>
<li>2022-06-14 MRI - brain
<ul>
<li>Known a case of lung cancer. Numerous enhancing nodular lesions over
both cerebral hemispheres and cerebellum and brainstem, compatible with
metastases.</li>
<li>Prominence of cerebral cortical sulci, gyri atrophy and
proportionate ventricular dilatation.</li>
<li>Mild periventricular small vessel disease. NO acute ischemic
infarct.</li>
</ul></li>
<li>2022-06-09 Patho - lung transbronchial biopsy
<ul>
<li>Lung, RML/RLL, bronchoscopic biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show bronchial mucosa with invasive solid and acinar tumor
cells in submucosa and lymphatic vessels.</li>
<li>The immunohistochemical stains reveal TTF-1(+), Napsin A(-), WT-1(-)
and PAX8(-). The results are in favor of primary lung
adenocarcinoma.</li>
</ul></li>
<li>2022-06-09 Body Fluid Cytology - bronchial washing
<ul>
<li>Smears show benign bronchial and squamous cells and clusters of
atypical hyperchromatic and pleomorphic cells. Malignancy is favored.
Please correlate with the clinical presentation.</li>
</ul></li>
<li>2022-05-27 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>There is a well-defined mild heterogeneous mass in RLL of the lung,
measuring 9 cm in size (the largest dimension) that may be bronchogenic
carcinoma with total obstruction of RLL bronchus and RLL collapse.
<ul>
<li>In addition, there are multiple small nodules in both lung that are
c/w lung to lung metastases.</li>
<li>There are several enlarged nodes in the paratracheal space that may
be metastastic nodes.<br />
</li>
<li>There is massive right side pleura effusion with lobulated
thickening in the visceral pleura that may be pleura tumor seeding.
Please correlate with pleura effusion cytology.</li>
</ul></li>
<li>There is a poor enhancing lesion 5 mm in S8 of the liver that may be
flow artifact or tumor?</li>
<li>There is minial wall thickening of right UPJ causing hydronephrosis
and delayed contrast excretion of right kidney.
<ul>
<li>Please correlate with retrograde pyelography to R/O chronic UPJO or
urothelial cell carcinoma.</li>
</ul></li>
<li>There is a cystic lesion in right adnexa measuring 3.2 cm in size
but no evidence of wall thickening or mural nodule.
<ul>
<li>Simple right ovarian cyst is highly suspected.</li>
<li>Please correlate with GYN. sonography.</li>
<li>In addition, There is a exophytic soft tissue mass measuring 4.4 cm
in size protruding from right side uterus with central calcification
that may be myoma.</li>
</ul></li>
<li>There are diffuse bony metastases in the T-spine, L-spine and
pelvis.</li>
<li>There are soft tissue lesions in the omentum that are c/w tumor
seeding.</li>
</ul></li>
<li>Impression:
<ul>
<li>Primary lung cancer in RLL with lung to lung metastases, right
pleura metastases, diffuse bony metastases, and carcinomatosis is
suspected.<br />
</li>
<li>Chronic UPJO or urothelial cell carcinoma at right UPJ causing
obstructive uropathy is suspected. Please correlate with retrograde
pyelography.</li>
</ul></li>
</ul></li>
<li>2022-05-27 Gynecologic ultrasonography
<ul>
<li>IUD in situ</li>
<li>Multiple myomas</li>
</ul></li>
<li>2022-05-12 MRI - L-spine
<ul>
<li>Findings
<ul>
<li>Diffuse numerous lesions with T1-hypointensity and mild
T2-hyperintensity involving both anterior and posterior elements of
every vertebral body from C4 to S5 and iliac bones vivisble in these
images, indicating bony metastases.</li>
<li>General bulging disc, hypertrophic yellow ligaments and enlarged
facets causing mild to moderate spinal canal stenosis and bilateral mild
to moderate neuroforaminal narrowing at L1-2-3-4-5-S1, esp L4-5.</li>
<li>Mild scoliosis of L-spine.</li>
<li>Dilatation of right renal calyces andproximal ureter, indicating
obstructive uropathy.</li>
<li>A well-deifned cystic mass, about 37 mm, with T1-hypointensity and
T2-hyperintensity in right aspect of pelvic cavity. R/O right ovarin
cystic tumor.</li>
<li>Massive pleural effusion in right lung field with right lung
collapse.</li>
</ul></li>
<li>IMP:
<ul>
<li>Diffuse bony metastases involving vertebral column and bony pelvis
as described.</li>
<li>Right hydronephrosis and hydroureter.</li>
<li>Suspected right ovarian cystic tumor (37 mm).</li>
<li>Right massive pleural effusion.</li>
<li>Suggest further evaluation.</li>
</ul></li>
</ul></li>
<li>2022-05-12 Bone densitometry - spine
<ul>
<li>L-spines BMD (AP view) performed by DXA revealed:
<ul>
<li>AP L-spines, BMD of L1-4 0.711 gms/cm2, about 3.1 SD below the peak
bone mass ( 68 %) and 0.1 SD above the mean of age-matched people ( 103
%).</li>
</ul></li>
<li>IMP: osteoporosis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-20 Dermatology
<ul>
<li>A
<ul>
<li>This patient suffered from erytheamtous patches on vaginala area for
days</li>
<li>Imp:
<ul>
<li><ol style="list-style-type: decimal">
<li>Intetrigo</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Dyshidrotic dermatitis</li>
</ol></li>
</ul></li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Sinpharderm * 1 tube + topsym cream * 2 tubes/bid(feet)</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Zalain cream * 1 tubes/bid</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-16 Radiation Oncology
<ul>
<li>A
<ul>
<li>This 78-year-old woman case of Lung adenocarcinoma with brain and
bone metastases, stage IV. Lower back pain developed. Whole body bonew
scan on 2022/06/15 showed T-L spine bone metastasis.</li>
<li>Palliative RT is indicated. CT-simulation will be arranged on
2022-06-20. Plan to deliver 30 Gy/ 10 fx to the spine T11-L3. RT will
start around 2022-06-21 or -06-22. Thank you very much.</li>
</ul></li>
</ul></li>
<li>2022-06-08 Dermatology
<ul>
<li>A
<ul>
<li>This patient suffered from erytheamtous patches on vaginal area for
months</li>
<li>Imp: Subacute dermatitis</li>
<li>Suggestion:
<ul>
<li><ol style="list-style-type: decimal">
<li>Zalain cream * 2 tubes/bid</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Zaditen 1 */Bid</li>
</ol></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-05-27 Urology
<ul>
<li>A
<ul>
<li>Right hydronephrosis + creatinine: normal</li>
<li>PCN was suggested if further C/T is indicated.</li>
<li>After discussed with the patient and families, they refused
PCN.</li>
<li>Consult us again if they changed their mind.</li>
</ul></li>
</ul></li>
<li>2022-05-27 Obstetrics and Gynecology
<ul>
<li>A
<ul>
<li>78y/o, female, G3P3. Admitted due to diffuse bony metastases
involving vertebral column and bony pelvis. Pleural effusion s/p
tapping, cytology: Malignancy (+)</li>
<li>S:
<ul>
<li>Back pain for 1 year</li>
<li>The pain was diffuse to whole body and can not take care of herself
in recent month</li>
</ul></li>
<li>O:
<ul>
<li>Elevated tumor marker, CEA:941, CA153:405, CA125:364.8,
CA199:358</li>
<li>Abdominal cT on 2022/05/27 showed right pleural effusion, rigth
hydroneprosis, uterine myoma and R/O overain tumor.</li>
<li>Sono: uterus: AVf: 5.3x3.5cm, IUD in situ, EM:0.57</li>
<li>Uterine myoma about 4.6x3.7cm and 2.2x1.7cm</li>
<li>CDS: no fluid</li>
</ul></li>
<li>IMP:
<ul>
<li>IUD in situ</li>
<li>Uterine myoma</li>
</ul></li>
<li>P:
<ul>
<li>Tumor biopsy may be arranged after discussion with the family</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>{valganciclovir not for herpes}</p>
<ul>
<li>There is a diagnosis of an unspecified herpesvirus infection.</li>
<li>Valganciclovir is a nucleoside analog group of antiviral medication
that is used to treat cytomegalovirus (CMV) infections. It is not
effective against herpes simplex virus (HSV) infection. ( <a href="https://www.sciencedirect.com/science/article/pii/B9780128012383994066" class="uri">https://www.sciencedirect.com/science/article/pii/B9780128012383994066</a>
)</li>
<li>Most patients with a first episode of genital HSV can be treated
with oral therapy. IV acyclovir is typically reserved for the management
of complicated infection (eg, central nervous system and disseminated
disease). ( <a href="https://www.uptodate.com/contents/treatment-of-genital-herpes-simplex-virus-infection" class="uri">https://www.uptodate.com/contents/treatment-of-genital-herpes-simplex-virus-infection</a>
)</li>
<li>The 2021 United States Centers for Disease Control and Prevention
(CDC) guidelines recommend any of the following oral treatment options
(doses based on normal renal function). Therapy should be administered
for 7 to 10 days. However, on occasion, a patient may continue to have
new lesions even after completing a 10-day course. When this happens,
the course is typically extended by five to seven days.
<ul>
<li>Acyclovir: 400 mg three times daily</li>
<li>Famciclovir: 250 mg three times daily</li>
<li>Valacyclovir: 1000 mg twice daily</li>
</ul></li>
<li>All three agents appear to have similar efficacy for the treatment
of a first episode of genital herpes, and the margins of safety and
tolerability are excellent. Valacyclovir is generally administered since
it is dosed less frequently than the others, although oral acyclovir may
be preferred in certain settings as it can be less expensive.</li>
</ul>
</div>
</div>
<div id="section-558" class="section level1">
<h1>700953139</h1>
<div id="section-559" class="section level2">
<h2>220624</h2>
<p>{pseudomyxoma peritonei}</p>
<ul>
<li>Lab data
<ul>
<li>CA-199
<ul>
<li>2022-06-17 141.06 U/mL</li>
<li>2022-06-02 171.303 U/mL</li>
<li>2022-05-10 137.16 U/mL</li>
<li>2022-04-22 128.052 U/mL</li>
<li>2022-04-21 137.226 U/mL</li>
<li>2022-03-25 195.97 U/mL</li>
<li>2022-03-09 223.51 U/mL</li>
<li>2022-02-18 225.74 U/mL</li>
<li>2022-02-04 217.96 U/mL</li>
<li>2021-12-07 223.03 U/mL</li>
<li>2021-11-19 251.47 U/mL</li>
<li>2021-11-09 180.081 U/mL</li>
<li>2021-10-22 216.17 U/mL</li>
<li>2021-10-05 185.36 U/mL</li>
<li>2021-09-14 161.169 U/mL</li>
<li>2021-07-23 138.66 U/mL</li>
<li>2021-07-13 136.710 U/mL</li>
<li>2021-04-20 197.23 U/mL</li>
<li>2021-04-07 221.4 U/mL</li>
<li>2021-03-26 182.849 U/mL</li>
<li>2021-03-23 188.093 U/mL</li>
<li>2021-03-08 187.400 U/mL</li>
<li>2021-02-19 231.475 U/mL</li>
<li>2021-02-04 222.5 U/mL</li>
<li>2021-02-04 229.390 U/mL</li>
<li>2021-01-15 195.585 U/mL</li>
<li>2021-01-04 117.21 U/mL</li>
<li>2020-12-31 183.1 U/mL</li>
<li>2020-12-23 196.630 U/mL</li>
<li>2020-12-23 204.470 U/mL</li>
<li>2020-12-04 219.81 U/mL</li>
<li>2020-11-25 232.83 U/mL</li>
<li>2020-11-09 284.23 U/mL</li>
<li>2020-10-02 273.88 U/mL</li>
<li>2020-08-04 215.15 U/mL</li>
</ul></li>
<li>CA-125
<ul>
<li>2022-06-17 120.114 U/mL</li>
<li>2022-06-02 61.224 U/mL</li>
<li>2022-05-10 47.427 U/mL</li>
<li>2022-04-19 38.267 U/mL</li>
<li>2021-10-22 45.773 U/mL</li>
<li>2021-10-05 49.708 U/mL</li>
<li>2021-09-14 40.944 U/mL</li>
<li>2021-07-23 38.211 U/mL</li>
<li>2021-07-13 35.203 U/mL</li>
<li>2021-04-20 31.553 U/mL</li>
<li>2021-04-07 31.265 U/mL</li>
<li>2021-03-23 29.899 U/mL</li>
<li>2021-02-04 35.661 U/mL</li>
<li>2020-10-06 113.319 U/mL</li>
<li>2020-08-04 421.600 U/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-06-16 Abdomen - standing (diaphragm)
<ul>
<li>Spondylosis with scoliosis of the L-spine with convex to right
side.</li>
<li>Ascites is noted.</li>
<li>Wedge deformity at left lateral aspect of L2 and L3 vertebral body
and right lateral aspect of L4 vertebral body are noted. Please
correlate with clinical symptom and history.</li>
<li>Pseudomyxoma peritonei with multiple curvelinear calcification in
the peritoneum.</li>
</ul></li>
<li>2022-04-15 CT - abdomen, pelvis
<ul>
<li>FINDINGS:
<ul>
<li>Prior CT (2022/01/11) identified carcinomatosis (pseudomyxoma
peritonei) in peritoneal cavity and lesser sac with indentation defects
at the liver capsule are noted again, stable in size that is compatible
with stable disease.</li>
<li>Few small renal cysts on both kidney are noted.</li>
<li>Spondylosis with scoliosis of the L-spine with convex to right side.
Disc space narrowing with marginal osteophyte formation and vacuum
phenomenon from L2 to L5.</li>
<li>Bilateral mild Pleura effusion are noted.</li>
</ul></li>
<li>IMP:
<ul>
<li>Carcinomatosis (pseudomyxoma peritonei) show stable disease.</li>
</ul></li>
</ul></li>
<li>2022-03-08 Standing KUB
<ul>
<li>Curvelinear calcification in the whole abdomen is noted that is c/w
pseudomyxoma peritonei.</li>
<li>Ascites is noted.</li>
<li>Compression fracture of L3, L4 and L5 vertebral body causing
Spondylosis with scoliosis of the L-spine with convex to left side.</li>
</ul></li>
<li>2022-03-08 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Hypoinflation of both lung is noted.</li>
<li>Left hemi-diaphragm elevation is noted, which may be due to left
lower lung volume decrease.</li>
<li>Prominence of right hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
</ul></li>
<li>2022-01-11 CT - abdomen, pelvis
<ul>
<li>findings
<ul>
<li>There are diffuse soft tissue tumores in the peritoneum with
calcifications, suggesting peritoneal carcinomatosis. Stationary.</li>
<li>Left renal cyst, 1.8cm.</li>
</ul></li>
<li>impression
<ul>
<li>Diffuse peritoneal carcinomatosis, stationary.</li>
<li>Left renal cyst.</li>
<li>Lumbar spine scoliosis.</li>
</ul></li>
</ul></li>
<li>2021-10-09 CT - abdomen, pelvis
<ul>
<li>findings
<ul>
<li>Cystic lesions (n&gt;30) with calcified wall inside abdominal cavity
is found. In comparison with CT dated on 2021-07-06, the size and
extension of the lesions are stationary.</li>
<li>Clear bilateral basal lungs is found.</li>
<li>Scoliotic alignment of the thoracolumbar spine is noted.</li>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>No evidence of liver tumor but the liver surface is compressed by
calcified cystic lesions.</li>
<li>Tortous aorta with calcification is noted.</li>
</ul></li>
<li>Imp:
<ul>
<li>Colon cancer with Cancerous carcinomatosis. Stationary.</li>
</ul></li>
</ul></li>
<li>2021-07-06 CT - abdomen, pelvis
<ul>
<li>findings
<ul>
<li>There are diffuse soft tissue tumores in the peritoneum with
calcifications, suggesting peritoneal carcinomatosis. Stationary.</li>
<li>Left renal cyst, 1.8cm.</li>
<li>Lumbar spine scoliosis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Diffuse peritoneal carcinomatosis, stationary.</li>
<li>Left renal cyst.</li>
<li>Lumbar spine scoliosis.</li>
</ul></li>
</ul></li>
<li>2021-04-21 Patho - colon biopsy
<ul>
<li>Cecum, biopsy — Tubulovillous adenoma with low grade dysplasia and
focal high grade dysplasia.<br />
</li>
<li>Section(s) show(s) fragment(s) of villous polypoid colonic mucosal
tissue with proliferative finger-like mucinous glands lined by cells
containing hyperchromatic, elongated nuclei with low grade dysplasia.
There is focal high grade dysplasia.</li>
</ul></li>
<li>2021-04-20 Colonoscopy
<ul>
<li>Findings
<ul>
<li>90cm to cecum, ulcerative lesion at cecum, biopsy</li>
<li>multiple external compression over S colon, and D colon</li>
</ul></li>
<li>Diagnosis
<ul>
<li>ulcerative lesion primary tumro or secondary invasion are both
consider</li>
</ul></li>
<li>Suggestion
<ul>
<li>follow pathology</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2021-04-16 CXR
<ul>
<li>S/P pacemaker.</li>
<li>No active lung lesion.</li>
<li>Borderline cardiomegaly.</li>
<li>Thoracolumbar spondylosis and scoliosis.</li>
</ul></li>
<li>2021-04-16 ECG
<ul>
<li>Sinus rhythm with Premature atrial complexes</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2021-03-22 CT - abdomen, pelvis
<ul>
<li>Progression of peritoneal carcinomatosis.</li>
</ul></li>
<li>2021-01-17 CXR
<ul>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Hypoinflation of both lung is noted.</li>
<li>Left hemi-diaphragm elevation is noted, which may be due to left
lower lung volume decrease.</li>
<li>Prominence of right hilar shadow is noted, which may be engorged
central pulmonary vessels or adenopathy, please correlate clinically and
close follow-up.</li>
<li>Spondylosis with scoliosis of the T-spine with convex to right
side</li>
</ul></li>
<li>2020-12-11 CT - abdomen
<ul>
<li>Carcinomatosis (pseudomyxoma peritonei) show progressive
disease.</li>
</ul></li>
<li>2020-08-21 Patho - soft tissue tumor, extensive resection
<ul>
<li>diagnosis
<ul>
<li>A. Labeled as “peritoneal carcinomatosis”, biopsy with frozen
section (F2020-332FS) — mucnous adenocarcinoma. IHC stains: CK20 (+),
pax-8 (-), GI origin is considered.<br />
</li>
<li>B. Labeled as “peritoneal carcinomatosis: omentum and small
intstinal tumor”, biopsy (S2020-11921A) — mucinous adenocarcinoma<br />
</li>
<li>C. Labeled as “peritoneal carcinomatosis: right pelvic wall tumor”,
biopsy (S2020-11921B) — mucinous adenocarcinoma.<br />
</li>
</ul></li>
<li>microscopic description
<ul>
<li>Sections of F20-332FSA1-2, S20-11921A1-4 and B show mucnous
adenocarcinoma.</li>
<li>IHC stains: CK20 (+), pax-8 (-), GI origin is considered.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>2020-08-07 Colonoscopy
<ul>
<li>Findings
<ul>
<li>The scope reach the transverse colon near hepatic flexure under fair
colon preparation; a large ulcerative tumor occupying almost whole colon
lumen thus the scope could not be passed through: highly suspect colon
cancer: biopsy was taken for six pieces.</li>
<li>diverticulosis: sigmoid colon</li>
</ul></li>
<li>Diagnosis
<ul>
<li>transverse colon tumor(near hepatic flexure), suspect colon cancer,
post biopsy (incomplete exam: insertion to transverse colon only because
of tumor obstruction)</li>
<li>diverticulosis: sigmoid colon</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-08-19
<ul>
<li>Surgery
<ul>
<li>Bilateral DBJ insertion</li>
</ul></li>
<li>Finding
<ul>
<li>Bilateral DBJ insertion, 6Fr 24cm DBJ, was performed smoothly</li>
</ul></li>
<li>Procedure
<ul>
<li>Under ETGA</li>
<li>Lithotripsy position</li>
<li>Drapping and disinfection as usual</li>
<li>6Fr 24cm DBJ was inserted smoothly</li>
<li>Patient stood the procedure well</li>
</ul></li>
</ul></li>
<li>2020-08-19
<ul>
<li>Surgery
<ul>
<li>Diagnosis: Peritoneal carcinomatosis</li>
<li>Operation: exploratory laparotomy and tumor excision</li>
</ul></li>
<li>Finding
<ul>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: atrophy, tense contact with bladder,</li>
<li>Adnexa:
<ul>
<li>LAD: not seen due to severe adhesion and tumor seeding</li>
<li>RAD: not seen due to severe adhesion and tumor seeding</li>
</ul></li>
<li>CDS: invisible due to tumor mass occupied</li>
<li>Ascites: bloody , about 500 ml</li>
<li>Omentum: multiple hard, variablesized nodules</li>
<li>Liver: grossly normal &amp; smooth</li>
<li>Appendix: not seen due to severe adhesion and tumor mass
occupied</li>
<li>Multiple mucin-contained mass about 3~5 cm over intestine,
peritonium and pelvic wall</li>
<li>Residue tumor: multiple tumors, maximal diameter about 5 cm, over
intestine, colon and peritoneal wall</li>
<li>Note
<ul>
<li>Estimated blood loss:minimal</li>
<li>Blood transfusion:nil</li>
<li>Complication:nil</li>
</ul></li>
</ul></li>
<li>Procedure
<ul>
<li>Put the patient on the lithotomy position</li>
<li>Vaginal douching, on Foley, skin disinfection with beta-iodine, and
skin draping.</li>
<li>Make midline vertical skin incision and open the abdominal wall
layer by layer.</li>
<li>Serous ascites 20 ml, send for cytology</li>
<li>Apply auto-retractor and pack up the intestine.</li>
<li>Dissect the tumor and send for frozen section: mucinous
adenocarcinoma</li>
<li>Consult CRS for futher evaluation</li>
<li>Insert a 15 J-P drain at the cul-de-sac.</li>
<li>Close the abdomen layer by layer.</li>
<li>Skin approximation with 4-0 Dexon. </li>
</ul></li>
</ul></li>
<li>2020-08-05
<ul>
<li>Surgery
<ul>
<li>Dilatation and curettage</li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: Anteversion, 5 cm.</li>
<li>Scanty endocervical and some endometrial tissue were curetted
out.</li>
<li>A pollyp about 1.5x0.5cm at 1 o’clock was protuding from
cervix.</li>
<li>Estimated blood loss: minimal, Blood transfusion: nil, complication:
nil.</li>
</ul></li>
<li>Procedure
<ul>
<li>Put the patient on lithotomy position.</li>
<li>Douching, skin disinfection and skin draping as usual.</li>
<li>Sounding: Anteversion, 5 cm.</li>
<li>Cervical dilatation to Hegar No. 8.</li>
<li>Curette endocervical canal and uterine cavity.</li>
<li>Polypectomy was perfomred.</li>
<li>Check bleeding.</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2020-09-02 Family Medicine
<ul>
<li>Q
<ul>
<li>Colonscopy was performed on 2020/08/07 which revealed transverse
colon tumor (near hepatic flexure), suspect colon cancer but biopsy
showed tubular adenoma. CRS was consulted for exp.Lap with tissue proven
and possible colostomy or ileostomy. Then she transfered to GYN ward on
2020/08/18 and underwent 1) Bilateral Double J insertion 2) exploratory
laparotomy and tumor excision on 2020/08/19. Family refused colostomy or
ileostomy. During the surgery, little tumor tissue was removed due to
severe adhesion. Pathology on 2020/08/19 showed mucinous adenocarcinoma.
IHC stains: CK20(+), pax-8 (-), GI origin is considered. Post operation
then transfer to SICU for care on 2020/8/19-20. She still complained of
abdominal fullness and vomiting. Owing to elevated D-dimer, Clexane was
given. After evaluation by CRS Dr. Chen, repeated surgery for colostomy
is not suggested due to poor prognosis. IPP and family meeting done on
2020/08/27 and she was transferred to oncology ward for further
management. At ONC ward, consciousness clear and vital signs was stable.
Abdominal fullness and pitting edema 4+ was noted. Keep liquid diet,
smofkabiven and albumin infusion. Owing to terminal stage of mucinous
adenocarcinoma of colon with peritoneal carcinomatosis metastasis, we
need your expertise for hospice combined care, thanks.</li>
</ul></li>
<li>A
<ul>
<li>Due to terminal stage of mucinous adenocarcinoma of colon with
peritoneal carcinomatosis metastases, we were consulted for further
evaluation.</li>
<li>When we visited, the patient lied on bed and her family stood by
her. Her consciousness was clear and she asked that what time could she
receive treatment. We will arrange hospice combined care first.</li>
</ul></li>
</ul></li>
<li>2020-08-12 Colorectal Surgery
<ul>
<li>After admissoin, self paid of albumin with diuretics was given for
right massive pleural effusion and ascites. Empirical antibiotics with
Flumarin was given from 8/2 to 8/4, we shifted to Tapimycin from 8/4 due
to still fever with chills and we repeat the blood culture. Owing to
suspect ovarian or colon caner,series of examination were done. EGD
showed Reflux esophagitis LA Classification grade A. PPI with Dexilant
was given from 2020/8/4.</li>
<li>Reports:
<ul>
<li>Gynecologist was also consulted and D&amp;C done on 2020/08/06 which
endometrium curretage/biopsy showed endometrial polyp with few bland
mucnous gland.</li>
<li>Bone scan on 2020/08/06 revealed No strong evidence of bone
metastasis.</li>
<li>Colonscopy was performed on 2020/08/07 which revealed transverse
colon tumor(near hepatic flexure), suspect colon cancer.Biospy on
2020/08/12 showed tubular adenoma.</li>
<li>Abdomen: soft, mild marked distended, palpable irregular masses(+),
no peritoneal signs</li>
<li>Passage of little liquid stool</li>
<li>Tumor markers all elevated (CEA, CA19-9, CA12-5)</li>
</ul></li>
<li>A: Peritoneal carcinomatosis with massive ascites and right pleural
effusion, origin?</li>
<li>P:
<ul>
<li>Please consult RAD or CS for right pleural effusion drainage, and
sent for cytology</li>
<li>Suggest echocardiography and pulmonary function test for pre-op
evaluation</li>
<li>Exp.Lap with tissue proven and possible colostomy or ileostomy may
be considered for further oncological treatment</li>
<li>We’ll follow this patient and arrange the operation next week</li>
<li>Please inform us if any problems</li>
</ul></li>
</ul></li>
<li>2020-08-04 Obstetrics and Gynecology
<ul>
<li>Q
<ul>
<li>This 69 y/o woman is a case of HTN without medication control. She
also denied any other systemic disease. According to this patient and
her daughter, her poor appetite and B.W loss(&gt;5 Kg) in recent 2
weeks. Associated symptoms with fever and BT up to 38.0 degree C,
oligouria, SOB, abdomen fullness, vomit (epigastric juice) and minimal
dark stool passage. She ever to GI OPD on 7/30 where MgO plus Gascon
plus Morpide were given and abdomen echo/PES were perform. However, her
SOB with abdomen fullness progress on 8/01. Then she was sent to our ER.
TOCC(-)</li>
<li>At ER, her vital signs 100/18/37.2 and BP 150/75mmHg. Lab revealed
no leukocytosis VBG no acidosis and U/A(-). Microcytic anemia (Hb:7.9
MCV/MCH:66.1/19.1), Alb 2.9 and CRP elevated 16.43 were noted. CxR
revealed right pleural effusion and cardiomegaly. Abdomen CT was perfrom
on 2020/08/01 which revealed suspected peritoneal carcinomatosis with
massive ascites and pleural effusion. Suggest tissue study (ovary
origin? appendix origin?). Chest tapping was perform and drainage
1000ml. Under the impression of ovarian cancer with massive ascites and
pleural effusion. She was admitted for further management. After
admission, we arranged the bone scan on 8/5 and pending for tumor marker
data. We need your expertise for further treatment, thanks.</li>
</ul></li>
<li>A
<ul>
<li>P3, menopaused</li>
<li>C.C: SOB with abdomen fullness for 2 weeks</li>
<li>O:
<ul>
<li>no vaginal bleeding, no lifting pain</li>
<li>Echo: Endometrial thickning with papillary mass like lesion,
Bilateral adnexa mass. Cul-de-sac: with some ascites, abdominal mass,
suspect omentum cake.</li>
</ul></li>
<li>Imp:
<ul>
<li>endometrial thickning</li>
<li>pelvic mass with ascites, origin unknown</li>
</ul></li>
<li>P:
<ul>
<li>arrange D&amp;C on 2020/08/05</li>
<li>arrange colonsocpy</li>
<li>sent abdominal ascites and pleural effusion to cell block</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-06 ~ undergoing - FOLFIRI</li>
<li>2022-03-17 ~ 2022-04-28 - FOLFIRI + ramucirumab (3 times)</li>
<li>2021-09-02 ~ 2022-02-25 - FOLFIRI + bevacizumab (8 times)</li>
<li>2021-08-13 - FOLFIRI</li>
<li>2021-06-02 ~ 2021-07-30 - FOLFIRI + bevacizumab (4 times)</li>
<li>2021-05-10 - FOLFIRI</li>
<li>2020-11-23 ~ 2021-04-26 - FOLFIRI + bevacizumab (11 times)</li>
<li>2020-09-07 ~ 2020-11-10 - FOLFIRI (6 times)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Nowadays, cytoreductive surgery (CRS) associated with hyperthermic
intraperitoneal chemotherapy (HIPEC) represents the only treatment with
potential chances of cure and long-term disease control of patients
affected by PMP.</li>
<li>Exploratory laparotomy and tumor excision was performed on
2020-08-19, however the tumor adhesions were too serious, obscuring the
surgical field and could not be removed completely. When surgery is not
indicated due to comorbidities or for unresectable disease, systemic
chemotherapy is considered, with the main aim to avoid progression and
control symptoms. In general, a relatively unresponsiveness and
chemoresistance of PMP cells to systemic chemotherapy is reported, due
to their low proliferation rate and the uncertain drug availability in
the mucinous microenvironment of tumor nodules. Moreover, tumor response
is difficult to evaluate with standard radiological criteria, as PMP
masses are mostly composed of mucin and it is unlikely to obtain a
significant shrinkage even in case of full activity on tumoral cells.
The results of systemic chemotherapy showed a response rate ranging
between 8-20%, median OS between 26-56 months, and 1-year OS rate of
84-91. ( <a href="https://pubmed.ncbi.nlm.nih.gov/34885075/" class="uri">https://pubmed.ncbi.nlm.nih.gov/34885075/</a> )</li>
<li>While CA-199 has remained relatively stationary in first half of
2022, CA-125 has trended upward in the last three months.</li>
<li>Lab data
<ul>
<li>CA-199
<ul>
<li>2022-06-17 141.060 U/mL</li>
<li>2022-06-02 171.303 U/mL</li>
<li>2022-05-10 137.160 U/mL</li>
<li>2022-04-22 128.052 U/mL</li>
<li>2022-04-21 137.226 U/mL</li>
<li>2022-03-25 195.970 U/mL</li>
<li>2022-03-09 223.510 U/mL</li>
<li>2022-02-18 225.740 U/mL</li>
<li>2022-02-04 217.960 U/mL</li>
</ul></li>
<li>CA-125
<ul>
<li>2022-06-17 120.114 U/mL</li>
<li>2022-06-02 61.224 U/mL</li>
<li>2022-05-10 47.427 U/mL</li>
<li>2022-04-19 38.267 U/mL</li>
</ul></li>
</ul></li>
<li>FOLFIRI has been used to treat the patient since September 2020 by
IVD. In practice, chemotherapy can also be administered
intraperitoneally in the PMP patients. Intraperitoneal administration of
chemotherapy is designed to maximize the chemotherapeutic dose delivered
to peritoneal tumor nodules while minimizing systemic toxicity. ( <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754301/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754301/</a>
)</li>
</ul>
</div>
</div>
<div id="section-560" class="section level1">
<h1>700022404</h1>
<div id="section-561" class="section level2">
<h2>220623</h2>
<p>{CNS DLBCL}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-06-22 MRI - brain
<ul>
<li>Findings
<ul>
<li>An intra-axial tumor, about 48 mm, with heterogeneous enhancement,
diffuse restriction, central necrosis and perifocal white matter edema,
involving right temporofrontal lobe, and causing mass effect (including
effacement of right hemicerebral cortical sulci, compression and
displacement of lateral ventricles and midline shift to left
side).<br />
</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>S/P right frontotemporal craniotomy.</li>
<li>Diffuse mild luminal irregularity without obvious stenosis of major
intracranial arteries in MRA study (including bilateral ICAs, MCAs,
ACAs, PCAs and VAs and BA).</li>
</ul></li>
<li>IMP: Right frontotemporal tumor with mass effect. Suspected
recurrent lymphoma.</li>
</ul></li>
<li>2022-06-22 CT - brain
<ul>
<li>Findings
<ul>
<li>decreased intraventricular and extraventricular CSF spaces in the
right supratentoral region.</li>
<li>a nodular lesion, about 52mm, in the right temporal lobe and right
basal ganglion with moderate perifocal edema</li>
<li>unremarkable change in the skull base</li>
</ul></li>
<li>IMP: an intra-axial tumor in the right temporal lobe and right basal
ganglion.</li>
</ul></li>
<li>2022-03-29 MRI - brain: Right temporo-occipital enhancing tumors,
regressed. Comparison: 2021/12/22 Brain CT, 2021/12/09 Brain MRI</li>
<li>2022-03-28 CT - abdomen, pelvis: Right pulmonary hilar
lymphadenopathy, stationary.</li>
<li>2021-12-22 CT - Brain: Right temporoparietal tumors (lymphoma?) with
progression mass effect as compare with CT study on 20211205, suggest
clinical correlation.</li>
<li>2021-12-09 MRI - Brain: Recurrent brain lymphoma. Old insults in
left caudate head and splenium, stationary and mild general brain
atrophy.</li>
<li>2021-12-05 CT - Brain: Ill-defined heteregeneous lesions in right
temporoparietal lobes. Brain metastasis or contusion hemorrhage, suggest
clinical correlation. Focal hyperdensity along left frontal horn,
suspected focal hematoma.</li>
<li>2021-09-09 MRI - Brain: old insults in left caudate head and
splenium, stationary as comapred with MRI on 20210609.</li>
<li>2021-06-09 MRI - Brain: focal increased enhancement in the
periventricular region of the right parietal lobe.</li>
<li>2020-07-09 CT, MRI: showed no definite evidence of extra-crainial
metastasis. (TMUH)</li>
<li>2020-06-20 MRI: CNS lesion, then biopsy revealed DLBCL. (TMUH)</li>
<li>2020H1 Initial presentation with blurred vision, especially, right
eye, and personality change. (TMUH)</li>
</ul></li>
<li>lab data
<ul>
<li>Methotrexate (Toxic: 24hr &gt; 10, 48hr &gt; 1, 72h &gt; 0.1, unit:
umol/L)
<ul>
<li>2022-04-30 &lt;0.040</li>
<li>2022-04-29 0.070</li>
<li>2022-04-28 0.557</li>
<li>2022-04-02 0.138</li>
<li>2022-04-01 0.530</li>
<li>2022-03-11 0.041</li>
<li>2022-03-10 0.133</li>
<li>2022-03-09 1.181</li>
<li>2022-02-14 0.045</li>
<li>2022-02-13 0.119</li>
<li>2022-02-12 2.548</li>
<li>2022-01-25 0.061</li>
<li>2022-01-24 1.784</li>
<li>2022-01-23 0.091</li>
<li>2021-12-31 0.043</li>
<li>2021-12-30 0.160</li>
<li>2021-12-29 2.552</li>
<li>2021-03-05 0.071</li>
<li>2021-03-04 0.214</li>
<li>2021-03-03 1.141</li>
<li>2021-01-26 0.046</li>
<li>2021-01-25 0.175</li>
<li>2021-01-25 1.032</li>
<li>2020-12-30 &lt;0.040</li>
<li>2020-12-29 0.058</li>
<li>2020-12-28 1.379</li>
<li>2020-12-28 0.218</li>
<li>2020-12-02 &lt;0.040</li>
<li>2020-12-01 0.065</li>
<li>2020-11-30 0.239</li>
<li>2020-11-30 0.902</li>
<li>2020-11-05 0.083</li>
<li>2020-11-04 0.151</li>
<li>2020-11-03 0.333</li>
<li>2020-11-02 1.185</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-03 Rehabilitation
<ul>
<li>Assessment
<ul>
<li>Diffuse large B-cell lymphoma with CNS invasion, stage IV s/p
chemotherapy with MTR and chemotherapy with HD MTX, brain local
recurrent</li>
<li>brain MRI 20211209: recurrent brain lymphoma and old insults in left
caudate head and splenium, stationary and mild general brain
atrophy.</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: ambulation independent. transfer independent.</li>
</ul></li>
</ul></li>
<li>2021-12-25 Neurosurgery
<ul>
<li>Q
<ul>
<li>This 68-year-old man patient is a case of Diffuse large B-cell
lymphoma with CNS invasion, stage IV s/p chemotherapy with MTR and
chemotherapy with HD MTX, brain local recurrent. Dizziness with nausea
in 2021/12. Brain CT on 2021/12/05 showed 1) Ill-defined heteregeneous
lesions in right temporoparietal lobes. Brain metastasis or contusion
hemorrhage, suggest clinical correlation. 2) Focal hyperdensity along
left frontal horn, suspected focal hematoma. 3) Brain atrophy. Brain MRI
on 2021/12/09 showed recurrent brain lymphoma and old insults in left
caudate head and splenium, stationary and mild general brain atrophy.
Chest CT on 2021/12/11 showed no evidence of lymphadenopathy in the
study, calcified coronary arteries is found and tiny nodule at Right
lower lobe, stable. This time, for con’s drowsy with dizziness since
yesterday. Therefore, he was snet to our ER and Brain CT on 2021/12/22
showed 1) Right temporoparietal tumors (lymphoma?) with progression mass
effect as compare with CT study on 2021-12-05, suggest clinical
correlation. 2) Brain atrophy. Now, for evaluate brain tumor operation.
Thank you.</li>
</ul></li>
<li>A
<ul>
<li>The 68 y/o male a patient with diffuse large B-cell lymphoma with
CNS invasion, stage IV s/p chemotherapy with MTR and chemotherapy with
HD MTX, brain local recurrent. We are consulted for surgical
opinion.</li>
<li>We had well-explained risk and outcome to patient’s family. Surgical
intervention is recommended if family agree and accept the risk and
ouctome. (If Brain MRI with enhancement is not able to be done, please
arrange CT with enhancement for navigation if possible for pre-operation
evaluation)</li>
</ul></li>
</ul></li>
<li>2020-10-30 Neurosurgery
<ul>
<li>This 67-year-old man patient is a case of Diffuse large B-cell
lymphoma with CNS invasion, stage IV. This time, for right shoulder pain
radiation to finger for weeks.</li>
<li>brain MRI favor post treatment change in corpus callosum and left
inferior caudate head. band encephalomalacia in RT lateral occipital
lobe. Mild cortical brain atrophy. no enhancing brain mass or
nodule.</li>
<li>x-ray s/p C3-4 ACDF with lower cervical spondylosis</li>
<li>Plan: pain control, NS OPD follow-up</li>
</ul></li>
<li>2020-10-27 Ophthalmology
<ul>
<li>Q
<ul>
<li>This 67-year-old man patient is a case of CNS DLBCL, stage IVA.
Crystal lymphoma invasion with bilateral blurred vision. Now, for
bilateral eye evaluate and examnation. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>BV od for several months concurrent with CNS DLBCL</li>
<li>subjective VA stable compare to previous condition</li>
<li>patient refuse further work up for media opacity and cause of retina
infiltrate od</li>
<li>BCVA: 0.2/0.6</li>
<li>IOP 16/16</li>
<li>Fd photo od: nasal and superior satellite retina infiltrate media
mild blurred</li>
</ul></li>
</ul></li>
</ul></li>
<li>treatment
<ul>
<li>2021-12 ~ ongoing - methotrexate + temozolomide</li>
<li>2020-07 ~ 2021-03 - methotrexate + temozolomide + rituximab</li>
</ul></li>
<li>underlying diseases
<ul>
<li>DM and HTN are under medication management.</li>
</ul></li>
</ul>
<div id="section-562" class="section level3">
<h3>==========</h3>
</div>
<div id="section-563" class="section level3">
<h3>2022-06-23</h3>
<ul>
<li>The patient had vomiting, poor appetite, drowsiness, and
incontinence during last two days. 2022-06-22 Updated images revealed an
intra-axial tumor in the right temporal lobe and right basal ganglion
that could be a recurrent lymphoma with decreased intraventricular and
extraventricular CSF spaces in the right supratentoral region.</li>
<li>Underlying health conditions are treated with corresponding drugs
without issues.</li>
</ul>
</div>
<div id="section-564" class="section level3">
<h3>2022-05-18</h3>
<ul>
<li>MRI (2022-03-29) and CT (2022-03-28) images showed stable right
hilar lymphadenopathy, and regressed tumors in the right
temporo-occipital region, as compared to the images taken in Dec 2021.
The current regimen appears to have some beneficial effects.</li>
<li>According to lab records, methotrexate levels never reached toxicity
levels. Lab data reported on 2022-05-09 indicated that liver and kidney
function, CBC, WBC DC, electrolytes and b2 microglobulin were generally
normal. The last item reinforced the aforementioned results of
images.</li>
<li>Urine glucose 2+ reported on 2022-05-17 (blood sugar data points
since this hospitalization: 232, 203, 176). In patients with normal
kidney function, significant glycosuria does not generally occur until
the plasma glucose concentration exceeds 180 mg/dL (10 mmol/L). DM is an
important factor affecting the prognosis of patients with DLBCL.
Moreover, hyperglycemia during treatment is related to the poor
prognosis of patients with DLBCL. (reference: <a href="https://pubmed.ncbi.nlm.nih.gov/33858047/" class="uri">https://pubmed.ncbi.nlm.nih.gov/33858047/</a> ) SGLT2
inhibitor might serve as an optional alternative agent of lowering blood
sugar.</li>
</ul>
</div>
<div id="section-565" class="section level3">
<h3>2022-03-28</h3>
<ul>
<li>Recurrent DLBCL with brain mets, in progression (2021-12-22
CT).</li>
<li>The patient got good response with methotrexate + temozolomide +
rituximab during July 2020 to March 2021, and he is now on methotrexate
+ temozolomide since December 2021.</li>
<li>No IHC or Karyotype or FISH results found in HIS5.</li>
<li>The frequency of CNS involvement in systemic NHL varies depending at
least partially upon the aggressiveness of the NHL subtype.
Approximately 2 to 10 percent of patients with aggressive subtypes of
systemic NHL (eg, DLBCL) will experience direct involvement of the CNS
at some time during their course. The incidence is much higher in highly
aggressive NHL (eg, Burkitt lymphoma/leukemia, lymphoblastic lymphoma)
and lower in indolent NHL (eg, follicular lymphoma). Peripheral nervous
system (PNS) involvement by lymphoma is rare.</li>
<li>It is unknown whether the risk of CNS relapse has changed as initial
treatment of these diseases has evolved. Several retrospective studies
have suggested that the incidence may be lower among patients with B
cell NHL treated with rituximab-containing therapy or
etoposide-containing therapy. Other studies have found no difference in
the incidence of CNS relapse in the pre- versus post-rituximab era.
<ul>
<li><a href="https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma" class="uri">https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma</a></li>
</ul></li>
<li>Diffuse large B-cell lymphoma with secondary involvement of the
central nervous system treated with R-IDARAM (rituximab 375 mg/m2 IV day
1; methotrexate 12.5 mg by intrathecal injection day 1; idarubicin 10
mg/m2/day IV days 1 and 2; dexamethasone 100 mg/day IV infusion over 12
h days 1-3; cytosine arabinoside 1000 mg/m2/day IV over 1 h days 1 and
2; and methotrexate 2000 mg/m2 IV over 2 h day 3.) and median follow-up
for surviving patients was 49 months. At 2 years, estimated
progression-free survival (PFS) was 39% and overall survival (OS) was
52%. Encouraging outcomes were reported in patients with new disease,
with 5-year estimated PFS of 50% and OS 75%.
<ul>
<li><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13867" class="uri">https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13867</a></li>
</ul></li>
</ul>
</div>
<div id="section-566" class="section level3">
<h3>2022-02-11</h3>
<ul>
<li>brain DLBCL recurrence, in progression.</li>
<li>the patient got good response with MTR when first introduced since
2020H2, he is now on the same regimen.
<ul>
<li>reference: “Therapy of primary CNS lymphoma: role of intensity,
radiation, and novel agents” - <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142584/pdf/bloodbook-2017-565.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142584/pdf/bloodbook-2017-565.pdf</a></li>
</ul></li>
<li>autologous stem cell transplatation could be a worth trying
alternative option if the patient younger.
<ul>
<li>reference: “The role of autologous stem cell transplantation in
primary central nervous system lymphoma” - <a href="https://ashpublications.org/blood/article/127/13/1642/34766/The-role-of-autologous-stem-cell-transplantation" class="uri">https://ashpublications.org/blood/article/127/13/1642/34766/The-role-of-autologous-stem-cell-transplantation</a></li>
</ul></li>
<li>if poor response proved under current regimen, then Ibrutinib might
be an opt-in to the regimen.</li>
</ul>
</div>
<div id="section-567" class="section level3">
<h3>2022-01-24</h3>
<ul>
<li>blood sugar lab readings are above normal range under current mix of
biguanide (metformin), DPP4i (sitagliptin) and sulfonylurea
(glimepiride).</li>
<li>if a rapid increase of blood sugar is found, then some regular
insulin might be considered.</li>
</ul>
</div>
</div>
</div>
<div id="section-568" class="section level1">
<h1>701277494</h1>
<div id="section-569" class="section level2">
<h2>220623</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-10 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Left pneumothorax.</li>
<li>Much regression (1.6x5.0cm) of right liver margin metastases.</li>
</ul></li>
<li>2022-02-08 Patho - Liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy - Consistent with metastatic endometroid
carcinoma, poorly differentiated<br />
</li>
<li>IHC: ER (+), PR (focal +), Vimentin (+), and PAX8 (+).</li>
</ul></li>
<li>2022-01-29 CT - Lung, mediastinum, pleura
<ul>
<li>Liver surface meta and lung meta. The liver meta progressed.</li>
<li>There is no previous chest CT for comparison. the lung meta might be
new.</li>
</ul></li>
<li>2022-01-11 CT - Liver, spleen, biliary duct, pancreas
<ul>
<li>S/P hysterectomy and oophorectomy.</li>
<li>Recurrent/peritoneal carcinomatosis in RUQ (subphrenic region with
indentation of liver surface).</li>
<li>Subpleural nodule, 0.5cm in LLL.</li>
</ul></li>
<li>2021-12-20 MRI - Pelvis
<ul>
<li>S/P hysterectomy and oophorectomy.</li>
<li>Irregularity at liver surface (srs11 img11 and 18), carcinomatosis
or artifact?</li>
</ul></li>
<li>2021-05-20 Patho - uterus neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, endometrium, staging surgery - Endometrioid carcinoma, grade
3<br />
</li>
<li>Uterus, myometrium, staging surgery - Involved by tumor ( &gt; 1/2
thickness)<br />
</li>
<li>AJCC 8th edition Pathology stage: pT1bN0 (If cM0), FIGO IB, pStage
IB</li>
</ul></li>
<li>IHC: ER: positive (90%), PR: positive (90%), CK(+), vimentine(+),
p63(+), Napsin A(-)</li>
</ul></li>
<li>2021-04-29 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, D&amp;C - poorly differentiated carcinoma</li>
<li>ER(+), PR(+), p16(focal +), p63(focal +), and Vimentin(+).</li>
</ul></li>
<li>2021-04-23 MRI - Pelvis
<ul>
<li>suspected endometrial malignancy, if proven malignancy, cstage
T1bN0M0.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-02 Urology
<ul>
<li>Q
<ul>
<li>The patient complaints frequent urination at night for 2weeks, so we
need your help, thanks a lot!!</li>
</ul></li>
<li>A
<ul>
<li>I have visit this patient and review the history. She compliant
about nocturia for 3 weeks.</li>
<li>The possible etiologies including urinary tract infection,
overactive bladder or nocturnal polyuria.</li>
<li>Please check U/A, U/C first and may treat UTI first as your
expertise for at least one week if proved infection.</li>
<li>If there’s no evidence about UTI, Detrusitol 1# QD and Minirin 1# HS
could be used for the other etiologies if no contraindications.</li>
<li>Uro. OPD follow up is indicated. Thanks for your consultation.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-05-20 ATH + BSO
<ul>
<li>Staging surgery for endometrial cancer.</li>
<li>Pathology and cytology pending.</li>
<li>Residual tumor: not seen residual tumor.</li>
</ul></li>
<li>2021-04-29
<ul>
<li>D&amp;C, diagnostic and theraputic      </li>
<li>Endometrial hyperplasia </li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-06-18 ~ 2021-08-02: 4500cGy/25fx pelvic, 1200cGy/3fx vis IVRT
to vaginal cuff mucosa surface.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-03-01 ~ ongoing: paclitaxel + carboplatin</li>
<li>2021-06-22 ~ 2021-07-27: cisplatin 6 cycles as part of CCRT.</li>
</ul></li>
</ul>
<div id="section-570" class="section level3">
<h3>==========</h3>
</div>
<div id="section-571" class="section level3">
<h3>2022-06-23</h3>
<ul>
<li>Following paclitaxel and carboplatin treatment since early March,
the CT scan performed on 2022-05-10 showed significant regression of
right liver margin metastases.</li>
<li>Nocturia complained in late February is no longer in the list of
problems.</li>
<li>Blood glucose levels were 228 and 224 mg/dL since this
hospitalization, and the patient might need to be followed up in order
to check whether there is diabetes present.</li>
</ul>
</div>
<div id="section-572" class="section level3">
<h3>2022-03-02</h3>
<ul>
<li>disease progresses, liver mets has been proved s/p cisplatin-based
CCRT (Jun ~ Jul 2021) s/p ATH + BSO (Apr ~ May 2021).</li>
<li>the patient just starts receiving paclitaxel + carboplatin during
this hospitalization.</li>
<li>lenvatinib plus pembrolizumab showed promising antitumor activity in
patients with advanced endometrial carcinoma who have experienced
disease progression after prior systemic therapy, regardless of tumor
MSI status.
<ul>
<li>source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479759/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479759/</a></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-573" class="section level1">
<h1>701343649</h1>
<div id="section-574" class="section level2">
<h2>220621</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-04 CT - abdomen, pelvis
<ul>
<li>Post-operative change at LLL of the lung is suspected.</li>
<li>The differential diagnosis include residual metastasis.</li>
</ul></li>
<li>2022-03-16 Patho - lung total/lobe/segmental
<ul>
<li>Pathologic Diagnosis
<ul>
<li>Lung, left, upper lobe, lingula, segmentectomy — Adenocarcinoma,
moderately differentiated, consistent with metastatic colonic tumor</li>
<li>Lung, left, lower lobe, wedge resection — Adenocarcinoma, moderately
differentiated, consistent with metastatic colonic tumor</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality: Separate tumor nodules of same histopathologic type
in different lobe</li>
<li>Histologic Type (select all that apply): Adenocarcinoma</li>
<li>IHC stains reveal CDX2(+) and TTF-1(-)</li>
<li>The morphology and immunohistochemical stains are consistent with
metastatic colonic tumor.<br />
</li>
<li>Histologic Grade: G2: Moderately differentiated</li>
<li>Visceral Pleura Invasion: PL1</li>
<li>Lymphovascular Invasion (select all that apply): present</li>
</ul></li>
</ul></li>
<li>2022-02-14 PET
<ul>
<li>Glucose hypermetabolism in the lower third of esophagus and soft
tissue of RUQ of abdomen, probably s/p radiotherapy change.<br />
</li>
<li>Glucose hypermetabolism in the gastro-hepatic space, the nature is
to be determined (metastatic lymph nodes or other nature?). Please
correlate with other clinical findings for further evaluation.<br />
</li>
<li>Glucose hypermetabolism in the left upper and left lower lungs,
compatible with cancer with lung metastases.</li>
<li>Increased FDG uptake in the uterus, probably physiological uptake of
FDG or benign in nature. Please correlate with other clinical findings
for further evaluation and to rule out other possibilities.<br />
</li>
<li>S-colon cancer s/p treatment, ycTxNxM1b, stage IVB (AJCC 8th ed.),
by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2022-01-28 CT - abdomen, pelvis
<ul>
<li>Lung metastases S/P C/T show partial response.</li>
<li>Liver metastasis S/P C/T shows complete response.</li>
</ul></li>
<li>2021-10-26 Abdominal Ultrasonography
<ul>
<li>Liver:
<ul>
<li>Suboptimal examination, the area near the diaphragm couldn’t be seen
well. Smooth liver surface. No definite lesion could be seen.</li>
</ul></li>
<li>Biliary system:
<ul>
<li>No gallbladder stone. No CBD dilatation.</li>
</ul></li>
</ul></li>
<li>2021-10-25 Patho - colon segmental resection for tumor
<ul>
<li>Pathologic Diagnosis
<ul>
<li>Tumor, sigmoid colon, laparoscopic AR — Adenocarcinoma<br />
</li>
<li>Bilateral cutting ends, ditto — Free from tumor<br />
</li>
<li>Lymph nodes, mesocolic, dissection — Tumor metastasis (3/17), with
extracapsular extension (2/3)<br />
</li>
<li>AJCC pathologic stage — pT4aN1bcM1a, stage IVA<br />
</li>
</ul></li>
<li>Microscopic Examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: G2, moderately differentiated<br />
</li>
<li>Depth of invasion: visceral peritoneum<br />
</li>
<li>Angiolymphatic invasion: present<br />
</li>
<li>Perineural invasion: present<br />
</li>
<li>Circumferential (radial) margin of rectosigmoid: Involved<br />
</li>
<li>Lymph node metastasis, mesocolic: positive (3/17)<br />
</li>
<li>Extranodal involvement: present (2/3)<br />
</li>
<li>Pathological TNM Stage: pT4aN1bcM1b, stage IVB<br />
</li>
<li>Additional pathologic findings: focal tumor necrosis<br />
</li>
</ul></li>
<li>Immunohistochemistry
<ul>
<li>CDX-2(+), MLH1(+), PMS2(+), MSH2(+) and MSH6(+) for tumor</li>
</ul></li>
<li>Addendum
<ul>
<li>Admission and OP note recorded a case of sigmoid cancer with liver
and lung metastasis (cT3N0M1) according to serial examinations in Fu Jen
Catholic University Hospital, but after examination and team discussion
in our hospital, no definite lesion was seen in liver, so clinical M
stage is modified from M1b (stage IVB) to M1a (stage IVA)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-16
<ul>
<li>Surgery
<ul>
<li>VATS, lingular segementectomy + LLL wedge resections + RLND</li>
</ul></li>
<li>Finding
<ul>
<li>Metastatic nodule about 1.2cm in diameter, at lingula segement and
LLL x2 s/p lingula segmentectomy + LLL wedge resections x 2</li>
<li>No malignant pleural effusion noted</li>
<li>Lymph nodes dissection over para-aortic, AP window, hilar and
interlobar.</li>
</ul></li>
</ul></li>
<li>2021-10-22
<ul>
<li>Surgery
<ul>
<li>Laparoscopic LAR        </li>
</ul></li>
<li>Finding
<ul>
<li>Tumor at sigmoid colon cancer with liver, lung metastasis and
obstruction, cT4N0M1b</li>
<li>Anastomosis is done</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-12-15 ~ undergoing - FOLFIRI + bevacizumab</li>
<li>2021-11-09 ~ 2021-12-03 - FOLFIRI</li>
</ul></li>
</ul>
<div id="section-575" class="section level3">
<h3>==========</h3>
</div>
<div id="section-576" class="section level3">
<h3>2022-06-21</h3>
<ul>
<li>On the basis of the lab results reported on 2022-06-14, the patient
is expected to be able to tolerate the current regimen as in the
past.</li>
<li>The TPR, BP, and SpO2 have remained stable since being
hospitalized.</li>
</ul>
</div>
<div id="section-577" class="section level3">
<h3>2022-06-02</h3>
<ul>
<li>This patient was diagnosed with sigmoid cancer with lung mets
following surgical operations on the colon (2021-10-22) and lung
(2022-03-16). He is currently receiving Folfiri since 2021-11-09 (plus
bevacizumab since 2021-12-15).</li>
<li>CT on 2022-01-28 showed a partial response to lung mets, however, CT
on 2022-05-04 showed possibly residual lung mets.</li>
<li>The results of lab tests on 2022-05-26 indicated that liver and
kidney function, electrolytes, and blood cell counts were grossly
normal, which were considered acceptable to receive the regimen.</li>
<li>No issue with active prescription.</li>
</ul>
</div>
<div id="section-578" class="section level3">
<h3>2022-05-17</h3>
<ul>
<li>This patient was diagnosed with sigmoid cancer with lung mets s/p
surgical operations on the colon (on 2021-10-22) and lung (on
2022-03-16) and has been receiving FOLFIRI since 2021-11-09 (plus
bevacizumab since 2021-12-15).</li>
<li>CT on 2022-01-28 showed a partial response to lung mets, however CT
on 2022-05-04 revealed a possible residural metastasis in the
lungs.</li>
<li>Lab data on 2022-05-10 showed that liver and kidney function,
electrolytes, CBC and biomarkers were generally normal.</li>
<li>No issue with active prescription.</li>
</ul>
</div>
</div>
</div>
<div id="section-579" class="section level1">
<h1>701385445</h1>
<div id="section-580" class="section level2">
<h2>220620</h2>
<p>{alpha-fetoprotein-producing esophageal adenocarcinoma with liver
metastasis, T4N2M1 stage IVB}</p>
<ul>
<li>lab data
<ul>
<li>Alkaline phosphatase (34~104)
<ul>
<li>2022-06-20 300 U/L</li>
<li>2022-06-17 208 U/L</li>
</ul></li>
<li>LDH (140~271)
<ul>
<li>2022-06-20 1087 U/L</li>
<li>2022-06-17 838 U/L</li>
</ul></li>
<li>S-GOT/AST (13~39)
<ul>
<li>2022-06-20 95 U/L</li>
<li>2022-06-17 45 U/L</li>
<li>2022-06-13 24 U/L</li>
<li>2022-06-09 16 U/L</li>
<li>2022-06-06 20 U/L</li>
<li>2022-06-01 31 U/L</li>
<li>2022-05-29 32 U/L</li>
<li>2022-05-12 48 U/L</li>
</ul></li>
<li>S-GPT/ALT (&lt;41)
<ul>
<li>2022-06-20 51 U/L</li>
<li>2022-06-17 15 U/L</li>
<li>2022-06-13 9 U/L</li>
<li>2022-06-09 8 U/L</li>
<li>2022-06-06 13 U/L</li>
<li>2022-06-01 17 U/L</li>
<li>2022-05-29 22 U/L</li>
<li>2022-05-12 54 U/L</li>
</ul></li>
<li>Albumin (3.5~5.7)
<ul>
<li>2022-06-20 2.5 g/dL<br />
</li>
<li>2022-06-13 2.4 g/dL<br />
</li>
<li>2022-06-09 2.5 g/dL<br />
</li>
<li>2022-06-01 2.2 g/dL<br />
</li>
<li>2022-05-29 2.3 g/dL<br />
</li>
<li>2022-05-26 1.9 g/dL<br />
</li>
</ul></li>
<li>Albumin % (54.0~60.3)
<ul>
<li>2022-05-28 43.3 %<br />
</li>
</ul></li>
<li>2022-05-28
<ul>
<li>Zinc, Zn 417 ug/L<br />
</li>
<li>Protein, total 3.8 g/dL<br />
</li>
<li>Albumin 43.3 %<br />
</li>
<li>Alpha-1 4.7 %<br />
</li>
<li>Alpha-2 11.3 %<br />
</li>
<li>Beta 21.2 %<br />
</li>
<li>Gamma 19.5 %<br />
</li>
<li>M-peak Negative<br />
</li>
<li>A/G Ratio 0.8<br />
</li>
</ul></li>
<li>2022-05-27
<ul>
<li>Anti-ds DNA Antibody &lt;0.5 IU/ml</li>
<li>Anti-ENA SS-A(Ro) 0.6 EliA U/ml<br />
</li>
<li>Anti-ENA SS-B(La) &lt;0.3 EliA U/ml<br />
</li>
</ul></li>
<li>2022-05-23
<ul>
<li>Anti-HBs 49.32 mIU/mL</li>
</ul></li>
<li>2022-05-17
<ul>
<li>Anti-HBc Reactive 7.40 S/CO<br />
</li>
<li>AFP 14232.3 ng/mL</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-31 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Pleura effusion of right and left costal-phrenic angle</li>
<li>Linear infiltration over right and left lower lung zone is noted.
please correlate with clinical symptom to rule out inflammatory
process.</li>
</ul></li>
<li>2022-05-26 Visceral Angiography 2 vessels
<ul>
<li>Tumor enhancement at lower esophagus and stomach. No evidence of
active bleeding.</li>
</ul></li>
<li>2022-05-26 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Esophageal tumor with surface friability, 30cm below the insicor
extent to cardia</li>
<li>Superficial gastritis</li>
<li>Duodenal polyps, bulb</li>
<li>Duodenal subepithelial lesion, 2nd portion, suspected lymphatic
cyst</li>
</ul></li>
<li>Suggestion
<ul>
<li>If acitive bleeding, consider angiography for embolization and
surgical intervention. Endoscopic treatment is NOT suitable for tumor
bleeding. (Hemospray powder was not available in our hospitial)</li>
</ul></li>
</ul></li>
<li>2022-05-19 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Compatible with AFP-producing carcinoma,
poorly differentiated, metastatic</li>
<li>The sections show a picture compatible with metastatic AFP-producing
carcinoma, poorly differentiated, composed of extensive and nearly total
tumor necrosis, with a tiny solid nest of viable polygonal neoplastic
cells.</li>
<li>IHC, tumor cells reveal: CK7(-), CK20(-), and AFP (scattered tumor
cells +). Suggest clinic correlation.</li>
</ul></li>
<li>2022-05-19 2D transthoracic echocardiography
<ul>
<li>Dilated LA and aortic root</li>
<li>Thickening of IVS and LVPW</li>
<li>Adequate LV and RV systolic function</li>
<li>Possibly impaired LV relaxation</li>
<li>Calcified mitral annulus with mild to moderate MR, mild TR and
PR</li>
<li>AV sclerosis with mild AR</li>
<li>No regional wall motion abnormalities</li>
</ul></li>
<li>2022-05-18 Patho - colon biopsy
<ul>
<li>Intestine, large, ascending colon, biopsy — hyperplastic polyp</li>
<li>Intestine, large, descending colon, biopsy — hyperplastic polyp</li>
<li>Intestine, large, sigmoid colon, biopsy — hyperplastic polyp</li>
</ul></li>
<li>2022-05-17 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Imaging Report Form for Esophageal Carcinoma
<ul>
<li>Large esophageal tumor with GE junction invasion, lymph nodes
metastsais. Liver tumors, suspected liver metastasis. cstage
T4N2M1.</li>
<li>Left pleural effusion. Bilateral basal lung atelectasis.</li>
</ul></li>
</ul></li>
<li>2022-05-16 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>liver tumors: suspected HCC, or metastatic tumors</li>
<li>liver hyperechoic tumor, S1: suspected hemangioma</li>
<li>liver parenchymal disease</li>
<li>mild gallbladder wall thickening</li>
</ul></li>
<li>Suggestion
<ul>
<li>4 phase CT or dynamic MRI study</li>
</ul></li>
</ul></li>
<li>2022-05-13 Patho - esophageal biopsy
<ul>
<li>Esophagus, middle to lower, biopsy — Poorly differentiated
adenocarcinoma</li>
<li>Section shows pieces of solid sheets and glandular tumor cells
infiltrating in fibrous tissue.</li>
<li>The immunohistochemical stains reveal CK(+), CK7(-), CK20(-),
CK5/6(-), p40(-), CDX2(+), TTF-1(equivocal), Napsin A(-), CD56(-), and
PSA(-). The results are in favor of poorly differentiated
adenocarcinoma.</li>
<li>Addendum: The immunohistochemical stains reveal alpha-fetoprotein
(focal +), Hepatocyte(equivocal), Arginase (-), and Her-2/neu (Ab):
Negative (0). The results are in favor of gastric or esophageal primary
tumor.</li>
</ul></li>
<li>2022-05-12 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Esophageal tumor, 30cm below the insicor extent to cardia, s/p
biopsy</li>
<li>Superficial gastritis</li>
<li>Duodenal polyps, bulb</li>
<li>Duodenal subepithelial lesion, 2nd portion, suspected lymphatic
cyst</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue biopsy result</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-25 Radiation Oncology
<ul>
<li>Under the impression of Adenocarcinoma of M-L/3 esophagus, with
liver metastases, cT4N2M1, with active tumor bleeding, palliative RT is
indicated. CT-simulation will be arranged today. Plan to deliver 40 Gy/
20 fx to the M-L/3 esophageal tumor.</li>
</ul></li>
<li>2022-05-25 Hemato-Oncology
<ul>
<li>Impression:
<ul>
<li>Alpha-fetoprotein producing esophageal adenocarcinoma with liver
metastasis, T4N2M1 stage IVb</li>
<li>Anemia, subacute GI bleeding related</li>
<li>Fever, suspect transfusion reaction, mix with infection and tumor
fever</li>
<li>Staphylococcus aureus bacteremia</li>
<li>Hypertension</li>
</ul></li>
<li>Suggestion:
<ul>
<li>We wound like to take over this case if you agree</li>
<li>Consult radio-oncologist for CCRT</li>
<li>Arrange port A insertion</li>
<li>CCRT is indicated for esophagus cancer local tumor bleeding control
and followed by palliative chemotherapy for metastasis disease</li>
<li>Add entecarvir for chemotherapy HBV flare up prophylaxis (Anti-Hbc
positive)</li>
<li>LPRBC to keep Hb&gt;=8, May consider give vena before blood
transfusion (history of suspect transfusion reaction)</li>
<li>Check Ca for frequent blood transfusion</li>
<li>Pending anemia survey (Fe, TIBC, Ferrtin, folic acid, vitamin B12).
May also check serum EP, TSH, Freee T4, ANA, C3, C4, Anti-dsDNA, RF,
Anti-Ro/Anti-La)</li>
<li>Thanks for your consultation. If there is any problem, please feel
free to let us known.</li>
</ul></li>
</ul></li>
<li>2022-05-18 Infectious Disease
<ul>
<li>Q
<ul>
<li>Intermittent fever occur, 20220515 blood culture was showed
Staphylococcus aureus (OSSA), we need your exerpance assessment the
infcetion source and advice, thnak you~</li>
</ul></li>
<li>A
<ul>
<li>Antibiotcs with stazilin 1g iv q8h is suggested for OSSA
bacteremia.</li>
<li>Please arrange CV-echo.</li>
<li>F/u B/C 3 days later.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-05-25 ~ undergoing - M-L/3 esophageal tumor 32 Gy/ 16 fx.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-06-01 ~ undergoing - FOLFOX6</li>
</ul></li>
</ul>
<p>[memo]</p>
<ul>
<li>Pathology IHC results
<ul>
<li>Esophageal biopsy pathology (2022-05-13) IHC revealed CK(+), CK7(-),
CK20(-), CK5/6(-), p40(-), CDX2(+), TTF-1(equivocal), Napsin A(-),
CD56(-), PSA(-), alpha-fetoprotein(focal +), Hepatocyte(equivocal),
Arginase(-), Her-2/neu(Ab): Negative(0).</li>
<li>Liver biopsy pathology (2022-05-19) IHC revealed CK7(-), CK20(-),
and AFP (scattered tumor cells +).</li>
</ul></li>
<li>CK7−/CK20− could mean ( <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923363/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923363/</a> )
<ul>
<li>Prostate adenocarcinoma</li>
<li>Renal (clear cells)</li>
<li>Hepatocellular carcinoma</li>
<li>Adrenocortical carcinoma</li>
<li>Non-seminoma germ cell tumours</li>
<li>Mesothelioma</li>
<li>Small cell lung carcinoma</li>
<li>Gastric adenocarcinoma</li>
</ul></li>
<li>Oesophagus: CDX2+/−, CEA+, CDH17+, MUC1−/+, MUC5AC−/+, SATB2−</li>
<li>Liver: HepPar1+, CD10+, pCEA+, mCEA−, AFP+, Glypican-3+,
Arginase-1+, CK19−</li>
</ul>
<p>[assessment]</p>
<ul>
<li>This is a 57 y/o male was diagnosed with alpha-fetoprotein-producing
esophageal adenocarcinoma with liver metastasis in May 2022, T4N2M1
stage IVB, and has been receiving CCRT with FOLFOX6 regimen since late
May 2022.</li>
<li>The liver enzyme levels have been rising for the last two weeks
which should be addressed while daily Baraclude (entecavir) 0.5mg has
been prescribed since a recent OPD visit on 2022-06-17.
<ul>
<li>S-GOT/AST (13~39)
<ul>
<li>2022-06-20 95 U/L</li>
<li>2022-06-17 45 U/L</li>
<li>2022-06-13 24 U/L</li>
<li>2022-06-09 16 U/L</li>
</ul></li>
<li>S-GPT/ALT (&lt;41)
<ul>
<li>2022-06-20 51 U/L</li>
<li>2022-06-17 15 U/L</li>
<li>2022-06-13 9 U/L</li>
<li>2022-06-09 8 U/L</li>
</ul></li>
<li>ALT/AST ratio
<ul>
<li>2022-06-20 1.86</li>
<li>2022-06-17 3.00</li>
<li>2022-06-13 2.66</li>
<li>2022-06-09 2.00</li>
</ul></li>
</ul></li>
<li>Hypoproteinemia, which is unlikely to be caused by proteinuria
(2022-06-20 blood creatinine 0.57 mg/dL, eGFR 156.60) could be the
result of malnutrition? or probably the result of impaired protein
synthesis due to liver mets.
<ul>
<li>Albumin
<ul>
<li>2022-06-20 2.5 g/dL<br />
</li>
<li>2022-06-13 2.4 g/dL<br />
</li>
<li>2022-06-09 2.5 g/dL<br />
</li>
<li>2022-06-01 2.2 g/dL<br />
</li>
<li>2022-05-29 2.3 g/dL<br />
</li>
<li>2022-05-26 1.9 g/dL<br />
</li>
</ul></li>
</ul></li>
<li>After correction for hypoalbuminemia, serum calcium falls within
normal range (2.3 mmol/L). ( <a href="https://www.mdcalc.com/calcium-correction-hypoalbuminemia" class="uri">https://www.mdcalc.com/calcium-correction-hypoalbuminemia</a>
, based on unadjusted Ca 1.96 mmol/L, normal albumin 4 g/dL)</li>
</ul>
</div>
</div>
<div id="section-581" class="section level1">
<h1>700983554</h1>
<div id="section-582" class="section level2">
<h2>220617</h2>
<ul>
<li>exam finding
<ul>
<li>2022-06-15 CXR
<ul>
<li>Enlargement of right hilum.</li>
</ul></li>
<li>2022-06-15 EKG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2022-02-24 SONO - neck (lymph node)
<ul>
<li>Sonography of neck revealed some LNs in bil. neck.</li>
</ul></li>
<li>2021-12-02 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac crest, biopsy — Compatible with acute myeloid
leukemia with partial remission<br />
</li>
<li>The sections show hypercellular marrow (80%). The M/E ratio about
8:1 in CD71 immunostain. Both granulocytic and megakaryocytic
proliferation with occasional small megakaryocytes are present. Clusters
of MPO+ myeloid cells(30%) and CD68+ monocytes (15%) can be identified.
Scattered CD34+ and/or CD117+ blasts,constitue 10% of marrow cells are
evident. The finding is compatible with acute myeloid leukemia with
partial remission. Suggest bone marrow smear evaluation and clinic
correlation.</li>
</ul></li>
<li>2021-11-15 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>Skin, right groin, excisional biopsy — Acute leukemia involvement
<ul>
<li>Microscopically, it shows skin tissue with marked infiltration of
leukemic tumor cells in the dermis with focal necrosis. The tumor cells
show nuclear hyperchromasia, plemorphism, coarse chromatin, prominent
nucleoli and high N/C ratio.<br />
</li>
</ul></li>
<li>Skin, left groin, excisional biopsy — Acute leukemia involvement
<ul>
<li>Microscopically, it shows skin tissue with marked infiltration of
leukemic tumor cells in the dermis. The tumor cells show nuclear
hyperchromasia, plemorphism, coarse chromatin, prominent nucleoli and
high N/C ratio.<br />
</li>
</ul></li>
<li>Skin, left thigh, excisional biopsy — Acute leukemia involvement
<ul>
<li>Microscopically, it shows skin tissue with ulceration, focal
necrosis, hemorrhage and dense infiltration of leukemic tumor
cells.<br />
</li>
<li>Immunohistochemical stain reveals MPO(+), CD10(focal+),
CD117&amp;CD34(+, 25%), TdT(-), CD20(focal+, &lt;5%), CK(-), CD3(+, 5%),
CD138(+, &lt;5%), Bcl-2(+), Bcl-6(+), cyclin d1(-).</li>
</ul></li>
</ul></li>
<li>2021-09-14 EKG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2021-09-13 2D Transthoracic Echocardiography
<ul>
<li>Dilated LA</li>
</ul></li>
<li>2021-09-01 CT - abdomen, pelvis
<ul>
<li>FINDINGS:
<ul>
<li>There is splenomegaly and the greatest anterior-posterior dimention
measuring 14.7 cm.</li>
<li>There are multiple variable sized enlarged lymph nodes in
gastrohepatic ligament, hepatoduodenal ligament, mesentery, and
bilateral inguinal area. please correlate with clinical condition.</li>
<li>A hepatic cyst measuring 0.5 cm in S4 is suspected. Please correlate
with sonography.</li>
</ul></li>
<li>IMP:
<ul>
<li>Splenomegaly.</li>
<li>There are multiple variable sized enlarged lymph nodes in
gastrohepatic ligament, hepatoduodenal ligament, mesentery, and
bilateral inguinal area.</li>
</ul></li>
</ul></li>
<li>2021-09-01 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — acute leukemia.</li>
<li>IHC stains: CD117: 30%; CD34: 30 %; MPO: 20-30%, LCA: 50-60%; CD10:
&lt;10% (of the nucleated cells). Please correlate with other laboratory
results such as one marrow smear, hemogram, and flow cytometry.<br />
</li>
<li>Section shows piece(s) of bone marrow with 70% cellularity and M:E
ratio of approximately 4:1. Three cell lineages are present with left
shift of leukocytes, inculding many immature leukocytes, many
lymphocytes, plasma cell and eosinophils. Megakaryocytes are adequate in
number.<br />
</li>
</ul></li>
<li>2021-08-31 EKG
<ul>
<li>Sinus tachycardia</li>
</ul></li>
<li>2019-04-12 EKG
<ul>
<li>Sinus tachycardia</li>
<li>Rightward axis</li>
<li>Borderline ECG</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2011-11-11 Plastic and Reconstructive Surgery
<ul>
<li>Q
<ul>
<li>This 41-year-old man has
<ul>
<li>Acute myeloblastic leukemia</li>
<li>AIDS under Atripla</li>
<li>Left dorsal foot cellulitis with ulcer and left medial thigh
ulcer</li>
<li>Latent syphilis.<br />
</li>
</ul></li>
<li>He is admitted to recieve target therapy for acute myeloblastic
leukemia.
<ul>
<li>After admission, blood examination revealed WBC:303.62 <em>10^3/uL,
Hb: 4.9 g/dL, Plt: 96 </em>10^3/uL, Band 2%, Neurophil: 0%, Blast: 87.0,
and Uric acid: 9.2mg/dL.<br />
</li>
<li>Blood trasfusion with pack-RBC 4U and LPR 2U were given. Normal
saline 1500ml and 1.5mg Rasburicase were administered to correct his
uric acid.</li>
<li>Blood test today morning showed improvement and the treatment will
be continued.<br />
</li>
<li>Bilateral inguinal masses 7x7cm were discovered. The masses are
hard, round, elevated, and mildy pigmented. Tenderness was also
noted.</li>
</ul></li>
<li>Due to the bilateral inguinal masses, we would like to consult you
for arranging I&amp;D or other appropriate management for the patient.
Thank you very much.</li>
</ul></li>
<li>A
<ul>
<li>41 y/o male patient
<ul>
<li>Right groin mass with partial necrosis</li>
<li>Left groin mass</li>
<li>Left thigh mass</li>
</ul></li>
<li>A
<ul>
<li>underlying history: Acute myeloblastic leukemia, AIDS under Atripla,
Latent syphilis.</li>
<li>I had visited the patient and explained to him and his father, the
patient reported that these masses gradually enlarged within 1
month.</li>
<li>Those masses were hard, firm and non-movable without obvious
infectoin sign.</li>
<li>The tumor border was ill-defined.</li>
<li>Partial necrosis of the tumor was suspected.</li>
<li>The possibility of malignant tumor was informed.</li>
<li>It’s not possible nor suitable for complete excision.</li>
<li>Tissue proof first is recommended</li>
</ul></li>
<li>Plan
<ul>
<li>We will arrange biopsy of these 3 lesions and debridement of right
groin area next Monday</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-09-02 Infectious Disease
<ul>
<li>Q
<ul>
<li>For advice on antibiotics for new onset of fever in an HIV patient
with leukemia.
<ul>
<li>This is a 40 year old man who admitted to the hospital for the
treatment of acute leukemia.</li>
<li>He had underlying HIV infection and was previously seen at your OPD.
This time during hospitalization, he was found to have elevated levels
of TPHA and RPR/VDRL titers.</li>
<li>On 20210902, his body temperature was elevated up to &gt;38 C and
elevated level of WBC but did not complain of any discomfort in
particular.</li>
</ul></li>
<li>Please kindly assist to evaluate the patient and advise us on the
management of the condition. Thank you.</li>
</ul></li>
<li>A
<ul>
<li>Assessment
<ul>
<li>40-year-old HIV infection male patient, with loss of follow up with
HAART (Highly Active Antiretroviral Therapy) for two years, now admitted
due to acute leukemia.</li>
<li>No HIV viral load data is available, CD4 count up to 2905, leukemoid
reaction related, white count high to 52800.</li>
<li>Besides HIV infection, he had received 3-dose penicillin injection
in Jan 2018, and now syphilis RPR titer is high to 128.</li>
<li>Benzathin penicillin retreatment is necessary.</li>
<li>HAART with Atripla has been restarted since yesterday.</li>
</ul></li>
<li>Suggestion
<ul>
<li>continue Atripla.</li>
<li>Benzathin penicillin injection with 2.4 million units IM once a week
for 3 weeks.</li>
<li>Follow up RPR titer 3 months later.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-08-31 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>for on port-a</li>
<li>this is a 40-year-old male who has the history of human
immunodeficiency virus and the INF follow-up, Atripla using since 2017
until 2019, due to the viral load &lt;20, CD4:1046.</li>
<li>this time, he is admitted for ALL chemotherapy treatment, so we need
your help for on port-a, think a lot!!</li>
</ul></li>
<li>A
<ul>
<li>we will arrange port-A implantation this w4</li>
</ul></li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>HIV 1 Viral Loads
<ul>
<li>2022-04-15 83.2 copies/mL</li>
<li>2022-01-17 30.1 copies/mL</li>
<li>2021-09-08 29100 copies/mL</li>
</ul></li>
<li>HIV-1 RNA
<ul>
<li>2019-08-23 &lt;20 copies/mL</li>
<li>2019-02-01 &lt;20 copies/mL</li>
<li>2018-11-09 37 copies/mL</li>
<li>2018-05-11 &lt;20 copies/mL</li>
<li>2018-02-09 191 copies/mL</li>
</ul></li>
<li>HIV Ab EIA (enzyme immunoassay)
<ul>
<li>2021-09-01 Reactive</li>
<li>2018-01-03 Reactive</li>
</ul></li>
<li>CD3+∕CD4+ Helper T
<ul>
<li>2022-04-12 46.7 % 593 /uL</li>
<li>2022-01-12 45.8 % 1195 /uL<br />
</li>
<li>2021-09-01 32.9 % 2905 /uL<br />
</li>
<li>2019-08-22 40.4 % 1345 /uL<br />
</li>
<li>2019-01-30 38.0 % 1046 /uL<br />
</li>
<li>2018-11-07 37.1 % 1161 /uL<br />
</li>
<li>2018-05-09 35.5 % 980 /uL<br />
</li>
<li>2018-02-07 32.9 % 880 /uL<br />
</li>
</ul></li>
<li>CD3+∕CD8+ Suppressor T
<ul>
<li>2022-04-12 44.5 % 565 /uL<br />
</li>
<li>2022-01-12 44.4 % 1160 /uL<br />
</li>
<li>2021-09-01 50.6 % 4459 /uL<br />
</li>
<li>2019-08-22 37.9 % 1260 /uL<br />
</li>
<li>2019-01-30 40.3 % 1108 /uL<br />
</li>
<li>2018-11-07 40.8 % 1277 /uL<br />
</li>
<li>2018-05-09 44.7 % 1233 /uL<br />
</li>
<li>2018-02-07 48.9 % 1310 /uL<br />
</li>
</ul></li>
<li>CD4/CD8 Ratio
<ul>
<li>2022-04-12 1.0 Ratio<br />
</li>
<li>2022-01-12 1.0 Ratio<br />
</li>
<li>2021-09-01 0.7 Ratio<br />
</li>
</ul></li>
<li>CD3 T Cells
<ul>
<li>2022-04-12 92.3 %</li>
<li>2022-01-12 91.6 %</li>
<li>2021-09-01 79.4 %</li>
<li>2019-08-22 80.5 %</li>
<li>2019-01-30 80.4 %</li>
<li>2018-11-07 79.2 %</li>
<li>2018-05-09 83.2 %</li>
<li>2018-02-07 84.5 %</li>
</ul></li>
<li>CD19 B Cells
<ul>
<li>2022-04-12 1.4 %<br />
</li>
<li>2022-01-12 3.0 %<br />
</li>
<li>2021-09-01 7.7 %<br />
</li>
<li>2019-08-22 10.0 %<br />
</li>
<li>2019-01-30 10.3 %<br />
</li>
<li>2018-11-07 10.6 %<br />
</li>
<li>2018-05-09 9.1 %<br />
</li>
<li>2018-02-07 6.2 %<br />
</li>
</ul></li>
<li>CD16+56 NK
<ul>
<li>2021-09-01 8.9 %</li>
</ul></li>
<li>CMV viral load assay
<ul>
<li>2021-10-08 Target not deteceted IU/mL<br />
</li>
<li>2021-09-06 Target not deteceted IU/mL</li>
</ul></li>
<li>CMV IgG
<ul>
<li>2021-09-01 Reactive 1,201.3 AU/mL</li>
</ul></li>
<li>CMV IgM
<ul>
<li>2021-09-01 Nonreactive 0.10 Index<br />
</li>
</ul></li>
<li>TPHA (Treponema Pallidum Hemagglutination Assay)
<ul>
<li>2022-04-12 Reactive 1: 5120<br />
</li>
<li>2021-09-01 Reactive &gt;1:20480<br />
</li>
<li>2018-11-08 Reactive 1: 5120<br />
</li>
<li>2018-05-21 Reactive 1: 5120<br />
</li>
</ul></li>
<li>RPR/VDRL (Rapid Plasma Reagin / Veneral Disease Research Laboratory
test)
<ul>
<li>2022-04-12 Reactive 1: 64<br />
</li>
<li>2021-09-01 Reactive 1:128<br />
</li>
</ul></li>
<li>STS-RPR (Serological Test for Syphilis - Rapid Plasma Reagin)
<ul>
<li>2018-11-07 Reactive 1: 4<br />
</li>
<li>2018-05-21 Reactive 1: 4<br />
</li>
<li>2018-01-03 Reactive 1:64<br />
</li>
</ul></li>
<li>Procalcitonin (PCT)
<ul>
<li>2022-06-15 1.29 ng/mL</li>
<li>2022-03-23 0.64 ng/mL</li>
<li>2021-11-15 0.65 ng/mL</li>
<li>2021-11-12 0.52 ng/mL</li>
<li>2021-10-07 0.40 ng/mL</li>
<li>2021-10-04 0.37 ng/mL</li>
<li>2021-09-27 0.64 ng/mL</li>
<li>2021-09-20 0.60 ng/mL</li>
<li>2021-09-06 0.39 ng/mL</li>
<li>2021-09-01 0.26 ng/mL</li>
</ul></li>
<li>CRP (C-reactive protein)
<ul>
<li>2022-06-16 12.35 mg/dL</li>
<li>2022-06-15 17.87 mg/dL</li>
<li>2022-03-23 6.08 mg/dL</li>
<li>2022-03-18 8.13 mg/dL</li>
<li>2021-12-20 1.73 mg/dL</li>
<li>2021-12-18 0.84 mg/dL</li>
<li>2021-12-16 0.94 mg/dL</li>
<li>2021-12-14 1.42 mg/dL</li>
<li>2021-12-12 2.45 mg/dL</li>
<li>2021-12-10 0.92 mg/dL</li>
<li>2021-12-08 0.90 mg/dL</li>
<li>2021-12-06 1.06 mg/dL</li>
<li>2021-12-03 1.13 mg/dL</li>
<li>2021-12-01 1.33 mg/dL</li>
<li>2021-11-30 1.91 mg/dL</li>
<li>2021-11-29 1.87 mg/dL</li>
<li>2021-11-27 1.90 mg/dL</li>
<li>2021-11-25 2.44 mg/dL</li>
<li>2021-11-24 4.03 mg/dL</li>
<li>2021-11-23 5.19 mg/dL</li>
<li>2021-11-22 3.43 mg/dL</li>
<li>2021-11-19 4.70 mg/dL</li>
<li>2021-11-18 5.63 mg/dL</li>
<li>2021-11-17 7.42 mg/dL</li>
<li>2021-11-16 8.85 mg/dL</li>
<li>2021-11-15 7.62 mg/dL</li>
<li>2021-11-14 6.37 mg/dL</li>
<li>2021-11-12 5.53 mg/dL</li>
<li>2021-11-11 3.69 mg/dL</li>
<li>2021-11-10 4.15 mg/dL</li>
<li>2021-09-27 5.71 mg/dL</li>
<li>2021-09-22 4.78 mg/dL</li>
<li>2021-09-20 7.14 mg/dL</li>
<li>2021-09-14 10.05 mg/dL</li>
<li>2021-09-08 2.03 mg/dL</li>
<li>2021-09-06 7.04 mg/dL</li>
<li>2021-09-01 3.78 mg/dL</li>
<li>2021-08-31 3.62 mg/dL</li>
<li>2019-08-22 0.49 mg/dL</li>
<li>2018-12-16 8.26 mg/dL</li>
<li>2018-02-07 1.34 mg/dL</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>AML
<ul>
<li>2022-06-16 azacitidine 75mg/m2 for 7 days</li>
<li>2022-03-18 azacitidine 75mg/m2 for 7 days</li>
<li>2021-11-22 azacitidine 75mg/m2 for 7 days</li>
</ul></li>
<li>HIV
<ul>
<li>2021-09-08 ~ ongoing - Atripla (efavirenz 600mg + emtricitabine
200mg + tenofovir 300mg) HS PO</li>
<li>2018-01-10 ~ 2019-08 - Atripla (efavirenz 600mg + emtricitabine
200mg + tenofovir 300mg) HS PO</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Sinus tachycardia has been observed for over 12 months (EKG
2022-06-15, 2021-09-14, 2021-8-31, 2021-04-21).</li>
</ul>
</div>
</div>
<div id="section-583" class="section level1">
<h1>700202562</h1>
<div id="section-584" class="section level2">
<h2>220614</h2>
<p>{multiple myeloma}</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-09 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Plasma cell myeloma</li>
<li>The specimen submitted consisted of one strip of bone marrow tissue
measuring 2.1 x 0.3 x 0.3 cm in size, fixed in B-5 solution. Grossly, it
was tan in color and bony hard in consistence. All embedded for sections
after short decalcification.</li>
<li>The sections show a picture of plasma cell myeloma, composed of
hypocellular marrow (45%) for her age. Interstitial distribution of
plasma cells, comprised 10-20% nucleated cells in CD138 immunostain. The
plasam cells also show lambda light chain restriction. M/E ratio about
1/4~5, hyperplasia of erythroid and hypoplasia of myeloid series,
hyperplastic megakaryocytes with focal mononucleation and
hyposegmentation and no increase of blast, which highlights by CD61,
CD71, CD34, CD117 and MPO immunostains. Follow up.</li>
</ul></li>
<li>2021-12-30 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — myeloma.</li>
<li>IHC stains: CD117: &lt;2%; CD34: &lt;2 %; MPO: &lt;5%, CD71: 10-20
%, CD138: 70-80%, and light chain of kappa and lambda show a predominant
lambda sub-population. (of the nucleated cells).<br />
</li>
<li>Specimen submitted in formalin consists of 1 piece(s) of tan, rod
shape bone marrow tissue measuring 1.6 x 0.2 x 0.2 cm. All for section
in one cassette after decalcification.<br />
</li>
<li>Section shows piece(s) of bone marrow with 70% cellularity and M:E
ratio of approximately 5:1. Three cell lineages are present with a
predoimant plasmcytoid cells. Megakaryocytes are adequate in
number.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Hematopoietic Progenitor Cell (HPC) Ratio
<ul>
<li>2022-05-31 0.20 %<br />
</li>
<li>2022-05-30 0.33 %<br />
</li>
</ul></li>
<li>CD45 + Total leukocyte
<ul>
<li>2022-05-31 309430 /uL</li>
<li>2022-05-31 55666 /uL</li>
<li>2022-05-30 372040 /uL</li>
</ul></li>
<li>CD34+ Count
<ul>
<li>2022-05-31 4940 /uL</li>
<li>2022-05-31 102 /uL</li>
<li>2022-05-30 8140 /uL</li>
</ul></li>
<li>%CD34+
<ul>
<li>2022-05-31 1.60 %<br />
</li>
<li>2022-05-31 0.18 %</li>
<li>2022-05-30 2.19 %</li>
</ul></li>
<li>WBC
<ul>
<li>2022-05-31 62.43 *10^3/uL<br />
</li>
<li>2022-05-31 65.69 *10^3/uL<br />
</li>
<li>2022-05-30 56.24 *10^3/uL<br />
</li>
<li>2022-05-30 54.79 *10^3/uL<br />
</li>
<li>2022-05-29 21.76 *10^3/uL<br />
</li>
<li>2022-05-28 4.57 *10^3/uL<br />
</li>
<li>2022-05-26 3.07 *10^3/uL<br />
</li>
<li>2022-05-25 7.57 *10^3/uL<br />
</li>
<li>2022-05-23 21.61 *10^3/uL<br />
</li>
<li>2022-05-19 7.44 *10^3/uL<br />
</li>
<li>2022-04-22 18.42 *10^3/uL<br />
</li>
<li>2022-04-15 10.56 *10^3/uL<br />
</li>
<li>2022-04-01 12.93 *10^3/uL<br />
</li>
<li>2022-03-25 8.36 *10^3/uL<br />
</li>
<li>2022-03-11 9.42 *10^3/uL<br />
</li>
<li>2022-03-04 6.47 *10^3/uL<br />
</li>
<li>2022-02-18 12.45 *10^3/uL<br />
</li>
<li>2022-02-11 4.78 *10^3/uL<br />
</li>
<li>2021-12-22 5.68 *10^3/uL<br />
</li>
</ul></li>
<li>HGB
<ul>
<li>2022-05-31 9.9 g/dL<br />
</li>
<li>2022-05-31 10.4 g/dL<br />
</li>
<li>2022-05-30 10.2 g/dL<br />
</li>
<li>2022-05-30 10.8 g/dL<br />
</li>
<li>2022-05-29 11.6 g/dL<br />
</li>
<li>2022-05-28 11.4 g/dL<br />
</li>
<li>2022-05-26 10.8 g/dL<br />
</li>
<li>2022-05-25 11.2 g/dL<br />
</li>
<li>2022-05-23 12.4 g/dL<br />
</li>
<li>2022-05-19 12.9 g/dL<br />
</li>
<li>2022-04-22 11.3 g/dL<br />
</li>
<li>2022-04-15 12.0 g/dL<br />
</li>
<li>2022-04-01 11.2 g/dL<br />
</li>
<li>2022-03-25 10.8 g/dL<br />
</li>
<li>2022-03-11 10.2 g/dL<br />
</li>
<li>2022-03-04 9.4 g/dL<br />
</li>
<li>2022-02-18 9.0 g/dL<br />
</li>
<li>2022-02-11 8.8 g/dL<br />
</li>
<li>2021-12-22 8.7 g/dL<br />
</li>
</ul></li>
<li>PLT
<ul>
<li>2022-05-31 73 *10^3/uL<br />
</li>
<li>2022-05-31 93 *10^3/uL<br />
</li>
<li>2022-05-30 131 *10^3/uL<br />
</li>
<li>2022-05-30 153 *10^3/uL<br />
</li>
<li>2022-05-29 198 *10^3/uL<br />
</li>
<li>2022-05-28 230 *10^3/uL<br />
</li>
<li>2022-05-26 289 *10^3/uL<br />
</li>
<li>2022-05-25 348 *10^3/uL<br />
</li>
<li>2022-05-23 408 *10^3/uL<br />
</li>
<li>2022-05-19 420 *10^3/uL<br />
</li>
<li>2022-04-22 482 *10^3/uL<br />
</li>
<li>2022-04-15 354 *10^3/uL<br />
</li>
<li>2022-04-01 413 *10^3/uL<br />
</li>
<li>2022-03-25 424 *10^3/uL<br />
</li>
<li>2022-03-11 394 *10^3/uL<br />
</li>
<li>2022-03-04 319 *10^3/uL<br />
</li>
<li>2022-02-18 329 *10^3/uL<br />
</li>
<li>2022-02-11 290 *10^3/uL<br />
</li>
<li>2021-12-22 303 *10^3/uL</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-19 cyclophosphamide 2500mg/m2</li>
<li>2022-02-11 ~ 2022-04-22 - bortezomib 1.3mg/m2 (day 4, day 7) (8
times) within VTD (bortezomib + thalidomide + dexamethasone)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-585" class="section level1">
<h1>700841543</h1>
<div id="section-586" class="section level2">
<h2>220613</h2>
<p>{gastric cancer with colon mets s/p subtotal gastrectomy and partial
T-colectomy}</p>
<p>[subjective]</p>
<ul>
<li>2020-08-03
<ul>
<li>fasting epigastric discomfort for 1-2 weeks</li>
<li>fullness(-), nausea(-)</li>
</ul></li>
<li>2021-04-14
<ul>
<li>epigasrtalgia for for 2-3 months</li>
<li>mild response to strocain and h2 blocker from other hopsital but
still discomfort</li>
<li>hunger pain (+) improving after intake</li>
</ul></li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-11 CT - abdomen, pelvis
<ul>
<li>S/P gastric operation. Small bowel ileus with massive ascites.</li>
<li>Bil. liver cysts (up to 2.6cm).</li>
</ul></li>
<li>2022-05-09 Abdomen - standing (diaphragm)
<ul>
<li>Presence of ileus.</li>
</ul></li>
<li>2022-05-09 Abdominal Ultrasonography
<ul>
<li>suspected liver parenchymal disease</li>
<li>liver cysts</li>
<li>pancreas obscured</li>
<li>spleen obscured</li>
<li>ascites: moderate to large amount</li>
</ul></li>
<li>2022-04-22 CT - lung/mediastinum/pleura
<ul>
<li>s/p partial gastrectomy with massive ascites. Stationary.</li>
<li>regression of right lower lobe opacity, previous infection is
favored.</li>
</ul></li>
<li>2022-04-14 CT - abdomen, pelvis
<ul>
<li>Gastric cancer s/p operation. Massive ascites. Small bowel
ileus.</li>
<li>A patchy density (1.7mm) at RLL.</li>
</ul></li>
<li>2022-01-14 CT - abdomen, pelvis
<ul>
<li>s/p subtotal gastrectomy</li>
<li>there are several hepatic cysts in both lobes and the largest one
2.2 cm in size</li>
</ul></li>
<li>2021-10-07 CT - abdomen, pelvis
<ul>
<li>Gastric cancer s/p operation.</li>
<li>A nodule (3.7mm) at LUL.</li>
</ul></li>
<li>2021-10-05 CXR
<ul>
<li>Blurring of right heart border is noted.</li>
</ul></li>
<li>2021-06-21 Standing KUB; 2021-06-18 KUB
<ul>
<li>Small bowel obstruction is suspected. Please correlate with contrast
enhanced CT.</li>
<li>S/P ileostomy? please correlate with clinical condition.</li>
</ul></li>
<li>2021-05-25 Small bowel series
<ul>
<li>Dilatation of proximal small bowel. Collapse of distal ileum and
colon</li>
<li>The transmit time is less than 24 hours.</li>
</ul></li>
<li>2021-05-07 patho - stomach subtotal/total (tumor)
<ul>
<li>pathologic diagnosis
<ul>
<li>Stomach, subtotal gastrectomy — Poorly cohesive carcinoma
(signet-ring cell carcinoma)<br />
</li>
<li>Lymph nodes, LN dissection — Metastatic carcinoma (3/32)<br />
</li>
<li>AJCC Pathologic staging — pT4aN2M1, stage IV</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Poorly cohesive carcinoma, signet-ring cell type
(signet-ring cell carcinoma) (Lauren classification: diffuse type)<br />
</li>
<li>Histologic grade: Poorly differentiation (G3)<br />
</li>
<li>Depth of tumor invasion: Tumor invades the serosa<br />
</li>
<li>Margins: Free; Distance from closest margin: 3 mm (radial
margin)<br />
</li>
<li>Perineural invasion: Present<br />
</li>
<li>Lymphovascular space invasion: Present<br />
</li>
<li>Regional lymph nodes: Metastatic carcinoma (3/32)<br />
</li>
<li>Extracapsular extension: Absent<br />
</li>
<li>Omentum: Free of tumor invasion<br />
</li>
<li>Additional pathologic findings: Metastatic carcinoma of T-colon
(S2021-07224)<br />
</li>
<li>Pathologic Staging: pT4aN2M1; Stage IV<br />
</li>
<li>IHC (S2021-06134): HER2(-), MLH1(+), PMS2(+), MSH2(+), MSH6(+)<br />
</li>
</ul></li>
</ul></li>
<li>2021-05-07 patho - colon segmental resection for tumor
<ul>
<li>Transverse colon, partial resection — Poorly cohesive carcinoma
(signet-ring cell carcinoma), metastatic</li>
<li>Histology Grade: Poorly differentiated<br />
</li>
</ul></li>
<li>2021-04-29 CT - whole abdomen, pelvis
<ul>
<li>imaging stage: T1aN0M0, stage I.</li>
</ul></li>
<li>2021-04-20 patho - stomach biopsy
<ul>
<li>greater curvature side of lower body - adenocarcinoma.</li>
<li>IHC stains: CK highlights neoplastic cells. Her2/neu: negative
(score=0).</li>
</ul></li>
<li>Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA Classification grade B</li>
<li>Esophageal phlebectasia, lower esophagus</li>
<li>Gastric ulcer, GC, lower body, s/p Bx</li>
<li>Atrophic gastritis, antrum</li>
</ul></li>
<li>Suggestion：
<ul>
<li>Pending Bx and CLO</li>
<li>PPI tx</li>
</ul></li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CA125
<ul>
<li>2022-05-16 114.7 U/mL</li>
<li>2022-04-25 95.9 U/mL</li>
<li>2022-04-18 139.0 U/mL</li>
<li>2022-03-14 157.8 U/mL</li>
<li>2022-02-19 102.4 U/mL</li>
<li>2022-01-11 31.0 U/mL</li>
<li>2021-12-21 17.7 U/mL</li>
<li>2021-11-16 19.9 U/mL</li>
<li>2021-10-06 18.7 U/mL</li>
<li>2021-09-06 31.5 U/mL</li>
<li>2021-08-27 26.7 U/mL</li>
<li>2021-07-27 34.5 U/mL</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-06-23 Infectious disease
<ul>
<li>This 64-year-old man patient is a case of Gastric cancer with lymph
nodes metastasis s/p subtotal gastrectomy with T-colectomy and D2+ lymph
node dissection, pT4aN2M1, stage IV. Chemotherapy with FOLFOX (Oxalip
65mg/m2, LV 400mg/m2, 5FU 2400mg/m2) on 2021/06/16~2021/06/18. IP
chemotherapy with 5FU(400mg/m2) + Gentamycin 40mg + Rolikan 40ml on
2021/06/16. Abdominal pain with Peritonitis with ascites/C showed
Acinetobacter ursingii and Candida parapsilosis bacteria. Abdominal pain
improving after antibiotic with Flumarin 1000mg iv q8h since 2021/06/18.
Now, for evaluate antibiotic therapy for ascites/C showed Acinetobacter
ursingii and Candida parapsilosis bacteria.</li>
<li>Antibiotics with tapimycin 4.5g iv q8h and diflucan 200mg iv qd is
suggested.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-05-06 surgery
<ul>
<li>subtotal gastrectomy with LN 1,3,4,5,6,7,8,9,110,12a and 14v
dissection</li>
<li>partial T-colectomy</li>
<li>IPCT with Mitomycin C 25mg/m2(42mg) for 2 hrs</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-25 ~ 2021-11-26 - completed RT to the preOP tumor bed and
adjacent lymphatic drainage area: 45 Gy/ 25 fx</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-07 ~ 2022-03-15 - FOLFOX (6 times)</li>
<li>2021-10-26 ~ 2021-11-23 - 5-Fu (4 times), CCRT</li>
<li>2021-06-16 ~ 2021-10-07 - FOLFOX (6 times)</li>
<li>2021-05-07 - 5-Fu 500mg/m2(839mg) day 1~5, leucovorin 34mg day 1,
gentamicin</li>
<li>2021-05-06 - mitomycin-C, gentamicin</li>
</ul></li>
</ul>
<div id="section-587" class="section level3">
<h3>==========</h3>
</div>
<div id="section-588" class="section level3">
<h3>2022-06-13</h3>
<ul>
<li>The patient presented to the emergency department (2022-06-11) with
symptoms of severe upper abdominal pain (VAS 9, 3 days of on and off
abdominal pain with yellow vomitus once per day). Small bowel
obstruction has been listed as an active problem since his
admission.</li>
<li>Previously, small bowel obstruction was noted on KUB 2021-06 and
Small Bowel Series 2021-05-25, which showed proximal small bowel
dilatation and collapse of the distal ileum and colon.</li>
<li>Proximal small bowel obstruction (duodenum, proximal jejunum) can
cause severe nausea and vomiting; as a result, patients typically cease
taking in food or liquids orally.</li>
<li>Gaslan (dimethylpolysiloxane) 40mg TID PO and Mopride (mosapride
citrate) 5mg TID PO have been prescribed since 2022-06-06.</li>
<li>In the past few weeks, ascites and pitting edema have been observed;
if the condition persists, some diurectics might be helpful.</li>
<li>Heart rate 90 -&gt; 120 on 2012-06-12, please keep monitoring the
state of hemodynamics.</li>
<li>All the oral drugs in active prescription can be administered with
nasogastric tube.</li>
</ul>
</div>
<div id="section-589" class="section level3">
<h3>2021-08-27</h3>
<ul>
<li>recent lab data unremarkable, liver and kidney functions no
abnormality, overall not bad.</li>
<li>2021-08-27 around 10:30 visiting the patient (accompanied by his
wife)
<ul>
<li>he felt soreness/ache (not pain) in his left arm during the first
30min when premedication being administrated in last three
hospitalization. rule out left arm compression or cruch caused symptom.
cause remains unknown.</li>
<li>mild oral mucosa damage, some triamcinolone acetonide oral ointment
(nincort or oralog, the former is available now) for local treatment
might be of help.</li>
<li>mild diarrhea, not often, could be monitored with PRN antidiarrheal
agent e.g. loperamide (2mg/cap is available now)</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-590" class="section level1">
<h1>701350720</h1>
<div id="section-591" class="section level2">
<h2>220613</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-27 MRI - brain
<ul>
<li>Finding
<ul>
<li>Mild increases in the size of the enhacning nodular lesions
identified in previous MTI on 20220420.</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>No midline shift, nor mass effect.</li>
<li>Focal T1 and T2 hypintensity lesion in right temporal skull, r/o
hemangioma. Stationary as compared with MRI on 20220304.</li>
<li>Mottled T2-hyperintensity in left pooly aerated mastoid, indicating
mastoiditis.</li>
</ul></li>
<li>IMP: Multiple brain metasases. Mild progression as comapred with MRI
on 20220420.</li>
</ul></li>
<li>2022-05-26 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Soft tissue mass at left lower lobe up to 4.cm in largest dimension
with attachment with left hemithorax is found.</li>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Enlarged left thyroid up to 4.6cm in largest dimension. Stable.</li>
<li>There is bilateral pleural effusion.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered. In progression.</li>
<li>One fillling defect is found at right pulmonary trunk is found.
Pulmonary embolism is considered.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Low density lesions are found at both lobes of liver is found. In
comparison with CT dated on 2022-03-03, the lesions are stationary.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Left lower lobe lung cancer with stationary size.</li>
<li>However, the bone meta and liver meta progressed.</li>
<li>Right pulmonary embolism is also noted. Suggest further
treatment.</li>
</ul></li>
</ul></li>
<li>2022-04-20 MRI - brain
<ul>
<li>Findings
<ul>
<li>No remarkable finding of cerebrospinal fluid spaces.</li>
<li>A total of 5 enhancing dots at subcortical region at bilateral
frontal lobes, left parietal lobe, left occipital lobe and left basal
ganglion. Multiple brain metasatses are considered.</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>No midline shift, nor mass effect.</li>
<li>Focal T1 and T2 hypintensity lesion in right temporal skull, r/o
hemangioma. Stationary as compared with MRI on 20220304.</li>
<li>Mottled T2-hyperintensity in left pooly aerated mastoid, indicating
mastoiditis.</li>
</ul></li>
<li>IMP: Multiple brain metasases as described. Progressive change as
comapred with MRI on 20220304.</li>
</ul></li>
<li>2022-04-14 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Nodular lesion at left thyroid up to 5.1cm in largest dimension is
found. Stationary.</li>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Lobulated mass at left lower lobe up to 3.1cm in largest dimension
is found. In comparison with CT dated on 2022-03-03, the lesion
regressed.</li>
<li>Spiculated nodule at left upper lobe up to 1.04cm is found.
Stable.</li>
<li>No evidence of bilateral pleural effusion.</li>
<li>Small lymph nodes are found in the mediastinum.</li>
<li>Tiny nodular lesion at right lower lobe up to 0.2cm in largest
dimension.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>Nodular lesion at S7 of liver up to 0.8cm in largest dimension is
found.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>LEFT LOWER LOBE mass with left upper lobe and right lower lobe lung
meta and bone meta. In regression.</li>
<li>Left thyroid mass. 5.1cm</li>
</ul></li>
</ul></li>
<li>2022-03-04 MRI - brain
<ul>
<li>Findings
<ul>
<li>No remarkable finding of cerebrospinal fluid spaces.</li>
<li>A small intra-axial enhancing dot at corticomedullary juction region
of left anterior frontal lobe, much maller than that on 20220112
MRI.</li>
<li>A new enhancing dot at corticomedullary juction region of left
posterior frontal lobe. suspected metastasis.</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>No midline shift, nor mass effect.</li>
<li>Focal T1 and T2 hypintensity lesion in right tmeporal skull,
suspected hemangioma. Stationary as compared with MRI on 20210112.</li>
<li>No remarkable finding of bilateral orbital contents and optic
nerves.</li>
<li>No remarkable finding of nasopharynx visible in these images.</li>
<li>Mottled T2-hyperintensity in left pooly aerated mastoid, indicating
mastoiditis.</li>
<li>Diffuse mild mucosal thickening in bilateral paranasal sinsues,
indicating chronic paranasal sinusitis.</li>
</ul></li>
<li>IMP:
<ul>
<li>Regression of the metasattic lesion at left frontal lobe.</li>
<li>However, a suspicious metastatic lesion appears at left posterior
frontal lobe.</li>
</ul></li>
</ul></li>
<li>2022-03-03 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Thyroid nodule at left side up to 4.6cm in largest dimension.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Cavitatory lesion at left lower lobe up to 3.4cm in largest
dimension. Reactive pleural effusion is found. In comparison with CT
dated on 2022-01-13, the tumor regressed in size.</li>
<li>Diffuse Sclerotic and lytic changes of the bony structure is found.
Bony metastasis is considered.</li>
<li>Diffuse tiny nodules scattered at both lungs is found. Lung meta is
considered. In regression.</li>
<li>One spluclated nodule at left upper lobe up to 9.5mm in largest
dimension. stable.</li>
<li>Chains of lymph nodes are found at AP window and subcarinal region.
Stationary.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>Left lower lobe lung cancer with mediatinal lymphadenopathy,
bilateral lung meta, bone meta.</li>
<li>The ovarall tumor extension and size are in regression.</li>
<li>Right Thyroid nodule. Suggest follow up.</li>
</ul></li>
</ul></li>
<li>2022-02-25 MRI - T-spine
<ul>
<li>Findings
<ul>
<li>Numerous enhancing lesions involving every vertebral body of
thoracic spine, causing vertebral body compression and spinal canal
stenosis due to extensive soft tissue mass, most svere at T3-4 and T9-10
with cord compression and ill-defined intramedullary
T2-hyperintensity.</li>
<li>Multiple metastatic lesions in bialetrla ribs.</li>
<li>A huge soft tissue tumor in left lower lung, with left pleural
effusion.</li>
<li>Several T2-hyperintense lesions in right lobe of liver. D/D:
metastases or cysts. -IMP:</li>
<li>C/W lung cancer with diffuse bony metastases in ribs and thoracic
spine (with compressive myelopathy at T3-4 and T9-10 levels).</li>
</ul></li>
</ul></li>
<li>2022-01-09 Tc-99m MDP whole body bone scan
<ul>
<li>Highly suspected multiple bone metastases in multiple C-, T- and
L-spine, sacrum, sternum, bilateral rib cages, scapulae, and bilateral
multiple pelvic bones.</li>
</ul></li>
<li>2022-01-13 CT - lung/mediastinum/pleura
<ul>
<li>Findings
<ul>
<li>Chest:
<ul>
<li>Soft tissue nodule at left lobe thyroid up to 5.3cm in largest
dimension with tracheal deviation to right side is found.
Stationary.<br />
</li>
<li>Lobulated nodule at left lower lobe up to 7.7cm in largest dimension
is found. In comparison with CT dated on 2021-12-21, the lesion is
slightly enlarged.<br />
</li>
<li>Mild left pleural effusion is found.</li>
<li>Spicualted nodule at left upper lobe up to 1.0cm in largest
dimension is found. In regression.</li>
<li>Several tiny nodules at both lungs. Stationary in size and
numbers.</li>
<li>Enlarged lymph nodes are found at AP window and paratracheal
region.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
<li>No evidence of abnormal soft tissue mass at pelvic cavity.</li>
<li>No definite inguinal or pelvic sidewall LAP</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>LEFT LOWER LOBE lung cancer with bilateral lung meta, extensive bone
meta.</li>
<li>The primary tumor enlarged slightly. The lung meta are
statinary.</li>
<li>Mediastinal lymph nodes, in slighlty enlargement.</li>
</ul></li>
</ul></li>
<li>2022-01-12 MRI - brain
<ul>
<li>A small intra-axial enhancing nodular lesion, about 5 mm, with mild
perifocal edema in left frontal lobe, indicating metastasis.</li>
</ul></li>
<li>2021-12-28 CXR
<ul>
<li>A nodular opacity projecting in the left lower lung is noted that is
c/w lung cancer. Please correlate with CT.</li>
</ul></li>
<li>2021-12-28 Patho - lung wedge biopsy
<ul>
<li>Lung, LLL, CT-guide biopsy—adenocarcinoma, moderately
differentiated<br />
</li>
<li>The immunohistochemical stains reveal TTF-1(+), Napsin A(+), p40(-),
and CD56(-). The results are supportive for the diagnosis.</li>
</ul></li>
<li>2021-12-27 MRI - L-spine
<ul>
<li>IMP: Bony metastasis involving L2, L4, L5 and S1 vertebral bodies
and bilateral iliac wings. Mild lumbar spondylosis.</li>
</ul></li>
<li>2021-12-21 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Lung Carcinoma</li>
<li>Impression (Imaging stage): T4N2M1c, stage IVB</li>
</ul></li>
<li>2021-12-26 CXR
<ul>
<li>an oval-shaped mass over LLL, high possibly of a malignant lesion,
suggest do CT study</li>
<li>Displacement of the tracheal axis to right at thoracic inlet
and</li>
<li>superior mediastinum probably due to enlarged thyroid gland or</li>
<li>lymph node enlargement</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>PD-L1
<ul>
<li>2022-01-06
<ul>
<li>Pathologic Report for PD-L1 (SP142) Assay (Ventana) S2021-19566
<ul>
<li>Tumor type: Adenocarcinoma<br />
</li>
<li>Tumor location: Lung<br />
</li>
<li>Testing assay: SP142 Assay (Ventana)<br />
</li>
<li>Testing platform: BenchMark XT<br />
</li>
<li>Detection system: OptiView DAB IHC Detection Kit and OptiView
Amplification Kit<br />
</li>
<li>Control slide result: Pass,<br />
</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells): Yes,</li>
</ul></li>
<li>Result:
<ul>
<li>Tumor cell (TC) staining assessment: TC category: TC &lt; 1%<br />
</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC &lt; 1%<br />
</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.<br />
</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-28 Orthopedics
<ul>
<li>Q
<ul>
<li>for suspected lumbar nerve compression evaluation.</li>
<li>This is a 60 year-old male, who denied having any history. He
complaimts low back pain with radiation to right thigh after trauma 6 Ms
ago, and limping gait, he came to our Ortho OPD follow-up, then he
received the L-spine MRI on 2021/12/27. However, he was admitted for LLL
lung cancer T4N2M1c stage IVB, intrathoracic goiter evaluation. So we
need your help for suspected lumbar nerve compression evaluation.</li>
</ul></li>
<li>A
<ul>
<li>The MRI revealed bony metastasis involving L2, L4, L5 and S1
vertebral bodies and bilateral iliac wings. No nerve compression was
noticed at present.</li>
<li>Suggestion:
<ul>
<li>Tx of lung ca as your specialty</li>
<li>Consult radiooncologist for possible radiotherapy, if
indicated.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-01-26 ~ undergoing - carboplatin + pemetrexed + BGB-A317
tislelizumab + BGB-A1217 ociperlimab (BGB trial)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-592" class="section level1">
<h1>701376921</h1>
<div id="section-593" class="section level2">
<h2>220613</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-26 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Metastatic adenocarcinoma, consistent with
colonic primary</li>
<li>The specimen submitted consists of three strips of yellow gray soft
tissue, labeled liver, measuring up to 0.4 x 0.1 x 0.1 cm. All for
section.</li>
<li>The secvtions show metastastic adenocarcinoma, composed of columnar
neoplastic cells, arranged in glandular and cribriform patterns with
desmoplastic stromal reaction.</li>
<li>IHC, tumor cells reveal: CK7(-), CK20(+), and CDX2(+). The finding
is consistent with colonic primary.</li>
</ul></li>
<li>2022-05-23 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Liver tumors, S4-S5-S8 and S6, suspected hepatocellular
carcinoma</li>
<li>Hepatic tumor encasing right portal vein</li>
<li>Suspect left partial hepatectomy</li>
<li>Suspect gallbladder adenomyomatosis</li>
<li>Gall stone</li>
<li>Splenomegaly</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image for hepatic tumor survey</li>
<li>Follow liver function test and AFP</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-24 Gastroenterology
<ul>
<li>Q
<ul>
<li>The 61 y/o woman has S-colon adenocaricnoma with liver and lung
metastases s/p treatment in ShuangHo Hospital. She transfered to our OPD
for secondary opinion. Due to liver function impairmenet, so we need
your help for management.</li>
<li>O
<ul>
<li>GOT 33 -&gt; 113</li>
<li>GPT 17 -&gt; 153.</li>
<li>Abd echo was done on 20220523, report showed one huge hyperechoic
lesion with hypoechoic rim, at least 13.16x12.71cm in size, was noted at
S4, S5 and S8. One 4.44cm hyperechoic lesion was noted at S6, Hepatic
lobe S2 and S3 was invisible.</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>61F, a case of S-colon adenocaricnoma with liver and lung metastases
s/p treatment in ShuangHo Hospital</li>
<li>S
<ul>
<li>Conscious clear</li>
</ul></li>
</ul></li>
<li>O
<ul>
<li><span class="citation">@Abdominal</span> echo (20220523)
<ul>
<li>Liver tumors, S4-S5-S8 and S6, suspected hepatocellular
carcinoma</li>
<li>Hepatic tumor encasing right portal vein</li>
<li>Suspect left partial hepatectomy</li>
<li>Suspect gallbladder adenomyomatosis</li>
<li>Gall stone</li>
<li>Splenomegaly</li>
</ul></li>
<li><span class="citation">@LAB</span>
<ul>
<li>AST: 33 (5/3) -&gt; 99 (5/19) -&gt; 113 (5/24)<br />
</li>
<li>ALT: 17 (5/3) -&gt; 102 (5/19) -&gt; 153 (5/24)<br />
</li>
<li>Bilirubin total: 0.57 (5/20)<br />
</li>
<li>Bilirubin direct: 0.18 (5/20)<br />
</li>
<li>Albumin: 3.5 (5/20)<br />
</li>
<li>Creatinine: 0.73 (5/19)<br />
</li>
<li>Alkaline phosphatase: 365 (5/19)<br />
</li>
<li>CA-199: 242.62<br />
</li>
<li>CEA: 183.415</li>
</ul></li>
</ul></li>
<li>A:
<ul>
<li>Abnormal liver function, suspect hepatic tumor related</li>
</ul></li>
<li>P:
<ul>
<li>Check Anti HAV IgM, HBsAg, anti-Hbs Ab, anti-Hbc Ab, Anti HCV Ab to
exclude viral hepatitis</li>
<li>Check HBeAg, Anti HBe Ab, HBV DNA</li>
<li>Regular/close monitor AST/ALT, TBI, PT, APTT, Ammonia, GGT, ALP</li>
<li>Avoid hepatic toxic agent if possible (or adjust dose), simplify
medication</li>
<li>Silymarin 1#~2# TID (GOT and GPT &gt;= 2X ULN covered by NHI)</li>
<li>If patient had symptoms of abdominal fullness, may arrange abdominal
echo for ascites evaluation (consider ascites tapping if available)</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-27 ~ undergoing - FOLFIRI + ramucirumab</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-594" class="section level1">
<h1>700148929</h1>
<div id="section-595" class="section level2">
<h2>220610</h2>
<p>{high grade B-cell lymphoma}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-09 Nasopharyngoscopy
<ul>
<li>Infiltrative soft tissue lesion involving R Meckel’s cave, superior
orbital fissure, foramen rotundum, pterygopalatine fossa, and also
foramen ovale, along the course of trigeminal nerve. Suspect Tolosa-Hung
syndrome, lymphoma or sarcoidosis.</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
<li>2022-06-02 Nerve Conduction Velocity (NCV), Electromyography (EMG)
<ul>
<li>Findings
<ul>
<li>MNCV: no recordable response in left peroneal nerve and left ulnar
nerve; decreased CMAPs amplitude of left median, right peroneal and
bilateral tibial nerves; slow motor conduction velocity of left median,
left peroneal and right ulnar nerve across elbow</li>
<li>SNCV: no recordable response in left ulnar and sural nerves; delayed
SNAPs onset latency and decreased amplitude of right sural nerve; slow
sensory conduction velocity of right ulnar and sural nerves</li>
<li>F-wave: no recordable response of left ulnar and peroneal nerves;
delayed responses of left median, right peroneal and right tibial
nerves</li>
<li>H-reflex: no recordable response of left lower limb; delayed
response of right lower limb</li>
</ul></li>
<li>Conclusion
<ul>
<li>This NCV study suggested left lower cervical and bilateral
lumbosacral radiculopathy (worse in the left), left median axonal
neuropathy, right ulnar neuropathy across elbow and right ulnar
neuropathy.</li>
<li>Please correlate with clinical features.</li>
</ul></li>
</ul></li>
<li>2022-05-27 MRA - brain
<ul>
<li>Findings
<ul>
<li>brain atrophy with prominent sulci, fissures and dilated
ventricles.</li>
<li>multiple nonspecific hyperintense patches in T2WI at bilateral
periventricular white matter, leukoaraiosis is considered.</li>
<li>no abnormal bright up on DWI to suggest recent infarct.</li>
<li>increased soft tissue with abnormal enhancement involving right
Meckel’s cave, with extension to superior orbital fissure, foramen
rotundum, pterygopalatine fossa, and also to foramen ovale, along the
course of trigeminal nerve. This is not obviously seen in previous MRI
on 20220221. Possible etiology may include: inflammatory (Tolosa-Hunt
syndrome), tumor (lymphoma, less likely: trigeminal neuroma,
meningioma), or sarcoidosis.</li>
<li>TOF MRA shows patent and unremarkable intracranial arteries.</li>
</ul></li>
<li>Impression
<ul>
<li>Infiltrative soft tissue lesion involving right Meckel’s cave,
superior orbital fissure, foramen rotundum, pterygopalatine fossa, and
also foramen ovale, along the course of trigeminal nerve. Suspect
Tolosa-Hung syndrome, lymphoma or sarcoidosis.</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
</ul></li>
<li>2022-04-18 Nerve Conduction Velocity (NCV), Electromyography (EMG)
<ul>
<li>Findings
<ul>
<li>The facial NCV and blink reflex study showed:
<ul>
<li>Facial NCV (ENOG) : 0% R/L amplitude ratio</li>
<li>Absent signal in right facial nerve.</li>
</ul></li>
<li>Absent ipsilateral R1 by right trigeminal nerve stimulation</li>
<li>Absent ipsilateral R2 &amp; Absent contralateral R2 by right
trigeminal nerve stimulation.</li>
</ul></li>
<li>Conclusion
<ul>
<li>These findings suggest right facial neuropathy.</li>
<li>Advise clinical correlation.</li>
</ul></li>
</ul></li>
<li>2022-04-13 Patho - interveterbral disc
<ul>
<li>Bone and joint, vertebra, cervical 3-4, 4-5 ,5-6 , anterior cervical
discectomy — Confirmed</li>
<li>Specimen submitted in formalin consists of multiple pieces of tan,
irregular tissue with the largest piece measuring 1.5 x 1 x 0.5 cm.
Representative tissue for section in one cassette after
decalcification.</li>
<li>Section shows pieces of bone, degenerated ligament, and
cartilage.</li>
</ul></li>
<li>2022-04-09 CT - brain
<ul>
<li>Brain atrophy.</li>
<li>No evidence of ICH, SAH or SDH.</li>
<li>No evidence of space occupying lesion in the brain parenchyma is
found.</li>
</ul></li>
<li>2022-02-21 MRA - brain
<ul>
<li>Mild Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2022-01-28 CT - lung/mediastinum/pleura
<ul>
<li>Minimal left breast soft tissue at lower part, in regression.</li>
<li>LEFT LOWER LOBE nodule. Stable, old insult is favored.</li>
</ul></li>
<li>2021-12-10 MRI - c-spine
<ul>
<li>Degenerative spinal and disc disease.</li>
<li>Herniated disc at posterior central C3-4 level, causing moderate
adjacent spinal cord compression.</li>
<li>Mild C4-5, C5-6, C6-7 spinal cord compression.</li>
<li>Bilateral C4-5, C5-6, C6-7 neuroforaminal narrowing.</li>
</ul></li>
<li>2021-10-12 CT - abdomen, pelvis
<ul>
<li>Residual nodule at left breast, residual tumor activity is
considered.<br />
</li>
<li>No evidence of lymphadenopathy other than left breast.</li>
</ul></li>
<li>2021-06-19 CT - lung/mediastinum/pleura
<ul>
<li>Lymphoma s/p C/T with C/T</li>
<li>Regression of bilateral breast mass with residual mass at left
breast and no visible lymphadenopathy in the current study.</li>
</ul></li>
<li>2021-04-07 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the left nasal cavity, bilateral breasts,
and left lobe of the liver, probably lymphoma with involvement of
multiple extralymphatic organs.<br />
</li>
<li>Glucose hypermetabolism in the right maxilla, bilateral femurs,
tibiae, and left fibia, probably lymphoma with involvement of the bone
marrows.<br />
</li>
<li>Increased FDG accumlation in bilateral renal pelvis and colon,
probably physiological uptake of FDG.</li>
<li>Lymphoma, stage IV (AJCC 8th ed.), by this F-18 FDG PET/CT
scan.</li>
</ul></li>
<li>2021-03-24 Patho - breast biospy
<ul>
<li>diagnosis
<ul>
<li>Breast, right, core biopsy — high grade B-cell lymphoma</li>
<li>Breast, left, core biopsy — high grade B-cell lymphoma</li>
</ul></li>
<li>Section shows cores of breast tissue with diffusely infiltration of
large lymphoid cells.</li>
<li>IHC: CD20(+), CD3(-), CD10(+), BCL2(+), BCL6(+), MUM1(+), cMYC(-),
CD5(-), and CD30(-). The Ki-67 is about 80%.</li>
<li>The results are in favor of high grade B-cell lymphoma.</li>
</ul></li>
<li>2021-03-16 CT - lung/mediastinum/pleura
<ul>
<li>two lt lung nodules up to 6 mm, stationary, favor intrapulmonary
LNs.</li>
<li>regression of Rt inguinal LNs as compare with CT study on
20201027.</li>
<li>post treatment change with calcification in anterior
mediastinum.</li>
<li>bilateral breast masses.</li>
</ul></li>
<li>2020-10-27 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Stationary right inguinal lymph nodes.</li>
<li>Liver cysts.</li>
</ul></li>
<li>2020-06-29 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Some LNs (up to 6mm) at bil. inguinal regions.</li>
</ul></li>
<li>2020-04-30 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy - Hypocellularity and free from lymphoma
involvement<br />
</li>
<li>Sections show 5-20 % cellularity. The M/E ratio is about 1/1 - 2/3.
Megakaryocytes are found about 0-1/HPF. No increase of blasts is noted.
There are no granulomas,foreign malignant cells, nor aggregation of
atypical lymphocytes.</li>
</ul></li>
<li>2020-02-18 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Stationary right inguinal lymph nodes as compare with CT study on
20180802.</li>
<li>Liver cysts.</li>
</ul></li>
<li>2019-10-11 Surgical pathology Level IV
<ul>
<li>In-hospital
<ul>
<li>pathologic diagnosis - Breast, right, excision - Follicular
lymphoma</li>
<li>Histology type: B-cell neoplasms, Follicular lymphoma</li>
<li>Follicular lymphoma - grading: 2, predominantly diffuse pattern</li>
<li>IHC: CK(-), CD3(-), CD20(+), CD10(+), BCL2(+), BCL6(+), CD5(-),
CD21(-), CyclinD1(-), SOX11(-), and cMYC(-)</li>
</ul></li>
<li>Dr. KungChao Chang
<ul>
<li>Breast, right, excision: Extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma)</li>
<li>Sections show breast parenchyma diffusely replaced by small to
medium-sized lymphoid tumor cells with slightly irregular nuclei,
inconspicuous nucleoli and focally abundant pale cytoplasm.
Lymphoepithelial lesions are present, highlighted by cytokeratin
immunostain.</li>
<li>Immunohistochemically, these cells are positive for CD20, CD79a,
bcl-2 and MNDA (focal) but negative for CD3, CD5, CD10, cyclin D1,
SOX11, IRTA1, HGAL, LMO2, CD21 and c-MYC. Bcl-6 is focally positive for
some cells, probably tumor cells. The Ki-67 proliferative index is
around 40%. The lymphoepithelial lesions are evident but many cells
infiltrating ductal epithelium are negative for CD20 or CD79a but
focally positive for MNDA. The CD10-positive cells are mainly stromal
cells (fibroblasts) not lymphocytes.</li>
</ul></li>
</ul></li>
<li>2019-10-28 SONO - breast
<ul>
<li>Post-op scar in right breast.</li>
<li>Right breast tumor, suspected fibroadenoma.</li>
<li>Left breast nodule with central hyperechoic, suspected intramammary
lymph node, suggest following up.</li>
</ul></li>
<li>2019-10-09 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesion in the right breast, suggesting
lymphoma involving a single extralymphatic organ in the absence of any
lymph node involvement.</li>
<li>Mild glucose hypermetabolic lesions in bilateral palatine tonsils,
probably chronic inflammation/infection process.<br />
</li>
<li>Mild glucose hypermetabolic lesions in the colon, probably
physiological uptake of FDG.</li>
<li>Lymphoma, c-stage IE (AJCC 8th ed.), by this F-18-FDG PET/CT
scan.</li>
</ul></li>
<li>2018-08-02 CT - abdomen
<ul>
<li>S/P operation. No evidence of tumor recurrence.</li>
<li>Liver cysts (up to 1.2cm). Grade 3 fatty liver.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-09 Radiation Oncology
<ul>
<li>Q
<ul>
<li>For evaluating and possible image-guided tissue proof</li>
<li>The 68 year old woman had Hypothyroidism under medical, Sleep
disorder, Diffuse large B-cell lymphoma with multiple extralymphatic
involvement over supra and infradiaphramatic region, Lugano stage IV,
Herniated disc at posterior central C3-4 level, Autoimmune disease not
eleswhere classified under rheumatology regular outpatient
follow-up.</li>
<li>She complaint of neck pain and left ulnar area soreness, pain and
numbness for for a month, left grips weakness and opponents weakness
(left 4,5 fingers claw hand), ulnar side. And severe left ulnar area
pain,soreness and numbness. Medical treatment and physical therapy was
ineffective at all.</li>
<li>She visited our neurosurgery clinic, follow NCV study suggested left
lower cervical radiculopathy, left median mild axonal neuropathy and
left ulnar neuropathy across elbow post left cubital tunnel syndrome for
neurolysis/cubital tunnel closure and anterior transposition on
2022/01/06.</li>
<li>She has left limbs weakness and numbness were noted and left drop
foot. No evidence of spinal metastasis lesion from MRI in WanFang
Hospital on 2022/03/21, but suspect compression fracture at T7. NCV and
CMG were done, report showed mononeuritis multiplex.</li>
<li>Bone scan showed degnerative change of T8, T10 and L3 is first
cinsidered on 2022/03/25. Right facial palsy, drooling, and mildly
slurred speech was noted on 2022/04/07 morning on awakening. The
neurologist suggested arranging a brain CT with contrast, which did not
reveal any ICH, SAH, or SDH, and no space-occupying lesion in the brain
parenchyma was found. The neurosurgeon suggested surgical
intervention due to a previous C-spine MRI showing C4-5 herniated
intervertebral disc  disease with spinal canal stenosis.</li>
<li>After discussion and the fullexplanation with the patient and her
son, she decided to undergo anterior cervical discectomy for C3-4, C4-5,
and C5-6 and anterior spinal fusion on 2022/04/12. She still felt right
facial numbness. Arrange blink test, facial nerve stimulation and showed
these findings suggest right facial neuropathy.</li>
<li>Brain MRA on 2022-05-27 revealed Infiltrative soft tissue lesion
involving right Meckel’s cave, superior orbital fissure, foramen
rotundum, pterygopalatine fossa, and also foramen ovale, along the
course of trigeminal nerve. Suspect Tolosa-Hung syndrome, lymphoma or
sarcoidosis. Brain atrophy and leukoaraiosis.</li>
<li>Nasopharyngoscopy on 2022-06-09 showed Infiltrative soft tissue
lesion involving R Meckel’s cave, superior orbital fissure, foramen
rotundum, pterygopalatine fossa, and also foramen ovale, along the
course of trigeminal nerve. Suspect Tolosa-Hung syndrome, lymphoma or
sarcoidosis. Brain atrophy and leukoaraiosis.</li>
<li>Under the impression of Diffuse large B-cell lymphoma with multiple
extralymphatic involvement over supra and infradiaphramatic region,
Lugano stage IV, PS:0, suspect relapse in brain .</li>
</ul></li>
</ul></li>
<li>2022-04-14 Rehabilitation
<ul>
<li>A
<ul>
<li>Objective
<ul>
<li>imaging studies
<ul>
<li>20220221 brain MRA
<ul>
<li>Mild Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>20220409 brain CT
<ul>
<li>Brain atrophy.</li>
<li>No evidence of ICH, SAH or SDH.</li>
<li>No evidence of space occupying lesion in the brain parenchyma is
found.</li>
</ul></li>
<li>20220413 c spine x ray
<ul>
<li>Post disectomy and disc grafting C3/4/5/6.</li>
</ul></li>
</ul></li>
<li>physical examination
<ul>
<li>20220414 14:09 T/P/R: 36.0℃ / 89bpm / 17bpm BP:152/81mmHg</li>
<li>height: 154.0 Body weight: 56.3 BMI:23.7 Consciousness: E4V5M6</li>
<li>right facial palsy, suspected peripheral type</li>
<li>Cognition: oriented could follow orders</li>
<li>Speech: no aphasia, no dysarthira</li>
<li>Swallowing: NG (-). no dysphagia.</li>
<li>drooling on right side. right face numbness + hypoethesia</li>
<li>no choking</li>
<li>Sphincter: Foley (-), stool continence</li>
<li>MP: RUE 5 / RLE 5 / LUE 4+ / LLE 4</li>
<li>Functional status: needs min assistance in transfer</li>
<li>BADL: needs min assistance</li>
</ul></li>
</ul></li>
<li>Assessment
<ul>
<li>C3-6 herniated intervertebral disc with spinal stenosis post
anterior cervical discectomy for C3-4, C4-5, and C5-6 and anterior
spinal fusion on 2022/04/12</li>
<li>facial numbness, suspected peripheral facial palsy</li>
<li>pending blink reflex</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>Goal: improve ADL ability, improve lower limb endurance</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Neurology
<ul>
<li>Q
<ul>
<li>The 69 y/o woman has endometrium cancer and diffuse large B-cell
lymphoma with multiple extralymphatic involvement over supra and
infradiaphramatic region, Lugano stage IV. This time, she has left limbs
weakness, numbness, painful sensation and unsteady gait for months on
WanFang Hospital and Taipei Medical University Hospital treatment. She
was brought to ED for left leg severe pain on 4/5. We need your help for
management.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>This is a 68 year old woman had aHx of
<ul>
<li>Diffuse large B-cell lymphoma with multiple extralymphatic
involvement over supra and infradiaphramatic region, Lugano stage IV,
s/p C/T (doxorubicin? liposomal doxorubicin? epirubicin?) and R/T (until
2022-03 for left breast)</li>
<li>Cervical cancer endometrium carcinoma s/p radical hysterectomy on
2002?08/03?</li>
<li>Hypothyroidism under medication</li>
<li>Herniated disc at posterior central C3-4 level</li>
<li>Left cubital tunnel syndrome for neurolysis/cubital tunnel closure
and anterior transposition on 2022/01/06</li>
<li>Autoimmune disease not eleswhere classified under rheumatology
regular OPD follow-up</li>
</ul></li>
<li>She suffered from subacute progressive left arm numbness since 2
months ago during R/T; leg pain (burning sensation) and numbness since 1
month ago. Bilateral bottuck numbness, urine retention, constipation,
annus less sensation when using toilet paper since 0.5 month ago. Right
facial palsy, drooling, and mild slurred speech was noted on 2022047
morning on awakening.</li>
</ul></li>
<li>O
<ul>
<li>NE
<ul>
<li>GCS: E4V5M6</li>
<li>VF: intact</li>
<li>pupil 3/3 t/t</li>
<li>EOM: free</li>
<li>right facial palsy, central or peripheral</li>
<li>right V1-3 hypoesthesia</li>
<li>hearing: left hearing loss (baseline)</li>
<li>mild dysarthria</li>
<li>tongue in the mid</li>
<li>motor
<ul>
<li>5/P5D3</li>
<li>5/P4D1</li>
</ul></li>
<li>Left
<ul>
<li>shoulder rotation, arm abduction, elbow flexion, elbow extension,
wrist extension:5</li>
<li>finger extension, finger flexion: 4</li>
<li>finger abduction, finger adduction: 3</li>
<li>thumb abduction: 4</li>
<li>left interosseous muscle atrophy</li>
<li>claw hand</li>
</ul></li>
<li>hip flexion, hip adduction, knee extension: 4</li>
<li>hip abduction, hip extension: 3</li>
<li>foot dorsiflexion, plantarflexion inversion, eversion: 1</li>
<li>extension of toes: 2</li>
</ul></li>
<li>sensory:
<ul>
<li>hypoesthesia over
<ul>
<li>right face, right head over</li>
<li>bilateral medial antebrachial cutaneous and left ulnar</li>
<li>bilateral buttoack and left below knee, left femoral cutaneous</li>
</ul></li>
</ul></li>
<li>brain MRA (20220222): Mild Brain atrophy with bilateral
periventricular ischemic/aging white matter change.</li>
<li>MRI: C4-5 HIVD</li>
</ul></li>
<li>A
<ul>
<li>impression: mononeuropathy multiplex; Bell’s palsy</li>
</ul></li>
<li>P
<ul>
<li>suggestion:
<ul>
<li>arrange NCV and EMG</li>
<li>arrange blink test, facial nerve stimulation test</li>
<li>arrange brain CT with contrast</li>
<li>give prednisolone 5mg 11# per day (devide to 3 times), then decrease
2# per day since day 6</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-04-22 Infectious Disease
<ul>
<li>Q
<ul>
<li>The 68 year old woman is a case of diffuse large B-cell lymphoma
with multiple extralymphatic involvement over supra and
infradiaphramatic region, Lugano stage IV,PS:0</li>
<li>She received C1 R-CHOP (Adriamycin shift to self paid of Lipo-dox)
was administered on 2021/04/08 ~ 2021/04/09.</li>
<li>This time, she suffered dysuria for about 2 days and frequency and
urgency also suffered swelling nose for about 1 day with headache. She
then had fever for about 2 days.</li>
<li>At ER, hemogram showed neutropenia with ANC 362, elevated CRP. CXR
was clear. Water view’s mild obliteration of the right maxillary
sinus.</li>
<li>Empiric antibiotics with Cefepime was given for neutropenic
fever</li>
<li>We need your expertise for antibiotics used, thanks</li>
</ul></li>
<li>A
<ul>
<li>Consultation for neutropenic fever.</li>
<li>68-year-old B-cell lymphoma female patient, who received recent
chemotherapy, has neutropenic fever now.</li>
<li>White count 630 with ANC only 362 yesterday.</li>
<li>There is rhinitis symptoms, and Water’s view shows suspect right
maxillary sinusitis.</li>
<li>CxR film shows clear lungs, that no urinalysis data available for
interpretation.</li>
<li>Patient is receiving cefepime now, which would be appropriated for
her.</li>
<li>Suggestion:
<ul>
<li>Check urinalysis and send urine for culture.</li>
<li>Continue Cefepime.</li>
<li>Consult ENT specialist for scope examination.</li>
<li>Check blood culture report.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-06 Left cubital tunnel syndrome for neurolysis/ cubital
tunnel closure and anterior transposition
<ul>
<li>Left ulnar area numbness/ grips muscular atropy and weakness/ claw
hand.</li>
<li>Prominent left epicondyl of humerus. Severe adhesion around ulnar
nerve both at para-epicondyl area, including proxiaml cutibal tunnel
are/ cubital tunnel inside and distal area to FCU area.</li>
</ul></li>
<li>2002-08-03 radical hysterectomy at NTUH</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-04-08 ~ 2021-09-08 - R-CHOP (cyclophosphamide, doxorubicin,
vincristine, prednisone plus rituximab)</li>
<li>2020-01-20 ~ 2020-03-11 - R-COP (cyclophosphamide, vincristine,
prednisone plus rituximab)</li>
</ul></li>
</ul>
<div id="section-596" class="section level3">
<h3>==========</h3>
</div>
<div id="section-597" class="section level3">
<h3>2022-06-10</h3>
<ul>
<li>Brain MRA (2022-05-27) revealed:
<ul>
<li>Infiltrative soft tissue lesion involving right Meckel’s cave,
superior orbital fissure, foramen rotundum, pterygopalatine fossa, and
also foramen ovale, along the course of trigeminal nerve. Suspect
Tolosa-Hung syndrome, lymphoma or sarcoidosis.</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
<li>The above described infiltrative soft tissue lesion at trigeminal
nerve course is consistent with the finding of NCV (2022-04-18). DLBCL
with CNS involved?</li>
<li>There is no cure or specific treatment for vanishing white matter
(leukoarailsis) so far.</li>
<li>Neurological symptoms might be prioritized?</li>
<li>HR &gt; 100, potential hypoperfusion?</li>
<li>No issue with active prescription.</li>
</ul>
</div>
<div id="section-598" class="section level3">
<h3>2022-04-06</h3>
<ul>
<li>The patient underwent R-COP from 2020-01 to 2020-03 after
pathologically proving follicular lymphoma in October 2019, then
received R-CHOP from 2021-04 to 2021-09 after pathologically proving
high grade B-cell lymphoma in March 2021.</li>
<li>There would be an increased risk of CNS involvement for patients
with double-hit or triple-hit high-grade b-cell lymphomas (in this case,
cMYC(-), BCL2(+), BCL6(+)), but CNS involvement was not proven by brain
MRA on 2022-02-21.</li>
<li>While the standard of care is not established, the following
induction regimens have been reported:
<ul>
<li>RCHOP (used in 2021)  - DA-EPOCH-R  - Potentially toxic regimens;
performance status and comorbidities should be considered
<ul>
<li>R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin,
and dexamethasone alternating with high-dose methotrexate and
cytarabine)</li>
<li>R-CODOX-M/R-IVAC (rituximab-cyclophosphamide, vincristine,
doxorubicin with methotrexate/ifosfamide, etoposide, and
cytarabine)</li>
</ul></li>
</ul></li>
<li>Laboratory results reported on 2022-03-29 indicated normal liver and
kidney function, along with slightly lower CBC readings.</li>
</ul>
</div>
</div>
</div>
<div id="section-599" class="section level1">
<h1>700622927</h1>
<div id="section-600" class="section level2">
<h2>220608</h2>
<div id="section-601" class="section level3">
<h3>==========</h3>
</div>
<div id="section-602" class="section level3">
<h3>2022-06-08</h3>
<p>[cyclosporine-A TDM]</p>
<ul>
<li>The level of serum cyclosporine-A gradually increases (normal range
100~400 ng/mL), please monitor for potential adverse reactions such as
post-transplant diabetes mellitus, drug-induced gingival overgrowth,
drug-induced thrombotic microangiopathy, neurotoxicity. (Recent
laboratory data do not indicate liver toxicity, nephrotoxicity,
hyperkalemia, or hypertension.)
<ul>
<li>2022-06-06 307.0</li>
<li>2022-06-02 287.9</li>
<li>2022-04-09 165.8</li>
</ul></li>
</ul>
</div>
<div id="section-603" class="section level3">
<h3>2022-05-04</h3>
<p>[Minutes of the Interprofessional Practice Meeting and Family
Meeting]</p>
<ul>
<li>This was the second meeting held on 2022-05-04 at 10:00 in the ward,
the first meeting being held on 2022-03-30. The patient’s son
participated in the meeting via a smart phone.</li>
<li>Dr. Kao explained the treatment schedule to the patient family, as
well as the prognosis and possible risks.</li>
<li>The patient asked questions about her small amount of bleeding from
the catheter needle wound and the soybean-based meals in the hospital.
These questions got immediate feedback, as she understood that willpower
is an indispensable element of treatment for the disease.</li>
</ul>
</div>
<div id="section-604" class="section level3">
<h3>2022-03-30</h3>
<p>[Interprofessional Practice Meeting and Family Meeting following
up]</p>
<ul>
<li>This meeting was held on 2022-03-30 at 9:00 in the ward, the patient
was present, as was her son.</li>
<li>Dr. Kao explained the treatment plan of the disease to the patient
family, as well as the prognosis and possible risks, and
interprofessional practice team members were present for inquiries.</li>
<li>For the transplant will need relatively rare used drugs, the
pharmacy should prepare in advance to ensure that the drugs are readily
available and Dr. Kao will provide an updated version of conditioning
agent schedule.</li>
</ul>
</div>
</div>
</div>
<div id="section-605" class="section level1">
<h1>701009623</h1>
<div id="section-606" class="section level2">
<h2>220606</h2>
<p>{follicular lymphoma}</p>
<ul>
<li>exam finding
<ul>
<li>2022-06-02 CT - abdomen, pelvis
<ul>
<li>With and without contrast enhancement CT of abdomen shows:
<ul>
<li>Distended stomach and proximal small bowel.</li>
<li>Unremarkable chagne of the liver, spleen, pancreas, and
kidneys.</li>
<li>Peritoneal stranding at low abdomen. Wall thickening and increased
enhancement of terminal ileum.</li>
<li>Surgical clips and stiches over abdomen.</li>
<li>No bony destructive lesion on these images.</li>
<li>Penetrating atherosclerotic ulcer at abdominal aorta, infrarenal
segment.</li>
</ul></li>
<li>Impression
<ul>
<li>Gastric and proximal small bowel distension</li>
<li>Terminal ileum thickening and peritoneal stranding, due to
lymphoma?</li>
<li>Suggest small bowel series to r/o obstruction if progression of
bowel distension</li>
</ul></li>
</ul></li>
<li>2022-06-01 Abdominal Ultrasonography
<ul>
<li>c/w, Ileus</li>
<li>Liver cyst, small, S7</li>
</ul></li>
<li>2022-05-31 Standing KUB
<ul>
<li>Presence of ileus.</li>
<li>S/P operation with retention of surgical clips.</li>
<li>Intact bony structure(s).</li>
</ul></li>
<li>2021-09-18 CT - abdomen, pelvis
<ul>
<li>Infrarenal AAA (2.1cm) with mural thrombus and ulceration.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-06-03 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>Patient admit to Cardinal Tien hospital on for operation for
malignant lyphoma on 20210730, Brain MRA on 20210731 showed left MCA,
PCA infarction with hemorrahge transformation. S/P HBO (Hyperbaric
Oxygen Therapy) for 10 sessions, under rehab program .</li>
<li>NG(-), Foley(-)</li>
<li>Palpitations, epigastric pain with nausea, crampy sensation and
shaking chills for 3 days. TOCC(-). No known allergy.</li>
<li><a href="mailto:2022/04/11@TMUH" class="email">2022/04/11@TMUH</a>
Abd CT:
<ul>
<li>Penetrating aortic ulcer (PAU) noted at infrarenal aorta, no obvious
interval change.</li>
<li>Post op chage of small bowel. Some prominent LNs at mesentery, no
interval change.</li>
</ul></li>
<li>2022/06/01 Abd SONO
<ul>
<li>dilated A-colon and D-colon was noted.</li>
<li>Diagnosis:
<ul>
<li>c/w, Ileus</li>
<li>Liver cyst, small, S7</li>
</ul></li>
</ul></li>
<li>2021/09/18 CT Abd:
<ul>
<li>Infrarenal AAA (2.1cm) with mural thrombus and ulceration.</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>67 y/o male small bowel lymphoma s/p segmental resection</li>
<li>bloating and abdominal pain but subside</li>
<li>PE: soft, no tenderness</li>
<li>CT: Terminal ileum thickening and peritoneal stranding, due to
lymphoma?</li>
<li>P: suggest admission and further evaluation</li>
</ul></li>
</ul></li>
<li>2021-09-24 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 66-year-old man with history of:
<ul>
<li>Mesentric tumor in small bowel, s/p exploratory laparotomy with
tumor excision and resection of jejunum for about 160cm on 2021-07-30,
pathology report: malignant lymphoma</li>
<li>Small bowel syndrome</li>
<li>Abdominal aorta aneurysm, measuring 2.1cm</li>
<li>Pulmonary hypertension</li>
<li>Atrial fibrillation with right bundle branch block</li>
<li>Anemia, suspected chromic inflammation of GI tract<br />
</li>
</ul></li>
<li>He had found one big mass at lower middle abdomen for one month. He
went to GI department in Cardinal Tien Hospital on 2021-07-16. Abdominal
echo revealed left intra-abdominal tumor, 10.2x8.8cm. Abdominal CT was
arranged on 2021-07-19 and showed (1) suspected tumor, 8.9x8.8x6.3cm, in
small intestine with retroperitoneal lymphadenopathy; (2) abdominal
aorta aneurysm and focal dissection. Exploratory laparotomy with
excision of intraabdominal tumor and resection of jejunum about 160cm
was performed on 2021-07-30. Pathalogy report of operation finding
revealed a follicular lymphoma, grade 2, in the mesentry, measuring
11x10x6.5cm, immunoreactive for CD20, bcl-2 and CD10 and non-reactive
for CD3, CD5, CD21, CD23 and cyclin D1. After operation, acute onset of
conscious disturbance with right limbs weakness was noted in 2021-07-31
early morning. Brain MRA on 2021-07-31 revealed recent infarction in the
left middle cerebral artery (MCA) and posterior cerebral artery (PCA)
territory with suspicious hemorrhagic transformation at the left
temporal area and basal ganglia. Cardiac ultrasound on 2021-08-02 showed
LVEF: 75.7% and moderate pulmonary hypertension. Whole body PET scan on
2021-08-11 showed suspicious inflammatory change in right lower lobe of
lung and no evidence of abnormal FDG uptake throughout whole body region
elsewhere. His consciousness was alert and E4VAM6.</li>
<li>With impression of left MCA and PCA infarction with hemorrhagic
transformation on 2021/07/31 with right hemiplegia, dysphagia and
aphasia, he was transferred to our PM&amp;R ward on 2021/09/15 for
further rehabilitation treatment.</li>
<li>We need your expertise for evaluation of follicular lymphoma s/p
tumor excision.</li>
<li>Pathology report in Cardinal Tiem Hospital
<ul>
<li>Gross Description
<ul>
<li>The specimen submitted consisted of 2 parts. Part(A) was a segment
of small intestine measuring 102 cm in length and up to 3 cm in
diameter, fixed in formalin.</li>
<li>Grossly, the small intestine showed unremarkable. There was a tumor
measuring 11 x 10 x 6.5 cm in the mesentery. Part(B) was a piece of soft
tissue labelled mesentery lymph nodes, measuring 9 x 4 x 2 cm in size
and 30 gm in weight. Representative sections were taken.</li>
</ul></li>
<li>Microscopic description
<ul>
<li>Microscopically, sections of the mesentery tumor and mesentery lymph
nodes show numerous variably sized, back to back neoplastic follicles.
Most have absent or attenuated mantle zones. Occasional larger admixed
centroblasts are seen.</li>
<li>The tumor cells are immunoreactive for CD20, bcl-2 and CD10, and
non-reactive for CD3, CD5, CD21, CD23 and cyclin D1. The morphological
and immunohistochemical features are compatible with follicular
lymphoma, grade 2. Sections of jejunum and both cut ends show chronic
inflammatory cell infiltration in the mucosa.</li>
</ul></li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>Paitent examined and Chart reviewed. A case of intestinal lymphoma
is noted. I am consulted for further evaluation and management.</li>
<li>My suggestions:
<ul>
<li>Please complete staging work, e.g., Chest/Abd/Pelvis CT, PET-CT,
bone marrow study. All is covered by National Health Insurance.</li>
<li>Please check lab: Anti-HCV, Anti-HBs Ab, Anti-HBc Ab, HBs Ag, LDH,
Beta2-microglobulin.</li>
<li>Already discussed with patient and family.</li>
<li>Any problem, please let me know.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-09-22 Cardiac Surgery
<ul>
<li>Q
<ul>
<li>After admission, follow-up abdominal CT with/without contrast for
abdominal aortic aneurysm was performed on 20210918 and showed one
infrarenal AAA (2.1cm) with mural thrombus and ulceration. His systolic
blood pressure was around 140 mmHg and sometimes above 150mmHg recently.
We need your expertise for evaluation of abdominal aortic aneurysm and
target of blood pressure control. Thank you so much!</li>
</ul></li>
<li>Q
<ul>
<li>Thanks for consultation.</li>
<li>CTA showed a small, if it can be diagnosed as, AAA. The diamter is
21mm. Blood pressure is well controled.</li>
<li>There is no current indication for surgical intervention.
Conservative treatment with aggressive BP control is recommended. OPD
f/u is recommended.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient was diagnosed with follicular lymphoma based on
pathology results from Cardinal Tien Hospital and has undergone
exploratory laparotomy with excision of intraabdominal tumor as well as
resection of about 160cm of jejunum on 2021-07-30 at that hospital
during the third quarter of 2021. Is it possible that the staging workup
has not been completed, or that the records collected at Cardinal Tien
Hospital have not been totally transferred?</li>
<li>First line therapy for follicular lymphoma grade 1 or 2 could be the
following regimens:
<ul>
<li>Bendamustined + obinutuzumabe or rituximab</li>
<li>CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) +
obinutuzumabe or rituximab</li>
<li>CVP (cyclophosphamide, vincristine, prednisone) + obinutuzumabe or
rituximab</li>
<li>Lenalidomide + rituximab</li>
</ul></li>
<li>CT 2021-09-18 revealed an infrarenal abdominal aortic aneurysm
(2.1cm) with mural thrombi and ulceration, while CT 2022-06-01
demonstrated a penetrating atherosclerotic ulcer at the abdominal aorta,
infrarenal segment. In the TPR records since this hospital stay, SBP
fluctuates between 135 and 180 mmHg, BP might not be considered well
controlled, and this patient has no cardiac medicine or cardiac surgery
follow up records since 2021-09, perhaps some consultation might be
appropriate.</li>
<li>In this case, the patient has a history of atrial fibrillation and
right bundle branch block. However, only antihypertensive medication
Sevikar is prescribed now.</li>
<li>All the oral drugs in active prescription can be administered with
nasogastric tube.</li>
</ul>
</div>
</div>
<div id="section-607" class="section level1">
<h1>701391119</h1>
<div id="section-608" class="section level2">
<h2>220601</h2>
<p>{steroid conversion}</p>
<p>An approximate corticosteroid dosing conversion</p>
<ul>
<li>Approximately 4mg of dexamethasone is equivalent to 4mg of
betamethasone.</li>
<li>The current dose of betamethasone 4g IVD Q8H may be switched to
Limeson (dexamethasone 4mg/tab) 1# PO Q8H.</li>
</ul>
</div>
</div>
<div id="section-609" class="section level1">
<h1>701364241</h1>
<div id="section-610" class="section level2">
<h2>220531</h2>
<ul>
<li>exam finding
<ul>
<li>2022-03-15 Patho - pancreas biopsy
<ul>
<li>Labeled as “pancreatic head”, incision biopsy — adenocarcinoma.</li>
<li>Section shows 1 piece of pancreatic tissue with irreular shaped
adenocarcinoma.</li>
<li>IHC stains: CK19 (+), CA-199 (equivocal), CK7 (+), CK20 (-). The
pattern in conjunction with elevated levels of serum lipase and CA-19-9
is compatible with pancteatic origin.</li>
</ul></li>
<li>2022-03-08 MRI - pancreas
<ul>
<li>Suspected a tumor (1.8cm) at pancreatic head with biliary tree and
p-duct dilatation.</li>
</ul></li>
<li>2022-03-07 Endoscopic Ultrasound, EUS
<ul>
<li>Diagnosis
<ul>
<li>Pancreatic head tumor with CBD invasion, highly suspected pancreatic
cancer</li>
<li>Dilated biliary tree</li>
</ul></li>
<li>Suggestion
<ul>
<li>Correlate with other imaging</li>
<li>Consult surgeon for indication of operation</li>
</ul></li>
</ul></li>
<li>2022-03-07 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Suspicious pancreatic head tumor</li>
<li>Dilated biliary tree</li>
<li>Distended GB with sludge</li>
<li>Dilated MPD</li>
</ul></li>
<li>Suggestion
<ul>
<li>Correlate with other imaging</li>
</ul></li>
</ul></li>
<li>2022-03-03 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Pancreatic Carcinoma</li>
<li>Impression (Imaging stage): T1cN0M0, stage IA</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-23 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>for chemotherapy</li>
<li>This 48 y/o male was a case of pancreatic head cancer with
obstructive s/p PTCD on 3/9. Further operation was performed on 3/14.
Operation finding showed pancreatic head tumor with PV encasement &gt;
270 degree and partial SMA invasion dilated CBD up to 1.8cm multiple LN
enlarge at duodenal ligament and paraaorta. So Roux-en-Y
hepaticojejunostomy + GJ anastomosis + cholecystectomy was done. After
operation with well oral intake and condition become stable, we need you
help for further chemotherapy for this patient.</li>
</ul></li>
<li>A
<ul>
<li>This 48 y/o male was a case of pancreatic head CA wt obstructive s/p
PTCD on 3/9. Op was performed on 3/14 22. Op finding showed pancreatic
head tumor with PV encasement &gt; 270 degree and partial SMA invasion
dilated CBD up to 1.8cm multiple LN enlarge at duodenal ligament and
paraaorta. Roux-en-Y hepaticojejunostomy + GJ anastomosis +
cholecystectomy was done.</li>
<li>Palliative or pre-neoadjuvant C/T is to be proposed.</li>
<li>Image study:
<ul>
<li>Pancreas MRI (3/8 22):
<ul>
<li>Findings
<ul>
<li>Suspected a tumor (1.8cm) at pancreatic head with biliary tree and
p-duct dilatation.</li>
<li>Distention of gallbladder.</li>
<li>No ascites, nor enlarged lymph node.</li>
<li>No abnormal intensity in bilateral basal lungs.</li>
</ul></li>
<li>IMP: Suspected a tumor (1.8cm) at pancreatic head with biliary tree
and p-duct dilatation.</li>
</ul></li>
<li>Abd CT (3/3 22):
<ul>
<li>Findings
<ul>
<li>Wall thickening of distal CBD with biliary tree and p-duct
dilatation.</li>
<li>Distention of gallbladder.</li>
<li>Patency of portal vein.</li>
<li>No ascites, nor enlarged lymph node.</li>
<li>No abnormal density at bilateral basal lungs.</li>
</ul></li>
<li>IMP: Wall thickening of distal CBD with biliary tree and p-duct
dilatation suspected tumor.</li>
</ul></li>
</ul></li>
<li>Dx: R/I local advanced pancreatic CA, stage, unamenable to
resection.</li>
<li>Medical advice:
<ul>
<li>It will be possible to be cured only in the patient whose pancreatic
cancer is amenable to total surgical resection ( R0 resection ). The
pacnreatic tumor of this pt seeems to be unresectable.<br />
</li>
<li>Pancreatic CA divided into 2 main kinds of carcinoma, one is
adenocarcinoma, another is neuroendocrine tumor. Both should be subject
to complete resection for cure.</li>
<li>But the two kinds of cancer have totally different Tx pattern. For
unresectable pancreatic adenocarcinoma, the first treatment of choice is
palliative C/T wt FOLFIRINOX or Gemcitabine-based C/T. As for
unresectable neuroendocrine tumors, the first treatment of choice may be
targeted therapy wt Sutent (sunitinib).</li>
<li>If pancreatic tumor is not subjected to resection, biopsy of
pancreatic tumor may be indicated for definitive Dx. Tx will be arranged
according to accurate pathologic Dx.</li>
<li>If pancreatic adenocarcinoma is proved, pre-Op neoadjuvant C/T wt
FOLFIRINOX or CCRT (concurrent chemoradiation therapy) over pancreatic
tumor may be first priority of Tx for this pt to make pancreatic tumor
shrink &amp; may render Op feasible.
<ul>
<li>Post-CCRT, abd CT will be done to evaluate Op feasibility.</li>
<li>Palliative C/T regimens for local advanced pancreatic CA or
metastatic Dz may be:
<ul>
<li>FOLFIRINOX ( self-paid ) ( preferred )</li>
<li>Gemcitabine + albumin-bound paclitaxel</li>
<li>Gemcitabine + erlotinib ( at mets dz )</li>
<li>Gemcitabine-based combination C/T</li>
<li>Gemcitabine alone</li>
<li>Capecitabine or continous infusion 5-FU.</li>
<li>TS-1 ( Phase III Clinical Study (GEST) of TS-1 in pt wt local
advanced &amp; metastatic pancreatic CA, reported at JCO 2013 March. ) (
not included at NCCN guideline recommendation )<br />
</li>
</ul></li>
<li>Recent data showed FOLFIRINOX offered better survival benefit than
Gemcitabine-based C/T.</li>
</ul></li>
</ul></li>
<li>If pancreatic neuroendocrine tumor (pNET) is proved, pNET (or NET)
can be classified as local, regional, or advanced dz. Treatment goal
should be curative where possible, with the use of pharmacological Tx as
necessary.
<ul>
<li>If complete resection wt curative-intent can be achieved for the
pNET pt without evidence of residual dz, adjuvant C/T for post-Op NET pt
is not necessary. </li>
<li>No adjuvant C/T is suggested. C/T is only considered if recurrence
is proved.</li>
</ul></li>
<li>As for the pt wt unresctable local advanced or metastatic NET,
variable target therapy drugs are available:
<ul>
<li>mTOR inhibitor everolimus ( Afinitor, 5mg / #, 2# QD)</li>
<li>tyrosine kinase inhibitor sunitinib ( Sutent).</li>
<li>VEGF inhibitor Bevacizumab (Avastin).</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-23 Radiation Oncology
<ul>
<li>Q
<ul>
<li>for CCRT</li>
<li>This 48 y/o male was a case of pancreatic head cancer with
obstructive s/p PTCD on 3/9. Further operation was performed on 3/14.
Operation finding showed pancreatic head tumor with PV encasement &gt;
270 degree and partial SMA invasion dilated CBD up to 1.8cm multiple LN
enlarge at duodenal ligament and paraaorta. So Roux-en-Y
hepaticojejunostomy + GJ anastomosis + cholecystectomy was done. After
operation with well oral intake and condition become stable, we need you
help for further CCRT for this patient. Thanks for your time!!</li>
</ul></li>
<li>A
<ul>
<li>Subjective:
<ul>
<li>History: This 48 y/o male was a case of pancreatic head cancer with
obstructive jaundice s/p PTCD on 2022/3/09. BW loss of 7-8 kg in 3
months is noted. Further operation was performed on 3/14. Operation
finding showed pancreatic head tumor with PV encasement &gt; 270 degree
and partial SMA invasion, dilated CBD up to 1.8cm, multiple enlarged
LAPs at duodenal ligament and paraaortic region. Roux-en-Y
hepaticojejunostomy + GJ anastomosis + cholecystectomy was done. After
operation, he can tolerate soft diet now.
<ul>
<li>Previous RT: denied.</li>
<li>Other disease: denied.</li>
<li>Family history: denied.</li>
</ul></li>
<li>Habit: Alcohol: denied; Smoking: denied; betel nut: denied.</li>
<li>Single. Caregiver: his brother (also single). Job: nil. No economic
stress.</li>
<li>Language: Mandarin. Taiwanese.</li>
<li>Religion: Nil.</li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2022/3/23: No SCF LAPs. Minimal icteric sclera. 43.8 kg (51 kg
before).</li>
<li>Pathology, 2022/03/15: Labeled as ‘pancreatic head’, incision biopsy
— adenocarcinoma. IHC stains: CK19 (+), CA-199 (equivocal), CK7 (+),
CK20 (-). The pattern in conjunction with elevated levels of serum
lipase and CA-19-9 is compatible with pancreatic origin.</li>
<li>Images:
<ul>
<li>CT, 2022/3/03: Wall thickening of distal CBD with biliary tree and
p-duct dilatation suspected tumor.</li>
<li>MRI, 2022/3/08: Suspected a tumor (1.8cm) at pancreatic head with
biliary tree and p-duct dilatation. No enlarged regional LNs. No
ascites. No liver metastasis.</li>
</ul></li>
<li>LAB, 2022/3/07: CEA 4.80; CA199, 1471.32.</li>
</ul></li>
<li>Diagnosis:
<ul>
<li>Pancreatic head cancer, adenocarcinoma, with PV encasement &gt; 270
degree and partial SMA invasion, dilated CBD up to 1.8cm (obstructive
jaundice), multiple enlarged LAPs at duodenal ligament and paraaortic
region, cT4N1M0, stage III, s/p PTCD on 2022/3/09, s/p Roux-en-Y
hepaticojejunostomy + GJ anastomosis + cholecystectomy on 2022/3/14;
ECOG =1.</li>
</ul></li>
<li>Plan:
<ul>
<li>CCRT to pancreatic head tumor and LAPs for 5000cGy/25 fx is
suggested for tumor control &amp; down staging. Aggressive nutritional
support is suggested due to BW loss of 7-8 kg in 3 months. CT simulation
is arranged on March 29, 08:30 am. Treatment will be started on March 31
if his surgical wound heals well. Diet education and tolerable exercise
is suggested.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-09 Radiological Diagnosis
<ul>
<li>Q
<ul>
<li>Reason: for biliary tract drainage</li>
<li>This 48-year-old male with anxiety had regular taken medication from
local psychiatric clinic. Abdomen MRI revealed Suspected a tumor (1.8cm)
at pancreatic head with biliary tree and p-duct dilatation. We sincerely
need your expertise for his further evaluation and arrangement of
biliary tract drainage.</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, PTCD is
indicated.</li>
</ul></li>
</ul></li>
<li>2022-03-08 General and Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>Reason: for pancreatic head tumor</li>
<li>This 48-year-old male with anxiety had regular taken medication from
local psychiatric clinic. This time, he was admitted for obstructive
jaundice. Abdomen CT revealed wall thickening of distal CBD with biliary
tree and p-duct dilatation suspected tumor. EUS revealed pancreatic head
tumor with CBD invasion, highly suspected pancreatic cancer, and dilated
biliary tree. MRI would be arranged on 2022/03/08 12:00. We sincerely
need your expertise for his further evaluation and management.</li>
</ul></li>
<li>A
<ul>
<li>S
<ul>
<li>According to the patient, he had weight loss of 7kg recently,
postprandial diarrhea and poor appetite.</li>
</ul></li>
<li>O
<ul>
<li>Lab data on 2022-03-07
<ul>
<li>CA199 1471.32 U/mL<br />
</li>
<li>Bilirubin total 16.82 mg/dL<br />
</li>
<li>Bilirubin direct 8.63 mg/dL<br />
</li>
<li>S-GOT/AST 137 U/L<br />
</li>
<li>S-GPT/ALT 292 U/L<br />
</li>
<li>Alkaline phosphatase 427 U/L<br />
</li>
<li>r-GT 708 U/L<br />
</li>
</ul></li>
<li>Abdomen CT: Wall thickening of distal CBD with biliary tree and
p-duct dilatation suspected tumor.</li>
<li>EUS: Pancreatic head tumor with CBD invasion</li>
</ul></li>
<li>Impression: pancreatic head tumor, dilated biliary tree</li>
<li>Suggestions:
<ul>
<li>PTGBD insertion first due to hyperbilirubinemia.</li>
<li>Adequate nutrition due to weight loss.</li>
<li>Pending IgG4 and MRI report.</li>
<li>We will evaluate the need of surgery after the tests.</li>
</ul></li>
<li>We would like to follow up this patient, feel free to contact
us.</li>
</ul></li>
</ul></li>
</ul></li>
<li>VS note
<ul>
<li>2022-04-11
<ul>
<li>Local advanced pancreatic head tumor with partial SMA invasion &amp;
dilated CBD &amp; multiple LN enlarge at duodenal ligament &amp;
paraaorta s/p Roux-en-Y hepaticojejunostomy + GJ anastomosis +
cholecystectomy on 3/14 22 &amp; s/p PTCD on 3/9 22.</li>
<li>XRT started on 4/6 22.</li>
<li>#1 pre-Op neoadjuvant CCRT with 5-FU (200mg/m2) IVF 24 hr plus R/T
on 4/11 22. .</li>
<li>encourage pt to eat more food.</li>
<li>Stable vital sign. MBD today.</li>
</ul></li>
<li>2022-04-08
<ul>
<li>admitted for #1 CCRT with 5-FU (200mg/m2) on 4/8 22 due to
pancreatic head CA wt obstructive s/p PTCD on 3/9 22, s/p Op on 3/14 22.
Op finding showing local advanced dz wt pancreatic head tumor with PV
encasement &gt; 270 degree and partial SMA invasion dilated CBD up to
1.8cm &amp; multiple LN enlarge at duodenal ligament and paraaorta.
Roux-en-Y hepaticojejunostomy + GJ anastomosis + cholecystectomy.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-14
<ul>
<li>Surgery
<ul>
<li>Roux-en-Y hepaticojejunostomy</li>
<li>GJ anastomosis</li>
<li>cholecystectomy</li>
</ul></li>
<li>Finding
<ul>
<li>pancreatic head tumor with PV encasement &gt; 270 degree and partial
SMA invasion</li>
<li>dilated CBD up to 1.8cm</li>
<li>multiple LN enlarge at duodenal ligament and paraaorta</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-04-06 ~ 2022-05-10 - CCRT to pancreatic head tumor and LAPs for
5000cGy/25 fx</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-05-30 ~ undergoing - FOLFIRINOX</li>
<li>2022-04-11 ~ 2022-05-09 - 5-Fu (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pancreatic head cancer has been diagnosed (CT 2022-03-03) and proven
to be adenocarcinoma (pathology 2022-03-15).</li>
<li>CCRT was provided to the patient starting in early April and
continuing through early May 2022, following the starting of FOLFIRINOX
since this hospital stay.</li>
<li>Lab data on 2022-05-30 showed grossly normal except for elevated
AST/ALT, however the administration of regimen should not likely to be
affected.</li>
<li>TPR remains stable during this hospitalization. No issue with active
prescription.</li>
</ul>
</div>
</div>
<div id="section-611" class="section level1">
<h1>700898650</h1>
<div id="section-612" class="section level2">
<h2>220530</h2>
<p>{potential drug interactions}</p>
<ul>
<li>all the oral drugs in active prescription can be administered with
nasogastric tube.</li>
<li>some potential drug interactions should be addressed:
<ul>
<li>cation exchange resin - antacid
<ul>
<li>Calicum polystyrene sulfonate (CPS) removes potassium by exchanging
calcium ions for potassium ions in the intestine before the resin is
excreted from the body.</li>
<li>The combined use of calcium carbonate (500mg PO TID) and kalimate
(calcium polystyrene sulfonate, 4gm PO TID) might result in metabolic
alkalosis and/or loss of efficacy of the cation exchange resin.</li>
<li>Cation exchange resins such as CPS binds magnesium and calcium ions,
and may thereby prevent binding and neutralizing of bicarbonate ions in
the small intestine. Additionally, this binding might attenuate the
therapeutic effects of the exchange resin. Prescribing information for
CPS highlights this risk of alkalosis with cation-donating antacids, but
does not give specific recommendations for action.</li>
<li>To minimize this interaction, consider: a) separating the doses of
calcium polystyrene sulfonate and calcium carbonate by 2 or more hours;
b) administering CPS rectally; or c) choosing an alternative acid
reducing agent (e.g. H2-antagonist). Monitor for metabolic alkalosis and
attenuation of CPS effects if concomitant therapy cannot be
avoided.</li>
</ul></li>
<li>CNS depressants
<ul>
<li>The concomitant use of two or more drugs (clonazapam 0.5mg BID and
fexofenadine 60mg BID) that have the potential to depress CNS function
(either as a therapeutic intention or a side effect) is often clinically
appropriate. However, it is important to recognize that the risk of
unwanted effects may increase with such use.</li>
<li>Consider the duration of CNS depressant use and each patient’s
response (particularly tolerance to CNS depressant effects) when
selecting additional agents and their doses. Dose reductions of one or
both CNS depressant agents may be necessary. Monitor for additive
CNS-depressant effects whenever two or more CNS depressants are
concomitantly used.</li>
<li>Advise patients to avoid any unprescribed, illicit, or recreational
use of other CNS depressants.</li>
</ul></li>
<li>CNS depressant - metaclopramide
<ul>
<li>Metoclopramide might enhance the CNS depressant effect of CNS
Depressants.</li>
<li>Metoclopramide prescribing information states that metoclopramide
might impair the mental and/or physical abilities required for the
performance of hazardous tasks such as operating machinery or driving a
motor vehicle. Concomitant use of central nervous system (CNS)
depressants or drugs associated with EPS may increase this effect (eg,
alcohol, sedatives, hypnotics, opiates, anxiolytics).</li>
<li>Please monitor patients for increased CNS depressant effects (eg,
somnolence, drowsiness) if metoclopramide is combined with CNS
depressants.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-613" class="section level1">
<h1>701390387</h1>
<div id="section-614" class="section level2">
<h2>220526</h2>
<p>{tachycardia}</p>
<ul>
<li>underlying condition
<ul>
<li>visually impairment</li>
<li>dementia</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-25 CT - abdomen, pelvis
<ul>
<li>There is a well-defined poor enhancing lesion measuring 1.2 x 1 cm
in the spleen. Please correlate with sonography and MRI.</li>
<li>There are few small ground-glass opacity on RLL of the lung that may
be inflammatory process. please correlate with clinical condition and
chest CT.</li>
<li>Compression fracture of T12 vertebral body. please correlate with
clinical condition, old film, or MRI.</li>
</ul></li>
<li>2022-05-25 Chest PA
<ul>
<li>Ground glass opacity in right lung.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Normal size of heart.</li>
<li>Intact bony structure(s).</li>
</ul></li>
<li>2022-05-25 Electrocardiography
<ul>
<li>Atrial fibrillation with rapid ventricular response</li>
<li>Nonspecific ST abnormality</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-05-25
<ul>
<li>CRP 20.77 mg/dL</li>
<li>WBC 11.17 *10^3/uL</li>
<li>Neutrophil 82.9 %</li>
<li>urine Bacteria 3+</li>
<li>urine Sediment-WBC &gt;=100</li>
<li>urine Leukocyte esterase 3+</li>
</ul></li>
<li>2022-05-17
<ul>
<li>Covid-19 confirmed</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Tachycardia remains evident (over 120 on 0222-05-26 morning) even
under prescribed bisoprolol, with a faster breathing rate (22/min on
0222-05-25 morning) and without a high blood pressure (93/60 on
0222-05-26 04:42, this patient has HTN history). An analysis of blood
gas might provide some insight into the underlying condition (sequelae
of hypoventilation caused by Covid-19)?</li>
<li>Lab results on 2022-05-25 revealed CRP 20.77 mg/dL, WBC 11.17
*10^3/uL, Neutrophil 82.9 %, urine Bacteria 3+, Sediment-WBC &gt;=100,
Leukocyte esterase 3+</li>
<li>Bacterial infection is treated with Brosym (cefoperazone +
sulbactam) 4g Q12H IVD since 2022-05-25. There is currently no culture
outcome available.</li>
<li>No issue with current medication. Please monitor the effects of
ABX.</li>
</ul>
</div>
</div>
<div id="section-615" class="section level1">
<h1>700588193</h1>
<div id="section-616" class="section level2">
<h2>220525</h2>
<ul>
<li>exam finding
<ul>
<li>2022-06-01 CT - abdomen, pelvis
<ul>
<li>Findings:
<ul>
<li>There are multiple well-defined variable-sized thin wall cysts on
both lung that is c/w lymphangiomyomatosis. In addition, mild right side
Pleura effusion is noted.</li>
<li>There are three fatty masses on both hepatic lobes and the largest
one measuring 1.8 cm in S4 that may be lipomas or angiomyolipomas.</li>
<li>Right kidney shows enlarged in size and multiple angiomyolipomas.
S/P left nephrectomy? All of these findings are c/w tuberous sclerosis
after correlate with prior MRI of brain.</li>
<li>S/P hysterectomy. There is ascites, multiple soft tissue lesions in
the omentum and pelvis that is c/w carcinomatosis.</li>
<li>There are multiple osteoblastic change in the ribs, T-and L-spine
vertebral body, sacrum, and bilateral ilium that are c/w bony
metastases. In addition, There are multple enlarged nodes in para-aortic
space and para-cava space that are c/w Multiple LNs metastases.</li>
<li>The urinary bladder shows small size (passive compression by the
omentum tumor) and S/P suprapubic cystostomy.</li>
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, and spleen.<br />
</li>
<li>There is no bowel wall thickening, and no bowel obstruction.<br />
</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>Impression:
<ul>
<li>Carcinomatosis, bone metastases, and Multiple LNs metastases in
para-aortic space and para-cava space are noted.</li>
</ul></li>
</ul></li>
<li>2022-05-30 KUB
<ul>
<li>Fecal material store in the colon.</li>
<li>Relative Increase soft tissue density projecting at right middle
abdomen and left paracolic gutter space is suspected. Please correlate
with sonography and CT.</li>
<li>S/P drainage catheter insertion from right pelvis and the tip
projecting at the midline lower pelvis.</li>
<li>There are several osteoblastic lesions in the sacrum and bilateral
ilium that may be bony metastases?</li>
</ul></li>
<li>2022-05-24 EKG
<ul>
<li>Normal sinus rhythm</li>
<li>T wave abnormality, consider inferior ischemia</li>
<li>Prolonged QT</li>
</ul></li>
<li>2022-04-19 Patho - uterus with or without SO non-neoplastic/prolapse
<ul>
<li>Uterus Endometrial Cancer Checklist<br />
</li>
<li>Diagnosis:
<ul>
<li>Uterus, endometrium, total hysterectomy — Large cell neuroendocrine
carcinoma with focal small cell neuroendocrine carcinoma<br />
</li>
<li>Uterus, myometrium, total hysterectomy — Large cell neuroendocrine
carcinoma with focal small cell neuroendocrine carcinoma, by direct
invasion<br />
</li>
<li>Uterus, cervix, total hysterectomy — Large cell neuroendocrine
carcinoma with focal small cell neuroendocrine carcinoma, by direct
invasion<br />
</li>
<li>Ovary, right, oophorectomy — Neuroendocrine carcinoma,
metastatic</li>
<li>Ovary, left, oophorectomy — Negative for malignancy</li>
<li>Fallopian tube, bilateral, salpingectomy — Negative for
malignancy</li>
<li>Lymph node, left iliac, dissection — Neuroendocrine carcinoma,
metastatic (2/5)</li>
<li>Lymph node, left obturator, dissection — Neuroendocrine carcinoma,
metastatic (1/6)</li>
<li>Lymph node, right iliac, dissection — Negative for malignancy
(0/3)</li>
<li>Lymph node, right obturator, dissection — Neuroendocrine carcinoma,
metastatic (3/10)</li>
<li>Lymph node, left para-aortic, dissection — Negative for malignancy
(0/1)</li>
<li>Lymph node, right para-aortic, dissection — Neuroendocrine
carcinoma, metastatic (1/2)</li>
<li>Omentum, omentectomy — Neuroendocrine carcinoma, metastatic</li>
<li>Urinary bladder, partial cystectomy — The sections of urinary
bladder show tumor invasion in muscular propria. The resection margin is
involved by tumor.</li>
<li>AJCC 8th edition Pathology stage: pStage IVB, pT3bN2aM1; FIGO Stage:
IVB</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Large cell neuroendocrine carcinoma with focal
small cell neuroendocrine carcinoma.</li>
<li>The immunohistochemical stains reveal CK(-), EMA(-), CD56(+),
Synaptophysin(+), Chromogranin A(+), CD10(-), Cyclin D1(-), SMA(-),
Desmin(-), h-Caldesmon(focal +), CD99(focal +), Melan A(-),
a-inhibin(-).</li>
<li>Histologic Grade: Not available
<ul>
<li>FIGO Grading System applies to endometrioid carcinomas only. Serous,
clear cell, transitional, small cell and large cell neuroendocrine
carcinomas, undifferentiated/dedifferentiated carcinomas, and
carcinosarcomas are generally considered to be high grade and it is not
recommended to assign a histologic grade to these tumor types.)</li>
</ul></li>
<li>Myometrial Invasion: present (whole thickness)</li>
<li>Uterine Serosa Involvement: Present<br />
</li>
<li>Cervical Stromal Involvement: Present<br />
</li>
<li>Other Tissue/ Organ Involvement: Right ovary, Parametrium, side not
specified, Omentum</li>
<li>Margins (required only if cervix and/or parametrium/paracervix is
involved by carcinoma)
<ul>
<li>Ectocervical/Vaginal Cuff Margin: Free<br />
</li>
<li>Parametrial/Paracervical Margin: Not Free</li>
</ul></li>
<li>Lymphovascular Invasion: Present</li>
<li>Regional Lymph Nodes: left iliac: 2/5; left obturator: 1/6; right
iliac: 0/3; right obturator: 3/10; left para-aortic: 0/1; right
para-aortic: 1/2<br />
</li>
<li>Additional Pathologic Findings: Metastatic tumors, measuring up to
0.1 x 0.1 cm, are seen in omentum.</li>
</ul></li>
</ul></li>
<li>2022-04-19 Ascites
<ul>
<li>Diagnosis: Positive for malignancy</li>
<li>Microscopic description: Many small clusters of neoplastic cells
present.</li>
</ul></li>
<li>2022-04-19 Frozen section
<ul>
<li>Preliminary diagnosis: Uterus, corpus, biopsy — malignant tumor
(round blue cell tumor), wait immunohistochemical stains for final
diagnosis</li>
</ul></li>
<li>2022-04-07 Gynecologic ultrasonography
<ul>
<li>Pelvis mass suspected uterine myoma degeneration (uterine pain),
sized 9.57X8.34 cm</li>
</ul></li>
<li>2022-02-16 Peripheral Vascular Test: AV fistula
<ul>
<li>Access type:AV fistula</li>
<li>Site:left forearm</li>
<li>Clinical problem:maturation evaluation</li>
<li>Age of vascular access: 6 weeks</li>
<li>Result: S/P left radiocephalic AV fistula, VF at inflow radial
artery (diameter 3.5mm) 313-403 ml/min, inflow anastomotic diameter
8.2mm(wide patent), juxta-anastomotic cephalic vein diameter 4.8 - 4.6 -
3.3 mm, proposed A-puncture site cephalic vein diameter 5.5mm (depth
3.1mm), continuous forearm cephalic vein, proposed elbow V-puncture site
cephalic vein diameter 5.5mm (depth 3.2mm), cubital vein 6.6mm, patent
cubitocephalic vein with upperarm cephalic vein diameter 6.8mm and PS 42
cm/s, discontinuity between cubital and upper arm basilic vein,
continuous flow pattern over draining cephalosubclavian vein indicating
no overt outflow obstruction</li>
<li>Recommendation
<ul>
<li>Borderline maturation of left radiocephalic AV fistula, may start to
use as dialysis access sited</li>
<li>Keep on gripping exercise</li>
</ul></li>
<li>Suggestion: Clinical follow up</li>
</ul></li>
<li>2021-12-23 2D transthoracic echocardiography
<ul>
<li>Dilated LA and LV; Adequate LV systolic function with normal resting
wall motion</li>
<li>Septal hypertrophy</li>
<li>Minimal pericardiac effusion</li>
<li>Mild MR, moderate TR</li>
<li>Mild pulmonary hypertension</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2021-11-25 MRA - brain
<ul>
<li>Findings
<ul>
<li>Multiple subcortical T2- and FLAIR-hyperintensities in bilateral
cerebral hemispheres. suspected cortical tubers,</li>
<li>Multiple nodualr lesions along walls of lateral ventricles.</li>
</ul></li>
<li>IMP: Tuberous sclerosis.</li>
</ul></li>
<li>2021-10-22 SONO Renal
<ul>
<li>Left kidney, absent s/p nephrectomy.</li>
<li>Right multiple renal tumors, c/w angiomyolipomas.</li>
<li>Liver tumor, ( 1.3cm) , suspected hemangioma.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-06-06 Urine Culture - micturition
<ul>
<li>Trichosporon asahii - colony count &gt; 100,000 CFU/cc</li>
</ul></li>
<li>2022-05-28 Urine Culture - catheterization
<ul>
<li>Staphylococcus aureus - colony count 2,000 CFU/cc</li>
<li>Antibiotic SIR MIC(mcg/mL)
<ul>
<li>Oxacillin S 0.5</li>
<li>Penicillin R &gt;=0.5</li>
<li>Vancomycin S 1</li>
<li>Linezolid S 2</li>
<li>Tetracycline S &lt;=1</li>
<li>Moxifloxacin S &lt;=0.25</li>
<li>Trimethoprim/Sulfamethoxazo S &lt;=10</li>
<li>Gentamicin S &lt;=0.5</li>
<li>Ciprofloxacin S &lt;=0.5</li>
<li>Tigecycline S &lt;=0.12</li>
</ul></li>
</ul></li>
<li>2022-04-21 VRE Culture - anal swab
<ul>
<li>No VRE</li>
</ul></li>
<li>2022-04-21 CRE Culture - anal swab
<ul>
<li>No CRE</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-04-18
<ul>
<li>Surgery
<ul>
<li>Diagnosis: Uterine malignancy with severe abdominal wall adhesion
and bladder invansion</li>
<li>Frozen section: Uterus, corpus, biopsy — malignant tumor (round blue
cell tumor), wait immunohistochemical stains for final diagnosis</li>
<li>Operation:
<ul>
<li>Debulking surgery</li>
<li>Adhesiolysis     - Finding</li>
</ul></li>
<li>Uterus: Multiple papillary lesion over the uterine surface and
invansive to the posterior bladder wall</li>
<li>Frozen section: Uterus, corpus, biopsy — malignant tumor (round blue
cell tumor), wait immunohistochemical stains for final diagnosis</li>
<li>Bilateral adnexa: grossly normal</li>
<li>Bilateral pelvic lymph nodes: normal(-), enlarged(+),
indurated(-)</li>
<li>CDS: moderate bloody ascites, about 500 ml, sent for cytology</li>
<li>Severe adhesion between omentum and abdominal peritoneum, s/p
adhesiolysis</li>
<li>Severe adhesion between posterior bladder wall and uterus, and
malignant invasion of the uterus to bladder, s/p partial cystectomy by
urologic surgeon.</li>
<li>Omentum: multiple hard, variablesized nodules (5~20 mm in diameter)
infracolic omentectomy was done.</li>
<li>Liver: grossly normal &amp; smooth</li>
<li>Appendix: grossly normal</li>
</ul></li>
</ul></li>
<li>2022-04-18
<ul>
<li>Surgery: partial cystectomy</li>
<li>Finding: uterus tumor with bladder invasion over dome and posterior
wall</li>
</ul></li>
<li>2022-01-13
<ul>
<li>Surgery
<ul>
<li>Long-term hemodialysis catheter implantation via right IJV</li>
<li>Intraoperative sonography</li>
</ul></li>
<li>Finding
<ul>
<li>Sonographic localization of right IJV</li>
<li>C-arm fluoroscopic confirmation of catheter tip</li>
<li>Free blood withdrawal of A/V routes</li>
</ul></li>
</ul></li>
<li>2021-12-23
<ul>
<li>Surgery
<ul>
<li>Left radiocephalic AV fistula creation</li>
<li>Intraoperative sonography</li>
</ul></li>
<li>Finding
<ul>
<li>Moderate-sized cephalic vein with continuity to elbow, small radial
artery</li>
<li>S/P left AV fistula, thrill(++)</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Micturition urine culture (2022-06-06) found Trichosporon asahii
colony count &gt; 100,000 CFU/cc which is treated with teicoplanin
currently.</li>
<li>Vomit OB 3+ (2022-06-06) which is being treated with
pantoprazole.</li>
<li>RBC 2.84 *10^6/uL, HGB 7.5 g/dL (2022-06-06), anemia is treated with
Recormon epoetin beta 5000 unit SC QW5, LPRBC is also prepared.</li>
</ul>
</div>
</div>
<div id="section-617" class="section level1">
<h1>700526699</h1>
<div id="section-618" class="section level2">
<h2>220524</h2>
<p>700526699</p>
<p>{drug identification}</p>
<p>Total 14 drugs for identification.</p>
<p>The 10 identified items has been shown as following while the other 4
items still remain unknown:</p>
<ul>
<li>Musco (ambroxol hydrochloride 30mg)</li>
<li>Viartril-S (glucosamine sulfate, polycrystalline 314mg)</li>
<li>Madopar (levodopa 100mg, benserazide 25mg)</li>
<li>MgO (magnesium oxide 250mg)</li>
<li>Merislon (betahistine 6mg)</li>
<li>Evoxac (cevimeline 30mg)</li>
<li>Clopid (clopidogrel hydrogen sulphate 97.875mg)</li>
<li>Rivotril (clonazepam 2mg)</li>
<li>Xanax (alprazolam 0.25mg)</li>
<li>Solaxin (chlorzoxazone 200mg)</li>
</ul>
<p>These drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-619" class="section level1">
<h1>701240441</h1>
<div id="section-620" class="section level2">
<h2>220523</h2>
<p>{upper GI bleeding}</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-22 CT - abdoemn, pelvis
<ul>
<li>Without contrast Abdomen CT showed unremarkable change in the
organs</li>
</ul></li>
<li>2022-05-04 CT - abdomen, pelvis
<ul>
<li>. Please correlate with gastroscopy.</li>
<li>Adenomas in bilateral adrenal gland.</li>
</ul></li>
<li>2022-05-04 Electrocardiography
<ul>
<li>Normal sinus rhythm</li>
<li>Left ventricular hypertrophy with repolarization abnormality</li>
<li>Prolonged QT</li>
</ul></li>
<li>2022-05-04 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>No active bleeder nor coffee ground material was noted during this
exam.</li>
<li>Suboptimal study due to patient’s inability to tolerate the
procedure</li>
<li>Reflux esophagitis LA Classification grade B</li>
<li>Ulcerative mucosa, lower esophagus</li>
<li>Superficial gastritis</li>
</ul></li>
<li>Suggestion：
<ul>
<li>Suggest repeat endoscopy for esophageal ulcer biopsy and detailed
examination later</li>
</ul></li>
</ul></li>
<li>2021-05-14 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Negative finding</li>
</ul></li>
<li>Suggestion
<ul>
<li>OPD f/u</li>
<li>Follow liver function test and AFP</li>
<li>Some area of liver,especially liver dome and S1 was diffcult to
approach and easy missed</li>
</ul></li>
</ul></li>
</ul></li>
<li>Lab data
<ul>
<li>2022-05-22
<ul>
<li>gastric juice Clarity Turbid</li>
<li>gastric juice Color Brown</li>
<li>gastric juice OB 3+</li>
<li>Bilirubin total 1.09mg/dL</li>
<li>WBC DC 94%</li>
<li>CRP 1.3mg/dL</li>
<li>K 2.7mmol/L</li>
<li>serum Glucose 154mg/dL</li>
<li>WBC 11.1*10^3/uL</li>
</ul></li>
<li>2021-05-13 ( Hepatitis B FAQ <a href="https://www.immunize.org/catg.d/p4090.pdf" class="uri">https://www.immunize.org/catg.d/p4090.pdf</a> )
<ul>
<li>HBsAg Reactive 4431.01</li>
<li>Anti-HBc Reactive, 7.6</li>
<li>Anti-HBs 0</li>
<li>Anti-HCV Nonreactive, 0.05</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>TPR, BP were all within normal limits during this hospitalization,
however, gastric juice OB 3+, slightly elevated Bilirubin total, WBC,
WBC DC, CRP and serum Glucose were recorded on 2022-05-23.</li>
<li>EGD was performed on 2022-05-04 and no active bleeding was observed
(in a suboptimal condition). There might be a need for a re-endoscopy.
CT on 2022-05-04 showed sliding hiatus hernia. Patients with documented
pathologic acid reflux who have complete or partial response to proton
pump inhibitors (PPIs) are good candidates for one of the antireflux
procedures. The choice of procedure depends on whether a clinically
significant hiatal hernia is present. ( <a href="https://www.uptodate.com/contents/hiatus-hernia" class="uri">https://www.uptodate.com/contents/hiatus-hernia</a> )</li>
<li>Presently, the patient is rehydrated, receiving appropriate dose of
PPI, and receiving potassium gluconate for his low potassium level
accordingly. All the oral drugs in active prescription can be
administered with nasogasric tube. No issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-621" class="section level1">
<h1>700340565</h1>
<div id="section-622" class="section level2">
<h2>220520</h2>
<p>{small bowel ileus}</p>
<p>[assessment]</p>
<ul>
<li>This patient is diagnosed with small bowel ileus and had past
history of colon cancer in situ s/p OP, inguinal hernia s/p OP.</li>
<li>Small bowel obstruction can be functional or mechanical, the latter
is caused by intraluminal or extraluminal mechanical compression. In
developed countries, adhesion is the most common cause, followed by
hernias, malignancies, and various other infectious and inflammatory
disorders.</li>
<li>TPR 36.2/63/18, BP 122/52 (2022-05-20 05:35), WBC 7.37*10^3/uL,
Neutrophil 93.1%, CRP 1.75mg/dL (2022-05-19)</li>
<li>Currently, no fever, tachycardia, hypotension, or altered mental
state have been observed. If any of these systemic signs develop,
additional laboratory testing may include: Arterial blood gas, serum
lactate, blood culture, and procalcitonin.</li>
<li>The basic plain radiographic examination should include an upright
chest film and upright and supine abdominal films, abdomen - standing
(diaphragm) has been scheduled on 2022-05-20. CT of the abdomen could
also be helpful, however, due to the low renal function, contrast might
be contraindicated.</li>
<li>The patient is currently rehydrated and using laxatives to stimulate
the intestinal lining. His underlying diseases (AF, HTN, CKD) are
treated with corresponding self-carried drugs.</li>
<li>No issue with active prescription.</li>
</ul>
</div>
</div>
<div id="section-623" class="section level1">
<h1>700900778</h1>
<div id="section-624" class="section level2">
<h2>220520</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-04 CT - abdomen, pelvis
<ul>
<li>Recurrent HCCs in left hepatic lobe S/P treatment show stable
disease.</li>
</ul></li>
<li>2022-02-15 CT - abdomen, pelvis
<ul>
<li>Progression of HCCs and portal venous thrombosis. Progression.</li>
</ul></li>
<li>2022-01-24 CT - lung/mediastinum/pleura
<ul>
<li>no abnormality in both lungs or central airways for the cause of
hemoptysis.</li>
</ul></li>
<li>2022-01-11 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Recurrent HCCs and portal venous thrombosis. Progression.</li>
</ul></li>
<li>2022-01-05 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Cirrhosis of liver</li>
<li>Liver tumor, S3, S6, suspicious newly lesion</li>
<li>liver tumor, S4, suspicious HCC post TACE or RFA effect, suspected
viable tumor</li>
</ul></li>
<li>Suggestion
<ul>
<li>arrange liver dynamic CT</li>
</ul></li>
</ul></li>
<li>2021-07-30 CT - abdomen
<ul>
<li>Recurrent HCC 7.17 x 4.61 cm in S3/4 liver is suspected.</li>
<li>The differential diagnosis include cholangiocarcioma.</li>
<li>Please correlate with tumor marker, MRI, or biopsy.</li>
</ul></li>
<li>2021-07-28 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>HCC post segment 6, 7, 8, segmental hepatectomy</li>
<li>HCC post RFA with viable HCC s/p TACE</li>
<li>Liver cirrhosis</li>
<li>Liver cyst</li>
<li>GB sludge?</li>
<li>Fatty liver, mild</li>
<li>Fatty pancreas</li>
</ul></li>
<li>Suggestion
<ul>
<li>Please correlate with other image studies</li>
<li>Please arrange CT or MRI</li>
</ul></li>
</ul></li>
<li>2021-06-18 MRI = liver, spleen
<ul>
<li>Recurrent HCC 2.8 x 2.3 cm in S2/3 liver is highly suspected.</li>
</ul></li>
<li>2021-03-24 CT - abdomen
<ul>
<li>Recurrent HCC 2.2 cm in S3 liver is highly suspected.</li>
<li>The differential diagnosis include cholangiocarcioma.</li>
<li>Please correlate with tumor marker and MRI.</li>
</ul></li>
<li>2021-01-11 MRI - liver, spleen
<ul>
<li>HCC s/p RFA without viable tumor.</li>
</ul></li>
<li>2020-10-21 MRI - liver, spleen
<ul>
<li>HCC in S4 S/P RFA shows complete response.</li>
</ul></li>
<li>2020-06-20 CT - abdomen
<ul>
<li>HCC s/p RFA and Op. No evidence of recurrent HCC in the study</li>
<li>Calcified coronary arteries is found.</li>
</ul></li>
<li>2020-05-05 CT - abdomen
<ul>
<li>Post-op at right lobe liver, developed washout nodule, 1.17cm in
S8/4 region, r/o recurrent HCC.</li>
<li>Liver cyst.</li>
<li>Ascending colon diverticula.</li>
</ul></li>
<li>2019-11-05 CT - abdomen
<ul>
<li>Post-op at right lobe liver, focal low density along the surgical
margin, regression.</li>
<li>Liver cyst.</li>
<li>Ascending colon diverticula.</li>
</ul></li>
<li>2019-05-14 CT - abdomen
<ul>
<li>S/P surgical resection S5/6/7 and part of S3 of the liver.</li>
<li>There is no evidence of tumor recurrence.</li>
<li>A hepatic cyst 2.1 cm in S3.</li>
</ul></li>
<li>2019-03-26 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S3, partial hepatectomy — Hepatocellular carcinoma,
recurrent<br />
</li>
<li>Pathologic Staging (AJCC): Stage II at least (rpT2Nx(cMx))</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Hepatocellular carcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Cytological grade: Ⅲ<br />
</li>
<li>Tumor necrosis: Absent<br />
</li>
<li>Inflammatory cell infiltration: Moderate<br />
</li>
<li>Tumor capsule: Encapsulated with focal infiltrative border<br />
</li>
<li>Satellite nodule: Absent<br />
</li>
<li>Venous (Large Vessel) Invasion: Absent<br />
</li>
<li>Portal Vein Thrombosis: (-)；Capsular vein invasion: (-)<br />
</li>
<li>Perineural Invasion: Not identified<br />
</li>
<li>Bile duct Invasion: Absent<br />
</li>
<li>Pathologic Staging (rpTNM): Stage II at least (rpT2Nx(cMx))<br />
</li>
<li>Margins
<ul>
<li>Parenchymal Margin: Uninvolved by invasive carcinoma, 0.5 cm from
closest margin<br />
</li>
<li>Hepatic capsule: Uninvolved by invasive carcinoma<br />
</li>
</ul></li>
<li>Additional Pathologic Findings: Focal fatty change in tumor cells
and large cell dysplasia</li>
<li>Hepatitis: Hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score=4 (interphase hepatitis=1/4,
confluent necrosis=0/6, focal necrosis=1/4, portal inflammation=2/4)
(Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F4 (Corresponding Metavir F3, septal fibrosis)</li>
<li>Fatty Change: Present (10%)<br />
</li>
</ul></li>
</ul></li>
<li>2019-03-26 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S7, partial hepatectomy — Hepatocellular carcinoma,
recurrent<br />
</li>
<li>Pathologic Staging (AJCC): Stage II at least (rpT2Nx(cMx))</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Hepatocellular carcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Cytological grade: Ⅲ<br />
</li>
<li>Tumor necrosis: Mild<br />
</li>
<li>Inflammatory cell infiltration: Moderate<br />
</li>
<li>Tumor capsule: Encapsulated with focal infiltrative border<br />
</li>
<li>Satellite nodule: Absent<br />
</li>
<li>Venous (Large Vessel) Invasion: Absent<br />
</li>
<li>Portal Vein Thrombosis: (-)；Capsular vein invasion: (+)<br />
</li>
<li>Perineural Invasion: Not identified<br />
</li>
<li>Bile duct Invasion: Absent<br />
</li>
<li>Pathologic Staging (rpTNM): Stage II at least (rpT2Nx(cMx))<br />
</li>
<li>Margins
<ul>
<li>Parenchymal Margin: Uninvolved by invasive carcinoma, 0.8 cm from
closest margin<br />
</li>
<li>Hepatic capsule: Uninvolved by invasive carcinoma<br />
</li>
</ul></li>
<li>Additional Pathologic Findings: Fatty change in tumor cells and
Large cell dysplasia</li>
<li>Hepatitis: Hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score=4 (interphase hepatitis=1/4,
confluent necrosis=0/6, focal necrosis=1/4, portal inflammation=2/4)
(Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F4 (Corresponding Metavir F3, septal fibrosis)<br />
</li>
<li>Fatty Change: Present (10%)<br />
</li>
</ul></li>
</ul></li>
<li>2019-03-22 Visceral Angiography 2 vessels
<ul>
<li>IMP: Bil. liver tumors suspected recurrent HCCs</li>
</ul></li>
<li>2019-03-08 MRI - abdomen
<ul>
<li>Hepatoma measuring 2.1 cm in S3 of the liver is first
impressed.<br />
</li>
<li>Please correlate with clinical condition and AFP.<br />
</li>
<li>According to AJCC staging system,8th edition, CT staging of
HCC:T1N0Mx</li>
</ul></li>
<li>2018-06-19 CT - abdomen
<ul>
<li>HCC, s/p segmental hepatectomy</li>
<li>No evidence of local recurrence</li>
</ul></li>
<li>2018-01-11 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, segment 6, 7, 8, segmental hepatectomy — Hepatocellular
carcinoma<br />
</li>
<li>Pathologic Staging (AJCC): Stage II (pT2Nx(cMx)</li>
</ul></li>
</ul></li>
<li>2018-01-05 Visceral Angiography 2 vessels
<ul>
<li>Right liver tumor suspected HCC as described. Another small
perfusion defect (5mm) at right hepatic lobe.</li>
</ul></li>
<li>2017-12-13 CT - abdomen
<ul>
<li>Imaging Report Form for Hepatocellular Carcinoma
<ul>
<li>A poor enhancing tumor (4.6cm) in S7 of liver suspected hypovascular
HCC.</li>
<li>Hepatocellular carcinoma (T1N0Mx, radiology staging: stage I)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-05-14 Radiofrequency ablation
<ul>
<li>Course: By sono-guided, RFA probe (COVUDIEN Cool-tip ACT 2030, 17
Fr) was inserted into the S4/5 tumor with whiteout appearance. (stop
after 2 pauses)</li>
<li>Time:
<ul>
<li>1st (inf part) 5:56, Power (Max100- Min60); Impedance (Max100-
Min65); cool time 4:32, temp: 76C</li>
<li>2nd (sup part) 4:32, Power (Max 90- Min60); Impedance (Max95-
Min65); cool time 3:08, temp: 75C</li>
</ul></li>
<li>Findings: HCC post RFA</li>
</ul></li>
<li>2020-05-29 Radiofrequency ablation
<ul>
<li>Course: By sono-guided, RFA probe (COVUDIEN Cool-tip ACT 2020, 17
Fr) was inserted into the S4/8 tumor with whiteout appearance. (stop
after 1 pause)</li>
<li>Time: total 6:11; Power (Max80- Min60); Impedance (Max125-
Min85)</li>
<li>Findings: HCC post RFA</li>
</ul></li>
<li>2019-03-25 Partial hepatectomy
<ul>
<li>Finding
<ul>
<li>rcurrent S3 tumor 2.0 x 1.2 x 1.2 cm</li>
<li>S7 tumor 2.5 x 2.0 x 2.0 cm</li>
<li>mild fibrosis</li>
</ul></li>
</ul></li>
<li>2018-01-10 Segemental hepatectomy-three segement
<ul>
<li>Finding
<ul>
<li>4.2 x 3.5 x 3.0 cm hepatic tumor at S6-7-8</li>
<li>small nodule at S6 suspected FNH or small HCC</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-11 ~ undergoing - FOLFOX</li>
<li>2022-01-25 - atezolizumab + bevacizumab</li>
<li>2021-05-12 ~ 2021-08-16 - nivolumab</li>
<li>2019-04-23 ~ 2019-07-02 - sorafenib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Under the current regimen, the recurrent HCC in the left hepatic
lobe was stable on a recent CT (20202-05-04).</li>
<li>No issue with active prescription.</li>
</ul>
</div>
</div>
<div id="section-625" class="section level1">
<h1>701000332</h1>
<div id="section-626" class="section level2">
<h2>220518</h2>
<p>{Vulvar Cancer}</p>
<p>[exam findings]</p>
<ul>
<li><p>2023-05-11 CXR</p>
<ul>
<li>Ground glass opacities in bil. lungs.</li>
</ul></li>
<li><p>2023-05-02 CXR</p>
<ul>
<li>Rt subpulmonary effusion</li>
<li>patchy bilateral areas of consolidation and ground-glass opacities
as well as reticular opacities over both lungs</li>
<li>Osteoblastic metastasis in spine and ribs</li>
</ul></li>
<li><p>2023-04-26 MRA - brain</p>
<ul>
<li>Clinical information: Multiple lung metastases from carcinoma of the
vulva, s/p excision, s/p simple vulvectomy, rcT1b(cN0)M1, stage IVB</li>
<li>Findings:
<ul>
<li>Scattered numerous enhancing nodular lesions over whole cerebrum and
cerebellum. The largest one (2.6cm) over left cerebellar lobe. Favor
metastases.</li>
<li>Multifocal peritumoral edema over cerebral hemispheres and left
cerebellar lobe.</li>
<li>MR angiography of the brain shows normal intracranial vessel
including circle of willis.</li>
</ul></li>
</ul></li>
<li><p>2023-04-07 CT - abdomen</p>
<ul>
<li>Indication and History
<ul>
<li>Vulvar ca with lung and bone met status</li>
<li>Skull palpable mass (20201002) which grew up for 6 months -&gt;
improved after RT and chemo (20210105)</li>
<li>asks for follow up myoma due to she feels vulvar discomfort of rt
vulvar tumor.</li>
</ul></li>
<li>Findings:
<ul>
<li>There is IHDs dilatation and an ill-defined equivocal poor enhancing
lesion 1 cm in S2 of the liver. Please correlate with MRI.</li>
<li>There are multiple osteoblastic change of the T-spine and L-spine
that are c/w osteoblastic bony metastases.</li>
<li>Right side Pleura effusion</li>
<li>The gallbladder shows small contracted.</li>
</ul></li>
<li>Impression:
<ul>
<li>There is IHDs dilatation and an ill-defined equivocal poor enhancing
lesion 1 cm in S2 of the liver. Please correlate with MRI.</li>
<li>There are multiple osteoblastic change of the T-spine and L-spine
that are c/w osteoblastic bony metastases.</li>
</ul></li>
</ul></li>
<li><p>2023-02-24 Tc-99m MDP bone scan with SPECT</p>
<ul>
<li>The Tc-99m MDP bone scan with SPECT 3 hrs after injection of 20 mCi
of radiotracer revealed increased activity in the skull, both rib cages,
multiple C-, T- and L-spines, sternum, left sternocalvicular junction,
left S-I joint and left femoral shaft, in whole body survey.</li>
<li>IMPRESSION: In comparison with the previous study on 2021/08/09,
some new bone lesions are noted and most of the previous bone lesions
are more evident, indicating multiple bone metastases in
progression.</li>
</ul></li>
<li><p>2023-02-22 Skull PA + Lat.</p>
<ul>
<li>Several small nodular defects in the skull are suspected. please
correlate with clinical condition or CT.</li>
</ul></li>
<li><p>2023-02-02 SONO - chest</p>
<ul>
<li>pleural effusion, but only trivial amounts</li>
<li>right side.</li>
</ul></li>
<li><p>2023-01-31 Mammography</p>
<ul>
<li>Screening digital mammography of both breasts with MLO and CC views:
<ul>
<li>Old mammographic study: 2021-01-15 (BIRADS 1)</li>
<li>Breast composition: category c (The breasts are heteregeneously
dense, which may obscure small masses).</li>
</ul></li>
<li>Impression: Dense breast. No mammographic evidence of malignancy,
suggest clinical correlation and regular follow up.
<ul>
<li>BI-RADS: Category 1: negative. - annual screening.</li>
</ul></li>
</ul></li>
<li><p>2022-12-29 CT - abdomen</p>
<ul>
<li>History and indication: Multiple lung metastases from carcinoma of
the vulva, s/p excision, s/p simple vulvectomy, rcT1b(cN0)M1, stage
IVB</li>
<li>With and without-contrast CT of abdomen-pelvis revealed:
<ul>
<li>S/P operation.</li>
<li>Multiple bony metastases.</li>
<li>A patchy density (3.2cm) at RUL. Right pleural effusion.</li>
<li>Retroversion of uterus. A tumor (3.0cm) at uterus.</li>
</ul></li>
<li>Impression:
<ul>
<li>S/P operation.</li>
<li>Multiple bony metastases.</li>
<li>A patchy density (3.2cm) at RUL. Right pleural effusion.</li>
</ul></li>
</ul></li>
<li><p>2023-03-19, -03-10, -02-05, -01-15, 2022-10-28, -10-25, -09-27,
-09-22, -08-22, -06-24 CXR</p>
<ul>
<li>S/P metalic autosuture projecting at right upper lung zone.</li>
<li>Few nodular opacity projecting in right lung are suspected. Please
correlate with CT.</li>
<li>Right diaphragmatic tenting is noted, which may be due to lung
volume decrease of RUL.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
<li>Osteoblastic change of right upper ribs are suspected that are
compatible with bony metastases after correlate with CT.</li>
</ul></li>
<li><p>2022-09-06 CT - abdomen</p>
<ul>
<li>Clinical vulva cancer.</li>
<li>Sclerotic densities in the bones, suspected bone metastasis.</li>
<li>Uterine tumor, suspected uterine myoma.</li>
<li>Regression of left lobe liver hypodense lesions.</li>
<li>Bilateral pleural effusion, more prominent at right side.</li>
<li>Consolidations in right lower lung.</li>
<li>Fibrotic infiltrates in RUL.</li>
</ul></li>
<li><p>2022-08-16 Gynecologic ultrasonography</p>
<ul>
<li>LT adnexae: free</li>
<li>Uterine myoma</li>
</ul></li>
<li><p>2022-07-05 Laryngoscopy</p>
<ul>
<li>Findings
<ul>
<li>bi nasopharynx smooth, hypopharynx smooth mucosa, normal vocal
function, right vocal cord anterior part edema,</li>
</ul></li>
<li>Conclusion
<ul>
<li>chronic corditis</li>
<li>no evidence of vocal palsy</li>
</ul></li>
</ul></li>
<li><p>2022-06-16 Neurosonology</p>
<ul>
<li>Normal vessel wall in bilateral extracranial carotid arteries.</li>
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows.</li>
<li>Poor left temporal windows for transcranial insonation.</li>
</ul></li>
<li><p>2022-06-16 Brainstem Auditory Evoked Potentials, BAEP</p>
<ul>
<li>Findings
<ul>
<li>Normal absolute and inter-peak interval latencies of brainstem
auditory evoked potentials from both ear.</li>
</ul></li>
<li>Conclusion
<ul>
<li>Normal BAEP.</li>
</ul></li>
</ul></li>
<li><p>2022-06-15 MRI - brain</p>
<ul>
<li>mild dilated intraventricular and extraventricular CSF spaces</li>
<li>punctate white matter gliosis in the bilateral frontal, parietal and
parietal lobes; old lacunar infarction in the pons.</li>
<li>unremarkable change in the skull base</li>
<li>no abnormal brain parenchymal enhancement.</li>
</ul></li>
<li><p>2022-06-02 CT - lung/mediastinum/pleura</p>
<ul>
<li>Finding
<ul>
<li>Chest
<ul>
<li>Septal infiltration and peribronchovascular bundle infiltration is
found at residual lung fields. In comparison with CT dated on
2022-02-23, the lesion is stationary.</li>
<li>Bilateral hilar and mediastinal lymphadenopathy is found.</li>
<li>Patent airway is found.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Right pleural effusion is found.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>Increased intestinal gas is found.</li>
<li>Low density lesion at left lobe liver is found, causing left IHD
focal dilatation. Stable.</li>
<li>The spleen, pancreas, both kidneys and adrenals are intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>There is no ascites accumulation at abdominal cavity.</li>
</ul></li>
</ul></li>
<li>Imp: Compatible with bilateral lung mets, liver and bone meta with
stationary tumor extension.</li>
</ul></li>
<li><p>2022-05-24 Gynecologic ultrasonography</p>
<ul>
<li>Uterine myoma</li>
</ul></li>
<li><p>2022-04-08 Chest XR</p>
<ul>
<li>S/P port-A implantation.</li>
<li>S/P metalic autosuture projecting at right upper lung zone.</li>
<li>Few nodular opacity projecting in right lung are suspected. Please
correlate with CT.</li>
<li>Fibrosis at right upper lung is noted. Please correlate with
clinical history and CT.</li>
<li>Right diaphragmatic tenting and right hilum elevation is noted,
which may be due to lung volume decrease of RUL.</li>
<li>Osteoblastic change of right upper ribs are suspected that are
compatible with bony metastases after correlate with CT.</li>
</ul></li>
<li><p>2022-03-14 Laryngoscopy</p>
<ul>
<li>subacute corditis, improved with vocal cord fibrotic change</li>
<li>no evidence of vocal palsy</li>
</ul></li>
<li><p>2022-03-11 Chest XR</p>
<ul>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
</ul></li>
<li><p>2022-03-01 Gynecologic ultrasonography</p>
<ul>
<li>Uterine myoma</li>
</ul></li>
<li><p>2022-02-23 CT - lung/mediastinum/pleura</p>
<ul>
<li>Multiple lung metastases from carcinoma of the vulva, s/p excision,
s/p simple vulvectomy, rcT1b(cN0)M1, stage IVB</li>
<li>comparison made with previous CT dated on 2021/11/06
<ul>
<li>Lungs
<ul>
<li>stationary of metastatic nodules and septal and peribronchovascular
interstial thickening in both lungs (most severe at RUL and LLL)</li>
<li>stationary of metastatic lymphadenopathy in Rt precarinal space and
both hila</li>
</ul></li>
<li>Vessels:
<ul>
<li>Aorta: normal caliber, minimal atherosclerotic change of aortic
arch.</li>
<li>Central pulmonary arteries: normal caliber.</li>
</ul></li>
<li>Heart: normal in size of cardiac chambers.</li>
<li>Pleura: bilateral pleural effusions and scattered Rt upper pleural
thickening.</li>
<li>Chest wall: small LNs in left supraclavicular fossa</li>
<li>Visible abdominal contents:
<ul>
<li>several poorly enhanced areas in peripheral S6 and left lobe of
liver, stable.</li>
<li>normal appearance of gallbladder.<br />
</li>
<li>unremarkable of the spleen, adrenal glands, pancreas, and both
kidneys. no enlarged lymph node. no onvious ascites.</li>
</ul></li>
<li>Visualized bones: blastic metastatic change in multiple vertebrae,
sternum, and ribs, stable.</li>
</ul></li>
<li>Impression:
<ul>
<li>stationary metastatic lung, liver, bony lesions, and LAPs in
mediastinum and hila, as compared with CT dated on 2021/11/06</li>
</ul></li>
</ul></li>
<li><p>2022-01-17 Laryngoscopy</p>
<ul>
<li>acute corditis, maybe related to previous Foster use</li>
<li>no evidence of vocal palsy</li>
</ul></li>
<li><p>2022-01-03 Laryngoscopy</p>
<ul>
<li>acute corditis, maybe related to previous Foster use or
chemotherapy</li>
<li>no evidence of vocal palsy</li>
</ul></li>
<li><p>2021-11-06 CT - lung/mediastinum/pleura</p>
<ul>
<li>Compatible with vulva cancer with left lower lobe lung meta. In
progression.</li>
<li>Mediastinal lymphadenopathy, stable</li>
<li>Liver and adrenal meta. In progression.</li>
<li>Bone meta. stationary.</li>
</ul></li>
<li><p>2021-10-26 Bronchodilator test</p>
<ul>
<li>FVC: 50%, FEV1: 44%, FEV1/FVC: 72%.</li>
<li>negative bronchodilator test.</li>
</ul></li>
<li><p>2021-08-09 Tc-99m MDP whole body bone scan</p>
<ul>
<li>The Tc-99m MDP bone scan with SPECT 3 hrs after injection of 20 mCi
of radiotracer revealed increased activity in the left parietal region
of the skull, both rib cages, multiple C-, T- and L-spine, sternum, left
sternocalvicular junction, upper portion of left S-I joint and left
femoral shaft, in whole body survey.</li>
<li>Impression: In comparison with the previous study on 2021/04/09, all
lesions are old and show less evident, indicating multiple bone
metastases with partial response to current therapy.</li>
</ul></li>
<li><p>2021-07-19 CT - lung/mediastinum/pleura</p>
<ul>
<li>regression metastatic lung lesions and LAPs in mediastinum and hila,
but progression of bony metastasis compared with Ct on 2021/04/15.</li>
</ul></li>
<li><p>2021-04-09 Patho</p>
<ul>
<li>Skin, left post-auricular, excision - poorly differentiated
carcinoma, metastatic.</li>
<li>IHC: ER positive (strong, &gt;95%), PR: positive (moderate, 90%),
CK20(-), P40(-), CEA(+).</li>
</ul></li>
<li><p>2021-02-25 Patho</p>
<ul>
<li>scalp metastatic cancer nodule</li>
<li>IHC: CD56(-), GATA-3(+), mamoglobin(focal +). The pattern is the
same as those of S2019-15699/S2019-15746.</li>
</ul></li>
<li><p>2021-01-29 MRA - Brain</p>
<ul>
<li>A newly developed left cerebellar metastasis.</li>
<li>Marked regression of the left parietal skull and scalp
metastasis.</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
<li><p>2021-01-13 CT</p>
<ul>
<li>metastasis 1.2cm in S2 liver is suspected.</li>
<li>there are three soft tissue nodules in left diaphragm.</li>
</ul></li>
<li><p>2020-10-28 Tc-99m MDP whole body bone scan</p>
<ul>
<li>Suspected Ca with multiple bone mets in the left parietal region of
the skull, both rib cages, some T- and L-spine, and left femoral shaft,
M/3.</li>
<li>Suspected benign lesions in C-spine, maxilla, mandible, bilateral
sternocalvicular nctions, shoulders, elbows, knees, and right foot.</li>
</ul></li>
<li><p>2020-10-21 CT</p>
<ul>
<li>newly developed T3 vertebral metastasis.</li>
</ul></li>
<li><p>2020-07-06 MRI - Brain</p>
<ul>
<li>Left parietal scalp, skull metastasis with intracranial
extension.</li>
</ul></li>
<li><p>2020-07-03 CT</p>
<ul>
<li>post operative change at right upper lobe with pleural thickening,
in progression.</li>
<li>recurrent pleural meta is favored.</li>
</ul></li>
<li><p>2019-09-18 Patho</p>
<ul>
<li>Lung, right, upper, middle, lower lobe, wedge resection - poorly
differentiated carcinoma, metastatic.</li>
<li>Histologic Type: carcinoma, The morphology is consistent with
S2017-19644.</li>
<li>IHC: GATA3(+), Mammaglobin A(focal +), ER(+, 100%), PR(+, 20%),
HER-2/Neu(Ab): Negative (1+), PAX8(-), p63(-), Uroplakin II(-),
CK5/6(-), Chromogranin A(-), CD56(-), and TTF-1(-). The Ki-67 is about
40%. The results are most compatible with breast origin.</li>
</ul></li>
<li><p>2019-09-05 CT: multiple lung nodules, favor metastatic
lesions.</p></li>
<li><p>2019-06-03 CT: uterine myoma is suspected.</p></li>
<li><p>2017-12-13 CT: a 3.0cm tumor at uterus.</p></li>
<li><p>2017-11-28 Patho</p>
<ul>
<li>Right vulva, excision biopsy - Carcinoma, margin positive.</li>
<li>IHC: GATA-3(+), GCDFP-15(-), CK7(+), CK20(-), p40(-), p16(focal +),
HMB-45(-).</li>
</ul></li>
</ul>
<p>[consultation]</p>
<ul>
<li>2023-05-15 Family Medicine
<ul>
<li>Q
<ul>
<li>The 64 y/o woman has vulva cancer with mulitple lung and brain mets
/p chemotherapy and under RT. Due to con’s disturbance with V/S
unstable, so we need your help for hospice care. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>64-year-old female, DM, HTN, dyslipidemia
<ul>
<li>Vulva cancer with mulitple lung and brain metastasis s/p
chemotherapy, under radiotherapy</li>
<li>This time suffer from alteration of consciousness</li>
<li>Consciousness E3V3M5, ECOG 4</li>
<li>Advance Care Planning Document” or “Advance Directive.” (+)</li>
<li>We will arrange hospice combine care and follow up her
condition</li>
<li>Consider hospice ward if families agreed with palliative
treatment</li>
<li>Thanks for your consultation.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2023-04-26 Radiation Oncology
<ul>
<li>A
<ul>
<li>A: Carcinoma of the vulva, right aspect, s/p excision, with positive
margin, s/p simple vulvectomy, stage pT1b(cN0M0), s/p radiotherapy, with
lung metastastases, s/p operation (thoracoscopic segmentectomy of lung,
thorecoscopic excision of mediastinal tumor, thoracoscopic wedge or
partial resection of the Lung), and s/p chemotherapy, with left parietal
scalp and skull metastasis, s/p chemotherapy and radiotherapy, and
status during chemotherapy, with multiple brain metastases.</li>
<li>P: Radiotherapy is indicated for this patient with the following
indicators: multiple brain metastases.
<ul>
<li>Goal: palliation</li>
<li>Treatment target and volume: metastatic brain lesions</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 2400cGy/12 fractions of the metastatic
brain lesions</li>
<li>The patient already received radiotherapy before. The treatment
modality and the possible effects of re-irradiation were well explained
to the patient and her husband. They understand and agree to receive
radiotherapy, The treatment planning of radiotherapy will be started at
0930, 2023-05-03.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2023-04-24 Neurology
<ul>
<li>Q
<ul>
<li>She was admitted for chemotherapy on 4/24,but according to family,
she began to repetitively chew with her mouth and slurred speech was
noted for one week, suspect parkinson’s disease.</li>
<li>We need your expertise for further management, thanks</li>
</ul></li>
<li>A
<ul>
<li>repeated praying in the morning 1 week ago, vertigo in these
days</li>
<li>NE: aware, fluent speech, chewing of mouth, suspect right visual
hemineglect, left side weakness and dysmetria
<ul>
<li>with equivocal left Babinski signs</li>
</ul></li>
<li>Impression:
<ul>
<li>suspect recurrent brain metastasis and encephalopathy</li>
</ul></li>
<li>Suggest:
<ul>
<li>brain MRA with contrast might be arranged</li>
<li>I would like to follow up this patient. Thank you for your
consultation.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-06-13 Neurology
<ul>
<li>Q
<ul>
<li>The 63 y/o woman has Multiple lung metastases from carcinoma of the
vulva, s/p excision, s/p simple vulvectomy, rcT1b(cN0)M1, stage IVB. She
has dizziness progress in recently days. Anemia, but no SOB or
tachycardia condition, so we need your help for dizziness management.
Thanks!</li>
</ul></li>
<li>A
<ul>
<li>This is a 63 y/o woman with history of vulvar carcinoma with
multiple lung metastases and cerebellar
metastasis, s/p excision, s/p simple vulvectomy, rcT1b(cN0)M1,
stage IVB. She complained positional dizziness and vertigo sensation
while lying down for one week. Anemia was also noted. Piracetam and
betahistin were prescibed since 20220610. She felt better after taking
betahistin. She denied focal weakness, unsteady gait, falling, nausea,
vomiting, headache, tinnitus, and hearing impairment.</li>
<li>NE
<ul>
<li>GCS: E4V5M6<br />
-VF: no hemianopia -light reflex: 3/3 +/+ -EOM: free and full -no facial
palsy<br />
-Muscle power:<br />
-RUE/LUE: 5/5 -RLE/LLE: 5/5 -Babinki: plantar/plantar -Sensory: intact
and symmetric -FNF: np dysmetria -HKS: no dysmetria -Gait: narrow base,
steady -Tandem gait: no falling.</li>
</ul></li>
<li>Exam
<ul>
<li>2021/01/29 brain MRI: left cerebellar metastasis</li>
<li>2022/06/12 Hb:8.9</li>
</ul></li>
<li>Assessment
<ul>
<li>central vertigo, suspected brain metastasis, suspected VBI
(Vertebrobasilar insufficiency)</li>
</ul></li>
<li>Suggestion
<ul>
<li>arrange brain MRI with/without contrast to r/o new brain
metastasis.</li>
<li>arrange carotid-duplex, BAEP.</li>
<li>Keep current Nilasen 1 tab BID.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-25 Oral and Maxillofacial Surgery
<ul>
<li>Q
<ul>
<li>The 63 y/o woman has Multiple lung metastases from carcinoma of the
vulva, s/p excision, s/p simple vulvectomy ,rcT1b(cN0)M1,stage IVB. She
received chemotherapy on 1/25-1/27.</li>
<li>Due to complicated extraction of tooth 24, we need your help for
removed stitches on 1/27.</li>
</ul></li>
<li>A
<ul>
<li>We had removed stitches of oral cavity were done.</li>
<li>Education home care.</li>
</ul></li>
</ul></li>
<li>2021-04-29 Neurosurgery
<ul>
<li>Q
<ul>
<li>For suspect radiculopathy due to bone metastasis of spine</li>
<li>A case of vulvar carcinoma with lung, liver and bone metastases in
progression</li>
<li>This 62 y/o woman with DM, cerebral vascular calcification, left
breast benign neoplam s/p excision, right vulvar carcinoma s/p
vulvectomy on 2018/01/15. She also received chemtherapy, immunotherapy
Opdivo. However, the disease still progressed. CT in March showing
mediastinal LN, lung, liver and bone metastases in progression. This
time, She was admitted for salvage treatment.</li>
<li>Right shoulder and arm pain was complained. Bone scan on 2021/04/09
revealed increased activity in the left parietal region of the skull,
both rib cages, multiple C-, T- and L-spine, sternum, left
sternocalvicular junction, upper portion of left S-I joint and left
femoral shaft in whole body survey.</li>
<li>Due to bone mets of spine noted, we need your expertise for whether
there’s rediculopathy due to bone meta of spine and further management
suggestion.</li>
</ul></li>
<li>A
<ul>
<li>We areconsulted due to bone metastasis (spine).</li>
<li>Suggest conservative treatment (medication) first.</li>
<li>Surgical intervention is not recommended at present.</li>
<li>C-spine MRI with may be arranged if the sign of radiculomyelopathy
worsening.</li>
</ul></li>
</ul></li>
<li>2020-11-20 Oral and Maxillofacial Surgery
<ul>
<li>A
<ul>
<li>Due to we need do the XGEVA, so we need your help for
management.</li>
</ul></li>
<li>Q
<ul>
<li>This is a 62 female suffer from tooth pain over lower left jaw for a
while.</li>
<li>S: She complain tooth pain when drinking water.<br />
</li>
<li>O: 45: cervical abrasion without pulp exposed, EPT(+), Cold test(+),
lingering pain(?)(patient can not distingulish), percussion(-),
palpation(-) probing WNL.</li>
<li>A: tooth 45 pulpitis</li>
<li>P:
<ul>
<li>Take dental Pano film and physical examination for evaluation.</li>
<li>Explain the finding and treatment plan to the patient.</li>
<li>Suggest desensitization toothpast first</li>
<li>OPD for 45 OD or endodontic treatment if irriversable pulpitis
occur. Do not need to extraction at this moment.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[surgical operation]</p>
<ul>
<li>2021-04-08 Excision of left post-auricular tumor</li>
<li>2021-02-25 Excision of scalp tumor</li>
<li>2018-01-15 Vulvectomy</li>
<li>2017-11-28 Excision of right upper vulvar major</li>
</ul>
<p>[chemoimmunotherapy]</p>
<ul>
<li><p>2023-03-20 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p>
<ul>
<li>dexamethasone 4mg + diphenhydramine 30mg + granisetron 2mg + NS
250mL</li>
</ul></li>
<li><p>2023-02-22 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p>
<ul>
<li>dexamethasone 4mg + diphenhydramine 30mg + granisetron 2mg + NS
250mL</li>
</ul></li>
<li><p>2023-02-06 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p>
<ul>
<li>dexamethasone 4mg + diphenhydramine 30mg + granisetron 2mg + NS
250mL</li>
</ul></li>
<li><p>2023-01-15 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p>
<ul>
<li>dexamethasone 4mg + diphenhydramine 30mg + granisetron 2mg + NS
250mL</li>
</ul></li>
<li><p>2022-12-26 - irinotecan liposome 70mg/m2 97mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p></li>
<li><p>2022-11-25 - irinotecan liposome 70mg/m2 97mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p></li>
<li><p>2022-11-04 - irinotecan liposome 70mg/m2 97mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p></li>
<li><p>2022-10-13 - irinotecan liposome 70mg/m2 97mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p></li>
<li><p>2022-09-27 - irinotecan liposome 70mg/m2 97mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3880mg 46hr</p></li>
<li><p>2022-09-05 - irinotecan liposome 70mg/m2 96mg 1.5hr + leucovorin
400mg/m2 550mg 2hr + fluorouracil 2800mg/m2 3850mg 46hr</p></li>
<li><p>2022-08-22 - irinotecan liposome 70mg/m2 96mg 1.5hr + leucovorin
400mg/m2 540mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p></li>
<li><p>2022-07-29 - irinotecan liposome 70mg/m2 96mg 1.5hr + leucovorin
400mg/m2 540mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p></li>
<li><p>2022-07-13 - irinotecan liposome 70mg/m2 96mg 1.5hr + leucovorin
400mg/m2 540mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p></li>
<li><p>2022-06-28 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 540mg 2hr + fluorouracil 2800mg/m2 3800mg 46hr</p></li>
<li><p>2022-06-15 - irinotecan liposome 70mg/m2 95mg 1.5hr + leucovorin
400mg/m2 540mg 2hr + fluorouracil 2800mg/m2 3790mg 46hr</p></li>
<li><p>2022-05-30 - irinotecan liposome 70mg/m2 90mg 1.5hr + leucovorin
400mg/m2 530mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</p></li>
<li><p>2022-05-06 - irinotecan liposome 70mg/m2 90mg 1.5hr + leucovorin
400mg/m2 530mg 2hr + fluorouracil 2800mg/m2 3700mg 46hr</p></li>
<li><p>XXXX</p></li>
<li><p>2021-12-27 ~ undergoing - Onivyde (irinotecan liposome) +
FL</p></li>
<li><p>2021-04-28 ~ 2021-12-03 - FOLFOX + Bevacizumab</p></li>
<li><p>2020-11-24 ~ 2021-04-06 - Nivolumab</p></li>
<li><p>2020-10-02 -</p></li>
<li><p>2020-07-23 ~ 2020-09-25 - Cisplatin + Vinorelbine, Vinorelbine,
take turns alternately</p></li>
<li><p>2019-10 ~ 2019-12 - Cisplatin + Paclitaxel</p></li>
</ul>
<div id="section-627" class="section level3">
<h3>==========</h3>
</div>
<div id="section-628" class="section level3">
<h3>2022-09-28</h3>
<p>[assessment]</p>
<ul>
<li>The blood sugar level was 76 mg/dL on 2022-09-28 06:05; Glimet
(glimepiride plus metformin) might be held temperately. Please follow up
on the new serum glucose readings.</li>
</ul>
</div>
<div id="section-629" class="section level3">
<h3>2022-06-13</h3>
<p>[assessment]</p>
<ul>
<li>CT 2022-06-02 showed the bilaterial lung mets was stationary.</li>
</ul>
</div>
<div id="section-630" class="section level3">
<h3>2022-05-30</h3>
<p>[assessment]</p>
<ul>
<li>Compared to the previous CT images, which were taken on 2021-11-06,
the last CT images on 2022-02-23 revealed metastatic lung, liver, bones,
and a LAP in the mediastinum and hilar region were stationary. It is
possible that a new CT scan will be necessary.</li>
<li>Since 2020-04-10, almost every CXR has shown fibrosis in the right
upper lung. If lung fibrosis becomes a concern, nintedanib or
pirfenidone are likely to provide some relief.</li>
<li>The blood sugar recorded was 142 mg/dL (2022-05-30 06:54, HbA1c 6.8%
2022-05-24) while on Galvus Met (vildagliptin + metformin) and Glimet
(glimepiride + metformin). In the event of a spike observed, some
insulin may be beneficial.</li>
</ul>
</div>
<div id="section-631" class="section level3">
<h3>2022-03-17</h3>
<p>[assessment]</p>
<ul>
<li>In contrast to previous CT images on 2021-11-06, CT images updated
on 2022-02-23 showed stationary metastatic lung, liver, bones, and LAPs
in the mediastinum and hilar region.</li>
<li>Lab tests reported on 2022-03-16 indicated no abnormalities in liver
and kidney function, but low WBC, RBC, and HGB levels were observed,
which should be monitored as usual in patients undergoing
chemotherapy</li>
<li>According to the blood sugar level as of 2022-03-17, the level is
slightly low, which should be noted and monitored if anti-DM drugs need
to be adjusted.</li>
</ul>
</div>
</div>
</div>
<div id="section-632" class="section level1">
<h1>701385762</h1>
<div id="section-633" class="section level2">
<h2>220517</h2>
<ul>
<li>initial presentation
<ul>
<li>2022-05-12 Emergency
<ul>
<li>abd pain for 1 week, poor appetitie for 3 days</li>
<li>lower leg edema 3+</li>
<li>bloody stool passage once months ago</li>
<li>denied abd Op hx</li>
<li>BW: 65 kg -&gt; 40+ kg in half a year</li>
<li>Single. This patient lives in the north, and her family lives in the
south</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-16 Gynecologic ultrasonography
<ul>
<li>Asites(+)</li>
<li>IMP: Pelvis mass:145x88mm with blood flow.</li>
</ul></li>
<li>2022-05-12 Chest PA erect view
<ul>
<li>Faint aveolar opacity over left lower lobe is found.</li>
<li>Another opacity over right lower lobe is found.</li>
<li>Patent airway is found.</li>
<li>Normal heart size.</li>
</ul></li>
<li>2022-05-12 CT - abdomen, pelvis
<ul>
<li>Abdominal CT with and without enhancement revealed:
<ul>
<li>Solid soft tissue necrotic mass at pelvis probably originates from
left ovary is found up to 10.59cm in largest dimension. Ovarian cancer
is favored.</li>
<li>Massive ascites with free air at pelvic cavity, suspected
peritonitis.</li>
<li>Several low density heterogeneous tumors are found at both lobes of
liver up to 8.6cm at S5/6 of liver.</li>
<li>Bilateral mild pleural effusion is found.</li>
<li>Thrombus formation at INFERIOR VENA CAVA is found. Please exclude
the possibility of pulmonary embolism if there is dyspnea.</li>
</ul></li>
<li>IMp:
<ul>
<li>Huge pelvic mass with liver necrotic tumors, ovarian cancer with
liver meta is most likely.</li>
<li>Massive ascites with air pockets, suspected peritonitis.</li>
<li>INFERIOR VENA CAVA thrombus formation.</li>
</ul></li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Blood K (potassium)
<ul>
<li>2022-05-17 2.4 mmol/L</li>
</ul></li>
<li>D-dimer
<ul>
<li>2022-05-17 2420.90 ng/mL(FEU)</li>
</ul></li>
<li>Gastric Juice OB
<ul>
<li>2022-05-16 3+</li>
</ul></li>
<li>Blood WBC
<ul>
<li>2022-05-12 23.11 *10^3/uL</li>
<li>2022-05-14 27.18 *10^3/uL</li>
</ul></li>
<li>WBC DC (differential count) Neutrophil
<ul>
<li>2022-05-17 98%</li>
<li>2022-05-14 99%</li>
</ul></li>
<li>Blood CRP
<ul>
<li>2022-05-12 14.09 mg/dL</li>
</ul></li>
<li>Blood Albumin
<ul>
<li>2022-05-17 2.3 g/dL</li>
<li>2022-05-12 1.9 g/dL</li>
</ul></li>
<li>Blood Total Protein
<ul>
<li>2022-05-17 4.8 g/dL</li>
</ul></li>
<li>Urine Bacteria
<ul>
<li>2022-05-12 3+</li>
</ul></li>
<li>Blood CEA
<ul>
<li>2022-05-14 54.77 ng/mL</li>
</ul></li>
<li>Blood CA125
<ul>
<li>2022-05-14 100.58 U/mL</li>
</ul></li>
<li>Blood CA199
<ul>
<li>2022-05-14 100.58 U/mL</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-16 Gynecology and Obstetrics
<ul>
<li>Suggestion and plan:
<ul>
<li>Compatible with CT report, pelvic mass 15x8 cm, with ascites.</li>
<li>Please check d-dimer, aFP, LDH.</li>
<li>Please arrange panendoscopy and colonscopy.</li>
<li>Ascites cell block</li>
<li>If these data are available, contact us</li>
</ul></li>
</ul></li>
<li>2022-05-12 Colorectal Surgery
<ul>
<li>Assessment
<ul>
<li>huge heterogeneous tumor in the pelvis with marked ascites, diffuse
carcinomatosis and liver metastases, colon origin or GYN cancer is
considered</li>
</ul></li>
<li>Plan
<ul>
<li>We had well explained her terminal cancer disease to the patient and
her friend (family?) and they can understand.</li>
<li>Due to diffuse carcinomatosis and liver metastases, her disease is
unresectable and incurable, and has been in very terminal stage, we
suggested palliative treatment and hospice consultation.</li>
<li>We would like to follow this patient.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The presence of a large heterogeneous tumor in the pelvis, with
ascites, diffuse carcinomatosis, and liver metastases from the colon or
gynecological origin could be considered (2022-05-12 CT abd, 2022-05-16
SONO Gyn). Further investigation is needed, working up now.</li>
<li>Heart rate roughly maintained at more than 100 beats per minute
(from TPR records), this tendency of tachycardia might be caused by
inferior vena cava thrombosis (2022-05-12 CT) decreased preload,
decreased cardiac output, and leads to increased frequency.</li>
<li>The active prescription rehydrates, adjusts electrolytes, and
supplements albumin with no problems.</li>
<li>Urine bacteria 3+ (2022-05-12) is treated with Brosym (cefoperazone,
sulbactam) since 2022-05-13, body temperature never reached 37 degrees
these days.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-634" class="section level1">
<h1>700350760</h1>
<div id="section-635" class="section level2">
<h2>220513</h2>
<ul>
<li>diagnosis
<ul>
<li>gastrointestinal hemorrhage</li>
<li>hypo-osmolality and hyponatremia</li>
<li>hypovolemic shock</li>
<li>acute posthemorrhagic anemia</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-10 Chest PA erect view
<ul>
<li>Presence of ileus.</li>
<li>Ground glass opacity in right lung.</li>
<li>Normal appearance of trachea and bil. main bronchus.</li>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2022-05-09 Abdominal Ultrasonography
<ul>
<li>Suspected bladder wall thickening</li>
<li>Prostate hypertrophy</li>
<li>Stool impaction</li>
<li>Ascites, small</li>
<li>Pleural effusion, bilateral</li>
<li>Pericardial effusion</li>
<li>Parenchymal renal disease and renal cysts, both</li>
</ul></li>
<li>2022-05-06 Esophagogastroduodenoscopy (EGD)
<ul>
<li>Incomplete study due to much coffee ground material and looping</li>
<li>Reflux esophagitis LA Classification grade B</li>
<li>Superficial gastritis</li>
<li>Deformed antrum</li>
<li>Suggestion: 2nd look endoscopy is warranted only if ACITVE BLEEDING
sign or PERSISTED Tarry stool.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<p>Harnalidge (tamsulosin) 0.4mg PO QDAC should be replaced with Urief
(silodosin) 8mg PO QD as a preferred alternative.</p>
</div>
</div>
<div id="section-636" class="section level1">
<h1>700376437</h1>
<div id="section-637" class="section level2">
<h2>220513</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-09 CT - abdomen, pelvis
<ul>
<li>Multiple HCCs with peritoneal seeding, LNs/ lung/ bony metastases
and massive ascites.</li>
</ul></li>
<li>2022-05-09 KUB
<ul>
<li>Diffuse hepatomegaly with poor defination of both kidneys, spleen,
and psoas shadows, and inferiorly displaced bowel loops</li>
<li>Abdominal ascites</li>
</ul></li>
<li>2022-05-09 Chest PA erect view
<ul>
<li>Numerous nodules of variable sizes throughout both lungs due to
metastases.</li>
<li>Normal heart size</li>
<li>Costophrenic angles are preserved</li>
<li>Diffuse hepatomegaly</li>
</ul></li>
<li>2022-04-25 Paracentesis
<ul>
<li>Procedure
<ul>
<li>Ascites tapping</li>
</ul></li>
<li>Course
<ul>
<li>After echo localization, local anesthesia was performed at RLQ and
2200ml serosanguinous ascites was drained out with 18Fr catheter.</li>
</ul></li>
<li>Findings
<ul>
<li>Massive clear ascites was noted.</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-04-23 Chest PA erect view
<ul>
<li>There are multiple nodular opacity projecting in both lung that may
be metastases. Please correlate with CT.</li>
</ul></li>
<li>2022-04-18 KUB
<ul>
<li>Ascites and hepatomegaly is noted.</li>
</ul></li>
<li>2022-04-14 CT - abdomen, pelvis
<ul>
<li>Progression of bil. HCCs with PVT, peritoenal seeding, LNs, spine,
lung metastases. Massive ascites.</li>
</ul></li>
<li>2022-04-14 Paracentesis
<ul>
<li>Procedure
<ul>
<li>Ascites tapping</li>
</ul></li>
<li>Course
<ul>
<li>After echo localization, local anesthesia was performed at RLQ and
2200ml serosanguinous ascites was drained out with 18Fr catheter.</li>
</ul></li>
<li>Findings
<ul>
<li>Massive clear ascites was noted.</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-03-22 Paracentesis
<ul>
<li>Procedure
<ul>
<li>Ascites tapping</li>
</ul></li>
<li>Course
<ul>
<li>18G needle was inserted at RLQ under echo guided insertion.</li>
</ul></li>
<li>Findings
<ul>
<li>2000ml clear yellowish ascites was drained. 75ml was sent to lab
exam</li>
</ul></li>
<li>Complication
<ul>
<li>No immediate complication</li>
</ul></li>
</ul></li>
<li>2022-03-18 CT - CTA, chest
<ul>
<li>D-dimer 3280 suspected pulmonary embolism</li>
<li>Imp:
<ul>
<li>Huge HCC at right lobe liver with previous rupture, PV thrombosis
and left lobe tumor, lung mets.</li>
<li>No evidence of pulmonary embolism nor aortic dissection is
found.</li>
<li>Massive ascites and bilateral mild pleural effusion.</li>
</ul></li>
</ul></li>
<li>2022-03-17 Chest PA/AP view
<ul>
<li>There are multiple nodular opacity projecting in both lung that may
be metastases. Please correlate with CT.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
</ul></li>
<li>2022-03-16 Paracentesis
<ul>
<li>Ascites tapping 3000mL</li>
</ul></li>
<li>2022-02-15 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Impression:
<ul>
<li>Huge HCCs with portal veins invasion, newly developed left lobe
HCCs.</li>
<li>Peritoneal carcinomatosis, T-spine metastasis, diffuse lung
metastasis. Disease in progression.</li>
</ul></li>
</ul></li>
<li>2022-03-14 KUB
<ul>
<li>Ascites is noted.</li>
</ul></li>
<li>2022-01-21 Tc-99m MDP whole body bone scan
<ul>
<li>Mildly increased activity in the lower T-spines. Degenerative change
may show this picture.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Increased activity in bilateral shoulders and hips, compatible with
benign joint lesions.</li>
</ul></li>
<li>2021-11-20 CT - abdomen, pelvis
<ul>
<li>Huge hepatic tumors (up to 29cm) at S4-5-6-7-8 with right portal
vein thrombosis and hemoperitoneum. No evidence of active bleeding.</li>
<li>Multiple lung metastases.</li>
</ul></li>
<li>2021-10-12 Visceral Angiography 2 vessels
<ul>
<li>DSA of celiac trunk and SMA via right common femoral artery puncture
revealed:
<ul>
<li>The necessarity and risks of the procedure was well explanined to
patient family before the angiography. The patient family understood the
risks of incomplete procedure, bleeding, infection, organ injury.
Questions were answered, and all wished to procedure. Informed consent
was obtained.</li>
<li>Thrombosis of right portal vein.</li>
<li>Hypervascular tumors at S4 and right hepatic lobe c/w HCCs. No
evidence of active bleeding.</li>
<li>No procedure-related complication during the whole procedure. Remain
the arterial sheath (4 Fr) at right inguinal region. Thanks for your
further care.</li>
</ul></li>
<li>IMP: Bil. HCCs with right portal vein thrombosis as described.</li>
</ul></li>
<li>2021-10-12 CT - CTA, abdomen
<ul>
<li>History and indication: abdominal pain</li>
<li>Protocol: 4mm slice thickness, axial scan and coronal
reconstruction</li>
<li>CTA of abdomen revealed:
<ul>
<li>Huge hepatic tumors (up to 26cm) at S4-5-6-7-8 with right portal
vein thrombosis and rupture causing hemoperitoneum.</li>
<li>Multiple lung metastases.</li>
<li>Normal appearance of spleen, pancreas, adrenals and kidneys.</li>
<li>Normal appearance of gallbladder.</li>
<li>Intact bony structures.</li>
<li>No enlarged lymph node.</li>
<li>No obvious extraluminal free air.</li>
<li>No abnormal density of heart.</li>
</ul></li>
<li>Imaging Report Form for Hepatocellular Carcinoma
<ul>
<li>Impression (Imaging stage): T4N0M1, stage IVB</li>
</ul></li>
</ul></li>
<li>2021-10-12 Abdominal Ultrasonography
<ul>
<li>Hepatic tumor, multiple, probably metastatic tumor</li>
<li>Ascites</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-10 Family Medicine
<ul>
<li>Q
<ul>
<li>For Hospice care.</li>
<li>A 46-year old man patient is a case of liver cell carcinoma with
lung and bone metastasis. admitted to ICU for AKI with GI bleeding.</li>
<li>Nasal cannula support.</li>
<li>Current problem: Con’s clear, the family and the patient prefer
palliative care. We need your specialist to evaluate and Hospice.
Thanks.</li>
</ul></li>
<li>A
<ul>
<li>After discussion, I decided to arrange hospice combine care for him
first. Our nurse will contact the family.</li>
<li>Indication: liver cell carcinoma with lung and bone metastases</li>
<li>Plan: hospice combined care</li>
</ul></li>
</ul></li>
<li>2022-05-09 Nephrology
<ul>
<li>Geneal weakness, dsypnea, poor appetite, coffee ground vomitus and
tarry stool passage note for about 1 wk</li>
<li>Vital signs: BP 115/65mmHg, PR 101/min, RR 20/min, SPO2 98%</li>
<li>Lab data
<ul>
<li>BUN: 22 -&gt; 130</li>
<li>Cre: 1.03 -&gt; 9.17</li>
<li>Na: 129, K: 6.2</li>
<li>T bil: 9.74, GOT: 121, GPT: 88, Albumin: 3.4</li>
<li>PH: 7.245, PCO2: 34.2, HCO3: 14.5, BE: -12.3</li>
<li>CXR: numerous nodules of variable sizes throughout both lungs due to
metastases</li>
<li>EKG: sinus tachycardia</li>
</ul></li>
<li>Impression:
<ul>
<li>Acute kidney injury stage 3 suspect prerenal or postrenal</li>
<li>HCC with lung metastases, supsect short survival period</li>
</ul></li>
<li>Suggestion:
<ul>
<li>On foley and record urine output
<ul>
<li>First medical treatment for hyperkalemia and metabolic acidosis</li>
<li>Follow up ABG, electrolyte (ABG: Artery Blood Gas)</li>
<li>Check Abdomen CT to rule out other obstructive uropathy</li>
<li>If progressive refractory metabolic acidosis, hyperkalemia, fluid
overload and anuria, we will arrange RRT if patient and family agree
(RRT: Rapid Response Team)</li>
<li>Patient refuse HD and prefer medical treatment first when we explain
the condtion to him in ER</li>
<li>Consider hospice care if patinet prefer DNR</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-18 Cardiology
<ul>
<li>Q
<ul>
<li>The 46 y/o man has hepatocellular carcinoma with right portal vein
thrombosis and lung metastasis, cT4N0M1, stage IVB, BCLC: C, child
score: A, under Kyetruda and Nexavar treatment. Due to SOB and elevated
d-dimer level, the CTA was done and report showed huge HCC at right lobe
liver with previous rupture, PV thrombosis and left lobe tumor, lung
mets. We need your help for thrombosis assessment. Thanks!</li>
</ul></li>
<li>A
<ul>
<li>We were consutled for HCC associated PVT.</li>
<li>CT finding on 20220318 showed
<ul>
<li>Huge HCC at right lobe liver with previous rupture, PV thrombosis
and left lobe tumor, lung meta.</li>
<li>No evidence of pulmonary embolism nor aortic dissection is
found.</li>
<li>Massive ascites and bilateral mild pleural effusion.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Liver cirrhosis with portal vein thrombosis easy occured in
late‐stage liver cirrhosis; it is very poor prognosis. anticoagulation
with warfarin maybe some benefit and also increasing fatal risks,
including bleeding, tumor bleeding. Maybe you could discuss with GI
man.</li>
<li>There is no specific endovascular intervention for malignancy and
cirrhosis related portal vein thrombosis.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-23 General Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>For management of HCC</li>
<li>This 46-year-old man has past medical history of chronic hepatitis
B, Liver cirrhosis; HCC with lung metastasis, rupture, s/p emergent TAE,
portal vein thrombosis. Stage T4N0M1: IVb, BCLC stage C; undergoing R/T.
F/U in GS and R/T OPD; undergoing 1st immunotherapy with Nivolumab 100mg
(By GS surgeon).</li>
<li>This time, due to he suffered from shortness of breath, poor intake
and tarry stool for 2 days. He was brought to our ER for help. Under the
impression of: 1) GI bleeding, favor variceal or PUD bleeding both
considered related; 2) HCC with lung metastasis. he was admitted to our
ward for further treatment.</li>
<li>After admission, NPO with IV fluid supplement and high dose PPI pump
was used. Glyperssin 1amp Iv Q6H was used to correct favor EV, GV
bleeding. Explained this condition to himself (including do EGD for
further survey) but he refused. There was no tarry/bloody stool nor
vomiting coffee ground found after medical treatment. Try clear liquid
diet since 20211122 by himself request. Last time follow up hemogram on
20211123 revealed Hb:8.1 g/dL. Now, due to he request consulted GS
Dr. Chen visited. We need your further survey and management of
HCC.</li>
</ul></li>
<li>A
<ul>
<li>huge HCC over right lobe with lung metastasis</li>
<li>liver cirrhosis, child A</li>
<li>under R/T and nivolumab Tx now</li>
<li>we will take over this case</li>
</ul></li>
</ul></li>
<li>2021-10-21 Gastroenterology
<ul>
<li>Q
<ul>
<li>This 46 years old male a case of rupture HCC with lung metastasis
cT4N0M1, stage IVB s/p angiography (no active bleeding) on 20211012.
Hepatitis survey revealed HBsAg: reactive, Anti-HBc: reactive, Anti-HBs:
nonreactive, Anti-HCV(-), HBV DNA is pending. We need your expertise for
HBV treatment.</li>
</ul></li>
<li>A
<ul>
<li>46M</li>
<li>PHx: denied</li>
<li>PI: rupture HCC with lung metastasis cT4N0M1, stage IVB s/p
angiography (no active bleeding)</li>
<li>Plan
<ul>
<li>For immunotherapy, may prescribe self-paid baraclude 0.5mg QD
(prescribe 1mg to peel half can save money)</li>
<li>NHI does not cover</li>
<li>GI OPD follow up</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-10-20 Radiation Oncology
<ul>
<li>Assessment: HCC, stage cT4N0M1, with lung meatstases.</li>
<li>Plan: Radiotherapy is indicated for this patient with the following
indicators: Huge hepatic tumors (up to 26cm) with mild dyspnea</li>
<li>Goal: palliation</li>
<li>Treatment target and volume: hepatic tumor</li>
<li>Technique: VMAT/IGRT</li>
<li>Preliminary planning dose: 5000cGy/20 fractions</li>
<li>The treatment modality and the possible effects of radiotherapy were
well explained to the patient. He understand and would like to receive
radiotherapy. The treatment planning of radiotherapy will be started at
2PM, 2021-10-25.</li>
</ul></li>
<li>2021-10-12 General Gastroenterological Surgery
<ul>
<li>Q
<ul>
<li>After feeling something rupure on his RUQ on 20211008, he started
severe diffused abdominal, diarrhea, urinary frequency/dysurea, nausea
sensation, easily dyspnea and dizziness.</li>
<li>Left leg numbness aggressive in recently.</li>
<li>BW loss 10 kg in 1/2 yr.</li>
<li>20211006 AFP: 22898, HBV-Ag: (+)</li>
<li>20211012 Abdomen echo:
<ul>
<li>Hepatic tumor, multiple, probably metastatic tumor</li>
<li>Ascites</li>
</ul></li>
<li>Past history: Left leg trauma s/p surgery</li>
<li>Allergy: nil</li>
<li>TOCC: (-)</li>
</ul></li>
<li>A
<ul>
<li>emergent TAE</li>
<li>admit to ICU</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient has advanced HCC with lung mets, AKI, indicating poor
prognosis. Paracentesis has been performed several times in recent
months for ascites tapping. Hospice combined care has been arranged this
week.</li>
<li>Low RBC and HGB readings (2.66 * 10^6/uL, 8.4 g/dL 2022-05-13) might
be caused by GI bleeding, 2022-05-11 vein blood gas PO2 64mmHg, O2
saturation 89%. Ventilation becomes more important when oxygenation is
low.</li>
<li>Hyperphosphatemia and hypocalcemia might result from renal
dysfunction. 2022-05-13 blood ammonia 100 umol/L, BUN 120 mg/dL. If the
patient does not wish to undergo hemodialysis, lactulose or lactitol
might alleviate hyperammonemia.</li>
</ul>
</div>
</div>
<div id="section-638" class="section level1">
<h1>701264039</h1>
<div id="section-639" class="section level2">
<h2>220513</h2>
<p>{mediastinum small cell carcinoma with pericardial effusion with SVC
syndrome, stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-11 CT - lung/mediastinum/pleura
<ul>
<li>suspected IPF (idiopathic pulmonary fibrosis)</li>
<li>Extensive mediasitinal lymphadenopathy, in regression with mild
SUPERIOR VENA CAVA compression.</li>
</ul></li>
<li>2022-01-19 Chest PA/AP view
<ul>
<li>S/P median sternotomy with metalic wires fixation.</li>
<li>Patchy opacity projecting at right suprahilum and Diffuse miliary
lesions on both lung are notd.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette</li>
</ul></li>
<li>2021-12-08 Patho - soft tissue biopsy
<ul>
<li>diagnosis
<ul>
<li>Mediastinum, biopsy - Small cell carcinoma</li>
<li>Thymus, thymectomy - Involution</li>
<li>Lymph node, regional, thymectomy - Negative for malignancy
(0/2)</li>
</ul></li>
<li>IHC: CD56(+), chromogranin(+), CK(+), LCA(-) and TTF-1(-).</li>
</ul></li>
<li>2021-12-07 Cell block
<ul>
<li>suspect small cell carcinoma</li>
<li>smears and cell block show small clusters of malignant tumor cells
with inconspicuous nuclei, high N/C ratio, scanty cytoplasm,
pleomorphism, hyperchromasia and nuclear molding.
<ul>
<li>reference: S2021-18038</li>
</ul></li>
</ul></li>
<li>2021-12-03 CT - chest
<ul>
<li>T4N3M0, stage IIIC
<ul>
<li>T4: Tumor &gt; 7cm or tumor of any size invading one or more of the
following: diaphragm , mediastinum, heart, great vessels, trachea,
recurrent laryngeal nerve, esophagus, vertebral body, carina, separate
tumor nodule(s) in a different lobe of the ipsilateral lung.</li>
<li>N3: Contralateral mediastinal, contralateral hilar, ipsilateral or
contralateral scalene, or supraclavicular lymph node(s).</li>
<li>M0: No distal metastasis (in this study)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-07
<ul>
<li>surgery
<ul>
<li>partial pericardiectomy</li>
<li>thymectomy</li>
<li>mediatinal tumor biopsy</li>
</ul></li>
<li>finding
<ul>
<li>Some masses at mediastinum with mass effect to SVC.</li>
<li>Pericardial effusion.</li>
<li>Bil. lung fibrosis.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-10 ~ undergoing: etoposide + cisplatin</li>
<li>2021-04-07 ~ undergoing: nintedanib (for interstitial lung
diseases)</li>
</ul></li>
</ul>
<div id="section-640" class="section level3">
<h3>==========</h3>
</div>
<div id="section-641" class="section level3">
<h3>2022-05-13</h3>
<ul>
<li>No updated image since last hospitalization. Last CT on 2022-03-11
showed suspected IPF and mediastinal lymphadenopathy, the latter was in
regression under recent regimen [etoposide + cispaltin].</li>
<li>Patients with extensive-stage small cell lung cancer are generally
treated with chemotherapy and immunotherapy. Extensive-stage disease is
not considered to be curable, and the goals of treatment are to relieve
symptoms caused by the cancer and to prolong life.</li>
<li>People who respond well to chemotherapy may be given radiation
therapy to the brain to prevent the development of brain metastases, and
may also receive radiation therapy to the chest. Radiation therapy may
also be used to treat other areas of the body to relieve symptoms caused
by the spread of cancer. As this patient also has pulmonary fibrosis,
treatment outcomes for patients with lung cancer and IPF were generally
poor, and exacerbations resulting from treatment were frequent. (source:
<a href="https://www.nature.com/articles/s41598-021-87747-1" class="uri">https://www.nature.com/articles/s41598-021-87747-1</a>
)</li>
<li>In order to determine whether radiotherapy is feasible, there is a
published article that states that patients with lung cancer associated
with ILD have a poor prognosis. They are at high risk of severe and even
fatal radiation pneumonitis. Careful patient selection is necessary,
appropriate high-risk consenting and strict lung dose-volume constraints
should be used, if these patients are to be treated with thoracic
radiotherapy (reference: Is Thoracic Radiotherapy an Absolute
Contraindication for Treatment of Lung Cancer Patients With Interstitial
Lung Disease? A Systematic Review <a href="https://pubmed.ncbi.nlm.nih.gov/35168842/" class="uri">https://pubmed.ncbi.nlm.nih.gov/35168842/</a> )</li>
<li>2022-05-12 vein blood gas PO2 23mmHg, O2 saturation 36%. When
oxygenation is low, ventilation becomes more important. Under 100% O2
mask, the patient’s respiratory rate remains at approximately 18 ~ 22
per minute so far during this hospital stay.</li>
<li>NT-proBNP was found to be 521 ng/mL and CKMB was 7.0 ng/mL on
2022-05-11, suggesting possible myocardial injury. Could myocardial
injury be the result of low oxygenation? The blood pressure (105/62
2022-05-13 04:28) currently under antihypertensive agent (amlodipine +
valsartan) was “too normal” in readings with somewhat tachycarida (&gt;
100 pulse/min) even when CRP was 4.39 mg/dL and WBC was 13.45
<em>10</em>3/uL. The coronary perfusion should be monitored if it is
always adequate.</li>
</ul>
</div>
<div id="section-642" class="section level3">
<h3>2022-04-01</h3>
<ul>
<li>This patient presented with stage IV mediastinum small cell
carcinoma, recent CT scan taken on 2022-03-11 showed extensive
mediastinal lymphadenopathy, in regression with mild superior vena cava
compression.</li>
<li>The goals of management for malignant SVC syndrome are to alleviate
symptoms and treat the underlying disease. Treatment of the underlying
cause depends on the type of cancer, the extent of disease, and the
overall prognosis, which is closely linked to histology and whether or
not prior therapy has been administered.</li>
<li>The patient has been receiving [nintedanib] since April 2021 then
[etoposide + cispaltin] have been added since mid December 2021 s/p
[partial pericardiectomy and thymectomy] early December 2021. According
to the aforementioned CT examination results, the current treatment
should still be effective.</li>
<li>Laboratory data indicate slight low serum magnesium levels for
months since the end of 2021. This might be related to the
administration of cisplatin. MgO tablets are currently being
administered.</li>
</ul>
</div>
<div id="section-643" class="section level3">
<h3>2022-03-11</h3>
<ul>
<li>It is common for patients with SCLC to have extensive stage of the
disease. Unlike limited-stage cancers, extensive-stage cancers are not
recommended to be treated with high radiation doses intended to cure the
disease.</li>
<li>T4N3Mo, stage IIIC, was shown in the CT images of 2021-12-03, which
is classified as a limited but not extensive stage using VA system in
NCCN guidelines.</li>
<li>Using individual patient data from four randomized studies,
meta-analysis has been conducted to compare cisplatin-based versus
carboplatin-based regimens for patients with SCLC. Among the 663
patients included in this meta-analysis, 32% had a limited-stage disease
and 68% had an extensive-stage disease. As a result, no significant
difference was observed in response rate (67% vs. 66%), progression-free
survival (PFS) (5.5 vs. 5.3 months), or overall survival (9.6 vs. 9.4
months) in patients treated with cisplatin-containing versus
carboplatin-containing regimens, indicating equivalent efficacy in
patients with SCLC.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/22473169/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22473169/</a></li>
</ul></li>
<li>Trilaciclib or G-CSF may be used as prophylactic options to reduce
the incidence of chemotherapy-induced myelosuppression in patients
receiving platinum/etoposide (might plus immunocheckpoint inhibitor if
applicable) containing regimens or topotecan containing regimens.</li>
<li>Electrolyte disorders including hyponatremia, hypokalemia and
hypomagnesemia might be associated with administration of cisplatin or
carboplatin. Lab readings for Na, K, and Mg in the past few months have
been low. Monitoring is needed.
<ul>
<li>reference: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00779/full" class="uri">https://www.frontiersin.org/articles/10.3389/fonc.2020.00779/full</a></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-644" class="section level1">
<h1>700936145</h1>
<div id="section-645" class="section level2">
<h2>220511</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-09 KUB
<ul>
<li>Degeneration of bony structures.</li>
<li>Stool retention in bowl.</li>
</ul></li>
<li>2022-05-09 Chest PA erect view: Essential negative findings</li>
<li>2022-05-04 CT - abdomen, pelvis: Unremarkable</li>
<li>2022-05-04 KUB: Unremarkable</li>
<li>2022-05-04 Chest PA erect view
<ul>
<li>Lung markings: focal increased density in the left middle lung
field. Please f/u.</li>
</ul></li>
</ul></li>
<li>2022-05-10 admission
<ul>
<li>cheif complaint
<ul>
<li>This 59 year-old male has the histories of 1) DM; 2) Hypertension;
3) Hyperlipidemia; 4) HBV.</li>
<li>This time, he suffered from palpitations, epigastric pain with
nausea, crampy sensation and shaking chills for 3 days. The
epigastralgia was persistent but no radiation. There was no fever, no
cold sweating, diarrhea or constipation accompanied. He denied alcohol
drinking recently, hematemesis or tarry stool passage and no tea-color
urine found. He visited our ER for help. At ER, vital sign was BT:36.6C,
BP:141/88mmHg, PR:103/min, RR:18/min, SpO2 96% under room air. Con’s:
E4V5M6. PE revealed tenderness over epigastric area. Lab data revealed
leukocytosis (25.73 *10^3/uL) with elevation of CRP level (8.44 mg/dL),
impaired liver function (ALT/AST 263/222 IU/L) and hyperbilirubinemia
(total Bil 4.53 mg/dl), prominent elevation of lipase level (870
U/L).</li>
<li>Under the impression of acute pancreatitis, he was admitted to our
GI ward for further evaluation and management.</li>
</ul></li>
<li>past history
<ul>
<li>DM</li>
<li>HTN</li>
<li>Hyperlipidemia</li>
<li>HBV</li>
<li>Denied other admission or operation history. </li>
</ul></li>
<li>family history
<ul>
<li>Family history is unremarkable.</li>
<li>There is no family history of cancer, hypertension, mental diseases
or asthma.</li>
<li>No members of the family with diabetes.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Vital signs (TPR 36.8/70/16, BP 122/71, SpO2 95%, 2022-05-11 04:45)
were stable during this hosptial stay so far.</li>
<li>Active prescription
<ul>
<li>Fluid replacement with 0.9% NaCl, lactated ringers (Ca 2.19 mmol/L
2022-05-11), nako no.5</li>
<li>Pain management with Tramadol</li>
<li>Symptom mitigation with serine protease inhibitor gabexate
mesilate</li>
<li>Use silymarin as a hepatoprotectant</li>
<li>Brosym (cefoperazone + sulbactam) for possible infection.</li>
<li>High blood sugar level treated with human insulin</li>
<li>Diovan (valsartan) for underlying hypertension</li>
</ul></li>
<li>Up to 20 percent of patients with acute pancreatitis develop an
extrapancreatic infection (eg, bloodstream infections, pneumonia, and
urinary tract infections). When an infection is suspected, antibiotics
should be started while the source of the infection is being determined.
However, if cultures are negative and no source of infection is
identified, antibiotics should be discontinued. Culture order might be
considered.</li>
<li>No issue with current medication</li>
</ul>
</div>
</div>
<div id="section-646" class="section level1">
<h1>701050716</h1>
<div id="section-647" class="section level2">
<h2>220511</h2>
<ul>
<li>exam finding
<ul>
<li>2022-05-10 Chest PA/AP view
<ul>
<li>Blunted right costophrenic angle.</li>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2022-04-25 PD-L1 Immunostaining
<ul>
<li>Tumor Cell (TC) staining assessment &lt; 1%</li>
</ul></li>
<li>2022-04-08 KUB
<ul>
<li>S/P double J catheter insertion in place, left side.</li>
<li>Lumbar spondylosis.</li>
<li>Calcification in the pelvic cavity, could be due to phlebolith.</li>
</ul></li>
<li>2022-04-07 Renal ultrasound
<ul>
<li>Impression
<ul>
<li>Mild hydronephrosis, left kidney.</li>
<li>Mass lesion in the urinary bladder, suspected Bladder tumor,
suspected bladder blood clot.</li>
<li>Suspected dislocation of left double-J catheter</li>
</ul></li>
<li>Suggestion
<ul>
<li>Follow up KUB to detect the location of double-J catheter.</li>
<li>Cystscopic study is recommended.</li>
</ul></li>
</ul></li>
<li>2022-04-06 ECG
<ul>
<li>Atrial fibrillation</li>
<li>Left axis deviation</li>
<li>Incomplete right bundle branch block</li>
<li>Poor wave progression V1~3</li>
<li>Possible Inferior infarct, age undetermined</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2022-04-05 Chest PA erect view
<ul>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Tortuosity of thoracic aorta</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
<li>Patchy consolidation of the right lower lung is suspected.</li>
<li>please correlate with clinical condition or CT.</li>
</ul></li>
<li>2022-03-03 KUB
<ul>
<li>S/P double J catheter insertion in place, left side.</li>
<li>Lumbar spondylosis.</li>
<li>Calcification in the pelvic cavity, could be due to phlebolith.</li>
</ul></li>
<li>2022-03-02 Patho - urinary bladder TUR
<ul>
<li>Pathologic diagnosis
<ul>
<li>Urianry bladder, “tumor”, TURBT — Invasive urothelial carcinoma,
high-grade</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic type: Urothelial carcinoma, invasive</li>
<li>Histologic grade: High-grade</li>
<li>Tumor configuration: Nodular</li>
<li>Muscularis propria: Present</li>
<li>Lymphovascular invasion: Not identified</li>
<li>Microscopic tumor extension: Tumor invades muscularis propria</li>
</ul></li>
</ul></li>
<li>2022-03-01 ECG
<ul>
<li>Sinus rhythm with Premature ventricular complexes</li>
<li>Inferior infarct, age undetermined</li>
</ul></li>
<li>2022-02-23 CT - lung/mediastinum/pleura
<ul>
<li>atherosclerosis of aorta with ascending aorta dilatation 4.5 cm in
caliber.</li>
<li>moderate 2V-CSD. small pericardial effusion.</li>
<li>subsegmental atelectasis of RML.</li>
<li>substantial subpleural paraseptal emphysema at anterior LUL.</li>
</ul></li>
<li>2022-02-11 CT - abdomen, pelvis
<ul>
<li>UCC of the urinary bladder with left UVJ invasion causing
obstructive uropathy.</li>
</ul></li>
<li>2022-02-10 Chest PA erect view
<ul>
<li>Port-A catheter inserted into SVC via left subclavian vein.</li>
<li>Blunting of right costophrenic angle due to pleural effusion</li>
<li>moderate enlarged cardiac silhoutte may be due to dilated cardiac
chambers (LAD and LVD) and prominent cardiophrenic angle mediastinal fat
pad</li>
<li>patch at right inferior paracardiac lung region, could be
atelectasis of RML</li>
</ul></li>
<li>2021-12-30 CXR
<ul>
<li>S/P Port-A infusion catheter insertion.</li>
<li>Right pleural effusion. Ground glass opacity in RLL.</li>
<li>Atherosclerosis of the aorta.</li>
<li>Suggest clinical correlation.</li>
</ul></li>
<li>2021-11-20 CT - abdomen, pelvis (ShuangHo Hospital)
<ul>
<li>Urinary bladder cancer s/p treatment, still thickening of urinary
bladder wall.</li>
<li>Lt hydroureteronephrosis.</li>
<li>Loculated fluid or urinary diverticulum at left pelvic region.</li>
<li>Consolidation over right basal lung with pleural effusion.
Ubsegmental atelectasis over left basal lung.</li>
</ul></li>
<li>2021-09-27 Pathology (SH2119345, ShuangHo Hospital)
<ul>
<li>Urinary bladder, TUR-BT, urothelial carcinoma, nested variant.</li>
<li>Urinary bladder, labeled as “tumor base, TUR-BT” urothelial
carcinoma.</li>
<li>Some muscle tissue invaded by the carcinoma is seen.</li>
</ul></li>
<li>2021-09-17 CT - abdomen (ShuangHo Hospital)
<ul>
<li>Enhancing soft tissue (5.8cm) at left posterior urinary bladder wall
with hyperdense collection in the urinary bladder.</li>
<li>Left severe hydroureteronephrosis noted, suspect UVJ invasion. C/W
urinary bladder cancer causing hematuria, suspect UVJ invasion. (UVJ:
ureterovesical junction)</li>
</ul></li>
<li>2020-08-13 Exercise Electrocardiogram
<ul>
<li>Resting ECG: Normal sinus rhythm</li>
<li>Exercise: Nonspecific ST change</li>
<li>Conclusion
<ul>
<li>negative for myocardial ischemia</li>
<li>isolated VPCs at the exam</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-04 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>Cigarette smoking for more than 50 years, quitted this September
after diagnosis of bladder cancer, hypertension for 20 years and DM,
hyperlipidemia, gastric ulcer. Due to pneumonia and he was discharged
from MICU at ShuangHo Hospital in 2021-12. He mentioned productive
cough, mild chest discomfort, easy shortness of breath while fast
walking, walking stairs about 2-3 floors, lower limbs edema after
discharge. In our service, he also has cough with pneumonia under
antibiotic treatment. The lung function test showed small airway
obstruction, resulting in low lung volume with significant response to
bronchodilator, so we need your help for COPD?</li>
</ul></li>
<li>A
<ul>
<li>Assessment
<ul>
<li>bladder cancer on CCRT by ShuangHo</li>
<li>PN with parapneumonic pleural effuison, acute respiratory failure,
110-12, tx at ShuangHo - with residual RML abscess and lung
consoidation, residual pleural effuison</li>
<li>COPD, under sipolto by ShuangHo, ex-smoking, PFT showed both
restriction and airway obstruction.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Due to the CXR had no interval change since 2021-12-04, and pt did
not have toxic sign clinically, only f/u was suggested</li>
<li>Add spiolto 2 puff QD for him.</li>
<li>Check TB sputum X 3 days</li>
<li>OPD F/U</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-02
<ul>
<li>Surgery
<ul>
<li>TURBT and left URS exam        </li>
</ul></li>
<li>Finding
<ul>
<li>Diffuse thickening of urinary bladder wall at left lateral
wall    </li>
<li>U/O was identified after TURBT; incomplete URS exam, no tumor, no
stone was found until the level of upper ureter</li>
</ul></li>
</ul></li>
<li>2021-09 TURBT, transurethral resectionof bladder tumor, ShuangHo
Hospital</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-12 ~ 2021-11-19 - 4500cGy/25 fractions of the whole bladder
and 5040cGy/28 fractions of the bladder tumor.</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-10-12 ~ 2021-11-19 - 5Fu + cisplatin, 3 times, CCRT, ShuangHo
Hospital.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>CXR (2022-05-10) revealed blunted right costophrenic angle and
atherosclerosis of the aorta. Lab data (2022-05-10) showed generally
normal results.</li>
<li>Respiratory symptoms are well-managed with self-carried drugs in
active prescription.</li>
<li>PD-L1 tumor cell &lt; 1% (2022-04-25), the effectiveness of
pembrolizumab, nivolumab or avelumab might not be very great.</li>
<li>The genetic alteration of FGFR3/FGFR2 has not been confirmed, so it
is unclear whether erdafitinib should be considered.</li>
<li>Regimen for treatment of the cacner could be
<ul>
<li>Gemcitabine and cisplatin followed by avelumab maintenance therapy,
or</li>
<li>DDMVAC (dose-dense methotrexate, vinblastine, doxorubicin, and
cisplatin) with growth factor support followed by avelumab maintenance
therapy</li>
</ul></li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-648" class="section level1">
<h1>700152280</h1>
<div id="section-649" class="section level2">
<h2>220510</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-23 Patho - lumph node region resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Endometrium, uterus, frozen and LSC staging surgery — Endometrioid
carcinoma, grade 3</li>
<li>Myometrium, uterus, ditto — Tumor invasion, greater than half
thickness</li>
<li>Cervix, uterus, ditto — Free from tumor, atrophy with Nabothian
cysts</li>
<li>Left ovary, ditto — Free from tumor, corpus albicans</li>
<li>Left fallopian tube, ditto — Free from tumor, paratubal cysts</li>
<li>Right ovary, ditto — Free from tumor, corpus albicans</li>
<li>Right fallopian tube: free from tumor, paratubal cysts</li>
<li>Lymph node, left iliac, dissection — Free from tumor metastasis
(0/12)</li>
<li>Lymph node, left oburator, ditto — Tumor metastasis (1/19)</li>
<li>Lymph node, right iliac, ditto — Free from tumor metastasis
(0/11)</li>
<li>Lymph node, right oburator, ditto — Tumor metastasis (1/16)</li>
<li>Parametrium, bilateral — Free from tumor</li>
<li>AJCC Pathologic stage — pT1bN1a, if cM0, stage IIIC1 / FIGO stage
IIIC1</li>
</ul></li>
<li>macroscopic examination
<ul>
<li>Operation Procedure: frozen section and LSC staging surgery (TAH,
BSO and BPLND)</li>
<li>Specimens include: Uterus, bilateral ovaries, fallopian tubes and
pelvic LNs</li>
<li>Tumor site: endometrium</li>
<li>Tumor size: 4.2 x 3.7 cm</li>
<li>The myometrium: up to 1.3 cm in thickness</li>
<li>The cervix : mucoid cyst</li>
<li>Adnexa (bilateral): bilateral ovaries and bilateral tubes are not
invaded by tumor</li>
<li>Lymph nodes: left iliac LNs; left obturator LNs; right iliac LNs and
right obturator LNs</li>
<li>Representative sections as follows: [Reference: F2022-00124 FS:
endometrial mass, A1: R’t ovary + F-tube, A2: L’t ovary + F-tube, A3-A5:
uterus from fundus to cervix, A6-A8: tumor + serosa(ink), A9: tumor +
endocervix, A10: cervix, A11: R’t parametrium, A12: L’t parametrium]
<ul>
<li>A1-A2: left iliac LNs;</li>
<li>B1-B2: left obturator LNs;</li>
<li>C1-C3: right iliac LNs;</li>
<li>D1-D2: right obturator LNs.</li>
</ul></li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology type: Endometrioid carcinoma</li>
<li>Histology grade: Grade 3</li>
<li>Depth of invasion: greater than half thickness of myometrium, less
than 0.1 cm away from serosa</li>
<li>Lymphovascular invasion: present</li>
<li>The cervical stroma involvement:: absent</li>
<li>Resection margins of the cervix: Free, 2.8 cm away from tumor</li>
<li>Additional pathologic findings: focal tumor necrosis</li>
<li>Lymph nodes:
<ul>
<li>left iliac LNs: free from tumor metastasis (0/12)</li>
<li>left oburator LNs: tumor metastasis (1/19) without extracapsular
extension (0/1)</li>
<li>right iliac LNs: free from tumor metastasis (0/11)</li>
<li>right oburator LNs: tumor metastasis (1/16) without extracapsular
extension (0/1)</li>
</ul></li>
<li>Immunohistochemistry: WT-1(-), CK(+), ER(-), PR(-) and vimentin(+.
focal) for tumor</li>
</ul></li>
</ul></li>
<li>2022-02-23 Frozen section
<ul>
<li>Mass, endometrial cavity, frozen section — Adenocarcinoma</li>
</ul></li>
<li>2022-03-20 CT - abdomen, pelvis
<ul>
<li>A mass lesion (4.6cm) in uterus.</li>
<li>Left liver cyst (6.5mm).</li>
</ul></li>
<li>2022-03-20 Gynecologic ultrasonography
<ul>
<li>A 54 x 42 mm mass with flow was noted in endometrial cavity,
submucosal myoma with degeneration or endometrial malignancy need to be
ruled out</li>
<li>Bilateral adnexae: free</li>
</ul></li>
<li>2021-11-16 CT - lung/mediastinum/pleura
<ul>
<li>Lungs:
<ul>
<li>areas of patchy expiratory air-trapping in both lower lobes,
indicating small airways disease.</li>
<li>an ill-defined ground glass nodule at posterobasal segment of LLL
(about 7 mm in largest axial dimension) as compared with previous CT
study.</li>
</ul></li>
<li>Impression:
<ul>
<li>LLL-S10 ill-defined GGO 7 mm, suggest f/u LDCT at 12 months later.
(GGO: ground glass opacity; LDCT: low dose CT)</li>
<li>small airways disease in both lower lobes of lungs.</li>
</ul></li>
</ul></li>
<li>2021-11-02 SONO - breast
<ul>
<li>Bilateral breasts fibroadenomas. Suggest follow up.</li>
<li>BI-RADS category 2, Benign finding.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-23
<ul>
<li>Diagnosis:
<ul>
<li>Endometrial cancer (Frozen section: Adenocarcinoma)</li>
<li>Intra-abdominal adhesions (right site, surgical history: s/p
appendectomy)</li>
</ul></li>
<li>Operation:
<ul>
<li>Laparoscopic gynecologic oncology staging surgery (LAVH + BSO +
bilateral pelvic lymphectomy)</li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: normal size, smooth surface, papillary mass in uterus
cavity</li>
<li>Bilateral adnexa: grossly normal</li>
<li>Bilateral pelvic lymph nodes: normal(-), enlarged(+),
indurated(-)</li>
<li>CDS: free</li>
<li>Adhesion over right abdominal wall</li>
</ul></li>
</ul></li>
<li>2018-11-06 Intracapsular (extracapsular) lens extractionunder
microscope + IOL insertion</li>
</ul></li>
<li>lab data
<ul>
<li>2022-04-08
<ul>
<li>HBsAg negative, value 0.384</li>
<li>Anti-HCV negative, value 0.0336</li>
<li>Anti-HBc positive, value 0.00706</li>
<li>Anti-HBs positive, value 34</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-19 ~ undergoing - paclitaxel + carboplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>For this post-operative endometrial cancer patient, the current
regimen is preferred, and the patient was able to tolerate the regimen
during last hospitalization.</li>
<li>Laboratory results on 2022-05-09 indicated that liver and kidney
function, CBC and electrolytes were generally normal.</li>
<li>Baraclude (entecavir 0.5mg) QDAC is used for the management of
heptatitis virus B.</li>
</ul>
</div>
</div>
<div id="section-650" class="section level1">
<h1>700140236</h1>
<div id="section-651" class="section level2">
<h2>220509</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-07 Chest PA/AP view
<ul>
<li>Increased infiltration over RLL. May be active infection.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
</ul></li>
<li>2022-05-07 MRA - brain
<ul>
<li>Patchy area of acute ischemic infarct over right anterior MCA
territory. (MCA: Middle Cerebral Artery)</li>
<li>Also focal acute ischemic cortical infarcts over both superior
frontal and parietal lobes and right occipital lobe.</li>
<li>Multifocal areas of old infarction over left PICA territory, left
PCA territory and left cerebral hemispheres. (PICA: Posterior Inferior
Cerebellar Artery; PCA: Posterior Cerebral Artery)</li>
<li>MR angiography of the brain shows atherosclerotic change of
intracranial and carotid vessels.</li>
</ul></li>
<li>2022-05-07 CT - brain
<ul>
<li>Focal area of faint hypodense change over right frontal lobe, may be
recent ischemia. Multifocal areas of old ischemic infarcts over left
PICA territory, left PCA territory and left cerebral hemispheres. One
old lacuna infarct within right putamen. There is no intracranial
hemorrhage seen.</li>
<li>The posterior structures including the brain stem, cerebellum and CP
angles look normal. However, the beam-hardening artifact over the skull
base may hamper the film reading.</li>
<li>Please take notice that non-enhanced CT scan is limited in the
detection of acute ischemic infarction (particularly within the first 6
hours), small vascular lesion, neoplasm, infectious/toxic/metabolic
disease. Recommend correlate with clinical condition.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-07 Neurology
<ul>
<li>This 79 y/o woman has a history of arrhythmia, old stroke with left
limbs ataxia, lung adenocarcinoma s/p and suspicious lung abscess. She
had had anticoagulant before but discontinued medication since last
year. She was able to walk slowly and could live alone with ADLs
independently. Today her son visited her at around 11am and found her
slow speech and left limbs weakness. Therefore she was sent to our ER
for help. According to the patient’s and family’s statement, the patient
could talk normally on the phone last night and this morning she had
breakfast between 8:30-9:00. For acute ischemic stroke, I was
consulted.</li>
<li>NE
<ul>
<li>E4V5M6 slowly speech,</li>
<li>left hemineglect and hemianopia</li>
<li>right gaze deviation</li>
<li>left facial palsy</li>
</ul></li>
<li>MP
<ul>
<li>upper &gt;4/3</li>
<li>lower &gt;4/3</li>
</ul></li>
<li>sensation: intact</li>
<li>FNF: left dysmetria</li>
<li>brain CT: right MCA territory equivocal hypodense lesion, left
cerebellar/occipital region old insult</li>
<li>impression: right MCA large infarct</li>
<li>suggestion:
<ul>
<li>do MRA/MRI stat and consider EVT accordingly (EVT: endovascular
thrombectomy)</li>
<li>give aspirin 1# stat and IV Ns 40ml/hr</li>
<li>neurology ward admission</li>
</ul></li>
<li>Brain MRI: right frontal infarct, patent large vessel</li>
</ul></li>
</ul></li>
<li>progress note
<ul>
<li>Problem: Acute infarcts in right frontal lobe, onset on
2022/05/07</li>
<li>Assessment: Dysarthria and left side weakness</li>
<li>Plan:
<ul>
<li>Keep closely monitor neurological signs and vital signs Q4H ~
Q6H</li>
<li>Keep adequate IV hydration with normal saline at 40ml/hr</li>
<li>Keep antiplatelets agents: Bokey 1# QD</li>
<li>H2 block or PPI after acute stroke stage</li>
<li>Stroke etiology survey: Arrange sugar, lipid, carotid duplex, ABI,
cardiosonography, 24 holter if need</li>
<li>Explained to the patient and family about current condition and
managment</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Acute ischemic infarction in the right anterior MCA territory
occurred on 2022-05-07 in the morning. GCS remained at E4V4M5 during
this hospitalization so far. Lab data 2022-05-07 showed slightly
elevated CRP 1.22 mg/dL, WBC 12.22 *10^3/uL, Neutrophil 88%, and CXR
revealed increased infiltration over RLL, body temperature was no more
than 37 degree Celsius.</li>
<li>No issue with blood sugar (115 mg/dL 2022-05-08 17:43, 129 mg/dL
2022-05-09 06:17).</li>
<li>A tendency toward tachycardia (111 pulse/min 2022-05-09 04:14) might
indicate hypoperfusion in the infarcted area, however, blood pressure
has been kept at a very “normal” level (131/72), there might be no need
of administration of beta-blocker yet at this moment.</li>
</ul>
</div>
</div>
<div id="section-652" class="section level1">
<h1>700580399</h1>
<div id="section-653" class="section level2">
<h2>220509</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-02 MRI - brain
<ul>
<li>MRA shows patency of the major vessels of the Willis circle,
bilateral ICAs and vertebrobasilar trunk.</li>
<li>Imp: Abnormal signal intensity change (with water movement
restriction) on caudate nucleus, posterior corpus callosum and possible
bil. medial temporal lobes (uncus), cause?<br />
</li>
</ul></li>
<li>2022-04-29 Electroencephalography
<ul>
<li>Abnormal, marked continuous diffuse cortical dysfunction in
bilateral hemsiphere</li>
</ul></li>
<li>2022-04-28 CT - brain
<ul>
<li>IMP: No evidence of intracranial hemorrhage.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-05-05 Mental Health
<ul>
<li>Q
<ul>
<li>This is a 47 y/o female who had HX of depression for 10+ years ago,
but poor medication compliance. (Medication as Estazolam, Trazodone and
Alprazolam).</li>
<li>This time, she was admmited to our MICU for the impression of 1)
encephalopathy favor hypoglycemia and suicide (BZD over dose).</li>
<li>Now, consciou became E4M5V1 (with eyes contect but can not obey) and
irritable, we need your expirence for evaluation!</li>
</ul></li>
<li>A
<ul>
<li>Psychiatric impression:
<ul>
<li>suspected delirium, mixed level of activity</li>
<li>suspected neurocognitive disorder due to another medical condition
(unknown time duration of concious loss when sending to hospital)</li>
</ul></li>
<li>Clinical course:
<ul>
<li>This is a 47 y/o female, with history of depression, taking
Estazolam, Trazodone, Alprazolam.</li>
<li>She was sent to ER on 20220428, coma, found in bedroom by family.
Lab data showed hypoglycemia, BZD positive in urine, not sure if she has
drug overdose. She was then admitted to ICU, intubation in 20220429,
extubation 20220505 morning. We are consulted for conscious disturbance
and irritable.</li>
<li>MSE: Confusional in conscious, mental muddy and perplexity features.
kempt, lying on the bed, not agitated, with O2 mask and NG tube. She has
fair eye-contact, intermittently smiling, quit, seems like unable to
understand instruction well. She couldn’t express, most of the time she
stares when being asked question, only occasionally making sounds with
hoarsening voice, incomprehensible. According to caregiver, she becomes
more agitated and irritable at night, and physical restraint was applied
last night. Unable to follow order to eye-tracing, or moving specific
limb. Unable to answer her name, age.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Please stablize medical condition as your expertise and monitor
mental condition.</li>
<li>Psychiatric medication is not essential under current condition.
Psychiatric evalutaion will be provided if the patient become more
clear.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>During this hospitalization, the blood sugar levels were greater
than 100 mg/dL, except for the first measurement of 86 mg/dL on the TPR
panel. Hyperglycemia might be reclassified as an inactive item on the
problem list.</li>
<li>GCS E4V2-3M5 2022-05-09 08:27, alprazolam 0.5mg was administrated.
If the patient’s mental status becomes clear, then a mental health
consultation may be considered.</li>
<li>There are drugs prescribed to treat underlying conditions, as well
as supportive care provided. No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-654" class="section level1">
<h1>700522990</h1>
<div id="section-655" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-05 Abdominal Ultrasonography
<ul>
<li>Periampullary tumor, causing CBD/MPD obstruction, close to or
invaded to IVC, with PTCD in situ</li>
<li>C/W cholangitis change, lower CBD</li>
<li>C/W A-colon cancer, with luminal stricture but no evidence of
obstruction</li>
<li>Pancreatic cystic lesions, head-body, suspected IPMN</li>
<li>GB polyps</li>
<li>Hepatic cyst, left lobe</li>
<li>Renal cyst, LK</li>
</ul></li>
<li>2022-05-04 CT - abdomen, pelvis
<ul>
<li>suspected colon cancer</li>
<li>suspected pancreatic head or ampulla vater cancer.</li>
</ul></li>
<li>2022-05-04 CT - brain
<ul>
<li>no acute intracranial hemorrhage</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Bilirubin total
<ul>
<li>2022-05-06 9.97 mg/dL</li>
<li>2022-05-04 16.82</li>
</ul></li>
<li>S-GPT/ALT
<ul>
<li>2022-05-06 55 U/L</li>
<li>2022-05-04 67</li>
</ul></li>
<li>S-GOT/AST
<ul>
<li>2022-05-04 113 U/L</li>
</ul></li>
<li>RBC
<ul>
<li>2022-05-06 3.61 *10^6/uL</li>
<li>2022-05-04 3.92</li>
</ul></li>
<li>HGB
<ul>
<li>2022-05-06 7.9 g/dL</li>
<li>2022-05-04 8.7</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-05 PTCD drainage</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>2022-05-06 04:45 vital signs TPR 35.9/68/16, BP 132/64 were
relatively stable, low energy consumption. This patient has been
diagnosed with primary hypertension, her tissue perfusion might be less
than usual. No antihypertensive agents are prescribed currently.</li>
<li>The abdominal ultrasonography performed on 2022-05-05 showed
periampullary tumors causing CBD/MPD obstruction and A-colon tumor with
luminal stricture, which might need further evaluation to determine if
they should/could be resected.</li>
<li>After PTCD drainage on 2022-05-05, bilirubin total decreased to 9
mg/dL (2022-05-06) from 16 mg/dL (2022-05-04).</li>
<li>RBC decreased to 3.61 (2022-05-06) from 3.92 (2022-05-04), HGB
decreased to 7.9 (2022-05-06) from 8.7 (2022-05-04). ABO, Rh typing,
antibody screening have been performed on 2022-05-06.</li>
<li>There are no records of drug allergies in the database. There are no
issues with the current medication.</li>
</ul>
</div>
</div>
<div id="section-656" class="section level1">
<h1>701254197</h1>
<div id="section-657" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-04 SONO chest
<ul>
<li>right side minimal amount of pleural effusion, 600cc serosangious
fluid was drained out for symptom relief.</li>
</ul></li>
<li>2022-03-03 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Pleura effusion of right costal-phrenic angle</li>
<li>Few nodular opacity projecting in the both lung are suspected.
Please correlate with CT.</li>
</ul></li>
<li>2022-02-25 CT - abdomen, pelvis
<ul>
<li>FINDINGS:
<ul>
<li>Prior CT identified an ill-defined mild heterogeneous enhancing mass
in left hepatic lobe is noted again, increasing in size that is c/w
cholangiocarcinoma S/P C/T with progressive disease.</li>
<li>Prior CT identified several metastatic lymph nodes in gastrohepatic
ligament, hepatoduodenal ligament, para-aortic space and para-cava space
are noted again, mild increasing in size that is c/w progressive
disease.</li>
<li>Prior CT identified several small metastasis on both lung are noted
again, mild increasing in size.</li>
<li>Prior CT identified mild right side Pleura effusion is noted again,
increasing in volume.</li>
<li>Ascites in the abdomen and pelvis is noted.</li>
<li>Prior CT identified tumor seeding in bilateral ovary (more severe on
right side) are noted again, stable in size.</li>
<li>Segmental sigmoid colon shows enhancement and thickening that may be
tumor seeding in left ovary with sigmoid invasion? Please correlate with
colonoscopy.</li>
<li>S/P colostomy at left transverse colon.</li>
<li>S/P R/T device implantation in the vagina is suspected? please
correlate with clinical history.</li>
<li>Compression fracture of T12 vertebral body.</li>
</ul></li>
<li>IMP:
<ul>
<li>Cholangiocarcinoma at Lt lobe liver shows progressive disease.</li>
</ul></li>
</ul></li>
<li>2021-11-26 Patho - liver biopsy needle/wedge
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, CT-guided biopsy — Adenocarcinoma, moderately differentiated,
compatible with cholangiocarcinoma</li>
<li>IHC shows: CK7(+), CK20(few tumor cells+), and Hepatocyte(-).</li>
</ul></li>
</ul></li>
<li>2021-11-24 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver shows mild increasing
size.</li>
</ul></li>
<li>2021-08-11 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver shows mild increasing
size.</li>
<li>Lobulated metastatic tumor in right ovary shows mild increasing in
size. please correlate with clinical condition.</li>
</ul></li>
<li>2021-06-06 CT - abdomen, pelvis
<ul>
<li>Lobulated metastatic tumor in right ovary shows mild increasing in
size. please correlate with clinical condition.</li>
<li>Segmental sigmoid colon shows enhancement and thickening that may be
normal variation or tumor? Please correlate with colonoscopy.</li>
</ul></li>
<li>2021-04-13 CT - abdomen, pelvis
<ul>
<li>Stationary of left lobe cholangiocarcinoma and lymph nodes
metastasis.</li>
<li>Stationary peritoneal carcinomatosis.</li>
<li>Suspected right ovarian metastasis, stationary.</li>
<li>Colon diverticulosis.</li>
<li>Multiple lung nodules, suspected lung metastasis.</li>
</ul></li>
<li>2021-03-31 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver with metastasis in right
ovary, metastatic lymph nodes in gastrohepatic ligament, hepatoduodenal
ligament, and para-aortic space, and lung metastases show stable
disease.</li>
</ul></li>
<li>2020-12-24 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Cholangiocarcinoma: T2N2M1, stage IV</li>
</ul></li>
<li>2020-03-05 Pathology at TMUH
<ul>
<li>colonoscopy biopsy - showing adenocarcinoma (CK7+, CDX2-, P40-,
CD20-, ER-, PR-, PA8X-)</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-02-20 T-colostomy and intra-abdominal tumor excision</li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-04-20 4.42 ng/mL<br />
</li>
<li>2022-03-29 5.37</li>
<li>2022-03-09 5.56</li>
<li>2022-02-11 6.65</li>
<li>2021-11-23 18.18</li>
<li>2021-10-26 19.05</li>
<li>2021-09-24 15.90</li>
<li>2021-08-17 14.77</li>
<li>2021-07-20 14.81</li>
<li>2021-06-22 14.92</li>
<li>2021-05-24 12.44</li>
<li>2021-04-13 9.68</li>
<li>2021-03-17 9.98</li>
<li>2021-02-17 9.07</li>
<li>2021-01-20 8.42</li>
<li>2020-12-23 8.64</li>
<li>2020-11-10 10.77</li>
<li>2020-10-14 9.25</li>
</ul></li>
<li>CA125
<ul>
<li>2022-04-20 350.9 U/mL<br />
</li>
<li>2022-03-29 386.6</li>
<li>2022-03-09 329.8</li>
<li>2020-12-23 26.8</li>
<li>2020-11-10 26.2</li>
<li>2020-10-14 26.7</li>
</ul></li>
<li>CA199
<ul>
<li>2022-04-20 120.56 U/mL<br />
</li>
<li>2022-03-29 113.47</li>
<li>2022-03-09 119.88</li>
<li>2022-02-11 130.83</li>
<li>2021-11-23 237.10</li>
<li>2021-10-26 195.89</li>
<li>2021-09-24 154.07</li>
<li>2021-08-17 125.27</li>
<li>2021-07-20 92.50</li>
<li>2021-06-22 89.58</li>
<li>2021-05-24 72.72</li>
<li>2021-04-13 73.86</li>
<li>2021-03-17 72.85</li>
<li>2021-02-17 56.65</li>
<li>2021-01-20 51.93</li>
<li>2020-12-23 46.93</li>
<li>2020-11-10 55.32</li>
<li>2020-10-14 51.87</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-12-01 ~ 2022-01-04 RT to the ovarian metastases: 50 Gy/ 25 fx
completed</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-03 ~ undergoing - gemcitabine + carboplatin</li>
<li>2021-08-23 ~ 2021-11-11 - FOLFOX (5-Fu + oxaliplatin)</li>
<li>2021-06-22 ~ 2021-08-17 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2021-05-25 ~ 2021-05-26 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2021-04-27 ~ 2021-05-11 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2020-08-28 ~ 2021-03-16 - Gemcitabine 1000 mg/m2 and Carboplatin AUC
2 on 2020-08-28, -09-11, -09-24, -10-08, -10-20, -11-03, -11-11, -11-30,
-12-09, -12-25, -12-31, 2021-01-13, -01-20, -02-03, -02-17, -02-24,
-03-09, -03-16.
<ul>
<li>The cisplatin was shifted to carboplatin due to elevated level of
creatinine upto 1.5 (eGFR down to 37 mL/min/1.73 m2) on 2020-08-27.</li>
<li>Best response: SD.</li>
<li>Discontinuation: PD in liver. (PD date:2020-12-24)</li>
</ul></li>
<li>2020-03-17 ~ 2020-08-13 - Gemcitabine 1000 mg/m2 and Cisplatin 30
mg/m2 on 2020-03-17, 03-24, 04-07, 04-14, 04-28, 05-05, 05-19, 05-26,
06-09, 06-17, 07-02, 07-09, 08-03, 08-13.
<ul>
<li>Best response: SD.</li>
<li>Discontinuation: The creatinine level was increased during regular
lab test. (PD date: nil)</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient diagnosed with cholangiocarcinoma (in early 2020) has
previously undergone T-colostomy and intra-abdominal tumor excision
(2020-02), [gemcitabine + cisplatin] (2020-03 ~ 2020-08), [gemcitabine +
carboplatin] (2020-08 ~ 2021-03), CAL056 (2021-04 ~ 2021-08), FOLLFOX
(2021-08 ~ 2021-11), RT (2021-12 ~ 2022-01), and is now on [gemcitabine
+ carboplatin] (2022-03 ~ undergoing).</li>
<li>Following consecutive CT scans conducted over the past 12 months,
the disease appeared to be mildly advancing unidirectionally.</li>
<li>Both RBC and HGB have rebounced (3.72 (2022-05-06) &lt;- 3.12
(2022-05-04), 10.3 (2022-05-06) &lt;- 8.6 (2022-05-04), respectively).
In the blood lab, sodium (134 mmol/L), potassium (3.2 mmol/L), and
magnesium (1.3 mg/dL) levels were low (2022-05-04). MgSO4 10% 20mL IVD
QD has been prescribed.</li>
</ul>
</div>
</div>
<div id="section-658" class="section level1">
<h1>701345193</h1>
<div id="section-659" class="section level2">
<h2>220506</h2>
<p>{ovarian clear cell carcinoma stage IA}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-17 Gynecologic ultrasonography
<ul>
<li>No obvious uterine or ovarian lesion</li>
</ul></li>
<li>2021-12-06 Patho
<ul>
<li>debulking surgery
<ul>
<li>total abdominal hysterectomy + bilateral salpingo-oophorectomy +
omentectomy + bilateral pelvic lymphnode dissection</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Ovary, right, oophorectomy - clear cell carcinoma; AJCC 8th edition:
pStage IA, pT1aN0(if cM0); FIGO stage: IA<br />
</li>
<li>Ovary,left, oophorectomy - Endometrioma<br />
</li>
<li>Histologic Type: Clear cell carcinoma</li>
<li>IHC: Napsin A(focal +), PAX8(+), WT-1(-), p53(wild type), and
PR(-).<br />
</li>
<li>Histologic Grade: Clear cell carcinoma is not graded.<br />
</li>
</ul></li>
</ul></li>
<li>2021-11-03 CT
<ul>
<li>Cystic adenocarcinoma of the left ovary is suspected.<br />
</li>
<li>Small ground-glass opacity 3.5 mm in LLL of the lung, nature?</li>
<li>The differential diagnoses include primary lung cancer, metastasis,
or benign lesion?</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>S-GPT/ALT
<ul>
<li>2022-05-05 71 U/L</li>
<li>2022-04-28 47 U/L</li>
<li>2022-04-21 66 U/L</li>
<li>2022-04-06 58 U/L</li>
<li>2022-03-24 29 U/L</li>
<li>2022-03-09 38 U/L</li>
<li>2022-02-24 33 U/L</li>
<li>2022-02-15 38 U/L</li>
<li>2022-01-25 26 U/L</li>
<li>2022-01-13 34 U/L</li>
<li>2021-12-23 39 U/L</li>
<li>2021-12-01 17 U/L</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-03 debulking surgery (total abdominal hysterectomy +
bilateral salpingo-oophorectomy + omentectomy + Bilateral Pelvic
Lymphnode Dissection) + enterolysis</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-04 ~ undergoing - paclitaxel + carboplatin</li>
</ul></li>
</ul>
<div id="section-660" class="section level3">
<h3>==========</h3>
</div>
<div id="section-661" class="section level3">
<h3>2022-05-06</h3>
<ul>
<li>S-GPT/ALT has been elevated above the normal range since April 2022
<ul>
<li>2022-05-05 71 U/L</li>
<li>2022-04-28 47 U/L</li>
<li>2022-04-21 66 U/L</li>
<li>2022-04-06 58 U/L</li>
<li>2022-03-24 29 U/L</li>
<li>2022-03-09 38 U/L</li>
<li>2022-02-24 33 U/L</li>
<li>2022-02-15 38 U/L</li>
<li>2022-01-25 26 U/L</li>
</ul></li>
<li>The infusion of 3-hour infusion paclitaxel in the current regimen
might have to be adjusted to 135 mg/m2 if ransaminases less than 10
times ULN and bilirubin levels are 1.26 to 2 times ULN.</li>
</ul>
</div>
<div id="section-662" class="section level3">
<h3>2022-04-12</h3>
<ul>
<li>For this ovarian clear cell carcinoma stage IA patient, IV
platinum-based therapy could serve as preferred first-line treatment,
specifically speaking paclitaxel + carboplatin Q3W, this is just the
treatment the patient receiving now, as from early Jan 2022.</li>
<li>The patient tolerates the current regimen well according to nursing
notes. Alternatively, albumin-bound paclitaxel may be considered if the
patient experiences hypersensitivity to paclitaxel.</li>
<li>Three months after the debulking surgery on 2021-12-03, a
gynecologic ultrasonography on 2022-03-17 found no evidence of uterine
or ovarian lesions. So far, so good.</li>
</ul>
</div>
<div id="section-663" class="section level3">
<h3>2022-01-26</h3>
<ul>
<li>for this ovarian clear cell carcinoma stage IA patient, IV
platinum-based therapy could serve as preferred first-line treatment,
specifically speaking Paclitaxel + Carboplatin Q3W, this is just the
treatment the patient receiving now, as from early Jan 2022.</li>
<li>if patient experienced a hypersensitivity reaction to paclitaxel,
then albumin-bound paclitaxel might be considered as an
alternative.</li>
<li>no apparent intolerence observed during this hospitalization.</li>
<li>no issue found in active medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-664" class="section level1">
<h1>701374584</h1>
<div id="section-665" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-05 CT - abdomen, pelvis
<ul>
<li>Massive ascites.</li>
<li>Swelling of pancreas.</li>
<li>General subcutaneous edema.</li>
</ul></li>
<li>2022-05-05 KUB
<ul>
<li>Some calcifications in pelvic cavity.</li>
<li>Presence of ileus.</li>
<li>Intact bony structure(s).</li>
</ul></li>
<li>2022-05-05 Chest PA erect view
<ul>
<li>Essential negative findings of the air way, mediastinum, heart,
lungs, pleura, diaphragm and thoracic cage.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Items in active problem list were treated with corresponding agents
<ul>
<li>metabolic acidosis - sodium bicarbonate</li>
<li>hyperkalemia - calcium polystyrene sulfonate</li>
<li>hypertension - nifedipine, clonide, doxazosin, carvedilol</li>
<li>type II diabetes - linagliptin, repaglinide</li>
</ul></li>
<li>Beta-blockers can potentially increase blood glucose concentrations
and antagonize the action of oral hypoglycemic drugs, however the odds
are greater for selective beta blockers than for carvedilol. reference:
<a href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0967-1" class="uri">https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0967-1</a></li>
<li>There are no records of drug allergies in the database. There are no
issues with the current medication.</li>
</ul>
</div>
</div>
<div id="section-666" class="section level1">
<h1>701096428</h1>
<div id="section-667" class="section level2">
<h2>220505</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-11 CT - abdomen, pelvis
<ul>
<li>Indication: Right ovarian cancer, pT2bN0; stage IIB; FIGO stage IIB
post Debulking surgery s/p C/T with BEP recurrence s/p Debulking surgery
on 2021/10/25</li>
<li>Abdominal CT with and without enhancement revealed:
<ul>
<li>s/p ATH and BSO.</li>
<li>Soft tissue mass at right pelvic floor up to 3.44*1.65cm in largest
dimension. In comparison with CT dated on 2021-10-04, the lesion
regressed.</li>
<li>s/p drainage tube placement at pelvis is found.</li>
<li>Wall thickening of the urinary bladder is found.</li>
<li>One cystic change at splenic tip up to 0.6cm in largest dimension is
found. Stable. Simple cyst is considered.</li>
<li>Calcified coronary arteries is found.</li>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>IMp:
<ul>
<li>Right ovarian cancer s/p BSO and ATH with recurrence s/p dubulking
surgery. Residual soft tissue mass at right pelvis side wall. In
regression.</li>
<li>Wall thickening of the urinary bladder, post op. change? Ovarian
seeding at bladder out-layer? Suggest closely follow up.</li>
</ul></li>
</ul></li>
<li>2022-02-18 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
</ul></li>
<li>2021-10-26 Patho - soft tissue tumor, extenstive resection
<ul>
<li>S2021-14976:
<ul>
<li>Soft tissue, pelvic, excision — consistent with recurrent malignant
ovarian sex cord tumor<br />
</li>
</ul></li>
<li>F2021-420:
<ul>
<li>Soft tissue, pelvic, excision — consistent with recurrent malignant
ovarian sex cord tumor<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-25 Frozen section
<ul>
<li>Preliminary diagnosis:
<ul>
<li>Soft tissue, pelvic, biopsy — consistent with recurrent malignant
tumor<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-12 Whole body PET scan
<ul>
<li>An inhomogenous glucose hypermetabolic lesion in the right posterior
lower pelvic cavity. A recurrent tumor should be considered.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions.
Inflammatory process may show this picture.</li>
<li>Increased FDG uptake in bilateral masseter muslces and increased FDG
accumulation in the colon, rectum, both kidneys and bilateral ureters.
Physiological FDG uptake/accumulation is more likely.</li>
</ul></li>
<li>2021-10-04 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. A soft tissue lesion (3.6x5.4cm) at right pelvic
cavity with some cystic component suspected tumor recurrence.</li>
</ul></li>
<li>2021-08-16 Patho - soft tissue debridment
<ul>
<li>Skin and soft tissue, left anterior thigh., fasciectomy — Necrosis
and acute inflammation.</li>
</ul></li>
<li>2021-08-13 CT - left femur
<ul>
<li>Abscess formation at left anterior thigh (vastus medialis muscle)and
iliopsoas muscle</li>
<li>Cellulitis of left thigh</li>
<li>Post-OP change of pelvis with a mass lesion in right perirectal
region.</li>
</ul></li>
<li>2021-05-20 Patho - soft tissue tumor, extensive resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Ovary right, debulking surgery — Compatible with malignant ovarian
sex cord tumor</li>
<li>Lymph nodes, pelvic, bilateral, BPLND — Negative for malignancy</li>
<li>Soft tissue, pelvic, debulking surgery — Metastatic tumor</li>
<li>AJCC 8 th edition, Pathology stage: pT2bN0; stage IIB; FIGO stage
IIB</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Compatible with malignant ovarian sex cord
tumor<br />
</li>
<li>Histologic grade: High grade<br />
</li>
<li>Regional Lymph Nodes: All lymph nodes negative for tumor cells
<ul>
<li>number of lymph node examined: 4 (left iliac), 1 (left obturator), 4
(right iliac), 1 (right obturator)<br />
</li>
</ul></li>
<li>Pathologic Stage
<ul>
<li>Primary Tumor: pT2b (tumor extension and/or implants on other pelvic
tissues)</li>
<li>Regional Lymph Nodes: pN0 (no regional lymph node metastasis)</li>
<li>Distant Metastasis: Not applicable</li>
</ul></li>
<li>Specimen labled “pelvic tumor”: Compatible with malignant ovarian
sex cord tumor with pelvic seeding</li>
<li>IHC: WT1(+), CAM 5.2(+), CK(-), Inhibin(-), CD117(focally weakly+),
DOG1(-), Desmin(-), Smooth mucle actin(-), CD34(-), S100(-), MDM2(-),
STAT6(-)<br />
</li>
</ul></li>
</ul></li>
<li>2021-05-19 Frozen section
<ul>
<li>Ovary right, frozen section — Favor malignant (pleomorphic
epitheloid tumor cells with necrosis), tumor nature wait for paraffin
section</li>
</ul></li>
<li>2021-05-13 Gynecologic ultrasonography
<ul>
<li>suspected pelvis mass &gt; 25cm, malignancy can not be ruled
out</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-25
<ul>
<li>operation
<ul>
<li>Excision of pelvic cancer</li>
<li>HIPEC</li>
<li>IOUS</li>
<li>Tenckhoff insertion     - finding</li>
<li>s/p midline incision</li>
<li>Adhesion of small bowel was encountered.</li>
<li>IOUS: a recurrent ovarian cancer in the pelvic cavity adjacent to
rectum</li>
<li>Pathologic report of frozen section: malignancy</li>
<li>HIPEC regimen: Lipodox 30mg/m^2 + Carboplatin AUC 5</li>
<li>Drain: 15 Fr Blake drain x 1 in the pelvic cavity</li>
<li>Tenckhoff catheter from RLQ</li>
</ul></li>
</ul></li>
<li>2021-10-25
<ul>
<li>surgery
<ul>
<li>Debulking surgery + adhesiolysis     - finding</li>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: s/p hysterectomy</li>
<li>Adnexa: s/p Bilateral Salpingo-oophorectomy</li>
<li>CDS: adhesion with intestines</li>
<li>Moderate adhesion between omentum, small &amp; large intestines and
CDS</li>
<li>A 5x4 cm mass at right pelvic cavity with cystic component, beside
the rectum.</li>
<li>s/p bilateral cystoscopic catheterization insertion before the
operation</li>
</ul></li>
</ul></li>
<li>2021-08-13
<ul>
<li>surgery
<ul>
<li>Deep debridement + fasciectomy + primary closure</li>
</ul></li>
<li>finding
<ul>
<li>An abscess with necrotizing fasciitis and gas gangrene is found
about 10*20cm in size over the left anterior thigh.</li>
</ul></li>
</ul></li>
<li>2021-05-19
<ul>
<li>operation
<ul>
<li>enterolysis</li>
<li>excision of intraabdominal tumor</li>
</ul></li>
<li>finding
<ul>
<li>s/p hystectomy</li>
<li>a bulky tumor mass in pelvic cavity with adhesion to small bowel and
rectum</li>
<li>several bleeders in pelvic wall</li>
</ul></li>
</ul></li>
<li>2021-05-19
<ul>
<li>surgery
<ul>
<li>Pelvic tumor, suspect malignancy</li>
<li>Frozen: sarcoma</li>
<li>Debulking surgery (tumor excision + pelvic lymph nodes dissection+
Cytoreduction surgery + infracolic omentectomy )        </li>
</ul></li>
<li>finding
<ul>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: s/p hysterectomy</li>
<li>Adnexa: pelvic tumor 10*10 cm, invasion to posterior pelvic wall,
intra-op rupture(+)</li>
<li>CDS: invisible due to tumor mass occupied</li>
<li>Ascites: bloody , about 500 ml</li>
<li>Bilateral pelvic lymph nodes: normal(+), enlarged(-),
indurated(-)</li>
<li>Omentum: normal appearance, infracolic omentectomy was done.</li>
<li>Liver: grossly normal &amp; smooth</li>
<li>Appendix: grossly normal.</li>
<li>After the operation, suboptimal debulking surgery was achieved.</li>
<li>Residue tumor: multiple tumors, maximal diameter more than 1 cm,
over rectum and peritonealwall and bladder base</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-05-05 - paclitaxel + cisplatin</li>
<li>2022-04-19 - paclitaxel</li>
<li>2022-04-12 - paclitaxel + cisplatin</li>
<li>2022-03-16 - paclitaxel</li>
<li>2022-03-09 - paclitaxel + cisplatin</li>
<li>2022-02-16 - paclitaxel</li>
<li>2022-02-08 - paclitaxel + cisplatin</li>
<li>2022-01-13 - paclitaxel</li>
<li>2022-01-05 - paclitaxel + cisplatin</li>
<li>2021-12-24 - paclitaxel</li>
<li>2021-12-16 - paclitaxel + cisplatin</li>
<li>2021-11-22 - paclitaxel + cisplatin</li>
<li>2021-10-23 - liposome doxorubicin + carboplatin</li>
<li>2021-09-22 - bleomycin</li>
<li>2021-09-13 - bleomycin + etoposide + cisplatin</li>
<li>2021-07-14 - bleomycin + etoposide + cisplatin</li>
<li>2021-07-01 - bleomycin</li>
<li>2021-06-24 - bleomycin</li>
<li>2021-06-17 - bleomycin + etoposide + cisplatin (BEP)</li>
</ul></li>
</ul>
<div id="section-668" class="section level3">
<h3>==========</h3>
</div>
<div id="section-669" class="section level3">
<h3>2022-05-05</h3>
<ul>
<li>The CT (2022-04-11) showed a residual soft tissue mass over the
right pelvis side wall in regression, as well as a thickening of the
bladder wall. At least a partial response was achieved by the current
regimen [paclitaxel + cisplatin] so far.</li>
<li>The blood concentrations of cations have remained relatively low in
recent months. Mg 1.4 mg/dL, K 3.8 mmol/L, Na 134 mmol/L (2022-05-03),
Ca 2.01 mmol/L (2022-04-18). Following administration of magnesium
sulfate injections, Mg rebounded to 2.0 mg/dL on 2022-05-05.</li>
<li>Poor control of blood sugar levels. A record of 422 mg/dL was
obtained 2022-05-05 07:33, one hour after 8 units of insulin actrapid
were administered. No HbA1c data found in recent 3 months.</li>
<li>The last “acute embolism and thrombosis of unspecified deep veins of
lower extremity” was diagnosed in cardiology OPD on 2021-11-19. There is
no cardiology follow-up record since then, so it is unclear if the
thrombosis risk remains for the purpose of determining the need for
edoxaban.</li>
</ul>
</div>
<div id="section-670" class="section level3">
<h3>2022-04-08</h3>
<ul>
<li>Systemic therapy regimens for patients with recurrent advanced sex
cord stromal tumors might include paclitaxel + carboplatin, EP
(etoposide + cisplatin), or BEP (bleomycin + etoposide + cisplatin). The
patient had received BEP from June to September 2021 and has been
receiving paclitaxel + cisplatin since November 2021.</li>
<li>The last three consecutive analyses of body fluid cytology (ascites,
on 2022-02-18, 2022-03-14, 2022-03-18) after debulking surgery with
HIPEC (2021-10-25) did not reveal granuloma or malignancy. Regarding the
cancer, so far, not bad.</li>
<li>Low serum magnesium level (1.6mg/dL on 2022-04-06) has been managed
with prescribed magesium sulfate injection, however, high blood sugar
reading (359mg/dL at 17:23 on 2022-04-07) should be monitored closely to
determine whether a hypoglycemic agent is needed.</li>
</ul>
</div>
</div>
</div>
<div id="section-671" class="section level1">
<h1>701113992</h1>
<div id="section-672" class="section level2">
<h2>220504</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Esophagus cancer (Squamous cell carcinoma) with right middle lobe
lung metastasis, cT4bN2M1, stage IVB, s/p Tr and jejunostomy on
2022-02-18</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-03 Chest PA/AP view
<ul>
<li>Ground glass opacity in RUL.</li>
</ul></li>
<li>2022-04-18 Abdominal Ultrasonography
<ul>
<li>liver parenchyma disease (incomplete exam of liver)</li>
<li>bilateral renal cysts</li>
<li>pancreas obscured</li>
<li>left pleural effusion</li>
</ul></li>
<li>2022-04-06 Chest PA/AP view
<ul>
<li>S/P tracheostomy</li>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Spondylosis of the T-spine</li>
<li>Blunting of bilateral costal-phrenic angle is noted, which may be
due to pleura effusion?</li>
<li>Increased lung markings on both lower lung are noted. Please
correlate with clinical condition.</li>
<li>Otherwise, there is no significant abnormality of the chest. (Note
that ground-glass lesion, small nodule or retrocardiac lesion might be
missed on plain chest radiography.)</li>
</ul></li>
<li>2022-03-26 MRI - brain
<ul>
<li>Without- and with-contrast multiplanar cerebral MRI (including axial
and coronal T1W FLAIR, axial and sagittal T2WI, axial T2W FLAIR, and
axial DW images; using 4 mm thickness for sagittal section and 5 mm
thickness for the others) and cerebral TOF MRA reveal:
<ul>
<li>General enlargement of cistern spaces and cortical sulci, indicating
general brain atrophy.</li>
<li>Dilatation of ventricles, periventricular T2-hyperintense caps and
flattening corpus callosum, indicating hydrocephalus.</li>
<li>Diffuse T2-hyperintensities in periventricular deep white matters,
indicating leukoaraiosis.</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>No midline shift, nor space-occupying lesion.</li>
<li>No remarkable finding of skull base and bony structures.</li>
<li>No remarkable finding of bilateral orbital contents and optic
nerves.</li>
<li>No remarkable finding of nasopharynx visible in these images.</li>
<li>Diffuse luminal irregularity with mild segmental stenosis of major
intracranial arteries in MRA study (including bilateral ICAs, MCAs,
ACAs, PCAs and VAs and BA).</li>
</ul></li>
<li>IMP:
<ul>
<li>General brain atrophy.</li>
<li>Hydrocephalus.</li>
<li>Leukoaraiosis.</li>
<li>Intracranial artherosclerosis.</li>
</ul></li>
</ul></li>
<li>2022-03-24 ENT hearing test
<ul>
<li>Tymp:
<ul>
<li>R’t type A; L’t type Ad.</li>
</ul></li>
<li>ART:
<ul>
<li>Bil absent.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR TO POOR</li>
<li>Average RE 63 dB HL; LE 65 dB HL.</li>
<li>Bil moderate to profound mixed type HL.</li>
</ul></li>
</ul></li>
<li>2022-03-23 Nasopharyngoscopy
<ul>
<li>Rt. side tympanic membrane was in pattern of post tympanoplasty</li>
<li>Lt. side atrophic scar</li>
</ul></li>
<li>2022-03-16 Tc-99m MDP whole body bone scan
<ul>
<li>Increased radioactivity in the sternum, the nature is to be
determined (post-traumatic change or other nature?), suggesting
follow-up with bone scan in 3 months for investigation.</li>
<li>Suspected benign lesions in the right rib cage, some lower C-, upper
T- and L2-5 spines, bilateral sternoclavicular junctions, shoulders,
right S-I joint, and knees.</li>
</ul></li>
<li>2022-02-16 Patho - esophageal biopsy
<ul>
<li>Esophageal tumor, 20-25 cm below incisors, biopsy — Squamous cell
carcinoma</li>
<li>Microscopically, the sections show a picture of squamous cell
carcinoma, poorly differentiated of the esophageal tumor tissue
characterized by solid tumor cell nests show enlarged, hyperchromatic
and pleomorphic nuclei infiltrate in the stroma with focal
necrosis.</li>
<li>Immunohistochemical stains of CK(+); P16(-), P63(+) and P53 (+,
scant) for tumor.</li>
</ul></li>
<li>2022-02-15 CT - lung/mediastinum/pleura
<ul>
<li>advanced lower cervical esophageal cancer or Cervithorocic junction
esophageal cancer with extensive adjacent structures involvement and
regional LNs metastases d/d includes large conglomerated metastatic
LAP.</li>
<li>LLL pneumonia and RML metatasis of lung.</li>
</ul></li>
<li>2022-02-15 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis：
<ul>
<li>Highly suspect esophageal cancer, 20-25cm below the incisor, s/p
biopsy</li>
<li>Esophageal stenosis, 20cm below the incisor</li>
<li>Gastric subepithelial lesion, fundus</li>
<li>Superficial gastritis</li>
</ul></li>
<li>Suggestion：
<ul>
<li>Pursue pathology result</li>
</ul></li>
</ul></li>
<li>2022-02-15 Bronchoscopy
<ul>
<li>Bronchoscopic diagnosis:
<ul>
<li>Upper airway external compression over upper trachea</li>
<li>left lower lobe bronchus: sputum impaction s/p bronchoscopic
sunction</li>
</ul></li>
</ul></li>
<li>2022-02-14 Esophagogastroduodenoscopy
<ul>
<li>Esophagus：
<ul>
<li>Luminal stenosis with acute angle was noted at 20cm below the
incisor, suspect external compression. The endoscopy could not pass
through it.</li>
</ul></li>
<li>Diagnosis：
<ul>
<li>Esophageal stenosis, 20cm below the incisor, suspect external
compression by left neck mass</li>
</ul></li>
<li>Suggestion：
<ul>
<li>arrange CT: neck ~ chest</li>
<li>If EGD was indicated, slim-caliber scope is needed</li>
</ul></li>
</ul></li>
<li>2017-05-25 Pelvis - THR
<ul>
<li>Marked disk space narrowing with spurs formation at L3-L4, L4-L5
levels due to spondylosis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-14 Rehabilitation
<ul>
<li>Dx: Cervithorocic junction esophageal cancer with extensive adjacent
structures involvement and regional LNs metastases d/d includes large
conglomerated metastatic LAP. LLL pneumonia and RML metatasis of
lung</li>
<li>swallowign evaluation
<ul>
<li>no drooling</li>
<li>no choking with 3cc water</li>
<li>tongue ROM: intact</li>
<li>tongue muscle power : fair</li>
<li>delayed reflex (prolonged oral holding)</li>
<li>hyoid bone elevation: fair.</li>
<li>foreign body sensation during swallowing</li>
<li>no dyspnea upon examination</li>
</ul></li>
<li>Plan
<ul>
<li>arrange swallowing training</li>
<li>consider arrnage PMR Dr. Wu’s OPD follow up for further OPD
swallowing trainign program. Maybe arrange VFSS in the future</li>
</ul></li>
</ul></li>
<li>2022-03-28 Dermatology
<ul>
<li>Q
<ul>
<li>For skin rash &amp; icthing at back</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered frpm erythematous papules-patches on trunk for
days.</li>
<li>Imp: Subacute dermatities</li>
<li>Suggestion:
<ul>
<li>Sinphardema 1 tubes, bid</li>
<li>Topsym cream 5 tubes, bid</li>
<li>Zaditen 1, bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-23 ENT
<ul>
<li>Q
<ul>
<li>For right ear tinnitus</li>
<li>This 85-year-old man, a patient of Eso cancer with Lns mets S/P Tr
&amp; J-tube inserted. He was admitted for CCRT. He complained of right
ear tinnitus for 2 days. We need expertise to evaluate his condition
thanks!</li>
</ul></li>
<li>A
<ul>
<li>Local finding via scope:
<ul>
<li>Rt. side tympanic membrane was in pattern of post tympanoplasty</li>
<li>Lt. side atrophic scar</li>
</ul></li>
<li>The tinnitus may be due to chemotherapy</li>
<li>We’ll arrange PTA exam this afternoon, thanks for your
consultation.</li>
</ul></li>
</ul></li>
<li>2022-03-09 Rehabilitation
<ul>
<li>Assessment
<ul>
<li>respiratory failure s/p intubation</li>
<li>advanced lower cervical esophageal cancer or Cervithorocic junction
esophageal cancer with extensive adjacent structures involvement and
regional LNs metastases<br />
</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>W5 starts with standing balance training. caregiver transfer skills
training. next W1 ambulation trianing.</li>
</ul></li>
<li>Goal
<ul>
<li>Recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
<li>2022-02-17 General and Gastroenterological Surgery.
<ul>
<li>Q
<ul>
<li>This time, he was admitted to MICU for treatment of hypercapnea
respiratory failure post intubation with ventilator since 20220214.
After admission, NG tube insert was done but failure. Dut to long term
NPO status, so we need your help for TPN nutrition supply, thanks !</li>
</ul></li>
<li>A
<ul>
<li>obj?
<ul>
<li>A case of esophageal cancer with obstruction who request nutrition
support.</li>
<li>General appearance: ill looking</li>
<li>GI tract: Dysphagia (+), Abd pain (-), Abd distension (-), Nausea
(-), Vomiting (-), Diarrhea (-), Poor appetite (+), Poor digestion (-),
BW loss (-) , stool (+), Bowel sound (+)<br />
</li>
<li>Feeding: NPO (NG tube insert failure)</li>
<li>Allergy: NKA</li>
<li>Nutrition assessment: BH 172cm, BW 57.8kg, IBW 65kg, 89% IBW, BMI
19.5, BEE (calculated based on IBW) 1246kcal, TEE 1943kcal</li>
<li>Lab data: Alb 2.9, BUN 26, Cr 0.58, Na 133, K 3.6, BS 100</li>
<li>According to the patient’s present conditions, parenteral nutrition
will be suitable for nutrition supply. We will follow this case for
adjustment of optimal nutrition support.</li>
</ul></li>
<li>PN suggestion:
<ul>
<li>F/U preAlb. ALP. rGT. T/D Bil GOT GPT TG</li>
<li>DC Bfluid 1000ml QD</li>
<li>SMOFkabiven central 1477ml QD, 61.5ml/hr</li>
<li>Lyo-Povigent 4ml/QD (add in TPN) (if out of stock, then use
B-complex 1ml/QD and Vitacicol 2ml/QD in TPN)</li>
<li>Addaven 10ml/QD (add in TPN)</li>
<li>Total fluid 30-40ml/kg/day (2000-2500ml/day)</li>
<li>Feeding gastrostomy or feeding jejunostomy ASAP</li>
</ul></li>
<li>PN monitor items
<ul>
<li>Check BW QW5 and record I/O Q8H</li>
<li>Check one touch Q6H for 2days, if stable QD check</li>
<li>Please control BS &lt; 200 mg/dl with RI sliding scale</li>
<li>QW1 check CBC/DC</li>
<li>QW1 check BUN. Cr. AST. ALT. T/D Bil. TG. ALP. rGT. Na. K. Cl. Ca.
P. Mg. Zinc. Alb. Prealbumin or Transferrin</li>
<li>if TPN not sufficient, use YF5 or D10W instead.</li>
</ul></li>
<li>postscript
<ul>
<li>20220218 op, on feeding gastrostomy or feeding jejunostomy</li>
<li>20220218 Sent to OR DC TPN, post-op PPN supply and try EN as soon as
possible.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-16 Radiation Oncology
<ul>
<li>Assessment
<ul>
<li>Suspicious advanced lower cervical esophageal cancer or
cervithorocic junction esophageal cancer with extensive adjacent
structures involvement and regional LNs metastases.</li>
</ul></li>
<li>Plan
<ul>
<li>Radiotherapy can be considered for this patient if positive
pathology report available and his condition stable (including
respiration such as if s/p tracheostomy). Further discussion in tumor
board (20220218).</li>
</ul></li>
</ul></li>
<li>2022-02-16 Thoracic Surgery
<ul>
<li>Q
<ul>
<li>For tumor excision and tracheostomy</li>
<li>This 85-year-old male who had past history of: 1) BPH; 2) Thyroid
cancer with squsamous cell carcinoma (Cheng Hsin general hospital in
20211126 report).</li>
<li>According to the description of the patient’s family and medical
record. He suffered from poor appetite and general weakness since
2021-12, he went to VGHTPE and left neck neoplasm was noted by CT.
Panendoscopy showed one protruding ulcerative lesion with luminal
narrowing and easily contact bleeding was noted at 20 to 21 cm of
incisor. The ordinary scope could not pass through the stenosis and we
then shifted to nasoendoscope. Biopsy was done on 20220110 and pending
biopsy result.</li>
<li>This time, progressive shortness of breath and fever intermittently
since 20220210, he was sent to our ER for help. At ER, his consciousness
clear, marked dyspnea with desaturation, stridor and left decreased
breath sound were noted. ABG analysis showed CO2 retension (PaCO2: 61.8
-&gt; 85.8 mmHg). Emergency intubation with ventilator was done. He was
admitted to MICU for treatment of 1) hypercapnea post intubation with
ventilator; 2) Suspect esophageal cancer survey.</li>
<li>After admission, keep on ventilator support. EGD was done which
showed Esophageal stenosis, 20cm below the incisor, suspect external
compression by left neck mass. Chest CT showed advanced lower cervical
esophageal cancer or Cervithorocic junction esophageal cancer with
extensive adjacent structures involvement and regional LNs metastases
d/d includes large conglomerated metastatic LAP. LLL pneumonia and RML
metatasis of lung. So we need your help for tumor excision and
tracheostomy evaluation, thanks!</li>
</ul></li>
<li>A
<ul>
<li>I have visited the patient and reviwed the images. If his family
agree treatment, I will arrange tracheostomy, port-A and feeding
jejunostomy. Thanks for your consultation!!</li>
</ul></li>
</ul></li>
<li>2022-02-14 Anesthesiology
<ul>
<li>Q
<ul>
<li>For difficult intubation
<ul>
<li>This 85 y/o male patient had history of suspect esophageal
cancer.</li>
<li>This time, he was admitted to MICU for hypercapnea with respiratory
failure post intubation with ventilator. After admisison to MICU,
irritable and dyspnea, stridor were noted. so we change endotracheal
tube but difficult intubation, so we need your help, thanks!</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>We were consulted for emergent intubation.</li>
<li>A #6.5 ETT was placed via McGrath and fiber-scope fixed at
25cm.</li>
<li>Bil. breathing sounds were noticed equally.</li>
<li>SpO2 was 99-100% after the procedure.</li>
<li>Please f/u CXR.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-18 tracheostomy + port-A + jejunostomy
<ul>
<li>7.0mm ID, 120mm length bivona tracheal tube in place</li>
<li>8Fr. polysite port-A via right cephalic vein</li>
<li>18 Fr. jejunosotmy tube</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient is an elderly male suffering from esophageal cancer
(squamous cell carcinoma) with RML lung mets following tracheostomy and
jejunostomy (Op on 2022-02-18).</li>
<li>The advanced age could necessitate shared decision-making prior to
cancer-specific treatment, taking into account the patient’s overall
life expectancy. Alternatively, the following regimen in combination
with RT might also be considered:
<ul>
<li>Paclitaxel + carboplatin</li>
<li>Fluorouracil + oxaliplatin</li>
<li>Fluorouracil + cisplatin</li>
</ul></li>
<li>The S-GPT/ALT level was normal in early 2022-04, rose above 50 U/L
on 2022-04-11 and reached 113 U/L on 2022-05-03. No hepatitis virus lab
data were found. During that period, no medications other than herbal
medicine were prescribed according to in-hospital records. Access to
NHI-PharmaCloud is not authorized. Further study might be needed.</li>
<li>There could be a decrease in ventilation efficiency due to lung
mets, making oxygenation more important. Lab data showed RBC
3.62*10^3/uL and HGB 10.8g/dL on 2022-05-03, both below normal limits.
There might be a need for monitoring.</li>
<li>Pneumonia at RUL is treated with Tapimycin 4.5g IVD Q6H
currently.</li>
</ul>
</div>
</div>
<div id="section-673" class="section level1">
<h1>700167626</h1>
<div id="section-674" class="section level2">
<h2>220503</h2>
<ul>
<li>There is only one item remaining on the list of current active
problems: fever with UTI since 2022-04-29.</li>
<li>Escherichia coli 33000 CFU/cc were found in urine culture, and
Staphylococcus epidermidis were found in blood culture.</li>
<li>Following administration of Flumarin (flomoxef) 1000mg IVD Q12H
since 2022-04-29, the patient’s temperature became stable on 2022-05-02
afternoon, and no higher than 37 degrees Celsus observed so far.</li>
<li>Underlying diseases are managed with corresponding medicine.</li>
</ul>
</div>
</div>
<div id="section-675" class="section level1">
<h1>701186882</h1>
<div id="section-676" class="section level2">
<h2>220503</h2>
<p>[objective]</p>
<ul>
<li><p>This 43 years old female patient has the history of: 1) Chronic
kidney disease for 10 years; 2) Ulcerative colitis with medical
treatment for 20 years; 3) Fourth degree hemorrhoids status post
hemorrhoidectomy on 20210623; 4) Left arteriovenous fistula on
20220124.</p></li>
<li><p>diagnosis</p>
<ul>
<li>chronic kidney disease, stage 5</li>
<li>anemia, unspecified</li>
<li>ulcerative colitis without complications</li>
<li>fever, unspecified</li>
</ul></li>
<li><p>exam finding</p>
<ul>
<li>2022-05-02 Abdominal Ultrasonography
<ul>
<li>Parenchymal renal disease</li>
<li>Renal cyst, right</li>
<li>Gallbladder sludge</li>
<li>Minimal ascites</li>
</ul></li>
<li>2022-03-08 Abdominal Ultrasonography
<ul>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2021-11-19 Renal ultrasound
<ul>
<li>Chronic renal parenchymal disease, advanced degree</li>
</ul></li>
<li>2021-06-23 Patho - hemorrhoids
<ul>
<li>Anus, hemorrhoidectomy — hemorrhoid</li>
<li>Microscopically, it shows dilatation of venous plexus with
congestion.</li>
</ul></li>
</ul></li>
<li><p>lab data</p>
<ul>
<li>2022-03-11
<ul>
<li>HSV 1 IgG positive</li>
<li>HSV 1 IgG Value 53.6 RU/mL</li>
<li>HSV 2 IgG negative</li>
<li>HSV 2 IgG Value &lt; 0.50</li>
<li>HSV 1 IgM negative</li>
<li>HSV 1 IgM Value 0.05</li>
<li>HSV 2 IgM negative</li>
<li>HSV 2 IgM Value 0.08</li>
</ul></li>
<li>2022-03-10
<ul>
<li>EB VCA IgA positive</li>
<li>EB VCA IgA Value 1.9</li>
<li>EB VCA IgG positive</li>
<li>EB VCA IgG Value 8.6</li>
<li>Toxoplasma IgG negative IU/mL</li>
<li>Toxoplasma IgG Value 0.2 IU/mL<br />
</li>
<li>Toxoplasma IgM negative</li>
<li>Toxoplasma IgM-index 0.05</li>
<li>HLA A 11<br />
</li>
<li>HLA A 24<br />
</li>
<li>HLA B 60<br />
</li>
<li>HLA B 61<br />
</li>
<li>HLA C 9<br />
</li>
<li>HLA C 10<br />
</li>
</ul></li>
<li>2022-03-09
<ul>
<li>EB VCA IgM negative</li>
<li>EB VCA IgM Value 0.0<br />
</li>
<li>VZV IgM negative</li>
<li>VZV IgM Value 0.1</li>
<li>CMV_IgG Reactive<br />
</li>
<li>CMV_IgG Value 937.1 AU/mL<br />
</li>
<li>CMV IgM Nonreactive<br />
</li>
<li>CMV IgM Value 0.19 Index<br />
</li>
</ul></li>
<li>2022-03-08
<ul>
<li>VZV IgG positive</li>
<li>VZV-G Value 3.1</li>
</ul></li>
<li>2022-02-22
<ul>
<li>Thyroglobulin 12.95 ng/mL<br />
</li>
</ul></li>
<li>2022-02-21
<ul>
<li>RPR/VDRL Nonreactive<br />
</li>
<li>RH(D) Positive<br />
</li>
<li>Blood type ABO O<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.28 S/CO</li>
<li>Anti-HBc Nonreactive<br />
</li>
<li>Anti-HBc-Value 0.14 S/CO</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.08 S/CO<br />
</li>
<li>Anti HTLV I/II Nonreactive<br />
</li>
<li>Anti HTLV I/II Value 0.06 S/CO<br />
</li>
<li>HIV Ab-EIA Nonreactive<br />
</li>
<li>Anti-HIV Value 0.05 S/CO<br />
</li>
<li>Anti-HBe S/CO<br />
</li>
<li>Anti-HBe Nonreactive<br />
</li>
<li>Anti-HBe Ratio 1.56 S/CO<br />
</li>
<li>Anti-HBs 376.18 mIU/mL<br />
</li>
<li>HBeAg(EIA) S/CO<br />
</li>
<li>HBeAg Nonreactive<br />
</li>
<li>HBeAg(Value) 0.362 S/CO<br />
</li>
<li>RF &lt;10 IU/mL<br />
</li>
<li>CA125 14.8 U/mL<br />
</li>
<li>CA153 7.7 U/mL<br />
</li>
<li>CA199 34.20 U/mL<br />
</li>
<li>CEA 3.62 ng/mL<br />
</li>
<li>AFP 2.1 ng/mL<br />
</li>
</ul></li>
<li>2020-05-14
<ul>
<li>ANA Negative<br />
</li>
</ul></li>
<li>2020-05-13
<ul>
<li>Zinc,Zn 621 ug/L<br />
</li>
</ul></li>
<li>2020-05-11
<ul>
<li>Anti-ENA SS-A(Ro) 0.4 EliA U/ml<br />
</li>
<li>Anti-ENA SS-B(La) 0.4 EliA U/ml<br />
</li>
<li>TPHA &lt;1:80<br />
</li>
</ul></li>
<li>2020-05-08
<ul>
<li>RPR/VDRL Nonreactive<br />
</li>
<li>Ferritin 105.3 ng/mL<br />
</li>
<li>T3 0.88 ng/dL<br />
</li>
<li>TSH 1.373 uIU/mL<br />
</li>
<li>Free-T4 0.80 ng/dL<br />
</li>
<li>Ferritin 110.1 ng/mL</li>
</ul></li>
</ul></li>
<li><p>surgical operation</p>
<ul>
<li>2022-01-24 Creation of LT wrist AVF        
<ul>
<li>Left Radial Artery: Calcification(-), Diameter(2.3)mm</li>
<li>Cephalic Vein: Stenosis(-),
Fibrosis(-),Transpostion(-),Diameter(3.0)mm</li>
<li>Anastomosis of Left Radial artery &amp; cephalic vein with 7-0
prolene.   </li>
</ul></li>
<li>2021-06-23 Hemorrhoidectomy        
<ul>
<li>Prolasped hemorrhoids at 3,7,11 o’clock        </li>
<li>Easy bleeding, Naldebain</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<p>This patient has CKD stage 5 adminitted on 2022-04-29</p>
<p>CKD stage 5, high Creatinine, high BUN, high phosphorus, low calcium,
low bicarbonate normal CRP and WBC AV shunt</p>
</div>
</div>
<div id="section-677" class="section level1">
<h1>701361784</h1>
<div id="section-678" class="section level2">
<h2>220429</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-27 Chest
<ul>
<li>Lung markings: emphysematous change in the bilateral lung
fields</li>
</ul></li>
<li>2022-03-26
<ul>
<li>Fecal material store in the colon.</li>
<li>Spondylosis of the L-spine is noted.</li>
</ul></li>
<li>2022-03-26 Femur LT
<ul>
<li>Left femoral intersubtrochanteric fracture, s/p ORIF</li>
</ul></li>
<li>2022-03-14 Chest
<ul>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2022-03-08 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving multiple
lymph nodes on both sides of the diaphragm, spleen, stomach and
bones/bone marrow (stage IV).</li>
</ul></li>
<li>2022-03-07 Bone densitometry - hip
<ul>
<li>Right hip, BMD is 0.537 gms/cm2, about 2.8 SD below the peak bone
mass (63%) and 0.3 SD below the mean of age-matched people (95%).</li>
<li>Osteoporosis</li>
</ul></li>
<li>2022-02-25 Patho - lymphnode biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Left subhepatic lesion, CT-guide biopsy — High grade B cell
lymphoma, favor diffuse large B-cell lymphoma<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology type: high grade B cell lymphoma shows medium to large
atypical lymphoid cells with nucleoli, frequent apoptosis and focal
tumor necrosis.</li>
<li>Immunohistochemistry: CK(-), CD3(-), CD20(+), Bcl-2(-), CD30(-),
CD10(+), Bcl-6(+), C-MYC(+, 80%), cyclin-D1(-) and Ki-67:&gt;90% for
tumor. According to all above histopathologic findings, it is in favor
of diffuse large B-cell lymphoma, and Burkitt’s lymphoma is less likely,
but can not be entirely excluded due to limited specimen.</li>
</ul></li>
</ul></li>
<li>2022-02-18 MRI - liver, spleen (non-contrast)
<ul>
<li>Non-contrast MRI has limitation in diagnosis of solid organ
pathology, bowel loop lesion, and vascular system abnormality. We
recommend contrast enhanced MRI if patient’s renal function can tolerate
Gd-DTPA injection.
<ul>
<li>There are several lobulated soft tissue masses in the hepatic hilum,
gastrohepatic ligament, hepatoduodenal ligament, aortocaval space, and
right perirenal space. In addition, One enlarged node measuring 1.9 x
1.4 cm in right supradiaphram cardiac-phrenic space is noted. Three soft
tissue masses in the omentum are noted. Malignant lymphoma is highly
suspected.</li>
<li>There is a well-defined heterogeneous mass measuring 5 x 3.2 cm in
the submucosal layer of the gastric body that may be lymphoma. Please
correlate with gastroscopy.</li>
<li>There is edematous wall thickening and distension of the
gallbladder, and mild dilatations of IHDs and CHD. Please correlate with
clinical condition.</li>
<li>Both kidney show small size and thin renal parenchyma that are
compatible with chronic renal disease. Please correlate with renal
function.</li>
<li>Mild ascites is noted.</li>
<li>Mild right side pleura effusion is noted.</li>
<li>There is no focal abnormality in the pancreas and spleen.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>Malignant lymphoma is highly suspected. Please correlate with biopsy
and serum LDH level.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-17
<ul>
<li>Anti-HBc reactive, 4.57 S/CO</li>
<li>Anti-HCV nonreactive, 0.10 S/CO</li>
<li>HBsAg nonreactive, 0.34 S/CO</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-19 cardiology
<ul>
<li>Q
<ul>
<li>For hypertension poor control</li>
<li>This 72-year-old female, a pt of double-hit DLBCL at troperitoneal
fossa, Lugano stage IV Dx in Feb 2022 S/P C/T. She was admitted for
chemotherapy. Owing to high blood perssure was noted (195/91 mmHg) and
anti-hypertensive agent was given but still poor control. We need
expertise to evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>This is a 72 years old lady who was admitted for Diffuse large B
cell lymphoma under R-DA-EPOCH therapy. We were consulted for poor
control BP</li>
<li>Current medication
<ul>
<li>concor 5mg 1# qd</li>
<li>hyzaar 1# qd</li>
</ul></li>
<li>exam
<ul>
<li>BP: 195/91 (most of the day: SBP&gt;160)</li>
<li>HR: 80</li>
<li>EKG: LVH pattern</li>
<li>CXR: normal heart size</li>
<li>Cr 2.0</li>
<li>UA 10.5;</li>
</ul></li>
<li>Impression
<ul>
<li>Hypertensive cardiovascular disease with poor cpntrol; suspected C/T
induced.</li>
</ul></li>
<li>Suggestion
<ul>
<li>May add sevikar 1# qd; regular use of apresoline if SBP still
&gt;160 mmHg.</li>
<li>DC hyzare due to significant hyperuricemia.</li>
<li>Check chemotherapy side effect (whether using tyrosine kinase
inhibitor? VEGF inhibitor?), and change regimen if feasible.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-25 cardiology
<ul>
<li>S: abdominal pain</li>
<li>O:
<ul>
<li>Labs
<ul>
<li>Cr: 1.75 -&gt; 2.43 -&gt; 1.2</li>
<li>CRP: 4</li>
<li>Na/K: 136/4.2</li>
</ul></li>
<li>Cardiac echo: EF: 70%
<ul>
<li>Normal LV systolic function with normal wall motion.</li>
<li>Hypertrophic cardiomyopathy without outflow tract obstruction; LV
diastolic dysfunction Gr 1.</li>
</ul></li>
<li>Current BP medications
<ul>
<li>PO concor and po hyzaar</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Hypertensive cardiovascular disease, without acute hypertensive
crisis</li>
<li>Hypertrophic cardiomyopathy without outflow tract obstruction</li>
<li>Suspected cholangiocarcinoma or suspected lymphoma</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Adequate pain control if patient is in pain due to fracture or
abdominal pain.</li>
<li>Add norvasc 1# qd - bid.</li>
<li>to keep concor 5 mg qd</li>
</ul></li>
</ul></li>
<li>2022-02-23 radiological diagnosis
<ul>
<li>According to the clinical condition and imaging findings, biopsy is
indicated.</li>
</ul></li>
<li>2022-02-16 surgery
<ul>
<li>a huge tumor near liver hilum, liver origin? pancreatic origin? or
lymphoma
<ul>
<li>admission for tumor survey</li>
<li>check MRI and tumor markers after admission</li>
<li>check HBsAg, anti-HCV, anti-HBs, anti-HBc</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-15 ~ undergoing - R-DA-EPOCH, Dose-adjusted EPOCH-R,
<ul>
<li>etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin,
plus rituximab
<ul>
<li><a href="https://www.uptodate.com/contents/image?imageKey=ONC%2F88411" class="uri">https://www.uptodate.com/contents/image?imageKey=ONC%2F88411</a></li>
<li>drugs
<ul>
<li>Rituximab, 375 mg/m2 IV, Day 0 or 1</li>
<li>Etoposide, 50 mg/m2 per day IV, Days 1 to 4 (96 hours)</li>
<li>Doxorubicin, 10 mg/m2 per day IV, Days 1 to 4 (96 hours)</li>
<li>Vincristine, 0.4 mg/m2 per day IV (dose not capped), Days 1 to 4 (96
hours)</li>
<li>Cyclophosphamide, 750 mg/m2 IV, Day 5</li>
<li>Prednisone, 60 mg/m2 orally twice daily, Administer first dose 30
minutes prior to chemotherapy on day 1., Days 1 to 5</li>
<li>Granulocyte colony stimulating factor (G-CSF), Start day 6</li>
</ul></li>
</ul></li>
<li>Pretreatment considerations:
<ul>
<li>Hydration
<ul>
<li>Patients receiving cyclophosphamide should maintain adequate oral
hydration (2 to 3 L/day) and void frequently to reduce risk of
hemorrhagic cystitis.</li>
</ul></li>
<li>Emesis risk
<ul>
<li>MODERATE.</li>
</ul></li>
<li>Prophylaxis for infusion reactions
<ul>
<li>Premedicate with acetaminophen and diphenhydramine, with or without
an H2 receptor blocker, 30 minutes prior to at least the first and
second infusions of rituximab.</li>
</ul></li>
<li>Vesicant/irritant properties
<ul>
<li>Doxorubicin and vincristine are vesicants; avoid extravasation.
Etoposide is an irritant.</li>
</ul></li>
<li>Infection prophylaxis
<ul>
<li>Primary prophylaxis with hematopoietic growth factors is an
essential component of this regimen. Regular or pegylated G-CSF may be
used according to center policy. In addition, due to the risk of
developing Pneumocystis jiroveci pneumonia and other opportunistic
infections, consider the use of antimicrobial prophylaxis.</li>
</ul></li>
<li>Dose adjustment for baseline liver or renal dysfunction
<ul>
<li>Adjustment of initial cyclophosphamide, doxorubicin, etoposide, and
vincristine doses may be needed for preexisting liver dysfunction. In
addition, dose adjustment of etoposide and cyclophosphamide may be
required for renal dysfunction.</li>
</ul></li>
<li>Hepatitis screening
<ul>
<li>Patients should be screened for hepatitis B and C prior to starting
rituximab, and, if positive, considered for antiviral prophylaxis.</li>
</ul></li>
<li>Cardiac screening
<ul>
<li>Doxorubicin is associated with cardiomyopathy, the incidence of
which is related to cumulative dose. Assess baseline LVEF prior to
initiation of therapy. Dose alterations should be considered for LVEF
&lt;50%, and doxorubicin therapy is contraindicated in patients with
LVEF &lt;30% at initiation, those with recent myocardial infarction,
severe myocardial dysfunction, severe arrhythmia, or previous therapy
with high cumulative doses of doxorubicin or any other
anthracyclines.</li>
</ul></li>
<li>CNS prophylaxis
<ul>
<li>The need for CNS prophylaxis is determined based upon the
aggressiveness of the tumor reflected in the histology, organ
involvement, and presence or absence of high risk features.</li>
</ul></li>
<li>HIV screening
<ul>
<li>Patients should be screened for HIV prior to starting therapy.
Consider reducing the initial dose of cyclophosphamide to 187 mg/m2 if
CD4 &lt;100/microL at diagnosis.</li>
</ul></li>
<li>Neurotoxicity
<ul>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine.</li>
</ul></li>
</ul></li>
<li>Monitoring parameters:
<ul>
<li>CBC with differential and platelet count twice weekly during
treatment.</li>
<li>Assess basic metabolic panel (creatinine and electrolytes) and liver
function prior to each subsequent treatment cycle.</li>
<li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically
during dose-adjusted EPOCH-R therapy, as clinically indicated.</li>
<li>Carriers of hepatitis B or C should be monitored for clinical and
laboratory signs of active infection during and following completion of
therapy. Rituximab should be discontinued if reactivation occurs.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-679" class="section level3">
<h3>==========</h3>
</div>
<div id="section-680" class="section level3">
<h3>2022-04-29</h3>
<ul>
<li>SBP 190~140 (most times &gt; 150), DBP 65~90, HR no less than 100
pulse per minite since 2022-04-28 this hospitalization so far, under
Concor (bisoprolol 5mg, QD), Sevikar (amlodipine 5mg + olmesartan 20mg,
QD) prescribed as self-carried drugs since 2022-04-29. Chemotherapy has
not yet been administered for now in this hospital stay.</li>
<li>WBC 310/uL, Neutrophil 18%, CRP 5.24 mg/dL, RBC 2.6<em>10^6/uL, HGB
8.0g/dL, PLT 43</em>10^3/uL, normal urine exam results on 2022-04-28,
body temperature 39.3 degree Celsius at 07:41 2022-04-29.</li>
<li>Primary prophylaxis with hematopoietic growth factors should be a
component of the R-DA-EPOCH regimen. Chemotherapy induced cytopenia is
managed with Granocyte (lenograstim 250mcg, QD). Elevations of CRP occur
in association with acute and chronic inflammation due to a range of
causes, including infectious diseases and noninfectious inflammatory
disorders. Elevated CRP with fever is managed with Tapimycin
(piperacillin 2g + tazobactam 0.25g, Q8H). Due to the risk of developing
Pneumocystis jiroveci pneumonia and other opportunistic infections, the
use of antimicrobial prophylaxis might be necessary. reference: <a href="https://pubmed.ncbi.nlm.nih.gov/11929754/" class="uri">https://pubmed.ncbi.nlm.nih.gov/11929754/</a></li>
<li>Doxorubicin is associated with cardiomyopathy, the incidence of
which is related to cumulative dose. The baseline LVEF prior to
chemotherapy initiation on 2022-02-22 was 70%, this does not suggest a
dose alteration.</li>
<li>The patient was screened for hepatitis B and C prior to starting
rituximab and is now receiving Vemlidy (tenofovir alafenamide 25mg QDCC)
for her HBV infection.</li>
</ul>
</div>
<div id="section-681" class="section level3">
<h3>2022-04-18</h3>
<ul>
<li>Pathology on 2022-02-25 revealed that C-MYC(+, 80%), BCL-2(-),
BCL-6(+), high-grade B-cell lymphoma (HGBL) with translocations of MYC
and BCL6, also known as double-hit lymphoma, is frequently associated
with poor prognostic factors, including elevated LDH, bone marrow and
central nervous system involvement, and high IPI score.</li>
<li>PET on 2022-03-08 indiated involvement of multiple lymph nodes on
both sides of the diaphragm, spleen, stomach and bones/bone marrow,
stage IV.</li>
<li>DA-EPOCH-R has been in use since 2022-03-15, the LDH has decreased
to 181 U/L (2022-04-15, WNL) from its peak of 1364 U/L (2022-03-16),
which might hint an improvement, and no evidence of CNS involvement has
yet been confirmed.</li>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine. Metoclopramide and
sennoside have been prescribed.</li>
<li>Hypomagnesemia (1.4 mg/dL 2022-04-18) is treated with MgSO4 10% 20mL
IVD QD currently.</li>
</ul>
</div>
</div>
</div>
<div id="section-682" class="section level1">
<h1>700126665</h1>
<div id="section-683" class="section level2">
<h2>220427</h2>
<p>{synchronous double (breast and colon) primary tumors s/p MRM s/p
hemicolectomy}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-03-16 CT - abdomen, pelvis
<ul>
<li>Liver metastases S/P C/T show progressive disease.</li>
<li>Mechanical small bowel obstruction is noted. However, the transition
zone is hard to identify. The differential diagnosis include tumor
seeding or adhesion.</li>
<li>A soft tissue nodule 5 mm in LUQ omentum is noted that may be tumor
seeding. Ascites in right subphrenic space and Morison pouch.</li>
</ul></li>
<li>2022-02-08 ultrasound - abdomen
<ul>
<li>Hepatic tumor, nature to be determinated</li>
<li>Hepatic cyst, GB stone</li>
</ul></li>
<li>2022-01-20 esophagogastroduodenoscopy
<ul>
<li>suspected gastric intestinal metaplasia, antrum and low body, s/p
biopsy at antrum, GC</li>
</ul></li>
<li>2021-11-30 CT - ABD
<ul>
<li>Post-op at the colon and small bowel loops.</li>
<li>RLQ peritoneal soft tissue tumors, suspected carcinomatosis.</li>
<li>Newly developed liver tumors, suspected liver metastasis.</li>
<li>Liver and renal cysts.</li>
</ul></li>
<li>2021-08-03 patho - small intestine resection for tumor
<ul>
<li>mucinous adenocarcinoma, colonic origin</li>
<li>IHC: CK7(-), CK20(+), CDX2(+) and GATA-3(-), colonic origin</li>
</ul></li>
<li>2021-07-27 whole body PET scan
<ul>
<li>two glucose hypermetabolic lesions in the liver, some glucose
hypermetabolic lesions in the abdominal cavity and a glucose
hypermetabolic lesion in the umbilicus. metastatic lesions should be
considered first.</li>
</ul></li>
<li>2021-01-20 patho - colon segmental resection for tumor
<ul>
<li>tumor, transverse colon, SILS left hemicolectomy - mucinous
adenocarcinoma - pT3N0 (if cM0), stage IIA</li>
</ul></li>
<li>2021-01-19 patho - breast mastectomy with regional lymph nodes
<ul>
<li>breast, right, modified radical mastectomy - invasive carcinoma.
grade 2.</li>
<li>lymph node, right axilla, lymphadenecomy - metastatic
carcinoma.</li>
<li>pathology stage: pT2 pN2 (if cM0); anatomic stage: IIIA, pathology
prognostic stage: IIIA</li>
</ul></li>
<li>2021-01-12 patho - colorectal polyp
<ul>
<li>adenocarcinoma. IHC stain: EGFR(+); PMS2(+), MSH6(+), MSH2(+),
MLH1(+).</li>
</ul></li>
<li>2020-12-28 patho - lymphnode biopsy
<ul>
<li>axilla, right, core biopsy - invasive carcinoma.</li>
<li>IHC stains: CK (+).</li>
</ul></li>
<li>2020-12-28 patho - breast biopsy (no margin)
<ul>
<li>invasive carcinoma, no special type.</li>
<li>IHC stains: ER (+, strong intensity, 95%), PR(-), Her2/neu: negative
(score=0), Ki-67(&lt;2%).</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-01-18 Rehabilitation
<ul>
<li>Imp
<ul>
<li>Right breast invasive carcinoma with axillary metastasis</li>
<li>Lymphoma 30+ yrs ago</li>
<li>T-colon cancer found in 2020/12</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation and home program
education</li>
<li>Goal: Functional ability ID, maintain ROM, prevent post-OP
complications</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-08-02 surgical operation
<ul>
<li>local excision abdominal wall tumor + small bowel resection with
anastomosis</li>
</ul></li>
<li>2021-01-19 surgical operation
<ul>
<li>right breast MRM (modified radical mastectomy)</li>
<li>SILS (single incision laparoscopic surgery) left hemicolectomy +
laparoscopic adhesionolysis</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-15 ~ -07-30
<ul>
<li>2400cGy/12 fractions (6 MV photon) to rt chestwall and SCF lymph
nodes</li>
</ul></li>
</ul></li>
<li>chemo regimen
<ul>
<li>2022-03-18 ~ undergoing - FOLFOX</li>
<li>2021-11-16 ~ 2022-03-02 - FOLFIRI</li>
<li>2021-08-20, -11-03
<ul>
<li>5-Fu (fluorouracil) + Covorin (leucovorin)</li>
</ul></li>
<li>2021-04-28, -05-19, -05-26
<ul>
<li>Nolbaxol (docetaxel)</li>
</ul></li>
<li>2021-02-02, -02-24, -03-17, -04-08
<ul>
<li>Lipo-Dox (liposome doxorubicin) + Endoxan (cyclophosphamide)</li>
</ul></li>
</ul></li>
</ul>
<div id="section-684" class="section level3">
<h3>==========</h3>
</div>
<div id="section-685" class="section level3">
<h3>2022-04-27</h3>
<ul>
<li>The patient admitted to receive FOLFOX treatment, the current
regimen being used since 2022-03-18.</li>
<li>No images have been updated since last hospitalization. The lab data
reported on 2022-04-25 showed slightly elevated levels of BUN (43
mg/dL), creatinine (1.32 mg/dL), bilirubin total (1.26 mg/dL) and
decreased level of potassium (3.2 mmol/L); these results should not
affect the chemotherapy procedure.</li>
<li>TPR 36/106/17, BP 105/59 recorded at 19:50 2022-04-26. Insufficient
blood pressure caused a faster pulse?</li>
<li>Drugs prescribed in the OPD have been put as self-carried items in
the list of active medications.</li>
</ul>
</div>
<div id="section-686" class="section level3">
<h3>2022-04-12</h3>
<ul>
<li>A patient with synchronous double primary cancers s/p surgery;
systemic therapy was initially focused on breast cancer from 2021-02 to
2021-05, and then refocused on colon cancer from 2021-08 based on
clinical judgment.</li>
<li>The CEA and CA199 levels have been trending upward from 43ng/mL and
59U/mL (2021-12-13) to 130ng/mL and 83U/mL (2022-04-07) respectively.
Abdominal CT on 2022-03-16 showed progression of liver mets and possible
peritoneal seeding.</li>
<li>As a result of the disease being resistant to FOLFIRI, the regimen
has switched to FOLFOX since 2022-03-18.</li>
<li>Sundowning-like behaviors were observed during last hospital stay
(2022-03-12 ~ 2022-03-31). According to nursing notes, these behaviors
did not occur since this admission.</li>
<li>Lab data reported on 2022-04-06 showed normal liver and kidney
function and no obvious abnormalities with CBC and WBC readings.</li>
</ul>
</div>
<div id="section-687" class="section level3">
<h3>2022-03-15</h3>
<ul>
<li>Lab data reported on 2022-03-15 showed stool OB 3+, stool glutamate
dehydrogenase (GDH) positive, Clostridium difficile toxin A/B
negative.</li>
<li>Colonization with nontoxinogenic strains also affords protection.
This observation suggests that the initial colonizing strain may occupy
a microbial niche in the large intestine that is protective against
superinfection with a new toxin-producing C. difficile strain</li>
<li>The antibiotics most frequently implicated in predisposition to C.
difficile infection (CDI) include fluoroquinolones, clindamycin,
penicillins, and cephalosporins.</li>
</ul>
</div>
<div id="section-688" class="section level3">
<h3>2022-02-25</h3>
<ul>
<li>no updated exam findings as of last hospitalization
(2022-02-10).</li>
<li>new lab data showed lower serum potassium 3.2mmol/L (reported on
2022-02-22) is treated with 0.298% KCl in NaCl 500mL IVD QD.</li>
<li>neutrophil is just above 1500/uL (WBC 2910/uL, Neutrophil 58%,
2022-02-22) should be regularly monitored.</li>
</ul>
</div>
<div id="section-689" class="section level3">
<h3>2022-02-10</h3>
<ul>
<li>synchronous double primary cancers s/p surgical operation
<ul>
<li>systemic therapy had been focused on breast cancer from 2021-02 to
2021-05, then refocused on colon cancer since 2021-08 based on clinical
judgement.</li>
<li>time serial CEA readings trend up slowly from 2021-07-27 25.48ng/mL
to 2022-02-07 66.56ng/mL during last half year.</li>
<li>newly found liver tumor could be another metastatic lesion.</li>
</ul></li>
<li>drugs approved by FDA for both breast cancer and colon cancer
include: 5-FU, capecitabine, pembrolizumab.
<ul>
<li>polyp patho showed pMMR, pembrolizumab might not be indicated.</li>
<li>bevacizumab might be considered if no contraindication.</li>
</ul></li>
<li>EGFR overexpression (up-regulation or amplification) or mutation is
usually associated with progression and resistance of epithelial tumors.
<ul>
<li>reference: Wang Z. ErbB receptors and cancer. Methods Mol Biol.
(2017)1652:3-35. <a href="doi:10.1007/978-1-4939-7219-7_1" class="uri">doi:10.1007/978-1-4939-7219-7_1</a></li>
<li>cetuximab or panitumumab might be considered if no
contraindication.</li>
</ul></li>
<li>liver and kidney functions showed no abnormality based on ALT, AST,
and creatinine reported on 2022-02-07.
<ul>
<li>introduction of irinotecan should not likely to be restricted.</li>
</ul></li>
<li>no drug allergy recorded in database, no issue found in current
medication.</li>
</ul>
</div>
<div id="section-690" class="section level3">
<h3>2021-09-08</h3>
<ul>
<li>synchronous double primary cancers s/p surgical operation
<ul>
<li>systemic therapy had been focused on breast cancer from 2021-02 to
2021-05, refocused on colon cancer since 2021-08 based on clinical
judgement.</li>
</ul></li>
<li>drugs approved by FDA for both breast cancer and colon cancer
include: 5-FU, capecitabine, pembrolizumab.
<ul>
<li>polyp patho showed pMMR, pembrolizumab might not be indicated.</li>
</ul></li>
<li>liver and kidney functions showed no obvious abnormality based on
ALT, AST, and creatinine reported on 2021-09-02.
<ul>
<li>introduction of irinotecan should not likely to be restricted
because of hepatic dysfunction.</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-691" class="section level1">
<h1>700529746</h1>
<div id="section-692" class="section level2">
<h2>220426</h2>
<ul>
<li>2022-04-25 Chest PA/AP view
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2022-04-22 Chest PA/AP view
<ul>
<li>S/P operation.</li>
<li>S/P Port-A infusion catheter insertion.</li>
<li>S/P VP.</li>
<li>Patch density at bil. lungs.</li>
</ul></li>
<li>2022-04-18 MRI - upper abdomen
<ul>
<li>S/P operation.</li>
<li>Multiple LNs, lung and liver metastases.</li>
<li>Bil. pleural effusion.</li>
</ul></li>
<li>2022-04-18 Chest PA + Lat. LT
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2022-04-01 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine, lower T- and upper L-spines
and lower L-spines. Degenerative change may show this picture. Please
correlate with other imaging modalities for further evaluation.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Increased activity in the right shoulder, bilateral hips and right
knee, compatible with benign joint lesions.</li>
</ul></li>
<li>2022-03-31 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy — adenocarcinoma, moderately
differentiated, consistent with metastatic colonic origin</li>
<li>Sections show neoplastic glandular cells infiltrating in a fibrotic
stroma and proliferating along the alveolar wall with focal tumor
necrosis.</li>
<li>The immunohistochemical stains reveal TTF-1(-) and CDX2(+). The
results are consistent with metastatic colonic adenocarcinoma. Please
correlate with the clinical presentation and image study.</li>
</ul></li>
<li>2022-03-31 Chest PA/AP view
<ul>
<li>no pneumothorax s/p transthoracic needle biopsy of RML nodule.</li>
</ul></li>
<li>2022-03-31 Whole body PET scan
<ul>
<li>Multiple glucose hypermetabolic lesions in bilateral lungs. Multiple
lung metastases should be considered first. Please correlate with other
clinical findings for further evaluation and to rule out other
possibilities.</li>
<li>Some glucose hypermetabolic lesions in the right and left lobes of
the liver. Liver metastases should be watched out.</li>
<li>Glucose hypermetabolism in bilateral pulmonary hilar and multiple
mediastinal lymph nodes and in multiple abdominal lymph nodes,
compatible with metastatic lymph nodes.</li>
<li>Prominent glucose hypermetabolism in a focal area in the right lobe
of the thyroid gland. The nature is to be determined (thyroid
malignancy? other nature?). Please also correlate with other clinical
findings for further evaluation.</li>
<li>Glucose hypermetabolism in a focal area in the right parotid gland
and in a focal area in the left parotid gland. The nature is to be
determined (some kind of parotid lesions? metastases? other
nature).</li>
<li>Mild glucose hypermetabolism in some left lower neck lymph nodes and
glucose hypermetabolism in the left shoulder. Inflammation is more
likely.</li>
</ul></li>
<li>2022-03-31 MRI - brain
<ul>
<li>General brain atrophy. An old infarct in right corona radiata.</li>
<li>No evidence of brain metastases based on this non-contrast MRI.</li>
</ul></li>
<li>2022-03-21 CT - lung/mediastinum/pleura
<ul>
<li>multiple nodules in both lungs, favors metastatic tumors</li>
<li>suspect combined lung edema, pleural effusion, and LAD and LVD of
heart. extensive 3V-CAD.</li>
</ul></li>
<li>2022-03-17 Chest PA erect view
<ul>
<li>Cardiomegaly and tortuosity of the thoracic aorta.</li>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
<li>S/P internal fixation of C-spine.</li>
</ul></li>
<li>2021-11-01 Chest PA erect view
<ul>
<li>A nodular opacity projecting in the right lower lung is suspected.
Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2021-10-27 Patho - colorectal polyp
<ul>
<li>Colon, anastomotic site, s/p biopsy.(A) — Tubular adenoma with low
grade dysplasia</li>
<li>Colon, T-colon, s/p biopsy.(B) — Hyperplastic polyp</li>
<li>Colon, D-colon, s/p biopsy.(C) — Hyperplastic polyp</li>
<li>Colon, S-colon, 20 cm from AV, s/p hot snare polypectomy and
S-colon, 18 cm from AV, s/p cold snare polypectomy (D) — Tubulovillous
adenomas with low grade dysplasia.</li>
</ul></li>
<li>2020-11-20 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably moderate myocardial ischemia with possible a small portion
of severe ischemia at the apex and anterior wall and mild to moderate
myocardial ischemia at the anterolateral wall.</li>
<li>Mild reverse redistribution of radioactivity to the basal
inferolateral wall, either normal variant or myocardial ischemia may
show this picture.</li>
</ul></li>
<li>2020-09-26 MRA - brain
<ul>
<li>Moderate stenosis in the bilateral cavernous ICAs, esp, left side.
Please correlate with cerebral angiography.</li>
</ul></li>
<li>2020-06-03 Patho - colon segmental resection for tumor
<ul>
<li>Pathologic diagnosis
<ul>
<li>Large intestine, hepatic flexure colon, SILS right hemicolectomy —
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Resection margins: free<br />
</li>
<li>Lymph node, mesocolic, dissection — metastatic adenocarcinoma
(7/16)<br />
</li>
<li>Lymph node, IMA / SMA, dissection — N/A.<br />
</li>
<li>Pathology stage: pT3N2b(If cM0); pStage IIIC<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: moderately differentiated<br />
</li>
<li>Depth of invasion: pericolorectal tissue<br />
</li>
<li>Angiolymphatic invasion: Present.<br />
</li>
<li>Perineural invasion: Not identified.<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified.</li>
<li>Circumferential (radial) margin of rectum: Uninvolved<br />
</li>
<li>Lymph node metastasis, mesocolic: Positive (7/ 16)<br />
</li>
<li>Lymph node metastasis,, IMA / SMA: N/A.<br />
</li>
<li>Extranodal involvement: Present.<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT) pT3: Tumor invades through the muscularis propria
into pericolorectal tissues<br />
</li>
<li>Regional Lymph Nodes (pN) pN2b: Seven or more regional lymph nodes
are positive<br />
</li>
<li>Distant Metastasis (pM) pMX<br />
</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Not
identified<br />
</li>
<li>Additional pathologic findings: None identified.<br />
</li>
<li>TNM descriptors: N/A.<br />
</li>
<li>Tumor regression grading S/P CCRT: N/A.</li>
</ul></li>
</ul></li>
<li>2020-06-02 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T3N2M0, stage IIIB</li>
</ul></li>
<li>2020-06-02 Patho - colon biopsy
<ul>
<li>Colon, hepatic flexure, biopsy — Adenocarcinoma.</li>
<li>IHC stains: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
</ul></li>
<li>2020-06-02 Patho - colorectal polyp
<ul>
<li>Colon, transverse, polypectomy — Tubular adenoma with low grade
dysplasia</li>
</ul></li>
<li>2020-02-07 Paho - intradermal nevus
<ul>
<li>Skin, excision biopsy — Basal cell carcinoma, solid type, 0.1 cm
away from the closest (side and deep) margin.</li>
<li>IHC stains: adipophilic(-), EMA(-), Ber-EP4(+).</li>
</ul></li>
<li>2019-11-04 MRA - brain
<ul>
<li>Diffuse arteriosclerosis with multi-focal stenoses.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2019-04-17 CPA - carotid phonoangiograph
<ul>
<li>Sonographic diagnosis
<ul>
<li>Multi-focal mild stenosis in bil BIF, bil ICA, right ECA; mild
atheromatous lesions in right SCA, right CCA.</li>
<li>Normal extracranial carotid, vertebral, and right intracranial basal
cerebral arterial flows; severe stenotic flow in right ICA, bil ECA,
left SCA; mild to moderate stenotic flow in right PCA and right
ECA.</li>
<li>Poor temporal windows for left transcranial insonation.</li>
<li>Normal bilateral ophthalmic arterial flows.</li>
<li>Suggest MRA (neck+intracranial arteries) for further study if no
contraindication.</li>
</ul></li>
</ul></li>
<li>2018-12-21 KUB
<ul>
<li>Osteoporosis, mild scoliosis and spondylosis of L-spine. S/P VP at
T12. S/P TPS and disc prosthesis at L3-4-5. Mottled bowel gas
pattern.</li>
</ul></li>
<li>2018-10-17 CPA - carotid phonoangiograph
<ul>
<li>Sonographic diagnosis
<ul>
<li>Severe stenosis with severe stenotic flow in right proximal ICA;
moderate to severe stenosis with mildly increased flow velocity in left
proximal ECA; moderate stenosis in right distal CCA and right BIF;
multi-focal mild stenosis in right proximal &amp; mid CCA, left distal
CCA, left BIF and left proximal ICA; moderate atheromatous lesions in
left mid CCA.</li>
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows; severe stenotic flow in right proximal ICA and
BA; mild stenotic flow in left ECA and right intracranial VA; smaller
caliber and decreased flow in right cervical VA, indicated
hypoplasia.</li>
<li>Poor temporal windows for bilateral transcranial insonation.</li>
<li>Normal bilateral ophthalmic arterial flows.</li>
<li>Suggest MRA (neck+intracranial arteries) for further study if no
contraindication.</li>
</ul></li>
</ul></li>
<li>2018-09-03 CT - brain
<ul>
<li>No brain lesion.</li>
<li>Intracranial ICAs and VAs atherosclerosis.</li>
<li>Age-appropriate cerebral atrophy.</li>
</ul></li>
<li>2018-06-27 Upper GI panendoscopy
<ul>
<li>Erosive esophagitis (La Gr A-) 　　- Hiatal hernia</li>
</ul></li>
<li>2018-06-20 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably (1) moderate myocardial ischemia in the apex and anterior
wall (LAD territory) and (2) mild myocardial ischemia in the basal
lateral wall (LCx-M territory) of the left ventricle.</li>
<li>No post-stress dilatation of the left ventricle.</li>
</ul></li>
<li>2017-03-24 Upper GI panendoscopy
<ul>
<li>gastric shallow ulcers and erosions, antrum</li>
</ul></li>
<li>consultation
<ul>
<li>2021-10-21 Gastroenterology
<ul>
<li>PI
<ul>
<li>ADHF, with pulmonary edema, s/p ETT+MV 10/08-10/14</li>
</ul></li>
<li>S
<ul>
<li>still tarry stool today</li>
</ul></li>
<li>O
<ul>
<li>E4V5M6</li>
<li>Hb: 11.7-&gt;8.6-&gt;9.2</li>
<li>EGD: no active bleeder</li>
</ul></li>
<li>A
<ul>
<li>Black with dark green stool, suspected LGIB</li>
</ul></li>
<li>P
<ul>
<li>Arrange colonscopy on 10/23 AM if the patient and family understand
the risk of CFS (organ perforation… etc)</li>
<li>Add transamine<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-18 Rehabilitation
<ul>
<li>Q
<ul>
<li>For CHF of cardiopulmonary muscle endurance training and muscle
strengthening exercise.</li>
<li>2021/10/08 heart echo showed: EF = 21.1%; Dilated LA; Poor LV
systolic function, generalized hypokinesis, especiaaly IVS; Concentric
LV hypertrophy, Impaired LV relaxation; Moderate MR.<br />
</li>
<li>This 76 year old female had a past history of
<ul>
<li>NSTEMI, s/p stent placement at ShuangHo Hospital 202109 under Bokey
+ Blingta</li>
<li>3-V-D s/p PTCA and Rota, 2 stents over RCA on 20161019</li>
<li>Pneumonia</li>
<li>Chronic kidney disease stage 4</li>
<li>Hypertension</li>
<li>T2DM control with Humalog Mix25 38u BID</li>
<li>Anemia, gastric OB 3+, UGIB cannot be ruled out</li>
<li>Colon Ca, pT3N2bM0, stage IIIC s/p laparoscopic right colectomy on
20200603</li>
<li>C4-5-6-7 HIVD s/p op in 201310 and L3-4-5 s/p op in 20130529.</li>
<li>PUD hx</li>
</ul></li>
<li>According to her husband, she experienced dyspnea for last weeks.
The symptoms persisted and progressed despite of OPD follow up. Thus she
came to our ED for help. At ER, CXR revealed bilateral pulomonary
inflitration, suggesting acute pulmonary edema. Breathing pattern was
swallow and fast. Intubation was performed after informed consent. Under
the impression of acute decompensated heart failure with pulmonary
edema, she was admitted into ICU for further medical care. After
admitted to MICU, 2D echo was done and showed Dilated LA, Poor LV
systolic function, generalized hypokinesis, especiaaly IVS, Concentric
LV hypertrophy, Impaired LV relaxation, Moderate MR. EF was 21% under
Simpson method. Lasix 40mg Q12H was given and much urine output and BW
loss were noted. Empirical Abx with rocephine was also prescribed since
20211008. Mexiletine and Ivabradine was given. Due to no active bleeding
sign, oral diet was resumed and PPI was shifted to oral. However, acute
on CKD was noted on 20211012, suspected pre-renal AKI. Lasix was tapered
off, minimal IV hydration with 500cc NS QD was given. The ventilator was
tapered smoothly. T-piece was tried on 20211013. On 20211014, extubation
was done and BIPAP support was given. The patient weaning off BIPAP soon
after 1 day. She also tolerated oral diet well. F/u CXR and lab were
both improved with residual left consolidation. No fever was noted thus
Ceftriaxone was discontinued after 1 wk. Under stable condtion, she was
transfered to ward on 20211018.</li>
</ul></li>
<li>A
<ul>
<li>Rehabilitation programs: Bedside PT cardiopulmonary rehabilitation
programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
<li>May arrange PM&amp;R OPD follow-up for further phase 2 cardiac
rehabilitation program as needed</li>
</ul></li>
</ul></li>
<li>2021-10-08 Cardiology
<ul>
<li>BILATERAL pulmonary edema noted s/p intuvbation. With her creatine
3.2, no obvious progression compared her last creatinine study.</li>
<li>Received cath at nearby hostpital for LAD. No obvious lower limb
swelling this time.</li>
<li>Last echoc was performd at 202012 with preserved LV function, thus,
the pulmonary edema cause would multi-factorial, pending on admission to
MICU by ER doctor.</li>
</ul></li>
<li>2020-12-16 Nephrology
<ul>
<li>Q
<ul>
<li>Reason: for CKD stage 4 assessment</li>
<li>This is a 75 years old lady who has CAD s/p stent, DM for 20+ years,
Ca colon s/p op in June 2020.</li>
<li>Patient was admitted for planned CAG on 20191216, However, we noted
patient had renal anemia, (Hb : 8.6 with eGFR &lt; 15) (Stool OB:
negative Oct 2020). currently using plavix, progressive renal function
impairment.</li>
<li>We arranged Ca,P, iPTH, Iron profile, Ferritin, renal echo, urine
analysis and proteinuria screening</li>
<li>WE consult you for assessment of EPO SC usage and CKD managment with
your superior profession.</li>
</ul></li>
<li>A
<ul>
<li>Impression
<ul>
<li>CKD stage 4, suspect DM nepropathy relatd</li>
<li>CAD s/p stent</li>
<li>DM</li>
<li>Ca colon s/p op on June 2020.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Stage 4 cannot use EPO</li>
<li>Nephrology OPD follow up was suggested</li>
<li>Treat the underlying diseases as your expertise</li>
<li>Avoid nephrotoxc agents</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-06-03 SILS right hemicolectomy </li>
<li>2020-02-07 skin excision
<ul>
<li>a flesh color papule with hyperpigmented dots on nose for years
-&gt; suspected BCC</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-25 ~ undergoing - FOLFIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This DM related CKD stage 4 patient has advanced colon cancer with
lung mets s/p left hemicolectomy on 2020-06-03. She has been receiving
FOLFIRI as from this hospitalization.</li>
<li>Lab data on 2022-04-25 showed BUN 70mg/dL, urine creatinine
3.95mg/dL, eGFR 11.71, HGB 9.0 g/dL, serum uric acid 8.8 mg/dL.
Hyperuricemia is managed with Feburic (febuxostat) 40mg PO QD
currently.</li>
<li>There are no irinotecan dosage adjustments provided in the
manufacturer’s labeling (has not been studied) for kidney impairment,
please use with caution and monitor closely. Use of irinotecan in
patients with dialysis is not recommended by the manufacturer; however,
literature suggests reducing weekly dose from 125 mg/m2 to 50 mg/m2 and
administer after hemodialysis or on nondialysis days. Irinotecan is
associated with early and late diarrhea, both of which may be severe
(atropine has been subscribed as a pre-/co-treatment in the regimen). In
the event the patient develops diarrhea, supportive care (e.g. fluid and
electrolyte replacement, loperamide, antibiotics, etc.) should be
provided as needed.</li>
<li>The patient has two stents for her coronary artery disease.
Cardiotoxicity observed with 5-FU includes myocardial
infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac
failure, sudden death, ECG changes, and cardiomyopathy. There is no
recommended dose for resumption of 5-FU administration following
development of cardiac toxicity, and the drug should be discontinued.
She is also taking Plavix (clopidogrel) for her stents, for bevacizumab
has the potential to cause hypertension, hemorrhage, and
thromboembolism, so the patient should be closely monitored if
bevacizumab is also administered.</li>
<li>Erythropoietin 5000U weekly could be considered as an additional
item if no contraindiction, until the reading backs to 11 g/dL.</li>
</ul>
</div>
</div>
<div id="section-693" class="section level1">
<h1>700886156</h1>
<div id="section-694" class="section level2">
<h2>220425</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-02 ECG
<ul>
<li>Atrial fibrillation with rapid ventricular response</li>
<li>ST &amp; T wave abnormality, consider lateral ischemia</li>
</ul></li>
<li>2022-03-30 CT - lung/mediastinum/pleura
<ul>
<li>recurrent esophageal cancer with spinal metastasis, in
progresion.</li>
<li>post op change in RML and RUL.</li>
<li>small amount of pleural effusion, exudative, in regression.</li>
<li>dendritic change or old fibrosis at LLL and lingula</li>
</ul></li>
<li>2021-12-23 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Pleura effusion of right and left costal-phrenic angle</li>
<li>S/P posterior instrumentation fixation at T-spine</li>
</ul></li>
<li>2021-12-22 SONO - chest
<ul>
<li>Pleural effusion, moderate, left</li>
<li>Atelectasis, RML, RLL and RUL</li>
</ul></li>
<li>2021-12-15 CT
<ul>
<li>Hemangioma or Metastasis 1.1 cm in S2/4 is highly suspected.</li>
</ul></li>
<li>2021-10-29 Patho - Interveterbral disc
<ul>
<li>T6 pathologic fx</li>
<li>Bone and joint, vertebra, T6 body, corpectomy - Neuroendocrine
carcinoma.</li>
<li>IHC: CK (+, intermediate intensity), S-100 protein (+), CK7 (-),
CK20 (-), CD117 (-), CD56 (+, intermediate intensity), p40 (-), TTF-1
(-). Ki-67: 20%.</li>
</ul></li>
<li>2021-10-23 MRI - T-spine
<ul>
<li>T5-6-7 metastases with thecal sac and spinal cord compression.</li>
</ul></li>
<li>2021-10-19 CT
<ul>
<li>recurrent esophageal cancer with spinal metastasis.</li>
<li>post op change in RML and RUL.</li>
<li>small amount of pleural effusion, exudative, in progression, and
nonspecific inflammation or fibrosis in left lower lung,
stationary.</li>
</ul></li>
<li>2021-04-20 CT
<ul>
<li>post op change in RML and RUL.</li>
<li>small amount of Rt pleura, exudative, post op change? and
nonspecific inflammation or fibrosis in left lower lung,
stationary.</li>
</ul></li>
<li>2021-01-19 CT
<ul>
<li>post op change in RML and RUL.</li>
<li>small amount of Rt pleura, exudative, post op change? and
nonspecific inflammation or fibrosis in left lower lung.</li>
</ul></li>
<li>2020-09-29 Patho - Lung wedge biopsy
<ul>
<li>Lung, RML, VATS pneumolysis+ RML wedge - necrotizing granuloma</li>
<li>IHC: CK7(-), TTF-1(+ at pneumocytes), Ki-67: &lt;10%.</li>
</ul></li>
<li>2020-09-28 Frozen section
<ul>
<li>Lung, RML, frozen section - Necrosis with focal atypia (reactive
change or AAH?)</li>
</ul></li>
<li>2020-09-03 CT
<ul>
<li>s/p esophagectomy with gastric tube reconstruction.</li>
<li>Tiny nodular lesion at right middle lobe, suspected lung meta.</li>
</ul></li>
<li>2020-06-02 CT
<ul>
<li>new RML nodules, favor metastatic lesions.</li>
<li>residual small amount of Rt pleura and nonspecific inflammation in
left lower lung.</li>
</ul></li>
<li>2019-07-09 CT
<ul>
<li>Pleura effusion, stationary and increased volume of pericardial
effusion.</li>
<li>post op change in RLL and nonspecific inflammation in left lower
lung, stationary.</li>
<li>No abnormal soft-tissue mass or LAP in the mediastinum.</li>
</ul></li>
<li>2018-03-29 Whole body PET scan
<ul>
<li>In comparison with the previous study on 2017-04-17, the glucose
hypermetabolic lesion between the descending aorta and the thoracic
spine is more prominent. Recurrent malignancy should be considered.</li>
<li>Glucose hypermetabolism in the right supraclavicular fossa. The
nature is to be determined (metastatic lesion? other nature?).</li>
<li>Glucose hypermetabolism in both lobes of the thyroid gland and left
cricoarytenoid area. The nature is to be determined (inflammation? other
nature?).</li>
</ul></li>
<li>2017-03-27 Surgical pathology Level V
<ul>
<li>Lung, RLL, wedge resection - Squamous cell carcinoma x 3, poorly
differentiate (G3), metastatic<br />
</li>
<li>IHC:
<ul>
<li>the large tumor reveal CK5/6(+), p40(weak +), p63(+), and
TTF-1(-).<br />
</li>
<li>the 2 small tumors reveal p40(+), CD56(-), and TTF-1(-).</li>
</ul></li>
</ul></li>
<li>2017-03-15 CT
<ul>
<li>Indication: Esophageal cancer, M/3, squamous cell carcinoma,
cT2N2M0, with Rt paratracheal and subcarinal LAP metastasis, Rt vocal
cord paralysis, s/p PortA on 2016-01-15, s/p CCRT since 2016-01-21 to
2016-03-03 s/p esophagectomy &amp; LN dissection on 2016-04-23, ypT3N0
(cM0) with involved circumferential (adventitial) margin s/p
fistulectomy on 2016-06-17.</li>
<li>s/p esophagectomy and gastric tube reconstruction.</li>
<li>A RLL nodule, recurrent tumor in lung?</li>
<li>Inflammation in LLL-basal segments.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-28
<ul>
<li>Surgery
<ul>
<li>Esophagal cancer with T5-6-7 spinal metastasis; tumor excision and
ant/ post fixation; Modified LECA approach</li>
</ul></li>
<li>Finding
<ul>
<li>Esophageal tumor s/p previous op.</li>
<li>T5-6-7 metastastic tumor with T6 pathologic fracture/ epidural
circumferential cord compression, more at anterolateral area;</li>
<li>Circumferential epidural tumor 3x3x3cm caused severe cord
compression;</li>
</ul></li>
</ul></li>
<li>2020-09-28
<ul>
<li>Surgery
<ul>
<li>VATS pneumolysis + RML wedge</li>
</ul></li>
<li>Finding
<ul>
<li>severe intra-pleura cavity adhesion due to previous RLL wedge for
esophagus SCC metastasis</li>
<li>one nodule about 1cm with caseating granuloma and calcification was
found in RML</li>
<li>Estimated blood loss: 150mL.</li>
<li>one 20 Fr. straight chest tubes were inserted via right 7th
ICS. </li>
</ul></li>
</ul></li>
<li>2019-07-29
<ul>
<li>Diagnosis
<ul>
<li>Pericardial effusion</li>
</ul></li>
<li>PCS code
<ul>
<li>68049B</li>
</ul></li>
<li>Finding
<ul>
<li>Moderate serosangious pericardial effusion was noted about
300mL.</li>
<li>One 14 Fr. pig-tail was inserted via left 7th ICS.</li>
</ul></li>
</ul></li>
<li>2017-03-27
<ul>
<li>Diagnosis
<ul>
<li>RLL lung nodule</li>
</ul></li>
<li>PCS code
<ul>
<li>67051B</li>
</ul></li>
<li>Finding
<ul>
<li>One firm nodular lesion was noted over RLL, size about 1.5cm in
diameter.</li>
<li>One 28 Fr. straight chest tube was inserted via right 8th ICS.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-04-12 ~ 2018-05-07: 4500cGy/18 fractions (15 MV photon) to
para-T6 tumor (part of CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-04-22 - PFL (cisplatin + 5-Fu + leucovorin)</li>
<li>2021-12-16 ~ 2022-03-29 - cisplatin + etoposide</li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-21 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This 74-yrear-old man patient is a case of Esophageal cancer, M/3,
squamous cell carcinoma, cT2N2M0, with Rt paratracheal and subcarinal
LAP metastasis, Rt vocal cord paralysis, s/p PortA on 20160115, s/p CCRT
since 20160121 to 20160303 s/p esophagectomy &amp; LN dissection on
20160423, ypT3N0 (cM0) with involved circumferential (adventitial)
margin s/p fistulectomy on 20160621 with lung metastasis s/p resection
on 201703 s/p adjuvant C/T, last on 20180108 with 2nd mediastinum
relapse in 201803 s/p salvage RT on 20180507.</li>
<li>Pericardial effusion s/p Thoracoscopic Pericardial Window and
Pneumonolysis, extrapleural.</li>
</ul></li>
<li>A
<ul>
<li>I was consulted wheezing and suspected COPD of the patient</li>
<li>objective
<ul>
<li>PFT in 2017: normal screening, no further data</li>
<li>CXR cardiomegaly and left PE</li>
<li>Fibroreticular infiltration in right lung field</li>
<li>Mediastinum widening</li>
<li>Diffuse pleural thickening was found bilaterally, especially on
right</li>
</ul></li>
<li>assessment
<ul>
<li>recurrent esophageal ca with multiple mets</li>
<li>suspected COPD</li>
<li>restrictive lung ventilatory defect was suspected for bilateral
irregularly thickened pleurae</li>
</ul></li>
<li>plan
<ul>
<li>keep current bronchodilator nebulization</li>
<li>inform high risk of acute respiratory failure, plan of further
tx?</li>
<li>sputum AFS/TB cultures x 3 days</li>
<li>chest echo for left pleural effusion if dyspnea</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-03 ENT
<ul>
<li>Q: Current problem:
<ul>
<li>Tinnitus since 2021-10-29.</li>
<li>Post-op wound suspected CSF leakage. Remove drain on
2021-10-30.<br />
</li>
<li>We will give AcetaZOLAMAX 250 mg/tab (AcetaZOLAMIDE) and Diphenidol
S.C 25mg/tab use.</li>
<li>We need your expertise for further management.</li>
</ul></li>
<li>A
<ul>
<li>L&gt;R pulsatile tinnitus for 3 days.</li>
<li>PE:
<ul>
<li>Ear drum: bil intact, L ear drum atrophic scar</li>
<li>EAC: clean</li>
<li>Bedside scope: smooth NPx, OPx, HPx</li>
</ul></li>
<li>Tymp:
<ul>
<li>R’t type A; L’t type A with round peak.</li>
</ul></li>
<li>ART: Bil absent.</li>
<li>PTA:
<ul>
<li>Average RE 49 dB HL; LE 79 dB HL.</li>
<li>R’t normal to severe SNHL.</li>
<li>L’t moderately severe to profound mixed type HL.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>keep current Betahistine 1# BID</li>
<li>ENT OPD follow up for PTA and hearing aid evaluation</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-01 Rehabilitation
<ul>
<li>Q
<ul>
<li>This 73-year-old patient has past history of
<ul>
<li><ol style="list-style-type: decimal">
<li>Coronary artery disease,</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hypertension,</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Enlarged prostate with lower urinary tract symptoms,</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Gout,</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Middle third esophageal squamous cell carcinoma with lung metastasis
pathology stage: Stage IV, pT3N0M1 s/p CCRT,</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Hypothyroidism,</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>AF,</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Hyperlipidemia,</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Right middle lobe lung nodule status post-video-assisted thoracic
surgery pneumolysin and right middle lung wedge resection on
2020-09-28.<br />
</li>
</ol></li>
</ul></li>
<li>He was a regular follow-up at our OPD. This time, he suffered from
left leg clumsiness and weakness for two weeks. Mild lower chest pain.
He was being referred from Oncology OPD. T-spine MRI with/without
contrast showed T5-6-7 metastases with thecal sac and spinal cord
compression. After discussing with the patient and his family surgical
risk. He was admitted for surgical intervention. Esophagal cancer with
T5-6-7 spinal metastasis post tumor excision and posterior fixation on
20211028. Post-operative course was uneventful. His discomfort was
relieved a lot.</li>
<li>Current problem:
<ul>
<li>Chest pain improve.</li>
<li>He complaint still left leg clumsiness and weakness.</li>
<li>Muscle power: Upper limbs: Rt 5 Lt 5; Lower limbs: Rt 5 Lt 4-5</li>
<li>Gait: unstable gait. Need use a walker to walk.</li>
</ul></li>
<li>We need your expertise for physical therapy.</li>
</ul></li>
<li>A
<ul>
<li>MP:
<ul>
<li>upper limbs 5/5</li>
<li>lower limbs</li>
<li>Quadriceps R/L 5/4</li>
<li>Knee extensors R/L 5/4</li>
<li>Ankle dorsiflexors R/L 4/4</li>
<li>Ankle plantar flexors R/L 4/4</li>
<li>toe extensors 4/4</li>
<li>BADL: max A</li>
<li>ambulation: now walker with min A</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: GYM PT + OT rehabilitation programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-695" class="section level3">
<h3>==========</h3>
</div>
<div id="section-696" class="section level3">
<h3>2022-04-25</h3>
<ul>
<li>After receiving etoposide + cisplatin since December 2021, the
patient’s chemotherapy regimen has been changed to 5-FU + cisplatin
since this hospitalization following 2022-03-30 CT evidence of
progression. The new regimen is generally tolerated by the patient.</li>
<li>A variety of underlying diseases such as coronary artery disease,
hypertension, enlarged prostate, lower urinary tract symptoms, gout,
hypothyroidism, AF, and hyperlipidemia are currently treated with
appropriate medications.</li>
<li>Lab data on 2022-04-20, liver and kidney functions, serum
electrolytes and blood cell counts were grossly normal, except decreased
WBC level of 2780/uL (neutrophil 58%) which should be noted.</li>
</ul>
</div>
<div id="section-697" class="section level3">
<h3>2022-03-30</h3>
<ul>
<li>No updated images for this patient since last hospital stay. Lab
data reported on 2022-03-29 indicated that the CBC readings were below
normal ranges and CEA (6.02 ng/mL), SCC (1.7 ng/mL) were above normal
ranges.</li>
<li>EP (etoposide + cisplatin) has been administered since December 2021
for his neuroendocrine carcinoma, and the patient has no intolerance
during this hospitalization according to nursing note.</li>
<li>Pembrolizumab can be considered for patients with dMMR/MSI-H or
advanced tumor mutational burdenhigh (TMB-H) tumors that have progressed
following prior treatment and have no satisfactory alternative treatment
options.</li>
<li>In the event hypothyroidism remains a diagnosis (no updated lab data
found since 2022), then levothyroxine (Eltroxin) might be
considered.</li>
</ul>
</div>
<div id="section-698" class="section level3">
<h3>2022-03-02</h3>
<ul>
<li>EP (etoposide + cisplatin) is applied since Dec 2021 and the patient
tolerates the treatment during this hospitalization.</li>
<li>if somatostatin receptor (SSR) is proved positive, then octreotide
or lanreotide might be an optional add-on.</li>
</ul>
</div>
</div>
</div>
<div id="section-699" class="section level1">
<h1>700973989</h1>
<div id="section-700" class="section level2">
<h2>220422</h2>
<p>{esophageal squamous cell carcinoma with liver and lung mets}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-20 SONO - chest
<ul>
<li>left side moderate hemothroax, s/p chest tapping 600 ml bloody
effusion for study and s/s relief</li>
<li>right side moderate pleural effusion, s/p chest tapping 350 ml for
study</li>
</ul></li>
<li>2022-04-13 Chest PA (erect) view
<ul>
<li>A poorly defined huge mass over over medial RUL and midlung zone
with multiple nodular opacities in both lungs, due to metastases</li>
<li>Bilateral pleural effusions</li>
<li>Superior mediastinal widening due to lymph node enlargement,</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Otherwise, there is no significant abnormality of the chest. (Note
that ground-glass lesion, small nodule or retrocardiac lesion might be
missed on plain chest radiography.)</li>
</ul></li>
<li>2022-04-11 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in both rib cages, some T-and L-spine,
bilateral sternoclavicular junctions, shoulders, S-I joints, right
femoral trochanters, and right knee.</li>
</ul></li>
<li>2022-04-08 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy — squamous cell carcinoma, please
correlate with the clinical presentation and image study to
differentiate primary or metastatic tumor</li>
<li>Sections show solid sheets of hyperchromatic tumor cells
infiltrating in a fibrotic stroma. Focal keratinization is seen.</li>
<li>The immunohistochemical stains reveal p40(+), and TTF-1(-). Please
correlate with the clinical presentation and image study to
differentiate primary or metastatic tumor.</li>
</ul></li>
<li>2022-04-07 MRI - brain
<ul>
<li>No obvious intracranial lesion.</li>
<li>Large patchy area of encephalomalacia over left PCA territory.</li>
<li>Also small areas of old infarction over right frontal lobe, right
medial occipital lobe, bilateral cerebellar lobe.</li>
<li>Mild periventricular small vessel disease. NO acute ischemic
infarct.</li>
</ul></li>
<li>2022-04-06 Cell block
<ul>
<li>Suggestive of malignancy<br />
</li>
<li>The smears and cell block show lymphocytes, reactive mesothelial
cells and a few atypical cell nests, which immunocytochemistry shows
TTF-1(-), Napsin-A(-) and P40(+, scant) for atypical cells, suggestive
of malignancy. According to cytomorphologic finding, it is compatible
with metastatic squamous cell carcinoma. Please refer to S2022-05907 and
clinical correlation for tumor origin.</li>
</ul></li>
<li>2022-04-02 CT - chest
<ul>
<li>Imaging stage: T4aN3M1, stage IVB</li>
</ul></li>
<li>2022-04-01 Pathology - esophageal biopsy
<ul>
<li>Esophageal tumor, 27 and 40 cm below the incisors, biopsy — Squamous
cell carcinoma, moderately differentiated</li>
<li>Microscopically, the sections show a picture of squamous cell
carcinoma, moderately differentiated characterized by solid tumor nests
with enlarged, hyperchromatic and pleomorphic nuclei infiltratde in the
stroma with focal keratin formation and some necrotic debris.</li>
</ul></li>
<li>2022-03-31 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA A</li>
<li>Highly suspected esophageal cancer, 27-40cm, s/p biopsy</li>
<li>Superficial gastritis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-21 family medicine
<ul>
<li>Q:
<ul>
<li>The 66-year-old male has history of Type II Diabetes mellitus and
Hypertension under Chang Gung OPD follow up and esophageal cancer with
lung and liver meta. He suffer from short of breath for one day. He came
to our ER for help on 20220402. Under the impression of esphogeal
cancer, jejunostomy performed on 20220414 and intubated ETT at the same
day. The patient prefer palliative care, so extubated on 20220418.
However, tachypnea with short of breath were noted, NIPPV
supportive.</li>
<li>Current problem: We need Hospice care and take over the patient for
palliative care.</li>
</ul></li>
<li>A:
<ul>
<li>66y/o gentleman just dx advanced esophageal cancer</li>
<li>Dyspnea s/p intubation now with BIPAP</li>
<li>DNR +</li>
<li>ECOG 4</li>
<li>Would put p’t on Hospice ward list.</li>
<li>Our share care would follow up.</li>
</ul></li>
</ul></li>
<li>2022-04-20 Thoracic Medicine
<ul>
<li>Q:
<ul>
<li>The 66-year-old male has history of Type II Diabetes mellitus and
Hypertension under Chang Gung OPD follow up and esophageal cancer with
lung and liver meta. He suffer from short of breath for one day. He came
to our ER for help on 20220402. Under the impression of esphogeal
cancer, jejunostomy performed on 20220414 and intubated ETT at the same
day. The patient prefer palliative care, so extubated on 20220418.
However, tachypnea with short of breath were noted, NIPPV
supportive.</li>
<li>Current problem: We need your specialist to arrange pleural
drainage.</li>
</ul></li>
<li>A:
<ul>
<li>A case of heavy smoking with COPD, admitted due to esophageal cancer
s/p palliative feeding jejunostomy.</li>
<li>Bed-side chest echo had been done and showed right side serosanguous
exudative PE and left side hemothorax, s/p chest tapping with left side
350ml and right side 600ml.</li>
<li>Suggestion:
<ul>
<li>Left side chest tube drainage for hemothorax.</li>
<li>Add foster 2puff BID, spiriva 2puff HS.</li>
<li>F/U prn.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-18 Infectious Disease
<ul>
<li>Q:
<ul>
<li>Esophgeal Ca with lung metastasis s/p Feeding jejunostomy</li>
<li>Developed high fever suspected pneumonia</li>
</ul></li>
<li>A:
<ul>
<li>Antibiotic therapy should be adjusted according to the results of in
vitro sensitivity testing.</li>
<li>NO treatment for colonization. Do NOT use steroid.</li>
</ul></li>
</ul></li>
<li>2022-04-09 Hemato-Oncology
<ul>
<li>Impression:
<ul>
<li>Esophageal cancer with liver and lung metastasis</li>
<li>Type II Diabetes mellitus</li>
<li>Hypertension</li>
<li>Old CVA</li>
</ul></li>
<li>Suggestion:
<ul>
<li>We will discuss with patient about further treatment after complete
work up</li>
<li>Please check AntiHbc, SCC</li>
<li>May consult chest surgeon for port A insertion and involve in this
case.</li>
<li>Consult GI to involve in this case (esophagus stent? or
gastrostomy?)</li>
<li>Consult RT for CCRT</li>
</ul></li>
</ul></li>
<li>2022-04-06 Radiological Diagnosis
<ul>
<li>Q: for chest CT guiding biopsy of lung mass, sinecrely need your
professional evaluation</li>
<li>Q:
<ul>
<li>This 66-year-old patient is a case of bilateral lung nodules,
suspected metastasis or primary lung cancer.</li>
<li>CT-guided biopsy is indicated. Please chek platelet, PT, and aPTT
before this procedure. We will inform the risk of insufficient specimen,
pneumothorax, hemorrhage, infection, and air embolism to the patient and
the family.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient, who suffers from esophageal squamous cell carcinoma
with liver and lung metastases, has been placed on the hospice waiting
list on 2022-04-21.</li>
</ul>
</div>
</div>
<div id="section-701" class="section level1">
<h1>701198481</h1>
<div id="section-702" class="section level2">
<h2>220422</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-01 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-22 Abdomen - Standing(Diaphragm)
<ul>
<li>Air-fluid level in the bowel at the upper abdomen is noted that may
be bowel obstruction? Please correlate with contrast enhanced CT.</li>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected.</li>
</ul></li>
<li>2022-03-09 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-07 Abdomen - Standing(Diaphragm)
<ul>
<li>Multiple segment of small intestine show air-fluid level that are
c/w bowel obstruction.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-04 CT - abdomen, pelvis
<ul>
<li>Carcinomatosis induce mechanical bowel obstruction is
suspected.</li>
</ul></li>
<li>2022-03-04 KUB
<ul>
<li>Increased intestinal gas is found.</li>
<li>Stool impaction at the abdominal cavity is noted.</li>
</ul></li>
<li>2021-11-23 CT - abdomen, pelvis
<ul>
<li>Stationary of pancreatic tail low density lesion.</li>
<li>More prominent soft tissue density in RLQ, suspected
carcinomatosis.</li>
<li>Stationary of bilateral lung nodules, suspected lung
metastasis.</li>
</ul></li>
<li>2021-11-09 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 20210120, no prominent
change is noted, suggesting no strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the maxilla, middle T-spines, lower
L-spines, sacrum, bilateral sacroiliac joints, shoulders,
sternoclavicular junctions, hips, and knees,</li>
</ul></li>
<li>2021-09-21 CT - abdomen, pelvis
<ul>
<li>Small bowel ileus, suspected adhesion.</li>
<li>Relative increased density in RLQ, suspected carcinomatosis.</li>
<li>Stationary of pancreatic lesion.</li>
<li>Left lower lung nodule, suspected lung metastasis.</li>
</ul></li>
<li>2021-07-13 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-07-12 CT - abdomen, pelvis
<ul>
<li>Stationar condition of pancreatic cancer and peritoneal
carcinomatosis as compared with previous CT study on 20210511.</li>
</ul></li>
<li>2021-05-11 CT - abdomen, pelvis
<ul>
<li>Dilated pancreatic duct at tail portion. The pancreatic condition is
stationary.</li>
<li>No evidence of mestastatic lesion in the study.</li>
</ul></li>
<li>2021-04-18 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-03-02 CT - abdomen, pelvis
<ul>
<li>Suspected rupture appendicitis.</li>
<li>Suspected abscess in the pelvic cavity.</li>
</ul></li>
<li>2021-01-20 Tc-99m MDP bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in middle T-spine, lower L-spine, sacrum,
sacroiliac joints, shoulders, sternoclavicular junctions, hips, and
knees.</li>
</ul></li>
<li>2021-01-19 CT - abdomen, pelvis
<ul>
<li>Non-visualization of the pancrreatic tumor. Either current therpay
is effective or the diagnostic method should be further
investigated.</li>
</ul></li>
<li>2020-12-14 Abdomen - Standing(Diaphragm)
<ul>
<li>Transitional vertebra of L5-S1, left side.</li>
</ul></li>
<li>2020-10-12 CT - abdomen, pelvis
<ul>
<li>Stationar condition of pancreatic cancer and peritoneal
carcinomatosis as compared with previous CT study on 20200706.</li>
</ul></li>
<li>2020-07-20 Tc-99m MDP bone scan
<ul>
<li>Mildly and non-focally increased radiotracer uptake in middle
T-spine, lower L-spine, and sacrum that had been less evident in
comparison with the previous study on 20200204, degenerative spine
diseases may show such a picture.</li>
<li>Probably degenerative joint lesions in shoulders, sternoclavicular
junctions, sacroiliac joints, hips, and knees.</li>
<li>No definite evidence of osteoblastic skeletal metastasis by this
bone scan.</li>
</ul></li>
<li>2020-07-06 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Much regression of pancreatic cancer and peritoneal
carcinomatosis.</li>
</ul></li>
<li>2020-04-07 CT - abdomen, pelvis
<ul>
<li>Pancreatic malignancy s/p treatment.</li>
<li>Regression of peritoneal carcinomatosis.</li>
</ul></li>
<li>2020-02-04 Tc-99m MDP bone scan with SPECT
<ul>
<li>Increased activity in the lower C-spine and lower L-spine.
Degenerative change may show this picture. However, please correlate
with other imaging modalities for further evaluation and to rule out
other possibilities.</li>
<li>Increased activity in the bilateral shoulders, bilateral
sternoclavicular junctions, hips, knees, ankles and both feet,
compatible with benign joint lesion.</li>
</ul></li>
<li>2020-01-02 CT - abdomen
<ul>
<li>Pancreatic carcinoma imaging stage: T1cN1M1, Stage IV</li>
<li>Other findings: mild repression of primary tumor and peritoneal
seeding</li>
</ul></li>
<li>2019-09 Pathology - omentum (at VGHTPE)
<ul>
<li>pancreatic adenocarcinoma, metastatic, cT4N1M1</li>
<li>CK7(+), CK20(-).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-04-19 8.36 ng/mL</li>
<li>2022-04-08 8.734</li>
<li>2022-04-06 8.86</li>
<li>2022-03-23 5.451</li>
<li>2022-02-22 10.47</li>
<li>2022-02-08 8.176</li>
<li>2022-01-19 5.384</li>
<li>2022-01-03 6.370</li>
<li>2021-12-21 5.508</li>
<li>2021-11-25 7.414</li>
<li>2021-04-28 2.419</li>
<li>2021-04-20 2.64</li>
<li>2021-03-04 1.607</li>
<li>2021-01-14 1.155</li>
<li>2020-12-09 1.343</li>
<li>2020-12-08 1.11</li>
<li>2020-11-06 1.757</li>
<li>2020-10-02 1.591</li>
<li>2020-08-28 1.875</li>
<li>2020-08-04 0.749</li>
<li>2020-04-13 1.86</li>
<li>2020-02-27 2.766</li>
<li>2019-12-31 3.478</li>
<li>2019-11-05 2.995</li>
<li>2019-10-16 2.789</li>
</ul></li>
<li>CA199
<ul>
<li>2022-04-19 10566.2 U/mL</li>
<li>2022-04-08 10638</li>
<li>2022-04-06 5603.49</li>
<li>2022-03-23 10346.6</li>
<li>2022-02-22 9232.6</li>
<li>2022-02-08 8534.6</li>
<li>2022-01-19 8673.8</li>
<li>2022-01-03 9546</li>
<li>2021-12-21 8695.7</li>
<li>2021-12-17 3930.36</li>
<li>2021-12-03 11539.95</li>
<li>2021-11-25 11030.5</li>
<li>2021-11-09 16219.4</li>
<li>2021-10-13 12661</li>
<li>2021-09-17 5472.1</li>
<li>2021-09-07 6671.4</li>
<li>2021-08-06 3643.3</li>
<li>2021-07-23 4275.3</li>
<li>2021-07-09 2841.0</li>
<li>2021-06-25 3306.2</li>
<li>2021-06-18 3287.4</li>
<li>2021-06-08 3073.35</li>
<li>2021-05-25 3015.7</li>
<li>2021-05-12 3141.6</li>
<li>2021-04-28 2667.2</li>
<li>2021-04-20 1630.65</li>
<li>2021-04-01 1143.5</li>
<li>2021-03-19 701.39</li>
<li>2021-03-04 354.060</li>
<li>2021-02-24 335.25</li>
<li>2021-01-15 177.130</li>
<li>2021-01-14 169.370</li>
<li>2020-12-16 110.182</li>
<li>2020-12-08 156.614</li>
<li>2020-11-06 71.735</li>
<li>2020-10-02 38.132</li>
<li>2020-08-28 23.155</li>
<li>2020-08-11 21.897</li>
<li>2020-07-31 20.589</li>
<li>2020-07-20 19.681</li>
<li>2020-06-24 23.338</li>
<li>2020-05-29 29.415</li>
<li>2020-04-30 64.378</li>
<li>2020-04-13 68.09</li>
<li>2020-04-08 145.41</li>
<li>2020-02-27 493.18</li>
<li>2020-02-04 678.54</li>
<li>2019-12-31 1127.2</li>
<li>2019-12-03 1981.5</li>
<li>2019-11-14 3700</li>
<li>2019-11-05 4329.2</li>
<li>2019-10-18 8888.3</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-15 - gemcitabine</li>
<li>2022-04-07 - carboplatin + gencitabine</li>
<li>2021-09-29 ~ 2022-03-21 - FOLFIRI?</li>
<li>2020-09-14 - FOLF (irinotecan to be plused)</li>
<li>2020-02-13 - 2021-09-07 - gemcitabine + nal-paclitaxel</li>
<li>2020-02-06 - gemcitabine</li>
<li>2019-10-21 ~ 2020-01-20 - FOLFIRINOX (experienced
oxaliplatin-allergic shock 2020-01)</li>
<li>2019-10-07 - oxalip 150 mg iv q2wk plus TS-1 60 mg 3tab bid and
folic acid 2tab bid</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Initially diagnosed with pancreatic carcinoma (T1cN1M1, Stage IV) in
September 2019, followed by FOLFIRINOX between 2019-10 and 2020-01;
following oxaliplatin allergy, the regimen changed to gemcitabine +
nal-paclitaxel until 2021-09; following lung metastases, the regimen
changed to 5-Fu + irinotecan until 2022-03; following
carcinomatosis-induced mechanical bowel obstruction, the regimen changed
to carboplatin + gencitabine since 2022-04.</li>
<li>The patient experienced severe back pain on 2022-04-20 night and was
taken to the Emergency Department. Morphine 5mg IVD PRNQ4H is prescribed
to treat the pain.</li>
<li>Lab readings on 2022-04-21 were CRP 7.53mg/dL, urine bacteria 3+,
urine OB 2+, urine sediment RBC 6-9/HPF, urine sediment WBC 50-99/HPF.
Body temperature did not exceed 37.5 degrees during this hospital stay
for now. The blood culture has been ordered, but the results are not yet
available. Empirical antibiotics ceftriaxone 2000mg IVD QD are being
used since 2022-04-22.</li>
<li>Vemlidy (tenofovir alafenamide) is used to treat underlying positive
HBsAg.</li>
</ul>
<p>            </p>
</div>
</div>
<div id="section-703" class="section level1">
<h1>700466967</h1>
<div id="section-704" class="section level2">
<h2>220421</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-14 MRI - brain
<ul>
<li>A left posterior cerebellar tumor, consistent with metastasis.</li>
</ul></li>
<li>2022-04-14 CT - brain
<ul>
<li>One mass lesion (2.8cm in size) over left cerebellar lobe with
perifocal edema. Compatible with a metastasis.<br />
</li>
<li>Mild dilatation of ventricles.</li>
<li>The posterior structures including the brain stem, cerebellum and CP
angles look normal.</li>
</ul></li>
<li>2022-04-14 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy — consistent with metastatic
choriocarcinoma</li>
<li>Section shows alveolar tissue with infiltration of large pleomorphic
tumor cells and tumor necrosis.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), beta-hCG(+),
GATA-3(+), TTF-1(-), OCT3(-), PLAP(-), and SALL4(equivocal). The results
are consistent with metastatic choriocarcinoma. Please correlate with
the clinical presentaiton and lab study.</li>
</ul></li>
<li>2022-04-12 CT - chest
<ul>
<li>bilateral lung metastatic tumors.</li>
<li>two hepatic hemangiomas up to 35 mm.</li>
</ul></li>
<li>2022-04-08 MRA - brain
<ul>
<li>Left cerebellar metastasis.</li>
</ul></li>
<li>2022-04-08 CT - brain
<ul>
<li>Probably left cerebellar metastasis.</li>
</ul></li>
<li>2021-12-20 Chest PA/AP view
<ul>
<li>a large consolidation with lobulated contour over Rt lower lobe, in
regression as compared with previous chest image</li>
<li>near complete resolution of the LLL small nodule post transthoracic
needle biopsy</li>
</ul></li>
<li>2021-12-14 Chest PA/AP view</li>
<li>diffuse consolidation in Rt lower lobe stationary as compared with
previous chest image</li>
<li>a nodular opacity (well-defined) over LLL</li>
<li>2021-12-14 Patho - lung transbronchial biopsy
<ul>
<li>Lung, LLL, CT-guide biopsy — Scant atypical cells present<br />
</li>
<li>Sections show alveolar lung tissue with interstitial fibrosis and
scant atypical cells in fibrous stroma.</li>
<li>The immunohistochemical stains reveal CK(+), p40(-), TTF-1(-),
Napsin A(-), CD56(-), SALL4(-), and OCT4(-). Please correlate with the
clinical presentation and lab study. Further examination is
suggested.</li>
</ul></li>
<li>2021-12-07 SONO - chest
<ul>
<li>lung consolidation, suspected abscess</li>
</ul></li>
<li>2021-12-06 Chest PA (erect) view
<ul>
<li>Radiopacity in right middle and lower lung zone, suspected mass or
loculated pleural lesion</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-04-12
<ul>
<li>LDH 776 U/L<br />
</li>
<li>beta-HCG &gt;265200 mIU/mL<br />
</li>
<li>AFP 207.4 ng/mL</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-12 hemato-oncology
<ul>
<li>This 22-year-old male patient had past history of
<ul>
<li>Testis cancer status post operation at Tri-Service General Hospital
for 2 years ago.</li>
<li>Pneumonia and lung abscess in 2021-12 at Taipei Tzu Chi
Hospital</li>
<li>RLL and LLL solid nodules, suspected lung metastases on 20211229 at
Tri-Service General Hospital.<br />
</li>
</ul></li>
<li>This time, he suffered from headache and dizzness for one week. He
was brough to our emergency room for help. Arrival at our emergency
room, initial consciousness remained E4M6V5. Labortory data showed
normal range of WBC, but elevated CRP (11.60mg/dl). Brain CT was done,
which showed a 2.2cm heterogeneous hyperdense nodule at left cerebellum,
associated with vasogenic edema. Brain metastasis is first considered.
Brain MRI was performed, which revealed a 2.2cm rim-enhancing nodule at
left cerebellum, associated with vasogenic edema. Brain metastasis is
first considered. Multiple nodular and mass over bilateral lung were
found. Consulted Neurosurgeon was done cause by suspected brain
metastases of left cerebellum. He then admitted to SICU for neurological
condition monitoring and further management on 2022-04-08. After SICU,
he remained conscious during ICU stay. Under anti-swelling agent as
Mannitol and Medason were used. PPI for ulcer prevention. Anticonvulsant
agent as Keppra was given. He will arrange lung CT this afternoon.
<ul>
<li>Tumor marker: B-HCG: &gt;265200, <a href="AFP:207.4" class="uri">AFP:207.4</a>, LDH:?</li>
<li>Chest CT: pending</li>
<li>Brain CT: left cerebellar metastasis.</li>
<li>Brain MRI: left cerebellar metastasis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Suspect recurrent nonseminal germ cell tumor with lung and brain
metastasis</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Pending chest CT report, check LDH</li>
<li>Arrange CT guide biopsy for suspect lung metastasis</li>
<li>If proof recurrent non seminoma germ cell tumor, arrange port A
insertion</li>
<li>Arrange pulmonary function test: FRC + DLCO</li>
<li>Wait for CT-guided biopsy of lung tumor that will be done on 4/14
22. If recurrent germ cell tumor wt lung mets &amp; L cerebellar mets is
Dx, palliative C/T will be started soon.</li>
<li>Germ cell tumor may be well responsive to palliative C/T wt
BEP.</li>
<li>As for L cerebellar mets tumor, may consult radiation oncologist for
R/T evaluation.</li>
<li>may check AFP, b-HCG as well.</li>
</ul></li>
</ul></li>
<li>2022-04-08 Neurosurgery
<ul>
<li>Q:
<ul>
<li>cough with blood-tinged sputum for 2 weeks</li>
<li>headache with dizziness after waking up for one week</li>
<li>no fever, no sore throat or runny nose, no SOB, no chest pain</li>
<li>PMH: testis cancer s/p op, Rt lung cyst</li>
<li>allergy: denied</li>
</ul></li>
<li>A:
<ul>
<li>A case of 22 y/o male; Testis cancer s/p; Headache/dizziness
progressed for 1+ week;</li>
<li>A brain CT showed a 2.2cm heterogeneous hyperdense nodule at left
cerebellum, associated with vasogenic edema. Brain metastasis is first
considered.</li>
<li>A brain MRI with Gd showed a 2.2cm rim-enhancing nodule at left
cerebellum, associated with vasogenic edema. Brain metastasis is first
considered.</li>
<li>P: ICU care; mannitol/ steroid; Tumor excision indicated;</li>
</ul></li>
</ul></li>
<li>2021-12-13 Radiological Diagnosis
<ul>
<li>Q: 22 year old male with past history of prostate cancer s/p OP 2
years ago admitted this time due to RLL pneumonia (suspected abscess)
and treated with Brosym, Colistin, and Targocid. CT also showed an 1.3
cm nodule over left lower lungs. Thus, we needed your expertise for
CT-giuded biopsy for left lower lung nodule.</li>
<li>A: This 22-year-old patient is a case of LLL nodule, r/o malignancy.
CT-guided biopsy is indicated. Please chek platelet, PT, and aPTT before
this procedure. We will inform the risk of insufficient specimen,
pneumothorax, hemorrhage, infection, and air embolism to the patient and
the family.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Not sure if orchiectomy has been performed.</li>
<li>Bleomycin + Etoposide + Cisplatin might be indicated.</li>
<li>Additionally, opioids may be a viable option for this patients with
moderate to severe pain. (reference: <a href="https://www.ncbi.nlm.nih.gov/books/NBK554435/" class="uri">https://www.ncbi.nlm.nih.gov/books/NBK554435/</a> )</li>
<li>Besides analgesics, non-pharmacological interventions that can
control pain over a longer period of time might also be considered. The
following interventions are available to treat cancer pain (not
exhaustive, reference: <a href="https://pubmed.ncbi.nlm.nih.gov/31140913/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31140913/</a>):
<ul>
<li>Epidural and selective nerve root block</li>
<li>Radiofrequency ablation and cryoablation</li>
<li>Vertebral augmentation</li>
<li>Intrathecal drug delivery</li>
<li>Spinal cord stimulation</li>
<li>Dorsal root ganglion stimulation</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-705" class="section level1">
<h1>700803304</h1>
<div id="section-706" class="section level2">
<h2>220420</h2>
<p>{ovarian cancer}</p>
<ul>
<li>history
<ul>
<li>Right ovarian cancer status post suboptimal debulking surgery (right
salpingo-oophorectomy (RSO) + bilateral pelvic lymphadenectomy +
cytoreductive surgery + infracolic omentectomy + Appendectomy) and
hyperthermic intra-peritoneal chemotherapy on 2021-11-01.</li>
<li>Uterine myoma and left ovarian cyst s/p ATH + LSO</li>
<li>Type 2 diabetes mellitus with unspecified complications</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-01-21 SONO - abdomen
<ul>
<li>Fatty liver, moderate</li>
<li>GB adenomatosis</li>
</ul></li>
<li>2021-11-21 CT
<ul>
<li>Focal small bowel ileus.</li>
<li>Colonic diverticula.</li>
</ul></li>
<li>2021-11-02 Patho - ovary (tumor)
<ul>
<li>Pathologic diagnosis
<ul>
<li>Ovarian tumor, right, frozen + debulking surgery - Carcinosarcoma
and endometriosis</li>
<li>Pelvic tumor, debulking surgery - Tumor present</li>
<li>AJCC Pathologic staging: pT2bN0, if cM0, stage IIB</li>
<li>IHC
<ul>
<li>Carcinoma component: CK(+)<br />
</li>
<li>Sarcoma component: vimentin(+), CK(-), WT-1(-), ER(-), SMA(-),
myogenin(-), CDK4(-), beta-HCG(-), CD10(+) and cyclin-D1(+, focal),
CD31(+, focal)<br />
</li>
<li>Lymphovascular space invasion: present<br />
</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-10-27 CT - whole abdomen, pelvis
<ul>
<li>Right ovarian malignant tumor with carcinomatosis is highly
suspected. Please correlate with CA125 and ascites cytology.</li>
<li>Right side obstructive uropathy is noted.</li>
<li>Several small lymph nodes in para-aortic and para-cava space.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-11-01
<ul>
<li>HIPEC</li>
<li>Excision of intraabdominal tumor</li>
<li>Omentectomy</li>
<li>Appendectomy</li>
<li>Tenckhoff tube insertion<br />
</li>
<li>Right ovarian tumor, Frozen section: malignancy, type to be
determined</li>
<li>status post Laparoscopic Assisted Vaginal Hysterectomy(LAVH) + Left
Salpingo-oophorectomy (LSO)</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12 ~ ongoing: paclitaxel + carboplatin</li>
<li>2021-10-30: Liposome doxorubicin + carboplatin</li>
</ul></li>
</ul>
<div id="section-707" class="section level3">
<h3>==========</h3>
</div>
<div id="section-708" class="section level3">
<h3>2022-04-20</h3>
<ul>
<li>The patient was diagnosed with ovarian cancer following suboptimal
debulking surgery on 2021-11-01, and has been treated with paclitaxel +
carboplatin since December 2021.</li>
<li>The findings in the lab on 2022-04-20 were generally typical.</li>
<li>Readings of blood sugar in the ward fluctuated up to 430 mg/dL at
06:12 on 2022-04-21, which should be addressed (self-carried metformin
has been prescribed on the active medication list). Additional insulin
might be considered if blood sugar levels remain unruly.</li>
</ul>
</div>
<div id="section-709" class="section level3">
<h3>2022-03-23</h3>
<ul>
<li>At present, the patient is receiving platin-based chemotherapy
without intolerance during this hospital stay; no apparent abnormalities
were found in laboratory results reported on 2022-03-22.</li>
<li>Blood sugar readings tested in the ward fluctuated up to 211 mg/dL
at 06:30 on 2022-03-23, which should be addressed (self-carried
metformin has been prescribed in active medication list).</li>
</ul>
</div>
<div id="section-710" class="section level3">
<h3>2022-03-02</h3>
<ul>
<li>the patient is currently receiving platin-based chemotherapy without
intolerance.</li>
<li>most recent HbA1c recorded 7.3% on 2021-10-27, blood sugar tested
328mg/dL at 06:48 on 2022-03-02, metformin prescribed at Metab &amp;
Endoc OPD might be considered if needed.</li>
</ul>
</div>
</div>
</div>
<div id="section-711" class="section level1">
<h1>700127501</h1>
<div id="section-712" class="section level2">
<h2>220419</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-30 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis:
<ul>
<li>Reflux esophagitis LA grade A</li>
<li>Superficial gastritis</li>
<li>Gastric erosions, body, GC</li>
<li>Doudenal ulcers with duodenitis, bulb to 3rd portion</li>
<li>Incomplete study of esophagus due to residual food</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Pursue CLO test result</li>
</ul></li>
</ul></li>
<li>2022-03-27 Sacrum &amp; coccyx
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>moderate decreased L5/S1 joint space</li>
</ul></li>
<li>2022-03-27 L-spine Lat
<ul>
<li>loss of the natural curvature of the spine</li>
<li>mild spondylolisthesis at L5-S1</li>
<li>severe decreased disc space in the L5/S1 disc</li>
<li>unremarkable change in the paravertebral region</li>
<li>compression racture at T11 vertebral body</li>
</ul></li>
<li>2022-03-27 CT - abdomen, pelvis
<ul>
<li>suspected duodenal perforation</li>
</ul></li>
<li>2022-02-16 CT - lung/mediastinum/pleura
<ul>
<li>breast cancer with hematogeneous and lymphatic metastases in both
lungs, and spine metastasis, and bilateral pleural effusions, in
progression as compared with previous CT on 20210921.</li>
<li>suspect associated with infection or drug toxicity in the
lungs.</li>
</ul></li>
<li>2022-02-15 Chest
<ul>
<li>S/P port-A implantation.</li>
<li>Multiple nodular opacity projecting in the both lung are noted that
may be metastases. Please correlate with CT.</li>
<li>Presence of old fracture(s) at the bil. ribs and right clavicle are
noted that may be bony metastases? Please correlate with CT.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura thickening or effusion?</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2021-09-21 CT - chest
<ul>
<li>S/P right breast operation. Bil. lung metastases.</li>
<li>Suspected metastases at T10.</li>
</ul></li>
<li>2021-09-10 Chest
<ul>
<li>Port-A catheter inserted into cavo-atrial junction via left
subclavian vein.</li>
<li>Multiple ill-defined nodules of variable sizes and reticular
abndormality throughout in both lungs due to metastases.</li>
<li>A large increased opacity shadow over lateral Rt hemithorax,
extrapulmonary lesion</li>
<li>Absence of medial half of Rt clavicle and focal bone defects at Rt
humeral head</li>
<li>Old fracture of many Lt ribs</li>
<li>Osteoblastic metastasis in spine</li>
</ul></li>
<li>2021-08-16 KUB
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-05-21 CT - lung/mediastinum/pleura
<ul>
<li>S/P mastectomy at right side.</li>
<li>Diffuse lung meta, stationary.</li>
<li>Right humoral head bony invasion. Stable.</li>
<li>Bone mets at lumbar spine</li>
</ul></li>
<li>2021-02-06 CT - lung/mediastinum/pleura
<ul>
<li>Compatible with breast cancer lung meta, stationary in lung
mets.</li>
<li>Bone mets at right clavicle. stable.</li>
</ul></li>
<li>2020-12-14 Pathology - bronchus biopsy
<ul>
<li>Diagnosis
<ul>
<li>Lung, side?, CT-guide biopsy — metastatic breast carcinoma of no
special type<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Section shows cores of alveolar lung tissue with irregular
neoplastic glands infiltration.</li>
<li>IHC: GATA3(+) and TTF-1(-). The results are consistent with
metastatic breast carcinoma of no special type.</li>
</ul></li>
<li>Immunohistochemical Study
<ul>
<li>ER (Ab): Positive(95%, strong)<br />
</li>
<li>PR (Ab): Negative<br />
</li>
<li>Her-2/neu (Ab): Negative (1+)<br />
</li>
<li>Ki-67: 20%</li>
</ul></li>
</ul></li>
<li>2020-10-23 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with bilatral lung mets and right clavicle mets.</li>
</ul></li>
<li>2020-10-15 CT - brain
<ul>
<li>Mild brain atrophy and intracranial atherosclerotic disease</li>
</ul></li>
<li>2020-09-14 ABR, Auditory brainstem evoked response
<ul>
<li>R’t 60 dB nHL</li>
<li>L’t 55 dB nHL</li>
</ul></li>
<li>2020-03-13 CT - lung/mediastinum/pleura
<ul>
<li>Diffuse lung mets and bone mets. In progression.</li>
</ul></li>
<li>2019-07-17 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with lung metastasis with fibrosis, slightly in
progression.</li>
</ul></li>
<li>2018-01-30 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with lung metastasis, stationary.</li>
</ul></li>
<li>2017-10-25 CT - lung/mediastinum/pleura
<ul>
<li>Lung metastasis still present.</li>
</ul></li>
<li>2017-03-23 SONO - breast
<ul>
<li>A small right breast calcification.</li>
<li>Post OP with Edema at right axillary region.</li>
<li>Small left breast nodules and cysts.</li>
<li>BI-RADS: 2, Benign findings</li>
</ul></li>
<li>2017-03-21 CT - lung/mediastinum/pleura
<ul>
<li>D/D lung edema and/or pulmonary lymphagitic carcinomatosis.</li>
<li>LVD of heart.</li>
<li>Rt shoulder and arm post treatment change or edema.</li>
</ul></li>
<li>2017-02-17 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine and lower L-spines.
Degenerative change may show this picture. Please correlate with other
imaging modalities for further evaluation.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
<li>Increased activity in the right shoulder, left sternoclavicular
junction, right elbow, right wrist, bilateral knees and right foot.
Either benign joint lesion such as arthritis or post-traumatic change
may show this picture. However, please correlate with other clinical
findings for further evaluation and to rule out other
possibilities.</li>
<li>No prominent bone abnormality was noted elsewhere.</li>
</ul></li>
<li>2008-07-14 CT
<ul>
<li>bilateral multiple pulmonary metastasis</li>
<li>pT2N2M1, stage IV</li>
</ul></li>
<li>2008-06 Pathology
<ul>
<li>Infiltrating ductal carcinoma, grade II with pectoralis major muscle
invasion</li>
<li>IHC: ER(+) 5% score 1, PR(+) 20% score 1, Her2(-)</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2008-06-16 MRM at Taipei City Hospital FuYou Branch</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-15 ~ undergoing - ribociclib</li>
<li>2020-12-25 ~ undergoing - exemestane</li>
<li>2017-02-03 ~ 2020-12-18 - letrozole</li>
<li>2008-07-10 ~ 2008-09-16 doxorubicin + cyclophosphamide; (then
docetaxel, letrozole, vinorelbine?)</li>
</ul></li>
</ul>
<div id="section-713" class="section level3">
<h3>==========</h3>
</div>
<div id="section-714" class="section level3">
<h3>2022-04-19</h3>
<p>[tube feeding]</p>
<ul>
<li>All oral PPIs should not be ground.</li>
<li>PPIs are easily protonated and therefore unstable at acid pH. In
gastric juice, this would result in inactivation before absorption. This
is why some PPIs are enteric coated. Following absorption, they
partition by ionic trapping into the acidic environment of the parietal
cell cytoplasm, where the unstable sulphonamide/sulphenic acid species
that result from protonation form irreversible disulphide bonds with
cysteine residues in the proton pump.</li>
<li>Pariet FC (rabeprazole 20mg/tab) is film-coated and not intended for
tube feeding. It could be replaced with Takepron (lansoprazole
30mg/tab), Nexium (esomeprazole 40mg/tab) or Dexilant (Dexlansoprazole
60mg/cap), with opening the capsule and pouring out the small granules
into drinking water prior to tube feeding.</li>
</ul>
</div>
<div id="section-715" class="section level3">
<h3>2022-04-18</h3>
<ul>
<li>This patient was diagnosed with breast cancer (ER+ PR- HER2-,
2020-12-14 pathology, s/p MRM) with lung and spine mets in progress
(2022-02-16 CT) and was treated with exemestane since 2020-12-25, and
with ribociclib since 2022-03-15.</li>
<li>The current regimen (aromatase inhibitor and CDK4/6 inhibitor) is a
treatment of choice for HR+ HER2- postmenopausal recurrent or stage IV
breast cancer.</li>
<li>All the listed underlying health conditions have been managed with
corresponding drugs. As TPR readings remain relatively stable, blood
sugar readings fluctuate at a higher range, which should be
addressed.</li>
<li>Kisqali (ribociclib) prescribed at 2022-04-15 OPD has been filled to
2022-04-29. Severe, life-threatening, and/or fatal interstitial lung
disease (ILD) and/or pneumonitis may occur with ribociclib (and other
cyclin-dependent kinase inhibitors). Symptoms of ILD/pneumonitis may
include hypoxia, cough, dyspnea, or interstitial infiltrates on
radiologic exam. (exclude infectious, neoplastic, and other causes for
pulmonary toxicity.) Kisqali (ribociclib) is currently suspended.</li>
</ul>
</div>
</div>
</div>
<div id="section-716" class="section level1">
<h1>700379547</h1>
<div id="section-717" class="section level2">
<h2>220419</h2>
<p>{Recurrent hepatocellular carcinoma with Lung and C-spine, T-spine
and L-spine metastasis cT2N0M1 stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-01 KUB
<ul>
<li>S/P operation with retention of surgical clips.</li>
<li>Stool retention in the bowel.</li>
<li>Degeneration and spondylosis of L-S spine.</li>
</ul></li>
<li>2022-03-18 CT - abdomen, pelvis
<ul>
<li>Multiple bony metastases on the T-and L-spine, and bilateral ilium
show progressive disease.</li>
<li>Compression fracture of L5 vertebral body is noted.</li>
<li>Right lower Lung metastases show progressive disease.</li>
</ul></li>
<li>2022-02-25 Patho - omentum biopsy
<ul>
<li>diagnosis
<ul>
<li>Tissue, site unspecified, CT-guide biopsy — hepatocellular
carcinoma</li>
<li>Microscopically, it shows hepatocellular carcinoma composed of
neoplatic cells with hyperchromatic nuclei, fine granular cytoplasm,
arranged in trabecular pattern with greater than 3 cell thick
cords.<br />
</li>
<li>IHC: CK7(-), CK19(-), arginase(+), CD10(-), and hepatocytes(+).</li>
</ul></li>
</ul></li>
<li>2022-02-25 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
<li>2022-02-18 MRI - upper abdomen
<ul>
<li>Multiple HCCs at left hepatic lobe are noted.</li>
<li>Multiple bony metastases on the T-and L-spine are suspected.</li>
<li>Lung metastasis 1.1 cm at RLL is noted.</li>
</ul></li>
<li>2022-01-11 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Post-op at right lobe liver.</li>
<li>Diffuse HCCs, progression.</li>
<li>Lung and bone metastasis.</li>
<li>Suspected left renal cysts, up to 2.1cm.</li>
</ul></li>
<li>2021-12-15 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple HCCs at left hepatic lobe are suspected.</li>
<li>Lung metastasis 1.1 cm at RLL is highly suspected.</li>
</ul></li>
<li>2021-10-14 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P liver operation. Several recurrent HCCs (0.3-0.9) at remnant
liver.</li>
<li>A nodule (9mm) at RLL r/o metastases.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-09-01 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two viable HCCs 1.1 cm in S2 and 0.7 cm in S4 are suspected.</li>
<li>Two recurrent HCCs 0.6 cm and 0.5 cm in S4 are suspected.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-07-21 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two recurrent HCCs 1.8 cm in S2 and 0.7 cm in S4 are highly
suspected. Please correlate with AFP.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-06-02 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two recurrent HCCs 1.6 cm in S2 and 0.7 cm in S4/8 are highly
suspected. Please correlate with AFP.</li>
<li>Prior CT identified HCC in S4/8 of the liver S/P TACE on 20210513
shows complete response.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-05-19 Abdominal Ultrasonography
<ul>
<li>Liver tumors, suspected recurrent HCCs</li>
<li>Liver cirrhosis with mild splenomegaly</li>
<li>Liver lesions, spspect tumor scars or regeneration nodules</li>
<li>Invisible GB</li>
</ul></li>
<li>2021-05-06 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P liver operation. Two recurrent HCCs (1.1cm, 1.3cm, srs3, img13,
15) at S2 and right liver margin.</li>
<li>A nodule (6mm) at RLL r/o metastases.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-02-25 Patho - liver partial resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S6-7, segmentectomy — Hepatocellular carcinoma,
recurrent<br />
</li>
<li>Pathologic Staging: rpT2Nx(cM0), Stage II at least</li>
</ul></li>
</ul></li>
<li>2021-02-03 MRI - liver, spleen
<ul>
<li>Imaging stage: T2N0M0, stage II</li>
</ul></li>
<li>2020-11-03 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P RFA and S/P cholecystectomy.</li>
<li>Post-op at left lobe liver with focal enhancement at S4 around the
surgical region, probably vascular shunting. Suggest clinical
correlation and follow up study.</li>
<li>Renal cysts.</li>
<li>Minimal ascites in the pelvic cavity.</li>
</ul></li>
<li>2020-09-21 CT - abdomen, pelvis
<ul>
<li>Long segmental wall edema of esophagus and duodenum. Distention of
stomach.</li>
<li>S/P liver operation and cholecystectomy. Liver cirrhosis.</li>
</ul></li>
<li>2020-08-17 MRI - liver, spleen
<ul>
<li>Liver cirrhosis with portal hypertension and splenomegaly. HCC s/p
operation and RFA without tumor recurrence.</li>
</ul></li>
<li>2020-06-17 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Liver cirrhosis with HCC at S6 s/p RFA. No evidence of local
recurrence is found.</li>
</ul></li>
<li>2020-03-16 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>HCCs s/p operation, TACE and RFA. Residual and recurrent HCCs
(3-8mm) at right hepatic lobes.</li>
</ul></li>
<li>2020-02-04 Embolization (TAE) - abdomen
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2019-11-28 MRI - liver, spleen
<ul>
<li>Liver cirrhosis.</li>
<li>HCC at S6 s/p RFA with recurrent tumor adjacent to the lesion.
Suggest further treatment.</li>
</ul></li>
<li>2019-09-18 CT - liver, spleen, biliary duct
<ul>
<li>Liver cirrhosis with HCC s/p RFA and TACE, no evidence of local
recurrence in the study.</li>
</ul></li>
<li>2019-07-03 CT - liver, spleen, biliary duct
<ul>
<li>Liver cirrhosis.</li>
<li>HCC s/p op. and RFA with suspected tumor recurrence at S7. Malignant
liver neoplasm, primary;</li>
</ul></li>
<li>2019-05-20 Surgical pathology Level V
<ul>
<li>Liver, sono-guided biopsy — Consistent with hepatocellular carcinoma
and liver cirrhosis</li>
<li>The sections show a picture liver cirrhosis, composed of
regenerative nodules separated by broad fibrous bands. Scant atypical
cells arranged in thin trabecular pattern can be found.</li>
<li>IHC: Glutamine synthetase(+), HSP70(+), glypican-3(+) and CK7(-).
The IHC finding is consistent with hepatocellular carcinoma.</li>
</ul></li>
<li>2019-03-12 CT - liver, spleen, biliary duct
<ul>
<li>S/P operation. A recurrent HCC (9mm) in S6 of liver.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2018-09-07 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S5, partial hepatectomy — Hepatocellular carcinoma<br />
</li>
<li>Liver, S6, partial hepatectomy — Combined
hepatocellular-cholangiocarcinoma<br />
</li>
<li>Specimen labeled “surface tumor”, frozen section — Regenerative
nodule<br />
</li>
<li>Pathologic Staging: ypT2Nx(cM0), Stage II at least</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Diagnosis: Hepatocellular carcinoma(S5) and combined
hepatocellular-cholangiocarcinoma(S6)</li>
<li>Histologic Grade: G2 (Moderately differentiated, both tumors)</li>
<li>Tumor Extension: Tumor confined withing liver (both tumors)</li>
<li>Pathologic Stage Classification
<ul>
<li>Primary Tumor (pT): ypT2 (multiple tumors, none &gt;5 cm)<br />
</li>
<li>Regional Lymph Nodes (pN): ypNx (No lymph nodes submitted)<br />
</li>
<li>Distant Metastasis (pM): Not applicable<br />
</li>
</ul></li>
<li>Additional Pathologic Findings: Chronic hepatitis C</li>
<li>Ishak modified staging of fibrosis: Cirrhosis (F6)<br />
</li>
<li>IHC: Cholangiocarcinoma component reveals CK7(+), Hepa1(-),
Arginase-1(-)</li>
</ul></li>
</ul></li>
<li>2017-07-10 MRI - liver, spleen
<ul>
<li>HCC s/p RFA. A poor enhancing nodule (1.5cm) in S6 of liver without
interval change.</li>
<li>Liver cirrhosis with regenerative nodules, portal hypertension and
splenomegaly.</li>
</ul></li>
<li>2017-02-16 CT - liver, spleen, biliary duct
<ul>
<li>HCC s/p RFA. Liver cirrhosis with splenomegaly.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2021-08-13 PIVIKA-II 62.36 mAU/mL (normal &lt; 40)</li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-17 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-11-03 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-09-02 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-07-22 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-06-21 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-05-13 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-02-24
<ul>
<li>surgery - laparoscope assist right posterior segmntectomy S6-7</li>
<li>finding - two hepatic tumors at S7 and scaring at S6 and S6
postresected scarring</li>
</ul></li>
<li>2020-05-29 RFA, Radiofrequency ablation - HCC</li>
<li>2020-05-06 PEIT, Sonography guided percutaneous ethanol
injection</li>
<li>2019-08-23 Embolization (TAE) - abdomen
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2018-09-06 Partial Hepatectomy</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2020-05-05 ~ 2022-01-10 - nivolumab</li>
<li>2020-04-01 ~ 2021-03-19 - lenvatinib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient underwent partial hepatectomy on 2018-09-06, PEIT on
2020-05-06, RFA on 2020-05-29, 7 times of TACE between 2019-08-23 and
2021-12-17, and Lenvatinib from 2020-04-01 to 2021-03-19 as well as
Nivolumab from 2020-05-05 to 2022-01-10. The patient’s disease has
progressed based on 2022-03-18 CT.</li>
<li>Historically, traditional chemotherapy agents have not shown great
efficacy in the treatment of HCC when used in advanced stage of disease,
in particular in case of progression after locoregional therapy. FOLFOX
is listed in NCCN HCC guideline as a category 2B regimen. In the event
of MSI-H/dMMR being proven, dostarlimab-gxly might be tried (also
category 2B).</li>
</ul>
</div>
</div>
<div id="section-718" class="section level1">
<h1>701361740</h1>
<div id="section-719" class="section level2">
<h2>220415</h2>
<p>{Acute myeloid leukemia}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-22 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy — Acute myeloid leukemia</li>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, no remission, composed of hypocellular marrow for her age
(20-30%). The blasts are small-sized with round nuclei, and small amount
of cytoplasm, 70-80% of nucleated cells.</li>
<li>Immunohistochemistry shows CD34(+), CD117(+) and MPO(-) for blast,
CD61(+, megakaryocytes) and CD71(+, erythroid series) revealed
hypoplasia of megakaryocyte and erythroid series.</li>
</ul></li>
<li>2022-02-22 Abdominal Ultrasonography
<ul>
<li>Indication: pancytopenia</li>
<li>Diagnosis: possible liver lesion or false lesion, S5/8</li>
</ul></li>
<li>2022-02-21 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy — Compatible with acute myeloid leukemia</li>
<li>The sections show normocellular marrow (35%). The marrow space is
partially replaced by a population of medium-sized immature cells with
oval nucleus and high N/C ratio, constitue 50% of marrow cells.</li>
<li>IHC, the immture cells reveal: CD34(+), CD117(+), TdT(rare+),
CD3(-), CD20(-), CD79a(-). The finding is compatible with acute myeloid
leukemia. Suggest bone marrow smear study and flow cytometry
evaluation.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-03-11
<ul>
<li>HLA A-high 11:01</li>
<li>HLA B-high 39:01</li>
<li>HLA C-high 07:02</li>
<li>HLA DRB1
<ul>
<li>HLA DQ-high 04:02, 06:01</li>
<li>HLA DQ-high 04:10, 08:03</li>
</ul></li>
</ul></li>
<li>2022-03-04
<ul>
<li>FLT3/ITD mutation undetectable</li>
<li>NPM1 mutation undetectable</li>
</ul></li>
<li>2022-03-03 Aspiration
<ul>
<li>CD2 NA</li>
<li>CD3 1.53</li>
<li>CD4 NA</li>
<li>CD5 0.25</li>
<li>CD7 0.15</li>
<li>CD8 NA</li>
<li>CD10 0.82</li>
<li>CD11b 59.4</li>
<li>CD13 76.3</li>
<li>CD14 0.13</li>
<li>CD15 NA</li>
<li>CD16 0.9</li>
<li>CD19 19.16</li>
<li>CD19/kappa NA</li>
<li>CD19/Lambda NA</li>
<li>CD20 0.23</li>
<li>CD23 NA</li>
<li>CD25 NA</li>
<li>CD33 87.26</li>
<li>CD34 98</li>
<li>CD38 NA</li>
<li>CD56 0.15</li>
<li>CD103 NA</li>
<li>CD117 0.04</li>
<li>CD138 NA</li>
<li>FMC7 NA</li>
<li>HLA-DR 99.76</li>
<li>MPO NA</li>
<li>TdT NA</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-04 ~ undergoing - idarubicin + cytarabine, 3 + 7</li>
</ul></li>
</ul>
<div id="section-720" class="section level3">
<h3>==========</h3>
</div>
<div id="section-721" class="section level3">
<h3>2022-04-15</h3>
<ul>
<li>The patient almost 60 was recently diagnosed with AML and has been
receiving idarubicin and cytarabine (3 + 7) since 2022-03-04.</li>
<li>For patients with AML, FLT3/ITD marks poor survival in younger
(&lt;60 years) but not in older (60-74 years) and NPM1 mutation marks
good survival in older, but not younger. reference: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094014/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094014/</a></li>
<li>The patient’s lab results of FLT3/ITD and NPM1 were undetectable
(2022-03-04), not revealing much direction in terms of risk
stratification.</li>
<li>Neutropenic fever and HBV are treated with corresponding ABX and
entecavir, respectively. No issue with current medication.</li>
</ul>
</div>
<div id="section-722" class="section level3">
<h3>2022-03-23</h3>
<p>[Quinolones-Antacids Interactions]</p>
<p>objective</p>
<ul>
<li>Drugs listed in current medication
<ul>
<li>Cravit (levofloxacin 500mg/tab) 1.5 tab PO QDAC</li>
<li>Strocain (oxethazaine, polymigel i.e. aluminum hydroxide + calcium
carbonate + magnesium carbonate) 5mg/tab 1 tab PO TIDAC</li>
</ul></li>
</ul>
<p>assessment</p>
<ul>
<li>Antacids may decrease the absorption of quinolones in the setting of
oral administration of quinolones.
<ul>
<li>Antacids interacting members: Almagate, Aluminum Hydroxide, Calcium
Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium
Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate
<ul>
<li>Exception: Sodium Bicarbonate</li>
</ul></li>
<li>Quinolones interacting members: Ciprofloxacin (Systemic),
Delafloxacin, Enoxacin, Gemifloxacin, Levofloxacin (Systemic),
Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin,
Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin,
Zabofloxacin
<ul>
<li>Exception: Levofloxacin (Oral Inhalation)</li>
</ul></li>
</ul></li>
</ul>
<p>suggestion</p>
<ul>
<li>Either administration of Cravit 30 minutes before Strocain or
lowering of Strocain to QLAC + QNAC is recommended.</li>
</ul>
</div>
</div>
</div>
<div id="section-723" class="section level1">
<h1>701328847</h1>
<div id="section-724" class="section level2">
<h2>220413</h2>
<ul>
<li>diagnosis
<ul>
<li>Mantle cell lymphoma involving in bilateral neck lymph nodes,
supraclavicular lymph nodes, mediastinal and bilateral pulmonary hilar
lymph nodes and some bilateral axillary lymph nodes and the soft tissue
in the right buttock, bone marrow(+), PS:0, Lugano stage IV, MIPI 6.7,
high risk, HCT-CI score:0 (low risk, non-relapse mortality 14% at
2years)</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-18 CT - lung/mediastinum/pleura
<ul>
<li>Mild splenomegaly</li>
<li>No evidence of lymphadenopathy in the study.</li>
<li>Dilated aortic root.</li>
</ul></li>
<li>2022-02-08 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy — Consistent with myelodysplastic
syndrome</li>
<li>Sections show 30-50 % cellularity with marked decreased erythroid
cells. Atypical small and hypolobated megakaryocytes are found about
3-8/HPF. Some megakaryocytes are positive for CD34. The CD34 and CD117
show no increased blasts. The immunohistochemical stain of Hemoglobin A
show scant residual erythroid cells. The immunohistochemical stains of
CD3 and CD20 show some CD3-positive lymphocytes without CD20-positive
lymphocytes.</li>
<li>The morphology is consistent with myelodysplastic syndrome.</li>
</ul></li>
<li>2022-01-13 MRA - brain
<ul>
<li>Cerebral white matter FLAIR-hyperintensitie. Suspected
demyelineation process due to ischemia or chemotherapy.</li>
</ul></li>
<li>2021-12-17 CT - lung/mediastinum/pleura
<ul>
<li>No evidence of lymphadenopathy in the study but borderline
splenomegaly is noted.</li>
</ul></li>
<li>2021-09-16 Patho - bone marrow biopsy
<ul>
<li>diagnosis
<ul>
<li>Bone marrow, iliac, clinically: newly diagnosed in China with first
time chemotherapy), biopsy — Mantle cell lymphoma.</li>
<li>IHC: CD3(-), CD20(+), bcl-2(+), bcl-6(-), Cyclin-D1(focal +).<br />
</li>
</ul></li>
<li>microscopic description
<ul>
<li>Section shows piece(s) of bone marrow with 50% cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
are multiple minute aggregates of small atypical lymphoid cells.</li>
</ul></li>
</ul></li>
<li>2021-09-07 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma of low to median
FDG uptake involving multiple lymph nodes on the same side of the
diaphragm as mentioned above (stage II).</li>
<li>Mildly increased FDG uptake in a focal area in the soft tissue in
the right buttock. The nature is to be determined (inflammation? other
nature?).</li>
<li>Increased FDG accumulation in both kidneys and left ureter.
Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2021-09-07 CT - neck
<ul>
<li>Multiple enlarged bil. neck LNs, esp. at right posterior cervical
space, supraclavicular fossa and axilla.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-15 - ESHAP (etoposide, methylprednisolone, cytarabine,
cisplatin)</li>
<li>2022-02-14 - rituximab</li>
<li>2021-12-28 - R-DHAP
<ul>
<li>R - rituximab (also called Mabthera), a type of targeted cancer drug
called a monoclonal antibody</li>
<li>DH - dexamethasone, which is a steroid</li>
<li>A - cytarabine (also known as Ara C), a chemotherapy drug</li>
<li>P - cisplatin, a chemotherapy drug</li>
</ul></li>
<li>2021-12-01 - R-CHOP, rituximab, cyclophosphamide,
hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride),
vincristine (Oncovin) and prednisone</li>
<li>2021-11-08 - R-DHAP</li>
<li>2021-09-16, -10-12 - R-CHOP</li>
<li>2021-08-04 - R-CHOP (in mainland China)</li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-12 Neurology
<ul>
<li>Assessment
<ul>
<li>Peripheral vertigo, suspected platinum based chemotherapy
related</li>
</ul></li>
<li>Suggestion
<ul>
<li>Arrange BAEP, Intracranial and carotid doppler ultrasound, check BP
at lying, sitting and standing with 3 minutes interval each
position.</li>
<li>Use diphenidol and meclizine routinely.</li>
<li>MRA brain with/without contrast may be arranged if new neurological
deficit occured.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-725" class="section level3">
<h3>==========</h3>
</div>
<div id="section-726" class="section level3">
<h3>2022-04-13</h3>
<p>[Interprofessional Practice Meeting and Family Meeting]</p>
<ul>
<li>The postponed meeting rescheduled at 10:30 2022-04-13 in the ward,
the patient was present, as was her son.</li>
<li>Dr. Kao explained the treatment plan of the disease to the patient
family, as well as the prognosis and possible risks, and
interprofessional practice team members were present for inquiries.</li>
</ul>
</div>
<div id="section-727" class="section level3">
<h3>2022-04-12</h3>
<p>[mesna administration]</p>
<ul>
<li>mesna administration via ntravenous route
<ul>
<li>dilute with D5W, NS, LR, D5-0.2%NaCl, D5-0.33%NaCl, or D5-0.45%NaCl
to a final concentration of 20 mg/mL</li>
<li>following initial puncture of multidose vial, use within 8 days</li>
<li>following dilution, store at 25 degrees C and use within 24
hours</li>
<li>do not mix with epirubicin, cyclophosphamide, cisplatin,
carboplatin, or nitrogen mustard</li>
<li>if mixed with ifosfamide in the same IV bag, do not exceed a final
ifosfamide concentration of 50 mg/mL</li>
</ul></li>
<li>the patient is 50kgw, scheduled dose is 12mg/kg, 600mg should be
dissolved in at least 30mL aforementioned solvent, injection 30 min is
recommended.</li>
</ul>
</div>
<div id="section-728" class="section level3">
<h3>2022-04-11</h3>
<ul>
<li>The arranged IPP meeting (TP1110411001) has been postponed until
further notice.</li>
<li>There is no TP53 mutation lab data found.</li>
<li>The patient has been treated with RCHOP, alternating RCHOP/RDHAP,
R-ESHAP during Aug 2021 to Feb 2022.</li>
<li>The results of two consecutive bone marrow biopsies revealed mantle
cell lymphoma (2021-09-16) and myelodysplastic syndrome (2022-02-08).
High-dose therapy (HDT) and autologous stem cell rescue (ASCR) might be
indicated. There will be a patient family meeting to discuss ASCR in the
near future.</li>
<li>During this hospital stay, phenytoin was prescribed to prevent
intravenous busulfan induced seizures in recipients of hematopoietic
cell transplantation. Phenytoin is primarily metabolized by the liver to
inactive metabolites with &lt;5% of active drug excreted unchanged in
the urine, making routine dose adjustments for kidney dysfunction
unnecessary. Lab results reported on 2022-04-11 indicated slight
elevations of ALT (44 U/L, normal &lt; 41) and creatinine (1.4 mg/dL,
normal &lt; 1.3), which did not require adjusting the pheytoin
dose.</li>
</ul>
</div>
<div id="section-729" class="section level3">
<h3>2022-01-11</h3>
<p>[objective]</p>
<p>Creatinine lab data: - 2022-01-10 1.25mg/dL - 2022-01-07 1.43mg/dL -
2022-01-03 0.93mg/dL</p>
<p>[assessment]</p>
<ul>
<li>serum creatinine elevates slightly above normal range during ABX
administration.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no immediate dose adjustment needed for now, keep monitoring renal
function as regular to check the trend.</li>
</ul>
</div>
</div>
</div>
<div id="section-730" class="section level1">
<h1>700306021</h1>
<div id="section-731" class="section level2">
<h2>220412</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-14 Patho - pancreas biopsy
<ul>
<li>Labeled as pancreatic head, EUS fine needle biopsy -
adenocarcinoma.</li>
<li>Section shows core of tissue with irregular neoplastic glands and
markedly desmoplastic stroma.</li>
<li>IHC stains: CK19(+), CA19-9(+), CD56(-), p40(-).</li>
</ul></li>
<li>2022-03-14 Fine needle aspiration cytology - pancreas
<ul>
<li>Pancreatic head tumor: adenocarcinoma</li>
</ul></li>
<li>2022-03-11 Endoscopic Retrograde CholangioPancreatography, ERCP
<ul>
<li>Pancreatic head tumor with CBD invasion, s/p TPS, s/p ERBD</li>
<li>Marked dilatation of biliary tree</li>
<li>Inadvertent performance of partial pancreatography</li>
</ul></li>
<li>2022-03-11 Endoscopic ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Pancreatic head tumor, s/p EUS/FNB</li>
<li>Tumor invasion of CBD with marked biliary dilatation</li>
<li>Gastric shallow ulcers and erosions, antrum</li>
<li>Hiatal hernia</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue pathology and cytology result</li>
<li>Give PPI after the procedure</li>
</ul></li>
</ul></li>
<li>2022-03-10 MRI - pancreas
<ul>
<li>Pancreatic head cancer (3.3cm) with common hepatic artery, SMA, SMV,
proximal main portal vein, CBD, p-duct. duodenal invasion and LNs
metastases (T4N1M0, stage III).</li>
</ul></li>
<li>2022-03-10 Echocardiography
<ul>
<li>Dilated LA, LV</li>
</ul></li>
<li>2022-03-08 MRI - pancreas
<ul>
<li>In favor of pancreatic head tumor with SMA, SMV, portal vein, distal
CBD, p-duct and duodenal invasion. Some LNs at hepatic hilar
region.</li>
</ul></li>
<li>2022-03-07 Endoscopic ultrasonography
<ul>
<li>Pancreatic tumor with cystic components, head, probable pancreatic
cancer</li>
<li>MPD dilatation</li>
<li>CBD dilatation and sludge</li>
<li>Distended GB with sludge</li>
<li>Esophageal erosion, lower esophagus</li>
</ul></li>
<li>2022-03-07 Abdominal sonography
<ul>
<li>Pancreatic head tumor, suspected cancer</li>
<li>Bilateral IHD and CBD dilatation</li>
<li>Distented gallbladder</li>
</ul></li>
<li>2022-03-05 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Soft tissue mass at uncinate process of the pancreas with
obliteration of the CBD up to 2.09cm is found, causing IHDs and CBD
dilatation. Pancreatic cancer is suspected. The SMV is attached by the
tumor.</li>
</ul></li>
<li>2020-07-06 MRA - brain
<ul>
<li>T2 hyperintensities in bilaetral white matter and periventricular
region, suspected chronic ischemic or other demyelinating white matter
change.</li>
<li>Brain atrophy.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-08 Gastroenterology &amp; General Surgery
<ul>
<li>Impression
<ul>
<li>Pancreatic head tumor, IHDs and CBD dilatation</li>
</ul></li>
<li>Suggestions:
<ul>
<li>Insert PTCD/endo stent first due to hyperbilirubinemia.</li>
<li>Check blood sugar HbA1c, glucose AC/PC.</li>
<li>Arrange cardiopulmonary function tests such as cardiac echo and lung
function test due to old age.</li>
<li>We will evaluate the need of the operation after her
hyperbilirubinemia subsided.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-29 ~ 2022-04-11 - 720cGy/4 fractions (15 MV photon) to
pancreatic head tumor and lymphatics</li>
<li>Neoadjuvant C/T and R/T for 5040cGy/28 fractions is sugested for
downstage and tumor control.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-28 ~ undergoing - FOLFIRINOX, pre-Op neoadjuvant C/T
<ul>
<li>oxaliplatin 50mg/m2 2hr</li>
<li>irinotecan 90mg/m2 2hr</li>
<li>leucovorin 400mg/m2</li>
<li>5-Fu 2000mg/m2 46hr</li>
</ul></li>
</ul></li>
</ul>
<p>[reference]</p>
<ul>
<li>FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with
advanced pancreatic cancer: A population-based cohort study. <a href="https://dx.doi.org/10.4251/wjgo.v12.i3.332" class="uri">https://dx.doi.org/10.4251/wjgo.v12.i3.332</a>
<ul>
<li>FOLFIRINOX was administered according to the standard schedule
validated by the PRODIGE 4/ACCORD 11 study. This regimen consisted of a
combination of oxaliplatin (85 mg/m2, over 2 h), followed by leucovorin
(400 mg/m2, over 2 h), with the addition through a Y-connector, after 30
min, of irinotecan (180 mg/m2, over 90 min), followed by 5-FU (400
mg/m2) by intravenous bolus, on Day 1. Then, a continuous intravenous
infusion of 5-FU (2400 mg/m2) was administered over 46 h starting on Day
1.
<ul>
<li>oxaliplatin 85mg/m2 2hr</li>
<li>leucovorin 400mg/m2 2hr</li>
<li>irinotecan 180mg/m2 90min</li>
<li>5-FU 400mg/m2 IV bolus</li>
<li>5-FU 2400mg/m2 46h</li>
</ul></li>
<li>FOLFOXIRI consisted of the same molecules with a reduced dose of
irinotecan and no bolus 5-FU, according to the GONO regimen used in
metastatic colorectal cancer: Irinotecan (165 mg/m2, over 1 h), followed
by oxaliplatin (85 mg/m2) and leucovorin (200 mg/m2) concomitantly over
2 h through a Y‐connector, on Day 1; and followed by a continuous
intravenous infusion of 5-FU (3200 mg/m2) over 48 h starting on Day 1.
<ul>
<li>irinotecan 165mg/m2 1hr</li>
<li>oxaliplatin 85mg/m2</li>
<li>leucovorin 200mg/m2 2hr</li>
<li>5-FU 3200mg/m2 48hr</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There is a case of pancreatic head cancer with common hepatic
artery, superior mesenteric artery, superior mesenteric vein, proximal
main portal vein, CBD, pancreatic duct, duodenal invasion and lymph node
metastases (2022-03-10 MRI).</li>
<li>If jaundice is present, placement of a self-expanding metal stent is
recommended, preferably via ERCP. ERBD was performed via ERCP on
2022-03-11. Bilirubin total decreased from its peak of 13.75mg/dL on
2022-03-07 to 1.86mg/dL on 2022-04-11.</li>
<li>The patient has been given 720cGy/4 fractions (15 MV photon) to
treat the pancreatic head tumor and lymphatics (2022-03-29 to
2022-04-11) and has been receiving neoadjuvant FOLFIRINOX to downstage
the tumor since 2022-03-28.</li>
<li>Tumor/somatic gene profiling is recommended for patients with
locally advanced/metastatic disease who are candidates for anti-cancer
therapy to identify uncommon mutations. Consider specifically testing
for actionable somatic findings including, but not limited to: fusions
(ALK, NRG1, NTRK, ROS1), mutations (BRAF, BRCA1/2, HER2, KRAS, PALB2),
and mismatch repair (MMR) deficiency (detected by tumor IHC, PCR, or
NGS). Testing on tumor tissue is preferred; however, cell-free DNA
testing can be considered if tumor tissue testing is not feasible.</li>
<li>The laboratory results reported on 2022-04-11 showed normal ALT and
creatinine readings as well as lower WBC (2930/uL, Neutrophil 58%),
which should not affect the chemotherapy treatment in this hospital
stay.</li>
<li>No drug allergy records found in database, no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-732" class="section level1">
<h1>700026574</h1>
<div id="section-733" class="section level2">
<h2>220411</h2>
<p>{Left renal cell carcinoma with metastatic mediastinal
lymphadenopathies and suspecious RUL lung metastasis, liver and bone
metastases s/p chemotherapy and radiotherapy}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-10 Pelvis THR &amp; Rt Hip Lat; KUB &amp; L-spine
<ul>
<li>Lucent lesions in L5, S1, right acetabulum.</li>
</ul></li>
<li>2022-04-10 CT - abdomen
<ul>
<li>Bony metastases.</li>
<li>Dilatation of A- and T-colon.</li>
<li>Collapse of gallbladder with small stones (2-3mm). Small CBD stones
(2-3mm).</li>
</ul></li>
<li>2022-04-10 Chest
<ul>
<li>Presence of ileus.</li>
<li>Fracture of right ribs with union.</li>
<li>Ground glass opacity in right lung.</li>
</ul></li>
<li>2022-04-01 Chest
<ul>
<li>Several nodular opacity projecting in the right upper lung are
suspected. Please correlate with CT.</li>
<li>Left hemi-diaphragm elevation was noted that is compatible with
bronchiectasis with collapse after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura thickening.</li>
</ul></li>
<li>2022-02-23 Tc-99m MDP bone scan with SPECT
<ul>
<li>In comparison with the previous study on 20200911, some new bone
lesions in both rib cages are noted, suggesting multiple bone metastases
in progression. However, several previous bone lesions in multiple T-
and L-spine, sternum, right humeral head, and right iliac bone become
less evident, indicating partial respopnse to current therapy.</li>
<li>Suspected benign lesions at bilateral knees.</li>
</ul></li>
<li>2022-02-22 CT - abdomen, pelvis
<ul>
<li>Bone meta at left rib, L5 and right acetabulum, Suggest further
treatment.</li>
</ul></li>
<li>2022-02-21 KUB
<ul>
<li>Fracture of right acetabulum is suspected.</li>
</ul></li>
<li>2020-09-11 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 20200407, some new bone
lesions are noted and some of the previous bone lesions are more
evident, suggesting multiple bone metastases in progression.</li>
<li>No prominent change is noted in the lower C-spine and right
sternoclavicular junction. Degenerative change may show this
picture.</li>
</ul></li>
<li>2020-04-22 Chest
<ul>
<li>A nodular opacity projecting in the ventral aspect of RUL of the
lung is suspected that is compatible with metastasis after correlate
with chest CT.</li>
<li>Band-like atelectasis in RLL and LUL of the lung.</li>
<li>Patchy opacity projecting at the left lower medial lung zone and
Left hemi-diaphragm elevation was noted that is compatible with
bronchiectasis with collapse after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura thickening.</li>
</ul></li>
<li>2020-04-07 Tc-99m MDP bone scan
<ul>
<li>Prominently increased activity in the L5 spine, sternum and right
iliac bone. Bone metastases should be considered. Please correlate with
other imaging modalities for further evaluation.</li>
<li>Increased activity in the lower C-spine, some middle and lower
T-spines, right sternoclavicular junction and right humeral head. Either
degenerative change or bone metastases may show this picture. Please
keep follow-up for further evaluation.</li>
<li>Some hot and faint spots in bilateral rib cages and mildly increased
activity in the lesser trochanter of right femur. The nature is to be
determined (post-traumatic change? bone metastasis? other nature?).</li>
</ul></li>
<li>2020-03-18 MRI - L-spine
<ul>
<li>tumors in the L5 and right iliac bone.</li>
</ul></li>
<li>2019-12-13 CT - lung/pleura, chest and upper abdomen
<ul>
<li>Compatible with RCC lung meta and mediastinal lymph nodes,
stable.</li>
</ul></li>
<li>2019-09-11 CT - lung/pleura, chest and upper abdomen
<ul>
<li>no mediastinal LAP and no lung nodule on this F/U study.</li>
<li>stationary atelectatic basal segments with air-bronchograms of the
LLL.</li>
</ul></li>
<li>2019-06-06 CT - lung/pleura, chest and upper abdomen
<ul>
<li>no mediastinal LAP and no lung nodule on this F/U study.</li>
<li>stationary atelectatic basal segments with air-bronchograms of the
LLL.</li>
</ul></li>
<li>2019-03-06 CT - chest and upper abdomen
<ul>
<li>RCC with resolution of left lung and mediastinal LNs metastasis as
compared with previous CT study.</li>
</ul></li>
<li>2018-11-21 CT - chest and upper abdomen
<ul>
<li>RCC with left lung and mediastinal LNs metastasis, further in
regression as compared with previous CT study.</li>
</ul></li>
<li>2018-08-23 CT - chest and upper abdomen
<ul>
<li>RCC with lung and mediastinal LNs metastasis, further in regression
as compared with previous CT study.</li>
</ul></li>
<li>2018-05-09 CT - chest and upper abdomen
<ul>
<li>RCC with lung and mediastinal LNs metastasis, in regression compared
with previous CT study.</li>
</ul></li>
<li>2018-02-13 CT - chest and upper abdomen
<ul>
<li>Metastatic mediastinal and left hilar LAPs and Lt Main bronchus with
left lung atelectasis.</li>
</ul></li>
<li>2017-10-14 Renal Echo
<ul>
<li>Absence of left kidney with hypertrophy of right side kidney</li>
<li>History of RCC s/p left side nephrectomy</li>
</ul></li>
<li>2017-10-11 CT - chest and upper abdomen
<ul>
<li>suspected endobronchial CA in left main bronchus with obstructive
pneumonitis.</li>
</ul></li>
<li>2017-08-03 MRI - kidney, adrenals
<ul>
<li>S/P left nephrectomy with residual minimal fatty infiltrates in left
renal fossa.</li>
<li>GB stones.</li>
</ul></li>
<li>2017-05-06 CT - abdomen
<ul>
<li>S/P left nephrectomy with fluid density in left renal fossa, seroma,
abscess or hematoma?<br />
</li>
<li>Thickening/edema of small bowel loops around surgical region.</li>
</ul></li>
<li>2017-03-24 CT - abdomen
<ul>
<li>Left renal tumor, suspected RCC, suspicious renal venous branch
invasion. Cstage T3N0Mx.</li>
</ul></li>
<li>2017-03-22 Renal Echo
<ul>
<li>Left renal tumor was noted at Taipei CGMH</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-02 ~ 2022-03-15 - 3000cGy/10 fractions (IMRT) to Rt iliac
bone, palliative</li>
<li>2020-03-27 ~ 2020-04-06 - 3000cGy/10 fractions (6 MV photon) to L5,
&amp; 3000cGy/10 fractions to Rt hip</li>
<li>2018-08-16 ~ 2018-08-31 - 3600cGy/12 fractions (6 MV photon) to Rt
humeral head</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-17 ~ 2022-04-11 - everolimus</li>
<li>2022-03-17 - denosumab</li>
<li>2022-02-19 ~ 2022-02-26 - axitinib</li>
<li>2018-03-02 ~ 2020-06-17 - axitinib</li>
<li>tried oral sunitinib, axitinib (Cheng Hsin General Hospital)</li>
</ul></li>
</ul>
<div id="section-734" class="section level3">
<h3>==========</h3>
</div>
<div id="section-735" class="section level3">
<h3>2022-04-11</h3>
<ul>
<li>The patient was diagnosed with RCC with metastatic mediastinal LAPs,
suspected RUL lung metastases, liver and bone metastases and is
currently enrolled in hospice combined care (since 2022-03-11).</li>
<li>He is now taking everolimus (since 2022-03-17 s/p axitinib) and has
tried denosumab to prevent pathological spontaneous fractures, as well
as opioid analgesics to relieve pain.</li>
<li>Serum calcium 1.55mmol/L (normal 2.2 ~ 2.65) and magnesium 1.8mg/dL
(normal 1.9 ~ 2.7) reported on 2022-04-10. In patients with
hypomagnesemia, hypocalcemia is difficult to correct without first
normalizing the serum magnesium concentration. The patient’s serum
magnesium was just slight below normal range and currently treated with
oral magnesium oxide and calcium carbonate without issues.</li>
<li>Urine bacteria (1+) were reported on 2022-04-10; since everolimus is
also an immunosuppressive agent, some ABX might be considered to prevent
an infection from worsening.</li>
</ul>
</div>
<div id="section-736" class="section level3">
<h3>2022-03-18</h3>
<ul>
<li>The RCC patient with multiple bone metastases in progression
(2022-02-23 CT), has been treated with axitinib and sunitinib.</li>
<li>If the conditions are covered by the national health insurance or a
commercial insurance, or the patient is financially able to afford the
medication, immunotherapy might also be considered as an add-on
treatment.</li>
<li>Some regimens in which drug used in immunotherapy can be found,
including but not limited to:
<ul>
<li>axitinib + pembrolizumab</li>
<li>cabozantinib + nivolumab</li>
<li>lenvatinib + pembrolizumab</li>
<li>ipilimumab + pembrolizumab</li>
</ul></li>
<li>Hospice care is being considered by the patient and his family.</li>
<li>Caregivers have an urgent problem of controlling pain for patients
at home that needs to be resolved. Besides analgesics,
non-pharmacological interventions that can control pain over a longer
period of time might also be considered.</li>
<li>The following interventions are available to treat metastatic bone
cancer pain (not exhaustive, reference: <a href="https://pubmed.ncbi.nlm.nih.gov/31140913/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31140913/</a>):
<ul>
<li>Epidural and selective nerve root block</li>
<li>Radiofrequency ablation and cryoablation</li>
<li>Vertebral augmentation</li>
<li>Intrathecal drug delivery</li>
<li>Spinal cord stimulation</li>
<li>Dorsal root ganglion stimulation</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-737" class="section level1">
<h1>700815802</h1>
<div id="section-738" class="section level2">
<h2>220411</h2>
<p>{Recurrence nasopharyngeal carcinoma with skull base destruction and
cranial nerve (V2, VI) invasion , liver metastasis and multiple lung
metastases in progression.yT4N2M1,stageIVB}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-24 Chest
<ul>
<li>Borderline cardiomegaly</li>
<li>Increased lung markings on both lower lung are noted.</li>
<li>Hypoinflation of both lung is noted.</li>
</ul></li>
<li>2022-02-19 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Progression of liver metastases.</li>
<li>Multiple lung metastases.</li>
</ul></li>
<li>2021-10-19 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal residual enhancing soft-tissue at Rt
skull base, pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis and paranasal sinusitis,
stationary.</li>
</ul></li>
<li>2021-09-25 CT - abdomen, pelvis
<ul>
<li>Liver metastasis with tumors regression (partial remission)</li>
</ul></li>
<li>2021-06-16 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple metastases on both hepatic lobes show stable disease or
progressive disease.</li>
</ul></li>
<li>2021-04-28 Nasopharyngoscopy
<ul>
<li>bulging tumor over NP, subside</li>
<li>NPC s/p CCRT with recur</li>
</ul></li>
<li>2021-04-22 SONO - abdomen
<ul>
<li>liver tumors, bil. propable metastases</li>
<li>suspected liver cyst, right</li>
<li>suspected right renal cyst</li>
</ul></li>
<li>2021-02-26 CT - abdomen, pelvis
<ul>
<li>Multiple metastases on both hepatic lobes show stable disease.</li>
</ul></li>
<li>2021-02-08 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatment with residual abnormal signal intensity at
skull base, stationary as compared with MRI on 2020817.</li>
</ul></li>
<li>2021-02-01 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200213, increased
radiotracer uptake in skull base had been slightly less evident,
probably indicating post-treatment inflammatory change. Please correlate
with other imaging modalities to exclude the possibility of malignant
local bone invasion.</li>
<li>Mildly and non-focally increased radiotracer uptake in lower L-spine
and sacrum, degenerative spine diseases may show such a picture.</li>
<li>Some faint hot areas in maxilla and mandible, dental lesions may
show such a picture.</li>
<li>Probably degenerative joint lesions in shoulders, sternoclavicular
junctions, manubriosternal joint, sacroiliac joints, and hips.</li>
<li>No definite evidence of distant osteoblastic skeletal metastasis by
this bone scan.</li>
</ul></li>
<li>2021-01-05 GI bleeding embolization
<ul>
<li>Duodenal hemorrhage s/p TAE.</li>
</ul></li>
<li>2021-01-04 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA classification grade A</li>
<li>Incomplete study of stomach and doudenum</li>
<li>Duodenal ulcers, 2nd portion, s/p hemostasis with injection, APC
&amp; hemoclipping</li>
</ul></li>
<li>Suggestion
<ul>
<li>Transfer to ICU for intensive care and monitor</li>
<li>NPO with high dose PPI for at least 3 days</li>
<li>Angiography is suggested if active bleeding develops</li>
</ul></li>
</ul></li>
<li>2020-11-17 CT - abdomen, pelvis
<ul>
<li>Liver metastsis, regression.</li>
<li>Liver cysts.</li>
<li>Right renal cyst.</li>
</ul></li>
<li>2020-10-12 Nasopharyngoscopy
<ul>
<li>bulging tumor over NP, subside</li>
<li>npc s/p ccrt with mets</li>
</ul></li>
<li>2020-09-22 Patho - colon biopsy
<ul>
<li>Rectum, biopsy - Nonspecific proctitis with superficial ulcer</li>
</ul></li>
<li>2020-09-18 Patho - stomach biopsy
<ul>
<li>Stomach, antrum, PW &amp; LC side, biopsy - ulcer. No H.pylori
present</li>
</ul></li>
<li>2020-08-17 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal residual enhancing soft-tissue at Rt
skull base, pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis and paranasal sinusitis.</li>
</ul></li>
<li>2020-08-12 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple metastases on both hepatic lobes.</li>
</ul></li>
<li>2020-08-04 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy — Metastatic non-keratinizing squamous
carcinoma, consistent with nasopharynx primary</li>
<li>The secvtions show non-keratinizing squamous cell carcinoma,
composed of nests of poorly differentiated neoplastic cells in fibrous
stroma.</li>
<li>IHC, tumor cells reveal: CK7(-), CK20(-), p40 (+) and Hepa-1(weakly
+). The finding is consistent with metastatic nasopharyngeal
carcinoma.</li>
</ul></li>
<li>2020-07-29 CT - CTA, chest
<ul>
<li>no acute pulmonary embolism.</li>
<li>multiple HCC in both lobes.</li>
</ul></li>
<li>2020-05-07 SONO - abdomen
<ul>
<li>fatty liver, mild</li>
<li>liver tumors, bil. propable metastases</li>
<li>suspected liver cyst, left</li>
<li>suspected fatty infiltration of pancreas</li>
<li>suspected right renal cyst</li>
<li>s/p cholecystectomy</li>
</ul></li>
<li>2020-03-26 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure, and clivus still visible, stationaryas compared
with MRI 2019/11/26</li>
<li>Chronic mastoiditis and otitis media.</li>
<li>Thyroid goiter.</li>
</ul></li>
<li>2020-02-24 Nasopharyngoscopy
<ul>
<li>npc s/p ccrt with recur</li>
</ul></li>
<li>2020-02-13 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20180613, the hot spot in
the skull base is less evident. Please correlate with other imaging
modalities for further evaluation.</li>
<li>The previous hot spot in the suerolateral aspect of the left orbital
area of the skull is less evident and the previous rib lesions
disappeared, probably more benign in nature.</li>
<li>Suspected benign lesions in bilateral sternoclavicular junctions,
shoulders, knees, and feet.</li>
</ul></li>
<li>2020-02-10 CT - abdomen
<ul>
<li>No interval change of liver lesions.</li>
<li>Right renal cyst (2.4cm).</li>
</ul></li>
<li>2019-11-26 MRI - Nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis.</li>
</ul></li>
<li>2019-10-18 CT - abdomen
<ul>
<li>Indication: NPC with liver Metastasis in S5 s/p RFA, for follow
up</li>
<li>Impression: Prior CT identified metastasis in S5 S/P RFA shows
complete response.</li>
</ul></li>
<li>2019-07-23 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Hepatic tumor, probably metastatic tumor (S5-6)</li>
<li>Hepatic tumor, probably post RFA change (S8, according hx and
CT)</li>
<li>Hepatic cyst</li>
<li>Postcholecystectomy</li>
</ul></li>
<li>2019-07-15 CT - abdomen
<ul>
<li>Liver tumors s/p RFA. suspected residual tumor in S6 of liver.</li>
</ul></li>
<li>2019-06-03 MRI - nasopharynx
<ul>
<li>Indication:
<ul>
<li>NPC, with skull base destruction and cranial nerve (V2, VI)
invasion, cT4N2M0. s/p CCRT and adjuvant RT.</li>
</ul></li>
<li>Impression:
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic Right mastoiditis.</li>
</ul></li>
</ul></li>
<li>2019-05-21 Surgical pathology Level V
<ul>
<li>Liver, needle biopsy — Metastatic undifferentiated carcinoma.</li>
</ul></li>
<li>2019-05-21 SONO guide biopsy
<ul>
<li>Metastasis in S5 of the liver is suspected.</li>
</ul></li>
<li>2019-04-23 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Diagnosis
<ul>
<li>Hepatic tumor, probably metastaic tumor</li>
<li>GB stone, multiple</li>
<li>Splenomegaly, mild</li>
</ul></li>
<li>Suggestion
<ul>
<li>refer to medical ONC for further evaluation and treatment</li>
</ul></li>
</ul></li>
<li>2019-04-11 CT - abdomen
<ul>
<li>A faint enhancing lesion (2.1cm, srs501, img19) in S5 of liver.</li>
</ul></li>
<li>2019-02-27 Whole body PET scan
<ul>
<li>No significantly increased FDG uptake in bilateral N-P regions and
skull base was noted, indicating response to current therapy.</li>
<li>Glucose hypermetabolism in the left lobe of the thyroid gland, the
nature is to be determined (functioning nodule, benign or malignant
neoplasm, or others ?), suggesting biopsy for further
investigation.</li>
<li>Glucose hypermetabolism in the right lobe of the liver and in a
nodular lesion in the RLQ of abdomen, the nature is also to be
determined (benign or malignancy/metastasis ?).</li>
</ul></li>
<li>2019-02-19 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with post R/T change abnormal enhancing soft-tissue at
Rt skull base, pterygopalatine fissure and clivus, stationary.<br />
</li>
<li>Chronic Right mastoiditis.</li>
</ul></li>
<li>2018-12-11 SONO - abdomen
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst, left lobe</li>
<li>Gall stone</li>
<li>Renal cyst, left kidney</li>
<li>Splenomegaly</li>
</ul></li>
<li>2018-11-13 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with post R/T change abnormal enhancing soft-tissue at
Rt pterygopalatine fissure and clivus, suggest F/U.</li>
<li>Right mastoiditis.</li>
</ul></li>
<li>2018-06-13 Tc-99m MDP whole body bone scan
<ul>
<li>A hot spot at the skull base, NPC with local bone involvement should
be considered, suggesting F-18 FDG PET/CT scan for further
investigation.</li>
<li>Three hot spots in the right 8th to 10th ribs, respectively, the
nature is to be determined (post-traumatic change or other nature?).
Please follow up bone scan in 3 months.</li>
<li>Suspected benign lesions in the left rib cage, bilateral
sternoclavicular junctions, shoulders, knees, and feet.</li>
</ul></li>
<li>2018-06-12 MRI - nasopharynx
<ul>
<li>NPC T4N2Mx</li>
<li>Right mastoiditis.</li>
</ul></li>
<li>2018-05-28 Surgical pathology Level IV
<ul>
<li>Nasopahrynx, biopsy — Non-keratinizing carcinoma, undifferentiated
(lymphoepithelialcarcinoma) (WHO-2B).</li>
<li>IHC stain: CK (+).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>EBV
<ul>
<li>2021-03-01 1236copies/mL (normal &lt; 120)</li>
<li>2019-11-11 &lt;120</li>
<li>2019-02-02 252</li>
<li>2018-09-17 &lt;120</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-01-07
<ul>
<li>Surgery
<ul>
<li>duodenal ulcer suture ligation</li>
<li>trucal vagotomy wth pyloroplasty</li>
</ul></li>
<li>Finding
<ul>
<li>active duodenal 2nd portion ulcer bleeding</li>
<li>chronic DU with bulb deformity</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-07-13 ~ 2018-08-23 - completed RT to the bil. neck lymphatic
drainage area: 50 Gy/ 25 fx. The NP tumor and LAPs: 70 Gy/ 35 fx.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-04 ~ undergoing - 5-Fu + Leucovorin</li>
<li>2021-07-09 ~ 2021-12-03 - Doxorubicin</li>
<li>2021-05-11 ~ 2021-06-07 - 5-Fu + Leucovorin</li>
<li>2020-08-27 ~ 2020-12-22 - 5-Fu + Leucovorin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This is a patient with non-keratinizing nasopharyngeal carcinoma
(2018-05-28 pathology).</li>
<li>According to medical images during the last 12 months (2021-04 and
2022-04), the primary lesions (s/p CCRT, now on FL) are generally
stable, however, liver metastases (s/p RFA) appear to have
developed.</li>
<li>Nivolumab might be an optional alternative for nonkeratinizing NPC
that has previously been treated.</li>
</ul>
</div>
</div>
<div id="section-739" class="section level1">
<h1>700174551</h1>
<div id="section-740" class="section level2">
<h2>220408</h2>
<p>{rectal cancer with liver mets s/p LAR and liver partial
resection}</p>
<p>[objective]</p>
<ul>
<li><p>exam finding</p>
<ul>
<li>2022-04-06 Abdominal sonography
<ul>
<li>post cholecystectomy</li>
<li>parenchymal liver disease</li>
</ul></li>
<li>2022-03-08 CT - abdomen, pelvis
<ul>
<li>Rectal cancer s/p operation. Wall thickening of proximal
A-colon.</li>
<li>Mild regression of liver metastases.</li>
</ul></li>
<li>2021-12-08 CT - abdomen, pelvis
<ul>
<li>Metastasis 1.5 cm in S7 of the liver is highly suspected.</li>
</ul></li>
<li>2021-08-27 Patho - liver partial resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S2-3, segmental hepatectomy — Metastatic rectal
adenocarcinoma<br />
</li>
<li>Liver, S5, segmental hepatectomy — Metastatic rectal
adenocarcinoma<br />
</li>
<li>Liver, S8, segmental hepatectomy — All specimen taken for section
and no metastatic carcinoma present<br />
</li>
<li>Tumor regression grade: Grade 4/5 (cancer cells &gt; fibrosis)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Diagnosis: Metastatic rectal adenoarcinoma x3<br />
</li>
<li>Histologic grade: Moderately differentiated<br />
</li>
<li>Tumor growth pattern: Infiltrating<br />
</li>
<li>Tumor pseudocapsule: Present<br />
</li>
<li>Tumor necrosis: Present (50%)<br />
</li>
<li>Parenchymal margin: Uninvolved by carcinoma<br />
</li>
<li>Distance of invasive carcinoma from closest margins: 0.4 cm
(S5)<br />
</li>
<li>Vascular invasion: Not identified<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Tumor regression grade: Grade 4 (residual cancer cells predominate
over fibrosis)<br />
</li>
<li>Non-neoplastic liver parenchyma: Perivenular congestion,
regeneration of hepatocytes, mild lymphocytic portal inflammation, and
mild fatty change (10%)</li>
</ul></li>
</ul></li>
<li>2021-06-15 CT - abdomen, pelvis
<ul>
<li>rectal cancer s/p LAR and autosuture with liver mets.</li>
<li>the liver mets regressed.</li>
</ul></li>
<li>2021-02-18 Patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>Large intestine, rectum, robotic-assisted low anterior resection —-
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Lymph node, mesocolic, dissection —- Adenocarcinoma, metastatic
(1/21)<br />
</li>
<li>AJCC 8th edition Pathology stage: pStage IIIB, pT3N1a(if cM0), or
pStage IVA, pT3N1a(if cM1a), Please correlate with the clinical
presentation and image study</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: adenocarcinoma</li>
<li>Histology Grade: moderately differentiated<br />
</li>
<li>Depth of invasion: mesocolic soft tissue<br />
</li>
<li>Angiolymphatic invasion: Present.<br />
</li>
<li>Perineural invasion: Present.<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified.<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 16 mm from
the margin</li>
<li>Lymph node metastasis, mesocolic: 1/21<br />
</li>
<li>Lymph node metastasis, IMA / SMA: not received<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT): pT3: Tumor invades through the muscularis
propria into pericolorectal tissues<br />
</li>
<li>Regional Lymph Nodes (pN): pN1a: One regional lymph node is
positive<br />
</li>
<li>Distant Metastasis (pM): if cM0 or cM1a(CT finding)<br />
</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Tubulovillous
adenoma.<br />
</li>
<li>S2021-02016 IHC: EGFR(+), PMS2(+), MLH1(+), MSH2(+), and
MSH6(+).<br />
</li>
</ul></li>
</ul></li>
<li>2021-02-08 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T2N1bM1a stage IVA</li>
</ul></li>
<li>2021-02-05 Patho - colorectal polyp
<ul>
<li>Large intestine, rectum, 10 cm from anal verge, biopsy —
Adenocarcinoma, moderately differentiated<br />
</li>
<li>IHC: EGFR(+), PMS2(+), MLH1(+), MSH2(+), and MSH6(+).<br />
</li>
</ul></li>
<li>2021-02-04 Colonoscopy
<ul>
<li>A mass was noted in the rectum, size 3cm, 10cm from anal verge,
suspected malignancy.</li>
</ul></li>
<li>2020-09-01 Renal echo
<ul>
<li>parenchymal renal disease</li>
</ul></li>
</ul></li>
<li><p>lab data</p>
<ul>
<li>2021-03-08 NRAS/KRAS mutation not detected</li>
</ul></li>
<li><p>surgical operation</p>
<ul>
<li>2021-08-26
<ul>
<li>surgery
<ul>
<li>S2-3 resection</li>
<li>S8 and S5 partial resection</li>
<li>LC</li>
</ul></li>
<li>finding
<ul>
<li>S2-3 two hypoechoic tumor + 1.5cm in diameter suspected hypoechoic
tumor 1.2cm at S8</li>
<li>superifcal small tumor at S5 near GB</li>
<li>echo didn’t find any tumor at right posterior segment</li>
</ul></li>
</ul></li>
<li>2021-02-17
<ul>
<li>surgery
<ul>
<li>Robotic-assisted low anterior resection        </li>
</ul></li>
<li>finding
<ul>
<li>Rectal cancer 4<em>3.5</em>2 cm at 10 cm from AV</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2021-04-27 ~ undergoing - FOLFIRI + bevacizumab</li>
<li>2021-03-12 ~ 2021-04-12 - FOLFIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient with rectal cancer and liver mets has received FOLFIRI
since 2021-03-12 (plus bevacizumab since 2021-04-27) s/p LAR
(2021-02-17) and liver partial resection (2021-08-26).</li>
<li>Available molecular review results include: pMMR, EGFR(+), NRAS/KRAS
WT; no BRAF, HER2, NTRK results found.</li>
<li>Recent surveillance detected suspected mets in S7 (CT, 2021-12-08)
and proximal A-colon wall thickening (CT, 2022-03-08), CEA fluctuates
within a narrow range of 10 to 13 ng/mL since November 2021.</li>
<li>There is still some progression of the disease (albeit at a slower
rate?)</li>
</ul>
</div>
</div>
<div id="section-741" class="section level1">
<h1>700598345</h1>
<div id="section-742" class="section level2">
<h2>220407</h2>
<p>{Acute myeloblastic leukemia, not having achieved remission}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, (AML, S/P induction C/T and consolidation C/T x
2), biopsy - Normal cellularity.</li>
<li>IHC: CD117: &lt;1 %; CD34: &lt;1 %; MPO: 20-30%, CD61: 5-10%; CD71:
70-75% (of the nucleated cells).</li>
<li>Section shows piece(s) of bone marrow with 40% cellularity and M:E
ratio of approximately 1:3. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
is no malignancy present.</li>
</ul></li>
<li>2022-03-09 CT - lung/mediastinum/pleura
<ul>
<li>pulmonary infection or leukemic infiltration in both lungs.</li>
</ul></li>
<li>2021-12-14 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Hypocellularity and no increase of
blast</li>
<li>Hypocellularity for her age, 5-10%</li>
<li>Marked hypoplasia of all three lineages<br />
</li>
<li>No obviously increase of blast</li>
</ul></li>
<li>2021-11-29 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Compatible with acute myeloid
leukemia</li>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, composed of hypercellular marrow (70-80%) with proliferative
blasts about 30% of nucleated cells, which immunohistochemistry shows
CD34(+), CD117(+) and MPO(+). Besides, hypoplasia of erythroid series
and megakaryocytes highlights by CD61(+, megakaryocytes) and CD71(+,
erythroid series) is also noted. Clinical and bone marrow smear
correlation is advised.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-03-18 P.jiroveci DNA-Sp undetectable</li>
<li>2021-12-09 FLT3-D835 mutation undetectable</li>
<li>2021-12-02 Aspiration
<ul>
<li>CD2 NA</li>
<li>CD3 0.39</li>
<li>CD4 NA</li>
<li>CD5 0.14</li>
<li>CD7 61.64</li>
<li>CD8 NA</li>
<li>CD10 1.15</li>
<li>CD11b 2.5</li>
<li>CD13 77.23</li>
<li>CD14 5.23</li>
<li>CD15 NA</li>
<li>CD16 2.28</li>
<li>CD19 1.14</li>
<li>CD19/kappa NA</li>
<li>CD19/Lambda NA</li>
<li>CD20 NA</li>
<li>CD23 NA</li>
<li>CD25 NA</li>
<li>CD33 99.86</li>
<li>CD34 92.71</li>
<li>CD38 NA</li>
<li>CD56 0.05</li>
<li>CD103 NA</li>
<li>CD117 83.82</li>
<li>CD138 NA</li>
<li>FMC7 NA</li>
<li>HLA-DR 95.7</li>
<li>MPO NA</li>
<li>TdT NA</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-07 ~ undergoing - cytarabine (high dose Ara-C, HiDAc,
300mg/m2 IVD 3h Q12H D1,3,5 total 5 doses or 200mg/m2 3h Q12H D1-4 total
8 doses) + daunorubicin (45mg/m2 IV D1-3)</li>
<li>2021-12-02 - idarubicin (45-80mg/m2 d1-3) + cytarabine (100-200mg/m2
d1-7)</li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-02 Dr. YaoRen Xu
<ul>
<li>Q
<ul>
<li>This 40 year-old female patient who has history of childhood
epilepsy under medication was admitted via the OPD due to leukocytosis
with anemia and thrombocytopenia. The PB smear showed increase blast
cells (40-60%). Acute leukemia is considered. She was admitted for bone
marrow biopsy and AML was confirmed. We will start chemotherapy with
regimen of Idarubicin + Cytarabine - 3 + 7 days.</li>
<li>She is unmarried, G0P0 and no GYN history. For prevention of
excessive bleeding, we need to halt her menstrual cycle.</li>
</ul></li>
<li>A
<ul>
<li>consider to halt menstrual cycle due to thrombocytopenia</li>
<li>no active GYN problems</li>
<li>Danazol 200ml 1# BID PO may be considered, no more than 6 months,
can be administered during chemotherapy course.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-743" class="section level3">
<h3>==========</h3>
</div>
<div id="section-744" class="section level3">
<h3>2022-04-07</h3>
<ul>
<li>The patient with AML (2021-11-29 bone marrow biopsy pathology)
without the FLT3-D835 mutation (2021-12-09 undetectable) was treated
with high dose cytarabine + daunorubicin starting on 2022-01-07,
following idarubicin + cytarabine (3+7) in December 2021.</li>
<li>The last two consecutive bone marrow biopsy pathology (2021-12-14
and 2022-03-24) showed no obviously increase of blast and normal
cellularity. So far, so good.</li>
<li>There were no other obvious abnormalities found except an elevated
level of uric acid of 7.6 mg/dL reported on 2022-04-06, which might be
controlled with febuxostat or benzbromarone.</li>
</ul>
</div>
<div id="section-745" class="section level3">
<h3>2022-03-11</h3>
<p>[compatibility]</p>
<p>The combination of calcium gluconate, magnesium sulfate, and
potassium chloride in 0.9% sodium chloride normal saline is
compatible.</p>
</div>
<div id="section-746" class="section level3">
<h3>2022-01-10</h3>
<p>Lab data reported on 2022-01-10</p>
<ul>
<li>RBC 3.44*10^6/uL</li>
<li>HGB 9.4g/dL</li>
</ul>
<p>Danol (Danazol) androgen is prescribed to pause menses to maintain
RBC, HGB levels in the setting of chemotherapy.</p>
</div>
</div>
</div>
<div id="section-747" class="section level1">
<h1>700728977</h1>
<div id="section-748" class="section level2">
<h2>220407</h2>
<p>{rectal cancer cT2N1bM0 stage IIIA}</p>
<p>[subjective]</p>
<ul>
<li>2021-07-12 having anal fresh bleeding on and off prior to visiting
OPD.</li>
<li>family history: two younger brothers died because of colon
cancer.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2021-11-04 Patho - colon segmental resection for tumor
<ul>
<li>Large intestine, rectum, low anterior resection —- No residual
viable tumor, s/p neoadjuvant CCRT<br />
</li>
<li>Resection margins: free<br />
</li>
<li>Lymph node, mesocolic, dissection - Negative for malignancy
(0/17)</li>
<li>Lymph node, IMA / SMA, dissection - Not received</li>
<li>AJCC 8th edition Pathology stage: ypT0N0(if cM0)</li>
</ul></li>
<li>2021-10-20 Patho - colon biopsy
<ul>
<li>Large intestine, rectum, biopsy - non-specific colitis with
fibrosis</li>
</ul></li>
<li>2021-10-19 CT - abdomen, pelvis
<ul>
<li>Compatible with rectal cancer s/p CCRT with swelling of the sigmoid
colon.</li>
</ul></li>
<li>2021-07-20 CT - lung/mediastinum/pleura
<ul>
<li>combined emphysema and pulmonary fibrosis.</li>
<li>old RUL TB change.</li>
</ul></li>
<li>2021-07-16 Patho - colorectal polyp
<ul>
<li>Rectum, 8 cm from anal verge, biopsy — Adenocarcinoma<br />
</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and MSH6(+).<br />
</li>
</ul></li>
<li>2021-07-15 CT - abdomen, pelvis
<ul>
<li>for colorectal carcinoma T2N1bM0 IIIA</li>
</ul></li>
<li>2021-07-15 Colonoscopy
<ul>
<li>suspected rectal malignancy, 8cm from anal verge, s/p biopsy</li>
<li>diverticula, sigmoid colon, with lumen narrowing</li>
<li>mixed hemorrhoid</li>
</ul></li>
<li>2020-11-24 CT - brain
<ul>
<li>Brain atrophy</li>
<li>Atherosclerosis of vertebral arteries</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-11-03
<ul>
<li>Low anterior resection
<ul>
<li>Adenocarcinoma of rectum, cT2N1bM0, Stage IIIA s/p neoadjuvant
CCRT</li>
<li>Anastomosis by CDH 29#, TISSEL 4ml covered on anastomosis site</li>
<li>TA contour for low anterior resection</li>
<li>Protective ileostomy was created on RLQ area</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-28 ~ 2021-09-07 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and 5040cGy/28 fractions (15MV photon) of the rectal tumor area.
(pre-op CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-14 ~ undergoing - FOLFOX</li>
<li>2021-08-03 - 5-Fu + leucovorin (pre-op CCRT)</li>
</ul></li>
</ul>
<div id="section-749" class="section level3">
<h3>==========</h3>
</div>
<div id="section-750" class="section level3">
<h3>2022-04-07</h3>
<ul>
<li>The patient was diagnosed with T2N1bM0 stage IIIA rectal cancer and
had LAR in Nov 2021 following pre-op CCRT during the 3rd quarter of that
year; he is currently undergoing adjuvant FOLFOX regimen since Dec
2021.</li>
<li>A colon segmental resection pathology on 2021-11-04 revealed no
residual viable tumor and evaluated the disease as ypT0N0 (if cM0).</li>
<li>As of 2022-03-29, the laboratory data showed normal liver and kidney
function as well as slightly lower blood cell counts, which should not
affect the chemotherapy course.</li>
<li>HBV is managed with Baraclude (entecavir) currently.</li>
</ul>
</div>
<div id="section-751" class="section level3">
<h3>2021-08-05</h3>
<p>[initial presentation]</p>
<ul>
<li>2021-07-12 having anal fresh bleeding on and off prior to visiting
OPD.</li>
<li>family history: two younger brothers died because of colon
cancer.</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-07-15 colonoscopy:
<ul>
<li>suspected rectal malignancy, 8cm from anal verge.</li>
<li>diverticula, sigmoid colon, with lumen narrowing.</li>
<li>mixed hemorrhoid</li>
</ul></li>
<li>2021-07-16 patho - colorectal polyp
<ul>
<li>adenocarcinoma</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and MSH6(+)</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2021-07-15 CT - whole adbomen, pelvis:
<ul>
<li>imaging stage: cT2N1bM0, IIIA</li>
</ul></li>
</ul>
<p>[treatment &amp; plan]</p>
<ul>
<li>pre-Op CCRT then Op
<ul>
<li>radio
<ul>
<li>4500cGy/25frac for pelvic
<ul>
<li>900cGy/5frac from 2021-08-04 to 2021-08-06</li>
</ul></li>
<li>5040cGy/28frac for rectal tumor bed</li>
</ul></li>
<li>chemo
<ul>
<li>5-Fu + leucovorin from 2021-08-04</li>
</ul></li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>CCRT just started, to wait and see.</li>
<li>adjuvant chemo with cetuximab/panitumumab (EGFR+) might be indicated
after resection operation.
<ul>
<li>no RAS, BRAF, or other immune checkpoint biomarkers tested found in
charts yet.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>HBV
<ul>
<li>2021-07-23 lab data
<ul>
<li>Anti-HBc Reactive</li>
<li>Anti-HBs 31.38mIU/mL</li>
</ul></li>
<li>medication
<ul>
<li>baraclude (entecavir 0.5mg) QDAC</li>
</ul></li>
</ul></li>
<li>combined pulmonary fibrosis and emphysema
<ul>
<li>2021-07-20 CT lung/mediastinum/pleura found</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>CCRT just kicked off and HBV is managed by entecavir, no medication
issue observed.</li>
</ul>
</div>
</div>
</div>
<div id="section-752" class="section level1">
<h1>700713215</h1>
<div id="section-753" class="section level2">
<h2>220406</h2>
<p>{hepatic failure, cirrhosis of liver, hepatorenal syndrome,
esophageal varices, gastric varices, ascites, type 2 diabetes ellitus,
hyperlipidemia, anemia}</p>
<ul>
<li>All the oral drugs can be administered with nasogastric tube.</li>
<li>For the patient with hepatorenal syndrome, albumin (lower serum
reading 2.8 g/dL reported on 2022-04-06) might be an option to combine
with terlipressin (currently prescribed).</li>
</ul>
</div>
</div>
<div id="section-754" class="section level1">
<h1>700733699</h1>
<div id="section-755" class="section level2">
<h2>220406</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>liver cell carcinoma</li>
<li>recurrence hepatocellular carcinoma with lung and bone metastasis,
stage IV</li>
<li>hepatitis B virus related liver cirrhosis, child A</li>
<li>essential (primary) hepertension</li>
<li>type 2 diabetes mellitus without complications</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-07 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>HCC s/p right hepatic lobectomy and RFA at S2, S3 and S4.</li>
<li>Bilateral Lung meta, stationary.</li>
<li>Bone meta. Suggest bone scan study.</li>
</ul></li>
<li>2021-11-24 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Cholangiocarcinoma at S3 liver is highly suspected.</li>
<li>The differential diagnosis include metastasis (colon cancer?) and
atypical HCC. Please correlate with tumor marker and MRI. Biopsy is
indicated.</li>
<li>Two metastases in S3 are suspected.</li>
</ul></li>
<li>2021-11-23 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>In comparison with the previous study on 20210720, some of the
previous bone lesions are a little more evident, suggesting multiple
bone metastases in a little more progression.</li>
<li>Suspected benign lesions in bilateral shoulders.</li>
</ul></li>
</ul></li>
<li>chemmoimmunotherapy
<ul>
<li>2020-03 ~ undergoing - lenvatinib</li>
<li>2020-01-17 ~ 2020-12-22 - nivolumab</li>
<li>2019-09 ~ 2019-12 - sorafenib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient with advanced HCC (lung and bone mets) has been treated
with sorafenib (Sept to Dec in 2019), Nivolumab (in 2020) and Lenvatinib
(since March 2020), he refuses to be resuscitated and has been referred
to the hospice ward waiting list.</li>
</ul>
</div>
</div>
<div id="section-756" class="section level1">
<h1>700769250</h1>
<div id="section-757" class="section level2">
<h2>220331</h2>
<p>{ovary cancer s/p oophrocystectomy}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-15 Patho - uterus
<ul>
<li>pathologic diagnosis
<ul>
<li>Ovary, right, debulking surgery (s/p oophorcystectomy) - No residual
tumor</li>
<li>Ovary, left, debulking surgery - Negative for malignancy</li>
<li>Fallopian tube, bilateral, debulking surgery - Negative for
malignancy</li>
<li>Uterus, corpus,debulking surgery - Adenocarcinoma, seeding</li>
<li>Uterus, cervix, debulking surgery - Negative for malignancy</li>
<li>Omentume, debulking surgery- - Peritonitis</li>
<li>Labeled “utreosaroligment” - Negative for malignancy</li>
<li>Labeled “rectum” - Negative for malignancy</li>
<li>Labeled “right abdominal wall” - Negative for malignancy</li>
<li>AJCC 8th edition Pathology stage: pT2aNO(if cM0); FIGO IIA; AJCC
stage IIA</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Adenocarcinoma, mixed endometrioid type and
mucinous type</li>
<li>Histologic grade: grade 1<br />
</li>
<li>IHC: CK(+), Calretinin(focal+), CD68(+), PAX8(-); Reference:
S2022-01793</li>
</ul></li>
</ul></li>
<li>2022-02-11 CT - pelvis
<ul>
<li>An enlarged nodes in left pelvic side wall measuring 2.3 cm in size
is noted.</li>
</ul></li>
<li>2022-02-04 Patho - ovary biopsy, wedge resection
<ul>
<li>Diagnosis:
<ul>
<li>Ovary, right, laparoscopic oophorocystectomy —- Adenocarcinoma,
mixed endometrioid type and mucinous type, grade 1
<ul>
<li>IHC stains: WT( focal +), PAX-8 (-), p53 (wild type), Napsin-A (-),
ER (-), PR (-).</li>
<li>pT1c2 pNx (if cM0); FIGO stage: IC2, at least.</li>
</ul></li>
</ul></li>
<li>Gross description:
<ul>
<li>Tumor Site: Right ovary</li>
<li>Ovarian Surface Involvement - Absent</li>
<li>Fallopian Tube Surface Involvement - no tissue submitted.</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Mixed epithelial carcinoma: endometrioid grade 1
(60%) and mucinous grade 1 (40%).</li>
<li>Histologic Grade - WHO Grading System-G1: Well differentiated</li>
<li>IHC: WT( focal +), PAX-8 (-), p53 (wild type), Napsin-A (-), ER (-),
PR (-).</li>
</ul></li>
</ul></li>
<li>2022-01-31 CT - abdomen, pelvis
<ul>
<li>A lobulated right adnexal mass (9.0x6.8x10.2cm). Suspect TOA,
ovarian torsion, or ovarian cystic tumor.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-14
<ul>
<li>Excision of abdominal wall tumor</li>
<li>Excision of greater omentum and rectal serosa tumor</li>
<li>IOUS (intraoperative ultrasound)</li>
</ul></li>
<li>2022-01-31
<ul>
<li>ROV teratoma with rupture</li>
<li>pelvic adhesion</li>
<li>Laparoscopic oophorocystectomy + pelvic adhesionlysis       </li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-09, -03-30 - paclitaxel + carboplatin</li>
</ul></li>
<li>underlying disease
<ul>
<li>chronic viral hepatitis B without delta-agent</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient was diagnosed with ovarian adenocarcinoma, mixed
endometrioid and mucinous type in early 2022 s/p oophrcystectomy
(2022-01-31) and excision of abdominal wall tumor and greater omentum
and rectal serosa tumor (2022-02-14).</li>
<li>paclitaxel + carboplatin is a preferred regimen for both
endometrioid and mucinous ovarian cancers, and the patient has been
receiving this regimen since 2022-03-09.</li>
<li>According to CBC results on 2022-03-29, there was a slight decrease
in readings, not expected to affect chemotherapy.</li>
<li>HBV is managed with Baraclude (entecavir). No issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-758" class="section level1">
<h1>700814298</h1>
<div id="section-759" class="section level2">
<h2>220330</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Pancreatic cancer, T3N1M1 (M1 diagnosed by CT), stage IV, tail,
status post endoscopic ultrasound-guided fine-needle biopsy on
2021-10-07</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-21 CT - abdomen, pelvis
<ul>
<li>Pancreatic cancer with liver mets and adrenal mets. In
progression.</li>
<li>Paraaortic lymphadenopathy, stable</li>
<li>Diffuse lung consoliations. Nature to be determined.</li>
<li>Air pockets inside the urinary bladder, suspected emphysematous
cystitis.</li>
</ul></li>
<li>2022-01-07 CT - brain
<ul>
<li>Old lacunar infarcts.</li>
<li>Encephalomalacic change in left temporal lobe.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2021-12-07 CT - abdomen, pelvis
<ul>
<li>Pancreatic tail cancer with liver mets. The primary tumor is
decreased in size but the liver mets progressed.</li>
<li>Paraaortic lymphadenopathy, in regression.</li>
<li>LEFT LOWER LOBE consolidation.</li>
</ul></li>
<li>2021-10-07 Patho - pancreas biopsy
<ul>
<li>Pancreas, EUS-FNB - adenocarcinoma, moderately differentiated<br />
</li>
<li>Sections show pancreas with neoplastic glandular cells infiltrating
in fibrous stroma.</li>
</ul></li>
<li>2021-10-07 Needle aspiration cytology
<ul>
<li>Smears show necrotic debris and clusters of atypical, hyperchromatic
cells. Malignancy is favored.</li>
</ul></li>
<li>2021-10-04 CT - abdomen, pelvis
<ul>
<li>suspected pancreas CA with splenic vessels and stomach
invasions</li>
<li>Liver and para-aortic lymph node metastases</li>
</ul></li>
<li>2018-07-23 MRA - brain
<ul>
<li>recent ischemic of left MCA territory due to severe stenosis in
distal M1 an M2 of left MCA.</li>
<li>Brain atrophy. Multiple lacunar infarcts, deep cerebral hemisphere
and cerebellum.</li>
<li>Bilateral subcortical and periventricular white matter change
(leukoaraiosis).</li>
</ul></li>
<li>2018-07-20 CT - brain
<ul>
<li>Brain atrophy and lacunar infarcts.</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-10-26 ~ undergoing - gemcitabine + nab-paclitaxel</li>
</ul></li>
<li>past history
<ul>
<li>Gout arthritis for 40+ years</li>
<li>CVA with right side hemiparesis and motor aphasia since 2018-07</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Patient presents with stage IV T3N1M1 pancreatic cancer with
paraaortic LAP, liver mets, and adrenal mets.</li>
<li>Fusions (ALK, NRG1, NTRK, ROS1), mutations (BRAF, BRCA1/2, HER2,
KRAS, PALB2), and MMR status were not found in HIS5.</li>
<li>FOLFIRINOX or gemcitabine + nab-paclitaxel would be preferred
regimens. The patient has been receiving the latter since late October
2021.</li>
<li>This patient has just been arranged for hospice combined care on
2022-03-29.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-760" class="section level1">
<h1>700799013</h1>
<div id="section-761" class="section level2">
<h2>220329</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-25 CT - lung/mediastinum/pleura
<ul>
<li>Consolidation over both lungs. Pneumonia is favored.</li>
<li>Bilateral pleural effusion</li>
</ul></li>
<li>2022-01-11 Patho - omentum biopsy
<ul>
<li>Tissue, labeled LUQ omentum, CT-guide biopsy - adenocarcinoma,
seeding<br />
</li>
<li>IHC: CDX-2(+), CK7(-), CK20(-). The tumor is compatible with GI
tract origin.<br />
</li>
<li>Microscopically, it shows adenocarcinoma composed of irregular
neoplastic glands with infiltrative growth pattern, tumor necrosis and
stromal fibrosis. The tumor cells display hyperchromatic nuclei with
pleomorphism, prominent nucleoli, high N/C ratio and mitotic
figures.<br />
</li>
</ul></li>
<li>2021-11-24 CT - abdomen, pelvis
<ul>
<li>One Metastasis in LUQ omentum S/P C/T show partial response.</li>
<li>Two metastases in RLQ mesentery, and left lower pelvis (with urinary
bladder invasion) S/P C/T show stable disease.</li>
</ul></li>
<li>2021-08-13 CT - abdomen, pelvis
<ul>
<li>Three Metastases 3.6 x 2.6 cm in the LUQ omentum area, 1.3 x 0.7 cm
in RLQ mesentery, and 3.2 cm in left lower pelvis (with urinary bladder
invasion) are noted.</li>
<li>Intrapulmonary lymph node in LLL of the lung is suspected and it
shows stable in size and feature as compared with prior CT.</li>
</ul></li>
<li>2021-04-28 Whole body PET scan
<ul>
<li>Glucose-hypermetabolism in the soft tissue in the LUQ of abdomen,
lower pelvis, and RLQ of abdomen, probably tumor recurrence.<br />
</li>
<li>Glucose-hypermetabolic lesions in the right shoulder and right
elbow, probably post-traumatic change.<br />
</li>
<li>Increased FDG uptake in bilateral pulmonary hilar region, probably
reactive nodes or physiological uptake of FDG.</li>
<li>Colon cancer s/p treatment with tumor recurrence, rcTxNxM1c, stage
IVC (AJCC 8th ed.), by this F-18 FDG PET scan.</li>
</ul></li>
<li>2021-04-20 CT - abdomen, pelvis
<ul>
<li>Some infiltration at right anterior abdominal wall is found,
regional inflammation is considered</li>
<li>No evidence of soft tissue mass at pancreas.</li>
</ul></li>
<li>2021-01-18 CT - abdomen, pelvis
<ul>
<li>R-S colon cancer s/p operation. Some LNs at mediastinum and bil.
inguinal regions.</li>
<li>Stationary condition and lung nodules.</li>
</ul></li>
<li>2021-11-19 Patho - colon segmental resection for tumor
<ul>
<li>diagnosis
<ul>
<li>Tumor, rectosigmoid, left hemicolectomy — Residual mucinous
adenocarcinoma<br />
</li>
<li>Bilateral cutting ends, ditto — Free of tumor invasion<br />
</li>
<li>Lymph node, mesocolic, dissection — Free of tumor metastasis (0/18)
with acellular mucin deposit (7/18)<br />
</li>
<li>Pelvic lesion, frozen section — Acellular mucin, compatible with
tumor regression<br />
</li>
<li>AJCC pathologic stage — ypT3N0 (if cM0), stage IIA</li>
</ul></li>
</ul></li>
<li>2020-10-05 CT - abdomen, pelvis
<ul>
<li>S-colon cancer as described (mild regression). T4bN2bM1a (IVa).</li>
</ul></li>
<li>2020-07-02 CT - abdomen, pelvis
<ul>
<li>S-colon cancer T4bN2bM1a (IVa).</li>
</ul></li>
<li>2020-06-30 Patho - colon biopsy
<ul>
<li>Sigmoid colon, 20 cm from anal verge, biopsy — Adenocarcinoma</li>
<li>IHC: EGFR(+), MLH1(-), PMS2(-), MSH2(+), and MSH6(+).<br />
</li>
<li>Comment: The tumor cells show loss of expression of the mismatch
repair proteins MLH1 and PMS2. This pattern is likely to be sporadic
(MLH1 promoter hypermethylation), although it is possible due to Lynch
or related syndromes.</li>
</ul></li>
<li>2020-06-30 Patho - colorectal polyp
<ul>
<li>Rectum, 10 cm from anal verge, polypectomy — Adenocarcinoma in
high-grade tubulovillous adenoma<br />
</li>
<li>The sections show adeocarcinoma in tubulovillous adenoma, composed
of rectal mucosal tissue with atypical glands lined by pseudostratified,
high-grade dysplastic columnar cells, in tubular, cribriform and villous
arrangement. Focal desmoplastic stromal reaction is present.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-03-11 Closure of T-loop colostomy</li>
<li>2020-11-18 Exp. Lap with sigmoidectomy</li>
<li>2020-07-06 T-loop colostomy</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2020-07-22 ~ 2020-08-31 - 4500cGy/25 fractions of the pelvic, and
5040cGy/28 fractions of the tumor bed area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-06-11 ~ 2022-02-23 - FOLFOX + bevacizumab</li>
<li>2020-07-16 ~ 2021-05-24 - FOLFIRI</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-762" class="section level1">
<h1>701342376</h1>
<div id="section-763" class="section level2">
<h2>220329</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-28 Colonoscopy
<ul>
<li>colon diverticulum, cecum, ascending colon</li>
</ul></li>
<li>2022-03-08 CT - abdomen, pelvis
<ul>
<li>S/P gastrectomy, splenectomy and pancreas operation. Fat stranding
of upper peritoneal cavity.</li>
</ul></li>
<li>2021-10-28 Patho - small intestine resction (not tumor)
<ul>
<li>Small intestine, distal ileum, segmental resection - Consistent with
Meckel diverticulum<br />
</li>
<li>Sections show ileal tissue with a diverticulum lined by gastric
mucosal tissue. The morphology is consistent with Meckel
diverticulum.<br />
</li>
</ul></li>
<li>2021-10-28 Patho - stomach subtotal/total (tumor)
<ul>
<li>pathologic diagnosis
<ul>
<li>Stomach, lesser curvature, total gastrectomy - Adenocarcinoma,
moderately differentiated</li>
<li>Esophagus, total gastrectomy - Adenocarcinoma, by direct invasion
with negative resection margin</li>
<li>Duodenum, total gastrectomy - Negative for malignancy<br />
</li>
<li>Liver, left lateral segment, segmentectomy - Negative for malignancy
- Acute suppurative inflammation<br />
</li>
<li>Pancreas, distal, distal pancreatectomy - Negative for
malignancy</li>
<li>Spleen, splenectomy - Negative for malignancy<br />
</li>
<li>Omentum, omentectomy - Negative for malignancy<br />
</li>
<li>Liver, caudate lobe, specimen B, resection - Negative for malignancy
- Acute suppurative inflammation<br />
</li>
<li>Proximal esophagus, specimen C, resection - Negative for
malignancy<br />
</li>
<li>Margin: free<br />
</li>
<li>Lymph node, lesser curvature, dissection - Negative for malignancy
(0/8)<br />
</li>
<li>Lymph node, greater curvature, dissection - Negative for malignancy
(0/14)<br />
</li>
<li>Lymph node, peri-pancreatic, dissection - Negative for malignancy
(0/12)<br />
</li>
<li>AJCC 8th edition pT4aN0 (if cM0) pStage IIB,<br />
</li>
<li>F2021-423: Esophagus, resection margin, excision - Negative for
malignancy<br />
</li>
</ul></li>
<li>microscopic examnation
<ul>
<li>Histologic Type: Lauren classification of adenocarcinoma: Intestinal
(tubular) type; The immunohistochemical stain Her-2/neu (Ab) is
negative.</li>
<li>Histologic Grade: G2: Moderately differentiated<br />
</li>
<li>Tumor Extension: Tumor invades esophagus, the serosa (visceral
peritoneum) and attached to the liver and pancreas capsule. No direct
invasion in the liver and pancreas parenchyma is found. The subserosal
liver parenchyma reveals acute suppurative inflammation. The
immunohistocehmical stain of CK reveals no invasive tumor. The spleen,
duodenum and omentum are free of tumor.<br />
</li>
<li>Additional Pathologic Findings
<ul>
<li>Intestinal metaplasia: absent<br />
</li>
<li>Low-grade dysplasia: absent<br />
</li>
<li>High-grade dysplasia: present<br />
</li>
<li>Helicobacter pylori-type gastritis<br />
</li>
<li>Autoimmune atrophic chronic gastritis: absent<br />
</li>
<li>Polyp(s): absent</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-27
<ul>
<li>Total gastrectomy with D2+ LN dissection
<ul>
<li>En-block left lateral segmentectomy with caudate loberesection with
distal pancreatectomy with splenectomy</li>
</ul></li>
<li>Distalsmallbowel segmental resection with anastomsois</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-12-02 ~ 2021-12-06 - 540cGy/3 fractions (15 MV photon) to
anastomosis and regional lymphatics</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-24, -02-07, -02-22, -03-09, -03-28 - FOLFOX</li>
<li>2021-12-08, -12-13, -12-20, -12-27, 2022-01-03 - 5-FU</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>gastric cancer pT4aN0 cM0 stage IIB s/p gastrectomy with D2+ LN
dissection (2021-10-27) followed by post-Op CCRT (5-FU, early Dec 2021
to early Jan 2022) and adjuvant chemotherapy (FOLFOX, since late Jan
2022).</li>
<li>tumor pathology (2021-10-28) showed Her-2/neu (Ab) negative. no
MSI/MMR, PD-L1 results found in HIS5</li>
<li>patients who have undergone primary D2 lymph node dissection are
preferred to receive [capecitabine + oxaliplatin] and [fluorouracil +
oxaliplatin], the latter is what the patient is getting now.</li>
<li>no adverse reaction found in nursing note for now during this
hospital stay. no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-764" class="section level1">
<h1>700070771</h1>
<div id="section-765" class="section level2">
<h2>220325</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-12 CT - abdomen, pelvis
<ul>
<li>S/P liver and colon operation. No evidence of tumor recurrence.</li>
</ul></li>
<li>2022-02-07 SONO - abdomen
<ul>
<li>Post-op at right lobe liver. Calcified spot in the liver.<br />
</li>
<li>Right renal cyst.</li>
<li>Left renal stone.</li>
</ul></li>
<li>2011-11-04 CT - abdomen, pelvis
<ul>
<li>S/P liver and colon operation. Some fluid and air collection at
right subphrenic region. Bil. pleural effusion with adjacent lung
collapse.</li>
</ul></li>
<li>2021-10-29 Patho - liver partial resection
<ul>
<li>Liver, S6-7, segmental hepatectomy — Metastatic adenocarcinoma,
consistent with colonic primary<br />
</li>
<li>Tumor regression grade: Grade 4/5 (cancer cells &gt; fibrosis)</li>
</ul></li>
<li>2021-09-22 CT - abdomen, pelvis
<ul>
<li>S/P right hemicolectomy. There is no evidence of tumor
recurrence.</li>
<li>Two metastasis in S7 and S4 S/P C/T show partial response.</li>
<li>A newly-developed metastasis or flow artifact 0.5 cm in S6 liver is
suspected.</li>
</ul></li>
<li>2021-05-20 NRAS/KRAS, BRAF not detected</li>
<li>2021-05-17 MRI - liver, spleen
<ul>
<li>Two poor enhancing tumors (0.4cm, 2.6cm) in S8 of liver suspected
metastases.</li>
</ul></li>
<li>2021-04-28 Patho - colon segmental resection for tumor
<ul>
<li>Pathologic diagnosis
<ul>
<li>Tumor, ascending colon, SILS R’t hemicolectomy — Adenocarcinoma</li>
<li>Resection margins, bilateral, ditto — Free from tumor invasion</li>
<li>Lymph node, mesocolic, dissection — Free from tumor metastasis
(0/23)<br />
</li>
<li>Appendix, excision — Fecalith and free from tumor<br />
</li>
<li>AJCC pathologic stage — pT3N0, cM1a, compatible with stage IVA</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology: adenocarcinoma<br />
</li>
<li>Histology Grade: G2: moderately differentiated<br />
</li>
<li>Depth of invasion: pericolonic fat<br />
</li>
<li>Angiolymphatic invasion: Present<br />
</li>
<li>Perineural invasion: Present<br />
</li>
<li>Discontinuous extramural tumor extension: NOT present<br />
</li>
<li>Circumferential (radial) margin of rectosigmoid: NOT involved<br />
</li>
<li>Lymph node metastasis, mesocolic: free from tumor metastasis
(0/23)<br />
</li>
<li>Lymph node metastasis, IMA / SMA: N/A<br />
</li>
<li>Extranodal involvement: N/A<br />
</li>
<li>Pathological TNM Stage: pT3N0, but cM1a (liver meta), compatible
with stage IVA<br />
</li>
<li>Type of polyp in which invasive carcinoma arose: N/A<br />
</li>
<li>Additional pathologic findings: focal necrosis and abscess<br />
</li>
<li>TNM descriptors: N/A<br />
</li>
<li>Tumor regression grading S/P CCRT: N/A<br />
</li>
</ul></li>
</ul></li>
<li>2021-04-22 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the proxinal portion of the ascending
colon and some adjacent lymph nodes, compatible with primary colon
malignancy with some adjacent lymph node metastases.</li>
<li>A glucose hypermetabolic lesion in the segment 7 of the liver. A
metastatic lesion may show this picture.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions.
Inflammatory process may show this picture.</li>
</ul></li>
<li>2021-04-19 CT - abdomen, pelvis
<ul>
<li>T3N2aM1a, stage IVA</li>
</ul></li>
<li>2021-04-16 Patho - colorectal polyp
<ul>
<li>Colon, ascending, biopsy — Adenocarcinoma.</li>
<li>IHC: EGFR(focal +); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-28 laparoscope S6-7 resection
<ul>
<li>solid tumor at S7</li>
<li>suspected small nodule at S6.</li>
</ul></li>
<li>2021-04-28 SILS Right-hemicolectomy
<ul>
<li>Adenocarcinoma of ascending colon, cT3N2aM1a (liver mets) stage
IVa</li>
<li>Huge tumor with tissue edema suspecting as T4 lesion.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-06 ~ ongoing - FOLFIRI plus bevacizumab since</li>
</ul></li>
<li>initial presentation
<ul>
<li>unintentional body weight loss 6 kgs in half year before diagnosed
with cancer.</li>
<li>exertional dyspnea and intermittent right abdomen pain were noted
without bowel habit change.</li>
<li>iOFBT(+)</li>
</ul></li>
<li>underlying disease
<ul>
<li>type 2 diabetes</li>
<li>chronic hepatitis B</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Patient with colon cancer with liver mets after SILS right
hemicolectomy (2021-04-28) and liver S6/S7 resection (2021-10-28) is
receiving FOLFIRI plus bevacizumab since June 2021. Recent CT
(2022-02-12) and SONO (2022-02-07) have revealed no signs of
recurrence.</li>
<li>Lab results reported on 2022-03-15 indicated no abnormality in liver
or kidney functions, but a slight pancytopenia was detected. The lower
blood counts should not affect the application of chemoimmunotherapy
during this hospital stay.</li>
<li>Chronic hepatitis B and type 2 diabetes are managed with
corresponding drugs.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-766" class="section level1">
<h1>700464889</h1>
<div id="section-767" class="section level2">
<h2>220325</h2>
<p>{hypopharyngeal and supraglottic cancer, cT4bN2b cM0, stage IV with
recurrent lung mets, progression of mets pulmonary lesions and
mediastinal/hilar LAP}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-10 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
<li>lung mets proved in 2018-11, no local recurrence found according to
PE and fiber</li>
</ul></li>
<li>2022-02-15 CT - lung/mediastinum/pleura
<ul>
<li>progression of metastatic pulmonary lesions and distant metastatic
LAP as compared with previous CT on 20210823.</li>
</ul></li>
<li>2022-01-06 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
<li>lung mets proved in 2018-11, no local recurrence found according to
PE and fiber</li>
</ul></li>
<li>2021-11-30 Nasopharyngoscopy
<ul>
<li>saliva cumulation at hypopharynx and rt. piriform sinus</li>
</ul></li>
<li>2021-10-07 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
</ul></li>
<li>2021-08-23 CT - lung/mediastinum/pleura
<ul>
<li>progression of metastatic pulmonary lesions and mediastinal and
hilar LAP as compared with previous CT on 20210216.</li>
</ul></li>
<li>2021-05-14 MRI - Larynx
<ul>
<li>Post-treatment change at hypopharynx and larynx, without evidence of
recurrence. Less edema as compared with previous MRI on 20181107.</li>
</ul></li>
<li>2021-05-11 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 1.15 cm.<br />
</li>
<li>Two renal cyst 2.37 cm in left lower pole and 0.91 cm in right
middle pole are noted.</li>
</ul></li>
<li>2021-02-16 CT - lung/mediastinum/pleura
<ul>
<li>stationary of metastatic pulmonary lesions and progression of
mediastinal and hilar LAP as compared with previous CT on 20200827.</li>
</ul></li>
<li>2020-11-17 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 0.68 cm.<br />
</li>
<li>Two renal cyst 1.57 cm in left lower pole and 1 cm in right middle
pole are noted.</li>
</ul></li>
<li>2020-08-27 CT - lung/mediastinum/pleura
<ul>
<li>right upper lobe, left lingula lobe and right lower lobe lung mets,
stable.</li>
</ul></li>
<li>2020-06-02 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 0.68 cm.<br />
</li>
<li>A renal cyst measuring 1.38 cm in left lower pole is noted.</li>
</ul></li>
<li>2020-03-10 CT -lung/mediastinum/pleura
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, stationary as compared with previous CT study on
20191216.</li>
</ul></li>
<li>2019-12-16 CT
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, in regression as compared with previous CT study on
20190916.</li>
</ul></li>
<li>2019-09-16 CT
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, in regression as compared with previous CT study on
20190717.</li>
</ul></li>
<li>2019-07-17 CT
<ul>
<li>diffsue lung metastatic lesions and mediastinal lymphadenopathy,
stable.</li>
</ul></li>
<li>2019-06-22 CT
<ul>
<li>metastatic tumors at bilateral lungs and medastinal and hilar
lymphadenopathy, in progression as compared with previous CT study.</li>
</ul></li>
<li>2019-04-19 CT
<ul>
<li>pulmonary necrotic metastatic tumors at bilateral lungs and
medastinal lymphadenopathy, in progression.</li>
</ul></li>
<li>2019-01-25 CT
<ul>
<li>compatible with hypopharyngeal cancer with lung mets. in
regression.</li>
</ul></li>
<li>2018-11-07 MRI - Larynx
<ul>
<li>Post-RT changes at hypopharynx and larynx, without evidence of
recurrence. Stationary as compared with MRI on 20180524.</li>
</ul></li>
<li>2018-11-07 Surgical pathology Level IV
<ul>
<li>Malignant hypopharynx neoplasm, pyriform sinus</li>
<li>Lung, side?, needle biopsy - squamous cell carcinoma, moderately
differentiated, origin?</li>
<li>IHC: p40(+), TTF-1(focal weak positive), and CD56(focal weak
positive). The results are in favor of squamous cell carcinoma.</li>
<li>Please correlate with the clinical presentation to differentiate
primary or metastatic tumor.</li>
</ul></li>
<li>2018-11-06 Surgical pathology Level IV
<ul>
<li>Malignant hypopharynx neoplasm, pyriform sinus</li>
<li>Lung, side?, bronchoscopic biopsy - squamous cell carcinoma,
moderately differentiated, origin?</li>
<li>IHC: p40(+), TTF-1(focal weak positive), and CD56(focal weak
positive). The results are in favor of squamous cell carcinoma.</li>
<li>Please correlate with the clinical presentation to differentiate
primary or metastatic tumor.</li>
</ul></li>
<li>2018-10-30 CT
<ul>
<li>hypopharynx cancer s/p RT s/p CT with lung and mediastinal-hilum LNs
metastasis.</li>
</ul></li>
<li>2018-05-24 MRI - nasopharynx
<ul>
<li>Post R/T and C/T change in right pyriform sinus and adjacent
hypopharynx, stationary.</li>
</ul></li>
<li>2017-11-28 MRI - nasopharynx
<ul>
<li>Post R/T and C/T change in right pyriform sinus and adjacent
hypopharynx, seems stationary.</li>
</ul></li>
<li>2017-05-26 MRI - larynx
<ul>
<li>Right hypopharynx CA, post CT and R/T, stationary in size of
abnormal soft-tissue combined more prominent post R/T change as compared
with MRI on 20161121.</li>
</ul></li>
<li>No earlier data available before 2017.</li>
</ul></li>
<li>Chemoimmunotherapy
<ul>
<li>2022-02-23, -03-24 - 5-FU + cisplatin + gemcitabine + nivolumab</li>
<li>2021-09-10, -10-04, -11-01, -11-30, -12-27, 2022-01-17 - 5-FU +
cisplatin + docetaxel + cetuximab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>On CT images taken from the second half of 2019 through 2020,
metastatic lesions in bilateral lungs, mediastinal and hilar
lymphadenopathy remained stationary. However, on 2021-02-16 CT images,
progression of mediastinal and hilar LAP was observed, then on
2021-08-23 and 2022-02-15 CT images, metastatic pulmonary lesions and
distant metastatic LAP were observed.</li>
<li>From September 2021 to January 2022, the patient was treated with
chemoimmunotherapy comprising 5-FU + cisplatin + docetaxel + cetuximab,
followed by 5-FU + cisplatin + gemcitabine + nivolumab from February
2022 onwards.</li>
<li>The new regimen has been administered to the patient for the second
time during this hospitalization, and it will take time for the
responses to be confirmed.</li>
<li>The patient’s low serum magnesium reading on 2022-03-24 was treated
with MgSO4 IVD QD.</li>
</ul>
</div>
</div>
<div id="section-768" class="section level1">
<h1>700542356</h1>
<div id="section-769" class="section level2">
<h2>220325</h2>
<ul>
<li>Patient was transferred from Cardinal Tien Hospital with a diagnosis
of suspected MDS and urinary tract infection. Our emergency room did not
note any obvious signs of discomfort, such as fever, chills, chest pain,
dyspnea, or abdominal pain.</li>
<li>The following laboratory results were obtained on 2022-02-24: CRP
4.84 mg/dL, serum glucose 454 mg/dL, WBC 1040/uL, HGB 7.4 g/dL, PLT
3000/uL, NT-proBNP 5006 pg/mL, urine OB 3+, urine bacteria 1+, APTT 38
sec.</li>
<li>The blood culture result is not out yet. Symptomatic treatment is
being provided to the patient currently. No issue is identified with the
current medication.</li>
</ul>
</div>
</div>
<div id="section-770" class="section level1">
<h1>700372070</h1>
<div id="section-771" class="section level2">
<h2>220322</h2>
<ul>
<li>exam findings
<ul>
<li>2022-01-28 CT
<ul>
<li>suspected lower third esophageal wall thickening. stable.</li>
</ul></li>
<li>2021-09-24 CT
<ul>
<li>borderline wall thickening at lower third esophagus is found.</li>
</ul></li>
<li>2021-09-24 Esophagogastroduodenoscopy
<ul>
<li>gastric intestinal metaplasia, antrum</li>
</ul></li>
<li>2021-09-09 Patho
<ul>
<li>Diagnosis
<ul>
<li>Lung, left lower lobe, history of hypopharyngeal and eosphaeal
carcinomas, s/p CT and RT, now VATS lobectomy (S2021-12142A) with biopsy
for forzen section (F2021-348FS) - squamous cell carcinomas x2, favor
metastatic.</li>
<li>IHC: CK5/6(+), p40(+), Napsin-A(-), TTF-1(-), CD56(-).<br />
</li>
<li>pM1 pStage: IVC.<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality - Separate tumor nodules of same histopathologic type
in same lobe</li>
<li>Histologic Type - Invasive squamous cell carcinoma,
keratinizing</li>
<li>Histologic Grade - G2: Moderately differentiated</li>
<li>Spread Through Air Spaces (STAS) - Present</li>
<li>Visceral Pleura Invasion - Not identified</li>
<li>Lymphovascular Invasion - Present<br />
</li>
</ul></li>
</ul></li>
<li>2021-08-02 Whole body PET scan
<ul>
<li>The lesions of glucose hypermetabolism in the right cervical lymph
nodes are old and show much less prominent compared with the previous
study on 2020-09-21, indicating recurrent tumor with partial response to
current therapy.</li>
<li>Glucose hypermetabolism in the mediastinal lymph nodes and bilateral
pulmonary hilar lymph nodes, probably reactive nodes. Please keep follow
up to exclude the possibility of distant lymph node metastasis in these
regions.</li>
<li>Glucose hypermetabolism in the left lower lung, probably another
primary or secondary lung cancer, suggesting biopsy for further
investigation.</li>
<li>Probably inflammatory change at the left shoulder joint.</li>
<li>Recerrent hypopharyngeal cancer s/p treatment with partial response
to current therapy; another primary or secondary lung cancer in the left
lower lung (if proved), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2021-07-22 MRI - Larynx
<ul>
<li>focal increased soft tissue in the right hypopharynx. Please
f/u.</li>
<li>focal enhancement in the right maxillary bone, surrounding the
tooth</li>
</ul></li>
<li>2021-07-05 CT
<ul>
<li>minimal emphysema in LUL and RUL.</li>
<li>new solid nodule in LLL, primary tumor or metastasis, suggest
f/u.</li>
</ul></li>
<li>2020-10-02 Patho - Lymph node region resection
<ul>
<li>pStage: rpTXN3b (cM0); rp Stage IVB (2020-10-16 ENT tumor board
consensus)<br />
</li>
</ul></li>
<li>2020-09-21 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a right level IV cervical lymph node,
suggesting malignant involvement in an ipsilateral regional lymph
node.</li>
<li>Mild to moderate glucose hypermetabolism in bilateral pulmonary
hilar lymph nodes, reactive change from locoregional inflammation may be
considered. Please keep follow up, however, to exclude the possibility
of distant lymph node metastasis in these regions.</li>
<li>Mild glucose hypermetabolism in left lower cervical lymph nodes and
mediastinal lymph nodes, reactive change in response to locoregional
inflammation may show such a picture.</li>
<li>Right hypopharyngeal cancer s/p CCRT with tumor recurrence,
rcTxN1M0, r-stage III at least (AJCC 8th ed.), by this F-18-FDG PET/CT
scan.</li>
</ul></li>
<li>2020-09-10 MRI - Larynx
<ul>
<li>an enlarged lymph node in the right lower carotid space.</li>
</ul></li>
<li>2020-03-10 MRI - Larynx
<ul>
<li>thick soft tissue, tight space, suspected residual/recurrent tumor
in right pyriform sinus.</li>
</ul></li>
<li>2019-12-09 MRI - Nasopharynx
<ul>
<li>residual tumor at right pyriform sinus. no enlarged lymph node. s/p
operation at left tongue and neck.</li>
</ul></li>
<li>2019-07-04 CT - Mediastinum
<ul>
<li>Recurrent tongue base tumor at right pyriform sinus, in regression
as compared with previous PET/CT.</li>
<li>No evidence of tumor recurrence along the course of the
esophagus.</li>
</ul></li>
<li>2019-06-17 Whole body PET scan
<ul>
<li>A glucose hypermetabolic mass in right supraglottic region,
compatible with the primary lesion of laryngeal cancer.</li>
<li>Glucose hypermetabolism in the right level II and III cervical lymph
nodes, suggesting malignant involvement in multiple ipsilateral regional
lymph nodes.</li>
<li>Supraglottic laryngeal cancer, cTxN2bM0, stage IVA (AJCC 8th ed.),
by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2019-06-14 MRI - Larynx
<ul>
<li>Right hypopharynx CA, T4aN2bMx stage IVA</li>
</ul></li>
<li>2019-06-13 Patho
<ul>
<li>Labeled as “right supraglottic tumor”, biopsy - Squamous cell
carcinoma, moderately differentiated.</li>
<li>IHC stains: p40(+), p16(-, 0%).</li>
</ul></li>
<li>2017-08-02 Patho
<ul>
<li>Diagnosis
<ul>
<li>Paralysis of vocal cords or larynx, bilateral, partial; Malignant
tongue neoplasm, tip and lateral; Inflammatory conditions, abscess,
osteitis, osteomyelitis, periostitis, sequestrum of jaw bone; Acute
gingivitis; Atrophy of salivary gland;</li>
<li>Esophagus, upper, 20cm and 30cm from incisor, biopsy - Squamous cell
carcinoma.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2020-11-06 ~ 2020-12-02
<ul>
<li>3600cGy/18 fractions of the recurrent nodal with extranodal
extension area.</li>
</ul></li>
<li>2019-09-17 ~ 2019-11-06
<ul>
<li>5000cGy/25 fractions (6MV photon) of the primary hypopharyngeal to
supraglottic tumor, right neck involved nodal, bilateral neck,</li>
<li>7000cGy/35 fractions of the reduced hypopharyngeal to supraglottic
tumor, right neck involved nodal area.</li>
</ul></li>
<li>2017-08-16 ~ 2017-09-22
<ul>
<li>4500cGy/25 fractions (15MV photon) of the esophageal tumor, tract,
to regional lymphatic nodal,</li>
<li>5040cGy/28 fractions of the esophageal tumor area.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2021-10 ~ ongoing Fluorouracil + Carboplatin + Paclitaxel</li>
<li>2021-01 ~ 2021-06 Fluorouracil + Cisplatin + Docetaxel</li>
<li>2020-11 ~ 2020-12 Carboplatin (CCRT)</li>
</ul></li>
</ul>
<div id="section-772" class="section level3">
<h3>==========</h3>
</div>
<div id="section-773" class="section level3">
<h3>2022-03-22</h3>
<ul>
<li>The last medical image update occurred on 28 January 2022. Treatment
with Fluorouracil + Carboplatin + Paclitaxel has been ongoing since
October 2021.</li>
<li>Serum glucose(AC) remained above normal (128mg/dL 2022-03-09),
however HbA1C reading went down to 7.5% (2022-03-09) from 8.0%
(2021-12-06), which is a positive sign.</li>
<li>More than one year of below normal serum magnesium and above normal
serum creatinine.</li>
<li>Cisplatin and, to a much lesser extent, carboplatin therapy, is
associated with hypomagnesemia, more so than any other electrolyte
deficiency. Hypomagnesemia affects 40%~90% of patients on cisplatin; in
contrast, 10% of patients treated with carboplatin or oxaliplatin
experience hypomagnesemia. Platinum-induced hypomagnesemia can persist
for up to 6 years after cessation of treatment and is primarily
attributed to renal Mg wasting.
<ul>
<li>reference: <a href="https://kidney360.asnjournals.org/content/kidney360/2/1/154.full.pdf" class="uri">https://kidney360.asnjournals.org/content/kidney360/2/1/154.full.pdf</a></li>
</ul></li>
<li>It is possible to treat hypomagnesemia without acute symptoms with
oral Mg supplementation and by eliminating medications that may be
contributing to the hypomagnesemia, however, the latter may not be the
optimal option during chemotherapy. MgO is presently in active
medication for the patient.</li>
</ul>
</div>
</div>
</div>
<div id="section-774" class="section level1">
<h1>701204933</h1>
<div id="section-775" class="section level2">
<h2>220322</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-14 CT - whole abdomen, pelvis
<ul>
<li>S/P right hemicolectomy. There is no evidence of tumor
recurrence.</li>
</ul></li>
<li>2021-12-31 Abdomen Ultrasound
<ul>
<li>chronic liver parenchymal disease</li>
<li>suspect GB polyp</li>
<li>cholecystopathy</li>
<li>suspect tiny stones, left kidney</li>
</ul></li>
<li>2021-08-26 Patho - colon segmental resection for tumor
<ul>
<li>Large intestine, ascending colon, laparoscopic right hemicolectomy -
Adenocarcinoma, moderately differentiated</li>
<li>Lymph node, mesocolic, dissection - metastatic carcinoma<br />
</li>
<li>pT3 pN2a (if cM0) Pathology stage: IIIB.<br />
</li>
<li>Histologic Type - Adenocarcinoma<br />
</li>
<li>Histologic Grade - G2 Moderately differentiated<br />
</li>
<li>Tumor Extension-Tumor invades through the muscularis propria into
pericolorectal tissue with no involvement of visceral peritoneum serosal
surface.<br />
</li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Regional Lymph Nodes - Number of Lymph Nodes Involved/Examined: 4/15
with extranodal extension.<br />
</li>
<li>Ancillary Studies - The result of biopsy specimen: S2021-09938<br />
</li>
<li>IHC: EGFR(+), PMS2(+), MLH-1(+), MSH-2(+), MSH-6(+)</li>
</ul></li>
<li>2021-08-16 CT - whole abdomen, pelvis
<ul>
<li>Imaging stage: T3N1bM0, stage IIIB</li>
</ul></li>
<li>2021-08-03 Patho - colon biopsy
<ul>
<li>Intestine, large, hepatic flexure colon, biopsy -
adenocarcinoma<br />
</li>
<li>Microscopically, it shows adenocarcinoma composed of a proliferation
of irregular neoplastic glands with areas of cribriform architecture,
and infiltrative growth pattern. The tumor cells display hyperchromatic
nuclei with pleomorphism, prominent nucleoli, high N/C ratio and mitotic
figures.</li>
</ul></li>
<li>2021-08-03 Colonoscopy
<ul>
<li>suspect colon cancer, hepatic flexure, s/p biopsy</li>
<li>internal hemorrhoid</li>
</ul></li>
<li>2021-01-31 CT - whole abdomen, pelvis
<ul>
<li>suspected acute pancreatitis, suggest clinical lab data
correlation.</li>
<li>small gallbladder stone. collapsed gallbladder with wall thickening,
suspected chronic cholecystitis.</li>
<li>left renal stone without obstruction.</li>
<li>relative thickening renal pelvis wall, right side.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-08-25 SILS Right-hemicolectomy - Proximal T-colon tumor</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-10-12 ~ ongoing - FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The survival benefit of adding oxaliplatin to adjuvant
fluoropyrimidines in patients with resected stage III colon cancer has
been shown in multiple randomized trials, and benefit appears to be
evident across diverse practice settings and patient subgroups.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer" class="uri">https://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer</a></li>
</ul></li>
<li>After undergoing right hemicolectomy on 2021-08-25, the patient has
been treated with FOLFOX regimen since mid-October 2021. There is no
evidence of peripheral neuropathy mentioned in nursing notes or medical
records in 2022.</li>
</ul>
</div>
</div>
<div id="section-776" class="section level1">
<h1>701355468</h1>
<div id="section-777" class="section level2">
<h2>220322</h2>
<p>{Malignant neoplasm of rectosigmoid junction, stage cT3N0M0, stage
IIA}</p>
<p>[objective]</p>
<ul>
<li>radiotherapy
<ul>
<li>2022-01-17 ~ 2022-03-07 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and 5040cGy/28 fractions of the rectal tumor bed area.</li>
</ul></li>
</ul>
<div id="section-778" class="section level3">
<h3>==========</h3>
</div>
<div id="section-779" class="section level3">
<h3>2022-03-22</h3>
<ul>
<li>On 2022-01-11, the cancer multidisciplinary meeting recommended
pre-operative CCRT for this patient.</li>
<li>The patient has been undergoing CCRT treatment since mid-January
2022, and has started the FOLFOX regimen during this hospital stay.</li>
<li>There were no extreme anomalies in the laboratory data reported on
2022-03-17, 18, 21.</li>
<li>In nursing notes, adverse events of grade 0 have been recorded at
11:55 on 2022-03-22.</li>
<li>No issue with current medication.</li>
</ul>
</div>
<div id="section-780" class="section level3">
<h3>2022-02-22</h3>
<ul>
<li>this 78-year-old male diagnosed with malignant neoplasm of
rectosigmoid junction in early Jan 2022 is on pre-Op CCRT since
mid-Jan.</li>
<li>lab data reported on 2022-02-16 showed no dysfunction of liver and
kidney, and slightly lower blood counts.</li>
<li>hypertension, gout and HBV are under treatment of corresponding
self-carried drugs
<ul>
<li>bisoprolol, valsartan</li>
<li>febuxostat</li>
<li>entecavir</li>
</ul></li>
<li>no issue with current medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-781" class="section level1">
<h1>701312127</h1>
<div id="section-782" class="section level2">
<h2>220321</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-07 Chest PA/AP view
<ul>
<li>Normal heart size.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Faint aveolar opacity over RIGHT LOWER LOBE is found.</li>
<li>Right pleural effusion is found.</li>
</ul></li>
<li>2022-02-21 CT - abdomen, pelvis
<ul>
<li>Mild progression of lymphoma.</li>
<li>Right pleural effusion with adjacent lung collapse. Some nodules at
bil. lungs.</li>
</ul></li>
<li>2022-02-09 Chest PA (Erect) view
<ul>
<li>A nodular opacity projecting in the right lower lung is suspected.
Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of bilateral costal-phrenic angle is noted, which may be
due to pleura effusion?</li>
</ul></li>
<li>2022-01-10 CT - abdomen, pelvis
<ul>
<li>Follicular lymphoma S/P C/T show partial response.</li>
</ul></li>
<li>2021-10-08 Chest AP
<ul>
<li>S/P port-A implantation.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
</ul></li>
<li>2021-10-05 Ga-67 Whole body inflammation scan with SPECT
<ul>
<li>Increased radiotracer uptake in bilateral lungs, bilateral pulmonary
hilar regions, left mediastinum, stenum, spines, and S-I joints, the
nature is to be determined (lymphoma involving regions, inflammation or
other nature ?).</li>
<li>Increased radiotracer accumulation in the colon, probably
physiological radiotracer accumulation.</li>
<li>No prominent abnormal focal radiotracer uptake is noted
elsewhere.</li>
</ul></li>
<li>2021-10-01 CT - whole abdomen, pelvis
<ul>
<li>Follicular lymphoma S/P C/T show partial response.</li>
</ul></li>
<li>2021-07-19 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - B-cell lymphoma involvement<br />
</li>
<li>Microscopically, it shows positive for B-cell lymphoma composed of
foci of lymphoid aggregation with follicular architecture.</li>
<li>IHC: CD20(+), Bcl-2(+), CD10(+), MPO(+), Bcl-6(+, at germinal
center), CD71(focal+), CD117(-), CD34(-).<br />
</li>
</ul></li>
<li>2021-07-16 Chest PA (Erect) view
<ul>
<li>S/P port-A implantation.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
<li>Increased lung markings on both lower lung are noted.</li>
</ul></li>
<li>2021-07-16 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving multiple
lymph nodes on both sides of the diaphragm, spleen and sacrum (stage
IV).</li>
<li>Mildly and diffusely increased FDG uptake in the bone marow of the
skeleton. The nature is to be determined (lymphoma? bone marrow
hyperplasia?).</li>
</ul></li>
<li>2021-07-12 Patho - lymphnode biopsy
<ul>
<li>Lymph node, right axillary, sono guide biopsy - Follicular lymphoma,
grade 2<br />
</li>
<li>Histology type: B-cell neoplasms, Follicular lymphoma, grade 2<br />
</li>
<li>IHC: CD3(-), CD20(+), CD10(+), BCL2(+), BCL6(+), Cyclin D1(-),
CD56(-), and CK(-).</li>
</ul></li>
<li>2021-07-09 CT - CTA, chest
<ul>
<li>Diffuse enlarged lymph nodes, suspected lymphoma.</li>
<li>Bilateral pleural effusion with lung collapse.</li>
<li>GB stone.</li>
<li>Ascites.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2022-03-18 - bendamustine + obinutuzumab</li>
<li>2022-02-09 - rituximab</li>
<li>2021-11-17 - R-CHOP (Rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone)</li>
<li>2021-10-27 - R-CHOP</li>
<li>2021-09-22 - R-CHOP</li>
<li>2021-09-01 - R-CHOP</li>
<li>2021-08-03 - R-CHOP</li>
<li>2021-07-19 - R-CHOP
<ul>
<li>R-CHOP Regimen - An immunochemotherapy regimen consisting of
rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride
(doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used
to treat both indolent and aggressive forms of non-Hodgkin lymphoma.
<ul>
<li>Regimen - cycle length 21 days.
<ul>
<li>Rituximab
<ul>
<li>375 mg/m2 IV</li>
<li>Dilute in NS or D5W to a final concentration of 1 to 4 mg/mL.
Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments
every 30 minutes to a maximum of 400 mg/hour, as tolerated. For
subsequent infusions, administer 20% of the total dose over the first 30
minutes and the remaining 80% over 60 minutes, as tolerated. The
90-minute infusion schedule should NOT be used in patients who have
clinically significant cardiovascular disease or have a circulating
lymphocyte count &gt;=5000/microL.</li>
<li>Day 1</li>
</ul></li>
<li>Cyclophosphamide
<ul>
<li>750 mg/m2 IV</li>
<li>Dilute in 250 mL NS or D5W and administer over 30 minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Doxorubicin
<ul>
<li>50 mg/m2 IV</li>
<li>Dilute in 50 mL NS or D5W and administer over three to five
minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Vincristine
<ul>
<li>1.4 mg/m2 IV (max dose 2 mg)</li>
<li>Dilute in 50 mL NS or D5W and administer over 15 to 20 minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Prednisone
<ul>
<li>100 mg orally</li>
<li>Administer 30 minutes prior to chemotherapy on day 1, then every 24
hours on days 2 to 5.</li>
<li>Days 1 to 5</li>
</ul></li>
</ul></li>
<li>Pretreatment considerations:
<ul>
<li>Hydration
<ul>
<li>Patients receiving cyclophosphamide should maintain adequate oral
hydration (2 to 3 L/day) and void frequently to reduce risk of
hemorrhagic cystitis.</li>
</ul></li>
<li>Emesis risk
<ul>
<li>MODERATE (30 to 90% risk of emesis).</li>
</ul></li>
<li>Prophylaxis for infusion reactions
<ul>
<li>Premedicate with acetaminophen and diphenhydramine, with or without
an H2 blocker, 30 minutes prior to at least the first and second
infusions of rituximab.</li>
</ul></li>
<li>Vesicant/irritant properties
<ul>
<li>Doxorubicin and vincristine are vesicants; avoid extravasation.</li>
</ul></li>
<li>Infection prophylaxis
<ul>
<li>The risk of febrile neutropenia with this regimen is 10 to 20%;
primary prophylaxis with hematopoietic growth factors should be
considered on an individual basis, particularly for high-risk patients
such as those with preexisting neutropenia, advanced disease, poor
performance status, or patients age 65 years or older.</li>
</ul></li>
<li>Dose adjustment for baseline liver or renal dysfunction
<ul>
<li>Adjustment of initial cyclophosphamide, doxorubicin, and vincristine
doses may be needed for preexisting liver dysfunction. In addition, dose
adjustment of cyclophosphamide may be required for renal
dysfunction.</li>
</ul></li>
<li>Hepatitis screening
<ul>
<li>Patients should be screened for hepatitis B and C virus prior to
starting rituximab, and if positive, considered for antiviral
prophylaxis.</li>
</ul></li>
<li>Cardiac screening
<ul>
<li>LVEF should be evaluated prior to initiation of therapy. Dose
alterations should be considered for LVEF &lt;50%, and doxorubicin
therapy is contraindicated in patients with LVEF &lt;30% at initiation.
Infusion times and schedule may be adjusted to decrease the risk of
cardiotoxicity in individuals at high risk for its development.</li>
</ul></li>
<li>Neurotoxicity
<ul>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine.</li>
</ul></li>
</ul></li>
<li>Monitoring parameters:
<ul>
<li>CBC with differential and platelet count weekly during
treatment.</li>
<li>Assess basic metabolic panel (creatinine and electrolytes) and liver
function prior to each subsequent treatment cycle.</li>
<li>LVEF should be evaluated periodically based on LVEF at initiation of
therapy and cumulative dose of doxorubicin.</li>
<li>Carriers of hepatitis B or C should be monitored for clinical and
laboratory signs of active infection during and following completion of
therapy. Rituximab should be discontinued if reactivation occurs.</li>
</ul></li>
<li>Suggested dose modifications for toxicity:
<ul>
<li>Myelotoxicity
<ul>
<li>Treatment should be delayed until ANC is &gt;1500/microL and
platelet count is &gt;100,000/microL. If a patient develops grade 4 (ANC
&lt;500/microL) neutropenia or febrile neutropenia with any cycle, G-CSF
support is added to the regimen for subsequent cycles. If grade 4
neutropenia or febrile neutropenia occurs despite G-CSF support, or if
the patient develops grade 3 (25,000 to 50,000/microL) or 4
(&lt;25,000/microL) thrombocytopenia with any cycle, the doses of
cyclophosphamide and doxorubicin should be decreased by 50% for
subsequent cycles.</li>
</ul></li>
<li>Neuropathy
<ul>
<li>Dose adjustment of vincristine may be necessary if the severity of
neuropathy persists or worsens. No specific guidelines are available for
dose adjustments.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>A patient with stage II, III, or IV FL is usually not cured by
conventional treatment. Remissions can be achieved, but relapses are not
uncommon. The treatment is intended to relieve symptoms, reverse
cytopenias, and improve the quality of life. Despite not being curative,
a modern therapy that incorporates anti-CD20 antibodies can prolong
survival. The goal of modern chemoimmunotherapy regimens is usually to
achieve a complete response, however, a significant minority of patients
treated with these regimens will only show a partial response.
Additional therapy (e.g., maintenance) may result in complete recovery
in some of these patients. As well, for this group as a whole, some
interventions, such as maintenance therapy and obinutuzumab, prolong
progression-free survival but do not improve overall survival.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/initial-treatment-of-stage-ii-to-iv-follicular-lymphoma" class="uri">https://www.uptodate.com/contents/initial-treatment-of-stage-ii-to-iv-follicular-lymphoma</a></li>
</ul></li>
<li>During the period of Mid-July 2021 through Mid-November 2021, this
patient received R-CHOP, then had rituximab prescribed on 2022-02-09. CT
images taken on 2021-10-01 and 2022-01-10 indicated partial response,
however CT images taken on 2022-02-21 showed mild progression.</li>
<li>During this hospitalization, the patient begins receiving his new
chemoimmunotherapy regimen of bendamustine plus obinutuzumab without
issue.</li>
<li>Underlying diseases include HTN and DM (admission diagnosis), drugs
for the latter have not been prescribed as active medication and no
updated blood sugar lab readings found within these 3 months.</li>
</ul>
</div>
</div>
<div id="section-783" class="section level1">
<h1>700980179</h1>
<div id="section-784" class="section level2">
<h2>220318</h2>
<p>{Peripheral T-Cell Lymphoma, PTCL, relapsed}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-26 CT - neck
<ul>
<li>Necrotic tumor at right neck, much smaller in size and less
enhancement as compared with CT scan on 20211228.</li>
</ul></li>
<li>2021-12-28 CT - neck
<ul>
<li>Probably abscess with deep neck infection at right upper neck.
Differential diagnosis suspected necrotic tumor mass with
infection.</li>
</ul></li>
<li>2021-11-25 Whole body PET scan
<ul>
<li>Increased FDG uptake in bilateral tonsils and a right upper neck
lymph node, compatible with residual lymphoma. In comparison with the
previous study on 20210107, the FDG avid lesions in bilateral tonsils
and a right upper neck lymph node are less evident. Other previous
lesions in the nasopharynx and other bilateral neck lymph nodes
disappeared.<br />
</li>
<li>Increased FDG uptake in the stomach. Inflammation is more
likely.</li>
<li>No prominent change is noted in the mild FDG avid lesions in some
mediastinal lymph nodes, right pulmonary hilar lymph nodes and left
adrenal gland, possibly more benign in nature.</li>
<li>Increased FDG accumulation in both kidneys and bilateral ureters.
Physiological FDG accumulation may show this picture.</li>
</ul></li>
<li>2021-11-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - No evidence of T-cell lymphoma
involvement</li>
<li>The sections show normocellular marrow (35%). M/E ratio = 4:1. The
erythroid precursors are not remarkable. The myeloid cells show good
maturation. The megakaryocytes are normal in number with few small
megakatyocytes. No lymphoid aggregates can be found. There is no
evidence of T-cell lymphoma involvement in CD20, CD3, CD4 and CD8
immunostains. Suggest further bone marrow smear evaluation and clinic
correlation.</li>
</ul></li>
<li>2021-11-10 Patho - tonsil biopsy
<ul>
<li>Diagnosis
<ul>
<li>Tonsil, left, tumor excision — Peripheral T-cell lymphoma<br />
</li>
<li>Tonsil, right, tumor excision — Peripheral T-cell lymphoma</li>
</ul></li>
<li>Histologic type: Peripheral T-cell lymphoma</li>
<li>Immunophenotyping: CD3(+), CD20(-), CD4(+), CD8(focal+), and
CD30(focal+)</li>
</ul></li>
<li>2021-11-09 Frozen section
<ul>
<li>Tonsil, left, frozen section — Atypical lymphoid cell infiltration,
compatible with lymphoma involvement.</li>
</ul></li>
<li>2021-11-03 CT - neck
<ul>
<li>C/W residual oropharyngeal lesions, mild regression as compared with
CT scna on 20210106.</li>
</ul></li>
<li>2021-01-07 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving the
nasopharynx, bilateral tonsils and multiple bilateral neck lymph
nodes.</li>
<li>Milldy increased FDG uptake in some mediastinal lymph nodes and
right pulmonary hilar lymph nodes. Inflammation is more likely.</li>
<li>Milldy increased FDG uptake in the left adrenal gland. The nature is
to be determined (benign tumor? other nature?).</li>
<li>Increased FDG accumulation in both kidneys and right ureter.
Physiological FDG accumulation may show this picture.</li>
</ul></li>
<li>2021-01-06 CT - neck
<ul>
<li>Bilateral tonsillar lesions and bilateral neck LAPs. R/O lymphoma
(stage II).</li>
</ul></li>
<li>2020-12-28 Patho - tonsil biopsy
<ul>
<li>Tonsil, right, biopsy —- Malignant T-cell lymphoma</li>
<li>Histology type: T-cell neoplasms, in favor of Peripheral T-cell
lymphoma<br />
</li>
<li>Immunohistochemical stain profiles: CD3(+), CD4(+), CD8(-), CD56(-),
Granzyme B(-), CD30(+), ALK(-), and CK(-).<br />
</li>
<li>Fungal hyphe is seen in necrotic debris. The PAS special stain is
positive.</li>
</ul></li>
<li>2020-12-26 Nasopharyngoscopy
<ul>
<li>Ulcerative lesion over right tonsil upper pole and right
palatopharyngeal arch</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-10 ~ ongoing Folotyn (pralatrexate)</li>
<li>2021-01-11 ~ 2021-05-13 CHOP (cyclophosphamide, doxorubicin
hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and
prednisone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pralatrexate is indicated to treat relapsed PTCL. The patient is
taking pralatrexate currently since early December 2021, and CT scans
(2022-01-26 versus 2021-12-28) demonstrated improvements.</li>
<li>Hepatotoxicity and LFT abnormalities have been observed with
pralatrexate use. Persistent abnormalities may indicate hepatotoxicity.
In the period 2021-12-01 to now, S-GPT/ALT readings have ranged from
15U/L to 403U/L, with 77U/L being reported on 2022-03-17.</li>
<li>Package insert revealed 30% of patients treated with pralatrexate
experienced edema, which should be addressed.</li>
</ul>
</div>
</div>
<div id="section-785" class="section level1">
<h1>701148578</h1>
<div id="section-786" class="section level2">
<h2>220318</h2>
<p>{Nasopharyngenl Carcinoma - NPC, non-keratinizing carcinoma}</p>
<p>[objective]</p>
<ul>
<li>Exam findings
<ul>
<li>2021-11-24 PET
<ul>
<li>Glucose hypermetabolic lesions in the post. aspect of nasal septum,
nasal cavity, and part of left NP region, compatible with recurrent
tumor of NPC.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral mediastinal lymph nodes
and bilateral pulmonary hilar lymph nodes, probably reactive nodes.</li>
<li>Glucose hypermetabolic lesion in the right femoral shaft, the nature
is to be determined (post-traumatic change, benign or even another
primary malignant neoplasm of bone, or other nautre?), suggesting
further investigation.<br />
</li>
<li>NPC s/p treatment with tumor recurrence, rcTxN0M0, by this F-18 FDG
PET scan.</li>
</ul></li>
<li>2021-11-01 Patho - Larynx biopsy
<ul>
<li>Nasopahrynx, biopsy - Non-keratinizing carcinoma, undifferentiated
(lymphoepithelialcarcinoma) (WHO-2B).</li>
<li>IHC: CK(+), EBER(+).</li>
</ul></li>
<li>2021-11-01 MRI - Nasopharynx
<ul>
<li>A soft tissue tumor, about 27 mm x 22 mm x 24 mm, with relatively
homogeneous mild T1- and T2-hyperintensity and faint enhancement
involving posterior aspect of nasal septum, posterior nostril, florr of
sphenoid sinus and part of left nasopharyngeal wall.</li>
<li>Diffuse fluid accumulation in bilateral sphenoid sinuses.</li>
</ul></li>
<li>2020-11-02 MRI - Nasopharynx
<ul>
<li>Markedly regressed bil. neck LNs.</li>
</ul></li>
<li>2020-04-22 MRI - Nasopharynx
<ul>
<li>C/W NPC T4N2Mx, Stage IVA. Progressive change as compared with MRI
on 2019-12-04.</li>
</ul></li>
<li>2019-12-05 PET
<ul>
<li>The FDG PET findings are compatible with nasopharyngeal malignancy
with invasion to the skull base and possible intracranial
extension.</li>
<li>Glucose hypermetabolism in bilateral retropharyngeal lymph nodes and
multiple right neck level II to III and left neck level II lymph nodes,
compatible with metastatic lymph nodes.</li>
<li>Mild glucose hypermetabolism in the lesser trochanter of right
femur. The nature is to be determined (post-traumatic change? other
nature?).</li>
</ul></li>
<li>2019-12-04 MRI - Nasopharynx
<ul>
<li>Bilateral NPC, at least T4N2Mx, stage IVA.</li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2020-05 ~ 2020-06:
<ul>
<li>6090cGy/29 fractions (6 MV photon) to NPX tumor and bilateral neck
LAPs (incomplete).</li>
<li>2020-06-22 RT side effect evaluation: radiation mucositis, grade 2;
pharyngitis, grade 2; dermatitis, grade 2; N/V, grade 1; esophagitis,
grade 1; xerostomia, grade 2.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2020-11 ~ ongoing: carboplatin + fluorouracil</li>
<li>2019-12 ~ 2020-06: cisplatin, 2020-04-21 + UFT</li>
</ul></li>
</ul>
<p>[objective] ??</p>
<ul>
<li>radiotherapy
<ul>
<li>2022-02 ~ ?? CCRT?</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-14 ~ ongoing - 5-FU + carboplatin</li>
<li>2021-11-29 ~ 2022-01-10 - carboplatin (weekly)</li>
</ul></li>
</ul>
<div id="section-787" class="section level3">
<h3>2022-03-18</h3>
<ul>
<li>Nivolumab could be added optionally to the treatment regimen for
patients suffering from recurrent or metastatic non-keratinizing
disease.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/29584545/" class="uri">https://pubmed.ncbi.nlm.nih.gov/29584545/</a></li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-788" class="section level1">
<h1>701240249</h1>
<div id="section-789" class="section level2">
<h2>220315</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-02 Patho - bone marrow biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Bone marrow, biopsy - acute myeloid leukemia</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, composed of hypercellular marrow (&gt;90%). The marrow space
is almost completely replaced by blasts.</li>
</ul></li>
<li>Immunohistochemistry: CD34(+, 60%), CD117(+, 60%), MPO(+, 10%),
CD61(+, megakaryocytes) and CD71(+, erythroid series).</li>
</ul></li>
<li>2022-02-25 CT - lung/mediastinum/pleura
<ul>
<li>Right middle lobe and right lower lobe subsegmental
consolidation.</li>
</ul></li>
<li>2022-01-12 Patho - bone marrow biopsy
<ul>
<li>pancytopenia<br />
</li>
<li>Bone marrow, iliac, biopsy - Normal cellular marrow.</li>
<li>IHC stains: CD117: &lt;2%; CD34: &lt;2 %; MPO: 10%, CD61: &lt;2 %;
CD71: 20%, CD138: 5% (of the nucleated cells). Kappa and lambda light
chains: no predominant monoclonal sub-population.<br />
</li>
<li>Section shows piece(s) of bone marrow with 50 % cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
is no metastatic malignancy present.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-790" class="section level1">
<h1>701272755</h1>
<div id="section-791" class="section level2">
<h2>220315</h2>
<p>[subjective]</p>
<ul>
<li>2021-03-04 cough for several months, CT scan at ShuangHo Hospital
showed a necrotic mass at anterosuperior mediastinum, suspected
malignant thymoma.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-11 CT - brain
<ul>
<li>multiple brain metastases.</li>
</ul></li>
<li>2022-02-17 CT - lung/mediastinum/pleura
<ul>
<li>s/p thymectomy with recurrent soft tissue at anterior mediastinum
and lymph nodes at subcarina region. stationary as compred with previous
CT.</li>
</ul></li>
<li>2021-1-17 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>subcutanoeus nodule over right back</li>
<li>diagnosis - soft tissue, back, excisional biopsy - Metastatic
thymoma - Margin free</li>
<li>IHC: P40(+), CK5/6(+), CD5(focal+).</li>
</ul></li>
<li>2021-11-04 CT - lung/mediastinum/pleura
<ul>
<li>Residual low density lesion at anterior mediatinum, in
regression.</li>
<li>Some lymph nodes are found at paracaval region. Stable.</li>
<li>The pleural effusion is not visualized in the current study.</li>
</ul></li>
<li>2021-09-08 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>Diagnosis - Skin and soft tissue, previous right chest tube wound,
excisional biopsy - metastatic thymoma<br />
</li>
<li>IHC: CK5/6(+), p40(+), CD5(-), and CD117(-). The results are
consistent with metastatic thymoma. The deep resection margin is
involved by tumor.</li>
</ul></li>
<li>2021-08-03 CT - lung/mediastinum/pleura
<ul>
<li>recurrent or residual mediastinal invasive thymoma with mediastinal
LAP and bilateral pleural effusions suspected mediastinal abscess.</li>
</ul></li>
<li>2021-04-13 Patho - meiastinum mass
<ul>
<li>anterior mediastinal tumor with pericardial and LUL invasion</li>
<li>Thymus, excision - Invasive thymoma, poorly differentiated, AJCC 8th
edition: pStage IIIA, pT3N0 (if cM0), at least
<ul>
<li>The peripheral resection margin is involved<br />
</li>
</ul></li>
<li>Lung, LUL, wedge resection - Invasive thymoma, by direct invasion,
with negative resection margin.</li>
<li>IHC CK5/6(+), p63(+), CD117(-), CD5(-), TTF-1(-), GATA3(-) and
CD56(-).</li>
</ul></li>
<li>2021-03-18 Patho - thymus tumor
<ul>
<li>Mediastinal tumor</li>
<li>Diagnosis: Thymus, CT-guide needle biopsy - in favor of invasive
thymoma</li>
<li>IHC: CK5/6(+), p63(+), TTF-1(-), Naspin A(-), CD56(-),
Calretinin(-), PAX8(-), and CD117(-). The results are in favor of
invasive thymoma, but metastatic squamous cell carcinoma or urothelial
carcinoma can not be excluded.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-09-08
<ul>
<li>Surgery: Removal of granuloma</li>
<li>Finding: Erythematous granuloma over previous right chest tube
wound. suspected stitches-related and tumor seeding.</li>
</ul></li>
<li>2021-04-12
<ul>
<li>Surgery: Radical left side pericardiectomy with tumor mobilization
and excision.</li>
<li>Finding: A huge, stiff anterior mediastinal mass tightly adhered to
ASAo/MPA and extended to left anterior chest wall. We meticulously
divided the InV and LIJV and tumor debulking from surroundings.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-05-14 ~ 2021-07-05: 4500cGy/25 fractions of the thymic tumor,
and 6480cGy/36 frcations of the reduced thymic tumor area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-06 vincristine + cyclophosphamide</li>
<li>2022-01-05 cisplatin + doxorubicin</li>
<li>2021-12-01 vincristine + cyclophosphamide</li>
<li>2021-11-29 cisplatin + doxorubicin</li>
<li>2021-10-20 vincristine + cyclophosphamide</li>
<li>2021-10-18 cisplatin + doxorubicin</li>
<li>2021-09-20 vincristine + cyclophosphamide</li>
<li>2021-09-20 cisplatin + doxorubicin</li>
<li>2021-08-11 vincristine + cyclophosphamide</li>
<li>2021-08-09 cisplatin + doxorubicin</li>
<li>2021-07-13 vincristine + cyclophosphamide</li>
<li>2021-07-13 cisplatin + doxorubicin</li>
<li>2021-05-15 ~ 2021-06-29: cisplatin (part of CCRT)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-792" class="section level1">
<h1>700309329</h1>
<div id="section-793" class="section level2">
<h2>220309</h2>
<p>{rt breast ca (TNBC), cT2N0M0 stage IB}</p>
<ul>
<li>exam finding
<ul>
<li>2020-11 recurrence</li>
</ul></li>
<li>surgical operation
<ul>
<li>2018-10 at WanFang Hospital</li>
</ul></li>
<li>chemotherapy
<ul>
<li>ongoing oral vinorelbine</li>
<li>2021-05 ~ 2021-10 Eribulin / Xeloda</li>
<li>2021-02 ~ 2021-04: Taxol + Gem</li>
<li>2020-12 ~ 2021-01 EP x 3</li>
<li>2018-18 ~ ?: post-Op adjuvant CAP</li>
<li>2018-07 ~ 2018-09 pre-Op neoadjuvant TAC x 3</li>
<li>2018-05 ~ 2018-06 pre-Op neoadjuvant C/T x CEF x 3</li>
</ul></li>
<li>shared decision making
<ul>
<li>2022-03-01
<ul>
<li>effective Tx option had been tried and failed. hospice care had been
recommended at WanFang Hospital.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Use of preoperative systemic therapy may provide important
prognostic information based on response to therapy. Achieving a
pathologic complete response (pCR) to neoadjuvant therapy is associated
with favorable disease-free and OS in early-stage breast cancer. The
correlation between pathologic response and long-term outcomes in
patients with early-stage breast cancer is strongest for patients with
triple-negative breast cancer.
<ul>
<li>references:
<ul>
<li>Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant
therapy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol 2008;26:1275-1281. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18250347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/18250347</a>.</li>
<li>Cortazar P, Zhang L, Untch M, et al. Pathological complete response
and long-term clinical benefit in breast cancer: the CTNeoBC pooled
analysis. Lancet 2014;384:164-172. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24529560" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/24529560</a>.</li>
<li>von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact
of pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012;30:1796-1804. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22508812" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/22508812</a>.</li>
</ul></li>
</ul></li>
<li>Different subsequent chemotherapy regimen did not yield satisfactory
results for this patient.</li>
<li>Biomarkers such as BRCA1/2, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, or
TMB-H not found in the system, or targeted drugs may provide an
alternative approach.</li>
</ul>
</div>
</div>
<div id="section-794" class="section level1">
<h1>700835850</h1>
<div id="section-795" class="section level2">
<h2>220304</h2>
<p>[subjective]</p>
<ul>
<li>2021-12 the patient noted vaginal bleeding and coital pain after
sexual intercourse, and post-voiding vaginal bleeding developed
afterwards.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-25 Patho - uterus neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Tumor, uterine endocervix, radical hysterectomy -
Carcinosarcoma</li>
<li>Tumor, uterine fundus, ditto - Serous carcinoma, high grade</li>
<li>Myometrium, ditto - Tumor invasion, less than half thickness</li>
<li>Parametria, bilateral, ditto - Free from tumor, two reactive lymph
nodes at R’t parametrium</li>
</ul></li>
<li>AJCC pathological stage
<ul>
<li>endometrial cancer - pT1aN0, if cM0, stage IA</li>
<li>cervical cancer - pT1b1N0, if cM0, stage IB1 / FIGO stage IA1</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Tumor 1
<ul>
<li>Tumor location: Fundus</li>
<li>Myometrium involvement: involved, less than 0.2 cm in depth</li>
<li>Tumor type: high grade serous carcinoma</li>
<li>Histologic grade: high grade</li>
<li>Immunohistochemistry: P16(+), P53(+), WT-1(+, focal), ER(+, focal)
and PR(+, focal)</li>
</ul></li>
<li>Tumor 2
<ul>
<li>Tumor location: Between low body and endocervix</li>
<li>Corpus involvement: involved, focal</li>
<li>Tumor type: homologous type carcinosarcoma</li>
<li>Histologic grade: high grade</li>
<li>Depth of invasion: less than 0.1 cm, &lt;1/2 cervical wall</li>
<li>Immunohistochemistry:
<ul>
<li>carcinoma component: P16(+), P53(+), WT-1(+, focal), CK(+),
vimentin(-), CD10(-)</li>
<li>Sarcoma component: vimentin(+), CD10(+, focal), WT-1(+, focal),
P16(+), P53(+), CK(-)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-11 MRI - pelvis
<ul>
<li>Clinical cervical polypectomy, carcinosarcoma. No evidence of
advanced lesion.</li>
<li>Soft tissue in the uterine cavity (fundus and lower body), suspected
polyps or endometrial tumors, suggest further study.</li>
</ul></li>
<li>2022-01-03 Patho - cervix/endometrial polyp
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, cervix, polypectomy - Carcinosarcoma</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show carcinosarcoma, composed of a adenocarcinomatous
component admixed with a high-grade sarcomatous component.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-24 radical hysterectomy</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-18 ~ 4500cGy/25 fractions of the pelvis, and 1200cGy/3
fractions by IVRT to vaginal cuff mucosa surface.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-03 ~ ongoing: cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Surgical findings without nodes, margins and parametrium
infiltrations, s/p radical hysterectomy (2022-01-24), pelvic EBRT and
concurrent platinum-containing chemotherapy were recommended for stage
IB1 cervical cancer.</li>
<li>concurrent platinum-containing chemotherapy with EBRT utilizes
cisplatin as a single agent. currently, the patient is being
hospitalized to receive her first chemotherapy dose. in case of
cisplatin intolerance, carboplatin may be used instead.</li>
<li>regular cytology can be considered for detection of lower genital
tract dysplasia and for immunocompromised patients, although its value
in detection of recurrent cervical cancer is limited.</li>
</ul>
</div>
</div>
<div id="section-796" class="section level1">
<h1>700267431</h1>
<div id="section-797" class="section level2">
<h2>220303</h2>
<p>{Compatibility for both Tapimycin and KCl in Suntose}</p>
<ul>
<li>tapimycin in suntose: compatible</li>
<li>potassium chloride in suntose: compatible</li>
<li>both tapimycin and KCl in suntose: no compatibility data availabe
yet, not recommended.</li>
</ul>
</div>
</div>
<div id="section-798" class="section level1">
<h1>700334023</h1>
<div id="section-799" class="section level2">
<h2>220303</h2>
<p>{Panceratic carcinoma, cT1N1M1 (left neck subclavicle mets), stage
IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-17 CT - lung/mediastinum/pleura
<ul>
<li>distal pancreatic cancer with regression of neck LNs metastases but
progression of retroperitoneal para-aortic LNs metastases, new left
adrenal metastasis, and resolution cystic component at pancreatic tail
as compared with previous chest, neck, and abdominal CT exams.</li>
<li>favor hepatic cysts, cannot totally rule out small metastatic
lesions, stationary</li>
</ul></li>
<li>2021-10-11 CT - neck
<ul>
<li>multiple left low neck and supraclavicular fossa LAPs.</li>
</ul></li>
<li>2021-09-20 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>A soft tissue nodule (2.5cm) at LUQ.</li>
<li>Enlarged LNs at paraaortic region.</li>
</ul></li>
<li>2021-06-12 CT - whole abdomen, pelvis
<ul>
<li>metastatic paraaortic lymph nodes with partial response.</li>
<li>atrophy of pancreatic tail with dilated P-duct.</li>
<li>suspected liver cysts.</li>
</ul></li>
<li>2021-03-05 Patho - lymphnode biopsy
<ul>
<li>tissue, intraabdominal lymph node, biopsy - poorly differentiated
carcinoma</li>
<li>IHC: CK7(+), CDX-2(+), CK(+), CK20(-).</li>
</ul></li>
<li>2021-03-05 Cytology
<ul>
<li>positive for malignancy<br />
</li>
<li>smears show clusters of atypical tumor cells with nuclear
hyperchromasia, pleomorphism and high N/C ratio.</li>
</ul></li>
<li>2021-03-04 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the hypopharynx. The nature is to be
determined (inflammation/infection? malignancy?).</li>
<li>A glucose hypermetabolic in the left upper abdomen just between the
stomach and spleen. Malignancy (colon malignancy?) in this region should
be watched out. However, no prominent abnormal focal FDG uptake was
noted in the pancreas.</li>
<li>Glucose hypermetabolism in multiple left neck level V and left
supraclavicular lymph nodes, a mediastinal A-P window lymph node and
multiple abdominal paraaortic and right plevic lymph nodes, compatible
with multiple metastatic lymph nodes.</li>
<li>Mild glucose hypermetabolism in the stomach, some mediastinal right
paratracheal lymph nodes, right pulmonary hilar lymph nodes and a left
axillary lymph node. Inflammatory process is more likely.</li>
</ul></li>
<li>2021-02-22 Patho - soft tissue
<ul>
<li>Lymph node, left neck, excision - metastatic carcinoma, poorly
differentiated consistent with gastrointestinal or pancreatobiliary
origin</li>
<li>IHC: CK7(focal +), CK20(-), CDX2(+), CK5/6(-), TTF-1(-), CD56(-),
and GATA3(-).</li>
</ul></li>
<li>2021-02-18 CT - lung/mediastinum/pleura
<ul>
<li>Atrophy of the pancreatic tail with dilated distal pancreatic duct
is found. suspected IPMT, suggest EUS/ERCP.</li>
<li>Lymphadenopathy at left thoracic inlet and paraaortic region.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-02-22 Excision - a 1.5x2x2 cm soft tumor over L’t supraclavicle
region.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02 ~ ongoing: 5-Fu + leucovorin + irinotecan liposome, Q2W</li>
<li>2021-04 ~ 2022-01: gemcitabine + nal-paclitaxel, Q2W</li>
<li>2021-03: gemcitabine</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Most recent CT images (2022-01-17) showed regression of neck LNs
metastases, progression of retroperitoneal para-aortic LNs metastases,
new left adrenal metastasis. Each metastasis has its own ups and downs.
In general, the disease is still advancing.</li>
<li>FOLFIRINOX or modified FOLFIRINOX should be limited to those with
ECOG 0-1.</li>
<li>Gemcitabine + albumin-bound paclitaxel is reasonable for patients
with ECOG 0-2. (Apr 2021 to Jan 2022)</li>
<li>5-FU + leucovorin + liposomal irinotecan is a reasonable subsequent
therapy option for patients with ECOG 0-2. (since Feb 2022)</li>
<li>Sympathomimetics for glaucoma prescribed by ophthalmology OPD might
be added as a self-carried item into current medication.</li>
</ul>
</div>
</div>
<div id="section-800" class="section level1">
<h1>701252496</h1>
<div id="section-801" class="section level2">
<h2>220302</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-01 CT
<ul>
<li>bilateral lung, mediastinal and supraclavicular LNs, chest wall,
pleural, bony, and liver metastases, in progression as compared with CT
on 2022-01-19.</li>
<li>multiple numerous nodules of variable sizes throughout in both lungs
due to metastasis.</li>
</ul></li>
<li>2022-01-19 CT
<ul>
<li>bilateral lung, mediastinal and supraclavicular LNs, chest wall,
pleural, and liver metastases, in progression as compared with CT on
2021-11-09.</li>
<li>multiple numerous nodules of variable sizes throughout in both lungs
due to metastasis.</li>
</ul></li>
<li>2021-12-20 Pelvis &amp; Bilat. Hip Lat
<ul>
<li>osteolytic bony lesion in left lower sacrum and right pubic bone are
suspected.</li>
</ul></li>
<li>2021-12-01 Hearing test
<ul>
<li>bil. moderately severe to profound HL.</li>
</ul></li>
<li>2021-11-09 CT
<ul>
<li>bilateral lung, mediastinal LNs, chest wall, and liver metastases,
in progression as compared with CT on 2021-09-06.</li>
</ul></li>
<li>2021-09-06 CT
<ul>
<li>bilateral lung, mediastinal LNs, chest wall, and liver metastases,
in progression as compared with CT on 2021-07-02.</li>
</ul></li>
<li>2021-07-02 CT
<ul>
<li>esophageal cancer s/p esophagectomy and gastric tube reconstruction.
No regional recurrence is found.</li>
<li>bilateral lung meta with enlarged size is found.</li>
<li>s/p jejunal stomy.</li>
</ul></li>
<li>2021-03-24 Patho - soft tissue biopsy / simple excision (non lipoma)
<ul>
<li>skin, infra-gluteal fold, right, excision - metastatic adenosquamous
carcinoma, compatible with esophageal primary</li>
</ul></li>
<li>2021-03-16 CT
<ul>
<li>favor bilateral lung and mediastinal LNs metastases and
bronchiolitis or endobronchial spreadinf nodules, and residal posterior
wall thickening at M/3 of esophages</li>
</ul></li>
<li>2021-02-01 Patho - soft tissue biopsy / simple excision (non lipoma)
<ul>
<li>skin, scalp, incisional biopsy - compatible with metastatic
adenosquamous carcinoma from esophagus<br />
</li>
<li>IHC: CK7(+), CK5/6(+), and p63(focal +).</li>
</ul></li>
<li>2021-01-19 Patho - esophagus subtotal/total resection
<ul>
<li>Esophagus, middle third, VATS esophagectomy - Adenosquamous
carcinoima, poorly differentiated, s/p CCRT<br />
</li>
<li>Soft tissue, peri-gastric, specimen 1, dissection - Adenosquamous
carcinoima, metastatic (1/10)<br />
</li>
<li>Lymph node, group 5, dissection - Adenosquamous carcinoima,
metastatic (1/2)<br />
</li>
<li>Pathology stage:
<ul>
<li>ypStage IIIB, ypT3N1(if cM0)</li>
<li>if brain metastasis is proofed, ypStage IVB, ypT3N1(if cM1)</li>
</ul></li>
</ul></li>
<li>2021-01-06 Whole body PET scan
<ul>
<li>The glucose hypermetabolic lesions in the middle portion of the
esophagus, in mediastinal lymph nodes, and in bilateral pulmonary hilar
lymph nodes come to less evident compared with the previous study on
2020-10-16, compatible with esophageal malignancy s/p treatment.<br />
</li>
<li>However, glucose hypermetabolic lesions in the left lower lung and
right lower lung become more prominent, suggesting lung metastases.</li>
</ul></li>
<li>2021-01-05 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2020-10-13, the lesion in
the region about left 3rd costovertebral junction is new. The nature is
to be determined (post-traumatic change? other nature?).</li>
<li>No prominent change is noted in other bone lesions, possibly more
benign in nature.</li>
</ul></li>
<li>2021-01-05 MRI - Brain
<ul>
<li>A small enhancing nodule in right caudate nucleus head. Seems
slightly increase in size (4.7 mm), suggest follow up.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2021-01-04 CT
<ul>
<li>M/3 thoracic esophageal cancer, significant regression of a sessile
like intralumal mass in posterior wall as compared with CT on
2020-09-30.</li>
<li>no regional LAP. inflammation or infection in RLL and LLL of
lungs.</li>
</ul></li>
<li>2020-10-23 MRI - Spectroscopy
<ul>
<li>An enhancing lesion (3 mm) in right caudate nucleus. Metastasis is
first considered until proved otherwise.</li>
</ul></li>
<li>2020-10-16 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion involving the middle portion of the
esophagus, compatible with primary esophageal malignancy. Besides, there
were two small focal areas of glucose hypermetabolism in the lower
portion of the esophagus. Esophageal malignancy involving these two
small focal areas should be considered.</li>
<li>Glucose hypermetabolism in multiple bilateral supraclavicular lymph
nodes and multiple mediastinal lymph nodes (more than 7 lymph nodes), in
bilateral pulmonary hilar lymph nodes and in two upper abdominal lymph
nodes. Metastatic lymph nodes may show this picture.</li>
<li>Some small glucose hypermetabolic lesions in bilateral lung fields.
Lung metastases should be watched out.</li>
</ul></li>
<li>2020-10-15 Patho - Esophageal biopsy
<ul>
<li>Esophagus, 34, 37-38 cm below incisors, biopsy - Squamous cell
carcinoma, poorly differentiated<br />
</li>
</ul></li>
<li>2020-10-15 MRI - Brain
<ul>
<li>A metastatic lesion (3 mm) in right caudate nucleus. Left lateral
nasopharyngeal mucosal thickening.</li>
</ul></li>
<li>2020-09-30 CT
<ul>
<li>Esophageal Carcinoma</li>
<li>Imaging stage: T2N1M0, stage IIIA</li>
</ul></li>
<li>2020-09-28 Patho - Esophageal biopsy
<ul>
<li>Esophagus, middle third, 25-30 cm below incisor, biopsy - Squamous
cell carcinoma, poorly differentiated</li>
</ul></li>
<li>2020-09-28 Esophagogastroduodenoscopy, EGD
<ul>
<li>Suspect esophageal cancer, middle third, 25-30 cm below incisor s/p
biopsy x 3</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-01-18 VATS + esophagectomy + laparoscopy gastric tube
reconstruction</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-02-22 ~ 2021-03-05 18Gy/6fx to the whole brain The .
<ul>
<li>whole brain: 18Gy/6fx</li>
<li>rt caudate nucleus metastatic tumor: 30Gy/10fx</li>
<li>scalp boost: 9Gy/3fx (4MeV electron)</li>
</ul></li>
<li>2020-11-02 ~ 2020-12-11 50.4Gy/28fx to the esophagus, Rt hilar LAPs,
and adjacent lymphatic drainage area (part of preOp neoadjuvant
CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12 ~ ongoing: 5-Fu + cisplatin + paclitaxel</li>
<li>2021-07 ~ 2021-11: FOLFIRI</li>
<li>2021-03 ~ 2021-07: 5-Fu + cisplatin + docetaxel</li>
<li>2020-11 ~ 2020-12: 5-Fu + cisplatin (PF, part of preOp neoadjuvant
CCRT)</li>
</ul></li>
</ul>
<div id="section-802" class="section level3">
<h3>==========</h3>
</div>
<div id="section-803" class="section level3">
<h3>2022-03-02</h3>
<ul>
<li>for recurrent, metastatic esophageal squamous cell carcinoma with
general weakness and fatigue, if ECOG score &lt;= 2 or Karnofsky score
&gt;= 60%, then microsatellite and PD-L1 testing might be performed for
those previously not done, to expand the subsequent choice like
nivolumab or pembrolizumab.</li>
<li>if NTRK gene fusion positive proved, entrectinib or larotrectinib
could also serve as an optional choice.</li>
</ul>
</div>
<div id="section-804" class="section level3">
<h3>2021-05-17</h3>
<p>[tube feeding]</p>
<p>The oral drugs in active medication including:</p>
<ul>
<li>keto (ketorolac 10mg)</li>
<li>neurontin (gabapentin 100mg)</li>
<li>tramacet (tramadol 37.5mg, acetaminophen 325mg)</li>
</ul>
<p>All the above drugs can be grinded and administrated via NG tube</p>
</div>
</div>
</div>
<div id="section-805" class="section level1">
<h1>700867682</h1>
<div id="section-806" class="section level2">
<h2>220301</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>2022-01-26 dischargenote
<ul>
<li>Recurrent hepatocellular carcinoma, rypT3N0(cM0), Stage IIIA; status
post 3rd Transarterial chemoembolization on 2022-01-25, BCLC: B,
ECOG:1</li>
<li>Liver cirrhosis with moderate splenomegaly, child score: A</li>
<li>Hypertension</li>
<li>Type 2 diabetes mellitus without complications</li>
<li>Enlarged prostate without lower urinary tract symptoms</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-02-25 MRI - L-spine
<ul>
<li>multiple bone tumors</li>
<li>herniated discs in the L2/3, L3/4 and L4/5 discs</li>
<li>mild spondylolisthesis at L4-5</li>
</ul></li>
<li>2022-01-17 MRI - Liver, Spleen
<ul>
<li>HCC s/p operation. Liver cirrhosis with splenomegaly. Multiple
recurrent HCCs (up to 2.0cm) in liver.</li>
</ul></li>
<li>2021-11-19 CT - ABD
<ul>
<li>Four newly-developed HCCs or pseudolesions in S8 and S2 are
suspected? Please correlate with MRI.</li>
<li>Viable HCC in S7 of the liver is suspected. Please correlate with
MRI.</li>
</ul></li>
<li>2021-09-09 MRI
<ul>
<li>HCC at right lobe liver up to 6.6cm with several satellite smaller
lesions at right lobe.</li>
<li>Lymphadenopathy at retroperitonum, paraaoritc and hepatic hilar
region.</li>
</ul></li>
<li>2021-08-25 CT - ABD
<ul>
<li>HCC 6.8 x 4.6 cm in S7 of the liver is suspected. Please correlate
with AFP and MRI to evaluate the tumor margin.</li>
<li>Two Recurrent HCCs 1.4 cm in S7 and 1.1 cm in S6 of the liver are
suspected. The differential diagnosis include dysplastic nodules. Please
correlate with MRI.</li>
<li>HCC or flow artifact 1.6 cm in S5 liver is suspected.</li>
</ul></li>
<li>2021-08-16 SONO - ABD
<ul>
<li>HCC status post S5 segmenectomy and cholecystectomy</li>
<li>Fatty liver, moderate</li>
<li>Liver cirrhosis with moderate splenomegaly</li>
<li>Fatty pancreas</li>
<li>Left renal stone</li>
</ul></li>
<li>2021-07-28 SONO - Kidney
<ul>
<li>Bilateral chronic change with large sized kidney suspect diabetic
nephropahty</li>
<li>Left renal stone</li>
</ul></li>
<li>2020-04-17 SONO = Kidney
<ul>
<li>Left moderate hydronephrosis</li>
</ul></li>
<li>2019-03-11 Surgical pathology Level V
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S5, partial hepatectomy - Hepatocellular carcinoma<br />
</li>
<li>Pathologic Staging: pT1bNx(cMx); Stage IB at least</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic type: Hepatocellular carcinoma, predominantly clear
cell<br />
</li>
<li>Histologic Grade: G3 (Poorly differentiated)<br />
</li>
<li>Cytological grade: Grade III<br />
</li>
<li>Tumor necrosis: Present (10%)<br />
</li>
<li>Inflammatory cell infiltration: Moderate<br />
</li>
<li>Tumor capsule: Partially ncapsulated with infiltrative border<br />
</li>
<li>Satellite nodule: Absent<br />
</li>
<li>Bile duct Invasion: Absent<br />
</li>
<li>Hepatitis: Non-B, non-C<br />
</li>
<li>Ishak Modified HAI Grading: Score=3 (interphase hepatitis=0/4,
confluent necrosis=0/6, focal necrosis=1/4, portal inflammation=2/4)
(Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)<br />
</li>
<li>Fatty Change: Marked (70%)</li>
</ul></li>
</ul></li>
<li>2019-02-26 Visceral Angiography 2 vessels
<ul>
<li>Right hepatic tumor suspected HCC</li>
</ul></li>
<li>2019-02-26 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Fatty liver , severe</li>
<li>Liver tumor, S5, suspicious HCC</li>
<li>Renal stone, left</li>
<li>Accessory spleen</li>
</ul></li>
<li>2019-01-30 SONO - ABD
<ul>
<li>Bilateral parenchymal renal disease.</li>
<li>Left mild hydronephrosis.</li>
<li>Left renal stones.</li>
<li>Liver tumor.</li>
</ul></li>
</ul></li>
<li>Lab data
<ul>
<li>AFP
<ul>
<li>2022-01-17 103 ng/mL</li>
<li>2021-10-26 19</li>
<li>2021-08-16 20</li>
<li>2019-02-26 2</li>
</ul></li>
<li>S-GPT/ALT
<ul>
<li>2022-01-26 92 U/L</li>
<li>2022-01-17 35</li>
<li>2021-12-07 28</li>
<li>2021-12-01 62</li>
<li>2021-10-26 22</li>
<li>2021-09-24 43</li>
</ul></li>
<li>S-GOT/AST
<ul>
<li>2022-02-27 97 U/L</li>
<li>2022-01-26 279</li>
<li>2022-01-17 112</li>
<li>2021-12-01 87</li>
<li>2021-10-26 26</li>
<li>2021-09-24 53</li>
<li>2021-09-22 36</li>
</ul></li>
</ul></li>
<li>Embolization
<ul>
<li>2022-01-25 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-11-30 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2021-09-23 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2021-10-05 ~ 2021-11-08: 5000cGy/25 fractions (15 MV photon) to
hepatic hilum &amp; paraaortic LAPs.</li>
</ul></li>
<li>Medication
<ul>
<li>2021-01 ~ ongoing: lenvatinib 10mg QD</li>
<li>2021-10-12, -10-26, -11-30: nivolumab 100, 100, 40mg,
respectively<br />
</li>
<li>2021-09 ~ 2022-01: sorafenib 200mg BIDAC</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Recurrent HCC progressed, bone mets observed by MRI on 2022-02-25
s/p 3 times of TAE in 2021-09, 2021-11, 2022-01, s/p nivolumab (Oct, Nov
2021), sorafenib (Sep 2021 ~ Jan 2022) and lenvatinib (since Jan
2022).</li>
<li>Neither pembrolizumab nor atezolizumab used in advanced HCC setting
are covered by the most updated NHI policy (2022-02-23 version). However
atezolizumab/bevacizumab for Child-Pugh Class A patients is recommended
as a preferred regimen by NCCN (2021 version 5).</li>
<li>First-line nivolumab treatment did not significantly improve overall
survival compared with sorafenib, but clinical activity and a favourable
safety profile were observed in patients with advanced hepatocellular
carcinoma. Thus, nivolumab might be considered a therapeutic option for
patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are
contraindicated or have substantial risks.
<ul>
<li>source: <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/fulltext" class="uri">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/fulltext</a></li>
</ul></li>
<li>There are limited data supporting the use of FOLFOX, and use of
chemotherapy in the context of a clinical trial is preferred.
<ul>
<li>source: <a href="https://pubmed.ncbi.nlm.nih.gov/23980077/" class="uri">https://pubmed.ncbi.nlm.nih.gov/23980077/</a></li>
</ul></li>
<li>If NTRK gene fusion is positive, then larotrectinib or entrectinib
might be opt-in as subsequent line use.</li>
<li>Lenvatinib was non-inferior to sorafenib in overall survival in
advanced hepatocellular carcinoma. This drug is prescirbed as part of
current medication.
<ul>
<li>source: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext" class="uri">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext</a></li>
<li>source: <a href="https://pubmed.ncbi.nlm.nih.gov/30993651/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30993651/</a></li>
</ul></li>
<li>In addition to dermatologic adverse effects, since lenvatinib could
increase the possibility of hypertension (45% to 73%; severe
hypertension 3%; UpToDate) which is a underlying disease the patient
has, a closer blood pressure monitoring might be needed.</li>
</ul>
</div>
</div>
<div id="section-807" class="section level1">
<h1>700962200</h1>
<div id="section-808" class="section level2">
<h2>220301</h2>
<p>{myelodysplastic syndrome}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-16 Patho - bone marrow biopsy
<ul>
<li>Diagnosis - Bone marrow, biopsy - Compatible with myelodysplastic
syndrome</li>
<li>IHC:
<ul>
<li>MPO: positive for myeloid series</li>
<li>CD71: positive for erythroid series</li>
<li>CD61: positive for megakaryocytes</li>
<li>CD117: positive for blast</li>
<li>CD34: positive for blast</li>
</ul></li>
<li>Microscopically, the sections show pictures as follows:
<ul>
<li>Cellularity 30-40%</li>
<li>M/E ratio about 1/2, left shift maturation of both myeloid and
erythroid series</li>
<li>Megakaryocyte proliferation, 30% with dysplastic change.
Immunohistochemistry of CD34(+) and CD61(+)</li>
<li>Blast cells about 5%</li>
<li>According to all above histopathologic findings and clinical
presentation, it is compatible with myelodysplastic syndrome.</li>
</ul></li>
</ul></li>
<li>2021-09-27 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, buttock, biopsy - Hypocellularity</li>
<li>IHC:
<ul>
<li>MPO: positive for myeloid series<br />
</li>
<li>CD71: positive for erythroid series<br />
</li>
<li>CD61: positive for megakaryocytes<br />
</li>
<li>CD117: positive for blast<br />
</li>
<li>CD34: positive for blast<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Hypocellularity for her age, 5-10%</li>
<li>M/E ratio about 1/3, hypoplasia of myeloid series and hyperplasia of
erythroid series</li>
<li>Megakaryocyte proliferation, 20-30% with interstitial or
paratrabecular distribution</li>
<li>No obviously increase of blast (5%)<br />
</li>
<li>According to all above histopathologic findings and clinical
history, the differential diagnosis includes myelodysplastic syndrome
(MDS) or therapy-associated reactive change.</li>
</ul></li>
</ul></li>
<li>2020-09-04, -08-14 CT
<ul>
<li>S/P hysterectomy.</li>
<li>Hepatosplenomegaly, nature?</li>
</ul></li>
<li>2019-10-17 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the middle T-spines and L4-5 spines.
Degenerative change may show this picture.</li>
<li>Increased activity in the maxilla. The nature is to be determined
(dental problem? other nature?).</li>
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?).</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, elbows, knees and right ankle. Benign joint
lesion is more likely.</li>
</ul></li>
<li>2016-05-17 Pathology
<ul>
<li>Uterus, endometrium, staging surgery - carcinosarcoma, Grade 3</li>
<li>pTNM: pT1bNO(cM0) , FIGO stage: IB.</li>
<li>Uterus, myometrium, staging surgery - involved by carcinosarcoma
(&gt; 1/2 thickness) - adenomyosis.</li>
</ul></li>
<li>2016-05-06 MRI
<ul>
<li>Endometrial tumor, suspected malignancy, cstage T1aN0Mx.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2016-05-10 laparoscopic gynecology staging surgery (LAVH + BSO +
BPLND + omentectomy); laparoscopic adhesionolysis.</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2016-06-16 ~ 2016-08-01: 4500cGy/25fx (15MV photon) of the pelvic,
and 900cGy/3fx via IVRT to vaginal cuff mucosa surface area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2016-06-01, -06-23, -08-10, -09-06, -11-14.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Allogeneic hematopoietic cell transplantation (HCT) is the treatment
with the highest potential to cure MDS. However, because of advanced
age, comorbid conditions, lack of adequately matched donors, and/or
patient preferences, only a small subset of patients with MDS are
candidates for allogeneic HCT. HLA typing should be performed if
hematopoietic cell transplant (HCT) approach is not ruled out.</li>
<li>For most patients with MDS, the goals of care are to lessen
symptoms, improve the quality of life, and prolong survival, while
minimizing treatment-related toxicity. IPSS/IPSS-R could be applied to
categorize prognostic risk group.</li>
<li>If del(5q) is confirmed, then lenalidomide might be considered for
IPSS low/intermediate MDS.</li>
<li>lab data uric acid 11.8, eGFR 30.11 reported on 2022-02-28,
allopurinol (50 mg daily) or febuxostat (no dosage adjustment necessary)
might be considered if no contraindication.</li>
</ul>
</div>
</div>
<div id="section-809" class="section level1">
<h1>701049704</h1>
<div id="section-810" class="section level2">
<h2>220301</h2>
<p>[objective]</p>
<ul>
<li>underlying disease
<ul>
<li>ESRD and dependence on renal dialysis (QW135)</li>
</ul></li>
<li>exam finding
<ul>
<li>2021-12-23 CT
<ul>
<li>Right hilar lung meta, in regression.</li>
<li>Mediasitnal lymphadenopathy, regressed.</li>
<li>s/p left nephrectomy.</li>
</ul></li>
<li>2021-09-24 CT
<ul>
<li>Bladder ca. with right pulmonary hilar meta, causing right lung
partial collapse and bilatral pleural effusion. The tumor is stationary
in size and extension.</li>
</ul></li>
<li>2021-08-13 CT
<ul>
<li>Lung metastases show decreasing in size.</li>
</ul></li>
<li>2021-04-21 bronchoscopy
<ul>
<li>right main residual endobronchial tumors s/p electrocautery.</li>
<li>RUL and right intermediate bronchus endobronchial tumors, cannot be
approached.</li>
</ul></li>
<li>2021-04-21 patho - bronchus biopsy
<ul>
<li>sections show solid sheets of hyperchromatic tumor cells in a
fibrotic stroma. keratinization is focally seen.</li>
<li>IHC: CK5/6(+), p63(+), GATA3(+), TTF-1(-), and CD56(-). the results
are consistent with metastatic urothelial carcinoma.</li>
</ul></li>
<li>2021-04-16 bronchoscopy
<ul>
<li>autofluorescence: abnormal mucosa over right main bronchus</li>
<li>right main bronchus: total occlusion by tomor s/p biopsy for 1
specimen with mild bloody oozing s/p epinephrin 0.5 amp local spray</li>
<li>EBUS: endobronchial tumor over right main bronchus.</li>
</ul></li>
<li>2021-03-25 chest PA (erect) view
<ul>
<li>extensive opacification and volume reduce and nodular opacities over
Rt lung, in progression associated Rt pleural effusion as compared with
previous image</li>
<li>obliteration of Rt main bronchus</li>
<li>small nodular opacities over left lung</li>
</ul></li>
<li>2021-02-19 CT - lung/mediastinum/pleura
<ul>
<li>right middle lobe lung cancer with right lower lobe lung mets is
suspected.</li>
</ul></li>
<li>2020-10-29 chest AP
<ul>
<li>extensive consolidation in Rt upper lobe and extensive ground glass
opacity over Rt mid and lower lung zones</li>
</ul></li>
<li>2020-10-16 patho - urinary bladder TUR
<ul>
<li>histologic type: papillary urothelial carcinoma, invasive, with
marked squamous differentiation</li>
<li>histologic grade: high-grade</li>
<li>tumor configuration: papillary</li>
<li>mascularis propria: present</li>
<li>microscopic tumor extension: tumor invades subepithelial connective
tissue</li>
<li>VENTANA PD-L1 (SP142) assay for urothelial carcinoma: PD-L1
expression &lt;5% IC</li>
</ul></li>
<li>2020-08-17 patho - urethra biopsy
<ul>
<li>urothelial carcinoma, low-grade.</li>
<li>muscularis propria not present.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-01-16 Transurethral Resection of Bladder Tumor, TURBT</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10: 60Gy/30fx to the Rt hilar mets.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-11: VAC(vinblastin 3mg/m2, doxorubicin 22.5mg/m2, carboplatin
50mg)</li>
<li>2021-05 ~ 2021-09: gemcitabine + carboplatin</li>
<li>2020-11 ~ 2020-12: doxorubicin (intravesical)</li>
</ul></li>
</ul>
<div id="section-811" class="section level3">
<h3>==========</h3>
</div>
<div id="section-812" class="section level3">
<h3>2022-03-01</h3>
<ul>
<li>hypotenstion 80/40 around 2022-03-01 01:00 ~ 02:00 was mitigated to
110/55 at 08:20 later the same day.</li>
<li>HGB 8.2 g/dL reported on 2022-02-28, EPO 5000U weekly could be
considered if no contraindiction, until the reading backs to 11
g/dL.</li>
</ul>
</div>
<div id="section-813" class="section level3">
<h3>2021-08-31</h3>
<p>[lowering BP gently]</p>
<p>visiting the patient at around 16:45 on 2021-08-30, he did not
complain of discomfort or unwellness these days, however he shared his
experience of dizziness and fainting when SBP below 160mmHg since years
ago. lowering blood pressure should be in a gentle way.</p>
</div>
<div id="section-814" class="section level3">
<h3>2021-08-30</h3>
<p>[assessment]</p>
<ul>
<li>Low HGB
<ul>
<li>EPO worked, RBC and HGB increased gradually, still some gap to
normal range.</li>
</ul></li>
<li>hypertenstion
<ul>
<li>drugs act as antihypertensive agents:
<ul>
<li>captopril (angiotensin converting enzyme inhibitor)</li>
<li>nicorandil (guanylyl cyclase stimulator; K channel activator)</li>
<li>amlodipine (Ca channel blocker)</li>
</ul></li>
<li>for an ESRD patient, diurectics might not be indicated</li>
<li>sodium had fallen to the lower margin of normal range, no need to
restrict Na intake.</li>
<li>interdialytic BP of &lt;140/80 mmHg could be set an the target
<ul>
<li>there were argues on beta-blockers application to NSTEMI patient,
source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721004/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721004/</a></li>
<li>increase dialysis time: the length or frequency of sessions is often
effective in reducing target dry weight.</li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep routine CBC monitoring as usual.</li>
<li>increase dialysis time might be considered if blood pressure remains
high too long. ### 2021-08-26</li>
</ul>
<p>[assessment]</p>
<ul>
<li>this is an ESRD patient on hemodialysis with multiple
comorbidities.</li>
<li>chemo drug dosing - source: <a href="https://pubmed.ncbi.nlm.nih.gov/30942181/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30942181/</a>
<ul>
<li>doxorubicin:
<ul>
<li>hemodialysis: consider administering 75% of the original dose.</li>
</ul></li>
<li>carboplatin:
<ul>
<li>hemodialysis: carboplatin dose (mg) = target AUC x 25; administer on
a nondialysis day, hemodialysis should occur between 12 to 24 hours
after carboplatin dose.</li>
</ul></li>
</ul></li>
<li>hypochromemia
<ul>
<li>HGB 7.8g/dL reported on 2021-08-26 remains low for now.</li>
<li>epoetin beta 5000 unit SC QW3 prescribed since 2021-08-24.</li>
</ul></li>
<li>not received chemo yet since this hospitalization.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>drugs prescribed for NSTEMI found in PharmCloud, refilled items
listed as following, might be set as patient-carried ones into active
medication if no contraindication…
<ul>
<li>famotidine 20mg QD</li>
<li>clopidogrel 75mg QD</li>
<li>aspirin 100mg QD</li>
<li>amiodarone QD</li>
<li>nitroglycerin ASORDER</li>
<li>nicorandil 5mg HS</li>
<li>amlodipine 5mg ASORDER</li>
<li>atorvastatin 20mg QD</li>
</ul></li>
</ul>
</div>
</div>
</div>
<div id="section-815" class="section level1">
<h1>700105459</h1>
<div id="section-816" class="section level2">
<h2>220223</h2>
<p>{SCC of tongue, cT4N1M0, s/p total glossectomy, right mandibular
osteotomy, right marginal mandibulectomy, selective neck dissection,
wide excision of malignant left lower gum SCC and marginal
mandibulectomy, teeth extraction of #46, tracheotomy and free flap
reconstruction}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-02-10 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: Bilateral lung meta, in progression.</li>
<li>S/p tracheal tube placement with its tip in place.</li>
<li>S/P NG tube placement.</li>
</ul></li>
<li>2021-10-25 Chect PA (Erect) view
<ul>
<li>Few nodular opacity projecting in the right upper and left lower
lung is noted.</li>
</ul></li>
<li>2021-10-22 CT - Lung/Mediastinum/Pleura
<ul>
<li>Right upper lobe and left lower lobe lung meta.</li>
<li>Recurrent lymphadenopathy at right level II and level III and left
parapharyngeal space.</li>
</ul></li>
<li>2021-10-19 CT - Neck
<ul>
<li>Status post tracheostomy.</li>
<li>Postoperative change in the oral cavity and neck, and
post-irradiation change.</li>
<li>Suspect tumor recurrence or infection at left parapharyngeal space
involving medial pterygoid muscle.</li>
<li>Necrotic nodal recurrence at right level II and left level III.</li>
<li>RUL nodule (2.1cm), suspect lung metastasis.</li>
</ul></li>
<li>2021-10-18 LN aspiration
<ul>
<li>Left neck mass: Positive for malignancy
<ul>
<li>Two wet smears show multiple dysplastic sqaumous cell clusters,
compatible with metastatic squamous cell carcinoma.</li>
</ul></li>
</ul></li>
<li>2021-08-16 Patho - oral cancer (wide excision + lymph node)
<ul>
<li>pathologic diagnosis
<ul>
<li>Tongue, total glossectomy - Moderately differentiated squamous cell
carcinoma</li>
<li>Oral cavity, right retromolar region, right marginal mandibulectomy
- Moderately differentiated squamous cell carcinoma</li>
<li>Oral cavity, left mandible region, wide excision - Severe dysplasia
with ulcer</li>
<li>Pathology stage: pT4a(m)N0(if cM0); AJCC stage IVA</li>
</ul></li>
</ul></li>
<li>2021-08-03 PET
<ul>
<li>Glucose hypermetabolism in the left aspect of the tonge with
invasion to the mouth floor and left aspect of soft palate, compatible
with malignancy involving these regions.</li>
<li>Glucose hypermetabolism in the some left neck level II, left
submandibular and left level IV lymph nodes, compatible with metastatic
lymph nodes.</li>
<li>Mild glucose hypermetabolism in some right neck level II and right
submandibular lymph nodes. The nature is to be determined (inflammatory
process? other nature?).</li>
<li>Glucose hypermetabolism in a focal area in the right aspect of
mandible. The nature is to be determined (dental problem? other
nature?).</li>
<li>Glucose hypermetabolism in the right shoulder and in the right
pulmonary hilar region, compatible with inflammatory process.</li>
</ul></li>
<li>2021-08-02 Patho - Gingival/oral mucosa biopsy
<ul>
<li>Labeled as “left lateral tongue”, biopsy - squamous cell
carcinoma.</li>
<li>IHC: P16(-, 0%); p40(+).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>SCC
<ul>
<li>2022-02-08 5.7ng/mL</li>
<li>2021-08-04 6.1</li>
<li>2021-08-03 5.8</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-08-13
<ul>
<li>Total glossectomy</li>
<li>R mandibular osteotomy</li>
<li>R marginal mandibulectomy</li>
<li>Selective neck dissection</li>
<li>Wide excision of malignant L lower gum SCC+ marginal
mandibulectomy</li>
<li>Extraction of #46 (at anterior margin of skip L lower gum SCC)</li>
<li>Tracheotomy</li>
<li>Free left anterolateral thigh flap resurfacing to the intra-oral
defect</li>
<li>Open reduction of mandible and internal fixation with reconstruction
plates</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-04 ~ 2021-11-22: bil. neck 50Gy/25fx. The tongue preOP tumor
site: 66Gy/33fx. The gross LAPs: 70Gy/35fx</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-03 ~ ongoing: 5-Fu + cisplatin + cetuximab, biweekly</li>
<li>2021-10-27 ~ 2021-11-22: cisplatin weekly</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-817" class="section level1">
<h1>700509991</h1>
<div id="section-818" class="section level2">
<h2>220215</h2>
<p>{gastric cancer, stage IIA, extra-capsular spread (ECS) positive}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-24 Patho - stomach subtotal/total (tumor)
<ul>
<li>Diagnosis - Tumor, stomach, subtotal gastrectomy -
Adenocarcinoma</li>
<li>AJCC Pathologic staging - pT2N1, if cM0, stage IIA</li>
</ul></li>
<li>2021-12-20 Patho - stomach biopsy
<ul>
<li>Diagnosis
<ul>
<li>Stomach, antrum GC side, s/p biopsy (A) - Adenocarcinoma.
<ul>
<li>IHC: Her2/neu: negative (score=1+).</li>
</ul></li>
<li>Stomach, prepyloric antrum, s/p biopsy (B) - low grade
dysplasia.</li>
</ul></li>
</ul></li>
<li>2021-12-18 CT - abdomen, gastric filling with water
<ul>
<li>Gastric carcinoma
<ul>
<li>T2N1M0, stage IIA</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-23 radical subtotal gastrectomy with D2 lymph nodes
dissection.</li>
</ul></li>
<li>treatment
<ul>
<li>post-Op adjuvant CCRT with 5-FU 24 hr QD x 5 per wk x 6 plus R/T on
2022-02-14.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>several targeted therapeutic agents, trastuzumab,
pembrolizumab/nivolumab, and entrectinib/larotrectinib have been
approved by the FDA for use in gastric cancer.
<ul>
<li>trastuzumab is based on testing for HER2 overexpression.</li>
<li>pembrolizumab/nivolumab are based on testing for MSI by PCR or
NGS/MMR by IHC, PD-L1 immunohistochemical expression, or high tumor
mutational burden (TMB) by NGS.</li>
<li>FDA granted approval for the use of select TRK inhibitors for NTRK
gene fusion-positive solid tumors.</li>
</ul></li>
<li>when limited tissue is available for testing, or the patient is
unable to undergo a traditional biopsy, sequential testing of single
biomarkers or use of limited molecular diagnostic panels may quickly
exhaust the sample. in these scenarios, comprehensive genomic profiling
via a validated NGS assay performed in a CLIA-approved laboratory may be
used for the identification of HER2 amplification, MSI status, MMR
deficiency, TMB, and NTRK gene fusions. the use of IHC/ISH/targeted PCR
should be considered first followed by additional NGS testing as
appropriate.</li>
<li>no drug allergy recorded in database, no issue found with current
medication.</li>
</ul>
</div>
</div>
<div id="section-819" class="section level1">
<h1>700926086</h1>
<div id="section-820" class="section level2">
<h2>220215</h2>
<p>[objective]</p>
<ul>
<li>Exam findings
<ul>
<li>2022-02-11 CT
<ul>
<li>Prior CT identified few small LNs at para-aortic space and bil.
inguinal regions show stationary.</li>
</ul></li>
<li>2021-11-08 MRI
<ul>
<li>Cervical spondylosis with diffuse spinal canal stenosis, cord
compression and neuroforaminal narrowing, esp C3-4 with compressive
myelopathy.</li>
</ul></li>
<li>2021-10-29 PET
<ul>
<li>Lymphoma of low FDG uptake involving multiple lymph nodes on both
sides of the diaphragm and bone marrow may show this picture (stage
IV).</li>
<li>Increased FDG uptake in the soft tissues around bilateral hips.
Inflammation is more likely.</li>
</ul></li>
<li>2021-10-20 Patho - bone marrow biopsy
<ul>
<li>Diagnosis
<ul>
<li>Bone marrow, iliac, biopsy — Lymphoma, B cell type</li>
<li>IHC:
<ul>
<li>CD3 and CD20: a predominant small sized B lymphoid cells
subpopulation;</li>
<li>CD138: 50%;</li>
<li>kappa and lambda: approximately 2:1.</li>
<li>bcl-2 (+, 90%) bcl-6 (-) (of the nucleated cells).</li>
<li>Serum immunoglobin levels show evelated both IgG and IgM
levels.</li>
<li>KI-67: marked variation from areas to areas ranging 5% to 60% and
averaing 20% to 25%.</li>
</ul></li>
</ul></li>
<li>Microscopic
<ul>
<li>Section shows piece(s) of bone marrow with 100 % cellularity a mixed
small lymphocytes subpopulation and plasmacytoid cell
subpupulation.</li>
<li>The bone marrow findings in conjunction with serum immunoglbulin
levels is suggestive of B cell lymphoma, small B cell type, or
lymphoplasmacytoid cell type. Probably a polyclonal Waldemstrom-like
lymphoma.</li>
</ul></li>
</ul></li>
<li>2021-07-24 CT
<ul>
<li>Minimal opacity over B6 (superior segment) of right lower lobe,
right middle lobe, and left upper lobe is found.</li>
<li>Small lymph nodes at bilateral axillary, supraclavicular and
abdominal paraaortic region.</li>
</ul></li>
<li>2020-10-23 MRA - Brain
<ul>
<li>Mild general brain atrophy. Subcortiacl arteriosclerotic
encephalopathy.</li>
</ul></li>
<li>2020-10-05 Clinical Dementia Rating (CDR)
<ul>
<li>Score 1</li>
</ul></li>
<li>2020-09-19 CT
<ul>
<li>Small LNs at retroperitoneum, bil. axillary and bil. inguinal
regions.</li>
</ul></li>
<li>2020-09-01 Patho - bone marrow biopsy
<ul>
<li>Diagnosis
<ul>
<li>Bone marrow, iliac, biopsy - Proliferation of lymphoplasmacytic
cells.</li>
<li>IHC:
<ul>
<li>CD20 (80-90%);</li>
<li>CD138 (weak intensity, approximately 50%);</li>
<li>kappa and lambda: no predominant subpopulation.</li>
<li>CD3: &lt;10%. (of the nucleated cells).</li>
</ul></li>
<li>The possibility of lymphoplasmycitc lymphoma/ Waldenström
macroglobulinemia (WM) cannot be excluded.</li>
</ul></li>
<li>Microscopic
<ul>
<li>Section shows one piece of bone marrow with 90% cellularity and M:E
ratio of approximately 5:1.</li>
<li>Three cell lineages are present with a predominant of
leukocytes.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2021-11-16 ~ up to now: R-CVP (rituximab, cyclophosphamide,
vincristine, prednisone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>the most updated NCCN clinical practice guidelines for B-Cell
Lymphomas (evidence blocks, version 5.2021 - Sep 22, 2021) suggests
small cell testing panel: CD5, CD10, CD21, CD23, cyclin D1, BCL2, BCL6,
Ki-67, CD11c, CD25, CD103 for differential diagnosis. not all items
found in patho records.</li>
<li>lab data reported on 2022-02-14 revealed no abnormality of liver and
kidney functions.</li>
<li>CT on 2022-02-11 showed stable LNs at para-aortic space and bil.
inguinal regions.</li>
<li>involved-site RT (ISRT) might not be indicated for the stage IV
disease.</li>
<li>the patient is on R-CVP regimen which is recommend in the
guidelines. R-CHOP (rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone) might be an alternative.</li>
<li>no drug allergy recorded in database. no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-821" class="section level1">
<h1>701349358</h1>
<div id="section-822" class="section level2">
<h2>220215</h2>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-02 Patho - stomach subtotal/total (tumor)
<ul>
<li>stomach, antrum, subtotal gastrectomy - signet-ring cell
carcinoma</li>
<li>small intestine, duodenum, subtotal gastrectomy - signet-ring cell
carcinoma, by direct invasion</li>
<li>omentum, omentectomy - negative for malignancy</li>
<li>lymph node - signet-ring cell carcinoma, metastatic</li>
<li>pT2N3b(if cM0), pStage IIIB</li>
<li>gross configuration: for advanced carcinoma (Borrmann
classification): Type III
<ul>
<li>ulcerated with poorly defined infiltrative margins</li>
</ul></li>
<li>histologic type: adenocarcinoma, Lauren classification of
adenocarcinoma: diffuse type</li>
<li>histologic grade: G3 - poorly differentiated, undifferentiated</li>
<li>tumor extension: tumor invades the muscularis propria</li>
<li>lymphovascular Invasion, perineural invasion, intestinal metaplasia,
high-grade dysplasia, polyps: absent</li>
</ul></li>
<li>2021-11-30 Patho - stomach biopsy
<ul>
<li>stomach, antrum, biopsy — signet-ring cell carcinoma<br />
</li>
<li>IHC: CK(+), Her-2/neu (Ab)(-).<br />
</li>
</ul></li>
<li>2021-11-30 Esophagogastroduodenoscopy
<ul>
<li>highly suspected gastric cancer, antrum, Borrmann type 3, sp
biopsy</li>
</ul></li>
<li>2021-11-29 CT - abdomen gastric filling with water
<ul>
<li>T2N2M0, stage IIA</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02 Adjuvant RT to anastomosis and regional lymphatics for
4500cGy/25fx is suggested for locoregional control.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-14 starts 5-FU</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-823" class="section level1">
<h1>700276060</h1>
<div id="section-824" class="section level2">
<h2>220209</h2>
<p>{Thalidomide/Dexamethasone Interaction}</p>
<p>Dexamethasone might enhance the dermatologic adverse effect and/or
thrombogenic effect of Thalidomide.</p>
<p>Consider using venous thromboembolism prophylaxis in patients with
multiple myeloma who are receiving both thalidomide and dexamethasone,
particularly if the patient is newly diagnosed or has other risk factors
for thromboembolism. Low-molecular-weight heparin or warfarin (at INR of
2.0-3.0) have been proposed as reasonable prophylactic agents. Regarding
the potential dermatologic interaction between thalidomide and
dexamethasone, monitor for any evidence of dermatologic events,
particularly maculopapular or erythematous rash. If evident,
discontinuation of drug therapy or dosage reduction may be required.</p>
</div>
</div>
<div id="section-825" class="section level1">
<h1>701023219</h1>
<div id="section-826" class="section level2">
<h2>220208</h2>
<ul>
<li>Lab findings
<ul>
<li>MRI - nasopharynx
<ul>
<li>Right NPC with neck LAPs. T2N3M0 stage IVA.</li>
</ul></li>
<li>2021-08-04 Patho - nasopharyngeal/oropharyngeal biopsy
<ul>
<li>Nasopharyngeal carcinoma, non-keratinizing and poorly
differentiated</li>
<li>IHC: CK(+).</li>
</ul></li>
<li>2021-08-04 Nasopharyngoscopy
<ul>
<li>rt np tumor.</li>
</ul></li>
<li>2021-07-29 Patho - lymphnode biopsy
<ul>
<li>Labeled as “right neck”, biopsy - Lymph node with round blue cell
tumor, metastatic.</li>
<li>IHC: CK(+), poorly differentiated carcinoma. EBV(-), p16(-).</li>
<li>Please check nasopharynx, oropharynx, supra- and sub-glottis
first.</li>
</ul></li>
</ul></li>
<li>Surgical operation
<ul>
<li>2021-08-17 removing an enlarged lymph node over right posterior
neck.</li>
</ul></li>
<li>Regimen
<ul>
<li>2021-11 ~ ongoing Cisplatin + Fluorouracil</li>
<li>2021-08 ~ 2021-10 Cetuximab</li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2021-08-20 ~ 2021-10-11
<ul>
<li>5000cGy/25 fractions of the nasopharyngeal to bilateral neck,</li>
<li>6000cGy/30 fractions of the nasopharyngeal tumor and involved
nodal,</li>
<li>7000cGy/35 fractions of the reduced nasopharyngeal tumor and
involved nodal lesions.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-827" class="section level1">
<h1>700731496</h1>
<div id="section-828" class="section level2">
<h2>220128</h2>
<p>{possible drug interaction: Dasatinib / Histamine H2 Receptor
Antagonists}</p>
<p>[objective]</p>
<ul>
<li>current medication includes:
<ul>
<li>Sprycel (Dasatinib 50mg) 1# PO QD</li>
<li>Ulstop (Famotidine 20mg) 1# PO BID</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Histamine H2 Receptor Antagonists might decrease the absorption of
Dasatinib.</li>
<li>Coadministration of H2RAs and Dasatinib may reduce dasatinib
concentrations and efficacy.</li>
<li>Dasatinib prescribing information states histamine H2 receptor
antagonists (H2RAs) should not be coadministered with dasatinib due to
the risk of reduced dasatinib concentrations and efficacy. Given the
longer-term acid suppression achieved with H2-antagonist or proton pump
inhibitor therapy, the manufacturer suggests the use of antacids (with
2-hour dose separation) if acid-reducing therapy is required.</li>
<li>The likely mechanism for this apparent interaction is impaired
absorption of dasatinib, which does appear to display pH-sensitive
solubility, due to the increase in gastric pH caused by a H2-receptor
antagonist.</li>
<li>references:
<ul>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor
antagonists and proton pump inhibitors on dasatinib pharmacokinetics in
Japanese leukemia patients. Cancer Chemother Pharmacol.
2012;69(4):999-1004.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/22147077/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22147077/</a></li>
</ul></li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ:
Bristol-Myers Squibb Company; September 2016.</li>
<li>Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of
gastric acid pH modulators on the bioavailability of oral dasatinib in
healthy subjects. J Clin Pharmacol. 2009;49(6):700-709.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/19395585/" class="uri">https://pubmed.ncbi.nlm.nih.gov/19395585/</a></li>
</ul></li>
<li>Matsuoka A, Takahashi N, Miura M, et al. H2-receptor antagonist
influences dasatinib pharmacokinetics in a patient with
Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother
Pharmacol. 2012;70(2):351-352.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/22678358/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22678358/</a></li>
</ul></li>
<li>Koutake Y, Taniguch J, Yasumori N, et al. Influence of proton pump
inhibitors and H2-receptor antagonists on the efficacy and safety of
dasatinib in chronic myeloid leukemia patients. Int J Hematol.
2020;111(6):826-832.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/32152877/" class="uri">https://pubmed.ncbi.nlm.nih.gov/32152877/</a></li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Antacids should be taken 2 hours before or after dasatinib
administration if acid-reducing therapy is needed.</li>
</ul>
</div>
</div>
<div id="section-829" class="section level1">
<h1>701032519</h1>
<div id="section-830" class="section level2">
<h2>220127</h2>
<p>{marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
(MALT lymphoma)}</p>
<p>[objective]</p>
<ul>
<li>Exams
<ul>
<li>2022-01-11 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in some focal areas in bilateral lung
fields. Residual lymphoma should be considered. However, in comparison
with the previous study on 2021/08/19, the previous glucose
hypermetabolic lesions in bilateral lung fields are either less evident
or disappeared.<br />
</li>
<li>Glucose hypermetabolism in some mediastinal and bilateral pulmonary
hilar lymph nodes. Inflammation is more likely.</li>
<li>Increased FDG accumulation in the colon, both kidneys and bilateral
ureters. Physiological FDG accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2022-01-04 CT - Lung/Mediastinum/Pleura
<ul>
<li>post op change in LUL</li>
<li>regression nodular lesions of both lungs as compared with CT on
2021/8/18.</li>
</ul></li>
<li>2021-08-20 Patho
<ul>
<li>Bone marrow, iliac, biopsy - Negative for malignancy<br />
</li>
<li>Microscopically, it shows 15% of cellularity, prsence of trilineage
cellular component and some megakaryocytes.</li>
<li>IHC: CD20(-), CD34(-), CD117(-), CD3(-), CD138(-), MPO(+),
CD71(+).</li>
</ul></li>
<li>2021-08-19 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in multiple focal areas in bilateral lung
fields, compatible with lymphoma.</li>
<li>Glucose hypermetabolism in some mediastinal lymph nodes. The nature
is to be determined (inflammation? other nature?).</li>
<li>Increased FDG accumulation in the left neck muscle, both kidneys and
bilateral ureters. Physiological FDG accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2021-08-18 CT - ABD - whole abdomen, pelvis
<ul>
<li>Lymphoma s/p treatment show partial response.</li>
</ul></li>
<li>2021-07-26 Patho
<ul>
<li>Lung, right upper lobe, CT-guide biopsy - Extranodal marginal zone
lymphoma of MALT type with amyloidosis</li>
<li>The immunohistochemical analysis shows that these cells are positive
for CD20, bcl-2, and CD43, and negative for CD3, BCL6, and CD23. CD138
highlights increased plasma cells, but kappa and lambda are
inconclusive. CD68 is positive for the foreign-body giant cells. CK
highlights lymphoepithelial lesions.<br />
</li>
<li>Taken together, extranodal marginal zone lymphoma of MALT type with
amyloidosis is considered.<br />
</li>
</ul></li>
<li>2020-10-13 Patho
<ul>
<li>Lung, RUL, CT-guide biopsy - interstitial fibrosis and lymphoplasma
cells infiltration<br />
</li>
<li>The immunohistochemical stains of CD3, CD20, CD138, and Ki-67 show
mixed lymphoid and plasma cells population with lymphoid follicles.</li>
<li>The immunohistochemical stain of CK reveals no invasive tumor. No
amyloid deposition is seen.</li>
</ul></li>
</ul></li>
<li>Surgery
<ul>
<li>2019-12-30
<ul>
<li>One nodular lesion was noted over left apex of LUL, another one
nodule was noted over LUL, size about 0.8cm and 1.5 cm.</li>
<li>Frozen section: benign lesion.</li>
</ul></li>
</ul></li>
<li>Regimen
<ul>
<li>2021-08 ~ ongoing R-CVP (R-COP)
<ul>
<li>Rituximab 375mg/m2 IV D1</li>
<li>Cyclophosphamide 750mg/m2 IV D1</li>
<li>Vincristine 1.4mg/m2 IV D1</li>
<li>Prednisone 40mg/m2 PO D1-5</li>
<li>repeat every 21 days for a max of 8 cycles</li>
</ul></li>
</ul></li>
</ul>
<div id="section-831" class="section level3">
<h3>==========</h3>
</div>
<div id="section-832" class="section level3">
<h3>2022-01-27</h3>
<ul>
<li>This 80-year-old male patient was diagosed with extranodal marginal
zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 2021
summer, being receiving R-CVP since 2021-08 and partial response was
seen in early Jan 2022 based on CT and PET images.</li>
<li>R-CHOP, R-CVP (which is being usd now), Bendamustine + Rituximab,
are candidate regimen as first-line therapy. no issue with current
regimen.</li>
<li>Consolidation with rituximab 375mg/m2 one dose every 8~12wk for up
to 24 mo could be an optional extended therapy for future
consideration.</li>
</ul>
</div>
<div id="section-833" class="section level3">
<h3>2022-01-10</h3>
<p>COPD is listed as one of the diagnoses (but not in current problem
list) in this hospitalization, however no corresponding medication
prescribed yet.</p>
<p>Some bronchodilators such as beta agonists, antimuscarinic agents, or
methylxanthines might be considered later after other acute symptoms
mitigated.</p>
</div>
</div>
</div>
<div id="section-834" class="section level1">
<h1>700560024</h1>
<div id="section-835" class="section level2">
<h2>220125</h2>
<p>{marginal zone lymphomas}</p>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2021-09-14 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: lymphadenopathy in the axillary and abdominal regions,
involving both sides of diaphgrams.</li>
</ul></li>
<li>2021-09-07 Patho - lymphnode biopsy
<ul>
<li>Lymph node, axillary, left, biopsy - Small B-cell lymphoma,
compatible with marginal zone lymphoma.
<ul>
<li>Immunophenotyping: CK(-), CD3(-), CD20(+), CD5(-), CD23(+), CD43(-),
CD10(-/+), Cycline D1(-).</li>
</ul></li>
</ul></li>
<li>2020-11-20 Patho
<ul>
<li>Stomach, antrum, PW, biopsy - Suspicious lymphoid infiltrate,
probably extranodal marginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma) with Helicobacter pylori infection.
<ul>
<li>IHC, the small lymphoid cells: CD3(-), CD20(+), BCL2(+), CD5(-),
CD10(-), and CD43(-).</li>
</ul></li>
<li>Stomach, low body, GC side, biopsy - Suspicious lymphoid infiltrate,
probably extranodal marginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma) with Helicobacter pylori infection.
<ul>
<li>IHC, the small lymphoid cells: CD3(-), CD20(+), BCL2(+), CD5(-),
CD10(-), and CD43(-).</li>
</ul></li>
</ul></li>
</ul></li>
<li>treatment
<ul>
<li>2021-10 ~ ongoing - R-CHOP</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>first-line therapy regimens for marginal zone lymphomas could be:
<ul>
<li>CHOP(cyclophosphamide, doxorubicin, vincristine, prednisone) +
Rituximab</li>
<li>CVP(cyclophosphamide, vincristine, prednisone) + Rituximab</li>
<li>Bendamustine + Rituximab</li>
</ul></li>
<li>the patient is receiving R-CHOP without much intolerance.</li>
<li>no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-836" class="section level1">
<h1>700149178</h1>
<div id="section-837" class="section level2">
<h2>220124</h2>
<p>This 92-year-old woman diagnosed by NTUH in 2021 Dec wtih advanced
ascending colon cancer with lung, paraaortic LN, peritoneal
carcinomatosis, cT4aN2bM1c, stage IVC.</p>
<p>Take into account of the patient’s age, intensive therapy might not
be most appropriate, a vanilla regimen like FOLFOX could be a candidate
for systematic treatment.</p>
<p>KRAS, NRAS, BRAF, HER2, MSI/MMR, NTRK fusion, dihydropyrimidine
dehydrogenase test might be ordered optionally if related data from NTHU
is not anticipated.</p>
</div>
</div>
<div id="section-838" class="section level1">
<h1>700191057</h1>
<div id="section-839" class="section level2">
<h2>220124</h2>
<p>{lung cancer with bone and brain metastasis}</p>
<p>[lab data]</p>
<ul>
<li>PD-L1(28-8) 2021-04-08 TC &lt; 1%</li>
<li>ROS1 2021-03-24 not detected</li>
<li>PD-L1(22C3) 2021-03-22 TPS &lt; 1%</li>
<li>EGFR 2021-03-19 G719X not detected</li>
<li>EGFR 2021-03-19 Exon19 deletion not detected</li>
<li>EGFR 2021-03-19 S768I not detected</li>
<li>EGFR 2021-03-19 T790M not detected</li>
<li>EGFR 2021-03-19 Exon20 insertion not detected</li>
<li>EGFR 2021-03-19 L858R not detected</li>
<li>EGFR 2021-03-19 L861Q not detected</li>
<li>ALK IHC 2021-03-18 negative</li>
</ul>
<p>[exam findings] (not completed)</p>
<ul>
<li>2023-05-04 MRI - brain
<ul>
<li>Known a case of lung cancer with brain metastasis. As compared with
prior MRI (2023/03/08), disseminated leptomeningeal metastasis of whole
cerebrum. Metastatic lesions over cerebellum and both temporal lobes are
in worse condition.</li>
<li>Severe paranasal sinusitis.</li>
<li>Left mastoiditis.</li>
</ul></li>
<li>2023-05-02 CXR
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Diffuse Bony metastases.</li>
</ul></li>
<li>2023-03-14 MRI - C-spine
<ul>
<li>Several mass lesions within C4, C5, C6 and T1 vertebral bodies,
compatible with metastases.</li>
<li>No actual disk protrusion or cord compression.</li>
<li>The cervical spinal cord shows normal size and signal intensity
without evidence of compressive edema, ischemia or myelomalacia. There
is no extrinsic compresson of the cord.</li>
<li>The neural foramina of the cervical spine are patent. No impingement
is seen.</li>
</ul></li>
<li>2023-03-09 CT - chest
<ul>
<li>Indication: Lung cancer with bone and brain mets</li>
<li>Chest CT with and without IV contrast ehnancement shows:
<ul>
<li>s/p left upper lobe op.</li>
<li>Minimal atelectatic change at bilateral lower lobes is found.</li>
<li>S/p port-A placement with its tip at Superior vena cava</li>
<li>Non-specific lymph nodes are found at bilateral paratracheal
region.</li>
<li>Sclerotic and lytic changes of the bony structure is found. Bony
metastasis is considered.</li>
<li>s/p cholecystectomy.</li>
</ul></li>
<li>Imp:
<ul>
<li>s/p left upper lobe op.</li>
<li>Diffuse bone meta.</li>
<li>Non-specific lymph nodes at bilateral paratracheal region.</li>
</ul></li>
</ul></li>
<li>2023-03-08 MRI - brain
<ul>
<li>r/o leptomeningeal metastasis in the bilateral posterior cranial
fossa.</li>
</ul></li>
<li>2023-03-01 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 2022-12-05, all of
above-mentioned bone lesions are old and show stationary or less
evident, and no new lesion of increased tracer uptake is noted in this
study, indicating metastatic bone disease with partial response to
current therapy.</li>
</ul></li>
</ul>
<p>[immunochemotherapy]</p>
<ul>
<li>2022-01-21 ~ ongoing
<ul>
<li>Nivolumab + Ipilimumab + Pemetrexed + Carboplatin
<ul>
<li>Nivolumab 3mg/kg D1 Q3W</li>
<li>Ipilimumab 1mg/kg D1 Q6W</li>
<li>Pemetrexed 500mg/m2 D1 Q3W*2cycles</li>
<li>Carboplatin AUC 5~6 D1 Q3W*2cycles</li>
</ul></li>
</ul></li>
<li>2021-10-22 ~ 2022-01-04
<ul>
<li>Nivolumab + Ipilimumab
<ul>
<li>Nivolumab 3mg/kg D1 Q3W</li>
<li>Ipilimumab 1mg/kg D1 Q6W</li>
</ul></li>
</ul></li>
<li>2021-03-25 ~ 2021-10-21
<ul>
<li>Gefitinib 250mg QD</li>
</ul></li>
</ul>
<p>[consultation]</p>
<ul>
<li>2021-02-17 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>for suspect multiple myeloma, metastases</li>
<li>This 49-year-old female was Dx (1) Leukocytosis, suspect intra
abdominal infection (2) Suspect multiple myeloma, metastases (3)
Hypertension (4) Fracture of 7th ribs in 2020-12. This time, she was
admission because bilateral lower leg edema for two days. She complained
for lower back pain while mobile and right back sorenss for 3 months and
subside while lying down. She has suffered from fracture of left 7th rib
and right little toe pain and local redness. According to the patient,
she has visited Ortho OPD and Rheumatology OPD for the recurrent
multiple joint pain. She came to our ER. CT image revealed retroversion
of uterus with tumors (up to 6.3cm) suspected myomas and Multiple
osteolytic lesions at bony structures. DDX: multiple myeloma,
metastases. Please evaluation her condition by your expertise. Thank you
very much.</li>
</ul></li>
<li>A
<ul>
<li>Patient examined and Chart reviewed. A case of multiple bony
destruction is noted. I am consulted for the possible etiolgy.</li>
<li>My suggestions:
<ul>
<li>Complete CT scan work-up e.g., Chest CT, to rule out CEA-elevated
lung cancer or CEA/CA153-elevated breast cancer</li>
<li>Please survey breast conditin, using breast sono and/or mammography
to rule out CEA/CA153-elevated breast cancer</li>
<li>Please check Protein EP/IFE, kappa/lambda chain to rule out myelopma
or light chain disease</li>
<li>Please perform EGD and colonoscopy to rule out CEA-elevated GI
cancer</li>
<li>If no clue from the afroementioned examinations, bone marrow biopsy
is mandatory.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<div id="section-840" class="section level3">
<h3>==========</h3>
</div>
<div id="section-841" class="section level3">
<h3>2022-01-24</h3>
<ul>
<li>pembrolizumab is approved for NSCLC with PD-L1 expression levels ≥
1%, it is not the case here.</li>
<li>for NSCLC with no specific mutations, if progression on PD-1/PD-L1
inh, using a PD-1/PD-L1 inh might not be recommended.</li>
<li>there is no issue found in current medication.</li>
</ul>
</div>
</div>
</div>
<div id="section-842" class="section level1">
<h1>700974194</h1>
<div id="section-843" class="section level2">
<h2>220124</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 6 items.</p>
<p>the 4 identified items has been shown as following while the other 2
items still remain unknown: - Megajohn - megestrol 160mg - Kentamin -
thiamine 50mg, pyridoxine 50mg, cyanocobalamin 500mcg - Romicon-A -
lysozyme 20mg, dextromethorphan 20mg, cresolsulfonate 90mg - Olmetec -
olmesartan medoxomil 20mg</p>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-844" class="section level1">
<h1>701358139</h1>
<div id="section-845" class="section level2">
<h2>220124</h2>
<p>[objective]</p>
<p>This is a patient diagnosed by TSGH with poorly differential gastric
adenocarcinoma with carcinomatosis and metastatic lymphadenopathy and
bone metastasis, cT4aN3aM1, stage IV, seeking for second opinion on
2022-01-21.</p>
<ul>
<li>Lab readings:
<ul>
<li>2022-01-22 Urine: Bacteria 2+</li>
<li>2022-01-22 Abdomen - standing diaphragm: Ascites is highly
suspected.</li>
<li>2022-01-22 Chest PA - erect view:
<ul>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
<li>Discoid atelectasis in LLL of the lung is suspected.</li>
</ul></li>
<li>2022-01-21 Blood K 3.0mmol</li>
<li>2022-01-21 Blood gas - vein:
<ul>
<li>PO2 65mmHg</li>
<li>O2 Saturation 92%</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>fluid balance, hypokalemia
<ul>
<li>NAKO No.5</li>
<li>KCl inj</li>
<li>Radi-K</li>
<li>Spironolactone</li>
</ul></li>
</ul></li>
</ul>
<p>[Assessment]</p>
<ul>
<li>Empirical ABX might be considered if applicable based on symptoms
prior to culture outcome.</li>
<li>The following tests could be optionally ordered for future therapy
choice if no related data gathered from TSGH.
<ul>
<li>Microsatellite Instability (MSI) or Mismatch Repair (MMR)</li>
<li>PD-L1</li>
<li>HER2, high tumor mutation burden, NTRK gene fusion</li>
</ul></li>
<li>Mirabegron (beta-3 agonist) might diminish the antihypertensive
effect of Doxazosin (alpha-1 blocker).</li>
<li>The mirabegron prescribing information reports dose-dependent
increases in blood pressure with use. In healthy volunteers mirabegron
(at doses of up to 50 mg) produced mean maximum increases in
systolic/diastolic blood pressure of 3.5/1.5 mm Hg versus placebo.
However, in overactive bladder (OAB) patients, including those with
pre-existing hypertension, receiving a maximum dose of mirabegron 50 mg,
the systolic/diastolic blood pressure was only 0.5 to 1 mm Hg greater
than placebo. OAB patients infrequently reported worsening of
pre-existing hypertension with mirabegron. Both systolic and diastolic
blood pressure increases were reversible with the discontinuation of
mirabegron.</li>
<li>Lab data serum potassium 3.0mmol/L reported on 2022-01-24 showed the
reading below normal range (3.5~5.1), KCl inj and potassium sparing
diuretic Spironolactone have been prescribed.</li>
</ul>
</div>
</div>
<div id="section-846" class="section level1">
<h1>701164753</h1>
<div id="section-847" class="section level2">
<h2>220120</h2>
<ul>
<li><p>Diagnosis: Splenic flexure colon obstruction and massive ascites
suspected carcinomatosis status post T-loop colostomy on
2021-08-27.</p></li>
<li><p>2021-08-30 Patho - omentum tumor, extensive resection</p>
<ul>
<li>Omentum, frozen section + end transverse colostomy - Metastatic
adenocarcinoma.</li>
</ul></li>
<li><p>2021-08-25 Patho - colorectal polyp</p>
<ul>
<li>IHC: CK(+), CK7(-), CK20(-), CDX2(+), CD56(-), LCA(-), PSA(-), and
AMACR(-).
<ul>
<li>The morphology and immunohistochemical stains are not typical for
colonic adenocarcinoma.</li>
<li>The CDX2 is positive, in favor of GI tract, pancreas, and biliary
tract.</li>
<li>The PAS and AMACR are negative, so disfavor prostate origin.</li>
<li>The CD56 and LCA are negative, so disfavor neuroendocrine tumor and
lymphoma.</li>
<li>Please correlate with the clinical presentaion, and image study,
such as PET or gastroscope, for tumor origin.</li>
</ul></li>
</ul></li>
<li><p>Medication</p>
<ul>
<li>2021-09 ~ gogoing - FOLFIRI (plus bevacizumab since 2021-10)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-848" class="section level1">
<h1>701313105</h1>
<div id="section-849" class="section level2">
<h2>220120</h2>
<ul>
<li>Lab
<ul>
<li>2021-08 Patho - overy tumor
<ul>
<li>IHC: CK7 (+), CK20 (-), p53 (-), Napsin-A(-), WT-1 (-).</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>20210823 ~ ongoing - Paclitaxel, Carboplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-850" class="section level1">
<h1>700042050</h1>
<div id="section-851" class="section level2">
<h2>220119</h2>
<p>[objective]</p>
<ul>
<li>lab data:
<ul>
<li>Na 2022-01-18 125mmol/L</li>
<li>K 2022-01-18 2.7mmol/L</li>
<li>Mg 2022-01-18 1.8mg/dL</li>
<li>Free T4
<ul>
<li>2021-10-15 1.3ng/dL</li>
<li>2021-08-17 0.95ng/dL</li>
</ul></li>
<li>TSH
<ul>
<li>2021-10-15 14.46uIU/mL</li>
<li>2021-08-17 0.117uIU/mL</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>Radi-K (potassium gluconate)</li>
<li>MgO</li>
<li>Eltroxin (levothyroxine)</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>In addition to current Radi-K administration, the low serum K might
be induced by low serum Mg, bioavailability of Mg from oral MgO is
around 5~10%, MgSO4 Inj might be considered to pump up serum Mg more
rapidly.</li>
<li>Last thyroid hormone related lab records were taken more than 3
months ago, there is no updated data to follow up the hyped TSH, which
could be ordered if no contraindication.</li>
</ul>
</div>
</div>
<div id="section-852" class="section level1">
<h1>700073358</h1>
<div id="section-853" class="section level2">
<h2>220119</h2>
<ul>
<li><p>no drug allergy recorded in database.</p></li>
<li><p>CBC reported on 2022-01-18 showed items below normal ranges:</p>
<ul>
<li>WBC 2.96*10^3/uL</li>
<li>RBC 3.47*10^6/uL</li>
<li>HGB 11.8g/dL</li>
</ul></li>
<li><p>no liver or kidney dysfuncion shown in recent lab data.</p></li>
<li><p>the drugs prescribed at neurology OPD have been included in
active medication, no issue found.</p></li>
</ul>
</div>
</div>
<div id="section-854" class="section level1">
<h1>701011322</h1>
<div id="section-855" class="section level2">
<h2>220119</h2>
<ul>
<li><p>CBC reported on 2022-01-18 showed items below normal ranges:</p>
<ul>
<li>WBC 3.17*10^3/uL (Neutrophil 65%)</li>
<li>RBC 3.27*10^6/uL</li>
<li>HGB 8.6g/dL</li>
<li>PLT 73*10^3/uL</li>
</ul></li>
<li><p>no drug allergy recorded in database.</p></li>
<li><p>no liver or kidney dysfuncion shown in recent lab data based on
AST, ALT, BUN, Creatinine, eGFR.</p></li>
<li><p>no issue found in active medication.</p></li>
</ul>
</div>
</div>
<div id="section-856" class="section level1">
<h1>700145757</h1>
<div id="section-857" class="section level2">
<h2>220118</h2>
<p>[objective]</p>
<p>Lab data - Free T4 - 2022-01-14 2.26ng/dL (normal 0.58~1.35) -
2021-10-05 1.94ng/dL - TSH - 2022-01-14 0.027uIU/mL (normal 0.38~5.33) -
2021-10-05 &lt;0.005uIU/mL</p>
<p>PE - body weight - 2022-01-14 65kgw - 2022-01-09 68kgw</p>
<p>Medication - Eltroxin (levothyroxine 50mcg/tab) #1 BIDAC</p>
<p>[assessment]</p>
<ul>
<li>The patient is diagnosed with nontoxic goiter.</li>
<li>Thyroid dysfunction - If the goiter is due to Hashimoto’s
thyroiditis or severe iodine deficiency, patients may have symptoms of
hypothyroidism (eg, fatigue, constipation, cold intolerance). If due to
multinodular goiter (with autonomy) or Graves’ disease, patients may
have symptoms of hyperthyroidism (eg, palpitations, dyspnea on exertion,
unexplained weight loss).</li>
<li>Low TSH, high free T4, weight loss reported.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Eltroxin tapered to QDAC or Q2DAC and then test TSH, free T4 one
week later to check the trend.</li>
</ul>
</div>
</div>
<div id="section-858" class="section level1">
<h1>700712820</h1>
<div id="section-859" class="section level2">
<h2>220112</h2>
<ul>
<li>2022-01-11 CT: Brain
<ul>
<li>Imp: Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2021-10-27 MRA: Brain
<ul>
<li>Imp: Brain metastases. General brain atrophy. Hydrocephalus.
Leukoaraiosis.</li>
</ul></li>
<li>2021-08-17 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
<li>2021-08-16 PD-L1 (SP142)
<ul>
<li>Tumor type: formalin fixed paraffin embedded tissue block -
peritoneal and omental tumor (lung adenocarcinoma metastasis)<br />
</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells): Yes</li>
<li>Result
<ul>
<li>Tumor cell (TC) staining assessment:
<ul>
<li>TC category: TC &lt; 1%<br />
</li>
<li>Percentage of PD-L1 expressing tumor cells (%TC): 0%<br />
</li>
</ul></li>
<li>Tumor-infiltrating immune cell (IC) staining assessment:
<ul>
<li>IC category: IC &lt; 1%<br />
</li>
<li>Proportion of tumor area occupied by PD-L1 expressing
tumor-infiltrating immune cells (% IC): 0%<br />
</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.<br />
</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-08-11 Pathology - peritoneum biopsy
<ul>
<li>Labeled as “diffuse seeding tumor over peritoneum and omentum”,
biopsy — adenocarcinoma.</li>
<li>IHC stains:
<ul>
<li>CK7 (+), CK20 (-): disfavor gastrointestinal origin;</li>
<li>PAX-8 (-), WT-1 (-): disfavor ovarian origin;</li>
<li>TTF-1 (+): comaptible with pulmonanry origin.</li>
</ul></li>
</ul></li>
<li>2021-08-10 Cell block - 50 cc orange cloudy pleural effusion
<ul>
<li>The smears and cell block show lymphocytes, reactive mesothelial
cells and many hyperchromatic atypical epithelial cell clusters,
compatible with pulmonary adenocarcinoma.</li>
</ul></li>
<li>2021-08-09 Surgery - laparoscopic peritoneal tumor biopsy
<ul>
<li>Finding: multiple seeding tumors over liver surface, omentum,
peritoneum, and mesentary</li>
</ul></li>
</ul>
<div id="section-860" class="section level3">
<h3>==========</h3>
</div>
<div id="section-861" class="section level3">
<h3>2022-01-12</h3>
<p>[hyponatremia, hypoosmolality]</p>
<p>objective</p>
<ul>
<li>lab data
<ul>
<li>2022-01-12 blood osmolality 254mOsm/Kg (normal 275~295)</li>
<li>2022-01-12 blood sodium 119mmol/L (normal 136-145)</li>
</ul></li>
<li>body weight
<ul>
<li>2022-01-11 54kgw</li>
<li>2022-01-04 58kgw</li>
</ul></li>
<li>medication
<ul>
<li>3% NaCl 300mL IVD QD</li>
<li>Saline 0.9% 500mL IVD QD</li>
</ul></li>
</ul>
<p>assessment</p>
<ul>
<li>body weight decreased 4kgw within a week might hint some kind of
volume depletion.</li>
<li>solute repletion with administering 0.9% and 3% NaCl as of
2022-01-12.</li>
<li>reference: <a href="https://sci-hub.se/10.1016/S0889-8529(03)00004-5" class="uri">https://sci-hub.se/10.1016/S0889-8529(03)00004-5</a></li>
</ul>
<p>suggestion</p>
<ul>
<li>no issue found in current medication.</li>
<li>recheck serum sodium as regular until problem solved.</li>
<li>might need to evaluate etiology of depletion hypoosmolality.</li>
</ul>
</div>
<div id="section-862" class="section level3">
<h3>2021-08-24</h3>
<p>[initial presentation]</p>
<ul>
<li>2021-01-22 left back pain for 1 year -&gt; congenital
spondylolisthesis</li>
<li>2021-07-09 left flank region pain in recent days, AZ covid-19
vaccination on 2021-06-21.</li>
<li>2021-07-16 remained abdominal pain, multiple, no obvious tenderness,
migratory abdominal pain, radiating to perineum region on left, tingling
sensation.</li>
</ul>
<p>[definite diagnosis &amp; disease extent]</p>
<ul>
<li>2021-07-16 CT - whole abdomen, pelvis:
<ul>
<li>carcinomatosis is suspected.</li>
<li>metastases on both hepatic lobes are suspected.</li>
<li>tumor seeding in left CP angle pleura is suspected.
<ul>
<li>lung cancer 1.7 cm in LLL of the lung is suspected.</li>
</ul></li>
</ul></li>
<li>2021-07-20 abdominal ultrasound:
<ul>
<li>hepatic tumor, multiple, probably metastatic tumor</li>
<li>dilated CBD, ascites, left pleural effusion</li>
</ul></li>
<li>2021-07-22 CT - lung/mediastinum/pleura
<ul>
<li>left upper lobe tumor, suspected lung cancer T2N2Mx</li>
<li>cancerous peritonitis and liver mets, suspected GI origin.</li>
</ul></li>
<li>2021-07-22 lab:
<ul>
<li>AFP 4.4 ng/mL WNL</li>
<li>CEA 107ng/mL &gt; ULN</li>
<li>CA125 474U/mL &gt; ULN</li>
<li>CA199 65U/mL &gt; ULN</li>
<li>CA153 114U/mL &gt; ULN</li>
<li>SCC 1.1ng/mL WNL</li>
</ul></li>
<li>2021-07-23 cytology - ascites:
<ul>
<li>abundant high-grade atypical cells with nuclear hyperchromasia,
pleomorphism and prominent nucleoli.</li>
</ul></li>
<li>2021-07-26 colonoscopy:
<ul>
<li>colon polyp, suspected adenoma, ascending colon, s/p cold snare
polypectomy.</li>
<li>diverticula, cecum and ascending colon.</li>
</ul></li>
</ul>
<p>[plan &amp; treatment]</p>
<p>[effect &amp; side effect]</p>
<p>[ongoing problem]</p>
</div>
</div>
</div>
<div id="section-863" class="section level1">
<h1>700527901</h1>
<div id="section-864" class="section level2">
<h2>220111</h2>
<p>{Diffuse Large B Cell Lymphoma}</p>
<p>[objective]</p>
<ul>
<li>MRI reported on 2021-12-28
<ul>
<li>Tonsillar fossa, 2cm &lt; size &lt; 4cm, no regional nodal
metastasis, T2N0M0</li>
</ul></li>
<li>patho reported on 2021-12-30 - right tonsil biopsy
<ul>
<li>Diagnosis: diffuse large B cell lymphoma</li>
<li>IHC: CD20(+), CD3(-), CD10(-), CD30(-), CK(-), Bcl-2(+), Bcl-6(+,
focal), C-MYC(+, 30-40%), Ki-67 70-80% for tumor</li>
</ul></li>
<li>LDH reported on 2022-01-10 136U/L (normal 140~271)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>B-cell lymphomas with translocations of MYC and BCL2 and/or BCL6
(double-/triple-hit lymphoma), elevated LDH not seen, bone marrow and
CNS involvement not checked.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no drug allergy recorded in database, no issue found in active
medication.</li>
<li>if localized high-grade B-cell lymphomas is confirmed, then
consolidative ISRT might be considered.</li>
</ul>
</div>
</div>
<div id="section-865" class="section level1">
<h1>700766397</h1>
<div id="section-866" class="section level2">
<h2>220111</h2>
<p>CT and MRI on 2022-01-05 suggested possible malignant tumor in the
right adrenal gland measuring 8.2 x 10 x 9 cm.</p>
<p>Chromogranin A 918ng/mL, ACTH &lt; 5g/mL</p>
<p>lab data in early Jan 2022 did not backup hyperaldosteronism,
hypercortisonlemia (i.e. both in normal range).</p>
<p>hypertenstion and/or tachycardia might have been mitigated by Concor
(bisoprolol), higher readings of blood sugar (since mid Dec 2021) might
have been reduced by Galvus Met (vildagliptin + metformin), these
symptoms could be caused by neuroendocrine tumors.</p>
</div>
</div>
<div id="section-867" class="section level1">
<h1>701273730</h1>
<div id="section-868" class="section level2">
<h2>220110</h2>
<p>{Cancer of Unknown Primary}</p>
<ul>
<li>Additional reference
<ul>
<li>Cancer of Unknown Primary: A Review on Clinical Guidelines in the
Development and Targeted Management of Patients with the Unknown Primary
Site
<ul>
<li>source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820325/pdf/cureus-0011-00000005552.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820325/pdf/cureus-0011-00000005552.pdf</a></li>
</ul></li>
<li>NCCN Clinical Practice Guideline - Occult Primary (Cancer of Unknown
Primary [CUP])
<ul>
<li>source: <a href="https://www.nccn.org/professionals/physician_gls/pdf/occult_blocks.pdf" class="uri">https://www.nccn.org/professionals/physician_gls/pdf/occult_blocks.pdf</a></li>
</ul></li>
<li>Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?
<ul>
<li>source: <a href="https://sci-hub.se/10.7150/jca.42880" class="uri">https://sci-hub.se/10.7150/jca.42880</a></li>
</ul></li>
<li>Cancer of Unknown Primary Sites: What Radiologists Need to Know and
What Oncologists Want to Know
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603700/pdf/nihms449402.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603700/pdf/nihms449402.pdf</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-869" class="section level1">
<h1>701356176</h1>
<div id="section-870" class="section level2">
<h2>220110</h2>
<p>[Objective]</p>
<p>Lab data reported on 2022-01-10 and some prescribed medication: - CRP
9.17mg/dL (normal &lt;1), WBC 166*10^3/uL (normal 3.9~10.6) &lt;=
Tapimycin (Piperacillin + Tazobactam) - Blood Uric Acid 16.3mg/dL
(normal 4.4~7.6) &lt;= Fasturtec (Rasburicase) - Calcium 4.04 mmol/L
(normal 2.2~2.65) &lt;= Miacalcic (Calcitonin) - Magnesium 1.4mg/dL
(normal 1.9~2.7) - Triglyceride (TG) 524mg/dL (normal &lt;150), HDL-C
5mg/dL (normal &gt;40) - Benz(BZO) intoxication positive (normal
negative)</p>
<p>[Assessment/Suggestion]</p>
<ul>
<li>MgO might be considered for hypomagnesemia.</li>
<li>Flumazenil might be considered for benzodiazepine intoxication.
<ul>
<li>Unable to access PharmaCloud now, might need to find out why
intoxication happened.</li>
</ul></li>
<li>Statins might be considered for hypertriglyceridemia later after
acute symptoms been controlled.</li>
</ul>
</div>
</div>
<div id="section-871" class="section level1">
<h1>700404241</h1>
<div id="section-872" class="section level2">
<h2>220107</h2>
<p>[Objective]</p>
<ul>
<li>Adenocarcinoma of descending-sigmoid colon with partial obstruction
status post laparoscopic left hemicolectomy on 2021-10-13, pT3N1aM0,
pStage IIIB.
<ul>
<li>IHC stains: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+) based on
colon segmental resection, reported on 2021-10-20.</li>
</ul></li>
<li>Chronic viral hepatitis B without delta-agent.</li>
<li>Lab data reported on 2022-01-04 showing basically normal readings at
CBC, WBC, ALT, AST, bilirubin total, creatinine, eGFR, and slightly
elevated BUN 30mg/dL.</li>
<li>All RAS and BRAF mutation not detected, reported on 2021-11-03.</li>
</ul>
<p>[Assessment]</p>
<ul>
<li>FOLFOX 3-6 mo or CAPEOX 3 mo is preferred as adjuvant treatment for
T3N1M0 colon cancer patients. This patient is now on FOLFOX course.</li>
<li>Nivolumab or Pembrolizumab might not be preferred for this pMMR
patient.</li>
<li>Panitumumab or Cetuximab might be applicable as RAS and BRAF proved
wildtype for the left-sided patient.</li>
<li>HER2, NTKR data not found yet.</li>
<li>Hepatitis B virus might reactivate in the setting of chemotherapy.
Baraclude (Entecavir) has been prescribed.</li>
</ul>
<p>[Suggestion]</p>
<ul>
<li>No issue found in active medication. Keep tracking CEA, CT as
regular.</li>
</ul>
</div>
</div>
<div id="section-873" class="section level1">
<h1>700098157</h1>
<div id="section-874" class="section level2">
<h2>220106</h2>
<p>High Serum glucose 235mg/dL (2022-01-05), Lactic Acid 4.9mmol/L
(2022-01-06), NAKO NO.5 500mL IVD BID and Saline 500mL IVD QD are
prescribed.</p>
<p>High CRP 13.47mg/dL (2022-01-05), Procalcitonin (PCT) 8.37ng/mL
(2022-01-06) suggest (probable bacterial) infectious process with
systemic consequences. Tapimycin and Targocid are prescribed.</p>
</div>
</div>
<div id="section-875" class="section level1">
<h1>700753433</h1>
<div id="section-876" class="section level2">
<h2>211019</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 7 items.</p>
<p>the 3 identified items has been shown as following while the other 4
items still remain unknown:</p>
<ul>
<li><p>Utapine F.C. Tablet (quetiapine fumarate 25mg) - bipolar
disorder, schizophrenia</p></li>
<li><p>Zoloft F.C. Tablet (sertraline hydrochloride 50mg) - major
depressive disorder (unipolar), obsessive-compulsive disorder, panic
disorder, posttraumatic stress disorder, premenstrual dysphoric
disorder, social anxiety disorder</p></li>
<li><p>Anxiedin Tablet (lorazepam 0.5mg) - anxiety</p></li>
</ul>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-877" class="section level1">
<h1>700029300</h1>
<div id="section-878" class="section level2">
<h2>210930</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 13 items.</p>
<p>the 9 identified items are listed as following, however, the other 4
items still remain unknown:</p>
<ul>
<li>Galvus Met (Metformin HCl 850mg, Vildagliptin 50mg)</li>
<li>Betmiga (Mirabegron 25mg)</li>
<li>Avodart (Dutasteride 0.5mg)</li>
<li>Mequitine (Mequitazine 5mg)</li>
<li>Co-Tareg (Valsartan 80mg, Hydrochlorothiazide 12.5mg)</li>
<li>Nonin (Glimepiride 2mg)</li>
<li>Bokey (Aspirin 100mg)</li>
<li>Crestor (Rosuvastatin 10mg)</li>
<li>Levozine (Levocetirizine 5mg)</li>
</ul>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-879" class="section level1">
<h1>700043762</h1>
<div id="section-880" class="section level2">
<h2>210928</h2>
<p>{potential drug interactions, vitamin supplement}</p>
<p>[objective]</p>
<ul>
<li>items listed in active medication including:
<ul>
<li>emetrol (domperidone 10mg/tab) 2 tab PO TIDAC</li>
<li>rivotril (clonazepam 0.5mg/tab) 1 tab PO HS</li>
<li>keppra (levetiracetam 100mg/ml) 3 ml PO BID</li>
<li>calquene (acalabrutinib 100mg) 1 tab PO Q12H</li>
</ul></li>
<li>lab data reported on 2021-09-25
<ul>
<li>gastric juice OB 3+</li>
<li>RBC 2.78*10^6/mL</li>
<li>HGB 9.8g/dL</li>
<li>MCV 101fL</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>there are drugs in active medication might have potential
interactions:
<ul>
<li>acalabrutinib &lt;&gt; lansoprazole
<ul>
<li>PPI might decrease the serum concentration of acalabrutinib.</li>
<li>with the long-lasting effect of PPIs, separation of doses might not
eliminate the interaction.</li>
<li>acalabrutinib AUC was decreased by 43% when co-administered with the
PPI omeprazole (40 mg for 5 days) according to studies of healthy
subjects. this decreases in acalabrutinib concentrations might reduce
acalabrutinib activity, so the acalabrutinib labeling recommends that if
treatment with a gastric acid reducing agent is required, a histamine-2
receptor antagonist (H2RA) or an antacid should be considered, with
separation of administration to minimize the likelihood of a significant
interaction.
<ul>
<li>reference: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf" class="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf</a></li>
</ul></li>
</ul></li>
<li>clonazepam &lt;&gt; levetiracetam
<ul>
<li>CNS depressants may enhance the adverse/toxic effect of other CNS
depressant</li>
</ul></li>
</ul></li>
<li>emetrol (domperidone) dosing
<ul>
<li>10mg x 3 times (max) a day stated in package insert, however,
prescirbed daily dose is 60mg.</li>
</ul></li>
<li>suspected GI bleeding
<ul>
<li>somewhat anemia, MCV reading above upper limit of normal.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>H2 antagonists such as cimetidine (stogamet 300mg/tab, tagamet
200mg/2ml/amp available in stock), famotidine (ulstop 20mg/tab, ulcertin
20mg/2ml/amp available), ranitidine (not available in hospital),
nizatidine (not available) could be considered to shift PPI off.</li>
<li>please monitor for additive CNS-depressant effects whenever two or
more CNS depressants are concomitantly used.</li>
<li>symptoms of domperidone overdosage may include agitation, altered
consciousness, convulsions, disorientation, somnolence and
extrapyramidal reactions. there is no specific antidote to domperidone,
but in the event of overdose, standard symptomatic treatment should be
given.</li>
<li>some vit B12, folic acid might help to increase HGB.</li>
</ul>
<p>thanks and regards,</p>
</div>
</div>
<div id="section-881" class="section level1">
<h1>700826905</h1>
<div id="section-882" class="section level2">
<h2>210927</h2>
<p>{dedifferentiated liposarcoma}</p>
<p>[tube feeding]</p>
<ul>
<li>most oral drugs in active medication are patient-carried for her
underlying diseses, all the oral drugs can be administered via NG
tube.</li>
</ul>
<p>[objective]</p>
<ul>
<li>2021-04-22 patho - peritoneum biopsy
<ul>
<li>pathologic diagnosis: compatible with dedifferentiated
liposarcoma</li>
<li>composed of fascicles of markedly pleomorphic spindle tumor cells
embedded in myxoid stroma. subtle lipogenic tumor cells are found. foci
of tumor necrosis are present.</li>
<li>IHC: CK(-), S100(focal +), CD34(-), smooth muscle actin(-), MDM2
(+), and CDK4(+).</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>palbociclib might be considered for the treatment of unresectable
dedifferentiated liposarcoma
<ul>
<li>palbociclib, an inhibitor of cyclin-dependent kinases (CDKs) 4 and
6, induced objective tumor response and a favorable PFS of 56% to 66% in
patients with CDK-4-amplified, well-differentiated or dedifferentiated
liposarcoma in a phase II study.</li>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/23569312/" class="uri">https://pubmed.ncbi.nlm.nih.gov/23569312/</a></li>
</ul></li>
<li>pembrolizumab demostrated clinical activity in resectable
dedifferentiated liposarcoma with a 20% overall response rate in a phase
II study.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/30249211/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30249211/</a></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-883" class="section level1">
<h1>700054780</h1>
<div id="section-884" class="section level2">
<h2>210920</h2>
<div id="section-885" class="section level3">
<h3>==========</h3>
</div>
<div id="section-886" class="section level3">
<h3>2021-09-20</h3>
<p>[mesna compatibility for common solutions]</p>
<p>reply for the consultation from the ward, mesna is compatible with: -
D5W (Dextrose 5% in water) - D5NS (Dextrose 5% in sodium chloride 0.9%)
- D5W - 1/2 NS (Dextrose 5% in sodium chloride 0.45%) - NS (Normal
saline (Sodium chloride 0.9%)) - Lactated Ringer’s Injection</p>
</div>
<div id="section-887" class="section level3">
<h3>2021-09-15</h3>
<p>[post IPP meeting following up]</p>
<p>busulfan inventory</p>
<ul>
<li>the schedule and regimen for PBSCT for the patient was disclosed in
the meeting (with his spouse) held on 2021-09-15 10:30 in the ward.</li>
<li>the estimated total amount of busulfan used in the time table is 12
vials.
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
64.8kg</li>
<li>4 vials per day for 3 days (2021-09-16, 2021-09-17, 2021-09-18)</li>
<li>staff to dispense regimen during weekend are arranged.</li>
<li>stock in medicine storeroom has been confirmed enough in
quantity.</li>
</ul></li>
</ul>
<p>preparation and administration precautions</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 1.79m2 -&gt; amount
716mg.</li>
<li>total solution containing 716mg etoposide should be no less than
1790mL.</li>
</ul></li>
<li>mesna administration rate
<ul>
<li>where ifosfamide or cyclophosphamide is used (like this patient) as
an iv bolus:
<ul>
<li>mesna is given by intravenous injection over 15-30 minutes at 20% of
the simultaneously administered oxazaphosphorine on a weight for weight
basis (w/w). the same dose of mesna is repeated after 4 and 8 hours (as
listed in the regimen schedule).
<ul>
<li>reference: <a href="https://www.medicines.org.uk/emc/product/1838/smpc" class="uri">https://www.medicines.org.uk/emc/product/1838/smpc</a></li>
<li>reference: drug package insert</li>
</ul></li>
</ul></li>
<li>taking a conservative approach as conclusion, 30 minutes should be
safe for adult.</li>
</ul></li>
</ul>
<p>underlying diseases</p>
<ul>
<li>underlying diseases are managed with corresponding medicine without
issues.
<ul>
<li>HTN and CAD s/p stent splacement
<ul>
<li>concor (bisoprolol) 2.5mg PO QD</li>
<li>norvasc (amlodipine) 2.5mg PO QD</li>
<li>tulip (atorvastatin) 10mg PO QOD</li>
</ul></li>
<li>HBV infected
<ul>
<li>baraclude (entecavir) 0.5mg PO QDAC</li>
</ul></li>
<li>SLE
<ul>
<li>plaquenil (hydroxychloroquine) 200mg PO QOD</li>
</ul></li>
</ul></li>
</ul>
<p>medical compliance</p>
<ul>
<li>the patient showed somewhat self-assertive in the meeting, pleading
with tactful words might be needed to prevent potential undesired
events.</li>
</ul>
</div>
</div>
</div>
<div id="section-888" class="section level1">
<h1>700142452</h1>
<div id="section-889" class="section level2">
<h2>210915</h2>
<p>{hypoalbuminemia and proteinuria caused by UTI induced nephrotic
syndrome?}</p>
<p>[tube feeding]</p>
<ul>
<li>all the oral drugs in active medication can be administered via NG
tube.</li>
</ul>
<p>[objective]</p>
<ul>
<li>serum Ca 2.03mmol/L 2021-09-15</li>
<li>Creatine kinase-MB 25.7ng/mL 2021-09-14</li>
<li>creatinine 1.67mg/dL 2021-09-14</li>
<li>albumin 2.8g/dL 2021-09-14</li>
<li>CRP 4.87mg/dL 2021-09-14</li>
<li>urine data reported on 2021-09-14
<ul>
<li>PRO 2+</li>
<li>OB 2+</li>
<li>bacteria 3+</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>elevated CKMB reading could mean possible heart muscle damage.
(NT-proBNP 7946pg/mL 2020-02-09)</li>
<li>UTI is treated with Sintrix (Ceftriaxone Na) 1000mg IVD QD since
2021-09-15 for 7 days for now.</li>
<li>in patients with hypoalbuminemia, total serum calcium concentration
will change in parallel to the albumin concentration and may not
accurately reflect the physiologically important ionized (or free)
calcium concentration.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>heart condition might be followed up if no other
considerations.</li>
<li>first priority might be to mitigate UTI, please keep current
medication and monitoring the effects routinely as usual.</li>
<li>urine culture might be of help to choose more adequate antimicrobial
in the coming days.</li>
</ul>
</div>
</div>
<div id="section-890" class="section level1">
<h1>701331484</h1>
<div id="section-891" class="section level2">
<h2>210914</h2>
<p>[tube feeding]</p>
<ul>
<li>all the oral drugs in active medication can be administered with NG
tube.</li>
</ul>
<p>[iron supplement]</p>
<ul>
<li>foliromin is prescribed.<br />
</li>
<li>coadministration ferrous suppement with vit. C would somewhat
increase iron intake.
<ul>
<li>source
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/2507689/" class="uri">https://pubmed.ncbi.nlm.nih.gov/2507689/</a></li>
<li><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772395" class="uri">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772395</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-892" class="section level1">
<h1>700842358</h1>
<div id="section-893" class="section level2">
<h2>210913</h2>
<p>[drug interaction]</p>
<ul>
<li>total 22 items in active medication (indlucing 3 in-hospital
prescribed and 19 patient-carried drugs) have been reviewed without
combinations to be avoided.</li>
</ul>
<p>[objective]</p>
<ul>
<li>CKD stage 3 management at Shuang Ho Hospital</li>
<li>patient-carried drug Furide (furosemide) 40mg QD listed in active
medication.</li>
<li>lab data reported on 2021-09-13 showed readings above normal limits
<ul>
<li>creatinine 4.83mg/dL</li>
<li>eGFR 12.58</li>
<li>BUN 78mg/dL</li>
<li>Bil T 15.42mg/dL</li>
<li>Bil D 8.89mg/dL</li>
<li>Alkaline phosphatase 243IU/L</li>
</ul></li>
<li>serum electrolytes Na, K reported on 2021-09-13 showed normal.</li>
<li>relatively low blood pressure recorded on 2021-09-11, -09-12</li>
</ul>
<p>[assessment]</p>
<ul>
<li>this patient’s liver and kidney functions are somewhat
impaired.</li>
<li>furosemide
<ul>
<li>for a patient with eGFR &lt;= 30 mL/minute/1.73m2, higher doses may
be required to achieve desired diuretic response due to decreased
secretion into the tubular fluid. however, single doses &gt;160 to 200
mg are unlikely to result in additional diuretic effect.</li>
<li>diminished natriuretic effect with increased sensitivity to
hypokalemia and volume depletion in cirrhosis.</li>
</ul></li>
<li>diuretics
<ul>
<li>dosing is empiric and frequently determined by the elimination of
edema for CKD stage 4 to 5.</li>
<li>spironolactone leads to natriuretic response in patients with
cirrhosis and ascites or heart failure, particularly used with a loop or
a thiazide-type diuretic or both.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor furosemide effect to see if dose increasing or
considering spironolactone is needed.</li>
</ul>
</div>
</div>
<div id="section-894" class="section level1">
<h1>700640254</h1>
<div id="section-895" class="section level2">
<h2>210907</h2>
<p>{ovary cancer s/p debulking surgery}</p>
<p>[history]</p>
<ul>
<li>laparoscopic myomectomy 10 years ago.</li>
</ul>
<p>[initial presentation]</p>
<ul>
<li>abdominal fullness with palpable mass over right side, poor
appetite, easily fullness and nausea sensation when eat a lot, less
urine output with voiding hesitation, back soreness and excertional
dyspnea since 2021-06.</li>
<li>constipation since 2021-07.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-07-27 abdominal ultrasound
<ul>
<li>cystic lesion, suspected cystic tumor, lower abdomen</li>
</ul></li>
<li>2021-07-28 CT - whole abdomen, pelvis
<ul>
<li>findings
<ul>
<li>a lobulated cystic mass with enhancing mural nodules and few septa
in the lower abodmen and pelvis, measuring 20.6 x 12.8 x 26 cm (width x
depth x cranial-caudal length). cystic adenocarcinoma of the right ovary
is highly suspected.</li>
<li>soft tissue nodules and fatty stranding in the omentum of right
middle abdomen that may be carcinomatosis. correlate with
peritoneoscopy.</li>
<li>poor enhancing lesions in the uterus that are compatible with
myomas. ill-defined enhancing lesions in the uterine myometrium that are
compatible with adenomyosis.</li>
</ul></li>
<li>image stage
<ul>
<li>T1aN0M0, stage IA</li>
</ul></li>
</ul></li>
<li>2021-08-16 patho - ovary tumor
<ul>
<li>histologic type: clear cell carcinoma</li>
<li>histologic grade: high grade</li>
<li>regional lymph nodes: left iliac: 0/1; left obturator: 0/3; right
iliac: 0/3; right obturator: 0/6; left paraaortic: 0/1; right
para-aortic: 0/1.</li>
<li>leiomyomas and endometriosis are seen in myometrium. endometrioma is
found in left ovary.</li>
<li>aggregation of histiocytes is present in the omentum.</li>
<li>IHC stains: PAX8(+), Napsin A(+), WT-1(-), PR(-), and p53(-).</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-08-16 debulking surgery (ATH + BSO + cytoreduction surgery +
omentectomy + LN dissection)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>clear cell carcinoma of the ovary is a relatively less common
ovarian cancer, since the patient is just in her early fifties, her
liver and kidney functions showed no abnormality (lab data reported on
2021-08-13), IV platinum-based therapy might be applicable.
<ul>
<li>paclitaxel + carboplatin every 3 weeks for 3 to 6 cycles (hearing
test done 2021-09-07 morning)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-896" class="section level1">
<h1>701205775</h1>
<div id="section-897" class="section level2">
<h2>210907</h2>
<p>{unresectable liver tumor}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-08-26 coffee ground vomiting, gastrointestinal hemorrhage,
hypovolemic shock.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-08-27 abdominal ultrasound
<ul>
<li>liver tumors, both lobe</li>
<li>parenchymal liver disease</li>
<li>cholecystopathy</li>
<li>minimal ascites</li>
</ul></li>
<li>2021-08-27 CT - whole abdomen, pelvis
<ul>
<li>findings:
<ul>
<li>lobulated patchy geographic poor enhancing cystic-like lesions in
right lobe and S4 of the liver, the largest one measuring 14.3 cm in the
largest dimension, with patent flow of both lobe portal vein and hepatic
vein.</li>
<li>several enlarged nodes in the hepatoduodenal ligament are noted and
the largest one measuring 2.5 cm that may be metastatic nodes?</li>
<li>liver infarction is highly suspected?</li>
<li>the differential diagnosis include angiosarcoma,
poorly-differentiated HCCs, and metastases.</li>
<li>the liver shows irregular contour that may be cirrhosis. enlarged of
the spleen (long axis: 12 cm) and minimal ascites in right subphrenic
and right perihepatic space that may be portal hypertension.</li>
</ul></li>
<li>imaging stage:
<ul>
<li>T3N1M0, stage IVA.</li>
</ul></li>
</ul></li>
<li>2021-08-30 patho - liver biopsy needle/wedge, sono-guided aspiration
<ul>
<li>hepatocellular carcinoma, composed of nests of well differentiated
neoplastic hepatocytes, arranged in pseudoglandular and trabecular
patterns. extensive coagulative necrosis and hemorrhage are
present.</li>
</ul></li>
<li>2021-08-30 MRI - liver, spleen
<ul>
<li>bil. liver tumors, angiosarcoma is first considered.</li>
</ul></li>
</ul>
<p>[underlying disease]</p>
<ul>
<li>T2DM, GERD, HTN, hyperlipidemia</li>
</ul>
<p>[assessment]</p>
<ul>
<li>liver tumor
<ul>
<li>tumor too large to be resectable (low anticipated liver reserve and
remnant). this patient is in her early sixties with multiple
comorbidities (and probable portal hypertenstion), being a candidate for
transplant might be an option but not a highly realistic one.</li>
<li>limiting tumor growth or downsizing it to mitigate possible
encephalopathy, ascites, hypoalbuminemia, prolonged prothrombin time,
hyperbilirubinemia, would be on a general right track in a short-term to
medium-term time scale.</li>
<li>bevacizumab might not be applicable at the present time for its
possible cardiovascular (heart failure), GI (perforation), HTN,
hemorrhage adverse reactions.</li>
<li>patient-carried stivarga (regorafenib 40mg PO QD) has been listed in
active medication since 2021-09-01 during this hospitalization.</li>
</ul></li>
<li>current symptoms and most of underlying diseases are managed under
following drugs without issues:
<ul>
<li>encephalopathy
<ul>
<li>lactul (lactulose) 13.32g PO QD</li>
</ul></li>
<li>prolonged prothrombin time
<ul>
<li>katimin (phytomenadione) 10mg IVD QD</li>
</ul></li>
<li>cachexia
<ul>
<li>megest (megestrol) 160mg PO TID</li>
</ul></li>
<li>edema, ascite
<ul>
<li>plasbumin (human albumin) 50ml IVD BID</li>
<li>furosemide 20mg IVD BID</li>
<li>spironolactone 25mg PO BID</li>
</ul></li>
<li>GERD
<ul>
<li>takepron (lansoprazole) 30mg PO QDAC</li>
</ul></li>
<li>HTN
<ul>
<li>concor (bisoprolol) 1.25mg PO BID</li>
</ul></li>
<li>T2DM
<ul>
<li>actrapid hm insulin 4unit SC BIDAC</li>
<li>relinide (repaglinide) 1mg PO TIDAC15</li>
<li>trajenta (linagliptin) 5mg PO QDAC</li>
</ul></li>
</ul></li>
<li>pravafen (pravastatin 40mg, fenofibrate 160mg) QD for hyperlipidemia
(lab data on 2021-08-05 remained high readings) listed in PharmaCloud
could be considered to add to active medication as a patient-carried
item.</li>
</ul>
</div>
</div>
<div id="section-898" class="section level1">
<h1>700965860</h1>
<div id="section-899" class="section level2">
<h2>210906</h2>
<p>{colon cancer with suspected liver mets and peritoneal seeding}</p>
<p>[initial presentation]</p>
<ul>
<li>2020-11 underwent a health examination arranged by the company and
found multiple liver nodules (2.7 cm).</li>
<li>2021-05 began to suffer from abdominal cramps after eating (below
umbilicus) and the symptom can be relieved after defecation.
<ul>
<li>no radiation pain, abdominal distension, burning sensation, nausea,
vomiting, diarrhea, constipation, appetite change.</li>
</ul></li>
<li>2021-08 LMD abdomenal echo found multiple liver tumors.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-08-18 abdominal ultrasound
<ul>
<li>liver tumors, multiple, suspect metastasis</li>
<li>several mixed echoic tumors with peripheral low echogenicity, and
the largest one 8 cm x 3.9 cm was at S4/8</li>
</ul></li>
<li>2021-08-19 CT, ABD - liver, spleen, biliary duct, pancreas
<ul>
<li>multiple liver tumors suspected metastases.</li>
<li>wall thickening of cecum and S-colon.</li>
<li>a soft tissue nodule (1.3cm) in pelvic cavity suspected tumor
seeding.</li>
<li>some LNs at paraaortic region suspected metastases.</li>
</ul></li>
<li>2021-08-20 coloscopy
<ul>
<li>suspect colon cancer with impending obstruction, sigmoid colon, 30cm
above AV, s/p biopsy</li>
<li>a large ulcerative tumor involving the whole circumference with
lumen narrowing and the scope can not pass through it, s/p biopsy</li>
</ul></li>
<li>2021-08-23 patho - colon biopsy
<ul>
<li>adenocarcinoma - pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>IHC stains: EGFR(+), PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>staging workup is ongoing.
<ul>
<li>liver mets and peritoneal seeding are suspected, should be stage IVC
if both confirmed positive.</li>
</ul></li>
<li>diverting ostomy or bypass or stenting might be indicated for
imminent obstruction at colon lesion.</li>
<li>liver and kidney functions showed no abnormality (lab data on
2021-09-06, 2021-08-16); neither HBV nor HCV was active; systemic
therapy would be indicated for this chemo-naive patient.
<ul>
<li>FOLFOX or CAPEOX could be an option, bevacizumab could also be
added.</li>
<li>pembrolizumab, nivolumab might not be indicated for pMMR (PMS2(+),
MSH6(+), MSH2(+), MLH1(+)).</li>
</ul></li>
<li>KRAS/NRAS/BRAF lab data not found in chart yet.</li>
</ul>
</div>
</div>
<div id="section-900" class="section level1">
<h1>700261411</h1>
<div id="section-901" class="section level2">
<h2>210901</h2>
<p>{hypophosphatemia, hypokalemia}</p>
<p>[objective]</p>
<ul>
<li>lab data reported on 2021-09-01
<ul>
<li>K(Potassium) 3.0mmol/L, normal 3.5-5.1</li>
<li>P(Phosphous) 1.7mg/dL, normal 2.5-5.0</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>available drug
<ul>
<li>potassium phosphate injection 20mL/amp which contains K 88mEq and P
60mM.</li>
</ul></li>
<li>dosing
<ul>
<li>for patients with mild to moderate hypokalemia (serum potassium 3.0
to 3.4 mEq/L) who do not have ongoing urinary potassium losses, initial
administration of 20 to 80 mEq/day is recommended.</li>
<li>serum phosphate level 1.5 to 2.2 mg/dL, initial 0.16 to 0.32 mmol/kg
(12.8mmol to 25.6mmol for this 80kg patient) over 4 to 6 hours.</li>
</ul></li>
<li>stability
<ul>
<li>must dilute in NS or D5W to a total volume of 100mL or 250mL</li>
<li>for IV infusion only into a central or peripheral vein</li>
<li>do not infuse with calcium-containing intravenous fluids</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>half to one ampoule of 20mL potassium phosphate in no less than
100mL NS or 250mL D5W infusion 4 to 6 hours is recommended.</li>
<li>please monitor serum K, P and EKG routinely to check if the
intervention gets the readings back to normal.</li>
</ul>
</div>
</div>
<div id="section-902" class="section level1">
<h1>700990402</h1>
<div id="section-903" class="section level2">
<h2>210831</h2>
<p>{UTI, hypoalbuminemia}</p>
<p>[objective]</p>
<ul>
<li>2018-04-03 robotic assisted laparoscopic radical cystectomy + pelvic
lymph nodedissection + ileal pouch (ShuangHo hospital)
<ul>
<li>cystectomy and ileal conduit for bladder cancer s/p adjuvant
radiotherapy, bilateral PCN insertion, and T-colostomy.</li>
</ul></li>
<li>2020-05 right femoral neck fracture s/p bipolar hemiarthroplasty
(ShuangHo hospital)</li>
<li>2021-05-24 CT - abnominal
<ul>
<li>a 9cm pelvic mass, suspected to be recurrent tumor.</li>
</ul></li>
<li>2021 early Jane bilateral PCN placing and colostomy done for
obstructive ileus, followed with adjuvant radiotherapy in Cardinal Tien
hospital.</li>
<li>2021-06-25 Gyn ultrasound: uterine mass of 5x5cm at the posterior
wall of myometrium without clear margin. D&amp;C and ECC showed
inflammation and scanty gland cells with squamous metaplasia.</li>
<li>2021-07-13 LAVH, BSO, excision. adhesiolysis for severe adhesion of
small intestine.</li>
<li>2021-07-21 chest AP
<ul>
<li>bilateral lung tumors, suspected lung metastasis.</li>
</ul></li>
<li>2021-08-04 CT - brain
<ul>
<li>a right frontal lobe. suspected abscess or tumor.</li>
</ul></li>
<li>2021-08-04 MRI - brain
<ul>
<li>right frontal tumor (19 mm) with mass effect. metastasis is first
considered. D/D: abscess.</li>
<li>a suspected aneurysm (2.6 mm x 2.7 mm) near right M1
bifurcation.</li>
</ul></li>
<li>2021-08-30 urine lab data
<ul>
<li>sediment RBC 6-9</li>
<li>sediment WBC 10-19</li>
<li>leucocyte ester 2+</li>
<li>OB 1+</li>
</ul></li>
<li>2021-08-22, 23 urine culture - catheterized and patient urinated
midstream
<ul>
<li>Klebsiella pneumoniae, Escherichia coli</li>
</ul></li>
<li>bilirubin direct 0.32mg/dL (2021-08-23)</li>
<li>albumin
<ul>
<li>2021-08-23 2.7g/dL</li>
<li>2021-07-26 3.1g/dL</li>
<li>2021-07-22 3.0g/dL</li>
<li>2021-07-19 2.8g/dL</li>
<li>2021-07-01 2.9g/dL</li>
<li>2021-06-24 2.8g/dL</li>
</ul></li>
<li>prealbumin
<ul>
<li>2021-07-26 10.04mg/dL</li>
<li>2021-07-14 10.64mg/dL</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>UTI still ongoing (8/30 urine lab data), 1 week tapimycin
administrated until 9/1 morning, imipenem might be an alternative
successor for both cultured Klebsiella pneumoniae and Escherichia coli
are imipenem-sensitive (MIC&lt;=0.25, low creatinine reading) if no
other considerations.</li>
<li>S-GPT/ALT and S-GOT/AST (8/23) showed no abnormality, however,
bilirubin flucturated above normal range for at least 3 months. both
albumin and prealbumin remain low, if no evidence supports
liver-dysfunction-caused hypoalbuminemia for now, to improve patient’s
nutritional status could be tried. HBV and HCV might also be tested (no
in-hospital records seen yet).</li>
<li>underlying diseases or symptoms are managed with drugs in active
prescription, no issue found.
<ul>
<li>type 2 DM
<ul>
<li>metformin 500mg PO BID</li>
<li>linagliptin 5mg PO QD</li>
</ul></li>
<li>hypertension
<ul>
<li>amlodipine 5mg PO QD</li>
</ul></li>
<li>parkinson’s disease
<ul>
<li>bendopar (levodopa 100mg, benserazide 25mg) PO BID+HS</li>
<li>amentadine 100mg PO BID</li>
</ul></li>
<li>flatulence
<ul>
<li>dimethylpolysiloxane 40mg PO BID</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-904" class="section level1">
<h1>700031883</h1>
<div id="section-905" class="section level2">
<h2>210830</h2>
<p>{esophageal scc with lung and stomach mets}</p>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2018-04-26 surgical pathology level IV
<ul>
<li>esophagus, 26 cm below incisor, biopsy - moderately differentiated
squamous cell carcinoma</li>
<li>IHC stains P40(+), p63(+), CK(+), CDX-2(-).</li>
</ul></li>
<li>2018-05-07 CT - mediastinum
<ul>
<li>imp: M/3 esophageal tumor T1N0Mx.</li>
</ul></li>
<li>2019-08-20 CT - mediastinum
<ul>
<li>LUL cancer T1aN0MO stage IA1.</li>
</ul></li>
<li>2019-11-21 CT - mediastinum
<ul>
<li>s/p esophagectomy with gastric tube reconstruction.</li>
<li>left upper lobe nodule.</li>
</ul></li>
<li>2021-06-03 PET whole body scan
<ul>
<li>glucose hypermetabolic lesion in the left paratracheal area,
compatible with recurrent malignancy.</li>
<li>mild glucose hypermetabolism in a right submandibular lymph node, a
right neck level III lymph node, bilateral pulmonry hilar regions and in
some focal areas in bilateral buttocks.</li>
</ul></li>
<li>2021-06-25 cell block cytology &amp; needle aspiration cytology
<ul>
<li>stypical hyperchromatic pleomorphic tumor cells with focal
keratinization.</li>
<li>metastatic squamous cell carcinoma is favored.</li>
</ul></li>
<li>2021-06-25 patho - stomach biopsy
<ul>
<li>nests of hyperchromatic tumor cells infiltration in fibrous tissue.
keratinization is focally present.</li>
<li>IHC stains CK5/6(+), p40(+), TTF-1(-), Napsin A(-), CD56(-), and
Synaptophyin(-).</li>
<li>the results are in favor of metastatic squamous cell carcinoma.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2018-06-04 op for scc of middle third esophagus
<ul>
<li>the esophagus was dissected, and retrosternal route was created and
connected to abdomen.</li>
<li>the gastric tube was draw up to the cervical incision via
retrosternal route.</li>
</ul></li>
<li>2019-11-29 VATS left upper lobe wedge resection, lobectomy with
RLND.</li>
<li>2021-07 up to now: CCRT
<ul>
<li>chemo part - PF 2021-07-29, -08-27
<ul>
<li>75mg/m2 day 1</li>
<li>1000mg/m2 day 1~4</li>
</ul></li>
<li>radio part - 3440Gy/19fx 2021-07-01 ~ -07-27</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>visiting the patient at around 16:40 on 2021-08-30. he said the
treatments were generally well-tolerated and he did not experience any
side effects need intervention during this hospitalization.</li>
<li>overall good, no issue on medication.</li>
</ul>
</div>
</div>
<div id="section-906" class="section level1">
<h1>700295989</h1>
<div id="section-907" class="section level2">
<h2>210826</h2>
<p>{duplicated NSAIDs}</p>
<p>[objective]</p>
<ul>
<li>NSAIDs listed in active medication as following:
<ul>
<li>Laston (ketorolac) 30mg IM PRNQ6H</li>
<li>Deflam-K (diclofenac) 25mg PO QID</li>
<li>Deflam-K (diclofenac) 25mg PO QID - patient carried</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>diclofenac could be administered up to 200mg per day.</li>
<li>diclofenac exceeding 100 mg per day might increase risk of vascular
events.</li>
<li>ketorolac is also classified as NSAID.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>either in-hospital prescribed or patient carried diclofenac could be
discontinued if no other clinical considerations.</li>
</ul>
</div>
</div>
<div id="section-908" class="section level1">
<h1>701255029</h1>
<div id="section-909" class="section level2">
<h2>210826</h2>
<p>{potential drug interaction}</p>
<p>[objective]</p>
<ul>
<li>the following drugs are listed in active medication:
<ul>
<li>morphine, tramadol</li>
<li>cyproheptadine, quetiapine</li>
<li>atorvastatin</li>
<li>daptomycin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>atorvastatin is an HMG-CoA reductase inhibitors which might enhance
the adverse effect of daptomycin, the risk of skeletal muscle toxicity
might be increased.</li>
<li>cyproheptadine and quetiapine coadministered with opioid agonists
i.e. morphine and tramadol might enhance the CNS depressant effect.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign of the potential adverse effects mentioned
above.</li>
</ul>
</div>
</div>
<div id="section-910" class="section level1">
<h1>700522826</h1>
<div id="section-911" class="section level2">
<h2>210825</h2>
<p>{breast cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>left breast lump found since 2021 May/June</li>
</ul>
<p>[definite diagnose, disease extent]</p>
<ul>
<li>2021-07-23 SONO breast, Mammography
<ul>
<li>hyperdense tumors in left breast, 4.9cm (subareolar region) and
1.7cm (deep central), suspected malignancy, suggest biopsy.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy-appropriate
action should be taken.</li>
</ul></li>
<li>2021-07-23 Patho - breast biopsy
<ul>
<li>breast, 4/5’ and 12’ region, left, invasive carcinoma characterized
by proliferation of tumor cells with infiltrative growth pattern, ductal
differentiation and stromal fibrosis.</li>
<li>the tumor cell shows hyperchromatic nuclei, plemorphism and high N/C
ratio.</li>
<li>IHC stain ER(-), PR(-), Her2/neu(3+), p53(+), Ki-67 index 20%.</li>
</ul></li>
<li>2021-08-06 Patho - lymphnode biopsy
<ul>
<li>benigh lymph node tissue, IHC stain CK(-)</li>
</ul></li>
<li>2021-08-09 Tc-99m MDP bone scan
<ul>
<li>no strong evidence of bone metastasis.</li>
</ul></li>
<li>2021-08-09 CT - abdomen, pelvis
<ul>
<li>left breast tumor (2.1cm, 4.9cm) with skin invasion suspected
cancer.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>chemo regimen AC (doxorubicin/cyclophosphamide) since
2021-08-25.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>cT3N0 her2-positive, tumor &gt; 1cm, chemo with trastuzumab (or
pertuzumab) could be indicated.
<ul>
<li>however, there are limited data to confirm chemo regimen for those
&gt; 70 y of age.</li>
</ul></li>
<li>CBC WNL, liver and kidney function well, based on most recent lab
data.</li>
<li>no drug allergy record found in database.</li>
<li>MSI/MMR, PD-L1, BRCA1/2, PIK3CA tests could also be considered.</li>
</ul>
</div>
</div>
<div id="section-912" class="section level1">
<h1>700371268</h1>
<div id="section-913" class="section level2">
<h2>210824</h2>
<p>{tube feeding}</p>
<p>meitifen (diclofenac Na 75mg) PO QD which is controlled-release
design might be changed to defram-k (diclofenac K 25mg) PO TID</p>
</div>
</div>
<div id="section-914" class="section level1">
<h1>700770648</h1>
<div id="section-915" class="section level2">
<h2>210824</h2>
<p>{preparation and precaution - mephalan, post-IPP meeting following
up}</p>
<p>patient family meeting and IPP meeting was held at 10:00 on
2021-08-24.</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient has been
disclosed in the meeting.</p></li>
<li><p>melphalan dosing as a conditioning agent, 140mg/m2 or 200mg/m2
are more commonly seen. source:</p>
<ul>
<li><a href="https://www.uptodate.com/contents/melphalan-drug-information" class="uri">https://www.uptodate.com/contents/melphalan-drug-information</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830386/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830386/</a></li>
<li><a href="https://www.astctjournal.org/article/S1083-8791(17)30965-5/fulltext" class="uri">https://www.astctjournal.org/article/S1083-8791(17)30965-5/fulltext</a></li>
</ul></li>
<li><p>the estimated total amount of melphalan used prior to the
scheduled transplantation would be 8 vials.</p>
<ul>
<li>based on melphalan 50mg/vial, dose 100mg/m2 (according to the time
table), body surface area 1.64m2.</li>
<li>4 vials per day for 2 days (2021-08-29, 2021-08-30).</li>
<li>8 vials in stock has been confirmed by the medicine storeroom.</li>
</ul></li>
<li><p>preparation and administration precautions of mephalan:</p>
<ul>
<li>expiration time is 60 minutes after preparation (the duration
including infusion time) according to package insert.
<ul>
<li>staff in chemo preparation room will inform the ward when the
melphalan preparation is done.</li>
</ul></li>
<li>based on lab data reported on 2021-07-09 and 2021-07-30, liver and
kidney have no abnormality, no dose adjustment is needed.</li>
</ul></li>
<li><p>damage of the oral mucosa together with profound myelo- and
immunosuppression after transplantation may lead to local and systemic
infections.</p>
<ul>
<li>other side effects in the early period may include bleeding due to
thrombocytopenia as well as pain, nutrition, and articulation impairment
caused by mucositis.</li>
<li>in the first year after transplantation, oral cavity is affected by
delayed complications like hyposalivation, taste disorders, and dentin
hypersensitivity, which often importantly decrease the patients’ quality
of life.</li>
<li>oral and maxillofacial surgery department has been consulted for
this.</li>
<li>if oral mucosa damage happens, some triamcinolone acetonide oral
ointment (nincort or oralog, the former is available now) for local
treatment might be of help.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-916" class="section level1">
<h1>701118237</h1>
<div id="section-917" class="section level2">
<h2>210820</h2>
<p>{sepsis and pancytopenia with underlying DLBCL}</p>
<p>[subjective]</p>
<ul>
<li>this 64 y/o female patient sent by her family to our ER on
2021-08-11 for her dizziness and hypotension after having
chemotherapy.</li>
<li>underlying history of (neck) diffuse large B cell lymphoma</li>
</ul>
<p>[objective]</p>
<ul>
<li>2021-08-11 ER Imp: sepsis, unspecified organism</li>
<li>DLBCL
<ul>
<li>2019-09-24 CT, neck-hypopharynx:
<ul>
<li>diffuse enlarged lymph nodes on both sides of neck, more prominent
on right side.</li>
<li>D/D: lymphoproliferative disease, metastases.</li>
</ul></li>
<li>2019-09-27 surgical pathology level IV:
<ul>
<li>pathologic diagnosis
<ul>
<li>Lymph node, level IV, right neck, dissection— B- cell lymphoma</li>
<li>Lymph node, level III, right neck, dissection— B- cell lymphoma</li>
</ul></li>
<li>Histology type:
<ul>
<li>B-cell lymphoma (favor diffuse large B-cell lymphoma)</li>
</ul></li>
<li>Immunohistochemical stain profiles:
<ul>
<li>CD20(+), Bcl-2(+), CD3(focal positive at the background T-cells),
Bcl-6(+), Sox11(-), cyclin-D(-), CD10(-), Ki-67 index:70%, CD5 (focal+),
c-myc(-), CD23(-).</li>
</ul></li>
</ul></li>
<li>2020-11 bone marrow transplant, followed up at NTUH</li>
<li>2021-05 recurrence, neck mass noted</li>
<li>2021-07 PET showed progressing</li>
<li>2021-08-06 chemotherapy endoxan (cyclophosphamide) prescirbed
(according to PharmaCloud), pre-chemotherapy WBC 1600</li>
</ul></li>
<li>Lab data
<ul>
<li>RBC 2021-08-20 3.45*10^6/uL</li>
<li>HGB 2021-08-20 10.1g/dL</li>
<li>PLT 2021-08-20 52*10^3/uL</li>
<li>WBC
<ul>
<li>2021-08-20 3.65*10^3/uL</li>
<li>2021-08-18 1.69</li>
<li>2021-08-17 1.02</li>
<li>2021-08-16 0.43</li>
<li>2021-08-14 0.10</li>
<li>2021-08-13 0.08</li>
<li>2021-08-11 0.10</li>
</ul></li>
<li>CRP
<ul>
<li>2021-08-16 15mg/dL</li>
<li>2021-08-11 12</li>
</ul></li>
<li>urine culture on 2021-08-17: after 48 hours, &lt;1000 CFU/ml</li>
<li>blood culture on 2021-08-12: no growth for 5 days aerobically &amp;
anaerobically</li>
</ul></li>
<li>medication
<ul>
<li>granocyte (lenograstim) 250mcg SC QD since 2021-08-12</li>
<li>cefim (cefepime) 2000mg IVD Q12H 2021-08-12 to 2021-08-18</li>
<li>eraxis (anidulafungin) 100mg IVD QD</li>
<li>targocid (teicoplanin) 600mg IVD Q12H~QD 2021-08-12 to
2021-08-16</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>sepsis
<ul>
<li>urine culture and blood culture found no obvious infection</li>
<li>body temp no higher than 36.8 since last week</li>
<li>CRP still showed elevated.</li>
<li>after days of ABX administration, the infection should has been
mitigated.</li>
</ul></li>
<li>pancytopenia
<ul>
<li>WBC has been boosted by lenograstim</li>
<li>RBC and PLT still below than LLN, but moved out of critical
range.</li>
<li>the condition has been improved.</li>
</ul></li>
<li>DLBCL
<ul>
<li>alkylating agent been paused (not listed in active medication)
because of pancytopenia.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>ABX might be deescalated when CRP goes down and no other infectious
sign shows up.</li>
<li>DLBCL treatment should be restarted as soon as possible when the
patient gets in stable condition.
<ul>
<li>no chemo or target drugs other than cyclophosphamide found in
PharmaCloud, based on the limited info, ISRT after RCHOP might be a
treatment option.</li>
<li>uric acid, beta-2 microglobulin could also be followed up when
having DLBCL treatment.</li>
</ul></li>
<li>HBV, HCV lab data not found in in-hospital database, could be
ordered.</li>
</ul>
</div>
</div>
<div id="section-918" class="section level1">
<h1>701034857</h1>
<div id="section-919" class="section level2">
<h2>210816</h2>
<p>{liver cancer with bone mets}</p>
<p>[initial presentation]</p>
<ul>
<li>2017~ abdominal fullness</li>
</ul>
<p>[definite diagnosis, disease extent, effect &amp; side effect]</p>
<ul>
<li>2017-09-20 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; postcholecystectomy; liver cyst; hepatic
tumors, three suspected HCC</li>
</ul></li>
<li>2018-04-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE without viable tumor.</li>
</ul></li>
<li>2018-07-25 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; postcholecystectomy; liver cyst; probable
hepatic tumor; renal stone, left</li>
</ul></li>
<li>2018-12-26 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>liver cirrhosis; postcholecystectomy; hepatic tumor, nature?</li>
</ul></li>
<li>2019-03-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCC s/p TACE with recurrent HCC at S3 and S7.</li>
</ul></li>
<li>2019-05-08 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; hepatic tumors, two c/w HCC; increased
risk of RFA due to near diaphargm</li>
</ul></li>
<li>2019-06-29 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCC s/p op. and TACE with viable tumor at S7.; liver cirrhosis.</li>
</ul></li>
<li>2019-09-23 MRI, liver, spleen
<ul>
<li>a recurrent HCC (2.0cm) in S7 of liver.</li>
</ul></li>
<li>2020-02-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE. a recurrent HCC (2.9cm) in S7 of
liver.</li>
</ul></li>
<li>2020-05-13 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, two probable hcc</li>
</ul></li>
<li>2020-12-30 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, three c/w hcc</li>
</ul></li>
<li>2021-05-24 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE. recurrent HCCs (up to 4.3cm) in S7-8 of
liver. some lucent lesions in left pelvic bone probable metastases.</li>
</ul></li>
<li>2021-05-26 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, five c/w HCC (two s/p TACE with
viable tumors, three recurrent).</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>HCC op and TACE done at other hospital in late 2017.</li>
<li>entecavir been used years ago, restarted from 2021-07-03
(self-paid).</li>
<li>nexavar (sorafenib) 200mg BIDAC tappered to QDAC because of poor
appetite, dizziness, malaise.</li>
<li>palliative RT to the Lt shoulder to deliver at least 30 Gy/ 10 fx
started in the middle third of 2021-08.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>medication
<ul>
<li>no issues with the following indications
<ul>
<li>HCC
<ul>
<li>nexavar (sorafenib 200mg) PO QDAC (Child-Pugh Class A)</li>
</ul></li>
<li>HBV, cirrhosis
<ul>
<li>baraclude (entecavir 0.5mg) PO QDAC</li>
<li>baogan (silymarin 150mg) PO BID</li>
</ul></li>
</ul></li>
<li>potential interaction
<ul>
<li>the antitumor activity of sorafenib might be potentially reduced by
neomycin for the later may decrease the serum concentration of the
former.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>palliative RT is appropriate for symptom control and/or prevention
of complications from metastatic lesions, such as bone (like this
patient) or brain.</li>
</ul></li>
<li>patient wants to take herbal medicine.
<ul>
<li>not being followed up with chinese medicine department since late
2017</li>
<li>no herbal medicine items disclosed in PharmaCloud.</li>
</ul></li>
<li>dMMR/MSI-H, NTRK, BRCA1/2 gene tests not found in the charts</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>introduce the patient to visit our chinese medicine OPD to get
‘scientfic chinese medicine’ rather than using unknnow herbal
medicine.</li>
<li>shorten the use time of meomycin to avoid potential drug interaction
with sorafenib.</li>
<li>dMMR/MSI-H, NTRK, BRCA1/2 gene tests might be ordered if
needed.</li>
<li>the patient seemed being hesitating to have curative care for a not
short while and hopping from and to WanFang hospital for medical demand,
having him to meet with social-work staff might be of help to get his
considerations behind.</li>
</ul>
</div>
</div>
<div id="section-920" class="section level1">
<h1>701326125</h1>
<div id="section-921" class="section level2">
<h2>210816</h2>
<p>{some preparation before tube feeding}</p>
<p>active medication is reviewed, all the oral drugs can be administered
via NG tube.</p>
<p>acetin (acetylcysteine) and nexium (esomeprazole) should be dissolved
in adequate drinking water prior to tube feeding.</p>
</div>
</div>
<div id="section-922" class="section level1">
<h1>701326360</h1>
<div id="section-923" class="section level2">
<h2>210816</h2>
<p>{switch drug for tube feeding}</p>
<p>active medication has been reviewed, all the oral drugs can be
administered via NG tube.</p>
<p>Harnalidge (tamsulosin) 0.4mg PO QDAC replaced by Urief (silodosin)
8mg PO QD is recommended.</p>
</div>
</div>
<div id="section-924" class="section level1">
<h1>700321047</h1>
<div id="section-925" class="section level2">
<h2>210812</h2>
<p>{statin dose intensity and equivalency}</p>
<p>All the oral drugs in active medication have been reviewed and can be
administered via NG tube.</p>
<p>Pravafen has not been found in active medication yet.</p>
<p>Pravafen should not be grinded or half-peeled. It contains
fenofibrate 160mg and pravastatin 40mg, there is Lipanthyl Supra
(fenofibrate 160mg) available in hospital, however pravastatin 40mg is
out of stock for now.</p>
<p>Fluvastatin 80mg, lovastatin 80mg, simvastatin 20mg, pitavastatin
2mg, atorvastatin 10mg, rosuvastatin 5mg are alternatives for
pravastatin 40mg. reference: <a href="http://www.mqic.org/pdf/UMHS_Statin_Dose_Intensity_and_Equivalency_Chart.pdf" class="uri">http://www.mqic.org/pdf/UMHS_Statin_Dose_Intensity_and_Equivalency_Chart.pdf</a></p>
</div>
</div>
<div id="section-926" class="section level1">
<h1>701320982</h1>
<div id="section-927" class="section level2">
<h2>210812</h2>
<p>{lung cancer with brain mets}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-07-12 being diagnosed as hypnic headache at LMD.</li>
<li>2021-07-26 intermittent occipital headache accompanied with Rt limbs
weakness for 2 weeks, exacerbated since 2021-07-24.</li>
</ul>
<p>[definite diagnose, disease extent]</p>
<ul>
<li>2021-07-26 CT, brain:
<ul>
<li>masses in right cerebrum; DDx: metastasis, meningiomas.</li>
<li>midline shift (11mm) and impending uncal herniation.</li>
</ul></li>
<li>2021-07-26 MRI, brain:
<ul>
<li>bifrontal and right medial temporal tumors, favor metastases, with
brain herniation.</li>
</ul></li>
<li>2021-07-27 CT, lung/mediastinum/pleura:
<ul>
<li>LUL lung cancer, T4N3M1c, stage IVB.</li>
</ul></li>
<li>2021-07-28 whole body PET scan:
<ul>
<li>glucose hypermetabolism in the right cerebral cortex, probably the
primary or secondary (priority) brain malignancy.</li>
<li>glucose hypermetabolism in the left upper lung and left lower lung
pleura, probably lung cancer with lung to lung metastases.<br />
</li>
<li>glucose hypermetabolism in bilateral mediastinal lymph nodes and
bilateral SCF lymph nodes, probably lung cancer with regional lymph
nodes metastases.<br />
</li>
<li>left upper lung cancer (if proved), cT4N3M1c, stage IVB.</li>
</ul></li>
<li>2021-07-30 patho, lung transbronchial biopsy:
<ul>
<li>adenocarcinoma, moderately to poorly differentiated. solid nests and
glandular cells infiltrating in a fibrotic stroma.</li>
<li>ICH stains: TTF-1(+), Napsin A(+), p40(-), CD56(-) are supportive
for lung cancer diagnosis.</li>
</ul></li>
<li>2021-08-04 PD-L1:
<ul>
<li>tumor cell (TC) staining assessment: &lt;1%</li>
<li>tumor-infiltrating immune cell (IC) staining assessment: &lt;1%</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>Radiotherapy
<ul>
<li>palliative RT for brain metastases is indicated.</li>
<li>delivering 18 Gy/ 6 fx to the whole brain and then boost the
bi-frontal and Rt medial temporal tumors to 36 Gy/ 12 fx.</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>active medication without issues
<ul>
<li>brain mets:
<ul>
<li>Mannitol 20% 100mL IVD Q8H</li>
<li>Keppra (levetiracetam) 500mg PO BID</li>
</ul></li>
<li>insomnia:
<ul>
<li>Anxiedin (lorazapam) 0.5mg PO PRNHS</li>
</ul></li>
<li>constipation:
<ul>
<li>MgO 500mg PO TID</li>
</ul></li>
</ul></li>
<li>PD-L1 &lt;1% is known. EGFR, KRAS, ALK, POS1, BRAF V600E, NTRK,
METex14, RET might be tested</li>
<li>if CCRT is applicable, the chemo option could be:
<ul>
<li>carboplatin + pemetrexed</li>
<li>cisplatin + pemetrexed</li>
<li>paclitaxel + carboplatin</li>
<li>etooside + cisplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-928" class="section level1">
<h1>701253142</h1>
<div id="section-929" class="section level2">
<h2>210811</h2>
<p>{cecal cancer}</p>
<p>[initial presentation, definite diagnosis, disease extent]</p>
<ul>
<li>2019-12-15 CT at TMUH: cecal or appendiceal malignancy with adjacnet
infiltration, few prominent regional lymph nodes and liver metastasis.
<ul>
<li>no blood stool and no stool impaction could be noted prior to the CT
exam.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-02-10 ~ 2020-11-xx: biweekly high dose 5-fluorouracil and
leucovorin (HDFL) at TMUH?
<ul>
<li>outcome: partial response</li>
</ul></li>
<li>2020-12-07 ~ up to now : continuing HDFL.
<ul>
<li>plus UFT (tegafur + uracil) from 2020-09 ~ 2020-12.</li>
<li>plus Xeloda (capecitabine) from 2021-05 ~ up to now.</li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>2020-11-07 CT, ABD:
<ul>
<li>regression of cecum tumor and liver metastasis.</li>
<li>right adrenal tumor, suspect adrenal mestasis, mild
progression.</li>
</ul></li>
<li>2021-02-22 CT, ABD:
<ul>
<li>stable condition of cecal tumor and liver metastases.</li>
<li>wall thickening of urinary bladder, right aspect.</li>
<li>mild regression of right adrenal tumor.</li>
</ul></li>
<li>2021-04-13 KUB:
<ul>
<li>S/P posterior instrumentation fixation from T10 To L5.</li>
<li>S/P laminectomy of L2, L3, and L4; partial laminectomy of L5</li>
<li>vacuum phenomenon of L4-5.</li>
<li>fecal material store in the colon.</li>
</ul></li>
<li>2021-04-15 KUB:
<ul>
<li>S/P posterior longitudinal transpedicular screws and rods
fixation.</li>
<li>stool retention in the bowel.</li>
</ul></li>
<li>2021-05-22 CT, ABD:
<ul>
<li>borderline heart size.</li>
<li>s/p posterior fixation of the lumbar spine</li>
<li>cecal tumor with liver meta, right adrenal meta(?), statinoary.</li>
</ul></li>
<li>2021-07-16 CT, ABD: left hydronephrosis and hydroureter. focal wall
thickening of urinary bladder. urinary bladder and left lower ureter
tumors should be ruled out.</li>
<li>2021-08-02 kidney ultrasound: right renal cyst.</li>
<li>2021-08-02 bladder sonography: post-void residual volume 297ml</li>
<li>CEA
<ul>
<li>2021-08-10 _9.55ng/mL</li>
<li>2021-07-06 11.17</li>
<li>2021-06-08 10.43</li>
<li>2021-05-11 _5.05</li>
<li>2021-04-13 _5.63</li>
<li>2021-03-17 _4.50</li>
<li>2021-02-03 _5.34</li>
<li>2021-01-06 10.98</li>
<li>2020-12-22 16.63</li>
<li>2020-12-03 32.41</li>
<li>2020-11-05 40.06</li>
<li>2020-09-25 21.92</li>
</ul></li>
<li>CA199
<ul>
<li>2021-08-10 _37.74U/mL</li>
<li>2021-07-06 _42.15</li>
<li>2021-06-08 _37.56</li>
<li>2021-05-11 _24.28</li>
<li>2021-04-13 _27.14</li>
<li>2021-03-17 _25.11</li>
<li>2021-02-03 _26.37</li>
<li>2021-01-06 _31.50</li>
<li>2020-12-22 _41.91</li>
<li>2020-12-03 _95.77</li>
<li>2020-11-05 119.26</li>
<li>2020-09-25 119.70</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>BPH
<ul>
<li>medication
<ul>
<li>Avodart (dutasteride) 0.5mg PO QD</li>
<li>Betmiga (mirabegron) 50mg PO QD</li>
<li>Urief (silodosin) 8mg PO QD</li>
</ul></li>
</ul></li>
<li>HTN
<ul>
<li>medication
<ul>
<li>Diovan (valsartan) 80mg PO QD</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>patient is relatively stable with slow tumor progression.</li>
<li>mirabegron is a CYP2D6 inhibitor which might increase the serum
concentration of metoclopramide (10mg IVD PRNQ6H).
<ul>
<li>CYP2D6 is an enzyme responsible for metoclopramide metabolism.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-930" class="section level1">
<h1>700081580</h1>
<div id="section-931" class="section level2">
<h2>210810</h2>
<p>{renal glucosuria?}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-07-15 left inguinal mass for 3 weeks refer from LMD.</li>
<li>2021-07-16 CT - abdomen, pelvis:
<ul>
<li>a well-defined soft tissue mass measuring 2.6 x 2.3 cm in left
inguinal area.</li>
<li>differential diagnosis include undescended testis.</li>
</ul></li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-07-28 patho - lymph node regiion resection:
<ul>
<li>labeled as ‘inguinal tumor’, tumor excision - in situ follicular
neoplasm.
<ul>
<li>IHC stains: CD3 and CD20: a predominant B cell subpopulation;</li>
<li>bcl-2 (+), bcl-6 (+), CD10 (+) of the follicules.<br />
</li>
<li>CD23 (-), cyclin-D (-).<br />
</li>
</ul></li>
<li>sections show lymph node with proliferative lymphocytes
deminstrating pseudofollicles.</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2021-08-10 CT - abdomen, pelvis:
<ul>
<li>only one enhanced lymph node at left inguinal region.</li>
<li>the rest of the body part is free of lymphadenopathy.</li>
</ul></li>
</ul>
<p>[objective]</p>
<ul>
<li>2021-07-27 lab data:
<ul>
<li>urine glucose 4+</li>
<li>urine bacteria 1+</li>
<li>serum glucose 103mg/dL</li>
</ul></li>
<li>creatinine WNL:
<ul>
<li>2021-08-08 0.83mg/dL</li>
<li>2021-07-27 0.74mg/dL</li>
<li>2021-07-15 0.85mg/dL</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>patients with renal glycosuria, glucose is excreted in the urine in
the presence of normal or low concentrations of blood glucose.</li>
<li>there is a lowered renal threshold to glucose and, in some cases, a
reduction in the rate at which the renal tubules are able to reabsorb
glucose.</li>
<li>in most affected individuals, renal glycosuria is a benign
condition, resulting in no apparent symptoms. however, in some cases,
glycosuria may be pronounced enough to result in excessive urination
(polyuria), excessive thirst (polydipsia), and other associated
symptoms.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>if any symptomatic sign is observed, appropriate testing should be
conducted to rule out diabetes and to regularly monitor those with
confirmed renal glycosuria.</li>
<li>genetic counseling will be of benefit for affected individuals and
their families. other treatment for this condition is symptomatic and
supportive.</li>
</ul>
</div>
</div>
<div id="section-932" class="section level1">
<h1>700223143</h1>
<div id="section-933" class="section level2">
<h2>210806</h2>
<p>{flumarin side effect monitoring}</p>
<p>[objective]</p>
<ul>
<li>flumarin (flomoxef sodium) dosing for adult:
<ul>
<li>susceptible infections IV usual dosage: 1 to 2 g per day in 2
divided doses</li>
<li>may increase to 4g per day in 3 to 4 divided doses if needed for
severe or refractory infections.</li>
</ul></li>
<li>flumarin 1g IVD QD is prescribed.</li>
<li>estimated creatinine clearance 10ml/min using the Cockcroft-Gault
equation is based on:
<ul>
<li>age 28 years old</li>
<li>body weight 62.65kg (2021-08-05)</li>
<li>creatinine 7.00mg/dL (2021-08-06)</li>
</ul></li>
<li>according to the drug’s package insert, half-life t1/2:
<ul>
<li>healthy adult: 49.6min</li>
<li>patient with 5 &lt; CrCl &lt; 20: 6.95hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>half-life for the patient could be 8.4 times long compared to normal
renal function adults.</li>
<li>prescribed dose is a quarter of upper limit of daily use, not as low
as one eighth, might increase the possibility of adverse reactions.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any signs of adverse reactions possibly caused by
flumarin including:
<ul>
<li>dermatologic: skin rash</li>
<li>endocrine &amp; metabolic: increased gamma-glutamyl transferase</li>
<li>gastrointestinal: diarrhea</li>
<li>hematologic and oncologic: anemia, eosinophilia,
granulocytopenia</li>
<li>hepatic: increased serum alkaline phosphatase, increased serum ALT,
increased serum AST</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-934" class="section level1">
<h1>700834580</h1>
<div id="section-935" class="section level2">
<h2>210806</h2>
<p>{cancer workup}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-06-30 left leg knee and thigh pain for more than one month,
progresson</li>
<li>2021-07-14 limping gait, severe pain lower back radiating to left
hip and lower leg</li>
</ul>
<p>[objective]</p>
<ul>
<li>lab data (2021-07-28)
<ul>
<li>CA125 645U/mL</li>
<li>CA199 &gt;19610U/mL</li>
<li>CEA 613ng/mL</li>
<li>CA153 WNL</li>
<li>AFP WNL</li>
<li>SCC WNL</li>
</ul></li>
</ul>
<p>[definite diagnosis &amp; staging workup]</p>
<ul>
<li>still in workup, could be lung to bone mets, evidences observed
including:
<ul>
<li>2021-07-15 MRI L-spine:
<ul>
<li>tumors in the left iliac bone and right sacrum. origin?</li>
</ul></li>
<li>2021-08-04 Tc-99m MDP bone scan:
<ul>
<li>lung cancer with multiple bone metastases in the lower part of the
sternum, posterolateral aspect of the left 10th rib, and left iliac bone
is highly suspected.</li>
</ul></li>
<li>2021-08-05 bronchoscopy:
<ul>
<li>right intermediate bronchus submucosal tumor.</li>
<li>RLL orifice submucosal tumor, some protuding to the mucosa layer,
with RLL bonchus narrowing.</li>
</ul></li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>pain
<ul>
<li>morphine 15mg PO Q6H</li>
<li>morphine 5mg IVD PRNQ6H</li>
</ul></li>
<li>constipation
<ul>
<li>through (sennoside) 24mg PO HS</li>
<li>bisacodyl 10mg RECT PRNQD</li>
<li>MgO 500mg PO Q6H</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>post nasal dripping
<ul>
<li>actein (acetylcysteine) 200mg PO BID</li>
<li>sindecon nasal spray 1 puff NA BID</li>
</ul></li>
<li>hyperlipidemia
<ul>
<li>crestor (rosuvastatin) 10mg PO QD</li>
</ul></li>
<li>insomnia
<ul>
<li>anxiedin (lorazepam) 0.5mg PO HS</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>main activity is to control (pain) symptoms for now</li>
<li>constipation which could be an adverse reaction of morphine has been
mitigated with stimulant laxatives.</li>
</ul>
</div>
</div>
<div id="section-936" class="section level1">
<h1>700039230</h1>
<div id="section-937" class="section level2">
<h2>210729</h2>
<p>{post IPP meeting following up}</p>
<ul>
<li><p>the schedule and regimen for PBSCT for the patient was disclosed
in the meeting held on 2021-07-28 10:30.</p></li>
<li><p>the estimated total amount of busulfan used in the time table is
15 vials.</p>
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
75kg</li>
<li>5 vials per day for 3 days (2021-07-28, 2021-07-29, 2021-07-30)</li>
</ul></li>
<li><p>staff dispensing regimen during weekend are arranged.</p></li>
<li><p>preparation and administration precautions:</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 1.9m2 -&gt; amount
760mg.</li>
<li>total solution containing 760mg etoposide will be no less than
1900mL.</li>
</ul></li>
</ul></li>
</ul>
<p>{mesna administration rate}</p>
<ul>
<li>where ifosfamide or cyclophosphamide is used (like this patient) as
an iv bolus: mesna is given by intravenous injection over 15-30 minutes
at 20% of the simultaneously administered oxazaphosphorine on a weight
for weight basis (w/w). the same dose of mesna is repeated after 4 and 8
hours (as listed in the regimen schedule).
<ul>
<li>reference: <a href="https://www.medicines.org.uk/emc/product/1838/smpc" class="uri">https://www.medicines.org.uk/emc/product/1838/smpc</a></li>
<li>reference: drug package insert</li>
</ul></li>
<li>taking a conservative approach as conclusion, 30 minutes should be
safe for adult.</li>
</ul>
</div>
</div>
<div id="section-938" class="section level1">
<h1>700274711</h1>
<div id="section-939" class="section level2">
<h2>210729</h2>
<p>{colon cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2019-08 intermittent low abdominal cramping pain and fullness, LMD
FOBT positive.</li>
</ul>
<p>[definite diagnosis and disease extent]</p>
<ul>
<li>2019-09-19 patho, hemicolectomy:
<ul>
<li>descending colon, adenocarcinoma, moderately differentiated</li>
<li>IHC stains - EGFR(+), PMS2(+), MLH1(+), MSH2(+), MSH6(+).</li>
<li>pStage IVA, pT3N0M1a</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2019-09-18 laparoscopic left hemicolectomy</li>
<li>2020-01-06 ~ 2020-03-16 FOLFOX x 6 (biweekly for 3 months,
adjuvant)</li>
<li>2021-07-09 VATS RUL wedge resection</li>
<li>2021-07-27 ~ up-to-now FOLFIRI</li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>2021-07-09 patho, lung wedge biopsy:
<ul>
<li>adenocarcinoma, IHC stains: CK7(-), CK20(+), CDX2(+), TTF-1(-).</li>
<li>the morphology and immunohistochemical stains are consistent with
metastatic colonic tumor.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>colon cancer
<ul>
<li>assessment
<ul>
<li>FOLFIRI is introduced in the end of July 2021 soon thereafter lung
mets wedge resection</li>
<li>MMR proficient, KRAS/NRAS not detected, BRAF, HER2 lab data not
found.</li>
<li>updated CEA, CA199 within normal limits.</li>
</ul></li>
<li>suggestion
<ul>
<li>keep the ongoing new regimen and surveilling every 3 to 6
months.</li>
<li>bevacizumab might be indicated.</li>
</ul></li>
</ul></li>
<li>HBV
<ul>
<li>lab
<ul>
<li>2021-07-23
<ul>
<li>Anti-HBc reactive</li>
<li>Anti-HBc-Value 5.56 S/CO</li>
</ul></li>
<li>2021-07-22
<ul>
<li>S-GPT/ALT 23 U/L</li>
<li>S-GOT/AST 23 U/L</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>baraclude (entecavir 0.5mg) PO QDAC</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>HTN
<ul>
<li>BP around 130/80 plus or minus 10 the first 2 days this
hospitalization.</li>
<li>medication
<ul>
<li>norvasc (amlodipine 5mg) PO QD</li>
<li>syntrend (carvedilol 25mg) PO QD</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>BPH
<ul>
<li>medication
<ul>
<li>avodart (dutasteride 0.5mg) PO HS</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>hypertriglyceridemia
<ul>
<li>lab
<ul>
<li>2021-07-08 494mg/dL</li>
<li>2021-03-31 261mg/dL</li>
<li>2021-01-08 339mg/dL</li>
<li>2020-11-11 322mg/dL</li>
<li>2020-04-13 592mg/dL</li>
</ul></li>
<li>assessment
<ul>
<li>elevated serum TG for at least 1+ year.</li>
</ul></li>
<li>suggestion
<ul>
<li>statin could be considered if not contraindicated.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-940" class="section level1">
<h1>700890235</h1>
<div id="section-941" class="section level2">
<h2>210727</h2>
<p>{coadministration of Decan and Juluca}</p>
<p>[objective]</p>
<ul>
<li>active medication include
<ul>
<li>Decan (dexamethasone) 6mg IVD QD</li>
<li>Juluca (dolutegravir 50mg, rilpivirine 25mg) 1 tab PO QNCC</li>
</ul></li>
<li>lab data on 2021-07-22 showed lower lymphocyte percentage, however
other items were within normal range:
<ul>
<li>WBC 9.20*10^3/uL</li>
<li>Lymphocyte 14.3%</li>
<li>Lymphocyte count 1320/uL</li>
<li>CD3+/CD4+ Helper T 31.7%</li>
<li>CD3+/CD4+ Helper T C 418/uL</li>
<li>CD3+/CD8+ Suppre T 31.8%</li>
<li>CD3+/CD8+ Suppre T C 419/uL</li>
<li>CD4/CD8 Ratio 1.0</li>
<li>T Cells (CD3) 61.9%</li>
<li>B Cells (CD19) 9.7%</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>rilpivirine prescribing information lists coadministration with
multiple-dose dexamethasone as contraindicated due to a risk of
decreased rilpivirine concentrations and loss of virologic
response.</li>
<li>the presumed primary mechanism of interaction between these agents
is dexamethasone induction of CYP3A4 mediated rilpivirine
metabolism.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please keep monitoring virologic responses.</li>
</ul>
</div>
</div>
<div id="section-942" class="section level1">
<h1>700539680</h1>
<div id="section-943" class="section level2">
<h2>210722</h2>
<p>{vaccination for splenectomised patients}</p>
<p>[objective]</p>
<ul>
<li>this patient had splenectomy done on 2021-05-12 (huge spleen,
&gt;30cm in length, weight 2000g)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>splenectomised patients are at risk for severe and overwhelming
infections with encapsulated bacteria, bloodborne parasites.</li>
<li>measures for preventing these infections include patient and family
education, vaccination against encapsulated bacteria.</li>
<li>vaccines are available to against bacteria such as Streptococcus
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Bordetella
holmesii.</li>
<li>these vaccines are all in inactivated, noncellular form, not
classified as attenuated, relatively safe for patients receiving
chemotherapy.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>as a general guide, vaccine dose could be administered when patient
is in stable condition and during chemo window period. the dose should
be repeated no less than 6 months after chemotherapy.</li>
</ul>
</div>
</div>
<div id="section-944" class="section level1">
<h1>701282961</h1>
<div id="section-945" class="section level2">
<h2>210722</h2>
<p>{suspected MDS}</p>
<p>[objective]</p>
<ul>
<li>2021-07-12 patho - bone marrow biopsy:
<ul>
<li>piece(s) of bone marrow with 70-80% cellularity and M:E ratio of
approximately 1:4.</li>
<li>three cell lineages are present with normal maturation of
leukocytes.</li>
<li>megakaryocytes are increased in number with nuclear atypia.
myelodysplastic syndrome with no excessive blasts cannot be
excluded.</li>
<li>IHC stains (of the nucleated cells):
<ul>
<li>CD117: &lt;1%</li>
<li>CD34: &lt;1%</li>
<li>MPO: 10-15%</li>
<li>CD61: 10-15%</li>
<li>CD71: 70-80%</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>driver mutations are detected in &gt;90 percent of cases of MDS.
most commonly mutated genes are DNMT3A, TET2, IDH genes, ASXL1, TP53,
RUNX1, SF3B1, U2AF1, SRSF2, ZRSR2.</li>
<li>chromosomal abnormalities are presumptive evidence of MDS in
patients with otherwise unexplained refractory cytopenia and no
morphologic evidence of dysplasia, including:
<ul>
<li>unbalanced chromosomal abnormalities:
<ul>
<li>loss of chromosome 7 or del(7q)</li>
<li>del(5q) or t(5q)</li>
<li>del 20(q)</li>
<li>isochromosome 17q or t(17p)</li>
<li>loss of chromosome 13 or del(13q)</li>
<li>del(11q)</li>
<li>del(12p) or t(12p)</li>
<li>del(9q)</li>
<li>idic(X)(q13)</li>
</ul></li>
<li>balanced chromosomal abnormalities:
<ul>
<li>t(11;16)(q23.3;p13.3)</li>
<li>t(3;21)(q26.2;q22.1)</li>
<li>t(1;3)(p36.3;q21.2)</li>
<li>t(2;11)(p21;q23.3)</li>
<li>inv(3)(q21q26.2) or t(3;3)(q21.2;q26.2)</li>
<li>t(6;9)(p23;q34.1)</li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no issue with current medication, chromosome tests has just been
ordered on 2021-07-22, treatment plan will be more clear after having
the outcome.</li>
</ul>
</div>
</div>
<div id="section-946" class="section level1">
<h1>700825772</h1>
<div id="section-947" class="section level2">
<h2>210721</h2>
<p>{Rectal Cancer with UTI}</p>
<p>[objective]</p>
<ul>
<li>exams
<ul>
<li>2021-07-20 urine culture: Escherichia coli.</li>
<li>2021-05-18 patho - vaginal biopsy:
<ul>
<li>adenocarcinoma characterized by solid, villous or tubular pattern of
tumor cells with necrosis.</li>
<li>immunohistochemistry shows CDX-2(+); MLH1(+), MSH2(+), MSH6(+),
PMS2(+) and GATA-3(-) for tumor cells, compatible with recurrent rectal
adenocarcinoma.</li>
</ul></li>
<li>2021-05-17 CT - ABD:
<ul>
<li>rectal cancer s/p operation. a soft tissue lesion (3.0x4.1cm) at
right presacral region. some nodules (up to 1.1cm) in bil. lungs.</li>
</ul></li>
<li>2021-01-26 CT - ABD:
<ul>
<li>post-op at the rectum with recurrence in presacral region,
involvement of distal ureter and sigmoid colon.</li>
<li>progression of right hydronephrosis and hydroureter.</li>
<li>left lower lung nodule, suspected lung metastasis.</li>
</ul></li>
<li>2020-08-27 whole body PET:
<ul>
<li>in comparison with the previous study on 2019/12/23, a new glucose
hypermetabolic lesion in the midline pre-sacral region. malignancy with
local recurrence should be watched out.</li>
<li>another new glucose hypermetabolic lesion in the upper lobe of left
lung. the nature is to be determined (a metastatic lesion? other
nature?).</li>
<li>no prominent change was noted in the previous lesion in right
pre-sacral region.</li>
</ul></li>
<li>2020-04-02 CT - lung/mediastinum/pleura
<ul>
<li>left upper lobe and right upper lobe dense nodules, old insult is
more favored.</li>
</ul></li>
</ul></li>
<li>tests
<ul>
<li>Fecal Occult Blood 4+ (2021-07-17)</li>
<li>CEA 46ng/mL (2021-05-24), 48ng/mL (2021-04-27), 63ng/mL
(2021-03-30), 31ng/mL (2021-02-26), 0.8ng/mL (2020-07-17)</li>
<li>CA199 172U/mL (2021-05-24), 221U/mL (2021-04-27), 299U/mL
(2021-03-30), 228U/mL (2021-02-26), 16U/mL (2020-03-24)</li>
<li>hs-Troponin I 109pg/mL (2021-07-17)</li>
<li>CRP 42mg/dL (2021-07-17)</li>
<li>Lactic Acid 3.5mmol/L (2021-07-17)</li>
</ul></li>
<li>medication
<ul>
<li>UFT (tegafur 100mg, uracil 224mg) BID PO with Folina (folinate 15mg)
BID PO since 2021-03-02.
<ul>
<li>the same drugs have been prescirbed shortly in Feb and May each for
28-day in 2017.</li>
</ul></li>
<li>Flumarin (flomoxef sodium 1000mg) IVD Q12H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>rectal cancer was first diagnosed in 2016, shortly thereafter
followed with RT 5040cGy/28 and the disease has been controlled for not
long years.</li>
<li>patient’s family have lost several relative elders these consecutive
years, care burdens let the lineal descendent caregivers exhausted.
hospice care is arranged.</li>
<li>oral prodrug of 5-FU for rectal cancer, lactulose for ileus,
tramadol for pain control, ABX for UTI, no issue with the
medication.</li>
<li>according to the time serial tumor markers level, the disease
somewhat responded to 5-FU prodrug since 2021 March.</li>
<li>hs-Troponin I has played an important role in the risk
stratification of patients during the in-hospital phase of acute
coronary syndrome, the elevated level should be concerned.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep monitoring progresstion of the infection and signs of acute
heart attack.</li>
<li>no adjustment for medication is needed.</li>
</ul>
</div>
</div>
<div id="section-948" class="section level1">
<h1>700948740</h1>
<div id="section-949" class="section level2">
<h2>210716</h2>
<p>{potential interactions among lorazepam, olanzapine, morphine and
labetalol}</p>
<p>[objective]</p>
<ul>
<li>concurrent medication:
<ul>
<li>lorazepam 2mg IVD PRNQ4H</li>
<li>olanzapine 5mg PO HS</li>
<li>morpine 5mg IVD PRNQ4H</li>
<li>labetalol 25mg IVD PRNQ8H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>coadministered lorazepam, olanzapine, morphine might enhance the CNS
depressant effect.</li>
<li>olanzapine might enhance the adverse effect of lorazepam
(benzodiazepine).
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/15889948/" class="uri">https://pubmed.ncbi.nlm.nih.gov/15889948/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/20156413/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20156413/</a></li>
</ul></li>
</ul></li>
<li>labetalol might enhance the hypotensive effect of olanzapine and
morphine.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign such as anterograde amnesia, drowsiness,
sedated stated, hypotension… to see if change is needed.</li>
</ul>
</div>
</div>
<div id="section-950" class="section level1">
<h1>701300783</h1>
<div id="section-951" class="section level2">
<h2>210716</h2>
<div id="section-952" class="section level3">
<h3>==========</h3>
</div>
<div id="section-953" class="section level3">
<h3>2021-07-08</h3>
<p>{potential interaction when coadministering alprazolam,
metoclopramide, olanzapine}</p>
<p>[objective]</p>
<p>the following items are listed in active medication: - alpraline
(alprazolam, 0.5mg/tab) 1 tab PO HS - promeran (metoclopramide,
3.84mg/tab) 1 tab PO TIDAC - zyprexa zydis (olanzapine, 5mg/tab) 1 tab
PO HS</p>
<p>[assessment]</p>
<ul>
<li>metoclopramide might enhance the adverse/toxic effect of olanzapine.
<ul>
<li>this could associate with development of extrapyramidal reactions or
neuroleptic malignant syndrome.</li>
</ul></li>
<li>olanzapine might enhance the adverse/toxic effect of alprazolam.
<ul>
<li>due to risks of additive adverse effects (e.g., cardiorespiratory
depression, excessive sedation).</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>if any above suspected symptom is observed, please discontinue the
coadministration.</li>
</ul>
</div>
<div id="section-954" class="section level3">
<h3>2021-07-16</h3>
<p>{potential interactions among alprazolam, olanzapine and
zolpidem}</p>
<p>[objective]</p>
<ul>
<li>concurrent medication:
<ul>
<li>alprazolam 0.5mg PO HS</li>
<li>olanzapine 5mg PO HS</li>
<li>zolpidem 10mg PO HS</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>coadministered alprazolam, olanzapine and zolpidem might enhance the
CNS depressant effect.</li>
<li>olanzapine might enhance the adverse effect of alprazolam
(benzodiazepine).
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/15889948/" class="uri">https://pubmed.ncbi.nlm.nih.gov/15889948/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/20156413/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20156413/</a></li>
</ul></li>
</ul></li>
<li>clinical significance of this interaction may be lower with oral
forms.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign such as drowsiness, fatigue, sedation,
ataxia, memory impairment, irritability, cognitive dysfunction,
dysarthria, dizziness to see if change is needed.</li>
</ul>
</div>
</div>
</div>
<div id="section-955" class="section level1">
<h1>701239654</h1>
<div id="section-956" class="section level2">
<h2>210706</h2>
<p>{post-IPP meeting following up}</p>
<p>patient family meeting and IPP meeting was held at 10:00 on
2021-07-06</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient has been
disclosed in the meeting.</p></li>
<li><p>the estimated total amount of melphalan used in the time table is
6 vials.</p>
<ul>
<li>based on melphalan 50mg/vial, dose 100mg/m2, body surface area
1.425m2.</li>
<li>3 vials per day for 2 days (2021-07-07, 2021-07-08).</li>
<li>the amount has been secured by medicine storeroom.</li>
</ul></li>
<li><p>preparation and administration precautions of mephalan:</p>
<ul>
<li>expiration time 1.5hr after preparation (the duration including
infusion time) according to package insert.</li>
<li>based on lab data reported on 2021-07-05, liver and kidney have no
abnormality, no dose adjustment needed.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-957" class="section level1">
<h1>701243405</h1>
<div id="section-958" class="section level2">
<h2>210630</h2>
<p>[initial presentation]</p>
<ul>
<li>2021-05-07 intermittent lower abdominal pain for 3 weeks. pain was
relieved after taking acetaminophen and diclofenac but recurred since 4
days ago. associated symptoms: constipation for 2 days, hiccup, nausea,
poor appetite.</li>
</ul>
<p>[definite diagnosis]</p>
<p>2021-05-06 CT - abd - loculated fluid accumulation at uterus up to
9.7*7.1cm in largest dimension is found. - uterine abscess is considered
first. 2021-05-11 patho - ovary (tumor) - taiwan society of pathology
was consulted to diagnose: malignant spindle cell and epithelioid cell
neoplasm. - IHC: SALL4/BRG1/INI1(+), glypican/SATB2/cyclinD1( focal+);
SS18-SSX/OCT4/CD30/ETV4/MDM2/S100/NUT/MyoD1(-).<br />
- molecular pathology: SS18(-)(poor quality); chr12p/q FISH: failed. -
comment: - while the majority of it was composed of relatively uniform
spindle cells, gland-like components were also notable, in conjunction
with the strong TLE1 immunostaining, justifying your original
consideration of synovial sarcoma. - the degree of nuclear atypia would
be somewhat too high for synovial sarcoma, and TLE1 expression is not
specific. both SS18-SSX IHC and SS18 FISH performed to exclude this
possibility. - given the gland-like structures which reminded yolk sac
tumor, SALL4 (multifocally positive) and glypican (weakly positive,
mainly in the gland-like structures) staining were performed and
somewhat supported the speculation, albeit neither convincing nor
specific enough. - attempt to pursue some molecular evidence of
isochromosome 12p with chr12p, chr12q, and chr12 centromere FISH failed.
- other possibilities including myoepithelial carcinoma were not
supported by the current immunostaining results. - the case was reviewed
by one senior GYN pathologist, one GU pathologist, and another soft
tissue pathologist, and no conclusion could be drawn. - while a germ
cell tumor with a component of yolk sac tumor and sarcomatoid
transformation could not be excluded, the overall pathologic and
clinical features would be atypical. - perhaps a genomewide study aiming
at copy number variation/LOH might help in this regard. - note: some of
the original immunostaining showed CK weak+, TLE1+, SMA f+, GFAP-.
2021-07-13 patho - ovary (tumor) - diagnosis: pelvic tumor, debulking
surgery - compatible with recurrent malignant neoplasm. - the sections
show a picture of spindle and epithelioid cell tumor characterized by
spindle, ovoid or epithelioid tumor cells with congestion, hemorrhage,
extensive necrosis, active mitoses, arranged in solid, focal fascicular
or focal gland-like or rossette-like pattern, compatible with tumor
recurrence.</p>
<p>[treatment]</p>
<ul>
<li>2021-05-10 debulking surgery (BSO + cytoreduction surgery +
infracolic omentectomy + appendectomy) for malignant left ovarian
tumor.</li>
<li>2021-06-11 BEP (bleomycin + etoposide + cisplatin)</li>
<li>2021-08-13 doxorubicin</li>
</ul>
<div id="section-959" class="section level3">
<h3>==========</h3>
</div>
<div id="section-960" class="section level3">
<h3>2021-06-30</h3>
<p>{form virless (acyclovir) to famvir (famciclovir)}</p>
<p>[objective]</p>
<ul>
<li>being diagnosed with herpes virus infection.</li>
<li>virless 500mg IVD Q8H ends by 2021-06-30 and famvir (famciclovir)
250mg PO TID starts from 2021-07-01.</li>
<li>ALT elevated few days ago, newer lab data reported on 2021-06-30 and
2021-06-28 showd liver and kidney function normal.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>oral famciclovir excretion is primarily renal, and dose reduction is
recommended in patients with impaired renal function.
<ul>
<li>no observed kidney problem, no adjustment need.</li>
</ul></li>
<li>hepatic impairment
<ul>
<li>a 44% decrease in the Cmax of penciclovir (active metabolite) was
noted in patients with mild-to-moderate impairment</li>
<li>impaired conversion of famciclovir to penciclovir may affect
efficacy becaused of declined first pass effect.</li>
<li>source <a href="https://clinicalinfo.hiv.gov/en/drugs/famciclovir/tablet-film-coated" class="uri">https://clinicalinfo.hiv.gov/en/drugs/famciclovir/tablet-film-coated</a></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor the liver and kidney function as before, if liver
function deteriorates, then adjust agent to maintain effect might be
considered.</li>
</ul>
</div>
<div id="section-961" class="section level3">
<h3>2021-06-28</h3>
<p>{reported thrombotic microangiopathy with acyclovir}</p>
<p>[objective]</p>
<ul>
<li>thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic
syndrome (HUS), manifestations of thrombotic microangiopathy, have been
reported with acyclovir/valacyclovir
<ul>
<li>source:
<ul>
<li>Bell WR, Chulay JD, Feinberg JE. Manifestations resembling
thrombotic microangiopathy in patients with advanced human
immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis
trial (ACTG 204). Medicine (Baltimore). 1997;76(5):369-380. doi:
10.1097/00005792-199709000-00004.</li>
<li>Bukhari S, Aslam HM, Awwal TA, Christmas D, Wallach SL.
Valacyclovir-induced thrombotic thrombocytopenic purpura. Cureus.
2020;12(5):e8156. doi: 10.7759/cureus.8156.</li>
<li>Moake JL. Thrombotic microangiopathies. N Engl J Med.
2002;347(8):589-600. doi: 10.1056/NEJMra020528.</li>
<li>Trachtman H. HUS and TTP in children. Pediatr Clin North Am.
2013;60(6):1513-1526. doi: 10.1016/j.pcl.2013.08.007.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Bilirubin direct 0.06(6/28)</li>
<li>Bilirubin total 0.45(6/28)</li>
<li>S-GPT/ALT 59(6/28), 117(6/25)</li>
<li>Creatinine 0.67(6/28), 0.41(6/25)</li>
</ul></li>
<li>acitve medication
<ul>
<li>virless (acyclovir) 500mg IVD Q8H</li>
<li>imperan (metoclopramide) 10mg IVD PRNQ6H</li>
<li>loperamide 2mg PO PRNQ6H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>thrombotic microangiopathy mechanism:
<ul>
<li>idiosyncratic; leading to intravascular platelet-fibrin
microthrombi, vascular damage, hemolysis, and thrombocytopenia. in HUS,
this injury is believed to be initiated by uncontrolled activity of the
alternative complement pathway, while TTP features a reduction in
activity of ADAMTS13, the metalloprotease responsible for cleaving
ultra-large von Willebrand factor multimers.</li>
<li>source: Trachtman H. HUS and TTP in children. Pediatr Clin North Am.
2013;60(6):1513-1526. doi: 10.1016/j.pcl.2013.08.007.</li>
</ul></li>
<li>bilirubin within normal range, no sign of TTP and HUS in nursing
records.</li>
<li>urinary retention and constipation could caused by herpes viral
infection of the S2-S4 dermatome. accouding to active medication and
nursing record, these should not be an issue.
<ul>
<li>source:
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613994/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613994/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/19530489/" class="uri">https://pubmed.ncbi.nlm.nih.gov/19530489/</a></li>
</ul></li>
</ul></li>
<li>liver function improved based on lowered ALT data, creatinine
elevated but still in normal range.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep current medication, acyclovir prescription will be end on 6/30,
please continue to prescribe if the condition need.</li>
</ul>
</div>
<div id="section-962" class="section level3">
<h3>2021-06-24</h3>
<p>{acyclovir to treat herpes virus infection in HBV active carrier}</p>
<p>[objective]</p>
<ul>
<li>Lab
<ul>
<li>2021-06-23
<ul>
<li>S-GOT/AST 68U/L</li>
<li>S-GPT/ALT 103U/L</li>
<li>creatinine 0.47mg/dL</li>
<li>eGFR 151</li>
</ul></li>
<li>2021-05-17
<ul>
<li>Anti-HBc Reactive</li>
<li>Anti-HBs 41mIU/mL</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>baraclude (entecavir) 0.5mg PO QD</li>
<li>virless (acyclovir) 500mg IVD Q8H</li>
</ul></li>
</ul>
<p>[accessment]</p>
<ul>
<li>AST within 2x ULN, ALT within 3x ULN, liver function not so good but
far from failure.</li>
<li>renal function tests showed no abnormaility.</li>
<li>the major route of acyclovir elimination is the renal excretion of
unchanged drug (&gt; 85%). liver plays no major roles in metabolism.
<ul>
<li>source <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825963/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825963/</a></li>
</ul></li>
<li>acyclovir can inhibit hepatitis B viral replication especially using
higher dose.
<ul>
<li>source <a href="https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840080642" class="uri">https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840080642</a></li>
<li>source <a href="https://academic.oup.com/jac/article-abstract/11/3/223/784017" class="uri">https://academic.oup.com/jac/article-abstract/11/3/223/784017</a></li>
</ul></li>
<li>acyclovir and its alternatives, e.g. cidofovir, foscarnet,
ganciclovir, all need to be adjusted dose based on CrCl but not on liver
function.</li>
<li>possible adverse reactions
<ul>
<li>acyclovir: acute renal failure, neurologic toxicity.</li>
<li>entecavir: increased serum alanine aminotransferase. (&gt;5 x ULN:
11% to 12%; &gt;10 x ULN and &gt;2 x baseline: 2%), increased serum
creatinine (1% to 2%)</li>
</ul></li>
<li>there is no drug interaction of risk level A or greater identified
between acyclovir, entecavir and current chemo regimen.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>regularily monitor liver and kidney functions the same as before, no
adjustment needed.</li>
</ul>
</div>
</div>
</div>
<div id="section-963" class="section level1">
<h1>701304862</h1>
<div id="section-964" class="section level2">
<h2>210625</h2>
<p>{potential abx absorption problem}</p>
<p>[objective]</p>
<ul>
<li>active medication including:
<ul>
<li>Cravit (levofloxacin 500mg/tab) 1.5tab PO QDAC</li>
<li>Smecta (dioctahedral smectite 3gm/k) 1pk PO TIDAC</li>
</ul></li>
<li>the above items used at the same time in the morning.</li>
</ul>
<p>[accessment]</p>
<ul>
<li>the adsorbent properties of smecta may interfere with the rates
and/or levels of absorption of other substances, e.g. cravit.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>it is recommended not to administer any other drugs at the same time
as smecta.</li>
<li>cravit could be shifted to HS to decouple administration time and
still keep the same daily dose.</li>
</ul>
</div>
</div>
<div id="section-965" class="section level1">
<h1>700373891</h1>
<div id="section-966" class="section level2">
<h2>210618</h2>
<p>{tube feeding}</p>
<p>all the oral drugs in active medication have been reviewed, the
following two items can be peeled half but should not be grinded: -
Curam (amoxicillin 875 mg, clavulanic acid 125 mg, tab) - film coated -
Pentop (pentoxifylline 400mg, tab)</p>
<p>and the following item can not be peeled half or grinded: - Nexium
(esomeprazole 40mg, tab)</p>
<p>the alternatives to above items, respectively, could be: - Soonmelt
(amoxicillin 500mg, clavulanic acid 100mg, vial), if half-peeled Curam
still too big to be fed. - there is no other drug containing same active
ingredient with Pentop in the inventory, so please peel it (not too
fine) to fit the tube. - Takepron (lansoprazole 30mg, tab) should not be
grinded but can be peeled half.</p>
</div>
</div>
<div id="section-967" class="section level1">
<h1>701275722</h1>
<div id="section-968" class="section level2">
<h2>210524</h2>
<p>{tube feeding}</p>
<p>all the oral drugs in active medication can be administrated via NG
tube except following items which should not be grinded:</p>
<ul>
<li>nexium (esomeprazole): please dissolve it with adequate drinking
water prior to tube feeding.</li>
<li>protase (pancrelipase): please open the capsule and mix the granules
with pH&lt;5.5 liquid food prior to tube feeding.</li>
<li>oxynorm (oxycodone): if injection is not preferred, then fentanyl
patch such as ‘durogesic d-trans’ or ‘fentanyl transdermal path PPCD’
might be an alternative.</li>
</ul>
</div>
</div>
<div id="section-969" class="section level1">
<h1>700061689</h1>
<div id="section-970" class="section level2">
<h2>210517</h2>
<p>{tube feeding}</p>
<p>the oral drug takepron (lansoprazole, 30mg/tab) in active medication
should not be grinded, while it can be peeled in half.</p>
<p>there is also an iv version takepron (lansoprazole, 30mg/vial) can be
the alternative.</p>
</div>
</div>
<div id="section-971" class="section level1">
<h1>700990347</h1>
<div id="section-972" class="section level2">
<h2>210513</h2>
<p>{Tube Feeding}</p>
<p>all the oral drugs in current medication can be administrated via NG
tube.</p>
<p>actein effervescent (acetylcysteine) should not be grinded, please
dissolve the drug in adequate amount of drinking water prior to tube
feeding.</p>
</div>
</div>
<div id="section-973" class="section level1">
<h1>700072580</h1>
<div id="section-974" class="section level2">
<h2>210512</h2>
<p>{post IPP meeting following up}</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient is disclosed
in the meeting.</p></li>
<li><p>the estimated total amount of busulfan used in the time table is
15 vials.</p>
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
85kg</li>
<li>5 vials per day for 3 days (2021-05-12, 2021-05-13, 2021-05-14)</li>
<li>pharmacy staff in charge of drug purchasing will get the inventory
ready before the coming prescribing.</li>
</ul></li>
<li><p>people for dispensing regimen during weekend are also
arranged.</p></li>
<li><p>preparation and administration precautions:</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 2m2 -&gt; amount 800mg.</li>
<li>total solution containing 800mg etoposide will be no less than
2000mL.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-975" class="section level1">
<h1>701284346</h1>
<div id="section-976" class="section level2">
<h2>210512</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 6 items.</p>
<p>the 4 identified items has been shown as following while the other 2
items still remain unknown: - sinemet (carbidopa 25mg, levodopa 100mg) -
urief (silodosin 4mg) - rivotril (clonazepam 2mg) - through (sennoside
12mg)</p>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-977" class="section level1">
<h1>700150240</h1>
<div id="section-978" class="section level2">
<h2>210510</h2>
<p>{problem list}</p>
<p>the active problems listed in the TPR sheet are shown as
following:</p>
<ul>
<li>pneumonia</li>
<li>UTI</li>
<li>hypertension</li>
<li>ileus</li>
<li>hyponatremia</li>
</ul>
<p>[objective]</p>
<ul>
<li>urine OB 1+ (2021-05-08)</li>
<li>urine bacteria 1+ (2021-05-08)</li>
<li>CRP 5.39 (2021-05-08)</li>
<li>D-dimer 1763ng/mL (2021-05-08)</li>
<li>hs-Troponin I 49pg/mL (2021-05-08)</li>
<li>Na 121mmol/L (2021-05-08)</li>
<li>BUN 57mg/dL (2021-05-08)</li>
<li>Creatinine 1.71mg/dL (2021-05-08)</li>
<li>WBC 15.55 (2021-05-08)</li>
<li>RBC 2.68 (2021-05-08)</li>
<li>MCV 97.4 (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08)</li>
<li>no defecation recorded in these 2 days</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs, including blood pressure, looks relatively stable.</li>
<li>if no other special consideration exists, the first priority should
be controlling the infections.</li>
<li>brosym 2000mg IVD Q12H has been prescribed to control the infection
since 2021-05-09.</li>
<li>the lower serum sodium might be improved by intaking salted
food.</li>
<li>lab data showed a higher serum glucose level, an one-point datum
might not lead to its trend, more data to form a time series of blood
sugar monitoring is recommended.</li>
<li>MCV almost touched the upper limit of the normal range, some folic
acid and/or vit B12 supplements might be helpful for the mild
anemia.</li>
<li>some laxative agent might be helpful for the ileus.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring changes of infection signs.</li>
<li>invite dietitian to help the patient to eat more salted diets and to
see if any other diet issue found, then get sodium tested few days
later.</li>
<li>order regular scheduled blood sugar tests to build its trend.</li>
<li>folacin (folic acid 5mg) and/or kentamin (thiamine 50mg, pyridoxine
50mg, cyannocobalamin 500mcg) are available in pharmacy inventory now,
each of them could be administrated QD or BID, which is
recommended.</li>
<li>if still no defecation before 2021-05-11, then dulcolax (bisacodyl
5mg) QD or BID could be considered to prescribe, and administrated until
defecation or 3 days then reevaluate the condition.</li>
</ul>
</div>
</div>
<div id="section-979" class="section level1">
<h1>700350999</h1>
<div id="section-980" class="section level2">
<h2>210510</h2>
<p>{problem list}</p>
<p>active problems listed in 2021-05-08 14:14 DutyNote containing 2
items: - urinary tract infection - right lower lung pneumonia</p>
<p>[subj/obj]</p>
<ul>
<li>admitted on 2021-05-08 for lethargy, weakness for 5 days and fever
for 1 day.</li>
<li>with underlying HFrEF, bladder cancer s/p TURBT, HCVD, CKD and DM,
been regularly followed up at our cardiology, urology, metabolism
departments.</li>
<li>bladder cancer causing voiding difficulties and UTI</li>
<li>K 3.1mmol/L (2021-05-10), 3.1mmol/L (2021-05-08)</li>
<li>BUN 123mg/dL (2021-05-10), 101mg/dL (2021-05-08)</li>
<li>Creatinine 4mg/dL (2021-05-10), 3mg/dL (2021-05-08)</li>
<li>eGFR 15 (2021-05-10), 20 (2021-05-08)</li>
<li>CRP 8.63 (2021-05-10), 5.31 (2021-05-08)</li>
<li>RBC 4x10^6/uL (2021-05-10), 3.7x10^6/mL (2021-05-08)</li>
<li>HGB 11.6g/dL (2021-05-10), 10.8 (2021-05-08)</li>
<li>MCV 84.8 fL (2021-05-10), 86.2 fL (2021-05-08)</li>
<li>urine OB 2+, sediment-RBC 6-9, sediment-WBC &gt;= 100, Bacteria 3+
(2021-05-08)</li>
<li>hs-Troponin I 385pg/mL (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08), records fluctuate between
126-226 from 2021-05-08 19:00 to 2021-05-10 11:30.</li>
<li>HbA1c 8.1 (2021-04-27), 8.6 (2021-03-01), 10.1 (2020-12-11), 9.6
(2020-09-17), 9.8 (2020-06-24)</li>
<li>Uric Acid 4.6mg/dL (2021-03-01), 6.1 (2021-01-19), 8.1 (2020-12-11),
9.3 (2020-09-17), 8.6 (2020-06-24)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs looks relatively stable:
<ul>
<li>body temp no more than 37.5 degrees Celsius since 2021-05-08, the
fever has subsided.</li>
<li>most of time SBP ranges in around 120-130, DBP 60-80, 3-day data
showed BP is under well management.</li>
</ul></li>
<li>if there is no other special consideration, the first priority
should be controlling the infections.
<ul>
<li>avelox (moxifloxacin) 400mg IVD QD has been administrated since
2021-05-09 and scheduled till 2021-05-15.</li>
<li>the patient has poor renal function, but no dosage adjustment
necessary for avelox administration.</li>
</ul></li>
<li>although fever has gone, the rising CRP might hint the infection is
still ongoing.</li>
<li>the lower serum potassium might caused by uretropic
(furosemide).</li>
<li>lab data showed that blood suger flucturates in short-term (serum
glucose), however the management is getting better in mid-term (HbA1c).
<ul>
<li>using humalog mix50 pen (insulin lispro 50%, insulin lispro
protamine 50%) QDAC and QNAC now.</li>
</ul></li>
<li>MCV almost touched the lower limit of the normal range, some iron
supplements might be helpful for boosting up the hemoglobin level.</li>
<li>uric acid seems fell into normal range for months, xanthine oxidase
inhibitor could be no more necessary.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring any change of infection signs.</li>
<li>invite dietitian to help the patient to get more
potassium-containing food, and/or consider to shift uretropic
(furosemide) to potassium sparing spironolactone.</li>
<li>foliromin (ferrous sodium citrate, 50mg) BID for 2-4 weeks to
levelup hemoglobin is recommended, administrated in combination with vit
C to help absorption can be considered.</li>
<li>if there is no special consideration, discontinuation feburic
(febuxostat) is recommended.</li>
</ul>
</div>
</div>
<div id="section-981" class="section level1">
<h1>700385854</h1>
<div id="section-982" class="section level2">
<h2>210507</h2>
<p>{colon cancer}</p>
<p>[subj/obj]</p>
<ul>
<li>diagnosed with sigmoid adenocarcinoma in 2020 Apr with liver,
paraaortic LNs, and peritoneal carcinomatosis, cT3N2bM1c, stage
IVc.</li>
<li>received FOLFIRI 80% dose and 11 times panitumumab from May to Oct
in 2020 at Taoyuan General Hospital of Ministry of Health and
Welfare.</li>
<li>patho colon biopsy on 2020-11-26 showed one huge tumor was noted at
sigmoid colon (30cm from anal verge) and the lumen was near completely
obstructed.</li>
<li>colonic tissue with invasive irregular neoplastic glands.
immunohistochemical stains reveal CDX2(+) EGFR(+), PMS2(+), MLH1(focal
+), MSH2(+), and MSH6(+).</li>
<li>received FOLFIRI 6 times from 2020 Nov to 2021 Mar (C1D1, C1D15,
C2D1, C2D15, C3D1, C3D15) in our hospital prior to this
hospitalization.</li>
<li>NRAS/KRAS reported on 2020-12-15 showing not detected.</li>
<li>CEA 16.62ng/mL(2021-01-26), 8.52ng/mL(2020-11-17).</li>
<li>BRAF lab data not found.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>patients with tumors originating on the right side of the colon
(hepatic flexure through cecum) are unlikely to respond to cetuximab and
panitumumab in first-line therapy for metastatic disease.</li>
<li>EGFR(+), KRAS/NRAS WT gene and left-sided tumor - panitumumab is
purchased and will be ready for the patient in days.</li>
<li>immune checkpoint inhibitors might not an ideal option for
non-dMMR/MSI-H tumor - MLH1(focal +), MSH2(+), MSH6(+).</li>
<li>according to CEA lab data, the condition might not be improved after
one year FOLFIRI.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might order CT scan to gather new evidence on treatment effect.</li>
<li>If evidence shows that the cancer is getting more advanced, then
shift FOLFIRI to FOLFOX or CAPEOX (each regimen can be used in
combination with bevacizumab) could be considered.</li>
</ul>
<hr />
<p>{substance dependence}</p>
<p>[subj/obj]</p>
<ul>
<li>lab test showed evidence of using addictive drug.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>should help the patient get rid of those illegal drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange or refer the patient to an addiction treatment center
or clinic to get some alternative e.g. methadone.</li>
</ul>
<hr />
<p>{returning to society}</p>
<p>[subj/obj]</p>
<ul>
<li>his family members avoid to contact him.</li>
<li>no job, no income</li>
<li>not standing on his own feet yet (financially)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>being not reintegrated to the society will push him closer to the
additive drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange social work department staff to see if any help could
be offered to him.</li>
</ul>
</div>
</div>
<div id="section-983" class="section level1">
<h1>700134931</h1>
<div id="section-984" class="section level2">
<h2>000000</h2>
<p>{colon cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-01-22 RBC 3.42x10^6/uL, HGB 6.6g/dL, blood transfusion pRBC 2U
on 2021-02-12.</li>
<li>2021-02-19 stool occult blood: positive</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-03-15 colonoscopy: probable advanced colon cancer, ascending
colon, ileocecal valve involvement suspected</li>
<li>2021-03-19 patho: adenocarcinoma, IHC stain: EGFR(+), PMS2(-),
MLH-1(-), MSH-2(+), MSH-6(+)</li>
</ul>
<p>[disease extent &amp; staging]</p>
<ul>
<li>2021-03-16 CT, ABD:
<ul>
<li>low density lesions at both lobes of liver is found. liver simple
cysts are considered.</li>
<li>compatible with ascending colon cancer, regional lymphadenopathy,
T2N2aMo -&gt; M1 (with liver mets)</li>
</ul></li>
</ul>
<p>[treatment &amp; plan]</p>
<ul>
<li>biweekly, Q2WK
<ul>
<li>covorin (leucovorin) 400mg/m2, with 250mL N/S, 2hr</li>
<li>5-Fu (fluorouracil) 400mg/m2, with 100mL N/S, 10min</li>
<li>5-Fu (fluorouracil) 2400mg/m2, with 500mL N/S, 46hr</li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>NA</li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>chronic ischemic heart disease</li>
<li>type 2 diabetes mellitus</li>
<li>hypercholesterolemia</li>
<li>polyosteoarthritis</li>
</ul>
</div>
</div>
<div id="section-985" class="section level1">
<h1>700180657</h1>
<div id="section-986" class="section level2">
<h2>000000</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>2018-02 diagnosed with adenocarcinoma of S-colon, cT3N0M0.</li>
<li>2018-02-14 pathology
<ul>
<li>large intestine, sigmoid colon, laparoscopic LAR —- Adenocarcinoma,
moderately differentiated.</li>
<li>IHC stains: EGFR (+), PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+).</li>
<li>foci of mesenteric endometrosis, CK7 (+) and CK20 (-), with
fibrosis.</li>
<li>AJCC 8th ed. staging: pT3N0 (cMx); pStage: IIA at least (if cM0).
<ul>
<li>primary tumor pT3 - tumor invades through the muscularis propria
into pericolonic tissues</li>
<li>regional lymph nodes pN0 - no regional lymph node metastasis</li>
<li>distant Metastasis pMx<br />
</li>
</ul></li>
</ul></li>
<li>2018-12-25 CT: soft tissue mass with necrotic margin at surface of
uterus up to 2.9cm in largest dimension which is new in comparison to CT
dated on 2018-06-02.</li>
<li>2019-01-03 PET
<ul>
<li>a glucose hypermetabolic lesion on the superior aspect of the
uterus. should be malignancy with pelvic seeding on the uterus.</li>
<li>increased FDG accumulation in the right lateral aspect of the
abdomen and pelvic region and in the anterior aspect of the pelvic
region.</li>
</ul></li>
<li>2019-01-04 sigmoidfiberscopy: an ulcerative tumor, about 1/3
circumferential bowel lumen at 18cm above AV (RS-colon) with easy
contact bleeding previous anastomosis (10cm AAV) looked well.</li>
<li>2019-01-10 low anterior resection (LAR) and hysterectomy plus
bilateral salpingo-oophorectomy (BSO) recurrent 3cm tumor (favor
seeding) involving uterus and upper rectum and a segment of small bowel
was identified.
<ul>
<li>IHC stains: CK20(+), CK7(focal+), vimentine(-)</li>
<li>patho: rT4bN0M1a, stage IVA. 2019-09-20 received 12th Avastin &amp;
14th FOLFOX6, mild fingers and feet numbness, pigmentation on breast
skin. 2019-10-15 refilled Xeloda (capecitabine), mild fatigue, nausea,
abdomen discomfort. 2019-11-26 refilled Xeloda (capecitabine), nail and
finger pigmentation, mild fatigue and numbness. 2020-03-25 CT: a known
newly-developed soft tissue nodule measuring 0.6 cm in right pelvic wall
is noted again, increasing in size. 2020-04-07 PET</li>
<li>a glucose hypermetabolic lesion in the right anterior pelvic wall,
compatible with a metastatic lesion.</li>
<li>multiple glucose hypermetabolic lesions in the left lower abdomen
and in the pelvic cavity and a glucose hypermetabolic lesion in the left
upper abdomen. 2020-11-07 CT: multiple soft tissue nodules in the
peritoneum (upper abdomen and pelvic cavity), up to 1.7cm in left pelvic
cavity, suspected peritoneal carcinomatosis. 2021-02-20 CT: progression
of peritoneal tumors with left lower ureter invasion causing left
hydronephrosis and hydroureter.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-04-28 _8.64</li>
<li>2021-03-29 15.23</li>
<li>2021-03-02 16.89</li>
<li>2021-01-23 13.56</li>
<li>2020-10-28 _5.044</li>
<li>2020-06-22 12.062</li>
<li>2020-03-18 _8.714</li>
<li>2019-12-09 _2.008</li>
<li>2019-08-16 _0.866</li>
<li>2019-04-30 _1.534</li>
<li>2018-12-10 15.635</li>
<li>2018-09-10 _2.047</li>
</ul></li>
<li>regimen
<ul>
<li>2018-03-03 ~ __________: Ufur (tegafur + uracil)</li>
<li>__________ ~ 2020-07-03: FOLFOX + Avastin (bevacizumab)</li>
<li>2020-07-17 ~ 2021-02-19: FOLFIRI + Cyramza (ramucirumab)</li>
<li>2021-03-31 ~ up to now : RegoNivo (Opdivo (nivolumab) + Stivarga
(regorafenib))</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+) -&gt; not dMMR, EGFR (+),
pembrolizumab might not be indicated.</li>
<li>no KRAS/NRAS/BRAF lab data found.</li>
<li>after using 5-FU, FOLFOX plus anti-VEGF bevacizumab as adjuvant
first-line therapy for more than one year (2018 Mar ~ 2020 Jul), the
disease progressed, then the regimen was shifted to FOLFIRI plus
anti-VEGFR2 ramucirumab as second-line therapy. the two regimen are
listed in NCCN clinical practice guidelines.</li>
<li>the cancer has been progressed in 2020Q4 ~ 2021Q1, regimen shifted
to RegoNivo since end of 2021 March.
<ul>
<li>nivolumab - anti-PD1, usually used in combination with anti-CTLA4
i.e. ipilimumab, to treat adults with metastatic colorectal cancer that
is microsatellite instability-high (MSI-H) or mismatch repair deficient
(dMMR), and patient have tried treatment with a fluoropyrimidine,
oxaliplatin, and irinotecan.</li>
<li>regorafenib inhibits multiple kinases including VEGF1, VEGF2, VEGF3,
PDGFR, FGFR involved in tumor angiogenesis and KIT, RET, RAF-1, BRAF
involved in oncogenesis.</li>
<li>RegoNivo regimen is supported by articles, e.g. “<a href="https://pubmed.ncbi.nlm.nih.gov/32343640/">Regorafenib Plus
Nivolumab in Patients With Advanced Gastric or Colorectal
Cancer</a>”</li>
</ul></li>
<li>possible toxicity for RegoNivo regimen
<ul>
<li>nivolumab can result in significant immune-mediated adverse
reactions due to T-cell activation and proliferation. These
immune-mediated reactions may involve any organ system, with the most
common reactions being pneumonitis, enterocolitis, hepatitis,
dermatitis, hypophysitis, nephritis, and thyroid dysfunction.</li>
<li>regorafenib:
<ul>
<li>hypertension occurs in nearly 30% of patients. usually occurs within
6 weeks of starting therapy and is well controlled with oral
antihypertensive medications.</li>
<li>skin toxicity in the form of hand-foot syndrome and skin rash occur
in up to 45% and 26%, respectively. generally appears within the first
cycle of drug treatment.</li>
</ul></li>
</ul></li>
</ul>
<p>[suggest/plan]</p>
<ul>
<li>monitor any sign of toxicity caused by nivolumab and
regorafenib.</li>
<li>keep tracking tumor markers including CEA</li>
<li>update chest, abdomen, and pelvic CT (and/or PET) every 3-6
months.</li>
</ul>
</div>
</div>
<div id="section-987" class="section level1">
<h1>700290223</h1>
<div id="section-988" class="section level2">
<h2>000000</h2>
<p>{intrahepatic cholangiocarcinoma}</p>
<p>[initial presentaion]</p>
<ul>
<li>2006-04 Echo
<ul>
<li>Liver cirrhosis (HCV related), liver cysts status post left
lobectomy</li>
<li>Parenchymal renal disease with bilateral renal cysts, GB polyps,
multiple</li>
</ul></li>
<li>2008-10 HCC s/p operation left lobectomy</li>
<li>2010-03-03 Recurrent HCC in S6 s/p S6-segmentectomy</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-04-09 Patho liver biopsy
<ul>
<li>adenocarcinoma, poorly differentiated, compatible with
cholangiocarcinoma</li>
<li>IHC: CK7(+), CK20(focal+), Hepa-1(-) and Arginase-1(-)</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>cT2N0M0, stage II</li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-05-26 ~ 2021-05-20 CCRT 3240cGy/18 fractions, gemcitabine</li>
</ul>
<p>[effect and side effect]</p>
<ul>
<li>2021-07-13 CT, ABD
<ul>
<li>s/p op. over left lobe liver with residual choalangiocarcinoma at S4
and liver meta.</li>
<li>the ovarall treatment response is stationary except slghtly increaed
metastatic size.</li>
<li>gallstones.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<p>HCV, Cirrhosis, Child A - 2021-03-30 - HBsAg Nonreactive - Anti-HBc
Reactive - Anti-HCV Reactive</p>
<p>hypertention, portal hypertension varicose vein GERD type 2 DM</p>
</div>
</div>
<div id="section-989" class="section level1">
<h1>700348580</h1>
<div id="section-990" class="section level2">
<h2>000000</h2>
<ul>
<li><p>2018-10 diarrhea on and off</p></li>
<li><p>2020-11-12 patho - colon biopsy</p>
<ul>
<li>pieces of colonic tissue with invasive irregular neoplastic
glands.</li>
<li>immunohistochemical stains - EGFR(+), PMS2(+), MLH1(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li><p>2020-11-12 CT, ABD: cT3N2aMia, stage IVA Re-evaluation on
12/14/2020 slightly decreased in tumor size.</p></li>
<li><p>2020 late Nov ~ 2021 early Jan CCRT, FU/LV 5040 cGy/28Fx in hope
of receiving sphincter preserving surgery (Last RT on 1/5).</p></li>
<li><p>2021 Feb there after chemo FOLFOX</p></li>
<li><p>2021-02-18 CT, ABD: much regression of rectal cancer.</p></li>
</ul>
<p>2021-03-10 Op Method: Abdominoperineal resection (APR)<br />
Finding: 1. Tumor in rectum, cT3N2aM1a (enlarged nodes in left external
iliac chain) 2. End S colostomy is done over LLQ<br />
3. One JV drain at pelvic area</p>
<p>rectal cancer, cT3N2aM1a s/p CCRT, was admitted for scheduled
laparoscopic APR with permanent colostomy. - 2021-03-18 patho -
abdomino-perineum resection - ypT3N1aMia stage IVA</p>
<p>2021-05-13 Self-Monitoring of Blood Glucose,SMBG QDAC</p>
<p>PatMRNo, PatID, PatName, PatBDate, PatGender</p>
<p>Brosym 4g Q12H</p>
<p>assumed 50kg body weight with Cockcroft-Gault formula, the estimated
CrCl is 25mL/min, daily maximal dose is 4g (2g Q12H) according to
package insert.</p>
<p>cefoperazone sulbactam</p>
<p>daily maximal 4g (2g Q12H)</p>
<p>Nexium (esomeprazole) should not be grinded, shifting to Takepron
(lansoprazole) is recommended.</p>
<p>Actein should be dissolved in adequate drinking water prior to tube
feeding.</p>
<p>thanks and regards,</p>
<p>all the oral drugs in active medication can be administrated via NG
tube except Doxaben XL (doxazosin) which is release-controlled.</p>
<p>Urief (silodosin) is recommended as an alternative to switch
Doxaben.</p>
<p>thanks and regards,</p>
<p>omeprazole lansoprazole pantoprazole rabeprazole</p>
</div>
</div>
<div id="section-991" class="section level1">
<h1>700360779</h1>
<div id="section-992" class="section level2">
<h2>000000</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-02 Chest AP portable
<ul>
<li>right internal jugular central venous catheter with tip in the
SVC</li>
<li>normal size of heart<br />
</li>
<li>residual hazy areas of increased opacity with reticular opacities in
Lt lung and Rt lower lung zone</li>
</ul></li>
<li>2022-04-29 Renal ultrasound
<ul>
<li>Parenchymal renal disease.</li>
<li>Perirenal fluid accumulation over right lower kidney, suspected
Inflammatory or infectious process.</li>
</ul></li>
<li>2022-04-21 CT - lung/mediastinum/pleura
<ul>
<li>Interstitial pneumonitis at both lungs.</li>
<li>Heart failure.</li>
<li>Calcified coronary arteries is found.</li>
</ul></li>
<li>2022-04-21 Cardiac ultrasound
<ul>
<li>normal chamber size</li>
<li>concentric LV hypertrophy</li>
</ul></li>
<li>2022-04-20 MRI - liver, spleen
<ul>
<li>Lobulated soft tissue lesions, passive atelectasis, or effusions in
bilateral posterior basal CP angle are suspected. Please correlate with
CT.</li>
<li>The liver and spleen shows hypointensity on T2WI that may be iron
deposition. please correlate with clinical condition.</li>
<li>Artifact or fluid collection in right upper abdominal wall is
suspected? Please correlate with CT.</li>
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, &amp; both kidney.<br />
</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>2022-04-12 Standing KUB
<ul>
<li>Wedge deformity of L1 vertebral body is suspected. Please correlate
with lateral view.</li>
<li>Spondylosis of the L-spine is noted.</li>
<li>Disc space narrowing with marginal osteophyte formation and vacuum
phenomenon of L4-5.</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-04-13 Electrocardiography
<ul>
<li>Sinus tachycardia with Premature atrial complexes with Aberrant
conduction</li>
</ul></li>
<li>2022-04-01 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle third esophagus with slightly decreased
in size.</li>
</ul></li>
<li>2022-02-11 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle third esophagus s/p trial with statonary
primary tumor size and extension as well as the mediastinal lymph nodes
s/p jejunostomy.</li>
</ul></li>
<li>2022-01-27 GI series
<ul>
<li>suspected esophageal rupture or ulceration at esophageal tumor,
middle third esophagus.</li>
</ul></li>
<li>2022-01-11 CT - lung/mediastinum/pleura
<ul>
<li>middle third esophageal cancer, significant improvement and
persisted multiple small LNs in visceral and left anterior prevascular
spaces compared with CT on 2021/11/18.</li>
</ul></li>
<li>2021-12-29 Renal ultrasound
<ul>
<li>bilateral chronic change of both kidneys.</li>
</ul></li>
<li>2021-11-18 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle esophagus with main tumor
regression.</li>
<li>Lymphadenopathy in the mediastinum. Stable</li>
<li>s/p jejunostomy.</li>
<li>Calcified coronary arteries is found.</li>
</ul></li>
<li>2021-11-03 Standing KUB
<ul>
<li>Spondylosis of the L-spine is noted.</li>
<li>Disk space narrowing of L4/5.</li>
<li>Compression fracture of L1 vertebral body.</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-09-27 MRI - brain
<ul>
<li>No evidence of brain metastasis.</li>
</ul></li>
<li>2021-09-23 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer up to 8.9*2.95cm with regional and mediasitnal
lymphadenopathy. Stationary as compared with previous CT on
2021-08-30.</li>
</ul></li>
<li>2021-09-09 Tc-99m MDP whole body bone scan
<ul>
<li>Mildly increased activity in the middle to lower T-spines and some
L-spines. Degenerative change may show this picture. Please correlate
with other imaging modalities for further evaluation.</li>
<li>Some faint hot spots in bilateral rib cages and mildly increased
activity in the right femoal neck. The nature is to be determined
(post-traumatic change? other nature?). Please follow up bone scan for
further evaluation.</li>
<li>Increased activity in bilateral shoulders, left hip, bilateral knees
and left ankle, compatible with benign joint lesions.</li>
</ul></li>
<li>2021-09-08 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the middle esophagus, compatible with the
primary malignancy of esophagus.<br />
</li>
<li>Glucose hypermetabolism in bilateral mediastinal lymph nodes, cancer
with regional lymph nodes metastases should be considered, suggesting
further investigation.<br />
</li>
<li>Increased FDG uptake in the right upper and right lower lungs, the
nature is to be determined (inflammation/infection process or distant
mets?), suggesting further investigation also.<br />
</li>
<li>Esophageal cancer, cTxN2M0-1, by this F-18 FDG PET/CT scan.</li>
</ul></li>
<li>2021-09-06 Patho - esophageal biopsy
<ul>
<li>Upper esophagus, biopsy — Severe dysplasia at least<br />
</li>
<li>Microscopically, the sections show a picture of severe dysplasia at
least characterized by pleomorphic and hyperchromatic atypical squamous
cells with focal ulceration, lymphoid follicle with germinal center,
without convincing stromal invasion.<br />
</li>
<li>Immunohistochemistry of P16(-), P53(+), P63(+) and CK(+) for
dysplastic cell. However, more advanced lesion can not be excluded
entirely. Closely follow up and repeat biopsy is advised, if clinically
indicated.</li>
</ul></li>
<li>2021-09-04 MRI - brain
<ul>
<li>no evidence of brain metastasis.</li>
</ul></li>
<li>2021-08-30 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Esophageal Carcinoma
<ul>
<li>Impression (Imaging stage): T4N2M0</li>
</ul></li>
</ul></li>
<li>2021-08-30 Patho - esophageal biopsy
<ul>
<li>Diffusely circumferential mucosal erosions with frability were noted
at upper esophagus(30cm~20cm below the inscisor). Upper esophageal
tissue peel off spontaneously when endoscopy pass through it. We used
net to removed it out and sent for pathology.</li>
<li>Upper esophagus, 30-20 cm below the incisor, peel removal — Squamous
cell carcinoma<br />
</li>
<li>Immunohistochemistry shows CK(+), P63(+), P53(+) and P16(-) for
tumor cell.</li>
</ul></li>
<li>2021-08-27 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Diffuse esophageal erosions with oozing, upper esophagus, s/p
pathology evaluation</li>
<li>Esophageal ulcers, multiple, middle and low esophagus</li>
<li>Superficial gastritis</li>
<li>Suspect Brunner’s gland hyperplasia, bulb</li>
</ul></li>
<li>Suggestion
<ul>
<li>Admission for observation</li>
<li>Endoscopic hemostasis for upper esophagus was difficult. Consider
angiography if still active bleeding</li>
<li>Persue pathology result</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-29 General and Gastroenterological Surgery.
<ul>
<li>Q
<ul>
<li>For TPN</li>
<li>This 66-year-old man patient is a case of squamous cell carcinoma of
upper to middle third esophageal with bilateral mediastinal lymph nodes
metastasis, cT4aN2M1, Stage IVB s/p Port-A and feeding jejunostomy, s/p
BGB-A317, BGB-A1217 and cisplatin plus 5-FU and chronic kidney disease,
stage 3 (Creatinine 2.11 mg/dL). This time, for fever with B/S on
20220403 showed Enterococcus faecium and Acinetobacter baumannii complex
infection and Port-A blood culture showed GPC. Remove Port-A on
20220408. Intabated ETT on 20220421 due to severe metabolic acidosis and
dyspnea. Transferred to ICU for severe sepsis on 20220421. Jejunostomy
created on 20210906. However, ostomy wound reddish and leak, so NPO
since 20220425.</li>
</ul></li>
<li>A
<ul>
<li>obj?
<ul>
<li>A case of esophageal cancer with j-tube leakage who request
nutrition support.</li>
<li>General appearance: ill looking</li>
<li>GI tract: Dysphagia (-), Abd pain (-), Abd distension (-), Nausea
(-), Vomiting (-), Diarrhea (-), Poor appetite (+), Poor digestion (-),
BW loss (-) , stool (+), Bowel sound (-)<br />
</li>
<li>Feeding: NPO</li>
<li>Allergy: NKA</li>
<li>Nutrition assessment: BH 164cm, BW 66.2kg, UBW 56.8 kg, IBW 59.2kg,
96% IBW, BMI 21, BEE (calculated based on IBW) 1251kcal, TEE
1952kcal</li>
<li>Lab data: Alb 2.9, BUN 26, Cr 0.58, Na 133, K 3.6, BS 100</li>
<li>According to the patient’s present conditions, parenteral nutrition
plus enteral feeding (place ND tube if achieved as tolerance) will be
suitable for nutrition supply. We will follow this case for adjustment
of optimal nutrition support.</li>
</ul></li>
<li>PN suggestion:
<ul>
<li>DC Bfluid 1000ml（RI 4U）and D10W 500ml（RI 12U）QD</li>
<li>DC D50W 80ml Q6H（RI 8U each time）</li>
<li>D50W 500ml QD run 20.8ml/hr（add RI 10U ）</li>
<li>Amino-Hepa 1000ml QD</li>
<li>Lyo-Povigent 4ml/QD（add in TPN）(if out of stock, then use
B-complex 1ml/QD and Vitacicol 2ml/QD in TPN)</li>
<li>Addaven 10ml/QD（add in TPN）</li>
</ul></li>
<li>PN monitor items
<ul>
<li>Check BW QW5 and record I/O Q8H</li>
<li>Check one touch Q6H for 2days, if stable QD check</li>
<li>Please control BS &lt; 200 mg/dl with RI sliding scale</li>
<li>QW1 check CBC/DC</li>
<li>QW1 check BUN. Cr. AST. ALT. T/D Bil. TG. ALP. rGT. Na. K. Cl. Ca.
P. Mg. Zinc. Alb. Prealbumin or Transferrin</li>
<li>if TPN not sufficient, use YF5 or D10W instead.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-22 Rheumatology and Immunology
<ul>
<li>Q
<ul>
<li>For IVIG (autoimmune disorders)</li>
<li>Current problem: We need your specialist to evaluate and screen the
patient, to exclude auto-immune disease or suitable administration of
intravenous immune globulin (IVIG).</li>
</ul></li>
<li>A
<ul>
<li>History review were performed. Patient was admitted to ICU due to
acute respiratory failure after receiving check point inhibitor therapy
for esophagus SCC. I was consulted for immunotherapy for possible
drug-related ILD.</li>
<li>Suggestion:
<ul>
<li>Treatment as current your expert’s management and infection
control.</li>
<li>For IVIG dosage (1-2g/kg), please prescribe IVIG 60g, divided by 3
days therapy as below:
<ul>
<li>Day 1:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
<li>Day 2:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
<li>Day 3:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
</ul></li>
<li>Consider to add actemra 1AMP (162mg) SC as adjunctive therapy for
ILD.</li>
<li>Please monitor clinical condition after therapy. If not effective,
then plasma exchange maybe considered.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-22 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>For abnormal thyroid enzymes</li>
<li>Current problem: We need your specialist to evaluate and
differential diganosis as sick euthyroid or medical advice.</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>HR: 66-135</li>
<li>SBP: 110-200+</li>
<li>Possible related medication: methylprednisolone (since
20220418)</li>
<li>AST/ALT: 68/119</li>
<li>BUN/Cr: 69/2.88</li>
<li>Na: 142, K: 3.4</li>
<li>TSH/FT4: 1.952/0.58</li>
<li>FT3: 1.4</li>
<li>ATPO, ATG, TSH receptor Ab: unavailable</li>
<li>ACTH/Cortisol: 5.3/7.86 (20220419), steroid (+)</li>
</ul></li>
<li>A: R/I sick euthyroid syndrome</li>
<li>Suggestions:
<ul>
<li>No need of any treatment at this timing</li>
<li>Recheck TSH/FT4 (biochemistry) 2 weeks later</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-21 Nephrology
<ul>
<li>Q
<ul>
<li>For AKI with metabolic acidosis</li>
<li>Current problem: HD is prefer, We need your specialist to
evaluate.</li>
</ul></li>
<li>A
<ul>
<li>Lab data:
<ul>
<li>PH: 7.18, PCO2: 29, PO2: 146, HCo3:10.8, BE: -16.2</li>
<li>WBC: 21.42, Hb:11.0, PLt: 346</li>
<li>CEA: 9.96, SCC:3.1</li>
<li>GPT: 224, GOT: 105, T.bil: 7.26, D.bil: 4.77, LDH: 330, lipase: 288,
amylase: 150, rGT: 768</li>
<li>BUN/cre : 25/1.68 (20220330) -&gt; 27/2.11 (20220404) -&gt; 29/2.94
(20220414) -&gt; 49/5.00 (20220418) -&gt; 82/4.15(20220420)</li>
<li>U/O: 1420ml -&gt; 56ml</li>
<li>Vital signs: E2V5M4, BP: 179/105mmHg</li>
<li>PE: Under MV ventilator FiO2: 60%, no limb edema</li>
<li>CT chest: interstitial pneumonitis at both lungs</li>
<li>Cardiac echo: LVEF 71.5%, concentric LVH</li>
</ul></li>
<li>Impression:
<ul>
<li>Acute kidney injury stage 3 on CKD with metabolic acidosis</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Check serum lactate, ketone, Cl, FeNa, FeBUN, urine osmolarity,
blood osmolality</li>
<li>Check Urine for analysis</li>
<li>Correct metabolic acidosis and follow up ABG</li>
<li>Adequate IV fluid hydration</li>
<li>Avoid nephrotoxic drugs</li>
<li>If there is refractory metabolic acidosis, electrolyte imbalance,
fluid overload, oliguria, we will arrange RRT if family agree</li>
</ul></li>
<li>20220428 Follow up:
<ul>
<li>Still metabolic acidosis (nonAG)</li>
<li>Check urine AG and add sodium bicarbonate 2# bid</li>
<li>Arrange renal echo</li>
<li>We will follow up this case</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-19 Gastroenterology
<ul>
<li>Q
<ul>
<li>This 66-year-old man patient is case of squamous cell carcinoma of
upper to middle third esophageal with bilateral mediastinal lymph nodes
metastasis, cT4aN2M1, Stage IVB s/p Port-A and feeding jejunostomy, s/p
BGB-A317, BGB-A1217 and cisplatin plus 5-FU.</li>
<li>This time, for progression abnormal liver function, R/O IO therapy
side effect.</li>
</ul></li>
<li>A
<ul>
<li>Rule out other possibilities before considering BGB-A317-,
BGB-A1217-induced hepatitis.
<ul>
<li>Check ALKP, rGT, ALB, PT, APTT, LDH to complete liver study</li>
<li>Check Anti HAV IgM, HBsAg, anti-Hbs Ab, Anti HCV Ab</li>
<li>Check antinuclear antibodies (ANA), smooth muscle antibody (SMA),
Epstein Barr virus (EBV) IgM, cytomegalovirus (CMV) PCR</li>
<li>Check thyroid and adrenal function</li>
<li>Regularly/closely monitor AST/ALT, TBI, PT, APTT, Ammonia, GGT, ALKP
(every two days)</li>
<li>Avoid hepatic toxic agent if possible(or adjust dose), simplify
medication</li>
<li>silymarin 1#~2# TID</li>
</ul></li>
<li>When other possibilities have been excluded or the liver has
decompensated and a checkpoint inhibitor-related immune hepatitis is
suspected, steroids may be administered for immune-mediated hepatitis:
(reference: Sanjeevaiah, A., Kerr, T., &amp; Beg, M. S. (2018). Approach
and management of checkpoint inhibitor-related immune hepatitis. Journal
of gastrointestinal oncology, 9(1), 220–224. <a href="https://doi.org/10.21037/jgo.2017.08.14" class="uri">https://doi.org/10.21037/jgo.2017.08.14</a> )
<ul>
<li>Initial dose of 0.5 to 1 mg/kg/day of prednisone for Grade 2
hepatitis</li>
<li>Initial dose of 1 to 2 mg/kg/day of prednisone for Grade 3 or
greater hepatitis, followed by a slowly taper about one month</li>
<li>Based on severity of liver enzyme elevations, withhold or
discontinue BGB-A317, BGB-A1217</li>
<li>Consider liver biopsy for alternate etiology and add mycophenylate
mofetil 1g PO BID if no improvement after 3 days of steroid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Infectious Disease
<ul>
<li>Q
<ul>
<li>This time, for fever with B/S on 20220403 showed Enterococcus
faecium and Acinetobacter baumannii complex infection and Port-A blood/C
showed GPC. Port-A catheter removed on 20220408.</li>
</ul></li>
<li>A
<ul>
<li>The Enterococcus is susceptible to ampicillin.</li>
<li>The Acinetobacter is susceptible to pip/tazo.</li>
<li>Agree with your use of tapimycin. Adjust the dose to 2.25g iv q6h
according to the renal function.</li>
<li>Recheck B/C 3 days later. Please consider to remove the port-A if
persistent bacteremia.</li>
<li>Arrange CV-echo to exclude endocarditis.</li>
</ul></li>
</ul></li>
<li>2022-03-16 Dermatology
<ul>
<li>This patient suffered from dyskeratotic nails for years.</li>
<li>Imp: Tinea unguim, subacute dermatitis</li>
<li>Suggestion:
<ul>
<li>Excelderm crema 2 tubes, bid</li>
<li>Topsym cream 4 tubes, bid</li>
</ul></li>
</ul></li>
<li>2021-12-28 Nephrology
<ul>
<li>Q
<ul>
<li>Consultation for renal dysfunction (eGFR 20) and electrolyte
imbalance (K 2.5, Mg 4, Ca 1.84, Na 126).</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>AKI Stage 3, cause to be determined</li>
<li>Hypokalemia suspect extrarenal loss related</li>
<li>Hyponatremia suspect extrarenal loss related</li>
</ul></li>
<li>Suggestions:
<ul>
<li>check FeNa, urine Na, urine osmo, urine K, urine Cl, urine
creatinine, urine Mg</li>
<li>check blood osmo, cortisol, ACTH, thyroid functions, total CO2</li>
<li>potassium supplement</li>
<li>adequate hydration</li>
<li>record I/O and body weight qd</li>
<li>avoid nephrotoxic agents</li>
<li>keep hemodynamic stable</li>
<li>arrange renal echo</li>
<li>recheck electrolytes, renal functions and total CO2</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-24 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>For evaluate hypothyroidism therapy</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>BH: 166 cm, BW: 61.1 kg</li>
<li>HR: 78-114</li>
<li>Possible related medication: nil</li>
<li>AST/ALT: 16/17</li>
<li>BUN/Cr: 94/3.30</li>
<li>Na: 140, K: 3.9</li>
<li>TSH/FT4: 7.543/1.00</li>
<li>FT3: 3.1</li>
<li>ATPO, ATG, TSH receptor Ab: unavailable</li>
<li>ACTH/Cortisol: unavailable</li>
</ul></li>
<li>A: Subclinical hypothyroidism</li>
<li>Suggestions:
<ul>
<li>Check anti-TPO Ab, anti-thyroglobulin Ab, ACTH/cortisol</li>
<li>Recheck TSH/FT4</li>
<li>No need of thyroxine supplement at this moment</li>
<li>Endocrine OPD F/U</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-09-07 Hemato-Oncology
<ul>
<li>Patient examined anc Chart reviewed. A case of T4N2Mx, Stage IV ESCC
is noted. I am consulted for further evalution and mangmenet.</li>
<li>My suggestions are:
<ul>
<li>Arrange discussion with patient and family (already the afternoon on
2021-09-11)</li>
<li>The patient is preliminarily fit the clinical trial of Phase I BGB
at Cohort 6.</li>
<li>Please do not perform radiotherapy at present, which is requested by
trial.</li>
<li>If necessary, I might take over this case.</li>
</ul></li>
</ul></li>
<li>2021-09-02 Radiation Oncology
<ul>
<li>Subjective:
<ul>
<li>History: This 66-years-old male patient has been drinking alcohol
for 30-40 years (half glass per day). He has suffered from progressive
dysphagia and BW loss of 10 kg for 2 months. He can tolerate soft diet
now. Due to the EGD showed suspicious esophageal lesion, r/i malignancy,
chest CT on 2021/08/30 reported esophageal carcinoma, cT4N2M0. Pathology
report showed squamous cell carcinoma, moderately differentiated.
Staging workup is ongoing.</li>
<li>Previous RT: denied.</li>
<li>Other disease: Gastric ulcer with bleeding and hemorrhoid for 12
years.</li>
<li>Family history: denied.</li>
<li>Habit: smoking, 1 PPD for 30 yr, quitted for 15 yr; alcohol: half
glass per day, just quitted; betel nut: denied.</li>
<li>Married. Caregiver: his wife. Job: retired buffet cook. No or mild
economic stress.</li>
<li>Language: Mandarin, Taiwanese.</li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2021/09/02: No palpable SCF LNs.</li>
<li>Pathology: 2021/8/30, Upper esophagus, 20-30 cm below the incisor,
peel removal — MD squamous cell carcinoma; CK(+), P63(+), P53(+) and
P16(-).</li>
<li>Images:
<ul>
<li>PED, 2021/8/30: diffusely circumferential mucosal erosions with
friability were noted at upper esophagus (20cm~30cm) below the incisor.
Upper esophageal tissue peel off spontaneously when endoscopy pass
through it. We used net to removed it out and sent for pathology.
Multiple ulcers were noted at middle and lower esophagus (from ECJ to
30cm below the incisor). Mucosal active oozing was noted at 23cm below
the incisor.</li>
<li>Chest CT, 2021/08/30: asymmetric esophageal wall thickening of
middle third of thoracic esophagus with severe luminal narrowing (length
7.5 cm, thickness 30 mm), with loss of fat planes between posterior wall
of trachea and left main bronchus. multiple small LNs in visceral and
left anterior prevascular spaces. Hila: no enlarged LN. IMP: middle
third esophageal cancer cT4N2. Nonspecific inflammation in LUL. Moderate
3V-CAD.</li>
<li>EUS, 2021/9/03: pending.</li>
<li>Bone scan, PET, 2021/9/06: pending.</li>
</ul></li>
</ul></li>
<li>Diagnosis: Esophageal cancer, M/3, MD SqCC, cT4N2M0 (pending staging
workup) with loss of fat planes between posterior wall of trachea and
left main bronchus, R &amp; L paratracheal and subcarinal LAP
metastasis; ECOG = 1.</li>
<li>Suggest: Radiotherapy.</li>
<li>Goal: Curative (pre-operative).</li>
<li>RT Plan:
<ul>
<li>Target &amp; Volume: Esophageal tumor and LAPs.</li>
<li>Technique: VMAT &amp; IGRT by linear accelerator.</li>
<li>Dose &amp; Fractionation: 5040cGy/28 fractions with concurrent
chemotherapy.</li>
</ul></li>
<li>Plan: Staging workup, PortA implantation and jejunostomy are
suggested. CCRT is suggested for downstage &amp; downsize. Possible
radiation effects (malaise, radiation esophagitis, pneumonitis) is told.
CT simulation will be arranged on 20210908 after PortA implantation and
jejunostomy are done. Diet education is given.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-24 Endoscopic esophageal dilatation
<ul>
<li>esophageal stenosis noted around 25~30 cm from incision</li>
<li>tumor resolution noted at endoscopic view</li>
<li>esophageal perforation at 9’ clock 25 cm from incision due to
fragile esophageal wall</li>
<li>dilatation successful upto 48 Fr. Bougie dilator</li>
</ul></li>
<li>2021-09-06 Feeding jejunostomy + port-A insertion</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-04, -02-18 - tislelizumab + ociperlimab</li>
<li>2021-11-03, -11-24, -12-15 - fluorouracial + cisplatin +
tislelizumab + ociperlimab</li>
<li>2021-10-13 - fluorouracil + cisplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-993" class="section level1">
<h1>700935936</h1>
<div id="section-994" class="section level2">
<h2>000000</h2>
<p>{rectal cancer}</p>
<ul>
<li>rectal cancer s/p LAR, pT3N0M0, stage IIA</li>
</ul>
<p>[initial presentation]</p>
<ul>
<li>2019/2020 bowel habit change, bloody stool, mucus stool,
tenesmus</li>
<li>2020 2nd half iFOBT(+)</li>
<li>2020-10-29 colonscopy showed one mass in the rectum 10cm from anal
verge</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2020-11-04 patho outcome
<ul>
<li>adenocarcinoma: section shows pieces of colonic tissue with invasive
irregular neoplastic glands.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul></li>
<li>2020-12-17 NRAS/KRAS not detected.</li>
</ul>
<p>[disease extent &amp; staging]</p>
<ul>
<li>2020-11-04 CT, ABD: cT3N2aM1a, IVA
<ul>
<li>there is soft tissue nodule in LLL of the lung.</li>
<li>there is a suspicious soft tissue nodule in RLL of the lung.</li>
</ul></li>
<li>2020-11-23 patho: pT3N0, stage IIA (if cM0)
<ul>
<li>Histology: Adenocarcinoma</li>
<li>Histology Grade: G2: moderately differentiated</li>
<li>Angiolymphatic invasion: present</li>
<li>Perineural invasion: present</li>
<li>LLL nodule, frozen section: intrapulmonary lymph node (0/1) with
anthracosis</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-11-18 3D VATS wedge resection
<ul>
<li>one nodular lesion was noted over LLL, size about 0.5cm in
diameter.</li>
<li>frozen section showed benign lesion.</li>
</ul></li>
<li>2020-11-18 Robotic-assist low anterior resection</li>
<li>2020 Dec CCRT 4320cGy/24 with 5FU(400mg/m2)/LV(20mg/m2)</li>
<li>2021 Jan CCRT 5400cGy/30 with 5FU(400mg/m2)/LV(20mg/m2)</li>
<li>2021 Feb thereafter biweekly FOLFOX</li>
<li>2021-06-01 CT: no evidence of recurrent/residual tumor in the
study.</li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>updated CT on 2021-06-01 shows current treatment still works</li>
<li>no side effect graded more than CTCAE grade 1 is found</li>
<li>active medication reviewed without issue:
<ul>
<li>metoclopramide, prophylaxis or treatment of nausea and vomiting
associated with emetogenic cancer chemotherapy</li>
<li>clonazepam, for anxiety disorder or rapid eye movement sleep
behavior disorder</li>
<li>sennoside, laxative/stimulant for constipation</li>
<li>acetylcysteine, mucolytic agent</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>suspected covid-19 resolved
<ul>
<li>2021-05-25 rapid test positive</li>
<li>2021-05-26 real-time pcr negative</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-995" class="section level1">
<h1>701057711</h1>
<div id="section-996" class="section level2">
<h2>000000</h2>
<ul>
<li>D-colon cancer obstruction s/p self expandable metalic stent placed
on 2020-07-16, and single-incision laparoscopic surgery (SILS) with left
hemicolectomy on 2020-07-22</li>
<li>patho colon segmental resection for tumor reported on 2020-07-28:
<ul>
<li>tumor, descending colon, laparoscopic low anterior resection (LAR) -
adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - Tumor metastasis (2/16) without
extracapsular extension (0/2).</li>
<li>AJCC pathologic staging pT4aN1b (if cM0), stage IIIB.</li>
<li>histology grade G2: moderately differentiated with focal tumor
necrosis, abscess and mucin production.</li>
<li>ImmunoHistoChemistry for tumor cells: EGFR(+, 100%), PMS2(+),
MLH1(+), MSH2(+) and MSH6(+).</li>
</ul></li>
<li>mFOLFOX6 adjuvant chemotherapy 12 cycles from 2020-08-14 to
2021-01-22.</li>
<li>metastatic adenocarcinoma over left lower lung status post
video-assisted thoracic surgery left lower lung wedge resection on
2021-02-26.</li>
<li>shift chemo regimen to FOLFIRI since 2021-03-26.</li>
</ul>
<p>Decreased chemotherapy dose to 67 % for grade 3 diarrhea with blody
weight loss. Decreased chemotherapy dose to 75 % for grade 2 diarrhea
with blody weight loss.</p>
</div>
</div>
<div id="section-997" class="section level1">
<h1>701257485</h1>
<div id="section-998" class="section level2">
<h2>000000</h2>
<ul>
<li>Hx: chronic viral hepatitis B without delta-agent</li>
<li>2020-10-22 abdominal fullness without stool passage for days, lower
abd mass with ascites -&gt; CT: focal wall thickening at sigmoid colon
and descending colon junction with severely dilated proximal colon and
ileum is found. colon cancer with obstruction is considered.</li>
<li>2020-10-23 sigmoidoscopy: one mass was noted in the DS colon with
near total obstruction Size 3.6 cm. ( 50 cm from anal verge) s/p 9-cm
stent under fluoroscopy.</li>
<li>2020-11-10 patho: colon, descending-sigmoid, left hemicolectomy -
adenocarcinoma, moderately differentiated.
<ul>
<li>IHC stain: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1(+).</li>
<li>tissue labeled as ‘gastric superficial lesion’, biopsy - metastatic
carcinoma.</li>
<li>staging: pT3pN0pM1c, pStage IVC.</li>
</ul></li>
<li>regimen
<ul>
<li>2020-11-27 ~ 2020-12-15, _3 times: FOLFIRI</li>
<li>2020-12-29 ~ 2021-05-13, 11 times: FOLFIRI + Avastin
(bevacizumab)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-999" class="section level1">
<h1>701263241</h1>
<div id="section-1000" class="section level2">
<h2>000000</h2>
<p>701263241__999999__MNote</p>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li><p>2019-05-21 colonoscopy: one ulceative mass lesion with lumen
stenosis over 15 cm from anal verge, patho - adenocarcinoma.</p></li>
<li><p>2019-06-12 laparoscopic anterior resection and partial
cystectomy, findings:</p>
<ul>
<li>sigmoid cancer with direct invasion to urinary bladder, enlarged
LNs, and extraserosal surface invasion, but no peritoneal seedings, no
liver surface lesion.</li>
<li>poorly differentiated, signet ring cell (+), lymphovascular invasion
(+), perineural invasion (+), LN (+, 10/16), urinary bladder margin (+),
pericolorectal tissues (+), MSH-6 intact, PMS-2 intact</li>
<li>ATCC 8 pT4bN2bMx, stage IIIC (if M0).</li>
</ul></li>
<li><p>2019-09-10 CT: recurrence over left pelvis, and omentum of
LLQ.</p></li>
<li><p>stayed in USA for months, lost following up in Taiwan health care
provider.</p></li>
<li><p>2021-01-04 CT abdomen: colon cancer s/p operation with peritoneal
carcinomatosis with massive ascites, T0N0M1c, Stage IVC.</p></li>
<li><p>2021-04-06 CT abdomen, pelvis:</p>
<ul>
<li>massive ascites with suspected omental cake is found.</li>
<li>the severity of the ascites is stationary.</li>
<li>right pleural effusion, probably reactive pleural effusion.</li>
</ul></li>
<li><p>2021-04-16 ascites tapping: 3075cc clear yellowish ascites was
drained.</p></li>
<li><p>2021-04-20 cyto, ascites: smears show clusters of pleomorphic
tumor cells. the morphology is consistent with metastatic
adenocarcinoma.</p></li>
<li><p>CEA</p>
<ul>
<li>2021-05-04 46.48ng/mL</li>
<li>2021-04-13 36.13ng/mL</li>
<li>2021-03-22 26.25ng/mL</li>
<li>2021-02-02 27.45ng/mL</li>
<li>2020-12-15 22.34ng/mL</li>
</ul></li>
<li><p>CA199</p>
<ul>
<li>2021-05-04 8.51U/mL</li>
<li>2020-12-15 8.63U/mL</li>
</ul></li>
<li><p>CA125</p>
<ul>
<li>2021-04-13 115.4U/mL</li>
<li>2021-03-22 _56.6U/mL</li>
<li>2021-02-02 _48.0U/mL</li>
<li>2020-12-15 _30.8U/mL</li>
</ul></li>
<li><p>regimen</p>
<ul>
<li>2019-09-23 ~ 2020-01-22: FOLFIRI plus bevacizumab, 8 times</li>
<li>2021-01-13 ~ up to now : FOLFIRI plus bevacizumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>KRAS/NRAS/BRAF not found in sheets</li>
<li>2 (MSH-6, PMS-2) of 4 MMR proteins remain intact, pembrolizumab
might not be indicated.</li>
</ul>
</div>
</div>
<div id="section-1001" class="section level1">
<h1>701265877</h1>
<div id="section-1002" class="section level2">
<h2>000000</h2>
<p>701265877</p>
<p>{Colon cancer}</p>
<p>[subj/obj]</p>
<ul>
<li><p>(transverse) colon cancer with liver metastases, cT4aN1aM1c,
stage IV s/p LPS right extended and hemicolectomy on 2020-03-26 and
seedings over omentum found.</p>
<ul>
<li>patho peritoneum metastases, pT4aN2aM1c, stage IVc s/p
radiofrequency ablation (RFA) with switch controller (SWC) x3 on
2020-08-25.</li>
<li>patho result: poorly differentiated, EGFR (+), wildtype RAS,
proficient MMR but B-Raf V600E mutation.</li>
</ul></li>
<li><p>chemo (palliative) from 2020-04-27 with FOLFOXIRI (ox: self-paid;
iri: insurance covered) with bevacizumab.</p></li>
<li><p>chest echography on 2021-02-23 showed right thorax pleural
effusion s/p drainage of 600 cc.</p></li>
<li><p>CXR on 2021-03-09 showed right thorax small pleural
effusion.</p></li>
<li><p>CEA:</p>
<ul>
<li>1.85ng/mL(2021-05-04)</li>
<li>1.35ng/mL(2021-04-20)</li>
<li>1.18ng/mL(2021-04-06)</li>
<li>1.59ng/mL(2021-03-23)</li>
<li>1.90ng/mL(2021-03-09)</li>
</ul></li>
<li><p>CA199:</p>
<ul>
<li>11764U/mL(2021-05-04)</li>
<li>4875U/mL(2021-04-20)</li>
<li>2068U/mL(2021-04-06)</li>
<li>1388U/mL(2021-03-23)</li>
<li>1557U/mL(2021-03-09)</li>
</ul></li>
</ul>
<p>for 3 consecutive weeks then 1 week off as a cycle</p>
<p>Oral target therapy with Cobimetinib 20mg 1# po QD (self-carried)
(for 3 consecutive weeks then 1 week off as a cycle) from
2021/02/24~2021/0314. Oral target therapy with Dabrafenib 75mg 2# po
Q12H (self-carried) (for 3 consecutive weeks then 1 week off as a cycle)
from 2021/02/24. Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg)
(C1D1) on 2021/02/24, (C1D15) on 2021/03/10, (C2D1) on 2021/03/24,
(C2D15) on 2021/04/07. Oral target therapy with Mekinisc 2mg 1# po
QDAC(self-paid) from 2021/03/15 (for 3 consecutive weeks then 1 week off
as a cycle). Therefore, the treatment would be cetuximab plus
irinotecan(C1D15) and dabrafenib and MEK inhiitor, under the recognition
of T-colon cancer with metastases to liver, peritoneum and pleura, and
with B-Raf mutation. This time, she was admitted for Chemotherapy with
biweekly Erbitux(500mg)/Campto(100mg) (C3D1) on 2021/4/22.</p>
<p>Oral target therapy with Dabrafenib(Tafinlar) 75mg 1# po
BID(self-carried) from 2021/02/24 Oral target therapy with Mekinisc 2mg
1# po QDAC(self pay) from 2021/03/15. Chemotherapy with biweekly
Erbitux(500mg)/Campto(100mg) (C3D1) from on 2021/04/23</p>
</div>
</div>
<div id="section-1003" class="section level1">
<h1>701273749</h1>
<div id="section-1004" class="section level2">
<h2>000000</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>2021-03-06 CT, abdomen: A-colon tumor with pericolonic fat stranding
and enlarge lymphnode.</li>
<li>2021-03-07 laparoscopic right hemicolectomy for A-colon
adenocarcinoma with obstruction, patho:
<ul>
<li>AJCC 8 staging: pT4aN2b, G3, IIIC</li>
<li>adenocarcinoma, poorly differentiated, with neuroendocrine
feature.</li>
<li>tumor invades visceral peritoneum. bilateral resection margins are
free.</li>
<li>mesocolonic lymph node: positive for tumor metastasis (10/14) with
extranodal extension.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-05-04: 1.35ng/mL</li>
<li>2021-04-02: 1.47ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2021-05-04: _33.17U/mL</li>
<li>2021-04-02: 121.19U/mL</li>
</ul></li>
<li>regimen
<ul>
<li>FOLFOX since 2021-04-06</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>dMMR/MSI-H, KRAS/NRAS/BRAF lab data not found in sheets.</li>
<li>based on the short trend of CEA and CA199, we might consider the
condition is relatively stable.</li>
<li>for ‘T4, N1-2’ or ‘T any, N2’ (high-risk stage III) stage which
includes the patient, the preferred regimen as first-line adjuvant
treatment could be:
<ul>
<li>CAPEOX 3-6 months or</li>
<li>FOLFOX 6 months,</li>
<li>other treatment options for this stage include:
<ul>
<li>Capecitabine 6 months or</li>
<li>5-FU 6 months</li>
</ul></li>
</ul></li>
<li>current regimen is the standard startup treatment without
issue.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>have KRAS, NRAS, and BRAF mutation testing, microsatellite
instability or mismatch repair testing done, even HER2, NTRK testing if
possible.</li>
</ul>
</div>
</div>
<div id="section-1005" class="section level1">
<h1>701277089</h1>
<div id="section-1006" class="section level2">
<h2>000000</h2>
<p>{}</p>
<p>[initial presentation]</p>
<p>[definite diagnosis]</p>
<ul>
<li>2021-04-20 patho, pleural/pericardial biopsy:
<ul>
<li>skeletal muscle fibers and fibroadipose tissue with mild fibrosis
and chronic inflammatory cell infiltration.</li>
<li>IHC scant atypical cells: CK(+), CK7(+), CK20(-), TTF-1(-),
Calretinin(-), p63(-), and CD56(-).</li>
<li>The PAS and AFB special stains are negative.<br />
</li>
</ul></li>
<li>2021-07-06 patho, bronchus biopsy:
<ul>
<li>alveolar lung tissue with interstitial fibrosis and infiltration of
mucinous glandular cells.</li>
<li>IHC stains: CK(+), CK7(+), CK20(+), CDX2(+), TTF-1(-), and Napsin
A(-).</li>
<li>should check pancreas, billiary tract, stomach and else for tumor
origin.</li>
</ul></li>
<li>2021-07-12 patho, stomach biopsy:
<ul>
<li>gastric tissue infiltrated by neoplastic mucinous glands and signet
ring cells.</li>
<li>IHC stains: CK(+) and Her-2/neu (Ab)(-).</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>still working out</li>
</ul>
<p>[Summary]</p>
<p>This 67-year-old woman has the history of 1: Solitary pulmonary
nodule, r/o malignancy 2: Type 2 DM Parapneumonic effusion, right This
time, she has suffered from dyspnea for weeks. Since the symptom
exacerbation recent days. She was then brought to our ER for further
help. At ER, rapid screeing of COVID19 revealed negative finding. CXR
showed bilateral consolidation and pleural effusions, cardiomegaly. Lab
exam revealed elevated CRP. Under the impression of suspect COVID19
pnuemonia, right lung mass and bilateral pleural effusion, the patient
was admitted for further care on 20210629.</p>
<p>Bilateral pneumonia Bilateral pleural effusion r/o COVID -19
infection</p>
<p>=&gt; Abx with Brosym =&gt; Oxygen supplement =&gt; Oral radi-K =&gt;
Diuretic for bilateral plerual effusion =&gt; Transfer to CM ward if PCR
negative</p>
<p>==============================</p>
<p>This 67-year-old woman has the history of 1: Solitary pulmonary
nodule, r/o malignancy 2: Type 2 DM 3: Parapneumonic effusion,
right.Under the impression of suspect COVID19 pnuemonia, right lung mass
and bilateral pleural effusion, the patient was admitted for further
care on 20210629.After admission. antiboitc with Brosym for pneumonia
and fiuretic for bilateral plerual effusion were given. RT-PCR of
COVID-19 revealed negative finding. The patient might transfer to chest
ward for further management on 2021/06/29.</p>
<p>After CM ward, she has been orthopnea and dyspnea was noted, well
explained present condition and treatment plan to the patient and her
husband, emergency arrange cardiac echo and chest echo for right lung
mass, pericardial effusion and bilateral pleural effusion for
evaluation. Cardiac echo and chest echo was done and smoothly on 06/30,
cardiac echo showed moderate amount pericardial effusion, No RV
compression sign, No tamponade, No pericardial constriction at present,
recommended to consult with cardiac surgery for P.P. window. Chest echo
report showed Left side massive amount of pleural effusion, s/p
thoracentesis, yield 1000cc, serosanguos fluid. Right side minimal
amount of pleural effusion. She was transferre to SICU for intensive
care on 6/30. We consult CVS for moderate amount pericardial effusion
and P.P window surgery(Pericardiac effusion:1350cc) on 7/01. All
operation procedure smoothly and return SICU for postoperation care.
Weaning ventilaotr with etubated on 7/01. Under hemodynamic stable and
she will be transfer to ward for care.</p>
<p>After transfered to Chest ward on 7/3, Tumor marker showed elevated
CA-125, CA199, 7/6 CT guide biopsy was done and patho showed
adenocarcinoma with TFF-1(-), abdomen CT showed ascites and multiple
soft tissue nodules in the omentum, pending cytology, and lobulated
pleura thickening at right anterior basl CP angle that may be tumor
seeding or primary pleura tumor. brain MRI showed No brain nodule or
metastasis, EGD+colonscopy was done on 7/12 showed gastric
adenocarcinoma, bone scan was done on 7/13, whole body PET was done on
7/15 revealed prominent glucose hypermetabolic lesion in the right
lateral aspect of the pharyngeal wall, we will consult ENT for
assessment, she was transfered to hema ward on 7/16 for further
assessment and management.</p>
</div>
</div>
<div id="section-1007" class="section level1">
<h1>701365869</h1>
<div id="section-1008" class="section level2">
<h2>000000</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-19 Cell block - suspected malignant pleural effusion
<ul>
<li>SMEARS and CELLBLOCK: Many clusters of neoplastic cells
present.</li>
</ul></li>
<li>2022-03-25 MRI - brain
<ul>
<li>No evidence of brain metastasis.</li>
</ul></li>
<li>2022-03-23 PD-L1 (SP142) Assay (Ventana) S2022-4656
<ul>
<li>Result:
<ul>
<li>Tumor cell (TC) staining assessment: TC category: TC ＜ 1%</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC ＜ 1%</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
<li>2022-03-24 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower L-spines. Degenerative change may
show this picture. Please correlate with other imaging modalities for
further evaluation.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
<li>Some faint hot spots in the skull and bilateral rib cages. The
nature is to be determined (post-traumatic change? other nature?).
Please follow up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders and hips, compatible with
benign joint lesions.</li>
</ul></li>
<li>2022-03-21 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, right, CT-guide biopsy — adenocarcinoma, moderately
differentiated</li>
<li>Sections show acinar glandular tumor cells infiltrating in a
fibrotic stroma.</li>
</ul></li>
<li>2022-03-19 Chest PA/AP view
<ul>
<li>There are few nodular opacity projecting in right lung that may be
metastases. Please correlate with CT.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-03-19 MRI - pelvis
<ul>
<li>Soft tissue tumors in bilateral adnexa and uterus (surface region),
r/o carcinomatosis. Prominent right lower abdomen soft tissue, r/o
carcinomatosis (appendix origin?)</li>
<li>Prominent ascites and bowel ileus.</li>
<li>Right pleural seeding with effusion.</li>
</ul></li>
<li>2022-03-15 Cell block
<ul>
<li>SMEARS and CELLBLOCK: Many clusters of adenocarcinoma present.</li>
<li>IHC stains:
<ul>
<li>TTF-1(+), Napsin-A(+): favor pulmonary origin;</li>
<li>CK20(-): dis-favor GI origin;</li>
<li>GATA-3(-): dis-favor breast origin;</li>
<li>PAX-8 (-): dis-favor ovarain origin.</li>
</ul></li>
</ul></li>
<li>2022-03-15 Gynecologic ultrasonography
<ul>
<li>Ascites(+)</li>
<li>A mass 9.2x8.9mm in uterus</li>
</ul></li>
<li>2022-03-12 Chest PA (erect) view
<ul>
<li>Consolidation and pleural effusion in right chest</li>
</ul></li>
</ul></li>
</ul>
<p>The patient suffered from SOB, air hunger, cold sweat, and the cold
of four limbs, the 12 lead EKG: sinus tachycardia, the heart rate from
139bpm to 58bpm, the blood oxygen drop, changed the oxygen support with
NRM O2 fll, the SpO2 97%, then we can’t measure blood pressure, and the
patient consciousness become drowsy and the blood oxygen drop again,
under the NRM O2 full. The VS Xia talks about the patient’s condition to
the family, so gave the endo inserting, on levophed and Dopamin high
dose will be transferred to MICU.</p>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
